<SEC-DOCUMENT>0000070318-23-000010.txt : 20230221
<SEC-HEADER>0000070318-23-000010.hdr.sgml : 20230221
<ACCEPTANCE-DATETIME>20230217175619
ACCESSION NUMBER:		0000070318-23-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		156
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230221
DATE AS OF CHANGE:		20230217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TENET HEALTHCARE CORP
		CENTRAL INDEX KEY:			0000070318
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		IRS NUMBER:				952557091
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07293
		FILM NUMBER:		23644379

	BUSINESS ADDRESS:	
		STREET 1:		14201 DALLAS PARKWAY
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75254
		BUSINESS PHONE:		469-893-2200

	MAIL ADDRESS:	
		STREET 1:		14201 DALLAS PARKWAY
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75254

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NATIONAL MEDICAL ENTERPRISES INC /NV/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>thc-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:e5eb22bb-8cdc-4927-ae5c-e13f3ca3c3e1,g:f5e96eef-6bc4-43e3-b34d-7345446e971c,d:397b00e3dcff45d9b9c5c6459ba30276--><html xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:thc="http://www.tenethealth.com/20221231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>thc-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN18yLTEtMS0xLTI5MzcxMA_9e75c0e3-1f42-448f-93fb-dbca6995e37c">0000070318</ix:nonNumeric><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN180LTEtMS0xLTI5MzcxMA_b3198b1f-9578-4bc1-a041-ff1548138be8">false</ix:nonNumeric><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN18xMi0xLTEtMS0yOTM3MTA_89da6d9e-924b-4095-81fa-9f064930c671">2022</ix:nonNumeric><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN18xMy0xLTEtMS0yOTM3MTA_30839a6c-5c1d-4710-89ed-b54ba7d5c1dc">FY</ix:nonNumeric><ix:nonNumeric contextRef="i7e67596c4fbd48eea8785f354f1d98d8_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="iccd9ce39a7dc448ba011235d835f9e2f_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i52e0390579564677a1312d0789221786_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i997032dafb7b429994fd8eec46ba466e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="iae5ba870f1f4485e81af6c8bba7c493d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872">http://fasb.org/us-gaap/2022#LongTermInvestmentsAndReceivablesNet</ix:nonNumeric><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1">http://fasb.org/us-gaap/2022#LongTermInvestmentsAndReceivablesNet</ix:nonNumeric><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="ib7c8eda4b4d14ac49c4e91d6e7cb0cbc_D20220101-20221231" name="thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODY4_dfdfd5fb-468c-4e0d-afdb-50499803685f">P3D</ix:nonNumeric><ix:nonNumeric contextRef="ibfd7a9c8341e4fbb98014f10cc135b7a_D20220101-20221231" name="thc:GuaranteeObligationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkyNA_42d833b7-adcf-4193-8432-f964517997d1">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_0c2fc9bb-b93d-4b06-840f-178792b3529d">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_1d18318b-f1d8-462d-93f9-2c3eaf3de351">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg0Mzg_74a46396-62a0-44d1-87da-e5a77de5ca2f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg2MjE_fd2aa8ae-54d5-4b8a-b36d-1b3d0bc214ae">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZmJmMmE5OTM5YTA4NDYzZTk1NDJjNWEyMzYzNDkwYmIvdGFibGVyYW5nZTpmYmYyYTk5MzlhMDg0NjNlOTU0MmM1YTIzNjM0OTBiYl8xLTEtMS0xLTM1MTY3OQ_d3d3768e-10a2-46fd-b72b-535f0ee710ef">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZmJmMmE5OTM5YTA4NDYzZTk1NDJjNWEyMzYzNDkwYmIvdGFibGVyYW5nZTpmYmYyYTk5MzlhMDg0NjNlOTU0MmM1YTIzNjM0OTBiYl8yLTEtMS0xLTM1MTY3OQ_c1274d87-7681-4a4a-991b-44675e8010b2">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ife8dd83765da4cd98415083bc755446e_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZTNiZTFmMDJhMDU5NGIwNmE4NGNjMDE4NGM2ZmVkNWYvdGFibGVyYW5nZTplM2JlMWYwMmEwNTk0YjA2YTg0Y2MwMTg0YzZmZWQ1Zl8yLTEtMS0xLTM1MTY3Nw_ad452b51-c1a3-4a0b-8e20-31ef0c5106ff">50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i016c96b25eea4c4e852f3cb7e72aedf8_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZTNiZTFmMDJhMDU5NGIwNmE4NGNjMDE4NGM2ZmVkNWYvdGFibGVyYW5nZTplM2JlMWYwMmEwNTk0YjA2YTg0Y2MwMTg0YzZmZWQ1Zl8zLTEtMS0xLTM1MTY3Nw_bf576d78-663e-4d37-87ef-5e26c73ae846">50</ix:nonFraction><ix:nonNumeric contextRef="ic7cd6c10c8c74700867918c05b8d066e_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzItMS0xLTEtMjkzNzEw_5cf46639-be82-4299-9806-daa669b4346f">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="id8235d44217a459cb42567e761b66f1d_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzMtMS0xLTEtMjkzNzEw_976cf519-85aa-4c45-96c5-eadb9210aaea">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i5607340778f848eeba9562ba40506527_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzQtMS0xLTEtMjkzNzEw_f3f579ad-8616-44e1-9831-ad38615a3039">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ib32381cae0dc40e8971f9588ae25f535_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzUtMS0xLTEtMjkzNzEw_b749ec2f-8b4e-4d1c-ae52-765857c43fec">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i3fe036fe195e4e7d9cf7c4783fa3b8d6_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzYtMS0xLTEtMjkzNzEw_8ab62ad8-4d13-4c1a-bea1-bb8d3ea9fbde">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i2a8a661109d44f82ab8d85b5e23bfda3_I20221231" xsi:nil="true" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzctMS0xLTEtMjkzNzEw_e64c5f1e-d47c-4da5-b811-85c155561009"></ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i9b94c1f135f64a488e17326f4496bb5a_D20210101-20211231" decimals="4" name="thc:PurchasedEquityInJointVenturePercentageOfTotalShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTkvZnJhZzo3OGRhOTE5MDFmNDU0NjI2ODg4YzJhN2U5ZjA2ZTQwYi90ZXh0cmVnaW9uOjc4ZGE5MTkwMWY0NTQ2MjY4ODhjMmE3ZTlmMDZlNDBiXzYz_aea51f89-a345-4830-a438-197415caca2c">.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="thc-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cddf06bd574be2ad2b6db4f6c58e08_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i466f81b830d4456980895fd2849bc045_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1338325429bf43b1917d2b7a451f60b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8317271c934402ebe8d6b8414e1b396_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaeed20294de403f864897b4800c3076_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73837e4f8db9412e8f899038e1d69a38_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9537d740a09d4c659577fa85ae658fbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d874170404f42828e4c20e8b8df0183_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9554f40adca348fcb6728bf86c3ecdf7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d0733ad43146a38ea0933fae539a08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a99224736d148eb923d186edf1422a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89adc45b1f04cc7b5b5f7802b70f646_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34520ac68b949658c3caaf22edd6880_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfc3c23664d14313871878cccfd836b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68dbb9be4d814d51ad51baa9ef64725a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc7f69df573459097fdcb5d09e4778c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a3605c2b39491ba943fd1edfc38e57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3a3a91f53e143f88c4008add5713b37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8b2757ba2949ca8cd949137ff2242f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4961643c307a4f6f870dcae12b32be64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic970d8adef764f56901b3449b235a580_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd4726c880f4e148d4569ab39f1d407_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96beba9c82c45c1bc21607c1ff74f2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b513def6714ccda59af687a753af25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4668e92bb57b48e5b60535088433640e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3357e2680a954c2f9e9a7ea6681fe6ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00199680d78144a79e385f52ad262816_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44ff96f5e0b4207bd89a9ce5dd47a7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b9a7228a28d48dd8f40b5100d81ac6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4aa1e6e88f4448ac550047af2e16de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic697b5296a55464da1d3d7ed92f77ab2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92aac1e9ae304c2c9a6e91a2b9279e3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9e8ae8287042d59710ebc9811fd7fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6deeb898cc694b44af79dd598642335b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63be1af82c5a4ce08a55c20e64768dd2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i141f2bcca31f4b0380c3b5e8254e8c6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f75f50cbee4ce2a41dfe51c9ce7596_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2f751698934015b40a39f68b1a7b32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e1ff00656b4675b1053c1131354580_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b72ce7a7f084592ab6d37729017b52f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239bd2934060423182e137ce4439d676_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328d8102d6f44cfa952a21bd7c09daba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe4a381bd734a65ad42049eb3bae264_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="hospital"><xbrli:measure>thc:hospital</xbrli:measure></xbrli:unit><xbrli:unit id="healthcare_facility"><xbrli:measure>thc:healthcare_facility</xbrli:measure></xbrli:unit><xbrli:context id="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314717058c7b4b6fb0a8169f1a019fe3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:ConiferHealthSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id03e28a327e64655b42d061b206c91d2_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647dc680b9224e41a241261103ccd5aa_I20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f7c47ed3f1432b9993a85a212b93bc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6364b905b4f448f180aff1eec2cae8f0_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>thc:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2045a695149b44b7a235414628a53b37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaaaa5abc7244245b9b67813cd3b395d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f8148fcad34b6ba60172409bbf6668_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18501b1020814804b2eec3c3a49eda56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a68ee2c5334eff95979103621be27a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eeb9cc68a96448383cd633e3217c1f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9377069d70814572a175b579ec7a281d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab64915969534cf4956bafb8271dc248_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1a1807f7c64edaa3db3ee3ca10ea53_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece489c88064416a8f8ac688d1f70c95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa94d45bb7994110803e7156298da109_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndAmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c1b5e8fa8eb4e95875735d34c47d58a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:AccruedCompensationAndBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50ac87d72391498b913cf175b99fcea9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:AccruedCompensationAndBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87503b31cf9b44539e4e33a5a506f23a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i453df43ed989465c83339dfbcbbf1f2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd85c2d1a1374a65b8654ba74a6f38c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:CaptiveInsuranceSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe6626659d434b6cb1b41cc1706a572b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:CaptiveInsuranceSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2743e63d59e4952888f44efdbce4683_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747d501e6e0f41bd9ca9f27f5b091c1a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26aedf0885e647e29e1d889e0703be3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4465885b467846d392b87babc57179d9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85eb793e6b84363968e6ff370cb8b75_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9feb05943d7e4d72a6e4c70948071b28_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">thc:TexasHealthVenturesGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4437bef5e9b44a32b53fb9a7a5f9b32e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">thc:TexasHealthVenturesGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084834af07f94533b36d44d59a7a2b21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">thc:TexasHealthVenturesGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c80f6e03094431a9b9dc5696c76170_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic99a8eb5ba464ce4815b2681aa41727f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e67596c4fbd48eea8785f354f1d98d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed3bfef5ee649f29df0916da65a65ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5343d74439bf454aab6dd66ea2a9f13d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:NewlyConstructedHospitalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e69c97f00a4fd4be24bc4f694c6383_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a82f5c5f0b4bdea97702ea376fa880_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc879355fab3418bb4e9b23bb6b58cd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd9ce39a7dc448ba011235d835f9e2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1c5b7f55b147fe81cec433ecb2800a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4130035b4ffb4b2b9759276d80640702_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>thc:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i52e0390579564677a1312d0789221786_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ddaa71294141e9be1093eec432aaaa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df7801e84484df0aaf96468dbac66e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997032dafb7b429994fd8eec46ba466e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie118b0f2118146a497e17cce3c5da1f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9829aeea0346f490db02486d0b9fa4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:ComputerAndTelecommunicationEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5ba870f1f4485e81af6c8bba7c493d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d9b425fef84906a67c577eb496f953_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ad7bcccdb04247a3b2e90bbacf26bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1386fd3cb640aba64d28e810f688ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9047828c01704885a5dbf35dedddc704_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4595fd3300594bae87dfb53d46c07c84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b651d49dfde4a238741f373ca58bc2c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7868d9c4a59e48619659d721cc78888e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844a37e3831a44668dbcdd0ebafe40b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15bd4ee78bbe42988676a562c194f442_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5985c976394f5390431764b17623d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56dd31502d3d4194884bb9c9caf6d2ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c7defbef2a4e3b8612d7aba82bf5c3_I20221022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-22</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede14df2bae641aaae79e4148970642b_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7906fd4dea427ab980615c8e378f98_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e77f1a3cc942158bce2e26449d46fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24938975183a4055b12b952f44b451eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc28a960d044d118475b47b836ac7d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b5eb45d8444ba8ad4d24f039012736_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9971ae1d4d574f25af6bab80f8bcaf5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice05b8f807e4403893fdf7bd5fcacb5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib366e77f27444ed6a3e8856060b9bf21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78de6460b114c0bab0a7b968955449f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ac1ea0fa6641af836d8e80f2703fcb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:SelfPayPatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic549de21b71e42098463117277ec3417_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:SelfPayPatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e4506f61374f2e92951abf71b05057_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:SelfPayPatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied775d7b43794f9a9cfcd968393ab2cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CharityCarePatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b47f6e27bd4b2da194704a14b97d77_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CharityCarePatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25b38307f82433581aafb23c9f00d50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CharityCarePatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4166bca0f2b4df8b36ff5398d99c789_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cf6de3bc994080bc0ff271d5f1e7c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db4f9aeba2e456da8757c9a02d08c78_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c71cd81b16644ba893aa7255b08d6e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5123a758f7de455b8800a2a9ce940c2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a580d8694214bf884a09da9b2b1dbd8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4384be4a2dd447d87643cd3c2f0798d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e977fd989cb4d9390f31035ca2e4a2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b7db85097147a3877bb4389f2984a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib165a084700643e1b139d15df43a3b15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51529c7491145d285a730665f73c23d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b8ec068ae246cdbc6cfb42f8a12fc4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2366c9010b2e49cba43c03549f1d2ddf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c3e3d1b5bee4eeb8147e32baf77ae89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if536ced15ef94662b44301934aa1dae0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fabc80fff1241c29e2540d687490e0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a467f2558648978a9d48e2d2e603ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf46e0abc954d2a9519b9c790945c68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ad47d7e3c04f468af3c2713771b904_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4885c05ba74d4161a50b941fc56a1043_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afbba7a6c6f4934b189f3870051beac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e58b05cbc648e891cb8eb0308a9bd3_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9198bb96b0c34619839a103e26656c5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:UrgentCareCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b88533462e34354956300ca036d5a16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:PhiladelphiaBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2caa1d0849c540b493559deb02c5baae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c6f743bc7c41a9a1958950899659b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd5c058d4484de28c384ae0497a9cb0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i216cf3ae855e4607889370b5a9466471_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05fae90132d4c549fb7d1d0e2284c2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e348ef2f5949cfb83ccab43bf831b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:HospitalBuildingsAndMedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533053ff136948178e655a762abff3e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:BuildingsSubjectToImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194ea9513fe545cda7f1fc401e373fc3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9bab022f5344008a846ed40a785dfc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:GlobalBusinessCenterInTheRepublicOfPhilippinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87faa7579d7f4b91a4f182929ca4f1b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b84189bf5024247805cd0d9a5e0ea47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:GlobalBusinessCenterInTheRepublicOfPhilippinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ed061cd6934306b4066e74ce365959_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66efb75ed1542c3a0342c08477760c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:HospitalBuildingsAndMedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca9108158cb459d9c536f451843cd7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:BuildingsSubjectToImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f5b56532644469acafb2fdf2a8344a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22277913b4384752915cdfe34322cd7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:GlobalBusinessCenterInTheRepublicOfPhilippinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8169667563aa498e92398dfb1b02ac01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a09d299f6d4fce883b3595bf918a30_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622ee28e9f1e42d7aff972d73252f4c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae6361bfece4d29965dd05a7c7809e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a7e36b94de4011b826c46271390423_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4fb3c83283242f6bee137da54776fec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c821a80a1b41029dc25c50b51dfcea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8871456e17fc4ba49fffcdcb23ed7b71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i989bb5295fc74ba1aa10f7543aab0c09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b09f2c0b00a46fd93e77c46515311ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0da8add6a93946079dd9bfbe6ba2763c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57788fd689bc47bd813aec1a0ef11ee5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id060c1c1b2764c1bb2759e725cf12295_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde641ba54514fa09690f87fa89673d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697cb82b913848f2b26b5f92fc37e35e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461c58e253f64f09a6ac5dc3c2784b82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5404c8f217424e06babd62544ad4b7b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558c5a218dd0455d853b5f0e68d8b7c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afeea9e0df44876bc52904d8d7057fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17f96184b5f4ebd8db51025fe3377c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5599a9535d841a28d1c1e4b3ced46aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9b9cf6618c4aa6afd0b5bc92c8b85d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa72f8375f37499d86f928b68dff6f53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186d8e5c6032427baa46b10be1424d87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fba8ba8429243958c7942852541472e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0cb767709934643ac30a4e91dd1c63f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3540a60419084118bc740136b6cb62d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7488113b2f8a4008a0c1e41e64bbaa8d_D20210910-20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c0fd70eca44c388aba457549bc1bde_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95369c42fa7c411bb4958a0409bc9c80_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db931c86fe147d399a5218e8787b348_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5426987ed148420cbbfa4a0f0d7a191f_I20220615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8cce4fc2f848a2857f83e50a08eb16_I20220615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84fa693c2024155b0b1075bd91a66e2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8320d1db684d2e978228570390fbbc_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4c256aea654f0e81f827e0120eeca0_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774268ee073042e296346aebdcefdf00_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e3f3971b45492ebda95c4159ea5bed_I20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7daa6cd1b7be473ba7d7f3897a209175_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d2bb14dafb425e9e73ab20986d8aba_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216bb1419f01411cbe289ef91b5d9301_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74c040bcaea4ecfa1841b613ea39e5b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0319d75b304db7a61ce7e8160119f5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3bda72356c4c8a90a164544fdb3419_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58fa2d207abf4c7d930128ada13635f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1634d5e5c74227b8cb258fc3071474_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c9953574604a679693fb09557caf2c_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14f1fc180e441e2a02f1e6258051ea9_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied39b398e82143dbad504e93ddad6c70_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79724e46f9345fbb6283e854762c21b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbde1cbd711b43aab8f621cc2b3b071d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4470e4393114d6aa39323d7ec6f963f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d759b6ae6a43f7a40e0ef19d9f025e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339dc68a43b14d1cb043fb9d9e7bc4bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5976155b721e4588af99404df30450c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289e59d55e724f6d816c0df9b3f788d7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee7731e045f45ceb6027185e10efdf4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>thc:day</xbrli:measure></xbrli:unit><xbrli:context id="i807623c3e0804c008f81fdd3f1dfa3fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c60d6ea9404c3ab4509a64a435d111_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2bd835c2ea41418922c21a022a0229_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f604ea7a86499fbbfbc12bc96eb817_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f47cf0048e74feb8f6625b5de6e4a56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c8eda4b4d14ac49c4e91d6e7cb0cbc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:IncomeGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd7a9c8341e4fbb98014f10cc135b7a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:GuaranteeOfBusinessRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f0abb0a0e4a43e4bd6e824ef8f0e3b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:GuaranteeOfBusinessRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdd924a274f443fa92ca5c6423bdc2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:IncomeAndRevenueCollectionGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3bc6670142a4e808c1316df2aec4f4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:IncomeAndRevenueCollectionGuaranteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43dba714bb6f47bcba5217f722e33680_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:GuaranteedInvesteesOfThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0e89a0a42d34e7386bbd6bcb26e395d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:GuaranteedInvesteesOfThirdPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c4f60c37dd4423b655206fe804e2a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id54c892934f94ec9a1653dda6b70f552_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aefe441942b4b1b9964978feb391a61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:StockIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f70438f4b824837b203d53a4d4992cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b77940692a4f7db126c0242c3c5ac4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0107ed011a3a46fdb613b444b95af318_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a77c00b16741cd82fbfa2cd2e6aeef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c48ee9db11e4626a720073e3d52765c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8332ac81ea994fa080bd2c74aea55433_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c680273422d4752955e73ac5d10bd49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0038bf48844cf2b84aed399a6f80ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3031d28ff1b47d48f762be70d952bc5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa66aa2f15ca430daa47cd0bdc598c56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82dd3f9e68e54d33b184fd6660d2b3e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6525986e7cec4246bf79c66a19a22c42_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:CurrentEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5b8bc126dd41e49f8d133ce6a2f7e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:FormerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33f32827498430ea95e37c4de25591c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2c425940604ce3bb5200984c22a581_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0698fef50b441a8809d814d5874bd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9447e0acfdc8411fa545539e357b1624_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae413ceda20471eaa9654d788c7e9c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:ElevenQuarterVestingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="quarter"><xbrli:measure>thc:quarter</xbrli:measure></xbrli:unit><xbrli:context id="i5d49db19071d4e76af718a4ebfcd2551_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingFourYearFromGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica37af9eadb64144b4a83ab54b2eb4e1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc78025992d2498693e0cfe01b80263d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc06daccd6f4843bb75db0eba6fda8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd952e84dcc743b9af382bfd56d539a6_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonExecutiveChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792b9ba8d6434e31ba4998b638861429_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOverAThreeYearPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31c3d8b7cdb4518b73e55dc7378d317_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba5b2544884b47d884c4199111051b50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:EightQuarterVestingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9364d349beee475faa3c8ae75ca39b99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnFourthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f6dfe4070b40479c568783e37dbdb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82745fe1a5c149759ae2bb2ebd18c99f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingOneYearFromGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0e586f41214b669d46af8983e496a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:SeniorOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingOnFourthAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cb4a48480947cb934f8e6e7be5a3ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83afe2783741410d8c56a323ae90b6c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOverAThreeYearPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec7c07bedae422fb1e0fa272c435e3d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOnFourthAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d9270641be4b258d8e9d251500ed2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingAndSettledImmediatelyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ffe68638d7b4f33a12f20c24c63eaca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77704bd6df014d42ad1974f3065e00bb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddd4d4aa649e490fa03c3693ab1d3b6d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c513a239cd415cadbc7d515e826c84_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b782905e1e4e0eac9049059657f1b5_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i459d2687d88148ecb61b4fae2a62863b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dab5b2fbdc143c39fa76b787542f0df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:AdditionalProratedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ba779d997746cb97b06efbf30d887e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91ba56fa1e847e8a1c73049e8ae86f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:ElevenQuarterVestingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdc7d548925b41349d858624f9963b63_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingFourYearFromGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf51d35f981442c99167b2d957e6c469_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49aa4fd04a47497b9c081da63e6815a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40882d4788cd4504ab064fa6891d0693_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOverAThreeYearPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aafc61192254d9d93ce6bc583456021_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOnFourthAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf2066a73d3442da2799d558b87a606_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d78c92def194c19a4adbbb2259e22c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fc1015621a4924bfbb26ae78a46dad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3d6bba1c884c478022a01b2e6cb3bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a793f59564d4a279d849edac266ccd2_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e72837fb0e4ccaa451831a1f7d7152_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575d1fb3905042bda466ba37322c7021_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4992fa411a47474cb9b7e672161cc2b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2020USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87721822e7c147bfa5fc199473a92a04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29275879e7484df887acacaddf98d599_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8295862c62a64157b42db6f146e8c12d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc0d268ac814aaf82dd4c2c38f45afc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e7b2eaecfe4b418364da6c80616cdd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib640db27bdcd4bb98e4be184ed784de6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a0e4afed9c4d62a3cab9875677e71b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0a68e5520c4a67b603ea61aabf6d5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee76bd3ebc94aee84000b9861cc8925_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id872956450094631a6e69b7b3b22b116_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aeb8c24eb5e4d1fb3cc39f11508af94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c2a4e8b3584f25ba9995590bb44105_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f26d7b1bb2e411482df40eeb64c6fe2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a5b35347f794fff83ccb6182bcfaefe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60161593b56431198752c72b64076ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf31acec6aff4c96ae0465cc5661d7d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726bb4f7600248c880398c7ae29152c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b599704099d4411946c2b6a61490067_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d8fd82832242d3874ce46a1f5bda4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e2d35b46364527900ac62fe853f500_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ed17ca8f424eddbb76511ce975b7d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dea6f1094954116a3f68cf961f8ae89_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ced06d52d0948f2b33cd7c96c19ac99_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826c719c694345cbbd09a505858f05cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5f1bdfc3e69496d9d0b8fad4f514056_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>thc:plan</xbrli:measure></xbrli:unit><xbrli:context id="i3f46c6a3f87c4ea9a9fc91235eb3ce6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9911fb6980184642b2b91df127e81577_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e71186460e94813b374c45bf631f9e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1714de0eddf4a14b7a6a4d8e217cf42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8494255e124249a0a3eeafe8a1ec5580_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39222fbfc5de44bcbd66b5dd47d6c432_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7214f3a35494e78a472ea44db915760_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f659dcb43db4e5299ae2bd34817319b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a0335a3b4cd4570916a79350e8b8301_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8470639b4b74ccb87974669a576a9a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db9aaa63ebf4a2c9985af6bf21ba265_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b14503d12cd4ff1a8738f04383e21c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">thc:DefinedBenefitPlanAlternativeInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i804714da76e641858c08fb5432ea37ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a67fa33749c43db986a0beb057d4ac7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454a85da8698479a8e723e2cce4a6296_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6628865c9e54cb59a13c1563d995f42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a91a77e3d24e61a737e24af4f558eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8ac7ec5a3745248b611c964292857b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49284b149a704d88bdc9d6e996c457e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2b5e26a8054b03b96aa3a7fbeb79ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9ca9d71ea74bd0a7deec85ce36524a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e43f8ced2d426988a867fc0f0b14c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b87a25e42b480aac87219815bac866_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic93c45adbd6e4f78b04ad5d1b90243b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285ab10c7ac148e38a100d1ad2af2744_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia94c4bf4ebf248dc96407cf574d23a82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i166be3168d7f4ac7b806eb76ded856f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9280afba054c2f84e6e536996e9a74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f9676a3338438bbcb6a0fc6b10f019_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae60f4fa3854826b47d1a2b21ed0e58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5b28459d0dc443289dbd7f5a11180a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d79b4c21364b1e8d5b7aafdc463a8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2315eeff4c34c5b9d914e09c1031bdd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89da8ec516bc4c688a3f2e4138bd9130_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042c29b651e9422c9c3b8fc7734703e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f58b7435b945b38eab242b75e7de88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9461354d8d8d47dd881117ff98a3af8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c31677d6754a34bd494423b74a602e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2286f8106dae40a78e46d44361f52c75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9ea6ae06b14e35bad5e2ca1e409fde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af6470ab1cb4bff9fe84140822865d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if199fa14f8c442b6b5a44ca21380346d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f72100695fc4f70b93df4bc5ca16207_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1bdcec982d2405ab478007ab8e9cf72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cea09136b94497abde3744de16ffbb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d7173e0e014de1934a570e1112af04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5bb9664ade472286428ea8e0f32595_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2c8dfd6d53454598ef5cc59f8493f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6833358c1d6741f7a2f16c63211b57f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c06dc18705542b1b0f4578035465c35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d50cbc9ad614ba59c37a5e12995c52a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55523ac8a4c49a4b496cb9c6bc21731_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6551b57d1e4468b0725e4877eb3d2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if415ffa4ddcd4d20b4d45d7405511cef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4631c47e1f244bdd9e1c8d3c5f70454a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa63b9feebb74020bb298b5272d2cb91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686e590299944c6c873a2b143fb8bc32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800184fe85bb47b5a889821fbb17e7e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i585ae55410ba4bf0b908db0bc2194a89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea4687cc2d24bd4be9ac86b4b9f8bed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e833d841f1a420ba5b7b46bc27b98cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6531ba19db2c480e8abe335385484440_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc97a4820c542d4bf607e57b51505a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8cbfe439eef4938941ac808a39e48b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaadb2472f2014a5b80d77c42eb1bf932_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac9538659da4c918abe6bc8330da9fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54ea2398cb64048a475a0c8781dcff2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0650b7b45a99449c9af4ff648257c831_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8dd83765da4cd98415083bc755446e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016c96b25eea4c4e852f3cb7e72aedf8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2fd93f349c4e4c9ddc4ef367845986_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfbf92bb89634290b801e88029d92389_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b511b7a489f423484bdb8a101ff9a36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bb29332c7e349048cbb4839508b6add_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43e7382c8b743a7b9f53c2d06e8305a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca722478f4d4353be6a7b1b4eb2b7e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4086403e4e54685aed1e1243c892e5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c9ffc9de624831af0a297d262e7276_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if474534dcafd415d9534dbb0774b811e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476176f776be4198873c2255c05882ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694630452a604fb9ad2d2c6646397326_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8655e44515147ea8a7957f6e984603a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb013137715473a8be5f4a83d7293f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d0c6d3c86d49d0bae4aa0dd4b382e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0abd09d196974cba90b5e722e01a984c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e94e8fb0af4f14add5061334e930e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cce08bda3d542f198b8d18a883aec5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i865db5ff099a45238d86047cb5bf3f0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fbb8dc0a34648caadf9b08b028a9c30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedac06e53ae3427382872dc1d8f25c8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b58c9b298645b8821390d35d437e25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83eeaae00cd442549c9edcc2dc638e9e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib133b5b1591e4a4ea142acbda1961911_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bb12b1893946248b9ab7b6cb8bc7dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ff1d80e6bf43d59f82710f6d9d3b3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d397b0d9a54755805ebf13b24f0c3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48b6bbe6ee04e76973e637b31dbb932_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d591ea7d794a6bbfc70c45fa0ea665_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic533c479212f454fa40f5a81863983fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic480b7e478a9472e9d85fba3eb9c12f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc722d0c2684b039bc615d08fdc3ffb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c70f5ebc6e458cac8a2f6abf815c4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie964e8e69c1c4105a086707420629f2c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74f5e2d7ec046868cdc2f7fbd355aee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabec11c9436644b39b5f21992e4be853_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61aba57deafe4c6ba34e913edce4fa4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b470daff964cccbcf39b25959c3e24_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3950c1618554de69021cc2cc1a79848_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib396f0f65807418887a0c0af3e39a1e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceSelfpayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d6b8d0b42e425ba69ee9e7f0d7a8b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceSelfpayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9029942b52174f9f9c8908a424dc17c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceSelfpayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aeeeee831ed476884676b44fd6cfe29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceIndemnityAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14df2a1821346edbbccbb2de64905eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceIndemnityAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id127fd2a48b9468fb152d68215c3a4ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceIndemnityAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8650d876760f4a5db3ab633b09d01bc4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceExcludingPhysicianPracticesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide258a1d885e4c0f89deb490aea7e041_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceExcludingPhysicianPracticesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26398e525b5346e4b152c794c73a6fe5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceExcludingPhysicianPracticesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb3ce9661bd4d238e03107f7d28b516_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5ea9fc470eb4780a32a6b0b1b1a2a41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eff462dc0034c218f3464becc79363a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie464e81a78ca4b5bbc82e4f831a2f8fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6e909d5f7146e6b2f3799ec1c792e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fc34a3116b48039c40d17002cd0211_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ce7b2af81a45cebea65cf46c0e002e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e55bb2a3404d37ac0446903cd6f0ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4bd925e775946d38f284ce1b8382ffb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc1bcf836fb4be6bef17a04e3599061_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a76387d9429414d8b35662237a46f7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b36c3b506c460a83c8be8982727090_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1253b20e6f0b4e17802a597aa8a7b59f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia925e5b318a2405589428d1271dec1b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db4542a137447f59a1e7ac2c89d14d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530018987e3745d5abf91b8e5524fc98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b993383ef88460483182c2003d1d78f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1fb9caa7fb44fcbd2a4b49ddce2861_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0781fa826249423991780dca7297e0a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81914a8262974e3fbb3a025471f7eee8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54151a0b57be4cb78257f73d921ec0ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43649916a8a24c10835bd3035c29605c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareManagementFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fd6a31e00d4b11bd3304b198958511_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareManagementFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3991fafc3d4efdacdf716c9d96c74c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareManagementFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f3ed824e4544e3b60697a39097ec3c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareOtherSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43074c6c14b4410b81097a344a99a4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareOtherSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f1c997f82e4683bf9f1bfddca5dcbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareOtherSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8393dff26a4a4be89907f8a207404638_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323ccc8d9dff4644a7abebc08a38004c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i235f4a13d11d4df9becc252ef1dc9c7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ba16a76c64bd5ad24f4df995e560f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a93e729edc44dfbafaaf36efb815da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26388ca5abe346d88976ab4e56da4f3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c5cfbf30434593a6d78c97172bba64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c20159d864c4b41ba379ff416d148ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28537df01b624afa95022a135cf7d691_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24675d2632254bb2b6bc89b632413541_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f286017ca94e2bb6ddcf0fcc89ef42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4058f3d61484fcba0d030ec4ee43320_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7cd6c10c8c74700867918c05b8d066e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8235d44217a459cb42567e761b66f1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5607340778f848eeba9562ba40506527_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32381cae0dc40e8971f9588ae25f535_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe036fe195e4e7d9cf7c4783fa3b8d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8a661109d44f82ab8d85b5e23bfda3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09cf92dc60274d8584d52ce10bbca397_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibecd81c658874986bbada79239873a72_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:FloodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28407917ddcc4c2ea22b7337ab6cbb6f_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:EarthquakeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1758863eb749acbb352959ab071117_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:WindstormsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b5076fba4c4fdb855d3ab34e6a97b2_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:FireAndOtherPerilsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e926b75dbf3452ca4435e4d0c5a4087_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:FloodEarthquakeAndWindstormMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85b713fc7a9441c8397ecba316b3238_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:CaliforniaEarthquakeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76790a90cfa941e4bff3a5ae92dff3aa_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:FloodsAndWindstormsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6d901dd264433fbda22d0ff499fce6_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:NewMadridFaultEarthquakesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfc47e9f41b4cc8881d17b072c28e6d_D20220401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:OtherCatastrophicEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a5585dec099491a811760ed0c015749_D20220401-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946e83f23eab48c0977d5cc62313d926_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:InsuranceRecoveriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i929d5f3206d1415988b40ae29b248818_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:ProfessionalAndGeneralLiabilityReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a00e93147d34604be1c56fdcf1740bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:ProfessionalAndGeneralLiabilityReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bae571ac5a8443d9f4f6d6619c6e742_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce8af9e8c2243dab9e653703111fd49_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46385a1111194a8589fc66d33d240d12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99278a7c32f64fa0b070b36593467a59_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">thc:OtherMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6592cd4d757a46e2a3d6e589962ea2da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">thc:OtherMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia222bd0504b649a38f78d78bec2b6c91_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">thc:OtherMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe65d466f4f469d80f697fa5ae26073_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b3d4d738e04be3bf00f293d9edb4f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63f979e7be145bc9c86e0f440b39a75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2ea7fb5d834e519c54544ff665cc9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acbe1c3a707444594718d1fb713a4dd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b94c1f135f64a488e17326f4496bb5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5fa32817764caa8f2f7644c58ca52b_D20210101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73487c1fdc34b30b87fbe06f5951834_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4951aea584a14d4b873b83530d333b3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i082e53fec105442d97f902da195a0d31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea644fa13c540e892499ab2838c341d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0254fa58d5da4b66af614eec6e6b07a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d91a903a1a481fa20d8e476407ae20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a33773dbfe4b1c9e0db6630258d6d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e5bdf39f78442c999f04f849962c0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58845e096d6e4053baf993f0b5480e65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife847cb48ff64445b52e24dff42ab345_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016ade91fd494b2092c70d023aa6b142_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f311af9ca5b443ca38ce68247b5b1c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3ceb05ff4044a7c839c70944244e25e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie394bb97475d441db6f2d7fdbb59def8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b3f987c4664d6586d2dc3ce06561df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fe8572ea6c491aa3b643277fd661f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019176855e2e4e78a448696e0f58e777_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aaed855090043789ca397a60d4a8565_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedUrologyGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="surgery_center"><xbrli:measure>thc:surgery_center</xbrli:measure></xbrli:unit><xbrli:context id="id8d3a9179b7641f5bd9df2620d60173e_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedUrologyGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2022AcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a492066cbd4c4a85b96cb84a3068f3_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedUrologyGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2022AcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6616fd0402041209d851e0632005bb6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e686e617164f8788dbef7579035ca2_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58f6ac4316f4317ab753edc02419bea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="business"><xbrli:measure>thc:business</xbrli:measure></xbrli:unit><xbrli:context id="i7bc2ab83971e4498a02f300ccab65006_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2020SCDCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="surgical_center"><xbrli:measure>thc:surgical_center</xbrli:measure></xbrli:unit><xbrli:context id="ia66fc1c0750d4afda6c0d81b93a363b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2020SCDCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d5d769fdb2494fa847d0ee04defa5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i335893427cf548deb9b34f0425efb1a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d080dd82b644853b823fde9301748b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a110926660a4054af849fa472768d12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>thc:state</xbrli:measure></xbrli:unit><xbrli:context id="i201297e314ab451088f2cc2cd5577ad8_I20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="imaging_center"><xbrli:measure>thc:imaging_center</xbrli:measure></xbrli:unit><xbrli:context id="i1c476cd298284a1bafde8fdd47d49539_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86001c59573247b08eeb42c93d75f6f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e19c7717074970a71b4dccde90bc0b_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:UrgentCareCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18d9a3de8e841b08ffc82230780dc95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ceaf5394f94012b9da3e04b6ed796c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4376608b69a145f2998cf8f78326c6d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4247e435c1a48c9abfb49f3a445ea67_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6bdb8fda770486f97297332c7c0c2e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd670b142c346aba126a22c475f14a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa722f7986ca4c518e3bcdca37e64012_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb31be8d6de4e44a3f930dc03031843_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6544cc6587346acb00b26c710bc7751_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i133c13b23a124143877c18e0c045ff74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b95f4641f134e5c9fffaae2b5ca01e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000070318</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3872"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, DC&#160;20549</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:100%">Form&#160;<ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl80LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjMzN2E1Y2I3NDg5YjRkYzBiNTg3OGI1YTFmMDI5NmQ2XzEw_517d708d-5208-4055-8790-f5c8ef5dc243">10-K</ix:nonNumeric></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl82LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmUxYWQ0MDg3YTdjZDQwN2NiODk4ODFkMjNlOGE3ZTNjXzQ_31f6eb14-82c2-49d0-aca5-749d4889b1dd">&#253;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Annual report pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 for the fiscal year ended <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl82LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmUxYWQ0MDg3YTdjZDQwN2NiODk4ODFkMjNlOGE3ZTNjXzExOA_9d385f38-8552-4c69-956d-731d278eb3ee"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl82LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmUxYWQ0MDg3YTdjZDQwN2NiODk4ODFkMjNlOGE3ZTNjXzExOA_c19bd108-f921-4370-87e6-2f56f5e013e8">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl84LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmY4M2UwM2ZmMGRmMDQ4NjY4MTU2MmY4NDUzMGY2ZmQzXzU_ca7020bb-613c-4cdb-bbe5-493c3482cf3b">&#168;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Transition report pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commission File Number <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo2ZWVjZWNlNDU5Y2E0NGM4YTgzOWRiNzY4MjUwNmZlZF8yOA_b6cfa303-2ff4-4da1-ad37-ea31bcaf2860">1-7293</ix:nonNumeric></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:95%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xMy0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjpjY2IwNjIzNGI3YmY0Nzc5YjA4YjIzNGJhMzg5Y2E0MF81_600c9cb7-748b-4ea0-8a7b-32d548dbc90d">TENET HEALTHCARE CORP</ix:nonNumeric>ORATION</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of Registrant as specified in its charter)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xNi0xLTEtMS0zMDQ4MTc_ce0dd766-a127-41f1-bac8-5e9e86806ee3">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xNi01LTEtMS0zMDQ4MTk_c667cd8a-e495-4bee-8d05-10cd00e53505">95-2557091</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xOS0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo1NjkyZDFlZWE5MGI0ZTkwYWY4OTUwNTEwZGZlMDdmNl81_004f1891-aa7e-4aed-8813-f8f171b87fe6">14201 Dallas Parkway</ix:nonNumeric> </span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo3MjAwN2I1YTI1MTg0NjU4YTUyOGYxZWZiYWYxNGQ5Yl81_ed2bf061-65da-4977-a46b-2625aa1db030">Dallas</ix:nonNumeric>, <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo3MjAwN2I1YTI1MTg0NjU4YTUyOGYxZWZiYWYxNGQ5Yl85_db894590-3641-45e7-8966-b0d2bd844fea">TX</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo3MjAwN2I1YTI1MTg0NjU4YTUyOGYxZWZiYWYxNGQ5Yl8xMw_be549490-886a-444d-9739-ce1b9539d174">75254</ix:nonNumeric> </span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMy0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjpkNmI4ZTA2YTZiMGU0OTJhOGMxNDczMjk0Nzk1NGZjYl82_ddfc7706-fa5f-4e20-aa9e-a0fa5e542e67">469</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMy0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjpkNmI4ZTA2YTZiMGU0OTJhOGMxNDczMjk0Nzk1NGZjYl8xMA_ac35b66b-4580-42f7-852d-b164f146244f">893-2200</ix:nonNumeric> </span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.859%"><tr><td style="width:1.0%"></td><td style="width:3.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18xLTEtMS0xLTMwNDgyMQ_426522df-1a6d-48e6-b75f-d000641f1a50">Common stock, $0.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18xLTMtMS0xLTMwNDgyNQ_d7ed16e9-b14c-4185-80e3-3915e7f6ad86">THC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18xLTUtMS0xLTMwNDgyNQ_1bca8b05-9aa5-451c-a616-5c24d8dd8937">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18yLTEtMS0xLTMwNDgyNw_adffa69b-96a9-4f2c-9fb5-8b666f0998cf">6.875% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18yLTMtMS0xLTMwNDgzMA_db621103-48d8-4fdd-b2f4-8621323e72ad">THC31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18yLTUtMS0xLTMwNDgzMg_23c8829f-55f0-482a-89ae-d742449458bf">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> None</span></div></td></tr><tr style="height:6pt"><td colspan="24" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN18zLTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmM1Nzg1M2I2ZTYwMDRjOWRiNWExYzMxMzI2ZmQzNmZlXzEyNQ_782ae3e9-1cb6-4755-b6f0-96a6db6512d4">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN181LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjcyNDM0YmQ5MThlNTRhZjBhZWUzYmEzNDIyNTg2ZmI1XzE0NQ_4ef27d4c-de19-4952-8f88-429b91ebcb41">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#253;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Exchange Act during the preceding 12&#160;months, and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN183LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmViMDUzNTFkYWZlNTQ5NDY4NmIzN2JiODc5ODQ0NjljXzI0OA_77c683bd-ce84-453f-a431-486a49adb0fc">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#168;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T during the preceding 12 months. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN185LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmM4NmYzYjQ2YTMyYjQzYTI5ZGZiZGNlOTczOWE3YTU4XzIwNA_792ac5c0-3970-439b-81e3-a223ae1bf898">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#168;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company (each as defined in Exchange Act Rule&#160;12b-2).</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.537%"><tr><td style="width:1.0%"></td><td style="width:24.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6ZTdjMDJmNzY1ODg5NDI4NWExYjI2ODViYzI2YzAyMjIvdGFibGVyYW5nZTplN2MwMmY3NjU4ODk0Mjg1YTFiMjY4NWJjMjZjMDIyMl8wLTAtMS0xLTM2NTM3NS90ZXh0cmVnaW9uOjhkZjBjMDljNmM0MDQ0YmY5Mzk5YzhhYmEwZDU3N2Y2XzU_c05fe4b1-3a66-43e3-af1d-23044d4c4ee3">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#253;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#168;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div style="margin-bottom:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.537%"><tr><td style="width:1.0%"></td><td style="width:19.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6ODdhMDIxOWMzMWRiNDJjMjhjNjM5YmRkZTU4ZWVkZjUvdGFibGVyYW5nZTo4N2EwMjE5YzMxZGI0MmMyOGM2MzliZGRlNThlZWRmNV8wLTEtMS0xLTM2NTM4Mi90ZXh0cmVnaW9uOjk3NTAyMGI4MDBhNDQ3NTU4ZmY3ZmQ4MGM1YTU2YTY4XzMx_fd6b7938-a910-4214-82f1-708652adb5bc">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6ODdhMDIxOWMzMWRiNDJjMjhjNjM5YmRkZTU4ZWVkZjUvdGFibGVyYW5nZTo4N2EwMjE5YzMxZGI0MmMyOGM2MzliZGRlNThlZWRmNV8wLTMtMS0xLTM2NTM4Mi90ZXh0cmVnaW9uOjA4YjgzZjE0M2UxZjQxYTdiNTE0ODNjZTMzYTUwOWJhXzI5_a9acc481-a34c-4868-918b-8895e3730a11">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#168;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M18yLTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjJmY2E0ZTg2NDBiODQ2Yzg5NWFjNmEyNzM3YTAyNGZlXzM0MA_ecc65ccb-115b-4b9a-81da-3e546afb7108">&#253;</ix:nonNumeric></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">If securities are registered pursuant to Section 12(b) of the Exchange Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#168;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#168;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule&#160;12b-2). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M180LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjBhMjA5MWUzNTQ2ZDRlNDJhZWM2OTg0NzI4ZWVlNmZjXzExNQ_249786c0-e798-4fff-80c7-2502f732221e">&#168;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#253;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">As of June&#160;30, 2022, the aggregate market value of the shares of common stock held by non-affiliates of the Registrant (treating directors, executive officers who were SEC&#160;reporting persons, and holders of 10% or more of the common stock outstanding as of that date, for this purpose, as affiliates) was approximately $<ix:nonFraction unitRef="usd" contextRef="if3cddf06bd574be2ad2b6db4f6c58e08_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M182LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjc4MWJjOTk1NGI4MjQ1Mzk5YzBhMTA3ZTI4NmJmNWNkXzMyMg_3c23f456-9605-4c7a-9578-3ab9860e35f5">5.6</ix:nonFraction> billion based on the closing price of the Registrant&#8217;s shares on the New York Stock Exchange on that day. As of January&#160;31,&#160;2023, there were <ix:nonFraction unitRef="shares" contextRef="i466f81b830d4456980895fd2849bc045_I20230131" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M182LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjc4MWJjOTk1NGI4MjQ1Mzk5YzBhMTA3ZTI4NmJmNWNkXzQ1OA_c2acd828-95f4-4e8b-9ddf-107463c2e928">102,274,102</ix:nonFraction> shares of common stock outstanding.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M18xMC0wLTEtMS0zMDQ4NTM_b6eb5070-c68c-47a6-b968-067d89f0c916" escape="true">Portions of the Registrant&#8217;s definitive proxy statement for the 2023 annual meeting of shareholders are incorporated by reference into Part&#160;III of this Form&#160;10-K.</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_13">PART I&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_16">Item 1.&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_19">Item 1A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_19">17</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_22">Item 1B.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_22">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_25">Item 2.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_25">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_25">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_28">Item 3.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_28">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_31">Item 4.&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_31">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_34">PART II</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_37">Item 5.&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_37">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_40">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_40">Reserved</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_40">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_43">Item 7.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_43">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_151">Item 7A.&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_151">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_151">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_154">Item 8.&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_154">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_154">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_166">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_169">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_184">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_184">88</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_292">Item 9.&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_292">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_292">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_295">Item 9A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_295">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_295">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_298">Item 9B.&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_298">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_298">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_301">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_301">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_301">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_304">PART III</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_307">Item 10.&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_307">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_307">132</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_310">Item 11.&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_310">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_310">132</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_313">Item 12.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_313">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_313">132</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_316">Item 13.&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_316">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_316">132</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_319">Item 14.&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_319">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_319">132</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_322">PART IV</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_325">Item 15.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_325">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_325">133</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_343">Item 16.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_343">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_343">139</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_346">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_346">140</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_16"></div><div style="margin-bottom:6pt;margin-top:6pt"><span id="ia6d50f2767de41d99fd313bb61a20287_189054"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span id="ia6d50f2767de41d99fd313bb61a20287_189055"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenet Healthcare Corporation (&#8220;Tenet&#8221;) is a diversified healthcare services company with its headquarters in Dallas, Texas, and a Global Business Center (&#8220;GBC&#8221;) in Manila, Philippines. We operate our expansive, nationwide care delivery network through direct and indirect subsidiaries, including USPI Holding Company, Inc. (&#8220;USPI&#8221;), as well as downstream partnerships and joint ventures; the terms &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us,&#8221; as used in this report and unless otherwise stated or indicated by the context, refer to Tenet and these entities. At December&#160;31,&#160;2022, we operated 61&#160;acute care and specialty hospitals, as well as over 575 other healthcare facilities, including surgical hospitals, ambulatory surgery centers (each, an &#8220;ASC&#8221;), imaging centers, off-campus emergency departments (each, an &#8220;ED&#8221;) and micro&#8209;hospitals. In addition, we operate Conifer Health Solutions, LLC (&#8220;Conifer JV&#8221;), a joint venture that provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients. For financial reporting purposes, our business lines are classified into three separate reportable operating segments &#8211; Hospital Operations and other (&#8220;Hospital Operations&#8221;), Ambulatory Care and Conifer. Additional information about our operating segments is provided below; statistical data for the segments can be found in Item&#160;7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, of Part II of this report (&#8220;MD&amp;A&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the public health and economic effects of the COVID&#8209;19 pandemic continued to adversely impact our operating segments, as well as our patients, communities and employees, to varying degrees. Throughout MD&amp;A, we have: (1)&#160;provided additional information on the effects the pandemic has had on our results of operations; (2)&#160;disclosed the various actions we have taken, and are continuing to take, to increase our liquidity and mitigate the impact of reductions in our patient volumes and changes in our service mix and revenue mix; and (3)&#160;described various legislative actions that have alleviated some of the adverse financial impacts of the pandemic on our business. The ultimate extent and scope of the pandemic and the future effects it may have on us remain unknown. For information about risks and uncertainties related to COVID&#8209;19 that could affect our business, financial condition, results of operations and cash flows, we refer you to the Risk Factors section below.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3076"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPERATIONS</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3309"></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HOSPITAL OPERATIONS SEGMENT</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospitals, Ancillary Outpatient Facilities and Related Businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In 2022, we continued to make investments across our Hospital Operations segment to offer more convenient access to higher&#8209;demand and higher&#8209;acuity clinical service lines in the communities we serve. In September 2022, we opened a new acute care hospital, Piedmont Medical Center Fort Mill, in South&#160;Carolina; this newly constructed 100&#8209;bed facility includes an emergency department, multi&#8209;specialty operating rooms, an intensive care unit, and labor and delivery rooms. We also sold or closed three outpatient centers and exited some service lines at individual facilities in 2022, in each case because we believe they are no longer a core part of our long&#8209;term growth and synergy strategies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our subsidiaries operated 61 hospitals serving primarily urban and suburban communities in nine states. Our subsidiaries had sole ownership of 53 of these hospitals, six were owned or leased by entities that are majority owned by a Tenet subsidiary, and two were owned by third parties and leased by our wholly owned subsidiaries. Our Hospital Operations segment also included 109 outpatient centers at December&#160;31,&#160;2022, the majority of which are provider&#8209;based and freestanding imaging centers, off&#8209;campus hospital EDs and micro&#8209;hospitals, and provider&#8209;based ASCs. In addition, at December&#160;31,&#160;2022, our subsidiaries owned or leased and operated: a number of medical office buildings, all of which were located on, or nearby, our hospital campuses; over 750 physician practices with a network of employed physicians; several accountable care organizations and clinically integrated networks; and other ancillary healthcare businesses.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our general hospitals offers acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories and pharmacies; in addition, most have: intensive care, critical care and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal and obstetrics services; and outpatient services, including physical therapy. Many of our hospitals provide tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care and neurosurgery, and some also offer quaternary care in areas such as heart and kidney transplants. Moreover, a number of our hospitals offer advanced treatment options for patients, including limb&#8209;salvaging vascular procedures, acute level&#160;1 trauma services, comprehensive intravascular stroke care, minimally invasive cardiac valve replacement, cutting&#8209;edge imaging technology, and telemedicine access for select medical specialties. All of the hospitals in our Hospital Operations segment are licensed under appropriate state laws, and each is accredited by The Joint Commission. With such accreditation, our hospitals are deemed to meet the Medicare Conditions of Participation and Conditions for Coverage, and they are eligible to participate Medicare, Medicaid and other government&#8209;sponsored provider programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span id="i891b087598464b7eba8b86d06657b56d_201827"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists, by state, the hospitals wholly owned, operated as part of a joint venture, or leased and operated by our wholly owned subsidiaries at December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Licensed<br/>Beds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alabama</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brookwood Baptist Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Homewood</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JV/Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Citizens Baptist Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Talladega </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JV/Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Princeton Baptist Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Birmingham </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JV/Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelby Baptist Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Alabaster </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JV/Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walker Baptist Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Jasper </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JV/Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Arizona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abrazo Arizona Heart Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abrazo Arrowhead Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glendale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abrazo Central Campus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abrazo Scottsdale Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abrazo West Campus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodyear</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holy Cross Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nogales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Joseph&#8217;s Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tucson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Mary&#8217;s Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tucson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Desert Regional Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Palm Springs </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doctors Hospital of Manteca</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Manteca </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doctors Medical Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Modesto </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emanuel Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Turlock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fountain Valley Regional Hospital and Medical Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Fountain Valley </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hi-Desert Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Joshua Tree </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Kennedy Memorial Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Indio </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lakewood Regional Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Lakewood </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Los Alamitos Medical Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Los Alamitos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placentia Linda Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Placentia </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Ramon Regional Medical Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Ramon </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JV/Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenet Health Central Coast Sierra Vista Regional Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Luis Obispo </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenet Health Central Coast Twin Cities Community Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Templeton </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delray Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Delray Beach </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Good Samaritan Medical Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;West Palm Beach </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palm Beach Gardens Medical Center</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Palm Beach Gardens </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Mary&#8217;s Medical Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;West Palm Beach </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Boca Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Boca Raton </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MetroWest Medical Center &#8211; Framingham Union Campus</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Framingham</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MetroWest Medical Center &#8211; Leonard Morse Campus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natick</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Vincent Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worcester</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Licensed<br/>Beds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michigan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Children&#8217;s Hospital of Michigan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Detroit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detroit Receiving Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Detroit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harper University Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Detroit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huron Valley-Sinai Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Commerce Township </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hutzel Women&#8217;s Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Detroit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Institute of Michigan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Detroit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sinai-Grace Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Detroit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coastal Carolina Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Hardeeville</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Cooper Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Mount Pleasant </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hilton Head Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Hilton Head Island</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piedmont Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Rock Hill </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piedmont Medical Center Fort Mill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Fort Mill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tennessee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Francis Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Memphis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Francis Hospital &#8211; Bartlett</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bartlett</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Texas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baptist Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Antonio </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Hospitals of Providence East Campus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;El Paso </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Hospitals of Providence Memorial Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;El Paso </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Hospitals of Providence Sierra Campus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;El Paso </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Hospitals of Providence Transmountain Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;El Paso </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mission Trail Baptist Hospital</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Antonio </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nacogdoches Medical Center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nacogdoches </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Central Baptist Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Antonio </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Northeast Baptist Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Antonio </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resolute Health Hospital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;New Braunfels </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Luke&#8217;s Baptist Hospital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;San Antonio </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valley Baptist Medical Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Harlingen </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valley Baptist Medical Center &#8211; Brownsville</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Brownsville </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Owned </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Licensed Beds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Operated by a limited liability company formed as part of a joint venture with Baptist Health System, Inc. (&#8220;BHS&#8221;), a not&#8209;for&#8209;profit health system in Alabama; a Tenet subsidiary owned a 70% interest in the entity at December&#160;31,&#160;2022, and BHS owned a 30%&#160;interest.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In order to receive certain tax benefits for these hospitals, which were operated as nonprofit hospitals prior to our joint venture with BHS, we have entered into arrangements with the City of Talladega, the City of Birmingham, the City of Alabaster and the City of Jasper such that a Medical Clinic Board owns each of these hospitals, and the hospitals are leased to our joint venture entity. These capital leases expire between November&#160;2025 and September&#160;2036, but contain two optional renewal terms of 10 years each.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Specialty hospital.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Designated by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) as a critical access hospital.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Lease expires in May 2027.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Lease expires in July 2045.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Owned by a limited liability company formed as part of a joint venture with John Muir Health (&#8220;JMH&#8221;), a not&#8209;for&#8209;profit health system in the San&#160;Francisco&#160;Bay area; a Tenet subsidiary owned a 51% interest in the entity at December&#160;31,&#160;2022, and JMH owned a 49% interest. In January&#160;2023, we entered into a definitive agreement whereby JMH will acquire sole ownership of the hospital before the end of the year, subject to regulatory approvals and customary closing conditions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the utilization of licensed beds and other operating statistics at December&#160;31,&#160;2022 and 2021 can be found in MD&amp;A.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our Hospital Operations segment also included 42 imaging centers, 14 off&#8209;campus EDs and 10&#160;ASCs, all of which are operated as departments of our hospitals and under the same license, as well as 43 separately licensed, freestanding outpatient centers &#8211; typically at locations complementary to our hospitals &#8211; consisting of 25 imaging centers, 14 emergency facilities (13 of which are licensed as micro&#8209;hospitals), two ASCs and two urgent care centers. Approximately half of the outpatient centers in our Hospital Operations segment at December&#160;31,&#160;2022 were in Texas and California, the same states where we had the largest concentrations of licensed hospital beds. Strong concentrations of hospital beds and outpatient centers within operating areas may help us contract more successfully with managed care payers, reduce management, marketing and other expenses, and more efficiently utilize resources. However, these concentrations increase the risk that, should any adverse economic, regulatory, environmental, competitive or other condition (including surges of COVID&#8209;19 or other illnesses) occur in these areas, our overall business, financial condition, results of operations or cash flows could be materially adversely affected.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accountable Care Organizations and Clinically Integrated Networks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We own, control or operate one accountable care organization (&#8220;ACO&#8221;) and three clinically integrated networks (each, a &#8220;CIN&#8221;) &#8211; in Alabama, Arizona, Massachusetts and Texas &#8211; and participate in an additional ACO and an additional CIN with other healthcare providers for select operating areas in Arizona. An ACO is a group of providers and suppliers that work together to redesign delivery processes in an effort to achieve high&#8209;quality and efficient provision of services under contract with CMS. ACOs that achieve quality performance standards established by the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) are eligible to share in a portion of the amounts saved by the Medicare program. A CIN coordinates the healthcare needs of the communities served by its network of providers with the purpose of improving the quality and efficiency of healthcare services through collaborative programs, including contracts with managed care payers that create a high degree of interdependence and cooperation among the network providers. Because they promote accountability and coordination of care, ACOs and CINs are intended to produce savings as a result of improved quality and operational efficiencies.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3337"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMBULATORY CARE SEGMENT</span></div><div style="margin-bottom:4pt;text-indent:36pt"><span id="i2b44bc4753a54ea792030552b7fa7446_204237"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, USPI held indirect ownership interests in 442 ASCs and 24 surgical hospitals in 35 states.</span></div><div style="text-align:center;text-indent:36pt"><img src="thc-20221231_g1.jpg" alt="thc-20221231_g1.jpg" style="height:352px;margin-bottom:5pt;vertical-align:text-bottom;width:585px"/></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPI&#8217;s facilities offer a range of procedures and service lines, including, among other specialties: orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; pain management; otolaryngology (ear, nose and throat); gastroenterology; ophthalmology; and urology. At the beginning of 2022, we owned approximately 95% of USPI, and Baylor&#160;University Medical Center (&#8220;Baylor&#8221;) owned approximately 5%. Effective June&#160;30,&#160;2022, we purchased all of the shares in USPI that Baylor held on that date, which increased our ownership interest in USPI&#8217;s voting shares from 95% to 100%.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe USPI&#8217;s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in surgical techniques, medical technology and anesthesia, as well as the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in the outpatient setting will continue to increase over time. For these reasons, we remain focused on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. In July&#160;2022, USPI formed a joint venture with United Urology Group (&#8220;UUG&#8221;) and acquired ownership interests in 22 ASCs (three of which were then in development). Including the UUG centers, during the year ended December&#160;31,&#160;2022, we added over 35&#160;ASCs to our portfolio through acquisitions of majority and minority ownership interests, and we opened 15 new (or de novo) ASCs. Also during 2022, we increased our ownership interests in over 20 ASCs, which allowed us to consolidate their financial results. In addition, we are taking steps to grow our Ambulatory Care segment business by replacing high-volume, low&#8209;acuity services lines with service lines involving higher acuity cases. To that end, we closed or sold our ownership interests in a small number of centers that we believe are no longer part of our long-term growth strategy.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to have an ownership interest in and operate 575 to 600 ASCs by the end of 2025. In December&#160;2021, USPI and principals of Surgical Center Development (&#8220;SCD&#8221;) entered into a joint venture and development agreement under which USPI will have the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50 de novo ASCs through December&#160;2026. We believe that this arrangement will enable us to continue to sharpen our focus on the growth and expansion of ambulatory surgical services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operations of USPI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;USPI acquires and develops its facilities primarily through the formation of joint ventures with physicians and health systems. USPI&#8217;s subsidiaries hold ownership interests in the facilities directly or indirectly and operate the majority of its facilities on a day&#8209;to&#8209;day basis through management services contracts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate USPI&#8217;s facilities, structure our joint ventures, and adopt staffing, scheduling, and clinical systems and protocols with the goal of increasing physician productivity. We believe that this focus on physician satisfaction, combined with providing high&#8209;quality healthcare in a friendly and convenient environment for patients, will continue to increase the number of procedures performed at our facilities over time. Our joint ventures also enable health systems to offer patients, physicians and payers the cost advantages, convenience and other benefits of ambulatory care in a freestanding facility and, in certain areas, establish networks needed to manage the full continuum of care for a defined population. Further, these relationships allow the health systems to focus their attention and resources on their core businesses without the challenge of acquiring, developing and operating ancillary facilities.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3364"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONIFER SEGMENT</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly all of the services comprising the operations of our Conifer segment are provided by our Conifer JV or one of its direct or indirect wholly owned subsidiaries. At December&#160;31,&#160;2022, our Conifer Holdings, Inc. subsidiary (&#8220;Conifer Holdings&#8221;) owned 76.2% of the Conifer JV, and Catholic Health Initiatives (&#8220;CHI&#8221;) had a 23.8% ownership position. (As a result of its 2019 merger with Dignity Health, CHI is now a part of CommonSpirit Health.) The term &#8220;Conifer,&#8221; as used in Part&#160;I of this report and unless otherwise stated or indicated by the context, refers to Conifer Holdings, our Conifer JV, and their direct or indirect wholly owned subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Conifer provides comprehensive end&#8209;to&#8209;end and focused&#8209;point business process services, including hospital and physician revenue cycle management, patient communications and engagement support, and value&#8209;based care solutions, to hospitals, health systems, physician practices, employers and other clients.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer&#8217;s revenue cycle management solutions consist of: (1)&#160;patient services, including: centralized insurance and benefit verification; financial clearance, pre&#8209;certification, registration and check&#8209;in services; and financial counseling services, including reviews of eligibility for government healthcare or financial assistance programs, for both insured and uninsured patients, as well as qualified health plan coverage; (2)&#160;clinical revenue integrity solutions, including: clinical admission reviews; coding; clinical documentation improvement; coding compliance audits; charge description master management; and health information services; and (3)&#160;accounts receivable management solutions, including: third&#8209;party billing and collections; denials management; and patient collections. All of these solutions, which aim to assist clients in improving their cash flow, revenue, and physician and patient satisfaction, include ongoing measurement and monitoring of key revenue cycle metrics, as well as productivity and quality improvement programs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Conifer offers customized communications and engagement solutions to optimize the relationship between providers and patients. Conifer&#8217;s trained customer service representatives provide direct, 24&#8209;hour, multilingual support for (1)&#160;physician referral requests, calls regarding maternity services and other patient inquiries, (2)&#160;community education and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outreach, and (3)&#160;scheduling and appointment reminders. Conifer coordinates and implements marketing outreach programs, as well, to keep patients informed of screenings, seminars, and other events and services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer also offers value&#8209;based care solutions, including clinical integration, financial risk management and population health management, all of which aim to assist clients in improving the cost and quality of their healthcare delivery, as well as their patient outcomes. Conifer helps clients build CINs that provide predictive analytics and quality measures across the care continuum. In addition, Conifer facilitates the alignment and management of financial incentives among healthcare stakeholders through risk modeling and administration of various payment models. Furthermore, Conifer offers clients tools and analytics to improve quality of care and provide care management services for patients with chronic diseases by identifying high&#8209;risk patients, coordinating with patients and clinicians in managing care, and monitoring clinical outcomes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, Conifer provided one or more of the business process services described above to approximately 660 Tenet and non&#8209;Tenet hospital and other clients nationwide. Tenet and CHI facilities represented approximately 44% of these clients, and the remainder were unaffiliated health systems, hospitals, physician practices, self&#8209;insured organizations, health plans and other entities. We believe the pricing terms for the services Conifer provides to our facilities are commercially reasonable and consistent with estimated third-party terms. Conifer&#8217;s agreement with CHI to provide patient access, revenue integrity, accounts receivable management and patient financial services to CHI&#8217;s facilities expires on December 31, 2032. For the year ended December&#160;31,&#160;2022, approximately 34% of Conifer&#8217;s net operating revenues were attributable to its relationship with Tenet and approximately 46% were attributable to its relationship with CHI.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3391"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REAL PROPERTY</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The locations of our acute care and specialty hospitals and the number of licensed beds at each at December&#160;31,&#160;2022 are set forth in the table beginning on page <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i891b087598464b7eba8b86d06657b56d_201827">2</a>. The locations of USPI&#8217;s surgical hospitals and ASCs are reflected on the map on page <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2b44bc4753a54ea792030552b7fa7446_204237">4</a>. We lease the majority of our outpatient facilities in both our Hospital Operations segment and our Ambulatory Care segment. These leases typically have initial terms ranging from five to 10 years, and most of the leases contain options to extend the lease periods. Our subsidiaries also operate a number of medical office buildings, all of which are located on, or nearby, our hospital campuses. We own many of these medical office buildings; the remainder are owned by third parties and leased by our subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically lease our office space under operating lease agreements. Our corporate headquarters are located in Dallas, Texas. In addition, we maintain administrative offices in regions where we operate hospitals and other businesses, as well as our GBC in Manila. We believe that all of our properties are suitable for their respective uses and are, in general, adequate for our present needs.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3419"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PHYSICIANS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations depend in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who are members of the medical staffs of our hospitals and other facilities, as well as physicians who affiliate with us and use our facilities as an extension of their practices. Under state laws and other licensing standards, medical staffs are generally self&#8209;governing organizations subject to ultimate oversight by the facility&#8217;s local governing board. Members of the medical staffs of our facilities also often serve on the medical staffs of facilities we do not operate, and they are free to terminate their association with our facilities or admit their patients to competing facilities at any time. It is essential to our ongoing business and clinical program development that we attract an appropriate number of quality physicians in the specialties required to support our services and that we maintain good relations with those physicians.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have no contractual relationship with most of the physicians who practice at our hospitals and outpatient centers, at December&#160;31,&#160;2022, we owned over 750 physician practices, and our subsidiaries employed (where permitted by state law) or otherwise affiliated with over 1,450 physicians. Our ability to employ physicians is closely regulated, with a number of states prohibiting the corporate practice of medicine or otherwise regulating what types of entities may employ physicians, and we structure our arrangements with healthcare providers to comply with these state laws.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we continued to experience challenges in recruiting and retaining physicians. In some of the regions in which we operate, physician recruitment and retention are affected by a shortage of qualified physicians in certain higher-demand clinical service lines and specialties. Moreover, we continue to refine our physician base and provider programs to focus on experienced, high-quality and collaborative specialists.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EMPLOYEES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe each employee across our network has a role integral to our mission, which is to provide quality, compassionate care in the communities we serve. At December&#160;31,&#160;2022, we employed approximately 102,400 people (of which approximately 26% were part&#8209;time employees) in our three operating segments, as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, the employee headcount in our Hospital Operations segment remained substantially consistent with December&#160;31, 2021. Year over year, the headcount in our Ambulatory Care segment increased approximately 6%, partially due to our acquisition activity, and the headcount in our Conifer segment increased approximately 8% to support our continued growth and facilitate the transition of various administrative functions to our GBC. At December&#160;31,&#160;2022, we had employees in all 50&#160;U.S. states and the District of Columbia, as well as nearly 3,000 employees providing support across our entire network at our GBC. Approximately 32% of our employees are nurses.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board Oversight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our board of directors and its committees oversee human capital matters through regular reports from management and advisors. The board&#8217;s human resources committee (&#8220;HR Committee&#8221;) is responsible for establishing general compensation policies that (1)&#160;support our overall business strategies and objectives, (2)&#160;enhance our efforts to attract and retain skilled employees, (3)&#160;link compensation with our business objectives and organizational performance, and (4)&#160;provide competitive compensation opportunities for key executives. The HR Committee also provides, among other things, its perspectives regarding performance management, succession planning, leadership development, diversity, recruiting, retention and employee training. The board&#8217;s environmental, social and governance (&#8220;ESG&#8221;) committee, which was formed in 2021, provides oversight with respect to our ESG strategy and guidance on ESG matters that are relevant to our business.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESG Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Additional information regarding our approach to and progress in connection with ESG matters can be found in our most recent ESG Report, which is available on our website. The information found on our website, including the information in our ESG Reports, is not incorporated by reference into nor part of this or any other report or document we file with or furnish to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Resources Practices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We have established &#8211; and continue to enhance and refine &#8211; a comprehensive set of practices for recruiting, managing and optimizing the human resources of our organization. In many cases, we utilize objective benchmarking and other tools in our efforts in such areas as organizational effectiveness, engagement, voluntary turnover and staffing efficiencies.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits; Culture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In general, we seek to attract, develop and retain an engaged workforce, cultivate a high&#8209;performance culture that embraces data&#8209;driven decision&#8209;making, and improve talent management processes to promote diversity and inclusion. To that end, we offer:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a competitive range of compensation and benefit programs designed to reward performance and promote well&#8209;being, including an employee stock purchase plan, a 401(k) plan, health care and insurance benefits, health&#160;savings and flexible spending accounts, and paid time off;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">opportunities for continuing education and advancement through a broad range of clinical training and leadership development experiences, including in&#8209;person and online courses and mentoring opportunities;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a supportive, inclusive and patient&#8209;centered culture aligned with our values and based on respect for others;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">company&#8209;sponsored efforts encouraging and recognizing volunteerism and community service; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a code of conduct that promotes integrity, accountability and transparency, among other high ethical standards.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Safety and Welfare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We believe our employees comprise a community built on care, and we place a high priority on maintaining a secure and healthy workplace for them. We promote a culture of safety and reporting by connecting employee safety policies with patient safety policies, and we review and refine the policies regularly. At our hospitals, outpatient facilities, and other care sites, we align staffing to need in our nursing units, and we invest in appropriate training to improve the competency of our caregivers. In addition, we have heightened infection-prevention protocols, we maintain consistent availability of personal protective equipment and disinfection supplies, and we regularly provide concise and current infection prevention guidance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer resources to help employees manage challenging circumstances, including a comprehensive employee assistance program comprised of counseling services, financial guidance and legal aid. The Tenet Care Fund (the &#8220;Care Fund&#8221;) is a 501(c)(3) public charity that provides financial assistance to our employees who have experienced hardship due to, among other things, fires, natural disasters, catastrophic injuries and extended illnesses. The Care Fund is funded primarily by our employees for our employees.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We continue to focus on the hiring, advancement and retention of underrepresented populations to further our objective of fostering an engaging culture with a workforce and leadership teams that represent the communities we serve. As of December&#160;31,&#160;2022, our total workforce was approximately 78% female, and nearly 50% of our employees self&#8209;identified as racially or ethnically diverse. Approximately 55% of new employees (i.e., those we hired in 2022) self&#8209;identified as racially or ethnically diverse.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Diversity Council, which consists of leaders representing different facets of our enterprise, to support our overall diversity and inclusion efforts, including in the areas of recruiting, talent development, new&#8209;hire mentoring, community partnerships, and educational opportunities. The Diversity Council works to provide tools, guidelines and training with respect to best practices in these areas. In 2021, the Diversity Council provided oversight to our human resources department in the development and implementation of an enterprise-wide inclusive culture training session. In addition, the Diversity Council has established the following employee resource groups to support team members with similar backgrounds or shared interests: African American, Women&#8217;s Network, Asian/Pacific, LGBTQ+, Hispanic and Veteran. Each employee resource group has an executive sponsor to help in setting a unique mission and operating model for the group.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition; Staffing and Labor Trends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our operations are dependent on the availability, efforts, abilities and experience of management and medical support personnel, including nurses, therapists, pharmacists and lab technicians, among others. We have always competed with other healthcare providers in recruiting and retaining these employees; however, over the past several years, our industry has been facing considerable workforce challenges. Like other hospital companies, we continue to experience a shortage of advanced practice providers and critical&#8209;care nurses in certain disciplines and geographic areas. The COVID&#8209;19 pandemic exacerbated these shortages &#8211; and, thereby, competition for qualified candidates &#8211; as more employees chose to retire early, leave the workforce or take travel assignments. In addition, in some areas, the increased demand for care of patients with COVID&#8209;19, influenza and other respiratory viruses in our hospitals, as well as the direct impact of these illnesses on physicians, employees and their families, have put a strain on our resources and staff. As a result of the aforementioned challenges, we have been, and we may continue to be, required to enhance wages and benefits to recruit and retain experienced employees, pay premiums above standard compensation for essential workers, make greater investments in education and training for newly licensed medical support personnel, or hire more expensive temporary or contract employees, which we also compete with other healthcare providers to secure.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also depend on the available labor pool of semi-skilled and unskilled workers in each of the areas where we operate. In some of our communities, employers across various industries have increased their minimum wage, which has created more competition and, in some cases, higher labor costs for this sector of employees.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Union Activity and Labor Relations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;At December&#160;31,&#160;2022, approximately 26% of the employees in our Hospital Operations segment were represented by labor unions. Less than 1% of the total employees in both our Ambulatory Care and Conifer segments belong to a union. Unionized employees &#8211; primarily registered nurses and service, technical and maintenance workers &#8211; are located at 33 of our hospitals, the majority of which are in California, Florida and Michigan. Organizing activities by labor unions could increase our level of union representation in future periods, which could impact our labor costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are negotiating collective bargaining agreements with unions (whether such agreements are renewals or first contracts), work stoppages and strikes may be threatened or occur. Although relatively uncommon, extended strikes have had, and could in the future have, an adverse effect on our patient volumes, net operating revenues and labor costs at individual hospitals or in local markets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Staffing Ratio Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our acute care hospitals in California are required to maintain minimum nurse&#8209;to&#8209;patient staffing ratios, which impacts our labor costs. Moreover, from time to time, we are required to limit admissions if we do not have the necessary number of nurses available to meet the required ratios, which has a corresponding adverse effect on our revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3446"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HEALTHCARE SERVICES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our hospitals and outpatient facilities compete within local communities on the basis of many factors, including: quality of care; location and ease of access; the scope and breadth of services offered; reputation; and the caliber of the facilities, equipment and employees. Trends toward clinical and pricing transparency may also impact a healthcare facility&#8217;s competitive position in ways that are difficult to predict. In addition, the competitive positions of hospitals and outpatient facilities depend in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who are members of the medical staffs of those facilities, as well as physicians who affiliate with and use outpatient centers as an extension of their practices. Physicians often serve on the medical staffs of more than one facility, and they are typically free to terminate their association with such facilities or admit their patients to competing facilities at any time.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the hospitals that compete with our hospitals are owned by tax&#8209;supported government agencies, and many others are owned by not&#8209;for&#8209;profit organizations that may have financial advantages not available to our facilities, including (1)&#160;support through endowments, charitable contributions and tax revenues, (2)&#160;access to tax&#8209;exempt financing, and (3)&#160;exemptions from sales, property and income taxes. In addition, in certain areas where we operate, large teaching hospitals provide highly specialized facilities, equipment and services that may not be available at most of our hospitals. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existence or absence of state laws that require findings of need for construction and expansion of healthcare facilities or services (as described in the Healthcare Regulation and Licensing &#8211; Certificate of Need Requirements subsection below) may also impact competition. In recent years, the number of freestanding specialty hospitals, surgery centers, EDs and imaging centers in the geographic areas in which we operate has increased significantly. Some of these facilities are physician&#8209;owned. Moreover, we expect to encounter additional competition from system&#8209;affiliated hospitals and healthcare companies, as well as health insurers and private equity companies seeking to acquire providers, in certain regions in the future.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another major factor in the competitive position of a hospital or outpatient facility is the scope of its relationships with managed care plans. Health maintenance organizations (&#8220;HMOs&#8221;), preferred provider organizations (&#8220;PPOs&#8221;), third&#8209;party administrators, and other third&#8209;party payers use managed care contracts to encourage patients to use certain hospitals in exchange for discounts from the hospitals&#8217; established charges. Our ability to enter into, maintain and renew favorable contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans, as well as add new facilities to our existing agreements at contracted rates, significantly affects our revenues and operating results. Generally, we compete for managed care contracts on the basis of price, market reputation, geographic location, quality and range of services, caliber of the medical staff and convenience. Other healthcare providers may affect our ability to enter into acceptable managed care contractual arrangements or negotiate commercial rate increases. For example, some of our competitors may negotiate exclusivity provisions with managed care plans or otherwise restrict the ability of managed care companies to contract with us. Vertical integration efforts involving third&#8209;party payers and healthcare providers, among other factors, may increase competitive challenges.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategies are designed to help our hospitals and outpatient facilities remain competitive, to attract and retain an appropriate number of physicians of distinction in various specialties, as well as skilled clinical personnel and other healthcare professionals, and to increase patient volumes. To that end, we have made significant investments in equipment, technology, education and operational strategies designed to improve clinical quality at all of our facilities. In addition, we continually collaborate with physicians to implement the most current evidence&#8209;based medicine techniques to improve the way we provide care, while using labor management tools and supply&#8209;chain initiatives to reduce variable costs. Moreover, we participate in various value&#8209;based programs to improve quality and cost of care. We believe the use of these practices will promote the most effective and efficient utilization of resources and result in more appropriate lengths of stay, as well as reductions in readmissions for hospitalized patients. In general, we believe that quality of care improvements may have the effects of: (1)&#160;reducing costs; (2)&#160;increasing payments from Medicare and certain managed care payers for our services as governmental and private payers continue to move to pay&#8209;for&#8209;performance models, and the commercial market continues to move to more narrow networks and other methods designed to encourage covered individuals to use certain facilities over others; and (3)&#160;increasing physician and patient satisfaction, which may improve our volumes. It should be noted, however, that we do face competition from other health systems that are implementing similar strategies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have significantly increased our focus on operating our outpatient centers with improved accessibility and more convenient service for patients, increased predictability and efficiency for physicians, and (for most services) lower costs for payers than would be incurred with a hospital visit. We believe that emphasis on higher&#8209;demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service and participation in Medicare Advantage health plans that have been experiencing higher growth rates than traditional Medicare, among other strategies, will help us address competitive challenges in our markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that our future success depends, in part, on our ability to maintain and renew our existing managed care contracts and enter into new managed care contracts on competitive terms. To bolster our competitive position, we have sought to include all of our hospitals and other healthcare businesses in the related geographic area or nationally when negotiating new managed care contracts, which may result in additional volumes at facilities that were not previously a part of such managed care networks. We also continue to engage in contracting strategies that create shared value with payers.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">REVENUE CYCLE MANAGEMENT SOLUTIONS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer faces competition from existing participants and new entrants to the revenue cycle management business, some of which may have significantly greater capital resources than Conifer. In addition, the internal revenue cycle management staff of hospitals and other healthcare providers, who perform many of the functions addressed by our services, in effect compete with us. Moreover, providers who have previously made investments in internally developed solutions may choose to continue to rely on their own resources. We also currently compete with several categories of external participants who offer revenue cycle services, including: software vendors and other technology&#8209;supported revenue cycle management business process outsourcing companies; traditional consultants, either specialized healthcare consulting firms or healthcare divisions of large accounting firms; and large, non&#8209;healthcare focused business process and information technology outsourcing firms.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that competition for the revenue cycle management and other services Conifer provides is based primarily on: (1)&#160;knowledge and understanding of the complex public and private healthcare payment and reimbursement systems; (2)&#160;a track record of delivering revenue improvements and efficiency gains for hospitals and other healthcare providers; (3)&#160;the ability to deliver solutions that are fully integrated along each step of the revenue cycle; (4)&#160;cost&#8209;effectiveness, including the breakdown between up&#8209;front costs and pay&#8209;for&#8209;performance incentive compensation; (5)&#160;reliability, simplicity and flexibility of the technology platform; (6)&#160;understanding of the healthcare industry&#8217;s regulatory environment, as well as laws and regulations relating to consumer protection; and (7)&#160;financial resources to maintain current technology and other infrastructure.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be successful, Conifer must respond more quickly and effectively than its competitors to new or changing opportunities, technologies, standards, regulations and client requirements. Existing or new competitors may introduce technologies or services that render Conifer&#8217;s technologies or services obsolete or less marketable. Even if Conifer&#8217;s technologies and services are more effective than the offerings of its competitors, current or potential clients might prefer competitive technologies or services to Conifer&#8217;s technologies and services. Furthermore, increased competition has resulted and may continue to result in pricing pressures, which could negatively impact Conifer&#8217;s margins and growth rate.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3473"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEALTHCARE REGULATION AND LICENSING</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like others in the healthcare industry, we are subject to an extensive and complex framework of government regulation at the federal, state and local levels. These legal and regulatory standards relate to, among other topics: ownership and operation of facilities and physician practices; licensure, certification and enrollment in government programs; the necessity and adequacy of medical care; quality of medical equipment and services; relationships with and qualifications of physicians and employees; operating conduct, policies and procedures; screening, stabilization and transfer of individuals who have emergency medical conditions; rate-setting, billing and coding for services; the preparation and filing of cost reports; the handling of overpayments; contractual arrangements; relationships with referral sources and referral recipients; privacy and security; maintenance of adequate records; construction, acquisition, expansion and closure of healthcare facilities or services; environmental protection; compliance with fire prevention and building codes; debt collection; and communications with patients and consumers. In addition, various permits are required to dispense narcotics, operate pharmacies, handle radioactive materials and operate certain equipment. Our facilities are also subject to periodic inspection by governmental and other authorities to determine their compliance with applicable regulations, as well as the standards necessary for licensing and accreditation.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our healthcare facilities hold all required governmental approvals, licenses and permits material to the operation of their business. Furthermore, we have extensive policies and procedures in place to facilitate compliance with applicable laws, rules and regulations; however, these policies and procedures cannot ensure compliance in every case. Moreover, government regulations often change, and we may have to make adjustments to our facilities, equipment, personnel and services to remain in compliance.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential consequences for failing to comply with applicable laws, rules and regulations include (1)&#160;required refunds of previously received government program payments, (2)&#160;the assessment of civil monetary penalties, including treble damages, (3)&#160;fines, which could be significant, (4)&#160;exclusion from participation in federal healthcare programs and (5)&#160;criminal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sanctions, including sanctions against current or former employees. Our Medicare and Medicaid payments may be suspended pending even an investigation of what the government determines to be a credible allegation of fraud. Any of the aforementioned consequences could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HEALTHCARE REFORM</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;Affordable Care Act&#8221;), extended health coverage to millions of uninsured legal U.S. residents through a combination of private sector health insurance reforms and public program expansion. The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions, along with reductions in Medicare and Medicaid reimbursement to healthcare providers, including us. Of the nine states in which we operate hospitals, four have taken action in accordance with the Affordable Care Act to expand their Medicaid programs; however, over half of our licensed beds at December&#160;31,&#160;2022 were located in five states, namely Alabama, Florida, South Carolina, Tennessee and Texas, that have not expanded Medicaid under the law.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is ongoing uncertainty with respect to the ultimate net effect of the Affordable Care Act due to the potential for continued changes in the law&#8217;s implementation and how government agencies and courts interpret it. Moreover, we cannot predict what future action, if any, Congress might take to amend the Affordable Care Act. If future modifications or interpretations result in significantly fewer individuals having private or public health coverage, we likely will experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect our results of operations and cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also uncertainty regarding the potential impact of other healthcare-related reform efforts at the federal and state levels. Some reform initiatives, requirements and proposals could have a positive effect on our business, while others may increase our operating costs, negatively impact our case mix, adversely affect the reimbursement we receive for our services or require us to expend resources to modify certain aspects of our operations. Moreover, some current reforms could impact our competitive position, as well as our relationships with insurers and patients, including:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the No Surprises Act, which established federal protections that became effective in 2022 against balance billing for certain out&#8209;of&#8209;network services, including emergency care, and which, among other things, contains resolution procedures for payment disputes between providers and insurers through an impartial arbitration system; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMS&#8217; rules relating to hospital price transparency, which require that hospitals share payer-specific negotiated prices for certain healthcare services with the goal of making it easier for consumers to shop and compare prices across hospitals and estimate the cost of care before going to the hospital.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANTIFRAUD AND ABUSE LAWS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of federal statutes, and the regulations implementing them, govern our participation in the Medicare and Medicaid payment programs, including:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anti&#8209;kickback and antifraud and abuse amendments codified under Section&#160;1128B(b) of the Social Security Act (the &#8220;Anti&#8209;kickback Statute&#8221;), which prohibit the knowing and willful remuneration of anything of value intended to induce or reward patient referrals or the generation of business involving any item or service payable by federal healthcare programs, subject to certain government-established &#8220;safe harbor&#8221; exceptions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the False Claims Act (&#8220;FCA&#8221;), which prohibits the submission of claims for payment to government programs that are known to be, or should be known to be, fraudulent;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Stark law, which generally restricts physician referrals of Medicare or Medicaid patients to entities the physician or an immediate family member has a financial relationship with, regardless of any intent to violate the law, unless one of several exceptions applies; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Civil Monetary Penalties Law, which authorizes the Secretary of HHS to impose civil penalties for various forms of fraud and abuse involving the Medicare and Medicaid programs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The states in which we operate have adopted laws that prohibit payments in exchange for patient referrals, similar to the federal Anti&#8209;kickback Statute, or that otherwise prohibit fraud and abuse activities. Many states have also passed self&#8209;referral legislation similar to the Stark law. Often these state laws are broader in scope in terms of the providers and services regulated, and certain of the laws apply regardless of the source of payment for care. These statutes typically provide for criminal and civil penalties, as well as loss of licensure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Application to Our Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We regularly enter into financial arrangements with physicians and other providers in a manner we believe complies with the Anti&#8209;kickback Statute, the Stark law, and other applicable antifraud and abuse laws. At December&#160;31,&#160;2022, the majority of the surgical hospitals and ASCs in our Ambulatory Care segment were owned by joint&#160;ventures with physicians and/or health systems. In addition, we have contracts with physicians and non&#8209;physician referral sources providing for a variety of financial arrangements, including employment agreements, leases and professional service contracts, such as medical director agreements. We also provide financial incentives to recruit physicians to relocate to communities served by our hospitals, including income and collection guarantees and reimbursement of relocation costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, the primary focus of our quality, compliance and ethics program is compliance with the requirements of Medicare, Medicaid and other federally funded healthcare programs. However, if our arrangements are found to fail to comply with applicable antifraud and abuse laws, our operations could be adversely affected. In addition, any determination by a federal or state agency or court that USPI or one of its subsidiaries has violated any of these laws could give certain of our joint venture partners a right to terminate their relationships with us; and any similar determination with respect to Conifer could give Conifer&#8217;s clients the right to terminate their services agreements with us. Moreover, any violations by and resulting penalties or exclusions imposed upon USPI&#8217;s joint venture partners or Conifer&#8217;s clients could adversely affect their financial condition and, in turn, have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Enforcement Efforts and Qui Tam Lawsuits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The healthcare industry is subject to heightened and coordinated civil and criminal enforcement efforts from both federal and state government agencies. The U.S.&#160;Office of Inspector General, which is an independent and objective oversight unit of HHS, conducts audits, evaluations and investigations relating to HHS programs and operations and, when appropriate, imposes civil monetary penalties, assessments and administrative sanctions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers are also subject to qui tam or &#8220;whistleblower&#8221; lawsuits under the FCA, which allows private individuals to bring actions on behalf of the government, alleging that a hospital or healthcare provider has defrauded a government program, such as Medicare or Medicaid. If the government intervenes in the action and prevails, the defendant may be required to pay three times the damages sustained by the government, plus mandatory civil penalties for each false claim submitted to the government. As part of the resolution of a qui tam case, the qui tam plaintiff may share in a portion of any settlement or judgment. If the government does not intervene in the action, the qui tam plaintiff may continue to pursue the action independently. Qui tam actions can also be filed under certain state false claims laws if the fraud involves Medicaid funds or funding from state and local agencies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid significant amounts to resolve government investigations and qui tam matters brought against us in the past, and we are unable to predict the impact of any future actions on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) requires administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of protected health information (&#8220;PHI&#8221;) and sets forth the rights of patients to understand and control how their information is used and disclosed. We have developed a comprehensive set of policies and procedures in our efforts to comply with HIPAA, and similar state privacy laws, under the guidance of our ethics and compliance department. Our compliance officers and information security officers are responsible for implementing and monitoring enterprise&#8209;wide compliance with our HIPAA privacy and security policies and procedures. We have also created an internal web&#8209;based HIPAA training program, which is mandatory for all employees.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under HIPAA, we are required to report breaches of unsecured PHI to affected individuals without unreasonable delay, but not longer than 60&#160;days following discovery of the breach. We are also required to notify HHS and, in certain situations involving large breaches, the media. All non-permitted uses or disclosures of unsecured PHI are presumed to be breaches unless it can be established that there is a low probability the information has been compromised. Various state laws and regulations may also require us to notify the applicable state agency and affected individuals in the event of a data breach involving individually identifiable information.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the HIPAA privacy and security regulations may result in criminal penalties and in substantial civil penalties per violation. In addition to enforcement by HHS, state attorneys general are authorized to bring civil actions seeking either injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents. HHS may resolve HIPAA violations through informal means, such as allowing a company to implement a corrective action plan, but HHS has the discretion to move directly to impose monetary penalties and is required to impose penalties for violations resulting from willful neglect. We are also subject to any federal or state privacy-related laws that are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties and subject us to additional privacy and security restrictions. In addition, various states have enacted, and other states are considering, new laws and regulations concerning the privacy and security of consumer and other personal information. To the extent we are subject to such requirements, these laws and regulations often have far-reaching effects, are subject to amendments, changing requirements and updates to regulators&#8217; enforcement priorities, may require us to modify our data processing practices and policies, may require us to incur substantial costs and expenses to comply and may subject our business to a risk of increased potential liability. These laws and regulations often provide for civil penalties for violations, as well as a private right of action for data breaches, which may increase the likelihood or impact of data breach litigation.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UTILIZATION REVIEW COMPLIANCE AND HOSPITAL GOVERNANCE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Social Security Act and Medicare regulations generally require that services that may be paid for under the Medicare program or state healthcare programs are (1)&#160;provided economically and only when, and to the extent, they are medically reasonable and necessary, (2)&#160;of a quality that meets professionally recognized standards of healthcare, and (3)&#160;supported by appropriate evidence of medical necessity and quality. The Quality Improvement Organization program established under the Social Security Act seeks: to improve the effectiveness, efficiency, economy and quality of services delivered to Medicare beneficiaries; to preserve the Medicare Trust Fund by ensuring that Medicare pays only for services that are reasonable and necessary and that are provided in the most appropriate setting; and to protect Medicare beneficiaries by expeditiously addressing complaints, violations under the Emergency Medical Treatment and Active Labor Act, and other quality&#8209;related issues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increased scrutiny from outside auditors, government enforcement agencies and others, as well as an increased risk of government investigations and qui tam lawsuits, related to hospitals&#8217; Medicare observation rates and inpatient admission decisions. The term &#8220;Medicare observation rate&#8221; is defined as total unique observation claims divided by the sum of total unique observation claims and total inpatient short&#8209;stay acute care hospital claims. A low rate may raise suspicions that a hospital is inappropriately admitting patients that could be cared for in an observation setting. In addition, CMS has established a concept referred to as the &#8220;two&#8209;midnight rule&#8221; to guide practitioners admitting patients and contractors on when it is appropriate to admit individuals as hospital inpatients. Under the two&#8209;midnight rule, a Medicare patient should generally be admitted on an inpatient basis only when there is a reasonable expectation that the patient&#8217;s care will cross two midnights; if not, the patient generally should be treated as an outpatient, unless an exception applies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical and surgical services and practices are extensively supervised by committees of staff physicians at each of our healthcare facilities, are overseen by each facility&#8217;s local governing board, the members of which primarily are community members and physicians, and are reviewed by our clinical quality personnel. The local governing board also helps maintain standards for quality care, develop short&#8209;term and long&#8209;range plans, and establish, review and enforce practices and procedures, as well as approves the credentials, disciplining and, if necessary, the termination of privileges of medical staff members.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATE OF NEED REQUIREMENTS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states require state approval for construction, acquisition and closure of healthcare facilities, including findings of need for additional or expanded healthcare facilities or services. Certificates or determinations of need, which are issued by governmental agencies with jurisdiction over healthcare facilities, are at times required for capital expenditures exceeding a prescribed amount, changes in bed capacity or services, and certain other matters. Our subsidiaries operate acute care hospitals in five states that require a form of state approval under certificate of need programs applicable to those hospitals. Approximately 34% of our licensed hospital beds are located in these states (namely, Alabama, Massachusetts, Michigan, South&#160;Carolina and Tennessee). The certificate of need programs in most of these states, along with several others, also apply to ASCs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain necessary state approval can result in the inability to expand facilities, add services, acquire a facility or change ownership. Further, violation of such laws may result in the imposition of civil sanctions or the revocation of a facility&#8217;s license. We are unable to predict whether we will be required or able to obtain any additional certificates of need in any jurisdiction where they are required, or if any jurisdiction will eliminate or alter its certificate of need requirements in a manner that will increase competition and, thereby, affect our competitive position. In those states that do not have certificate of need requirements or that do not require review of healthcare capital expenditure amounts below a relatively high threshold, competition in the form of new services, facilities and capital spending is more prevalent.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our healthcare operations are subject to a number of federal, state and local environmental laws, rules and regulations that govern, among other things, our disposal of solid waste, as well as our use, storage, transportation and disposal of hazardous and toxic materials (including radiological materials). Our operations also generate medical waste that must be discarded in compliance with statutes and regulations that vary from state to state. In addition, our operating expenses could be adversely affected if legal and regulatory developments related to climate change or other initiatives result in increased energy or other costs. We could also be affected by climate change and other environmental issues to the extent such issues adversely affect the general economy or result in severe weather affecting the communities in which our facilities are located. At this time, based on current climate conditions and our assessment of existing and pending environmental rules and regulations, as well as treaties and international accords relating to climate change, we do not believe that the costs of complying with environmental laws, including regulations relating to climate change issues, will have a material adverse effect on our future capital expenditures, results of operations or cash flows. There were no material capital expenditures for environmental matters in the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANTITRUST LAWS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government and most states have enacted antitrust laws that prohibit specific types of anti&#8209;competitive conduct, including price fixing, wage fixing, anticompetitive hiring practices, restrictive covenants, concerted refusals to deal, price discrimination and tying arrangements, as well as monopolization and acquisitions of competitors that have, or may have, a substantial adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antitrust enforcement in the healthcare industry is a priority of the U.S.&#160;Federal Trade Commission (&#8220;FTC&#8221;). In recent years, the FTC has filed multiple administrative complaints and public comments challenging hospital transactions in several states. The FTC has focused its enforcement efforts on preventing hospital mergers that may, in the government&#8217;s view, leave insufficient local options for patient services, which could result in increased costs to consumers. In addition, the FTC has given increased attention to the effect of combinations involving other healthcare providers, including physician practices, as well as to the use of restrictive covenants that limit the ability of employees and others to engage in certain competitive activities. The FTC has also entered into numerous consent decrees in the past several years settling allegations of price&#8209;fixing among providers.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3502"></div><div style="margin-bottom:6pt;margin-top:12pt"><span id="i0414f6090f274d06ac37b0b0d443a3b5_17379"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LAWS AND REGULATIONS AFFECTING CONIFER&#8217;S OPERATIONS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer is subject to civil and criminal statutes and regulations governing consumer finance, medical billing, coding, collections and other operations. In connection with these laws and regulations, Conifer has been and expects to continue to be party to various lawsuits, claims, and federal and state regulatory investigations from time to time. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against Conifer or the effect that judgments, penalties or settlements in such matters may have on Conifer.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BILLING AND COLLECTION ACTIVITIES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Fair Debt Collection Practices Act (&#8220;FDCPA&#8221;) regulates persons who regularly collect or attempt to collect, directly or indirectly, consumer debts owed or asserted to be owed to another person. Certain of the accounts receivable handled by Conifer&#8217;s third&#8209;party debt collection vendors are subject to the FDCPA, which establishes specific guidelines and procedures that debt collectors must follow in communicating with consumer debtors, including the time, place and manner of such communications. Conifer audits and monitors its vendors for compliance, but there can be no assurance that such audits and monitoring will detect all instances of potential non&#8209;compliance.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states also regulate the billing and collection practices of creditors who collect their own debt, as well as the companies a creditor engages to bill and collect from consumers on the creditor&#8217;s behalf. These state regulations may be more stringent than the FDCPA. In addition, state regulations may be specific to medical billing and collections or the same or similar to state regulations applicable to third&#8209;party collectors. Certain of the accounts receivable Conifer or its billing, servicing and collections subsidiary, PSS Patient Solution Services,&#160;LLC, manages for its clients are subject to these state regulations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer is also subject to both federal and state regulatory agencies who have the authority to investigate consumer complaints relating to a variety of consumer protection laws, including but not limited to the Telephone Consumer Protection Act and its state equivalent. These agencies may initiate enforcement actions, including actions to seek restitution and monetary penalties from, or to require changes in business practices of, regulated entities. In addition, affected consumers may bring suits, including class action suits, to seek monetary remedies (including statutory damages) for violations of the federal and state provisions discussed above.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LAWS AND REGULATIONS AFFECTING OUR GBC</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations at our GBC in the Philippines are subject to certain U.S. healthcare industry-specific requirements, as well as U.S. and foreign laws applicable to businesses generally, including anti-corruption laws. One such law, the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), regulates U.S. companies in their dealings with foreign officials, prohibiting bribes and similar practices, and requires that they maintain records that fairly and accurately reflect transactions and appropriate internal accounting controls. FCPA enforcement actions continue to be a high priority for the SEC and the U.S. Department of Justice. Our failure to comply with the FCPA could result in the imposition of fines and other civil and criminal penalties, which could be significant. </span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3530"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPLIANCE AND ETHICS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our ethics and compliance department maintains our values&#8209;based ethics and compliance program, which is designed to: (1)&#160;help staff in our corporate, USPI and Conifer offices, hospitals, outpatient centers and physician practices meet or exceed applicable standards established by federal and state statutes and regulations, as well as industry practice; (2)&#160;monitor and raise awareness of ethical issues among employees and others, and stress the importance of understanding and complying with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and (3)&#160;provide a channel for employees to make confidential ethics and compliance&#8209;related reports anonymously if they choose. The ethics and compliance department operates independently &#8211; it has its own operating budget; it has the authority to hire outside counsel, access any company document and interview any of our personnel; and our chief&#160;compliance officer reports directly to our chief executive officer, as well as to the quality, compliance and ethics committee of our board of directors.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Program Charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quality, Compliance and Ethics Program Charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the governing document for our ethics and compliance program. Our adherence to the charter is intended to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support and maintain our present and future responsibilities with regard to participation in federal healthcare programs; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further our goals of operating an organization that (1)&#160;fosters and maintains the highest ethical standards among all employees, officers and directors, physicians practicing at our facilities, and contractors that furnish healthcare items or services, (2)&#160;values compliance with all state and federal statutes and regulations as a foundation of its corporate philosophy, and (3)&#160;aligns its behaviors and decisions with Tenet&#8217;s core values.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary focus of our quality, compliance and ethics program is compliance with the requirements of Medicare, Medicaid and other federally funded healthcare programs. Pursuant to the terms of the charter, our ethics and compliance department is responsible for, among other things, the following activities: (1)&#160;assessing, critiquing, and (as appropriate) drafting and distributing company policies and procedures; (2)&#160;developing, providing, and tracking ethics and compliance training and other training programs, including job&#8209;specific training to those who work in clinical quality, coding, billing, cost reporting and referral source arrangements, in collaboration with the respective department responsible for oversight of each of these areas; (3)&#160;creating and disseminating our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and obtaining certifications of adherence to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a condition of employment; (4)&#160;maintaining and promoting our Ethics Action Line, a 24&#8209;hour, toll&#8209;free hotline that allows for confidential reporting of issues on an anonymous basis and emphasizes our no&#8209;retaliation policy; and (5)&#160;responding to and resolving all compliance&#8209;related issues that arise from the Ethics Action Line and compliance reports received from facilities and compliance officers (utilizing any compliance reporting software that we may employ for this purpose) or any other source that results in a report to the ethics and compliance department.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All of our employees and officers, including our chief executive officer, chief financial officer and principal accounting officer, are required to abide by our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to advance our mission that our business be conducted in a legal and ethical manner. The members of our board of directors and all of our contractors having functional roles similar to our employees are also required to abide by our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standards therein reflect our basic values and form the foundation of a comprehensive process that includes compliance with all corporate policies, procedures and practices. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> covers such areas as quality patient care, compliance with all applicable statutes and regulations, appropriate use of our assets, protection of patient information and avoidance of conflicts of interest.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the program, we provide compliance training at least annually to every employee and officer, as well as our board of directors and certain physicians and contractors. All such persons are required to report incidents that they believe in good faith may be in violation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or our policies, and all are encouraged to contact our Ethics Action Line when they have questions about the standards or any ethics concerns. All reports to the Ethics Action Line are kept confidential to the extent allowed by law, and any individual who makes a report has the option to remain anonymous. Incidents of alleged financial improprieties reported to the Ethics Action Line or the ethics and compliance department are communicated to the audit committee of our board of directors. Reported cases that involve a possible violation of the law or regulatory policies and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures are referred to the ethics and compliance department for investigation, although certain matters may be referred out to the law or human resources department. Retaliation against anyone in connection with reporting ethical concerns is considered a serious violation of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, if it occurs, it will result in discipline, up to and including termination of employment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Availability of Documents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The full text of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quality, Compliance and Ethics Program Charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and a number of our ethics and compliance policies and procedures are published on our website, at www.tenethealth.com, under the &#8220;Our Commitment To Compliance&#8221; caption in the &#8220;About Us&#8221; section. Amendments to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any grant of a waiver from a provision of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requiring disclosure under applicable SEC rules will be disclosed at the same location as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our website.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3581"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSURANCE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry has seen significant increases in the cost of professional and general liability insurance due to increased claims and lawsuits in the ordinary course of business. We maintain captive insurance companies to self&#8209;insure for the majority of our professional and general liability claims, and we purchase insurance from third parties to cover catastrophic claims. Commercial insurance we purchase is subject to per&#8209;claim and policy period aggregate limits. If the policy period aggregate limit of any of these policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay other material claims applicable to that policy period. Any losses not covered by or in excess of the amounts maintained under our professional and general liability insurance policies will be funded from our working capital or other sources of liquidity.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the reserves recorded by our captive insurance subsidiaries, we maintain reserves, including reserves for incurred but not reported claims, for our self&#8209;insured professional liability retentions and claims in excess of the policies&#8217; aggregate limits, based on modeled estimates of losses and related expenses. Also, we provide standby letters of credit to certain of our insurers, which can be drawn upon under certain circumstances, to collateralize the deductible and self&#8209;insured retentions under a select number of our professional and general liability insurance programs.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also purchase property, cyber-liability and other insurance coverage from third parties. Our commercial insurance does not cover all claims against us and may not offset the financial impact of a material loss event. Moreover, commercial insurance may not continue to be available at a reasonable cost for us to maintain at adequate levels. The rise in the number and severity of hurricanes, wildfires, tornadoes and other weather events, whether or not precipitated by climate change, has created increased risk that is expected to lead to a rise in insurance premiums and reductions in coverage for property owners in the future. In addition, the risk of ransomware attacks, breaches or other disruptions to information technology systems is elevated in the current environment, which has caused an increase in cyber premiums and lower coverage limits. In April&#160;2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care hospital operations and involved the exfiltration of certain confidential company and patient information (the &#8220;Cybersecurity Incident&#8221;). We estimate that the Cybersecurity Incident had an adverse pre-tax impact of approximately $100&#160;million during the year ended December&#160;31,&#160;2022. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have filed a claim within our policy limits. For further information regarding our insurance coverage, see Note&#160;16 to our Consolidated Financial Statements.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3608"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPANY INFORMATION</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Our reports, proxy statements and other documents filed electronically with the SEC are available at the website maintained by the SEC at www.sec.gov.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website, www.tenethealth.com, also offers, free of charge, access to our annual, quarterly and current reports (and amendments to such reports), and other filings made with, or furnished to, the SEC as soon as reasonably practicable after such documents are submitted to the SEC. The information found on our website is not incorporated by reference into nor part of this or any other report or document we file with or furnish to the SEC.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3635"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward&#8209;looking statements&#8221; within the meaning of Section 27A of the Securities Act of&#160;1933 and Section 21E of the Exchange Act, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward&#8209;looking statements, including (but not limited to) disclosure regarding (1)&#160;the impact of the COVID&#8209;19 pandemic, (2)&#160;our future earnings, financial position, and operational and strategic initiatives, and (3)&#160;developments in the healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">industry. Forward&#8209;looking statements represent management&#8217;s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward&#8209;looking statements. Such factors include, but are not limited to, the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The public health and economic impacts of the COVID&#8209;19 pandemic on our future operations, financial condition and liquidity, particularly if the U.S.&#160;economy remains volatile for a significant period of time;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to enter into or renew managed care provider arrangements on acceptable terms; changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under managed care agreements; and the impact of the industry trends toward value&#8209;based purchasing and alternative payment models;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effects on our business of healthcare reform efforts, including the enactment of, or changes in, statutes and regulations affecting the healthcare industry generally; and regulatory developments, including reductions to Medicare and Medicaid payment rates or changes in reimbursement practices or to Medicaid supplemental payment programs;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success in recruiting and retaining physicians, nurses and other healthcare professionals as affected by the COVID&#8209;19 pandemic, competition and other factors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effect of competition generally, and clinical and price transparency regulations, on our business;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing, outcome and impact of: government investigations and litigation; changes in federal tax laws, regulations and policies; and future tax audits, disputes and litigation associated with our tax positions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Security threats, catastrophic events and other disruptions that affect our information technology and related systems;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to achieve operating and financial targets, attain expected levels of patient volumes, and identify and execute on measures designed to save or control costs or streamline operations;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operational and other risks associated with acquisitions, divestitures and joint venture arrangements, including the integration of newly acquired businesses;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of our significant indebtedness; the availability and terms of capital to refinance existing debt, fund our operations and expand our business; and our ability to comply with our debt covenants and, over time, reduce leverage;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effect that general adverse economic conditions (including inflation), consumer behavior and other factors have on our volumes and our ability to collect outstanding receivables on a timely basis, among other things; and increases in the amount of uninsured accounts, as well as deductibles, co&#8209;insurance amounts and co&#8209;pays for insured accounts; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other factors and risks referenced in this report and our other public filings.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering forward&#8209;looking statements, you should keep in mind the risk factors and other cautionary statements in this report. Should one or more of the risks and uncertainties described in this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward&#8209;looking statement. We specifically disclaim any obligation to update any information contained in a forward&#8209;looking statement or any forward&#8209;looking statement in its entirety, except as required by law.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward&#8209;looking statements attributable to us are expressly qualified in their entirety by this cautionary information.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_19"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual operating results or financial performance to be materially different from our expectations and make an investment in our securities risky. If one or more of the events discussed in this report were to occur, actual outcomes could differ materially from those expressed in or implied by any forward&#8209;looking statements we make in this report or our other filings with the SEC, and our business, financial condition, results of operations or liquidity could be materially adversely affected; furthermore, the trading price of our common stock could decline and our shareholders could lose all or part of their investment. Additional risks and uncertainties not presently known, or currently deemed immaterial, may also constrain our business and operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3662"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Overall Operations</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic continues to adversely impact our operations; we cannot predict whether or how any future laws and regulations related to or in response to the pandemic will affect us; and the lingering economic effects of the pandemic could harm our liquidity.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the public health and economic effects of the COVID&#8209;19 pandemic continued to adversely impact our operations, as well as our patients, communities and employees, to varying degrees. New variants of the virus caused additional outbreaks in 2022, and there continues to be a lack of clarity about the nature and degree of the health effects of COVID&#8209;19 over time. Known and unknown risks and uncertainties caused by the pandemic, including those described below, have had, and are continuing to have, a material impact on our business, financial condition, results of operations and cash flows; such risks and uncertainties may heighten other risks to our business as described herein.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surges of COVID&#8209;19 at various points throughout 2022 caused periodic spikes in COVID admissions at our hospitals and resulted in increased case cancellations in our Ambulatory Care segment. We have incurred and continue to incur additional costs to protect the health and well&#8209;being of patients and staff. In addition, the demand for care of COVID&#8209;19 patients in some of our hospitals put a strain on our resources and personnel. We have been required, and we may in the future be required, to temporarily reduce overall operating capacity or suspend certain services at individual facilities due to staffing constraints and other COVID&#8209;19-related factors.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described below, the pandemic also exacerbated previously existing workforce shortages&#160;&#8211; and, thereby, competition for qualified candidates&#160;&#8211; as more employees chose to retire early, leave the workforce or take travel assignments. Over the past several years, we have had to rely on higher&#8209;cost temporary and contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, throughout the pandemic, we have experienced significant price increases in medical supplies, particularly for personal protective equipment, and we have encountered supply-chain disruptions, including shortages and delays. In addition, our Ambulatory Care segment has been impacted by shipment delays in construction materials and capital equipment with respect to its de novo facility development efforts, which are a key part of our portfolio expansion strategy. COVID&#8209;19 surges and outbreaks of new variants could further impact the cost of medical supplies, and supply shortages and delays may impact our ability to see, admit and treat patients.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in detail in MD&amp;A, the various federal legislative actions provided relief measures intended to mitigate some of the adverse financial impacts of the COVID&#8209;19 pandemic on the healthcare industry. We are unable to predict whether future changes, if any, to these relief measures will negatively affect our business, financial condition, results of operations or cash flows. Furthermore, some of the measures allowing for flexibility in delivery of care and financial support for healthcare providers are available only for the duration of the public health emergency as declared by the Secretary of HHS, which is now scheduled to expire on May&#160;11,&#160;2023. The federal government and state and local governments may consider additional stimulus and relief efforts, but we are unable to predict whether any such measures will be enacted. There can also be no assurance that we will be eligible or apply for, or receive or benefit from, additional COVID&#8209;19&#8209;related stimulus assistance in the future, nor can there be any assurance as to the amount and type of assistance we may receive or seek or whether we will be able to comply with the applicable terms and conditions to retain such assistance. To the extent we do receive amounts or benefits under future relief measures related to or in response to the COVID&#8209;19 pandemic, we cannot predict how such assistance will affect our operations or whether it will offset the negative impacts on our operations arising from the pandemic.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad economic factors resulting from the pandemic, including higher inflation, increased unemployment rates in certain areas where we operate and reduced consumer spending, have impacted, and are continuing to impact, our service mix, revenue mix and patient volumes. Business closings and layoffs in the areas we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients to pay for services. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted, and there can be no assurance that we will be able to raise additional funds on terms acceptable to us, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the extent of the impact of the COVID&#8209;19 pandemic on our future operational and financial performance is currently uncertain and will depend on many factors outside of our control, including, among others: the duration, severity and trajectory of the pandemic, including the possible spread of potentially more contagious and/or virulent forms of the virus; future economic conditions, as well as the impact of government actions and administrative regulations on the hospital industry and broader economy, including through existing and any future stimulus efforts; the development, availability and widespread use of effective medical treatments and vaccines; the imposition of public safety measures; the volume of canceled or rescheduled procedures at our facilities; and the volume of COVID&#8209;19 patients across our care network. Moreover, we cannot predict when or if our hospital volumes and case mix will return to pre-pandemic levels, particularly given that millions of Americans could lose Medicaid coverage once states restart their eligibility determinations on April&#160;1,&#160;2023.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to enter into, maintain and renew managed care contractual arrangements on competitive terms, if we experience material reductions in the contracted rates we receive from managed care payers or if we have difficulty collecting from managed care payers, our results of operations could be adversely affected.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to enter into, maintain and renew favorable contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans, as well as add new facilities to our existing agreements at contracted rates, significantly affects our revenues and operating results. For the year ended December&#160;31,&#160;2022, approximately 70%, or $9.730&#160;billion, of our net patient service revenues for the hospitals and related outpatient facilities in our Hospital Operations segment was attributable to managed care payers, including Medicare and Medicaid managed care programs. Moreover, in 2022, our commercial managed care net inpatient revenue per admission from the hospitals in our Hospital Operations segment was approximately 81% higher than our aggregate yield on a per&#8209;admission basis from government payers, including managed Medicare and Medicaid insurance plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have thousands of managed care contracts with various HMOs and PPOs; however, our top 10 managed care payers generated 62% of our managed care net patient service revenues for the year ended December&#160;31,&#160;2022. Because of this concentration, we may experience a short or long&#8209;term adverse effect on our net operating revenues if we cannot renew, replace or otherwise mitigate the impact of expired contracts with significant payers. Furthermore, material payment delays and disputes between us and significant managed care payers could have a material adverse effect on our financial condition, results of operations or cash flows. At December&#160;31,&#160;2022, 66% of our net accounts receivable for our Hospital Operations segment was due from managed care payers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private payers are increasingly attempting to control healthcare costs through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment in managed care programs, such as HMOs and PPOs. Any negotiated discount programs we agree to generally limit our ability to increase reimbursement rates to offset increasing costs. Furthermore, the ongoing trend toward consolidation among non&#8209;government payers tends to increase their bargaining power over contract terms. Generally, we compete for these contracts on the basis of price, market reputation, geographic location, quality and range of services, caliber of the medical staff and convenience. Our relationships with payers, and reimbursement for the care we provide, may be further impacted by clinical and price transparency initiatives and out&#8209;of&#8209;network billing restrictions, including those in the No Surprises Act, which took effect January&#160;1,&#160;2022. In general, any material reductions in the contracted or out-of-network rates we receive for our services or any significant difficulties in collecting receivables from managed care payers could have a material adverse effect on our financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future changes in the Medicare and Medicaid programs or other government healthcare programs, including reductions in scale and scope, could have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid by governmental payers are reduced, if the scope of services covered by governmental payers is limited, or if we or one or more of our hospitals are excluded from participation in the Medicare or Medicaid program or any other government healthcare program, there could be a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31,&#160;2022, approximately 17% and 7% of our net patient service revenues for the hospitals and related outpatient facilities in our Hospital Operations segment were from the Medicare program and various state Medicaid programs, respectively, in each case excluding Medicare and Medicaid managed care programs. The Medicare and Medicaid programs are subject to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">statutory and regulatory changes, administrative and judicial rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating reimbursements, among other things; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements for utilization review; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state funding restrictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could materially increase or decrease payments from these government programs in the future, as well as affect the cost of providing services to our patients and the timing of payments to our facilities, which could in turn adversely affect our overall business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even prior to the COVID&#8209;19 pandemic, several states in which we operate faced budgetary challenges that resulted in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state&#8217;s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs or have received federal government waivers allowing them to test new approaches and demonstration projects to improve care. Federal government denials or delayed approvals of waiver applications or extension requests by the states in which we operate could materially impact our Medicaid funding levels. Continuing pressure on state budgets and other factors, including legislative and regulatory changes, could result in future reductions to Medicaid payments, payment delays or changes to Medicaid supplemental payment programs that could negatively impact our financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is essential to our ongoing business that we attract an appropriate number of quality physicians in the specialties required to support our services and that we maintain good relations with those physicians.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business and clinical program development depends in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who are members of the medical staffs of our hospitals and other facilities, as well as physicians who affiliate with us and use our facilities as an extension of their practices. Physicians are often not employees of the hospitals or surgery centers at which they practice. Members of the medical staffs of our facilities also often serve on the medical staffs of facilities we do not operate, and they are free to terminate their association with our facilities or admit their patients to competing facilities at any time. In addition, although physicians who own interests in our facilities are generally subject to agreements restricting them from owning an interest in competitive facilities, we may not learn of, or may be unsuccessful in preventing, our physician partners from acquiring interests in competitive facilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with system&#8209;affiliated hospitals and healthcare companies, as well as health insurers and private equity companies, in recruiting physicians, acquiring physician practices and, where permitted by law, employing physicians. In 2022, we continued to experience challenges in recruiting and retaining physicians. In some of the regions in which we operate, physician recruitment and retention are affected by a shortage of qualified physicians in certain higher-demand clinical service lines and specialties. Furthermore, our ability to recruit and employ physicians is closely regulated. For example, the types, amount and duration of compensation and assistance we can provide to recruited physicians are limited by the federal Anti&#8209;kickback Statute and Stark law, as well as other applicable antifraud and abuse laws and regulations. All arrangements with physicians must also be fair market value and commercially reasonable. If we are unable to attract and retain sufficient numbers of quality physicians by providing adequate support personnel, technologically advanced equipment, and facilities that meet the needs of those physicians and their patients, physicians may choose not to refer patients to our facilities, admissions and outpatient visits may decrease, and our operating performance may decline.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our labor costs have been, and we expect will continue to be, adversely affected by competition for staffing, the shortage of experienced nurses and other healthcare professionals, and labor union activity.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are dependent on the availability, efforts, abilities and experience of management and medical support personnel, including nurses, therapists, pharmacists and lab technicians, among others. We have always competed with other healthcare providers in recruiting and retaining these employees; however, over the past several years, our industry has been facing considerable workforce challenges. Like other hospital companies, we continue to experience a shortage of advanced practice providers and critical&#8209;care nurses in certain disciplines and geographic areas. The COVID&#8209;19 pandemic exacerbated these shortages &#8211; and, thereby, competition for qualified candidates &#8211; as more employees chose to retire early, leave the workforce or take travel assignments. We expect these impacts may persist beyond the duration of the pandemic. In addition, in some areas, the increased demand for care of patients with COVID&#8209;19, influenza and other respiratory viruses in our hospitals, as well as the direct impact of these illnesses on physicians, employees and their families, have put a strain on our resources and staff. As a result of the aforementioned challenges, we have been, and we may continue to be, required to enhance wages and benefits to recruit and retain experienced employees, pay premiums above standard compensation for essential workers, make greater investments in education and training for newly licensed medical support personnel, or hire more expensive temporary or contract employees, which we also compete with other healthcare providers to secure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also depend on the available labor pool of semi&#8209;skilled and unskilled workers in each of the areas where we operate. In some of our communities, employers across various industries have increased their minimum wage, which has created more competition and, in some cases, higher labor costs for this sector of employees. In addition, we expect that inflationary pressures, which we are unable to predict or control, will continue to impact our salaries, wages and benefits expense in the future. Furthermore, state&#8209;mandated nurse&#8209;staffing ratios in California affect not only our labor costs, but they also cause us to limit admissions if we do not have the necessary number of nurses available to meet the required ratios, which has a corresponding adverse effect on our revenues. If other states adopt similarly restrictive staffing laws, these impacts would be compounded and could be material.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased labor union activity is another factor that can adversely affect our labor costs. At December&#160;31,&#160;2022, approximately 26% of the employees in our Hospital Operations segment were represented by labor unions. Unionized employees&#160;&#8211; primarily registered nurses and service, technical and maintenance workers&#160;&#8211; are located at 33 of our hospitals, the majority of which are in California, Florida and Michigan. Organizing activities by labor unions could increase our level of union representation in future periods. When we are negotiating collective bargaining agreements with unions (whether such agreements are renewals or first contracts), work stoppages and strikes may be threatened or occur, as they did at one of our hospitals in 2021. Extended strikes have had, and could in the future have, an adverse effect on our patient volumes, net operating revenues and labor costs at individual hospitals or in local markets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our failure to successfully recruit qualified employees, manage attrition, avoid labor disruptions, control costs and plan for future labor needs could have a material adverse effect on our ability to treat patients and our overall business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our hospitals, outpatient centers and other healthcare businesses operate in competitive environments, and competition in our markets can adversely affect patient volumes and other aspects of our operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our hospitals and outpatient facilities compete within local communities on the basis of many factors, including: quality of care; location and ease of access; the scope and breadth of services offered; reputation; and the caliber of the facilities, equipment and employees. Furthermore, healthcare consumers are now able to access hospital performance data on quality measures and patient satisfaction, as well as standard charges for services, to compare competing providers. The No&#160;Surprises Act created additional price transparency requirements beginning January&#160;1,&#160;2022, including requiring providers to send to health plans of insured patients and to uninsured patients good faith estimates of the expected charges and diagnostic codes prior to the scheduled dates of services. If any of our hospitals achieve poor results (or results that are lower than our competitors) on quality measures or patient satisfaction surveys, or if our standard charges are or are perceived to be higher than our competitors, we may attract fewer patients. In addition, the competitive positions of hospitals and outpatient facilities depend in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who are members of the medical staffs of those facilities, as well as physicians who affiliate with and use outpatient centers as an extension of their practices. We compete with system&#8209;affiliated hospitals and healthcare companies, as well as health insurers and private equity companies, in recruiting physicians, acquiring physician practices and, where permitted by law, employing physicians.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the hospitals that compete with our hospitals are owned by tax&#8209;supported government agencies, and many others are owned by not&#8209;for&#8209;profit organizations that may have financial advantages not available to our facilities, including (1)&#160;support through endowments, charitable contributions and tax revenues, (2)&#160;access to tax&#8209;exempt financing, and (3)&#160;exemptions from sales, property and income taxes. In addition, in certain areas in which we operate, large teaching hospitals provide highly specialized facilities, equipment and services that may not be available at most of our hospitals. The existence or absence of state laws that require findings of need for construction and expansion of healthcare facilities or services may also impact competition. In recent years, the number of freestanding specialty hospitals, surgery centers, EDs and imaging centers in the geographic areas in which we operate has increased significantly. Some of these facilities are physician&#8209;owned.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another major factor in the competitive position of a hospital or outpatient facility is the scope of its relationships with managed care plans given that HMOs, PPOs, third&#8209;party administrators and other third&#8209;party payers use managed care contracts to encourage patients to use certain hospitals in exchange for discounts from the hospitals&#8217; established charges. Generally, we compete for managed care contracts on the basis of price, market reputation, geographic location, quality and range of services, caliber of the medical staff and convenience. Other healthcare providers may affect our ability to enter into acceptable managed care contractual arrangements or negotiate commercial rate increases. For example, some of our competitors may negotiate exclusivity provisions with managed care plans or otherwise restrict the ability of managed care companies to contract with us. Vertical integration efforts involving third&#8209;party payers and healthcare providers, among other factors, may increase competitive challenges.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our competitors are better able to attract patients, recruit physicians, expand services or obtain favorable managed care contracts at their facilities than we are, we may experience an overall decline in patient volumes.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be significantly and negatively impacted by security threats, catastrophic events and other disruptions affecting our information technology and related systems.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems are critical to the day&#8209;to&#8209;day operation of our business. We rely on our information technology to process, transmit and store clinical, financial and operational data that includes PHI, personally identifiable information, and proprietary and confidential business data. We utilize electronic health records and other information technology in connection with all of our operations, including our billing and other financial systems, supply chain and labor management tools. Our systems, in turn, interface with and rely on third&#8209;party systems that we do not control, including medical devices and other processes supporting the interoperability of healthcare infrastructures. We rely on these third&#8209;party providers to have appropriate controls to protect confidential information and other sensitive or regulated data. While we seek to obtain assurances that third parties will protect our information, there is a risk the security of data held by such third parties could be breached. We monitor and routinely test our security systems and processes and have a diversified data network that provides redundancies as well as other measures designed to protect the integrity, security and availability of the data we process, transmit and store. However, the information technology and infrastructure we use, and the third&#8209;party systems we interact with, have been, and will likely continue to be, subject to computer viruses, attacks by hackers, or breaches due to malfeasance or employee error. The COVID&#8209;19 pandemic placed additional stress on our information technology systems, and the risk of attack, breach or other disruption to these systems remains elevated in the current environment. In April&#160;2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information. We continue to face a heightened risk of cybersecurity threats targeting healthcare providers, including ransomware attacks.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, attacks on, or breaches or other disruptions to, our information technology assets or those of third parties that we rely upon could impact the integrity, security or availability of data we process, transmit or store. The preventive actions we take to reduce the risk of such incidents and protect our information technology may not be sufficient. As cybersecurity threats continue to evolve, we may not be able to anticipate certain attack methods in order to implement effective protective measures, and we continue to be required to expend significant additional resources to modify and strengthen our security measures, investigate and remediate any vulnerabilities in our information systems and infrastructure, and invest in new technology designed to mitigate security risks. Our insurance against cyber&#8209;risks and attacks may not provide the coverage we anticipate or offset the financial impact of a material loss event. In addition, the elevated risk of ransomware attacks, breaches and other disruptions to information technology systems in the current environment has caused increases in our cyber premiums and lower coverage limits.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties to whom we outsource certain of our functions, or with whom our systems interface and who may, in some instances, store our sensitive and confidential data, are also subject to the risks outlined above and may not have or use controls effective to protect such information. An attack, breach or other system disruption affecting any of these third parties could similarly harm our business. Further, successful cyber&#8209;attacks at other healthcare services companies, whether or not we are impacted, could lead to a general loss of consumer confidence in our industry that could negatively affect us, including harming the market perception of the effectiveness of our security measures or of the healthcare industry in general, which could result in reduced use of our services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our networks and technology systems have also experienced disruption due to planned events, such as system implementations, upgrades, and other maintenance and improvements, and they are subject to disruption in the future for similar events, as well as catastrophic events, including a major earthquake, fire, hurricane, telecommunications failure, terrorist attack or the like.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any ransomware attack, breach, system interruption or unavailability of our information systems or of third-party systems with access to our data could result in: the unauthorized disclosure, misuse, loss or corruption of such data; interruptions and delays in our normal business operations (including the collection of revenues); patient harm; potential liability under privacy, security, consumer protection or other applicable laws; regulatory penalties; and negative publicity and damage to our reputation. Any of these could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot predict the impact healthcare reform efforts may have on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions, along with reductions in Medicare and Medicaid reimbursement to healthcare providers, including us. However, there is ongoing uncertainty with respect to the ultimate net effect of the Affordable Care Act due to the potential for continued changes in the law&#8217;s implementation and how government agencies and courts interpret it. Moreover, we cannot predict what future action, if any, Congress might take to amend the Affordable Care Act. If future modifications or interpretations result in significantly fewer individuals having private or public health coverage, we likely will experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect our results of operations and cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also uncertainty regarding the potential impact of other healthcare-related reform efforts at the federal and state levels. Some reform initiatives, requirements and proposals could increase our operating costs, negatively impact our case mix, adversely affect the reimbursement we receive for our services or require us to expend resources to modify certain aspects of our operations. Moreover, some current reforms could impact our competitive position, as well as our relationships with insurers and patients, including the No Surprises Act and CMS&#8217; rules relating to hospital price transparency.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The industry trends toward value-based purchasing and alternative payment models may negatively impact our revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value&#8209;based purchasing and alternative payment model initiatives of both governmental and private payers tying financial incentives to quality and efficiency of care will increasingly affect the results of operations of our hospitals and other healthcare facilities, and may negatively impact our revenues if we are unable to meet expected quality standards. Medicare requires providers to report certain quality measures in order to receive full reimbursement increases for inpatient and outpatient procedures that were previously awarded automatically; each year, CMS updates these measures through refinement or removal of existing measures and the addition of new measures. Moreover, hospitals that meet or exceed certain quality performance standards will receive increased reimbursement payments, and hospitals that have &#8220;excess readmissions&#8221; for specified conditions will receive reduced reimbursement. The COVID&#8209;19 pandemic has been a disruptive force for CMS&#8217; quality measurement programs; as a result, we expect there will continue to be volatility with respect to readmission penalties in the near term. Furthermore, Medicare no longer pays hospitals additional amounts for the treatment of certain hospital&#8209;acquired conditions (&#8220;HACs&#8221;), unless the conditions were present at admission. Hospitals that rank in the worst 25% of all hospitals nationally for HACs in the previous year receive reduced Medicare reimbursements. In addition, the Affordable Care Act prohibits the use of federal funds under the Medicaid program to reimburse providers for treating certain provider&#8209;preventable conditions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act also created the CMS Innovation Center to develop and test innovative payment and service delivery models that have the potential to reduce Medicare, Medicaid or Children&#8217;s Health Insurance Program expenditures while preserving or enhancing the quality of care for beneficiaries. Congress has defined&#160;&#8211; both through the Affordable Care Act and previous legislation&#160;&#8211; a number of specific demonstrations for CMS to conduct, including bundled payment models. Generally, the bundled payment models hold hospitals financially accountable for the quality and costs for an entire episode of care for a specific diagnosis or procedure from the date of the hospital admission or inpatient procedure through 90&#160;days post&#8209;discharge, including services not provided by the hospital, such as physician, inpatient rehabilitation, skilled nursing and home health care. Provider participation in some of these models is voluntary; however, participation in certain other bundled payment arrangements is mandatory for providers located in randomly selected geographic locations. Under the mandatory models, hospitals are eligible to receive incentive payments or will be subject to payment reductions within certain corridors based on their performance against quality and spending criteria. It is difficult to predict what impact, if any, these demonstration programs will have on our inpatient volumes, net revenues or cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also trends among private payers toward value&#8209;based purchasing and alternative payment models for healthcare services. Many large commercial payers expect hospitals to report quality data, and several of these payers will not reimburse hospitals for certain preventable adverse events. We expect value&#8209;based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable at this time to predict how the industry trends toward value&#8209;based purchasing and alternative payment models will affect our results of operations, but they could negatively impact our revenues, particularly if we are unable to meet the quality and cost standards established by both governmental and private payers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Violations of existing regulations or failure to comply with new or changed regulations could harm our business and financial results.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospitals, outpatient centers and related healthcare businesses are subject to an extensive and complex framework of government regulation at the federal, state and local levels. These legal and regulatory standards relate to, among other topics: ownership and operation of facilities and physician practices; licensure, certification and enrollment in government programs; the necessity and adequacy of medical care; quality of medical equipment and services; relationships with and qualifications of physicians and employees; operating conduct, policies and procedures; screening, stabilization and transfer of individuals who have emergency medical conditions; rate&#8209;setting, billing and coding for services; the preparation and filing of cost reports; the handling of overpayments; contractual arrangements; relationships with referral sources and referral recipients; privacy and security; maintenance of adequate records; construction, acquisition, expansion and closure of healthcare facilities or services; environmental protection; compliance with fire prevention and building codes; debt collection; and communications with patients and consumers. In addition, various permits are required to dispense narcotics, operate pharmacies, handle radioactive materials and operate certain equipment. Our facilities are also subject to periodic inspection by governmental and other authorities to determine their compliance with applicable regulations, as well as the standards necessary for licensing and accreditation.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies and procedures we have in place to facilitate compliance with applicable laws, rules and regulations cannot ensure compliance in every case. Moreover, government regulations often change, and we may have to make adjustments to our facilities, equipment, personnel and services to remain in compliance. The potential consequences for failing to comply with applicable laws, rules and regulations include (1)&#160;required refunds of previously received government program payments, (2)&#160;the assessment of civil monetary penalties, including treble damages, (3)&#160;fines, which could be significant, (4)&#160;exclusion from participation in federal healthcare programs and (5)&#160;criminal sanctions, including sanctions against current or former employees. Our Medicare and Medicaid payments may be suspended pending even an investigation of what the government determines to be a credible allegation of fraud. Any of the aforementioned consequences could have a material adverse effect on our business, financial condition, results of operations or cash flows. Furthermore, even a public announcement that we are being investigated for possible violations of law could have a material adverse effect on the value of our common stock and our business reputation could suffer.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the healthcare industry continues to attract much legislative interest and public attention. We are unable to predict the future course of federal, state and local healthcare legislation, regulation or enforcement efforts. Further changes in the regulatory framework negatively affecting healthcare providers could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to substantial uninsured liabilities or increased insurance costs as a result of significant legal actions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to medical malpractice lawsuits, antitrust claims and other legal actions in the ordinary course of business. In addition, from time to time, we have been and expect to continue to be subject to regulatory proceedings and private litigation (including employee class action lawsuits) concerning our application of various federal and state labor laws, rules and regulations governing a variety of workplace wage and hour issues. Some of these actions involve large demands, as well as substantial defense costs. Even in states that have imposed caps on damages, litigants are seeking recoveries under new theories of liability that might not be subject to such caps. Our commercial insurance does not cover all claims against us and may not offset the financial impact of a material loss event. Moreover, commercial insurance may not continue to be available at a reasonable cost for us to maintain at adequate levels. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us or on our insurance costs. Additionally, professional and general liability insurance we purchase is subject to per-claim and policy period aggregate limits. If the policy period aggregate limit of any of these policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay other material claims applicable to that policy period. Any losses not covered by or in excess of the amounts maintained under insurance policies will be funded from our working capital or other sources of liquidity. Furthermore, one or more of our insurance carriers could become insolvent and unable to fulfill its or their obligations to defend, pay or reimburse us when those obligations become due. In that case or if payments of claims exceed our estimates or are not covered by insurance, it could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any future cost-reduction initiatives may not deliver the benefits we expect, and actions taken may adversely affect our business.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and level of profitability may depend, in part, on various cost&#8209;reduction initiatives, including the outsourcing of certain functions unrelated to direct patient care. We may encounter challenges in executing cost&#8209;reduction initiatives and not achieve the intended cost savings. In addition, we may face wrongful termination, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrimination or other legal claims from employees affected by any workforce reductions, and we may incur substantial costs defending against such claims, regardless of their merits. The threat of such claims may also significantly increase our severance costs. Workforce reductions, whether as a result of internal restructuring or in connection with outsourcing efforts, may result in the loss of numerous long&#8209;term employees, the loss of institutional knowledge and expertise, the reallocation of certain job responsibilities and the disruption of business continuity, all of which could negatively affect operational efficiencies and increase our operating expenses in the short term. Moreover, outsourcing and offshoring expose us to additional risks, such as reduced control over operational quality and timing, foreign political and economic instability, compliance and regulatory challenges, and natural disasters not typically experienced in the United States, such as volcanic activity and tsunamis.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trends affecting our actual or anticipated results may require us to record impairment and restructuring charges that may negatively impact our results of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of factors that have negatively affected our industry generally and our business specifically, we have been, and in the future expect to be, required to record various charges in our results of operations. During the year ended December&#160;31,&#160;2022, we recorded $94 million of impairment charges and $118 million of restructuring charges. Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility&#8217;s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long&#8209;lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material. We believe significant factors that contribute to adverse financial trends include reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. Future restructuring of our operating structure that changes our goodwill reporting units could also result in future impairments of our goodwill. Any such charges could negatively impact our results of operations.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3689"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Acquisitions, Divestitures and Joint Ventures</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">When we acquire new assets or businesses, we become subject to various risks and uncertainties that could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a number of acquisitions in recent years, and we expect to pursue additional transactions in the future. A key business strategy for USPI, in particular, is the acquisition and development of facilities, primarily through the formation of joint ventures with physicians and health system partners. With respect to planned or future transactions, we cannot provide any assurances that we will be able to identify suitable candidates, consummate transactions on terms that are favorable to us, or achieve synergies or other benefits in a timely manner or at all. Furthermore, companies or operations we acquire may not be profitable or may not achieve the profitability that justifies the investments made. Businesses we acquire may also have pre&#8209;existing unknown or contingent liabilities, including liabilities for failure to comply with applicable healthcare regulations. These liabilities could be significant, and, if we are unable to exclude them from the acquisition transaction or successfully obtain and pursue indemnification from a third party, they could harm our business and financial condition. In addition, we may be unable to timely and effectively integrate ASCs, physician practices and other businesses that we acquire with our ongoing operations, or we may experience delays implementing operating procedures, personnel and systems, which could impact the financial performance of the acquired business. Significant acquisitions have required, and may in the future require, a substantial investment of time and resources across our enterprise; these efforts may affect management focus and impact our ability to properly prioritize and successfully execute on our other strategic initiatives. Moreover, future acquisitions could result in the incurrence of additional debt and contingent liabilities, potentially dilutive issuances of equity securities, and increased operating expenses, any of which could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot provide any assurances that we will be successful in divesting assets we wish to sell.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to exit service lines and businesses that we believe are no longer a core part of our long&#8209;term growth and synergy strategies. We cannot provide any assurances that completed, planned or future divestitures or other strategic transactions will achieve their business goals or the benefits we expect.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past, and may in the future, fail to obtain applicable regulatory approvals, including FTC approvals, with respect to planned divestitures of assets or businesses. Moreover, we may encounter difficulties in finding acquirers or alternative exit strategies on terms that are favorable to us, which could delay the receipt of anticipated proceeds necessary for us to complete our planned strategic objectives. In addition, our divestiture activities have required, and may in the future require, us to retain significant pre&#8209;closing liabilities, recognize impairment charges (as discussed above) or agree to contractual restrictions that limit our ability to reenter a particular market, which may be material. Many of our acute care hospital divestitures also necessitate us entering into a transition services agreement with the buyer for information technology and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related services. As a consequence, we may be exposed to the financial status of the buyer for any payments under such transition services agreements or for transferred contractual liabilities, which could be significant.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our divestiture and other corporate development activities may present financial and operational risks, including (1)&#160;the diversion of management attention from existing core businesses, (2)&#160;adverse effects (including a deterioration in the related asset or business) from the announcement of the planned or potential activity, and (3)&#160;the challenges associated with separating personnel and financial and other systems.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USPI and our hospital-based joint ventures depend on existing relationships with key health system partners. If we are unable to maintain synergistic relationships with these systems, or enter into new relationships, we may be unable to implement our business strategies successfully.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPI and our hospital&#8209;based joint ventures depend in part on the efforts, reputations and success of health system partners and the strength of our relationships with those systems. Our joint ventures could be adversely affected by any damage to those health systems&#8217; reputations or to our relationships with them. In addition, damage to our business reputation could negatively impact the willingness of health systems to enter into relationships with us or USPI. If we are unable to maintain existing arrangements on favorable terms or enter into relationships with additional health system partners, we may be unable to implement our business strategies for our joint ventures successfully.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our joint venture arrangements are subject to a number of operational risks that could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested in a number of joint ventures with other entities when circumstances warranted the use of these structures, and we may form additional joint ventures in the future. These joint ventures may not be profitable or may not achieve the profitability that justifies the investments made. Furthermore, the nature of a joint venture requires us to consult with and share certain decision&#8209;making powers with unaffiliated third parties, some of which may be not&#8209;for&#8209;profit health systems. If our joint venture partners do not fulfill their obligations, the affected joint venture may not be able to operate according to its business or strategic plans. In that case, our results of operations could be adversely affected or we may be required to increase our level of financial commitment to the joint venture. Moreover, differences in economic or business interests or goals among joint venture participants could result in delayed decisions, failures to agree on major issues and even litigation. If these differences cause the joint ventures to deviate from their business or strategic plans, or if our joint venture partners take actions contrary to our policies, objectives or the best interests of the joint venture, our results of operations could be adversely affected. In addition, our relationships with not&#8209;for&#8209;profit health systems and the joint venture agreements that govern these relationships are intended to be structured to comply with current revenue rulings published by the Internal Revenue Service, as well as case law relevant to joint ventures between for&#8209;profit and not&#8209;for&#8209;profit healthcare entities. Material changes in these authorities could adversely affect our relationships with not&#8209;for&#8209;profit health systems and related joint venture arrangements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our participation in joint ventures is also subject to the risks that:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We could experience an impasse on certain decisions because we do not have sole decision&#8209;making authority, which could require us to expend additional resources on resolving such impasses or potential disputes.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to maintain good relationships with our joint venture partners (including health systems), which could limit our future growth potential and could have an adverse effect on our business strategies.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our joint venture partners could have investment or operational goals that are not consistent with our corporate&#8209;wide objectives, including the timing, terms and strategies for investments or future growth opportunities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our joint venture partners might become bankrupt, fail to fund their share of required capital contributions or fail to fulfill their other obligations as joint venture partners, which may require us to infuse our own capital into any such venture on behalf of the related joint venture partner or partners despite other competing uses for such capital.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The requirements in many of our existing joint ventures that one of our wholly owned subsidiaries provide a working capital line of credit to the joint venture could necessitate the allocation of substantial financial resources to the joint venture, potentially impacting our ability to fund our other short&#8209;term obligations.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provisions in some of our existing joint venture arrangements requiring mandatory capital expenditures for the benefit of the applicable joint venture could limit our ability to expend funds on other corporate opportunities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our joint venture partners may have competing interests in our markets that could create conflict of interest issues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any sale or other disposition of our interest in a joint venture or underlying assets of the joint venture may require consents from our joint venture partners, which we may not be able to obtain.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Certain corporate&#8209;wide or strategic transactions may also trigger other contractual rights held by a joint venture partner (including termination or liquidation rights) depending on how the transaction is structured, which could impact our ability to complete such transactions.</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Put/call arrangements and other joint venture exit rights could require us to utilize our cash flow, incur additional indebtedness or issue stock to satisfy the payment obligations in respect of such arrangements.</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our joint venture arrangements that involve financial and ownership relationships with physicians and others who either refer or influence the referral of patients to our hospitals or other healthcare facilities are subject to greater regulatory scrutiny from government enforcement agencies. While we endeavor to comply with the applicable safe harbors under the Anti&#8209;kickback Statute, certain of our current arrangements, including joint venture arrangements, do not qualify for safe harbor protection.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3715"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Conifer</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conifer operates in a highly competitive industry, and its current or future competitors may be able to compete more effectively than Conifer does, which could have a material adverse effect on Conifer&#8217;s margins and growth rate.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to market Conifer&#8217;s revenue cycle management, patient communications and engagement services, and value&#8209;based care solutions businesses. There can be no assurance that Conifer will be successful in generating new client relationships, including with respect to hospitals we or Conifer&#8217;s other clients sell, as the respective buyers of such hospitals may not continue to use Conifer&#8217;s services or, if they do, they may not do so under similar contractual terms. The market for Conifer&#8217;s solutions is highly competitive, and we expect competition may intensify in the future. Conifer faces competition from existing participants and new entrants to the revenue cycle management business, as well as from the staffs of hospitals and other healthcare providers who handle these processes internally. In addition, electronic medical record software vendors may expand into services offerings that compete with Conifer. To be successful, Conifer must respond more quickly and effectively than its competitors to new or changing opportunities, technologies, standards, regulations and client requirements. Moreover, existing or new competitors may introduce technologies or services that render Conifer&#8217;s technologies or services obsolete or less marketable. Even if Conifer&#8217;s technologies and services are more effective than the offerings of its competitors, current or potential clients might prefer competitive technologies or services to Conifer&#8217;s technologies and services. Furthermore, increased competition has resulted and may continue to result in pricing pressures, which could negatively impact Conifer&#8217;s margins and growth rate.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Violations of existing regulations or failure to comply with new or changed regulations could harm Conifer&#8217;s business and financial results.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer is subject to numerous federal, state and local consumer protection and other laws governing such topics as privacy, financial services, and billing and collections activities. Regulations governing Conifer&#8217;s operations are subject to changing interpretations that may be inconsistent among different jurisdictions. In addition, a regulatory determination made by, or a settlement or consent decree entered into with, one regulatory agency may not be binding upon, or preclude, investigations or regulatory actions by other agencies. Conifer&#8217;s failure to comply with applicable consumer protection and other laws could result in, among other things, the issuance of cease and desist orders (which can include orders for restitution or rescission of contracts, as well as other kinds of affirmative relief), the imposition of fines or refunds, and other civil and criminal penalties, some of which could be significant in the case of knowing or reckless violations. In addition, Conifer&#8217;s failure to comply with the statutes and regulations applicable to it could result in reduced demand for its services, invalidate all or portions of some of Conifer&#8217;s services agreements with its clients, give clients the right to terminate Conifer&#8217;s services agreements with them or give rise to contractual liabilities, among other things, any of which could have a material adverse effect on Conifer&#8217;s business. Furthermore, if Conifer becomes subject to fines or other penalties, it could harm Conifer&#8217;s reputation, thereby making it more difficult for Conifer to retain existing clients or attract new clients.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3741"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Indebtedness</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our level of indebtedness could, among other things, adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, and prevent us from meeting our obligations under the agreements relating to our indebtedness.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, we had approximately $15.079 billion of total long&#8209;term debt, as well as $116&#160;million in standby letters of credit outstanding in the aggregate under our senior secured revolving credit facility (as amended, &#8220;Credit Agreement&#8221;) and our letter of credit facility agreement (as amended, &#8220;LC Facility&#8221;). Our Credit Agreement is collateralized by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eligible inventory and patient accounts receivable, including receivables for Medicaid supplemental payments, of substantially all of our wholly owned acute care and specialty hospitals, and our LC Facility is guaranteed and secured by a first priority pledge of the capital stock and other ownership interests of certain of our hospital subsidiaries on an equal&#8209;ranking basis with our existing senior secured notes. From time to time, we expect to engage in additional capital market, bank credit and other financing activities, depending on our needs and financing alternatives available at that time.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense associated with our indebtedness offsets a substantial portion of our operating income. During 2022, our interest expense was $890&#160;million and represented 38% of our $2.333&#160;billion of operating income. As a result, relatively small percentage changes in our operating income can result in a relatively large percentage change in our net income and earnings per share, both positively and negatively. In addition:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our substantial indebtedness may limit our ability to adjust to changing market conditions and place us at a competitive disadvantage compared to our competitors that have less debt.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be more vulnerable in the event of a deterioration in our business, in the healthcare industry or in the economy generally, or if federal or state governments substantially limit or reduce reimbursement under the Medicare or Medicaid programs.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our debt service obligations reduce the amount of funds available for our operations, capital expenditures and corporate development activities, and may make it more difficult for us to satisfy our financial obligations.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are capital intensive and require significant investment to maintain buildings, equipment, software and other assets. Our substantial indebtedness could limit our ability to obtain additional financing to fund future capital expenditures, as well as working capital, acquisitions or other needs.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our significant indebtedness may result in the market value of our stock being more volatile, potentially resulting in larger investment gains or losses for our shareholders, than the market value of the common stock of other companies that have a relatively smaller amount of indebtedness.</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant portion of our outstanding debt is subject to early prepayment penalties, such as make&#8209;whole premiums; as a result, it may be costly to pursue debt repayment as a deleveraging strategy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our Credit Agreement, our LC Facility and the indentures governing our outstanding notes contain, and any future debt obligations may contain, covenants that, among other things, restrict our ability to pay dividends, incur additional debt and sell assets.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to generate sufficient cash to service all of our indebtedness, and we may not be able to refinance our indebtedness on favorable terms. If we are forced to take other actions to satisfy our obligations under our indebtedness, these actions may not be successful.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments on or to refinance our indebtedness depends on our financial and operating performance, which is subject to prevailing economic and competitive conditions and to financial, business and other factors that may be beyond our control. We cannot assure you that we will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to meet our debt service obligations is dependent upon the operating results of our subsidiaries and their ability to pay dividends or make other payments or advances to us. We hold most of our assets at, and conduct substantially all of our operations through, direct and indirect subsidiaries. Moreover, we rely on dividends or other intercompany transfers of funds from our subsidiaries to meet our debt service and other obligations, including payment on our outstanding debt. The ability of our subsidiaries to pay dividends or make other payments or advances to us will depend on their operating results and will be subject to applicable laws and restrictions contained in agreements governing the debt of such subsidiaries. Our less than wholly owned subsidiaries may also be subject to restrictions on their ability to distribute cash to us in their financing or other agreements and, as a result, we may not be able to access their cash flows to service their respective debt obligations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have regularly issued new notes to refinance our outstanding notes prior to their maturity, and we are likely to continue this practice in the future. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods should we seek additional funding. Moreover, global capital markets have experienced significant volatility and uncertainty in the past, and there can be no assurance that such financing alternatives will be available to us on favorable terms, or at all, should we determine it necessary or advisable to seek additional capital. In addition, our ability to incur secured indebtedness (which would generally enable us to achieve better pricing than the incurrence of unsecured indebtedness) depends in part on the value </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our assets, which depends, in turn, on the strength of our cash flows and results of operations, as well as on economic and market conditions and other factors.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our cash flows and capital resources are insufficient to fund our debt service obligations and we are unable to refinance our indebtedness on acceptable terms, we may be forced to reduce or delay investments and capital expenditures, including those required for physical plant maintenance or operation of our existing facilities, for integrating our historical acquisitions or for future corporate development activities, and such reduction or delay could continue for years. We also may be forced to sell assets or operations, seek additional capital, or restructure our indebtedness. We cannot assure you that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled debt service obligations, or that these actions would be permitted under the terms of our existing or future debt agreements, including our Credit Agreement, our LC Facility and the indentures governing our outstanding notes.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restrictive covenants in the agreements governing our indebtedness may adversely affect us.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement, our LC Facility and the indentures governing our outstanding notes contain various covenants that, among other things, limit our ability and the ability of our subsidiaries to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur, assume or guarantee additional indebtedness;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur liens;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide subsidiary guarantees;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consummate asset sales;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redeem debt that is subordinated in right of payment to outstanding indebtedness;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into sale and lease&#8209;back transactions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into transactions with affiliates; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consolidate, merge or sell all or substantially all of our assets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These restrictions are subject to a number of important exceptions and qualifications. In addition, under certain circumstances, the terms of our Credit Agreement require us to maintain a financial ratio relating to our ability to satisfy certain fixed expenses, including interest payments. Our ability to meet this financial ratio and the aforementioned restrictive covenants may be affected by events beyond our control, and we cannot assure you that we will meet those tests. These restrictions could limit our ability to obtain future financing, make acquisitions or needed capital expenditures, withstand economic downturns in our business or the economy in general, conduct operations or otherwise take advantage of business opportunities that may arise. In addition, a breach of any of these covenants could cause an event of default, which, if not cured or waived, could require us to repay the indebtedness immediately. Under these conditions, we are not certain whether we would have, or be able to obtain, sufficient funds to make accelerated payments.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite current indebtedness levels, we have the ability and may decide to incur substantially more debt or otherwise increase our leverage. This could further intensify the risks described above.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to incur additional indebtedness in the future, subject to the restrictions contained in our Credit Agreement, our LC Facility and the indentures governing our outstanding notes. We may decide to incur additional secured or unsecured debt in the future to finance our operations and any judgments or settlements or for other business purposes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement provides for revolving loans in an aggregate principal amount of up to $1.500 billion, with a $200 million subfacility for standby letters of credit. Our LC Facility provides for the issuance of standby and documentary letters of credit in an aggregate principal amount of up to $200&#160;million. At December&#160;31,&#160;2022, we had no cash borrowings outstanding under the Credit Agreement, and we had $116&#160;million of standby letters of credit outstanding in the aggregate under the Credit Agreement and the LC Facility. Based on our eligible receivables, $1.500&#160;billion was available for borrowing under the Credit Agreement at December&#160;31,&#160;2022. If new indebtedness is added or our leverage increases, the related risks that we now face could intensify.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_22"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_25"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure required under this Item is included in Item 1, Business, of Part I of this report.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_28"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material pending legal proceedings in which we are involved, see Note 17 to our Consolidated Financial Statements, which is incorporated by reference.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_31"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_37"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:40.5pt;text-indent:-38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our common stock is listed on the New York Stock Exchange under the symbol &#8220;THC.&#8221; As of February 10, 2023, there were 3,447 holders of record of our common stock. Our transfer agent and registrar is Computershare. Shareholders with questions regarding their stock certificates, including inquiries related to exchanging or replacing certificates or changing an address, should contact the transfer agent at (866) 229&#8209;8416.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Refer to Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, of Part&#160;III of this report, as well as Note 10 to our Consolidated Financial Statements, for information regarding securities authorized for issuance under our equity compensation plans.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Performance Graph</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The following graph shows the cumulative, five&#8209;year total return for our common stock compared to the following indices:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The S&amp;P 500, a stock market index that measures the equity performance of 500 large companies listed on the stock exchanges in the United States (in which we are not included);</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The S&amp;P 500 Health Care, a stock market index comprised of those companies included in the S&amp;P 500 that are classified as part of the healthcare sector (in which we are not included); and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A group made up of us and our healthcare provider peers (namely, Community Health Systems, Inc. (CYH), HCA&#160;Healthcare, Inc. (HCA), Tenet&#160;Healthcare Corporation (THC) and Universal&#160;Health Services, Inc. (UHS)), which we refer to as our &#8220;Peer&#160;Group&#8221; herein.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance data assumes that $100.00 was invested on December&#160;31, 2017 in our common stock and each of the indices. The data assumes the reinvestment of all cash dividends and the cash value of other distributions, if any. Moreover, in accordance with U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) regulations, the returns of each company in our Peer&#160;Group have been weighted according to the respective company&#8217;s stock market capitalization at the beginning of each period for which a return is indicated. The stock price performance shown in the graph is not necessarily indicative of future stock price performance.&#160;The performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of&#160;1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference into any of our filings under the Securities Act of&#160;1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:center;text-indent:36pt"><img src="thc-20221231_g2.jpg" alt="thc-20221231_g2.jpg" style="height:450px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenet Healthcare Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P Health Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peer Group</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repurchase of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In October&#160;2022, our board of directors authorized the repurchase of up to $1&#160;billion of our common stock through a share repurchase program. Purchases during the period from the commencement of the program through December&#160;31,&#160;2022 are presented in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Dollar Value of Shares That May Yet be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception through October&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November&#160;1 through November&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;1 through December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inception through December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,889</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,889</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These repurchases were made, and future repurchases will be made, in open&#8209;market or privately negotiated transactions, at management&#8217;s discretion subject to market conditions and other factors, and in a manner consistent with applicable securities laws and regulations. The share repurchase program does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time before its scheduled expiration date of December&#160;31,&#160;2024.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_40"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. RESERVED</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION TO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of this section, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide context to the analysis of our financial information, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&amp;A, which should be read in conjunction with the accompanying Consolidated Financial Statements, includes the following sections:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management Overview</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sources of Revenue for Our Hospital Operations Segment</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Results of Operations</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Critical Accounting Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business consists of our Hospital Operations and other (&#8220;Hospital Operations&#8221;) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#8209;hospitals and physician practices. At December&#160;31,&#160;2022, our subsidiaries operated 61&#160;hospitals serving primarily urban and suburban communities in nine states, including Piedmont Medical Center Fort Mill (&#8220;PMC&#160;Fort&#160;Mill&#8221;), the new acute care hospital we opened in South Carolina in September&#160;2022. Our Hospital Operations segment also included 109 outpatient centers at December&#160;31,&#160;2022, the majority of which are provider&#8209;based and freestanding imaging centers, off&#8209;campus hospital emergency departments and micro-hospitals, and provider&#8209;based ambulatory surgery centers (each, an&#160;&#8220;ASC&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment, through our USPI Holding Company, Inc. subsidiary (&#8220;USPI&#8221;), held ownership interests in 442 ASCs (300&#160;consolidated) and 24&#160;surgical hospitals (eight consolidated) in 35&#160;states at December&#160;31,&#160;2022. USPI&#8217;s facilities offer a range of procedures and service lines, including, among other specialties: orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; and urology. At the beginning of 2022, we owned approximately 95% of USPI, and Baylor University Medical Center (&#8220;Baylor&#8221;) owned approximately 5%. Effective June&#160;30,&#160;2022, we purchased all of the shares in USPI that Baylor held on that date for $406&#160;million, which increased our ownership interest in USPI&#8217;s voting shares from 95% to 100%. See Note 18 to the accompanying Consolidated Financial Statements and the Liquidity and Capital Resources section of MD&amp;A for additional information about this transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients through our Conifer Holdings, Inc. subsidiary (&#8220;Conifer&#8221;). At December&#160;31,&#160;2022, Conifer provided services to approximately 660&#160;Tenet and non&#8209;Tenet hospitals and other clients nationwide. Almost all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC, in which we own an interest of approximately 76%, or by one of its direct or indirect wholly owned subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all financial and statistical information included in MD&amp;A relates to our continuing operations, with dollar amounts expressed in millions (except per&#8209;adjusted&#8209;admission and per&#8209;adjusted&#8209;patient&#8209;day amounts). Continuing operations information includes, with respect to our Hospital Operations segment, the results of our same 60&#160;hospitals operated throughout the years ended December&#160;31,&#160;2022 and 2021, as well as the results of (1)&#160;PMC&#160;Fort&#160;Mill, which we opened in September&#160;2022, (2) the five Miami-area hospitals and certain related operations (the &#8220;Miami Hospitals&#8221;) we sold in August&#160;2021, (3) nearly 50 urgent care centers held in our Hospital Operations segment until their sale in April&#160;2021 and (4) 24 imaging centers following their transfer from our Ambulatory Care segment to our Hospital Operations segment in April&#160;2021. Continuing operations information for our Ambulatory Care segment includes the results of 40 urgent care centers held in this segment until their sale and the results of 24 imaging centers until their transfer to our Hospital Operations segment, both of which occurred in April&#160;2021. Continuing operations information excludes the results of our hospitals and other businesses classified as discontinued operations for accounting purposes. We believe this information is useful to investors because it includes the operations of all facilities in continuing operations for the entire time that we owned and operated them during the relevant period. In addition, continuing operations information reflects the impact of the addition or disposition of individual hospitals and other operations on our volumes, revenues and expenses. We present certain metrics as a percentage of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net operating revenues because a significant portion of our operating expenses are variable. In addition, we present certain metrics on a per&#8209;adjusted&#8209;admission and per&#8209;adjusted&#8209;patient&#8209;day basis to show trends other than volume.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, information presented in MD&amp;A for our Hospital Operations segment is described as presented on a same&#8209;hospital basis, which includes the results of our same 60&#160;hospitals operated throughout the years ended December&#160;31,&#160;2022 and 2021, and excludes the results of PMC&#160;Fort&#160;Mill, the Miami Hospitals, all of the urgent care centers we sold in April&#160;2021, the 24 imaging centers transferred from our Ambulatory Care segment to our Hospital Operations segment in April&#160;2021, and our discontinued operations. We present same&#8209;hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other operations that are comparable for the periods presented. Furthermore, same&#8209;hospital data may more clearly reflect recent trends we are experiencing with respect to volumes, revenues and expenses exclusive of variations caused by the addition or disposition of individual hospitals and other operations.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_49"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT OVERVIEW</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3000"></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement to Divest San Ramon Regional Medical Center&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into a definitive agreement to sell our 51% ownership interest in San Ramon Regional Medical Center and related operations to John&#160;Muir&#160;Health. We expect the transaction to be completed in 2023, subject to regulatory approvals and customary closing conditions.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_3049"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OPERATING ENVIRONMENT AND TRENDS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ongoing Impact of the COVID-19 Pandemic&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the COVID&#8209;19 pandemic continued to adversely impact our operations, as well as our patients, communities and employees, to varying degrees. As described in greater detail throughout MD&amp;A, ongoing waves of COVID&#8209;19 infections, changes in COVID&#8209;related patient acuity and broad economic factors resulting from the pandemic affected our patient volumes, service mix, revenue mix, operating expenses and net operating revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various federal legislative actions, including additional funding for the Public Health and Social Services Emergency Fund (&#8220;PRF&#8221;), mitigated some of the adverse financial impacts of the COVID&#8209;19 pandemic on our business. In the years ended December&#160;31,&#160;2022 and 2021, we received cash payments from the PRF and state and local grant programs totaling $196&#160;million and $215&#160;million, respectively, including $37&#160;million received during 2021 by our unconsolidated affiliates for whom we provide cash management services. We recognized $194&#160;million and $191&#160;million from these funds as grant income during the years ended December&#160;31,&#160;2022 and 2021, respectively. In addition, we recognized $14&#160;million in equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statement of Operations during the year ended December&#160;31,&#160;2021 from grant funds.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, throughout the pandemic, we have taken, and we continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and changes in our service mix and revenue mix. As described in further detail in the Liquidity and Capital Resources section of MD&amp;A, we issued new senior unsecured notes and senior secured first lien notes, redeemed existing senior unsecured notes and senior secured first lien notes, including those with the highest interest rate of all of our long&#8209;term debt, and amended our senior secured revolving credit facility (as amended to date, the &#8220;Credit Agreement&#8221;). We also decreased our employee headcount throughout the organization at the outset of the COVID&#8209;19 pandemic, and we deferred certain operating expenses that were not expected to impact our response to the pandemic. In addition, we reduced certain variable costs across the enterprise. Together with government relief packages, we believe these actions supported our ability to provide essential patient services during the initial uncertainty caused by the COVID&#8209;19 pandemic and continue to do so.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate extent and scope of the pandemic and its future impact on our business remain unknown. For information about risks and uncertainties related to COVID&#8209;19 that could affect our results of operations, financial condition and cash flows, see the Risk&#160;Factors section in Part&#160;I of this report.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Staffing and Labor Trends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We compete with other healthcare providers in recruiting and retaining qualified personnel responsible for the operation of our facilities. There is a limited availability of experienced medical support personnel nationwide, which drives up the wages and benefits required to recruit and retain employees. In particular, like others in the healthcare industry, we continue to experience a shortage of advanced practice providers and critical&#8209;care nurses in certain disciplines and geographic areas. The COVID&#8209;19 pandemic exacerbated this shortage as more employees chose to retire early, leave the workforce or take travel assignments. In addition, the Centers for Disease Control and Prevention has released data indicating that the 2022&#8209;23 influenza season has thus far been more acute than in prior years compounded by concurrent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID&#8209;19 surges and increases in other respiratory viral infections. In some areas, the increased demand for care of patients with COVID&#8209;19, influenza and other respiratory viruses in our hospitals, as well as the direct impact of these illnesses on physicians, employees and their families, have put a strain on our resources and staff. Over the past several years, we have had to rely on higher-cost temporary and contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers. In general, compensation rates typically rise when overall case rates and hospitalizations increase, whether due to COVID, flu or other illnesses.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also depend on the available labor pool of semi&#8209;skilled and unskilled workers in each of the areas where we operate. In some of our communities, employers across various industries have increased their minimum wage, which has created more competition and, in some cases, higher labor costs for this sector of employees.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply-Chain Disruptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Throughout the pandemic, we have experienced significant price increases in medical supplies, particularly for personal protective equipment (&#8220;PPE&#8221;), and we have encountered supply-chain disruptions, including shortages and delays. In addition, our Ambulatory Care segment has been impacted by shipment delays in construction materials and capital equipment with respect to its de novo facility development efforts, which are a key part of our portfolio expansion strategy.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation and Other General Economic Conditions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our business has been impacted by the rise in inflation and its effects on elective procedures, wages and costs. Other economic factors, including unemployment rates and consumer spending, affect our service mix, revenue mix and patient volumes. Business closings and layoffs in the areas we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients to pay for services. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity Incident</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In April&#160;2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information (the &#8220;Cybersecurity Incident&#8221;). During this time, our hospitals remained operational and continued to deliver patient care safely and effectively, utilizing well&#8209;established back&#8209;up processes. We immediately suspended user access to impacted information technology applications, executed extensive cybersecurity protection protocols, and took steps to restrict further unauthorized activity. Following the restoration of impacted information technology operations, we took additional measures to protect patient, employee and other data, as appropriate, in response to the Cybersecurity Incident.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruption from the Cybersecurity Incident placed pressure on our Hospital Operations segment&#8217;s volumes and earnings, particularly in April and May&#160;2022. We estimate that the Cybersecurity Incident had an adverse pre&#8209;tax impact of approximately $100&#160;million. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have insurance coverage and have filed a claim within our policy limits for these losses. We are unable to predict or control the timing or amount of insurance recoveries.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Industry Trends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We believe that several key trends are continuing to shape the demand for healthcare services: (1)&#160;consumers, employers and insurers are actively seeking lower&#8209;cost solutions and better value as they focus more on healthcare spending; (2)&#160;patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (3)&#160;the growing aging population requires greater chronic disease management and higher&#8209;acuity treatment; and (4)&#160;consolidation continues across the entire healthcare sector. Furthermore, the healthcare industry, in general, and the acute care hospital business, in particular, continue to be subject to significant regulatory uncertainty. Changes in federal or state healthcare laws, regulations, funding policies or reimbursement practices, especially those involving reductions to government payment rates, could have a significant impact on our future revenues and operations.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_4071"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STRATEGIES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expanding Our Ambulatory Care Segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. We believe USPI&#8217;s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in surgical techniques, medical technology and anesthesia, as well as the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase over time. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2022 and 2021, we invested $264&#160;million and $1.315&#160;billion, respectively, to acquire ownership interests in new ASCs, increase our ownership interests in existing facilities and invest in de&#160;novo facilities. In December&#160;2021, USPI entered into a joint venture and development agreement with SurgCenter Development (&#8220;SCD&#8221;) under which USPI has the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50&#160;de&#160;novo ASCs through December&#160;2026. In July&#160;2022, USPI formed a joint venture with United Urology Group (&#8220;UUG&#8221;) and acquired ownership interests in 22 ASCs (three of which were then in development). Including these UUG facilities, during the year ended December&#160;31,&#160;2022, we added 37 fully operational ASCs to our portfolio through acquisitions of majority and minority ownership interests and opened 15 de novo facilities, including two ASCs acquired from UUG while in the development stage. Also during 2022, we increased our ownership interests in 23 ASCs, which allowed us to consolidate their financial results.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Driving Growth in Our Hospital Systems</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We remain committed to better positioning our hospital systems and competing more effectively in the ever&#8209;evolving healthcare environment by focusing on driving performance through operational effectiveness, increasing capital efficiency and margins, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher&#8209;demand and higher&#8209;acuity clinical service lines (including outpatient lines), expanding patient and physician access, and optimizing our portfolio of assets. Over the past several years, we have undertaken enterprise&#8209;wide cost-efficiency measures, and we continue to transition certain support operations to our Global Business Center (&#8220;GBC&#8221;) in the Philippines. We incurred restructuring charges in conjunction with these initiatives in the year ended December&#160;31,&#160;2022, and we could incur additional restructuring charges in the future.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the marginal costs of providing certain services, and we use analytics to manage our operations and make staffing decisions. We also exit service lines, businesses and markets that we believe are no longer a core part of our long&#8209;term growth and synergy strategies. In April 2021, we divested the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments. In addition, we completed the sale of the Miami Hospitals in August&#160;2021. We intend to further refine our portfolio of hospitals and other healthcare facilities when we believe such refinements will help us improve profitability, allocate capital more effectively in areas where we have a stronger presence, deploy proceeds on higher&#8209;return investments across our business, enhance cash flow generation, reduce our debt and lower our ratio of debt&#8209;to&#8209;Adjusted EBITDA.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek advantageous opportunities to grow our portfolio of hospitals and other healthcare facilities. In September&#160;2022, we opened PMC&#160;Fort&#160;Mill, a new acute care hospital located in South Carolina. This 100&#8209;bed facility includes an emergency department, multi&#8209;specialty operating rooms, an intensive care unit, and labor and delivery rooms.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improving the Customer Care Experience&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1)&#160;establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2)&#160;expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; (3)&#160;offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; (4)&#160;improving our culture of service; and (5)&#160;creating health and benefit programs, patient education and health literacy materials that are customized to the needs of the communities we serve. Through these efforts, we intend to improve the customer care experience in every part of our operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Driving Conifer&#8217;s Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Conifer serves approximately 660&#160;Tenet and non&#8209;Tenet hospitals and other clients nationwide. In addition to providing revenue cycle management services to health systems and physicians, Conifer provides support to both providers and self&#8209;insured employers seeking assistance with clinical integration, financial risk management and population health management. We believe that our success in growing Conifer and increasing its profitability depends in part on our success in executing the following strategies: (1)&#160;attracting hospitals and other healthcare providers that currently handle their revenue cycle management processes internally as new clients; (2)&#160;generating new client relationships through opportunities from USPI and Tenet&#8217;s acute care hospital acquisition and divestiture activities; (3)&#160;expanding revenue cycle management and value&#8209;based care service offerings through organic development and small acquisitions; (4)&#160;leveraging data from tens of millions of patient interactions for continued enhancement of the value&#8209;based care environment to drive competitive differentiation; and (5)&#160;maximizing opportunities through automation and offshoring to improve the effectiveness and efficiency of Conifer&#8217;s services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improving Profitability&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus on growing patient volumes and effective cost management as a means to improve profitability. Our inpatient admissions have been constrained in recent years by the pandemic, increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co&#8209;pays, co&#8209;insurance amounts and deductibles, changing consumer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">behavior, and adverse economic conditions and demographic trends in certain areas where we operate. Our business has also been impacted by the rise in inflation and its effects on elective procedures, wages and costs. However, we also believe that emphasis on higher&#8209;demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans that have been experiencing higher growth rates than traditional Medicare, and contracting strategies that create shared value with payers should help us grow our patient volumes over time. We are also continuing to pursue new opportunities to enhance efficiency, including further integration of enterprise&#8209;wide centralized support functions, outsourcing additional functions unrelated to direct patient care, and reducing clinical and vendor contract variation.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reducing Our Leverage Over Time</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All of our long&#8209;term debt has a fixed rate of interest, except for outstanding borrowings, if any, under our Credit Agreement, and the maturity dates of our notes are staggered from 2024 through 2031. We believe that our capital structure helps to minimize the near&#8209;term impact of increased interest rates, and the staggered maturities of our debt allow us to retire or refinance our debt over time. It remains our long&#8209;term objective to reduce our debt and lower our ratio of debt&#8209;to&#8209;Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we redeemed or repurchased $2.597&#160;billion aggregate principal amount of our senior secured first lien and senior unsecured notes in advance of their maturity dates. We financed these transactions using a substantial portion of the proceeds from our issuance of $2.000&#160;billion aggregate principal amount of 6.125% senior secured first lien notes due 2030 (the &#8220;2030 Senior Secured First Lien Notes&#8221;) and cash on hand.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repurchasing Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In October 2022, our board of directors authorized the repurchase of up to $1&#160;billion of our common stock through a share repurchase program. Repurchases will be made in accordance with applicable securities laws and may be made at management&#8217;s discretion from time to time in open-market or privately negotiated transactions, subject to market conditions and other factors. The share repurchase program does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time before its scheduled expiration date of December&#160;31,&#160;2024. We paid approximately $250&#160;million to repurchase a total of 5,888,841 shares during the period from the commencement of the program through December 31, 2022, or an average of $42.45 per share.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute on our strategies and respond to the aforementioned trends in the current operating environment is subject to numerous risks and uncertainties, all of which may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward&#8209;Looking Statements and Risk Factors sections in Part&#160;I of this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENT RESULTS OF OPERATIONS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected operating statistics for our Hospital Operations and Ambulatory Care segments on a continuing operations basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.290%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations &#8211; hospitals and related outpatient facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of hospitals (at end of period)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted admissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paying admissions (excludes charity and uninsured)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured admissions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions through emergency department</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency department visits, outpatient</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total emergency department visits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total surgeries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient days &#8212; total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted patient days</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average length of stay (days)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average licensed beds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization of licensed beds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total visits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paying visits (excludes charity and uninsured)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured visits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated facilities (at end of period)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated cases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The change is the difference between the 2022 and 2021 amounts shown.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted admissions/patient days represents actual admissions/patient days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions/patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total admissions increased by 1,342, or 1.0% in the three months ended December&#160;31, 2022 compared to the three months ended December&#160;31, 2021, primarily due to elevated volumes of influenza cases and the opening of our new PMC&#160;Fort&#160;Mill hospital in September&#160;2022. Also during the 2022 period, total emergency department visits increased by 8.6%, due in part to the same factors. Total surgeries decreased by 1,891, or 2.1%, during the three&#8209;month period in 2022 compared to the same period in 2021. The increase in our Ambulatory Care segment&#8217;s total consolidated cases of 17.9% in the three months ended December&#160;31,&#160;2022, as compared to the same period in 2021, is primarily attributable to incremental case volume from our recently acquired ASCs.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net operating revenues by segment on a continuing operations basis:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.162%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations prior to inter-segment eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-segment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net operating revenues increased by $134 million, or 2.8%, in the three months ended December&#160;31,&#160;2022 compared to the same period in 2021. Our Hospital Operations segment&#8217;s net operating revenues prior to inter&#8209;segment eliminations for the three&#8209;month period in 2022 decreased $70&#160;million, or 1.8%, compared to the same period in 2021. This decrease was primarily due to lower COVID-related patient volumes and acuity, lower surgical volumes and a shorter average length of patient stay, partially offset by higher adjusted admissions and improved pricing yield. Net operating </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenues in our Ambulatory Care segment increased $191&#160;million, or 25.7%, in the three months ended December&#160;31,&#160;2022 compared to the three months ended December&#160;31,&#160;2021. This increase was mainly driven by our recently acquired ASCs, improved case volumes, incremental revenue from new service lines and negotiated commercial rate increases. Conifer&#8217;s revenues, net of inter&#8209;segment eliminations, increased $13&#160;million, or 6.4%, during the three months ended December&#160;31,&#160;2022 compared to the same period in 2021, primarily due to contractual rate increases and new business expansion. During the three months ended December&#160;31,&#160;2022 and 2021, we recognized grant income of $40&#160;million and $138&#160;million, respectively, which amounts are not included in net operating revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable days outstanding (&#8220;AR&#160;Days&#8221;) from continuing operations were 58.3&#160;days and 57.0&#160;days at December&#160;31,&#160;2022 and 2021, respectively. Our AR&#160;Days target is less than 55&#160;days. AR&#160;Days are calculated as our accounts receivable from continuing operations on the last date in the quarter divided by our net operating revenues from continuing operations for the quarter ended on that date divided by the number of days in the quarter. This calculation includes our Hospital Operations segment&#8217;s contract assets. The AR&#160;Days calculation excludes (1)&#160;urgent care centers operated under the MedPost and CareSpot brands, which we divested in April&#160;2021, (2)&#160;the Miami Hospitals, which we sold in&#160;August&#160;2021, and (3)&#160;our California provider fee revenues.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about selected operating expenses by segment on a continuing operations basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rent/lease expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Included in other operating expenses.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about our Hospital Operations segment&#8217;s selected operating expenses per adjusted admission on a continuing operations basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits per adjusted admission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies per adjusted admission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses per adjusted admission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total per adjusted admission</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted admissions represents actual admissions adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries, wages and benefits expense for our Hospital Operations segment increased $73 million, or 4.0%, in the three months ended December&#160;31,&#160;2022 compared to the same period in 2021. This increase was primarily attributable to higher contract labor and premium pay costs due to the pandemic, and annual merit increases for certain of our employees. These factors were partially offset by lower employee benefit costs and our continued focus on cost&#8209;efficiency measures. On a per&#8209;adjusted&#8209;admission basis, Hospital Operations salaries, wages and benefits expense increased 0.5% in the three months ended December&#160;31,&#160;2022 compared to the three months ended December&#160;31,&#160;2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplies expense for our Hospital Operations segment decreased $37 million, or 5.7%, during the three months ended December&#160;31,&#160;2022 compared to the three months ended December&#160;31,&#160;2021. This decrease was primarily attributable to lower COVID-related patient volumes and acuity, decreased surgical volumes and our cost&#8209;efficiency measures. These factors were partially offset by increased costs for certain supplies due to the COVID-19 pandemic, the impact of general market conditions and inflation. On a per&#8209;adjusted&#8209;admission basis, supplies expense decreased 9.1% in the three months ended December&#160;31,&#160;2022 compared to the three months ended December&#160;31,&#160;2021 due to the aforementioned factors.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for our Hospital Operations segment decreased $28 million, or 3.2%, in the three months ended December&#160;31,&#160;2022 compared to the same period in 2021. This decrease was primarily due to decreased costs associated with funding indigent care services by certain of our hospitals (which costs were substantially offset by reduced net patient revenues) and lower malpractice expense. On a per&#8209;adjusted&#8209;admission basis, other operating expenses in the three months ended December&#160;31,&#160;2022 decreased 6.2% compared to the three months ended December&#160;31,&#160;2021, primarily due to the factors described above, as well as increased adjusted admissions that reduce this cost metric due to various fixed costs in other operating expenses.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES OVERVIEW</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $858 million at December&#160;31,&#160;2022 compared to $1.208 billion at September&#160;30,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant cash flow items in the three months ended December&#160;31,&#160;2022 included:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net cash provided by operating activities before interest, taxes, discontinued operations, impairment and restructuring charges, and acquisition&#8209;related costs, and litigation costs and settlements of $738 million, including $41 million received from federal and state grants, and a $128 million payment of payroll taxes deferred during 2020;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures of $290 million;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest payments of $247 million;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$128 million of distributions paid to noncontrolling interests;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payments totaling $57 million for restructuring charges, acquisition&#8209;related costs, and litigation costs and settlements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchases of noncontrolling interests of $39 million;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchases of marketable securities and equity investments of $24 million;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Debt payments of $65 million, including an aggregate total of $24 million cash to retire portions of our 4.625%&#160;senior secured first lien notes due in July 2024 (our &#8220;July&#160;2024 Senior Secured First Lien Notes&#8221;) and September&#160;2024 (our &#8220;September&#160;2024 Senior Secured First Lien Notes&#8221;); and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$250 million of payments to purchase nearly six&#160;million shares of our common stock under the share repurchase program.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $1.083 billion in the year ended December&#160;31,&#160;2022 compared to $1.568&#160;billion in the year ended December&#160;31,&#160;2021. Key factors contributing to the change between 2022 and 2021 include the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$880 million of Medicare advances recouped or repaid in the year ended December&#160;31,&#160;2022 compared to $512&#160;million during 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$196&#160;million of cash received from pandemic-related grant programs in 2022 compared to $178&#160;million received in 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower interest payments of $89 million in 2022;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher income tax payments of $69 million in 2022;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of $61&#160;million in payments for restructuring charges, acquisition&#8209;related costs, and litigation costs and settlements in 2022; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing of other working capital items.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_55"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS SEGMENT</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity&#8209;based health insurance companies and uninsured patients.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the sources of net patient service revenues for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues from all sources:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes Medicare and Medicaid managed care programs.</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payer mix on an admissions basis for our hospitals, expressed as a percentage of total admissions from all sources, is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes Medicare and Medicaid managed care programs.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospitals and outpatient facilities are subject to various factors that affect our service mix, revenue mix and patient volumes and, thereby, impact our net patient service revenues and results of operations. These factors include, among others, changes in federal and state healthcare regulations; the business environment, economic conditions (including inflationary pressures) and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; hospital performance data on quality measures and patient satisfaction, as well as standard charges for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_58"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GOVERNMENT PROGRAMS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) is an agency of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) that administers a number of government programs authorized by federal law; it is the single largest payer of healthcare services in the United States. Medicare is a federally funded health insurance program primarily for individuals 65&#160;years of age and older, as well as some younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is co&#8209;administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation&#8217;s main public health insurance program for people with low incomes and is the largest source of health coverage in the United&#160;States. The Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;), which is also co&#8209;administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. Funding for the CHIP has been reauthorized through federal fiscal year (&#8220;FFY&#8221;) 2029.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;Affordable Care Act&#8221;), extended health coverage to millions of uninsured legal U.S. residents through a combination of private sector health insurance reforms and public program expansion. The expansion of Medicaid in 39&#160;states (including four of the nine states in which we operate acute care hospitals) and the District of Columbia is currently financed through:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative &#8220;productivity adjustments&#8221; to the annual market basket updates, which began in 2011 and do not expire under current law; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions to Medicare and Medicaid disproportionate share hospital (&#8220;DSH&#8221;) payments, which began for Medicare payments in FFY&#160;2014 and, under current law, are scheduled to commence for Medicaid payments in FFY&#160;2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act also includes measures designed to promote quality and cost efficiency in healthcare delivery and provisions intended to strengthen fraud and abuse enforcement.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions. Although a substantial portion of our patient volumes and, as a result, our revenues has historically been derived from government healthcare programs, reductions to our reimbursement under the Medicare and Medicaid programs as a result of the Affordable Care Act have been partially offset by increased revenues from providing care to previously uninsured individuals.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is ongoing uncertainty with respect to the ultimate net effect of the Affordable Care Act due to the potential for continued changes in the law&#8217;s implementation and how government agencies and courts interpret it. Moreover, we cannot predict what future action, if any, Congress might take to amend the Affordable Care Act. If future modifications or interpretations result in significantly fewer individuals having private or public health coverage, we likely will experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect our results of operations and cash flows. There is also uncertainty regarding the potential impact of other healthcare-related reform efforts at the federal and state levels. Some reforms may have a positive effect on our business, while others may increase our operating costs, adversely affect the reimbursement we receive or require us to modify certain aspects of our operations. Legislative and executive branch efforts related to healthcare reform could result in increased prices for consumers purchasing health insurance coverage, impact our competitive position, and affect our relationships with insurers and patients.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_61"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">edicare</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes &#8220;Part A&#8221; and &#8220;Part B&#8221;), is a fee&#8209;for&#8209;service (&#8220;FFS&#8221;) payment system. The other option, called Medicare Advantage (sometimes called &#8220;Part C&#8221; or &#8220;MA Plans&#8221;), includes health maintenance organizations (&#8220;HMOs&#8221;), preferred provider organizations (&#8220;PPOs&#8221;), private FFS Medicare special needs plans and Medicare medical savings account plans. Our total net patient service revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations segment for services provided to patients enrolled in the Original Medicare Plan were $2.369 billion, $2.615&#160;billion and $2.695 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided below. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under &#8220;Regulatory and Legislative Changes&#8221; below.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acute Care Hospital Inpatient Prospective Payment System</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Severity-Adjusted Diagnosis-Related Group Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Sections 1886(d) and 1886(g) of the Social Security Act set forth a system of payments for the operating and capital costs of inpatient acute care hospital admissions based on a prospective payment system (&#8220;PPS&#8221;). Under the inpatient prospective payment systems (&#8220;IPPS&#8221;), Medicare payments for hospital inpatient operating services are made at predetermined rates for each hospital discharge. Discharges are classified according to a system of Medicare severity&#8209;adjusted diagnosis&#8209;related groups (&#8220;MS&#8209;DRGs&#8221;), which categorize patients with similar clinical characteristics that are expected to require similar amounts of hospital resources. CMS assigns to each MS&#8209;DRG a relative weight that represents the average resources required to treat cases in that particular MS&#8209;DRG, relative to the average resources used to treat cases in all MS&#8209;DRGs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base payment amount for the operating component of the MS&#8209;DRG payment is comprised of an average standardized amount that is divided into a labor&#8209;related share and a nonlabor-related share. Both the labor&#8209;related share of operating base payments and the base payment amount for capital costs are adjusted for geographic variations in labor and capital costs, respectively. Using diagnosis and procedure information submitted by the hospital, CMS assigns to each discharge an MS&#8209;DRG, and the base payments are multiplied by the relative weight of the MS&#8209;DRG assigned. The MS&#8209;DRG operating and capital base rates, relative weights and geographic adjustment factors are updated annually, with consideration given to: the increased cost of goods and services purchased by hospitals; the relative costs associated with each MS&#8209;DRG; changes in labor data by geographic area; and other policies. Although these payments are adjusted for area labor and capital cost differentials, the adjustments do not take into consideration an individual hospital&#8217;s operating and capital costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outlier Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Outlier payments are additional payments made to hospitals on individual claims for treating Medicare patients whose medical conditions are more costly to treat than those of the average patient in the same MS&#8209;DRG. To qualify for a cost outlier payment, a hospital&#8217;s billed charges, adjusted to cost, must exceed the payment rate for the MS&#8209;DRG by a fixed threshold updated annually by CMS. A Medicare Administrative Contractor (&#8220;MAC&#8221;) calculates the cost of a claim by multiplying the billed charges by an average cost&#8209;to&#8209;charge ratio that is typically based on the hospital&#8217;s most recently filed cost report. Generally, if the computed cost exceeds the sum of the MS&#8209;DRG payment plus the fixed threshold, the hospital receives 80% of the difference as an outlier payment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Social Security Act, CMS must project aggregate annual outlier payments to all PPS hospitals to be not less than 5% or more than 6% of total MS&#8209;DRG payments (&#8220;Outlier Percentage&#8221;). The Outlier Percentage is determined by dividing total outlier payments by the sum of MS&#8209;DRG and outlier payments. CMS annually adjusts the fixed threshold to bring projected outlier payments within the mandated limit. A change to the fixed threshold affects total outlier payments by changing: (1)&#160;the number of cases that qualify for outlier payments; and (2)&#160;the dollar amount hospitals receive for those cases that qualify for outlier payments. Under certain conditions, outlier payments are subject to reconciliation based on more recent data.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disproportionate Share Hospital Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In addition to making payments for services provided directly to beneficiaries, Medicare makes additional payments to hospitals that treat a disproportionately high share of low&#8209;income patients. Prior to October&#160;1,&#160;2013, DSH payments were based on each hospital&#8217;s low income utilization for each payment year (the &#8220;Pre&#8209;ACA DSH Formula&#8221;). The Affordable Care Act revised the Medicare DSH adjustment effective for discharges occurring on or after October&#160;1,&#160;2013. Under the revised methodology, hospitals receive 25% of the amount they previously would have received under the Pre&#8209;ACA DSH Formula. This amount is referred to as the &#8220;Empirically Justified Amount.&#8221;</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitals qualifying for the Empirically Justified Amount of DSH payments are also eligible to receive an additional payment for uncompensated care (the &#8220;UC&#8209;DSH Amount&#8221;). The UC&#8209;DSH Amount is a hospital&#8217;s share of a pool of funds that the CMS Office of the Actuary estimates would equal 75% of Medicare DSH that otherwise would have been paid under the Pre&#8209;ACA DSH Formula, adjusted for changes in the percentage of individuals that are uninsured. Generally, the factors used to calculate and distribute UC&#8209;DSH Amounts are set forth in the Affordable Care Act and are not subject to administrative or judicial review. The statute requires that each hospital&#8217;s cost of uncompensated care (i.e., charity and bad debt) as a percentage of the total uncompensated care cost of all DSH hospitals be used to allocate the pool. As of December&#160;31,&#160;2022, 51 of our acute care hospitals qualified for Medicare DSH payments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statutes and regulations that govern Medicare DSH payments have been the subject of various administrative appeals and lawsuits, and our hospitals have been participating in such appeals, including challenges to the inclusion of the Medicare Advantage days used in the DSH calculation as set forth in the Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2005 Rates. We are unable to predict what action the Secretary of HHS might take with respect to the DSH calculation for prior periods in this regard or the outcome of the litigation; however, a favorable outcome of our DSH appeals could have a material impact on our future revenues and cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Graduate and Indirect Medical Education Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Medicare program provides additional reimbursement to approved teaching hospitals for the increased expenses incurred by such institutions. This additional reimbursement, which is subject to certain limits, including intern and resident full-time equivalent (&#8220;FTE&#8221;) limits, is made in the form of Direct Graduate Medical Education (&#8220;DGME&#8221;) and Indirect Medical Education (&#8220;IME&#8221;) payments. As of December&#160;31,&#160;2022, 30 of our hospitals were affiliated with academic institutions and were eligible to receive such payments.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPPS Quality Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Affordable Care Act also authorizes quality adjustments to Medicare IPPS payments under the following programs:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Value&#8209;Based Purchasing (&#8220;VBP&#8221;) Program &#8211; Under the VBP program, IPPS operating payments to hospitals are reduced by 2% to fund value&#8209;based incentive payments to eligible hospitals based on their overall performance on a set of quality measures;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hospital Readmission Reduction Program &#8211; Under this program, IPPS operating payments to hospitals with excess readmissions are reduced up to a maximum of 3% of base MS&#8209;DRG payments; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hospital&#8209;Acquired Conditions (&#8220;HAC&#8221;) Reduction Program &#8211; Under this program, overall inpatient payments are reduced by 1% for hospitals in the worst performing quartile of risk&#8209;adjusted quality measures for reasonable preventable hospital&#8209;acquired conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These adjustments, which CMS updates annually, are generally based on a hospital&#8217;s performance from prior periods.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Outpatient Prospective Payment System</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the outpatient prospective payment system (&#8220;OPPS&#8221;), hospital outpatient services, except for certain services that are reimbursed on a separate fee schedule, are classified into groups called ambulatory payment classifications (&#8220;APCs&#8221;). Services in each APC are similar clinically and in terms of the resources they require, and a payment rate is established for each APC. Depending on the services provided, hospitals may be paid for more than one APC for an encounter. CMS annually updates the APCs and the rates paid for each APC.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Psychiatric Facility Prospective Payment System</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inpatient psychiatric facility (&#8220;IPF&#8221;) prospective payment system (&#8220;IPF-PPS&#8221;) applies to psychiatric hospitals and psychiatric units located within acute care hospitals that have been designated as exempt from the hospital inpatient prospective payment system. The IPF-PPS is based on prospectively determined per&#8209;diem rates and includes an outlier policy that authorizes additional payments for extraordinarily costly cases. As of December&#160;31,&#160;2022, 19 of our general hospitals operated IPF units.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation Prospective Payment System</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rehabilitation hospitals and rehabilitation units in acute care hospitals meeting certain criteria established by CMS are eligible to be paid as an inpatient rehabilitation facility (&#8220;IRF&#8221;) under the IRF prospective payment system (&#8220;IRF&#8209;PPS&#8221;). Payments under the IRF&#8209;PPS are made on a per-discharge basis. The IRF&#8209;PPS uses federal prospective payment rates across distinct case&#8209;mix groups established by a patient classification system. As of December&#160;31,&#160;2022, we operated one freestanding IRF, and 15&#160;of our general hospitals operated IRF units.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician and Other Health Professional Services Payment System</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare uses a fee schedule to pay for physician and other health professional services based on a list of services and their payment rates referred to as the Medicare Physician Fee Schedule (&#8220;MPFS&#8221;). In determining payment rates for each service, CMS considers the amount of clinician work required to provide a service, expenses related to maintaining a practice and professional liability insurance costs. These three factors are adjusted for variation in the input prices in different markets, and the sum is multiplied by the fee schedule&#8217;s conversion factor (average payment amount) to produce a total payment amount.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost Reports</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final determination of certain Medicare payments to our hospitals, such as DSH, DGME, IME and bad debt expense, are retrospectively determined based on our hospitals&#8217; cost reports. The final determination of these payments often takes many years to resolve because of audits by the program representatives, providers&#8217; rights of appeal, and the application of numerous technical reimbursement provisions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For filed cost reports, we adjust the accrual for estimated cost report settlements based on those cost reports and subsequent activity, and we record a valuation allowance against those cost reports based on historical settlement trends. The accrual for estimated cost report settlements for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports and a corresponding valuation allowance is recorded as previously described. Cost reports must generally be filed within five months after the end of the annual cost report reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Claims Reviews</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS estimates that the overall 2022 Medicare FFS improper payment rate for the program is approximately 7.46%. The 2022 error rate for Hospital IPPS payments is approximately 3%. CMS has identified the FFS&#160;program as a program at risk for significant erroneous payments, and one of the agency&#8217;s stated key goals is to pay claims properly the first time. This means paying the right amount, to legitimate providers, for covered, reasonable and necessary services provided to eligible beneficiaries. According to CMS, paying correctly the first time saves resources required to recover improper payments and ensures the proper expenditure of Medicare Trust&#160;Fund dollars. CMS has established several initiatives to prevent or identify improper payments before a claim is paid, and to identify and recover improper payments after paying a claim. The overall goal is to reduce improper payments by identifying and addressing coverage and coding billing errors for all provider types. Under the authority of the Social Security Act, CMS employs a variety of contractors (e.g., MACs, Recovery Audit Contractors and Unified Program Integrity Contractors) to process and review claims according to Medicare rules and regulations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims selected for prepayment review are not subject to the normal Medicare FFS payment timeframe. Furthermore, prepayment and post&#8209;payment claims denials are subject to administrative and judicial review, and we pursue the reversal of adverse determinations where appropriate. We have established robust protocols to respond to claims reviews and payment denials. In addition to overpayments that are not reversed on appeal, we incur additional costs to respond to requests for records and pursue the reversal of payment denials. The degree to which our Medicare FFS claims are subjected to prepayment reviews, the extent to which payments are denied, and our success in overturning denials could have an adverse effect on our cash flows and results of operations.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Meaningful Use of Health Information Technology</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act, which is part of the American Recovery and Reinvestment Act of 2009, promotes the use of healthcare information technology by, among other things, providing financial incentives to hospitals and physicians to become &#8220;meaningful users&#8221; of electronic health record (&#8220;EHR&#8221;) systems and imposing penalties on those who do not. Under the HITECH Act and other laws and regulations, eligible hospitals that fail to demonstrate and maintain meaningful use of certified EHR technology and/or submit quality data every year (and have not applied and qualified for a hardship exception) are subject to a reduction of the Medicare market basket update. Eligible healthcare professionals are also subject to positive or negative payment adjustments based, in part, on their use of EHR technology. We continue to invest in the maintenance and utilization of certified EHR systems for our hospitals and employed physicians. Failure to do so could subject us to penalties that may have an adverse effect on our net revenues and results of operations.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_67"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid programs and the corresponding reimbursement methodologies vary from state&#8209;to&#8209;state and from year&#8209;to&#8209;year. Estimated revenues under various state Medicaid programs, including state&#8209;funded Medicaid managed care programs, constituted approximately 19.4%, 18.7% and 17.8% of the total net patient service revenues of our acute care hospitals and related outpatient facilities for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively. We also receive DSH and other supplemental revenues under various state Medicaid programs. For the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $644 million, $915&#160;million and $754&#160;million, respectively. The decrease between 2022 and 2021 was primarily attributable to changes in Medicaid program payments in California, Florida, Michigan and Texas. For Texas, we recognized $123 million of assessments to support the Texas Comprehensive Hospital Increase Reimbursement Program (&#8220;CHIRP&#8221;) following its approval in 2022. During the year ended December&#160;31,&#160;2022, we also recognized $245&#160;million of revenue related to CHIRP that is included in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Medicaid revenue rather than the DSH and other supplemental revenues classification due to the structure of the program.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even prior to the COVID-19 pandemic, several states in which we operate faced budgetary challenges that resulted in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state&#8217;s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs authorized under the Social&#160;Security Act.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continuing pressure on state budgets and other factors, including legislative and regulatory changes, could result in future reductions to Medicaid payments, payment delays or changes to Medicaid supplemental payment programs. Federal government denials or delayed approvals of waiver applications or extension requests by the states in which we operate could materially impact our Medicaid funding levels.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Medicaid and Managed Medicaid net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 were $2.692&#160;billion, $2.760&#160;billion and $2.427&#160;billion, respectively. During the year ended December&#160;31,&#160;2022, Medicaid and Managed Medicaid revenues comprised 35% and 65%, respectively, of our Medicaid&#8209;related net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment. All Medicaid and Managed Medicaid patient service revenues are presented net of provider taxes or assessments paid by our hospitals, which are reported as an offset reduction to FFS Medicaid revenue.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we cannot predict what actions the federal government or the states may take under existing or future legislation and/or regulatory changes to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section&#160;1115 waivers, we are unable to assess the effect that any such legislation or regulatory action might have on our business; however, the impact on our future financial position, results of operations or cash flows could be material.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_73"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Legislative Changes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare and Medicaid programs are subject to: statutory and regulatory changes, administrative and judicial rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating reimbursements, among other things; requirements for utilization review; and federal and state funding restrictions. Any of these factors could materially increase or decrease payments from these government programs in the future, as well as affect the cost of providing services to our patients and the timing of payments to our facilities. We are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid by governmental payers are reduced, if the scope of services covered by governmental payers is limited, or if we or one or more of our hospitals are excluded from participation in the Medicare or Medicaid program or any other government healthcare program, there could be a material adverse effect on our business, financial condition, results of operations or cash flows. Recent regulatory and legislative updates to the Medicare and Medicaid payment systems, as well as other government programs impacting our business, are provided below.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1886(d) of the Social&#160;Security Act requires CMS to update Medicare inpatient FFS payment rates for hospitals reimbursed under the IPPS annually. The updates generally become effective October&#160;1, the beginning of the FFY. In August&#160;2022, CMS issued final changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year&#160;2023 Rates (&#8220;Final IPPS Rule&#8221;). The Final IPPS Rule includes the following payment and policy changes, among others:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A market basket increase of 4.1% for MS&#8209;DRG operating payments for hospitals reporting specified quality measure data and that are meaningful users of EHR technology; CMS also finalized a 0.3% multifactor productivity reduction required by the Affordable Care Act and a 0.5% increase required by the Medicare Access and CHIP Reauthorization Act of 2015 that together result in a net operating payment update of 4.3% before budget neutrality adjustments;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Updates to the hospital VBP and HAC programs for FFY&#160;2023 due to the impact of the COVID-19 public health emergency, including: the implementation of a special scoring methodology for the VBP program that results in each hospital receiving a value&#8209;based incentive payment amount equal to the 2% reduction to its operating standardized amount; and suppression of all measures in the HAC reduction program resulting in no hospitals being penalized for FFY&#160;2023;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase in the cost outlier threshold from $30,988 to $38,859;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A 2.37% net increase in the capital federal MS&#8209;DRG rate; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Updates to the three factors used to determine the amount and distribution of Medicare UC&#8209;DSH Amounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to CMS, the combined impact of the payment and policy changes in the Final IPPS Rule for operating costs will yield an average 2.6% increase in Medicare operating MS&#8209;DRG&#160;FFS payments for hospitals in urban areas and an average 3.3% increase in such payments for proprietary hospitals in FFY&#160;2023. We estimate that all of the final payment and policy changes affecting operating MS&#8209;DRG and UC&#8209;DSH Amounts should result in a 3.7% increase in our annual Medicare FFS&#160;IPPS payments, which yields an estimated increase of approximately $55&#160;million. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative, regulatory or legal actions, admission volumes, length of stay and case mix, we cannot provide any assurances regarding our estimate of the impact of the payment and policy changes.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2022, CMS released the final policy changes and payment rates for the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System for calendar year (&#8220;CY&#8221;)&#160;2023 (&#8220;Final OPPS/ASC Rule&#8221;). The Final OPPS/ASC Rule includes the following payment and policy changes, among others:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An estimated net increase of 3.8% for the OPPS rates based on a market basket increase of 4.1%, reduced by a multifactor productivity adjustment required by the Affordable Care Act of 0.3%;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Removal of 11 services from the Inpatient Only List (which is the list of procedures that must be performed on an inpatient basis) after determining such services meet established criteria for removal;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establishment of an exemption for rural Sole Community Hospitals from the site-neutral Medicare reduced payment rate for clinic visits furnished in exempt off-campus, provider-based departments and payment for such visits at the full OPPS rate; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A 3.8% increase to the Ambulatory Surgical Center payment rates.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Final OPPS/ASC Rule made certain changes to CMS&#8217; 340B&#160;program, which allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) (&#8220;340B&#160;Hospitals&#8221;) to purchase drugs at discounted rates from drug manufacturers (&#8220;340B&#160;Drugs&#8221;). In the CY&#160;2018 final rule regarding OPPS payment and policy changes, CMS reduced the payment for 340B&#160;Drugs from the average sales price (&#8220;ASP&#8221;) plus 6% to the ASP minus 22.5% and made a corresponding budget&#8209;neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS (the &#8220;340B&#160;Payment Adjustment&#8221;). CMS retained the same 340B&#160;Payment Adjustment in the final rules regarding OPPS payment and policy changes for CYs&#160;2019 through 2022. Certain hospital associations and hospitals commenced litigation challenging CMS&#8217; authority to impose the 340B&#160;Payment Adjustment for CYs&#160;2018, 2019 and 2020. Following the initial court decisions and a series of appeals, the U.S. Supreme Court (the &#8220;Supreme&#160;Court&#8221;) unanimously ruled in June&#160;2022 that the decision to impose the 340B&#160;Payment Adjustment in CYs&#160;2018 and 2019 was unlawful, and the case was remanded to the lower courts to determine the appropriate remedy. In response to the Supreme&#160;Court&#8217;s decision, the 2023 Final OPPS/ASC Rule affirms that CMS is now applying the default rate, generally ASP plus 6%, to 340B&#160;Drugs and biologicals, and it has removed the 340B&#160;Payment Adjustment made in 2018. In January&#160;2023, the U.S. District Court for the District of Columbia issued an opinion remanding the case to HHS to determine the remediation for the prior years&#8217; underpayments. Before the issuance of this opinion, CMS had indicated that it is still evaluating how to apply the Supreme&#160;Court ruling to the cost years 2018 through 2022, and it expects to address the remedy for those cost years in a separate rulemaking that will be published prior to the CY 2024 proposed rule regarding OPPS payment and policy changes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS projects that the combined impact of the payment and policy changes in the Final OPPS/ASC Rule will yield an average 4.9% increase in Medicare FFS&#160;OPPS payments for hospitals in urban areas and an average 1.3% increase in Medicare FFS OPPS payments for proprietary hospitals. The projected annual impact of the payment and policy changes in the Final OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately $9&#160;million, which represents an increase of approximately 1.5%.</span></div><div style="margin-bottom:12pt;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the final payment and policy changes. In addition, it remains unclear at this time how CMS will finance any retroactive payments for 340B&#160;payments that were previously withheld given that the original policy was budget&#8209;neutral and HHS already redistributed the savings. We cannot predict the remedy that will be imposed, the timing thereof, or what further actions CMS or Congress might take with respect to the 340B&#160;program; however, it is possible that reversal of the 340B&#160;Payment Adjustment could have an adverse effect on our future net operating revenues and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment and Policy Changes to the Medicare Physician Fee Schedule&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2022, CMS released the CY&#160;2023 Medicare Physician Fee Schedule (&#8220;MPFS&#8221;) Final Rule (&#8220;MPFS Final Rule&#8221;). The MPFS Final Rule includes updates to payment policies, payment rates and other provisions for services reimbursed under the MPFS from January&#160;1 through December&#160;31,&#160;2023. Under the MPFS Final Rule, the CY&#160;2023 conversion factor, which is the base rate that is used to convert relative units into payment rates, was reduced from $34.61 to $33.06, due in part to the expiration of the one-time 3% payment increase provided for in CY&#160;2022 by the Protecting Medicare and American Farmers from Sequester Cuts Act (the &#8220;Sequester Cuts Act&#8221;), which was signed into law in December&#160;2021, as well as budget neutrality rules. However, the December&#160;2022 enactment of the Consolidated Appropriations Act, 2023 (&#8220;CAA, 2023&#8221;) provided a 2.5% positive adjustment to the MPFS CY&#160;2023 conversion factor, resulting in a CY&#160;2023 conversion factor of $33.89. We estimate the impact of the MPFS Final Rule in conjunction with the positive adjustment from the CAA, 2023 should result in a reduction of approximately $4&#160;million to our FFS&#160;MPFS revenues. Because of the uncertainty associated with various factors that may influence our future MPFS payments, including legislative, regulatory or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the final payment and policy changes.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act of 2020 and Related Legislation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several pieces of legislation (the &#8220;COVID Acts&#8221;) that include funding and other provisions to mitigate the economic effects of the COVID&#8209;19 pandemic have been signed into law since March&#160;2020. Provided below is a brief overview of certain provisions of the COVID Acts that have impacted our business and that may continue to impact our business to varying degrees in 2023. With the recent announcement that the public health emergency will end on May&#160;11,&#160;2023, and the subsequent unwinding of federal flexibilities and funding, there is no assurance or expectation that we will continue to receive or remain eligible for significant funding or assistance under the COVID Acts or similar measures in the future.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding for the Public Health and Social Services Emergency Fund&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts authorized $178&#160;billion in payments to be distributed to providers through the PRF. To receive distributions, providers are required to agree to certain terms and conditions, including, among other things, that the funds are being used for lost revenues and unreimbursed COVID&#8209;related costs as defined by HHS, and that the providers will not seek collection of out&#8209;of&#8209;pocket payments from a COVID&#8209;19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in-network provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by HHS. In January&#160;2021, HHS released updated reporting requirements that include lost revenues, expenses attributable to COVID-19 and non-financial information. The updated reporting requirements reflect certain provisions of the Consolidated Appropriations Act, 2021 and Other Extensions Act (&#8220;Consolidated Appropriations Act&#8221;) affecting the calculation of lost revenues, as well as the distribution of PRF funds among subsidiaries in a hospital system. Furthermore, HHS has indicated that it will be closely monitoring and, along with the U.S.&#160;Office of Inspector General, auditing providers to ensure that recipients comply with the terms and conditions of relief programs and to prevent fraud and abuse. All providers will be subject to civil and criminal penalties for any deliberate omissions, misrepresentations or falsifications of any information given to HHS. PRF funds not utilized by the established deadlines, generally 12 to 18&#160;months after receipt of the grant funds, will be recouped by HHS. Except for certain immaterial PRF payments we returned to HHS, we have formally accepted PRF payments issued to our providers and the terms and conditions associated with those payments, and we have complied with the reporting requirements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2022, 2021 and 2020, our Hospital Operations and Ambulatory Care segments combined recognized approximately $138&#160;million, $176&#160;million and $868&#160;million, respectively, of PRF grant income associated with lost revenues and COVID&#8209;related costs. We recognized an additional $14&#160;million and $17&#160;million of PRF grant income from our unconsolidated affiliates during 2021 and 2020, respectively. Our Hospital Operations and Ambulatory Care segments combined also recognized $56&#160;million, $15&#160;million and $14&#160;million of grant income from state and local grant programs during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Grant income recognized by our Hospital Operations and Ambulatory Care segments is presented in grant income, and grant income recognized through our unconsolidated affiliates is presented in equity in earnings of unconsolidated affiliates, in each case in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020. At December&#160;31,&#160;2022 and 2021, we had remaining deferred grant payment balances of $7&#160;million and $5&#160;million, respectively, which amounts were recorded in other current liabilities in the accompanying Consolidated Balance Sheets for those periods. We cannot predict whether additional distributions of grant funds will be authorized, and we cannot provide any assurances regarding the amount of grant income, if any, to be recognized in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare and Medicaid Payment Policy Changes&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts have also alleviated some of the financial strain on hospitals, physicians, other healthcare providers and states through a series of Medicare and Medicaid payment policy changes, as described below:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The CMS 2% sequestration reduction on Medicare FFS and Medicare Advantage payments to hospitals, physicians and other providers was suspended effective May&#160;1,&#160;2020 through December&#160;31,&#160;2021. The Sequester Cuts Act extended the 2% Medicare sequestration moratorium through March&#160;31,&#160;2022 and adjusted the sequestration to 1% for the period April&#160;1,&#160;2022 through June&#160;30,&#160;2022. Because further legislation was not passed, the full 2% reduction was restored effective July&#160;1,&#160;2022. The impact of the Sequester Cuts Act on our operations was an increase of approximately $39&#160;million of revenues in the six months ended June&#160;30,&#160;2022, after which the sequestration was fully reinstated.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID Acts instituted a 20% increase in the Medicare MS&#8209;DRG payment for COVID-19 hospital admissions for the duration of the public health emergency.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID Acts initially eliminated the scheduled nationwide reduction of $4&#160;billion in federal Medicaid DSH allotments in FFY&#160;2020 mandated by the Affordable Care Act and decreased the FFY&#160;2021 DSH reduction from $8&#160;billion to $4&#160;billion effective December&#160;1,&#160;2020. Subsequently, the FFY&#160;2021 DSH reduction was eliminated entirely and the remaining $8 billion of DSH reductions were delayed until FFY&#160;2024.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID Acts expanded the Medicare accelerated payment program, which provides prepayment of claims to providers in certain circumstances, such as national emergencies or natural disasters. Under the Consolidated Appropriations Act, providers could retain the accelerated payments for one year from the date of receipt before CMS commenced recoupment. During the year ended December&#160;31,&#160;2020, our hospitals and other providers applied for and received approximately $1.5&#160;billion of accelerated payments. No additional accelerated payment funds were applied for or received in the years ended December&#160;31,&#160;2022 and 2021. All advances received by our hospitals and other providers were either repaid or recouped during the years ended December&#160;31,&#160;2022 and 2021.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A 6.2% increase in the Federal Medical Assistance Percentage (&#8220;FMAP&#8221;) matching funds was instituted to help states respond to the COVID&#8209;19 pandemic. The additional funds became available to states effective January&#160;1,&#160;2020, and they were expected to remain available through the quarter in which the public health emergency period ends, provided that states met certain conditions. In addition, the COVID Acts established an incentive for states that had not already done so to expand Medicaid by temporarily increasing each such respective state&#8217;s FMAP for their base program by five percentage points for two years.</span></div><div style="margin-bottom:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts included a requirement that state Medicaid programs keep people continuously enrolled through the end of the month in which the COVID&#8209;19 public health emergency ends in exchange for the temporary increase to the FMAP. Under the CAA, 2023, the Medicaid continuous enrollment condition and the receipt of the temporary FMAP increase will no longer be tied to the continuation of the public health emergency. Effective March&#160;31,&#160;2023, the continuous enrollment condition will end and, on April&#160;1,&#160;2023, states can begin eligibility redeterminations on their Medicaid populations and the disenrollment of individuals no longer eligible. In addition, the CAA, 2023 provides for the phase-down of the 6.2% enhanced FMAP as follows: 6.2% through the first quarter of 2023; 5.0% through the second quarter of 2023; 2.5% through the third quarter of 2023; and 1.5% through the last quarter of 2023. The increased support will end entirely as of January&#160;1,&#160;2024.</span></div><div style="margin-bottom:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the uncertainty associated with various factors that may influence our future Medicare and Medicaid payments, including future legislative, legal or regulatory actions, or changes in volumes and case mix, there is a risk that actual payments received under, or the ultimate impact of, these programs will differ materially from our expectations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding for Uninsured Individuals&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts provided claims reimbursement to healthcare providers generally at Medicare rates for testing uninsured individuals for COVID&#8209;19 and treating uninsured individuals with a COVID&#8209;19 diagnosis. A portion of the funding could also be used to reimburse providers for COVID&#8209;19 vaccine administration to uninsured individuals. We recognized net operating revenues totaling $20&#160;million, $91&#160;million and $40&#160;million related to this program in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. This program stopped accepting reimbursement claims for the testing and treatment of uninsured individuals on March&#160;22,&#160;2022, and stopped accepting claims for vaccine administration to uninsured individuals on April&#160;5,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Changes&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning March&#160;27,&#160;2020, all employers were able to elect to defer payment of the 6.2% employer Social&#160;Security tax through December&#160;31,&#160;2020. Deferred tax amounts were required to be paid in equal amounts over two years, with payments due in December&#160;2021 and December&#160;2022. During the year ended December&#160;31,&#160;2020, we deferred Social Security tax payments totaling $275 million pursuant to this COVID Acts provision. In December&#160;2021, we repaid half of the outstanding deferred Social Security tax payments, and the remainder was repaid in December&#160;2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMS Innovation Models</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CMS Innovation Center develops and tests innovative payment and service delivery models that have the potential to reduce Medicare, Medicaid or CHIP expenditures while preserving or enhancing the quality of care for beneficiaries. Congress has defined &#8211; both through the Affordable Care Act and previous legislation &#8211; a number of specific demonstrations for CMS to conduct, including bundled payment models. Generally, the bundled payment models hold hospitals financially accountable for the quality and costs for an entire episode of care for a specific diagnosis or procedure from the date of the hospital admission or inpatient procedure through 90&#160;days post&#8209;discharge, including services not provided by the hospital, such as physician, inpatient rehabilitation, skilled nursing and home health care. Provider participation in some of these models is voluntary; for example, 19 hospitals in our Hospital Operations segment and three surgical hospitals in our Ambulatory Care segment participate in the CMS Bundled Payments for Care Improvement Advanced (&#8220;BPCIA&#8221;) program that became effective October&#160;1,&#160;2018, and USPI also holds the CMS contract for one physician group practice participating in the BPCIA program. Participation in certain other bundled payment arrangements is mandatory for providers located in randomly selected geographic locations. Under the mandatory models, hospitals are eligible to receive incentive payments or will be subject to payment reductions within certain corridors based on their performance against quality and spending criteria. In 2015, CMS finalized a five&#8209;year bundled payment model (that was subsequently extended for an additional three years), called the Comprehensive Care for Joint Replacement (&#8220;CJR&#8221;) model, which includes hip and knee replacements, as well as other major leg procedures. Eleven hospitals in our Hospital Operations segment and four surgical hospitals in our Ambulatory Care segment currently participate in the CJR&#160;model.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_79"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRIVATE INSURANCE</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Managed Care</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full&#8209;service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned &#8220;primary care&#8221; physician. The member&#8217;s care is then managed by his or her primary care physician and other network providers in accordance with the HMO&#8217;s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost&#8209;effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non&#8209;contracted healthcare providers for non&#8209;emergency care.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPOs generally offer limited benefits to members who use non&#8209;contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co&#8209;pays, co&#8209;insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high&#8209;deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 was $9.730&#160;billion, $9.985 billion and $9.022 billion, respectively. Our top 10 managed care payers generated 62% of our managed care net patient service revenues for the year ended December&#160;31,&#160;2022. In 2022, national payers generated 44% of our managed care net patient service revenues; the remainder came from regional or local payers. At December&#160;31,&#160;2022 and 2021, 66% and 67%, respectively, of our net accounts receivable for our Hospital Operations segment were due from managed care payers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#8209;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#8217;s bill is subject to adjustment on a patient&#8209;by&#8209;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at&#160;December&#160;31,&#160;2022, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $18 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1)&#160;changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2)&#160;changes in reimbursement levels when stop&#8209;loss or outlier limits are reached; (3)&#160;changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4)&#160;final coding of in&#8209;house and discharged&#8209;not&#8209;final&#8209;billed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients that change reimbursement levels; (5)&#160;secondary benefits determined after primary insurance payments; and (6)&#160;reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the years ended December&#160;31,&#160;2022, 2021 or 2020. In addition, on a corporate&#8209;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year&#8209;over&#8209;year aggregate managed care pricing improvements for some time, we have seen these improvements moderate in recent years, and we believe this moderation could continue into the future, subject to incremental pricing improvements to address inflationary pressures. In the year ended December&#160;31,&#160;2022, our commercial managed care net inpatient revenue per admission from the hospitals in our Hospital Operations segment was approximately 81% higher than our aggregate yield on a per-admission basis from government payers, including managed Medicare and Medicaid insurance plans.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnity</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31,&#160;2022 and 2021, 4.8% of our net patient service revenues for our hospitals and related outpatient facilities were derived from indemnity&#8209;based health plans. An indemnity&#8209;based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legislative Changes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The No Surprises Act (&#8220;NSA&#8221;) established federal protections, which became effective on January&#160;1,&#160;2022, against balance billing for patients who obtain medical services from physicians and other providers not chosen by the patient and outside of the patient&#8217;s health insurance network. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties. Among other things, the NSA limits the amount an insured patient will pay for (1)&#160;out-of-network emergency care (provided in hospital emergency departments and freestanding emergency facilities), and (2)&#160;scheduled out-of-network services (such as radiology, pathology and anesthesiology) at an in-network facility when the patient hasn&#8217;t been notified or provided consent. The NSA also prohibits insurers from assigning higher deductibles (and other cost-sharing charges) to patients for out-of-network care than they do for in-network care without patient notification and consent.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NSA, insurers and providers are given the opportunity to resolve disputed out&#8209;of&#8209;network reimbursement through negotiation and an independent dispute resolution (&#8220;IDR&#8221;) process, unless state law specifies a different approach. The IDR process has been utilized far more than anticipated, and there is currently a backlog of claims pending determination. Moreover, provider groups have been successful in challenging certain IDR-related provisions of the regulations promulgated under the NSA, claiming the regulations unfairly favor insurers in the determination of appropriate reimbursement amounts. We cannot predict the ultimate impact of this or any future litigation nor can we predict any future regulatory changes. In addition, we are unable to fully assess the ultimate impact of the NSA on our business at this time; however, based on our experience to this point, we believe that compliance with the provisions of the NSA will not have a material adverse effect on our financial condition, results of operations or cash flows.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_82"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UNINSURED PATIENTS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our uninsured patients are admitted through our hospitals&#8217; emergency departments and often require high&#8209;acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self&#8209;pay accounts receivable, which include amounts due from uninsured patients, as well as co&#8209;pays, co&#8209;insurance amounts and deductibles owed to us by patients with insurance, pose significant collectability problems. At December&#160;31,&#160;2022 and 2021, 5% and 4%, respectively, of our net accounts receivable for our Hospital Operations segment was self&#8209;pay. Further, a significant portion of our implicit price concessions relates to self&#8209;pay amounts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item&#160;1, Business&#160;&#8212;&#160;Regulations Affecting Conifer&#8217;s Operations, of Part&#160;I of this report. Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non&#8209;emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self&#8209;pay accounts, as well as co&#8209;pay, co&#8209;insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical&#8209;based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the longer term, several other initiatives we have previously announced should also help address the challenges associated with serving uninsured patients. For example, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact with Uninsured Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is designed to offer managed care&#8209;style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#8209;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for self&#8209;pay accounts and other factors that affect the estimation process. We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital&#8217;s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions, along with reductions in Medicare and Medicaid reimbursement to healthcare providers, including us. However, we continue to have to provide uninsured discounts and charity care due to the failure of certain states to expand Medicaid coverage and for persons living in the country who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated costs for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured patients</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity care patients</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER&#160;31,&#160;2022 COMPARED TO THE YEAR&#160;ENDED DECEMBER&#160;31,&#160;2021</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our consolidated net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, on a continuing operations basis:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-segment eliminations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(311)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(538)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, by operating segment on a continuing operations basis:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,&#160;2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conifer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,&#160;2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net operating revenues decreased by $311&#160;million, or 1.6%, for the year ended December&#160;31,&#160;2022 compared to the year ended December&#160;31,&#160;2021. Hospital Operations net operating revenues, net of inter&#8209;segment eliminations, decreased by $890&#160;million, or 5.7%, for the year ended December&#160;31,&#160;2022 compared to 2021, primarily due to the loss of revenues from the Miami Hospitals we sold in August&#160;2021, lower overall patient volumes, and decreased COVID-related volumes and acuity during 2022, partially offset by negotiated commercial rate increases. Our Hospital Operations segment also recognized grant income from federal, state and local grants totaling $190&#160;million and $142&#160;million during the years ended December&#160;31,&#160;2022 and 2021, respectively, which is not included in net operating revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ambulatory Care net operating revenues increased by $530&#160;million, or 19.5%, for the year ended December&#160;31,&#160;2022 compared to 2021. The change was primarily due to an increase from acquisitions of $453 million and same-facility growth of $146&#160;million, which was attributable to the impact of higher patient volumes, incremental revenue from new service lines and negotiated commercial rate increases. These impacts were partially offset by $69&#160;million of lower revenues compared to the prior&#8209;year period due to the sale of the Ambulatory Care segment&#8217;s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment in April&#160;2021. Our Ambulatory Care segment also recognized grant income from federal grants totaling $4&#160;million and $49&#160;million during the years ended December&#160;31,&#160;2022 and 2021, respectively, which is not included in net operating revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer net operating revenues increased by $49 million, or 3.9%, for the year ended December&#160;31,&#160;2022 compared to 2021. Conifer revenues from third&#8209;party clients, which revenues are not eliminated in consolidation, increased $80&#160;million, or 10.2%, for the year ended December&#160;31,&#160;2022 compared to 2021. These increases were primarily due to contractual rate increases and new business expansion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS BY SEGMENT</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are reported in three segments:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hospital Operations, which is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#8209;hospitals and physician practices;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ambulatory Care, which is comprised of USPI&#8217;s ASCs and surgical hospitals; and </span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conifer, which provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_91"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hospital&#160;Operations&#160;Segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present operating statistics, revenues and expenses of our hospitals and related outpatient facilities on a same&#8209;hospital basis, unless otherwise indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.290%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Same-Hospital <br/>Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Admissions,&#160;Patient&#160;Days&#160;and&#160;Surgeries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of hospitals (at end of period)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted admissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paying admissions (excludes charity and uninsured)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured admissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions through emergency department</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paying admissions as a percentage of total admissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured admissions as a percentage of total admissions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency department admissions as a percentage of total admissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgeries &#8212; inpatient</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgeries &#8212; outpatient</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total surgeries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient days &#8212; total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted patient days</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average length of stay (days)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed beds (at end of period)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average licensed beds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization of licensed beds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.693%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The change is the difference between 2022 and 2021 amounts shown.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted admissions/patient days represents actual admissions/patient days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions/patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.290%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Same-Hospital <br/>Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outpatient&#160;Visits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total visits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,063,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paying visits (excludes charity and uninsured)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,752,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured visits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency department visits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgery visits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paying visits as a percentage of total visits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity and uninsured visits as a percentage of total visits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The change is the difference between 2022 and 2021 amounts shown.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Same-Hospital <br/>Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selected revenue data &#8211; hospitals and related outpatient facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenue per adjusted admission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenue per adjusted patient day</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.693%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted admissions/patient days represents actual admissions/patient days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions/patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.</span></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Same-Hospital <br/>Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selected Operating Expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.290%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Same-Hospital <br/>Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selected Operating Expenses as a Percentage of Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The change is the difference between 2022 and 2021 amounts shown.</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Same&#8209;hospital net operating revenues decreased $304&#160;million, or 2.1%, during the year ended December&#160;31,&#160;2022 compared to the year ended December&#160;31, 2021. This decrease was due in part to lower overall patient volumes, decreased COVID&#8209;related volumes and acuity, and the adverse impact of the Cybersecurity Incident on patient volumes, partially offset by negotiated commercial rate increases. Our Hospital Operations segment also recognized grant income from federal, state and local grants totaling $190&#160;million and $142&#160;million in the years ended December&#160;31,&#160;2022 and 2021, respectively, which is not included in net operating revenues. Same&#8209;hospital admissions and outpatient visits decreased by 4.5% and 4.8%, respectively, in the year ended December&#160;31,&#160;2022 compared to 2021, primarily due to the factors described above.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our consolidated net accounts receivable by payer:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cost report settlements receivable and valuation allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-pay uninsured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-pay balance after insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated future recoveries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of accounts receivable is a key area of focus for our business. At December&#160;31,&#160;2022, our Hospital Operations segment collection rate on self&#8209;pay accounts was approximately 29.5%. Our self&#8209;pay collection rate includes payments made by patients, including co&#8209;pays, co&#8209;insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from uninsured patients and co&#8209;pays, co&#8209;insurance amounts and deductibles owed to us by patients with insurance at December&#160;31,&#160;2022, a 10% decrease or increase in our self&#8209;pay collection rate, or approximately 3.0%, which we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $11 million. There are various factors that can impact collection trends, such as changes in the economy and inflation, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, the volume of patients through our emergency departments, the increased burden of co&#8209;pays and deductibles to be made by patients with insurance, and business practices related to collection efforts. These factors, many of which have been affected by the pandemic, continuously change and can have an impact on collection trends and our estimation process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations segment collection rate from managed care payers was approximately 95.7% at December&#160;31,&#160;2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our implicit price concessions using hospital&#8209;specific goals and benchmarks such as (1)&#160;total cash collections, (2)&#160;point&#8209;of&#8209;service cash collections, (3)&#160;AR Days and (4)&#160;accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations segment of $2.462&#160;billion and $2.363&#160;billion at December&#160;31,&#160;2022 and 2021, respectively, excluding cost report settlements receivable and valuation allowances of $48&#160;million and $33&#160;million, respectively, at December&#160;31,&#160;2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Managed<br/>Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indemnity,<br/>Self-Pay<br/>and&#160;Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December&#160;31, 2022:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-60 days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61-120 days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121-180 days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over 180 days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December&#160;31, 2021:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-60 days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61-120 days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121-180 days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over 180 days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer continues to implement revenue cycle initiatives intended to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre&#8209;registration, registration, verification of eligibility and benefits, liability identification and collections at point&#8209;of&#8209;service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient advocates from Conifer&#8217;s Eligibility and Enrollment Services program (&#8220;EES&#8221;) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the EES, net of appropriate implicit price concessions. Based on recent trends, approximately 97% of all accounts in the EES are ultimately approved for benefits under a government program, such as Medicaid.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate amount of accounts receivable in the EES still awaiting determination of eligibility under a government program at December&#160;31,&#160;2022 and 2021 by aging category:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-60&#160;days&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61-120 days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121-180 days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over 180 days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries, Wages and Benefits</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Same&#8209;hospital salaries, wages and benefits expense increased $55&#160;million, or 0.8%, in the year ended December&#160;31,&#160;2022 compared to 2021. This increase was primarily attributable to higher contract labor and premium pay costs due to the pandemic, and annual merit increases for certain of our employees, all of which were partially offset by lower incentive compensation and employee benefit costs, as well as our continued focus on cost&#8209;efficiency measures. Same&#8209;hospital salaries, wages and benefits expense as a percentage of net operating revenues increased by 140&#160;basis&#160;points to 50.3% in the year ended December&#160;31, 2022 compared to the year ended December&#160;31,&#160;2021. This increase was primarily due to the impact of higher contract labor and premium pay costs, decreased patient volumes, and the Cybersecurity Incident on our patient revenues during the 2022 period. Salaries, wages and benefits expense for the years ended December&#160;31,&#160;2022 and 2021 included stock&#8209;based compensation expense of $43&#160;million and $41&#160;million, respectively.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplies</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Same&#8209;hospital supplies expense decreased $147 million, or 5.8%, in the year ended December&#160;31,&#160;2022 compared to 2021. The decrease was primarily attributable to lower overall patient volumes, reduced COVID&#8209;related volumes and acuity, and our cost&#8209;efficiency measures, partially offset by the increased cost of certain supplies as a result of the COVID&#8209;19 pandemic, the impact of general market conditions and inflation. Same&#8209;hospital supplies expense as a percentage of net operating revenues decreased by 60 basis points to 16.5% in the year ended December&#160;31,&#160;2022 compared to the year ended December&#160;31,&#160;2021, primarily due to the factors described above.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic created supply&#8209;chain disruptions, including shortages and delays, as well as significant price increases in medical supplies. During the year ended December&#160;31,&#160;2022, general market conditions and inflation also increased the cost of medical supplies. We strive to control supplies expense through product standardization, consistent contract terms and end&#8209;to&#8209;end contract management, improved utilization, bulk purchases, focused spending with a smaller number of vendors and operational improvements. The items of current cost&#8209;reduction focus include cardiac stents and pacemakers, orthopedics, implants and high&#8209;cost pharmaceuticals.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Expenses, Net</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Same&#8209;hospital other operating expenses decreased by $136&#160;million, or 4.0%, in the year ended December&#160;31,&#160;2022 compared to 2021. Same&#8209;hospital other operating expenses as a percentage of net operating revenues decreased by 50&#160;basis points to 22.4% in the year ended December&#160;31, 2022 compared to 22.9% in the year ended December&#160;31, 2021, primarily due to the net gains from the sale of assets noted below. The changes in other operating expenses included:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in gains from the sale of assets of $102&#160;million, which were classified as a reduction of other operating expenses, net; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased malpractice expense of $51&#160;million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31,&#160;2022 and 2021, other operating expenses for our Hospital Operations segment included $273&#160;million and $280&#160;million, respectively, of rent expense.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_94"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ambulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment is comprised of USPI&#8217;s ASCs and surgical hospitals. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a health system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. USPI operates facilities on a day&#8209;to&#8209;day basis through management services contracts. Our sources of earnings from each facility consist of:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management and administrative services revenues from the facilities USPI operates through management services contracts, computed as a percentage of each facility&#8217;s net revenues;&#160;and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our share of each facility&#8217;s net income (loss), which is computed by multiplying the facility&#8217;s net income (loss) times the percentage of each facility&#8217;s equity interests owned by USPI.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our role as an owner and day&#8209;to&#8209;day manager provides us with significant influence over the operations of each facility. For many of the facilities our Ambulatory Care segment holds an ownership interest in (158 of 466 facilities at December&#160;31,&#160;2022), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls 308</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than USPI is classified within net income available (loss attributable) to noncontrolling interests.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For unconsolidated affiliates, our statements of operations reflect our earnings in two line items:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">equity in earnings of unconsolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;our share of the net income (loss) of each facility, which is based on the facility&#8217;s net income (loss) and the percentage of the facility&#8217;s outstanding equity interests owned by USPI;&#160;and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">management and administrative services revenues, which is included in our net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;income we earn in exchange for managing the day&#8209;to&#8209;day operations of each facility, usually quantified as a percentage of each facility&#8217;s net revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment operating income is driven by the performance of all facilities USPI operates and by USPI&#8217;s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 66% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses, which is why we disclose certain statistical and financial data on a pro forma systemwide basis that includes both consolidated and unconsolidated (equity method) facilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unconsolidated facilities received cash payments from the PRF during 2021, and we recognized grant income of $14&#160;million from these funds; this income is included in equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2021. No additional grant income was recognized from our unconsolidated facilities during the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Year Ended December&#160;31,&#160;2022 Compared to the Year Ended December&#160;31,&#160;2021</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected revenue and expense information for our Ambulatory Care segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.162%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care net operating revenues increased by $530&#160;million, or 19.5%, during the year ended December&#160;31,&#160;2022 compared to 2021. The change was driven by an increase from acquisitions of $453&#160;million, as well as an increase in same&#8209;facility net operating revenues of $146 million, which was attributable to the impact of improved case volumes, incremental revenue from new service lines and negotiated commercial rate increases. These impacts were partially offset by lower revenues of $69&#160;million due primarily to the sale of USPI&#8217;s urgent care centers and the transfer of imaging centers to the Hospital Operations segment, both in April&#160;2021. Our Ambulatory Care segment also recognized grant income from federal grants totaling $4&#160;million and $49&#160;million during the years ended December&#160;31,&#160;2022 and 2021, respectively, which is not included in net operating revenues.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries, Wages and Benefits</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries, wages and benefits expense increased by $132&#160;million, or 19.1%, during the year ended December&#160;31,&#160;2022 compared to 2021. Salaries, wages and benefits expense was impacted by an increase from acquisitions of $121 million and an increase in same&#8209;facility salaries, wages and benefits expense of $41 million due primarily to higher surgical case volumes. These increases were partially offset by a decrease of $30 million due primarily to the sale of USPI&#8217;s urgent care centers and the transfer of imaging centers to the Hospital Operations segment. Salaries, wages and benefits expense as a percentage of net operating revenues decreased 10 basis points during the year ended December&#160;31,&#160;2022 compared to 2021 and included stock&#8209;based compensation expense of&#160;$11 million and $13&#160;million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplies</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplies expense increased by $187&#160;million, or 27.3%, during the year ended December&#160;31,&#160;2022 compared to 2021. The change was driven by an increase from acquisitions of $161&#160;million, as well as an increase in same&#8209;facility supplies expense of $32&#160;million due primarily to an increase in surgical cases at our consolidated centers and higher pricing of certain supplies as a result of the pandemic, the impact of general market conditions and inflation. Supplies expense as a percentage of net operating revenues increased 160&#160;basis&#160;points from 25.2% in the year ended December&#160;31,&#160;2021 to 26.8% in the year ended December&#160;31,&#160;2022. This change was driven by an increase in higher&#8209;acuity, supply&#8209;intensive surgeries and higher pricing of certain supplies.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Expenses, Net</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased by $49&#160;million, or 12.6%, during the year ended December&#160;31,&#160;2022 compared to 2021. The change was primarily driven by an increase from acquisitions of $61 million, partially offset by a decrease of $18&#160;million due primarily to the sale of USPI&#8217;s urgent care centers and the transfer of imaging centers to the Hospital Operations segment. Other operating expenses, net as a percentage of net operating revenues decreased from 14.3% during the year ended December&#160;31,&#160;2021 to 13.5% for 2022. Other operating expenses for our Ambulatory Care segment included $115&#160;million and $100&#160;million of rent expense for the years ended December&#160;31,&#160;2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Growth</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the year-over-year changes in our same&#8209;facility revenue and cases on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue per case</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Ventures with Health System Partners</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPI&#8217;s business model is to jointly own its facilities with local physicians and, in many of these facilities, a health system partner. Accordingly, as of December&#160;31,&#160;2022, the majority of facilities in our Ambulatory Care segment were operated in this model.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the amounts we paid to acquire various ownership interests in ambulatory care facilities:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.162%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in unconsolidated affiliates and consolidated facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,051)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information about the ownership structure of the facilities operated by our Ambulatory Care segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a health system partner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a health system partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total facilities operated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the change in the number of facilities operated by our Ambulatory Care segment since December 31, 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">De novo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dispositions/Mergers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total increase in number of facilities operated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we acquired controlling interests in 30 fully operational ASCs, 16 of which are located in Maryland, four in Florida, two in each of Arizona, Colorado and Tennessee, and four located in other states. All of these facilities are jointly owned with physicians, except one that is jointly owned with a health system partner and physicians. During 2022, we also acquired noncontrolling interests in seven ASCs, three of which are located in Texas, two in Washington and one in each of California and New&#160;Jersey. In total, we paid $178&#160;million to acquire controlling and noncontrolling interests in these facilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the year ended December&#160;31,&#160;2022, we paid an aggregate of $65&#160;million to acquire controlling ownership interests in 23 previously unconsolidated ASCs located in 11 geographically diverse states. Following our acquisition of a controlling interest in one of these ASCs, we contributed our ownership interest in it to a joint venture in which we have a noncontrolling ownership interest.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also regularly engage in the purchase of equity interests with respect to our investments in unconsolidated affiliates and consolidated facilities that do not result in a change in control. These transactions are primarily the acquisitions of equity interests in ASCs and the investment of additional cash in facilities that need capital for new acquisitions, new construction or other business growth opportunities. During the year ended December&#160;31,&#160;2022, we invested approximately $21&#160;million in such transactions.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_4063"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conifer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected revenue and expense information for our Conifer segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.162%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle and other services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle and other services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment&#8217;s operating revenues from third-party clients, which revenues are not eliminated in consolidation, increased $80&#160;million, or 10.2%, for the year ended December&#160;31,&#160;2022 compared to 2021. This increase was primarily attributable to contractual rate increases and new business expansion.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries, Wages and Benefits</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries, wages and benefits expense for Conifer increased $12 million, or 1.8%, in the year ended December&#160;31,&#160;2022 compared to 2021. Salaries, wages and benefits expense included stock&#8209;based compensation expense of $2&#160;million in both 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Expenses, Net</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for Conifer increased $27 million, or 11.7%, in the year ended December&#160;31, 2022 compared to 2021. This increase was primarily due to new business expansion, higher vendor utilization and increased recruiting expenses in 2022. For both of the years ended December&#160;31, 2022 and 2021, other operating expenses for our Conifer segment included $10 million of rent expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Restructuring Charges, and Acquisition-Related Costs</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our impairment and restructuring charges, and acquisition&#8209;related costs:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By segment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges during the year ended December&#160;31,&#160;2022 included $82&#160;million for the write&#8209;down of certain buildings and medical equipment located in one of our markets to their estimated fair values. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#8217; long&#8209;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included decreased revenues and lower patient volumes due to the pandemic and competition, as well as higher labor costs as a result of the pandemic. As a result, we updated the estimate of the fair value of the hospitals&#8217; long&#8209;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#8209;lived assets, an impairment charge was recorded for the difference in the amounts. We also recorded $12&#160;million of other impairment charges. For additional discussion, see Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the accompanying Consolidated Financial Statements. Impairment charges for the year ended December&#160;31,&#160;2022 were comprised of $86&#160;million from our Hospital Operations segment, $6&#160;million from our Ambulatory Care segment and $2&#160;million from our Conifer segment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges for the year ended December&#160;31,&#160;2022 consisted of $27&#160;million of employee severance costs, $16&#160;million related to the transition of various administrative functions to our GBC, $32&#160;million related to contract and lease termination fees, and $43&#160;million of other restructuring costs. Acquisition&#8209;related costs during 2022 consisted entirely of transaction costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges for the year ended December&#160;31,&#160;2021 were comprised of $5&#160;million from our Ambulatory Care segment, primarily related to the impairment of certain management contract intangible assets, and $3&#160;million from our Conifer segment. Restructuring charges during the year ended December&#160;31,&#160;2021 consisted of $14&#160;million of employee severance costs, $19&#160;million related to the transition of various administrative functions to our GBC and $24&#160;million of other restructuring costs. Acquisition&#8209;related costs during 2021 consisted entirely of transaction costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility&#8217;s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Investigation Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and investigation costs for the years ended December&#160;31,&#160;2022 and 2021 were $70 million and $116&#160;million, respectively. The decrease of $46&#160;million, or 39.7%, in 2022 as compared to 2021 was primarily due to higher costs associated with legal proceedings and governmental investigations during 2021. See Note&#160;17 to the accompanying Consolidated Financial Statements for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Gains on Sales, Consolidation and Deconsolidation of Facilities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021, we recorded net gains on sales, consolidation and deconsolidation of facilities of $445&#160;million, primarily comprised of a gain of $406&#160;million related to the sale of the Miami Hospitals in August&#160;2021, a gain of $14 million related to the sale of the majority of our urgent care centers in April&#160;2021, net gains of $22&#160;million related to consolidation changes of certain USPI businesses due to ownership changes and net gains of $3&#160;million related to other activity.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the year ended December&#160;31,&#160;2022 was $890&#160;million compared to $923&#160;million for the year ended December&#160;31,&#160;2021.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss from Early Extinguishment of Debt</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we incurred aggregate losses from the early extinguishment of debt of $109&#160;million. These losses primarily related to the redemption in full of our 7.500% senior secured first lien notes due 2025 (&#8220;2025&#160;Senior Secured First Lien Notes&#8221;) in February&#160;2022 and open market purchases and the subsequent redemption in full of our 6.750% senior unsecured notes due 2023 (the &#8220;2023&#160;Senior Unsecured Notes&#8221;) during the six months ended June&#160;30,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we incurred aggregate losses from the early extinguishment of debt of $74&#160;million. These losses related to the partial redemption of our July&#160;2024 Senior Secured First Lien Notes in September&#160;2021, the redemption in full of our 5.125% senior secured second lien notes due 2025 (the &#8220;2025&#160;Senior Secured Second Lien Notes&#8221;) in June&#160;2021 and the retirement in full of our 7.000% senior unsecured notes due 2025 (&#8220;2025&#160;Senior Unsecured Notes&#8221;) in March&#160;2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both 2022 and 2021, the net losses from early extinguishment of debt primarily related to the difference between the purchase prices and the par values of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we recorded income tax expense of $344 million in continuing operations on pre&#8209;tax income of $1.344 billion compared to income tax expense of $411 million in continuing operations on pre&#8209;tax income of $1.888 billion during the year ended December&#160;31,&#160;2021.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is presented below:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory federal rate of 21%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior-year provision to return adjustments and other changes in deferred&#160;taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the business interest expense disallowance rules took effect in 2022, resulting in a larger amount of interest disallowance compared to prior years. During the year ended December&#160;31,&#160;2022, the valuation allowance increased by $120&#160;million, including an increase of $123&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $2 million due to changes in the expected realizability of deferred tax assets. The balance in the valuation allowance as of December&#160;31,&#160;2022 was $177 million. During the year ended December&#160;31,&#160;2021, the valuation allowance increased by $2 million, including an increase of $2&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $2&#160;million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $2&#160;million due to changes in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December&#160;31,&#160;2021 was $57&#160;million.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income Available to Noncontrolling Interests</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income available to noncontrolling interests was $590 million for the year ended December&#160;31,&#160;2022 compared to $562 million for the year ended December&#160;31,&#160;2021. Net income available to noncontrolling interests in 2022 was comprised of $469 million related to our Ambulatory Care segment, $77 million related to our Conifer segment and $44&#160;million related to our Hospital Operations segment. Of the portion related to our Ambulatory Care segment, $9&#160;million related to the minority interest Baylor held in USPI until June&#160;30,&#160;2022.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_103"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information provided throughout this report, including our Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). However, we use certain non&#8209;GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Adjusted EBITDA&#8221; is a non&#8209;GAAP measure we define as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1)&#160;the cumulative effect of changes in accounting principle, (2)&#160;net loss attributable (income available) to noncontrolling interests, (3)&#160;income (loss) from discontinued operations, net of tax, (4)&#160;income tax benefit (expense), (5)&#160;gain (loss) from early extinguishment of debt, (6)&#160;other non&#8209;operating income (expense), net, (7)&#160;interest expense, (8)&#160;litigation and investigation (costs) benefit, net of insurance recoveries, (9)&#160;net gains (losses) on sales, consolidation and deconsolidation of facilities, (10)&#160;impairment and restructuring charges and acquisition&#8209;related costs, (11)&#160;depreciation and amortization, and (12)&#160;income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the foregoing non&#8209;GAAP measure is useful to investors and analysts because it presents additional information about our financial performance. Investors, analysts, company management and our board of directors utilize this non&#8209;GAAP measure, in addition to GAAP measures, to track our financial and operating performance and compare that performance to peer companies, which utilize similar non&#8209;GAAP measures in their presentations. The human resources committee of our board of directors also uses certain non&#8209;GAAP measures to evaluate management&#8217;s performance for the purpose of determining incentive compensation. We believe that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non&#8209;GAAP measures, as factors in determining the estimated fair value of shares of our common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. We do not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non&#8209;GAAP Adjusted EBITDA measure we utilize may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating our financial performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the reconciliation of Adjusted EBITDA to net income available to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income available to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from early extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from divested and closed businesses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders as&#160;a&#160;% of net operating revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA as a % of net operating revenues </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Adjusted EBITDA&#160;margin)&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_4155"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER&#160;31,&#160;2021 COMPARED TO THE YEAR&#160;ENDED DECEMBER&#160;31,&#160;2020</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of the results of operations for the year ended December&#160;31,&#160;2021 compared to the year ended December&#160;31,&#160;2020 can be found in our Annual Report on Form 10&#8209;K for the year ended December&#160;31,&#160;2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_112"></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH REQUIREMENTS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scheduled Contractual Obligations</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations to make future cash payments under contracts are summarized in the table below, all as of December&#160;31, 2022. Other than the repayment of long-term debt, we expect to use net cash generated from operating activities, cash on hand or borrowings under our Credit Agreement to satisfy the below obligations. Long&#8209;term debt maturities may be refinanced or repaid using net cash generated from operating activities or from the proceeds from sales of facilities.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.716%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term non-cancelable operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Academic teaching services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit plan obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology contract services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase orders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11.25pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,694</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,094</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts include both principal and interest.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement provides for revolving loans in an aggregate principal amount of up to $1.500&#160;billion, subject to borrowing availability, with a $200&#160;million subfacility for standby letters of credit. In March&#160;2022, we amended our Credit Agreement to, among other things, (1)&#160;decrease the aggregate revolving credit commitments from the previous maximum of $1.900&#160;billion to $1.500&#160;billion, (2)&#160;extend the Credit Agreement&#8217;s maturity date to March&#160;2027 and (3)&#160;replace the London Interbank Offered Rate (&#8220;LIBOR&#8221;) with the Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) and Daily Simple SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At December&#160;31, 2022, we had no cash borrowings outstanding under the Credit Agreement and less than $1&#160;million of standby letters of credit outstanding.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had outstanding senior unsecured and senior secured notes (&#8220;Senior Notes&#8221;) with an aggregate principal balance of $14.757&#160;billion. The Senior Notes generally require semi&#8209;annual interest payments and have maturity dates ranging from 2024 through 2031. Any outstanding principal and accrued but unpaid interest is due upon maturity.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated the following transactions affecting our Senior Notes in the year ended December&#160;31,&#160;2022:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the three months ended December&#160;31,&#160;2022, we paid $13&#160;million from cash on hand to repurchase $14&#160;million of the aggregate principal amount then outstanding of our July&#160;2024 Senior Secured First Lien Notes in advance of their maturity date through multiple open&#8209;market transactions.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Also during the three months ended December&#160;31,&#160;2022, we paid $11&#160;million from cash on hand to repurchase $11&#160;million of the aggregate principal amount then outstanding of our September&#160;2024 Senior Secured First Lien Notes in advance of their maturity date through multiple open&#8209;market transactions.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, we issued $2.000&#160;billion aggregate principal amount of our 2030 Senior Secured First Lien Notes. We pay interest on these notes semi&#8209;annually in arrears on June&#160;15 and December&#160;15 of each year, which payments commended on December&#160;15,&#160;2022. As further discussed below, we used a substantial portion of the issuance proceeds from the 2030 Senior Secured First Lien Notes, after payment of fees and expenses, to finance the redemption of our 2023&#160;Senior Unsecured Notes.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Through a series of open&#8209;market transactions during the six months ended June&#160;30,&#160;2022, we repurchased $124&#160;million aggregate principal amount outstanding of our 2023&#160;Senior Unsecured Notes using cash on hand. Following the issuance of our 2030 Senior Secured First Lien Notes in June&#160;2022, we used a substantial portion of the proceeds to redeem the then&#8209;remaining $1.748&#160;billion aggregate principal outstanding of the 2023&#160;Senior Unsecured Notes in advance of their maturity date. In total, we paid $1.933&#160;billion during the six months ended June&#160;30,&#160;2022 to retire our 2023&#160;Senior Unsecured Notes in full and recorded aggregate losses from early extinguishment of debt of $71&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2022, we paid $730&#160;million from cash on hand to redeem all $700&#160;million aggregate principal amount outstanding of our 2025&#160;Senior Secured First Lien Notes in advance of their maturity date. In connection with the redemption, we recorded a loss from early extinguishment of debt of $38&#160;million in the three months ended March&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, using the last 12 months of Adjusted EBITDA, our ratio of total long&#8209;term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 4.1x. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our Credit Agreement as a source of liquidity and acquisitions that involve the assumption of long&#8209;term debt. We seek to manage this ratio and increase the efficiency of our balance sheet by following our business plan and managing our cost structure, including through possible asset divestitures, and through other changes in our capital structure. As part of our long&#8209;term objective to manage our capital structure, we continue to evaluate opportunities to retire, purchase, redeem and refinance outstanding debt subject to prevailing market conditions, our liquidity requirements, operating results, contractual restrictions and other factors. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward&#8209;Looking Statements and Risk Factors sections in Part I of this report.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest payments, net of capitalized interest, were $848&#160;million, $937&#160;million and $962&#160;million in the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively. For the year ending December&#160;31,&#160;2023, we expect annual interest payments to be approximately $835&#160;million to $845&#160;million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of our long-term debt obligations are summarized in the table above. See Note 8 to the accompanying Consolidated Financial Statements for additional information about our long&#8209;term debt obligations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Obligations&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating lease agreements primarily for real estate, including off&#8209;campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as for medical office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. As of December&#160;31,&#160;2022, we had fixed payment obligations of $1.517&#160;billion under non&#8209;cancellable lease agreements. Future payments due in connection with our operating and finance leases, including imputed interest, are summarized in the table above. Additional information about our lease commitments is provided in Note 7 to the accompanying Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Academic Teaching Services&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts for academic teaching services with university and physician groups to support graduate medical education. These agreements contain various rights and termination provisions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Plan Obligations&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain three frozen, non&#8209;qualified defined benefit plans that provide supplemental retirement benefits to certain of our current and former executives. These plans are unfunded, and plan obligations are paid from our working capital. We also maintain a frozen, qualified defined benefit plan that benefits certain of our current and former employees in Detroit. See Note 10 to the accompanying Consolidated Financial Statements for additional information about our defined benefit plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information Technology Contracts&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into various non&#8209;cancellable contracts for information technology services and licenses as a normal part of our business. These contracts generally relate to information technology infrastructure support and services, software licenses for certain operational and administrative systems, and cybersecurity&#8209;related software and services. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Orders&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding short&#8209;term purchase commitments of $369 million at December&#160;31,&#160;2022, which we expect to pay within 12 months.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contractual Obligations</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Retirement Obligations&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset retirement obligations represent the estimated costs to perform environmental remediation work, which we are legally obligated to complete, at certain of our facilities upon their retirement. This work could include asbestos abatement, the removal of underground storage tanks and other similar activities. At December&#160;31,&#160;2022, the undiscounted aggregate future estimated payments related to these obligations was $184 million. We are unable to predict the timing of these payments due to the uncertainty and long timeframes inherent in these obligations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standby Letters of Credit&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standby letters of credit are required principally by our insurers and various states to collateralize our workers&#8217; compensation programs pursuant to statutory requirements and as security to collateralize the deductible and self&#8209;insured retentions under certain of our professional and general liability insurance programs. The amount of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collateral required is primarily dependent upon the level of claims activity and our creditworthiness. The insurers require the collateral in case we are unable to meet our obligations to claimants within the deductible or self&#8209;insured retention layers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a letter of credit facility (as amended to date, the &#8220;LC&#160;Facility&#8221;) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200&#160;million. Drawings under any letter of credit issued under the LC&#160;Facility accrue interest if not reimbursed within three business days. At December&#160;31,&#160;2022, we had $116&#160;million of standby letters of credit outstanding under the LC&#160;Facility. The timing of reimbursement payments is uncertain, as we cannot foresee when, or if, a standby letter of credit will be drawn upon.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our guarantees include minimum revenue guarantees, primarily related to physicians under relocation agreements and physician groups that provide services at our hospitals, as well as operating lease guarantees. At December&#160;31,&#160;2022, the maximum potential amount of future payments under these guarantees was $266&#160;million, of which $168&#160;million were recorded in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022. The timing and amount of future payments under these guarantees is uncertain.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional and General Liability Obligations&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, the current and long&#8209;term professional and general liability reserves included in our Consolidated Balance Sheet were $255&#160;million and $790&#160;million, respectively, and the current and long&#8209;term workers&#8217; compensation reserves included in our Consolidated Balance Sheet were $45 million and $93&#160;million, respectively. The timing of professional and general liability payments is uncertain as such payments depend on several factors, including the nature of claims and when they are received.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Baylor Put/Call Agreement&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 18 to the accompanying Consolidated Financial Statements, we had a put/call agreement (the &#8220;Baylor Put/Call Agreement&#8221;) with respect to the 5% ownership interest Baylor held in USPI until June&#160;30,&#160;2022. The Baylor Put/Call Agreement gave Baylor the option to annually put up to one-third of its total shares in USPI (the &#8220;Baylor Shares&#8221;) over a period of three years beginning in 2021. We had the right to call the difference between the number of shares Baylor put each year and the maximum number of shares it could have put.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares for that year (66.6% in total). In June&#160;2022, we entered into an agreement with Baylor (the &#8220;Share Purchase Agreement&#8221;) to complete the purchase of the Baylor Shares we called in 2021 and 2022 and to accelerate the acquisition of the remaining Baylor Shares eligible to be put/called in 2023. Under the terms of the Share Purchase Agreement, we agreed to pay Baylor $406&#160;million to buy its entire 5% voting interest in USPI. We paid $11&#160;million upon execution of the Share Purchase Agreement and are obligated to make additional non-interest bearing monthly payments of approximately $11&#160;million, which payments commenced in August&#160;2022. At December&#160;31,&#160;2022, we had liabilities of $135&#160;million recorded in other current liabilities and $190&#160;million in other long-term liabilities in the accompanying Consolidated Balance Sheet for the purchase of these shares.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in the SCD Centers&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPI continues to make offers in an ongoing process to acquire a portion of the equity interests in certain of the ASCs acquired from SCD in December&#160;2021 from the physician owners for consideration of up to approximately $250&#160;million. During the year ended December&#160;31, 2022, we made aggregate payments of $58&#160;million to acquire controlling interests in 18&#160;of these ASCs. We cannot reasonably predict how many additional physician owners will accept our offers to acquire a portion of their equity, nor the timing or amount of any remaining payments.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SCD Development Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In December&#160;2021, USPI and SCD&#8217;s principals entered into a joint venture and development agreement under which USPI has the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50&#160;de&#160;novo ASCs through December&#160;2026. The timing and amount of payments related to the development of these facilities is currently unknown.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the obligations described above, we had no off&#8209;balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Requirements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Expenditures&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), surgical hospital expansion focused on higher acuity services, equipment and information systems additions and replacements, introduction of new medical technologies (including robotics), design and construction of new facilities, and various other capital improvements. We continue to implement our portfolio diversification strategy into ambulatory surgery and have a baseline intention to invest $250&#160;million annually in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ambulatory business acquisitions and de novo facilities. Capital expenditures were $762&#160;million, $658&#160;million and $540&#160;million in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December&#160;31,&#160;2023 will total approximately $625&#160;million to $675 million, including $196&#160;million that was accrued as a liability at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the construction of and opened PMC&#160;Fort&#160;Mill to patients during the year ended December&#160;31,&#160;2022. This 100&#8209;bed facility includes an emergency department, multi&#8209;specialty operating rooms, an intensive care unit, and labor and delivery rooms. In addition, we broke ground in 2022 on a new healthcare campus in the Westover Hills area of San&#160;Antonio, Texas, which campus will include a hospital, ASC and medical office space. We expect construction of the Westover Hills facilities will cost approximately $230&#160;million over the construction period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By the beginning of 2030, all hospitals in California providing acute care services must meet standards that are intended to ensure that they remain intact and capable of continued operation following an earthquake. During 2022, we began planning for the nonstructural performance category (&#8220;NPC&#8221;) seismic requirements for our hospitals in California, which we expect to complete by the end of 2023 for review by the State. This analysis will clarify the NPC work required to be completed in future years to bring our hospitals in compliance with the building requirements by the 2030 deadline, and the results of the NPC planning will inform more detailed design and cost estimates after we receive State feedback. We will also determine any additional structural category performance (&#8220;SCP&#8221;) work, with required design and construction work in both categories coordinated. At this time, we are unable to reasonably estimate the amount of NPC and SCP work our hospitals will require or the potential cost to retrofit them. The additional NPC work required will not change the timing or general nature of our ongoing or currently planned NPC or SCP work on our buildings.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax payments, net of tax refunds, were $161&#160;million and $92&#160;million in the years ended December&#160;31,&#160;2022 and 2021, respectively. At December&#160;31,&#160;2022, our carryforwards available to offset future taxable income consisted of (1)&#160;federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $100 million pre&#8209;tax, $40&#160;million of which expires in 2024 to 2037 and $60 million of which has no expiration date, (2) charitable contribution carryforwards of approximately $45&#160;million expiring in 2025 through 2027 and (3)&#160;state NOL carryforwards of approximately $3.106&#160;billion expiring in 2023 through 2042 for which the associated deferred tax benefit, net of valuation allowance and federal tax impact, is $42&#160;million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize NOL carryforwards to reduce future taxable income may be limited under Section&#160;382 of the Internal Revenue Code if certain ownership changes in our company occur during a rolling three&#8209;year period. These ownership changes include purchases of common stock under share repurchase programs, the offering of stock by us, the purchase or sale of our stock by 5%&#160;shareholders, as defined in the Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5% shareholders result in aggregate increases that exceed 50&#160;percentage points during the three&#8209;year period, then Section&#160;382 imposes an annual limitation on the amount of our taxable income that may be offset by the NOL&#160;carryforwards or tax credit carryforwards at the time of ownership change.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic examinations of our tax returns by the IRS or other taxing authorities could result in the payment of additional taxes. The IRS has completed audits of our tax returns for all tax years ended on or before December&#160;31,&#160;2007. All disputed issues with respect to these audits have been resolved and all related tax assessments (including interest) have been paid. Our tax returns for years ended after December&#160;31,&#160;2007 and USPI&#8217;s tax returns for years ended after December&#160;31,&#160;2018 remain subject to audit by the IRS.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 (the &#8220;Tax Act&#8221;) was enacted in August&#160;2022. Among other things, the Tax Act implemented a corporate alternative minimum tax (&#8220;CAMT&#8221;) of 15% on book income of certain large corporations, a 1%&#160;excise tax on net stock repurchases and several tax incentives to promote clean energy. The provision pertaining to an excise tax on corporate stock repurchases imposes a nondeductible 1% excise tax on publicly traded corporations for the net value of certain stock that any such corporation repurchases. The value of the repurchases subject to the tax is reduced by the value of any stock the corporation issued during the tax year, including stock issued or provided to employees. The CAMT imposes a minimum tax on net income adjusted for certain items prescribed by the Tax Act. Both the CAMT and the excise tax provisions of the Tax Act are effective for tax years beginning after December&#160;31,&#160;2022. We are awaiting the publication of additional guidance related to the CAMT to fully assess its applicability and potential impact on our Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SOURCES AND USES OF CASH</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity for the year ended December&#160;31,&#160;2022 was primarily derived from net cash provided by operating activities and cash on hand. During 2022, we also received $196&#160;million of supplemental funds from federal and state grants provided under COVID-19 relief legislation. We had $858&#160;million of cash and cash equivalents on hand at December&#160;31,&#160;2022 to fund our operations and capital expenditures, and our borrowing availability under our Credit Agreement was $1.500&#160;billion based on our borrowing base calculation at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors. Our Credit Agreement provides additional liquidity to manage fluctuations in operating cash caused by these factors.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $1.083 billion in the year ended December&#160;31,&#160;2022 compared to $1.568&#160;billion in the year ended December&#160;31,&#160;2021. Key factors contributing to the change between 2022 and 2021 include the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$880 million of Medicare advances recouped or repaid in the year ended December&#160;31,&#160;2022 compared to $512&#160;million during 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$196&#160;million of cash received from pandemic-related grant programs in 2022 compared to $178&#160;million received in 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower interest payments of $89 million in 2022;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher income tax payments of $69 million in 2022;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of $61&#160;million in payments for restructuring charges, acquisition&#8209;related costs, and litigation costs and settlements in 2022; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing of other working capital items.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities totaled $808 million for the year ended December&#160;31,&#160;2022&#160;compared to $714&#160;million for the year ended December&#160;31,&#160;2021. Proceeds from the sale of facilities and other assets were $1.038&#160;billion lower during 2022 as compared to 2021, primarily due to the sale of the majority of our urgent care centers in April&#160;2021 and the sale of the Miami Hospitals in August&#160;2021, and capital expenditures were $104&#160;million higher in 2022 as compared to 2021. These amounts were substantially offset by a decrease of $986&#160;million in cash used to purchase businesses during 2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeds from the sales noted above, investing activity during the year ended December&#160;31,&#160;2021 included purchases of businesses totaling $1.220&#160;billion, primarily related to USPI&#8217;s acquisition activity. In addition, capital expenditures increased by $118&#160;million and purchases of equity interests increased $64&#160;million during 2021, as compared to the year ended December&#160;31,&#160;2020.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used net cash of $1.781&#160;billion and $936&#160;million for financing activities during the years ended December&#160;31,&#160;2022 and 2021, respectively. Financing activity during the year ended December&#160;31,&#160;2022 included aggregate payments against our borrowings of $2.851&#160;billion, the majority of which was used to retire $2.597&#160;billion aggregate principal amount outstanding of our Senior Notes in advance of their maturity dates, and payments totaling $250&#160;million under our stock repurchase program to reacquire nearly six&#160;million shares of our common stock. In addition, distributions to noncontrolling interest holders increased $137&#160;million during 2022 as compared to 2021, partially due to distributions of the proceeds from the sale of several medical office buildings to minority interest holders totaling $61&#160;million in 2022. The aforementioned payments were partially offset by the proceeds received from the issuance of our 2030 Senior Secured First Lien Notes during the year ended December&#160;31,&#160;2022. Financing activity during the year ended December&#160;31,&#160;2021 included proceeds from our issuance of $2.850&#160;billion aggregate principal amount of Senior Notes. We used a portion of these proceeds, together with the proceeds from our sale of the Miami Hospitals and cash on hand, to redeem and retire $2.988&#160;billion aggregate principal amount of our then-outstanding Senior Notes during 2021. Financing activity in 2021 also included the receipt of $37&#160;million of grant funds by our Ambulatory Care segment&#8217;s unconsolidated affiliates and their repayment of $104&#160;million of Medicare advances. Additionally, we paid total distributions to noncontrolling interest holders of $423&#160;million during the year ended December&#160;31,&#160;2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several structured payables arrangements that are a part of our strategy to make our procurement processes more efficient and cost effective. At December&#160;31,&#160;2022, we were paying approximately 6,300 vendors under these programs, with an annual charge volume of approximately $1.3&#160;billion. We do not expect these programs to result in any significant changes to our liquidity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our equity securities and our debt securities classified as available&#8209;for&#8209;sale at fair market value. The majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_121"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, our Credit Agreement provided for revolving loans in an aggregate principal amount of up to $1.500&#160;billion with a $200 million subfacility for standby letters of credit. In April 2021, we amended the Credit Agreement to, among other things, extend the duration of previous amendments that raised the aggregate revolving credit commitments from $1.500&#160;billion to $1.900&#160;billion, subject to borrowing availability. In March&#160;2022, we amended the revolving credit facility again to, among other things, (1)&#160;decrease the previous maximum aggregate revolving credit commitments from $1.900&#160;billion to $1.500&#160;billion, subject to borrowing availability, (2)&#160;extend the scheduled maturity date from September&#160;2024 to March&#160;2027 and (3)&#160;replace LIBOR with Term SOFR and Daily Simple SOFR (each, as defined in the Credit Agreement) as the reference interest rate. Obligations under the Credit Agreement are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first&#8209;priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1&#160;million of standby letters of credit outstanding. We were in compliance with all covenants and conditions in our Credit Agreement and, based on our eligible receivables, $1.500&#160;billion was available for borrowing at December&#160;31,&#160;2022. See Note 8 to the accompanying Consolidated Financial Statements for additional information about our Credit Agreement.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter of Credit Facility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LC&#160;Facility provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $200 million and matures in September&#160;2024. Obligations under the LC&#160;Facility are guaranteed and secured by a first&#8209;priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal&#8209;ranking basis with our senior secured first lien notes. At December&#160;31,&#160;2022, $116&#160;million of standby letters of credit were outstanding, and we were in compliance with all covenants and conditions in our LC&#160;Facility.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Note Issuances and Debt Refinancing Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;A detailed discussion of our debt transactions during the year ended December&#160;31,&#160;2022 is provided in the Cash Requirements subsection above. In the aggregate, we recognized a net loss from the early extinguishment of debt of $109 million in the year ended December&#160;31,&#160;2022 related to our retirement of certain Senior Notes prior to their scheduled maturity dates. This loss was primarily related to the difference between the purchase prices and the par values of the notes we retired, as well as the write&#8209;off of unamortized issuance costs associated with them.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_124"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIQUIDITY</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to experience negative impacts of the pandemic on our business to varying degrees. Surges of COVID&#8209;19 at various points throughout 2022 caused periodic spikes in COVID admissions at our hospitals and resulted in increased case cancellations in our Ambulatory Care segment. Throughout the pandemic, we have experienced significant price increases in medical supplies, particularly for personal protective equipment, and we have encountered supply-chain disruptions, including shortages and delays. In addition, our Ambulatory Care segment has been impacted by shipment delays in construction materials and capital equipment with respect to its de novo facility development efforts, which are a key part of our portfolio expansion strategy. The pandemic also exacerbated previously existing workforce shortages&#160;&#8211; and, thereby, competition for qualified candidates&#160;&#8211; as more employees chose to retire early, leave the workforce or take travel assignments. Over the past several years, we have had to rely on higher&#8209;cost temporary and contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers. We have been required, and we may in the future be required, to temporarily reduce overall operating capacity or suspend certain services at individual facilities due to staffing constraints and other COVID&#8209;19&#8209;related factors.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad economic factors resulting from the pandemic, including higher inflation, increased unemployment rates in certain areas where we operate and reduced consumer spending, have impacted, and are continuing to impact, our service mix, revenue mix and patient volumes. Business closings and layoffs in the areas we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients to pay for services. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken, and continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and changes in our service mix and revenue mix. These actions included the sale and redemption of various senior unsecured notes and senior secured notes, which eliminated any significant debt maturities until July 2024 and will reduce our future annual cash interest expense payments. In addition, we have continued cost-efficiency measures, as well as necessary cost reductions, to substantially offset incremental costs, including temporary staffing and premium pay, as well as higher supply costs for PPE. We have also sought to compensate for the pandemic&#8217;s disruption of our patient volumes and service mix by growing our services for which demand has been more resilient, including our higher&#8209;acuity service lines. While the length of time that will be required for our hospital patient volumes and mix to return to pre-pandemic levels is unknown, especially demand for lower&#8209;acuity services, we believe demand for our higher&#8209;acuity service lines will continue to grow over time. We believe our actions, together with government relief packages, supported our ability to provide essential patient services during the initial uncertainty caused by the pandemic and continue to do so.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash on hand fluctuates day&#8209;to&#8209;day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest payments and income tax payments. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future may cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, borrowing availability under our Credit Agreement and anticipated future cash provided by our operating activities should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to current and former joint venture partners, including those related to our Share Purchase Agreement with Baylor, and other presently known operating needs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual or regulatory commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section and the Risk Factors section in Part&#160;I of this report, including any costs associated with legal proceedings and government investigations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our balance sheet. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest except for borrowings under our Credit Agreement.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_130"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 24 to the accompanying Consolidated Financial Statements for a discussion of recently issued accounting standards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our critical accounting estimates to be those that (1)&#160;involve significant judgments and uncertainties, (2)&#160;require estimates that are more difficult for management to determine, and (3)&#160;may produce materially different outcomes under different conditions or when using different assumptions.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting estimates cover the following areas:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of net operating revenues, including contractual allowances and implicit price concessions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accruals for general and professional liability risks;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of long&#8209;lived assets;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of goodwill; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accounting for income taxes.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_136"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">REVENUE RECOGNITION</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third&#8209;party payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third&#8209;party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when (1)&#160;services are provided, and (2)&#160;we do not believe the patient requires additional services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments recognized for third&#8209;party payers, discounts provided to uninsured patients in accordance with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and estimated implicit price concessions related primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the traditional FFS Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost&#8209;based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as IME, DGME, DSH and bad debt expense reimbursement, which are based on our hospitals&#8217; cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule&#160;interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#8209;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#8217;s bill is subject to adjustment on a patient&#8209;by&#8209;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at&#160;December&#160;31,&#160;2022, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $18 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1)&#160;changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2)&#160;changes in reimbursement levels when stop&#8209;loss or outlier limits are reached; (3)&#160;changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4)&#160;final coding of in&#8209;house and discharged&#8209;not&#8209;final&#8209;billed patients that change reimbursement levels; (5)&#160;secondary benefits determined after primary insurance payments; and (6)&#160;reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the year ended December&#160;31,&#160;2022. In addition, on a corporate&#8209;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, patients who are covered by third&#8209;party payers are responsible for related co&#8209;pays, co&#8209;insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co&#8209;pays, co&#8209;insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#8209;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self&#8209;pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such as: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients; the volume of patients through our emergency departments; the increased burden of co&#8209;pays, co&#8209;insurance amounts and deductibles to be made by patients with insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record implicit price concessions, primarily related to uninsured patients and patients with co&#8209;pays, co&#8209;insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co&#8209;pays, co&#8209;insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (&#8220;EMTALA&#8221;). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non&#8209;emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1)&#160;we are unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2)&#160;a&#160;determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3)&#160;under physician orders we provide services to patients that require immediate treatment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our accounts receivable from uninsured patients and co-pays, co-insurance amounts and deductibles owed to us by patients with insurance at December&#160;31,&#160;2022, a 10% increase or decrease in our self&#8209;pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in a favorable or unfavorable adjustment to patient accounts receivable of approximately $11 million.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_139"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACCRUALS FOR GENERAL AND PROFESSIONAL LIABILITY RISKS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments. We consider the number of expected claims and average cost per claim to be the most significant assumptions in estimating accruals for general and professional liabilities. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in our consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimated reserves for professional and general liability claims will change significantly if future trends differ from projected trends. We believe it is reasonably likely for there to be a 500&#160;basis point increase or decrease in our&#160;frequency or severity trend. Based on our reserves and other information at December&#160;31,&#160;2022, a 500&#160;basis point&#160;increase in our frequency trend would increase the estimated reserves by $36 million, and a 500&#160;basis point decrease in our frequency trend would decrease the estimated reserves by $27 million. A&#160;500 basis point increase in our severity trend would increase the estimated reserves by $206 million, and a 500&#160;basis point decrease in our severity trend would decrease the estimated reserves by $130&#160;million. In addition, because of the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes, our ultimate liability for professional and general liability claims could change materially from our current estimates.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the case reserves and incurred but not reported and loss development reserves:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Case reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred but not reported and loss development reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total reserves</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several actuarial methods, including the incurred, paid loss development and Bornhuetter&#8209;Ferguson methods, are applied to our historical loss data to produce estimates of ultimate expected losses and the resulting incurred but not reported and loss development reserves. These methods use our specific historical claims data related to paid losses and loss adjustment expenses, historical and current case reserves, reported and closed claim counts, and a variety of hospital census information. These analyses are considered in our determination of our estimate of the professional liability claims, including the incurred but not reported and loss development reserve estimates. The determination of our estimates involves subjective judgment and could result in material changes to our estimates in future periods if our actual experience is materially different than our assumptions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malpractice claims generally take up to five years to settle from the time of the initial reporting of the occurrence to the settlement payment. Accordingly, the percentage of reserves at December&#160;31,&#160;2022 and 2021 representing unsettled claims was approximately 95% and 98%, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table, which includes both our continuing and discontinued operations, presents the amount of our accruals for professional and general liability claims and the corresponding activity therein:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for professional and general liability claims, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less losses recoverable from re-insurance and excess insurance carriers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense related to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred loss and loss expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid claims and expenses related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid claims and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus losses recoverable from re-insurance and excess insurance carriers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrual for professional and general liability claims, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total malpractice expense for continuing operations, including premiums for insured coverage and recoveries from third parties, was $276 million and $355&#160;million in the years ended December&#160;31,&#160;2022 and&#160;2021, respectively.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_142"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMPAIRMENT OF LONG-LIVED ASSETS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long&#8209;lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the asset group, we calculate the amount of an impairment charge only if the carrying value of the asset group exceeds the fair value. For purposes of impairment testing, all asset groups are evaluated at a level below that of the reporting unit, and their carrying values do not include any allocations of goodwill. The fair values of assets are estimated based on third&#8209;party appraisals, established market values of comparable assets or internally developed estimates of future net cash flows expected to result from the use and ultimate disposition of those assets. The estimates of these future net cash flows are based on assumptions and projections we believe to be reasonable and supportable. Estimates require our subjective judgments and take into account assumptions about revenue and expense growth rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of asset group and presume stable, improving or, in some cases, declining results, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report long&#8209;lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value estimates can change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the following risks:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future financial results, which can be impacted by volumes of insured patients and declines in commercial managed care patients, terms of managed care payer arrangements, our ability to collect amounts due from uninsured and managed care payers, loss of volumes as a result of competition, physician recruitment and retention, and our ability to manage costs such as labor costs, which can be adversely impacted by labor shortages, inflationary pressure on wages and union activity;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in payments from governmental healthcare programs and in government regulations, such as reductions to Medicare and Medicaid payment rates resulting from government legislation or rule&#8209;making or from budgetary challenges of states in which we operate;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">how the hospitals and ambulatory centers are operated in the future;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature of the ultimate disposition of the assets; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macro-economic conditions such as inflation, GDP growth and unforeseen technological advancements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we recorded $94&#160;million of impairment charges, of which $82&#160;million related to the impairment of certain buildings and medical equipment located in one of our markets. Of the total impairment charges recognized for the year ended December&#160;31,&#160;2022, $86 million related to our Hospital Operations segment, $6 million related to our Ambulatory Care segment and $2 million related to our Conifer segment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021, we recorded $8&#160;million of impairment charges, primarily related to the write&#8209;down of certain indefinite-lived management contracts within our Ambulatory Care segment to their estimated fair values. Of the total impairment charges recognized for the year ended December&#160;31,&#160;2021, $5 million related to our Ambulatory Care segment and $3 million related to our Conifer segment.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our most recent impairment analysis as of December&#160;31,&#160;2022, we had two asset groups, including three and five hospitals and related operations, respectively, with carrying values of $219&#160;million and $478&#160;million, respectively, whose estimated undiscounted future cash flows exceeded their respective carrying value by approximately 129% and 134%, respectively. The individual estimated undiscounted future cash flows of these long&#8209;lived asset groups may not be considered to be substantially in excess of cash flows necessary to recover the respective carrying value of their long-lived assets. Future adverse trends that necessitate changes in the estimates of the undiscounted future cash flows of either asset group could result in the estimated undiscounted future cash flows being less than the respective carrying value of the long&#8209;lived assets, which would require a fair value assessment of the affected asset group, and if the fair value amount is less than the carrying value of the asset group&#8217;s long&#8209;lived assets, material impairment charges could result.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_145"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMPAIRMENT OF GOODWILL</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the net estimated fair value of identifiable assets acquired and liabilities assumed in a business combination. Goodwill is determined to have an indefinite useful life and is not amortized, but is instead subject to impairment tests performed at least annually, or when events occur that would more likely than not reduce the fair value of the reporting unit below its carrying amount. For goodwill, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Further testing is required only if we determine, based on the qualitative assessment, that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying value. Otherwise, no further impairment testing is required. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value, with any impairment not to exceed the carrying amount of goodwill. Any impairment would be recognized as a charge to income from operations and a reduction in the carrying value of goodwill.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our business included three reportable segments &#8211; Hospital Operations, Ambulatory Care and Conifer. Our reportable segments are reporting units used to perform our goodwill impairment analysis, and goodwill is accordingly assigned to these reporting segments. We completed our annual impairment tests for goodwill as of October&#160;1,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocated goodwill balances related to our Hospital Operations, Ambulatory Care and Conifer segments were $2.806&#160;billion, $6.712&#160;billion and $605&#160;million, respectively, at December&#160;31,&#160;2022. We performed a separate qualitative analysis for our reporting units and, in each case, concluded it was more likely than not that the fair value of each reporting unit exceeded its respective carrying value. Factors considered in these analyses included recent and estimated future operating trends derived from macro&#8209;economic conditions, industry conditions and other factors specific to each reporting segment.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_148"></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACCOUNTING FOR INCOME TAXES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income/losses expected in future years;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The carryforward period associated with the deferred tax assets and liabilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, the valuation allowance increased by $120&#160;million, including an increase of $123&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $2 million due to changes in the expected realizability of deferred tax assets. The balance in the valuation allowance as of December&#160;31,&#160;2022 was $177 million. During the year ended December&#160;31,&#160;2021, the valuation allowance increased by $2&#160;million, including an increase of $2&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $2&#160;million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $2&#160;million due to changes in the expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December&#160;31,&#160;2021 was $57&#160;million. Deferred tax assets relating to interest expense limitations under Internal Revenue Code Section 163(j) have a full valuation allowance because the interest expense carryovers are not expected to be utilized in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&#160;the more likely than not recognition threshold is satisfied; (2)&#160;the position is ultimately settled through negotiation or litigation; or (3)&#160;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have adequately provided for our income tax receivables or liabilities and our deferred tax assets or liabilities, adverse determinations by taxing authorities or changes in tax laws and regulations could have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_151"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about certain of our market&#8209;sensitive financial instruments at December&#160;31,&#160;2022. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting period. The effects of unamortized discounts and issue costs are excluded from the table.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity&#160;Date,&#160;Years&#160;Ending&#160;December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars&#160;in&#160;Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed-rate long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;text-indent:-4.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average effective interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no affiliation with partnerships, trusts or other entities (sometimes referred to as &#8220;special&#8209;purpose&#8221; or &#8220;variable&#8209;interest&#8221; entities) whose purpose is to facilitate off&#8209;balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_157"></div><div style="margin-bottom:15pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To Our Shareholders:</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Management assessed the effectiveness of Tenet&#8217;s internal control over financial reporting as of December&#160;31,&#160;2022. This assessment was performed under the supervision of and with the participation of management, including the chief executive officer and chief financial officer.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making this assessment, management used criteria based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). Based on the assessment using the COSO framework, management concluded that Tenet&#8217;s internal control over financial reporting was effective as of December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenet&#8217;s internal control over financial reporting as of December&#160;31,&#160;2022 has been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is included herein. Deloitte &amp; Touche LLP has also audited Tenet&#8217;s Consolidated Financial Statements as of and for the year ended December&#160;31,&#160;2022, and that firm&#8217;s audit report on such Consolidated Financial Statements is also included herein.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;SAUMYA SUTARIA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DANIEL&#160;J.&#160;CANCELMI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saumya Sutaria, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Cancelmi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2023</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Tenet Healthcare Corporation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of Tenet Healthcare Corporation and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated Framework&#160;(2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31,&#160;2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated Framework&#160;(2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statement schedule as of and for the year ended December&#160;31,&#160;2022, of the Company and our report dated February&#160;17, 2023, expressed an unqualified opinion on those financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ DELOITTE &amp; TOUCHE LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dallas, Texas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Tenet Healthcare Corporation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Tenet Healthcare Corporation and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations, other comprehensive income (loss), changes in equity, and cash flows for each of the three years in the period ended December&#160;31,&#160;2022, and the related notes and the consolidated financial statement schedule listed in the Index at Item&#160;15 (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31,&#160;2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31,&#160;2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February&#160;17, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Revenues and Accounts Receivable - Refer to Notes 1, 3 and 15 to the financial statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reports net patient service revenues and accounts receivable at the amounts that reflect the consideration to which they expect to be entitled for providing patient care. As of and for the year ended December&#160;31,&#160;2022, the balances for net operating revenues, of which approximately 93% is net patient service revenues, and accounts receivable were $19.174&#160;billion and $2.943&#160;billion, respectively. The transaction price is based on gross charges for services provided, reduced by contractual adjustments recognized for third-party payers, discounts provided to uninsured patients in accordance with the Company&#8217;s Compact with Uninsured Patients, and estimated implicit price concessions related primarily to uninsured patients. The implicit price concessions are estimates developed by management based on their historical collection experience with these classes of patients using a portfolio approach.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the judgments necessary to estimate the implicit price concessions to determine the amount of net patient service revenues recognized and the value of accounts receivable as a result of inherent subjectivity in collection trends from changes in the economy, patient volumes, amounts to be paid by patients with insurance and other factors, auditing such estimates involved especially subjective judgments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to management&#8217;s estimates of the implicit price concessions used to determine the value of net patient service revenues and accounts receivable included the following, among others:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls over net patient service revenues and the valuation of accounts receivable, including those over the historical collections data and management&#8217;s analysis of their historical collection experience and judgments applied to develop their assumptions for implicit price concessions.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the methods and assumptions used by management to estimate the implicit price concessions by:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Testing the underlying data that served as the basis for the implicit price concession rates developed by management, including the historical collections data within the classes of patients, to evaluate whether the inputs to management&#8217;s estimate were reasonable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Comparing management&#8217;s prior-year expectation to actual amounts recorded during the current year.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We developed an independent estimate using historical collection data for each class of patients. We then compared the result to the implicit price concession estimate developed by management to evaluate the reasonableness of accounts receivable and revenues.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional and General Liability Reserves- Refer to Notes 1 and 16 to the financial statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management records an accrual for the portion of their professional and general liability risks, including incurred but not reported claims, for which they are self-insured and that are probable and can be reasonably estimated. As of December&#160;31,&#160;2022, the accrual for professional and general liability reserves was $1.045&#160;billion. This accrual is estimated based on internal and third-party modeled estimates of projected payments using case-specific facts and circumstances and the Company&#8217;s historical claim loss reporting, claim development and settlement patterns, reported and closed claim counts, and a variety of hospital census information.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the subjectivity of estimating the projected liability of reported and unreported claims, auditing the professional and general liability reserves involved especially subjective judgments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the professional and general liability reserves included the following, among others:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls related to the professional and general liability reserves, including those over the estimation of the projected liability of reported and unreported claims.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the data used by management to estimate the professional and general liability reserves by:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Testing the underlying data that served as the basis for the internal and third-party actuarial analyses, including historical claims, to evaluate that the inputs to the actuarial estimates were reasonable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Comparing management&#8217;s prior-year recorded balance to actual losses incurred during the current year.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our internal actuarial specialists, we developed an independent range of estimates of the professional and general liability reserves, using loss data, historical and industry claim development factors, among other factors, to derive a range of projections of ultimate losses, and compared our estimates to management&#8217;s estimates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjAvZnJhZzpjYzAyZDE2N2M2YzY0Y2Y5ODFkMjBmYzFiYzExZTAzNC90ZXh0cmVnaW9uOmNjMDJkMTY3YzZjNjRjZjk4MWQyMGZjMWJjMTFlMDM0XzI3NDg3NzkxNzk3MzU_36167ca0-99bf-4bee-9989-4465c04e0903">DELOITTE &amp; TOUCHE LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjAvZnJhZzpjYzAyZDE2N2M2YzY0Y2Y5ODFkMjBmYzFiYzExZTAzNC90ZXh0cmVnaW9uOmNjMDJkMTY3YzZjNjRjZjk4MWQyMGZjMWJjMTFlMDM0XzI3NDg3NzkxNzk3Mzc_ce82c216-5a91-4fba-ac6e-5473195b2dd1">Dallas, Texas</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2023</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2007.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_169"></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dollars in&#160;Millions</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQtMi0xLTEtMjkzNzEw_f89fe412-6e50-45d4-ba40-92be20c1bdbd">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQtNC0xLTEtMjkzNzEw_124cf15b-329d-416a-b5cf-441ab00e2df0">2,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzUtMi0xLTEtMjkzNzEw_03ce3369-4d9f-41ef-ae0a-122a4f7f6f59">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzUtNC0xLTEtMjkzNzEw_b06f2afe-587c-4ad7-892b-6bd72c740635">2,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories of supplies, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzYtMi0xLTEtMjkzNzEw_029f8895-dae0-428e-966a-8ab60f076a42">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzYtNC0xLTEtMjkzNzEw_a5415587-08c9-440e-860b-a04da0500f78">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzktMi0xLTEtMjkzNzEw_06a82de7-a67c-4e0a-9110-5923481c1f5b">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzktNC0xLTEtMjkzNzEw_053a7f53-f2eb-44d6-a25a-39f4adbc1d03">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEwLTItMS0xLTI5MzcxMA_2a60524c-d77f-4e61-bbc8-66ddef4c9928">5,981</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEwLTQtMS0xLTI5MzcxMA_bd40a4a5-6039-4238-bb56-714502b27be1">7,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermInvestmentsAndReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzExLTItMS0xLTI5MzcxMA_faec8d66-a82b-43c8-b17d-f1784ceb9593">3,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermInvestmentsAndReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzExLTQtMS0xLTI5MzcxMA_3025b71c-76a3-4ee4-9cbf-bce109c43b4f">3,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEyLTItMS0xLTI5MzcxMA_d6594ff1-2bd5-49f9-9d3e-7c03b46b782e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEyLTQtMS0xLTI5MzcxMA_69982a7d-7ca2-4f76-8378-84dc33b9f87b">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost, less accumulated depreciation and amortization</span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjdjMmU3OThjMTJiZDQ4YTVhNmFmN2JkYTg3ODM1N2ZkXzg1_ad634166-591f-4462-a1d2-1f5f3f14bac7">6,201</ix:nonFraction> at December&#160;31,&#160;2022 and $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjdjMmU3OThjMTJiZDQ4YTVhNmFmN2JkYTg3ODM1N2ZkXzk4_4fbbaee0-93f5-4eee-8b8b-7374e9cb26ba">5,960</ix:nonFraction> at December&#160;31,&#160;2021)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTItMS0xLTI5MzcxMA_060f8149-431c-42dd-bdc5-b81c48c1dcea">6,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTQtMS0xLTI5MzcxMA_ec1d321a-5b18-4270-b898-f52b68b7504e">6,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE0LTItMS0xLTI5MzcxMA_ba3af743-cb5c-4bc8-afb9-e09e88668a45">10,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE0LTQtMS0xLTI5MzcxMA_38b67bd6-e67d-426f-9492-31154d36570e">9,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, at cost, less accumulated amortization </span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjBlNTU0ZjlhNGNiMTQ1ZTZhNDFiOTA0ZmUxYzQ2Y2MyXzcw_9efff27e-4128-4cd8-9412-cd14b6f64ac1">1,428</ix:nonFraction> at December&#160;31,&#160;2022 and $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjBlNTU0ZjlhNGNiMTQ1ZTZhNDFiOTA0ZmUxYzQ2Y2MyXzgz_e10fe331-8111-4e78-9c54-ad5a0c74805c">1,374</ix:nonFraction> at December&#160;31,&#160;2021)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTItMS0xLTI5MzcxMA_c5d89e1b-08e2-42b4-849c-d325dd3d4b75">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTQtMS0xLTI5MzcxMA_36812eed-7d97-4dc4-a815-77cc5b87ebe7">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE2LTItMS0xLTI5MzcxMA_de55177f-a1ab-492c-bcdd-6b071c98d9ce">27,156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE2LTQtMS0xLTI5MzcxMA_70028934-5158-4c5a-a0eb-f170e8ac4123">27,579</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE5LTItMS0xLTI5MzcxMA_dce00e54-f35d-46de-a3fe-061712df42cd">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE5LTQtMS0xLTI5MzcxMA_59b2d614-91b8-44d2-b114-c594e8643ebd">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIwLTItMS0xLTI5MzcxMA_a1293e14-5559-495d-b378-f16b7e55ed72">1,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIwLTQtMS0xLTI5MzcxMA_abaf3296-c442-451b-aba7-90c7e5518eac">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIxLTItMS0xLTI5MzcxMA_876ddf55-568b-4169-a01a-9b7e234a0336">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIxLTQtMS0xLTI5MzcxMA_f31649db-6019-4f25-91d9-7887111bb6f3">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and general liability reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:SelfInsuranceReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIyLTItMS0xLTI5MzcxMA_e16e71bf-4985-4cad-a9a0-3cbc16d6c988">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:SelfInsuranceReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIyLTQtMS0xLTI5MzcxMA_73074958-f68f-400e-91d0-44b48f0fc649">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIzLTItMS0xLTI5MzcxMA_aae3975b-493e-4549-bb11-0adc14cd396e">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIzLTQtMS0xLTI5MzcxMA_c9e6225b-4dc8-4f7c-b392-10f698604654">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI1LTItMS0xLTI5MzcxMA_39eb322d-d3b3-441d-98c6-00d0565abf90">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI1LTQtMS0xLTI5MzcxMA_88f0db4d-b356-491f-a2e3-d496dc982256">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI2LTItMS0xLTI5MzcxMA_21453353-a7cc-42ab-b6a4-1305f97ed462">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI2LTQtMS0xLTI5MzcxMA_50b863ca-8837-4235-aac8-a40b83b39a53">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI3LTItMS0xLTI5MzcxMA_4c07aa23-6f88-43ee-a206-7ba68611698f">4,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI3LTQtMS0xLTI5MzcxMA_0c6b83ea-d9c7-4415-81d3-f4d5d3e6a5f0">5,109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI4LTItMS0xLTI5MzcxMA_10fc9f5d-7101-49fd-89b2-749f231b7918">14,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI4LTQtMS0xLTI5MzcxMA_461c24c4-d564-4ae5-86e7-a65b7d28a4ec">15,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and general liability reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:SelfInsuranceReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI5LTItMS0xLTI5MzcxMA_cd60d506-2b06-44c4-b215-f851ac1e6636">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:SelfInsuranceReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI5LTQtMS0xLTI5MzcxMA_e71a2d50-34e1-4422-bc92-640f184f09bc">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit plan obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMwLTItMS0xLTI5MzcxMA_374c57e6-99ce-4210-8d2c-7cdfa23f00c4">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMwLTQtMS0xLTI5MzcxMA_ffac478e-ed83-4961-b9ce-3132656942bd">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMxLTItMS0xLTI5MzcxMA_e6d3239d-3a0e-4d20-b8ef-cf7b3896f835">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMxLTQtMS0xLTI5MzcxMA_f5c0950a-6bf6-4cc3-817b-c787c953aaa5">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities &#8211; long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMyLTItMS0xLTI5MzcxMA_6e2e29c6-f55c-43b7-83c6-2a72f2487a05">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMyLTQtMS0xLTI5MzcxMA_894eadb7-1ea0-4d46-af4c-15d805430414">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMzLTItMS0xLTI5MzcxMA_b5f0ed00-b607-41b6-81bb-7c555572e2c0">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMzLTQtMS0xLTI5MzcxMA_97c74a27-98ad-4511-869b-7692330e9ba7">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM0LTItMS0xLTI5MzcxMA_d3023ba1-b68a-4f3c-ac0c-6f2637035b5e">22,548</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM0LTQtMS0xLTI5MzcxMA_ac707d53-5ae5-4819-a48c-e57311cc59bb">23,322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM1LTItMS0xLTI5MzcxMA_f565bbee-aae3-4326-9201-9cf08666e143"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM1LTQtMS0xLTI5MzcxMA_df3ae751-ac11-43fb-af7d-cba84b074365"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests in equity of consolidated subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM2LTItMS0xLTI5MzcxMA_f02b14a1-bdb2-4020-844d-8924128ff8e3">2,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM2LTQtMS0xLTI5MzcxMA_cd926cf3-0597-4e54-8ab0-e0a28da9947f">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzE5_200ed232-971d-4219-8310-148b26dce011"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzE5_ad46615e-b321-447f-af39-205f54f7e236">0.05</ix:nonFraction></ix:nonFraction> par value; authorized <ix:nonFraction unitRef="shares" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzQ0_6912a276-b253-40a0-a80f-6f4f67273327"><ix:nonFraction unitRef="shares" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzQ0_9dd4c4a8-0837-4fdc-b17f-f14ee36a305e">262,500,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzU1_7d051568-4bed-4f0a-97df-5f8c8e4eaadc">156,462,456</ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">issued at December&#160;31,&#160;2022 and <ix:nonFraction unitRef="shares" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1Xzgy_d0e3fecb-918c-4f8d-a08c-182b53859bd5">155,520,691</ix:nonFraction> shares issued at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTItMS0xLTI5MzcxMA_2865bb36-e0e2-49a0-af26-a34d275d2e63">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTQtMS0xLTI5MzcxMA_728dc95c-144c-4f5a-8841-fa73c83c088a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQwLTItMS0xLTI5MzcxMA_51cc1b07-cac9-43a6-ab42-d33a4446c38c">4,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQwLTQtMS0xLTI5MzcxMA_0cc6ddcc-c0c5-4b7e-b076-7d204bbea4ad">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQxLTItMS0xLTI5MzcxMA_5bf058ab-0bac-4469-8e0b-8c6a4fb499da">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQxLTQtMS0xLTI5MzcxMA_ef7948f0-cf67-495a-9e66-e29ef693adcb">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQyLTItMS0xLTI5MzcxMA_5dce8b94-6144-4079-bae6-40adf4cc74d2">803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQyLTQtMS0xLTI5MzcxMA_34c537bf-aeae-491a-a082-8b2d5a2a25f9">1,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock in treasury, at cost, <ix:nonFraction unitRef="shares" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmYxNDZkN2FlZjQ1MDRhMjM4NTA1ODJjZjg0YzQ5YjIyXzQw_053bf07b-d6ed-4ecc-bd29-e5b2506878b3">54,215,871</ix:nonFraction> shares at December&#160;31,&#160;2022 and </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmYxNDZkN2FlZjQ1MDRhMjM4NTA1ODJjZjg0YzQ5YjIyXzYx_d2314124-5dbe-48f0-ae78-658aaebe5a67">48,331,649</ix:nonFraction> shares at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTItMS0xLTI5MzcxMA_cde7e6fd-3dd5-447d-bff7-8fe354014abd">2,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTQtMS0xLTI5MzcxMA_b4f9fe03-803d-40bf-ae32-32e749485901">2,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ0LTItMS0xLTI5MzcxMA_5fc1bcaa-f017-49b1-8a9b-2ff09066461c">1,142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ0LTQtMS0xLTI5MzcxMA_ff7b0877-5672-4eb8-8951-8a9cfbf04862">1,028</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ1LTItMS0xLTI5MzcxMA_abbeb338-48ed-4f60-b021-eb2179c105ee">1,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ1LTQtMS0xLTI5MzcxMA_1bd2ef7c-91be-427c-91cd-04c7dc2ad7d6">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ2LTItMS0xLTI5MzcxMA_5da74a43-4824-4947-bdc0-23da79968b5a">2,459</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ2LTQtMS0xLTI5MzcxMA_f81ddcee-9c0e-44f7-96cf-5ef2964e517b">2,054</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ3LTItMS0xLTI5MzcxMA_59935e50-3a45-4f65-a762-f56d87777b0f">27,156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ3LTQtMS0xLTI5MzcxMA_3feb32bf-79f9-42db-821d-db08985758e1">27,579</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dollars in&#160;Millions, Except Per-Share Amounts</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzItMS0xLTEtMjkzNzEw_a0a5defb-0789-4ed1-93e3-5740e82286d6">19,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzItMy0xLTEtMjkzNzEw_edd1ec78-1eae-491f-897b-6023e17f43f3">19,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzItNS0xLTEtMjkzNzEw_26bba0fc-33ba-4c10-85a4-e78379be3037">17,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMtMS0xLTEtMjkzNzEw_ddc7d2c7-32f4-4c24-b6d3-670571f36698">194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMtMy0xLTEtMjkzNzEw_1ef38e4e-eda1-4d37-bd8d-a83f460a6016">191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMtNS0xLTEtMjkzNzEw_45966650-8759-449f-9ccb-3b982a486b12">882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQtMS0xLTEtMjkzNzEw_d893e43c-226e-4740-b704-c2f1fbabb8ee">216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQtMy0xLTEtMjkzNzEw_c10c02a3-cb95-422c-a2d0-34ec3f7ed81c">218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQtNS0xLTEtMjkzNzEw_8de7f276-b1d3-422c-8ec1-ef16696b399a">169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzYtMS0xLTEtMjkzNzEw_18665c36-149c-4f7a-af50-de35de4af3d9">8,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzYtMy0xLTEtMjkzNzEw_e9372136-bd0f-4670-9405-95433d6b44ce">8,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzYtNS0xLTEtMjkzNzEw_99fd425f-be04-450e-8c64-b830b00d2e6e">8,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzctMS0xLTEtMjkzNzEw_712c52b0-ff55-4a98-adb6-7a4021a326db">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzctMy0xLTEtMjkzNzEw_65b04504-21b5-48c3-91db-61e9c44652e2">3,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzctNS0xLTEtMjkzNzEw_9f25471d-87ed-48f7-912c-6850ab76df36">2,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzgtMS0xLTEtMjkzNzEw_b17e8efb-374d-45c4-9f5b-5eae2f81951a">3,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzgtMy0xLTEtMjkzNzEw_24e6f296-c537-4d70-9d14-0d1de057b570">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzgtNS0xLTEtMjkzNzEw_59a10dd5-5039-4fb0-b492-9147c2163f9f">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzktMS0xLTEtMjkzNzEw_1e6a6af7-95ef-40dc-86ba-91a9b6805277">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzktMy0xLTEtMjkzNzEw_d1fe4e62-edf9-4fcf-86e7-327bdbe2f570">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzktNS0xLTEtMjkzNzEw_6d61feca-824c-44df-b8e8-d8b995b3cbbe">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEwLTEtMS0xLTI5MzcxMA_9040f636-603d-46be-b253-0e51bad10363">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEwLTMtMS0xLTI5MzcxMA_b2826baa-7065-4b13-9dbc-a612e7242f22">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEwLTUtMS0xLTI5MzcxMA_e732c9ba-2b4d-496a-9d7a-aa54a1edbb12">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzExLTEtMS0xLTI5MzcxMA_f16593a1-fe9c-4435-ab8c-a9ae4a9822a2">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzExLTMtMS0xLTI5MzcxMA_dc2c2bc2-8d28-4e09-ae17-cced409cd029">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzExLTUtMS0xLTI5MzcxMA_27cd80e4-dc4c-4634-8e5b-855e0ca60f2c">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEyLTEtMS0xLTI5MzcxMA_e4cbbbcb-3087-4be4-95d6-ed49593a1b13">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEyLTMtMS0xLTI5MzcxMA_5799ee88-fcd7-48f7-b8ad-5b994dcc2c7a">445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEyLTUtMS0xLTI5MzcxMA_851babaf-a944-4a6a-90ca-a1c178c9bbaa">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEzLTEtMS0xLTI5MzcxMA_a6a527a2-cb7d-401d-8454-9e08a5dcde11">2,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEzLTMtMS0xLTI5MzcxMA_b16bbba3-48b1-41aa-a36d-4864a4239562">2,871</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEzLTUtMS0xLTI5MzcxMA_fc07fc2b-402e-4259-9ebf-1f3ffb9ede5d">1,989</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE0LTEtMS0xLTI5MzcxMA_ae9a92dc-2cac-494b-8f7a-b5c967ffb2d3">890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE0LTMtMS0xLTI5MzcxMA_af5908fe-7854-4580-bc2e-f51786058311">923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE0LTUtMS0xLTI5MzcxMA_12933246-b18f-46a8-9b79-6aa1fce6c773">1,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE1LTEtMS0xLTI5MzcxMA_86491642-3fe4-4916-95db-fe576582583e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE1LTMtMS0xLTI5MzcxMA_646b2d36-6722-46f0-801a-c4fa7e67399f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE1LTUtMS0xLTI5MzcxMA_bc496db4-6922-4346-a311-f5662709fad2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE2LTEtMS0xLTI5MzcxMA_6e446645-1fb9-4067-ba34-de6dd9a2d94c">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE2LTMtMS0xLTI5MzcxMA_53f2961a-3aaf-4c74-bb28-c08480c7570e">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE2LTUtMS0xLTI5MzcxMA_a4ec7580-1370-47fe-aea8-9bfa9cf4682e">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations, before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE3LTEtMS0xLTI5MzcxMA_6c3f0775-c1b7-4a0e-8d15-6b6d116c49cf">1,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE3LTMtMS0xLTI5MzcxMA_52e1b004-5838-4e8b-aaee-6bd0e8a8631f">1,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE3LTUtMS0xLTI5MzcxMA_0cb029d3-8773-438b-9eb1-5cc760ebe2ec">671</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE4LTEtMS0xLTI5MzcxMA_22781c6a-0c0d-4aee-88fc-e3312ac9aed7">344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE4LTMtMS0xLTI5MzcxMA_50f987a9-38c0-4655-986b-2391f53a38c2">411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE4LTUtMS0xLTI5MzcxMA_faa0ec47-535f-4259-a308-839ef3b6c814">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations, before discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE5LTEtMS0xLTI5MzcxMA_668d85a3-6860-4242-92ec-ddd8a5b40867">1,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE5LTMtMS0xLTI5MzcxMA_48531a71-a49c-4af2-848b-ca6affaf2548">1,477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE5LTUtMS0xLTI5MzcxMA_19621fe4-ee57-423a-8328-edb4411e4fb5">768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discontinued operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIxLTEtMS0xLTI5MzcxMA_a21ae71e-5d3e-4cd9-8365-fd49bdf47b69">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIxLTMtMS0xLTI5MzcxMA_114ca079-263e-484d-890a-d611b1fa26bf">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIxLTUtMS0xLTI5MzcxMA_6a11d6e3-cd1f-435e-8a93-d925a4184390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIzLTEtMS0xLTI5MzcxMA_353efe94-beec-4a0a-a84f-2a04da28f871">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIzLTMtMS0xLTI5MzcxMA_4df2f948-970b-40fd-993d-9c6c3dd37c1a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIzLTUtMS0xLTI5MzcxMA_48c834d2-1979-4af4-b48d-6f80def59e00">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI0LTEtMS0xLTI5MzcxMA_f1f60ffa-8cc3-48fa-b438-b4120e662a00">1,001</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI0LTMtMS0xLTI5MzcxMA_bd63172c-a5c9-47d7-980c-70f5d9f05651">1,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI0LTUtMS0xLTI5MzcxMA_9775d24d-a203-4d18-9e19-c9f0fd41e7c9">768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income available to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI1LTEtMS0xLTI5MzcxMA_b5803b8d-92ff-45a9-aeb8-90560ac099f8">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI1LTMtMS0xLTI5MzcxMA_1adb3e13-396c-4b65-8133-ce5482087f3f">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI1LTUtMS0xLTI5MzcxMA_04e48ecd-84c7-4f00-94ea-e045f0b42d9a">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI2LTEtMS0xLTI5MzcxMA_9e231260-c63e-4101-a51b-f73544232f09">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI2LTMtMS0xLTI5MzcxMA_809bb537-a042-4911-9d50-a110435fb9d9">914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI2LTUtMS0xLTI5MzcxMA_4369b44c-d41a-4ea9-b8c5-8da8d18d02ee">399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts available to Tenet Healthcare Corporation</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;common shareholders</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations, net of tax</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI4LTEtMS0xLTI5MzcxMA_4f52ac0d-b341-41c9-866a-5f93ca5d2c8f">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI4LTMtMS0xLTI5MzcxMA_d089b4a0-2065-432d-ae0c-700e49d5ffbd">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI4LTUtMS0xLTI5MzcxMA_d29977a9-b704-4966-8cd8-162917154967">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI5LTEtMS0xLTI5MzcxMA_4b8d5531-406e-4bfb-9a6c-ab85599df622">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI5LTMtMS0xLTI5MzcxMA_8bbea286-de81-422b-afef-c3354fb0ed50">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI5LTUtMS0xLTI5MzcxMA_51016837-a7cd-4b97-913e-61962b565e3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMwLTEtMS0xLTI5MzcxMA_06c71abd-2f57-4bcd-9ed0-56ca97a04636">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMwLTMtMS0xLTI5MzcxMA_eaae9c9f-e725-47fa-88e1-73bbb5e1181c">914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMwLTUtMS0xLTI5MzcxMA_d8db9f56-900c-481b-9f9d-73ad236d1a52">399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMzLTEtMS0xLTI5MzcxMA_16b47b03-f30f-4991-9974-31f180b8bafd">3.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMzLTMtMS0xLTI5MzcxMA_9819ede3-f051-46ba-bb6a-cb7c04d4c909">8.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMzLTUtMS0xLTI5MzcxMA_2e88de55-111c-416b-b464-b5f58d8b82f1">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM0LTEtMS0xLTI5MzcxMA_40e14091-e5ad-4320-9344-daca65c3dbe3">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM0LTMtMS0xLTI5MzcxMA_25db87be-eb14-497e-96b3-aa6373c825e9">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM0LTUtMS0xLTI5MzcxMA_82742840-7bc9-4c89-a123-160c55dd314d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM1LTEtMS0xLTI5MzcxMA_f57f7fea-e473-4120-bbc0-70dd3a94b35b">3.84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM1LTMtMS0xLTI5MzcxMA_e25606ae-e63b-4497-b791-199213941832">8.55</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM1LTUtMS0xLTI5MzcxMA_9cf75b35-ee9e-4a93-b022-bbef6060b9c2">3.80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM3LTEtMS0xLTI5MzcxMA_d5f846ca-0ed3-451b-8f83-200ca8f24c09">3.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM3LTMtMS0xLTI5MzcxMA_5610d9a4-fb3e-434d-a9e5-aed39241a30c">8.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM3LTUtMS0xLTI5MzcxMA_a04c3da4-44e2-4428-a8dd-eac89df250dd">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM4LTEtMS0xLTI5MzcxMA_165cbdcc-614e-44f8-ac88-0409db9aede9">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM4LTMtMS0xLTI5MzcxMA_df1578d8-8054-4a3b-b511-9b47e07d47ef">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM4LTUtMS0xLTI5MzcxMA_4a045fa6-2a61-4982-8ff8-b00a62aca5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM5LTEtMS0xLTI5MzcxMA_75c501b2-f76d-4aff-9ec5-f3130b3fb0bd">3.79</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM5LTMtMS0xLTI5MzcxMA_ae354540-c4ae-486c-a7d9-4a0824d4bbb7">8.42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM5LTUtMS0xLTI5MzcxMA_48e361dc-5022-4449-b184-499f14b492c0">3.75</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:-15.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares and dilutive securities outstanding (in thousands):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQxLTEtMS0xLTI5MzcxMA_7186b51e-3d15-4863-8e53-9366d63d87e3">106,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQxLTMtMS0xLTI5MzcxMA_b00ae0c9-0772-4d04-9112-4b110b499bda">106,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQxLTUtMS0xLTI5MzcxMA_0d611576-4ae6-4932-9916-083bd7f59e8e">105,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQyLTEtMS0xLTI5MzcxMA_b20b4f66-8bdf-4430-a723-9756a9f59573">110,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQyLTMtMS0xLTI5MzcxMA_2bd7a172-70f9-49ad-91eb-15b515040412">108,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQyLTUtMS0xLTI5MzcxMA_3438ce58-17e4-4c7f-8b8c-e52faa8711ca">106,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dollars in&#160;Millions</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzItMS0xLTEtMjkzNzEw_62d175d5-4548-4cd5-a852-469c13814622">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzItMy0xLTEtMjkzNzEw_3553c7ca-a087-4443-b154-ee6bd14ec8b4">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzItNS0xLTEtMjkzNzEw_85c5af83-fe2a-4249-8fc1-3bca363341f2">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for defined benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzQtMS0xLTEtMjkzNzEw_105531e6-f1ce-40f8-b93f-cf3a065881d9">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzQtMy0xLTEtMjkzNzEw_fa180081-3fae-4f2a-a91d-846ba9160ba8">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzQtNS0xLTEtMjkzNzEw_0843b516-d345-41a6-b35e-f2f146d96893">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss included in other non-operating</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzUtMS0xLTEtMjkzNzEw_c9dbc30d-4fad-4695-924c-ec83c362dc2c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzUtMy0xLTEtMjkzNzEw_a7e61fe8-e30c-449c-9aff-3c01fa106ad4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzUtNS0xLTEtMjkzNzEw_d54b813c-0299-4143-bb03-34e0c397dbc4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on debt securities held as available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzYtMS0xLTEtMjkzNzEw_48245b0d-1a8d-4aab-8de1-3b85b2347023">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzYtMy0xLTEtMjkzNzEw_8a612136-5673-4562-b9ea-4cf428c0269f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzYtNS0xLTEtMjkzNzEw_8fe371ed-344d-467e-86b6-73f248ff6a36">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzgtMS0xLTEtMjkzNzEw_cf06adeb-1ec4-4075-b7ec-31ba14c6b2b0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzgtMy0xLTEtMjkzNzEw_5c3e101a-4156-4e09-97a4-87618d153290">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzgtNS0xLTEtMjkzNzEw_88b30270-3664-4d08-aa99-7c6c2763770c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzktMS0xLTEtMjkzNzEw_32f0fa9e-2afb-474a-8008-f8d749b4da0e">69</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzktMy0xLTEtMjkzNzEw_71caeef5-6232-46ff-9563-fa42ac73081e">62</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzktNS0xLTEtMjkzNzEw_ba6781f0-9e52-4edd-8649-481235814d63">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense) related to items of other comprehensive </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEwLTEtMS0xLTI5MzcxMA_9741f417-2cdb-4982-a1e0-6e4ae078a77e">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEwLTMtMS0xLTI5MzcxMA_b04b17ba-821c-4864-b3b2-9e0da57893fc">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEwLTUtMS0xLTI5MzcxMA_d008f604-63b9-45a4-8c04-111c33ea9dfe">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzExLTEtMS0xLTI5MzcxMA_b4f97309-8816-4438-af2e-808e0b8e5efa">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzExLTMtMS0xLTI5MzcxMA_864e6efe-72a5-4be7-9603-a86e8b9f8254">48</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzExLTUtMS0xLTI5MzcxMA_6a437ad0-df76-4d67-8be2-859c44d1bc81">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEyLTEtMS0xLTI5MzcxMA_2c8af8c2-4025-410d-a513-82cdbed14a42">1,053</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEyLTMtMS0xLTI5MzcxMA_cc6fdc15-2677-492f-b8ed-52c1883ab019">1,524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEyLTUtMS0xLTI5MzcxMA_2d98883d-639a-4e13-b0a5-8be2264d95d7">744</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Comprehensive income to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEzLTEtMS0xLTI5MzcxMA_bf884d77-d289-4ab8-ab7f-450cdc86a07c">590</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEzLTMtMS0xLTI5MzcxMA_4c881713-4a85-4367-a7f3-b74d643a81ec">562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEzLTUtMS0xLTI5MzcxMA_73a93859-2bad-4d9b-9947-5469d53e4d6a">369</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income available to Tenet Healthcare Corporation common shareholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzE0LTEtMS0xLTI5MzcxMA_8fc6eef1-f2b4-450b-b626-0f1198eb4176">463</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzE0LTMtMS0xLTI5MzcxMA_ec76dc7a-6dbc-47ad-ab06-51a86384c2a5">962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzE0LTUtMS0xLTI5MzcxMA_6411b4ee-11ce-46f3-a129-c8638b40214d">375</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dollars in&#160;Millions, Share Amounts in Thousands</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Tenet&#160;Healthcare&#160;Corporation&#160;Shareholders&#8217;&#160;Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#160;Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issued&#160;Par<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8317271c934402ebe8d6b8414e1b396_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMS0xLTEtMjkzNzEw_3bf8645d-45f2-449f-a77b-fc9a43b93ec3">104,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8317271c934402ebe8d6b8414e1b396_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMy0xLTEtMjkzNzEw_d6d74abe-5b00-4690-b9b5-31d1ffbc0c2c">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaeed20294de403f864897b4800c3076_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtNS0xLTEtMjkzNzEw_d8133e86-03b8-4290-938c-d239c448780a">4,760</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73837e4f8db9412e8f899038e1d69a38_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtNy0xLTEtMjkzNzEw_5d1a9ee5-74bc-4bf0-a3e1-9d6d9a45213a">257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9537d740a09d4c659577fa85ae658fbc_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtOS0xLTEtMjkzNzEw_fa2a8e39-9b4a-4fed-a1ea-5162f55bc461">2,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d874170404f42828e4c20e8b8df0183_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMTEtMS0xLTI5MzcxMA_ae537235-e363-4c24-839d-7f52a8684e7b">2,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9554f40adca348fcb6728bf86c3ecdf7_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMTMtMS0xLTI5MzcxMA_62e55f5b-e3a9-4360-aba9-1473827db96c">854</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d0733ad43146a38ea0933fae539a08_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMTUtMS0xLTI5MzcxMA_310ed76f-0236-413f-bb6d-ec3094bb0fa4">437</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a99224736d148eb923d186edf1422a9_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzQtOS0xLTEtMjkzNzEw_d04dd257-76fc-4ffb-8664-2e68fa0dca0d">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzQtMTMtMS0xLTI5MzcxMA_30d8a9e7-007f-48e1-83b4-75396aee7a5b">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzQtMTUtMS0xLTI5MzcxMA_4003849a-ea0c-49b4-9460-f4c67bbf53fb">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzUtMTMtMS0xLTI5MzcxMA_4c09c7d3-a01c-43b2-8eed-d6a925ce0fd8">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzUtMTUtMS0xLTI5MzcxMA_1f1b3ded-f107-4242-bcfd-f36ceb725539">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia89adc45b1f04cc7b5b5f7802b70f646_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzYtNy0xLTEtMjkzNzEw_669f23c2-a511-4c0f-bc29-c07f9a8d9c21">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzYtMTUtMS0xLTI5MzcxMA_9c03397a-0758-4505-9d41-dddacca2ca14">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzctNS0xLTEtMjkzNzEw_bd210088-8009-4cbb-8ec0-0fd94358b241">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzctMTUtMS0xLTI5MzcxMA_56f2fdc1-ac40-4c76-9f6e-a659c3bfe474">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of businesses and noncontrolling interests, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzgtNS0xLTEtMjkzNzEw_4b3c6d72-cc36-48db-a7cf-3386a4192fb7">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzgtMTMtMS0xLTI5MzcxMA_4bab163e-7bc4-4586-9342-597f16efd831">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzgtMTUtMS0xLTI5MzcxMA_54c9492f-5afc-4061-93c8-73cb1454459a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia34520ac68b949658c3caaf22edd6880_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzktOS0xLTEtMjkzNzEw_4b482a95-affd-4a04-b847-f206c61f69d0">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc3c23664d14313871878cccfd836b7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzktMTUtMS0xLTI5MzcxMA_833facac-8d18-4a7b-9a94-3032354a6c09">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense, tax benefit and issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68dbb9be4d814d51ad51baa9ef64725a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEwLTEtMS0xLTI5MzcxMA_cf3a85f1-4010-42ca-850d-91bd5906260a">1,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEwLTUtMS0xLTI5MzcxMA_8f63660a-b7fd-431c-9ba8-d2a9d9bec6fe">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEwLTE1LTEtMS0yOTM3MTA_51490476-ad58-403b-b8ef-406abd493fe2">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacc7f69df573459097fdcb5d09e4778c_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTEtMS0xLTI5MzcxMA_cf394dbf-f088-47cc-a398-bd9d5241f8ee">106,070</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc7f69df573459097fdcb5d09e4778c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTMtMS0xLTI5MzcxMA_31705640-bc5b-47d9-9279-d63bacf4bb09">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a3605c2b39491ba943fd1edfc38e57_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTUtMS0xLTI5MzcxMA_aabe96ea-34a1-415d-a0e4-02946dc62586">4,844</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3a3a91f53e143f88c4008add5713b37_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTctMS0xLTI5MzcxMA_2d3e32e8-302f-40a1-8098-302c71c57894">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d8b2757ba2949ca8cd949137ff2242f_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTktMS0xLTI5MzcxMA_15ccea60-9957-464d-a61a-faa6f0f788ba">2,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4961643c307a4f6f870dcae12b32be64_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTExLTEtMS0yOTM3MTA_709f3223-b2ca-4fde-ab4a-bf7a6634909b">2,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic970d8adef764f56901b3449b235a580_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTEzLTEtMS0yOTM3MTA_e2836a9d-6145-44f0-a9d2-97a4a3a58af9">909</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTE1LTEtMS0yOTM3MTA_d8cd01a6-27df-422e-a1c5-7127ce50b258">937</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96beba9c82c45c1bc21607c1ff74f2d_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEyLTktMS0xLTI5MzcxMA_fe263c4a-e7a3-4143-93be-a7981b68d748">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEyLTEzLTEtMS0yOTM3MTA_eb3a693b-5b7d-48ba-a260-863518abd1d1">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEyLTE1LTEtMS0yOTM3MTA_ec90db2b-f1cf-4f26-91b9-f2b12414f3b7">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEzLTEzLTEtMS0yOTM3MTA_bc9ad593-5ffd-40f1-8a05-078017311725">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEzLTE1LTEtMS0yOTM3MTA_a0df95da-90c5-4ed2-853a-75145460d14d">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b513def6714ccda59af687a753af25_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE0LTctMS0xLTI5MzcxMA_381c18a5-68dd-4a12-b9f0-12902e214f9d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE0LTE1LTEtMS0yOTM3MTA_47932c22-e586-4c44-a753-be14d3596f6b">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4668e92bb57b48e5b60535088433640e_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE1LTUtMS0xLTI5MzcxMA_a66ac215-8f1f-492f-a95f-b80fc0978254">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE1LTE1LTEtMS0yOTM3MTA_627ccc6b-df08-4cf9-9e31-81fc3a539aad">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of businesses and noncontrolling interests, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE2LTEzLTEtMS0yOTM3MTA_a5a5244d-ffb9-48c6-9d88-9ab03712092a">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE2LTE1LTEtMS0yOTM3MTA_edf3abd3-8566-4af5-9dee-2f4f8404106d">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense, tax benefit and issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3357e2680a954c2f9e9a7ea6681fe6ac_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTEtMS0xLTI5MzcxMA_f5765252-bcf7-4200-84ee-9737c7c33a11">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3357e2680a954c2f9e9a7ea6681fe6ac_D20210101-20211231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTMtMS0xLTI5MzcxMA_b636ff77-038e-4b45-84a7-2ae8f34c056d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4668e92bb57b48e5b60535088433640e_D20210101-20211231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTUtMS0xLTI5MzcxMA_66709178-2fec-490a-9793-c791f8352fd5">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00199680d78144a79e385f52ad262816_D20210101-20211231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTExLTEtMS0yOTM3MTA_fe2512a3-0b8f-49d1-8a44-bd0e0dd02bf6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTE1LTEtMS0yOTM3MTA_99d97129-3015-4c82-b2fc-8e182997a500">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id44ff96f5e0b4207bd89a9ce5dd47a7c_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTEtMS0xLTI5MzcxMA_3f9e1e3d-7138-4e4f-a32a-f7f53a7505aa">107,189</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44ff96f5e0b4207bd89a9ce5dd47a7c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTMtMS0xLTI5MzcxMA_efe0db41-b46f-40b8-9d63-c641552f520b">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9a7228a28d48dd8f40b5100d81ac6a_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTUtMS0xLTI5MzcxMA_b8bc9e63-37c8-4780-b4b5-959a2181c648">4,877</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a4aa1e6e88f4448ac550047af2e16de_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTctMS0xLTI5MzcxMA_0b3c71ce-6483-4c25-ae4f-1c2b89ba4586">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic697b5296a55464da1d3d7ed92f77ab2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTktMS0xLTI5MzcxMA_64156fc1-0287-40ae-b25f-ab1a53b9d403">1,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92aac1e9ae304c2c9a6e91a2b9279e3b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTExLTEtMS0yOTM3MTA_41024ede-8a84-489c-8805-789c75f623ab">2,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9e8ae8287042d59710ebc9811fd7fb_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTEzLTEtMS0yOTM3MTA_4cb54307-9030-4ddc-9a30-ed3061ace5ea">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTE1LTEtMS0yOTM3MTA_6568178f-ffa5-46ee-840b-a81fc2c00df6">2,054</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6deeb898cc694b44af79dd598642335b_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIwLTktMS0xLTI5MzcxMA_9f5e8f82-c684-480d-a88c-527dfaeaef3d">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIwLTEzLTEtMS0yOTM3MTA_efc34495-a1be-4468-8856-b59a6a1d795a">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIwLTE1LTEtMS0yOTM3MTA_d3460608-68f7-46a5-b30f-dbaa748b9d59">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIxLTEzLTEtMS0yOTM3MTA_6bb2b1d7-d72e-4679-9245-a1f674065d99">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIxLTE1LTEtMS0yOTM3MTA_897d719e-3271-4cb3-ab31-ad1c6a09f5ee">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63be1af82c5a4ce08a55c20e64768dd2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIyLTctMS0xLTI5MzcxMA_a8e3eb12-2bfc-4bca-80ed-9aca12d83651">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIyLTE1LTEtMS0yOTM3MTA_0d1bf920-ad7e-4f6f-903c-bdedab711f65">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIzLTUtMS0xLTI5MzcxMA_a16a617c-0f2f-4864-8c0e-37ddc302a08b">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIzLTE1LTEtMS0yOTM3MTA_24997a7e-f785-4a53-9bc3-d2df2d971d35">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases (sales) of businesses and noncontrolling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231" decimals="-6" sign="-" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI0LTUtMS0xLTI5MzcxMA_bd264df9-2d21-4014-88f5-3f1c796eb945">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI0LTEzLTEtMS0yOTM3MTA_92812983-dfff-4409-b2e4-b184caefa5aa">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI0LTE1LTEtMS0yOTM3MTA_54ee0fbc-ba2b-4f6f-974b-913817800852">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i141f2bcca31f4b0380c3b5e8254e8c6a_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI1LTEtMS0xLTI5MzcxMA_c79ba721-c1be-4264-bfc9-b23d1cc62ed2">5,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58f75f50cbee4ce2a41dfe51c9ce7596_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI1LTExLTEtMS0yOTM3MTA_8836eff1-2d79-4062-8c0a-8225d9b6c0f6">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI1LTE1LTEtMS0yOTM3MTA_211b54af-9690-4398-9ec6-eea9fa3c7eda">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-6.75pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense, tax benefit and issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i141f2bcca31f4b0380c3b5e8254e8c6a_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI2LTEtMS0xLTI5MzcxMA_c23d939c-99b0-4fc5-8ca0-8eac90369b6f">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI2LTUtMS0xLTI5MzcxMA_24aeab6c-5afa-4677-8c0e-b011f5f9dcaf">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI2LTE1LTEtMS0yOTM3MTA_5ff987a3-88c7-408f-8cba-d10ffcd1cbb9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b2f751698934015b40a39f68b1a7b32_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTEtMS0xLTI5MzcxMA_c8a25005-c6a7-425b-93e9-bf9085f3f782">102,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2f751698934015b40a39f68b1a7b32_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTMtMS0xLTI5MzcxMA_33761491-14ff-4a0d-a205-9425b1a2d1bf">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e1ff00656b4675b1053c1131354580_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTUtMS0xLTI5MzcxMA_239d64f5-6f99-4e88-aca8-ce06e3fafb91">4,778</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b72ce7a7f084592ab6d37729017b52f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTctMS0xLTI5MzcxMA_a09983ca-f106-4356-b131-16e8de360720">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i239bd2934060423182e137ce4439d676_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTktMS0xLTI5MzcxMA_4578bf7b-e7a9-4590-822a-b31862c5556e">803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i328d8102d6f44cfa952a21bd7c09daba_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTExLTEtMS0yOTM3MTA_c7a076c9-4f33-4e3b-bd9c-e53556d3711f">2,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe4a381bd734a65ad42049eb3bae264_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTEzLTEtMS0yOTM3MTA_da7bd692-12d1-47c6-a4fd-508163b2cf5d">1,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTE1LTEtMS0yOTM3MTA_3032ab7e-2782-49e9-bfaa-af2a08293347">2,459</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dollars in&#160;Millions</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzItMS0xLTEtMjkzNzEw_aa5a5806-919c-46bd-a775-2657121a31aa">1,001</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzItMy0xLTEtMjkzNzEw_bcce2dad-6af3-4e7f-8fcb-f78e8c3daad6">1,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzItNS0xLTEtMjkzNzEw_933cccec-88a1-4095-9905-f46fa3bb1611">768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQtMS0xLTEtMjkzNzEw_cf7f5faa-a7b6-46b6-b4e3-f86d37bc5640">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQtMy0xLTEtMjkzNzEw_3fa7d316-4b9a-487a-91a9-d66c5899faa8">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQtNS0xLTEtMjkzNzEw_59580f87-2b58-40da-9006-50f7e5ef0681">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUtMS0xLTEtMjkzNzEw_ef4c0831-7157-4ab5-af68-d0e230aed080">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUtMy0xLTEtMjkzNzEw_375420c7-2ab6-4131-a307-b3a8be315c16">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUtNS0xLTEtMjkzNzEw_0d1b219b-f209-4169-b7e8-9bc0211837c0">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzYtMS0xLTEtMjkzNzEw_860e2f24-31bc-4987-955a-50ffa84ec07a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzYtMy0xLTEtMjkzNzEw_4d282ce5-b571-4107-8331-5d26a3a93f49">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzYtNS0xLTEtMjkzNzEw_d7b0b30a-6913-4330-9465-5a218d6a93d3">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzctMS0xLTEtMjkzNzEw_5e0a77ae-9d02-4e8a-a62e-a22deb901718">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzctMy0xLTEtMjkzNzEw_a08d8513-8d22-4246-b519-ce6010ae06f7">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzctNS0xLTEtMjkzNzEw_2797b63f-65c4-4f1f-a851-7a5a24c67c5a">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzgtMS0xLTEtMjkzNzEw_101de059-f1c1-4208-a819-56165747794c">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzgtMy0xLTEtMjkzNzEw_1c424ac3-db30-4e69-9214-e1312ad919fa">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzgtNS0xLTEtMjkzNzEw_a621709d-56aa-4e11-b05f-742822dde275">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzktMS0xLTEtMjkzNzEw_25fef7f2-ebd4-49d8-ac5e-74c84f29e3b8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzktMy0xLTEtMjkzNzEw_a680c122-9c92-4fdc-8f95-5963519853a7">445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzktNS0xLTEtMjkzNzEw_dd742a8c-5c4a-4e99-afa6-0a1900789f1c">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEwLTEtMS0xLTI5MzcxMA_745cfbbe-3bef-4553-bc33-1b4aae203246">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEwLTMtMS0xLTI5MzcxMA_cf387366-020e-4e4c-87fc-47e15d9bc49a">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEwLTUtMS0xLTI5MzcxMA_e3170ac4-6074-49d0-a839-8653e2b94894">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates, net of distributions received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzExLTEtMS0xLTI5MzcxMA_ca2860a8-6be8-4ad4-ab07-fb91a1bf0da5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzExLTMtMS0xLTI5MzcxMA_0d11e8c4-7f73-412d-9141-2dfa8a3f703e">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzExLTUtMS0xLTI5MzcxMA_15f261b5-7418-4b42-a85a-87fb40f5a1f3">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEyLTEtMS0xLTI5MzcxMA_853e6bb3-8af1-4085-97d3-57a6dc44f42a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEyLTMtMS0xLTI5MzcxMA_7b7a9ee1-0e7f-4741-b79b-bb79f250e3a5">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEyLTUtMS0xLTI5MzcxMA_48407eaf-d393-4df9-b519-048a5c40323c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax loss (income) from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEzLTEtMS0xLTI5MzcxMA_79aeb125-cda1-4bca-b18b-c8efe18fbc95">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEzLTMtMS0xLTI5MzcxMA_65a36f37-2491-41d6-8d33-aa10c50bd2f2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEzLTUtMS0xLTI5MzcxMA_aa11f43f-23d2-4266-8b03-1e9bdce8c289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains from the sale of investments and long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTEtMS0xLTM1MDEzMQ_474133c9-30ad-43bf-8431-51fe03b7120c">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTMtMS0xLTM1MDEzMQ_7e7e12c2-08bc-4e36-9a65-64cafe78fd7a">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTUtMS0xLTM1MDIwMg_af34824c-3235-4c6e-ac38-8421c8c6796e">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTEtMS0xLTI5MzcxMA_d25b7c4e-f3fc-4451-9357-586b25d19d69">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTMtMS0xLTI5MzcxMA_aec785cb-59b7-4d91-bf5a-bd7fde1b78f7">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTUtMS0xLTI5MzcxMA_5e7b68cd-2432-4a5c-ab3e-c7cfe49f9963">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in cash from operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE2LTEtMS0xLTI5MzcxMA_f2a5ab3a-8c69-48e6-a440-ca9b807fafb9">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE2LTMtMS0xLTI5MzcxMA_69092e93-439f-49aa-b0fa-64a8dad4148f">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE2LTUtMS0xLTI5MzcxMA_6720cc13-651c-436c-af6d-de6280d86049">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE3LTEtMS0xLTI5MzcxMA_23c5a8f4-e8a4-4078-a733-81e0dc3a9038">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE3LTMtMS0xLTI5MzcxMA_8bd5fd18-06db-479f-b7b0-761227292e4c">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE3LTUtMS0xLTI5MzcxMA_aba775a8-ac23-498e-ace8-682127127dd9">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE4LTEtMS0xLTI5MzcxMA_8347e383-784d-4c9b-8c48-854762949196">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE4LTMtMS0xLTI5MzcxMA_b94a3591-799d-4fea-aecf-7c74cccad853">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE4LTUtMS0xLTI5MzcxMA_5ee7aec2-416d-4174-908e-bd53becc0ca4">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, contract liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE5LTEtMS0xLTI5MzcxMA_ed9c7e39-7b7e-491e-bec6-277288a34e0f">898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE5LTMtMS0xLTI5MzcxMA_05a32db1-12b2-48d4-a45b-5011d18aed3d">584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE5LTUtMS0xLTI5MzcxMA_2e407e29-313d-4076-a284-224a8eb12adc">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIwLTEtMS0xLTI5MzcxMA_888ddb0b-db7e-4cc5-b282-aea4c74ce523">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIwLTMtMS0xLTI5MzcxMA_ffe5efc1-9209-44af-b6c9-b2bf51572f24">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIwLTUtMS0xLTI5MzcxMA_21592713-af76-4c98-895f-62c00490d455">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:PaymentsForRestructuringAndLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIxLTEtMS0xLTI5MzcxMA_c15e8c0a-749e-4158-92d7-9772146cece7">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:PaymentsForRestructuringAndLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIxLTMtMS0xLTI5MzcxMA_9ca7bb44-3fa4-406b-9eea-3c18d9cf3e7e">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:PaymentsForRestructuringAndLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIxLTUtMS0xLTI5MzcxMA_36ca084a-194f-4e91-9285-ccdfdef95e0b">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities from discontinued operations, excluding income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIyLTEtMS0xLTI5MzcxMA_2aec0499-73a5-47a8-9bde-1731844c506c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIyLTMtMS0xLTI5MzcxMA_a22027c3-862c-4f03-9a20-58c0a3e77ba6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIyLTUtMS0xLTI5MzcxMA_35cb8768-a425-429f-b590-9da9d7f0fa00">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIzLTEtMS0xLTI5MzcxMA_0edabba8-d20e-435f-9535-21b2ce87a44b">1,083</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIzLTMtMS0xLTI5MzcxMA_c4d74e15-4f07-4a6a-9ad1-389c8d4465f1">1,568</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIzLTUtMS0xLTI5MzcxMA_e9ce56d6-68aa-4387-98af-ae9626141a97">3,407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI1LTEtMS0xLTI5MzcxMA_b59497ff-5879-4867-9059-23917eac9d63">762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI1LTMtMS0xLTI5MzcxMA_edfc23cf-11d2-4736-aa0b-bf4912010f04">658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI1LTUtMS0xLTI5MzcxMA_2025ad87-2638-45ee-a64b-8094cc59532a">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of businesses or joint venture interests, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI2LTEtMS0xLTI5MzcxMA_56bb8009-4b0d-4e40-bfdb-78560008723d">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI2LTMtMS0xLTI5MzcxMA_d3230003-f67e-4501-9493-3b220d5d7338">1,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI2LTUtMS0xLTI5MzcxMA_a92e1d6a-aee2-47e3-bd0c-25adcd7b0b25">1,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of facilities and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI3LTEtMS0xLTI5MzcxMA_67abd402-3b17-4de6-a9c6-7047c4a71298">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI3LTMtMS0xLTI5MzcxMA_2bc7f74d-8616-4971-b2c8-cc342f118127">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI3LTUtMS0xLTI5MzcxMA_db53b767-772c-4f8e-a5bf-af8136ffef02">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities, long-term investments and other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI5LTEtMS0xLTI5MzcxMA_a6572935-f331-44dc-9168-869af82bdbcd">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI5LTMtMS0xLTI5MzcxMA_2e205491-7030-4d92-bd3c-0e82380592b6">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI5LTUtMS0xLTI5MzcxMA_7e03343b-f444-47be-9178-cad844b2c522">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities and equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMwLTEtMS0xLTI5MzcxMA_ff54da33-0081-4a75-a4de-88f14dac4881">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMwLTMtMS0xLTI5MzcxMA_b5b3efea-2998-4d44-8cac-bb6f516085bd">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMwLTUtMS0xLTI5MzcxMA_04b7e2ac-5b9d-4948-ab4e-0f5e09bbb4f6">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMxLTEtMS0xLTI5MzcxMA_e377d0e1-d3ab-4d81-b5bd-d09354ec2313">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMxLTMtMS0xLTI5MzcxMA_1c660166-63a3-4f14-b3aa-b6a35d72dcb0">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMxLTUtMS0xLTI5MzcxMA_061a61c5-39c7-4015-9967-d94af4be1f4c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMyLTEtMS0xLTI5MzcxMA_ed75ba69-22d1-42c1-b694-015e1a65dd4b">808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMyLTMtMS0xLTI5MzcxMA_38e82d65-53b6-4532-84e0-7c25b6772408">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMyLTUtMS0xLTI5MzcxMA_95fe72a6-84f3-4a3c-80d6-c5afe661ec76">1,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of borrowings under credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM0LTEtMS0xLTI5MzcxMA_1134538b-2898-46e2-87c0-2738cf97699e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM0LTMtMS0xLTI5MzcxMA_00e324a8-6b74-4a2e-becc-0533858d92e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM0LTUtMS0xLTI5MzcxMA_edd8edcc-a917-4b0c-9506-7f9c9f0e1c4e">740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings under credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM1LTEtMS0xLTI5MzcxMA_920dba94-ee2f-480b-8d43-51b4369c9543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM1LTMtMS0xLTI5MzcxMA_92a3fe13-cc25-4488-83a9-0f9b51cea3ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM1LTUtMS0xLTI5MzcxMA_197ef69e-2c87-47dd-a216-3dfa0c74643b">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM2LTEtMS0xLTI5MzcxMA_1834ba46-6548-46ab-aa1c-f926f2e82907">2,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM2LTMtMS0xLTI5MzcxMA_906d3b91-e39e-4e6f-810b-7a720254de7e">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM2LTUtMS0xLTI5MzcxMA_736e37e7-1789-46b0-82c1-9df2b9b03f6a">3,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from other borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM3LTEtMS0xLTI5MzcxMA_6413f256-f972-4ead-90a7-33ce399f51d3">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM3LTMtMS0xLTI5MzcxMA_b96da44c-9698-4674-9010-ba9a85f1f49f">2,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM3LTUtMS0xLTI5MzcxMA_ae8a403f-baab-4a6c-981f-193e6d79b8ab">3,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTEtMS0xLTM1MDAwOQ_ff4c8dfb-3be4-470b-88bc-56c26f2abbe4">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTMtMS0xLTM1MDAxNw_d22d80dc-86f0-4486-8361-e8be708c17b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTUtMS0xLTM1MDAzMA_3e6cca4f-1ceb-466b-8ccc-9e866dd23613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTEtMS0xLTI5MzcxMA_b270913e-eb64-494b-82ef-c5f390476a96">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTMtMS0xLTI5MzcxMA_e02ca555-c125-4373-a6d0-e50b6e1d74d2">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTUtMS0xLTI5MzcxMA_1be8fd14-8137-48ff-9526-3448bd32805c">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM5LTEtMS0xLTI5MzcxMA_221f6610-2e87-4e41-bf79-39e9ec1353f1">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM5LTMtMS0xLTI5MzcxMA_8da15a7d-5bb2-4776-87e6-ac486c270eef">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM5LTUtMS0xLTI5MzcxMA_54fd57d7-ffab-4b57-93a9-ecc0dd95db47">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQwLTEtMS0xLTI5MzcxMA_59fab9cb-6f44-4013-b0f6-101202f293e9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQwLTMtMS0xLTI5MzcxMA_fb7908bf-889f-4daa-b323-35bab69db460">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQwLTUtMS0xLTI5MzcxMA_3a09137b-0afd-431a-a9d7-bfe71150a69d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQxLTEtMS0xLTI5MzcxMA_9c06564e-32ff-4338-bf4e-4e6c1c83c2b2">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQxLTMtMS0xLTI5MzcxMA_6bf06201-fb7e-4d11-aae2-e5b44bd4c41e">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQxLTUtMS0xLTI5MzcxMA_c899956a-946a-4284-9d9e-06a8eb7aee38">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Medicare advances and grants received by unconsolidated affiliates, net of recoupment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQzLTEtMS0xLTI5MzcxMA_3c953056-0c2e-4000-b37f-1458a4de298e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQzLTMtMS0xLTI5MzcxMA_603ee5e2-5478-4184-b51d-60bc116a7472">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQzLTUtMS0xLTI5MzcxMA_a43fe32a-722b-4a16-89bd-dbbb7066d658">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ0LTEtMS0xLTI5MzcxMA_6301202c-bf14-48b0-a79d-86ea040e8da4">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ0LTMtMS0xLTI5MzcxMA_23d47d80-a12a-4d21-adfb-09acda16c5b4">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ0LTUtMS0xLTI5MzcxMA_3e7598d2-8185-4238-aabb-7f9dc8e06856">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ1LTEtMS0xLTI5MzcxMA_c3e16926-47a5-4aab-a75a-50af08236937">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ1LTMtMS0xLTI5MzcxMA_944eb3f5-2895-407b-953f-b4130577fd2b">936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ1LTUtMS0xLTI5MzcxMA_e0107849-4746-4c32-a2a5-7337f78eba1b">385</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ2LTEtMS0xLTI5MzcxMA_d18bbd83-bcff-4d14-89ad-cc26f9b74394">1,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ2LTMtMS0xLTI5MzcxMA_1ef874fc-7e08-474f-99e4-c00aff1bc129">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ2LTUtMS0xLTI5MzcxMA_d5d4d806-cc6e-4f1f-959e-d90be07ae37d">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ3LTEtMS0xLTI5MzcxMA_4d81fa7b-d589-4f6f-a5c1-a5f4699efc6d">2,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ3LTMtMS0xLTI5MzcxMA_34091a83-f74e-4ca7-a72d-f2751a035db4">2,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d0733ad43146a38ea0933fae539a08_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ3LTUtMS0xLTI5MzcxMA_0956f2a6-db19-432a-89de-8603bf7cd9ed">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ4LTEtMS0xLTI5MzcxMA_a8df6add-6f7a-4de5-986c-4db1bfcd672b">858</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ4LTMtMS0xLTI5MzcxMA_70c2c4a9-623c-4274-8e99-4195ef3285f0">2,364</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ4LTUtMS0xLTI5MzcxMA_2252c5ef-1fb8-4959-b9a6-13c7ff35d89d">2,446</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid, net of capitalized interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUwLTEtMS0xLTI5MzcxMA_15e08d9f-8937-4a2e-a03a-53160d2f2fb4">848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUwLTMtMS0xLTI5MzcxMA_de7a95b4-ca27-4d9b-aecb-dfc1cfcb6b00">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUwLTUtMS0xLTI5MzcxMA_e7888eef-5cd5-4edb-8a09-fd29bdad9e96">962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payments, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUxLTEtMS0xLTI5MzcxMA_e8c2d603-6eba-4c8d-9471-ea7b2f710c47">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUxLTMtMS0xLTI5MzcxMA_841ab964-c1a5-4491-ad9c-a1abbdbb76e3">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUxLTUtMS0xLTI5MzcxMA_687554b7-d5a5-4f10-838d-34bffa2de995">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_187"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTM5_42052dd2-c765-4dce-87d6-404420c0a835" continuedAt="i4520715ddf534983bee1db493cbbd690" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i4520715ddf534983bee1db493cbbd690" continuedAt="icfaa06f9182044bca404f0ba3ad3c341"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as &#8220;Tenet,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) is a diversified healthcare services company headquartered in Dallas, Texas. Our care delivery network includes our subsidiary USPI Holding Company, Inc. (&#8220;USPI&#8221;), which had indirect ownership interests in <ix:nonFraction unitRef="hospital" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfAmbulatorySurgeryCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzU0OTc1NTk5ODY1MA_b2b2ca3f-bee8-4ddd-8e2d-39a8b281b0a6">442</ix:nonFraction> ambulatory surgery centers and <ix:nonFraction unitRef="hospital" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfSurgicalHospitalsOperatedBySubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTIzNzE_19600bc7-87dc-4902-8eb2-a67bf2491dbd">24</ix:nonFraction>&#160;surgical hospitals at December&#160;31,&#160;2022. We hold noncontrolling interests in <ix:nonFraction unitRef="healthcare_facility" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfOutpatientCentersRecordedUsingEquityMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTIzODQ_82ae7aa7-ef49-4db0-8f1d-0da62de4ce23">158</ix:nonFraction> of these facilities, which are recorded using the equity method of accounting. We also operated <ix:nonFraction unitRef="hospital" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="INF" name="thc:NumberOfHospitalsOperated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTIzODA_322efc48-6bb9-4bd2-8b7f-11776d715cab">61</ix:nonFraction> acute care and specialty hospitals, <ix:nonFraction unitRef="healthcare_facility" contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231" decimals="INF" name="thc:NumberOfOutpatientFacilitiesOperated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzU0OTc1NTk5ODQ1Mg_021e9313-289c-4ba3-9c2f-f02de2975cb5">109</ix:nonFraction> other outpatient facilities, a network of employed physicians and a Global Business Center (&#8220;GBC&#8221;) in Manila, Philippines at December&#160;31,&#160;2022. In addition, we operate Conifer Health Solutions,&#160;LLC, in which we own an interest of approximately <ix:nonFraction unitRef="number" contextRef="i314717058c7b4b6fb0a8169f1a019fe3_I20221231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTI0MTM_8667ce91-84a8-4f98-b5ee-1e5c2528f6d5">76</ix:nonFraction>%, through our Conifer Holdings,&#160;Inc. subsidiary (&#8220;Conifer&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June&#160;30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (&#8220;Baylor&#8221;) in USPI for $<ix:nonFraction unitRef="usd" contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630" decimals="-6" name="thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MTYzMzI_fa8c3ef3-021a-4cc5-9bd4-a8c95825b1c6">406</ix:nonFraction>&#160;million, which increased our ownership interest in USPI&#8217;s voting shares from <ix:nonFraction unitRef="number" contextRef="i647dc680b9224e41a241261103ccd5aa_I20220629" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MTYzNDI_b3c1d141-1e18-4b2d-953e-ef3ac40f0990">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i20f7c47ed3f1432b9993a85a212b93bc_I20220630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MTYzNDY_92a366f0-dac1-4f41-9978-3b698155d42b">100</ix:nonFraction>%. See Note&#160;18 for additional information about this transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business consists of our Hospital Operations and other (&#8220;Hospital Operations&#8221;) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#8209;hospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of USPI, which holds indirect ownership interests in and manages ambulatory surgery centers and surgical hospitals. Our Conifer segment provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTI4_46fedbb7-8654-415b-afd4-1b6f61665148" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements include the accounts of Tenet and its wholly owned and majority&#8209;owned subsidiaries. We eliminate intercompany accounts and transactions in consolidation, and we include the results of operations of businesses that are newly acquired in purchase transactions from their dates of acquisition. We account for significant investments in other affiliated companies using the equity method. We also utilize the equity method when we have the ability to exercise significant influence over the affiliated company, despite not holding a significant percentage of its ownership interest. Unless otherwise indicated, all financial and statistical data included in these notes to our Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in&#160;millions (except per&#8209;share amounts).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, &#8220;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU&#160;2020-06&#8221;), effective as of January&#160;1,&#160;2022 using the modified retrospective method. Among other amendments, ASU&#160;2020-06 changed the accounting for diluted earnings&#8209;per&#8209;share for convertible instruments and contracts that may be settled in cash or stock. ASU&#160;2020-06 eliminated an entity&#8217;s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer&#8217;s election. Additionally, ASU&#160;2020-06 requires that the if&#8209;converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU&#160;2020-06, diluted weighted average shares outstanding increased by approximately <ix:nonFraction unitRef="shares" contextRef="i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt-sec:numwordsen" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDUyNzc_69806a86-621f-4593-a91b-f3c8bf16f59d">three</ix:nonFraction> million shares and diluted earnings per share available to Tenet common shareholders decreased by $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDUyNzA_e197d08a-59c7-43c0-a54c-5777ed41a3ac">0.01</ix:nonFraction> for the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1,&#160;2020, we adopted ASU 2016&#8209;13, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU 2016&#8209;13&#8221;), using the modified retrospective transition approach as of the period of adoption. The amendments in this ASU required a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Upon adoption of ASU 2016&#8209;13 on January&#160;1,&#160;2020, we recorded a cumulative effect adjustment to increase accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i6364b905b4f448f180aff1eec2cae8f0_I20200101" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxNzU_d5b50309-1884-45fc-8b71-c74dae3e0184">14</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior-year amounts have been reclassified to conform to the current&#8209;year presentation. Due to their increased significance, net gains from the sale of investments and long-lived assets are presented separately in the operating activities section of the accompanying Consolidated Statements of Cash Flows. In prior periods, this activity was included in other items, net within the operating activities section.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="icfaa06f9182044bca404f0ba3ad3c341" continuedAt="ic400544125cf4747b5df82b519697bb2"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTky_ff391054-51f1-4093-b931-16483339816a" escape="true">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID&#8209;19 pandemic has impacted all <ix:nonFraction unitRef="segment" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMyOTg1MzUwNTg4NjE_dec1b7ad-544a-4fd2-95d8-83917c74f0c6">three</ix:nonFraction> segments of our business, as well as our patients, communities and employees, to varying degrees since March&#160;2020. Throughout this time, federal, state and local authorities have undertaken several actions designed to assist healthcare providers in providing care to COVID&#8209;19 and other patients and to mitigate the adverse economic impact of the pandemic. Among other things, federal legislation (collectively, the &#8220;COVID Acts&#8221;) authorized aggregate grant payments of $178&#160;billion to be distributed through the Public Health and Social Services Emergency Fund (&#8220;PRF&#8221;) to healthcare providers who experienced lost revenues and increased expenses as a result of the COVID&#8209;19 pandemic. The COVID Acts also revised the Medicare accelerated payment program (&#8220;MAPP&#8221;) and permitted employers to defer payroll Social Security tax payments in 2020. Our participation in these programs and the related accounting policies are summarized below.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Income&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:ScheduleOfGrantFundsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMyOTg1MzUwMTk2OTA_908d7859-0bc3-4672-8d3a-724a2f4bf246" continuedAt="i2deee2aa3ca24b2cb04e26bf3e6ecc39" escape="true">As detailed in the table below, we received cash payments from the PRF and state and local grant programs during the years ended December&#160;31,&#160;2022, 2021 and 2020. Grant funds received by our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate are included in cash flows from operating activities in our consolidated statements of cash flows. Grant funds received by unconsolidated affiliates for which we provide cash management services (&#8220;Cash&#8209;Managed Affiliates&#8221;) are included in cash flows from financing activities.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i2deee2aa3ca24b2cb04e26bf3e6ecc39" continuedAt="i60bc26e69d204d87bd941e769e827ac4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funds received from COVID-19 relief programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzQtMi0xLTEtMzE0Mjcz_2bbe13a6-bbb1-4689-9532-0e2ce39debe2">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2045a695149b44b7a235414628a53b37_D20210101-20211231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzQtNC0xLTEtMzE0Mjcz_5720fb2d-92cc-4eea-9ab2-332d7c0ef855">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaaaa5abc7244245b9b67813cd3b395d_D20200101-20201231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzQtNi0xLTEtMzE0MzY0_a4ef707d-297b-445f-9dda-f6453443bde6">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzUtMi0xLTEtMzE0Mjcz_d46d5400-c552-408b-870f-c15903aec781">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzUtNC0xLTEtMzE0Mjcz_75642c07-f11c-451c-92ea-5d539c255f3d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzUtNi0xLTEtMzE0MzY0_478087b0-11c2-4430-acf5-17c90e7b2baf">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzYtMi0xLTEtMzE1MTk2_45732b10-d3de-49c1-92b6-882bc3065c49">196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzYtNC0xLTEtMzE1MTk2_017e16dd-8210-46f5-9b65-9030b7c7db07">178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzYtNi0xLTEtMzE1MjA0_dc16be48-987c-4baa-9f38-70467064a789">900</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#8209;Managed Affiliates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f8148fcad34b6ba60172409bbf6668_D20220101-20221231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzktMi0xLTEtMzE0Mjcz_f1118d81-689e-4d1e-8c8c-b63599476c66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18501b1020814804b2eec3c3a49eda56_D20210101-20211231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzktNC0xLTEtMzE0Mjcz_8ed08cc9-f9f3-44d9-83b5-a9523c70a568">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a68ee2c5334eff95979103621be27a_D20200101-20201231" decimals="-6" name="thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzktNi0xLTEtMzE0Mzcx_6d669259-e06e-45de-807b-d65c976779ed">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To receive distributions, providers must agree to certain terms and conditions, including, among other things, that the funds would be used for lost revenues and unreimbursed pandemic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related costs as defined by the U.S.&#160;Department of Health and Human Services (&#8220;HHS&#8221;), and that the providers will not seek collection of out</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pocket payments from a COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">network provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by the Secretary of HHS. PRF funds not utilized by the established deadlines, generally 12 to 18&#160;months after receipt, will be recouped by HHS.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize grant payments as income when there is reasonable assurance that we have complied with the conditions associated with the grant. The estimates we use to recognize grant income could change materially in the future based on our operating performance or fluctuations in the severity of COVID&#8209;19 outbreaks at individual locations, as well as the government&#8217;s grant compliance guidance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ic400544125cf4747b5df82b519697bb2" continuedAt="i5bc78f8681b94151b22e4144e842f7e6"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes grant </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income recognized by our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Ambulatory Care segments, which is presented in grant income, and grant income recognized through our unconsolidated affiliates, which is presented in equity in earnings of unconsolida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ted affiliates, in each case in our consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i60bc26e69d204d87bd941e769e827ac4" continuedAt="iea40e0450bd549df98f319c9061157ab"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income recognized from COVID-19 relief programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in grant income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzEzLTItMS0xLTI5MzcxMA_9a431039-6cf0-4d4a-9d38-06e480746c57">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2045a695149b44b7a235414628a53b37_D20210101-20211231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzEzLTQtMS0xLTI5MzcxMA_c863d555-fd8e-42fb-bc72-e8110e55cb28">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaaaa5abc7244245b9b67813cd3b395d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzEzLTYtMS0xLTMxNDM3OQ_b7b35c52-9a0d-4b4e-8ec6-a8e2f162bedc">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE0LTItMS0xLTI5MzcxMA_e94fa5b3-9d97-436e-a130-a2da52fb30f1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE0LTQtMS0xLTI5MzcxMA_5859e06d-80fd-4265-91b8-865b2baf461e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE0LTYtMS0xLTMxNDM4Mg_e6eb39dc-c139-4e08-a4bf-34252997a6a3">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE1LTItMS0xLTI5MzcxMA_e36950f4-6d42-4cf3-9ee6-0f8c54b8f4d9">194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE1LTQtMS0xLTI5MzcxMA_52c98d2d-e588-4838-be27-9c14a6ff21b0">191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE1LTYtMS0xLTMxNTIxMQ_07ad7260-5877-4bd6-ae93-096de0134523">882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in equity in earnings of unconsolidated affiliates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unconsolidated affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeb9cc68a96448383cd633e3217c1f9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE4LTItMS0xLTI5MzcxMA_af588407-ca92-4aa1-99e8-5a8aeff84e6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9377069d70814572a175b579ec7a281d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE4LTQtMS0xLTI5MzcxMA_fb84867b-e5ad-4423-9c64-e22258ff86b5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab64915969534cf4956bafb8271dc248_D20200101-20201231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE4LTYtMS0xLTMxNDM4OQ_e1c4b463-235c-4eee-801f-cc1e35020d21">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022 and 2021, we had remaining deferred grant payment balances of $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MzUyNjE_d0fc2330-484e-4ec5-8326-bc2c648f9567">7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MzUyNDY_228528a5-0ab7-42d2-a52e-ec0796012704">5</ix:nonFraction> million, respectively, which amounts were recorded in other current liabilities in the accompanying Consolidated Balance Sheets for those periods.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Accelerated Payment Program (MAPP)&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, when a healthcare facility is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the MAPP. The COVID Acts revised the MAPP to disburse payments to healthcare providers more quickly and to allow recipients to retain the advance payments for one year from the date of receipt before recoupment commenced through offsets of Medicare claims payments. Recipients were also permitted to repay the advance payments at any time. Our Hospital Operations and Ambulatory Care segments both received advance payments from the MAPP following its expansion under the COVID Acts in the year ended December&#160;31,&#160;2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 and 2021.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes MAPP advances received in prior periods that were repaid or recouped during the years ended December&#160;31,&#160;2022 and 2021. No advances were repaid or recouped during the year ended December&#160;31,&#160;2020. Advances to our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate were recouped through a reduction of their respective Medicare claims payments and, together with any repayments, are presented in cash flows from operating activities in our consolidated statements of cash flows. <ix:continuation id="iea40e0450bd549df98f319c9061157ab" continuedAt="i86889739b27c4fb3b7f00baecd1a9287">Advance payments to our Cash&#8209;Managed Affiliates were recouped through a reduction of those affiliates&#8217; Medicare claims payments and, together with any repayments, are presented in cash flows from financing activities.</ix:continuation></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i86889739b27c4fb3b7f00baecd1a9287"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAPP advances repaid or recouped:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzQtNi0xLTEtMzE0NDY4_569e06e8-a40e-4d46-9497-ff3265f1b0c1">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2045a695149b44b7a235414628a53b37_D20210101-20211231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzQtOC0xLTEtMzE0NDY4_9e9eeb94-0a6c-450b-a558-255c607fdb14">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzUtNi0xLTEtMzE0NDY4_29fadc7f-2b35-4f69-8d6a-52f73f1997e7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzUtOC0xLTEtMzE0NDY4_25e81aac-1aab-44d3-a7bf-ae23bbc03947">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzYtMS0xLTEtMzE1MjE2_4fd5aa8c-92a4-49d0-a663-9daa1a29b109">880</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzYtMy0xLTEtMzE0NDg3_7d90c4ef-1115-4ed6-a8c1-a4f2eefd51c6">512</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#8209;Managed Affiliates</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1a1807f7c64edaa3db3ee3ca10ea53_D20220101-20221231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzktNi0xLTEtMzE0NDY4_76a8d033-a963-4a9c-a08a-108e4d6d1b01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece489c88064416a8f8ac688d1f70c95_D20210101-20211231" decimals="-6" name="thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzktOC0xLTEtMzE0NDY4_65bbda11-c4a6-492b-9ae7-1becf5d281d6">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, all of the remaining MAPP advances we received were fully repaid or recouped, which resulted in no outstanding liability at December&#160;31,&#160;2022. In the accompanying Consolidated Balance Sheets, advances totaling $<ix:nonFraction unitRef="usd" contextRef="iaa94d45bb7994110803e7156298da109_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3Mzg3MTU_f43b7a6c-7fd5-4ba0-aa86-a8d05827e0f4">880</ix:nonFraction>&#160;million were included in contract liabilities at December&#160;31,&#160;2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferral of Employment Tax Payments&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts permitted employers to defer payment of the 6.2%&#160;employer Social Security tax beginning March&#160;27,&#160;2020 through December&#160;31,&#160;2020. Deferred tax amounts were required to be paid in equal amounts over two years beginning in December&#160;2021. We made a payment of $<ix:nonFraction unitRef="usd" contextRef="i3c1b5e8fa8eb4e95875735d34c47d58a_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDE0NjU_7f928a43-fd22-4a68-b085-2fafc52852ee">128</ix:nonFraction>&#160;million in December&#160;2021 and remitted the second and final payment of $<ix:nonFraction unitRef="usd" contextRef="i50ac87d72391498b913cf175b99fcea9_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE4MTI1NDU_015e0bcc-a981-4b1c-88d8-316126d006d6">128</ix:nonFraction>&#160;million in December&#160;2022, which resulted in no outstanding liability at December&#160;31,&#160;2022. At December&#160;31,&#160;2021, deferred Social Security tax payments totaling $<ix:nonFraction unitRef="usd" contextRef="i3c1b5e8fa8eb4e95875735d34c47d58a_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDE4Mzk_7f928a43-fd22-4a68-b085-2fafc52852ee">128</ix:nonFraction>&#160;million were included in accrued compensation and benefits in the accompanying Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i5bc78f8681b94151b22e4144e842f7e6" continuedAt="i4d86a72a062c4b2b85d00c492d39357e"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translation of Foreign Currencies</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTM2_86941d0e-198d-4cf6-9715-1010c9e3498c" escape="true">We formed our GBC in the Philippines during the year ended December&#160;31,&#160;2019. The GBC&#8217;s accounts are measured in its local currency (the Philippine peso) and then translated into U.S.&#160;dollars. All assets and liabilities denominated in foreign currency are translated using the current rate of exchange at the balance sheet date. Results of operations denominated in foreign currency are translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders&#8217; equity.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjI2_aca28f53-ce56-4d9d-996f-d97bc8d3e91b" continuedAt="i9a1cce84a70d4324ad188db1886b29a5" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Revenues</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net operating revenues in the period in which we satisfy our performance obligations under contracts by transferring services to our customers. Net operating revenues are recognized in the amounts we expect to be entitled to, which are the transaction prices allocated for the distinct services. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact with Uninsured Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Patient Service Revenues&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third&#8209;party payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third&#8209;party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when (1)&#160;services are provided, and (2)&#160;we do not believe the patient requires additional services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our patient service performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in FASB Accounting Standards Codification (&#8220;ASC&#8221;) 606&#8209;10&#8209;50&#8209;14(a) and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments recognized for third&#8209;party payers, discounts provided to uninsured patients in accordance with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and estimated implicit price concessions related primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop&#8209;loss payments). Because Medicare requires that a hospital&#8217;s gross charges be the same for all patients (regardless of payer category), gross charges are what hospitals charge all patients prior to the application of discounts and allowances.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i4d86a72a062c4b2b85d00c492d39357e" continuedAt="ide3fe5e67a1f461eb99679691c8ec3fe"><ix:continuation id="i9a1cce84a70d4324ad188db1886b29a5" continuedAt="if1b6a64ccae44c7b9c50a99bfe765057"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the traditional fee&#8209;for&#8209;service (&#8220;FFS&#8221;) Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost&#8209;based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense reimbursement, which are based on our hospitals&#8217; cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule&#160;interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzE5NjM5_ec7967a0-5443-41ae-a687-434f53e4ceda">five months</ix:nonNumeric> after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements with third&#8209;party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and our historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#8209;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#8217;s bill is subject to adjustment on a patient&#8209;by&#8209;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the years ended December&#160;31,&#160;2022, 2021 or 2020. In addition, on a corporate&#8209;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We know of no claims, disputes or unsettled matters with any payer that would materially affect our revenues for which we have not adequately provided in the accompanying Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, patients who are covered by third&#8209;party payers are responsible for related co&#8209;pays, co&#8209;insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co&#8209;pays, co&#8209;insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#8209;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self&#8209;pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such as: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients; the volume of patients through our emergency departments; the increased burden of co&#8209;pays, co&#8209;insurance amounts and deductibles to be made by patients with insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ide3fe5e67a1f461eb99679691c8ec3fe" continuedAt="i67eeaf7fdb71404eb12d7983dc15b632"><ix:continuation id="if1b6a64ccae44c7b9c50a99bfe765057"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record implicit price concessions, primarily related to uninsured patients and patients with co&#8209;pays, co&#8209;insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co&#8209;pays, co&#8209;insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (&#8220;EMTALA&#8221;). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non&#8209;emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1)&#160;we are unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2)&#160;a&#160;determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3)&#160;under physician orders we provide services to patients that require immediate treatment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per&#8209;diem amount for services received, subject to a cap. Except for the per&#8209;diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Patient advocates from our Eligibility and Enrollment Services program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conifer Revenues&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment recognizes revenue from its contracts when Conifer&#8217;s performance obligations are satisfied, which is generally as services are rendered. Revenue is recognized in an amount that reflects the consideration to which Conifer expects to be entitled.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, Conifer assesses the services specified in its contracts with customers and identifies a performance obligation for each distinct contracted service. Conifer identifies the performance obligations and considers all the services provided under the contract. Conifer generally considers the following distinct services as separate performance obligations:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue cycle management services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">value&#8209;based care services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient communication and engagement services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consulting services; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other client&#8209;defined projects.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer&#8217;s contracts generally consist of fixed&#8209;price, volume&#8209;based or contingency&#8209;based fees. Conifer&#8217;s long&#8209;term contracts typically provide for Conifer to deliver recurring monthly services over a multi&#8209;year period. The contracts are typically priced such that Conifer&#8217;s monthly fee to its customer represents the value obtained by the customer in the month for those services. Such multi&#8209;year service contracts may have upfront fees related to transition or integration work performed by Conifer to set up the delivery for the ongoing services. Such transition or integration work typically does not result in a separately identifiable obligation; thus, the fees and expenses related to such work are deferred and recognized over the life of the related contractual service period. For contracts in which the amortization period of the asset is one year or less, we have elected to apply the practical expedient provided by FASB ASC 340&#8209;40&#8209;25&#8209;4 and expense these costs as incurred.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for fixed&#8209;priced contracts is typically recognized at the time of billing unless evidence suggests that the revenue is earned or Conifer&#8217;s obligations are fulfilled in a different pattern. Revenue for volume&#8209;based contracts is typically recognized as the services are being performed at the contractually billable rate, which is generally a percentage of collections or a percentage of client net patient revenue.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i67eeaf7fdb71404eb12d7983dc15b632" continuedAt="i908707e8ffa94495bf985650665b41a0"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjE1_97c75515-bced-4b63-8f24-c24f4f66e16c" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDE1_18c3c6c9-795f-4036-826e-174a2811f018">858</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDIy_22b4e70e-befc-4cac-b00b-c98bbadc6ca7">2.364</ix:nonFraction> billion at December&#160;31,&#160;2022 and 2021, respectively. At December&#160;31,&#160;2022 and 2021, our book overdrafts were $<ix:nonFraction unitRef="usd" contextRef="i87503b31cf9b44539e4e33a5a506f23a_I20221231" decimals="-6" name="us-gaap:BankOverdrafts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDky_136a4d17-8090-474b-b001-176f6f45629a">266</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i453df43ed989465c83339dfbcbbf1f2b_I20211231" decimals="-6" name="us-gaap:BankOverdrafts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDk5_4350c607-3f6e-4567-93a1-157d947cccc4">226</ix:nonFraction> million, respectively, which were classified as accounts payable. At December&#160;31,&#160;2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="ibd85c2d1a1374a65b8654ba74a6f38c1_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NTc0_bace8258-a8f7-432c-9bf1-9fe749927ac3">140</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibe6626659d434b6cb1b41cc1706a572b_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NTgx_523b149d-6bd2-449c-8d3c-2b6859d54daa">188</ix:nonFraction> million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our insurance&#8209;related subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, 2021 and 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3Nzc5_180a4ed0-33f1-4c86-835f-a4ed96eadec8">196</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3Nzgz_141fb5bd-74db-49f4-af6d-340a04eab9bc">95</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3Nzkw_5b458e1b-3363-4809-a633-e63b60ad625b">93</ix:nonFraction>&#160;million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $<ix:nonFraction unitRef="usd" contextRef="ic2743e63d59e4952888f44efdbce4683_D20220101-20221231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3OTA3_ec5c2250-dc20-45e0-ab94-cdbc79b02e6b">191</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i747d501e6e0f41bd9ca9f27f5b091c1a_D20210101-20211231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3OTEx_ee0a6410-e814-4c50-8654-7bd6d2ec7c02">88</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i26aedf0885e647e29e1d889e0703be3e_D20200101-20201231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3OTE4_6efb4b49-7cc7-4485-abf4-572feb917239">85</ix:nonFraction>&#160;million, respectively, were included in accounts payable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we acquired all of Baylor&#8217;s <ix:nonFraction unitRef="number" contextRef="i4465885b467846d392b87babc57179d9_I20220630" decimals="2" name="thc:JointVentureOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc1NDE_a3041d17-b83f-4c34-b4a1-c08475ade0bc">5</ix:nonFraction>% voting ownership interest in USPI. We paid $<ix:nonFraction unitRef="usd" contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630" decimals="-6" name="thc:SharePurchaseAgreementPaymentForExecution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc1ODg_3c73c98e-483e-4738-8078-9015aa4ec4ba">11</ix:nonFraction>&#160;million from cash on hand and recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="if85eb793e6b84363968e6ff370cb8b75_I20220630" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc2NDA_fa00cf09-2373-4de2-b998-a60f311d084a">377</ix:nonFraction>&#160;million, the present value of the liability on the acquisition date, for the remainder of the purchase price. We recorded reductions in redeemable noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc4MTA_f86f2f9e-3e20-4322-8a78-38933d68de21">365</ix:nonFraction>&#160;million for the carrying value of Baylor&#8217;s ownership interest and $<ix:nonFraction unitRef="usd" contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630" decimals="-6" name="thc:GainLossFromPurchaseOfNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc4Njk_51af3758-aba1-4724-b1a8-c07412382df1">23</ix:nonFraction>&#160;million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares on the acquisition date. This has been reflected as noncash financing activity in the accompanying Consolidated Statement of Cash Flows for the year ended December&#160;31,&#160;2022. Payments made subsequent to the transaction&#8217;s close are reflected as cash activity within the financing section of our consolidated statements of cash flows. See Note&#160;18 for additional information about this transaction.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTYy_360d3aff-e015-446d-993d-f59d3c11fe17" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify investments in debt securities as either available&#8209;for&#8209;sale, held&#8209;to&#8209;maturity or as part of a trading portfolio. Our policy is to classify investments in debt securities that may be needed for cash requirements as &#8220;available&#8209;for&#8209;sale.&#8221; At December&#160;31,&#160;2022, we had no significant investments in debt securities classified as either held&#8209;to&#8209;maturity or trading. We carry debt securities classified as available&#8209;for&#8209;sale at fair value. We report their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss). We periodically evaluate available-for-sale securities in unrealized loss positions for credit impairment, using both qualitative and quantitative criteria. In the event a security is deemed to be impaired as the result of a credit loss, we record a loss in our consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry equity securities at fair value, and we report their unrealized gains and losses in other non-operating income, net, in our consolidated statements of operations. If the equity security does not have a readily determinable fair value, the carrying value of the security is adjusted only when there is a price change that is observable from a transaction of an identical or similar investment. We include realized gains or losses in our consolidated statements of operations based on the specific identification method.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Unconsolidated Affiliates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTgz_b3552afa-572a-4715-b953-a2ccb8b5b9d2" continuedAt="ia178b960d59046328d47a4478a5389fb" escape="true">We control <ix:nonFraction unitRef="healthcare_facility" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="INF" name="thc:NumberOfOutpatientCentersRecordedNotUsingEquityMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5Mjc0_5d9778b4-b1e3-445d-a34c-04ddad964f69">308</ix:nonFraction> of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (<ix:nonFraction unitRef="healthcare_facility" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="INF" name="thc:NumberOfOutpatientCentersRecordedUsingEquityMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5NDQ5_2870b4c9-f913-4fe0-8f19-23c75ce99749">158</ix:nonFraction> of <ix:nonFraction unitRef="healthcare_facility" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="INF" name="thc:NumberOfSurgicalCentersAndHospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5NDU1_634bfd66-d647-49e8-95a6-8752ce682756">466</ix:nonFraction> at December&#160;31,&#160;2022), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations. In the years ended December&#160;31,&#160;2021 and 2020, equity in earnings of unconsolidated affiliates included $<ix:nonFraction unitRef="usd" contextRef="i9377069d70814572a175b579ec7a281d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5ODc4_fb84867b-e5ad-4423-9c64-e22258ff86b5">14</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iab64915969534cf4956bafb8271dc248_D20200101-20201231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODg1MjA_e1c4b463-235c-4eee-801f-cc1e35020d21">17</ix:nonFraction>&#160;million, respectively, from PRF grants recognized by our Ambulatory Care segment&#8217;s unconsolidated affiliates. <ix:nonFraction unitRef="usd" contextRef="i8eeb9cc68a96448383cd633e3217c1f9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE4MDg5MjQ_af588407-ca92-4aa1-99e8-5a8aeff84e6f">No</ix:nonFraction> additional revenue was recognized from PRF grants by unconsolidated affiliates during the year ended December&#160;31,&#160;2022.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i908707e8ffa94495bf985650665b41a0" continuedAt="i3ecc70c5422f41ec97f34b3308eccbd3"><ix:continuation id="ia178b960d59046328d47a4478a5389fb"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information for equity method investees is included in the following table. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjMx_be4c1e9b-a817-44c0-b08a-d8ed67d30a38" continuedAt="i8cb6df5f95cd4c0b940c5b1df987fd9a" escape="true">For investments acquired during the reported periods, amounts below include <ix:nonFraction unitRef="number" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="INF" name="thc:PercentageInvesteeResultsReflected" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwMTU2_1c2d33dd-d6ac-4afc-a6c5-af71db3c47e7">100</ix:nonFraction>% of the investee&#8217;s results beginning on the date of our acquisition of the investment.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i8cb6df5f95cd4c0b940c5b1df987fd9a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzItMS0xLTEtMjkzNzEw_cd1fcee8-f67c-4e6c-9203-f225a60cccfe">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzItMy0xLTEtMjkzNzEw_aa4c09b8-b4cb-4f57-9909-cc5e86dfe0b9">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzItNS0xLTEtMjkzNzEw_68259031-c33b-4846-9008-a6e58ba1f85e">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzMtMS0xLTEtMjkzNzEw_d4943da6-f313-462a-91b1-48b3e2ab5a44">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzMtMy0xLTEtMjkzNzEw_39a43c86-ea43-4ad6-bdb1-11b3e20eae05">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzMtNS0xLTEtMjkzNzEw_bf83847f-ee4f-4256-8e72-450f976aafa9">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzQtMS0xLTEtMjkzNzEw_01b23d9b-640a-487c-81dd-4bd840b10bf4">479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzQtMy0xLTEtMjkzNzEw_15122de7-5ad5-4fe6-b83d-87183395000a">495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzQtNS0xLTEtMjkzNzEw_4f0ef794-d7ac-4c7d-a80c-490fce2ef932">516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzUtMS0xLTEtMjkzNzEw_f2279f85-ea4b-46ec-a117-46e8618b9ddb">878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzUtMy0xLTEtMjkzNzEw_963ff8b6-d8c3-4a30-a6c7-f7d99beafeee">855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzUtNS0xLTEtMjkzNzEw_9e90ce28-70d4-4d38-a48e-f1b87c06baf9">866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzYtMS0xLTEtMjkzNzEw_4fba14d1-5379-4726-97aa-c282b2b3f455">644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzYtMy0xLTEtMjkzNzEw_83d79137-f2ad-4dad-a444-48046a62d5a7">659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzYtNS0xLTEtMjkzNzEw_b3fa2abf-512a-4a80-8567-1c7a700e69ea">621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEwLTEtMS0xLTI5MzcxMA_97ab04bf-8008-4f5e-a787-e2ea9a720cb1">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEwLTMtMS0xLTI5MzcxMA_a446d09c-feb8-4f47-b049-d5ac99b8c150">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEwLTUtMS0xLTI5MzcxMA_3b45605f-af85-40cb-87f7-26a744c78c5a">2,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzExLTEtMS0xLTI5MzcxMA_56c9b186-3cf8-48a9-b083-da2b50a82161">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzExLTMtMS0xLTI5MzcxMA_e2dbc956-1765-4b3f-b1db-7fb338849dd1">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzExLTUtMS0xLTI5MzcxMA_b867bc36-4b0d-423f-9414-6329550a4cc0">702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to the investees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231" decimals="-6" name="thc:NetIncomeLossAttributableToInvestee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEyLTEtMS0xLTI5MzcxMA_d6c4fb6c-bbe1-4c43-93ec-0327b83ab102">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231" decimals="-6" name="thc:NetIncomeLossAttributableToInvestee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEyLTMtMS0xLTI5MzcxMA_f4e9d398-63a5-4f25-b508-c46ac4235c99">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231" decimals="-6" name="thc:NetIncomeLossAttributableToInvestee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEyLTUtMS0xLTI5MzcxMA_1ab9807f-cc81-4b51-a733-3ed205d2526d">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity method investment that contributed the most to our equity in earnings of unconsolidated affiliates during the years ended December&#160;31,&#160;2022, 2021 and 2020 was Texas Health Ventures Group, LLC (&#8220;THVG&#8221;), which is operated by USPI. THVG represented $<ix:nonFraction unitRef="usd" contextRef="i9feb05943d7e4d72a6e4c70948071b28_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNDQ3_e7573d00-cdb2-4929-8f45-2be260acecfa">89</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4437bef5e9b44a32b53fb9a7a5f9b32e_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNDUx_7080933a-39d9-4249-8f21-476b7c1f8da8">107</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i084834af07f94533b36d44d59a7a2b21_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNDU4_0ae8a3df-30cd-4977-924b-5fd853f014ca">85</ix:nonFraction>&#160;million of total equity in earnings of unconsolidated affiliates of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNTIx_397fcaa1-0d2b-4af8-b4f2-29439d9f00dd">216</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNTI1_908490e5-c60e-4efb-9ed1-acaf3ca556e7">218</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNTMy_2e5d80c6-9f92-415d-a27c-f2be067e5097">169</ix:nonFraction>&#160;million in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTk4_22cf3ed0-de43-401d-a637-fb0b938b3d1c" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions and improvements to property and equipment exceeding established minimum amounts with a useful life greater than one year are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. We use the straight&#8209;line method of depreciation for buildings, building improvements and equipment. The estimated useful life for buildings and improvements is primarily <ix:nonNumeric contextRef="ie1c80f6e03094431a9b9dc5696c76170_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDEw_024fe883-28c0-4840-9a30-c0f379ae7245">15</ix:nonNumeric> to <ix:nonNumeric contextRef="ic99a8eb5ba464ce4815b2681aa41727f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDE2_fab01ca7-6f90-44f1-90a6-d66325bf733d">40</ix:nonNumeric> years, and for equipment <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b">three</span> to <ix:nonNumeric contextRef="ibed3bfef5ee649f29df0916da65a65ef_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDQ0_f8c95bb9-9a2e-445d-bb73-68f28cbf930f">15</ix:nonNumeric> years. Newly constructed hospitals are usually depreciated over <ix:nonNumeric contextRef="i5343d74439bf454aab6dd66ea2a9f13d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMTA1_89d9a72e-e793-4d0b-8658-ea9d55c52cc4">50</ix:nonNumeric> years. Interest costs related to construction projects are capitalized. In the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, capitalized interest was $<ix:nonFraction unitRef="usd" contextRef="i49e69c97f00a4fd4be24bc4f694c6383_D20220101-20221231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMjMz_3bb45361-4ca1-4e9d-ab14-5b42ccbf8c8d">8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if2a82f5c5f0b4bdea97702ea376fa880_D20210101-20211231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMjM3_76e85585-a87e-4a97-8cc4-3ffbaa10fd23">4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc879355fab3418bb4e9b23bb6b58cd4_D20200101-20201231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMjQ0_4005272b-c66a-4720-8b23-cd5a53a818ba">5</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long&#8209;lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of an impairment charge only if the carrying value of the long&#8209;lived assets exceeds their fair value. The fair value of the asset is estimated based on third&#8209;party appraisals, established market values of comparable assets or internally developed estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. Estimates require our subjective judgments and take into account assumptions about revenue and expense growth rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of asset and presume stable, improving or, in some cases, declining results, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report long&#8209;lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTQ3_cb7e4e0d-9712-4b44-8ff8-760e5a5172d5" continuedAt="id79f8cba1aed43748a5dd3405b737229" escape="true">We determine if an arrangement is a lease at inception of the contract. Our right&#8209;of&#8209;use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right&#8209;of&#8209;use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. We use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. For our Hospital Operations and Conifer segments, we estimate our incremental borrowing rates for our portfolio of leases using documented rates included in our recent equipment finance leases or, if applicable, recent secured debt issuances that correspond to various lease terms. We also give consideration to information obtained from our bankers, our secured debt fair value and publicly available data for instruments with similar characteristics. For our Ambulatory Care segment, we estimate an incremental borrowing rate for each center by </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i3ecc70c5422f41ec97f34b3308eccbd3" continuedAt="ie16e6dc48f284790936fe9dab7eb8a8e"><ix:continuation id="id79f8cba1aed43748a5dd3405b737229"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing historical and projected financial data, estimating a hypothetical credit rating using publicly available market data and adjusting the market data to reflect the effects of collateralization.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are primarily for real estate, including off&#8209;campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. Our real estate lease agreements typically have initial terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8">five</span> to <ix:nonNumeric contextRef="ifd1c5b7f55b147fe81cec433ecb2800a_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDEx_47aa6705-361d-46c8-b3be-27e4c5c3aea5">10</ix:nonNumeric> years, and our equipment lease agreements typically have initial terms of <ix:nonNumeric contextRef="i4130035b4ffb4b2b9759276d80640702_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDgy_a36af152-9692-4b68-856f-049061d0040e">three years</ix:nonNumeric>. We do not record leases with an initial term of 12 months or less (short&#8209;term leases) in our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our real estate leases may include <ix:nonFraction unitRef="renewal_option" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="thc:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MjM5_3948d8c8-8732-4082-bdb1-bdda21c4aa53">one</ix:nonFraction> or more options to renew, with renewals that can extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce">five</span> to <ix:nonNumeric contextRef="i14ddaa71294141e9be1093eec432aaaa_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzI0_6dcfbb99-a2dd-4cac-9f60-a530c5c9c2d9">10</ix:nonNumeric> years. The exercise of lease renewal options is at our sole discretion. In general, we do not consider renewal options to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of our right&#8209;of&#8209;use assets and lease liabilities. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of our medical equipment leases have terms of <ix:nonNumeric contextRef="i5df7801e84484df0aaf96468dbac66e2_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1OTAz_c447b45b-496c-4235-9178-9cd3d31160d4">three years</ix:nonNumeric> with a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life, typically ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076">five</span> to <ix:nonNumeric contextRef="ie118b0f2118146a497e17cce3c5da1f7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDYy_31488af4-7497-4264-b5fc-fddccf0af8f3">seven years</ix:nonNumeric>. Similarly, some of our leases of information technology and telecommunications assets include a transfer of title and, therefore, have useful lives of <ix:nonNumeric contextRef="i2f9829aeea0346f490db02486d0b9fa4_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MjE3_0fcb1391-e599-4787-a0c8-15a81e9afacc">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the right&#8209;of&#8209;use asset or liability balances. Our lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the practical expedient that allows lessees to choose to not separate lease and non&#8209;lease components by class of underlying asset and are applying this expedient to all relevant asset classes. We have also elected the practical expedient package to not reassess at adoption (1)&#160;expired or existing contracts for whether they are or contain a lease, (2)&#160;the lease classification of any existing leases or (3)&#160;initial indirect costs for existing leases.</span></div></ix:continuation><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTcy_047ed465-9e0d-4db2-89db-a978171b225f" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of costs over the fair value of assets of businesses acquired. Goodwill and other intangible assets acquired in purchase business combinations and determined to have indefinite useful lives are not amortized, but instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level when events occur that require an evaluation to be performed or at least annually. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value. Estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consist of capitalized software costs, which are amortized on a straight&#8209;line basis over the estimated useful life of the software, which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e">three</span> to <ix:nonNumeric contextRef="i26d9b425fef84906a67c577eb496f953_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzE4_a6d79890-6d7b-4912-ad05-13030cc993cf">15</ix:nonNumeric> years, costs of acquired management and other contract service rights, most of which have indefinite lives, and miscellaneous intangible assets.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accruals for General and Professional Liability Risks</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQzOTgwNDY2OTU2MzY_ee6228df-7514-4551-a468-9b0fd998fe7f" escape="true">We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in our consolidated statements of operations.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ie16e6dc48f284790936fe9dab7eb8a8e"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTk0_53fa2cb1-934e-4d15-857c-ed6a2b713181" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income/losses expected in future years;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The carryforward period associated with the deferred tax assets and liabilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&#160;the more likely than not recognition threshold is satisfied; (2)&#160;the position is ultimately settled through negotiation or litigation; or (3)&#160;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjE3_2618c863-5d59-41d8-8874-3ad8a551a4c8" escape="true">We primarily operate acute care hospitals and related healthcare facilities. Our Hospital Operations segment generated <ix:nonFraction unitRef="number" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="2" name="thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQxNzMy_5aa839f9-c665-4e73-8d2b-7df224f60f0a">76</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="2" name="thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NjQwMzg_11e8c425-dff2-4937-b117-b5f6bc7eaefa">80</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="2" name="thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NjQwNDY_2683d7ca-ea37-48f1-9c14-a2cfd562e4d3">81</ix:nonFraction>% of our net operating revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Major decisions, including capital resource allocations, are made at the consolidated level, not at the market or hospital level. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs Associated with Exit or Disposal Activities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTkw_1e6a41da-3056-486e-85d8-4739eed64cae" escape="true">We recognize costs associated with exit (including restructuring) or disposal activities when they are incurred and can be measured at fair value, rather than at the date of a commitment to an exit or disposal plan.</ix:nonNumeric></span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_193"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzU0MA_6e235708-323d-4734-bd63-d3541e34769c" continuedAt="ifc9b7ae076e04f898cf6fe4ad07e01a5" escape="true">EQUITY</ix:nonNumeric></span></div><ix:continuation id="ifc9b7ae076e04f898cf6fe4ad07e01a5" continuedAt="i4bc3c80f8ac245ffbcb18c9426cb85a0"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our noncontrolling interests balances at December&#160;31,&#160;2022 and 2021 in the accompanying Consolidated Statements of Changes in Equity were comprised of $<ix:nonFraction unitRef="usd" contextRef="i42ad7bcccdb04247a3b2e90bbacf26bf_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzE3Mg_3104532a-064c-4e56-ad79-d69e15a615bb">132</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc1386fd3cb640aba64d28e810f688ae_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzE3OQ_db721c2f-ec8f-4cca-b88a-b5b0740640c6">128</ix:nonFraction> million, respectively, from our Hospital Operations segment, and $<ix:nonFraction unitRef="usd" contextRef="i9047828c01704885a5dbf35dedddc704_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzIzOQ_e6d9367f-92ee-40c7-91cc-2b4159d6dfe2">1.185</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i4595fd3300594bae87dfb53d46c07c84_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzI0Ng_ba8c0758-6b90-4abe-b5de-00479bd8f225">898</ix:nonFraction> million, respectively, from our Ambulatory Care segment.&#160;Our net income attributable to noncontrolling interests for the years ended December&#160;31,&#160;2022, 2021 and 2020 were comprised of $<ix:nonFraction unitRef="usd" contextRef="i1b651d49dfde4a238741f373ca58bc2c_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQwNg_ae87762e-6468-40b9-a538-44b7f2a78cb0">21</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7868d9c4a59e48619659d721cc78888e_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQxMA_7444ab71-3e38-45ba-a712-74fb62f7d1bb">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i844a37e3831a44668dbcdd0ebafe40b9_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQxNw_9cace607-88ea-49b5-bf38-0021705cf1f9">14</ix:nonFraction> million, respectively, from our Hospital Operations segment, and $<ix:nonFraction unitRef="usd" contextRef="i15bd4ee78bbe42988676a562c194f442_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQ3Nw_b77478d5-3f1e-42e0-9d72-85a37abeb234">221</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0e5985c976394f5390431764b17623d7_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQ4MQ_624ce6ea-35be-4e5d-996a-77805fb2b150">205</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56dd31502d3d4194884bb9c9caf6d2ee_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQ4OA_fc3dc2bc-4949-4554-8a01-57e824827440">169</ix:nonFraction> million, respectively, from our Ambulatory Care segment.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;22,&#160;2022, we announced that our board of directors had authorized the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="i34c7defbef2a4e3b8612d7aba82bf5c3_I20221022" decimals="-9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzEwOTk1MTE2MzA5MzU_32544e66-8c7c-4c49-8464-34ac0d6299b8">1</ix:nonFraction>&#160;billion of our common stock through a share repurchase program that expires on December&#160;31,&#160;2024. Under the program, shares can be purchased in the open market or through privately negotiated transactions in a manner consistent with applicable securities laws </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i4bc3c80f8ac245ffbcb18c9426cb85a0"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations, including pursuant to a Rule 10b5-1 plan maintained by the Company, at times and in amounts based on market conditions and other factors.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzMyOTg1MzQ4OTEyMzM_9f64602b-407f-4e39-a191-0d47682832e3" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes transactions completed under the repurchase program:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Dollar Value of Shares That May Yet be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception through October&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItMi0xLTEtMzA0ODYz_a71fcfde-ec4b-4698-9c69-a98234f56385">1,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItNC0xLTEtMzA0ODc5_2958a545-bd4a-49d2-ac0a-bff64c61c0ae">41.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItNi0xLTEtMzA0ODg1_3c8ff3df-a1ea-484d-bfa6-c36843861c5a">1,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede14df2bae641aaae79e4148970642b_I20221031" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItOC0xLTEtMzA0ODY5_ee370725-7051-440a-8ffb-3687507b5b71">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November&#160;1 through November&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtMi0xLTEtMzA0ODYz_d8d20a22-4e65-4a5c-86fc-18234ad0000e">4,089</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtNC0xLTEtMzA0ODgx_9bf58856-8eb8-4699-b33d-f23f2a8d5088">42.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtNi0xLTEtMzA0ODg3_006bcdea-556a-480c-a316-216eb67bbe1e">4,089</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7906fd4dea427ab980615c8e378f98_I20221130" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtOC0xLTEtMzA0ODcz_91a90e01-f3e3-407a-be37-d89848c856f9">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;1 through December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtMi0xLTEtMzE3MTU1_a14765d4-7e3e-462f-8c7a-c02a875be9f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtNC0xLTEtMzE3MjAy_91787176-b3ee-4de4-8503-b370d953cf81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtNi0xLTEtMzE3MTcz_0c4c8fac-2171-4d06-a308-c407dd4fcf9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtOC0xLTEtMzE3MjI5_dd82e40b-23b1-4e7d-8d25-17e1b420c369">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inception through December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtMS0xLTEtMjk2NDM3_452ce940-d958-4597-b6d0-135af3b95f2b">5,889</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtMy0xLTEtMjk2NDM3_6c5a131e-4377-4bea-941d-376976fa7cad">42.45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtNi0xLTEtMzA0ODg5_b3ba67bb-1650-4b87-8a87-e2402f71ba87">5,889</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_196"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:FinancingReceivablesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxODU_8c61b048-002f-43e5-8db3-4d6f09ff8630" continuedAt="i19f2560146564e34a466729162053269" escape="true">ACCOUNTS RECEIVABLE</ix:nonNumeric></span></div><ix:continuation id="i19f2560146564e34a466729162053269" continuedAt="ib85469153ede4360828ede352c1ffbfb"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxODY_2a00b50b-1f37-4fb1-9f75-33b0620fe0d5" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of accounts receivable are shown in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzMtMS0xLTEtMjkzNzEw_734483b2-7a1b-4cb7-9ebc-00191c3e785c">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzMtMy0xLTEtMjkzNzEw_f5e7b17c-49e3-4876-8eb6-2732ee4d0ad1">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated future recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:EstimatedFutureRecoveriesFromAccountsAssignedToConifer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzQtMS0xLTEtMjkzNzEw_62f6c41f-d007-44c7-b28b-5461b1c42649">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:EstimatedFutureRecoveriesFromAccountsAssignedToConifer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzQtMy0xLTEtMjkzNzEw_1b52eb4a-b9f9-4c0b-ae4e-17dcdc181c5e">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cost reports and settlements receivable and valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="thc:NetCostReportSettlementsReceivablePayableandValuationAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzUtMS0xLTEtMjkzNzEw_820a439f-fb64-4ee6-a5a9-2015b57c144b">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" sign="-" name="thc:NetCostReportSettlementsReceivablePayableandValuationAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzUtMy0xLTEtMjkzNzEw_52acea0a-279e-43ba-a0e0-65d83a2e4d19">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzgtMS0xLTEtMjkzNzEw_76b13a5d-f317-476d-b2ec-fb95af29fafe">2,943</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzgtMy0xLTEtMjkzNzEw_9fb7ee8c-46fc-416f-b6e2-353a86d9789d">2,770</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts that are pursued for collection through Conifer&#8217;s business offices are maintained on our hospitals&#8217; books and reflected in patient accounts receivable. Patient accounts receivable, including billed accounts and certain unbilled accounts, as well as estimated amounts due from third&#8209;party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. Estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital&#8217;s eligibility for Medicaid disproportionate share hospital payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in various provider fee programs, which help reduce the amount of uncompensated care from indigent patients and those covered by Medicaid. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxOTM_749b1129-f482-49af-a7c1-40bb06d7f618" continuedAt="i8060e36691464451b4bd0bbbfb959d21" escape="true">The following table summarizes the amount and classification of assets and liabilities in the accompanying Consolidated Balance Sheets related to California&#8217;s provider fee program:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i8060e36691464451b4bd0bbbfb959d21"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e77f1a3cc942158bce2e26449d46fb_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzMtMS0xLTEtMjkzNzEw_24188d01-e18f-4569-b173-93e8d7a65639">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24938975183a4055b12b952f44b451eb_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzMtMy0xLTEtMjkzNzEw_72c47f6e-e279-469c-baeb-4c096cc13e10">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc28a960d044d118475b47b836ac7d4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzQtMS0xLTEtMjkzNzEw_b081aab0-081c-4178-b3b6-e14ec663c6f5">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5eb45d8444ba8ad4d24f039012736_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzQtMy0xLTEtMjkzNzEw_a5538637-e834-4bc4-8de1-79675016638a">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9971ae1d4d574f25af6bab80f8bcaf5a_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzctMS0xLTEtMjkzNzEw_5d742298-b90b-48b7-b52a-b9c989abbe7d">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice05b8f807e4403893fdf7bd5fcacb5b_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzctMy0xLTEtMjkzNzEw_04bc1f54-c61e-4101-a9c2-08968fbc3e5e">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib366e77f27444ed6a3e8856060b9bf21_I20221231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzgtMS0xLTEtMjkzNzEw_cc64dedd-a3c2-48a8-8dba-e3a1c70493c4">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78de6460b114c0bab0a7b968955449f_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzgtMy0xLTEtMjkzNzEw_9b91fd58-816a-4bc2-a8b2-b91a021e89a4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ib85469153ede4360828ede352c1ffbfb"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:ScheduleOfEstimatedCostForCharityCareTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxOTg_952b15ca-8905-44eb-b3cd-d2dd6646e841" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated costs for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured patients</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ac1ea0fa6641af836d8e80f2703fcb_D20220101-20221231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzMtMS0xLTEtMjkzNzEw_beaf9745-c4d8-48ac-bb43-bf9428624cc6">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic549de21b71e42098463117277ec3417_D20210101-20211231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzMtMy0xLTEtMjkzNzEw_1d44abdf-b42f-41fe-a165-ce492c64121e">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e4506f61374f2e92951abf71b05057_D20200101-20201231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzMtNS0xLTEtMjkzNzEw_56e76894-777b-43ee-afff-789bf02d8bab">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity care patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied775d7b43794f9a9cfcd968393ab2cf_D20220101-20221231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzQtMS0xLTEtMjkzNzEw_02b48fdc-5761-481c-a9f6-06c972084c8b">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b47f6e27bd4b2da194704a14b97d77_D20210101-20211231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzQtMy0xLTEtMjkzNzEw_5194e309-a29d-45d6-a1c5-a4f047be1cdc">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25b38307f82433581aafb23c9f00d50_D20200101-20201231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzQtNS0xLTEtMjkzNzEw_0921d1ac-4718-4958-bc38-a42282047552">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 13pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzUtMS0xLTEtMjkzNzEw_23a9d331-3e11-473c-b6e0-4f1f3a526481">620</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzUtMy0xLTEtMjkzNzEw_5621e46e-d1b4-4ec8-b912-b714ab7a9514">747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:HealthCareOrganizationHealthCareCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzUtNS0xLTEtMjkzNzEw_67415fa4-af03-41a2-9574-343840e345db">764</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_199"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMxNzI_c1fcca56-ae9f-4401-87d2-e316b7ad7445" continuedAt="i7b1808080ab7468ea5a800b362064178" escape="true">CONTRACT BALANCES</ix:nonNumeric></span></div><ix:continuation id="i7b1808080ab7468ea5a800b362064178" continuedAt="i8a1162bfd41f49e0b26517ef6eed065c"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hospital Operations Segment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment&#8217;s contract assets were included in other current assets in the accompanying Consolidated Balance Sheets at December&#160;31,&#160;2022 or 2021. Approximately <ix:nonFraction unitRef="number" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="2" name="thc:ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzE2NDkyNjc0NjY1ODk_72f0c70f-7246-4593-9a39-5441443eda0a">88</ix:nonFraction>% of our Hospital Operations segment&#8217;s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, our Hospital Operations segment received advance payments from the MAPP following its expansion under the COVID Acts in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Hospital Operations segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMxNzU_1a062aa3-3fbe-4b14-83f9-43a7b4a7a9e6" continuedAt="ice5c4922ee704bc4bbbc22610fd1088b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract assets and contract liabilities, as well as their classification in our consolidated balance sheets, for our Hospital Operations segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzMtMi0xLTEtMjkzNzEw_a6668f45-5566-4e82-bb73-e6f0a01bdabc">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzMtNi0xLTEtMjkzNzEw_d3b792c0-effd-40ac-963b-500e54753f97">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzItMTItMS0xLTMxNzMzNA_df9bd75f-4ca8-4f9f-9b31-58f51d0144e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzQtMi0xLTEtMjkzNzEw_52f3750f-29f9-4165-b15e-efd9bfadbdf3">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzQtNi0xLTEtMjkzNzEw_622706b0-71ea-4cca-a3d1-a91cca2c93dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzMtMTItMS0xLTMxNzMzMg_9a31c29f-87d2-49eb-a3fd-453e96d8628c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25cf6de3bc994080bc0ff271d5f1e7c2_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzUtMi0xLTEtMjkzNzEw_b972eda8-f7b6-475c-9d72-bf436472943b">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7db4f9aeba2e456da8757c9a02d08c78_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzUtNi0xLTEtMjkzNzEw_7fd75415-c70c-4d57-82bf-4b4474685b92">876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c71cd81b16644ba893aa7255b08d6e6_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzQtMTItMS0xLTMxNTg5MQ_04a74974-bdea-41d6-b119-03638b2051a8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5123a758f7de455b8800a2a9ce940c2c_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzctMi0xLTEtMjkzNzEw_4b520a72-0d5c-4143-bef6-6d6d9db5ee33">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5123a758f7de455b8800a2a9ce940c2c_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzctNi0xLTEtMjkzNzEw_93bf174f-64ad-49a8-bb4d-aa3f46740cb3">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5123a758f7de455b8800a2a9ce940c2c_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzYtMTItMS0xLTMxNzM0Mg_8a388a2b-e3b8-4c86-aa32-403790402477">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzgtMi0xLTEtMjkzNzEw_a6668f45-5566-4e82-bb73-e6f0a01bdabc">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzgtNi0xLTEtMjkzNzEw_d3b792c0-effd-40ac-963b-500e54753f97">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzctMTItMS0xLTMxNzMzMg_df9bd75f-4ca8-4f9f-9b31-58f51d0144e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a580d8694214bf884a09da9b2b1dbd8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzktMi0xLTEtMjkzNzEw_ca96b014-7e6b-468f-9929-81833d11e5a8">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4384be4a2dd447d87643cd3c2f0798d_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzktNi0xLTEtMjkzNzEw_1bf3bd96-0ad0-417c-96f8-2d6c40c4a878">366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e977fd989cb4d9390f31035ca2e4a2e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzgtMTItMS0xLTMxNTkwNQ_3a106d08-abf9-481b-9210-b91133edd817">819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ambulatory Care Segment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment also received advance payments from the MAPP following its expansion in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Ambulatory Care segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.</span></div><ix:continuation id="ice5c4922ee704bc4bbbc22610fd1088b" continuedAt="i5fb18a40055b45c5b52ac945f2e8de14"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzMtMi0xLTEtMjkzNzEw_1eab0537-cfec-4f16-b3b2-066ba7d1c7cd">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzMtNC0xLTEtMjkzNzEw_7b2bf9c0-f1d6-4870-bdf2-9d8d649fe48b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib165a084700643e1b139d15df43a3b15_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzQtMi0xLTEtMjkzNzEw_937d597c-8aee-458d-84e6-eda5e437ecd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib165a084700643e1b139d15df43a3b15_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzQtNC0xLTEtMjkzNzEw_031303f1-3ad4-480a-8588-ccb0a349b500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib51529c7491145d285a730665f73c23d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzUtMi0xLTEtMjkzNzEw_b50d5bb3-9ea6-4591-a9ea-5ae754980dfc">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b8ec068ae246cdbc6cfb42f8a12fc4_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzUtNC0xLTEtMjkzNzEw_1fc1163a-82bc-4dcc-a8c4-68148407e5de">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzctMi0xLTEtMjkzNzEw_08e8eb07-9b84-40dd-af01-64d1b2592ba8">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzctNC0xLTEtMjkzNzEw_4321cf41-a49d-4cb3-b6b3-f1a69254fe69">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzgtMi0xLTEtMjkzNzEw_1edc5237-0042-4ecb-9051-4a13fa7bad45">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzgtNC0xLTEtMjkzNzEw_9db0a74c-6f61-4fbb-8360-231b06dc8d59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c3e3d1b5bee4eeb8147e32baf77ae89_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzktMi0xLTEtMjkzNzEw_e3513e0f-d018-46b4-8d58-1899bcbc7025">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if536ced15ef94662b44301934aa1dae0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzktNC0xLTEtMjkzNzEw_0fcc8c5b-2241-4807-a652-733c19050cee">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i8a1162bfd41f49e0b26517ef6eed065c" continuedAt="ifecac4242c0f4cb69f75859489e46b48"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conifer Segment</span></div><ix:continuation id="i5fb18a40055b45c5b52ac945f2e8de14"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of Conifer&#8217;s receivables, contract asset, and current and long&#8209;term contract liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Receivables</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Asset &#8211;<br/>Unbilled Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Current<br/>Deferred Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Long-Term<br/>Deferred Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtMi0xLTEtMzM1NDE2_55b9c53c-8a7f-4729-862d-093a349a4955">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtNC0xLTEtMzM1NDE2_5c2c1059-ee51-491d-9a46-8a90ccb89144">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtNi0xLTEtMzM1NDE2_d02fa899-e839-45d1-ab6b-8f3b0da23afe">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtOC0xLTEtMzM1NDE2_92ce6f26-94a6-4dc5-b9fb-b8bac4ec6759">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtMi0xLTEtMzM1NDE2_44bf85f3-e3d1-4806-a7a2-668137203d32">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtNC0xLTEtMzM1NDE2_6f5c0b47-34df-444a-9571-c6a56c61df92">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtNi0xLTEtMzM1NDE2_c0c44c9c-feec-4f7d-8375-2e98261391db">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtOC0xLTEtMzM1NDE2_a54ed2d5-8a50-4268-a435-0cb260e839a0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="thc:IncreaseDecreaseInContractWithCustomerReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtMi0xLTEtMzM1OTc3_7465cff8-0a2a-4117-8ab1-acdd38372f71">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtNC0xLTEtMzM1OTc5_22b8b7a1-d801-4a4d-85b0-17321f67fe79">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a467f2558648978a9d48e2d2e603ae_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtNi0xLTEtMzM1OTc5_e8080f6d-6d75-4de1-a4f9-4ea80bf27081">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf46e0abc954d2a9519b9c790945c68_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtOC0xLTEtMzM1OTc5_792e0ec9-2a30-451b-9dde-700f9c2aa2eb">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctMi0xLTEtMzM1NDE2_71459604-240a-4455-a1c8-eb98f1ee8285">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctNC0xLTEtMzM1NDE2_d22c084a-d9e4-4486-a54b-7c0dd82f1f46">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctNi0xLTEtMzM1NDE2_0578260a-d124-478c-9168-71ee066a2b75">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctOC0xLTEtMzM1NDE2_ddd4d97b-74b9-4cd8-b0a1-4cc7b1cc1397">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtMi0xLTEtMzM1NDE2_8b838a12-4187-4017-a809-95a4514037b8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtNC0xLTEtMzM1NDE2_6194e6d3-1c90-4331-8249-2f4400285d2e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtNi0xLTEtMzM1NDE2_e36f006f-6bb8-4338-a705-4caede280a74">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtOC0xLTEtMzM1NDE2_7bc8cf0b-ffab-45bf-94ef-463472e4d99f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" sign="-" name="thc:IncreaseDecreaseInContractWithCustomerReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktMi0xLTEtMzM1OTgx_9320b19e-9db9-4477-a640-b60b40bdceea">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktNC0xLTEtMzM1OTgx_d0e60da6-b451-4300-a19d-a471df4f46a9">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4885c05ba74d4161a50b941fc56a1043_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktNi0xLTEtMzM1OTgx_1f60a66d-e7b2-4297-800b-29898bfcbe26">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7afbba7a6c6f4934b189f3870051beac_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktOC0xLTEtMzM1OTgx_297c602e-5778-4ad7-91fa-26198989a8aa">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the opening and closing balances of Conifer&#8217;s contract assets and contract liabilities are primarily related to prepayments for those clients who are billed in advance, changes in estimates related to metric&#8209;based services, and up&#8209;front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment&#8217;s receivables and contract assets were reported as part of other current assets in the accompanying Consolidated Balance Sheets, and its current and long&#8209;term contract liabilities were reported as part of contract liabilities and contract liabilities&#160;&#8211;&#160;long&#8209;term, respectively, in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both of the years ended December&#160;31,&#160;2022 and 2021, Conifer recognized $<ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzE2NDkyNjc0NzE2MDg_b8852964-1abd-4776-a86f-71bfc71b0197"><ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzE2NDkyNjc0NzE2MDg_bbb927d8-527c-43bb-bbcf-3c7e55bdb304">56</ix:nonFraction></ix:nonFraction>&#160;million of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those clients who are billed in advance, changes in estimates related to metric&#8209;based services, and up&#8209;front integration services that are recognized over the service period.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized amortization expense related to deferred contract setup costs of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzI5MTA_51cd1935-62f5-4d4c-914b-b8d080c2e578"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzI5MTA_741831ae-5633-40b2-af32-126e4a72039d"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzI5MTA_b4b65827-d396-4d3a-b0a5-82c58eef384a">4</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million in each of the years ended December&#160;31,&#160;2022, 2021 and 2020. At December&#160;31,&#160;2022 and 2021, the unamortized customer contract costs were $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMwMzk_a25425e3-3c4c-424c-b7a4-77f86e34a32a">24</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMwNDY_5c29759c-7040-42f2-ad0b-2dcd89efdb33">23</ix:nonFraction>&#160;million, respectively, and were presented as part of investments and other assets in the accompanying Consolidated Balance Sheets.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_202"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI2Nzc_68d9ba38-78cd-4bb1-aba4-ba52ab8b906a" continuedAt="ibec29ff94fe64e49bcc47e00f5fe6c3c" escape="true">ASSETS AND LIABILITIES HELD FOR SALE</ix:nonNumeric></span></div><ix:continuation id="ibec29ff94fe64e49bcc47e00f5fe6c3c"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the sale of <ix:nonFraction unitRef="hospital" contextRef="ia4e58b05cbc648e891cb8eb0308a9bd3_D20210801-20210831" decimals="INF" name="thc:NumberOfHospitalsForSale" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzM2MjY_2dc2decc-cfac-4902-aafa-47f943d15d47">five</ix:nonFraction> Miami&#8209;area hospitals and certain related operations (the &#8220;Miami Hospitals&#8221;) held by our Hospital Operations segment in August&#160;2021, resulting in our recognition of a pre&#8209;tax gain on sale of $<ix:nonFraction unitRef="usd" contextRef="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfProperties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzM5MDg_d2782104-0a06-48af-88ed-f45478227438">406</ix:nonFraction> million in the year ended December&#160;31,&#160;2021. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June&#160;30, 2021, we completed the sale of the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments, and we also completed the separate sale of a Philadelphia&#8209;area building held by our Hospital Operations segment. We recorded a gain related to the sale of the urgent care centers of $<ix:nonFraction unitRef="usd" contextRef="i9198bb96b0c34619839a103e26656c5f_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfProperties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzUzNTI_fbd78893-846b-4c67-95c1-7012a72ba94e">14</ix:nonFraction> million and a gain of $<ix:nonFraction unitRef="usd" contextRef="i5b88533462e34354956300ca036d5a16_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfProperties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzUzNTY_8e954cd7-5f88-4fa6-a29c-c603b3b9282b">2</ix:nonFraction> million related to the sale of the building in Philadelphia in 2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains related to the sales described above were included in net gains on sales, consolidation and deconsolidation of facilities in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2021. <ix:nonFraction unitRef="usd" contextRef="i2caa1d0849c540b493559deb02c5baae_D20200101-20201231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI0NTQ_29c4a45f-7e88-46d3-985b-c0d38a8df90b"><ix:nonFraction unitRef="usd" contextRef="ib5c6f743bc7c41a9a1958950899659b0_D20210101-20211231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI0NTQ_b1ee69fb-83de-454b-9ca8-93ece14f53fa"><ix:nonFraction unitRef="usd" contextRef="i2dd5c058d4484de28c384ae0497a9cb0_D20220101-20221231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI0NTQ_d1f6e978-c6a7-4b7e-b7f1-db8a602ac3d3">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charge was incurred during the years ended December&#160;31,&#160;2022, 2021 or 2020 related to planned divestitures.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI2NzY_3215aff2-ac73-421a-92a2-acfff8c5e3e0" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents amounts included in income from continuing operations, before income taxes, related to significant components of our business that were recently disposed of:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.72pt;text-indent:-6.73pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miami Hospitals (includes a $<ix:nonFraction unitRef="usd" contextRef="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfProperties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246Nzc1Y2Q5ZDM1NmJhNDk0ODljNTZjMjczMzI5MmNjZDBfMzM_d2782104-0a06-48af-88ed-f45478227438">406</ix:nonFraction> million gain on sale in 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216cf3ae855e4607889370b5a9466471_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtMS0xLTEtMjkzNzEw_d099cfdb-aa32-461d-9027-0fe414a2926b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtMy0xLTEtMjkzNzEw_8d260d1b-23ba-4194-b6f5-5d67bde91ce9">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05fae90132d4c549fb7d1d0e2284c2b_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtNS0xLTEtMjkzNzEw_12cc410f-ff76-480f-861c-14c2a437f1ec">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzYzMjY_aa421d1c-8b65-4b53-88b6-6dd1ba32ad8f" continuedAt="i782271eddf8541849ddee6980be914ba" escape="true">IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS</ix:nonNumeric></span></div><ix:continuation id="i782271eddf8541849ddee6980be914ba" continuedAt="ifb89ecc343c844dcafa724cd17684481"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized impairment charges on long&#8209;lived assets in 2022, 2021 and 2020 because the fair values of those assets or groups of assets indicated that the carrying amount was not recoverable. The fair value estimates were derived from third&#8209;party appraisals, established market values of comparable assets, or internally developed estimates of future net cash flows. These fair value estimates can change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the future financial results of the facilities, how the facilities are operated in the future, changes in healthcare industry trends and regulations, and the nature of the ultimate disposition of the assets. In certain cases, these fair value estimates assume the highest and best use of facility assets in the future to a marketplace participant is other than as a medical facility. In these cases, the estimates are based on the fair value of the real property and equipment if utilized other than as a medical facility. The impairment recognized does not include the costs of closing the facilities or other future operating costs, which could be substantial. Accordingly, the ultimate net cash realized from the facilities, should we choose to sell them, could be significantly less than their impaired value.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility&#8217;s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our continuing operations consisted of <ix:nonFraction unitRef="segment" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzE2NDkyNjc0Njc4MDA_fb0d4a2f-a12d-490f-afdc-ef6a7a4b564e">three</ix:nonFraction> reportable segments &#8211; Hospital Operations, Ambulatory Care and Conifer.&#160;Our segments are reporting units used to perform our goodwill impairment analysis. We completed our annual impairment tests for goodwill as of October&#160;1,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost&#8209;effective structure, such as the establishment of support operations at our GBC. Certain restructuring and acquisition&#8209;related costs are based on estimates. Changes in estimates are recognized as they occur.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December&#160;31,&#160;2022</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we recorded impairment and restructuring charges and acquisition&#8209;related costs of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1MzU_cf0f279b-c931-4fb6-aaac-ed96b9e66686">226</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NDk_68256b1e-6c5b-4099-81e0-6ec84764dcb2">118</ix:nonFraction>&#160;million of restructuring charges, $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NTM_523df44d-abfe-4d11-8093-1f6cce703616">94</ix:nonFraction>&#160;million of impairment charges and $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NTc_a1fa849d-538a-4d2b-a808-c5de05490a9e">14</ix:nonFraction>&#160;million of acquisition&#8209;related costs. Impairment charges included $<ix:nonFraction unitRef="usd" contextRef="i87e348ef2f5949cfb83ccab43bf831b1_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzU0OTc1NTg0NDA3Mg_37f159b1-237a-4e70-a38e-8f5e9cbdfadd">82</ix:nonFraction>&#160;million for the write&#8209;down of certain buildings and medical equipment located in one of our markets to their estimated fair values, which assets are part of our Hospital Operations segment. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#8217; long&#8209;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included decreased revenues and lower patient volumes due to the pandemic and competition, as well as higher labor costs as a result of the pandemic. As a result, we updated the estimate of the fair value of the hospitals&#8217; long&#8209;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#8209;lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals&#8217; assets held and used for which impairment charges were recorded was $<ix:nonFraction unitRef="usd" contextRef="i533053ff136948178e655a762abff3e7_I20221231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzU0OTc1NTg0NDMyNw_9cde7868-575c-4741-a85b-947b36ad4958">167</ix:nonFraction>&#160;million at December&#160;31,&#160;2022. Impairment charges for the year ended December&#160;31,&#160;2022 were comprised of $<ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTk5OTg_b75eecd9-e0b5-4ef5-a0b6-7c11f18ecf95">86</ix:nonFraction>&#160;million from our Hospital Operations segment, $<ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NjAwNDA_dc999893-d1cf-4d55-b87f-f8f3a49d9060">6</ix:nonFraction>&#160;million from our Ambulatory Care segment and $<ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NjAwNzM_4e44d5ad-bd90-452d-8a6c-985036ddd65e">2</ix:nonFraction>&#160;million from our Conifer segment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges consisted of $<ix:nonFraction unitRef="usd" contextRef="i194ea9513fe545cda7f1fc401e373fc3_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NjE_06744d6d-d888-47ea-92ac-9cedbc52d686">27</ix:nonFraction>&#160;million of employee severance costs, $<ix:nonFraction unitRef="usd" contextRef="ied9bab022f5344008a846ed40a785dfc_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NjU_b1335b20-235d-4bda-ad8a-0e6eaa929db2">16</ix:nonFraction>&#160;million related to the transition of various administrative functions to our GBC, $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzU0OTc1NTg0MTU2OQ_e1e6909b-1c4e-4872-9624-8f1abf174128">32</ix:nonFraction>&#160;million of contract and lease termination fees, and $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1ODI_357b55f4-cef6-4f2a-85fd-a3fce812d967">43</ix:nonFraction>&#160;million of other restructuring costs. Acquisition&#8209;related costs consisted of $<ix:nonFraction unitRef="usd" contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231" decimals="-6" name="thc:BusinessCombinationAcquisitionRelatedTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM2Njk_35d9c4b5-d652-40cf-a861-bfa2554cc682">14</ix:nonFraction>&#160;million of transaction costs.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December&#160;31,&#160;2021</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021, we recorded impairment and restructuring charges and acquisition&#8209;related costs of $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NTA_9b3b4eb1-8ad4-4dbf-b6fd-bb5cd65e1e4a">85</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NjE_a6084606-6c62-43d8-9931-e8e28f117354">57</ix:nonFraction> million of restructuring charges, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NjU_646f710e-3b98-4cac-9bde-16f9b4b08360">8</ix:nonFraction> million of impairment charges and $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4Njk_049453e3-6b0a-4a79-8e43-ab11e36f877a">20</ix:nonFraction> million of acquisition&#8209;related costs. Restructuring charges consisted of $<ix:nonFraction unitRef="usd" contextRef="i87faa7579d7f4b91a4f182929ca4f1b4_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NzM_754881a0-1eb7-4233-ad55-ed6f5b4152ff">14</ix:nonFraction> million of employee severance costs, $<ix:nonFraction unitRef="usd" contextRef="i2b84189bf5024247805cd0d9a5e0ea47_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4Nzc_fbae209c-f388-4f18-817b-e95c43dca4e4">19</ix:nonFraction> million related to the transition of various administrative functions to our GBC and $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDU1MDY_1db0ec26-76c9-404c-8224-0b42bb60aa48">24</ix:nonFraction>&#160;million of other restructuring costs. Our impairment charges for the year ended December&#160;31,&#160;2021, comprised of $<ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4OTE_df5e58cb-83b2-48d2-846f-630ad15ef9d8">5</ix:nonFraction>&#160;million from our Ambulatory Care segment and $<ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4OTY_17c04c99-956b-450c-9c5c-442dd705bd41">3</ix:nonFraction>&#160;million from our Conifer segment, primarily consisted of charges to reduce the carrying value of certain management contract intangible assets held by our Ambulatory Care segment to their estimated fair value. Acquisition&#8209;related costs consisted of $<ix:nonFraction unitRef="usd" contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231" decimals="-6" name="thc:BusinessCombinationAcquisitionRelatedTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk5Mzk_b775109c-153f-4368-bce8-0530f4070835">20</ix:nonFraction>&#160;million of transaction costs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ifb89ecc343c844dcafa724cd17684481"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December&#160;31,&#160;2020</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2020, we recorded impairment and restructuring charges and acquisition&#8209;related costs of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyNzU_287db9b7-cc79-4731-833b-d2f7f2862967">290</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyNzk_5bcdfcf3-e567-42a2-a614-d6a38f856a95">92</ix:nonFraction> million of impairment charges, $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyODM_1a9d1926-440c-4f73-8071-4d75ea3682fc">184</ix:nonFraction> million of restructuring charges and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyODc_10dd7ab1-7250-4bee-8fdc-f6efcc38cbe8">14</ix:nonFraction> million of acquisition&#8209;related costs. Impairment charges included $<ix:nonFraction unitRef="usd" contextRef="ie66efb75ed1542c3a0342c08477760c1_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyOTE_063b2379-0656-407e-b4be-da0307b8e88b">76</ix:nonFraction> million for the write&#8209;down of hospital buildings to their estimated fair values, which assets are part of our Hospital Operations segment. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#8217; long&#8209;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. As a result, we updated the estimate of the fair value of the hospitals&#8217; long&#8209;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#8209;lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals&#8217; assets held and used for which impairment charges were recorded was $<ix:nonFraction unitRef="usd" contextRef="idca9108158cb459d9c536f451843cd7a_I20201231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMDM_0996e90f-9ae1-4e77-aa2c-73b9d428642a">483</ix:nonFraction> million at December&#160;31,&#160;2020. We also recorded $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMTM_22f32a05-1f55-49a2-8d4e-2023daf314b8">16</ix:nonFraction> million of other impairment charges. Restructuring charges consisted of $<ix:nonFraction unitRef="usd" contextRef="i47f5b56532644469acafb2fdf2a8344a_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMjA_c296aa50-fa67-46e1-8287-29f1d0cb9f26">65</ix:nonFraction> million of employee severance costs, $<ix:nonFraction unitRef="usd" contextRef="i22277913b4384752915cdfe34322cd7c_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMjQ_2ec1bda4-7209-4970-8f47-3c680c0609b9">50</ix:nonFraction> million related to the transitioning of various administrative functions to our GBC, $<ix:nonFraction unitRef="usd" contextRef="i8169667563aa498e92398dfb1b02ac01_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMzI_c9341e6d-1787-4ce7-bebe-ee96414c7245">23</ix:nonFraction> million of charges due to the termination of the USPI management equity plan, $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMjg_386a6934-1e86-441d-a779-702a6ad8255e">14</ix:nonFraction>&#160;million of contract and lease termination fees, and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMzk_0a332736-baed-44da-8641-4b1caea4be55">32</ix:nonFraction>&#160;million of other restructuring costs. Acquisition&#8209;related costs consisted of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:BusinessCombinationAcquisitionRelatedTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzNDM_2218792f-ec14-4505-a877-86f181fbf969">14</ix:nonFraction>&#160;million of transaction costs. Our impairment charges for the year ended December&#160;31,&#160;2020 were comprised of $<ix:nonFraction unitRef="usd" contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzE2NDkyNjc0Njc5Nzk_c29931fa-7a4b-49f7-ad10-d512e6515cb6">79</ix:nonFraction>&#160;million from our Hospital Operations segment, $<ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzNjg_7cd04b03-cfd7-4896-b4bb-2b711c796a2e">12</ix:nonFraction>&#160;million from our Ambulatory Care segment and $<ix:nonFraction unitRef="usd" contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzE2NDkyNjc0NjgwMDY_ff49a442-27e8-4e61-9b03-a94aebc79e15">1</ix:nonFraction>&#160;million from our Conifer segment.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_211"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzMQ_67568a3f-5edb-4116-bbcd-4a4a7c604ad8" continuedAt="ib94ee46d5c6e4e7eb42e42790a1fabb1" escape="true"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzMg_a98bae78-d2f2-431c-8582-25011050da75" continuedAt="i36a23e691d314e4784dfbda90fb7ad48" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ib94ee46d5c6e4e7eb42e42790a1fabb1" continuedAt="i4b9a3952bffa45d39718a5ac45a6399b"><ix:continuation id="i36a23e691d314e4784dfbda90fb7ad48" continuedAt="i530258b7aca0464082ea731afc27e7a2"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzMw_d56be158-05d3-4ed8-9cc5-78dd196b47d3" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our right&#8209;of&#8209;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1">Investments and other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtNC0xLTEtMjkzNzEw_faeeec71-a98b-4f0e-a6ea-ec0513abd997">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtNi0xLTEtMjkzNzEw_0d0fac12-55e4-4a4c-89c6-67ec4666926c">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost, less</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated depreciation and amortization</span></div></div></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtNC0xLTEtMjkzNzEw_419850a0-bbb6-4b0b-a6cf-1124e83a28bb">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtNi0xLTEtMjkzNzEw_26b0e56e-d7a1-4b74-ae82-e7c3becce6ab">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzUtNC0xLTEtMjkzNzEw_3cf917e7-ba69-4d17-8be8-8655f0f51463">1,432</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzUtNi0xLTEtMjkzNzEw_4e91dafe-87ed-4b8f-8545-3311b4fa252f">1,335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktNC0xLTEtMjkzNzEw_c3e9dfde-17d9-4fa4-a329-4b1e3969582c">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktNi0xLTEtMjkzNzEw_194657ec-c91d-4683-9bcc-e8c45961fd3e">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTQtMS0xLTI5MzcxMA_226b3279-ea7e-4a1c-8dd9-8063be1cc2e6">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTYtMS0xLTI5MzcxMA_e7417315-cf62-40d8-9132-b7e457f6ccb8">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzExLTQtMS0xLTI5MzcxMA_4b215c23-0607-4f80-b6c5-57138bd1e8ea">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzExLTYtMS0xLTI5MzcxMA_84ee66e9-b1ab-44ae-bf40-d02415def7a5">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTQtMS0xLTI5MzcxMA_2d7623c1-38e6-46e0-8237-f68f9873a547">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTYtMS0xLTI5MzcxMA_f52240d2-ac8f-41a3-abe4-8a03ca0b4d87">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTQtMS0xLTI5MzcxMA_b7fed45f-0afd-4233-a4a7-ed87079c5c8e">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTYtMS0xLTI5MzcxMA_83bc44cc-d8f7-4997-b053-ce56aa8988c0">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE1LTQtMS0xLTI5MzcxMA_f6039699-a839-47e6-bdb5-2ed313df5541">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE1LTYtMS0xLTI5MzcxMA_7e9c645b-867b-46b7-a0c8-e5ee111b0fdd">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE2LTQtMS0xLTI5MzcxMA_25a6a275-08f3-49b0-8b79-417114a7941c">1,517</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:LeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE2LTYtMS0xLTI5MzcxMA_b4f94125-5b8a-4a9f-9545-c89fe2e42aad">1,407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzNA_7a8d2c23-4e3e-40dd-a486-398e37872efa" continuedAt="i12821aa118f74f18ad826772e3fd062e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzItNi0xLTEtMjkzNzEw_b94404a8-e264-4134-b145-c6b902928d7b">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzItOC0xLTEtMjkzNzEw_401f939f-776a-4921-8818-659731a63fe4">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzItMTAtMS0xLTI5MzcxMA_4f72dd35-cc33-4d1c-999d-49d20ee35560">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzQtNi0xLTEtMjkzNzEw_25bf90c4-06bc-41a5-940e-8ba7624af550">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzQtOC0xLTEtMjkzNzEw_d2eafec4-045e-4fa6-a60b-8dbcdf513ab0">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzQtMTAtMS0xLTI5MzcxMA_57c67c7c-2e53-4ee1-8e75-9adf7fa023e3">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzUtNi0xLTEtMjkzNzEw_4d9f4121-9a14-42d2-b546-68d10db0c1e9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzUtOC0xLTEtMjkzNzEw_42751834-0bdf-4655-9960-d68799f31070">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzUtMTAtMS0xLTI5MzcxMA_1d7161b2-d491-4ab7-9eb3-bfe8b931a328">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzYtNi0xLTEtMjkzNzEw_3cb5811a-1c2a-443d-8933-09955f5d588e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzYtOC0xLTEtMjkzNzEw_0cf4194f-6a03-43e3-849a-f98db62322fa">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzYtMTAtMS0xLTI5MzcxMA_768bbc44-826a-4403-9beb-72bf8be319bc">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and short term-lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:VariableAndShorttermLeaseCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzctNi0xLTEtMjkzNzEw_a52c2757-b834-4256-8e6f-1d15e7cb59cf">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:VariableAndShorttermLeaseCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzctOC0xLTEtMjkzNzEw_5528619a-079f-4f05-8990-0fd8494c4e39">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:VariableAndShorttermLeaseCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzctMTAtMS0xLTI5MzcxMA_339bb2e5-c90f-4745-8de2-d3d63f556bd5">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzgtNi0xLTEtMjkzNzEw_e047a7de-be0d-4264-b416-fd0360353d09">478</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzgtOC0xLTEtMjkzNzEw_079fd808-e526-4d0f-b050-39513845820c">492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzgtMTAtMS0xLTI5MzcxMA_7f6f7626-f75e-43d0-805f-b007aa8f6ea2">500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i4b9a3952bffa45d39718a5ac45a6399b"><ix:continuation id="i530258b7aca0464082ea731afc27e7a2"><ix:continuation id="i12821aa118f74f18ad826772e3fd062e"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average lease terms and discount rates for operating and finance leases are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzMtMi0xLTEtMjkzNzEw_c033cd05-2727-4f83-b496-2ee38c427d95">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzMtNC0xLTEtMjkzNzEw_e2346acc-ee72-4572-ace2-ef58543dfe19">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzMtNi0xLTEtMjkzNzEw_47b50086-e8f3-4132-9a38-58bcfa369ba5">7.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzQtMi0xLTEtMjkzNzEw_82d8f3f7-0aeb-49a7-a869-02b6f28083dc">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzQtNC0xLTEtMjkzNzEw_30bb1378-68a8-4806-983c-98a4ed15a0ac">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzQtNi0xLTEtMjkzNzEw_bf192b90-cc47-4f63-ac1c-5973b88d6903">5.7</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzctMi0xLTEtMjkzNzEw_38417eeb-9065-45dc-b376-12133b7951c6">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzctNC0xLTEtMjkzNzEw_25591084-232e-4429-bd0b-26f8365b5c92">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzctNi0xLTEtMjkzNzEw_67993d09-55f8-4f8f-baf4-7ae9df403e45">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzgtMi0xLTEtMjkzNzEw_b82a4a3c-e770-4f84-9272-610d782b49bf">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzgtNC0xLTEtMjkzNzEw_426a8eea-a0de-4cba-94e4-b0af7c0eb97a">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzgtNi0xLTEtMjkzNzEw_51eef8a6-bdbe-4a11-97c7-0a12657ebd92">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow and other information related to leases is included in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzMtMi0xLTEtMjkzNzEw_ddd24982-0e7b-4ed5-b47a-9d48e94e713e">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzMtNC0xLTEtMjkzNzEw_dde9913f-7935-4560-89a5-e3509f10171e">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzMtNi0xLTEtMjkzNzEw_2ff5733c-6435-4b27-95ad-b9377c9d3978">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzQtMi0xLTEtMjkzNzEw_e4c355d3-16ae-48a9-9e50-6d35a792cc9a">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzQtNC0xLTEtMjkzNzEw_b15808a7-72e5-41f7-9cb2-c26b0ec39e52">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzQtNi0xLTEtMjkzNzEw_0ae8a8de-9fc2-44e7-8ff3-b7a833e17d8a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzUtMi0xLTEtMjkzNzEw_4a34280c-9148-444e-8029-923584e7a40e">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzUtNC0xLTEtMjkzNzEw_ed6d0f73-58ed-47fe-ab92-1c116fe9699e">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzUtNi0xLTEtMjkzNzEw_bbfdee15-a346-409e-a10e-a129dad2f4bf">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzgtMi0xLTEtMjkzNzEw_bf3c3489-0e9c-4486-b5e5-e5c1fd8f2ffa">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzgtNC0xLTEtMjkzNzEw_4f9c109b-bac4-4795-b1e6-d1a2115d3ed8">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzgtNi0xLTEtMjkzNzEw_f9969e3a-4cc0-43ed-8e0d-999ad3785413">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzktMi0xLTEtMjkzNzEw_cb64ed9f-830d-47ca-86d8-a98c8cd6f1d1">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzktNC0xLTEtMjkzNzEw_5ea169ef-a4f9-49bf-af4e-06909f97dd7b">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzktNi0xLTEtMjkzNzEw_7cbb1e25-3a64-41b4-9b70-ecf825013111">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzNQ_60733ca6-ac1f-4224-b7ca-6399695daa65" escape="true"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzNg_a4310bdb-52d5-4865-96de-59a4f5d628b1" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEtMi0xLTEtMjkzNzEw_be7402c9-aac8-40ca-a368-aa38d9aff234">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEtNC0xLTEtMjkzNzEw_151c29af-8f99-4c78-967a-c40e14aa92bb">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LesseeLeaseLiabilityPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEtNi0xLTEtMjkzNzEw_f870d0bb-1cad-4199-a7ab-d59175e9dbbc">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzItMi0xLTEtMjkzNzEw_9e851ed1-612a-4935-9e9d-19d0dae791d2">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzItNC0xLTEtMjkzNzEw_98f72c3f-8c20-492b-a463-6d50771b4cdb">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LesseeLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzItNi0xLTEtMjkzNzEw_0667bc33-8400-4e21-a320-dca8edc9f5bb">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzMtMi0xLTEtMjkzNzEw_205b64f0-9dc6-45d4-919d-0f7dc482cf70">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzMtNC0xLTEtMjkzNzEw_40d9a040-67eb-4294-ade4-9c887282cb40">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LesseeLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzMtNi0xLTEtMjkzNzEw_19f41448-8777-42d8-9758-0881859922da">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzQtMi0xLTEtMjkzNzEw_fc484d08-3915-4412-a48f-05adeb8682fe">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzQtNC0xLTEtMjkzNzEw_a79c7c11-55e2-4333-ad29-20e5adbde766">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LesseeLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzQtNi0xLTEtMjkzNzEw_b46729d9-fb5c-480f-af49-47c713133d2b">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzUtMi0xLTEtMjkzNzEw_cf48d74f-f16b-4597-87e1-6073b52ab634">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzUtNC0xLTEtMjkzNzEw_c950fffb-5894-412f-98d7-d1f9b9c62c10">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LesseeLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzUtNi0xLTEtMjkzNzEw_1e5c1f8e-b53c-47ac-bdc7-2a5949a827ef">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzYtMi0xLTEtMjkzNzEw_da47d23d-8ef5-4897-85b5-5591e222b7fb">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzYtNC0xLTEtMjkzNzEw_eaaf46e8-e6ee-498e-bc80-6c0ffce0c205">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LesseeLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzYtNi0xLTEtMjkzNzEw_9c3a8ed9-c072-40ec-99bc-30c4aff28961">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzctMi0xLTEtMjkzNzEw_75f78a90-6bdd-431e-87ca-4ec8722c80f0">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzctNC0xLTEtMjkzNzEw_b3026c2b-4508-4f7f-bbcd-e1e45ad67fb2">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzctNi0xLTEtMjkzNzEw_942a4779-1777-487a-b00d-339c88490e84">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzgtMi0xLTEtMjkzNzEw_6026fb41-ceb2-4af5-82a4-9b2feaeb3031">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzgtNC0xLTEtMjkzNzEw_a360c9ab-25d8-4078-8754-757ecc41668e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzgtNi0xLTEtMjkzNzEw_49396b42-ca78-4300-93fb-81954e0ffa33">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzktMi0xLTEtMjkzNzEw_5db13bd7-8bea-42fa-a76b-5f79c5f70e8b">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzktNC0xLTEtMjkzNzEw_09183d48-81a4-473d-a0e8-e19ae7d686ae">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzktNi0xLTEtMjkzNzEw_bd6453c0-3fd3-4aca-9f65-e9b755e16567">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEwLTItMS0xLTI5MzcxMA_95f0f268-f858-443b-997a-996c7b83a347">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEwLTQtMS0xLTI5MzcxMA_bc1f655c-c45d-4382-8305-875982f30aa0">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEwLTYtMS0xLTI5MzcxMA_becc0edf-9bd5-45e3-9e44-07000fa10ab6">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzExLTItMS0xLTI5MzcxMA_c55691b4-0fb6-4dbc-99e8-aca5ef4dabf6">1,046</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzExLTQtMS0xLTI5MzcxMA_9de72f78-6ce1-4c82-a1fb-1530358e765b">165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzExLTYtMS0xLTI5MzcxMA_ed6d15bd-dcbb-48f7-9aca-5cb43504b232">1,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31,&#160;2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfBuildings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg2MTE_d5cdb58a-2065-4c9f-9ccd-396824f4ebc1">147</ix:nonFraction> million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfProperties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg3MzA_4f46ca2d-c044-4473-b61d-1471eb6d5b73">69</ix:nonFraction>&#160;million from the sale of these buildings, included in other operating expenses, net in the accompanying Consolidated Statement of Operations, and we recognized right-of-use assets and operating lease obligations of $<ix:nonFraction unitRef="usd" contextRef="i59a09d299f6d4fce883b3595bf918a30_I20220331" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg5NDE_953b6c82-8d06-498f-9203-3bed691caa72"><ix:nonFraction unitRef="usd" contextRef="i59a09d299f6d4fce883b3595bf918a30_I20220331" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg5NDE_ba93962d-80da-4d4d-8fbc-ab7d762345bd">103</ix:nonFraction></ix:nonFraction>&#160;million, in each case in the three months ended March&#160;31,&#160;2022.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE0OTcz_ef6c8a91-7be2-4c29-beb8-230e918b10d7" continuedAt="ib2cef7d273614c8aa19ae406c3ed90c2" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="ib2cef7d273614c8aa19ae406c3ed90c2" continuedAt="ic7e7b4199ebd423b95b15bd2fadd8179"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE0OTc4_12ece894-ae51-4839-b81f-ca4f581f0701" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our long&#8209;term debt included in the accompanying Consolidated Balance Sheets:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i622ee28e9f1e42d7aff972d73252f4c8_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzMtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZmY2NTkyZTNmMDlmNDIzNDhhM2E4MDViYmU2MjBiZTNfNQ_53c299eb-4fee-43bc-a119-4b62584acad6">6.750</ix:nonFraction>% due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i622ee28e9f1e42d7aff972d73252f4c8_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzMtMS0xLTEtMjkzNzEw_7f8e92d8-f552-44db-bf43-53f109a5535a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae6361bfece4d29965dd05a7c7809e3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzMtMy0xLTEtMjkzNzEw_55683043-81b3-4888-9e53-e95737704e6e">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8a7e36b94de4011b826c46271390423_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzUtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZWEzYjJjNzJlOTZlNGNlNmFkZjBkMWZjNDlhY2NjM2FfNQ_be54f922-5973-4c86-8523-595a6f84e24a">6.125</ix:nonFraction>% due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a7e36b94de4011b826c46271390423_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzUtMS0xLTEtMjkzNzEw_6ed72f92-a903-4c5e-a136-a76d144ad61e">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4fb3c83283242f6bee137da54776fec_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzUtMy0xLTEtMjkzNzEw_88bfcd99-876b-4a04-a3a8-82122d609b42">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20c821a80a1b41029dc25c50b51dfcea_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzYtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246MzczNDAyY2JiZmIyNDNkNDlmNThkM2JjZDM4NTQ3ZDZfNQ_5d68e1c0-d4f5-4d9d-8c5d-61266cbf66d6">6.875</ix:nonFraction>% due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c821a80a1b41029dc25c50b51dfcea_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzYtMS0xLTEtMjkzNzEw_c1602abf-859e-4b1b-87f0-039090075e9f">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8871456e17fc4ba49fffcdcb23ed7b71_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzYtMy0xLTEtMjkzNzEw_d69ba4b1-8874-42ad-9892-a4e487310bcc">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured first lien notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzgtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDAzZmNhMDkzYWU4NDcwNThiNWM3MzU4N2U0YzgwZjRfNQ_455ad357-c451-4baf-bd73-ac3c16410fb4">4.625</ix:nonFraction>% due July 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzgtMS0xLTEtMjkzNzEw_934256e8-3ac0-48c6-9d73-ba162edda7e2">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989bb5295fc74ba1aa10f7543aab0c09_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzgtMy0xLTEtMjkzNzEw_03a2f41e-e1ea-48a5-89d4-44a2e186a6cc">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzktMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDVkMWI2YTRhNDVkNGI2YmJlOWZhNGI2YTIxMDEzNzVfNQ_f3379321-9c31-40a3-b4ef-2707fd65341e">4.625</ix:nonFraction>% due September 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzktMS0xLTEtMjkzNzEw_63f79986-c8a1-4d1d-859e-d415ba73c3ee">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da8add6a93946079dd9bfbe6ba2763c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzktMy0xLTEtMjkzNzEw_4fc1f93e-c80f-4e4b-b4d8-14d0b90a82c5">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57788fd689bc47bd813aec1a0ef11ee5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEwLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjRlMDQxYzhiMDk3ZTQyMDBiNmE2ZTBiN2E0OWFiOWZkXzU_51a20b15-b47f-4c68-a940-fd3435a58495">7.500</ix:nonFraction>% due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57788fd689bc47bd813aec1a0ef11ee5_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEwLTEtMS0xLTI5MzcxMA_37af0169-7ea2-4a78-b677-1112d2f4fc2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id060c1c1b2764c1bb2759e725cf12295_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEwLTMtMS0xLTI5MzcxMA_deb20864-2b2c-43ba-8cf4-18fa9fcbe303">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifde641ba54514fa09690f87fa89673d3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzExLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjE5NmViMWQzYmE3OTQ4MmFiMDY5OWIzNDBmNmFjZDQ0XzU_01d8dd46-0c25-47db-8359-2865035df752">4.875</ix:nonFraction>% due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde641ba54514fa09690f87fa89673d3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzExLTEtMS0xLTI5MzcxMA_0a0bc0f2-5c93-42ad-a1bb-5150abd3735b">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697cb82b913848f2b26b5f92fc37e35e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzExLTMtMS0xLTI5MzcxMA_59684d17-562e-4f54-b881-1a4aafeeb460">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i461c58e253f64f09a6ac5dc3c2784b82_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEyLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjNhMjQ5M2EwMjAzZDQxZDk5ZTI0NWNmOTkzMWJmZjgyXzU_fb69d99e-8dbb-4f2b-9d1f-c0fc3f7a4d54">5.125</ix:nonFraction>% due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461c58e253f64f09a6ac5dc3c2784b82_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEyLTEtMS0xLTI5MzcxMA_46340130-bd27-4702-b9a1-e8176978bced">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5404c8f217424e06babd62544ad4b7b8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEyLTMtMS0xLTI5MzcxMA_aee2ab3f-ae6b-4dcd-9a72-3ab3d641542c">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i558c5a218dd0455d853b5f0e68d8b7c6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmU4Y2NmZWY2ZWM5YzQ4NDBhY2NlZjQ4NzdmNDM2Yjk4XzU_3b4a7330-19b8-479e-b522-8f5a32fd4777">4.625</ix:nonFraction>% due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558c5a218dd0455d853b5f0e68d8b7c6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEzLTEtMS0xLTI5MzcxMA_87a6d680-18ed-43a8-915b-de935c9bf3fa">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afeea9e0df44876bc52904d8d7057fa_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEzLTMtMS0xLTI5MzcxMA_ab14fc4b-fb7c-4058-aa24-6f1cd820a9f5">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id17f96184b5f4ebd8db51025fe3377c6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE0LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjFiYTNiYTlmZDM2NDRmMWY5MzdlYzdhZTAyZTg2YTU3XzU_955c14f8-1974-4358-8aa6-03548d0ce111">4.250</ix:nonFraction>% due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17f96184b5f4ebd8db51025fe3377c6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE0LTEtMS0xLTI5MzcxMA_a973d900-ffb5-403c-b8dc-1d1081f89509">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5599a9535d841a28d1c1e4b3ced46aa_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE0LTMtMS0xLTI5MzcxMA_1674397f-0cbb-4b46-a6d5-0443bed0e2f9">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d9b9cf6618c4aa6afd0b5bc92c8b85d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjc5ZjBhZjM0ZDM5OTQ5MGNhZTVmNmIzYzY4OTIwYzlkXzQ_08be3e5b-ea73-433c-be79-917bb0315657">4.375</ix:nonFraction>% due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9b9cf6618c4aa6afd0b5bc92c8b85d_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTEtMS0xLTI5MzcxMA_b95c66b5-7754-4d18-8738-762453ce4186">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa72f8375f37499d86f928b68dff6f53_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTMtMS0xLTI5MzcxMA_d13037dc-5363-4af0-a70e-3ca6350a23d7">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i186d8e5c6032427baa46b10be1424d87_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTAtMS0xLTMxNjkwMS90ZXh0cmVnaW9uOjcxNzljYzVjZjcxMjQyNjE4OGU0OGMzOWRiMzYzZTBjXzEwOTk1MTE2Mjc4MTk_f29f544c-11e8-46a3-9556-db5ce1a5b7db">6.125</ix:nonFraction>% due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186d8e5c6032427baa46b10be1424d87_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTEtMS0xLTM0MzQwNQ_10e38e7d-b819-4392-8dec-cd64e677b404">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fba8ba8429243958c7942852541472e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTMtMS0xLTM0MzQwOQ_c1c1bc71-3557-4429-b850-243577730dba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured second lien notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0cb767709934643ac30a4e91dd1c63f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE4LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmIxYWVlNzcyMGE4MDRiZDRhODBmNTFmNGU1Yjc3MjJhXzU_cfa975ea-6304-45eb-9b7b-0da8e96806a6">6.250</ix:nonFraction>% due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb767709934643ac30a4e91dd1c63f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE4LTEtMS0xLTI5MzcxMA_d7c4f4a6-526d-4e7c-bf2d-a1e4df400e65">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3540a60419084118bc740136b6cb62d4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE4LTMtMS0xLTI5MzcxMA_94680902-0f5a-491d-8264-48a66daa1f2f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases, mortgages and other notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:FinanceLeasesAndMortgageNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE5LTEtMS0xLTI5MzcxMA_49b4c860-39fd-43c9-944c-eecf52917378">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:FinanceLeasesAndMortgageNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE5LTMtMS0xLTI5MzcxMA_57abe79e-ffab-44a7-9675-4e014710eb74">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized issue costs and note discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIwLTEtMS0xLTI5MzcxMA_bbd13d66-2513-49ef-a787-2f6d44fd7161">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIwLTMtMS0xLTI5MzcxMA_74e3cef6-b2b5-48a3-9fa7-2a9dcb170c5a">151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIxLTEtMS0xLTI5MzcxMA_a2e03732-79ef-49b8-8a9d-a12bee10c9f2">15,079</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIxLTMtMS0xLTI5MzcxMA_a53e4089-1bc3-4fb9-b732-cea16e5de4a8">15,646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIyLTEtMS0xLTI5MzcxMA_10a37ee8-41ed-47c0-9181-7e19162524bf">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIyLTMtMS0xLTI5MzcxMA_b72bbf50-cd63-4fea-af7c-13528de5a57d">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIzLTEtMS0xLTI5MzcxMA_f33ab3b4-fc48-4255-a61b-1c07263ea4f5">14,934</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIzLTMtMS0xLTI5MzcxMA_0726efa2-e7be-4c1b-b879-4e789bd0a24b">15,511</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes and Senior Unsecured Notes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2021, we redeemed approximately $<ix:nonFraction unitRef="usd" contextRef="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc0MzI_1bea6ae4-77c8-4bcb-bf49-7700044bbf5e">1.100</ix:nonFraction> billion of the then&#8209;outstanding $<ix:nonFraction unitRef="usd" contextRef="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc0NjA_281133dd-6c1d-4d3f-af8e-c4dc4e74947e">1.870</ix:nonFraction>&#160;billion aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEzNA_9bd230ec-51f0-4a97-84e4-a2942013c11b">4.625</ix:nonFraction>% senior secured first lien notes due July 2024 (&#8220;July 2024 Senior Secured First Lien Notes&#8221;) in advance of their maturity date. We paid $<ix:nonFraction unitRef="usd" contextRef="i7488113b2f8a4008a0c1e41e64bbaa8d_D20210910-20210910" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc2MzE_ff3a6ea7-2555-4169-b3b2-3be5490797ce">1.113</ix:nonFraction>&#160;billion to redeem the notes, which was primarily funded with the proceeds from the sale of the Miami Hospitals in August&#160;2021. During the three months ended December&#160;31,&#160;2022, we repurchased an additional $<ix:nonFraction unitRef="usd" contextRef="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc3OTg_1446c227-a3ff-416d-9014-2873572700ba">14</ix:nonFraction>&#160;million of the aggregate remaining principal amount of our July 2024 Senior Secured First Lien Notes through multiple open&#8209;market transactions. In total, we paid $<ix:nonFraction unitRef="usd" contextRef="i49c0fd70eca44c388aba457549bc1bde_D20221001-20221231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc5MTg_d48bfb2a-6cf4-4706-bb5c-285c6ca9d6d5">13</ix:nonFraction>&#160;million from cash on hand during the three&#8209;month period to repurchase the notes. In connection with these transactions, we recorded aggregate gains from early extinguishment of debt of less than $<ix:nonFraction unitRef="usd" contextRef="i49c0fd70eca44c388aba457549bc1bde_D20221001-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTgxMTM_91561f09-9e52-40ed-8f24-8b6d9de13cd7">1</ix:nonFraction>&#160;million during the three months ended December&#160;31,&#160;2022, and a loss of $<ix:nonFraction unitRef="usd" contextRef="i95369c42fa7c411bb4958a0409bc9c80_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTgxODE_934e1f87-5d2b-446e-9a74-6df38d82dcf4">20</ix:nonFraction>&#160;million in the three months ended September&#160;30,&#160;2021. The loss recognized in 2021 primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31,&#160;2022, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg0NzY_ef6011c8-a5ff-40d6-a2bf-64ce3714c679">11</ix:nonFraction>&#160;million of the then $<ix:nonFraction unitRef="usd" contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg0OTI_0926b00d-08dc-469b-95be-64dffc5aa56e">600</ix:nonFraction>&#160;million aggregate principal amount outstanding of our <ix:nonFraction unitRef="number" contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEzOQ_48a40cb2-137a-4b06-94ab-22023ad60fcb">4.625</ix:nonFraction>% senior secured first lien notes due September 2024 in advance of their maturity date. We made aggregate payments of $<ix:nonFraction unitRef="usd" contextRef="i5db931c86fe147d399a5218e8787b348_D20221001-20221231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzNzc1NA_a3eb42fe-bdfe-4bbb-b568-5eb9a7f534c6">11</ix:nonFraction>&#160;million from cash on hand through multiple open&#8209;market transactions to repurchase these notes. In connection with these repurchases, we recognized aggregate gains of less than $<ix:nonFraction unitRef="usd" contextRef="i5db931c86fe147d399a5218e8787b348_D20221001-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg4MjM_5351a264-79cf-4e23-9dfc-71b0dfc6267d">1</ix:nonFraction>&#160;million during the three months ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;15, 2022, we issued $<ix:nonFraction unitRef="usd" contextRef="i5426987ed148420cbbfa4a0f0d7a191f_I20220615" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg4ODA_1262c21e-1513-489d-9cd8-8d67cb298a2a">2.000</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i5426987ed148420cbbfa4a0f0d7a191f_I20220615" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEyNw_d94223ea-becc-4a3a-be13-4cc68890fd2e">6.125</ix:nonFraction>% senior secured first lien notes, which will mature on June&#160;15, 2030 (the &#8220;2030&#160;Senior Secured First Lien Notes&#8221;). We pay interest on the 2030&#160;Senior Secured First Lien Notes semi&#8209;annually in arrears on June&#160;15 and December&#160;15 of each year, which payments commenced in December&#160;2022. As further discussed below, we used a substantial portion of the issuance proceeds from the 2030&#160;Senior Secured First Lien Notes, after payment of fees and expenses, to finance the redemption of our <ix:nonFraction unitRef="number" contextRef="ifa8cce4fc2f848a2857f83e50a08eb16_I20220615" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODExOQ_daaf284c-924a-4bc0-9ab0-94dcef8fc7f6">6.750</ix:nonFraction>% senior unsecured notes due 2023 (the &#8220;2023&#160;Senior Unsecured Notes&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a series of open&#8209;market transactions during the six months ended June&#160;30,&#160;2022, we repurchased $<ix:nonFraction unitRef="usd" contextRef="id84fa693c2024155b0b1075bd91a66e2_I20220630" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk0ODc_20ff16a6-6bd5-4210-9cd5-d94c8bb8796b">124</ix:nonFraction>&#160;million aggregate principal amount outstanding of our 2023&#160;Senior Unsecured Notes using cash on hand. Following the issuance of our 2030&#160;Senior Secured First Lien Notes, we used a substantial portion of the proceeds to redeem the then-remaining $<ix:nonFraction unitRef="usd" contextRef="id84fa693c2024155b0b1075bd91a66e2_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk2NzE_1250244d-9031-4ae4-a4d4-b367b88034d9">1.748</ix:nonFraction>&#160;billion aggregate principal outstanding of the 2023&#160;Senior Unsecured Notes in advance of their maturity date. In total, we paid $<ix:nonFraction unitRef="usd" contextRef="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk3NzE_44aae5a4-22b6-453e-8106-88173045a7d6">1.933</ix:nonFraction>&#160;billion during the six months ended June&#160;30,&#160;2022 to retire all $<ix:nonFraction unitRef="usd" contextRef="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk4MzE_36f7daa3-fb8c-4e05-8d8d-763a047bf787">1.872</ix:nonFraction>&#160;billion aggregate principal amount </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ic7e7b4199ebd423b95b15bd2fadd8179" continuedAt="i7f13904e7fb2490691c5aaa3682b6f9b"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding of our 2023&#160;Senior Unsecured Notes, and we recorded aggregate losses from early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk5NTY_985f1602-fb12-4866-a016-0d3c9307c2b3">71</ix:nonFraction>&#160;million, primarily related to the difference between the purchase prices and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;23, 2022, we redeemed all $<ix:nonFraction unitRef="usd" contextRef="iac8320d1db684d2e978228570390fbbc_I20220223" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjAxNDg_cb072daa-77e8-4924-8140-c76abd3f6570">700</ix:nonFraction>&#160;million aggregate principal amount outstanding of our <ix:nonFraction unitRef="number" contextRef="iac8320d1db684d2e978228570390fbbc_I20220223" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEyMw_16753042-2888-4849-871f-bdf6d0e6faa3">7.500</ix:nonFraction>% senior secured first lien notes due 2025 in advance of their maturity date. We paid $<ix:nonFraction unitRef="usd" contextRef="i0b4c256aea654f0e81f827e0120eeca0_D20220223-20220223" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjAyODY_592e074a-e82c-4317-84ed-1e59c0022e6a">730</ix:nonFraction>&#160;million from cash on hand to redeem the notes. In connection with the redemption, we recorded a loss from early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i774268ee073042e296346aebdcefdf00_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjA0MjA_8a53b6d9-9a09-460d-b848-b4cafb297c93">38</ix:nonFraction>&#160;million in the three months ended March&#160;31,&#160;2022, primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;1, 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="i38e3f3971b45492ebda95c4159ea5bed_I20211201" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjA2NDY_03ba3092-61bd-4c15-883a-2ea036e17c0f">1.450</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i38e3f3971b45492ebda95c4159ea5bed_I20211201" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjA2ODA_b1f3d4cd-d1f3-4e26-b76f-ebdeb195733a">4.375</ix:nonFraction>% senior secured first lien notes, which will mature on January&#160;15, 2030 (the &#8220;2030&#160;Senior Secured First Lien Notes&#8221;). We will pay interest on the 2030&#160;Senior Secured First Lien Notes semi&#8209;annually in arrears on January&#160;15 and July&#160;15 of each year, which payments commended in July&#160;2022. We used the net proceeds from the issuance of the 2030&#160;Senior Secured First Lien Notes, after payment of fees and expenses, to finance the acquisition of a group of ambulatory surgery centers in December 2021 and for general corporate purposes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;2, 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="i7daa6cd1b7be473ba7d7f3897a209175_I20210602" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjExMjQ_e528449d-5a8b-48f4-bdeb-a6f13e4cfc4d">1.400</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i7daa6cd1b7be473ba7d7f3897a209175_I20210602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjExNTg_eaa26c8d-04d0-4c52-b013-a3baf98da78a">4.250</ix:nonFraction>% senior secured first lien notes, which will mature on June&#160;1, 2029 (the &#8220;2029&#160;Senior Secured First Lien Notes&#8221;). We pay interest on the 2029&#160;Senior Secured First Lien Notes semi&#8209;annually in arrears on June&#160;1 and December&#160;1 of each year, which payments commenced in December 2021. The proceeds from the sale of the 2029&#160;Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $<ix:nonFraction unitRef="usd" contextRef="ic0d2bb14dafb425e9e73ab20986d8aba_I20210602" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE1MjY_8559cbe8-2f2c-4634-a735-0ffc58c3c11e">1.410</ix:nonFraction> billion aggregate principal amount then outstanding of our <ix:nonFraction unitRef="number" contextRef="ic0d2bb14dafb425e9e73ab20986d8aba_I20210602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE1ODE_ad5447c1-8c4c-40c2-951c-d0ed4329aef5">5.125</ix:nonFraction>% senior secured second lien notes due 2025 (the &#8220;2025 Senior Secured Second Lien Notes&#8221;) in advance of their maturity date for approximately $<ix:nonFraction unitRef="usd" contextRef="i216bb1419f01411cbe289ef91b5d9301_D20210602-20210602" decimals="-6" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE3MjU_c4076836-d9f8-48ce-be63-169e36fe1059">1.428</ix:nonFraction> billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $<ix:nonFraction unitRef="usd" contextRef="ia74c040bcaea4ecfa1841b613ea39e5b_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE4MzU_9df8e452-6f7d-4e79-ad47-9db74ffff7ef">31</ix:nonFraction>&#160;million in the three months ended June&#160;30,&#160;2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we retired all $<ix:nonFraction unitRef="usd" contextRef="icd0319d75b304db7a61ce7e8160119f5_I20210331" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIwNjM_1e0983ee-76f5-4cdf-b306-331806acb5f3">478</ix:nonFraction>&#160;million aggregate principal amount outstanding of our <ix:nonFraction unitRef="number" contextRef="icd0319d75b304db7a61ce7e8160119f5_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIxMTM_5869fa6d-4177-4a21-8f31-70a9d7e74bd6">7.000</ix:nonFraction>% senior unsecured notes due 2025 in advance of their maturity date. We paid approximately $<ix:nonFraction unitRef="usd" contextRef="i6f3bda72356c4c8a90a164544fdb3419_D20210101-20210331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIyMDU_6beb377a-574e-45ed-82d8-49c04395b54c">495</ix:nonFraction>&#160;million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i6f3bda72356c4c8a90a164544fdb3419_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIzMzk_ff59b090-8659-4e8c-944c-4d126ee203d5">23</ix:nonFraction> million in the three months ended March&#160;31,&#160;2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our senior secured notes are guaranteed by certain of our wholly owned domestic hospital company subsidiaries and secured by a pledge of the capital stock and other ownership interests of those subsidiaries on either a first lien or second lien basis, as indicated in the table above. All of our senior secured notes and the related subsidiary guarantees are our and the subsidiary guarantors&#8217; senior secured obligations. All of our senior secured notes rank equally in right of payment with all of our other senior secured indebtedness. Our senior secured notes rank senior to any subordinated indebtedness that we or such subsidiary guarantors may incur; they are effectively senior to our and such subsidiary guarantors&#8217; existing and future unsecured indebtedness and other liabilities to the extent of the value of the collateral securing the notes and the subsidiary guarantees; they are effectively subordinated to our and such subsidiary guarantors&#8217; obligations under our senior secured revolving credit facility (as&#160;amended to date, the &#8220;Credit Agreement&#8221;) to the extent of the value of the collateral securing borrowings thereunder; and they are structurally subordinated to all obligations of our non&#8209;guarantor subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures setting forth the terms of our senior secured notes contain provisions governing our ability to redeem the notes and the terms by which we may do so. At our option, we may redeem our senior secured notes, in whole or in part, at any time at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjQwNzM_26cc5424-b263-4b26-8f5c-42db58439abe">100</ix:nonFraction>% of the principal amount of the notes redeemed plus the make&#8209;whole premium set forth in the related indenture, together with accrued and unpaid interest thereon, if any, to the redemption date. Certain series of the senior secured notes may also be redeemed, in whole or in part, at certain redemption prices set forth in the applicable indentures, together with accrued and unpaid interest. In addition, we may be required to purchase for cash all or any part of each series of our senior secured notes upon the occurrence of a change of control (as defined in the applicable indentures) for a cash purchase price of <ix:nonFraction unitRef="number" contextRef="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231" decimals="INF" name="thc:DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjQ2OTQ_c6190f82-652b-43a9-bca2-6e396b666b04">101</ix:nonFraction>% of the aggregate principal amount of the notes, plus accrued and unpaid interest.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our senior unsecured notes are general unsecured senior debt obligations that rank equally in right of payment with all of our other unsecured senior indebtedness, but are effectively subordinated to our senior secured notes described above, the obligations of our subsidiaries and any obligations under our Credit Agreement to the extent of the value of the collateral. We may redeem any series of our senior unsecured notes, in whole or in part, at any time at a redemption price equal </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i7f13904e7fb2490691c5aaa3682b6f9b" continuedAt="id7ae9496f82a4562926120da820e2c37"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to <ix:nonFraction unitRef="number" contextRef="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjUyNjU_aad2e7b9-ab01-4ead-9358-1faddbd27e03">100</ix:nonFraction>% of the principal amount of the notes redeemed, plus&#160;a make&#8209;whole premium specified in the applicable indenture, if any, together with accrued and unpaid interest to the redemption date.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement provides for revolving loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODUxODE_160901f3-ba1d-4e9c-92bf-327b74111b30">1.500</ix:nonFraction> billion with a $<ix:nonFraction unitRef="usd" contextRef="i58fa2d207abf4c7d930128ada13635f8_I20221231" decimals="INF" name="thc:LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODE0NA_56c26c2a-c916-4f46-aac1-1c194570b20d">200</ix:nonFraction>&#160;million subfacility for standby letters of credit. We amended our Credit Agreement in April 2020 to increase our borrowing availability in response to the COVID-19 pandemic. This amendment, among other things, (1)&#160;increased the aggregate revolving credit commitments from the previous limit of $<ix:nonFraction unitRef="usd" contextRef="i8d1634d5e5c74227b8cb258fc3071474_I20200331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODUxOTQ_e71ccc20-f130-4336-b5d3-4d0e5c00f51c">1.500</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i85c9953574604a679693fb09557caf2c_I20200430" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzUyNw_35ae8b85-fa3c-41ee-9691-44d7b0f221f0">1.900</ix:nonFraction> billion (the &#8220;Increased Commitments&#8221;), subject to borrowing availability, and (2)&#160;increased the advance rate and raise limits on certain eligible accounts receivable in the calculation of the borrowing base, in each case, for an incremental period of <ix:nonNumeric contextRef="ib14f1fc180e441e2a02f1e6258051ea9_D20200401-20200430" name="thc:PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzc3Mw_86dd520d-8c68-4bd9-847e-0f886839dcb3">364</ix:nonNumeric>&#160;days. In April 2021, we amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April&#160;2022 and reduce the interest rate margins. In March&#160;2022, we further amended our Credit Agreement to, among other things, (1)&#160;decrease the aggregate revolving credit commitments from the previous Increased Commitments to aggregate revolving credit commitments not to exceed $<ix:nonFraction unitRef="usd" contextRef="ied39b398e82143dbad504e93ddad6c70_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3NTE5MTY_3e95f10a-7a0e-4b1d-85a9-858a1d82b9f3">1.500</ix:nonFraction>&#160;billion, subject to borrowing availability, (2)&#160;extend the scheduled maturity date to March&#160;16,&#160;2027, and (3)&#160;replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) and Daily&#160;Simple&#160;SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At December&#160;31,&#160;2022, we had <ix:nonFraction unitRef="usd" contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzkzNg_a8d2b112-9589-48ea-b873-9898b86e2d07">no</ix:nonFraction> cash borrowings outstanding under the Credit Agreement, and we had less than $<ix:nonFraction unitRef="usd" contextRef="i58fa2d207abf4c7d930128ada13635f8_I20221231" decimals="-6" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwMDk_b66ae070-417e-4f90-ac25-cd3d9be135c0">1</ix:nonFraction> million of standby letters of credit outstanding. Based on our eligible receivables, $<ix:nonFraction unitRef="usd" contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwODk_1661188f-b28b-434d-89de-51f640be493e">1.500</ix:nonFraction>&#160;billion was available for borrowing at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding revolving loans accrue interest depending on the type of loan at either (a)&#160;a base rate plus an applicable margin ranging from <ix:nonFraction unitRef="number" contextRef="ie79724e46f9345fbb6283e854762c21b_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwMzU_beed9f72-cedb-454a-9e67-426b4e38abb3">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icbde1cbd711b43aab8f621cc2b3b071d_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwMzk_7fa01c88-4b90-49d8-bb4a-62a09e9bc424">0.75</ix:nonFraction>% per annum or (b)&#160;Term SOFR, Daily Simple SOFR or the Euro Interbank Offered Rate (EURIBOR) (each, as defined in the Credit Agreement) plus an applicable margin ranging from <ix:nonFraction unitRef="number" contextRef="ib4470e4393114d6aa39323d7ec6f963f_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNDM_52a30c2b-d649-4526-8c36-3c272cf5701b">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if4d759b6ae6a43f7a40e0ef19d9f025e_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNDc_220648de-f5db-4486-9cdb-607198cdd951">1.75</ix:nonFraction>% per annum and (in the case of Term SOFR and Daily Simple SOFR only) a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i339dc68a43b14d1cb043fb9d9e7bc4bd_D20220101-20221231" decimals="INF" name="thc:DebtInstrumentBasisSpreadOnCreditSpread" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNTE_ce2e474a-68ca-4eaf-8b9a-598bf1e38447">0.10</ix:nonFraction>%, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from <ix:nonFraction unitRef="number" contextRef="i5976155b721e4588af99404df30450c3_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNTk_cf4a9a50-ad6b-4e29-8e99-27aa253a2fcf">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i289e59d55e724f6d816c0df9b3f788d7_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNjM_9ebc34a7-01e2-451e-ae0f-c63dc7edcb68">0.375</ix:nonFraction>% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible inventory and accounts receivable, including self&#8209;pay accounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the Credit Agreement continue to be guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and secured by a first&#8209;priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letter of Credit Facility</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a letter of credit facility (as amended to date, the &#8220;LC Facility&#8221;) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTQzNTI_1d70a1a5-99c6-4ba9-b0dc-abcd07db7a76">200</ix:nonFraction>&#160;million. The scheduled maturity date of the LC Facility is September&#160;12,&#160;2024. Obligations under the LC Facility are guaranteed and secured by a first&#8209;priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal&#8209;ranking basis with our senior secured first lien notes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within <ix:nonFraction unitRef="day" contextRef="icee7731e045f45ceb6027185e10efdf4_D20220101-20221231" decimals="INF" name="thc:NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIxOTY_e9772911-83e9-4a45-9bee-593be48944dc">three</ix:nonFraction> business days after notice thereof accrue interest at a base rate plus a margin of <ix:nonFraction unitRef="number" contextRef="i807623c3e0804c008f81fdd3f1dfa3fd_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIyODM_1781b243-f582-4fc5-a66c-72134fed0956">0.50</ix:nonFraction>% per annum. An unused commitment fee is payable at an initial rate of <ix:nonFraction unitRef="number" contextRef="i03c60d6ea9404c3ab4509a64a435d111_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIzNTY_8d16915c-10fb-4945-b800-600220646153">0.25</ix:nonFraction>% per annum with a step up to <ix:nonFraction unitRef="number" contextRef="icee7731e045f45ceb6027185e10efdf4_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIzODg_555067ad-6daf-4639-b18a-500070a376da">0.375</ix:nonFraction>% per annum should our secured&#8209;debt&#8209;to&#8209;EBITDA ratio equal or exceed <ix:nonFraction unitRef="number" contextRef="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231" decimals="INF" name="thc:DebtInstrumentCovenantSecuredDebtToEbitdaRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI0NTg_2cc8ba9d-d1a4-49b4-b6bc-00e32724c7a6">3.00</ix:nonFraction> to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit accrues at a rate of <ix:nonFraction unitRef="number" contextRef="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231" decimals="INF" name="thc:DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI2MDc_5a7a22f1-aae6-4310-969b-38f3ad967645">1.50</ix:nonFraction>% per annum. An issuance fee equal to <ix:nonFraction unitRef="number" contextRef="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231" decimals="INF" name="thc:DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI2NDc_04e73db5-6e56-4991-b744-24db72389aab">0.125</ix:nonFraction>% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. The LC Facility is subject to an effective maximum secured debt covenant of <ix:nonFraction unitRef="number" contextRef="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231" decimals="INF" name="thc:DebtInstrumentCovenantMaximumSecuredDebtRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI4Njg_71c50ab5-35d4-4721-b6fe-26b4c5466b70">4.25</ix:nonFraction> to 1.00. At December&#160;31,&#160;2022, we had $<ix:nonFraction unitRef="usd" contextRef="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231" decimals="-6" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTQ5NTg_52f25054-bd30-4320-bac3-21ab78a1d4f4">116</ix:nonFraction>&#160;million of standby letters of credit outstanding under the LC&#160;Facility and were in compliance with all applicable covenants and conditions.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenants</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The indentures governing our senior secured notes contain covenants that, among other things, restrict our ability and the ability of our subsidiaries to incur liens, consummate asset sales, enter into sale and lease&#8209;back transactions or consolidate, merge or sell all or substantially all of our or their assets, other than in certain transactions between one or more of our wholly owned subsidiaries. These restrictions, however, are subject to a number of exceptions and qualifications. In particular, there are no restrictions on our ability or the ability of our subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities). In addition, the indentures governing our senior secured notes contain a covenant that neither we nor any of our </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="id7ae9496f82a4562926120da820e2c37"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries will incur secured debt, unless at the time of and after giving effect to the incurrence of such debt, the aggregate amount of all such secured debt (including the aggregate principal amount of senior secured notes outstanding and any outstanding borrowings under our Credit Agreement at such time) does not exceed the amount that would cause the secured debt ratio (as defined in the indentures) to exceed <ix:nonFraction unitRef="number" contextRef="i6f2bd835c2ea41418922c21a022a0229_D20220101-20221231" decimals="INF" name="thc:DebtInstrumentCovenantsOfSecuredDebtRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3MDY2ODc_4a2db3fc-6db3-4761-9de7-2330dfae8e90">4.00</ix:nonFraction> to 1.00.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The indentures governing our senior unsecured notes contain covenants and conditions that have, among other requirements, limitations on (1)&#160;liens on &#8220;principal properties&#8221; and (2)&#160;sale and lease&#8209;back transactions with respect to principal properties. A principal property is defined in the senior unsecured notes indentures as a hospital that has an asset value on our books in excess of <ix:nonFraction unitRef="number" contextRef="i13f604ea7a86499fbbfbc12bc96eb817_I20221231" decimals="INF" name="thc:DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3MDcxMTI_45d6d14d-dc3e-4e07-87ce-78703f010b07">5</ix:nonFraction>% of our consolidated net tangible assets, as defined in such indentures. The above limitations do not apply, however, to (1)&#160;debt that is not secured by principal properties or (2)&#160;debt that is secured by principal properties if the aggregate of such secured debt does not exceed <ix:nonFraction unitRef="number" contextRef="i8f47cf0048e74feb8f6625b5de6e4a56_I20221231" decimals="INF" name="thc:DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3MDczOTY_466b6ae0-fb68-4ed2-a7ae-d0751b41b9dd">15</ix:nonFraction>%&#160;of our consolidated net tangible assets, as further described in the indentures. The senior unsecured notes indentures also prohibit the consolidation, merger or sale of all or substantially all assets unless no event of default would result after giving effect to such transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our Credit Agreement contains customary covenants for an asset&#8209;backed facility, including a minimum fixed charge coverage ratio to be met if the designated excess availability under the revolving credit facility falls below $<ix:nonFraction unitRef="usd" contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231" decimals="INF" name="thc:LineOfCreditFacilityCovenantThresholdLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExMzQx_7ebdbc71-07cd-4304-82a9-d42c7668cdc9">150</ix:nonFraction> million, as well as limits on debt, asset sales and prepayments of certain other debt. The Credit Agreement also includes a provision, which we believe is customary in receivables&#8209;backed credit facilities, that gives our lenders the right to require that proceeds of collections of substantially all of our consolidated accounts receivable be applied directly to repay outstanding loans and other amounts that are due and payable under the Credit Agreement at any time that unused borrowing availability under the revolving credit facility is less than $<ix:nonFraction unitRef="usd" contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231" decimals="INF" name="thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODYx_ae013867-a880-4619-af56-e88611e7e246">150</ix:nonFraction> million for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODY4_dfdfd5fb-468c-4e0d-afdb-50499803685f">three</span> consecutive business days or if an event of default has occurred and is continuing thereunder. In that event, we would seek to re&#8209;borrow under the Credit Agreement to satisfy our operating cash requirements. Our ability to borrow under the Credit Agreement is subject to conditions that we believe are customary in revolving credit facilities, including that no events of default then exist.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Maturities</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE0OTgw_85f9437f-25da-44f4-a32a-dcf24501825a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future long&#8209;term debt maturities, including finance lease obligations were as follows as of December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including finance lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMS0xLTEtMjkzNzEw_a846446f-3776-4ab7-82dc-e3f8df653c65">15,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMy0xLTEtMjkzNzEw_4c1eef57-bc87-4fa7-87bb-7cf0f7b81787">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItNS0xLTEtMjkzNzEw_12825ed7-6b3b-4742-8eae-7b837f03dd0d">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItNy0xLTEtMjkzNzEw_e1becbf3-e8af-476c-b0fd-c0192d8e8db4">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItOS0xLTEtMjkzNzEw_66ccde77-6e2a-444b-98a9-4859dbb64314">2,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMTEtMS0xLTI5MzcxMA_74017115-0ee1-41ea-b166-e8d1028458ec">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMTMtMS0xLTI5MzcxMA_082c4a21-f88a-48dc-9536-c69fbed1c664">8,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_217"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:GuaranteesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzE2OTU_224fb97a-e743-4f45-823d-aa9aec46023d" continuedAt="ia8de07535cb34ea89a39b343814b1ff9" escape="true">GUARANTEES</ix:nonNumeric></span></div><ix:continuation id="ia8de07535cb34ea89a39b343814b1ff9"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our policy on physician relocation and recruitment, we provide income guarantee agreements to certain physicians who agree to relocate to fill a community need in the service area of one of our hospitals and commit to remain in practice in the area for a specified period of time. Under such agreements, we are required to make payments to the physicians in excess of the amounts they earn in their practices up to the amount of the income guarantee. The income guarantee periods are typically <ix:nonNumeric contextRef="i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231" name="thc:GuaranteeObligationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzUzNA_f86f119c-503f-46ae-8f5d-e12ce01e4756">12</ix:nonNumeric> months. If a physician does not fulfill his or her commitment period to the community, which is typically <ix:nonNumeric contextRef="i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231" name="thc:CommitmentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzYzNg_3b524e49-8e60-46ac-b710-75ab94e43556">three years</ix:nonNumeric> subsequent to the guarantee period, we seek recovery of the income guarantee payments from the physician on a prorated basis. We also provide revenue collection guarantees to hospital&#8209;based physician groups providing certain services at our hospitals with terms generally ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkyNA_42d833b7-adcf-4193-8432-f964517997d1">one</span> to <ix:nonNumeric contextRef="i2f0abb0a0e4a43e4bd6e824ef8f0e3b6_D20220101-20221231" name="thc:GuaranteeObligationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkzMA_73e9f633-e4f1-4d8d-a6e0-a80828fe0c2a">three years</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital&#8209;based physician groups providing certain services at our hospitals was $<ix:nonFraction unitRef="usd" contextRef="i0fdd924a274f443fa92ca5c6423bdc2e_I20221231" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzExNzk_ea2447ee-8731-4676-bba2-884ff8e98a5e">164</ix:nonFraction> million. We had a total liability of $<ix:nonFraction unitRef="usd" contextRef="ic3bc6670142a4e808c1316df2aec4f4b_I20221231" decimals="-6" name="us-gaap:GuaranteesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzEyMTE_4e19f6d2-8129-439c-b00b-246453c95170">143</ix:nonFraction> million recorded for these guarantees included in other current liabilities in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $<ix:nonFraction unitRef="usd" contextRef="i43dba714bb6f47bcba5217f722e33680_I20221231" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzE1Mjk_6c2de80a-0256-4c2c-b2b0-e5405a026fad">102</ix:nonFraction>&#160;million. Of the total, $<ix:nonFraction unitRef="usd" contextRef="ic0e89a0a42d34e7386bbd6bcb26e395d_I20221231" decimals="-6" name="thc:GuaranteeObligationCarryValueConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzE1NDc_bd5aac32-9856-4724-a77c-92f961588abf">25</ix:nonFraction>&#160;million relates to the obligations of consolidated subsidiaries, which obligations were recorded in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODk3_61b82d96-d268-44d3-9341-9daf48060558" continuedAt="i7d2542311b1e4d588a7e1e08e0088fe9" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i7d2542311b1e4d588a7e1e08e0088fe9" continuedAt="i26d82792b64d40a2ad814df4eaf5d541"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options and restricted stock units (&#8220;RSUs&#8221;) to certain of our employees and directors pursuant to our stock incentive plans. Stock options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire <ix:nonNumeric contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzOQ_baad0ee9-f060-4294-9632-54c982334139">10</ix:nonNumeric> years&#160;from the date of grant. An RSU is a contractual right to receive <ix:nonFraction unitRef="shares" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzQwNw_891a3f63-e292-41fc-869b-41d30b71beb5">one</ix:nonFraction> share of our common stock in the future, and the fair value of the RSU is based on our share price on the grant date. Typically, stock options and time&#8209;based RSUs vest one&#8209;third on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_0c2fc9bb-b93d-4b06-840f-178792b3529d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_1d18318b-f1d8-462d-93f9-2c3eaf3de351">three</span></span> anniversary dates of the grant; however, certain special retention awards may have different vesting terms. Shares underlying vested RSUs are generally distributed to participants (settled) immediately after the vesting date. In addition, grants of RSUs to our non&#8209;employee directors as part of their annual compensation vest immediately and are settled on the third anniversary of the date of grant, while initial grants to directors vest immediately but settle upon separation from the board. Compensation cost is measured by the fair value of the awards on their grant dates and is recognized over the requisite service period of the awards, whether or not the awards had any intrinsic value during the period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also grant performance&#8209;based RSUs that vest subject to the achievement of specified performance goals within a specified time frame. The performance&#8209;based RSUs may contain provisions that increase or decrease the number of RSUs that ultimately vest, depending upon the level of achievement. For certain of our performance&#8209;based awards, the number of options or RSUs that ultimately vest is also subject to adjustment based on the achievement of a market&#8209;based condition. These adjustments generally range from <ix:nonFraction unitRef="number" contextRef="if8c4f60c37dd4423b655206fe804e2a7_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1Mzk_f91a1881-7d8c-40e2-a01c-5f9211904ccc">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id54c892934f94ec9a1653dda6b70f552_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDU_04fa562a-8804-45aa-95a1-52055c6e1b00">200</ix:nonFraction>% of the number of RSUs initially granted. The fair value of awards that contain a market&#8209;based condition is estimated using a discrete model to analyze the fair value of the subject shares. The discrete model utilizes multiple stock paths, through the use of a Monte Carlo simulation, which paths are then analyzed to determine the fair value of the subject shares.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our stock&#8209;based compensation plans, awards granted under the plan vest and may be exercised as determined by the human resources committee of our board of directors. In the event of a change in control, the human resources committee of our board of directors may, at its sole discretion without obtaining shareholder approval, accelerate the vesting or performance periods of the awards.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, assuming outstanding performance&#8209;based stock options and RSUs for which performance has not yet been determined will achieve target performance, approximately <ix:nonFraction unitRef="shares" contextRef="i2aefe441942b4b1b9964978feb391a61_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI0OTQ_7499385a-8745-44e9-b6d9-d70bf6942b69">9.5</ix:nonFraction>&#160;million shares of common stock were available under our 2019 Stock Incentive Plan for future stock option grants and other equity incentive awards, including RSUs. The accompanying Consolidated Statements of Operations include pre-tax compensation costs related to our stock&#8209;based compensation arrangements of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQyMDk_1b9bd851-a26f-43f8-b665-945db758fc44"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQyMDk_6a9e8331-1bd0-470b-b5ed-59fd0641f758">56</ix:nonFraction></ix:nonFraction>&#160;million for each of the years ended December&#160;31,&#160;2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQyODI_bc212389-daf6-4b30-933b-e7458babcb5e">44</ix:nonFraction>&#160;million for the year ended December&#160;31,&#160;2020.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODgx_f1e8204a-ad33-4cb1-b0ed-85f3230695a8" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg<br/>Remaining Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f70438f4b824837b203d53a4d4992cb_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzItMi0xLTEtMjkzNzEw_5a38deda-a4f6-404e-b965-86304c7104e5">1,960,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f70438f4b824837b203d53a4d4992cb_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzItNC0xLTEtMjkzNzEw_18117e3a-bd64-4423-bf11-7164aed1097d">20.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzQtMi0xLTEtMjkzNzEw_62c2b2f9-0648-442c-abc0-cd5801e5fc15">987,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzQtNC0xLTEtMjkzNzEw_1a82a9af-4968-4540-b20b-b2fc60368c3d">17.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzUtMi0xLTEtMjkzNzEw_dcbe1fa1-7dc7-4480-aab8-fc101c1ae15f">60,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzUtNC0xLTEtMjkzNzEw_f88a3ae0-0cee-4a2c-9acf-cdf68844da57">23.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7b77940692a4f7db126c0242c3c5ac4_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzYtMi0xLTEtMjkzNzEw_a15f24c6-6ae5-4c95-9219-77dfd1ea2e8c">912,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b77940692a4f7db126c0242c3c5ac4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzYtNC0xLTEtMjkzNzEw_0076ffbd-1cda-46ed-a68e-07623cdea1f3">22.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzgtMi0xLTEtMjkzNzEw_810f2bf6-9bb3-430f-aab1-30278368c8ac">391,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzgtNC0xLTEtMjkzNzEw_a975633f-6acc-4db8-9550-1edf54321e7a">20.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0107ed011a3a46fdb613b444b95af318_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEwLTItMS0xLTI5MzcxMA_5de8f5b1-1de0-43c7-b566-5d21de91a8f8">520,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0107ed011a3a46fdb613b444b95af318_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEwLTQtMS0xLTI5MzcxMA_8485df64-1fca-4f5b-a4a5-4bbe8af910b4">23.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEyLTItMS0xLTI5MzcxMA_5d7902dd-e8aa-4367-b34c-d9307c76f20a">60,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEyLTQtMS0xLTI5MzcxMA_66e77d50-8917-438f-a6e4-a5dad1c8d082">28.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTItMS0xLTI5MzcxMA_8685d85c-7a08-4211-8987-d30a105fd953">460,947</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTQtMS0xLTI5MzcxMA_e18ec0d4-8f55-46a9-81ff-ac255df228b0">23.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTYtMS0xLTI5MzcxMA_951656e4-c434-48da-99dd-1df4a5e38ed5">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTgtMS0xLTI5MzcxMA_933238b9-8303-41ec-81d1-d511cfabfa4e">5.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzNzI_34effa6d-1c10-4d3e-8b59-6ba46212fd43"><ix:nonFraction unitRef="shares" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzNzI_5aa9f3fe-5e31-43b7-910e-befe79e70874"><ix:nonFraction unitRef="shares" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzNzI_ef71aecf-3271-4988-9d95-3b90ac74966d">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock options were granted during the years ended December&#160;31,&#160;2022, 2021 or 2020. There were <ix:nonFraction unitRef="shares" contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTMzNzE_ea5ba1f5-7e7e-451f-b36d-e4158bb20b30">60,051</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTMzNzY_e3dad0e1-e1c1-442f-88dc-24510c17f6f6">391,533</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTMzODQ_503254f7-4478-448e-967f-4c4d033a392b">987,471</ix:nonFraction> stock options exercised during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The stock options exercised in 2022 had an aggregate intrinsic value of approximately $<ix:nonFraction unitRef="usd" contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTM2Mzg_5e5f7c63-0fdc-4b73-97b8-f87d28f7564e">4</ix:nonFraction> million, and options exercised during 2021 and 2020 both had aggregate intrinsic values of approximately $<ix:nonFraction unitRef="usd" contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTM3NTA_0c9194cd-5594-4d9c-9c3c-ed43e94a4956"><ix:nonFraction unitRef="usd" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTM3NTA_e4abfb60-cb74-4edf-bf7f-8f47ca2620d2">15</ix:nonFraction></ix:nonFraction>&#160;million. All outstanding options were vested and exercisable at December&#160;31,&#160;2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i26d82792b64d40a2ad814df4eaf5d541" continuedAt="i57afe26682f2443f84f5983a3c52a8b2"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTEx_efd64ffc-9fc5-4c83-a8c8-66bfb8d26ceb" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about our outstanding stock options at December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding and Exercisable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range&#160;of&#160;Exercise&#160;Prices&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise&#160;Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i73a77c00b16741cd82fbfa2cd2e6aeef_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItMC0xLTEtMjkzNzEwL3RleHRyZWdpb246N2I0OGEwMDU3YTdjNGE1YWI3ZjkyOTFhZTY4NmVjNTJfNA_fc776dda-6e73-4cd4-a64e-2778053dac3f">18.99</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c48ee9db11e4626a720073e3d52765c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItMC0xLTEtMjkzNzEwL3RleHRyZWdpb246N2I0OGEwMDU3YTdjNGE1YWI3ZjkyOTFhZTY4NmVjNTJfMTA_e037fe5f-f530-4f91-835b-52ad655095bc">20.609</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8332ac81ea994fa080bd2c74aea55433_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItMi0xLTEtMjkzNzEw_287c4711-609d-49f5-a757-d2a8570df88c">293,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c680273422d4752955e73ac5d10bd49_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItNC0xLTEtMjkzNzEw_8bec67c8-3ad9-4d0a-85db-97bf18a67d0f">4.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8332ac81ea994fa080bd2c74aea55433_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItNi0xLTEtMjkzNzEw_6a8d795e-0fe1-4eca-8705-50a6f93be9bb">19.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icd0038bf48844cf2b84aed399a6f80ce_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246YjRiZDAyNTNkMTIwNDAzNzkxODFhZTMxNWU4MmQ0NjNfNA_60b9e4e6-7383-497d-96ae-a198c274ec88">20.61</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ie3031d28ff1b47d48f762be70d952bc5_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246YjRiZDAyNTNkMTIwNDAzNzkxODFhZTMxNWU4MmQ0NjNfMTA_11de5925-2caf-40ba-b3a8-bd6f0a45ffc4">35.430</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa66aa2f15ca430daa47cd0bdc598c56_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtMi0xLTEtMjkzNzEw_213aba94-b600-4eee-8088-f5749b0d631f">167,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82dd3f9e68e54d33b184fd6660d2b3e0_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtNC0xLTEtMjkzNzEw_3b40bce5-20d4-4054-89b7-7584b6498998">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa66aa2f15ca430daa47cd0bdc598c56_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtNi0xLTEtMjkzNzEw_a1c32e64-7234-41d2-b270-84fcd5a73680">29.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzQtMi0xLTEtMjkzNzEw_a797ae6a-c236-4f4a-b8a2-715d6a658522">460,947</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzQtNC0xLTEtMjkzNzEw_04a2ae8e-3ff4-4bb4-b7ae-7cf46fad688e">5.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzQtNi0xLTEtMjkzNzEw_577812dd-2f07-49e8-bea4-aeb02216e1af">23.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, <ix:nonFraction unitRef="number" contextRef="i6525986e7cec4246bf79c66a19a22c42_D20220101-20221231" decimals="3" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzM3NDc_619988c1-8241-458c-8968-4105bea993ce">42.3</ix:nonFraction>% of all our outstanding options were held by current employees and <ix:nonFraction unitRef="number" contextRef="idd5b8bc126dd41e49f8d133ce6a2f7e9_D20220101-20221231" decimals="3" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzM4MTY_37f3360b-c27e-44dd-9110-eceae7f2a433">57.7</ix:nonFraction>% were held by former employees. All of our outstanding options were in&#8209;the&#8209;money, that is, they had exercise price less than the $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzM5NDc_7862b977-1c0a-4035-997f-add275acc373">48.79</ix:nonFraction> market price of our common stock on December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs related to our stock-based compensation arrangements for the years ended December&#160;31,&#160;2021 and 2020 included $<ix:nonFraction unitRef="usd" contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODEyMjA_2f5a9d43-1ff7-41be-95ad-0283e053609d">1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODEyMjg_d4639986-5204-40c0-a987-f4d8b26f01d9">2</ix:nonFraction> million, respectively, of expense related to our stock options. We did <ix:nonFraction unitRef="usd" contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODEyOTQ_447b6a1b-5595-4119-9fac-50f79fdead87">not</ix:nonFraction> recognize any expense related to our stock options during the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODgy_0514439d-8342-4045-86cc-1c24129ef586" continuedAt="ib4637be279ca45e9808e0562c6aba62b" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Grant Date&#160;Fair<br/>Value&#160;Per&#160;Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic33f32827498430ea95e37c4de25591c_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEtMi0xLTEtMjkzNzEw_3fe5ea41-009e-4b81-bf40-09373b228b21">1,463,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic33f32827498430ea95e37c4de25591c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEtNC0xLTEtMjkzNzEw_71d8e59d-ba1e-4eec-a74e-88ea0170a0f4">25.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzItMi0xLTEtMjkzNzEw_14b200ce-efd8-43bd-bb1d-ae4c0ecc2b06">1,767,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzItNC0xLTEtMjkzNzEw_22520f76-4f3d-4c0e-8c1e-44097a38df08">27.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzMtMi0xLTEtMjkzNzEw_f91fa4db-5f34-4ffe-a585-72342cb8d37f">825,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzMtNC0xLTEtMjkzNzEw_a79ec50c-ed80-4070-8937-3c653861fd8a">25.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzQtMi0xLTEtMjkzNzEw_2172873c-9792-4e7b-af69-63e3db85d86b">310,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzQtNC0xLTEtMjkzNzEw_834039fa-c063-4507-910e-d1a312d23b78">32.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf2c425940604ce3bb5200984c22a581_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzUtMi0xLTEtMjkzNzEw_1002d30f-f22b-4892-8690-29e8aecd97c3">2,095,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf2c425940604ce3bb5200984c22a581_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzUtNC0xLTEtMjkzNzEw_150f9641-de1b-4337-9cc6-33ec63e52c7d">25.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzYtMi0xLTEtMjkzNzEw_bdfabc4c-8f34-4b0d-ad3e-98bc40d2ce43">900,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzYtNC0xLTEtMjkzNzEw_881f4ceb-7bae-47cc-b877-c5cfbc8ce5d4">58.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzctMi0xLTEtMjkzNzEw_d644e9d9-bbae-4c3f-be1e-6bc4e32403eb">765,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzctNC0xLTEtMjkzNzEw_6b228d63-7362-46e0-bcb9-e55957d317c1">30.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzgtMi0xLTEtMjkzNzEw_0e6aadd2-0a8d-4be1-9e75-d4a34ae8f663">58,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzgtNC0xLTEtMjkzNzEw_0bedeb29-3b74-45fd-93d6-b36b06c89740">37.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b0698fef50b441a8809d814d5874bd9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzktMi0xLTEtMjkzNzEw_a17856bc-663f-4763-bc84-fe0c1b0f374c">2,171,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b0698fef50b441a8809d814d5874bd9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzktNC0xLTEtMjkzNzEw_f7b59b47-a706-4a14-86d6-68db8389cf3c">40.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEwLTItMS0xLTI5MzcxMA_b823e66c-cf8e-4fac-8709-ebae1470de3b">641,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEwLTQtMS0xLTI5MzcxMA_7931da75-ec5f-492a-8a45-4b0bffc3b75a">80.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzExLTItMS0xLTI5MzcxMA_06940d9a-218e-402c-9efe-eb8f11799030">1,187,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzExLTQtMS0xLTI5MzcxMA_05c9a11c-9eee-4dd9-b2b2-51c89a08c3ba">37.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEyLTItMS0xLTI5MzcxMA_b67a9fbd-4de9-442f-b091-ca1cccebe68c">104,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEyLTQtMS0xLTI5MzcxMA_a3b7ce74-44b9-4307-93d2-9abd739b4ec2">53.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9447e0acfdc8411fa545539e357b1624_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEzLTItMS0xLTI5MzcxMA_3c60f95f-29b1-4a69-9605-a88bf5e3429d">1,520,418</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9447e0acfdc8411fa545539e357b1624_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEzLTQtMS0xLTI5MzcxMA_433d375d-cfe8-4829-98f1-5e2dc82c692b">66.36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we granted an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1MjY_0edfb9e2-6748-450d-b66a-cc637e398318">641,205</ix:nonFraction>&#160;RSUs. Of these, <ix:nonFraction unitRef="shares" contextRef="i1ae413ceda20471eaa9654d788c7e9c4_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1MzE_4ab68ebb-76e9-49a5-a1d1-cef6742764db">237,381</ix:nonFraction> will vest ratably over a <ix:nonNumeric contextRef="i1ae413ceda20471eaa9654d788c7e9c4_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMyOTg1MzQ5NjUxNDg_cb0700cd-5e1e-434b-9649-998b0294340e">three&#8209;year</ix:nonNumeric> period from the grant date, <ix:nonFraction unitRef="shares" contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQ2ODA_c01f0eaa-a11e-49e8-a0fd-72bda9e34503">53,716</ix:nonFraction> RSUs that were scheduled to vest ratably over <ix:nonFraction unitRef="quarter" contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQ3Mjg_c09589f0-e0e4-492c-b76b-3a779fd7230a">11</ix:nonFraction> quarterly periods, <ix:nonFraction unitRef="shares" contextRef="i5d49db19071d4e76af718a4ebfcd2551_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NDE_9ccce096-478e-4471-9113-65be97afe58b">9,215</ix:nonFraction> will vest ratably over a <ix:nonNumeric contextRef="i5d49db19071d4e76af718a4ebfcd2551_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMyOTg1MzQ5NjUxNTE_f37bb6da-f398-403d-9467-1f21fb4df484">four&#8209;year</ix:nonNumeric> period from the grant date, <ix:nonFraction unitRef="shares" contextRef="ica37af9eadb64144b4a83ab54b2eb4e1_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NTE_4a1f9267-283b-4359-861c-63bca91c0808">4,608</ix:nonFraction> will vest on the second anniversary of the grant date, and <ix:nonFraction unitRef="shares" contextRef="ibc78025992d2498693e0cfe01b80263d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NTY_ec3cb997-37e8-4193-9671-0e9fc36e786c">6,170</ix:nonFraction> will vest evenly on the third and fourth anniversaries of the grant date. We also granted <ix:nonFraction unitRef="shares" contextRef="ifdc06daccd6f4843bb75db0eba6fda8b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NzE_ef0a4750-345a-431a-bde4-6dea2712f924">35,482</ix:nonFraction>&#160;RSUs to our non&#8209;employee directors for the 2022-2023 board service year, which units vested and will settle as described above. In November 2022, we granted <ix:nonFraction unitRef="shares" contextRef="icd952e84dcc743b9af382bfd56d539a6_D20221101-20221130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTA2NTc_d052b429-0f6c-4b68-8157-848191ffd7dd">7,325</ix:nonFraction> to a non-executive member of the board of directors for their service as chairman of the board through the end of 2023. Unlike our normal grants to board members, these RSUs will vest on December&#160;31,&#160;2023 if the grantee serves as chairman through that date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we granted <ix:nonFraction unitRef="shares" contextRef="i792b9ba8d6434e31ba4998b638861429_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1OTM_855ff40d-ba3d-4d81-8fa1-4054e9cfbc0b">287,308</ix:nonFraction>&#160;performance&#8209;based RSUs during the year ended December&#160;31,&#160;2022; the vesting of these RSUs is contingent on our achievement of specified performance goals for the years 2022 to 2024. Provided the goals are achieved, the performance&#8209;based RSUs will vest on the third anniversary of the grant date. The actual number of performance&#8209;based RSUs that could vest will range from <ix:nonFraction unitRef="number" contextRef="if8c4f60c37dd4423b655206fe804e2a7_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI2NDM_f91a1881-7d8c-40e2-a01c-5f9211904ccc">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id54c892934f94ec9a1653dda6b70f552_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI2NTA_04fa562a-8804-45aa-95a1-52055c6e1b00">200</ix:nonFraction>% of the <ix:nonFraction unitRef="shares" contextRef="i792b9ba8d6434e31ba4998b638861429_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI2NTQ_855ff40d-ba3d-4d81-8fa1-4054e9cfbc0b">287,308</ix:nonFraction>&#160;units granted, depending on our level of achievement with respect to the performance goals.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021 we granted <ix:nonFraction unitRef="shares" contextRef="ib31c3d8b7cdb4518b73e55dc7378d317_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMTI_2e49235f-1a89-4799-b8b8-d9ba5fdddb32">561,788</ix:nonFraction> RSUs that vest based on the passage of time. The granted RSUs vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="iba5b2544884b47d884c4199111051b50_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMTg_7f87dff9-6a2d-47de-a7ac-a26ad9d065c4">263,180</ix:nonFraction> RSUs vest and settle ratably over a <ix:nonNumeric contextRef="iba5b2544884b47d884c4199111051b50_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzQzOTgwNDY1OTU0NjQ_e96fbe90-ef37-43a3-ab49-482ca10c2e61">three&#8209;year</ix:nonNumeric> period from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMjQ_50013ed2-b435-40b6-910b-8caa1d7a9cf6">189,215</ix:nonFraction> RSUs vest and settle ratably over <ix:nonFraction unitRef="quarter" contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY1Nw_d162953f-a7c4-4ac1-a4fb-37c04cfc013b">eight</ix:nonFraction> quarterly periods from the grant date;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i57afe26682f2443f84f5983a3c52a8b2" continuedAt="i8a8a02de88914c2dbfddafd9d66df31d"><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i9364d349beee475faa3c8ae75ca39b99_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMzA_5d901fd6-377a-4418-a271-1fcb662a7bec">53,341</ix:nonFraction> RSUs vest and settle on the fourth anniversary of the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="if0f6dfe4070b40479c568783e37dbdb1_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMzY_d39e6584-8bc1-405f-8c39-429a1a29bc7f">33,351</ix:nonFraction> RSUs vest and settle on the third anniversary of the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i82745fe1a5c149759ae2bb2ebd18c99f_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyNDI_4267ad19-60bc-49f9-9d83-124fb39a97a4">14,192</ix:nonFraction> RSUs vested on December&#160;31,&#160;2021 and settled in January 2022; and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i3b0e586f41214b669d46af8983e496a5_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyNTM_20ef5ba1-eb15-4964-be6f-c8dd2cccefc4">8,509</ix:nonFraction> RSUs, one-third of which vest and settle on the second anniversary of the grant date and the remainder of which vest and settle on the fourth anniversary.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021 we granted <ix:nonFraction unitRef="shares" contextRef="i67cb4a48480947cb934f8e6e7be5a3ac_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODg3OTY_f29b8258-6bb9-4ab1-85bf-f0e3a6b144be">298,492</ix:nonFraction> performance-based RSUs which vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i83afe2783741410d8c56a323ae90b6c5_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODk0Nzg_0b0d0f1f-e88a-445f-bbd5-e8804e676c22">244,259</ix:nonFraction> RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2023;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="ieec7c07bedae422fb1e0fa272c435e3d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODg4MTg_1b183440-937c-48e5-8e92-03cfbf845b4e">53,341</ix:nonFraction> RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2025; and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i02d9270641be4b258d8e9d251500ed2c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODg4MjQ_840412a6-5c66-4eef-a2d8-a021f47ed529">892</ix:nonFraction> RSUs vested and settled immediately as a result of our level of achievement with respect to performance&#8209;based RSUs granted in 2018.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual number of performance&#8209;based RSUs that could vest will range from <ix:nonFraction unitRef="number" contextRef="i4ffe68638d7b4f33a12f20c24c63eaca_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzUzMzI_e8bbfcea-c553-4015-aa8a-ebac92445d1d">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i77704bd6df014d42ad1974f3065e00bb_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzUzMzg_90b63b88-14c7-4c4a-a6a8-159d7931bdac">200</ix:nonFraction>% of the <ix:nonFraction unitRef="shares" contextRef="iddd4d4aa649e490fa03c3693ab1d3b6d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzYxNTE_512ea1ab-0a14-4a72-b0b4-6ba0d927c80f">297,600</ix:nonFraction> RSUs which did not vest immediately, depending upon our level of achievement with respect to the performance goals. During the year ended December&#160;31,&#160;2021, we also granted <ix:nonFraction unitRef="shares" contextRef="ic5c513a239cd415cadbc7d515e826c84_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzcxNDY_6d101ae8-0e64-4a82-9706-eb59b79643f1">39,738</ix:nonFraction> RSUs to our non&#8209;employee directors. These consisted of <ix:nonFraction unitRef="shares" contextRef="i25b782905e1e4e0eac9049059657f1b5_D20200501-20200531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzcxNTA_c009fa50-a654-4c7f-951b-1b4f2b4404ce">36,681</ix:nonFraction> RSUs for the 2021&#8209;2022 board service year, <ix:nonFraction unitRef="shares" contextRef="i459d2687d88148ecb61b4fae2a62863b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzcxNTQ_b8b7809a-f116-4df7-8ebe-0749b3413bd8">1,372</ix:nonFraction> for an initial grant to a new member of our board of directors and <ix:nonFraction unitRef="shares" contextRef="i4dab5b2fbdc143c39fa76b787542f0df_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTg5NTkzMA_ea76915e-7c3c-490a-ab4a-d326097464d2">1,685</ix:nonFraction> for a pro&#8209;rata annual grant to the same new member. While RSUs granted to our board of directors vest immediately, annual grants settle on the third anniversary of the grant date and initial grants settle upon separation from the board.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2020 we granted <ix:nonFraction unitRef="shares" contextRef="i46ba779d997746cb97b06efbf30d887e_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjE0OTg_3f3bdf50-1cf0-4c30-b8ab-51c82affc002">1,084,883</ix:nonFraction> RSUs that vest based on the passage of time. The granted RSUs vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="ie91ba56fa1e847e8a1c73049e8ae86f8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY0Mg_ee02a165-e760-4677-9166-39344c1b8bd0">607,198</ix:nonFraction> RSUs vest and settle ratably over a <ix:nonNumeric contextRef="ie91ba56fa1e847e8a1c73049e8ae86f8_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE3MDQyNDMwMzI0OTg2_94fb6fad-3ed8-44d7-9112-b21e165f35de">three&#8209;year</ix:nonNumeric> period from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY4OA_095bcca4-c53c-4d07-8b3e-68aabc0b37a9">359,713</ix:nonFraction> RSUs vest and settle ratably over <ix:nonFraction unitRef="quarter" contextRef="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY2Nw_74d206c9-a5c6-4aa1-a641-4db9f3ba1980">11</ix:nonFraction> quarterly periods from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="icdc7d548925b41349d858624f9963b63_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY5NA_05a2ce28-a112-4308-8cce-dab42a9a8e63">104,167</ix:nonFraction> RSUs vest and settle ratably over a <ix:nonNumeric contextRef="icdc7d548925b41349d858624f9963b63_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE3MDQyNDMwMzI0OTkw_e880963a-be05-4c00-8282-9e95e6bc8619">four-year</ix:nonNumeric> period from the grant date; and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="idf51d35f981442c99167b2d957e6c469_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcwMA_31ddb7dd-39ff-4b63-ad5c-95995b0e7d2e">13,805</ix:nonFraction> RSUs vest and settle on the third anniversary of the grant date.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2020 we granted <ix:nonFraction unitRef="shares" contextRef="i49aa4fd04a47497b9c081da63e6815a1_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcxMQ_6e835aa8-cb0f-4b4a-85e2-c3a2caf805ca">579,413</ix:nonFraction> performance-based RSUs which vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i40882d4788cd4504ab064fa6891d0693_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcxNw_4f8883ef-ca30-4f75-9313-8f70a3fe488e">499,285</ix:nonFraction> RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2022 and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:nonFraction unitRef="shares" contextRef="i0aafc61192254d9d93ce6bc583456021_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcyMw_d4e3a449-c1c6-4e59-9593-234f0568e5ea">80,128</ix:nonFraction> RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2023, all of which were subsequently forfeited.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual number of performance&#8209;based RSUs that could vest will range from <ix:nonFraction unitRef="number" contextRef="i4cf2066a73d3442da2799d558b87a606_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjczNw_3c537326-659d-4643-b350-7625d6600e51">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i0d78c92def194c19a4adbbb2259e22c1_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjc0MQ_6a713bb1-1768-41f7-bbc7-1311113952a8">200</ix:nonFraction>% of the <ix:nonFraction unitRef="shares" contextRef="i40882d4788cd4504ab064fa6891d0693_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjc1MA_4f8883ef-ca30-4f75-9313-8f70a3fe488e">499,285</ix:nonFraction> remaining RSUs granted, depending upon our level of achievement with respect to the performance goals. In May&#160;2020, we made an annual grant of <ix:nonFraction unitRef="shares" contextRef="i30fc1015621a4924bfbb26ae78a46dad_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjc1Nw_3b8a2ada-6a30-43cc-9819-d5bef70cd6fa">103,434</ix:nonFraction> RSUs to our non&#8209;employee directors for the 2020-2021 board service year, which units vested immediately and will settle in shares of our common stock on the third anniversary of the date of the grant.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the aforementioned aggregate numbers of time-based RSUs granted in 2022, 2021 and 2020 were <ix:nonFraction unitRef="shares" contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTk3NzA_c01f0eaa-a11e-49e8-a0fd-72bda9e34503">53,716</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTk3ODM_50013ed2-b435-40b6-910b-8caa1d7a9cf6">189,215</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjE1ODE_aea8760d-3085-4faa-aa34-7de66057a4aa">359,713</ix:nonFraction> RSUs, respectively, awarded to our former Executive Chairman. The RSUs granted in 2022 and 2020 were each scheduled to vest ratably over <ix:nonFraction unitRef="quarter" contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjE2NzY_c09589f0-e0e4-492c-b76b-3a779fd7230a">11</ix:nonFraction> quarterly periods, while the RSUs granted in 2021 were schedule to vest ratably over <ix:nonFraction unitRef="quarter" contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTk4OTc_4740228e-f627-45a2-b931-15531523d05b">eight</ix:nonFraction> quarterly periods. Additionally, in the aforementioned aggregate number of performance-based RSUs granted in 2022 were <ix:nonFraction unitRef="shares" contextRef="ifc3d6bba1c884c478022a01b2e6cb3bc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjAwMzQ_26127c72-b618-4f56-aea2-b7d11e3b30e9">53,716</ix:nonFraction> RSUs awarded to our former Executive Chairman. The unvested portion of these grants vested in October&#160;2022 in accordance with the disability provisions of the stock incentive plan.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs related to our stock-based compensation arrangements for the years ended December&#160;31,&#160;2022, 2021 and 2020 included $<ix:nonFraction unitRef="usd" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODE2Nzk_7c9e5bc9-a062-4453-b514-471220713bbb">45</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODE2OTM_b318a861-cbec-49c8-b26c-40c878bdd0f4">42</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODE2OTY_bf459dbd-f374-4ad2-8417-e46129178aed">30</ix:nonFraction> million of expense related to our RSUs, respectively. At December&#160;31,&#160;2022, there were $<ix:nonFraction unitRef="usd" contextRef="i9447e0acfdc8411fa545539e357b1624_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODMyMTU_4ef24ed8-5612-4f5b-b317-58c96006bbb6">33</ix:nonFraction> million of total unrecognized compensation costs related to RSUs. These costs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODMyMzA_f377acef-5856-471a-aabd-9794de2aacf3">1.8</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i8a8a02de88914c2dbfddafd9d66df31d" continuedAt="i44241845971e403a89218392cf5b3d77"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of the performance-based RSU grants, the number of units that will ultimately vest is subject to adjustment based on the achievement of a market-based condition. The fair value of these RSUs is estimated through the use of a Monte Carlo simulation. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTAy_83118a1b-d321-4ad3-87fa-d052197959f8" continuedAt="i8be7e496da434078ad1e5d4202cdff13" escape="true">Significant inputs used in our valuation of these RSUs included the following:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i8be7e496da434078ad1e5d4202cdff13"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItMi0xLTEtMjkzNzEwL3RleHRyZWdpb246ZjBhOTBlOWNhMTk1NDQxOWI3ZjcyOTU1YjI0YWIxZTRfNA_d6269311-ec7d-431c-9252-bff87a49b579">39.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItMi0xLTEtMjkzNzEwL3RleHRyZWdpb246ZjBhOTBlOWNhMTk1NDQxOWI3ZjcyOTU1YjI0YWIxZTRfOQ_de34d799-00f8-4552-aba5-4965ebcd8b16">68.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItNC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDIyMDc2YTliNDNhNGQ1M2E4NTEwYWNkNzE2YWI3NjNfMTA5OTUxMTYyNzc5MA_7b285622-e7b8-42d9-80d4-c8684c654baf">65.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItNC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDIyMDc2YTliNDNhNGQ1M2E4NTEwYWNkNzE2YWI3NjNfMTA5OTUxMTYyNzc5Ng_fc72bfbd-e27f-479c-9544-0fd822e76d84">79.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItNi0xLTEtMzYzODMyL3RleHRyZWdpb246YjFlNzRkMjZkM2RmNGJhNDk0ZjM2ZmU0MmMzZjU3MTVfNTQ5NzU1ODEzOTAy_9fcd0758-c06f-46b9-925d-2bf452ef646f">54.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtMi0xLTEtMjkzNzEwL3RleHRyZWdpb246MTExMzg3NjE1ZGRjNDJkY2JkNTQyOTZkNTJlOWU4ZmFfNA_5c9ee882-f89f-4708-9892-fd3dde8c07da">1.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtMi0xLTEtMjkzNzEwL3RleHRyZWdpb246MTExMzg3NjE1ZGRjNDJkY2JkNTQyOTZkNTJlOWU4ZmFfOQ_d4165425-2f0b-49c4-9930-e81872adfd96">1.7</ix:nonFraction>% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtNC0xLTEtMjkzNzEwL3RleHRyZWdpb246M2M3OWQ2ZWQ3YTBiNDE4MWJlNGIyNjA3ZjNmZWJkNjRfMTA5OTUxMTYyNzc4OA_9743a9e9-9755-4146-8673-d26b574a5b3a">0.1</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtNC0xLTEtMjkzNzEwL3RleHRyZWdpb246M2M3OWQ2ZWQ3YTBiNDE4MWJlNGIyNjA3ZjNmZWJkNjRfMTA5OTUxMTYyNzc5NA_abc158ce-7559-4a80-b199-f823c751dec4">0.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtNi0xLTEtMzYzODMyL3RleHRyZWdpb246ODBlMWY4MWVjNjEwNGFhYjkyNTg1M2I5NjQ4ODYwN2ZfNTQ5NzU1ODEzOTAw_b842ca4e-4852-46de-8207-3483671c48f6">1.2</ix:nonFraction>%</span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USPI Management Equity Plan</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 USPI Management Equity Plan</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, USPI adopted the USPI Holding Company, Inc. 2015 Stock Incentive Plan (&#8220;2015 USPI Management Equity Plan&#8221;) under which it granted non-qualified options to purchase nonvoting shares of USPI&#8217;s outstanding common stock to eligible plan participants, allowing the recipient to participate in incremental growth in the value of USPI from the applicable grant date. Under the 2015 USPI Management Equity Plan, the total pool of options consisted of approximately <ix:nonFraction unitRef="number" contextRef="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzgyMTQ_0711bdff-0038-4b78-91d3-9a3c884ac288">10</ix:nonFraction>% of USPI&#8217;s fully diluted outstanding common stock. Options had an exercise price equal to the estimated fair market value of USPI&#8217;s common stock on the date of grant. The option awards were structured such that they had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg0Mzg_74a46396-62a0-44d1-87da-e5a77de5ca2f">three</span> or <ix:nonNumeric contextRef="i0a793f59564d4a279d849edac266ccd2_D20150101-20151231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTE5_f310fc2a-3f86-44e9-b763-b2e3e0541e92">four year</ix:nonNumeric> vesting period in which half of the award vested in equal pro-rata amounts over the applicable vesting period and the remaining half vested at the end of the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg2MjE_fd2aa8ae-54d5-4b8a-b36d-1b3d0bc214ae">three</span> or <ix:nonNumeric contextRef="i0a793f59564d4a279d849edac266ccd2_D20150101-20151231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTEw_37bc067b-c023-4f68-9d09-cb3f7924fde3">four year</ix:nonNumeric> period. Any unvested awards were forfeited upon the participant&#8217;s termination of service with USPI, and vested options were required to have been exercised within <ix:nonNumeric contextRef="i22e72837fb0e4ccaa451831a1f7d7152_D20150101-20151231" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg3OTg_138c9fae-2ff5-45f4-9025-dc36342664df">90</ix:nonNumeric> days of termination. Once an award was exercised and the requisite holding period met, the participant was eligible to sell the underlying shares to USPI at their estimated fair market value. Payment for USPI&#8217;s purchase of any eligible nonvoting common shares could be made in cash or in shares of Tenet&#8217;s common stock.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the 2015 USPI Management Equity Plan and all unvested options granted under the plan were terminated in accordance with the terms of the plan. USPI repurchased all vested options and all shares of USPI stock acquired upon exercise of an option for approximately $<ix:nonFraction unitRef="usd" contextRef="i575d1fb3905042bda466ba37322c7021_D20200201-20200229" decimals="-6" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzkzNjc_1beef6ab-26d7-4bf7-ad09-9634aa906cc3">35</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 USPI Management Equity Plan</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, USPI adopted the USPI Holding Company, Inc. Restricted Stock Plan (&#8220;USPI Management Equity Plan&#8221;) to replace the terminated 2015 USPI Management Equity Plan. Under the USPI Management Equity Plan, USPI grants RSUs representing a contractual right to receive <ix:nonFraction unitRef="shares" contextRef="i4992fa411a47474cb9b7e672161cc2b0_D20220101-20221231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzk2MzE_4e7cc2f2-225b-4428-a7df-b9b4889f7170">one</ix:nonFraction> share of USPI&#8217;s non&#8209;voting common stock in the future. The vesting of RSUs granted under the plan varies based on the terms of the underlying award agreement. Once the requisite holding period is met, during specified times, the participant can sell the underlying shares to USPI at their estimated fair market value. At our sole discretion, the purchase of any non&#8209;voting common shares can be made in cash or in shares of Tenet&#8217;s common stock.</span></div><ix:continuation id="ib4637be279ca45e9808e0562c6aba62b"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity under USPI&#8217;s management equity plan during the years ended December&#160;31,&#160;2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Grant Date&#160;Fair<br/>Value&#160;Per&#160;Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception of Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItMi0xLTEtMzE5ODAx_614cf35c-2ad1-4829-bec7-d0b289563538">2,556,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItNC0xLTEtMzI1MDQ0_d976f946-7056-40f0-bf48-db62dac1fe9a">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtMi0xLTEtMzE5ODA4_563e962d-45d2-4682-90a0-118a13d3c69f">531,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtNC0xLTEtMzI1MDQ2_b6f0efd5-4e00-4e3f-bea8-b148e31b6c45">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87721822e7c147bfa5fc199473a92a04_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtMi0xLTEtMzI1MDUw_ae322bba-a770-4b68-b5c3-280796bdfcf4">2,025,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87721822e7c147bfa5fc199473a92a04_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtNC0xLTEtMzI1MDUw_dc7bf799-bc84-4a22-bbb9-f62d2ed5619b">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItMi0xLTEtMjkzNzEw_da7d13b3-bb20-411e-bab5-2f85b34308bc">76,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItNC0xLTEtMjkzNzEw_233b34ce-8384-465e-972e-3f1d4fab2adb">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtMi0xLTEtMjkzNzEw_c6a70cc7-3654-41cf-8258-adf9954b57b5">388,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtNC0xLTEtMjkzNzEw_432712c0-2897-4717-9550-8bc0410582e0">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtMi0xLTEtMjkzNzEw_3f2dd947-64af-419d-a5d0-df20ba808882">218,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtNC0xLTEtMjkzNzEw_794b5543-3f03-4e3d-907d-752f99eb908d">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29275879e7484df887acacaddf98d599_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzUtMi0xLTEtMjkzNzEw_e445d489-3ab5-4a8f-9087-5d5e43798f21">1,494,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29275879e7484df887acacaddf98d599_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzUtNC0xLTEtMjkzNzEw_b30ab49b-d28c-4b1f-84d2-31c546778bfa">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzctMi0xLTEtMjkzNzEw_1bc79e44-7569-4bf0-b41e-56b875ff5e4b">369,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzctNC0xLTEtMjkzNzEw_96987651-beee-4045-97de-beaad38b50cc">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzgtMi0xLTEtMjkzNzEw_badeb7fb-3f78-4e38-a9b0-e93382cc5881">202,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzgtNC0xLTEtMjkzNzEw_8b0adba7-002c-4fa4-85b7-c48b20d1d15c">34.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8295862c62a64157b42db6f146e8c12d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzktMi0xLTEtMjkzNzEw_bc77ca4a-8dfe-43c8-954c-c822c624b5d4">922,840</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8295862c62a64157b42db6f146e8c12d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzktNC0xLTEtMjkzNzEw_4a4db359-45ea-4860-a768-0c9f067707b2">34.13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPI did <ix:nonFraction unitRef="shares" contextRef="i9fc0d268ac814aaf82dd4c2c38f45afc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNjQwODg_005e81bf-40aa-4d78-ab01-fd7eb603570a">not</ix:nonFraction> make any grants under the USPI Management Equity Plan during the year ended December&#160;31,&#160;2022. During the year ended December&#160;31,&#160;2021, USPI granted <ix:nonFraction unitRef="shares" contextRef="i48e7b2eaecfe4b418364da6c80616cdd_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwMjM1_fa0049b5-382e-49ae-9a4f-86b131d4bfd2">76,990</ix:nonFraction> RSUs under its management equity plan. <ix:nonFraction unitRef="number" contextRef="ib640db27bdcd4bb98e4be184ed784de6_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTQ3OTA_b4e8b860-356e-4543-bca6-0a472bfa200e"><ix:nonFraction unitRef="number" contextRef="i36a0e4afed9c4d62a3cab9875677e71b_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTQ3OTA_f982cbc0-4ed3-45a7-bd3c-2bf239643f6d">Twenty</ix:nonFraction></ix:nonFraction>&#160;percent of these RSUs vests on each of the first and second anniversaries of the grant date, and the remaining <ix:nonFraction unitRef="number" contextRef="iff0a68e5520c4a67b603ea61aabf6d5f_D20210101-20211231" decimals="1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTQ4MDY_1eb35bb9-caeb-4158-b306-08274289f019">60</ix:nonFraction>% vests on the third </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i44241845971e403a89218392cf5b3d77" continuedAt="iaa2577c0560745feadccf40071d8ffec"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary of the grant date. In 2020, USPI granted <ix:nonFraction unitRef="shares" contextRef="i4ee76bd3ebc94aee84000b9861cc8925_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjYwNg_de0b67bd-36ca-4a14-86de-7cdd50649dcd">2,556,333</ix:nonFraction> RSUs, <ix:nonFraction unitRef="number" contextRef="id872956450094631a6e69b7b3b22b116_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwODUzMg_1019628f-0488-4ff5-9e31-2c1255610999"><ix:nonFraction unitRef="number" contextRef="i7aeb8c24eb5e4d1fb3cc39f11508af94_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwODUzMg_79d41b77-3238-475d-86f9-7d418a7cbe14"><ix:nonFraction unitRef="number" contextRef="id4c2a4e8b3584f25ba9995590bb44105_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwODUzMg_fb0fbb29-ee8c-4f02-8357-93a49c501415">20</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of which vest in each of the first three&#160;years on the anniversary of the grant date with the remaining <ix:nonFraction unitRef="number" contextRef="i0f26d7b1bb2e411482df40eeb64c6fe2_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjYyOA_99a7bc82-8f36-4cf1-97a5-8dbb84914dd0">40</ix:nonFraction>% vesting on the fourth anniversary of the grant date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2022 and 2021, USPI paid $<ix:nonFraction unitRef="usd" contextRef="i0a5b35347f794fff83ccb6182bcfaefe_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTUwODg_6d215df7-a1bb-4375-8555-539838f6ce93">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib60161593b56431198752c72b64076ff_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwNjYz_20bc2b07-b590-478e-96a0-2c0a2d787481">9</ix:nonFraction> million, respectively, to repurchase portions of the non&#8209;voting common stock shares issued under the USPI management equity plan. <ix:nonFraction unitRef="shares" contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231" decimals="INF" name="thc:NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNjQwOTc_050c1904-334e-4d52-a342-35c313569532">No</ix:nonFraction> shares were repurchased during the year ended December&#160;31,&#160;2020. At December&#160;31,&#160;2022, there were <ix:nonFraction unitRef="shares" contextRef="iaf31acec6aff4c96ae0465cc5661d7d4_D20220101-20221231" decimals="INF" name="thc:CommonStockSharesOutstandingAndEligibleToBeSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTUzMzg_3406bd77-cc7f-4bed-a582-72a883d8a3d2">98,374</ix:nonFraction> outstanding vested shares of non&#8209;voting common stock eligible to be sold to USPI.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, <ix:nonFraction unitRef="shares" contextRef="i726bb4f7600248c880398c7ae29152c6_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwODcx_2433deb3-f27d-444a-8fa8-dbb6db074f87">922,840</ix:nonFraction> RSUs were outstanding under USPI&#8217;s management equity plan, all of which are expected to vest. The accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020 included $<ix:nonFraction unitRef="usd" contextRef="i8b599704099d4411946c2b6a61490067_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMDY2_0f7ee077-5173-4f49-a483-107b1161cd6f">11</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i67d8fd82832242d3874ce46a1f5bda4d_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMDcw_da8b229c-ed3a-4a90-85db-b085e5b77738">13</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5e2d35b46364527900ac62fe853f500_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMDc3_ee2f40b4-ca45-44ec-a21e-a9c74e9dc321">12</ix:nonFraction> million, respectively, of pre-tax compensation costs related to USPI&#8217;s management equity plans.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee stock purchase plan under which we are currently authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i98ed17ca8f424eddbb76511ce975b7d3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMjkz_cf8f48e4-4808-417f-82a6-c1340c605e04">4,070,363</ix:nonFraction> shares of common stock to our eligible employees. As of December&#160;31,&#160;2022, there were approximately <ix:nonFraction unitRef="shares" contextRef="i98ed17ca8f424eddbb76511ce975b7d3_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMzgx_032397b4-fb99-4897-b00a-0a4a6f1a5b18">2.6</ix:nonFraction>&#160;million&#160;shares available for issuance under our employee stock purchase plan. Under the terms of the plan, eligible employees may elect to have between <ix:nonFraction unitRef="number" contextRef="i4dea6f1094954116a3f68cf961f8ae89_D20220101-20221231" decimals="2" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExNTI4_ba3b061b-0266-4cbf-838b-54da9b87bf6f">1</ix:nonFraction>%&#160;and <ix:nonFraction unitRef="number" contextRef="i1ced06d52d0948f2b33cd7c96c19ac99_D20220101-20221231" decimals="2" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExNTM1_1a49a31a-6d6c-46b0-bc8f-e9fb33bd25b4">10</ix:nonFraction>% of their base earnings withheld each quarter to purchase shares of our common stock. Shares are purchased at a price equal to <ix:nonFraction unitRef="number" contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExNjY0_caa4386c-be1c-4c8a-8668-9c5cc0f9e125">95</ix:nonFraction>% of the closing price on the last day of the quarter. The plan requires a <ix:nonNumeric contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODky_26011a9c-3bce-4035-b711-d974d7843a47">one&#8209;year</ix:nonNumeric> holding period for all shares issued. The holding period does not apply upon termination of employment. Under the plan, no individual may purchase, in any year, shares with a fair market value in excess of $<ix:nonFraction unitRef="usd" contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231" decimals="INF" name="thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExOTU0_905e9e4d-1fa8-4cf4-92c0-5030a9cd6666">25,000</ix:nonFraction>. The plan is currently not considered to be compensatory.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODk1_0e00d9f9-cded-4229-906d-9d6d87a97d03" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued the following numbers of shares under our employee stock purchase plan:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzItMi0xLTEtMjkzNzEw_6554463a-c847-4233-891c-2dcd9a46efb0">98,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i826c719c694345cbbd09a505858f05cf_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzItNC0xLTEtMjkzNzEw_bed9baf6-20e6-4bb2-a111-c684431809e1">89,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5f1bdfc3e69496d9d0b8fad4f514056_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzItNi0xLTEtMjkzNzEw_16fb1601-fbfa-4f1d-9c69-e0f58a0f1263">254,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231" decimals="2" name="thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzMtMi0xLTEtMjkzNzEw_23caae4b-e822-4796-aabb-b4b9fcca56c7">54.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i826c719c694345cbbd09a505858f05cf_D20210101-20211231" decimals="2" name="thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzMtNC0xLTEtMjkzNzEw_df3e3141-2e70-472b-8a22-ec038bbc73ca">63.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5f1bdfc3e69496d9d0b8fad4f514056_D20200101-20201231" decimals="2" name="thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzMtNi0xLTEtMjkzNzEw_27663990-98ab-4ba1-9a06-31f14c965816">19.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Retirement Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our employees, upon qualification, are eligible to participate in our defined contribution 401(k)&#160;plans. Under the plans, employees may contribute a portion of their eligible compensation, which we may match with employer contributions at our discretion. Employer matching contributions will vary depending on which of our subsidiaries employs the participant and whether the employee is covered under a collective bargaining agreement. Plan expenses, primarily related to our contributions to the plans, were $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNTMz_9219e843-ef4a-4196-bcb2-751b315a44dd">86</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNTM3_a8f031ea-4923-4430-a52d-57baf81a3edf">98</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNTQ0_f117c3c5-cc04-4b25-b45f-69f8528b7e4d">119</ix:nonFraction> million for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively. Such amounts are reflected in salaries, wages and benefits in the accompanying Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain <ix:nonFraction unitRef="plan" contextRef="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231" decimals="INF" name="thc:NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNzI3_e26af8c3-3025-41cd-82ba-e3ede8e768c6">three</ix:nonFraction> frozen non&#8209;qualified defined benefit pension plans (&#8220;SERPs&#8221;) that provide supplemental retirement benefits to certain of our current and former executives. These plans are not funded, and plan obligations for these plans are paid from our working capital. Pension benefits are generally based on years of service and compensation. Upon completing the acquisition of Vanguard Health Systems, Inc. on October&#160;1,&#160;2013, we assumed a frozen qualified defined benefit plan (&#8220;DMC Pension Plan&#8221;) covering substantially all of the employees of our Detroit market that were hired prior to June&#160;1,&#160;2003. The benefits paid under the DMC Pension Plan are primarily based on years of service and final average earnings. During the year ended December&#160;31,&#160;2019, the Society of Actuaries issued a new mortality base table (Pri&#8209;2012), which we incorporated into the estimates of our defined benefit plan obligations beginning December&#160;31,&#160;2019. During the year ended December 31,&#160;2020, the Society of Actuaries issued the MP-2020 mortality improvement scale, which we incorporated into the estimates of our defined benefit plan obligations at December 31,&#160;2020. During the year ended December 31,&#160;2021, the Society of Actuaries issued the MP&#8209;2021 mortality improvement scale, which we incorporated into the estimates of our defined benefit plan obligations at December&#160;31,&#160;2022 and&#160;2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="iaa2577c0560745feadccf40071d8ffec" continuedAt="i5c4181d4d39a4c04b8f79594fb421f86"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTIy_44638cb4-a0b0-4b67-85ba-2277d6c35483" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet impact, as well as the benefit obligations, funded status and rate assumptions associated with the SERPs and the DMC Pension Plan based on actuarial valuations prepared:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzQtMi0xLTEtMjkzNzEw_8f010291-01f5-4512-b83a-ed92519d07b5">1,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzQtNC0xLTEtMjkzNzEw_6d260872-e07e-46b8-b892-a85be1909e8a">1,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzYtMi0xLTEtMjkzNzEw_917a0fc0-6f7c-493e-b2ef-f6a915542dd0">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzYtNC0xLTEtMjkzNzEw_eda94d87-714f-44d0-a7d1-cc0c95180351">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzctMi0xLTEtMjkzNzEw_2e024218-a662-405e-8649-aeac93b948c0">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzctNC0xLTEtMjkzNzEw_91f67fcd-9871-4012-9f70-99e646f65bd5">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:DefinedBenefitPlanBenefitsPaidOrEmployerContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzgtMi0xLTEtMjkzNzEw_1350ca81-e08f-4a44-ad13-3ab97ab610cc">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:DefinedBenefitPlanBenefitsPaidOrEmployerContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzgtNC0xLTEtMjkzNzEw_bb1b3f3d-ec29-431e-8f10-573e36c271b2">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEwLTItMS0xLTI5MzcxMA_1b60fae0-9719-45a9-b020-319c5dbccc89">1,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEwLTQtMS0xLTI5MzcxMA_960237d0-5b2a-4392-8901-560f13b227f8">1,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plans assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEyLTItMS0xLTI5MzcxMA_38126000-c5ab-4783-b0c1-53e6ce359794">867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEyLTQtMS0xLTI5MzcxMA_f1800f74-aedb-44f2-a779-950e72bfc458">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEzLTItMS0xLTI5MzcxMA_65f541b3-645d-4298-a71e-d172c42b2c4b">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEzLTQtMS0xLTI5MzcxMA_aabe6415-4450-4169-b191-d017b37a388f">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE0LTItMS0xLTI5MzcxMA_abdc2679-199a-459c-a365-de0aa236341c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE0LTQtMS0xLTI5MzcxMA_1dc69d3f-4374-47e1-85bd-bcb434e741aa">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE1LTItMS0xLTI5MzcxMA_359b5405-fe68-4bd3-b9fe-489c486aee16">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE1LTQtMS0xLTI5MzcxMA_6aeb7197-0fc0-411e-b14c-42eb34e988f0">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE2LTItMS0xLTI5MzcxMA_a7a25821-42ef-4145-93dc-3d456c67f6e4">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE2LTQtMS0xLTI5MzcxMA_ceba2c12-bc4c-4724-8af1-7a597a4c13a8">867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status of plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE3LTItMS0xLTI5MzcxMA_2c718ef2-314d-4cdb-b362-6acf3e440014">354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE3LTQtMS0xLTI5MzcxMA_a69c4381-e7dc-49e4-80b6-02081633b23d">446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The accumulated benefit obligation at December&#160;31,&#160;2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NDE0_9ce982e7-0fd9-4ee1-9662-ba2c44f9476e">1.002</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NDIx_db4ab266-7068-49ab-85d8-58ad4beceaee">1.311</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the Consolidated Balance Sheets consist of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIwLTItMS0xLTI5MzcxMA_2ce5cc1b-4867-4fd3-bd52-6b860569a5f8">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIwLTQtMS0xLTI5MzcxMA_a5fbf446-772e-4414-9a1c-c07159a28b98">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIxLTItMS0xLTI5MzcxMA_dc692143-0166-4482-b152-389c43f4687f">331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIxLTQtMS0xLTI5MzcxMA_62f413a8-c928-49b5-8273-924e38a29934">421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIyLTItMS0xLTI5MzcxMA_d114f477-14c8-4cee-abb5-5628adab8d82">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIyLTQtMS0xLTI5MzcxMA_057a050b-3e36-4e26-9aa3-4e7e45b63fb3">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SERP Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f46c6a3f87c4ea9a9fc91235eb3ce6d_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI1LTItMS0xLTI5MzcxMA_88ae2033-c10e-4f12-be24-da6bbcae093c">5.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9911fb6980184642b2b91df127e81577_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI1LTQtMS0xLTI5MzcxMA_d286aacb-c532-43f0-979d-79e971230785">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f46c6a3f87c4ea9a9fc91235eb3ce6d_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI2LTItMS0xLTI5MzcxMA_4ac0d9cd-18c7-4857-b51d-b446face6f31">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9911fb6980184642b2b91df127e81577_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI2LTQtMS0xLTI5MzcxMA_499bcf32-f901-4a5b-aeb0-c22522e23a74">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMC Pension Plan Assumptions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e71186460e94813b374c45bf631f9e4_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzMwLTItMS0xLTI5MzcxMA_1a1ae6fc-6556-4add-a76c-0494b806012d">5.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1714de0eddf4a14b7a6a4d8e217cf42_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzMwLTQtMS0xLTI5MzcxMA_eeabb162-2b20-4027-b239-fb2a399503a9">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i5c4181d4d39a4c04b8f79594fb421f86" continuedAt="ib15ecaf88a7c4e27a7ad5ee0458dcec4"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTMx_1305fd37-8f09-42ed-9871-5c10868d2fbd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit costs and related assumptions are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMC0xLTEtMjkzNzEw_4f483039-27bc-4155-b76a-ffda72e9e3f6"><ix:nonNumeric contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" name="thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMC0xLTEtMjkzNzEw_6546235e-9b3a-48e8-9070-9732a68b44a6"><ix:nonNumeric contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" name="thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMC0xLTEtMjkzNzEw_70f7842c-e8c2-4a9c-8fb0-26721e2a1a09">Interest costs</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMi0xLTEtMjkzNzEw_8781c283-d7ce-449a-b214-cd7525a88026">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtNC0xLTEtMjkzNzEw_d20ef1a8-dcfc-46fa-94ef-6099b14bac8d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtNi0xLTEtMjkzNzEw_f3dc9d28-5741-441a-9a2d-9f0fc2fd06ea">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" name="thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMC0xLTEtMjkzNzEw_091b37a6-9a6c-43a7-8537-037162ea23bf"><ix:nonNumeric contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" name="thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMC0xLTEtMjkzNzEw_a83c63be-d50c-4087-9d49-c1826c34a5e3"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMC0xLTEtMjkzNzEw_add8dc48-a4f8-4c97-9306-a0a8d2417ca4">Expected return on plan assets</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMi0xLTEtMjkzNzEw_e63acf81-91d8-49cb-bd86-cd3cedfff61e">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtNC0xLTEtMjkzNzEw_31a89247-cfda-4a17-aeab-87eeb8980261">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtNi0xLTEtMjkzNzEw_b6145e96-fc59-456b-9468-9fdc85fb85fe">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzUtMi0xLTEtMjkzNzEw_fe87caa7-9ac2-4db0-89c2-9a4ab536f449">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzUtNC0xLTEtMjkzNzEw_696d6886-365d-4b07-88d7-890bda4e0efa">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzUtNi0xLTEtMjkzNzEw_fa1489e5-7fa8-4a2d-8d65-a573c5827bc5">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzctMi0xLTEtMjkzNzEw_2c3f833e-6e08-40cf-a8b9-95105ed6217c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzctNC0xLTEtMjkzNzEw_33b36df4-8631-4ad1-87ba-f7a68543f031">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzctNi0xLTEtMjkzNzEw_914dc007-0af2-4e70-b2ea-1b11f3e39420">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SERP Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEwLTItMS0xLTI5MzcxMA_d2230dc1-0990-4b71-975f-6d27f85b2603">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8494255e124249a0a3eeafe8a1ec5580_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEwLTQtMS0xLTI5MzcxMA_d6016acf-a132-40d4-955c-a317b32a7cb0">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39222fbfc5de44bcbd66b5dd47d6c432_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEwLTYtMS0xLTI5MzcxMA_50dbbe68-e983-4d18-8afb-08f7aed89de0">3.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEyLTItMS0xLTI5MzcxMA_9e8754a5-107b-4d2f-9065-7d7efb6dadbf">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8494255e124249a0a3eeafe8a1ec5580_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEyLTQtMS0xLTI5MzcxMA_f4bc1b7f-c73e-4221-beaa-822190589a74">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39222fbfc5de44bcbd66b5dd47d6c432_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEyLTYtMS0xLTI5MzcxMA_efb5e7d3-aa2d-42d1-a845-c3e25fa91a51">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Census date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMC Pension Plan Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7214f3a35494e78a472ea44db915760_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE3LTItMS0xLTI5MzcxMA_7642df62-1fbd-4260-b111-73e0d416c25a">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f659dcb43db4e5299ae2bd34817319b_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE3LTQtMS0xLTI5MzcxMA_140518a5-bcd9-4e3d-957f-a87c6cc7fe6c">2.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a0335a3b4cd4570916a79350e8b8301_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE3LTYtMS0xLTI5MzcxMA_6e259220-812b-4d39-ad80-2a3385a5834f">3.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term rate of return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7214f3a35494e78a472ea44db915760_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE4LTItMS0xLTI5MzcxMA_25408b24-000b-4a7b-b04a-29b09a1c2263">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f659dcb43db4e5299ae2bd34817319b_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE4LTQtMS0xLTI5MzcxMA_9b7d7461-0be3-40c3-ac3b-6fc41d395757">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a0335a3b4cd4570916a79350e8b8301_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE4LTYtMS0xLTI5MzcxMA_9e17eec6-ec30-4c43-b0f5-978a1b92978b">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Census date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the current year are based on assumptions determined at the valuation date of the prior year for the SERPs and the DMC Pension Plan.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded gain (loss) adjustments of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NzI2_bee3530d-df9e-4bbf-8bea-cdf589de281d">72</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NzMw_b09fcc7f-8647-4438-9059-4cce2268626e">61</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NzM3_5c4c00af-881b-4711-bed4-e30dc40f90d9">32</ix:nonFraction>)&#160;million in other comprehensive income in the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, to recognize changes in the funded status of our SERPs and the DMC Pension Plan. Changes in the funded status are recorded as a direct increase or decrease to shareholders&#8217; equity through accumulated other comprehensive loss. Net actuarial gains (losses) of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MDA2_3260baed-c7a8-4b3d-89bd-a142c604c601">63</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MDEw_2840c64e-5789-442a-bf49-ec877e2a5f3b">50</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MDE3_aa3bf9e1-e56c-49c9-9617-40ff210b0068">41</ix:nonFraction>)&#160;million were recognized during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, and the amortization of net actuarial loss of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MTM0_ab124fd9-3891-4716-9913-1b960c9062f4">9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MTM4_eae1fa4d-6ced-408c-865d-0df3a796a3df">11</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MTQ1_2b414406-9387-4b54-bf7f-33b0d4a018f5">9</ix:nonFraction>&#160;million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively, were recognized in other comprehensive income. Actuarial gains affecting the benefit obligation during the years ended December&#160;31,&#160;2022, 2021 and 2020 are primarily attributable to changes in the discount rate utilized for the SERP and DMC Pension Plan. Cumulative net actuarial losses totaled $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDMx_7279c2df-7ccd-4adb-9ba0-e76c39463013">222</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDM1_b1928d5e-edcd-4a74-b67d-23c790e538a5">294</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDQy_2b742573-0f1a-4b0a-84b4-e78e94dc572d">355</ix:nonFraction> million as of December&#160;31,&#160;2022, 2021 and 2020, respectively. There were <ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="INF" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNTQ5MjA_73770634-416b-4fbd-8148-e64232bd03bb"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="INF" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNTQ5MjA_9bb1be77-c93c-4645-9a57-78acd5469ad6"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="INF" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNTQ5MjA_d2b52b53-080a-47f6-ada9-605b6fdc2251">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> unrecognized prior service costs at December&#160;31,&#160;2022, 2021 and 2020 that had not yet been recognized as components of net periodic benefit cost.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop the expected long&#8209;term rate of return on plan assets assumption, the DMC Pension Plan considers the current level of expected returns on risk&#8209;free investments (primarily government bonds), the historical level of risk premium associated with the other asset classes in which the portfolio is invested and the expectations for future returns on each asset class. The expected return for each asset class is then weighted based on the target asset allocation to develop the expected long&#8209;term rate of return on assets assumption for the portfolio.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTI1_acd3f092-cbdb-4ebe-8d0d-910737589c4c" escape="true"><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average asset allocations by asset category as of December&#160;31,&#160;2022, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8470639b4b74ccb87974669a576a9a9_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzEtMi0xLTEtMjkzNzEw_1a7a6f83-c5b0-4a70-807e-033b62e1df6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8470639b4b74ccb87974669a576a9a9_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzEtNC0xLTEtMjkzNzEw_7992a3e6-136e-43c4-a26c-58dd13772726">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzMtMi0xLTEtMjkzNzEw_65a33db6-715e-4b84-911e-d89110392a5e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzMtNC0xLTEtMjkzNzEw_0ce68801-8174-4ecc-a70f-e6bc2f93e806">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7db9aaa63ebf4a2c9985af6bf21ba265_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzQtMi0xLTEtMjkzNzEw_2ea0aaf3-2342-4089-82cf-3c38f81f8a63">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7db9aaa63ebf4a2c9985af6bf21ba265_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzQtNC0xLTEtMjkzNzEw_726bde14-d3fb-46e6-aa84-ee2a9f981930">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b14503d12cd4ff1a8738f04383e21c5_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzUtMi0xLTEtMjkzNzEw_017927ab-3a7e-4c2e-8859-07c16d95887a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b14503d12cd4ff1a8738f04383e21c5_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzUtNC0xLTEtMjkzNzEw_144dbbe1-414e-4ad2-a19d-471e1b756e46">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DMC Pension Plan assets are invested in public commingled vehicles, segregated separately managed accounts, and private commingled vehicles, all of which are managed by professional investment management firms. The objective for all asset categories is to maximize total return without assuming undue risk exposure. The DMC Pension Plan maintains a well&#8209;diversified asset allocation that meets these objectives. The DMC Pension Plan assets are largely comprised of cash and cash equivalents, including but not limited to money market funds and repurchase agreements secured by U.S. Treasury or federal agency obligations, equity securities, including but not limited to the publicly traded shares of U.S. companies with various market capitalizations in addition to international and convertible securities, debt securities including, but not limited to, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ib15ecaf88a7c4e27a7ad5ee0458dcec4" continuedAt="i3ab538e476b3479ea13a93f2a9a57de4"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">domestic and foreign government obligations, corporate bonds, and mortgage&#8209;backed securities, and alternative investments. Alternative investments is a broadly defined asset category with the objective of diversifying the overall portfolio, complementing traditional equity and fixed&#8209;income securities and improving the overall performance consistency of the portfolio. Alternative investments may include, but are not limited to, diversified hedge funds in the form of professionally managed pooled limited partnership investments and investments in private markets via professionally managed pooled limited partnership interests.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each investment account, the DMC Pension Plan investment managers are responsible for monitoring and reacting to economic indicators, such as gross domestic product, consumer price index and U.S. monetary policy that may affect the performance of their account. The performance of all managers and the aggregate asset allocation are formally reviewed on a quarterly basis. The current asset allocation objective is to maintain a certain percentage within each asset class allowing for deviation within the established range for each asset class. The portfolio is rebalanced on an as&#8209;needed basis to keep these allocations within the accepted ranges.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as quoted prices for similar assets, interest rates and yield curves. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:ScheduleOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTI2_4fd66ca7-bb5a-4251-a161-e26ebc91ccbb" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the DMC Pension Plan assets measured at fair value on a recurring basis as of December&#160;31,&#160;2022 and 2021, aggregated by the level in the fair value hierarchy within which those measurements are determined.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8470639b4b74ccb87974669a576a9a9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtMi0xLTEtMjkzNzEw_cc9ec3a5-a668-4612-ab07-1c69f59ea05b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804714da76e641858c08fb5432ea37ae_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtNC0xLTEtMjkzNzEw_7f8d4f8d-4284-46a9-8b26-d4f46c00ea92">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a67fa33749c43db986a0beb057d4ac7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtNi0xLTEtMjkzNzEw_9641cdc2-35d7-42a4-9021-e14efb345040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454a85da8698479a8e723e2cce4a6296_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtOC0xLTEtMjkzNzEw_a393179c-7307-46f2-839a-4eee2a73ac07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItMi0xLTEtMjkzNzEw_e64ec16a-8d7e-4a22-bef7-8b7eb45c82ac">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6628865c9e54cb59a13c1563d995f42_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItNC0xLTEtMjkzNzEw_0f250a39-e62b-447e-97fa-e1e8a656cfb9">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a91a77e3d24e61a737e24af4f558eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItNi0xLTEtMjkzNzEw_f49ececb-1768-4e12-a999-2435bb3c7cb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8ac7ec5a3745248b611c964292857b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItOC0xLTEtMjkzNzEw_ebd495c7-7390-4c49-94c5-48c10434c44e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49284b149a704d88bdc9d6e996c457e0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtMi0xLTEtMjkzNzEw_88a0762f-5890-4737-b21c-cb1d6373ec6c">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2b5e26a8054b03b96aa3a7fbeb79ed_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtNC0xLTEtMjkzNzEw_b2cde2e1-aee5-4ace-9db2-1e949a18c296">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9ca9d71ea74bd0a7deec85ce36524a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtNi0xLTEtMjkzNzEw_85a0ab11-cf9a-4078-aaa6-bf0de2aaee91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e43f8ced2d426988a867fc0f0b14c2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtOC0xLTEtMjkzNzEw_c7ba0b2d-b980-491d-8732-bec2e4950fe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b87a25e42b480aac87219815bac866_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtMi0xLTEtMjkzNzEw_8e3549ed-a3dc-4c0e-b660-018029ded696">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93c45adbd6e4f78b04ad5d1b90243b5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtNC0xLTEtMjkzNzEw_6f8c1062-afa3-47e2-ac19-17365e541619">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285ab10c7ac148e38a100d1ad2af2744_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtNi0xLTEtMjkzNzEw_357969f8-f71e-446b-8330-a3b3a6d20cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94c4bf4ebf248dc96407cf574d23a82_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtOC0xLTEtMjkzNzEw_5ee590c3-90b9-47ba-8c2e-55b2b775dbd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166be3168d7f4ac7b806eb76ded856f0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctMi0xLTEtMjkzNzEw_fab7f402-832e-468d-873f-621db739e679">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9280afba054c2f84e6e536996e9a74_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctNC0xLTEtMjkzNzEw_e38a4eba-8c69-4977-baad-12c1d9262fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f9676a3338438bbcb6a0fc6b10f019_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctNi0xLTEtMjkzNzEw_b12aee82-c4a5-447e-b02b-8431c5dcff2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae60f4fa3854826b47d1a2b21ed0e58_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctOC0xLTEtMjkzNzEw_f9e4a6af-340e-4097-a9e9-d45ebd35f826">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5b28459d0dc443289dbd7f5a11180a1_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktMi0xLTEtMjkzNzEw_359a4192-ff47-4982-a22f-2c3cd1a60fa7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d79b4c21364b1e8d5b7aafdc463a8f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktNC0xLTEtMjkzNzEw_982986df-ba29-468b-8a35-de17204c1ad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2315eeff4c34c5b9d914e09c1031bdd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktNi0xLTEtMjkzNzEw_e1d16b28-b4a0-40d6-9995-0539a037c145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89da8ec516bc4c688a3f2e4138bd9130_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktOC0xLTEtMjkzNzEw_887457a7-99f5-4ab1-96f9-5afcfbea6eac">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e71186460e94813b374c45bf631f9e4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTItMS0xLTI5MzcxMA_bfd43554-b4d7-4d8f-8c5a-6856c7135c28">648</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042c29b651e9422c9c3b8fc7734703e7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTQtMS0xLTI5MzcxMA_a0c77f0e-f7ab-42dc-9f54-35474b1bf5ab">545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f58b7435b945b38eab242b75e7de88_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTYtMS0xLTI5MzcxMA_795cbc79-ab24-4adb-a671-ec8b22ac9663">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9461354d8d8d47dd881117ff98a3af8b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTgtMS0xLTI5MzcxMA_2d67fda8-4a5e-4043-883c-937044d46328">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c31677d6754a34bd494423b74a602e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtMi0xLTEtMjkzNzEw_712fab2e-340b-4c1b-a865-2df0cc78ddb3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2286f8106dae40a78e46d44361f52c75_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtNC0xLTEtMjkzNzEw_af68b784-90b4-4ee3-812b-a54823c8470d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9ea6ae06b14e35bad5e2ca1e409fde_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtNi0xLTEtMjkzNzEw_ca8a00eb-1bf5-4ad8-abc6-1cbc9d9d2789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af6470ab1cb4bff9fe84140822865d5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtOC0xLTEtMjkzNzEw_e0fe7013-0b84-4cab-9a5c-fb188475235e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if199fa14f8c442b6b5a44ca21380346d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItMi0xLTEtMjkzNzEw_8a4c3367-211f-4b21-ba14-567d63c1122c">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f72100695fc4f70b93df4bc5ca16207_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItNC0xLTEtMjkzNzEw_a818f998-aa50-473a-ba57-bc2c97c16a7c">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bdcec982d2405ab478007ab8e9cf72_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItNi0xLTEtMjkzNzEw_9cb33408-cead-43cf-b628-e00608041d96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cea09136b94497abde3744de16ffbb1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItOC0xLTEtMjkzNzEw_6da09937-3c9b-415c-8543-6d1221352198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7173e0e014de1934a570e1112af04_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtMi0xLTEtMjkzNzEw_02f11322-336c-4dfe-8fac-2754e3774008">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5bb9664ade472286428ea8e0f32595_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtNC0xLTEtMjkzNzEw_7f2f0bd6-6aad-4229-bf03-e2ec71ef3641">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2c8dfd6d53454598ef5cc59f8493f1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtNi0xLTEtMjkzNzEw_3847c489-d984-4258-89b7-eff85c7437ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6833358c1d6741f7a2f16c63211b57f3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtOC0xLTEtMjkzNzEw_472c5bb8-da7c-4b6e-b3a2-a36a4781b73d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c06dc18705542b1b0f4578035465c35_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtMi0xLTEtMjkzNzEw_050a9c7e-f92d-4980-8ef6-85bba6ac5f2c">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d50cbc9ad614ba59c37a5e12995c52a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtNC0xLTEtMjkzNzEw_3b44fa58-8b2c-4ccc-912c-deb68b488a37">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55523ac8a4c49a4b496cb9c6bc21731_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtNi0xLTEtMjkzNzEw_291f45b1-4411-457b-b347-724679b4c49a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6551b57d1e4468b0725e4877eb3d2a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtOC0xLTEtMjkzNzEw_cc0830ad-4729-4c2a-bd81-4088b8e680e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if415ffa4ddcd4d20b4d45d7405511cef_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctMi0xLTEtMjkzNzEw_a6dedeb0-81b2-4f2c-8781-b30924d749fd">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631c47e1f244bdd9e1c8d3c5f70454a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctNC0xLTEtMjkzNzEw_6c1779c6-a81b-41f2-b02d-aaf9f9dcfa5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63b9feebb74020bb298b5272d2cb91_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctNi0xLTEtMjkzNzEw_1194af0a-2250-4d5e-aa9c-10d5d31409e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686e590299944c6c873a2b143fb8bc32_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctOC0xLTEtMjkzNzEw_bf934639-3252-470e-841c-d34c7106c0c2">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800184fe85bb47b5a889821fbb17e7e9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtMi0xLTEtMzI1MDU3_8e286411-db81-40ce-9c93-82411f1ff316">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585ae55410ba4bf0b908db0bc2194a89_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNC0xLTEtMzIwODgx_86b226ae-4641-4628-976c-d50aafe5089c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea4687cc2d24bd4be9ac86b4b9f8bed_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNi0xLTEtMzIwODgx_1bc42207-5fcf-4f21-81a2-fd001c59cd29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e833d841f1a420ba5b7b46bc27b98cb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtOC0xLTEtMzIwODgx_f03392d4-7229-49b4-ac63-c7fe0d561a55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6531ba19db2c480e8abe335385484440_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtMi0xLTEtMjkzNzEw_f5ca4e90-2057-468a-9823-f2604c6a6a41">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc97a4820c542d4bf607e57b51505a9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNC0xLTEtMjkzNzEw_25cec06b-aafd-4a41-8df3-4108d1bb28ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8cbfe439eef4938941ac808a39e48b8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNi0xLTEtMjkzNzEw_e31c3710-cf29-4725-a712-822f594f181d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaadb2472f2014a5b80d77c42eb1bf932_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtOC0xLTEtMjkzNzEw_88cbb9ef-f464-4390-be2a-7274e9b2d1dd">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1714de0eddf4a14b7a6a4d8e217cf42_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktMi0xLTEtMjkzNzEw_6f4aa374-e1dc-45e0-82fd-c0edbe5efc58">867</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac9538659da4c918abe6bc8330da9fb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktNC0xLTEtMjkzNzEw_379b502c-85a8-4e99-b3e8-40fe8554cb92">784</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54ea2398cb64048a475a0c8781dcff2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktNi0xLTEtMjkzNzEw_10417b12-9a4e-4746-b592-a1b34f5a47bd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0650b7b45a99449c9af4ff648257c831_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktOC0xLTEtMjkzNzEw_1fb96b20-688a-443b-8783-c5208136ee3d">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODk2_c1616679-9abe-4e25-9855-4487a50dfe06" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future benefit payments to be made from the SERPs and the DMC Pension Plan, a portion of which will be funded from plan assets, for the next five years and in the aggregate for the five years thereafter:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.975%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending&#160;December&#160;31,&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Five Years Thereafter</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DefinedBenefitPlanExpectedFutureBenefitPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMi0xLTEtMjkzNzEw_ef9e3798-29ca-436a-9ded-39fdfdf26384">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItNC0xLTEtMjkzNzEw_01454eff-b215-445f-93de-a7819ab131f5">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItNi0xLTEtMjkzNzEw_91ea0193-2bf4-46fa-a8b7-ce02b023b42f">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItOC0xLTEtMjkzNzEw_c5f04477-9afa-4489-8a8a-63a6e56bf9a3">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMTAtMS0xLTI5MzcxMA_72e8a2d3-6d1c-4b6a-bd87-160db30f88f6">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMTItMS0xLTI5MzcxMA_9173279f-39e0-4643-9a75-01a5a9d8d898">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMTQtMS0xLTI5MzcxMA_1600d0de-04e0-4bcc-bc5e-ac600d2b153f">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3ab538e476b3479ea13a93f2a9a57de4">The SERP and DMC Pension Plan obligations of $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5NTYy_d743c679-0f51-4779-966c-0e46a10c23d8">354</ix:nonFraction>&#160;million at December&#160;31,&#160;2022 are classified in the accompanying Consolidated Balance Sheet as an other current liability of $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5NjY2_75ecec26-2b9f-4e83-826a-3730cd7c89a4">23</ix:nonFraction> million and defined benefit plan obligations of $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5NzA5_3893fe8c-d6fa-48f1-8934-6b042e5c569d">331</ix:nonFraction>&#160;million based on an estimate of the expected payment patterns. We expect to make total contributions to the plans of approximately $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODM1_a96edd8d-6b8a-44c1-9771-ffb3487bf5c9">23</ix:nonFraction>&#160;million for the year ending December&#160;31,&#160;2023.</ix:continuation></span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_226"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzI3MA_40a3b2ed-e424-4912-84a9-8211236a8146" continuedAt="i95ca1e52a5c8440884476f23aeee3589" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i95ca1e52a5c8440884476f23aeee3589"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzI3Mg_fa59e874-8003-4a74-b3c8-64042d86221b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of property and equipment are shown in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2fd93f349c4e4c9ddc4ef367845986_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzItMS0xLTEtMjkzNzEw_86cedbc1-c7c3-4e9c-b96d-64e4177bda29">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbf92bb89634290b801e88029d92389_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzItMy0xLTEtMjkzNzEw_0bf4a89f-c1d9-4392-94f4-f7b7da3ed699">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b511b7a489f423484bdb8a101ff9a36_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzMtMS0xLTEtMjkzNzEw_30263278-a821-4b3d-804e-94982efd6c0c">6,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb29332c7e349048cbb4839508b6add_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzMtMy0xLTEtMjkzNzEw_dfbe3c84-3ef4-466b-8b75-3d4bebe3e754">6,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43e7382c8b743a7b9f53c2d06e8305a_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzQtMS0xLTEtMjkzNzEw_4d1efc61-fb2f-4d27-ba08-9b32b9d361b3">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca722478f4d4353be6a7b1b4eb2b7e9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzQtMy0xLTEtMjkzNzEw_34bcc43a-c581-408d-94c5-89266a1809ff">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4130035b4ffb4b2b9759276d80640702_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzUtMS0xLTEtMjkzNzEw_9e30c512-d1a3-4a49-bb94-1eb848e611b5">4,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4086403e4e54685aed1e1243c892e5e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzUtMy0xLTEtMjkzNzEw_46cf2499-6724-45a5-a654-04495dbf9301">4,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzYtMS0xLTEtMjkzNzEw_a801e1a5-1af6-4259-a990-e8522ebdb982">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzYtMy0xLTEtMjkzNzEw_230e2fbf-66a5-4a93-a4b9-a68d2ed17783">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzctMS0xLTEtMjkzNzEw_48388e89-233e-459b-9664-c8bd99382227">12,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzctMy0xLTEtMjkzNzEw_42faf0be-c4b1-4597-b34e-dd92edf42db6">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzgtMS0xLTEtMjkzNzEw_38b120bb-ec7f-47de-abb0-cab7993bdc15">6,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzgtMy0xLTEtMjkzNzEw_c2874965-8431-4c60-906b-b7aaa369b5c5">5,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net property and equipment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzktMS0xLTEtMjkzNzEw_647f2da3-3b55-4901-b7ab-5ad65505f54e">6,462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzktMy0xLTEtMjkzNzEw_e16e1ba2-c65f-4d35-b012-84cac76d2f9f">6,427</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation and amortization and impairment write&#8209;downs related to assets held and used. We recognized depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzU0OTc1NTgxNDc1NA_2aac11f5-e209-49b3-9e69-f6b0c7074c6b">669</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzU0OTc1NTgxNDc2NA_c073d07e-886a-4a81-9fa3-7e683b805768">667</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzU0OTc1NTgxNDc3MQ_5c4160a4-c5fc-4e3b-a7fe-e06b2f7efe55">685</ix:nonFraction> million in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_229"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc2Mg_d4bae254-95c5-43f0-9961-126fd2363790" continuedAt="i42bbb3ae079a434cae4f4e7e8d82fbf5" escape="true">GOODWILL AND OTHER INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i42bbb3ae079a434cae4f4e7e8d82fbf5" continuedAt="i2b21ee221030438baf53ac1148b7216a"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc2Nw_f2e5013f-ef62-43da-9770-04ee49927336" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzQtMS0xLTEtMjkzNzEw_8965be94-91fc-4363-b011-daa6a6065f84">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if474534dcafd415d9534dbb0774b811e_I20201231" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzQtMy0xLTEtMjkzNzEw_fc25ebe7-0fba-432b-807c-cfbe6bfb512c">5,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzUtMS0xLTEtMjkzNzEw_390b327c-162c-47c4-b6f1-784f6318f604">2,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if474534dcafd415d9534dbb0774b811e_I20201231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzUtMy0xLTEtMjkzNzEw_19504b72-18c3-407b-bbf5-642fb94b447a">2,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzYtMS0xLTEtMjkzNzEw_1774b6c2-74e4-4f8c-9e78-6762daa19ad4">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if474534dcafd415d9534dbb0774b811e_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzYtMy0xLTEtMjkzNzEw_400d8499-fd6c-4f58-9323-88b674faccf7">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year and purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMS0xLTEtMzUyMzg5_b7456b13-a892-4bfe-ab61-b73a1f932651">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMy0xLTEtMzUyNDE3_ca96f8c1-23f6-4e3c-abc5-a774a504d899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill transferred from Ambulatory Care segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillTransfers" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMS0xLTEtMjkzNzEw_d89a8e7c-c9aa-4437-a9de-4dc87d133a5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMy0xLTEtMjkzNzEw_8e668c1d-425d-4770-997b-5bdd525ef03b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill related to assets held for sale and disposed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" sign="-" name="thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzgtMS0xLTEtMjkzNzEw_53725c1a-c0e7-4253-94bf-db8edf355576">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" sign="-" name="thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzgtMy0xLTEtMjkzNzEw_0f0d023e-1dd2-48a6-a2f9-6958e9d6fad8">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzktMS0xLTEtMjkzNzEw_7cda4d54-4c5c-439e-933b-9d21c3a2efff">2,806</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzktMy0xLTEtMjkzNzEw_87d9cc78-3969-45f7-b7ed-c5f96b6e2649">2,808</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at end of period:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEyLTEtMS0xLTI5MzcxMA_6b9c07fa-2a15-4df4-8162-9d2249947fee">5,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEyLTMtMS0xLTI5MzcxMA_e6ad03b3-ee9f-46c1-98f0-77e623e8a0aa">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEzLTEtMS0xLTI5MzcxMA_c6089ae0-e150-4311-96a7-f00387667f3c">2,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEzLTMtMS0xLTI5MzcxMA_b18f9d59-ccc7-4ed1-a1a4-5b408f3f5707">2,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE0LTEtMS0xLTI5MzcxMA_c364e171-be81-4b00-90a6-1d11f7d9c030">2,806</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE0LTMtMS0xLTI5MzcxMA_6338afdc-2f21-4cc6-863e-1e8954869924">2,808</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE3LTEtMS0xLTI5MzcxMA_d001a0b8-ab18-4551-a428-e935078587a3">5,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE3LTMtMS0xLTI5MzcxMA_54697c5e-4a88-4697-a227-99ff9ac2812a">5,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year and purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE4LTEtMS0xLTI5MzcxMA_225d9b0f-36d1-43e1-91a8-ac19cbdc6f7f">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE4LTMtMS0xLTI5MzcxMA_632ff58b-c44a-4879-a54b-af203499b957">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill transferred to Hospital Operations segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillTransfers" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE5LTEtMS0xLTI5MzcxMA_7885cfbe-2dec-4240-a6f8-5cb8c22a391a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE5LTMtMS0xLTI5MzcxMA_050d45c9-4f85-4c07-875d-9df433a9888f">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill related to assets held for sale and disposed or deconsolidated facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" sign="-" name="thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIwLTEtMS0xLTI5MzcxMA_ecfdcbf9-b513-4be7-bc80-66726e271769">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" sign="-" name="thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIwLTMtMS0xLTI5MzcxMA_f7f7c99f-8522-45b7-81d1-7b370f31f400">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib165a084700643e1b139d15df43a3b15_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIxLTEtMS0xLTI5MzcxMA_bd569a6c-41c7-4340-b568-afa307f8cf8e">6,712</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIxLTMtMS0xLTI5MzcxMA_94cc5697-bdf9-405f-a57f-d5e683587ef8">5,848</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI0LTEtMS0xLTI5MzcxMA_341c3e60-6576-45ac-b4ed-b2d36cd59f39">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI0LTMtMS0xLTI5MzcxMA_5201891c-77e9-40d6-add2-511f759104df">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI3LTEtMS0xLTI5MzcxMA_102f36af-173d-4330-8744-ce12918f2a79">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI3LTMtMS0xLTI5MzcxMA_07c982b5-7795-406e-bf0c-868afd2f9a80">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_300d8f5c-dde9-482f-84c0-2f10c08615e5"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_5229596d-a503-4e20-8e5e-567f8beac5ba"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_6cfaf57d-d7a1-4db3-96e2-d54d47359344"><ix:nonFraction unitRef="usd" contextRef="ib165a084700643e1b139d15df43a3b15_I20221231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_aa4a56c8-68ce-4ab5-8c0f-807b708a0ed4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> accumulated impairment losses related to the goodwill in our Ambulatory Care and Conifer segments at December&#160;31,&#160;2022 and 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i2b21ee221030438baf53ac1148b7216a"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc2MQ_bef24e48-b2b4-4e0d-b6dd-be8694cfccbe" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information regarding other intangible assets:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694630452a604fb9ad2d2c6646397326_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzItMS0xLTEtMjkzNzEw_ebf58bab-7ad8-4599-bde8-2c2a69d57321">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i694630452a604fb9ad2d2c6646397326_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzItMy0xLTEtMjkzNzEw_e80509ea-a10b-4a00-9603-f78b1af9d5e0">1,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694630452a604fb9ad2d2c6646397326_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzItNS0xLTEtMjkzNzEw_24cf702f-9377-4e10-bc75-80e3ba688a8d">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8655e44515147ea8a7957f6e984603a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzQtMS0xLTEtMjkzNzEw_4987a70c-04b2-40dd-bc69-8f94497b2598">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8655e44515147ea8a7957f6e984603a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzQtMy0xLTEtMjkzNzEw_28b497a6-dc3e-40e6-8fb0-ba14eaaca1e0">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8655e44515147ea8a7957f6e984603a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzQtNS0xLTEtMjkzNzEw_8f48c87d-e838-41fc-b1d9-e56b4c8e9da6">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb013137715473a8be5f4a83d7293f5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzUtMS0xLTEtMjkzNzEw_95d51c3c-2b33-4c56-982b-cf98da38493c">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb013137715473a8be5f4a83d7293f5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzUtMy0xLTEtMjkzNzEw_0e415929-2cde-49a3-903d-4715f7241c39">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb013137715473a8be5f4a83d7293f5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzUtNS0xLTEtMjkzNzEw_4509ea7b-a06e-4a4c-99b6-5ec706c79a28">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzYtMS0xLTEtMjkzNzEw_fa5277d7-8a97-48f2-a368-863eddd03d79">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzYtMy0xLTEtMjkzNzEw_75564df8-d11e-41ea-b651-97a7fce94b4c">1,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzYtNS0xLTEtMjkzNzEw_97b83bab-7731-46cf-a755-5e38d5eb5c43">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d0c6d3c86d49d0bae4aa0dd4b382e7_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTEtMS0xLTMyMDk3NA_4a2702e8-74d8-4eb0-806b-48ab623d0b39">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d0c6d3c86d49d0bae4aa0dd4b382e7_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTUtMS0xLTMyMDk3NA_dfc41ca3-3473-47da-8f71-399fc4fad443">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd09d196974cba90b5e722e01a984c_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTEtMS0xLTMyMTAwNQ_32e45e3b-ebea-4600-8951-b65232d69b3a">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd09d196974cba90b5e722e01a984c_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTUtMS0xLTMyNTA2Nw_f8196b06-6983-4962-8630-ff89e4fc11b8">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e94e8fb0af4f14add5061334e930e6_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzExLTEtMS0xLTMyMTAwNQ_a760ee8d-e7d1-45dd-b4d0-12ea21f3a0c3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e94e8fb0af4f14add5061334e930e6_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzExLTUtMS0xLTMyNTA2Nw_6ddd9bca-3b7f-4a3f-a948-74626981b8a0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEyLTEtMS0xLTMyNTA2Nw_e1099713-1eee-4c84-aa6c-0170b46c271e">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEyLTUtMS0xLTMyNTA2Nw_eca4f3be-24b1-4f80-a0a1-dd45639cb734">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEzLTEtMS0xLTMyNTA3Mw_9a7dcd94-5ea8-4eb3-b868-a0bcd8f16bcf">2,852</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEzLTMtMS0xLTMyNTA3NQ_8c35837e-e469-4ee9-a017-7e6c469ad002">1,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEzLTUtMS0xLTMyNTA3Nw_bd3a2861-9408-4fbe-965c-4f9c21b7f71a">1,424</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cce08bda3d542f198b8d18a883aec5c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE3LTEtMS0xLTMyMTA0OQ_3a13db85-2540-446d-806a-ed2e0a9da04a">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cce08bda3d542f198b8d18a883aec5c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE3LTMtMS0xLTMyMTA0OQ_eff4eb04-b3f2-41d9-83f2-5ee2a6ace616">1,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cce08bda3d542f198b8d18a883aec5c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE3LTUtMS0xLTMyMTA0OQ_2cb2985e-262a-457e-89a0-b2d27bd7bef2">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE4LTEtMS0xLTMyMTA1NA_9516e0ae-528b-4e90-899b-1709c7e42431">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE4LTMtMS0xLTMyMTA1NA_d1ea355e-c7e1-4a0b-a299-e9a7f4cbb3f3">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE4LTUtMS0xLTMyMTA1NA_eb3a272f-1658-475d-ae09-04271d641883">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865db5ff099a45238d86047cb5bf3f0c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE5LTEtMS0xLTMyMTA1NA_06192260-fbac-4402-b314-f6ddb59f5702">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i865db5ff099a45238d86047cb5bf3f0c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE5LTMtMS0xLTMyMTA1NA_35ea4de1-48ed-4e17-8063-e9deb9875d0d">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865db5ff099a45238d86047cb5bf3f0c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE5LTUtMS0xLTMyMTA1NA_dcdaecba-ddb0-4538-8d65-8abf9e0a78a4">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzIxLTEtMS0xLTMyNTA4NQ_1486e125-94f1-474f-947d-9cadf5ca4c35">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzIxLTMtMS0xLTMyNTA4NQ_4d0b5824-1210-4d5a-99a0-e10f6f59efa0">1,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzIxLTUtMS0xLTMyNTA4NQ_008cfe1e-1da6-4500-aac4-4d7955494146">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbb8dc0a34648caadf9b08b028a9c30_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI0LTEtMS0xLTMyMTA2OQ_f25f027c-0f4a-4865-99db-f780ab81abd4">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbb8dc0a34648caadf9b08b028a9c30_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI0LTUtMS0xLTMyNTA3MA_b6f7efda-5440-4528-9c48-624f57fe3b1a">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedac06e53ae3427382872dc1d8f25c8a_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI1LTEtMS0xLTMyMTA2OQ_f06005bd-9880-424e-be66-aa1d83ec0e03">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedac06e53ae3427382872dc1d8f25c8a_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI1LTUtMS0xLTMyNTA3MA_37a34872-541a-41a0-b28b-d0331e3e8d4f">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b58c9b298645b8821390d35d437e25_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI2LTEtMS0xLTMyMTA2OQ_b753f3de-6881-428a-9331-9673568ce723">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b58c9b298645b8821390d35d437e25_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI2LTUtMS0xLTMyNTA3MA_c43d7458-e855-4f4f-ac0c-18a9baa18873">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets with indefinite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI3LTEtMS0xLTMyNTA3MA_998e5b9a-91a4-42d0-9a84-802f416ea365">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI3LTUtMS0xLTMyNTA3MA_4ae96fad-4332-45aa-8be1-573f27f11fce">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI4LTEtMS0xLTMyNTA4Mw_11331bd0-212c-40fe-b211-bf4fed6fe120">2,871</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI4LTMtMS0xLTMyNTA4MQ_8ca0cd51-68c2-4cfa-89eb-1e5662e943ac">1,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI4LTUtMS0xLTMyNTA3OQ_55dd751e-df12-4449-9c0a-ebedcb4c2eee">1,497</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc1OQ_868ef784-92ae-4ee2-8432-368a84723c5a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future amortization of intangibles with finite useful lives as of December&#160;31,&#160;2022 was as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMS0xLTEtMjkzNzEw_b0561801-2e5a-42a1-9652-f9391485f8fc">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMy0xLTEtMjkzNzEw_76fec197-1fed-4c51-9987-cce2dcf5c06e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItNS0xLTEtMjkzNzEw_a241b5a6-f5d0-4b89-b85d-20eb02dc0fd6">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItNy0xLTEtMjkzNzEw_093e95da-6811-43bc-98bf-f99a25e1abdc">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItOS0xLTEtMjkzNzEw_91967e4b-4c31-4edc-9414-63edc14dd481">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMTEtMS0xLTI5MzcxMA_2e63b353-c09d-4440-9477-b57935a621fd">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMTMtMS0xLTI5MzcxMA_f8ee30be-7180-43aa-872c-b26d10894ac9">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzEwOTk1MTE2MjkzMTc_9c016977-93ad-4345-90ca-1649d5eea25f">172</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzY0MQ_99aa1d12-8e6a-4284-bc6a-6d7f723d6e7d">188</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzY0OA_903c0d13-5579-4c6f-ad20-051a87bc4a31">172</ix:nonFraction> million in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_235"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:OtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90ZXh0cmVnaW9uOmQ3NmUxMDdkZTNjODQwNjI5ZGIwM2NmZTVhZDg5YjhkXzMyOTg1MzQ4ODM5NjU_a97f1f9f-fc70-42ef-8baa-26a77f0de5c5" continuedAt="i28b389f0c9cb4d7b997dec312e92415d" escape="true">OTHER ASSETS</ix:nonNumeric></span></div><ix:continuation id="i28b389f0c9cb4d7b997dec312e92415d" continuedAt="i318a04fae16f47d1969a1845055685e7"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90ZXh0cmVnaW9uOmQ3NmUxMDdkZTNjODQwNjI5ZGIwM2NmZTVhZDg5YjhkXzMyOTg1MzQ4ODM5Njc_358f4aac-81e4-4a19-837c-a42d95d51d4c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of other current assets in the accompanying Consolidated Balance Sheets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzEtMi0xLTEtMzI5ODU3_aa811ef0-5875-456f-8608-33fc66261867">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzEtNC0xLTEtMzI5ODU3_fc776c7b-03b7-4fd9-a756-11b255bb939f">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzItMi0xLTEtMzI5ODU3_5eb18d3a-ce24-4748-957b-c52c90ea19d3">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzItNC0xLTEtMzI5ODU3_9e4b5395-ebf4-4cb9-b021-a63f8b7ee67f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California provider fee program receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83eeaae00cd442549c9edcc2dc638e9e_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtMi0xLTEtMzYyNjQy_da4e5310-6313-4390-a583-4189907b95b1">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib133b5b1591e4a4ea142acbda1961911_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtNC0xLTEtMzYyNjQ4_3030d07c-b1b7-4839-9e3c-cac540f4cab4">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from other government programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:ReceivablesFromGovernmentProgramsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzMtMi0xLTEtMzI5ODU3_e9318f4a-e52e-47d0-8671-c45b732aa943">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:ReceivablesFromGovernmentProgramsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzMtNC0xLTEtMzI5ODU3_86a28e9e-d388-4ac8-bb2d-057fc71bbace">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guarantees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:PhysicianAndGroupCoverageGuaranteesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtMi0xLTEtMzI5ODU3_24d6c5d0-6922-45b0-8a12-000ad313b0b5">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:PhysicianAndGroupCoverageGuaranteesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtNC0xLTEtMzI5ODU3_07542daf-bdc1-4e62-9dbf-91f22c2671cf">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-patient receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzUtMi0xLTEtMzI5ODU3_dd688f72-ed33-49c8-83fb-1133def4aee8">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzUtNC0xLTEtMzI5ODU3_30e5e054-f314-4882-9233-0fcad21c1424">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzYtMi0xLTEtMzI5ODU3_71f5ae6e-4aa4-4b91-8402-54a60d49dc9a">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzYtNC0xLTEtMzI5ODU3_1531b99d-7f30-4abc-a8d8-58d8c86a1b51">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzctMi0xLTEtMzMxNzE3_57afa752-9843-493a-9d96-9818245544db">1,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzctNC0xLTEtMzMxNzM1_6298111f-0141-4ae0-b047-d7bc52a7c7c8">1,557</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i318a04fae16f47d1969a1845055685e7"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:InvestmentsAndOtherNoncurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90ZXh0cmVnaW9uOmQ3NmUxMDdkZTNjODQwNjI5ZGIwM2NmZTVhZDg5YjhkXzMyOTg1MzQ4ODM5Njg_304e02f4-b024-4dc7-87c2-281596d4e081" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of investments and other assets in the accompanying Consolidated Balance Sheets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzItMS0xLTEtMjkzNzEw_7e7011ed-9b98-4f85-b9d5-cf0760ea9f94">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzItMy0xLTEtMjkzNzEw_2dd5fcb0-bf12-4e2a-b939-f746cb712f4b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments in unconsolidated healthcare entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzMtMS0xLTEtMjkzNzEw_9cfb9cd0-abd9-4a59-bf36-2fe6cd3d02cf">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzMtMy0xLTEtMjkzNzEw_99763e03-ff38-4de8-9550-413e79597e2a">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzQtMS0xLTEtMjkzNzEw_62867fa1-82d5-4c1c-950d-3cf34a392804">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzQtMy0xLTEtMjkzNzEw_767e1381-9c03-4a2b-bb01-fc4a4e0e3662">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:CashSurrenderValueOfLifeInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzUtMS0xLTEtMjkzNzEw_d2d50ddb-2ab3-4578-9cfd-a1ab3d7d7985">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:CashSurrenderValueOfLifeInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzUtMy0xLTEtMjkzNzEw_a694691d-2d69-4c26-8b38-6c4722d7c31d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DepositsAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzYtMS0xLTEtMjkzNzEw_488738eb-2b88-4cc9-a58e-5369ab955f47">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DepositsAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzYtMy0xLTEtMjkzNzEw_f1f7fb8f-5d4c-4dd3-9bda-ec1062d2502c">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California provider fee program receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzctMS0xLTEtMjkzNzEw_6f4f6bfd-dedc-45e3-a519-ed22c5b45911">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzctMy0xLTEtMjkzNzEw_395c5d87-7f6b-404d-94a8-32cd8ceea1ad">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzgtMS0xLTEtMjkzNzEw_7ddfce40-9732-43fd-aeb6-3998d20fd013">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzgtMy0xLTEtMjkzNzEw_8e999fc3-189f-4384-b10b-580d3c6dd2f2">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term receivables and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:OtherLongTermReceivablesAndOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzktMS0xLTEtMjkzNzEw_11a13a3c-996d-422a-8838-a5e47209ad1e">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:OtherLongTermReceivablesAndOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzktMy0xLTEtMjkzNzEw_cc9f3a52-63c0-4717-8f8e-be999ffa7bd7">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments and other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:LongTermInvestmentsAndReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzEwLTEtMS0xLTI5MzcxMA_b27da350-1cad-4c51-b806-6db90fb75381">3,147</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:LongTermInvestmentsAndReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzEwLTMtMS0xLTI5MzcxMA_d2f8f754-580f-4fd7-a621-2777b36b52cc">3,254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_238"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzI2MA_2056193e-dbb0-49ab-9867-efa566362e12" continuedAt="ie31edaa3267b4aaca729abb82be1eb17" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="ie31edaa3267b4aaca729abb82be1eb17"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzI1Ng_9c000996-9934-43c4-b437-eaf73948d6d6" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated other comprehensive loss was comprised of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for defined benefit plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1bb12b1893946248b9ab7b6cb8bc7dd_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzItMS0xLTEtMjkzNzEw_d2ed913f-2863-4d9b-8c1f-a43c1b03fe64">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72ff1d80e6bf43d59f82710f6d9d3b3a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzItMy0xLTEtMjkzNzEw_8691986b-eb27-4048-9df6-0746a389fe1f">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d397b0d9a54755805ebf13b24f0c3c_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzMtMS0xLTEtMjkzNzEw_5ecf9da5-6074-4843-9cfd-c5b8fd9b7018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48b6bbe6ee04e76973e637b31dbb932_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzMtMy0xLTEtMjkzNzEw_30d7c9dd-ede1-4397-a5fa-90dcbee350a5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5d591ea7d794a6bbfc70c45fa0ea665_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzQtMS0xLTEtMjkzNzEw_23d1a665-d52a-4703-92a9-e09b3868173d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic533c479212f454fa40f5a81863983fa_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzQtMy0xLTEtMjkzNzEw_d90086ec-b451-47d3-b035-c398abe619f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b72ce7a7f084592ab6d37729017b52f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzUtMS0xLTEtMjkzNzEw_7fc1d64a-52e4-4005-861d-5381e8f7071a">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a4aa1e6e88f4448ac550047af2e16de_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzUtMy0xLTEtMjkzNzEw_4293010c-37a4-40dc-ba25-6ec85234f96d">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) allocated to the adjustments for our defined benefit plans and unrealized gains on investments were approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzIwMQ_012e1602-1fe8-402e-a98c-6d45eaa1cfc0">18</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzQ5NDc4MDIzMjYyNDg_5c5c0c73-d065-4292-9d5e-62393024f8bf">1</ix:nonFraction>)&#160;million, respectively, for the year ended December&#160;31,&#160;2022, and the income tax expense allocated to the adjustments for our defined benefit plans was $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzIwOA_9a3b1c58-b039-40b9-a319-f41f15b0c79f">14</ix:nonFraction>&#160;million for the year ended December&#160;31,&#160;2021.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_241"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. <ix:continuation id="ifecac4242c0f4cb69f75859489e46b48" continuedAt="i194630ecaf06488088b8c34306eb3383">NET OPERATING REVENUES</ix:continuation></span></div><div style="margin-bottom:12pt;text-indent:36pt"><ix:continuation id="i194630ecaf06488088b8c34306eb3383" continuedAt="id61050f0ca0c4e8494751f2ec165e68d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.</span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="id61050f0ca0c4e8494751f2ec165e68d" continuedAt="i0288e38cca93486fa86b50400b7d384c"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzI0OTQ_4604135e-b6ad-4afd-b709-539c7cfe6c07" continuedAt="iae74b36bef4c4132b540df86eb8f3a25" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our sources of net operating revenues from continuing operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues from hospitals and related outpatient facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic480b7e478a9472e9d85fba3eb9c12f5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzQtMi0xLTEtMjkzNzEw_2d8d1e48-87d0-4423-8a03-e0309871bbf8">2,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc722d0c2684b039bc615d08fdc3ffb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzQtNC0xLTEtMjkzNzEw_170cd410-f128-4c00-b498-a53e1455e8e3">2,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c70f5ebc6e458cac8a2f6abf815c4c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzQtNi0xLTEtMjkzNzEw_16d1b3f0-9a04-48ed-9b04-fb75780d51c3">2,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie964e8e69c1c4105a086707420629f2c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzUtMi0xLTEtMjkzNzEw_43ab7e8c-7869-4fab-b92b-92d774090e6f">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74f5e2d7ec046868cdc2f7fbd355aee_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzUtNC0xLTEtMjkzNzEw_7c37a415-a752-4162-bf41-2de3a5753ffd">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabec11c9436644b39b5f21992e4be853_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzUtNi0xLTEtMjkzNzEw_769bf49d-4d21-45d6-b8e6-b6634776ce0b">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61aba57deafe4c6ba34e913edce4fa4c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzYtMi0xLTEtMjkzNzEw_eb7f4421-739e-49ef-9ca1-897ae797c722">9,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b470daff964cccbcf39b25959c3e24_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzYtNC0xLTEtMjkzNzEw_7e6e7c6b-bc1c-42f2-8596-bb15af1af81c">9,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3950c1618554de69021cc2cc1a79848_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzYtNi0xLTEtMjkzNzEw_e0fe79b4-18e0-4c10-a66d-a4e4479f9550">9,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib396f0f65807418887a0c0af3e39a1e6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzctMi0xLTEtMjkzNzEw_4b24cdf2-72f5-4c0d-b27b-5381137cb2da">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1d6b8d0b42e425ba69ee9e7f0d7a8b2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzctNC0xLTEtMjkzNzEw_62a5c2db-6c46-4f12-9cd1-7fc0f9819dc4">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9029942b52174f9f9c8908a424dc17c7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzctNi0xLTEtMjkzNzEw_4fccb9a4-f1d3-48e8-96d7-435e14e75865">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aeeeee831ed476884676b44fd6cfe29_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzgtMi0xLTEtMjkzNzEw_d4db1a74-733f-4bd3-b5e2-88625fdaa30c">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14df2a1821346edbbccbb2de64905eb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzgtNC0xLTEtMjkzNzEw_8e7fd6f3-35e7-4046-b1a4-5d6b0c9f002a">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id127fd2a48b9468fb152d68215c3a4ef_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzgtNi0xLTEtMjkzNzEw_2ccc0858-1b39-4549-9a22-73d2bbe387e5">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8650d876760f4a5db3ab633b09d01bc4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzktMi0xLTEtMjkzNzEw_792fbedb-7671-4976-b970-8769d5ad359a">13,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide258a1d885e4c0f89deb490aea7e041_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzktNC0xLTEtMjkzNzEw_4fc7d32a-3fab-42d4-8812-a7f11c6a207b">14,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26398e525b5346e4b152c794c73a6fe5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzktNi0xLTEtMjkzNzEw_4fbd45c3-8dc0-47c5-a92e-85af0db2dc75">13,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb3ce9661bd4d238e03107f7d28b516_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEwLTItMS0xLTI5MzcxMA_5c7164fb-b5e1-42e8-89f5-e48284523783">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ea9fc470eb4780a32a6b0b1b1a2a41_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEwLTQtMS0xLTI5MzcxMA_8d3ea3bc-91b1-4663-af64-c12461f4a5a2">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eff462dc0034c218f3464becc79363a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEwLTYtMS0xLTI5MzcxMA_9ba07fdf-6521-4be7-b675-2515b5184b6d">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie464e81a78ca4b5bbc82e4f831a2f8fd_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzExLTItMS0xLTI5MzcxMA_97830bf3-9470-4960-8f20-c3e0c7575a03">15,061</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6e909d5f7146e6b2f3799ec1c792e7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzExLTQtMS0xLTI5MzcxMA_a277bd79-44e6-45dc-a564-184d6f89e884">15,982</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fc34a3116b48039c40d17002cd0211_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzExLTYtMS0xLTI5MzcxMA_b5a4a05d-05e6-4c16-83fb-a75870dfdd49">14,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ce7b2af81a45cebea65cf46c0e002e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEyLTItMS0xLTI5MzcxMA_76d722a9-0d43-493f-8707-87b897a18511">3,248</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e55bb2a3404d37ac0446903cd6f0ae_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEyLTQtMS0xLTI5MzcxMA_8e98964f-8682-4a47-a269-47b51ed9627f">2,718</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bd925e775946d38f284ce1b8382ffb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEyLTYtMS0xLTI5MzcxMA_82f79209-c171-4770-acd5-2d1ebd17b6d6">2,072</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cc1bcf836fb4be6bef17a04e3599061_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEzLTItMS0xLTI5MzcxMA_69353d35-8735-440e-bb5d-2da39808e215">1,316</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a76387d9429414d8b35662237a46f7d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEzLTQtMS0xLTI5MzcxMA_0b380f24-e242-4d13-97f1-f23cd77473a0">1,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b36c3b506c460a83c8be8982727090_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEzLTYtMS0xLTI5MzcxMA_a9e8c1ea-0c12-455d-a17c-6aee27dd1bb0">1,306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inter-segment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1253b20e6f0b4e17802a597aa8a7b59f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE0LTItMS0xLTI5MzcxMA_d9a18a87-6e9d-4204-b49a-474b0a227d56">451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia925e5b318a2405589428d1271dec1b3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE0LTQtMS0xLTI5MzcxMA_a7446614-cde1-4707-83fb-8258fcf9fbf8">482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9db4542a137447f59a1e7ac2c89d14d3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE0LTYtMS0xLTI5MzcxMA_f81c28e7-2e8a-493b-9dae-b432e5c46c6c">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE1LTItMS0xLTI5MzcxMA_971de4c7-e968-49df-9f80-fd18c728ea24">19,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE1LTQtMS0xLTI5MzcxMA_417342a0-7dd6-497d-bcde-c523670feff6">19,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE1LTYtMS0xLTI5MzcxMA_102b1194-1110-499e-97af-66581fe8ae25">17,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:0.1%"></td><td style="width:2.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.646%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Primarily physician practices revenues.</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for prior&#8209;year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020 by $<ix:nonFraction unitRef="usd" contextRef="i530018987e3745d5abf91b8e5524fc98_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzg3Nw_e60e6471-bf50-4d31-81e5-6a80d2418353">10</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4b993383ef88460483182c2003d1d78f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzg4MQ_ffc3d5e7-99ae-40fe-ae18-09dc2f88ea6e">26</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc1fb9caa7fb44fcbd2a4b49ddce2861_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzg4OA_08231a95-7de9-41cf-9cf7-1dbe989b8296">6</ix:nonFraction>&#160;million, respectively. Estimated cost report settlements and valuation allowances were included in accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.</span></div><ix:continuation id="iae74b36bef4c4132b540df86eb8f3a25"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Ambulatory Care segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781fa826249423991780dca7297e0a1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzItMi0xLTEtMjkzNzEw_8b3ae718-cf91-4b6c-a68a-1dbef0fbf5e2">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81914a8262974e3fbb3a025471f7eee8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzItNC0xLTEtMjkzNzEw_dd57e62f-9347-462b-94a6-1233d2762404">2,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54151a0b57be4cb78257f73d921ec0ec_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzItNi0xLTEtMjkzNzEw_e61b5133-d730-48e0-8b4f-24e2ad5171f5">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43649916a8a24c10835bd3035c29605c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzMtMi0xLTEtMjkzNzEw_46b9fb38-5f48-4830-ab09-bfe08aa32cff">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fd6a31e00d4b11bd3304b198958511_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzMtNC0xLTEtMjkzNzEw_9b61f5c5-5882-4b0d-8fec-bb1e7516306f">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3991fafc3d4efdacdf716c9d96c74c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzMtNi0xLTEtMjkzNzEw_790866fc-6725-4052-8dc0-0240ec6c6693">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f3ed824e4544e3b60697a39097ec3c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzQtMi0xLTEtMjkzNzEw_39e660b5-62e6-45e0-9dbb-2508532c5bcb">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43074c6c14b4410b81097a344a99a4f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzQtNC0xLTEtMjkzNzEw_806202f9-1b9a-43fa-ac08-5e28b0b4860d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f1c997f82e4683bf9f1bfddca5dcbb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzQtNi0xLTEtMjkzNzEw_07def461-40cc-4b4a-9dff-e65d19cab9bd">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzUtMi0xLTEtMjkzNzEw_c4bee9a7-7ec7-48dd-be65-eab0e63fce2e">3,248</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzUtNC0xLTEtMjkzNzEw_6f089025-338b-4168-95d3-2b56dec22746">2,718</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzUtNi0xLTEtMjkzNzEw_7574ec8c-c813-4865-8e69-235ec628aba6">2,072</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Conifer segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8393dff26a4a4be89907f8a207404638_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzItMi0xLTEtMjkzNzEw_e2abb509-fc3b-4286-a916-03f6151410c6">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323ccc8d9dff4644a7abebc08a38004c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzItNC0xLTEtMjkzNzEw_12eba280-a9b0-4868-8898-58225f832f83">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235f4a13d11d4df9becc252ef1dc9c7c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzItNi0xLTEtMjkzNzEw_29ac1db5-1b56-444e-8754-46fc5505b290">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3ba16a76c64bd5ad24f4df995e560f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzMtMi0xLTEtMjkzNzEw_e208a42a-3724-4806-9864-da01bdd22442">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a93e729edc44dfbafaaf36efb815da_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzMtNC0xLTEtMjkzNzEw_c4ed4202-0ff7-4b31-8034-03972b8e865f">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26388ca5abe346d88976ab4e56da4f3a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzMtNi0xLTEtMjkzNzEw_849df78d-7fe1-4ae6-81e9-4ca011caed63">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5cfbf30434593a6d78c97172bba64_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzQtMi0xLTEtMjkzNzEw_6bd1d06f-c8ce-4a51-82e9-6ca2b84870e9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c20159d864c4b41ba379ff416d148ec_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzQtNC0xLTEtMjkzNzEw_933e8ca1-8414-4b1b-b300-a838857c1595">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28537df01b624afa95022a135cf7d691_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzQtNi0xLTEtMjkzNzEw_14c1f50c-7deb-4ea4-8173-20cd8b4bf5da">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24675d2632254bb2b6bc89b632413541_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzUtMi0xLTEtMjkzNzEw_3320806c-b6a4-4127-9ed7-74e8a77ee409">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f286017ca94e2bb6ddcf0fcc89ef42_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzUtNC0xLTEtMjkzNzEw_f3a0ce12-43b6-422d-9945-c3db240ef71c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4058f3d61484fcba0d030ec4ee43320_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzUtNi0xLTEtMjkzNzEw_f8310bc6-d408-4f77-a5fa-beec94bbea81">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzYtMi0xLTEtMjkzNzEw_8dee3ab4-2fc0-4125-b32f-88844a75cc3c">1,316</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzYtNC0xLTEtMjkzNzEw_46e3b57e-73d9-4a63-99f6-1ef836cd7a87">1,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzYtNi0xLTEtMjkzNzEw_965aa1f0-7d92-4f5d-9998-c02737637114">1,306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i0288e38cca93486fa86b50400b7d384c"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Obligations</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzI0ODc_d6d32858-0af6-4771-b6ed-a22bcee03262" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes Conifer&#8217;s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume&#8209; or contingency&#8209;based contracts, variable&#8209;based escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer&#8217;s contract with Catholic Health Initiatives (&#8220;CHI&#8221;), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed&#8209;fee revenue related to remaining performance obligations. Conifer&#8217;s contract term with CHI ends December&#160;31,&#160;2032.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMi0xLTEtMjkzNzEw_2b6e91e0-1d8e-4e62-8eb1-0526d1c5d054">5,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd6c10c8c74700867918c05b8d066e_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItNC0xLTEtMjkzNzEw_5387f1d7-704f-4254-9b1b-db7bf43c094f">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8235d44217a459cb42567e761b66f1d_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItNi0xLTEtMjkzNzEw_d808a14e-1bd1-41ee-a502-e30631506223">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5607340778f848eeba9562ba40506527_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItOC0xLTEtMjkzNzEw_c2778b77-948d-4394-8bf7-6560d4093ee3">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32381cae0dc40e8971f9588ae25f535_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMTAtMS0xLTI5MzcxMA_1555a56a-13b6-4a0f-af16-4816b85bf003">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe036fe195e4e7d9cf7c4783fa3b8d6_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMTItMS0xLTI5MzcxMA_d7fb3821-c39a-4c1a-a2a9-414587fbeefc">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8a661109d44f82ab8d85b5e23bfda3_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMTQtMS0xLTI5MzcxMA_9299aca4-86af-4f12-b2de-e20e51c8219f">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_247"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzI0MDg_77fbc3bb-d047-4a40-aaa2-c441d34a9276" continuedAt="ide97f362264c4519bff675951eb8b07e" escape="true">INSURANCE</ix:nonNumeric></span></div><ix:continuation id="ide97f362264c4519bff675951eb8b07e"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property Insurance</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April&#160;1, 2022 through March 31, 2023, we have coverage totaling $<ix:nonFraction unitRef="usd" contextRef="i09cf92dc60274d8584d52ce10bbca397_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceAnnualCoverageLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzQzNA_dcdf3db6-69eb-4351-b337-aead4d807f41">850</ix:nonFraction> million per occurrence, after deductibles and exclusions, with annual aggregate sub&#8209;limits of $<ix:nonFraction unitRef="usd" contextRef="ibecd81c658874986bbada79239873a72_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceMaximumCoveragePerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzUyMw_52335d6a-a1e5-46eb-8087-bfb0e6ea3db7">100</ix:nonFraction> million for floods, $<ix:nonFraction unitRef="usd" contextRef="i28407917ddcc4c2ea22b7337ab6cbb6f_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceMaximumCoveragePerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzUzOA_af55a0dc-dd31-4279-a091-ec9300ba55fa">200</ix:nonFraction>&#160;million for earthquakes and a per&#8209;occurrence sub&#8209;limit of $<ix:nonFraction unitRef="usd" contextRef="ibd1758863eb749acbb352959ab071117_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceMaximumCoveragePerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzU5MQ_fa064aa1-3c25-4812-a004-e7de9ed593ef">200</ix:nonFraction> million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $<ix:nonFraction unitRef="usd" contextRef="ie8b5076fba4c4fdb855d3ab34e6a97b2_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceMaximumCoveragePerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzc0Mw_bbd705b1-2f5c-43e2-9b00-02d486e77c83">850</ix:nonFraction> million limit of coverage per occurrence applies. Deductibles are <ix:nonFraction unitRef="number" contextRef="i28407917ddcc4c2ea22b7337ab6cbb6f_D20220401-20230331" decimals="INF" name="thc:PropertyInsuranceDeductiblePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzgwNA_aaf2421f-91f7-4677-a78a-e75a27b3ed1f"><ix:nonFraction unitRef="number" contextRef="i0e926b75dbf3452ca4435e4d0c5a4087_D20220401-20230331" decimals="INF" name="thc:PropertyInsuranceDeductiblePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzgwNA_b2608ac1-bfb1-431c-b2a2-e87a13a12d86">5</ix:nonFraction></ix:nonFraction>% of insured values up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="id85b713fc7a9441c8397ecba316b3238_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceDeductible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzg0NA_f8bf89e7-7a4a-4799-ad50-90f2c04d02ca">25</ix:nonFraction> million for California earthquakes, $<ix:nonFraction unitRef="usd" contextRef="i76790a90cfa941e4bff3a5ae92dff3aa_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceDeductible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzg3NQ_df54213b-cce2-4978-95a1-1c06d39af772">25</ix:nonFraction> million for floods and named windstorms, and <ix:nonFraction unitRef="number" contextRef="i5f6d901dd264433fbda22d0ff499fce6_D20220401-20230331" decimals="INF" name="thc:PropertyInsuranceDeductiblePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzkxNQ_f1737fbc-663e-4c49-a08f-af4a6de2cc33">2</ix:nonFraction>% of insured values for New Madrid fault earthquakes, with a maximum per&#8209;claim deductible of $<ix:nonFraction unitRef="usd" contextRef="i5f6d901dd264433fbda22d0ff499fce6_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceDeductible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzEwMDk_7595ec17-c54e-4d9f-97c6-092e940c3bc9">25</ix:nonFraction>&#160;million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $<ix:nonFraction unitRef="usd" contextRef="i9cfc47e9f41b4cc8881d17b072c28e6d_D20220401-20230331" decimals="-6" name="thc:PropertyInsuranceDeductible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzExMTc_fdf55e12-9154-448a-a251-1d3eeb00c09a">5</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also purchase cyber liability insurance from third parties. In April&#160;2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information (the &#8220;Cybersecurity Incident&#8221;). We estimate that the Cybersecurity Incident had an adverse pre&#8209;tax impact of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a5585dec099491a811760ed0c015749_D20220401-20221231" decimals="-6" name="thc:CybersecurityIncidentPreTaxEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzU0OTc1NTgyMDY2MA_418a8d71-609e-4f06-90e8-8d6dd13ac33d">100</ix:nonFraction>&#160;million during the year ended December&#160;31,&#160;2022. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have filed a claim within our policy limits. Insurance recoveries of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzEwOTk1MTE2MzQ1Nzk_c6d2b522-a778-47d3-8c1b-a7375eefed9a">14</ix:nonFraction>&#160;million related to this claim were received during the year ended December&#160;31,&#160;2022, $<ix:nonFraction unitRef="usd" contextRef="i946e83f23eab48c0977d5cc62313d926_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzU0OTc1NTgyMDY3OQ_31191b36-6f78-4d7d-aafa-b5e7dbeeebab">6</ix:nonFraction>&#160;million of which were recorded as net operating revenues.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional and General Liability Reserves</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are self&#8209;insured for the majority of our professional and general liability claims, and we purchase insurance from third&#8209;parties to cover catastrophic claims. At both December&#160;31,&#160;2022 and 2021, the aggregate current and long&#8209;term professional and general liability reserves in the accompanying Consolidated Balance Sheets was $<ix:nonFraction unitRef="usd" contextRef="i929d5f3206d1415988b40ae29b248818_I20221231" decimals="-6" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzE0NzU_574e9b90-666c-4311-be2f-83c88e36a9e4"><ix:nonFraction unitRef="usd" contextRef="i6a00e93147d34604be1c56fdcf1740bb_I20211231" decimals="-6" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzE0NzU_f709f1ae-88e2-4e38-91e6-8881f75f4888">1.045</ix:nonFraction></ix:nonFraction> billion. These reserves include the reserves recorded by our captive insurance subsidiaries and our self&#8209;insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial insurance we purchase is subject to per&#8209;claim and policy period aggregate limits. If the policy period aggregate limit of any of our policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay other material claims applicable to that policy period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malpractice expense of $<ix:nonFraction unitRef="usd" contextRef="i5bae571ac5a8443d9f4f6d6619c6e742_D20220101-20221231" decimals="-6" name="us-gaap:MalpracticeLossContingencyClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIxNDU_822b1f8d-83cd-42e6-8c41-f8d46ccfca9e">276</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2ce8af9e8c2243dab9e653703111fd49_D20210101-20211231" decimals="-6" name="us-gaap:MalpracticeLossContingencyClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIxNDk_f9d3bb3f-96ed-4853-91a0-a40e64ec07a1">355</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i46385a1111194a8589fc66d33d240d12_D20200101-20201231" decimals="-6" name="us-gaap:MalpracticeLossContingencyClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIxNTY_0333cfd4-d179-4a67-98a8-172f7f080e54">320</ix:nonFraction> million was included in other operating expenses, net, in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIzMjI_71c5561f-f87e-4cd7-b9c7-e78a656bd9fa">74</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIzMjY_57c92c57-e7c5-49c2-b3cb-818e5b48e2e9">131</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIzMzM_0b8d101e-9056-440e-8eb2-472e4fafe0e4">120</ix:nonFraction>&#160;million, respectively, related to adverse claims development for prior years.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_250"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzUzMjQ_f80345d8-67de-447f-8181-37b48a62fab1" continuedAt="icbe3e61142644f4db3e0f119ecbef607" escape="true">CLAIMS AND LAWSUITS</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbe3e61142644f4db3e0f119ecbef607" continuedAt="i8b8df8dcd11644ef9e40455e378bf841">We operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or &#8220;whistleblower&#8221; lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment&#8209;related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i8b8df8dcd11644ef9e40455e378bf841"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties associated with these matters, especially those involving governmental agencies, and the indeterminate damages sought in some cases, we are unable to predict the ultimate liability we may incur from these matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Investigation of Detroit Medical Center</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detroit Medical Center (&#8220;DMC&#8221;) is subject to an ongoing investigation commenced in October&#160;2017 by the U.S.&#160;Attorney&#8217;s Office for the Eastern District of Michigan and the Civil Division of the U.S. Department of Justice (&#8220;DOJ&#8221;) for potential violations of the Stark law, the Medicare and Medicaid anti&#8209;kickback and antifraud and abuse amendments codified under Section 1128B(b) of the Social Security Act, and the federal False Claims Act related to DMC&#8217;s employment of nurse practitioners and physician assistants (&#8220;Mid&#8209;Level Practitioners&#8221;) from 2006 through 2017. As previously disclosed, a media report was published in August&#160;2017 alleging that 14&#160;Mid&#8209;Level Practitioners were terminated by DMC earlier in 2017 due to compliance concerns. The DOJ issued a civil investigative demand to DMC for documents and interrogatories in September&#160;2021. In January&#160;2023, we reached a settlement in principle with the DOJ to resolve this matter, subject to certain conditions, and were fully reserved for such potential settlement at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, certain of the entities that purchased the operations of Hahnemann University Hospital and St.&#160;Christopher&#8217;s Hospital for Children in Philadelphia from us commenced Chapter&#160;11 bankruptcy proceedings. In the three months ended December&#160;31,&#160;2021, we established a reserve of $<ix:nonFraction unitRef="usd" contextRef="i99278a7c32f64fa0b070b36593467a59_D20211001-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzEwOTk1MTE2NDEyOTQ_637c626d-f703-4fdc-be55-48e141c3796d">23</ix:nonFraction>&#160;million for certain obligations related to the sale of the hospitals and the subsequent bankruptcy proceedings of the buyers. In the six months ended June&#160;30,&#160;2022, we made advance payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i6592cd4d757a46e2a3d6e589962ea2da_I20220630" decimals="-6" name="us-gaap:BankruptcyClaimsAmountPaidToSettleClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzEwOTk1MTE2NDEzMTQ_7fd1e466-7312-4089-88b1-7f0499d66aab">1</ix:nonFraction>&#160;million. In the three months ended September&#160;30,&#160;2022, the bankruptcy court approved a final settlement among the parties, and we made the remaining $<ix:nonFraction unitRef="usd" contextRef="ia222bd0504b649a38f78d78bec2b6c91_I20220930" decimals="-6" name="us-gaap:BankruptcyClaimsAmountPaidToSettleClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzEwOTk1MTE2NDEzMzg_abf82ce6-057b-4d42-9dc5-a65de867d456">22</ix:nonFraction>&#160;million in payments to fully resolve this matter.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor and privacy laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New claims or inquiries may be initiated against us from time to time. These matters could (1)&#160;require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2)&#160;cause us to incur substantial expenses, (3)&#160;require significant time and attention from our management, and (4)&#160;cause us to close or sell hospitals or otherwise modify the way we conduct business.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzUzMjY_fc1e38a6-7b83-4544-870d-d6b842253363" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances&#160;at<br/>Beginning<br/>of&#160;Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Litigation&#160;and<br/>Investigation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash<br/>Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances&#160;at<br/>End&#160;of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe65d466f4f469d80f697fa5ae26073_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtMS0xLTEtMjkzNzEw_86093556-2c41-4790-8caa-97d30539f48f">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtMy0xLTEtMjkzNzEw_a7a7621c-8b4c-48c5-a7b5-adeeab9b7942">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtNS0xLTEtMjkzNzEw_a5e62dd4-3ebd-4d66-84e1-2e52b0e98727">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231" decimals="-6" name="thc:LossContingencyAccrualOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtNy0xLTEtMjkzNzEw_8ba716d8-71be-4f5d-96a3-7fd2e5312cd0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b3d4d738e04be3bf00f293d9edb4f5_I20221231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtOS0xLTEtMjkzNzEw_a97f351d-c692-4c05-9e42-e3e99e8b2a42">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63f979e7be145bc9c86e0f440b39a75_I20201231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtMS0xLTEtMjkzNzEw_81fd9f98-40ff-4e3c-814f-7d15ca7f961c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtMy0xLTEtMjkzNzEw_110aa061-c4a2-4f1b-a7f9-9c2852315279">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtNS0xLTEtMjkzNzEw_f2f58924-c906-456b-b392-e502cc1d0c01">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231" decimals="-6" sign="-" name="thc:LossContingencyAccrualOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtNy0xLTEtMjkzNzEw_15826542-72c1-4fbc-9e0c-f3e6725e0236">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe65d466f4f469d80f697fa5ae26073_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtOS0xLTEtMjkzNzEw_cc18a2b5-3bfd-46c1-a418-51ba6d93deba">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2ea7fb5d834e519c54544ff665cc9a_I20191231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktMS0xLTEtMjkzNzEw_7b0c775f-381f-48b8-b311-a434086f0844">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktMy0xLTEtMjkzNzEw_b94ff4d2-9227-45db-bf1b-7691446fbfe8">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktNS0xLTEtMjkzNzEw_9f742fe5-4ea2-4642-84a1-9833393c9019">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231" decimals="-6" name="thc:LossContingencyAccrualOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktNy0xLTEtMjkzNzEw_40cd95ff-1e69-4ba2-8e75-a74ff803db7d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63f979e7be145bc9c86e0f440b39a75_I20201231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktOS0xLTEtMjkzNzEw_e3dbb667-1b04-4dc7-9618-10e5d046e3f7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzE4Mzg_b272f6bc-f2a7-4850-9499-496851bf3684" continuedAt="ic085e1873ce84bf0ad1d1d435605d1d8" escape="true">REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES</ix:nonNumeric></span></div><ix:continuation id="ic085e1873ce84bf0ad1d1d435605d1d8"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our put/call agreement (the &#8220;Baylor Put/Call Agreement&#8221;) with Baylor contained put and call options with respect to the <ix:nonFraction unitRef="number" contextRef="i4465885b467846d392b87babc57179d9_I20220630" decimals="2" name="thc:JointVentureOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzIxNTE_a3041d17-b83f-4c34-b4a1-c08475ade0bc">5</ix:nonFraction>% ownership interest Baylor held in USPI until June&#160;30,&#160;2022. The Baylor Put/Call Agreement gave Baylor the option to annually put up to one-third of its total shares in USPI (the &#8220;Baylor Shares&#8221;) over a period of three years beginning in 2021. We had the right to call the difference between the number of shares Baylor put each year and the maximum number of shares it could have put. Based on the nature of the Baylor Put/Call Agreement, Baylor&#8217;s minority interest in USPI was classified as a redeemable noncontrolling interest in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2021. During the years ended December&#160;31,&#160;2022 and 2021, we recognized accretion totaling $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzIyNzI_fa2c1cd4-7da2-4142-b598-b9d4fdb129b5">102</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzIyNzY_66c79483-2a00-4eac-8c04-efeaa55fe1ed">8</ix:nonFraction>&#160;million, respectively, and a corresponding decrease in additional paid-in capital related to Baylor&#8217;s minority interest in USPI.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase <ix:nonFraction unitRef="number" contextRef="i1acbe1c3a707444594718d1fb713a4dd_D20220101-20220630" decimals="3" name="thc:PurchasedEquityInJointVenturePercentageOfTotalShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ1NzI_b4741191-00f3-41da-bf14-cf24f0a21e40"><ix:nonFraction unitRef="number" contextRef="i9b94c1f135f64a488e17326f4496bb5a_D20210101-20211231" decimals="3" name="thc:PurchasedEquityInJointVenturePercentageOfTotalShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ1NzI_d4d87930-eb7e-40ac-9f3b-dfa4a4fa5dd0">33.3</ix:nonFraction></ix:nonFraction>% of the Baylor Shares for that year (<ix:nonFraction unitRef="number" contextRef="ieb5fa32817764caa8f2f7644c58ca52b_D20210101-20220630" decimals="3" name="thc:PurchasedEquityInJointVenturePercentageOfTotalShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ1ODA_01a3a2a9-bc47-49ef-882b-40fe448d1105">66.6</ix:nonFraction>% in total). In June 2022, we entered into an agreement with Baylor (the &#8220;Share Purchase Agreement&#8221;) to complete the purchase of the Baylor Shares we called in 2021 and 2022 and to accelerate the acquisition of the remaining Baylor Shares eligible to be put/called in 2023. Under the terms of the Share Purchase Agreement, we agreed to pay Baylor $<ix:nonFraction unitRef="usd" contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630" decimals="-6" name="thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ2ODc_fa8c3ef3-021a-4cc5-9bd4-a8c95825b1c6">406</ix:nonFraction>&#160;million to buy its entire <ix:nonFraction unitRef="number" contextRef="i4465885b467846d392b87babc57179d9_I20220630" decimals="2" name="thc:JointVentureOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ2OTg_a3041d17-b83f-4c34-b4a1-c08475ade0bc">5</ix:nonFraction>% voting ownership interest in USPI. We paid $<ix:nonFraction unitRef="usd" contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630" decimals="-6" name="thc:SharePurchaseAgreementPaymentForExecution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3MDI_3c73c98e-483e-4738-8078-9015aa4ec4ba">11</ix:nonFraction>&#160;million upon execution of the Share Purchase Agreement and are obligated to make <ix:nonNumeric contextRef="ia73487c1fdc34b30b87fbe06f5951834_D20220101-20221231" name="thc:SharePurchaseAgreementNumberOfMonthlyPayments" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3MTc_961eaa4e-2756-4f56-9e9b-dca0f394cf85">35</ix:nonNumeric> additional non-interest bearing monthly payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ia73487c1fdc34b30b87fbe06f5951834_D20220101-20221231" decimals="-6" name="thc:SharePurchaseAgreementMonthlyPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3MjE_b59586b5-6f5f-44c9-ab7a-c36329c8e74b">11</ix:nonFraction>&#160;million, which payments commenced in August&#160;2022. We recorded the present value of the purchase price as a liability on our balance sheet, with an offset to redeemable noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3Mzc_f86f2f9e-3e20-4322-8a78-38933d68de21">365</ix:nonFraction>&#160;million for the carrying amount of the shares and $<ix:nonFraction unitRef="usd" contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630" decimals="-6" name="thc:GainLossFromPurchaseOfNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3NDY_51af3758-aba1-4724-b1a8-c07412382df1">23</ix:nonFraction>&#160;million to additional paid&#8209;in capital for the difference between the carrying value and present value of the purchase price for the shares. At December&#160;31,&#160;2022, we had liabilities of $<ix:nonFraction unitRef="usd" contextRef="i4951aea584a14d4b873b83530d333b3c_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3NTk_d2f1afa4-9b7b-45ce-a2ad-81e8ee49c91e">135</ix:nonFraction>&#160;million recorded in other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i4951aea584a14d4b873b83530d333b3c_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3NzM_d0db0d18-e872-4f35-beef-0f32e8dae985">190</ix:nonFraction>&#160;million in other long-term liabilities in the accompanying Consolidated Balance Sheet for the purchase of these shares.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzE4MzU_007975d7-e25c-4e51-b5b8-895e4d890d87" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082e53fec105442d97f902da195a0d31_I20211231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzItMS0xLTEtMjkzNzEw_14f12542-d044-4cd6-90b1-d38ee44ec402">2,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea644fa13c540e892499ab2838c341d_I20201231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzItMy0xLTEtMjkzNzEw_287a3218-8725-404a-af40-c4ef49e4676c">1,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzMtMS0xLTEtMjkzNzEw_2370beb2-3827-415f-bf05-87fd355ff1c2">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzMtMy0xLTEtMjkzNzEw_2f40f561-64ab-4be7-86b5-0915e1826ed5">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzQtMS0xLTEtMjkzNzEw_4501abac-4be7-4978-b675-160f8cf22c0d">331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzQtMy0xLTEtMjkzNzEw_b9f6c78b-058b-44a1-9b5f-05491146a077">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzUtMS0xLTEtMjkzNzEw_5085552f-1b3f-4951-a42a-7bfb2a83eb9f">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzUtMy0xLTEtMjkzNzEw_a2e93971-9064-4354-8fc8-6a130cbdbfb1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases and sales of businesses and noncontrolling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzYtMS0xLTEtMjkzNzEw_2720f910-205f-4144-a1ba-8264247ce638">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzYtMy0xLTEtMjkzNzEw_bf28e1c1-cea4-440b-b2d5-f3b2c2c806e8">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at end of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254fa58d5da4b66af614eec6e6b07a5_I20221231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzctMS0xLTEtMjkzNzEw_bbc93d39-000d-4a04-b493-36ad29ab0240">2,149</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082e53fec105442d97f902da195a0d31_I20211231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzctMy0xLTEtMjkzNzEw_7972bec6-d6ba-4646-9e5e-e68b221b52d0">2,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzItMi0xLTEtMjkzNzEw_2df7ac66-3c8f-498e-b491-9a7b54e40ec4">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzItNC0xLTEtMjkzNzEw_49c9554b-0cea-413e-9748-17f2bb215800">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib165a084700643e1b139d15df43a3b15_I20221231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzMtMi0xLTEtMjkzNzEw_2dfcb320-36cf-492c-8c0d-6c3086a0e901">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzMtNC0xLTEtMjkzNzEw_39c91927-2898-4b93-95d3-8681c40df055">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzQtMi0xLTEtMjkzNzEw_9d40844b-c8a8-45bb-8ecb-652cc19bf0a6">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzQtNC0xLTEtMjkzNzEw_efda7773-0cd5-4f43-99e1-66e587ebddc8">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzUtMi0xLTEtMjkzNzEw_d7c8e94b-41e6-4dbc-96c5-27a665c67692">2,149</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzUtNC0xLTEtMjkzNzEw_f2d3c410-cb13-4cb8-97ef-4cd45a75513c">2,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzItMi0xLTEtMjkzNzEw_48d0b94a-794b-4657-8fcd-77bf3b7ac80b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzItNC0xLTEtMjkzNzEw_b1cd7eac-a0cf-4c43-9071-f0d29ad23123">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzItNi0xLTEtMjkzNzEw_540192bc-f4eb-4a37-9af4-3c1ef2005ad3">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzMtMi0xLTEtMjkzNzEw_f64bf817-a6c8-4cfb-85e8-e379df42f954">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzMtNC0xLTEtMjkzNzEw_19fa791a-667e-411f-8ec7-ac6f645beac9">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzMtNi0xLTEtMjkzNzEw_b1ce9170-8ee2-45c3-a37d-f33e5144159f">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzQtMi0xLTEtMjkzNzEw_6d88d77b-902e-4036-ab10-f0c70278208d">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzQtNC0xLTEtMjkzNzEw_0f4f8c19-0fa1-4300-b9ff-bfe849fbc0d3">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzQtNi0xLTEtMjkzNzEw_42936c3d-7b3a-4bbb-8790-b53a223ab51c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzUtMi0xLTEtMjkzNzEw_e6f95557-e808-405b-8571-149c9333812b">348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzUtNC0xLTEtMjkzNzEw_d06891e2-fae6-4e7c-bf32-0fa3e768267d">336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzUtNi0xLTEtMjkzNzEw_908a56fc-ceb8-4f44-a57c-bb54970e8526">186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 19. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5MzU_f0bc8135-e9ea-425d-a24d-f4b6f8d76090" continuedAt="ib8ec1fed4dcd460dbcc62c98ab2fe59f" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ib8ec1fed4dcd460dbcc62c98ab2fe59f" continuedAt="i2c6a3d148b6b41548cc71b6008d0ea5c"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NjI_bde3da50-d413-4346-82e2-0a641be63cf7" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for continuing operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzMtMS0xLTEtMjkzNzEw_050ceada-7b12-490d-b3e0-c6eaf619d114">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzMtMy0xLTEtMjkzNzEw_19b7e15b-3816-415e-9ced-03a27dd32244">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzMtNS0xLTEtMjkzNzEw_1a2ccec8-4351-4483-990b-1a6c6cd6f836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzQtMS0xLTEtMjkzNzEw_368dad73-90de-446a-9fe9-bdd9e637c989">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzQtMy0xLTEtMjkzNzEw_1c5a246d-2e53-4afd-8526-46e93ac6e1eb">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzQtNS0xLTEtMjkzNzEw_f0c3599e-8874-4342-829c-59120145a939">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzUtMS0xLTEtMjkzNzEw_58d67b34-d262-4074-8728-c0d99466e8e2">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzUtMy0xLTEtMjkzNzEw_f0017f14-2c09-4515-8c14-fdff819746c3">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzUtNS0xLTEtMjkzNzEw_57634492-628e-4072-95dd-eb27cd82c40c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzctMS0xLTEtMjkzNzEw_363a20d5-9d55-4473-9c59-4bdfc3009a67">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzctMy0xLTEtMjkzNzEw_42235d9c-cc32-42a7-9788-9bdd298c635d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzctNS0xLTEtMjkzNzEw_1c251e3d-2adb-4b76-9ded-b32e0215e70c">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzgtMS0xLTEtMjkzNzEw_329e6608-b814-44b6-9e87-b735e0a8f4b4">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzgtMy0xLTEtMjkzNzEw_d7107460-0403-43ab-8f74-8df60e78b12d">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzgtNS0xLTEtMjkzNzEw_560b2a86-832f-4632-9280-d41169750951">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzktMS0xLTEtMjkzNzEw_69d888d9-c694-45a4-beb0-730ca450a0dd">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzktMy0xLTEtMjkzNzEw_f31c5ab8-f03f-41cc-8153-f2e041bf8a72">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzktNS0xLTEtMjkzNzEw_b65bb8ee-84cf-4f41-8c73-f89bcffea072">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzEwLTEtMS0xLTI5MzcxMA_c973dcf7-ae34-44bc-9c60-2102fd28d4c5">344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzEwLTMtMS0xLTI5MzcxMA_b466c869-3d9a-4fc7-ab4f-c17218376a00">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzEwLTUtMS0xLTI5MzcxMA_92edb48b-dc5e-4c99-89ae-f6f6794f9240">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the amount of reported income tax expense (benefit) and the amount computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is presented below. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NTk_353a506b-c003-43e8-b826-0cfff88a4ab2" continuedAt="i18bd468c161a4ea9a4025106f87cd67c" escape="true">Foreign pre-tax loss was $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NTkyMjk_6004a7ef-d5c1-4522-890e-5ed9115bd562">8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NTkyMzQ_86f3a40e-ee39-4b2f-a6e2-9e76b9cad818">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NTkyNDI_dff16af3-4a8b-4cd4-9b69-7e342490ea1c">13</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and&#160;2020, respectively.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i18bd468c161a4ea9a4025106f87cd67c" continuedAt="ia3545c21a42443c8a418aacd633b072c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory federal rate of 21%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzItMS0xLTEtMjkzNzEw_87cdd4dd-cf79-47ce-86b4-6f674191dffd">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzItMy0xLTEtMjkzNzEw_489c1012-780e-46c4-8a1d-2b839ddb0781">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzItNS0xLTEtMjkzNzEw_d08b4e46-e12d-451a-b8f2-69bf0faba379">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzMtMS0xLTEtMjkzNzEw_f64e8226-24e2-47f5-a70e-81b458252514">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzMtMy0xLTEtMjkzNzEw_b6587ebf-7769-4483-b71f-d4156d51349b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzMtNS0xLTEtMjkzNzEw_a4bbd3b9-8ccc-417c-9a2d-82f50c552062">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzUtMS0xLTEtMjkzNzEw_314e3a71-137c-40d5-8fda-77de18382641">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzUtMy0xLTEtMjkzNzEw_d6b4fb8b-27f1-4ffe-bca2-406221341131">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzUtNS0xLTEtMjkzNzEw_d96e3054-2c0d-4a90-9ca4-3eed3b7eee41">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzYtMS0xLTEtMjkzNzEw_5efaa143-b609-4af6-922e-3d5e272e6860">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzYtMy0xLTEtMjkzNzEw_2d360be4-61ed-4b72-9302-69bb76dcf9e2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzYtNS0xLTEtMjkzNzEw_0dbaf4ce-fc6e-4a7b-a8ee-3cf53dbf3c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzctMS0xLTEtMjkzNzEw_a3cfa0c7-5924-47ab-8a89-f11668215cb3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzctMy0xLTEtMjkzNzEw_dd6f0623-83aa-47da-90b4-982375800ebe">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzctNS0xLTEtMjkzNzEw_4bcc1d58-d935-4269-bfe2-0f28b4a43207">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:IncomeTaxReconciliationNondeductibleExpenseLitigation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzgtMS0xLTEtMjkzNzEw_43694f90-0138-4680-93fd-ba8bf7f7455f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:IncomeTaxReconciliationNondeductibleExpenseLitigation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzgtMy0xLTEtMjkzNzEw_44ad474d-bd33-489f-9177-02e791b03306">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:IncomeTaxReconciliationNondeductibleExpenseLitigation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzgtNS0xLTEtMjkzNzEw_842d5382-03d0-43f6-b7ae-9547664b4611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired charitable contribution carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzktMS0xLTEtMjkzNzEw_5c060526-825a-497c-bdbb-be4601b71534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzktMy0xLTEtMjkzNzEw_446a6eae-9838-4959-87ae-5edf8a2ace17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzktNS0xLTEtMjkzNzEw_70246603-1613-4f98-b858-a5190ead751b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEyLTEtMS0xLTI5MzcxMA_4e349444-e9bb-4ed3-92e8-4aae7c0b217c">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEyLTMtMS0xLTI5MzcxMA_2cb101bd-7d1d-40e8-ad7f-2af6cb0fe7e9">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEyLTUtMS0xLTI5MzcxMA_0c721358-687d-4782-966f-0a53a2a3302d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEzLTEtMS0xLTI5MzcxMA_77a15628-49f9-4f2f-b831-c52eded035cd">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEzLTMtMS0xLTI5MzcxMA_84b083da-c1f2-430e-95cb-35228cd7921c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEzLTUtMS0xLTI5MzcxMA_6ea7eb9e-a7b2-429d-9f4e-745d24153a49">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior-year provision to return adjustments and other changes in deferred&#160;taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE1LTEtMS0xLTI5MzcxMA_f2565c91-c1ea-47d3-999e-21d9368187eb">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE1LTMtMS0xLTI5MzcxMA_9c748f63-89ec-4fe9-b46a-496bdddf4ec3">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE1LTUtMS0xLTI5MzcxMA_3bfc9a9f-d3e0-4969-bfb9-4a8544f72ee1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE2LTEtMS0xLTI5MzcxMA_493761c1-c7fe-4fb5-8ab4-0307b20561fa">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE2LTMtMS0xLTI5MzcxMA_d0ab72d6-c71d-42ed-bba5-4bc8fbd16c5a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE2LTUtMS0xLTI5MzcxMA_3d26e399-21df-4ac4-bfb1-344bf6936370">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE3LTEtMS0xLTI5MzcxMA_337d043a-14f6-4d90-acac-8b3522c57ffe">344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE3LTMtMS0xLTI5MzcxMA_6ea2aabe-a03a-4cc9-81dd-4f54e47ef653">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE3LTUtMS0xLTI5MzcxMA_74116ec6-4cf1-4f46-b57e-5d7d4cd6d346">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia3545c21a42443c8a418aacd633b072c">A change in the business interest expense disallowance rules took effect in 2022, resulting in a larger amount of interest disallowance compared to prior years.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts included a significant number of tax provisions applicable to individuals and businesses. For businesses, the COVID Acts made changes to the U.S. tax code relating to, among other things: (1) the business interest expense disallowance rules for 2019 and 2020; (2) net operating loss rules; (3) charitable contribution limitations; and (4) the realization of corporate alternative minimum tax credits. As a result of the change in the business interest expense disallowance rules, we recorded an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:IncomeTaxExpenseBenefitCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzU0OTc1NTgzOTk0MQ_6d5065bb-19fc-44b9-9086-940d3ccc7d40">88</ix:nonFraction> million during the year ended December&#160;31,&#160;2020 to decrease the valuation allowance for interest expense carryforwards due to the additional deduction of interest expense.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we filed an application with the Internal Revenue Service (&#8220;IRS&#8221;) to change our method of accounting for certain capitalized costs on our 2019 tax return. This change in tax accounting method resulted in additional interest expense being allowed on the 2019 and 2020 tax returns. We reduced our valuation allowance by an additional $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzU0OTc1NTgzOTUwMA_d99bb7d9-c621-40d0-aa23-ce6b4699ac0e">126</ix:nonFraction>&#160;million in the year ended December&#160;31,&#160;2020 related to the change in accounting method.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i2c6a3d148b6b41548cc71b6008d0ea5c" continuedAt="i1ac726852aa445f1b83ef5aa045e2281"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NTA_93615951-af17-456e-be0c-2f53aca5cfbd" continuedAt="idfc7f928b2eb4d80adcc0506e7e44e0f" escape="true">The following table discloses those significant components of our deferred tax assets and liabilities, including any valuation allowance:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="idfc7f928b2eb4d80adcc0506e7e44e0f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and fixed-asset differences</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzItMy0xLTEtMjkzNzEw_2392ea45-ba6a-45fb-82a9-368b1c1bf19d">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzItNy0xLTEtMjkzNzEw_122dc9be-70d6-4700-a7ee-5a4e6010a71e">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves related to discontinued operations and restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzMtMS0xLTEtMjkzNzEw_4afbb7ea-1452-4af4-9a2c-ca88c6df52d0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzMtNS0xLTEtMjkzNzEw_c796a0ce-4017-4eee-8f10-c1bb8a6ff8e8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables (doubtful accounts and adjustments)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzQtMS0xLTEtMjkzNzEw_24c9634c-f101-403a-8451-8a15344cd90f">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzQtNS0xLTEtMjkzNzEw_468df2a4-289c-4d7b-bcec-f40c0ba8d4a1">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare advance payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DeferredTaxAssetsMedicareAdvancePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzUtMS0xLTEtMjkzNzEw_8bc6a8f2-c48f-45f7-9d49-08326f01f407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredTaxAssetsMedicareAdvancePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzUtNS0xLTEtMjkzNzEw_0e0e45a7-5e23-43b4-ac5b-daae7f83efd1">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for retained insurance risks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzYtMS0xLTEtMjkzNzEw_839baf74-bddf-4096-b74d-1c7d3e2a6fe9">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzYtNS0xLTEtMjkzNzEw_00513d71-16a8-4fb0-b1d8-3e206f27e851">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzctMy0xLTEtMjkzNzEw_61fe35f8-9b99-4bed-b6b0-344e08c5cb94">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzctNy0xLTEtMjkzNzEw_4c7c06af-a655-417a-b067-9558fe65d91d">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DeferredTaxAssetsOtherLongTermLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzgtMS0xLTEtMjkzNzEw_231d9c3a-ffb9-4791-96b9-6483e9ecc56f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredTaxAssetsOtherLongTermLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzgtNS0xLTEtMjkzNzEw_cb841b11-3e54-4f75-900d-7a880bc86489">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzktMS0xLTEtMjkzNzEw_9722f091-172b-404e-bf8c-1cedb11da699">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzktNS0xLTEtMjkzNzEw_1afd9016-7dd6-4377-9858-153fb9e35034">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEwLTEtMS0xLTI5MzcxMA_e500d936-361e-4c32-bda8-1dd4517098fd">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEwLTUtMS0xLTI5MzcxMA_dc1b766f-f465-4b4f-a415-2d3942b50d17">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DeferredTaxLiabilitiesInvestmentsAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzExLTMtMS0xLTI5MzcxMA_a3b4d070-d8f2-40fc-99a7-c72603db258e">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredTaxLiabilitiesInvestmentsAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzExLTctMS0xLTI5MzcxMA_9a3ebfe6-7001-4cb2-927e-ca6a4072d876">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DeferredTaxAssetsInterestExpenseLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEyLTEtMS0xLTI5MzcxMA_366f3b89-7267-49de-8ce9-59b7ece422fd">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredTaxAssetsInterestExpenseLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEyLTUtMS0xLTI5MzcxMA_6bca50ef-1bfe-4385-9e17-69b4cdb6485d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEzLTEtMS0xLTI5MzcxMA_caa73c96-fc4c-4145-964d-862ccb712355">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEzLTUtMS0xLTI5MzcxMA_5fa9da15-c5eb-4da3-a9ec-6bff1eba45c6">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE0LTEtMS0xLTI5MzcxMA_f63c5ea9-6707-4208-b6f4-8808f778bb7a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE0LTUtMS0xLTI5MzcxMA_4a5ed381-9b8d-4202-b677-9a219ec1b4da">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use lease assets and obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTEtMS0xLTI5MzcxMA_c888966e-bd73-4eed-a6bd-6ac34b36919b">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="thc:DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTMtMS0xLTI5MzcxMA_2ddacf78-b546-40c0-8292-4bb521de6534">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTUtMS0xLTI5MzcxMA_828fdc49-b878-4f06-bc3a-b3153564beaa">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTctMS0xLTI5MzcxMA_53f36c00-803d-4801-8290-18f14822d9b3">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTEtMS0xLTI5MzcxMA_b8db7fe5-b8c7-4b75-97de-10f52910bc50">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTMtMS0xLTI5MzcxMA_d012e06d-4a61-4328-8bb5-825f2d30c658">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTUtMS0xLTI5MzcxMA_595fb7e6-99d7-454b-8165-44bb49406a6b">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTctMS0xLTI5MzcxMA_83bd909f-4b71-4a40-bd1e-50de9bc8dd5b">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTEtMS0xLTI5MzcxMA_aba68115-4923-40a1-9587-a252a4db5f9d">1,165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTMtMS0xLTI5MzcxMA_a1b3b8f6-192c-42d7-8df5-9367920b8f2b">1,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTUtMS0xLTI5MzcxMA_3cbc8021-1197-4852-963e-a053f03044fd">1,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTctMS0xLTI5MzcxMA_b50251ca-184d-46bc-b9bc-cddfbb246e33">1,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE4LTEtMS0xLTI5MzcxMA_8e1518f8-9328-41e4-b0f1-aee464629855">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE4LTUtMS0xLTI5MzcxMA_6cf3d140-7534-4237-a95f-e0e87cd666e4">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTEtMS0xLTI5MzcxMA_cb260ace-40d3-4b07-852a-68586cf37cec">988</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTMtMS0xLTI5MzcxMA_238fd2c2-c3b6-4b1a-a3df-fdc3282af96a">1,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTUtMS0xLTI5MzcxMA_6e4a9ca6-ec93-45b3-b9bb-7fde4cf2bd04">1,301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTctMS0xLTI5MzcxMA_88cb5ba7-1c6c-4d91-ac1d-23ba12bb5d43">1,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="thc:ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5Njg_247a4472-09a0-4b1e-9098-45de22de8dae" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the deferred tax assets and liabilities and the corresponding amounts reported in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzItMS0xLTEtMjkzNzEw_ffea5267-562d-4101-b80d-75a0b1593ab6">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzItMy0xLTEtMjkzNzEw_1c869b1b-60d6-4892-96e0-303a68fc277f">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzMtMS0xLTEtMjkzNzEw_6580dfc5-57b2-4fd9-910d-0ea13fff629a">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzMtMy0xLTEtMjkzNzEw_280d8b43-3d33-4d9a-b54b-14fe2e4b87b5">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" sign="-" name="thc:DeferredIncomeTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzQtMS0xLTEtMjkzNzEw_f2dbec57-209e-4e9b-87f7-2ef6299c040b">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="thc:DeferredIncomeTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzQtMy0xLTEtMjkzNzEw_f5d1cf13-634d-4ad1-8bae-031f10e78c4c">29</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, the valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI1NDE_e14af7ef-489f-4b63-9a10-2f58268a2ab7">120</ix:nonFraction>&#160;million, including an increase of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI1NzA_fee1e6ba-5613-4f14-81d4-77ee0231116c">123</ix:nonFraction>&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI2NTI_bcd74dd2-b40c-4366-8aad-b5ef25d0add5">1</ix:nonFraction> million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI3NjQ_196a18e9-c994-48db-9821-dadaf48432ab">2</ix:nonFraction> million due to changes in the expected realizability of deferred tax assets. The balance in the valuation allowance as of December&#160;31,&#160;2022 was $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI4ODQ_06ba9276-cad1-4c5e-9b67-c09160bd564d">177</ix:nonFraction> million. During the year ended December&#160;31,&#160;2021, the valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI5NTE_cce82b2c-6ac7-453c-9ae0-df00f2d58469">2</ix:nonFraction> million, including an increase of $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI5Nzk_81ab9d2b-be96-4e6e-9448-ae1492015198">2</ix:nonFraction>&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMwNjE_e2168614-5a00-4191-a2aa-0cac27997854">2</ix:nonFraction>&#160;million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMxNzI_1369ef6f-81b5-4d06-bc0e-b837bd3b7061">2</ix:nonFraction>&#160;million due to changes in the expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December&#160;31,&#160;2021 was $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMyOTk_e306fdac-13e7-4c73-abdf-5d94872894d0">57</ix:nonFraction> million. During the year ended December&#160;31,&#160;2020, the valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMzNjY_7ab17499-41c3-4d2d-a227-eb557b9f9854">226</ix:nonFraction> million, including a decrease of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMzOTU_30916e70-61dd-45af-8278-fb466dee0a02">211</ix:nonFraction> million due to limitations on the tax deductibility of interest expense, a decrease of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzM0MDE_c40839a5-9db3-4e72-a2b2-9961d439ee62">1</ix:nonFraction> million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzM0MjQ_c678c5a8-db6a-4046-9387-c5f5b1704a66">14</ix:nonFraction> million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance as of December&#160;31,&#160;2020 was $<ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzM1NTQ_d096b93c-3443-42a7-95b4-b55990d870e8">55</ix:nonFraction>&#160;million. Deferred tax assets relating to interest expense limitations under Internal Revenue Code Section 163(j) have a full valuation allowance because the interest expense carryovers are not expected to be utilized in the foreseeable future.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with FASB ASC 740-10-25, which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NzQ_131b1bd6-25ac-4f9b-9f9f-9c3b98df56ad" continuedAt="i5d0a4f4d82684415b6ac27ec8b4d6a07" escape="true">The following table summarizes the total changes in unrecognized tax benefits in continuing operations during the years ended December&#160;31,&#160;2022, 2021 and 2020. There were no such changes in discontinued operations. The additions and reductions for tax positions include the impact of items for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductions. Such amounts include unrecognized tax benefits that have impacted deferred tax assets and liabilities at December&#160;31,&#160;2022, 2021 and 2020.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i1ac726852aa445f1b83ef5aa045e2281"><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="i5d0a4f4d82684415b6ac27ec8b4d6a07"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:85.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1d91a903a1a481fa20d8e476407ae20_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzEtMS0xLTEtMjkzNzEw_39b89d3e-6c8b-4bfe-a5f0-6d1716c65cc5">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to a lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a33773dbfe4b1c9e0db6630258d6d1_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzItMS0xLTEtMjkzNzEw_a1980d20-d6da-45e9-8f2e-c015cb094ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e5bdf39f78442c999f04f849962c0a_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzMtMS0xLTEtMjkzNzEw_1fa758c4-86c0-4b99-911f-3e900e7f77aa">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to a lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58845e096d6e4053baf993f0b5480e65_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzQtMS0xLTEtMjkzNzEw_df17000d-d38d-4cb8-a6df-50e13f02554a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife847cb48ff64445b52e24dff42ab345_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzUtMS0xLTEtMjkzNzEw_951d1e0d-28a8-491d-9f63-bb8753b7108f">34</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to tax positions taken in prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016ade91fd494b2092c70d023aa6b142_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzYtMS0xLTEtMjkzNzEw_a0c3ecdd-8035-4905-8be9-e1c9e115ddb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f311af9ca5b443ca38ce68247b5b1c9_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzctMS0xLTEtMjkzNzEw_35ccc4db-a690-4b9b-8f8d-9575225f2b59">34</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits as of December&#160;31,&#160;2022 was $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzQ2NTQ_9772d61f-bfb4-4170-abfa-b7661addb2ec">34</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzQ2Njc_27e38f9b-eaf0-4298-9cfe-0c917b1b9572">32</ix:nonFraction>&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December&#160;31,&#160;2022, there was no change in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December&#160;31,&#160;2021 was $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUwNDM_0ff869c8-5bf5-46e2-9c46-1275862e81a2">34</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUwNTY_5dd89c88-519e-4373-90bf-930b1ee4de7d">32</ix:nonFraction>&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. Income tax expense in the year ended December&#160;31,&#160;2021 included expense of $<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzU0OTc1NTg0MjIzNg_7c37621a-20a0-453a-b548-f28efd39524b">3</ix:nonFraction>&#160;million in continuing operations attributable to an increase in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December&#160;31,&#160;2020 was $<ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUzMjE_d9242806-d6b9-48c6-b9b4-c14363dd73bb">31</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUzMzQ_f146c9e2-9600-4600-bbd9-0696b487c242">29</ix:nonFraction>&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December&#160;31,&#160;2020, there was no change in our estimated liabilities for uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Approximately $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NjI1OTM_64ede91e-1086-4439-9604-b4dca9dd4f19">1</ix:nonFraction> million of interest and penalties related to accrued liabilities for uncertain tax positions are included in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2022. Total accrued interest or penalties on unrecognized tax benefits as of December&#160;31,&#160;2022 was $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NjI2MDE_88412123-4b9a-4cf1-941b-1a93713eb36b">1</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS has completed audits of our tax returns for all tax years ended on or before December&#160;31,&#160;2007. All disputed issues with respect to these audits have been resolved and all related tax assessments (including interest) have been paid. Our tax returns for years ended after December&#160;31,&#160;2007 and USPI&#8217;s tax returns for years ended after December&#160;31,&#160;2018 remain subject to audit by the IRS.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, <ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="INF" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzYyOTc_94d74741-de43-46b1-bc27-abfe0a7ca9cc">no</ix:nonFraction> significant changes in unrecognized federal and state tax benefits are expected in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our carryforwards available to offset future taxable income consisted of (1)&#160;federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="if3ceb05ff4044a7c839c70944244e25e_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY2NzQ_a61d7059-9f55-4ff6-bf79-0b9143b54665">100</ix:nonFraction> million pre&#8209;tax, $<ix:nonFraction unitRef="usd" contextRef="if3ceb05ff4044a7c839c70944244e25e_I20221231" decimals="-6" name="thc:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY2ODY_21092bdf-f130-4bed-9090-505d6ac7ee8b">40</ix:nonFraction> million of which expires in 2024 to 2037 and $<ix:nonFraction unitRef="usd" contextRef="if3ceb05ff4044a7c839c70944244e25e_I20221231" decimals="-6" name="thc:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY3MjI_84f2c940-3dbb-494f-b52f-15a0948c07ed">60</ix:nonFraction> million of which has no expiration date, (2) charitable contribution carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY5MDk_a65bc1df-aba8-40fb-afac-6e89f12197a1">45</ix:nonFraction>&#160;million expiring in 2025 through 2027 and (3)&#160;state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ie394bb97475d441db6f2d7fdbb59def8_I20221231" decimals="-6" name="thc:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY5ODg_60d3df74-7012-44ee-a887-349b6dcafeba">3.106</ix:nonFraction>&#160;billion expiring in 2023 through 2042 for which the associated deferred tax benefit, net of valuation allowance and federal tax impact, is $<ix:nonFraction unitRef="usd" contextRef="ie394bb97475d441db6f2d7fdbb59def8_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzcxMTg_278be6a9-bebd-4f58-b549-647ab9f7d57d">42</ix:nonFraction>&#160;million. Our ability to utilize NOL carryforwards to reduce future taxable income may be limited under Section&#160;382 of the Internal Revenue Code if certain ownership changes in our company occur during a rolling three&#8209;year period. These ownership changes include purchases of common stock under share repurchase programs, the offering of stock by us, the purchase or sale of our stock by 5%&#160;shareholders, as defined in the Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5%&#160;shareholders result in aggregate increases that exceed 50 percentage points during the three&#8209;year period, then Section&#160;382 imposes an annual limitation on the amount of our taxable income that may be offset by the NOL&#160;carryforwards or tax credit carryforwards at the time of ownership change.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 20. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90ZXh0cmVnaW9uOjgxMjVmMDE0YTY2MDQ2YzQ5YWViMzliNTc3OGU5ZWViXzEyODM_5d218721-5c55-4ef6-9637-cf8c1082afa2" continuedAt="i030d307e0ad14df899145d6f98e105ef" escape="true">EARNINGS PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="i030d307e0ad14df899145d6f98e105ef"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90ZXh0cmVnaW9uOjgxMjVmMDE0YTY2MDQ2YzQ5YWViMzliNTc3OGU5ZWViXzEyODI_5bffb9b9-f9f3-45fa-9444-a643a7555190" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in&#160;millions and weighted average shares are expressed in thousands.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Available to Common Shareholders (Numerator)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Shares<br/>(Denominator)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per-Share<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzItMS0xLTEtMjkzNzEw_8d2dfb5b-dabe-4858-b4b2-b7806d92790e">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzItMy0xLTEtMjkzNzEw_0eab6586-fe3f-4343-afc7-080e111c74c4">106,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzItNS0xLTEtMjkzNzEw_776fae81-8f63-45f2-9e76-6ccac3fb480a">3.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DilutiveSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzMtMS0xLTEtMjkzNzEw_8cb1ab7f-45da-4296-8024-4bec56680a20">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzMtMy0xLTEtMjkzNzEw_73ba4f2b-c39f-486a-8762-ae063bdff0f8">3,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" sign="-" name="thc:EffectOfDilutiveSecuritiesPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzMtNS0xLTEtMjkzNzEw_756a4d3b-934b-4f90-90a2-827fe9af13ac">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzQtMS0xLTEtMjkzNzEw_31ed6f14-b4d3-421d-9f86-c3fd61bc81e1">418</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzQtMy0xLTEtMjkzNzEw_d4057300-4728-4c52-a5e5-2372fb7dddbf">110,516</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzQtNS0xLTEtMjkzNzEw_0cfd181c-9f3a-4f56-b7b8-501c2384c868">3.78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzYtMS0xLTEtMjkzNzEw_ee847482-d5d8-4fd9-be45-2483ab9a977d">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzYtMy0xLTEtMjkzNzEw_7304cc21-b091-4f87-ae3c-75812adc2194">106,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzYtNS0xLTEtMjkzNzEw_6fcc0c85-8f44-402e-a6c5-66dbdfc4dd23">8.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units and deferred compensation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DilutiveSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzctMS0xLTEtMjkzNzEw_0cff3ea7-6284-41d5-97ee-8fe188301abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzctMy0xLTEtMjkzNzEw_55d346ec-021d-47a9-8c2b-ed184397f634">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" sign="-" name="thc:EffectOfDilutiveSecuritiesPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzctNS0xLTEtMjkzNzEw_73fb6b8c-6a37-4b9a-af8e-fcc27741e5c4">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzgtMS0xLTEtMjkzNzEw_b639470f-0b2d-4275-b249-bd7824a220e2">915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzgtMy0xLTEtMjkzNzEw_75a82ab7-bc46-4b23-aadd-e3d912be584a">108,571</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzgtNS0xLTEtMjkzNzEw_ecd9521b-69fd-4a9c-adc1-49ecdfbd3a6d">8.43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEwLTEtMS0xLTI5MzcxMA_af0db189-d7fe-4804-966a-144d458d4c74">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEwLTMtMS0xLTI5MzcxMA_af056147-b126-4c85-8e8f-a840f73d85c5">105,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEwLTUtMS0xLTI5MzcxMA_aa5eb6b9-0e31-4f48-b9c5-d07cf5dbeadd">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units and deferred compensation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DilutiveSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzExLTEtMS0xLTI5MzcxMA_d67782f2-c6ad-4145-99e3-105baae0a718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzExLTMtMS0xLTI5MzcxMA_31d88933-5b2e-4708-b924-512c9e9c1a45">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" sign="-" name="thc:EffectOfDilutiveSecuritiesPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzExLTUtMS0xLTI5MzcxMA_dfd71372-7333-44f6-9b60-2de6f25490af">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted loss per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEyLTEtMS0xLTI5MzcxMA_3eb9028a-e033-4569-a96f-c66ba9fe6716">399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEyLTMtMS0xLTI5MzcxMA_7eee38e8-488d-4564-ac6a-7beb9d96091c">106,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEyLTUtMS0xLTI5MzcxMA_a04db026-b915-419e-aa45-6c2eabff561b">3.75</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, our convertible instruments consisted of an agreement related to the ownership interest in a Hospital Operations segment joint venture and RSUs issued under the USPI Management Equity Plan. Prior to our purchase of all of the shares underlying the Baylor Put/Call Agreement in June&#160;2022, that agreement was also included in our convertible instruments. Additional information about the RSUs issued under the USPI Management Equity Plan and our purchase of the shares underlying the Baylor Put/Call Agreement is included in Notes 10 and 18, respectively.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_268"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 21. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzIwNjM_ba1bef64-2b7f-4217-892c-8d624e795a3f" continuedAt="ic867c3e1772042e181f3eda505288306" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic867c3e1772042e181f3eda505288306" continuedAt="ibb76f3eea8ff4bb2948608f9bd6ba08b"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non&#8209;financial assets and liabilities. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Recurring Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non&#8209;financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long&#8209;lived assets held and used, long&#8209;lived assets held for sale and goodwill. As discussed in Note 6, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i87e348ef2f5949cfb83ccab43bf831b1_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzEwOTk1MTE2MzczODE_37f159b1-237a-4e70-a38e-8f5e9cbdfadd">82</ix:nonFraction>&#160;million to write down certain long&#8209;lived assets located in one of our markets to their estimated fair value during the year ended December&#160;31,&#160;2022. Based on our evaluation, we estimated the fair value of the long&#8209;lived assets to be $<ix:nonFraction unitRef="usd" contextRef="i54b3f987c4664d6586d2dc3ce06561df_I20221231" decimals="-6" name="thc:AssetsHeldforuseLongLivedFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzEwOTk1MTE2Mzc4NDU_ca6ee0d4-469d-406b-af99-f3876bbe5e44">167</ix:nonFraction>&#160;million. The inputs used to establish this fair value are considered to be Level&#160;2 inputs, which include inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="ibb76f3eea8ff4bb2948608f9bd6ba08b"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long&#8209;term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit&#160;Agreement are considered to be Level 2 inputs. At December&#160;31,&#160;2022 and 2021, the estimated fair value of our long&#8209;term debt was approximately <ix:nonFraction unitRef="number" contextRef="ie4fe8572ea6c491aa3b643277fd661f6_I20221231" decimals="3" name="thc:EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzIwMDI_f27e3b42-f137-4925-874e-8f65269ffff2">92.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i019176855e2e4e78a448696e0f58e777_I20211231" decimals="3" name="thc:EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzIwMDk_c883ee81-c926-438e-b9af-d3a74145b1ed">103.3</ix:nonFraction>%, respectively, of the carrying value of the debt.</span></div></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_274"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 22. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzQzMTg_daa54010-846f-49c9-a450-c7f7f2bb7a9f" continuedAt="iae0ba845114348a79a676c316876e187" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="iae0ba845114348a79a676c316876e187" continuedAt="i55d5e125b4e440cca9927d19aef7a5c6"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2022, we acquired controlling ownership interests in <ix:nonFraction unitRef="surgery_center" contextRef="i4aaed855090043789ca397a60d4a8565_D20220701-20220731" decimals="INF" name="thc:NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NjkzNDY_e48e6893-a858-45a8-b640-5ec42a3db68c">19</ix:nonFraction> fully operational ambulatory surgery centers and <ix:nonFraction unitRef="surgery_center" contextRef="id8d3a9179b7641f5bd9df2620d60173e_D20220701-20220731" decimals="INF" name="thc:NumberOfSurgicalCentersInDevelopmentStage" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NjkzNTY_fa1c81bd-a8ae-4db8-bd58-a0bca6f4a56d">three</ix:nonFraction> centers then in development from United Urology Group. We paid $<ix:nonFraction unitRef="usd" contextRef="id8d3a9179b7641f5bd9df2620d60173e_D20220701-20220731" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDQ4MjI_b025705d-0877-44db-84a8-d47399b9852b">104</ix:nonFraction> million, net of cash acquired, for our ownership interests in these facilities and recognized goodwill of $<ix:nonFraction unitRef="usd" contextRef="i64a492066cbd4c4a85b96cb84a3068f3_I20220731" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDQ4OTE_34b1860d-58ef-4ad9-bb28-7a6c1e3d47b1">316</ix:nonFraction> million. The aggregate acquisition date fair value of the non&#8209;controlling interests in the facilities we acquired was $<ix:nonFraction unitRef="usd" contextRef="i64a492066cbd4c4a85b96cb84a3068f3_I20220731" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDQ5OTQ_0ecefec1-bd41-42ad-94c8-08b041e42d26">223</ix:nonFraction> million. The acquisition of these facilities provided us with access to new markets and further diversified our ambulatory care services portfolio.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired controlling interests in an additional <ix:nonFraction unitRef="surgery_center" contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231" decimals="INF" name="thc:NumberOfSurgicalCentersAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDUyNDg_fd758cc5-27da-47d0-8e4a-d2288a5f7fcc">11</ix:nonFraction> ambulatory surgery centers through a series of transactions during the year ended December&#160;31,&#160;2022. We paid an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDU0MTA_2de7967e-6f18-4113-b74f-7f8bc2c57b18">65</ix:nonFraction> million, net of cash acquired, for these facilities. During 2022, we also acquired controlling interests in <ix:nonFraction unitRef="surgery_center" contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231" decimals="INF" name="thc:NumberOfSurgicalCentersRecordedUsingEquityMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NzEwODU_a819d6db-771d-4b36-9e6b-42ad86b8726b">23</ix:nonFraction> ambulatory surgery centers in which we previously owned a noncontrolling interest for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDYwODk_39c0ce68-57bd-4792-bdaf-6130a97ce0a7">65</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, subsidiaries of USPI acquired ownership interests in <ix:nonFraction unitRef="surgery_center" contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231" decimals="INF" name="thc:NumberOfSurgicalCentersAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2MzkxMzY_af76c272-85d2-4616-9529-07354e2e1842">86</ix:nonFraction> ambulatory surgery centers and related ambulatory support services (collectively, the &#8220;2021 SCD Centers&#8221;) from Surgical Center Development&#160;#3,&#160;LLC and Surgical Center Development&#160;#4,&#160;LLC (&#8220;SCD&#8221;). Of these, we acquired controlling interests in <ix:nonFraction unitRef="surgery_center" contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231" decimals="INF" name="thc:NumberOfAmbulatorySurgeryCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2MzkzNzA_412c11d8-ad31-450a-bd4d-28fa2cc8b8e1">15</ix:nonFraction> ambulatory surgery centers, noncontrolling interests in <ix:nonFraction unitRef="surgery_center" contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231" decimals="INF" name="thc:NumberOfSurgicalCentersRecordedUsingEquityMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Mzk0MzA_c8a3d674-703f-46b4-8ee7-ef911dcabf9e">57</ix:nonFraction> centers and interests in <ix:nonFraction unitRef="surgery_center" contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231" decimals="INF" name="thc:NumberOfSurgicalCentersInDevelopmentStage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Mzk0NTk_5b0305e4-4b1a-4d8a-b2e2-2170826eafbf">14</ix:nonFraction> centers still in the development stage. The newly acquired facilities augmented our Ambulatory Care segment&#8217;s existing musculoskeletal service line and expanded the number of markets it serves. We made a cash payment of $<ix:nonFraction unitRef="usd" contextRef="ib58f6ac4316f4317ab753edc02419bea_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDIyODg_a6d171ca-9527-4abb-8794-11ef4d69b27a">1.125</ix:nonFraction> billion, net of cash acquired, to acquire these facilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the 2021 SCD Centers, we paid an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDIzMDE_2147d2f6-1516-43c6-a895-bdb4ce99513b">74</ix:nonFraction> million to acquire controlling interests in <ix:nonFraction unitRef="business" contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Mzk4OTU_55cb757b-d2ab-43b3-b0e1-40111199e706">11</ix:nonFraction> outpatient businesses and various physician practices during the year ended December&#160;31,&#160;2021. During 2021, we also acquired controlling interests in <ix:nonFraction unitRef="hospital" contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231" decimals="INF" name="thc:NumberofHospitals" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDAwMzc_fcf86c6a-7846-4f7b-b4b2-2bca9e998a5f">three</ix:nonFraction> surgical hospitals and <ix:nonFraction unitRef="quarter" contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231" decimals="INF" name="thc:NumberOfSurgicalCentersAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM4MDA4_8a258726-ca52-4970-a6d3-c45e83acc0d5">two</ix:nonFraction> ambulatory surgery centers in which we previously owned a noncontrolling interest for $<ix:nonFraction unitRef="usd" contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDIzMTU_11d3ec2d-35e2-4a50-8152-a20af79820f1">21</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2020, USPI acquired controlling interests in <ix:nonFraction unitRef="surgical_center" contextRef="i7bc2ab83971e4498a02f300ccab65006_D20201201-20201231" decimals="INF" name="thc:NumberOfSurgicalCentersAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1NjY_10e8dd83-86ab-4adc-98ae-e28c70464fda">45</ix:nonFraction> ambulatory surgery centers (collectively, the &#8220;2020 SCD Centers&#8221;) from SurgCenter Development and physician owners. The fair value of the consideration conveyed for the 2020 SCD Centers was $<ix:nonFraction unitRef="usd" contextRef="i7bc2ab83971e4498a02f300ccab65006_D20201201-20201231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1NzM_d1c4b830-9239-49db-a406-387af825361a">1.115</ix:nonFraction>&#160;billion, consisting of a cash payment of $<ix:nonFraction unitRef="usd" contextRef="ia66fc1c0750d4afda6c0d81b93a363b5_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1ODY_5f68d2d6-9c98-4df8-8b52-8416dd78e9d5">1.097</ix:nonFraction>&#160;billion, fully funded using cash on hand, and the assumption of $<ix:nonFraction unitRef="usd" contextRef="ia66fc1c0750d4afda6c0d81b93a363b5_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1OTg_a9c13ce9-006a-4366-9662-1f44df486f93">18</ix:nonFraction>&#160;million of center&#8209;level debt.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the 2020 SCD Centers, we acquired ownership interests in <ix:nonFraction unitRef="business" contextRef="ic8d5d769fdb2494fa847d0ee04defa5b_D20200101-20201231" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI2MTY_782b2700-414e-4987-a297-b59cc96e3c48">10</ix:nonFraction> outpatient businesses (all of which are in our Ambulatory Care segment), and various physician practices during the year ended December&#160;31,&#160;2020.&#160;The aggregate purchase price for these acquisitions was $<ix:nonFraction unitRef="usd" contextRef="ic8d5d769fdb2494fa847d0ee04defa5b_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI2MjI_b53ebe54-f3ec-42dc-a059-f07b3d1d6743">80</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values.&#160;The excess of the purchase price allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2022 are preliminary. We are in process of assessing working capital balances as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying consolidated financial statements are subject to adjustment once the assessments and valuation work are completed and evaluated. Such adjustments will be recorded as soon as practical and within the measurement period as defined by the accounting literature. During the year ended December&#160;31,&#160;2022, we adjusted the initial purchase allocation of certain acquisitions completed in 2021 based on the results of completed valuations. These adjustments resulted in a net increase in goodwill of $<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NjI1Njc_04c2cea2-9244-42f9-91ab-8a1e9da9b9ba">7</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i55d5e125b4e440cca9927d19aef7a5c6"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzQzMjY_36d84762-b4c3-4ecb-b598-91501ff8af17" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary or final purchase price allocations for all the acquisitions made during the years ended December&#160;31,&#160;2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzItMS0xLTEtMjkzNzEw_1fec45be-3ce2-4cb5-ae81-48293efc83ae">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzItMy0xLTEtMjkzNzEw_8abf36af-672f-4b27-88dc-9f51c39a9357">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzItNS0xLTEtMjkzNzEw_5f93c02b-8d17-4150-867a-a6225d495720">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzMtMS0xLTEtMjkzNzEw_3a9088b6-22f1-4b1d-ad1b-7addf33d1357">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzMtMy0xLTEtMjkzNzEw_9512e570-c8de-4fd8-a8dc-425080fe4f4f">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzMtNS0xLTEtMjkzNzEw_feec70e4-41cf-4cbb-9c4f-73106fe56b25">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzQtMS0xLTEtMjkzNzEw_abcf4c5f-2468-4b55-b71a-30e16d67b627">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzQtMy0xLTEtMjkzNzEw_501fa898-b020-4850-afb5-4c65e857c9af">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzQtNS0xLTEtMjkzNzEw_e01c22b2-64dd-4eb1-bf76-80d5040c1fd8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzUtMS0xLTEtMjkzNzEw_8f53d93f-4411-4131-9fab-3ce68a407228">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzUtMy0xLTEtMjkzNzEw_c624e8f8-53b3-4395-8035-30fc2f663b21">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzUtNS0xLTEtMjkzNzEw_5e29096f-ee7f-44ad-acd8-6bec6c562183">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMS0xLTEtMzYyNzU2_9f4492be-f588-48bf-9181-2242f838b129">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMy0xLTEtMzYyNzU2_c1b0b0cd-71a9-48ec-a7ef-7223547aeff9">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtNS0xLTEtMzYyNzU2_59d0fa0d-2a91-48eb-b7df-d338e9679b2f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously held equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMS0xLTEtMjkzNzEw_34454e8b-83b7-4698-871e-7c7a761e7cf6">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMy0xLTEtMjkzNzEw_75c5b7b7-0684-4085-bc29-8ccc227c1e77">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtNS0xLTEtMjkzNzEw_1be1161b-d394-4419-b315-4a3b78a8ce2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzctMS0xLTEtMjkzNzEw_d99efac8-f7ec-4ed8-90b3-393be6f6cba4">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzctMy0xLTEtMjkzNzEw_256cd06d-61c2-4fbe-ae61-65fd20c54c8c">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzctNS0xLTEtMjkzNzEw_f61ea424-8635-4dde-9513-80486d88203e">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzgtMS0xLTEtMjkzNzEw_499f34c6-8176-4f97-ae1b-2094f59c4fea">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzgtMy0xLTEtMjkzNzEw_11e85226-c31a-4d22-86cf-899c7f11bddd">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzgtNS0xLTEtMjkzNzEw_3a2a46d9-71ab-48eb-b81b-72c9128d7182">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests in equity of consolidated subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzktMS0xLTEtMjkzNzEw_4bdd8819-c019-404e-9bc7-8c376c858aad">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzktMy0xLTEtMjkzNzEw_ed96ea76-174d-4e49-89b0-5ed1774f2d88">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzktNS0xLTEtMjkzNzEw_6dfb5009-9aa7-4ae5-9d3c-7803671f7ed5">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEwLTEtMS0xLTI5MzcxMA_33e0a8ef-e2b8-4996-a959-72ca05fd98c6">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEwLTMtMS0xLTI5MzcxMA_3d8a28f8-b71b-40e5-aa33-f5f8fd4aacbd">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEwLTUtMS0xLTI5MzcxMA_10383875-6553-4a3e-ab58-1672134b0216">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzExLTEtMS0xLTI5MzcxMA_d165e2b4-1194-485f-b60c-8371693d7091">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzExLTMtMS0xLTI5MzcxMA_19cd8ba0-ec62-4beb-aa34-2d02498b4469">1,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzExLTUtMS0xLTI5MzcxMA_c24d1afb-688e-4d33-b542-7c8612b593bd">1,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains on consolidations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEyLTEtMS0xLTI5MzcxMA_ffec8b85-47e0-4106-a6a8-2df72cc25caf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEyLTMtMS0xLTI5MzcxMA_c5d55fc3-1a41-4565-aa18-9b1894bfea2d">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEyLTUtMS0xLTI5MzcxMA_a1a7d95d-c18c-49c8-ba35-c7d3baaab2ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the facilities described above are included in our Ambulatory Care segment. The majority of the goodwill generated from our 2022 acquisitions will not be deductible for income tax purposes; however, the majority of the goodwill generated from our 2021 and 2020 transactions will be. The goodwill generated from these transactions can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. Approximately $<ix:nonFraction unitRef="usd" contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231" decimals="-6" name="thc:BusinessCombinationAcquisitionRelatedTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM1MjU_8c542d99-eb19-41a2-b026-43aec3d51499">14</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231" decimals="-6" name="thc:BusinessCombinationAcquisitionRelatedTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM1Mjk_6bba5c97-7beb-438e-97fc-26ac0e56c2e6">20</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231" decimals="-6" name="thc:BusinessCombinationAcquisitionRelatedTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM1MzY_35fe0b8f-0d07-45b4-ac39-393e29c11f00">14</ix:nonFraction> million in transaction costs related to prospective and closed acquisitions were expensed during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively, and are included in impairment and restructuring charges, and acquisition&#8209;related costs in the accompanying Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021, we recognized gains totaling $<ix:nonFraction unitRef="usd" contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTc3NjQ_822fbf78-7489-44b9-8de1-575e61766627">23</ix:nonFraction>&#160;million associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests. <ix:nonFraction unitRef="usd" contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Njg5NTI_609b6fbd-29e7-4469-be62-c90ec89b156d"><ix:nonFraction unitRef="usd" contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Njg5NTI_cba13333-75ff-40c7-80a4-c8ff5da7f346">No</ix:nonFraction></ix:nonFraction> such gains or losses were recognized in the years ended December&#160;31,&#160;2022 or 2020.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro Forma Information - Unaudited</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzQ5NDc4MDIzNjg3NDE_7e0fca00-d421-40fe-ac38-d2795094a8f4" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain pro forma information for Tenet as if the 2021 SCD Centers acquisition had occurred at the beginning of the year ended December&#160;31,&#160;2020:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231" decimals="-6" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzItMS0xLTEtMzYyMTE3_eb51627b-d345-499b-9496-05272ada4bcc">19,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231" decimals="-6" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzItMy0xLTEtMzYyMTE3_dc5a13de-50b4-4ff7-8aa5-e6aab9485b8b">17,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231" decimals="-6" name="thc:BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzMtMS0xLTEtMzYyMTE3_64ddcc7a-71e5-49e1-af41-edfcd921a4d6">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231" decimals="-6" name="thc:BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzMtMy0xLTEtMzYyMTE3_e5d34352-ed5a-4e46-9916-f27acf9d848a">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231" decimals="-6" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzQtMS0xLTEtMzYyMTE3_0415ae36-4699-42f4-b191-db6ee3866173">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231" decimals="-6" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzQtMy0xLTEtMzYyMTE3_4d96b1f2-8ae4-4eaa-a0f0-b36641aee45c">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share available to Tenet Healthcare Corporation </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzUtMS0xLTEtMzYyMTE3_98175f0a-b6fe-42c1-a97f-019269de68fc">8.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzUtMy0xLTEtMzYyMTE3_8920c611-1af1-4fdc-a735-aa918bd2fd41">3.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i397b00e3dcff45d9b9c5c6459ba30276_277"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 23. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzI1MDI_f9a5563c-da05-4f4f-934e-d925d41b107c" continuedAt="i6f71cd71d77e4c50be7828bd2b02549e" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i6f71cd71d77e4c50be7828bd2b02549e" continuedAt="i9a10dad708fb4a0399ff3496dd40d5a8"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business consists of our Hospital Operations segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#8209;hospitals and physician practices. At December&#160;31,&#160;2022, our subsidiaries operated <ix:nonFraction unitRef="hospital" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="INF" name="thc:NumberOfHospitalsOperatedBySubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzQyMg_54e4a860-048a-4cc3-a1f4-48e710100192">61</ix:nonFraction>&#160;hospitals serving primarily urban and suburban communities in <ix:nonFraction unitRef="state" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzQ4Nw_b7b2d7ef-0461-4d53-9f16-be3fa864146e">nine</ix:nonFraction>&#160;states, including the new acute care hospital we opened in September&#160;2022 in South Carolina. On April&#160;1, 2021, we transferred <ix:nonFraction unitRef="imaging_center" contextRef="i201297e314ab451088f2cc2cd5577ad8_I20210401" decimals="INF" name="thc:NumberOfImagingCentersTransferred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzUyMA_1c9f1e54-0342-4dd7-a0e8-dfe44b03fc3c">24</ix:nonFraction>&#160;imaging centers from our Ambulatory Care segment to our Hospital Operations segment. The total assets associated with the imaging centers transferred to our Hospital Operations segment constituted less than <ix:nonFraction unitRef="number" contextRef="i1c476cd298284a1bafde8fdd47d49539_D20210101-20210331" decimals="2" name="thc:SegmentReportingTransferOfAssetsPercentageOfTotalAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzczMA_c1eb750d-3f68-4f30-aabc-f3b3b181f226">1</ix:nonFraction>% of our consolidated total assets at March&#160;31,&#160;2021. Also in April&#160;2021, we completed the sale of the majority of the urgent care centers then held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, we completed the sale of the Miami Hospitals in August&#160;2021, all of which were held by our Hospital Operations segment.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:continuation id="i9a10dad708fb4a0399ff3496dd40d5a8" continuedAt="idb7d5db167124058a7f20b3297af501a"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment is comprised of the operations of USPI. At December&#160;31,&#160;2022, USPI had ownership interests in <ix:nonFraction unitRef="hospital" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfAmbulatorySurgeryCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzU0OTc1NTgyNDMzNA_b2b2ca3f-bee8-4ddd-8e2d-39a8b281b0a6">442</ix:nonFraction> ambulatory surgery centers (<ix:nonFraction unitRef="surgery_center" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfAmbulatorySurgeryCentersConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwMjg_372f189b-e246-4dc1-9c0c-f97500bb3934">300</ix:nonFraction> consolidated) and <ix:nonFraction unitRef="hospital" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfSurgicalHospitalsOperatedBySubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwNTA_8195e77a-deb5-46c2-b162-445e0908cf16">24</ix:nonFraction> surgical hospitals (<ix:nonFraction unitRef="hospital" contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231" decimals="INF" name="thc:NumberOfSurgicalHospitalsConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwNzQ_56152a7c-cb7e-4fbd-9508-3d90c304d022">eight</ix:nonFraction> consolidated) in <ix:nonFraction unitRef="state" contextRef="i86001c59573247b08eeb42c93d75f6f7_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwOTU_df009046-ce98-484c-9770-e534259f08ba">35</ix:nonFraction>&#160;states. In April&#160;2021, we completed the sale of <ix:nonFraction unitRef="hospital" contextRef="i82e19c7717074970a71b4dccde90bc0b_D20210401-20210430" decimals="INF" name="thc:NumberOfUrgentCareCentersSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTExODE_594e90f6-2a8d-4db2-8035-4c10894ce386">40</ix:nonFraction>&#160;urgent care centers then held by our Ambulatory Care segment to an unaffiliated urgent care provider and, as noted above, transferred <ix:nonFraction unitRef="imaging_center" contextRef="i201297e314ab451088f2cc2cd5577ad8_I20210401" decimals="INF" name="thc:NumberOfImagingCentersTransferred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEzMzE_1c9f1e54-0342-4dd7-a0e8-dfe44b03fc3c">24</ix:nonFraction>&#160;imaging centers from our Ambulatory Care segment to our Hospital Operations segment. Effective June&#160;30,&#160;2022, we purchased all of the shares previously held by Baylor in USPI for $<ix:nonFraction unitRef="usd" contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630" decimals="-6" name="thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTE1MTU_fa8c3ef3-021a-4cc5-9bd4-a8c95825b1c6">406</ix:nonFraction>&#160;million, which increased our ownership interest in USPI&#8217;s voting shares from <ix:nonFraction unitRef="number" contextRef="i647dc680b9224e41a241261103ccd5aa_I20220629" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTE2MTQ_b3c1d141-1e18-4b2d-953e-ef3ac40f0990">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i20f7c47ed3f1432b9993a85a212b93bc_I20220630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTE2MjE_92a366f0-dac1-4f41-9978-3b698155d42b">100</ix:nonFraction>%. See Note&#160;18 for additional information about this transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients. At December&#160;31,&#160;2022, Conifer provided services to approximately <ix:nonFraction unitRef="hospital" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-1" name="thc:NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzEzODY_c32766d5-3bfb-412d-8633-0e9dfd459ae5">660</ix:nonFraction>&#160;Tenet and non&#8209;Tenet hospitals and other clients nationwide. We have entered into an agreement documenting the terms and conditions of various services Conifer provides to Tenet hospitals (&#8220;RCM Agreement&#8221;), as well as an agreement documenting certain administrative services our Hospital Operations segment provides to Conifer. In March 2021, we entered into a month&#8209;to&#8209;month agreement amending the RCM Agreement effective January&#160;1,&#160;2021 (&#8220;Amended RCM Agreement&#8221;) to update certain terms and conditions related to the revenue cycle management services Conifer provides to Tenet hospitals. We believe the pricing terms for the services provided under the Amended RCM Agreement are commercially reasonable and consistent with estimated third&#8209;party terms. At December&#160;31,&#160;2022, we owned approximately <ix:nonFraction unitRef="number" contextRef="i314717058c7b4b6fb0a8169f1a019fe3_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzIxNzY_5a760f4f-7fae-48f6-9c61-b07d26dc8ebd">76</ix:nonFraction>% of Conifer Health Solutions, LLC, which is Conifer&#8217;s principal subsidiary.</span></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzI0OTU_9e654d69-01a6-4679-b836-e6052c6a90a4" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Consolidated Balance Sheets and Consolidated Statements of Operations, as applicable:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476176f776be4198873c2255c05882ac_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzMtMS0xLTEtMjkzNzEw_e9175705-e403-408b-9e9a-2dd5583cb929">15,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzMtMy0xLTEtMjkzNzEw_685126fd-34b0-483f-978b-92f0b161e65d">17,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if474534dcafd415d9534dbb0774b811e_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzMtNS0xLTEtMjkzNzEw_5861b183-1283-4db1-a558-08a7bacf9aa3">18,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib165a084700643e1b139d15df43a3b15_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzQtMS0xLTEtMjkzNzEw_de53536f-62da-4d4b-8f2f-4c9ee8541857">10,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzQtMy0xLTEtMjkzNzEw_78cf949f-de42-43f5-ab98-73099eae7b90">9,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzQtNS0xLTEtMjkzNzEw_e8d11458-083f-4d9c-9c4a-8bf6eb38f542">8,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231" decimals="-6" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzUtMS0xLTEtMjkzNzEw_b1daf8c3-5e4e-4924-a5a1-2dfe7a78b026">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231" decimals="-6" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzUtMy0xLTEtMjkzNzEw_7e979f77-1537-4599-bead-4cb941e1b59e">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzUtNS0xLTEtMjkzNzEw_d6a22a40-c0e4-43a0-a8be-4f443b4babd6">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzYtMS0xLTEtMjkzNzEw_08c66b8b-ce0a-46ed-8d7f-d21ad0f6859d">27,156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzYtMy0xLTEtMjkzNzEw_460be173-cbc2-4475-a7ca-abd0a97e5ab8">27,579</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzYtNS0xLTEtMjkzNzEw_d68bb19a-b60e-48e4-8d21-2c4eb894d497">27,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:5pt"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzI0OTc_05937e04-1f8d-4d96-9e5a-68cd9dfa8a08" continuedAt="i8f28e0a32ee0454d8416b2284e314d6a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzMtMS0xLTEtMjkzNzEw_70fbc80f-2f0a-45c5-b5bc-47cb420a387a">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzMtMy0xLTEtMjkzNzEw_61a7916b-fcfb-4fac-ba08-c08184a83a7a">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzMtNS0xLTEtMjkzNzEw_18b8eb56-db99-4e5c-9ba9-2e26d89de335">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzQtMS0xLTEtMjkzNzEw_c368703c-4e8e-4b39-864c-60a3189797e5">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzQtMy0xLTEtMjkzNzEw_aacd3104-1eb9-4e19-9cb3-a9c035b5927a">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzQtNS0xLTEtMjkzNzEw_93b8c48f-d541-42d7-92e5-cc7472895a9a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzUtMS0xLTEtMjkzNzEw_b55f17e8-f33d-4c2c-bd9d-a760a22bc12c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzUtMy0xLTEtMjkzNzEw_ca8b0156-b5eb-4e7a-9d4d-56015e43cd50">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzUtNS0xLTEtMjkzNzEw_99dfa60f-2b31-45e8-bad2-595c9733bc6a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzYtMS0xLTEtMjkzNzEw_bba46f12-6a88-4515-856a-1adcfe3f112b">762</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzYtMy0xLTEtMjkzNzEw_ac903541-dad1-4220-b416-2575fc60bb05">658</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzYtNS0xLTEtMjkzNzEw_9a8eb682-4d8e-4b0f-9719-67de8f43437c">540</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie464e81a78ca4b5bbc82e4f831a2f8fd_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzktMS0xLTEtMjkzNzEw_96f4bce5-9320-421b-9bbd-e7c7d0698392">15,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6e909d5f7146e6b2f3799ec1c792e7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzktMy0xLTEtMjkzNzEw_aa7d4114-35aa-45bb-a3b9-8188d4529b75">15,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fc34a3116b48039c40d17002cd0211_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzktNS0xLTEtMjkzNzEw_d4108a16-b9f7-46f3-b559-94407073af58">14,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ce7b2af81a45cebea65cf46c0e002e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEwLTEtMS0xLTI5MzcxMA_b8ce1ddd-fb95-45df-8d8c-006018dc22f0">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e55bb2a3404d37ac0446903cd6f0ae_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEwLTMtMS0xLTI5MzcxMA_b38258d2-d4ba-4eb5-81fc-3a0e7ffbb12d">2,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bd925e775946d38f284ce1b8382ffb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEwLTUtMS0xLTI5MzcxMA_7126e95f-1868-4985-a607-b58375343009">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18d9a3de8e841b08ffc82230780dc95_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEyLTEtMS0xLTI5MzcxMA_081a815a-c392-4f14-ae99-cd10c6a9e3c4">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ceaf5394f94012b9da3e04b6ed796c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEyLTMtMS0xLTI5MzcxMA_6f40ff5e-4539-4068-84dc-afb3070bc39e">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4376608b69a145f2998cf8f78326c6d3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEyLTUtMS0xLTI5MzcxMA_4d1c01ab-4966-45d4-b39c-5a220220dc58">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other clients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4247e435c1a48c9abfb49f3a445ea67_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEzLTEtMS0xLTI5MzcxMA_6b20adc3-73b4-4adb-99c8-8bbe0e72507f">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6bdb8fda770486f97297332c7c0c2e9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEzLTMtMS0xLTI5MzcxMA_baee1e8e-24fd-4a06-8cfd-d5098a697c18">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd670b142c346aba126a22c475f14a8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEzLTUtMS0xLTI5MzcxMA_2395c878-5b10-4bb4-87a0-42fc04458ca7">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Conifer revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cc1bcf836fb4be6bef17a04e3599061_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE0LTEtMS0xLTI5MzcxMA_6c875dab-91f1-45c4-b63b-8e8ed19c12df">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a76387d9429414d8b35662237a46f7d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE0LTMtMS0xLTI5MzcxMA_019081e9-74a2-4f38-89af-ca43301919ee">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b36c3b506c460a83c8be8982727090_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE0LTUtMS0xLTI5MzcxMA_1e17a532-ef9c-47ca-84dc-5d1426ab46c0">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-segment eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1253b20e6f0b4e17802a597aa8a7b59f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE1LTEtMS0xLTI5MzcxMA_2979d74a-8608-4002-be94-a281aa4a7929">451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia925e5b318a2405589428d1271dec1b3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE1LTMtMS0xLTI5MzcxMA_6d27f424-664a-485e-b406-d6b4b9191b4f">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9db4542a137447f59a1e7ac2c89d14d3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE1LTUtMS0xLTI5MzcxMA_aefeb727-c00a-4c4b-a6be-2325f2497c17">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE2LTEtMS0xLTI5MzcxMA_9d64db4c-4ea6-4e14-a523-a363acadd292">19,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE2LTMtMS0xLTI5MzcxMA_a605c4a0-ee24-480f-8485-438f1c60ad62">19,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE2LTUtMS0xLTI5MzcxMA_4da60c73-02e9-46b9-8891-456be8ed2009">17,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE5LTEtMS0xLTI5MzcxMA_52e215f2-a8e1-48ab-b656-93d6ef803c96">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE5LTMtMS0xLTI5MzcxMA_1d592820-05e6-4b71-891c-3c900effaab1">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE5LTUtMS0xLTI5MzcxMA_2bccc380-a71d-4914-ac4e-00291b3b7e3f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIwLTEtMS0xLTI5MzcxMA_da491b0c-ba0c-4e43-8f0c-39ac9b430f49">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIwLTMtMS0xLTI5MzcxMA_2a21ddd0-75d8-4874-a306-20857fbe67d1">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIwLTUtMS0xLTI5MzcxMA_c56d8f67-bccf-4cef-95e8-202dc6d53e73">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIxLTEtMS0xLTI5MzcxMA_b557b9c8-e0c9-4117-9b87-945a43a11896">216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIxLTMtMS0xLTI5MzcxMA_9736cb14-74e9-42d8-9a88-23003f4c6d95">218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIxLTUtMS0xLTI5MzcxMA_19f60d32-3c08-4c55-86f0-269eb7091d5e">169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><ix:continuation id="idb7d5db167124058a7f20b3297af501a"><ix:continuation id="i8f28e0a32ee0454d8416b2284e314d6a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzgtMS0xLTEtMjkzNzEw_840cc815-fd34-4117-b4ef-50759ab2c1e7">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzgtMy0xLTEtMjkzNzEw_daf7bd4e-61df-4909-9b4b-d4b8252c4ba3">1,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzgtNS0xLTEtMjkzNzEw_892e2531-8f61-4680-86ee-6a5ad8744c6e">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzktMS0xLTEtMjkzNzEw_efca1267-b66a-4550-b727-23334c42afdf">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzktMy0xLTEtMjkzNzEw_8cc5f8a0-dd53-42aa-a073-aa2b9990e750">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzktNS0xLTEtMjkzNzEw_6383ca7f-f48e-46fe-9f00-976f610e27e4">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzEwLTEtMS0xLTI5MzcxMA_5e98e01a-fdc6-4b34-9b58-6fc428c108a7">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzEwLTMtMS0xLTI5MzcxMA_99f723ec-1cd7-4f8e-951c-75077833e28f">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzEwLTUtMS0xLTI5MzcxMA_23568b43-591b-4fc0-866e-976396938f82">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzExLTEtMS0xLTI5MzcxMA_698b00f8-c8f9-4446-9da9-945852f823e5">3,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzExLTMtMS0xLTI5MzcxMA_5b79446e-ffd4-4c88-a91b-cf0988a03ce4">3,483</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzExLTUtMS0xLTI5MzcxMA_cdc119bd-1cef-4a0e-bdeb-173045fa8165">3,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIwLTEtMS0xLTI5MzcxMA_4023bf90-fc5b-43b8-85c5-4474286c2dad">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIwLTMtMS0xLTI5MzcxMA_19d3e4e5-f349-4825-92d3-d7bca11de28b">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIwLTUtMS0xLTI5MzcxMA_330d3ebb-e3e1-414b-ba0f-c1e359b86fba">739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIxLTEtMS0xLTI5MzcxMA_872569b3-97bf-4fde-bd9c-e0d85ae032cb">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIxLTMtMS0xLTI5MzcxMA_b994629e-aa49-48a1-9282-0069e7937f9d">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIxLTUtMS0xLTI5MzcxMA_68917734-d7cf-4b16-95da-7cf940b9a589">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIyLTEtMS0xLTI5MzcxMA_d1d4f7cc-84c9-410e-a0cd-d4b1d40ad084">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIyLTMtMS0xLTI5MzcxMA_b9ac9633-ec40-4c64-b648-6cffaf0d5b6a">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIyLTUtMS0xLTI5MzcxMA_26c3d7a4-031a-4e96-8ae0-7b6b8d6e7c8e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIzLTEtMS0xLTI5MzcxMA_f823d4bd-c088-48f0-bc6e-ae114e712749">841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIzLTMtMS0xLTI5MzcxMA_86b5a410-e349-4e52-8617-31fbeff8a996">855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIzLTUtMS0xLTI5MzcxMA_3a5078e8-5861-4a65-9a96-4906e18e78d0">857</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA&#160;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI1LTEtMS0xLTI5MzcxMA_45126754-5811-4f7e-8737-28aa63447612">3,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI1LTMtMS0xLTI5MzcxMA_d498012a-7cd3-4832-b602-5c9908114d22">3,483</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI1LTUtMS0xLTI5MzcxMA_0453ad5a-ad0f-4aa9-bfdc-11829ccc0ee6">3,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from divested and closed businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:IncomeLossFromDivestedAndClosedBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI2LTEtMS0xLTI5MzcxMA_ea19a8eb-57ab-42e6-86f2-87fa8c538583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="thc:IncomeLossFromDivestedAndClosedBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI2LTMtMS0xLTI5MzcxMA_f864371c-e23f-4835-ad67-299ae7cc45d0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:IncomeLossFromDivestedAndClosedBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI2LTUtMS0xLTI5MzcxMA_3b378113-9b63-44cf-82ba-e83105cc026e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI3LTEtMS0xLTI5MzcxMA_363f4154-8da1-4cfb-8d37-01f21b7a7aa8">841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI3LTMtMS0xLTI5MzcxMA_9e9ffc64-cbdd-4911-9b31-54bc1812490e">855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI3LTUtMS0xLTI5MzcxMA_7129c831-d8cb-496b-b1d3-fdd9bcf5ce78">857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI4LTEtMS0xLTI5MzcxMA_717d355f-699e-4e63-a966-64779ed9577c">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI4LTMtMS0xLTI5MzcxMA_29b28c2b-65a0-4e85-b1b5-7fcc01d402eb">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI4LTUtMS0xLTI5MzcxMA_e071357e-4255-4a4c-b941-654d7c2a482d">290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI5LTEtMS0xLTI5MzcxMA_d3c69c42-3ad6-4e8f-bb7d-1b18d5c91775">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI5LTMtMS0xLTI5MzcxMA_696fae1e-43c1-4c59-b7d8-9335b6f69613">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI5LTUtMS0xLTI5MzcxMA_f3aa3af3-de5d-409c-a363-927ca3c36344">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMwLTEtMS0xLTI5MzcxMA_6c740acf-fd3a-4301-9223-3f20bb65b237">890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMwLTMtMS0xLTI5MzcxMA_c658ef81-1fe7-4c93-8983-1fc3766f7130">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMwLTUtMS0xLTI5MzcxMA_82bb2949-1219-42df-90d0-2dd97e0d5137">1,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMxLTEtMS0xLTI5MzcxMA_4a34f400-e659-4508-bd50-9526f72669ab">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMxLTMtMS0xLTI5MzcxMA_5ade9127-a914-4c16-957b-28a5cbf9428d">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMxLTUtMS0xLTI5MzcxMA_f11970c6-07c8-410d-9f5c-c7183e384f95">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMyLTEtMS0xLTI5MzcxMA_b328e674-e248-46a1-8546-3147d0bd19cb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMyLTMtMS0xLTI5MzcxMA_2ee320bd-b8dc-43f4-9e1a-e9abdfd83666">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMyLTUtMS0xLTI5MzcxMA_23c5a3fc-824a-40aa-973a-882a6469256b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMzLTEtMS0xLTI5MzcxMA_e386feee-420b-4147-b63d-49ae905dc3b1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMzLTMtMS0xLTI5MzcxMA_e803e0c9-d058-41d8-ac2c-29bd3c2fcfd5">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMzLTUtMS0xLTI5MzcxMA_a3e297bb-a5ba-47b7-be4d-670a476adef3">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations, before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzM0LTEtMS0xLTI5MzcxMA_384fb1b6-2caa-4063-9a37-c8ee2ce6255b">1,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzM0LTMtMS0xLTI5MzcxMA_d64ca949-ef94-42a7-bd4d-6d12ab460676">1,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzM0LTUtMS0xLTI5MzcxMA_13eb049e-23e8-4c0a-bf87-291e7f3732f7">671</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></ix:continuation></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_280"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 24. <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yODAvZnJhZzphN2QyZjBhMDkwODc0ODY1YTYzOGYzM2UyM2I4NDk0OC90ZXh0cmVnaW9uOmE3ZDJmMGEwOTA4NzQ4NjVhNjM4ZjMzZTIzYjg0OTQ4XzQ2MjM_242207ea-ce0a-412f-bf7b-4bff179fb8e3" continuedAt="i14d81012c51c46bd8552a0db1c91b90b" escape="true">RECENT ACCOUNTING STANDARDS</ix:nonNumeric></span></div><ix:continuation id="i14d81012c51c46bd8552a0db1c91b90b"><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yODAvZnJhZzphN2QyZjBhMDkwODc0ODY1YTYzOGYzM2UyM2I4NDk0OC90ZXh0cmVnaW9uOmE3ZDJmMGEwOTA4NzQ4NjVhNjM4ZjMzZTIzYjg0OTQ4XzQ2MTg_fa56d421-b215-4d6d-8731-5ea8d85c75b9" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB issued ASU 2022&#8209;03, &#8220;Fair Value Measurement (Topic 820) &#8211; Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&#8221; (&#8220;ASU 2022&#8209;03&#8221;) in June&#160;2022. Through ASU 2022&#8209;03 the FASB clarified that an entity should measure the fair value of an equity security subject to contractual sale restriction the same way it measures an identical equity security that is not subject to such a restriction. Under this approach the contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, should not affect its fair value. ASU 2022&#8209;03 also enhanced the disclosure requirements related to these instruments. The ASU is effective for public entities for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years, and early adoption is permitted. For non&#8209;investment companies, ASU 2022&#8209;03 will be applied prospectively with adjustments resulting from the initial adoption recognized in earnings and disclosed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in ASU 2022&#8209;03 primarily affect the RSUs granted to our non&#8209;employee directors as part of their annual compensation, which vest immediately but cannot be sold until a three&#8209;year holding period has lapsed. Upon adoption, we expect to recognize an immaterial amount of incremental stock compensation expense related to these awards.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2021, the FASB issued ASU 2021-08, &#8220;Business Combinations (Topic 805) &#8211; Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221; (&#8220;ASU 2021-08&#8221;). The standard addresses diversity in practice related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 &#8211; Revenue from Contracts with Customers as if the acquirer had originated the contracts, as opposed to at their fair value on the acquisition date. ASU 2021-08 is effective for us beginning in 2023, with early adoption permitted. We are currently evaluating the impact of this standard to our financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span id="ia7d2f0a090874865a638f33e23b84948_25466"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 1, we adopted ASU&#160;2020-06 effective January&#160;1,&#160;2022 and adopted ASU 2016&#8209;13 effective January&#160;1,&#160;2020. We applied the modified retrospective transition approach as of the period of adoption for both ASU&#160;2020-06 and ASU 2016&#8209;13.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_292"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_295"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a&#8209;15(e) and 15d&#8209;15(e) under the Exchange Act, as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s report on internal control over financial reporting is set forth on page <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_157">79</a> and is incorporated herein by reference. The independent registered public accounting firm that audited the financial statements included in this report has issued an attestation report on our internal control over financial reporting as set forth on page <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_160">80</a>&#160;herein.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31,&#160;2022. In that period, management migrated our primary payroll processing system to a new human resource management system. We have appropriately considered the potential impact to our control design and related tests of operating effectiveness of internal control over financial reporting as of December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described above, there were no changes to our internal control over financial reporting during the quarter ended December&#160;31,&#160;2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_298"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_301"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_304"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_307"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item regarding the identity and business experience of our directors is set forth under the subsections &#8220;Nominees for Election to the Board of Directors,&#8221; &#8220;Director Nomination and Qualifications&#8221; and &#8220;Director Nominees&#8217; Qualifications and Experience&#8221; under the heading &#8220;Proposal 1 &#8211; Election of Directors,&#8221; and the information required by this Item regarding the identity and business experience of our executive officers is set forth under the heading &#8220;Executive&#160;Officers,&#8221; in each case in the definitive proxy materials we will file in connection with our 2023&#160;Annual Meeting of Shareholders. All such information is incorporated herein by reference in accordance with General Instruction G(3) to Form&#160;10&#8209;K.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on our Audit Committee and Audit Committee Financial Experts required by this Item is set forth under the caption &#8220;Corporate Governance and Board Practices &#8211; Committees&#8221; in the definitive proxy materials we will file in connection with our 2023&#160;Annual Meeting of Shareholders and is incorporated herein by reference in accordance with General&#160;Instruction G(3) to Form&#160;10&#8209;K.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information concerning our Code of Conduct, by which all of our employees and officers, including our chief&#160;executive officer, chief financial officer and principal accounting officer, are required to abide appears under Item 1, Business&#160;&#8211;&#160;Compliance and Ethics, of Part I of this report.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_310"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth under the headings &#8220;Executive Compensation Tables,&#8221; &#8220;Corporate&#160;Governance and Board Practices &#8211; Committees &#8211; HR Committee Interlocks and Insider Participation&#8221; and &#8220;Human&#160;Resources Committee Report&#8221; in the definitive proxy materials we will file in connection with our 2023&#160;Annual&#160;Meeting of Shareholders and is incorporated herein by reference in accordance with General Instruction G(3) to&#160;Form&#160;10&#8209;K.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_313"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about security ownership of certain beneficial owners required by this Item is set forth under the headings &#8220;Securities Ownership&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; in the definitive proxy materials we will file in connection with our 2023&#160;Annual Meeting of Shareholders and is incorporated herein by reference in accordance with General Instruction G(3) to Form&#160;10&#8209;K.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_316"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth under the headings &#8220;Corporate Governance and Board Practices&#160;&#8211;&#160;Certain Relationships and Related Person Transactions&#8221; and &#8220;Proposal&#160;1&#160;&#8211;&#160;Election of Directors&#160;&#8211;&#160;Director Nominees&#8217; Qualifications and Experience&#160;&#8211;&#160;Director Independence&#8221; in the definitive proxy materials we will file in connection with our 2023&#160;Annual Meeting of Shareholders and is incorporated herein by reference in accordance with General Instruction G(3) to Form&#160;10&#8209;K.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_319"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth under the heading &#8220;Proposal&#160;4&#160;&#8211;&#160;Ratification of the Selection of Independent Registered Public Accountants&#8221; in the definitive proxy materials we will file in connection with our 2023&#160;Annual Meeting of Shareholders and is incorporated herein by reference in accordance with General Instruction G(3) to Form&#160;10&#8209;K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_322"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_325"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_328"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements and notes thereto can be found on pages <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_166">83</a> through <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7d2f0a090874865a638f33e23b84948_25466">130</a>.</span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_331"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule II&#8212;Valuation and Qualifying Accounts (included on page <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i397b00e3dcff45d9b9c5c6459ba30276_349">141</a>).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules and financial statements of the Registrant are omitted because they are not applicable or not required or because the required information is included in the Consolidated Financial Statements or notes thereto.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_337"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, the following exhibits are filed with this report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Articles of Incorporation and Bylaws</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312508165765/dex3a.htm">Amended and Restated Articles of Incorporation of the Registrant, as amended and restated May&#160;8,&#160;2008 (Incorporated by reference to Exhibit 3(a) to Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30,&#160;2008, filed August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312508165765/dex3a.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312508165765/dex3a.htm">5,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312508165765/dex3a.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312508165765/dex3a.htm">2008)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000110465912068539/a12-23516_1ex3d1.htm">Certificate of Change Pursuant to NRS&#160;78.209, filed with the Nevada Secretary of State effective October&#160;10,&#160;2012 (Incorporated by reference to Exhibit&#160;3.1 to Registrant&#8217;s Current Report on Form&#160;8-K filed October&#160;11,&#160;2012)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">Amended and Restated Bylaws of the Registrant, as amended and restated effective January</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">3,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">2019 (Incorporated by reference to Exhibit 3.1 to Registrant&#8217;s Current Report on Form 8-K filed January</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">7,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000003/thc-201913bylaws.htm">2019)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments Defining the Rights of Security Holders, Including Indentures</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex4a.htm">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000091205701538499/a2063013zex-4_1.htm">Indenture, dated as of November 6, 2001, between the Registrant and The Bank of New York, as trustee (Incorporated by reference to Exhibit&#160;4.1 to Registrant&#8217;s Current Report on Form&#160;8-K filed November&#160;9,&#160;2001)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000091205701538499/a2063013zex-4_4.htm">Third Supplemental Indenture, dated as of November 6, 2001, between the Registrant and The&#160;Bank of New York, as trustee, relating to 6.875% Senior Notes due 2031 (Incorporated by reference to Exhibit&#160;4.4 to Registrant&#8217;s Current Report on Form&#160;8-K filed November&#160;9,&#160;2001)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312517206046/d408468dex42.htm">Twenty-Ninth Supplemental Indenture, dated as of June&#160;14,&#160;2017, among the Registrant, The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York, and the guarantors party thereto, relating to 4.625%&#160;Senior Secured First Lien Notes due&#160;2024 (Incorporated by reference to Exhibit&#160;4.2 to Registrant&#8217;s Current Report on Form&#160;8-K filed June&#160;16,&#160;2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312517206046/d408468dex43.htm">Senior Secured First Lien Notes Indenture, dated as of June&#160;14,&#160;2017, between THC&#160;Escrow&#160;Corporation&#160;III and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to 4.625%&#160;Senior Secured First Lien Notes due&#160;2024 (Incorporated by reference to Exhibit&#160;4.3 to Registrant&#8217;s Current Report on Form&#160;8-K filed June&#160;16,&#160;2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">Thirtieth Supplemental Indenture, dated as of February 5, 2019, among the Registrant, The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York, and the guarantors party thereto, relating to 6.250% Senior Secured Second Lien Notes due 2027 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">4.2 to Registrant&#8217;s Current Report on Form 8-K filed February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">6,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312519028930/d637393dex42.htm">2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex42.htm">Thirty-First Supplemental Indenture, dated as of August 26, 2019, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A. relating to 4.625%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex42.htm">Senior Secured First Lien Notes due 2024 (Incorporated by reference to Exhibit&#160;4.2 to Registrant&#8217;s Current&#160;Report on Form&#160;8-K filed August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex42.htm">26,&#160;2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex43.htm">Thirty-Second Supplemental Indenture, dated as of August 26, 2019, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A. relating to 4.875%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex43.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex43.htm">Senior Secured First Lien Notes due 2026 (Incorporated by reference to Exhibit&#160;4.3 to Registrant&#8217;s Current&#160;Report on Form&#160;8-K filed August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex43.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex43.htm">26,&#160;2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex44.htm">Thirty-Third Supplemental Indenture, dated as of August 26, 2019, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A. relating to 5.125%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex44.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex44.htm">Senior Secured First Lien Notes due 2027 (Incorporated by reference to Exhibit&#160;4.4 to Registrant&#8217;s Current&#160;Report on Form&#160;8-K filed August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex44.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519229556/d794751dex44.htm">26,&#160;2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">Thirty-Fifth Supplemental Indenture, dated as of June 16, 2020, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to 4.625%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">Senior Secured First Lien Notes due 2028 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">4.2 to Registrant&#8217;s Current Report on Form 8-K filed June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">16,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520170420/d217569dex42.htm">2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520247267/d26262dex42.htm">Thirty-Sixth Supplemental Indenture, dated as of September 16, 2020, between the Registrant and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to 6.125% Senior Notes Due 2028 (Incorporated by reference to Exhibit 4.2 to Registrant&#8217;s Current Report on Form 8-K filed September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520247267/d26262dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520247267/d26262dex42.htm">16,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520247267/d26262dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520247267/d26262dex42.htm">2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">Thirty-Seventh Supplemental Indenture dated as of June 2, 2021, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to 4.250%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">Senior Secured First Lien Notes due 2029 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">4.2 to Registrant&#8217;s Current Report on Form 8-K filed June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">2,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521179909/d104817dex42.htm">2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">Thirty-Eighth Supplemental Indenture dated as of December 1, 2021, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to 4.375%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">Senior Secured First Lien Notes due 2030 (Incorporated by Reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">4.2 to Registrant&#8217;s Current Report on Form 8-K filed December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">1,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312521345309/d235308dex42.htm">2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">Thirty-Ninth Supplemental Indenture, dated as of June 15, 2022, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to 6.125%</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">Senior Secured First Lien Notes due 2030 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">4.2 to Registrant&#8217;s Current Report on Form 8-K filed June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">15,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex42.htm">2022)</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material Contracts</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">, dated as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm"> March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">&#160;16,&#160;2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">, to that certain Amended and Restated Credit Agreement, dated as of October 19, 2010, among the Registrant, the lenders and issuers party thereto and Citicorp USA, Inc., as administrative agent, including as Exhibit A thereto a copy of the Amended and Restated Credit Agreement reflecting all amendments and restatements through </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">March&#160;16,&#160;2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm"> (Incorporated by reference to Exhibit 10.1 to Registrant&#8217;s Current Report on Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">&#160;17,&#160;2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522077759/d318813dex101.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000110465914017997/a14-7784_1ex10d1.htm">Letter of Credit Facility Agreement, dated as of March&#160;7,&#160;2014, among the Registrant, certain financial institutions party thereto from time to time as letter of credit participants and issuers, and Barclays Bank PLC, as administrative agent (Incorporated by reference to Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form&#160;8-K filed March&#160;10,&#160;2014)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312516712302/d260260dex101.htm">Amendment No. 1, dated as of September 15, 2016, to the Letter of Credit Facility Agreement, dated as of March 7, 2014, among the Registrant, certain financial institutions party thereto from time to time as letter of credit participants and issuers, and Barclays Bank PLC, as administrative agent (Incorporated by reference to Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form&#160;8-K dated filed September&#160;16,&#160;2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">Amendment No. 3, dated as of September 12, 2019, to the Letter of Credit Facility Agreement, dated as of March 7, 2014, by and among the Registrant, the LC participants and issuers party thereto and Barclays Bank PLC, as administrative agent (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">10.2 to Registrant&#8217;s Current Report on Form 8-K filed September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">13,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312519244876/d804731dex102.htm">2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">Amendment No. 4, dated as of March 19, 2020, to the Letter of Credit Facility Agreement, dated as of March 7, 2014, by and among the Registrant, the LC participants and issuers party thereto and Barclays Bank PLC, as administrative agent (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">10.1 to Registrant&#8217;s Current Report on Form 8-K filed March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">24,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312520083944/d886185dex101.htm">2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">Amendment No. 5, dated as of July 29, 2020, to the Letter of Credit Facility Agreement, dated as of March 7, 2014, by and among the Registrant, the LC participants and issuers party thereto, and Barclays Bank PLC, as administrative agent (Incorporated by reference to Exhibit 10(a) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">30,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">2020, filed August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">3,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000036/thc20200630ex10a.htm">2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000110465914017997/a14-7784_1ex10d2.htm">Guaranty, dated as of March&#160;7,&#160;2014, among Barclays Bank PLC, as administrative agent and the guarantors party thereto (Incorporated by reference to Exhibit&#160;10.2 to Registrant&#8217;s Current Report on Form&#160;8-K filed March&#160;10,&#160;2014)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312509045760/dex101.htm">Stock Pledge Agreement, dated as of March&#160;3,&#160;2009, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors&#160;party thereto (Incorporated by reference to Exhibit 10.1 to Registrant&#8217;s Current Report on Form&#160;8-K filed March&#160;5,&#160;2009)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000155837016003350/thc-20151231ex10h1ab2e5.htm">First Amendment to Stock Pledge Agreement, dated as of May&#160;8,&#160;2009, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit&#160;10(h) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December&#160;31,&#160;2015, filed February&#160;22,&#160;2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312509131777/dex101.htm">Second Amendment to Stock Pledge Agreement, dated as of June&#160;15,&#160;2009, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form&#160;8-K filed June&#160;16,&#160;2009)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000155837016003350/thc-20151231ex10j0921ed.htm">Third Amendment to Stock Pledge Agreement, dated as of March&#160;7,&#160;2014, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit&#160;10(j) to Registrant&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31,&#160;2015, filed February&#160;22,&#160;2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000155837016003350/thc-20151231ex10k400a19.htm">Fourth Amendment to Stock Pledge Agreement, dated as of March&#160;23,&#160;2015, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit 10(k) to Registrant&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015, filed February&#160;22,&#160;2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10m.htm">Fifth Amendment to Stock Pledge Agreement, dated as of December 1, 2016, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit 10(m) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed February 25, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10n.htm">Sixth Amendment to Stock Pledge Agreement, dated as of July 14, 2017, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit 10(n) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed February 25, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10o.htm">Seventh Amendment to Stock Pledge Agreement, dated as of February 5, 2019, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit 10(o) to Registrant&#8217;s Annual Report on Form 10-K for the year December 31, 2018, filed February 25, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312509045760/dex102.htm">Collateral Trust Agreement, dated as of March&#160;3,&#160;2009, by and among the Registrant, as pledgor, The&#160;Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors&#160;party thereto (Incorporated by reference to Exhibit&#160;10.2 to Registrant&#8217;s Current Report on Form&#160;8-K filed March&#160;5,&#160;2009)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(q)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex101.htm">Exchange and Registration Rights Agreement, dated as of June 15, 2022, among the Registrant, the guarantors party thereto and Barclays Capital Inc. as representative of the other initial purchasers of the notes named therein (Incorporated by reference to Exhibit 10.1 to Registrant&#8217;s Current Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522174770/d344017dex101.htm">8&#8209;K filed June 15, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(r)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521265516/d268536dex102.htm">Amended and Restated Employment Agreement between the Registrant and Saumya Sutaria, effective September 1, 2021 (Incorporated by reference to Exhibit 10.2 to Registrant&#8217;s Current Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521265516/d268536dex102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521265516/d268536dex102.htm">8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#8209;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521265516/d268536dex102.htm">K filed September 3, 2021)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000110465912075036/a12-20742_1ex10dc.htm">Letter from the Registrant to Daniel&#160;J.&#160;Cancelmi, dated September&#160;6,&#160;2012 (Incorporated by reference to Exhibit&#160;10(c) to Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30,&#160;2012, filed November&#160;7,&#160;2012)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(t)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000070318/000119312521265516/d268536dex101.htm">Amended and Restated Employment Agreement between the Registrant and Ronald A. Rittenmeyer, effective September 1, 2021 (Incorporated by reference to Exhibit 10.1 to Registrant&#8217;s Current Report on Form 8-K filed September 3, 2021)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(u)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10b.htm">Amendment No. 1 to Amended and Restated Employment Agreement between the Registrant and Ronald A. Rittenmeyer, effective as of February 25, 2022 (Incorporated by reference to Exhibit 10(b) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed April</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10b.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10b.htm">29,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10b.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10b.htm">2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522256098/d403443dex101.htm">Letter Agreement between the Registrant and Ronald A. Rittenmeyer, dated October 1, 2022 (Incorporated by reference to Exhibit 10.1 to Registrant&#8217;s Current Report on Form 8-K filed October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522256098/d403443dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522256098/d403443dex101.htm">3,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522256098/d403443dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000119312522256098/d403443dex101.htm">2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(w)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">Letter from the Registrant to Paola Arbour, dated May 3, 2018 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">10(e) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">31,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">2020, filed May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">4,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000028/thc-20200331ex10e.htm">2020)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">Offer of Employment from the Registrant to Thomas W. Arnst, amended and restated as of February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">2,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">2022 (Incorporated by reference to Exhibit 10(w) to Registrant&#8217;s Annual Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10w.htm">10-K for the year ended December 31, 2021, filed on February 18, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(y)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10y.htm">Letter from the Registrant to Lisa Foo, dated as of February 18, 2022*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(z)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031821000008/thc-20201231ex10hh.htm">Tenet Fifth Amended and Restated Executive Severance Plan, as amended and restated effective February 1, 2021 (Incorporated by reference to Exhibit 10(hh) to Registrant&#8217;s Annual Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031821000008/thc-20201231ex10hh.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031821000008/thc-20201231ex10hh.htm">10&#8209;K for the year ended December 31, 2020, filed February 19, 2021)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(aa)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10y.htm">Form of Amendment to Executive Severance Plan Agreement (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10y.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10y.htm">10(y) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 18, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(bb)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10cc.htm">Tenet Healthcare Corporation Tenth Amended and Restated Supplemental Executive Retirement Plan, as amended and restated effective April 1, 2018 (Incorporated by reference to Exhibit 10(cc) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed on February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10cc.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10cc.htm">25,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10cc.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000017/thc-20181231ex10cc.htm">2019)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(cc)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10ii.htm">Sixth Amended and Restated Tenet 2006 Deferred Compensation Plan, as amended and restated effective January 1, 2020 (Incorporated by reference to Exhibit 10(ii) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 24, 2020)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(dd)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000155837016007064/thc-20160630ex10a5ac447.htm">Sixth Amended and Restated Tenet Healthcare 2008 Stock Incentive Plan, as amended and restated effective March 10, 2016 (Incorporated by reference to Exhibit&#160;10(a) to Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30,&#160;2016, filed August&#160;1,&#160;2016)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ee)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000119312509035651/dex10aa.htm">Forms of Award used to evidence (i) initial grants of restricted stock units to directors, (ii) annual grants of restricted stock units to directors, (iii) grants of stock options to executives, and (iv)&#160;grants of restricted stock units to executives, all under the Amended and Restated Tenet Healthcare 2008&#160;Stock&#160;Incentive Plan (Incorporated by reference to Exhibit&#160;10(aa) to Registrant&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31,&#160;2008, filed February&#160;24,&#160;2009)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ff)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031818000011/thc-123117ex10hh.htm">Forms of Award used to evidence (i) grants of cash-based long-term performance awards, (ii) grants of non-qualified stock option performance awards and (iii) grants of restricted stock unit awards under the Sixth Amended and Restated Tenet&#160;Healthcare 2008 Stock Incentive Plan (Incorporated by reference to Exhibit 10(hh) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017, filed February 26, 2018)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(gg)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10qq.htm">Terms and Conditions of Restricted Stock Unit Award granted to Saumya Sutaria, M.D. on January&#160;31,&#160;2019 under the Tenet Healthcare 2008 Stock Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10qq.htm">(Incorporated by reference to Exhibit 10(qq) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 24, 2020)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(hh)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10rr.htm">Terms and Conditions of Restricted Stock Unit Award granted to Saumya Sutaria, M.D. on February&#160;27,&#160;2019 under the Tenet Healthcare 2008 Stock Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10rr.htm">(Incorporated by reference to Exhibit 10(rr) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 24, 2020)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031817000024/thc-20170930ex10c.htm">Terms and Conditions of Non-Qualified Stock Option Performance Awards granted to Ronald A. Rittenmeyer under the Tenet Healthcare 2008 Stock Incentive Plan (Incorporated by reference to Exhibit 10(c) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, filed November 7, 2017)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(jj)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000041/thc-20220630ex10b.htm">Tenet Healthcare 2019 Stock Incentive Plan, as amended by the First Amendment (Incorporated by reference to Exhibit 10(b) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000041/thc-20220630ex10b.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000041/thc-20220630ex10b.htm">30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000041/thc-20220630ex10b.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000041/thc-20220630ex10b.htm">2022, filed July 29, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(kk)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10tt.htm">Forms of Award used to evidence (i) initial grants of restricted stock units to directors and (ii)&#160;annual grants of restricted stock units to directors, each under the Tenet Healthcare 2019 Stock Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031820000014/thc-20191231ex10tt.htm">(Incorporated by reference to Exhibit 10(tt) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 24, 2020)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ll)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10ll.htm">Terms and Conditions of Restricted Stock Unit Award granted to J. Robert Kerrey on November&#160;3,&#160;2022 under the Tenet Healthcare 2019 Stock Incentive Plan*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(mm)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10mm.htm">Forms of Award used to evidence (i) grants of time-based restricted stock units to executives and (ii) grants of performance-based restricted stock units to executives, in each case after 2019 under the Tenet Healthcare 2019 Stock Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10mm.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(nn)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10e.htm">Forms of Award used to evidence (i) grants of time-based restricted stock units to executives and (ii) grants of performance-based restricted stock units to executives, in each case after 2021 under the Tenet Healthcare 2019 Stock Incentive Plan (Incorporated by reference to Exhibit 10(e) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed April 29, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(oo)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10ll.htm">Terms and Conditions of Restricted Stock Unit Awards and Terms and Conditions of Restricted Stock Unit Performance Awards, in each case granted to Saumya Sutaria, M.D. on September 1, 2021 under the Tenet Healthcare 2019 Stock Incentive Plan (Incorporated by reference to Exhibit 10(ll) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10ll.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10ll.htm">18,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10ll.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10ll.htm">2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(pp)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10c.htm">Forms of Award used to evidence (i) grants of time-based restricted stock units and (ii) grants of performance-based restricted stock units, in each case to Saumya Sutaria, M.D. after 2021 under the Tenet Healthcare 2019 Stock Incentive Plan (Incorporated by reference to Exhibit 10(c) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed April 29, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(qq)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10mm.htm">Form of Terms and Conditions of Restricted Stock Unit Awards granted to Ronald A. Rittenmeyer under the Tenet Healthcare 2019 Stock Incentive Plan (Incorporated by reference to Exhibit 10(mm) to Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10mm.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10mm.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10mm.htm">8,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10mm.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10mm.htm">2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(rr)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000029/thc-20220331ex10d.htm">Forms of Award used to evidence (i) grants of time-based restricted stock units and (ii) grants of performance-based restricted stock units, in each case to Ronald A. Rittenmeyer after 2021 under the Tenet Healthcare 2019 Stock Incentive Plan (Incorporated by reference to Exhibit 10(d) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed April 29, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ss)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10ss.htm">Terms and Conditions of Restricted Stock Unit Award and Terms and Conditions of Restricted Stock Unit Performance Award, in each case granted to Thomas W. Arnst</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10ss.htm"> under the Tenet Healthcare 2019 Stock Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10ss.htm">for the 2020-2022 performance period</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="thc-20221231ex10ss.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(tt)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000051/thc-20220930ex10b.htm">Tenet Special RSU Deferral Plan, amended and restated effective August 10, 2022 (Incorporated by reference to Exhibit 10(b) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed October 28, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(uu)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10qq.htm">Sixth Amended Tenet Healthcare Corporation Annual Incentive Plan, as amended and restated effective November 3, 2021 (Incorporated by reference to Exhibit 10(qq) to Registrant&#8217;s Annual Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10qq.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/70318/000007031822000013/thc-20211231ex10qq.htm">10-K for the year ended December 31, 2021, filed on February 18, 2022)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vv)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000007031819000039/thc-20190630ex10c.htm">Eighth Amended and Restated Tenet Executive Retirement Account, as amended and restated effective as of April 26, 2019 (Incorporated by reference to Exhibit 10(c) to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, filed August 5, 2019)*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ww)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/70318/000110465905051358/a05-18984_1ex10da.htm">Form of Indemnification Agreement entered into with each of the Registrant&#8217;s directors (Incorporated by reference to Exhibit&#160;10(a) to Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30,&#160;2005, filed November&#160;1,&#160;2005)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="thc-20221231ex21.htm">Consolidated Subsidiaries of the Registrant</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0900ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0900ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="thc-20221231ex23.htm">Consent of Deloitte &amp; Touche LLP (PCAOB ID No.</a> <ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zMzcvZnJhZzpmYmJkOTUwMGU2ZmI0MDk1YmVhNjUxZmM4MDk1ZTQ4ZC90YWJsZTpiN2M2OTllNGRmYWI0Yjk0YTQ5NjhjOTFhZDNmOWIwOS90YWJsZXJhbmdlOmI3YzY5OWU0ZGZhYjRiOTRhNDk2OGM5MWFkM2Y5YjA5Xzk1LTItMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmEyNDhmNWJjOTkwNzRmZDdhYjk2ZjVjYzBjOWE4MWU2XzUy_4a6b66b6-e88d-417e-af0d-5e365d652284">34</ix:nonNumeric>)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rule 13a-14(a)/15d-14(a) Certifications</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="thc-20221231ex31a.htm">Certification of Saumya Sutaria, M.D., Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="thc-20221231ex31b.htm">Certification of Daniel J. Cancelmi, Executive Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline" href="thc-20221231ex32.htm">Section 1350 Certifications of Saumya Sutaria, M.D., Chief Executive Officer, and Daniel&#160;J.&#160;Cancelmi, Executive Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101 SCH)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101 CAL)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101 DEF)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101&#160;LAB)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101&#160;PRE)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101&#160;INS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Inline XBRL Taxonomy Extension Instance Document &#8211; the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cover page from the Registrant&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 formatted in Inline XBRL (included in Exhibit 101)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*   Management contract or compensatory plan or arrangement</span></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_343"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_346"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TENET&#160;HEALTHCARE&#160;CORPORATION<br/>(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ R. SCOTT RAMSEY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Scott Ramsey</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Controller</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SAUMYA SUTARIA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saumya Sutaria, M.D.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL J. CANCELMI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Cancelmi</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ R. SCOTT RAMSEY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Scott Ramsey</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Controller</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JAMES L. BIERMAN</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James L. Bierman<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ RICHARD FISHER</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Fisher<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ MEGHAN M. FITZGERALD</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meghan M. FitzGerald, DrPH<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CECIL D. HANEY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cecil D. Haney<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ J. ROBERT KERREY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Robert Kerrey<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CHRIS LYNCH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris Lynch<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ RICHARD MARK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Mark<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ TAMMY ROMO</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tammy Romo<br/>Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 17, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ NADJA WEST</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nadja West, M.D.<br/>Director</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i397b00e3dcff45d9b9c5c6459ba30276_349"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i397b00e3dcff45d9b9c5c6459ba30276_10">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90ZXh0cmVnaW9uOmU4NmUyOTQ2Y2E2NjRlNzM5OTZhNDE1Zjk2YTAwZDk3XzEyNg_e6879f59-ffe8-4d3e-9b1d-b93cf981c81b" escape="true"><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II&#8212;VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at<br/>Beginning<br/>of&#160;Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Costs&#160;and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at<br/>End&#160;of<br/>Period</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa722f7986ca4c518e3bcdca37e64012_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtMS0xLTEtMjkzNzEw_e944dfd7-6922-414d-912c-49ed76b1cfc4">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtMy0xLTEtMjkzNzEw_076707d2-3c4d-4bea-a298-b830cd530b2e">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtNS0xLTEtMjkzNzEw_18ef484d-f6b7-4123-bd6f-4db624c7d741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231" decimals="-6" name="thc:ValuationAllowancesAndReservesReservesOfBusinessesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtNy0xLTEtMjkzNzEw_a42f058f-9334-42b6-8684-0775b575a1f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb31be8d6de4e44a3f930dc03031843_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtOS0xLTEtMjkzNzEw_269534b0-c28c-4082-8050-9d121dfeea34">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6544cc6587346acb00b26c710bc7751_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctMS0xLTEtMjkzNzEw_739df74e-1c65-49ee-9d64-5a104e8f1eb4">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133c13b23a124143877c18e0c045ff74_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctMy0xLTEtMjkzNzEw_b1c05d2d-7cd3-448f-af8f-11b5aa2650c2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133c13b23a124143877c18e0c045ff74_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctNS0xLTEtMjkzNzEw_ad1e3a14-a0fa-42d4-b9f5-24f8f1937186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133c13b23a124143877c18e0c045ff74_D20210101-20211231" decimals="-6" name="thc:ValuationAllowancesAndReservesReservesOfBusinessesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctNy0xLTEtMjkzNzEw_4e01ae7f-b813-4801-8bea-bffb5798df75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa722f7986ca4c518e3bcdca37e64012_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctOS0xLTEtMjkzNzEw_13ac5485-e5f9-4cc5-95ff-b60c1d4dcee6">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b95f4641f134e5c9fffaae2b5ca01e5_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtMS0xLTEtMjkzNzEw_47529dc1-3e3c-4924-9c24-55d1ca3d9d05">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtMy0xLTEtMjkzNzEw_d523f09e-6fdf-406f-9dd3-9cc3c16160ce">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtNS0xLTEtMjkzNzEw_e31811c5-9e7b-4f71-838f-eaa7da757bd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231" decimals="-6" name="thc:ValuationAllowancesAndReservesReservesOfBusinessesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtNy0xLTEtMjkzNzEw_15233c7f-4937-4278-8b6d-f78fdec1f37c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6544cc6587346acb00b26c710bc7751_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtOS0xLTEtMjkzNzEw_a8c4df21-94b8-4130-99c9-f13177e22428">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.586%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes amounts recorded in discontinued operations.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.A
<SEQUENCE>2
<FILENAME>thc-20221231ex4a.htm
<DESCRIPTION>EX-4.A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5b61f7353f584fa5a07d48aec733b832_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Tenet Healthcare Corporation (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#58; (1)&#160;common stock&#59; and (2) 6.875% Senior Notes due 2031 (&#8220;Senior Notes&#8221;). </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Common Stock</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation (the &#8220;Articles of Incorporation&#8221;) and our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4(a) is a part. We encourage you to read our Articles of Incorporation, our Bylaws and the applicable provisions of Chapter 78 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Revised Statutes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorized Capital Shares</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital shares consist of 1,050,000,000 shares of common stock, $0.05 par value, and 2,500,000&#160;shares of preferred stock, $0.15 par value. Outstanding shares of our common stock are not subject to redemption and are non-assessable.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors. Our common stock does not have cumulative voting rights. The affirmative vote of a majority of the holders of all outstanding shares, voting together and not by class, is required to approve any merger or consolidation or the sale of substantially all of our assets.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Special Meetings</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special meetings of the stockholders, for any purpose or purposes whatsoever, (a) may be called at any time by the Chairman of the board, the Chief Executive Officer, or the board of directors, and (b) shall be called by the Secretary of the Company upon the written request of one or more stockholders having Net Long Beneficial Ownership (as defined in the Bylaws) of at least 25% of all outstanding shares of our common stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may declare, and we may pay, dividends or other distributions on our outstanding shares in the manner and on the terms and conditions provided by the laws of the State of Nevada and the Articles of Incorporation, subject to any contractual restrictions to which we are then subject.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation Rights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a liquidation, dissolution or winding-up of our company, holders of common stock are entitled to share equally and ratably in the assets of our company, if any, remaining after the payment of all debts and liabilities of our company and the liquidation preference of any outstanding preferred stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendments to Bylaws</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the right of the stockholders to adopt, amend or restate, or repeal the Bylaws, our board of directors may adopt, amend or repeal any of the Bylaws, except as otherwise provided in the Bylaws, by the affirmative vote of a majority of directors. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advance Notice Requirements</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or other business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals of these kinds must be timely given in writing to the Secretary of the Company before the meeting at which the action is to be taken. Generally, to be timely, a stockholder&#8217;s notice to the Secretary must be delivered to or mailed and received at the Company&#8217;s corporate headquarters by the close of business not less than 90 days nor more than 120 days prior to the anniversary date of the immediately preceding annual meeting of stockholders&#59; provided, however, that in the event that the annual meeting is called for a date that is not within 30 days before or after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder in order to be timely must be so received not later than the close of business on the tenth day following the day on which the Company makes a public announcement of the date of the annual meeting. The notice must contain certain information specified in the Bylaws.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Written Consent by Stockholders</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any action that may be taken at any meeting of the stockholders, except election or removal of directors, may be taken without a meeting only if authorized by a writing signed by stockholders owning all of the shares of common stock entitled to vote on the action. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Rights and Preferences</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our common stock do not have any conversion or subscription rights, and their preemptive rights are limited as provided under Nevada law. The rights, preferences and privileges of holders of our common stock are subject to any series of preferred stock that we may issue in the future.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Listing&#59; Transfer Agent</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on New York Stock Exchange (&#8220;NYSE&#8221;) under the trading symbol &#8220;THC&#8221;. Our transfer agent and registrar is Computershare.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Senior Notes</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes were issued pursuant to an Indenture, dated as of November 6, 2001 (the &#8220;Base Indenture&#8221;), as supplemented with respect to the Senior Notes by the Third Supplemental Indenture, dated as of November 6, 2001 (the &#8220;Supplemental Indenture&#8221; and, together with the Base Indenture, the &#8220;Indenture&#8221;), between us and The Bank of New York Mellon Trust Company, N.A., as successor to The Bank of New York, as trustee. Each of the Base Indenture and the Supplemental Indenture is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4(a) is a part. The terms of the Senior Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939, as amended. The Senior Notes are subject to all such terms, and you should refer to the Indenture and the Trust Indenture Act for a statement thereof. The following description of the Senior Notes is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Indenture, including the definitions therein of terms used below. As used in this &#8220;Description of the Senior Notes,&#8221; the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Tenet Healthcare Corporation and not to any of our subsidiaries.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes have been issued in fully registered form, in denominations of $1,000 and integral multiples thereof, registered in the name of Cede &#38; Co., a nominee of The Depository Trust Company, or DTC. See &#8220;&#8212;Global Notes&#8221; below. The paying agent, registrar and transfer agent for the Senior Notes will be the corporate trust department of the trustee in New York, New York. Payment of principal will be made at maturity in immediately payable funds against surrender to the trustee.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time, without giving notice to or seeking the consent of the holders of the Senior Notes, issue notes having the same ranking and the same interest rate, maturity and other terms as the Senior Notes. Any additional notes having such similar terms, together with the Senior Notes previously outstanding, will constitute a single series of notes under the Indenture.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Amount&#59; Maturity</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes were offered in the aggregate principal amount of $450 million and have a maturity date of November&#160;15,&#160;2031. At December 31, 2022, $362 million aggregate principal amount of the Senior Notes remains outstanding.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the Senior Notes accrues at a rate of 6.875% per annum and is payable semi-annually in arrears on May&#160;15 and November 15 of each year to holders of record on the immediately preceding May&#160;1 and November&#160;1. Payments commenced on May 15, 2002. Interest on the Senior Notes accrues from the most recent date to which interest has been paid.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the Senior Notes is computed on the basis of a 360-day year comprised of twelve 30-day months. Principal, premium, if any, and interest on the Senior Notes is payable at our office or agency maintained for such purpose within the City and State of New York or, at our option, payment of interest may be made by check mailed to the holders of the Senior Notes at their respective addresses set forth in the register of holders of the Senior Notes&#59; provided that all payments with respect to Senior Notes as to which the holders have given wire transfer instructions to the paying agent on or prior to the relevant record date will be required to be made by wire transfer of immediately available funds to the accounts specified by such holders. Until otherwise designated by us, our office or agency in New York will be the office of the trustee maintained for such purpose.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Optional Redemption</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes are redeemable, in whole or in part, at any time, at our option, at a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of the principal amount of the Senior Notes being redeemed, or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments of principal and interest thereon, excluding accrued and unpaid interest to the date of redemption, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at the Adjusted Treasury Rate, plus 35 basis points,</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus, in either of the above cases, accrued and unpaid interest thereon to, but not including, the redemption date. The Senior Notes will not be subject to any mandatory sinking fund.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Adjusted Treasury Rate&#8221; means, with respect to any redemption date&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the yield, under the heading that represents the average for the immediately preceding week, appearing in the most recently published statistical release designated &#8220;H.15(519)&#8221; or any successor publication that is published weekly by the Board of Governors of the Federal Reserve System and that establishes yields on actively traded United States Treasury securities adjusted to constant maturity under the caption &#8220;Treasury Constant Maturities,&#8221; for the maturity corresponding to the Comparable Treasury Issue (if no maturity is within three months before or after the Remaining Life, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue shall be determined and the Adjusted Treasury Rate shall be interpolated or extrapolated from such yields on a straight line basis, rounded to the nearest month)&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if such release (or any successor release) is not published during the week preceding the calculation date or does not contain such yields, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Adjusted Treasury Rate shall be calculated on the third business day preceding the redemption date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Treasury Issue&#8221; means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the Senior Notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of those Senior Notes (&#8220;Remaining Life&#8221;).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Treasury Price&#8221; means, with respect to any redemption date, (1) the average of five Reference Treasury Dealer Quotations for such redemption date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than five such Reference Treasury Dealer Quotations, the average of all such quotations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Independent Investment Banker&#8221; means one of the Reference Treasury Dealers appointed by us.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer&#8221; means&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC and their respective successors&#59; provided that, if any of the foregoing ceases to be a primary U.S.&#160;Government securities dealer in New York City (a &#8220;Primary Treasury Dealer&#8221;), we will substitute another Primary Treasury Dealer&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other Primary Treasury Dealer selected by us.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer Quotation&#8221; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 5&#58;00 p.m., New York City time, on the third business day preceding such redemption date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If less than all of the Senior Notes are to be redeemed at any time, selection of notes for redemption will be made by the trustee in compliance with the requirements of the principal national securities exchange, if any, on which the notes to be redeemed are then listed, or, if the Senior Notes are not so listed, on a pro rata basis, by lot or by such method as the trustee deems fair and appropriate&#59; provided that notes with a principal amount of $1,000 will not be redeemed in part.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will mail a notice of redemption at least 30 but not more than 60 days before the redemption date to each holder of the Senior Notes to be redeemed. If the Senior Notes are to be redeemed in part only, the notice of redemption that relates to such notes will state the portion of the principal amount thereof to be redeemed. A new note in principal amount equal to the unredeemed portion thereof will be issued in the name of the holder thereof upon cancellation of the original note.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we default in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the Senior Notes or portions thereof called for redemption.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Indenture does not limit the aggregate principal amount of debt securities that may be issued thereunder. As permitted under the terms of the Base Indenture, we have issued, and may in the future issue, other debt securities under the Base Indenture constituting one or more separate series. The Senior Notes are general unsecured senior debt obligations that rank equally in right of payment with all of our other existing and future unsecured senior indebtedness, but are effectively subordinated to our senior secured notes, the obligations of our subsidiaries and any obligations under our credit facilities to the extent of the value of the collateral. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on Us and Our Subsidiaries</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on Liens.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Indenture provides that, except as described under &#8220;&#8212;Exception to Limitations&#8221; below, neither we nor any of our subsidiaries will issue, incur, create, assume or guarantee any debt secured by liens, mortgages, pledges, charges, security interests or other encumbrances upon any principal property (which means each of our hospitals that has a book value in excess of 5% of our consolidated net tangible assets), unless the Senior Notes will be secured equally and ratably with, or prior to, such debt. This restriction will not apply to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liens securing the purchase price or cost of construction of property or additions, substantial repairs, alterations or improvements, if the debt and the liens are incurred within 12 months of the acquisition, the completion of construction and full operation or the completion of such additions, repairs, alterations or improvement&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liens existing on property at the time of its acquisition by us or our subsidiaries or on the property of an entity at the time of the acquisition of such entity by us or our subsidiaries, provided that the liens were in existence prior to the closing of, and not incurred in contemplation of, such acquisition and, in the case of the acquisition of an entity, the liens do not extend to any assets other than those of the entity acquired&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liens in favor of us or a consolidated subsidiary&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liens existing on the date of the Supplemental Indenture&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain liens to governmental entities&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liens incurred within 90 days (or any longer period, not in excess of one year, as permitted by law), after acquisition of the related property arising solely in connection with the transfer of tax benefits in accordance with Section 168(f)(8) of the Internal Revenue Code&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any substitution or replacement of any lien referred to above, provided that the property encumbered by any substitute or replacement lien is substantially similar in nature to and no greater in value than the property encumbered by the lien that is being replaced&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any extension, renewal or replacement of any lien referred to above, provided the amount secured is not increased and it relates to the same property.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on Sale and Lease-Back Transactions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture provides that, except as described under &#8220;&#8212;Exception to Limitations&#8221; below, neither we nor any of our subsidiaries will enter into any sale and lease-back transaction with respect to any principal property with another person, other than us or one of our consolidated subsidiaries, unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our subsidiaries could incur debt secured by a lien on the property to be leased without securing the Senior Notes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lease is for three years or less&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">within 120 days, we apply the greater of the net proceeds of the sale of the leased property or the fair value of the leased property to the acquisition, construction, addition, repair, alteration or improvement of a principal property or the voluntary retirement of our long-term debt.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exception to Limitations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Notwithstanding the two covenants described above, we and any of our subsidiaries may issue, incur, create, assume or guarantee debt secured by liens or enter into any sale and lease-back transaction that would otherwise be subject to the restrictions on liens and sale and lease-back transactions described above, provided that (i) the aggregate amount of all our debt subject to the restriction on liens described above plus (ii) the aggregate attributable debt in respect of sale and lease-back transactions that is subject to the restriction on sale and lease-back transactions above, does not exceed 15% of our consolidated net tangible assets.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation, Merger and Sale of Assets.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Indenture provides that we may not consolidate with, or sell, convey or lease all or substantially all of our properties and assets to, or merge with or into, any other person, unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are the surviving corporation or the successor is a corporation organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes the due and punctual payment of the principal of and interest on all the Senior Notes and the due and punctual performance and observation of our covenants and obligations under the Indenture&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">immediately after giving effect to the transaction, no event of default, and no event which, after notice or lapse of time or both would become an event of default has occurred and is continuing under the Indenture.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Events of Default</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Indenture, each of the following constitutes an event of default with respect to the Senior Notes&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to pay the principal of or premium, if any, on the Senior Notes, at maturity or otherwise&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to pay any interest on the Senior Notes when due, continued for 30 days&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform, or the breach of, any of our covenants or warranties in the Indenture or the Senior Notes, continued for 90 days after written notice&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">events of bankruptcy, insolvency or reorganization with respect to us.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the events of default set forth above, an event of default will be deemed to have occurred with respect to the Senior Notes the event of a failure to pay at maturity or the acceleration of our indebtedness having an aggregate principal amount in excess of the greater of $25 million or 5% of our consolidated net tangible assets under the terms of the instrument under which that indebtedness is issued or secured if that indebtedness is not discharged or the acceleration is not annulled within 10 days after written notice.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any event of default with respect to the Senior Notes occurs and is continuing, either the trustee or the holders of at least 25% in principal amount of the Senior Notes then outstanding, by written notice to us and to the trustee, may declare the principal amount of the Senior Notes to be due and payable immediately. Notwithstanding the foregoing, in the case of an event of default arising from certain events of bankruptcy, insolvency or reorganization, all outstanding Senior Notes will automatically and without any action by the trustee or any holder, become immediately due and payable. After any such acceleration, but before a judgment or decree based on such acceleration, the holders of a majority in aggregate principal amount of the Senior Notes then outstanding may, under certain circumstances, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal of or interest on the Senior Notes, have been cured or waived as provided in the Indenture.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of the Indenture relating to the duties of the trustee in case an event of default occurs and is continuing, the trustee will be under no obligation to exercise any of its rights or powers under the Indenture at the request or direction of any of the holders, unless such holders have offered to the trustee reasonable indemnity. Subject to such provisions for the indemnification of the trustee, the holders of a majority in aggregate principal amount of Senior Notes then outstanding will have the right to direct the time, method and place of conducting any proceedings for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the Senior Notes.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No holder of a Senior Note will have any right to institute any proceeding with respect to the Indenture, or for the appointment of a receiver or a trustee, or for any other remedy thereunder, unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such holder has previously given the trustee written notice of a continuing event of default with respect to the Senior Notes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holders of at least 25% in the aggregate principal amount of the Senior Notes then outstanding have made written request, and such holder or holders have offered reasonable indemnity, to the trustee to institute such proceedings as trustee&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trustee has failed to institute such proceeding and the trustee has not received from the holders of a majority in aggregate principal amount of the Senior Notes then outstanding a direction inconsistent with such request within 60 days after such notice, request and offer.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such limitations, however, do not apply to a suit instituted by a holder of a Senior Note for the enforcement of payment of the principal of or interest on such Senior Note on or after its due date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defeasance and Covenant Defeasance</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect, at our option at any time, to have the provisions of the Indenture relating to defeasance and discharge of indebtedness and to defeasance of certain restrictive covenants applied to the Senior Notes.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Defeasance and Discharge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Indenture provides that, upon the exercise of our option, we will be discharged from all our obligations with respect to Senior Notes (except for certain obligations to exchange or register the transfer of notes, to replace stolen, lost or mutilated notes, to maintain paying agencies and to hold moneys for payment in trust), subject to the conditions precedent below.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Defeasance of Certain Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Indenture provides that, upon the exercise of our option with respect to the Senior Notes, we may omit to comply with certain restrictive covenants, including those described under &#8220;&#8212;&#160;Limitations on Us and Our Subsidiaries&#8221; above, and the occurrence of certain events of default will be deemed not to be or result in an event of default, in each case with respect to the Senior Notes, subject to the conditions precedent below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each case, the defeasance provision will be subject to our depositing in trust for the benefit of the holders of the Senior Notes to be defeased money or U.S. government obligations, or both, which, through the payment of principal and interest in respect thereof in accordance with their terms, will provide money in an amount sufficient to pay the principal of and any premium and interest on such notes on the stated maturity in accordance with the terms of the Indenture and the Senior Notes. We will also be required, among other things, to deliver to the trustee an opinion of counsel to the effect that holders of such notes will not recognize gain or loss for federal income tax purposes as a result of such deposit, defeasance and discharge and will be subject to federal income tax on the same amount, in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge were not to occur.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we exercised this option with respect to any Senior Notes and such notes were declared due and payable because of the occurrence of any event of default, the amount of money and U.S. government obligations so deposited in trust would be sufficient to pay amounts due on such notes at the time of their respective stated maturities but may not be sufficient to pay amounts due on such notes upon any acceleration resulting from such event of default. In such case, we would remain liable for such payments.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment, Supplement and Waiver</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in the next two succeeding paragraphs, the Indenture or the Senior Notes may be amended or supplemented with the consent of the holders of at least a majority in principal amount of the Senior Notes then outstanding (including consents obtained in connection with a tender offer or exchange offer for such notes), and any existing default or compliance with certain restrictive provisions of the Indenture may be waived with the consent of the holders of a majority in principal amount of the then outstanding Senior Notes (including consents obtained in connection with a tender offer or exchange offer for such notes).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without the consent of each holder affected, an amendment or waiver may not (with respect to any Senior Notes held by a non-consenting holder)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the principal of or change the fixed maturity of any Senior Note&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the rate of or change the time for payment of interest on any Senior Note&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">waive a default or event of default in the payment of principal of or premium, if any, or interest on the Senior Notes (except a rescission of acceleration of the applicable notes by the holders of at least a majority in aggregate principal amount thereof and a waiver of the payment default that resulted from such acceleration)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the place of payment of any Senior Note or make any Senior Note payable in money other than that stated in such note&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impair the right to institute suit for the enforcement of any payment on or with respect to any Senior Note&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any change in the provisions of the Indenture relating to waivers of past defaults or the rights of holders of Senior Notes to receive payments of principal of or premium, if any, or interest on such notes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the principal amount of Senior Notes whose holders must consent to an amendment, supplement or waiver&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any change in the foregoing amendment and waiver provisions, except to increase the required percentage or to provide that other provisions of the Indenture cannot be modified or waived without the consent of the holder of each outstanding Senior Note.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, without the consent of any holder of Senior Notes, we, together with the trustee, may amend or supplement the Indenture to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cure any ambiguity, defect or inconsistency, provided that such action does not adversely affect the holders in any material respect&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for uncertificated notes in addition to or in place of certificated notes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evidence the assumption of our obligations to holders of Senior Notes in the case of a merger, consolidation or sale of assets pursuant to the covenant described under the caption &#8220;&#8212;Limitations on Us and Our Subsidiaries&#8212;Consolidation, Merger and Sale of Assets&#8221;&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add covenants for the benefit of the holders of the Senior Notes or to surrender any right or power conferred upon us&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any change that does not adversely affect the legal rights under the Indenture of any such holder in any material respect&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add any additional events of default for the benefit of the holders of the Senior Notes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure the Senior Notes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish the form or terms of other series of debt securities as permitted under the Indenture&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comply with requirements of the Securities and Exchange Commission in order to effect or maintain the qualification of the Indenture under the Trust Indenture Act&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appoint a successor trustee.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in certain limited circumstances, we will be entitled to set any day as a record date for the purpose of determining the holders of Senior Notes entitled to give or take any direction, notice, consent, waiver or other action or to vote on any action under the Indenture, in the manner and subject to the limitations provided in the Indenture. In certain limited circumstances, the trustee will be entitled to set a record date for action by holders. If a record date is set for any action to be taken by holders, such action may be taken only by persons who are holders of outstanding Senior Notes on the record date. To be effective, the action must be taken by holders of the requisite principal amount of the Senior Notes within a specified period following the record date. For any particular record date, this period will be 180 days or such shorter period as may be specified by us (or the trustee, if it set the record date), and may be shortened or lengthened from time to time, but not beyond 180 days.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Trustee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York, is the trustee under the Indenture. The corporate trust office of the trustee is located in New York, New York.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain banking relations with affiliates of The Bank of New York Mellon Trust Company, N.A. The Bank of New York Mellon Trust Company, N.A. has also served from time to time as escrow agent under escrow agreements to which we are party. In addition, The Bank of New York Mellon Trust Company, N.A. is the trustee under other indentures pursuant to which we have issued debt. Pursuant to the Trust Indenture Act of 1939, as amended, should a default occur with respect to the Senior Notes, the trustee would be required to eliminate any conflicting interest as defined in the Trust Indenture Act of 1939, as amended, or resign as trustee with respect to the Senior Notes within 90 days of such default unless such default were cured, duly waived or otherwise eliminated.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee may resign at any time or may be removed by us. If the trustee resigns, is removed or becomes incapable of acting as trustee or if a vacancy occurs in the office of the trustee for any cause, a successor trustee shall be appointed in accordance with the provisions of the Indenture. The Indenture provides that in case an event of default </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occurs (and is not cured), the trustee will be required, in the exercise of its power, to use the degree of care of a prudent man in the conduct of his own affairs. Subject to such provisions, the trustee will be under no obligation to exercise any of its rights or powers under the Indenture at the request of any holder of Senior Notes, unless such holder has offered to the trustee security and indemnity satisfactory to it against any loss, liability or expense.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Notes</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes have been issued in the form of one or more registered notes in book-entry form, referred to as global notes. Each such global note is registered in the name of a nominee of DTC, as depositary, and has been deposited with The Bank of New York Mellon Trust Company, N.A., as custodian therefor. Interest in each such global note is not exchangeable for certificated notes in definitive, fully registered form, except in the limited circumstances described below. We will be entitled, along with the trustee and any other agent, to treat DTC or its nominee, as the case may be, as the sole owner and holder of the global notes for all purposes.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So long as DTC or its nominee or a common depositary is the registered holder of a global note, DTC or such nominee or common depositary, as the case may be, will be considered the sole owner and holder of such global note, and of the Senior Notes represented thereby, for all purposes under the Indenture and the Senior Notes and the beneficial owners of Senior Notes will be entitled only to those rights and benefits afforded to them in accordance with DTC's regular operating procedures. Upon specified written instructions of a DTC participant, DTC will have its nominee assist its participants in the exercise of certain holders' rights, such as a demand for acceleration or an instruction to the trustee. Except as provided below, owners of beneficial interests in a global note will not be entitled to have Senior Notes represented by a global note registered in their names, will not receive or be entitled to receive physical delivery of Senior Notes in certificated form and will not be considered the registered holders thereof under the Indenture.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ownership of beneficial interests in a global note will be limited to DTC participants or persons who hold interests through DTC participants. Ownership of beneficial interests in a global note is shown on, and the transfer of those ownership interests are effected through, records maintained by DTC or its nominee (with respect to interests of participants) or by any such participant (with respect to interests of persons held by such participants on their behalf). Payments, transfers, exchanges and other matters relating to beneficial interests in a global note may be subject to various policies and procedures adopted by DTC from time to time. None of the Company, the trustee or any of their agents will have any responsibility or liability for any aspect of DTC's or any DTC participant's records relating to, or for payments made on account of, beneficial interest in any global note, or for maintaining, supervising or reviewing any records relating to such beneficial interests.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interests in a global note will be exchanged for Senior Notes in certificated form if&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DTC notifies us that it is unwilling or unable to continue as a depositary for such global note or has ceased to be qualified to act as such or if at any time such depositary ceases to be a clearing agency registered under the Exchange Act, and we have not appointed a successor depositary within 90 days&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an event of default under the Indenture with respect to the Senior Notes has occurred and is continuing&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, in our sole discretion, determine at any time that the Senior Notes will no longer be represented by a global note.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of such an event, owners of beneficial interests in such global note will receive physical delivery of Senior Notes in certificated form. All certificated notes issued in exchange for an interest in a global note or any portion thereof will be registered in such names as DTC directs. Such notes will be issued in minimum denominations of $1,000 and integral multiples thereof and will be in registered form only, without coupons.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No beneficial owner of an interest in a global note will be able to transfer that interest except in accordance with DTC's applicable procedures, in addition to those under the Indenture and the Senior Notes.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors may hold their interest in a global note directly through DTC if they are participants or indirectly through organizations that are DTC participants. Accordingly, although owners who hold Senior Notes through DTC </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participants will not possess notes in definitive form, the participants provide a mechanism by which holders of Senior Notes will receive payments and will be able to transfer their interests.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of a certificated note may transfer such note, subject to compliance with the provisions of such legend, by surrendering it at (i) the office or agency maintained by us for such purpose in the Borough of Manhattan, The&#160;City of New York, which initially will be the office of the trustee maintained for such purpose or (ii) the office of any transfer agent we appoint.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will make all payments of principal and interest on the Senior Notes in immediately available funds so long as the Senior Notes are maintained in the form of global notes.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governing Law</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture and the Senior Notes provide that they are governed by, and interpreted in accordance with, the internal laws of the State of New York.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Listing</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes are listed on the NYSE under the trading symbol &#8220;THC31&#8221;.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.Y
<SEQUENCE>3
<FILENAME>thc-20221231ex10y.htm
<DESCRIPTION>EX-10.Y
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i31e7a01adc3547b69edfd4a874834acf_1"></div><div style="min-height:126.18pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10(y)</font></div><div style="text-align:center"><img alt="logos.jpg" src="logos.jpg" style="height:98px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 18, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisa Foo</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Address Omitted&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Address Omitted&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RE&#58;&#160;&#160;&#160;&#160;Position of Executive Vice President, Commercial Operations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Lisa, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I am delighted to promote you to the position of Executive Vice President, Commercial Operations with Tenet&#160;Healthcare (the Company).  The following memorializes the terms and conditions of this employment offer.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  Executive Vice President, Commercial Operations, where you will continue to report to me, Saumya&#160;Sutaria, Chief Executive Officer and will continue to be allowed to work remotely in Boston, MA.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Employment Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  Tenet Business Services Corporation </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  March 1, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; You will receive an annual base salary of $650,000, payable in accordance with the Company&#8217;s standard payroll practices, currently bi-weekly, subject to applicable tax withholdings.  </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Annual Incentive Plan (AIP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  Effective January 1, 2022, your target cash bonus award will be 75% of your base salary. The AIP is performance-based cash compensation tied to the achievement of annual performance goals. The level of payout will depend on the realization of that year&#8217;s goals in the Company&#8217;s discretion. Awards are subject to modification, including for extraordinary events and&#47;or failure to meet our quality, ethics or compliance guidelines. Participation in the AIP does not guarantee that an award will be made.  </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Stock Incentive Plan (SIP) Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  You will be recommended for an annual award for the 2022 planning cycle with an approximate grant date value of $1,000,000. Our awards are designed to align the incentives of our leadership team with the Company&#8217;s long-term performance. Each year, the Company determines eligibility, award value and type of award (including whether in stock and&#47;or cash or subject to performance conditions), with awards typically granted in February. Any award will be subject to the terms and conditions set forth in the applicable plan document and award agreement. Eligibility for the program does not guarantee an award will be made.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefits</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your position continues to be eligible for our comprehensive benefits package, including health and welfare benefits and the plans highlighted below.  All benefits are subject to the terms and conditions of the applicable plan documents, may be modified or terminated at any time, and may require special elections or the execution of additional agreements in order to participate. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Retirement Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  You will continue to be eligible to participate in the Company&#8217;s 401(k) retirement savings plan which offers pre-tax, after-tax, and ROTH contribution and possible discretionary employer match opportunities. In addition, you will continue to be eligible for the Company&#8217;s deferred compensation plan, which currently provides pre-tax deferral options with employer match opportunities. </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><div id="i31e7a01adc3547b69edfd4a874834acf_53"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Executive Retirement Account (ERA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  You will continue to be eligible to participate in the ERA, however, your annual employer contribution will be increased to 20% of your base salary under the terms and conditions provided in the ERA. Employer contributions are made on July 1 each year.  </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Executive Severance Plan (ESP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  You will continue to be eligible for the Tenet ESP which provides 18 months of certain benefits in the event of a Qualifying Termination as defined in the Plan.  To participate, you must sign and return a separate agreement that our executive benefits team will provide after your promotion start date. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Time Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  In addition to paid Company holidays, you are eligible for paid time off according to your tenure with the company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Terms and Conditions of Employment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality, Non-Compete, and Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  This offer is contingent upon your execution of the Agreement provided in Appendix A. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At-Will Employment&#59; Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  Your employment will be on an at-will basis, which means that either you or the Company may terminate the employment relationship, with or without notice and with or without cause, at any time. As used in this letter, the term &#8220;cause&#8221; shall include, but shall not be limited to, dishonesty, fraud, willful misconduct, breach of fiduciary duty, conflict of interest, commission of a felony, material failure or refusal to perform job duties in accordance with Company policies, a material violation of Company policy that causes harm to the Company or an affiliate, or other wrongful conduct of a similar nature and degree. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Company Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  You agree, as a condition to your employment, to abide by all Tenet Human Resources and other policies, procedures, rules and regulations currently in effect or that may be adopted from time to time, including the Tenet Standards of Conduct.  To the extent that any such policies, rules or regulations, or any benefit plans in which you are a participant, conflict with the terms of this letter, the actual terms of those policies or plans shall control. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conflict Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; This offer is contingent upon your execution of the Fair Treatment and Mutual Arbitration agreement provided in Appendix&#160;B, which includes final and binding arbitration as a resolution to any grievance that results from your employment or termination of employment with the Company. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please let us know if you have any questions &#8211; we are here to ensure you make a thoughtful and informed decision. To accept, please sign and return to &#91;email address omitted&#93; on the executive benefits team by February 24, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Best regards,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Saumya Sutaria</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enclosure</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cc&#58;&#160;&#160;&#160;&#160;Kelly Pool, Vice President, Human Resources </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acknowledged and Accepted&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Foo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02&#47;22&#47;2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Foo (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenet Business Services Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly L. Pool</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#47;22&#47;2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly Pool</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Human Resources</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisa Foo</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2 of 2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.LL
<SEQUENCE>4
<FILENAME>thc-20221231ex10ll.htm
<DESCRIPTION>EX-10.LL
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i57007343fba44e70b6b4e83ecdacd027_1"></div><div style="min-height:98.1pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10(ll)</font></div><div><img alt="image_1a.jpg" src="image_1a.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:123px"></div></div><div><font><br></font></div><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TENET HEALTHCARE 2019 STOCK INCENTIVE PLAN</font></div><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT AWARDS</font></div><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR ANNUAL GRANT TO DIRECTORS</font><font style="color:#9a793e;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br></font><font style="color:#9a793e;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Human Resources Committee (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) of Tenet Healthcare Corporation (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) is authorized under the Company&#8217;s 2019 Stock Incentive Plan, as such may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) to make awards of restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) and to determine the terms of such RSUs.</font></div><div style="margin-bottom:6pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">November 3, 2022</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), the Committee granted you, Joseph Robert Kerrey (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">You</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), RSUs subject to the terms and conditions in this certificate (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certificate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) and the Plan, which terms are incorporated herein by this reference.  Each capitalized term not otherwise defined herein will have the meaning given to such term in the Plan.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  The Committee has granted You RSUs representing </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,325</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Shares in consideration for your service on the Board.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Vesting and Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  Subject to your continued service from the Grant Date through December 31, 2023 (the &#8220;Vesting Date&#8221;), the RSUs will become 100 percent vested as of the Vesting Date and will be settled in Shares within 30 days following the Vesting Date.  In the event of your death or disability (as defined under section 409A(a)(2)(C)(ii) of the Internal Revenue Code), prior to the Vesting Date, vesting and settlement of the RSUs will be accelerated and the RSUs will vest upon such date of death or disability and be settled as soon as practicable, and in all events within 30 days, thereafter.   Upon settlement, You will recognize ordinary income and taxes will be due.    </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  In the event of a Change in Control the following provisions will apply&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">In the event of a Change in Control (other than the liquidation or dissolution of the Company which is approved by a majority of its shareholders) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">i.e</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">., a 409A compliant change in control) the RSUs will vest in full as of immediately prior to such Change in Control and will be settled within 60 days of the Change in Control.</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">In the event of a Change in Control in which a liquidation or dissolution of the Company is approved by a majority of its shareholders (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">i.e</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">., a non-409A compliant change in control), the RSUs will vest in full as of immediately prior to such Change in Control, will be converted to cash equal to the value of the RSUs immediately prior to the Change in Control and paid within 60 days of the Change in Control.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Rights as Shareholder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  You will not have any rights of a shareholder prior to the settlement of the RSUs, at which time You will have all of the rights of a shareholder with respect to the Shares received, including the right to vote those Shares and receive all dividends and other distributions, if any, paid or made with respect thereto.  Any Shares or cash distributed as dividends with respect to the Shares subject to the RSUs will be subject to the same vesting, settlement and deferral schedule as the underlying RSUs.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  Unless otherwise permitted pursuant to Section 12.3 of the Plan, the RSUs may not be transferred, assigned or made subject to any encumbrance, pledge, or charge.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  The value of the RSUs evidenced by this Certificate will not be included as compensation, earnings, salaries, or other similar terms used when calculating Your benefits under any employee benefit plan sponsored by the Company or a Subsidiary, except as such plan otherwise expressly provides.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">No Continued Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  Nothing in this Certificate will confer upon You any right to continue in the service of the Company as a member of the Board.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  By written notice to You, the Committee reserves the right to amend the Plan or the provisions of this Certificate provided that no such amendment will impair in any material respect Your rights under this Certificate without Your consent except as required to comply with applicable securities laws or Section 409A of the Internal Revenue Code.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  If any term or provision of this Certificate is declared by any court or government authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any term or provision of this Certificate not declared to be unlawful or invalid.  Any term or provision of this Certificate so declared to be unlawful or invalid shall, if possible, be construed in a manner that will give effect to such term or provision to the fullest extent possible while remaining lawful and valid.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Page &#124; 1</font></div></div></div><div id="i57007343fba44e70b6b4e83ecdacd027_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  A copy of the Plan has been made available to You and additional copies of the Plan are available upon request to the Company's Corporate Secretary at the Company's principal executive office during normal business hours.  To the extent that any term or provision of this Certificate violates or is inconsistent with an express term or provision of the Plan, the Plan term or provision shall govern and any inconsistent term or provision in this Certificate shall be of no force or effect.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Binding Effect and Benefit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  This Certificate shall be binding upon and, subject to the terms and conditions hereof, inure to the benefit of the Company, its successors and assigns, and You and Your successors and assigns.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Entire Understanding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  This Certificate and the Plan embody the entire understanding and agreement of the Company and You in relation to the subject matter hereof, and no promise, condition, representation or warranty, expressed or implied, not herein stated, shall bind the Company or You.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  This Certificate shall be governed by, and construed in accordance with, the laws of the State of Nevada.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;padding-right:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Electronic Signature&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#91;Electronic Signature&#93;</font></div><div style="margin-bottom:6pt;padding-left:198pt;padding-right:-18pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acceptance Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#91;Acceptance Date&#93;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tenet Healthcare Corporation&#160;&#160;&#160;&#160;Page &#124; 2</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.MM
<SEQUENCE>5
<FILENAME>thc-20221231ex10mm.htm
<DESCRIPTION>EX-10.MM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i634e25eb2c2f4f14aeac6bdfa306ec9b_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10(mm)</font></div></div><div><img alt="image_11.jpg" src="image_11.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENET HEALTHCARE 2019 STOCK INCENTIVE PLAN </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARDS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Human Resources Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors of Tenet Healthcare Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is authorized under the Company&#8217;s 2019 Stock Incentive Plan, as such may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to make awards of restricted stock units and to determine the terms of such restricted stock units.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Grant Date&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Committee granted you,</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Participant Name&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an award of restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The RSUs were granted by the Committee subject to the terms and conditions set forth below in this certificate (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The RSUs are also subject to the terms and conditions of the Plan, which is incorporated herein by this reference.  Each capitalized term not otherwise defined herein will have the meaning given to such term in the Plan.</font></div><div style="padding-right:-9pt;text-align:center"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee has granted You RSUs representing the right to receive </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Shares Granted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares in consideration for services to be performed by You for the Company or a Subsidiary of the Company.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to Sections 3 and 4 below, the RSUs will vest as follows&#58; (a)&#160;one-third will vest on the first anniversary of the Grant Date, (b)&#160;one-third will vest on the second anniversary of the Grant Date, and (c)&#160;one-third will vest on the third anniversary of the Grant Date (each one-year period, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Your employment terminates or if You cease providing services to the Company or a Subsidiary for any reason other than as set forth in Sections 3 or 4 below, Your unvested RSUs will automatically be cancelled upon such termination of employment or services in exchange for no consideration.</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Certain Termination Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:22.5pt;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.07pt">Death or Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  All unvested RSUs will fully vest on the date of Your termination of employment in the event Your employment is terminated for any of the following reasons&#58;</font></div><div style="padding-left:40.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-indent:-18.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">Death, or</font></div><div style="padding-left:22.5pt;text-indent:4.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-indent:-21.54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">Disability (as defined under section 409A(a)(2)(C)(ii) of the Code).</font></div><div style="text-indent:4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Retirement on or after age 62 or Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  On the date of Your termination of employment as a result of Your retirement on or after reaching age 62 or a Qualifying Termination, a pro-rated portion (based on the number of months You are actually employed during the applicable Vesting Period) of Your RSUs will vest and settle.</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event of a Change in Control, the following provisions will apply&#58;</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">If the successor company assumes the RSUs or substitutes other restricted stock units for such RSUs (or agrees to assume or substitute such awards) and You incur a Qualifying Termination within the Protection Period, unvested RSUs (or substitute restricted stock units) will fully vest on the later of (i) the date of Your Qualifying Termination or (ii) immediately prior to the occurrence of the Change in Control.</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">If the successor company does not assume the RSUs, or substitute other restricted stock units for the RSUs, unvested RSUs will fully vest immediately prior to the occurrence of the Change in Control.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event You incur a Qualifying Termination not within the Protection Period, the provisions of Section 3 will apply.</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Settlement&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Upon the vesting of Your RSUs, Your RSUs will be settled in Shares within 60 days and You will recognize ordinary income. Notwithstanding the foregoing, to the extent required to comply with Section 409A of the Code, if You are a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code, and the vesting of Your RSUs is triggered as a result of Your termination of employment, the delivery of Shares shall be delayed until (a) the six-month anniversary of Your separation from service (within the meaning of Section 409A) or, (b) if earlier, as soon as practicable following Your death.  The Company is required to withhold payroll taxes due with respect to that ordinary income.  Pursuant to the Plan, at its option the Committee either may (i) have the Company withhold Shares having a Fair Market Value equal to the amount of the tax withholding or (ii) require You to pay to the Company the amount of the tax withholding.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Rights as Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  You will not have any rights of a shareholder prior to the receipt of Your Shares, and will obtain such rights only upon Your receipt of the Shares, at which time You will have all of the rights of a shareholder with respect to the Shares received upon the vesting of those RSUs, including the right to vote those Shares and receive all dividends and other distributions, if any, paid or made with respect thereto.  Any Shares or cash distributed as dividends with respect to the Shares underlying the RSUs will be subject to the same vesting schedule as the underlying RSUs and shall be settled as provided in Section 5.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The RSUs generally may not be transferred, assigned or made subject to any encumbrance, pledge, or charge.  Limited exceptions to this rule apply in the case of death, divorce, or gift as provided in Section 12.3 of the Plan.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any RSUs You are granted hereunder and&#47;or Shares you receive in settlement of such RSUs shall be subject to recovery by the Company in the circumstances and manner provided in any Incentive Compensation Clawback Policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and You shall effectuate any such recovery at such time and in such manner as the Company may specify. For purposes of this Certificate, the term &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Compensation Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The value of the RSUs evidenced by this Certificate will not be included as compensation, earnings, salaries, or other similar terms used when calculating Your benefits under any employee benefit plan sponsored by the Company or a Subsidiary, except as such plan otherwise expressly provides.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Nothing in this Certificate will confer upon You any right to continue in the employ or service of the Company or any Subsidiary or affect the right of the Company or a Subsidiary to terminate Your employment at any time with or without cause.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  By written notice to You, the Committee reserves the right to amend the Plan or the provisions of this Certificate provided that no such amendment will impair in any material respect Your rights under this Certificate without Your consent except as required to comply with applicable securities laws or Section 409A of the Code.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If any term or provision of this Certificate is declared by any court or government authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any term or provision of this Certificate not declared to be unlawful or invalid.  Any term or provision of this Certificate so declared to be unlawful or invalid shall, if possible, be construed in a manner that will give effect to such term or provision to the fullest extent possible while remaining lawful and valid.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  A copy of the Plan has been made available to You and additional copies of the Plan are available upon request to the Company's Corporate Secretary at the Company's principal executive office during normal business hours.  To the extent that any term or provision of this Certificate violates or is inconsistent with an express term or provision of the Plan, the Plan term or provision shall govern and any inconsistent term or provision in this Certificate shall be of no force or effect.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Binding Effect and Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Certificate shall be binding upon and, subject to the terms and conditions hereof, inure to the benefit of the Company, its successors and assigns, and You and Your successors and assigns.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Entire Understanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Certificate and the Plan embody the entire understanding and agreement of the Company and You in relation to the subject matter hereof, and no promise, condition, representation or warranty, expressed or implied, not herein stated, shall bind the Company or You.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Certificate shall be governed by, and construed in accordance with, the laws of the State of Nevada, without reference to principles of conflict of laws.</font></div><div><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Electronic Signature&#58; </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Electronic Signature&#93;</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptance Date&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Acceptance Date&#93;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="i634e25eb2c2f4f14aeac6bdfa306ec9b_4"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><img alt="image_11.jpg" src="image_11.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENET HEALTHCARE 2019 STOCK INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT PERFORMANCE AWARDS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Human Resources Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors of Tenet Healthcare Corporation (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is authorized under the Company&#8217;s 2019 Stock Incentive Plan, as such may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to make awards of restricted stock units (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;) and to determine the terms of such RSUs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Grant Date&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Committee granted you, </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Participant Name&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an award of RSUs.  The RSUs were granted by the Committee subject to the terms and conditions set forth below in this certificate (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The RSUs are also subject to the terms and conditions of the Plan, which is incorporated herein by this reference.  Each capitalized term not otherwise defined herein will have the meaning given to such term in the Plan.</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee has granted You RSUs representing the right to earn </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Shares Granted&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares based upon target achievement of applicable performance goals (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Target RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and up to a maximum of ___% of the Target RSUs in consideration for services to be performed by You for the Company or a Subsidiary of the Company.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:22.5pt;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.07pt">Performance Period.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your RSUs are subject to a three&#8209;year performance period that begins on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ends on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Performance Measures.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your RSUs will provisionally vest based on the Company&#8217;s achievement of the performance goals as follows&#58; </font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-indent:-18.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">Between 0% and ___% of one-third of the Target RSUs will vest based on achievement of the 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance goals set forth in Appendix A for fiscal year 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="padding-left:22.5pt;text-indent:4.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-indent:-21.54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">Between 0% and ___% of one-third of the Target RSUs will vest based on achievement of the 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance goals established by the Committee and communicated to you promptly thereafter for fiscal year 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="padding-left:22.5pt;text-indent:4.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-indent:-24.31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">Between 0% and ___% of one-third of the Target RSUs will vest based on achievement of the 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance goals established by the Committee and communicated to you promptly thereafter for fiscal year 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:22.5pt"><font><br></font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following completion of the Performance Period, the provisionally vested RSUs will be subject to adjustment based on the Company&#8217;s Relative TSR (as defined in Appendix A) for the Performance Period as set forth in Appendix&#160;A.  The performance goals set forth in Appendix A for fiscal year 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and each of the performance goals established by the Committee for fiscal years 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The RSUs that have provisionally vested under Section 2 above will vest on the third anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If Your employment terminates or if You cease providing services to the Company or a Subsidiary for any reason prior to the Vesting Date, other than as set forth in Section 4 or 5 below, Your unvested RSUs (even if provisionally vested) will be automatically cancelled.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Certain Termination Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Your unvested RSUs will vest as follows in the event any of the following events (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Termination Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) occurs prior to the Vesting Date&#58;</font></div><div style="padding-left:22.5pt;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.57pt">Death or Disability (as defined under section 409A(a)(2)(C)(ii) of the Internal Revenue Code)&#58;  A pro-rated portion (based on the number of months You are actually employed during the Performance Period) of Your RSUs will vest on the date of such a Termination Event based on (i) the Company&#8217;s actual performance with respect to the applicable Performance Criteria during such completed portion of the Performance Period that has provisionally vested on or prior to such a Termination Event and (ii) assuming target achievement of the applicable Performance Criteria for such incomplete portion of the Performance Period that has not provisionally vested on or prior to such a Termination Event.</font></div><div style="padding-left:22.5pt;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:45pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Qualifying Termination or Retirement (retirement on or after age 62)&#58; A pro-rated portion (based on the number of months You are actually employed during the Performance Period) of Your RSUs will vest on the Vesting Date, taking into account the Company&#8217;s actual performance with respect to the applicable Performance Criteria.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event of a Change in Control, the following provisions will apply&#58;</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">If the successor company assumes the RSUs or substitutes other restricted stock units for such RSUs (or agrees to assume or substitute such awards) and you incur a Termination Event within the Protection Period, the unvested RSUs (or substitute restricted stock units) will vest as provided in Section 4 above.</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">If the successor company does not assume the RSUs, or substitute other restricted stock units for the RSUs, and if either (i)&#160;the Change in Control occurs within the Performance Period, then each of the Performance Criteria will be deemed to have been met at the target level and unvested RSUs representing the Target RSUs will fully vest immediately prior to the occurrence of the Change in Control or (ii)&#160;the Change in Control occurs after the end of the Performance Period, but prior to the Vesting Date, then Your provisionally vested RSUs will fully vest immediately prior to the occurrence of the Change in Control.</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">In lieu of (a) or (b), the Committee may declare the level at which the Performance Criteria are deemed to be met and the unvested RSUs will vest to that extent immediately prior to the occurrence of the Change in Control.</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Settlement&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Upon the vesting of Your RSUs, Your RSUs will be settled in Shares within sixty&#160;(60) days and You will recognize ordinary income.  Notwithstanding the foregoing, to the extent required to comply with Section 409A of the Code, if You are a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code, and the vesting of Your RSUs is triggered as a result of Your termination of employment, the delivery of Shares shall be delayed until (a) the six-month anniversary of Your separation from service (within the meaning of Section&#160;409A), or (b) if earlier, as soon as practicable following Your death.  The Company is required to withhold payroll taxes due with respect to that ordinary income.  Pursuant to the Plan, at its option the Committee either may (i) have the Company withhold Shares having a Fair Market Value equal to the amount of the tax withholding or (ii) require You to pay to the Company the amount of the tax withholding.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Rights as Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  You will not have any rights of a shareholder prior to the receipt of Your Shares, and will obtain such rights only upon Your receipt of the Shares, at which time You will have all of the rights of a shareholder with respect to the Shares received upon the vesting of those RSUs, including the right to vote those Shares and receive all dividends and other distributions, if any, paid or made with respect thereto.  Any Shares or cash distributed as dividends with respect to the Shares subject to the RSUs will be subject to the same vesting schedule and performance conditions as the underlying RSUs and shall be settled as provided in Section&#160;6.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any RSUs You are granted hereunder and&#47;or Shares you receive in settlement of such RSUs shall be subject to recovery by the Company in the circumstances and manner provided in any Incentive Compensation Clawback Policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and You shall effectuate any such recovery at such time and in such manner as the Company may specify. For purposes of this Certificate, the term &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Compensation Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34; means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company. Until the Company adopts such an Incentive Compensation Clawback Policy, the following clawback provision shall apply to the RSUs&#58; </font></div><div><font><br></font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that, within three years of the end of the Performance Period, the Company restates its financial results with respect to the Company&#8217;s performance during the Performance Period due to material non-compliance with any financial reporting requirement under the securities laws as generally applied and the Board of Directors determines Your fraud or misconduct caused or partially caused the need for the restatement, then the Board of Directors shall require You to immediately return to the Company the RSUs or any Shares you receive in settlement of the RSUs or the pre-tax income derived from any disposition of the Shares previously received in settlement of the RSUs (plus a reasonable rate of interest if deemed appropriate by the Board of Directors) that would not have been granted and&#47;or vested, as determined in the sole discretion of the Board, based upon the restated financial results.</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The RSUs generally may not be transferred, assigned or made subject to any encumbrance, pledge, or charge.  Limited exceptions to this rule apply in the case of death, divorce, or gift as provided in Section&#160;12.3 of the Plan.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The value of the RSUs evidenced by this Certificate will not be included as compensation, earnings, salaries, or other similar terms used when calculating Your benefits under any employee benefit plan sponsored by the Company or a Subsidiary, except as such plan otherwise expressly provides.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Nothing in this Certificate will confer upon You any right to continue in the employ or service of the Company or any Subsidiary or affect the right of the Company or a Subsidiary to terminate Your employment at any time with or without cause.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  By written notice to You, the Committee reserves the right to amend the Plan or the provisions of this Certificate provided that no such amendment will impair in any material respect Your rights under this Certificate without Your consent except as required to comply with applicable securities laws or Section 409A of the Code.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If any term or provision of this Certificate is declared by any court or government authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any term or provision of this Certificate not declared to be unlawful or invalid.  Any term or provision of this Certificate so declared to be unlawful or invalid shall, if possible, be construed in a manner that will give effect to such term or provision to the fullest extent possible while remaining lawful and valid.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  A copy of the Plan has been made available to You and additional copies of the Plan are available upon request to the Company's Corporate Secretary at the Company's principal executive office during normal business hours.  To the extent that any term or provision of this Certificate violates or is inconsistent with an express term or provision of the Plan, the Plan term or provision shall govern and any inconsistent term or provision in this Certificate shall be of no force or effect.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Binding Effect and Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Certificate shall be binding upon and, subject to the terms and conditions hereof, inure to the benefit of the Company, its successors and assigns, and You and Your successors and assigns.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Entire Understanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Certificate and the Plan embody the entire understanding and agreement of the Company and You in relation to the subject matter hereof, and no promise, condition, representation or warranty, expressed or implied, not herein stated, shall bind the Company or You.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Certificate shall be governed by, and construed in accordance with, the laws of the State of Nevada, without reference to principles of conflict of laws.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Electronic Signature&#58; </font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Electronic Signature&#93;</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptance Date&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Acceptance Date&#93;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.SS
<SEQUENCE>6
<FILENAME>thc-20221231ex10ss.htm
<DESCRIPTION>EX-10.SS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1c8cc9dda689419eb04563327c7ab5de_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10(ss)</font></div></div><div style="padding-left:6.7pt;padding-right:369.9pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:123px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENET HEALTHCARE 2019 STOCK INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS OF</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARD</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Human Resources Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors of Tenet Healthcare Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is authorized under the Company&#8217;s 2019 Stock Incentive Plan, as such may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to make awards of restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and to determine the terms of such RSUs.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">06&#47;02&#47;2020 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Committee granted you, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THOMAS W ARNST </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an award of RSUs. The RSUs were granted by the Committee subject to the terms and conditions set forth below in this certificate (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The RSUs are also subject to the terms and conditions of the Plan, which is incorporated herein by this reference. Each capitalized term not otherwise defined herein will have the meaning given to such term in the Plan.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Committee has granted You RSUs representing the right to receive 22,615 Shares in consideration for services to be performed by You for the Company or a Subsidiary of the Company.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Sections 3 and 4 below, the RSUs will vest as follows&#58; (a) one-third will vest 2&#47;28&#47;2021, (b)&#160;one-third will vest on 2&#47;28&#47;2022, and (c) one-third will vest on 2&#47;28&#47;2023 (each one-year period, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise expressly set forth in any written agreement with You or severance plan applicable to You, if Your employment terminates or if You cease providing services to the Company or a Subsidiary for any reason other than as set forth in Sections 3 or 4 below, Your unvested RSUs will automatically be cancelled in exchange for no consideration.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Certain Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Notwithstanding anything to the contrary, all unvested RSUs will fully vest on the date of Your termination of employment in the event Your employment is terminated for any of the following reasons&#58;</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-18.43pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9pt">Death, or</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-19.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.2pt">Disability (as defined under section 409A(a)(2)(C)(ii) of the Code), or</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-19.47pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.5pt">Qualifying Termination.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Retirement on or after age 62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise set forth in any written agreement with You or severance plan applicable to You, on the date of Your termination of employment as a result of Your retirement on or after reaching age 62 , a pro-rated portion (based on the number of months You are actually employed during the applicable Vesting Period) of Your RSUs will vest and settle.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes hereof, and for the avoidance of doubt, employment by any Tenet Healthcare Corporation consolidated subsidiary or affiliate (collectively, &#8220;Tenet&#8221;) will be treated as a continuation of Your employment for all purposes, and You will not be deemed to have experienced a termination of employment as long as You remain continuously employed by any such employer. Furthermore, in no event will a Qualifying Termination occur as the result of any voluntary resignation (without Good Reason) or solely by reason of a spin-off of Conifer Health Solutions, LLC (&#8220;Conifer&#8221;), any successor to Conifer, or the assets of Conifer.</font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise set forth in any written agreement with You or severance plan applicable to You, in the event of a Change in Control, the following provisions will apply&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">If the successor company assumes the RSUs or substitutes other restricted stock units for such RSUs (or agrees to assume or substitute such awards) and You incur a Qualifying Termination within the period beginning on the date that is six (6) months before the occurrence of a Change in Control and ending twenty-four (24) months after the occurrence of a Change in Control, unvested RSUs (or substitute restricted stock units) will fully vest on the later of (i) the date of Your Qualifying Termination or (ii)&#160;immediately prior to the occurrence of the Change in Control.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the successor company does not assume the RSUs, or substitute other restricted stock units for the RSUs, unvested RSUs will fully vest immediately prior to the occurrence of the Change in Control.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event You incur a Qualifying Termination not within the period beginning on the date that is six (6) months before the occurrence of a Change in Control and ending twenty-four (24) months after the occurrence of a Change in Control, the provisions of Section 3 will apply.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For purposes of this Section 4, any reference to the &#8220;Company&#8221; in the definition of &#8220;Change in Control&#8221; shall be deemed to refer to the &#8220;Company or Conifer Health Solutions, LLC&#8221; and references to the Board shall be deemed to refer to the Board of Directors of the Company or the Board of Managers of Conifer. Notwithstanding the foregoing, a spin-off of Conifer, any successor to Conifer, or the assets of Conifer shall not give rise to a &#8220;Change in Control.&#8221;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Settlement&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the vesting of Your RSUs, Your RSUs will be settled in Shares within 60&#160;days and You will recognize ordinary income. Notwithstanding the foregoing, to the extent required to comply with Section 409A of the Code, if You are a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code, and the vesting of Your RSUs is triggered as a result of Your termination of employment, the delivery of Shares shall be delayed until (a) the six-month anniversary of Your separation from service (within the meaning of Section 409A), or (b) if earlier, as soon as practicable following Your death. The Company is required to withhold payroll taxes due with respect to that ordinary income. Pursuant to the Plan, at its option the Committee either may (i) have the Company withhold Shares having a Fair Market Value equal to the amount of the tax withholding or (ii) require You to pay to the Company the amount of the tax withholding.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Rights as Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You will not have any rights of a shareholder prior to the receipt of Your Shares, and will obtain such rights only upon Your receipt of the Shares, at which time You will have all of the rights of a shareholder with respect to the Shares received upon the vesting of those RSUs, including the right to vote those Shares and receive all dividends and other distributions, if any, paid or made with respect thereto. Any Shares or cash distributed as dividends with respect to the Shares subject to the RSUs will be subject to the same vesting schedule as the underlying RSUs and shall be settled as provided in Section 5.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any RSUs You are granted hereunder and&#47;or Shares you receive in settlement of such RSUs shall be subject to recovery by the Company in the circumstances and manner provided in any Incentive Compensation Clawback Policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and You shall effectuate any such recovery at such time and in such manner as the Company may specify. For purposes of this Certificate, the term &#8220;Incentive Compensation Clawback Policy&#8221; means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The RSUs generally may not be transferred, assigned or made subject to any encumbrance, pledge, or charge. Limited exceptions to this rule apply in the case of death, divorce, or gift as provided in Section 12.3 of the Plan.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The value of the RSUs evidenced by this Certificate will not be included as compensation, earnings, salaries, or other similar terms used when calculating Your benefits under any employee benefit plan sponsored by the Company or a Subsidiary, except as such plan otherwise expressly provides.</font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Nothing in this Certificate will confer upon You any right to continue in the employ or service of the Company or any Subsidiary or affect the right of the Company or a Subsidiary to terminate Your employment at any time with or without cause.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. By written notice to You, the Committee reserves the right to amend the Plan or the provisions of this Certificate provided that no such amendment will impair in any material respect Your rights under this Certificate without Your consent except as required to comply with applicable securities laws or Section 409A of the Code.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any term or provision of this Certificate is declared by any court or government authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any term or provision of this Certificate not declared to be unlawful or invalid. Any term or provision of this Certificate so declared to be unlawful or invalid shall, if possible, be construed in a manner that will give effect to such term or provision to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A copy of the Plan has been made available to You and additional copies of the Plan are available upon request to the Company's Corporate Secretary at the Company's principal executive office during normal business hours. To the extent that any term or provision of this Certificate violates or is inconsistent with an express term or provision of the Plan, the Plan term or provision shall govern and any inconsistent term or provision in this Certificate shall be of no force or effect.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Binding Effect and Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Certificate shall be binding upon and, subject to the terms and conditions hereof, inure to the benefit of the Company, its successors and assigns, and You and Your successors and assigns.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Entire Understanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Certificate and the Plan embody the entire understanding and agreement of the Company and You in relation to the subject matter hereof, and no promise, condition, representation or warranty, expressed or implied, not herein stated, shall bind the Company or You.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Certificate shall be governed by, and construed in accordance with, the laws of the State of Nevada, without reference to principles of conflict of laws.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Electronic Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signed Electronically</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><div id="i1c8cc9dda689419eb04563327c7ab5de_4"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:369.55pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:123px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENET HEALTHCARE 2019 STOCK INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS OF</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT PERFORMANCE AWARD</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Human Resources Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors of Tenet Healthcare Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is authorized under the Company&#8217;s 2019 Stock Incentive Plan, as such may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to make awards of restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and to determine the terms of such RSUs.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">06&#47;02&#47;2020 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Committee granted you, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THOMAS W ARNST </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an award of RSUs. The RSUs were granted by the Committee subject to the terms and conditions set forth below in this certificate (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The RSUs are also subject to the terms and conditions of the Plan, which is incorporated herein by this reference. Each capitalized term not otherwise defined herein will have the meaning given to such term in the Plan. This Certificate amends and restates the terms of Your performance-based RSUs granted on the Grant Date.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Committee has granted You RSUs representing the right to earn 22,615 Shares based upon target achievement of applicable performance goals (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Target RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). One-third of the Target RSUs will be subject to Conifer Health performance for January 1, 2020 through December 31, 2020, with up to a maximum of 150% of such Target RSUs in consideration for services to be performed by You for the Company or a Subsidiary of the Company. The remaining two-thirds of the Target RSUs will be subject to Tenet Healthcare performance for January 1, 2021 through December 31, 2022, with up to a maximum of 200% of such Target RSUs in consideration for services to be performed by You to the Company or a Subsidiary of the Company.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Performance Period and Criteria.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Performance Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your RSUs are subject to a three-year performance period that began on January&#160;1,&#160;2020 and ends on December 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Performance Criteria. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your RSUs will provisionally vest based on the Company&#8217;s achievement of the performance goals as follows&#58;</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-18.79pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.36pt">Between 0% and 150% of one-third of the Target RSUs will vest based on achievement of the 2020 performance goals set forth set forth in Appendix A for fiscal year 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conifer Target RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-19.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.2pt">Between 0% and 200% of one-third of the Target RSUs will vest based on achievement of the 2021 performance goals established by the Committee and set forth in Appendix A for fiscal year 2021&#59; and</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-18.57pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.6pt">Between 0% and 200% of one-third of the Target RSUs will vest based on achievement of the 2022 performance goals established by the Committee and set forth in Appendix A for fiscal year 2022 (the Target RSUs referred to in clauses (ii) and (iii), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenet Target RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Following completion of the Performance Period, the provisionally vested RSUs will be subject to adjustment based on the Company&#8217;s Relative TSR (as defined in Appendix A) for the Performance Period as set forth in Appendix A. The performance goals set forth in Appendix A shall be collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Subject to Sections 4 and 5 below, the RSUs which have provisionally vested under Section 2 above will vest on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">02&#47;28&#47;2023 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Except as otherwise set forth in any written agreement with You or severance plan applicable to You, if Your employment terminates or if You cease providing services to the Company or a Subsidiary for any reason prior to the Vesting Date, other than as set forth in Section 4 or 5 below, Your unvested RSUs (even if provisionally vested) will be automatically cancelled in exchange for no consideration.</font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Certain Terminations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Your unvested RSUs will vest as follows in the event any of the following events (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Termination Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) occurs prior to the Vesting Date&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Qualifying Termination, Death or Disability (as defined under section 409A(a)(2)(C)(ii) of the Internal Revenue Code)&#58; (i) a pro-rated portion (based on the number of months You are actually employed during the Performance Period) of Your RSUs will vest on the date of such a Termination Event based on the Company&#8217;s actual performance with respect to the applicable Performance Criteria during such completed portion of the Performance Period prior to such a Termination Event and (ii) the remaining portion of Your RSUs will vest on the date of such a Termination Event assuming target achievement of the applicable Performance Criteria for such incomplete portion of the Performance Period following such a Termination Event.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Retirement (retirement on or after age 62)&#58; A pro-rated portion (based on the number of months You are actually employed during the Performance Period) of Your RSUs will vest on the Vesting Date, taking into account the Company&#8217;s actual performance with respect to the applicable Performance Criteria.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes hereof, and for the avoidance of doubt, employment by any Tenet Healthcare Corporation consolidated subsidiary or affiliate (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) will be treated as a continuation of Your employment for all purposes, and You will not be deemed to have experienced a termination of employment as long as You remain continuously employed by any such an employer. Furthermore, in no event will a Qualifying Termination occur as the result of any voluntary resignation (without Good Reason) or solely by reason of a spin-off of Conifer Health Solutions, LLC (&#8220;Conifer&#8221;), any successor to Conifer, or the assets of Conifer.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except as otherwise set forth in any written agreement with You or severance plan applicable to You, in the event of a Change in Control, the following provisions will apply&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">If the successor company assumes the RSUs or substitutes other restricted stock units for such RSUs (or agrees to assume or substitute such awards) and you experience a Termination Event within the period beginning on the date that is six (6) months before the occurrence of a Change in Control and ending twenty-four (24) months after the occurrence of a Change in Control, the unvested RSUs (or substitute restricted stock units) will vest as provided in Section 4 above.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the successor company does not assume the RSUs, or substitute other restricted stock units for the RSUs, and if (i) the Change in Control occurs within the Performance Period, then each of the Performance Criteria will be deemed to have been met at the target level and unvested RSUs representing the Target RSUs will fully vest immediately prior to the occurrence of the Change in Control or (ii) the Change in Control occurs after the end of the Performance Period, but prior to the Vesting Date, then Your provisionally vested RSUs will fully vest immediately prior to the occurrence of the Change in Control.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In lieu of (a) or (b), the Committee may declare the level at which the Performance Criteria are deemed to be met and the unvested RSUs will vest to that extent immediately prior to the occurrence of the Change in Control.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Section 5, any reference to the &#8220;Company&#8221; in the definition of &#8220;Change in Control&#8221; shall be deemed to refer to the &#8220;Company or Conifer Health Solutions, LLC&#8221; and references to the Board shall be deemed to refer to the Board of Directors of the Company or the Board of Managers of Conifer. Notwithstanding the foregoing, a spin-off of Conifer, any successor to Conifer, or the assets of Conifer shall not give rise to a &#8220;Change in Control.&#8221;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Settlement&#59; Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upon the vesting of Your RSUs, Your RSUs will be settled in Shares within 60&#160;days and You will recognize ordinary income. Notwithstanding the foregoing, to the extent required to comply with Section 409A of the Code, if You are a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code, and the vesting of Your RSUs is triggered as a result of Your termination of employment, the delivery of Shares shall be delayed until (a) the six-month anniversary of Your separation from service (within the meaning of Section 409A), or (b) if earlier, as soon as practicable following Your death. The Company is required to withhold payroll taxes due with respect to that ordinary income. Pursuant to the Plan, at its option </font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Committee either may (i) have the Company withhold Shares having a Fair Market Value equal to the amount of the tax withholding or (ii) require You to pay to the Company the amount of the tax withholding.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Rights as Shareholder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> You will not have any rights of a shareholder prior to the receipt of Your Shares, and will obtain such rights only upon Your receipt of the Shares, at which time You will have all of the rights of a shareholder with respect to the Shares received upon the vesting of those RSUs, including the right to vote those Shares and receive all dividends and other distributions, if any, paid or made with respect thereto. Any Shares or cash distributed as dividends with respect to the Shares subject to the RSUs will be subject to the same vesting schedule and performance conditions as the underlying RSUs and shall be settled as provided in Section 6.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Clawback.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Any RSUs You are granted hereunder and&#47;or Shares you receive in settlement of such RSUs shall be subject to recovery by the Company in the circumstances and manner provided in any Incentive Compensation Clawback Policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and You shall effectuate any such recovery at such time and in such manner as the Company may specify. For purposes of this Certificate, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Compensation Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company. Until the Company adopts such an Incentive Compensation Clawback Policy, the following clawback provision shall apply to the RSUs&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that, within three years of the end of the Performance Period, the Company restates its financial results with respect to the Company&#8217;s performance during the Performance Period due to material non-compliance with any financial reporting requirement under the securities laws as generally applied and the Board of Directors determines Your fraud or misconduct caused or partially caused the need for the restatement, then the Board of Directors shall require You to immediately return to the Company the RSUs or any Shares you receive in settlement of the RSUs or the pre-tax income derived from any disposition of the Shares previously received in settlement of the RSUs (plus a reasonable rate of interest if deemed appropriate by the Board of Directors) that would not have been granted and&#47;or vested, as determined in the sole discretion of the Board, based upon the restated financial results.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The RSUs generally may not be transferred, assigned or made subject to any encumbrance, pledge, or charge. Limited exceptions to this rule apply in the case of death, divorce, or gift as provided in Section 12.3 of the Plan.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Effect on Other Employee Benefit Plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The value of the RSUs evidenced by this Certificate will not be included as compensation, earnings, salaries, or other similar terms used when calculating Your benefits under any employee benefit plan sponsored by the Company or a Subsidiary, except as such plan otherwise expressly provides.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">No Employment Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nothing in this Certificate will confer upon You any right to continue in the employ or service of the Company or any Subsidiary or affect the right of the Company or a Subsidiary to terminate Your employment at any time with or without cause.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Amendment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> By written notice to You, the Committee reserves the right to amend the Plan or the provisions of this Certificate provided that no such amendment will impair in any material respect Your rights under this Certificate without Your consent except as required to comply with applicable securities laws or Section 409A of the Code.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If any term or provision of this Certificate is declared by any court or government authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any term or provision of this Certificate not declared to be unlawful or invalid. Any term or provision of this Certificate so declared to be unlawful or invalid shall, if possible, be construed in a manner that will give effect to such term or provision to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Construction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A copy of the Plan has been made available to You and additional copies of the Plan are available upon request to the Company's Corporate Secretary at the Company's principal executive office during normal business hours. To the extent that any term or provision of this Certificate violates or is inconsistent with an </font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">express term or provision of the Plan, the Plan term or provision shall govern and any inconsistent term or provision in this Certificate shall be of no force or effect.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Binding Effect and Benefit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This Certificate shall be binding upon and, subject to the terms and conditions hereof, inure to the benefit of the Company, its successors and assigns, and You and Your successors and assigns.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Entire Understanding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This Certificate and the Plan embody the entire understanding and agreement of the Company and You in relation to the subject matter hereof, and no promise, condition, representation or warranty, expressed or implied, not herein stated, shall bind the Company or You.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Governing Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This Certificate shall be governed by, and construed in accordance with, the laws of the State of Nevada, without reference to principles of conflict of laws.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Electronic Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signed Electronically</font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>thc-20221231ex21.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i419fb349e6ea41459152d7349b7797c4_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Consolidated Subsidiaries</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Tenet Healthcare Corporation</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">as of December 31, 2022</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 N 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street I, L.L.C.</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 N 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street II, L.L.C.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nebraska</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 N 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street III, Inc.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nebraska</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Abrazo Health Network EP Clinical Services, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advantage Health Care Management Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AHM Acquisition Co., Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alvarado Hospital Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AMC&#47;North Fulton Urgent Care #1, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AMC&#47;North Fulton Urgent Care #3, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AMC&#47;North Fulton Urgent Care #4, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AMC&#47;North Fulton Urgent Care #5, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">American Medical (Central), Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AMI&#47;HTI Tarzana Encino Joint Venture</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AMI Information Systems Group, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub (Heights), Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub (Hilton Head), Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub (North Ridge Hospital), Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub of California, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub of North Carolina, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub of South Carolina, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub of Texas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub (SFH), Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amisub (Twelve Oaks), Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Anaheim Hills Medical Imaging, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Anaheim MRI Holding, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona Care Network &#8211; Next, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona Health Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Asia Outsourcing US, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Atlanta Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Diagnostics, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Health Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Physician Alliance ACO, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Physician Alliance, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH BMC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH CBMC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH DevelopmentCo, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH NP Clinicians, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH PBMC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH SBMC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BBH WBMC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BCDC EmployeeCO, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHC-Talladega Pediatrics, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Accountable Care, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Affinity, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Integrated Physician Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Physician Performance Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Physicians Alliance for ACE, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Physicians Network, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BHS Specialty Network, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bluffton Okatie Primary Care, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Ancillary Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Baptist Health 1, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Baptist Health 2, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Baptist Imaging, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Center Development Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Development, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Diagnostic Imaging Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Garages, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Health Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Home Health, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Parking Associates, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Primary Network Care, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Women&#8217;s Diagnostic Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BT East Dallas JV, LLP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Cardiology, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Cyberknife, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Hand Practice, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Office Buildings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Parking Decks, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Physician Practices, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Retail Pharmacy, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BW Sports Practice, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Camp Creek Urgent Care, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cardiology Physicians Corporation, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cardiovascular Clinical Excellence at Sierra Providence, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Catawba-Piedmont Cardiothoracic Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cedar Hill Primary Care, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Center for Advanced Research Excellence, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Center for the Urban Child, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Central Carolina-IMA, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Central Texas Corridor Hospital Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Central Valley Quality Alliance, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CGH GP, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CGH Hospital, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chalon Living, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CHN Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CHVI Tucson Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CML-Chicago Market Labs, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Coast Healthcare Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Coastal Carolina Medical Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Coastal Carolina Physician Practices, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Coastal Carolina Pro Fee Billing, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Commonwealth Continental Health Care, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Community Connection Health Plan, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Community Hospital of Los Gatos, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Care Continuum Solutions, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Ethics and Compliance, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Global Business Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Republic of the Philippines</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Global Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Health Solutions, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Patient Communications, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Physician Services Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Physician Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Revenue Cycle Solutions, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer Value-Based Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conifer WFH Global Business Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Republic of the Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CRNAs of Michigan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delray Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delray Medical Physician Services, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Desert Regional Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Detroit Education &#38; Research</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">DigitalMed, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dignity&#47;Abrazo Health Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">DMC Detroit Receiving Hospital Premier Clinical Co-Management Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">DMC Education &#38; Research</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">DMC Harper University Hospital Premier Clinical Co-Management Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Doctors Hospital of Manteca, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Doctors Medical Center Neurosciences Clinical Co-Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Doctors Medical Center of Modesto, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Doctors Medical Center Orthopedics Clinical Co-Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cobb Urgent Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cooper Coastal Family Physicians, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cooper Community Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cooper Hyperbarics, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cooper OB&#47;GYN, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cooper Physician Network, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Cooper Primary Care Physicians, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA Hausman, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA Kelly, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus BHS&#47;SA NW Military, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA Overlook Parkway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA Schertz, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus BHS&#47;SA Southside, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA Thousand Oaks, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emerus&#47;BHS SA Westover Hills, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Enterprise Research Solutions, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">EPHC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">First Choice Physician Partners</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida Coast Medical and Surgical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">FMC Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Fort Bend Clinical Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Fountain Valley Regional Hospital and Medical Center</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">FryeCare Women&#8217;s Services, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Frye Regional Medical Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gardendale Surgical Associates, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gastric Health Institute, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia North Fulton Healthcare Associates, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia Northside Ear, Nose and Throat, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Good Samaritan Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Good Samaritan Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Greater Dallas Healthcare Enterprises</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Greater Northwest Houston Enterprises</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gulf Coast Community Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mississippi</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hardeeville Medical Group, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Harlingen Physician Network, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Harper-Hutzel AHP Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HC Hialeah Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCH Tucson Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN Emerus El Paso, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN Emerus Management Sub, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN Emerus Texas, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN EP Horizon City, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN EP Lee Trevino, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN EP Northeast, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN EP Sunland Park, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN Laboratories, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN Physicians, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HCN Surgery Center Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HDMC Holdings, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health &#38; Wellness Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Healthcare Insurance Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Alabama, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network CFMC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network DPH, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Georgia, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Hospitals (Dallas), Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Hospitals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Louisiana, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Missouri, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network North Carolina, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network South Carolina, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Tennessee, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare Network Texas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare SMG I, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare SMG II, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare SMG IV, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthcare UC Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Healthcare Underwriting Company, a Risk Retention Group</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vermont</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HealthCorp Network, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Services CFMC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Services HNMC, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Services Network Care, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Services Network Hospitals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Services Network Texas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hialeah Real Properties, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hilton Head Health System, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hilton Head Regional Healthcare, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hilton Head Regional OB&#47;GYN Partners, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hilton Head Regional Physician Network &#8211; Georgia, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hilton Head Regional Physician Network, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hitchcock State Street Real Estate, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HNMC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HNW GP, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HNW LP, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Holy Cross Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Home Health Partners of San Antonio, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hoover Doctors Group, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hoover Land, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hospital Development of West Phoenix, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hospital RCM Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Houston Northwest Partners, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Houston Specialty Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Houston Sunrise Investors, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HSRM International, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Imaging Center at Baxter Village, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">InforMed Insurance Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">JFK Memorial Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Journey Home Healthcare of San Antonio, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Laguna Medical Systems, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lakewood Regional Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lifemark Hospitals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lifemark Hospitals of Florida, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lifemark Hospitals of Louisiana, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Los Alamitos Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MacNeal Management Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MacNeal Physicians Group, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Magnetic Resonance Imaging of San Luis Obispo, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Meadowcrest Hospital, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Medplex Outpatient Medical Centers, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memphis Urgent Care #1, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memphis Urgent Care #2, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MetroWest HomeCare &#38; Hospice, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan Pioneer ACO, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan Regional Imaging, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mobile Imaging Management, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mobile Technology Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Modesto Radiology Imaging, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nacogdoches ASC-LP, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Ancillary, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National ASC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Diagnostic Imaging Centers, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Home Health Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National ICN, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Imaging Center Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Medical Services II, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Outpatient Services Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New England Physician Performance Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New H Acute, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Newhope Imaging Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Medical Horizons II, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NICH GP Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NMC Lessor, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NME Headquarters, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NME Properties Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NME Properties, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NME Property Holding Co., Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NME Psychiatric Hospitals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NME Rehabilitation Properties, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Fulton Medical Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Fulton Women&#8217;s Consultants, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Miami Medical Center, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NSMC Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NS Medical Billing Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NUCH of Georgia, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NUCH of Massachusetts, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NUCH of Michigan, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Olive Branch Urgent Care #1, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mississippi</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrNda Hospital Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Orthopedic Associates of the Lowcountry, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Paley Institute Global, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Palm Beach Gardens Community Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Palm Valley Medical Center Campus Association</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Park Plaza Hospital Billing Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PDN, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PHPS-CHM Acquisition, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PHPS, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Physician Performance Network, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Physician Performance Network of Tucson, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Carolina OB&#47;GYN of York County, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont&#47;Carolinas Radiation Therapy, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont East Urgent Care Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Express Care at Sutton Road, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Family Practice at Rock Hill, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont General Surgery Associates, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Physician Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Pulmonology, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Urgent Care and Industrial Health Centers, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont Urgent Care Center at Baxter Village, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Placentia-Linda Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pleasanton Diagnostic Imaging, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PMC Physician Network, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Practice Partners Management, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Premier ACO Physicians Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Premier Health Plan Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Premier Medical Specialists, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PSS Patient Solution Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Republic Health Corporation of Rockwall County</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nevada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Resolute Health Physicians Network, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Resolute Hospital Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">RHC Parkway, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">R.H.S.C. El Paso, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Rio Grande Valley Indigent Health Care Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">RLC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis-Arkansas Physician Network, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arkansas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis-Bartlett Physician Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Cardiology Associates, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Cardiovascular Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Center for Surgical Weight Loss, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Hospital-Bartlett, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Hospital Billing Center, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Hospital Medicare ACO, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Hospital Pro Fee Billing, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Medical Partners, East, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Medical Partners, General Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Physician Network, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Surgical Associates, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Vincent Physician Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">San Ramon Ambulatory Care, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">San Ramon Regional Medical Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SFMP, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SFMPE - Crittenden, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arkansas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shelby Baptist Affinity, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shelby Baptist Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sierra Providence Healthcare Enterprises</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sierra Providence Health Network, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sierra Vista Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sinai-Grace Premier Clinical Management Services LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SL-HLC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SLH Vista, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SMSJ Imaging Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SMSJ Tucson Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina Health Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina SeWee Family Medicine, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Southern Orthopedics and Sports Medicine, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Southwest Children&#8217;s Hospital, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Spalding Regional Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Spalding Regional OB&#47;GYN, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Spalding Regional Physician Services, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Springfield Service Holding Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SRRMC Management, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Joseph&#8217;s Hospital Surgical Co-Management, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Mary&#8217;s Hospital Cardiovascular Co-Management LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Mary&#8217;s Hospital Surgical Co-Management LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Mary&#8217;s Levee Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Mary&#8217;s Medical Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sun View Imaging, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Clinical Excellence at Desert Regional, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sylvan Grove Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">T1 Security, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Templeton Imaging, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Business Services Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet California, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TenetCare Frisco, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Employment, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Finance Corp.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Florida, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Florida Physician Services II, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Florida Physician Services III, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Florida Physician Services, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Global Business Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Republic of the Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Bucks County, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Graduate, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Hahnemann, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Nacogdoches ASC GP, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Philadelphia, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem Roxborough, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet HealthSystem St. Christopher&#8217;s Hospital for Children, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Hilton Head Heart, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Hospitals Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Patient Safety Organization, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Physician Resources, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Physician Services - Hilton Head, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Rehab Piedmont, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Relocation Services, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet SC East Cooper Hospitalists, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet South Carolina Lowcountry OB&#47;GYN, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet Ventures, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tenet WFH Global Business Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Republic of the Philippines</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TFPS IV, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TH Healthcare, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TH International Services Florida, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TPS VI of PA, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TSPE, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tucson Hospital Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tucson Physician Group Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Turlock Imaging Services, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Twin Cities Community Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UCC Tucson Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI Holding Company, Inc.<font style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">1</font></font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Baptist Lab Services, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Baptist Physician Performance Network</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Baptist Realty Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Baptist Wellness Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Health Care Network</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Health Financial Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr></table></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subsidiaries of this entity, in which Tenet Healthcare Corporation directly and indirectly held a 100% ownership interest effective December&#160;31,&#160;2022, are set forth in the table below.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Health Holding Company I, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Health Holding Company II, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Health Management, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Health Systems, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Holding Company I, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Holding Company II, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vanguard Physician Services, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VB Brownsville LTACH, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VBOA ASC GP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VBOA ASC Partners, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHM Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Partnership Number 1, L.P</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 1, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 3, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 5, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 6, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 7, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 8, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 9, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 11, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Acquisition Subsidiary Number 12, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Arizona Heart Institute, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Brownsville Hospital Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Children&#8217;s Hospital of Michigan, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Detroit Businesses, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Detroit Receiving Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Detroit Ventures, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Harlingen Hospital Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Harper-Hutzel Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Holding Company, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Huron Valley-Sinai Hospital, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Imaging Centers, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Anaheim, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Arrowhead, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Huntington Beach, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Illinois, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Michigan, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Michigan Staffing, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Orange County, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of Phoenix, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS of South Phoenix, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Outpatient Clinics, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Phoenix Health Plan, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Physicians of Michigan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-right:-6.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Rehabilitation Institute of Michigan, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS San Antonio Imaging Partners, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS San Antonio Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Sinai-Grace Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS University Laboratories, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Valley Health System, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Valley Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Valley Management Company, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS West Suburban Medical Center, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">VHS Westlake Hospital, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Walker Baptist Affinity, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Walker Street Imaging Care, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Watermark Physician Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">West Boca Medical Center, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">West Palm Healthcare Real Estate, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wilshire Rental Corp.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><div id="i419fb349e6ea41459152d7349b7797c4_93"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Consolidated Subsidiaries of USPI Holding Company, Inc.</font></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">45th Street MOB, LLC</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Abrazo Surgical Outpatient Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Ambulatory Surgical Care, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Center for Surgery &#8211; Vero Beach, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Regional Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Spine Center of Wisconsin, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wisconsin</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgery Center of Bethesda, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgery Center of Metairie LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgery Center of Northern Louisiana LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgery Center of Sarasota LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgery Center of Tampa LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgical Care of Clearwater, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgical Care of Lutz, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgical Care of St. Louis, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Advanced Surgical Concepts, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Center Celebration, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Center Davenport, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Center Mills Park, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Center Wellswood, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Center Winter Garden, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Centers Central Florida, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AdventHealth Surgery Centers West Florida, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AIG Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AIGB Global, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AIGB Group, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AIGB Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AIGB Management Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama Digestive Health Endoscopy Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alamo Heights Surgicare, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Aligned Orthopedic Partners&#47;USP Surgery Centers Bethesda, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Aligned Orthopedic Partners&#47;USP Surgery Centers Mid-Atlantic, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alliance Surgery Birmingham, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alliance Surgery, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amarillo Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ambulatory Surgical Associates, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ambulatory Surgical Center of Somerville, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Ambulatory Surgical Center of St. Louis, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">American Institute of Gastric Banding Phoenix, Limited Partnership</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">American Institute of Gastric Banding, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Anesthesia Partners of Gallatin, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">APN</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">ARC Worcester Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona Spine and Joint Hospital, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">ASC of New Jersey LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">ASC of Trinity, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">ASC Old Co., LP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ascension Providence&#47;USP Waco, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ascension Saint Thomas Lebanon Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ascension&#47;USP Florida Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">ASJH Joint Venture, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Atlantic Coast Surgical Suites LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Hampshire</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Atlantic Health-USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Audubon Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">AUS&#47;USP Arizona Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Avita&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Health&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Plaza Surgicare, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist Womens Health Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Baptist&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bartlett ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Beaumont Surgical Affiliates, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Berkshire Eye LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bloomington ASC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Blue Ridge&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bluffton Okatie Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Braselton Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Briarcliff Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bristol Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brookwood Baptist Health 3, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Brownsville Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Camp Lowell Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Care Physicians Arizona, A Professional Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Care Physicians, P.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CareSpot of Austin, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CareSpot of Memphis, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Carmel Specialty Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Castle Rock Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cedar Park Surgery Center, L.L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Central Jersey Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Central Virginia Surgi-Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Centura Ventures Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Centura&#47;USP Colorado Springs Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chandler Endoscopy Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Charlotte Endoscopic Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chattanooga Pain Management Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chesterfield Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CHIC&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Clarksville Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Coast Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado GI Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado Urologic Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Columbus Specialty Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Asheville, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Odessa LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Raleigh, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Spring Hill, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of St. Petersburg, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Tampa, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Waco, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Surgical Partners Holdings of Winston-Salem, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conroe Surgery Center 2, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Coral Ridge Outpatient Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Corpus Christi Surgicare, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CreAtiv Management Company, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">COUA&#47;USP Colorado Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Covenant&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Creekwood Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Crown Point Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CS&#47;USP General Partner, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CS&#47;USP Surgery Centers, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CUA&#47;USP Maryland Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware River Surgical Suites LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delray Beach ASC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Denville Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Desert Ridge Outpatient Surgery, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Desoto Surgicare Partners, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Destin Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">DeTar&#47;USP Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">DH&#47;USP SJOSC Investment Company, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dignity&#47;USP Phoenix Surgery Centers II, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Doctors Outpatient Surgery Center of Jupiter, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Durbin Crossing Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East Atlanta Endoscopy Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">East West Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Eastgate Building Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">El Mirador Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">El Paso Center for Gastrointestinal Endoscopy, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">El Paso Day Surgery, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">El Paso Urology Surgery Center Curie, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Emanate&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Encinitas Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Endoscopy ASC of Middle Georgia, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Endoscopy Consultants, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">EPIC ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Kansas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Eye Center of Nashville UAP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Eye Surgery Center of Nashville, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Fish Pond Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Flatirons Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida Springs Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Fort Worth Hospital Real Estate, LP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Foundation Bariatric Hospital of San Antonio, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Foundation San Antonio Borrower Sub, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Franklin Endo UAP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Franklin Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Frontenac Ambulatory Surgery &#38; Spine Care Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GAB Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gainesville Endoscopy ASC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gainesville Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gamma Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GCSA Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia Musculoskeletal Network, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GIA&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">G.I. Diagnostic and Therapeutic Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Glen Echo Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Golden Ridge ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Grand Rapids Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Great Lakes Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Greenville Physicians Surgery Center, LLP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Greenwood ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hagerstown Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Harbor Heights Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Harvard Park Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Haymarket Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Horizons of Kansas City, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Health Horizons of Murfreesboro, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Horizons&#47;Piedmont Joint Venture, L.L.C.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Healthmark Partners, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hill Country ASC Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hill Country Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HKRI Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HMHP&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HMH &#8211; USP Surgery Center at Coastal, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HMH &#8211; USP Surgery Center at Lakewood, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HMH &#8211; USP Surgery Center at Metropolitan, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Holston Valley Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Houston PSC, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HSS Palm Beach Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">HSS&#47;USP Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Hyde Park Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Intracoastal Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Jacksonville Endoscopy Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">KHS Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">KHS&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Kingsport Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lake Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lancaster Specialty Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lebanon Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Legacy Warren Partners, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Leonardtown Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Longleaf Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Lubbock ASC Holding Co, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Magnolia Surgery Center Limited Partnership</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Manchester Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maple Lawn Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Marion Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MASC Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mason Ridge Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">McLaren ASC of Flint, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Medical House Staffing, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Medplex Outpatient Surgery Center, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Alabama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Bay Area Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Endoscopy &#38; Surgery Center North Houston, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Endoscopy Center North Freeway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Specialty Hospital Kingwood, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Sugar Land Surgical Hospital, L.L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Brazoria, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Cypress, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Kingsland, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Kirby, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Main Street, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Pinecroft, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Preston Road, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Richmond, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Surgery Center Woodlands Parkway, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann Texas International Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann&#47;USP Surgery Centers II, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann&#47;USP Surgery Centers IV, LLP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Hermann West Houston Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Memorial Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Metro Specialty Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Metro Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Metropolitan Medical Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Bay Area, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Brazoria, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Kingsland, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Kingwood, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Kirby, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Main Street, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP North Freeway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP North Houston, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Richmond, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Sugar Land, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP TMC Endoscopy, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP West Houston, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MH&#47;USP Woodlands Parkway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Miami Surgical Suites LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan Outpatient Surgical Solutions, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mid Rivers Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mid-State Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mid State Endo UAP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Middle Tennessee Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Midland Memorial&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Midland Texas Surgical Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Midwest Digestive Health Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Midwest Specialty Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Millennium Surgical Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Minimally Invasive Surgery Center of NE, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Hampshire</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Minimally Invasive Surgicenter of Delray, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Minimally Invasive Surgicenter LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Monocacy Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mountain Empire Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Mount Pleasant Outpatient Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MSV Health&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Munster Specialty Surgery Center LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Murdock Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">MVH&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nassau Crossing Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">National Surgery Center Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Neuroplex ASC LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Horizons Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NKCH&#47;USP Briarcliff GP, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NKCH&#47;USP Liberty GP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NKCH&#47;USP Surgery Centers II, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NMC Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Anaheim Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Atlantic Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Hampshire</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Campus Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Denver Musculoskeletal Surgical Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Haven Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Shore Same Day Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Shore Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wisconsin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Valley Orthopedic Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northern Michigan Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NorthPointe Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northridge Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NorthShore&#47;USP Surgery Centers II, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northwest Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oregon</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northwest Georgia Orthopaedic Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northwest Regional ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northwest Regional Surgery Center LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Northwest Surgery Center, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Novant Health&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Novant&#47;UVA&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NSCH GP Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NSCH&#47;USP Desert Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NSN Revenue Resources, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Old Bridge Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Old Tesson Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Olive Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">One GI&#47;USP Memphis Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Onyx &#38; Pearl Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ophthalmology Anesthesia Services LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ophthalmology Surgery Center of Orlando, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Optimum Spine Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Orange Park Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Orlando Health&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oro Valley Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrthoArizona Surgery Center Gilbert, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrthoLink ASC Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrthoLink&#47;Georgia ASC, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrthoLink&#47;New Mexico ASC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrthoLink Physicians Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">OrthoLink Radiology Services Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Outpatient Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oxford Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pacific Endoscopy and Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pacific Endo-Surgical Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PAHS&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Palm Beach International Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">ParkCreek ASC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Parkwest Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Patient Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Peak Gastroenterology ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pearland Ambulatory Surgery Center, LP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pediatric Surgery Center &#8211; Odessa, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pediatric Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Physician&#8217;s Surgery Center of Chattanooga, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Physician&#8217;s Surgery Center of Knoxville, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Physicians Surgery Center of Tempe, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piccard Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Piedmont ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Point of Rocks Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Porter Musculoskeletal Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Potomac View Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Premier Adult and Children&#8217;s Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Premier ASC LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Premier at Exton Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prince Frederick Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prince William Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Professional Anesthesia Services LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Providence&#47;UCLA&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Providence&#47;USP Santa Clarita GP, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Providence&#47;USP South Bay Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Providence&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pueblo Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">PWSC Physician Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">RE Plano Med, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Reading Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Reading Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Reagan Street Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Red Cedar Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Redmond Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Resurgens Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Riva Road Surgical Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">River North Same Day Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Riverside Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Riverside Park Surgicenter, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Rock Hill Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Rockville Surgical Suites LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Rocky Mountain Endoscopy Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Roswell Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Safety Harbor ASC Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Francis Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Thomas Campus Surgicare, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Thomas Surgery Center New Salem, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Thomas&#47;USP &#8211; Baptist Plaza, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Thomas&#47;USP Surgery Centers II, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Saint Thomas&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Salmon Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Washington</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Same Day Management, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Same Day Surgery, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">San Antonio Endoscopy, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">San Fernando Valley Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">San Gabriel Valley Surgical Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">San Ramon Network Joint Venture, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Santa Barbara Outpatient Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Santa Clarita Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Savannah Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Schertz Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SCNRE, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Scottsdale Endoscopy ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Scripps&#47;USP Surgery Centers 2, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Seaside Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shore Outpatient Surgicenter, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shoreline Real Estate Partnership, LLP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shoreline Surgery Center, LLP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Sierra Vista Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Silver Cross Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Silver Cross&#47;USP Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Skyway Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Solantic Holdings Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South County Outpatient Endoscopy Services, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Denver Musculoskeletal Surgical Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Florida Ambulatory Surgical Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Plains Endoscopy Center Associates, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Suburban Surgical Suites, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Southeast Ohio Surgical Suites LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Southeastern Spine Institute Ambulatory Surgery Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Southwest Endoscopy, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Southwestern Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Specialty Surgicenters, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SSI Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Augustine Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Joseph&#8217;s Outpatient Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Louis Urology Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Luke&#8217;s&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Vincent Health&#47;USP, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">St. Vincent&#47;USP Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arkansas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Suburban Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Summit Ambulatory Surgical Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Summit View Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter at Paradise Valley LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter Camelback LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter Clearwater, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter Northeast LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Deer Valley LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Glen Burnie, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Greater Dallas, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Greater Jacksonville, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Northern Baltimore, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Palm Beach Gardens LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Pine Ridge, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Silver Spring, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of Southern Maryland, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of St. Lucie, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of the Potomac, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter of White Marsh, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter Pinellas, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">SurgCenter Tucson LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Affiliate of El Paso, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Surgery Center at Jensen Beach, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center at Mount Pleasant, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center at University Park, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center of Columbia, LP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center of Coral Gables, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center of Okeechobee, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center of Pembroke Pines, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center of Peoria, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Center of Scottsdale, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Centers of America II, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgery Centre of SW Florida, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Center Development #3 LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nevada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Center Development #4, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nevada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Elite of Avondale, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Health Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Institute Management, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgical Specialty Center of Mid-Atlantic, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgicare of Miramar, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surginet, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgis Management Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgis of Chico, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgis of Phoenix, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgis of Redding, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgis of Victoria, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Surgis, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tamarac Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tampa Bay Joint and Spine, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TENN SM, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Teton Outpatient Services LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wyoming</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texan Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas Orthopedics Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Theda Oaks Gastroenterology &#38; Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Three Springs ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Timonium Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Chattanooga, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Hershey, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Mount Laurel, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of North Haven, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Pittsburgh, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Pleasant Hills, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Princeton, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Sacramento, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Saginaw, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Titusville, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of West Penn, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Health of Westminster, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titan Management Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Titusville Center for Surgical Excellence, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TLC ASC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TOPS Specialty Hospital, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">TOSCA ASC Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Treasure Coast ASC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Tresanti Surgical Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Trinity Health of New England&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">True Medical Weight Loss, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">True Medical Wellness, LP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">True Results Georgia, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">True Results HoldCo, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">True Results Missouri, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tucson Digestive Institute, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Twin Cities Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP Lebanon Endo, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP Nashville Endoscopy, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of Arizona, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of California, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of Missouri, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of New Jersey, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of Oklahoma, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of Tennessee, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP of Texas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UAP SCOPES, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UA&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UMC Surgery Center Lubbock, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UMC&#47;USP Surgery Centers, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">UMP&#47;USP Resurgens ASC, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Underwood Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">United Anesthesia Partners, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">United Real Estate Development, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">United Real Estate Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">United Surgical Partners Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">United Surgical Partners International, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">University Surgery Center, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Upper Bay Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Urology ASC &#8211; Phoenix, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Urology Austin Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USP 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Ave Real Estate, Inc.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Acquisition Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Alexandria, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Assurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vermont</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Athens, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Atlanta, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Austin, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Bariatric, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Beaumont, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Bergen, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Bloomington, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Bridgeton, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP&#47;Carondelet Tucson Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Cedar Park, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Chesterfield, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Chicago, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Cincinnati, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Coast, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Columbia, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Connecticut, Inc</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Corpus Christi, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Creve Coeur, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Delaware, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Denver, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Des Peres, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Destin, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Domestic Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Effingham, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Encinitas Endoscopy, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Fenton, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Festus, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Florissant, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Fort Lauderdale, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Fort Worth Hospital Real Estate, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Fredericksburg, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Fresno, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Frontenac, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Gateway, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Harbour View, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP-HMH Surgery Center at Central Jersey, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP HMH Surgery Center at Shore, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Houston, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Indiana, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP International Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Jacksonville, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Jersey City, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Kansas City, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Knoxville, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Little Rock, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arkansas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Long Island, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Louisiana, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Louisiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Lubbock, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Maryland, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Mason Ridge, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Mattis, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Michigan, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Midland Real Estate, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Midland, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Midwest, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Mission Hills, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Montana, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Montana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Morris, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Mt. Vernon, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Nevada Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nevada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Nevada, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Nevada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP New Hampshire, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Hampshire</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP New Jersey, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Newport News, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP North Carolina, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP North Kansas City, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP North Texas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Northwest Arkansas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arkansas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Office Parkway, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Ohio RE, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP OKC, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP OKC Manager, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Oklahoma, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Olive, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Orlando, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Philadelphia, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Phoenix, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Portland, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oregon</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Reading, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Richmond II, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Richmond, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Sacramento, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP San Antonio, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Santa Barbara Surgery Centers, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Securities Corporation&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Silver Cross, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Siouxland, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Iowa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Somerset, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP South Carolina, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Southlake RE, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP&#47;SOS Joint Venture, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP St. Louis, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP St. Louis Urology, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP St. Peters, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Sunset Hills, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Tennessee, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Texas Air, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Texas, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP TJ STL, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Torrance, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Tucson, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Turnersville, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Virginia Beach, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Washington, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Washington</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Waxahachie Management, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Webster Groves, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP West Covina, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Westwood, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Winter Park, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USP Wisconsin, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wisconsin</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI Group Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI Physician Strategy Group, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI San Diego, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI Stockton, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USPI Surgical Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Utica&#47;USP Tulsa, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Oklahoma</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:72.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Entity</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">State or Other <br>Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Baptist Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Valley Baptist Surgery Center Real Estate, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ventana Surgical Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Veroscan, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Victoria Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Warner Park Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Webster Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wellington Endo, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wellstar&#47;USP Joint Venture I, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wellstar&#47;USP Joint Venture II, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">West Bozeman Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Montana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Westgate Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Westlake Hospital, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Westlawn Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Westminster Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Westminster Surgery Centers, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">WHASA, L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">White Fence Surgical Suites LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wilmington Endoscopy Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Windsor Mill Surgery Center LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Winter Haven Ambulatory Surgical Center, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Winter Park MOB RE, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wisconsin Specialty Surgery Center, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wisconsin</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Wymark Surgery Center, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">California</font></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>8
<FILENAME>thc-20221231ex23.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i286f088b17c54247ada9e434343a0f9e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in Registration Statement Nos. 033-57375, 333-00709, 333-01183, 333-38299, 333-41903, 333-41476, 333-41478, 333-48482, 333-74216, 333-151884, 333-151887, 333-166767, 333-166768, 333-191614, 333-196262, 333-212844, 333-212846, 333-231515, and 333-266856 on Form S-8 of our reports dated February&#160;17, 2023, relating to the consolidated financial statements and financial statement schedule of Tenet Healthcare Corporation and subsidiaries, and the effectiveness of Tenet Healthcare Corporation and subsidiaries&#8217; internal control over financial reporting, appearing in this Annual Report on Form 10-K of Tenet Healthcare Corporation for the year ended December&#160;31,&#160;2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte&#160;&#38; Touche LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dallas, Texas </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2023</font></div><div style="margin-bottom:18pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.A
<SEQUENCE>9
<FILENAME>thc-20221231ex31a.htm
<DESCRIPTION>EX-31.A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i94501355639241b5816c745f61ae3d75_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31(a)</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a)&#47;15d-14(a) Certification</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Saumya Sutaria, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Tenet Healthcare Corporation (the &#8220;Registrant&#8221;)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:18pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:51.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.277%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 17, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SAUMYA SUTARIA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saumya Sutaria, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.B
<SEQUENCE>10
<FILENAME>thc-20221231ex31b.htm
<DESCRIPTION>EX-31.B
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic14fc664c96b4634a5bff0337a4c47c9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31(b)</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule&#160;13a-14(a)&#47;15d-14(a)&#160;Certification</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel J. Cancelmi, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Tenet Healthcare Corporation (the &#8220;Registrant&#8221;)&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:18pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:51.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.277%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 17, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DANIEL J. CANCELMI</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Cancelmi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>11
<FILENAME>thc-20221231ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i234e7006351c4082a5b8089a3dabc966_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to Section&#160;1350 of Chapter 63</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Title 18 of the United States Code</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, the undersigned Saumya Sutaria and Daniel J. Cancelmi, being, respectively, the Chief Executive Officer and the Executive Vice President and Chief Financial Officer of Tenet Healthcare Corporation (the &#8220;Registrant&#8221;), do each hereby certify that (i)&#160;the Registrant&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31,&#160;2022 (the &#8220;Form&#160;10-K&#8221;), to be filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934 and (ii)&#160;the information contained in the Form&#160;10-K fairly presents, in all material respects, the financial condition and results of operations of the Registrant and its subsidiaries.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:51.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.277%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 17, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SAUMYA SUTARIA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saumya Sutaria, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 17, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DANIEL J. CANCELMI</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Cancelmi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. &#167;1350&#59; it is not being filed for purposes of Section&#160;18 of the Securities Exchange Act, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>thc-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5eb22bb-8cdc-4927-ae5c-e13f3ca3c3e1,g:f5e96eef-6bc4-43e3-b34d-7345446e971c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:thc="http://www.tenethealth.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.tenethealth.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="thc-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="thc-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="thc-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="thc-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.tenethealth.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.tenethealth.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_1" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITY" roleURI="http://www.tenethealth.com/role/EQUITY">
        <link:definition>0000010 - Disclosure - EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSRECEIVABLE" roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE">
        <link:definition>0000011 - Disclosure - ACCOUNTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTBALANCES" roleURI="http://www.tenethealth.com/role/CONTRACTBALANCES">
        <link:definition>0000012 - Disclosure - CONTRACT BALANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSANDLIABILITIESHELDFORSALE" roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE">
        <link:definition>0000013 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS" roleURI="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS">
        <link:definition>0000014 - Disclosure - IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.tenethealth.com/role/LEASES">
        <link:definition>0000015 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBT" roleURI="http://www.tenethealth.com/role/LONGTERMDEBT">
        <link:definition>0000016 - Disclosure - LONG-TERM DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GUARANTEES" roleURI="http://www.tenethealth.com/role/GUARANTEES">
        <link:definition>0000017 - Disclosure - GUARANTEES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>0000018 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000019 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETS" roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS">
        <link:definition>0000020 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERASSETS" roleURI="http://www.tenethealth.com/role/OTHERASSETS">
        <link:definition>0000021 - Disclosure - OTHER ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUES" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUES">
        <link:definition>0000023 - Disclosure - NET OPERATING REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INSURANCE" roleURI="http://www.tenethealth.com/role/INSURANCE">
        <link:definition>0000024 - Disclosure - INSURANCE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CLAIMSANDLAWSUITS" roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITS">
        <link:definition>0000025 - Disclosure - CLAIMS AND LAWSUITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES" roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES">
        <link:definition>0000026 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.tenethealth.com/role/INCOMETAXES">
        <link:definition>0000027 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERCOMMONSHARE" roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE">
        <link:definition>0000028 - Disclosure - EARNINGS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000029 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.tenethealth.com/role/ACQUISITIONS">
        <link:definition>0000030 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATION">
        <link:definition>0000031 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGSTANDARDS" roleURI="http://www.tenethealth.com/role/RECENTACCOUNTINGSTANDARDS">
        <link:definition>0000032 - Disclosure - RECENT ACCOUNTING STANDARDS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" roleURI="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS">
        <link:definition>0000033 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYTables" roleURI="http://www.tenethealth.com/role/EQUITYTables">
        <link:definition>0000036 - Disclosure - EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSRECEIVABLETables" roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables">
        <link:definition>0000037 - Disclosure - ACCOUNTS RECEIVABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTBALANCESTables" roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESTables">
        <link:definition>0000038 - Disclosure - CONTRACT BALANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSANDLIABILITIESHELDFORSALETables" roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALETables">
        <link:definition>0000039 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.tenethealth.com/role/LEASESTables">
        <link:definition>0000040 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTTables" roleURI="http://www.tenethealth.com/role/LONGTERMDEBTTables">
        <link:definition>0000041 - Disclosure - LONG-TERM DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSTables" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables">
        <link:definition>0000042 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>0000043 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSTables" roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables">
        <link:definition>0000044 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERASSETSTables" roleURI="http://www.tenethealth.com/role/OTHERASSETSTables">
        <link:definition>0000045 - Disclosure - OTHER ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>0000046 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESTables" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESTables">
        <link:definition>0000047 - Disclosure - NET OPERATING REVENUES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CLAIMSANDLAWSUITSTables" roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSTables">
        <link:definition>0000048 - Disclosure - CLAIMS AND LAWSUITS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables" roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables">
        <link:definition>0000049 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.tenethealth.com/role/INCOMETAXESTables">
        <link:definition>0000050 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERCOMMONSHARETables" roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables">
        <link:definition>0000051 - Disclosure - EARNINGS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.tenethealth.com/role/ACQUISITIONSTables">
        <link:definition>0000052 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>0000053 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails">
        <link:definition>0000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails">
        <link:definition>0000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails">
        <link:definition>0000056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Pandemic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails">
        <link:definition>0000057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Net Operating Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>0000058 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails">
        <link:definition>0000059 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Investments in Unconsolidated Affiliates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails">
        <link:definition>0000060 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
        <link:definition>0000061 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>0000062 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails" roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails">
        <link:definition>0000063 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYNoncontrollingInterestsDetails" roleURI="http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails">
        <link:definition>0000064 - Disclosure - EQUITY - Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYShareRepurchaseProgramsDetails" roleURI="http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails">
        <link:definition>0000065 - Disclosure - EQUITY - Share Repurchase Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSRECEIVABLEComponentsDetails" roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails">
        <link:definition>0000066 - Disclosure - ACCOUNTS RECEIVABLE - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails" roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails">
        <link:definition>0000067 - Disclosure - ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSRECEIVABLEAllowanceDetails" roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails">
        <link:definition>0000068 - Disclosure - ACCOUNTS RECEIVABLE - Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails" roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails">
        <link:definition>0000069 - Disclosure - CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTBALANCESConiferSegmentDetails" roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails">
        <link:definition>0000070 - Disclosure - CONTRACT BALANCES - Conifer Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTBALANCESContractCostsDetails" roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails">
        <link:definition>0000071 - Disclosure - CONTRACT BALANCES - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSANDLIABILITIESHELDFORSALENarrativeDetails" roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails">
        <link:definition>0000072 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails" roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails">
        <link:definition>0000073 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Significant Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails" roleURI="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails">
        <link:definition>0000074 - Disclosure - IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESBalanceSheetComponentsDetails" roleURI="http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails">
        <link:definition>0000075 - Disclosure - LEASES - Balance Sheet Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostsDetails" roleURI="http://www.tenethealth.com/role/LEASESLeaseCostsDetails">
        <link:definition>0000076 - Disclosure - LEASES - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalCashFlowInformationDetails" roleURI="http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails">
        <link:definition>0000077 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofLeaseMaturitiesDetails" roleURI="http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails">
        <link:definition>0000078 - Disclosure - LEASES - Schedule of Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.tenethealth.com/role/LEASESNarrativeDetails">
        <link:definition>0000079 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTScheduleofDebtDetails" roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails">
        <link:definition>0000080 - Disclosure - LONG-TERM DEBT - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTScheduleofDebtDetails_1" roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1">
        <link:definition>0000080 - Disclosure - LONG-TERM DEBT - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTNarrativeDetails" roleURI="http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails">
        <link:definition>0000081 - Disclosure - LONG-TERM DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTFutureMaturitiesDetails" roleURI="http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails">
        <link:definition>0000082 - Disclosure - LONG-TERM DEBT - Future Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GUARANTEESDetails" roleURI="http://www.tenethealth.com/role/GUARANTEESDetails">
        <link:definition>0000083 - Disclosure - GUARANTEES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails">
        <link:definition>0000084 - Disclosure - EMPLOYEE BENEFIT PLANS - Share-based Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSStockOptionsDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails">
        <link:definition>0000085 - Disclosure - EMPLOYEE BENEFIT PLANS - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails">
        <link:definition>0000086 - Disclosure - EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSEmployeeOptionsDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails">
        <link:definition>0000087 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails">
        <link:definition>0000088 - Disclosure - EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails">
        <link:definition>0000089 - Disclosure - EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails">
        <link:definition>0000090 - Disclosure - EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails">
        <link:definition>0000091 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails">
        <link:definition>0000092 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSAssetAllocationsDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails">
        <link:definition>0000093 - Disclosure - EMPLOYEE BENEFIT PLANS - Asset Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails">
        <link:definition>0000094 - Disclosure - EMPLOYEE BENEFIT PLANS - Fair Value of Assets and Future Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTComponentsDetails" roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails">
        <link:definition>0000095 - Disclosure - PROPERTY AND EQUIPMENT - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails" roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails">
        <link:definition>0000096 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails">
        <link:definition>0000097 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1" roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1">
        <link:definition>0000097 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails" roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails">
        <link:definition>0000098 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERASSETSScheduleofOtherCurrentAssetsDetails" roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails">
        <link:definition>0000099 - Disclosure - OTHER ASSETS - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails" roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails">
        <link:definition>0000100 - Disclosure - OTHER ASSETS - Schedule of Investments and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails">
        <link:definition>0000101 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails">
        <link:definition>0000102 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue By Source (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESNarrativeDetails" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails">
        <link:definition>0000103 - Disclosure - NET OPERATING REVENUES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails">
        <link:definition>0000104 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails">
        <link:definition>0000105 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue Composition, Conifer Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESPerformanceObligationDetails" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails">
        <link:definition>0000106 - Disclosure - NET OPERATING REVENUES - Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETOPERATINGREVENUESPerformanceObligationDetails_1" roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails_1">
        <link:definition>0000106 - Disclosure - NET OPERATING REVENUES - Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INSURANCEPropertyInsuranceDetails" roleURI="http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails">
        <link:definition>0000107 - Disclosure - INSURANCE - Property Insurance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INSURANCEProfessionalandGeneralLiabilityReservesDetails" roleURI="http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails">
        <link:definition>0000108 - Disclosure - INSURANCE - Professional and General Liability Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CLAIMSANDLAWSUITSNarrativeDetails" roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails">
        <link:definition>0000109 - Disclosure - CLAIMS AND LAWSUITS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CLAIMSANDLAWSUITSReconciliationsDetails" roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails">
        <link:definition>0000110 - Disclosure - CLAIMS AND LAWSUITS - Reconciliations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails" roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails">
        <link:definition>0000111 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails" roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails">
        <link:definition>0000112 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails" roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails">
        <link:definition>0000113 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESProvisionandDeferredTaxesDetails" roleURI="http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails">
        <link:definition>0000114 - Disclosure - INCOME TAXES - Provision and Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESFederalTaxReconciliationDetails" roleURI="http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails">
        <link:definition>0000115 - Disclosure - INCOME TAXES - Federal Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000116 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000117 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails" roleURI="http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails">
        <link:definition>0000118 - Disclosure - INCOME TAXES - Valuation Allowances and Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNOLandTaxCreditCarryforwardsDetails" roleURI="http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails">
        <link:definition>0000119 - Disclosure - INCOME TAXES - NOL and Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERCOMMONSHAREDetails" roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails">
        <link:definition>0000120 - Disclosure - EARNINGS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>0000121 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>0000122 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSPurchasePriceAllocationDetails" roleURI="http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails">
        <link:definition>0000123 - Disclosure - ACQUISITIONS - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaInformationDetails" roleURI="http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails">
        <link:definition>0000124 - Disclosure - ACQUISITIONS - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000125 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONReconcilingItemsDetails" roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails">
        <link:definition>0000126 - Disclosure - SEGMENT INFORMATION - Reconciling Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" roleURI="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
        <link:definition>0000127 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="thc_PerformanceBasedVestingAndSettledImmediatelyMember" abstract="true" name="PerformanceBasedVestingAndSettledImmediatelyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" abstract="false" name="ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_CharityCarePatientsMember" abstract="true" name="CharityCarePatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" abstract="true" name="FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" abstract="false" name="DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" abstract="false" name="LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_BuildingsSubjectToImpairmentChargesMember" abstract="true" name="BuildingsSubjectToImpairmentChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LeaseLiabilityNoncurrent" abstract="false" name="LeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_EightQuarterVestingPeriodMember" abstract="true" name="EightQuarterVestingPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_HospitalBuildingsAndMedicalEquipmentMember" abstract="true" name="HospitalBuildingsAndMedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LesseeLeaseLiabilityPaymentsDueYearFour" abstract="false" name="LesseeLeaseLiabilityPaymentsDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" abstract="false" name="ValuationAllowancesAndReservesReservesOfBusinessesSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" abstract="true" name="FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" abstract="false" name="BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" abstract="false" name="SharePurchaseAgreementAmountOfPaymentForMinorityInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" abstract="true" name="FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_OtherCatastrophicEventsMember" abstract="false" name="OtherCatastrophicEventsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_USPIManagementEquityPlanMember" abstract="true" name="USPIManagementEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" abstract="false" name="DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_OtherCustomersMember" abstract="true" name="OtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" abstract="false" name="LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" abstract="false" name="NumberOfOutpatientCentersRecordedUsingEquityMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_IncomeLossFromDivestedAndClosedBusinesses" abstract="false" name="IncomeLossFromDivestedAndClosedBusinesses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_UnitedUrologyGroupMember" abstract="true" name="UnitedUrologyGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" abstract="true" name="SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" abstract="false" name="NumberOfSurgicalCentersRecordedUsingEquityMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" abstract="false" name="NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" abstract="false" name="IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" abstract="true" name="SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_DeferredTaxAssetsMedicareAdvancePayments" abstract="false" name="DeferredTaxAssetsMedicareAdvancePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_PropertyInsuranceDeductible" abstract="false" name="PropertyInsuranceDeductible" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" abstract="false" name="ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_PerformanceBasedVestingOnFourthAnniversaryMember" abstract="true" name="PerformanceBasedVestingOnFourthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_AdditionalProratedRestrictedStockUnitsMember" abstract="true" name="AdditionalProratedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" abstract="false" name="StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="thc_LesseeLeaseLiabilityPaymentsDueYearFive" abstract="false" name="LesseeLeaseLiabilityPaymentsDueYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfImagingCentersTransferred" abstract="false" name="NumberOfImagingCentersTransferred" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_PropertyInsuranceDeductiblePercentage" abstract="false" name="PropertyInsuranceDeductiblePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" abstract="false" name="CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" abstract="false" name="OtherLongTermReceivablesAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" abstract="false" name="LesseeLeaseLiabilityPaymentsDueAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_SharePurchaseAgreementMonthlyPayment" abstract="false" name="SharePurchaseAgreementMonthlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_EffectOfDilutiveSecuritiesPerShareAmount" abstract="false" name="EffectOfDilutiveSecuritiesPerShareAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="thc_ElevenQuarterVestingPeriodMember" abstract="true" name="ElevenQuarterVestingPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_StockIncentivePlan2019Member" abstract="true" name="StockIncentivePlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_SharePurchaseAgreementPaymentForExecution" abstract="false" name="SharePurchaseAgreementPaymentForExecution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LossContingencyAccrualOther" abstract="false" name="LossContingencyAccrualOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" abstract="false" name="NumberOfOutpatientCentersRecordedNotUsingEquityMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_AdjustedSegmentEBITDAAbstract" abstract="true" name="AdjustedSegmentEBITDAAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNetCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" abstract="false" name="LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_A2015USPIManagementEquityPlanMember" abstract="true" name="A2015USPIManagementEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_AccruedCompensationAndBenefitsMember" abstract="true" name="AccruedCompensationAndBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" abstract="false" name="PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_NonEmployeeDirectorsMember" abstract="true" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfHospitalsOperatedBySubsidiaries" abstract="false" name="NumberOfHospitalsOperatedBySubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_UrgentCareCentersMember" abstract="true" name="UrgentCareCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" abstract="true" name="LongTermInvestmentsAndOtherAssetsAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_NumberOfAmbulatorySurgeryCentersConsolidated" abstract="false" name="NumberOfAmbulatorySurgeryCentersConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" abstract="true" name="SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LesseeLeaseLiabilityPaymentsDueYearThree" abstract="false" name="LesseeLeaseLiabilityPaymentsDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_PaymentsForRestructuringAndLitigationCosts" abstract="false" name="PaymentsForRestructuringAndLitigationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LeaseLiabilityUndiscountedExcessAmount" abstract="false" name="LeaseLiabilityUndiscountedExcessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" abstract="true" name="FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_HospitalOperationsMember" abstract="true" name="HospitalOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ScheduleOfGrantFundsTableTextBlock" abstract="false" name="ScheduleOfGrantFundsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_CaliforniaProviderFeeProgramMember" abstract="true" name="CaliforniaProviderFeeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" abstract="true" name="SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_FormerEmployeesMember" abstract="false" name="FormerEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfSurgicalCentersInDevelopmentStage" abstract="false" name="NumberOfSurgicalCentersInDevelopmentStage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_IncomeAndRevenueCollectionGuaranteeMember" abstract="true" name="IncomeAndRevenueCollectionGuaranteeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_EquityMethodInvestmentCashManagedAffiliatesMember" abstract="true" name="EquityMethodInvestmentCashManagedAffiliatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_HealthCareManagementFeesMember" abstract="true" name="HealthCareManagementFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LeaseLiabilitiesPaymentsDueAbstract" abstract="true" name="LeaseLiabilitiesPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_DeferredTaxAssetsInterestExpenseLimitation" abstract="false" name="DeferredTaxAssetsInterestExpenseLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NetIncomeLossAttributableToInvestee" abstract="false" name="NetIncomeLossAttributableToInvestee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" abstract="false" name="GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" abstract="false" name="DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" abstract="false" name="DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_SeniorOfficerMember" abstract="true" name="SeniorOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" abstract="false" name="RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_JointVentureOwnershipPercentage" abstract="false" name="JointVentureOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_VariableAndShorttermLeaseCosts" abstract="false" name="VariableAndShorttermLeaseCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" abstract="false" name="NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="thc_FloodsAndWindstormsMember" abstract="true" name="FloodsAndWindstormsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_GuaranteeObligationPeriod" abstract="false" name="GuaranteeObligationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_TimeBasedVestingOnFourthAnniversaryMember" abstract="true" name="TimeBasedVestingOnFourthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_GuaranteedInvesteesOfThirdPartiesMember" abstract="true" name="GuaranteedInvesteesOfThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_IncomeGuaranteeMember" abstract="true" name="IncomeGuaranteeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NewMadridFaultEarthquakesMember" abstract="true" name="NewMadridFaultEarthquakesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_A2020SCDCentersMember" abstract="true" name="A2020SCDCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfHospitalsForSale" abstract="false" name="NumberOfHospitalsForSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_ProfessionalAndGeneralLiabilityReservesMember" abstract="true" name="ProfessionalAndGeneralLiabilityReservesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" abstract="false" name="DebtInstrumentCovenantSecuredDebtToEbitdaRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" abstract="true" name="SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_SharePurchaseAgreementNumberOfMonthlyPayments" abstract="false" name="SharePurchaseAgreementNumberOfMonthlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_ExercisePriceRangeSecondMember" abstract="true" name="ExercisePriceRangeSecondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PerformanceBasedRestrictedStockUnitMember" abstract="true" name="PerformanceBasedRestrictedStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" abstract="true" name="ChangeInContractWithCustomerAssetNetCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_OtherMattersMember" abstract="true" name="OtherMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ConiferHealthSolutionsLLCMember" abstract="true" name="ConiferHealthSolutionsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" abstract="false" name="NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" abstract="true" name="ChangeInContractWithCustomerAssetNetNoncurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_NumberOfSurgicalHospitalsConsolidated" abstract="false" name="NumberOfSurgicalHospitalsConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_NumberofHospitals" abstract="false" name="NumberofHospitals" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" abstract="false" name="PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_BaylorUniversityMedicalCenterMember" abstract="true" name="BaylorUniversityMedicalCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfHospitalsOperated" abstract="false" name="NumberOfHospitalsOperated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" abstract="true" name="FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" abstract="false" name="SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" abstract="false" name="LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DebtInstrumentBasisSpreadOnCreditSpread" abstract="false" name="DebtInstrumentBasisSpreadOnCreditSpread" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" abstract="false" name="DeferredTaxLiabilitiesInvestmentsAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_IncomeTaxExpenseBenefitCARESAct" abstract="false" name="IncomeTaxExpenseBenefitCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" abstract="false" name="EstimatedFutureRecoveriesFromAccountsAssignedToConifer" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_HealthCareOtherSourcesMember" abstract="true" name="HealthCareOtherSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TenetHealthcareCorpMember" abstract="true" name="TenetHealthcareCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfUrgentCareCentersSold" abstract="false" name="NumberOfUrgentCareCentersSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_PercentageInvesteeResultsReflected" abstract="false" name="PercentageInvesteeResultsReflected" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="thc_NumberOfAmbulatorySurgeryCenters" abstract="false" name="NumberOfAmbulatorySurgeryCenters" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_NumberOfSurgicalCentersAndHospitals" abstract="false" name="NumberOfSurgicalCentersAndHospitals" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" abstract="false" name="DebtInstrumentCovenantMaximumSecuredDebtRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="thc_DebtInstrumentCovenantsOfSecuredDebtRatio" abstract="false" name="DebtInstrumentCovenantsOfSecuredDebtRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="thc_PropertyInsuranceAnnualCoverageLimit" abstract="false" name="PropertyInsuranceAnnualCoverageLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfSurgicalCentersAcquired" abstract="false" name="NumberOfSurgicalCentersAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_LineOfCreditFacilityCovenantThresholdLimit" abstract="false" name="LineOfCreditFacilityCovenantThresholdLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ReceivablesFromGovernmentProgramsCurrent" abstract="false" name="ReceivablesFromGovernmentProgramsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_AssetsHeldforuseLongLivedFairValueDisclosure" abstract="false" name="AssetsHeldforuseLongLivedFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" abstract="false" name="MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_GainLossFromPurchaseOfNoncontrollingInterests" abstract="false" name="GainLossFromPurchaseOfNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_UnitedSurgicalPartnersInternationalMember" abstract="true" name="UnitedSurgicalPartnersInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PurchasedEquityInJointVenturePercentageOfTotalShares" abstract="false" name="PurchasedEquityInJointVenturePercentageOfTotalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" abstract="false" name="NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_MiamiAreaHospitalsMember" abstract="true" name="MiamiAreaHospitalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_FinanceLeaseExpenseAbstract" abstract="true" name="FinanceLeaseExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_ComputerAndTelecommunicationEquipmentMember" abstract="true" name="ComputerAndTelecommunicationEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LeaseLiabilityPaymentsDue" abstract="false" name="LeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" abstract="false" name="LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_InsuranceCoverageTable" abstract="true" name="InsuranceCoverageTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" abstract="false" name="DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_CommonStockSharesOutstandingAndEligibleToBeSold" abstract="false" name="CommonStockSharesOutstandingAndEligibleToBeSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="thc_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_HospitalOperationsAndAmbulatoryCareMember" abstract="true" name="HospitalOperationsAndAmbulatoryCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" abstract="false" name="DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_CybersecurityIncidentPreTaxEffect" abstract="false" name="CybersecurityIncidentPreTaxEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" abstract="true" name="FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_FinanceLeasesAndMortgageNotes" abstract="false" name="FinanceLeasesAndMortgageNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" abstract="false" name="GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" abstract="true" name="GlobalBusinessCenterInTheRepublicOfPhilippinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_HealthCareClientContractsRevenueCycleServicesMember" abstract="true" name="HealthCareClientContractsRevenueCycleServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" abstract="false" name="ProceedsFromGrantsFromAffiliatesNetOfRecoupment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_HealthCarePatientServiceManagedCareMember" abstract="true" name="HealthCarePatientServiceManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract" abstract="true" name="PropertyandProfessionalandGeneralLiablityInsuranceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_HealthCareClientContractsOtherServicesMember" abstract="true" name="HealthCareClientContractsOtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TimeBasedVestingSettledOnSecondAnniversaryMember" abstract="true" name="TimeBasedVestingSettledOnSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_A2022AcquisitionMember" abstract="true" name="A2022AcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TimeBasedVestingFourYearFromGrantDateMember" abstract="true" name="TimeBasedVestingFourYearFromGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_CurrentEmployeesMember" abstract="false" name="CurrentEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" abstract="false" name="LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" abstract="false" name="NumberOfSurgicalHospitalsOperatedBySubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" abstract="false" name="DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" abstract="false" name="IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_CommitmentPeriod" abstract="false" name="CommitmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="thc_SelfPayPatientsMember" abstract="true" name="SelfPayPatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ConiferSegmentMember" abstract="true" name="ConiferSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TimeBasedVestingSettledOnFourthAnniversaryMember" abstract="true" name="TimeBasedVestingSettledOnFourthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_A2020USPIManagementEquityPlanMember" abstract="true" name="A2020USPIManagementEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_FloodEarthquakeAndWindstormMember" abstract="false" name="FloodEarthquakeAndWindstormMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PhysicianAndGroupCoverageGuaranteesCurrent" abstract="false" name="PhysicianAndGroupCoverageGuaranteesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DeferredTaxAssetsReconciliationAbstract" abstract="true" name="DeferredTaxAssetsReconciliationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_HealthCarePatientServiceSelfpayMember" abstract="true" name="HealthCarePatientServiceSelfpayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_WindstormsMember" abstract="false" name="WindstormsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" abstract="true" name="FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" abstract="false" name="LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_AmbulatoryCareMember" abstract="true" name="AmbulatoryCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" abstract="true" name="TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" abstract="false" name="ScheduleOfFairValueOfPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" abstract="true" name="FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_LesseeLeaseLiabilityPaymentsDueYearTwo" abstract="false" name="LesseeLeaseLiabilityPaymentsDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_HospitalOperationsSegmentMember" abstract="true" name="HospitalOperationsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" abstract="false" name="BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_A2021SCDCentersMember" abstract="true" name="A2021SCDCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PerformanceBasedVestingMember" abstract="true" name="PerformanceBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" abstract="false" name="ScheduleOfEstimatedCostForCharityCareTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_HospitalOperationsAndOtherMember" abstract="true" name="HospitalOperationsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_CaliforniaEarthquakeMember" abstract="true" name="CaliforniaEarthquakeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" abstract="false" name="ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" abstract="true" name="AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_DeferredIncomeTaxAssetsLiabilitiesNet" abstract="false" name="DeferredIncomeTaxAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" abstract="true" name="HealthCarePatientServiceExcludingPhysicianPracticesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" abstract="false" name="EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_PerformanceBasedVestingOverAThreeYearPeriodMember" abstract="true" name="PerformanceBasedVestingOverAThreeYearPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" abstract="true" name="TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" abstract="true" name="SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" abstract="false" name="NetCostReportSettlementsReceivablePayableandValuationAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_InsuranceRecoveriesMember" abstract="true" name="InsuranceRecoveriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" abstract="false" name="InvestmentsAndOtherNoncurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_TexasHealthVenturesGroupLlcMember" abstract="false" name="TexasHealthVenturesGroupLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PhiladelphiaBuildingMember" abstract="true" name="PhiladelphiaBuildingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfOutpatientFacilitiesOperated" abstract="false" name="NumberOfOutpatientFacilitiesOperated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_BusinessCombinationAcquisitionRelatedTransactionCosts" abstract="false" name="BusinessCombinationAcquisitionRelatedTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" abstract="false" name="LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" abstract="false" name="LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_HealthCarePatientServiceIndemnityAndOtherMember" abstract="true" name="HealthCarePatientServiceIndemnityAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NonExecutiveChairmanMember" abstract="true" name="NonExecutiveChairmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" abstract="false" name="PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" abstract="false" name="LesseeLeaseLiabilityPaymentsNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" abstract="false" name="DefinedBenefitPlanBenefitsPaidOrEmployerContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" abstract="false" name="DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_DefinedBenefitPlanAlternativeInvestmentsMember" abstract="true" name="DefinedBenefitPlanAlternativeInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" abstract="false" name="NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_TimeBasedVestingMember" abstract="true" name="TimeBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ShareBasedCompensationAwardTrancheFourMember" abstract="true" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" abstract="true" name="FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" abstract="false" name="SegmentReportingTransferOfAssetsPercentageOfTotalAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="thc_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_CaptiveInsuranceSubsidiariesMember" abstract="true" name="CaptiveInsuranceSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_PropertyInsuranceMaximumCoveragePerIncident" abstract="false" name="PropertyInsuranceMaximumCoveragePerIncident" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_TimeBasedVestingOneYearFromGrantDateMember" abstract="true" name="TimeBasedVestingOneYearFromGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_NewlyConstructedHospitalsMember" abstract="true" name="NewlyConstructedHospitalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_DefinedBenefitPlanExpectedFutureBenefitPayments" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" abstract="true" name="SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" abstract="false" name="ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" abstract="false" name="NetGainonSaleConsolidationAndDeconsolidationOfFacilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_DeferredTaxAssetsOtherLongTermLiabilities" abstract="false" name="DeferredTaxAssetsOtherLongTermLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_IncreaseDecreaseInContractWithCustomerReceivable" abstract="false" name="IncreaseDecreaseInContractWithCustomerReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_InsuranceCoverageLineItems" abstract="true" name="InsuranceCoverageLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" abstract="false" name="ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_HealthCarePatientServiceMedicaidMember" abstract="true" name="HealthCarePatientServiceMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_TimeBasedVestingSettledOnThirdAnniversaryMember" abstract="true" name="TimeBasedVestingSettledOnThirdAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_FireAndOtherPerilsMember" abstract="false" name="FireAndOtherPerilsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" abstract="false" name="GuaranteeObligationCarryValueConsolidatedSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>thc-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5eb22bb-8cdc-4927-ae5c-e13f3ca3c3e1,g:f5e96eef-6bc4-43e3-b34d-7345446e971c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3b2495-fa22-4be9-8565-09ef21516778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ff713487-2168-4ad0-8db1-9c2fc994b86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3b2495-fa22-4be9-8565-09ef21516778" xlink:to="loc_us-gaap_Liabilities_ff713487-2168-4ad0-8db1-9c2fc994b86f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_6f058e3d-6929-4c25-bc97-5012c9f629aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3b2495-fa22-4be9-8565-09ef21516778" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_6f058e3d-6929-4c25-bc97-5012c9f629aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e9e057b7-e143-4021-9dc0-6afa000a8d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3b2495-fa22-4be9-8565-09ef21516778" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e9e057b7-e143-4021-9dc0-6afa000a8d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6eb1af51-0ce8-4947-9f6c-c3f536128598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3b2495-fa22-4be9-8565-09ef21516778" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6eb1af51-0ce8-4947-9f6c-c3f536128598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a2b3b452-b6ab-4fc2-ab6f-1f650b4dc939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6984e6a-3ec0-49a0-9999-3ce6b511eff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b3b452-b6ab-4fc2-ab6f-1f650b4dc939" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6984e6a-3ec0-49a0-9999-3ce6b511eff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f021b91a-2e9f-40f9-ada4-83fa8870f078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b3b452-b6ab-4fc2-ab6f-1f650b4dc939" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f021b91a-2e9f-40f9-ada4-83fa8870f078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c37532c7-729e-4f64-b405-5862d654a358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b3b452-b6ab-4fc2-ab6f-1f650b4dc939" xlink:to="loc_us-gaap_InventoryNet_c37532c7-729e-4f64-b405-5862d654a358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8c333850-6488-4949-ac58-c0912f85fba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b3b452-b6ab-4fc2-ab6f-1f650b4dc939" xlink:to="loc_us-gaap_OtherAssetsCurrent_8c333850-6488-4949-ac58-c0912f85fba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_089ff287-676b-4b4e-af1e-2c27715bf7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:to="loc_us-gaap_AssetsCurrent_089ff287-676b-4b4e-af1e-2c27715bf7cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_ad61cf0d-e9de-4d27-ab5d-37cd24ead0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:to="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_ad61cf0d-e9de-4d27-ab5d-37cd24ead0f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_649e9f2f-060c-4d8b-bfad-56749c2980c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_649e9f2f-060c-4d8b-bfad-56749c2980c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3b8ccc3b-e588-4e0f-b815-574245a84a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:to="loc_us-gaap_Goodwill_3b8ccc3b-e588-4e0f-b815-574245a84a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_872e3635-ced9-4dff-a04d-07b26d8c0e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_872e3635-ced9-4dff-a04d-07b26d8c0e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c9b68b82-90c7-47d5-a4f5-2dbac339c591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f0b928d-f985-4c3d-9bf7-b0d18af67766" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c9b68b82-90c7-47d5-a4f5-2dbac339c591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c607c4e5-8f54-46bf-a715-ba221f9cd2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_df549e6b-cb02-4e55-8d1d-a61ff21b6a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c607c4e5-8f54-46bf-a715-ba221f9cd2e7" xlink:to="loc_us-gaap_CommonStockValue_df549e6b-cb02-4e55-8d1d-a61ff21b6a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7107b427-ad5d-409a-86e7-28359c63e14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c607c4e5-8f54-46bf-a715-ba221f9cd2e7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7107b427-ad5d-409a-86e7-28359c63e14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7632d2f-8cd7-43b3-b192-a887e11b3662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c607c4e5-8f54-46bf-a715-ba221f9cd2e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7632d2f-8cd7-43b3-b192-a887e11b3662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ee54c05f-60c0-4da4-9abe-18c7595b370f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c607c4e5-8f54-46bf-a715-ba221f9cd2e7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ee54c05f-60c0-4da4-9abe-18c7595b370f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_9172c1e2-902a-45ec-b0ca-75a9adb875d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c607c4e5-8f54-46bf-a715-ba221f9cd2e7" xlink:to="loc_us-gaap_TreasuryStockCommonValue_9172c1e2-902a-45ec-b0ca-75a9adb875d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a738555f-9c6f-4741-aa91-88ed3c94530d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a738555f-9c6f-4741-aa91-88ed3c94530d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_077c8869-6615-46e2-9693-9f92de12a0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_AccountsPayableCurrent_077c8869-6615-46e2-9693-9f92de12a0e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_31896875-2f0e-4431-bd4f-4620f5e23909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_31896875-2f0e-4431-bd4f-4620f5e23909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_0a35efac-44d3-484e-9dfd-34d6a04e11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_0a35efac-44d3-484e-9dfd-34d6a04e11d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_1b08e266-9670-422d-a252-876a84dec072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_InterestPayableCurrent_1b08e266-9670-422d-a252-876a84dec072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dfdce692-7c8d-4fea-9cc3-1204bc079dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dfdce692-7c8d-4fea-9cc3-1204bc079dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f7d136ae-841f-4f74-8be8-fcc33f55ceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d2d718f2-4f59-4fb9-b791-dc7abeef92b0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f7d136ae-841f-4f74-8be8-fcc33f55ceb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4e588f4-bf1a-4678-9636-65428b538ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0560b2c-7628-41d6-8f1e-796eef1cc1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4e588f4-bf1a-4678-9636-65428b538ca5" xlink:to="loc_us-gaap_StockholdersEquity_c0560b2c-7628-41d6-8f1e-796eef1cc1ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_594f663f-ab62-47c8-9f1f-c743d8398a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4e588f4-bf1a-4678-9636-65428b538ca5" xlink:to="loc_us-gaap_MinorityInterest_594f663f-ab62-47c8-9f1f-c743d8398a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fa34a9bd-3cce-42e8-94ee-7f15d03f858a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_LiabilitiesCurrent_fa34a9bd-3cce-42e8-94ee-7f15d03f858a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_51a1036c-34e9-4d3c-9a06-454c784a8e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_51a1036c-34e9-4d3c-9a06-454c784a8e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_1d4d85c7-68a0-47bf-9347-586570d2086c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_1d4d85c7-68a0-47bf-9347-586570d2086c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_152ac951-b221-4e37-82d8-42a413afcb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_152ac951-b221-4e37-82d8-42a413afcb91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_cc6f603f-2b68-4119-a94c-16c0cf836940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_cc6f603f-2b68-4119-a94c-16c0cf836940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_878aa4ac-28cf-4b6e-a5e7-e0c3afee26bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_878aa4ac-28cf-4b6e-a5e7-e0c3afee26bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55b115cd-9776-4ce6-98f2-2fbbbc2607d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abaaca31-0ada-4bb5-b895-60ba14daa106" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55b115cd-9776-4ce6-98f2-2fbbbc2607d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8d1a80ef-7f86-4018-99b3-cb143cf81e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1ef6cc22-40fd-48ca-b5fa-7cdf381ba69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8d1a80ef-7f86-4018-99b3-cb143cf81e3e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1ef6cc22-40fd-48ca-b5fa-7cdf381ba69f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_78b23ff4-dbae-4d44-8f01-8c8e6063be98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8d1a80ef-7f86-4018-99b3-cb143cf81e3e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_78b23ff4-dbae-4d44-8f01-8c8e6063be98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0e167c9d-f1b8-4af6-9044-0a8a3f4da77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0e167c9d-f1b8-4af6-9044-0a8a3f4da77c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_b912cabd-095b-45fc-9514-faf68b7e5590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_LaborAndRelatedExpense_b912cabd-095b-45fc-9514-faf68b7e5590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_57e77750-c9df-47d8-b776-65d7d74e0c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_SuppliesExpense_57e77750-c9df-47d8-b776-65d7d74e0c4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_9612543b-10cf-403f-b57e-c291a757c11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_9612543b-10cf-403f-b57e-c291a757c11c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_411ba56e-d2f6-4167-a58a-811f65683509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_411ba56e-d2f6-4167-a58a-811f65683509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_07dd6cee-97b9-4a8c-8b05-a15b355106ec" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_07dd6cee-97b9-4a8c-8b05-a15b355106ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f4de0f7a-842b-4b02-8729-d5fbafbc58a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f4de0f7a-842b-4b02-8729-d5fbafbc58a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_69405c53-1f60-4a4a-84cf-51c98068dca3" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_69405c53-1f60-4a4a-84cf-51c98068dca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_7111796b-c648-4721-beb5-6247128fb92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_7111796b-c648-4721-beb5-6247128fb92c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_795b7215-6754-481c-a26b-f5946090601c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_45fa2141-8dc0-498b-bcee-8cd8428ccd4c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_795b7215-6754-481c-a26b-f5946090601c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_af90499d-3dd5-47a9-90ae-afc2754d0b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28c182ae-89a8-45f2-8b4f-ae241a7962db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_af90499d-3dd5-47a9-90ae-afc2754d0b91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28c182ae-89a8-45f2-8b4f-ae241a7962db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c41e9c41-291e-4f2c-a862-dccff5c41dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_af90499d-3dd5-47a9-90ae-afc2754d0b91" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c41e9c41-291e-4f2c-a862-dccff5c41dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8a3ef9c2-2c21-4b89-b0ee-cc93c35ae5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_c708f61c-88de-4862-98db-09c338364fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8a3ef9c2-2c21-4b89-b0ee-cc93c35ae5de" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_c708f61c-88de-4862-98db-09c338364fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf7abd68-1e93-4899-b893-822524e56938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_770fe85a-3887-409d-88da-0c3a8d8d7569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_cf7abd68-1e93-4899-b893-822524e56938" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_770fe85a-3887-409d-88da-0c3a8d8d7569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_6492f25e-4cbb-494e-bccf-66a61776d3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_cf7abd68-1e93-4899-b893-822524e56938" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_6492f25e-4cbb-494e-bccf-66a61776d3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a8349d06-1cf6-4776-baa3-b1ca78e2c431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f716ea63-502e-44b0-a8fd-73e56445c742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a8349d06-1cf6-4776-baa3-b1ca78e2c431" xlink:to="loc_us-gaap_ProfitLoss_f716ea63-502e-44b0-a8fd-73e56445c742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5fd83762-8fcb-47e8-94f6-3467303191be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a8349d06-1cf6-4776-baa3-b1ca78e2c431" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5fd83762-8fcb-47e8-94f6-3467303191be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dcb331e4-8c9e-425c-bfc5-c8a2e52c90d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3862ef8b-c6dc-4566-a2be-500fdb2ab764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dcb331e4-8c9e-425c-bfc5-c8a2e52c90d5" xlink:to="loc_us-gaap_OperatingIncomeLoss_3862ef8b-c6dc-4566-a2be-500fdb2ab764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5cbcf9ce-4006-4ed9-b429-afbaaf202017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dcb331e4-8c9e-425c-bfc5-c8a2e52c90d5" xlink:to="loc_us-gaap_InterestExpense_5cbcf9ce-4006-4ed9-b429-afbaaf202017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1d0babc4-1b05-4baf-bc5b-448d719c2415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dcb331e4-8c9e-425c-bfc5-c8a2e52c90d5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1d0babc4-1b05-4baf-bc5b-448d719c2415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8e860b87-da58-4af0-aec1-61ad72ba42ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dcb331e4-8c9e-425c-bfc5-c8a2e52c90d5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8e860b87-da58-4af0-aec1-61ad72ba42ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63f1aebc-cd4c-4051-b613-74cadf64eb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10eb0ca0-611c-4703-b05c-e7249bc233bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63f1aebc-cd4c-4051-b613-74cadf64eb05" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10eb0ca0-611c-4703-b05c-e7249bc233bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f68ff90-72f2-4c8b-81c2-7caca2635887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63f1aebc-cd4c-4051-b613-74cadf64eb05" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f68ff90-72f2-4c8b-81c2-7caca2635887" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS_1"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_aa91f9dc-f00e-4db2-a47f-bcc4fed7669d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5133a300-2293-462d-b649-509973c1128f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_aa91f9dc-f00e-4db2-a47f-bcc4fed7669d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_5133a300-2293-462d-b649-509973c1128f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b8733f45-47e0-45ff-982d-b272de94fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_aa91f9dc-f00e-4db2-a47f-bcc4fed7669d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b8733f45-47e0-45ff-982d-b272de94fd23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1bf9aa7d-ad79-43e6-a184-483b1239b129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_05d2195e-4a9a-45cb-97eb-8c7fc409aa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1bf9aa7d-ad79-43e6-a184-483b1239b129" xlink:to="loc_us-gaap_ProfitLoss_05d2195e-4a9a-45cb-97eb-8c7fc409aa7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_03a607fb-cc7a-4d50-b037-720d4ed4c0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1bf9aa7d-ad79-43e6-a184-483b1239b129" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_03a607fb-cc7a-4d50-b037-720d4ed4c0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d652bc83-32be-4bad-b121-f405c67b633c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_37031767-4dea-4eef-b8c5-121805b6c7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d652bc83-32be-4bad-b121-f405c67b633c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_37031767-4dea-4eef-b8c5-121805b6c7ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_641cca50-6998-4145-a5b2-23780b7952c8" xlink:href="thc-20221231.xsd#thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d652bc83-32be-4bad-b121-f405c67b633c" xlink:to="loc_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_641cca50-6998-4145-a5b2-23780b7952c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_174b7deb-e68d-45e0-ac3f-80493bad6f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d652bc83-32be-4bad-b121-f405c67b633c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_174b7deb-e68d-45e0-ac3f-80493bad6f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_4969c2bc-b233-4614-809d-ab8958a832d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d652bc83-32be-4bad-b121-f405c67b633c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_4969c2bc-b233-4614-809d-ab8958a832d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fdbe8ed7-e203-46bc-8130-3149508d377a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bf97e250-fb87-4c48-a34b-8e796b274719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fdbe8ed7-e203-46bc-8130-3149508d377a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bf97e250-fb87-4c48-a34b-8e796b274719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1a0a3c24-f88a-422d-a5df-a3246c0c673e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fdbe8ed7-e203-46bc-8130-3149508d377a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1a0a3c24-f88a-422d-a5df-a3246c0c673e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7db6b11d-06e3-4a43-8a11-6d3e85179f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_46a38514-1011-4da2-8a7f-0b91e7ad5dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7db6b11d-06e3-4a43-8a11-6d3e85179f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_46a38514-1011-4da2-8a7f-0b91e7ad5dba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_ff6b908e-2226-46a3-89d5-9e703f9ec10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7db6b11d-06e3-4a43-8a11-6d3e85179f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_ff6b908e-2226-46a3-89d5-9e703f9ec10a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e967a80-861f-4f6c-9b11-e426dd1dbdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f41f35e3-11b7-4528-80a7-03a09fd10194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e967a80-861f-4f6c-9b11-e426dd1dbdb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f41f35e3-11b7-4528-80a7-03a09fd10194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df344de2-5622-42dc-a30c-6e2a9b9a6c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e967a80-861f-4f6c-9b11-e426dd1dbdb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df344de2-5622-42dc-a30c-6e2a9b9a6c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b4ffdb4-9fe5-4299-adea-ce7be9effb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e967a80-861f-4f6c-9b11-e426dd1dbdb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b4ffdb4-9fe5-4299-adea-ce7be9effb55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_908f8ae6-a451-4c5f-b4ab-e750fcd31941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_ProfitLoss_908f8ae6-a451-4c5f-b4ab-e750fcd31941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3f56349f-c2a2-4cd2-9540-f8a0e65e2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3f56349f-c2a2-4cd2-9540-f8a0e65e2b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93dca827-80e4-4855-bd21-e6bd47c4439b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93dca827-80e4-4855-bd21-e6bd47c4439b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d988ce7d-7948-4bfb-a137-342e609c458f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_ShareBasedCompensation_d988ce7d-7948-4bfb-a137-342e609c458f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_7f0df76a-6196-48b6-ba56-bab2400f0ed5" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_7f0df76a-6196-48b6-ba56-bab2400f0ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6670ef00-2131-47ed-98a0-e546e15bcdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6670ef00-2131-47ed-98a0-e546e15bcdc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4460370d-0a7e-4c3f-8f89-2f7b0527710f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4460370d-0a7e-4c3f-8f89-2f7b0527710f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_5dda130b-be10-4bd0-88e3-6a83d7b1baac" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_5dda130b-be10-4bd0-88e3-6a83d7b1baac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_80537401-922d-4d7d-9248-dd7742b1fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_80537401-922d-4d7d-9248-dd7742b1fd90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_769c9422-8a9b-412f-b149-e58ff1ad2fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_769c9422-8a9b-412f-b149-e58ff1ad2fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_945e7d00-0e95-4bde-8c08-a47a2b5da45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_945e7d00-0e95-4bde-8c08-a47a2b5da45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_95c77144-e69e-445b-b745-7636537bfa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_95c77144-e69e-445b-b745-7636537bfa01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_43b1d348-0e3a-479c-be5e-db9d09ff100b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_43b1d348-0e3a-479c-be5e-db9d09ff100b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_6195dca2-e201-4e91-9a8c-7201f83659d7" xlink:href="thc-20221231.xsd#thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_6195dca2-e201-4e91-9a8c-7201f83659d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_983d9ffb-14e0-47b8-afd5-25c2765a1f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_983d9ffb-14e0-47b8-afd5-25c2765a1f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9704047c-daf8-4c8e-97fb-71fa3a321c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9704047c-daf8-4c8e-97fb-71fa3a321c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2cc571d8-d802-41a6-acfb-57f680c07ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2cc571d8-d802-41a6-acfb-57f680c07ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PaymentsForRestructuringAndLitigationCosts_b7154d10-4de0-4eb0-a15b-743029605b40" xlink:href="thc-20221231.xsd#thc_PaymentsForRestructuringAndLitigationCosts"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_thc_PaymentsForRestructuringAndLitigationCosts_b7154d10-4de0-4eb0-a15b-743029605b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_50713178-3739-4d0b-82eb-d6f5cd191ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_50713178-3739-4d0b-82eb-d6f5cd191ff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2fbc6e1f-0002-4db8-a1f4-f696c3d5a24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbe5abd9-7de3-4533-b6dc-3c6026516200" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2fbc6e1f-0002-4db8-a1f4-f696c3d5a24b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_8913dde9-30ff-420b-a67f-7b8994e45f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_8913dde9-30ff-420b-a67f-7b8994e45f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_dd879eae-c067-4293-8859-bd9096ec5ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_dd879eae-c067-4293-8859-bd9096ec5ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ede2b366-4a7d-402b-b290-e77c74a7984b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ede2b366-4a7d-402b-b290-e77c74a7984b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_7361dc38-60e8-409e-9507-33d1fa5ec3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_7361dc38-60e8-409e-9507-33d1fa5ec3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_10aa8b03-59e6-493c-bdbe-99fcd1a9c0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_10aa8b03-59e6-493c-bdbe-99fcd1a9c0d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_5ec4ebbf-289d-4998-b45f-535a9beb0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_5ec4ebbf-289d-4998-b45f-535a9beb0e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_910a6fe2-6e8e-41bb-b9b8-f0b97722adcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_910a6fe2-6e8e-41bb-b9b8-f0b97722adcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_65352b74-c69c-4f1a-b3f4-3f3ac75c4f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_65352b74-c69c-4f1a-b3f4-3f3ac75c4f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_caccd474-8175-4dcf-af17-314933051691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_caccd474-8175-4dcf-af17-314933051691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_f81f7f48-5827-4b51-98a2-28cc73591d62" xlink:href="thc-20221231.xsd#thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_f81f7f48-5827-4b51-98a2-28cc73591d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d70e33ac-3f63-4208-b547-f0cc74607817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e62e9a3-633a-48aa-bf51-82be8819cc1a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d70e33ac-3f63-4208-b547-f0cc74607817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45c19640-045e-4ca7-a347-6cc6acae26e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45c19640-045e-4ca7-a347-6cc6acae26e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a699b95d-5067-4171-ad0b-d31618dd8ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a699b95d-5067-4171-ad0b-d31618dd8ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_138dc8b2-650b-4cb4-8460-7e8eaf7a68d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_138dc8b2-650b-4cb4-8460-7e8eaf7a68d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_774d4be4-0210-4f15-a6e6-05ca6b67ec60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_774d4be4-0210-4f15-a6e6-05ca6b67ec60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_e1f40074-b96a-4165-93ae-b21e6c191fe1" xlink:href="thc-20221231.xsd#thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:to="loc_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_e1f40074-b96a-4165-93ae-b21e6c191fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7f14aa90-c7bf-4705-94eb-71a687f3c08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d81050-1bba-4c43-91a4-af61655d5553" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7f14aa90-c7bf-4705-94eb-71a687f3c08f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLEComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6e60245b-982e-47bb-b910-3f9d2a7d6a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_73618442-2694-4211-bd6a-c32eb472b865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6e60245b-982e-47bb-b910-3f9d2a7d6a75" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_73618442-2694-4211-bd6a-c32eb472b865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_8c683036-dde3-4b36-a4f1-6717c0f438fb" xlink:href="thc-20221231.xsd#thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6e60245b-982e-47bb-b910-3f9d2a7d6a75" xlink:to="loc_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_8c683036-dde3-4b36-a4f1-6717c0f438fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_94bf8b8b-d232-478d-8187-7d060ad3e2f9" xlink:href="thc-20221231.xsd#thc_NetCostReportSettlementsReceivablePayableandValuationAllowances"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6e60245b-982e-47bb-b910-3f9d2a7d6a75" xlink:to="loc_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_94bf8b8b-d232-478d-8187-7d060ad3e2f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESBalanceSheetComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseRightOfUseAsset_80af5cae-caff-4a32-a8eb-90408dc67514" xlink:href="thc-20221231.xsd#thc_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_606aec2d-f3ef-48af-a638-98b859aa37de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseRightOfUseAsset_80af5cae-caff-4a32-a8eb-90408dc67514" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_606aec2d-f3ef-48af-a638-98b859aa37de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3184a11e-16e2-41a8-afc3-3981f245837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseRightOfUseAsset_80af5cae-caff-4a32-a8eb-90408dc67514" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3184a11e-16e2-41a8-afc3-3981f245837a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiability_c86a294b-626a-4f9b-80f7-d728b3a0056c" xlink:href="thc-20221231.xsd#thc_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e31490d5-1ac4-4268-9cbe-f3d5c6facf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiability_c86a294b-626a-4f9b-80f7-d728b3a0056c" xlink:to="loc_us-gaap_FinanceLeaseLiability_e31490d5-1ac4-4268-9cbe-f3d5c6facf2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6093b4f6-5fdc-49a9-91a2-8fcc9565e671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiability_c86a294b-626a-4f9b-80f7-d728b3a0056c" xlink:to="loc_us-gaap_OperatingLeaseLiability_6093b4f6-5fdc-49a9-91a2-8fcc9565e671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0d8994a0-335d-4c20-90bc-5958992d798a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_25784e48-1310-40b4-97d5-98e3b3397b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0d8994a0-335d-4c20-90bc-5958992d798a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_25784e48-1310-40b4-97d5-98e3b3397b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_52d81637-9219-4469-84f8-8677f89dc31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0d8994a0-335d-4c20-90bc-5958992d798a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_52d81637-9219-4469-84f8-8677f89dc31b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_7b2bab81-66e2-4ed2-819f-d9d7763c6836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1a0b70f5-923f-4dba-bd87-dc876a88d75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_7b2bab81-66e2-4ed2-819f-d9d7763c6836" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1a0b70f5-923f-4dba-bd87-dc876a88d75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0e49e407-305b-4bdf-8d6a-6c0adda1bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_7b2bab81-66e2-4ed2-819f-d9d7763c6836" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0e49e407-305b-4bdf-8d6a-6c0adda1bbee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_99aa3a9e-f8fe-4afa-a2c1-e72c52fef7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7a20c8ef-4b50-4270-9d99-4117569a3439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_99aa3a9e-f8fe-4afa-a2c1-e72c52fef7bb" xlink:to="loc_us-gaap_OperatingLeaseCost_7a20c8ef-4b50-4270-9d99-4117569a3439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeaseCost_8855d325-7c4e-4389-b772-a1e0a760d844" xlink:href="thc-20221231.xsd#thc_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_99aa3a9e-f8fe-4afa-a2c1-e72c52fef7bb" xlink:to="loc_thc_FinanceLeaseCost_8855d325-7c4e-4389-b772-a1e0a760d844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_VariableAndShorttermLeaseCosts_bb977308-46df-4b98-a1f0-ebf10b96822d" xlink:href="thc-20221231.xsd#thc_VariableAndShorttermLeaseCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_99aa3a9e-f8fe-4afa-a2c1-e72c52fef7bb" xlink:to="loc_thc_VariableAndShorttermLeaseCosts_bb977308-46df-4b98-a1f0-ebf10b96822d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeaseCost_df0ae9f7-a06c-4f49-b19e-b3f61a9561c2" xlink:href="thc-20221231.xsd#thc_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c9682e7a-afee-4595-9fcf-82a06f43cebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_FinanceLeaseCost_df0ae9f7-a06c-4f49-b19e-b3f61a9561c2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c9682e7a-afee-4595-9fcf-82a06f43cebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_99399e23-fede-46d6-8af4-8711b79ca8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_FinanceLeaseCost_df0ae9f7-a06c-4f49-b19e-b3f61a9561c2" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_99399e23-fede-46d6-8af4-8711b79ca8b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESScheduleofLeaseMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2fa3558a-1260-40e8-a729-a1d97fa8834a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2fa3558a-1260-40e8-a729-a1d97fa8834a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9e0ccd43-a69f-4744-9e98-5e3b2eb8745c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9e0ccd43-a69f-4744-9e98-5e3b2eb8745c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2ba03813-8559-4264-8fe9-95ec2a90bcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2ba03813-8559-4264-8fe9-95ec2a90bcd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_262d0b51-54b9-4dea-9a9a-cc61a5e40aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_262d0b51-54b9-4dea-9a9a-cc61a5e40aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_e7ab132c-1dde-403e-8611-4c45e160ecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_e7ab132c-1dde-403e-8611-4c45e160ecb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_77217739-0744-4cb0-b108-8e2a12b4abe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8013f1ec-a340-46c0-925b-3f1f2a7acd97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_77217739-0744-4cb0-b108-8e2a12b4abe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b3680d14-2b73-4555-9064-10ce7336b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b3680d14-2b73-4555-9064-10ce7336b9f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_80249e29-73e4-4853-b5ed-ab22b04ec288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_80249e29-73e4-4853-b5ed-ab22b04ec288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_81a37f0d-15f4-4362-808b-42ca192ded53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_81a37f0d-15f4-4362-808b-42ca192ded53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba6495a0-0665-47fd-bcef-436861614eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba6495a0-0665-47fd-bcef-436861614eb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2ca6f4eb-fd17-459f-8c63-b56663271b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2ca6f4eb-fd17-459f-8c63-b56663271b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_61667eed-fc22-4904-9f79-f16932f99271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3dd7aa97-a17d-412b-a99c-9778f4172bad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_61667eed-fc22-4904-9f79-f16932f99271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_80545c02-2ded-42f8-87fe-7d667c6450cb" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_80545c02-2ded-42f8-87fe-7d667c6450cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_c97cb98e-5965-4b12-975b-cd376ff33814" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_c97cb98e-5965-4b12-975b-cd376ff33814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearThree_b65a0718-6a66-46d5-97b8-e176762e3863" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearThree_b65a0718-6a66-46d5-97b8-e176762e3863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFour_7fea40c4-6b08-473a-ae5c-50a00dcc0812" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFour_7fea40c4-6b08-473a-ae5c-50a00dcc0812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFive_b1ece7f9-04f0-4e57-9788-38d8e7bf9053" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFive_b1ece7f9-04f0-4e57-9788-38d8e7bf9053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_33ef9352-2ecd-4c6e-b761-2fe105e338d2" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiabilityPaymentsDue_5f207dc8-fceb-4877-9178-db8796b15e10" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_33ef9352-2ecd-4c6e-b761-2fe105e338d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiability_1d5003ac-ecec-4335-a485-3cb29a252018" xlink:href="thc-20221231.xsd#thc_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityCurrent_e9dd3940-7ba5-4451-a2bc-6c3989cfef6c" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiability_1d5003ac-ecec-4335-a485-3cb29a252018" xlink:to="loc_thc_LeaseLiabilityCurrent_e9dd3940-7ba5-4451-a2bc-6c3989cfef6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityNoncurrent_822a33ea-a450-4791-a2c7-eda3c8d0733b" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_LeaseLiability_1d5003ac-ecec-4335-a485-3cb29a252018" xlink:to="loc_thc_LeaseLiabilityNoncurrent_822a33ea-a450-4791-a2c7-eda3c8d0733b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_ddbb3d83-fb71-47e2-97f9-189555d2f230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e4d6dd8b-628a-4ad6-8d93-fc881a180e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_ddbb3d83-fb71-47e2-97f9-189555d2f230" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e4d6dd8b-628a-4ad6-8d93-fc881a180e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_68693fdc-a42e-4017-9de4-0548939822f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_ddbb3d83-fb71-47e2-97f9-189555d2f230" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_68693fdc-a42e-4017-9de4-0548939822f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTScheduleofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_67488252-4827-43ae-a3ea-58d6817bab59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d6be9f4d-b240-4ff6-aeb3-65c33aeaaa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_67488252-4827-43ae-a3ea-58d6817bab59" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d6be9f4d-b240-4ff6-aeb3-65c33aeaaa6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeasesAndMortgageNotes_6253e355-4021-4302-a07a-61e21e040410" xlink:href="thc-20221231.xsd#thc_FinanceLeasesAndMortgageNotes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_67488252-4827-43ae-a3ea-58d6817bab59" xlink:to="loc_thc_FinanceLeasesAndMortgageNotes_6253e355-4021-4302-a07a-61e21e040410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7cdb2924-d280-45e1-9c01-f18b3970cd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_67488252-4827-43ae-a3ea-58d6817bab59" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7cdb2924-d280-45e1-9c01-f18b3970cd2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTFutureMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_ae9ed50f-7d9d-4d6d-a59c-a6f67e74afec" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_ae9ed50f-7d9d-4d6d-a59c-a6f67e74afec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_f12c1a0c-5b34-44ba-b855-a6c6a283eb4a" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_f12c1a0c-5b34-44ba-b855-a6c6a283eb4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_9d65a440-64a8-445f-aeaf-744b8eb528b9" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_9d65a440-64a8-445f-aeaf-744b8eb528b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_892d91a9-74a8-4086-8c7d-08d9859ca903" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_892d91a9-74a8-4086-8c7d-08d9859ca903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_43af4eba-c767-4a1f-97f2-e96c4752d2df" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_43af4eba-c767-4a1f-97f2-e96c4752d2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_00f28d7d-30cc-4c26-8220-fd5a1e585c0f" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_62b5f2c4-df6b-4ce6-b228-e743ed79046c" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_00f28d7d-30cc-4c26-8220-fd5a1e585c0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4d86a9d6-1331-4937-a3ca-91e759432e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_62ed41a6-d0fe-45e3-99f0-7e5575ed87e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4d86a9d6-1331-4937-a3ca-91e759432e4c" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_62ed41a6-d0fe-45e3-99f0-7e5575ed87e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f6c31af4-e1e2-45e6-9fc2-fde9a1b69d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4d86a9d6-1331-4937-a3ca-91e759432e4c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f6c31af4-e1e2-45e6-9fc2-fde9a1b69d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b7f53f2e-bf87-4a1f-ba11-4e1351052df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4d86a9d6-1331-4937-a3ca-91e759432e4c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b7f53f2e-bf87-4a1f-ba11-4e1351052df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_75b16aad-45f2-4bba-99e4-c5cf76aec3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ac041126-244d-40fd-9719-bf257b3b92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_75b16aad-45f2-4bba-99e4-c5cf76aec3dd" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ac041126-244d-40fd-9719-bf257b3b92f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_11b63d00-0e61-475e-ad0f-c76737270d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_75b16aad-45f2-4bba-99e4-c5cf76aec3dd" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_11b63d00-0e61-475e-ad0f-c76737270d32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanExpectedFutureBenefitPayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d236289c-d51c-4f15-a066-3997efc91f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d236289c-d51c-4f15-a066-3997efc91f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_8538bca0-91db-4b85-bdea-77d4112e7859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_8538bca0-91db-4b85-bdea-77d4112e7859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fcc1bbfc-8d8d-4703-94c1-b3e9e68d6e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fcc1bbfc-8d8d-4703-94c1-b3e9e68d6e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_70f38c6e-3552-4eb0-850e-822fcb06e078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_70f38c6e-3552-4eb0-850e-822fcb06e078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_da3c472a-8556-4b0d-be31-175af0750faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_da3c472a-8556-4b0d-be31-175af0750faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fd7c34ba-c348-428d-a87d-d82356219bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_b6b6e6f7-c9bc-4bac-a70e-32779fbb7ef8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fd7c34ba-c348-428d-a87d-d82356219bf8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#PROPERTYANDEQUIPMENTComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_37c00335-152b-4570-8c33-98aa35bf0081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a53e1ca8-9e1f-4e5a-ad03-3f2b1c0974c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_37c00335-152b-4570-8c33-98aa35bf0081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a53e1ca8-9e1f-4e5a-ad03-3f2b1c0974c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_fee83389-f034-4e99-9b08-ea96c0b14303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_37c00335-152b-4570-8c33-98aa35bf0081" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_fee83389-f034-4e99-9b08-ea96c0b14303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4059259c-035e-4a1b-902b-46c47ecd974a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_c796ef2c-de4b-4a0b-976d-4ffce003a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4059259c-035e-4a1b-902b-46c47ecd974a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_c796ef2c-de4b-4a0b-976d-4ffce003a20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_f484185a-c5b0-4c59-919f-059e03044686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4059259c-035e-4a1b-902b-46c47ecd974a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_f484185a-c5b0-4c59-919f-059e03044686" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1d0d6979-8000-4303-a206-a8ac09454085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f41a1875-bada-4366-aed1-14d2c9bee995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1d0d6979-8000-4303-a206-a8ac09454085" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f41a1875-bada-4366-aed1-14d2c9bee995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_203b8915-9b5b-40ae-affe-5b0122b100cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1d0d6979-8000-4303-a206-a8ac09454085" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_203b8915-9b5b-40ae-affe-5b0122b100cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10c014a7-6305-4de7-9219-7bbe4cfec826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ded3f2bb-4280-45e3-a17d-c6bae6b05d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10c014a7-6305-4de7-9219-7bbe4cfec826" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ded3f2bb-4280-45e3-a17d-c6bae6b05d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b48c8ce8-06a4-4b7e-8dac-b6472cfa3d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10c014a7-6305-4de7-9219-7bbe4cfec826" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b48c8ce8-06a4-4b7e-8dac-b6472cfa3d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_809f02a5-4bbd-47fa-8447-dd2c9f401049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_08251e0e-5e1e-4bff-98e6-c55ad1d1b671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_809f02a5-4bbd-47fa-8447-dd2c9f401049" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_08251e0e-5e1e-4bff-98e6-c55ad1d1b671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dee7e5d6-51d8-49f0-a1b4-90ab4a8cab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_809f02a5-4bbd-47fa-8447-dd2c9f401049" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dee7e5d6-51d8-49f0-a1b4-90ab4a8cab0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a8ddd7de-95ca-498c-b1c4-36dca408de58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dd9184fd-3b72-4a65-9e70-06cabe00eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a8ddd7de-95ca-498c-b1c4-36dca408de58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dd9184fd-3b72-4a65-9e70-06cabe00eae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_27b8db3b-23d8-4a32-af76-eb057a37cbee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a8ddd7de-95ca-498c-b1c4-36dca408de58" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_27b8db3b-23d8-4a32-af76-eb057a37cbee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a7d549d8-4d6c-4f9b-b7c2-ae67cb6db351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a7d549d8-4d6c-4f9b-b7c2-ae67cb6db351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c0be8c6-6b00-456e-a1cd-f874aeb6e884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c0be8c6-6b00-456e-a1cd-f874aeb6e884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2d9aeb8d-de2d-4131-ad28-4b14d05c5e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2d9aeb8d-de2d-4131-ad28-4b14d05c5e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5d5aecf5-8b7f-46e6-ac3d-047da52f8ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5d5aecf5-8b7f-46e6-ac3d-047da52f8ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3bc7eaec-c0f9-4565-859d-8f1f2d7e1496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3bc7eaec-c0f9-4565-859d-8f1f2d7e1496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03a5f01f-22d7-48f1-8237-024b9d7657a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_983614c4-b5a9-4c76-9fee-c3590c1b59da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03a5f01f-22d7-48f1-8237-024b9d7657a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETSScheduleofOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_f53810e3-448c-40d5-beba-b4f7ce8d2e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_f53810e3-448c-40d5-beba-b4f7ce8d2e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3f6ca359-62bc-45e9-b1a7-a6a0a8f851ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3f6ca359-62bc-45e9-b1a7-a6a0a8f851ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_bf9c86ff-3b16-41c8-a78a-5e0524a73562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_bf9c86ff-3b16-41c8-a78a-5e0524a73562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_10118aae-5a3f-497b-9d45-1fcf3dc8741c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:to="loc_us-gaap_OtherReceivables_10118aae-5a3f-497b-9d45-1fcf3dc8741c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent_5bc08867-182c-4b5d-b885-f1e499952b43" xlink:href="thc-20221231.xsd#thc_PhysicianAndGroupCoverageGuaranteesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:to="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent_5bc08867-182c-4b5d-b885-f1e499952b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ReceivablesFromGovernmentProgramsCurrent_e8409937-5aa5-4f77-af81-7bb7c671f124" xlink:href="thc-20221231.xsd#thc_ReceivablesFromGovernmentProgramsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_9540f990-a168-4f58-9083-a4294c2f5740" xlink:to="loc_thc_ReceivablesFromGovernmentProgramsCurrent_e8409937-5aa5-4f77-af81-7bb7c671f124" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_6681b434-dca7-427e-9669-15d1de2a7816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_6681b434-dca7-427e-9669-15d1de2a7816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_52771f48-6663-4f95-83df-26d194ee3c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_52771f48-6663-4f95-83df-26d194ee3c8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_f8df8aec-15ba-4cbe-a644-4e52cf66cc80" xlink:href="thc-20221231.xsd#thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:to="loc_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_f8df8aec-15ba-4cbe-a644-4e52cf66cc80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f664b4c1-fa44-43a9-a02e-240a5fc521b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f664b4c1-fa44-43a9-a02e-240a5fc521b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueOfLifeInsurance_556010d9-ec28-43cc-9130-b20a525a23a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueOfLifeInsurance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:to="loc_us-gaap_CashSurrenderValueOfLifeInsurance_556010d9-ec28-43cc-9130-b20a525a23a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d33b3744-bcaf-4ffc-b79d-85ec6bb7d754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_bf7e9ade-7dbb-4972-b39b-c015d969ef28" xlink:to="loc_us-gaap_LongTermInvestments_d33b3744-bcaf-4ffc-b79d-85ec6bb7d754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7df9b09d-ee97-4f39-8fee-e60293b1b829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a3553fe1-861c-4c9f-8f6f-61e411a01c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_7df9b09d-ee97-4f39-8fee-e60293b1b829" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a3553fe1-861c-4c9f-8f6f-61e411a01c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7eda5805-ab15-45d6-9377-171f31d34844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_7df9b09d-ee97-4f39-8fee-e60293b1b829" xlink:to="loc_us-gaap_EquityMethodInvestments_7eda5805-ab15-45d6-9377-171f31d34844" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESProvisionandDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55ed9c8c-9c22-451c-b13d-5a9b16a2e549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_07cbb96d-11c1-47cd-9637-19519e6138e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55ed9c8c-9c22-451c-b13d-5a9b16a2e549" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_07cbb96d-11c1-47cd-9637-19519e6138e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_330c8381-e763-4350-aca6-7a296e66e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55ed9c8c-9c22-451c-b13d-5a9b16a2e549" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_330c8381-e763-4350-aca6-7a296e66e3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_58144418-2041-4cb2-bab7-84f60edcdf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1cf8e92e-17cd-475e-a3ad-701e116c8a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_58144418-2041-4cb2-bab7-84f60edcdf81" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1cf8e92e-17cd-475e-a3ad-701e116c8a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1ab5285b-6c74-4aea-bd8b-31d47374e154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_58144418-2041-4cb2-bab7-84f60edcdf81" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1ab5285b-6c74-4aea-bd8b-31d47374e154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97df5209-8fa3-47cc-b974-b9c3df7889cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_b4ba28c3-4600-4ffb-8c3c-e5ab5f01c796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97df5209-8fa3-47cc-b974-b9c3df7889cf" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_b4ba28c3-4600-4ffb-8c3c-e5ab5f01c796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ec8283d7-ae4f-4782-b325-bc10d627c742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97df5209-8fa3-47cc-b974-b9c3df7889cf" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ec8283d7-ae4f-4782-b325-bc10d627c742" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESFederalTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_29e045b0-d325-4925-93a9-043ac8eb5561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_29e045b0-d325-4925-93a9-043ac8eb5561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_84e48217-cda5-4e1f-a6ad-5ad0d34f4884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_84e48217-cda5-4e1f-a6ad-5ad0d34f4884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_c7e02c52-cc69-4399-af25-2effa8fb6d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_c7e02c52-cc69-4399-af25-2effa8fb6d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_8b110795-3c3d-4e16-884b-5f8cea0c04aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_8b110795-3c3d-4e16-884b-5f8cea0c04aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_34fef16f-d839-4964-999c-c4b263648d96" xlink:href="thc-20221231.xsd#thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_34fef16f-d839-4964-999c-c4b263648d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_55b40d72-f404-40ad-b565-512e87924944" xlink:href="thc-20221231.xsd#thc_IncomeTaxReconciliationNondeductibleExpenseLitigation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_55b40d72-f404-40ad-b565-512e87924944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_f38a1838-1ee4-4a00-bcf9-0a59044ca205" xlink:href="thc-20221231.xsd#thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_f38a1838-1ee4-4a00-bcf9-0a59044ca205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6a1329a0-64a4-4829-8348-b4fc89b832dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6a1329a0-64a4-4829-8348-b4fc89b832dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b57e7c28-ded6-40f8-b785-343748cee906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b57e7c28-ded6-40f8-b785-343748cee906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_01eb7bf9-f988-4c1d-83d2-3cd09ebfc21b" xlink:href="thc-20221231.xsd#thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_01eb7bf9-f988-4c1d-83d2-3cd09ebfc21b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_014e0bfd-dda6-4df4-929e-2a7f6ab76004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f11e1777-0514-4dbe-9cdd-028833fddcac" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_014e0bfd-dda6-4df4-929e-2a7f6ab76004" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_00e7d1de-de44-474e-953d-011ef44dfa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d3d650ad-b334-437b-b604-1623e2f5423c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_00e7d1de-de44-474e-953d-011ef44dfa4c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d3d650ad-b334-437b-b604-1623e2f5423c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b211f7ba-07d8-49b1-a719-2eab35b6d113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_23f10e1c-834b-4fd7-ba15-21124d84ce47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b211f7ba-07d8-49b1-a719-2eab35b6d113" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_23f10e1c-834b-4fd7-ba15-21124d84ce47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0875b384-a29c-4131-aa4f-c96a33eadb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b211f7ba-07d8-49b1-a719-2eab35b6d113" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0875b384-a29c-4131-aa4f-c96a33eadb32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d115bd72-dded-49fc-a08e-b92422dc6034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b211f7ba-07d8-49b1-a719-2eab35b6d113" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d115bd72-dded-49fc-a08e-b92422dc6034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_0400f86e-231f-42fa-bb45-b0e3a7d66058" xlink:href="thc-20221231.xsd#thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b211f7ba-07d8-49b1-a719-2eab35b6d113" xlink:to="loc_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_0400f86e-231f-42fa-bb45-b0e3a7d66058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_e8c548a3-3a67-4d26-95bb-556b47b52bab" xlink:href="thc-20221231.xsd#thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b211f7ba-07d8-49b1-a719-2eab35b6d113" xlink:to="loc_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_e8c548a3-3a67-4d26-95bb-556b47b52bab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_90123010-f1ce-45ad-9aa6-f5652589c6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_90123010-f1ce-45ad-9aa6-f5652589c6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_e81fe226-0c3a-4ef3-9595-ae657dc02d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_e81fe226-0c3a-4ef3-9595-ae657dc02d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_0d92a92c-86f1-4981-88ae-eb7516cbd327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_0d92a92c-86f1-4981-88ae-eb7516cbd327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsOtherLongTermLiabilities_8bd93fe9-2e5e-4d4a-b7a9-aff58f777f16" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsOtherLongTermLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_thc_DeferredTaxAssetsOtherLongTermLiabilities_8bd93fe9-2e5e-4d4a-b7a9-aff58f777f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_409c3329-8537-4c64-a8b2-b8bd75e8539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_409c3329-8537-4c64-a8b2-b8bd75e8539d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_bd9bd46f-2026-41c2-8eac-6c7b9d564712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_bd9bd46f-2026-41c2-8eac-6c7b9d564712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsInterestExpenseLimitation_7ba2d6ac-b2bb-466e-8090-6835bda651da" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsInterestExpenseLimitation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_thc_DeferredTaxAssetsInterestExpenseLimitation_7ba2d6ac-b2bb-466e-8090-6835bda651da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f07c7f58-3464-41ab-b5f0-4d9492e6cc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f07c7f58-3464-41ab-b5f0-4d9492e6cc8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6082809c-01a7-49e7-a191-574e89e53242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6082809c-01a7-49e7-a191-574e89e53242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1fa75a87-f30f-4dc4-a2c3-5086dd9eb091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1fa75a87-f30f-4dc4-a2c3-5086dd9eb091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_8f0a3525-b131-47f4-9559-4d407d323929" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_8f0a3525-b131-47f4-9559-4d407d323929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsMedicareAdvancePayments_baeed7e4-c8a1-4af6-9f46-f9e73ae93561" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsMedicareAdvancePayments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c39ffa97-cca7-4c19-8a00-4962d569dad1" xlink:to="loc_thc_DeferredTaxAssetsMedicareAdvancePayments_baeed7e4-c8a1-4af6-9f46-f9e73ae93561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet_8b252ae1-ea70-433f-88e3-2cc5b0c5640e" xlink:href="thc-20221231.xsd#thc_DeferredIncomeTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_749ac8ad-272c-4520-9dfa-25df4b3e349d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet_8b252ae1-ea70-433f-88e3-2cc5b0c5640e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_749ac8ad-272c-4520-9dfa-25df4b3e349d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4326749f-af28-4730-bbed-6e6c624ccc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet_8b252ae1-ea70-433f-88e3-2cc5b0c5640e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4326749f-af28-4730-bbed-6e6c624ccc78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c24a0e8c-2a58-4743-adcf-0c45eada7ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_86eaf9aa-c9b2-46b3-964d-2c403eb87c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c24a0e8c-2a58-4743-adcf-0c45eada7ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_86eaf9aa-c9b2-46b3-964d-2c403eb87c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_453a914c-54be-46da-8a31-a8618b5b514e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c24a0e8c-2a58-4743-adcf-0c45eada7ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_453a914c-54be-46da-8a31-a8618b5b514e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EARNINGSPERCOMMONSHAREDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bdf0a88-1a48-42ab-a908-ee8123926b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_152dea57-0f34-4ebb-b410-ab8d0ec71b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bdf0a88-1a48-42ab-a908-ee8123926b94" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_152dea57-0f34-4ebb-b410-ab8d0ec71b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectOfDilutiveSecuritiesPerShareAmount_f58ac06a-763f-4739-899d-56861401a104" xlink:href="thc-20221231.xsd#thc_EffectOfDilutiveSecuritiesPerShareAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bdf0a88-1a48-42ab-a908-ee8123926b94" xlink:to="loc_thc_EffectOfDilutiveSecuritiesPerShareAmount_f58ac06a-763f-4739-899d-56861401a104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6749ac90-b04f-41ff-bd0b-c6d099aa290c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_bcb32bce-1633-42ef-bc57-715d301adf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6749ac90-b04f-41ff-bd0b-c6d099aa290c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_bcb32bce-1633-42ef-bc57-715d301adf09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities_548d0fcf-d494-4627-a721-7a658c6603bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6749ac90-b04f-41ff-bd0b-c6d099aa290c" xlink:to="loc_us-gaap_DilutiveSecurities_548d0fcf-d494-4627-a721-7a658c6603bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11747332-50a9-4710-b7eb-4a6df63a5752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05593d26-6ee6-44ba-b153-64b443cf9d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11747332-50a9-4710-b7eb-4a6df63a5752" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05593d26-6ee6-44ba-b153-64b443cf9d5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_02b18f2d-49dc-4261-9a3c-1eb2c2e4e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11747332-50a9-4710-b7eb-4a6df63a5752" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_02b18f2d-49dc-4261-9a3c-1eb2c2e4e4e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATIONReconcilingItemsDetails"/>
  <link:calculationLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8dd9388f-8e1b-4ca6-8434-0a15552629b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8dd9388f-8e1b-4ca6-8434-0a15552629b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_0eb4b6f2-9a8c-4322-a8dc-a330345c9f27" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_0eb4b6f2-9a8c-4322-a8dc-a330345c9f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e5253d3d-8617-48a3-9b7f-13625cbb18a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e5253d3d-8617-48a3-9b7f-13625cbb18a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_46110930-b6aa-4926-a6b3-08481566165e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_us-gaap_InterestExpense_46110930-b6aa-4926-a6b3-08481566165e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_ad5c30e0-0cc0-4485-b916-432ddf425118" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_ad5c30e0-0cc0-4485-b916-432ddf425118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7356e773-dfc7-4379-a8d6-a12c7893aae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7356e773-dfc7-4379-a8d6-a12c7893aae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeLossFromDivestedAndClosedBusinesses_1916884f-8d7f-4cbd-85cb-ec5791ba4751" xlink:href="thc-20221231.xsd#thc_IncomeLossFromDivestedAndClosedBusinesses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_thc_IncomeLossFromDivestedAndClosedBusinesses_1916884f-8d7f-4cbd-85cb-ec5791ba4751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_2da02edf-e7ad-4b77-8895-30c197296ec1" xlink:href="thc-20221231.xsd#thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_2da02edf-e7ad-4b77-8895-30c197296ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_775be544-4bc3-4079-9c16-33745d0a7ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bdd34cc8-90ee-45fc-a570-4bee92734a84" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_775be544-4bc3-4079-9c16-33745d0a7ec6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>thc-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5eb22bb-8cdc-4927-ae5c-e13f3ca3c3e1,g:f5e96eef-6bc4-43e3-b34d-7345446e971c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CoverPage" xlink:type="simple" xlink:href="thc-20221231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/CoverPage" xlink:type="extended" id="i7ec060a2118a4e16881a5c3d39ff55e0_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_48222c14-e26e-488d-9376-5dce4cc49214" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentType_48222c14-e26e-488d-9376-5dce4cc49214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7dfb063a-307b-4bf0-b348-599d1aad709b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentAnnualReport_7dfb063a-307b-4bf0-b348-599d1aad709b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_75e3a9ee-21e5-4f7c-8fd3-9b839008de86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentPeriodEndDate_75e3a9ee-21e5-4f7c-8fd3-9b839008de86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2c8fff9b-8d4e-4d4f-b265-2643839baca3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_CurrentFiscalYearEndDate_2c8fff9b-8d4e-4d4f-b265-2643839baca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_240d2dd9-e77e-4a5e-9533-f49f4891f702" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentTransitionReport_240d2dd9-e77e-4a5e-9533-f49f4891f702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_12ffb49a-756d-4f3e-b7c1-6645138dc456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityFileNumber_12ffb49a-756d-4f3e-b7c1-6645138dc456" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aeaa21bd-430d-4aa6-860d-95471fbd22c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityRegistrantName_aeaa21bd-430d-4aa6-860d-95471fbd22c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8931b7c4-4486-40e0-931f-ea867ea6e5e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8931b7c4-4486-40e0-931f-ea867ea6e5e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_11b07015-edb2-41f9-b0b4-edbc83ede8e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityTaxIdentificationNumber_11b07015-edb2-41f9-b0b4-edbc83ede8e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b4eca46a-e3f5-40be-a898-ded0c01e1928" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressAddressLine1_b4eca46a-e3f5-40be-a898-ded0c01e1928" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e883a23b-b794-40f1-a357-565925e2aa9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressCityOrTown_e883a23b-b794-40f1-a357-565925e2aa9e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_883ad68a-8fda-46a9-b809-09f94774ddb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressStateOrProvince_883ad68a-8fda-46a9-b809-09f94774ddb0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5a903e20-5a1c-4d07-9b58-85e48b4dd5f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressPostalZipCode_5a903e20-5a1c-4d07-9b58-85e48b4dd5f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a33a1313-b0ed-43d0-9a34-7492b1818496" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_CityAreaCode_a33a1313-b0ed-43d0-9a34-7492b1818496" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c44977c6-53f5-44be-bcc1-44bd5fc3e1bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_LocalPhoneNumber_c44977c6-53f5-44be-bcc1-44bd5fc3e1bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4e4a9434-8d4d-46a0-91fc-474c1315bebf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_Security12bTitle_4e4a9434-8d4d-46a0-91fc-474c1315bebf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d43dbdee-66aa-48b5-a77a-d01cf41f7a90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_TradingSymbol_d43dbdee-66aa-48b5-a77a-d01cf41f7a90" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e8ead6d-1e71-427f-a601-9b9704d81ca2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_SecurityExchangeName_5e8ead6d-1e71-427f-a601-9b9704d81ca2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bdeb5db1-a806-43ef-91ad-f8eb3bfd98e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bdeb5db1-a806-43ef-91ad-f8eb3bfd98e8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a2e60719-16e3-44e4-b8a8-301dad5ceccb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityVoluntaryFilers_a2e60719-16e3-44e4-b8a8-301dad5ceccb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_097f5b36-22a0-4462-9c2b-46780acc41c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityCurrentReportingStatus_097f5b36-22a0-4462-9c2b-46780acc41c9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7826db75-1b2c-4c1c-b8b1-97fc4ba64c0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityInteractiveDataCurrent_7826db75-1b2c-4c1c-b8b1-97fc4ba64c0f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b7b61c41-569b-46bb-b975-a62bf7136061" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityFilerCategory_b7b61c41-569b-46bb-b975-a62bf7136061" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_96fd80ee-e8d0-4efa-8a7b-c435d6258aef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntitySmallBusiness_96fd80ee-e8d0-4efa-8a7b-c435d6258aef" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c48d5b7a-4aec-4351-b382-b75e98356577" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityEmergingGrowthCompany_c48d5b7a-4aec-4351-b382-b75e98356577" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_7832080e-3918-4771-a047-5c16968e164a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_7832080e-3918-4771-a047-5c16968e164a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bc2cc840-bb7d-4a3b-a0a4-3d05d407f7cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityShellCompany_bc2cc840-bb7d-4a3b-a0a4-3d05d407f7cb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_030b5d16-82f3-484a-ab3d-fb4e93a4692f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityPublicFloat_030b5d16-82f3-484a-ab3d-fb4e93a4692f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dc71a592-f6e7-43f4-b5b1-698eefbe5cbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dc71a592-f6e7-43f4-b5b1-698eefbe5cbc" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e164d9db-544f-43ea-8640-05f2d379cbb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e164d9db-544f-43ea-8640-05f2d379cbb6" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_200274f3-58df-43de-a692-378d9de5a9a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityCentralIndexKey_200274f3-58df-43de-a692-378d9de5a9a6" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_74e9ba97-db4e-4e46-abdc-b4a3a32222a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_AmendmentFlag_74e9ba97-db4e-4e46-abdc-b4a3a32222a7" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e84c836a-414f-4068-a082-4be83cb93278" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentFiscalYearFocus_e84c836a-414f-4068-a082-4be83cb93278" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_35f13f65-c55d-478e-90fe-db3ef70c113b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_35f13f65-c55d-478e-90fe-db3ef70c113b" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:to="loc_us-gaap_ClassOfStockDomain_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:to="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e57aa4f6-d43c-4c5d-851a-8ba29fb732e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:to="loc_us-gaap_CommonStockMember_e57aa4f6-d43c-4c5d-851a-8ba29fb732e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0c9f3b5f-97c1-437d-aa26-25c7edf45212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:to="loc_us-gaap_SeniorNotesMember_0c9f3b5f-97c1-437d-aa26-25c7edf45212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:to="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_2f5474c7-c6db-4f01-a348-2071d8285f45_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:to="loc_dei_ExchangeDomain_2f5474c7-c6db-4f01-a348-2071d8285f45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_f8a443c9-db12-4849-a8d0-e34e9e2a3870" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:to="loc_dei_ExchangeDomain_f8a443c9-db12-4849-a8d0-e34e9e2a3870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_6ce8205f-f2d1-48dd-914b-89d071b477d7" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_f8a443c9-db12-4849-a8d0-e34e9e2a3870" xlink:to="loc_exch_XNYS_6ce8205f-f2d1-48dd-914b-89d071b477d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="iae4940ec8d744e09822cbbeadcf1adec_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6df73be1-28f6-44e3-8ccc-994584984b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6df73be1-28f6-44e3-8ccc-994584984b1c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3a656702-f094-4e92-9150-4abec5cb277d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3a656702-f094-4e92-9150-4abec5cb277d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e056628-6542-47a7-943e-4f9fe795a32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e056628-6542-47a7-943e-4f9fe795a32b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_66b2a37a-6ada-4856-9ce8-229e41eedc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_66b2a37a-6ada-4856-9ce8-229e41eedc0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_dc33c66d-bbe4-41c3-b41a-5f33aa6733cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_dc33c66d-bbe4-41c3-b41a-5f33aa6733cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dfc4912a-e16d-4b80-b563-fb8556e156a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dfc4912a-e16d-4b80-b563-fb8556e156a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_7d41f641-073f-4bca-b3e7-323e8e255e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_7d41f641-073f-4bca-b3e7-323e8e255e69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_0289902d-9ff2-422b-ab4e-d675f1dafa69" xlink:href="thc-20221231.xsd#thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_0289902d-9ff2-422b-ab4e-d675f1dafa69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f3a02b90-a7d1-48d9-b05d-31cc030be9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f3a02b90-a7d1-48d9-b05d-31cc030be9b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d94599f3-4c01-481c-9ca6-23b29073a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d94599f3-4c01-481c-9ca6-23b29073a2d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5fa265fd-9002-4764-80f0-8c58e768b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5fa265fd-9002-4764-80f0-8c58e768b4a3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_c2c57aae-f5d8-4835-9c58-2cd4ef5ca2b8" xlink:href="thc-20221231.xsd#thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_c2c57aae-f5d8-4835-9c58-2cd4ef5ca2b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4adf2e8a-6a05-4381-b7a7-7c6fdca56093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40c9904-0d07-40b7-8bf9-edd4f8ef0a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6df73be1-28f6-44e3-8ccc-994584984b1c" xlink:to="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_181f012c-fe46-4f60-b829-438a90dd8a30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:to="loc_us-gaap_EquityComponentDomain_181f012c-fe46-4f60-b829-438a90dd8a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:to="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95f1b25e-3d6c-4788-a4a8-adaa64e61e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_CommonStockMember_95f1b25e-3d6c-4788-a4a8-adaa64e61e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c835fdf8-73a7-461a-9726-a4c0ef848ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c835fdf8-73a7-461a-9726-a4c0ef848ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89962624-af91-478d-a840-4a51142a78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89962624-af91-478d-a840-4a51142a78c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d73827ee-fa0d-43a6-bcdd-6bedba488aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_RetainedEarningsMember_d73827ee-fa0d-43a6-bcdd-6bedba488aa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_bfd25d76-0a5d-47d4-aff2-cfbaa00bbf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_TreasuryStockCommonMember_bfd25d76-0a5d-47d4-aff2-cfbaa00bbf19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f7645b0a-5565-44fb-92d5-565fe58a3e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f7645b0a-5565-44fb-92d5-565fe58a3e53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_36d702a4-7017-4d7f-93cd-2d7c7d108f29_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_36d702a4-7017-4d7f-93cd-2d7c7d108f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4dd1af8-94e1-40cc-9518-36d4da84389a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4dd1af8-94e1-40cc-9518-36d4da84389a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_24887111-7fc3-42ce-b212-2ad33ef9182e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4dd1af8-94e1-40cc-9518-36d4da84389a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_24887111-7fc3-42ce-b212-2ad33ef9182e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails" xlink:type="extended" id="iac2521128b5845948484e220e3bdbc85_SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_3dc579c1-32e3-4ee8-810b-fca620b127e5" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_3dc579c1-32e3-4ee8-810b-fca620b127e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_ea8b3577-bb19-4ea1-924f-3241b557f8cc" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_ea8b3577-bb19-4ea1-924f-3241b557f8cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsOperated_8496aaa7-1ac0-48c0-a9e4-eaecc15d1512" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsOperated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfHospitalsOperated_8496aaa7-1ac0-48c0-a9e4-eaecc15d1512" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientFacilitiesOperated_7961c09a-f0de-4394-b332-77c2835a9066" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientFacilitiesOperated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfOutpatientFacilitiesOperated_7961c09a-f0de-4394-b332-77c2835a9066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1d2e204a-34c1-478e-a3ee-a65de1ed73dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1d2e204a-34c1-478e-a3ee-a65de1ed73dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_fa4b5b73-8f35-486c-9bcd-1d43c21f2d5d" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_fa4b5b73-8f35-486c-9bcd-1d43c21f2d5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85d2fde5-8ab1-4824-b6e2-1ea9fe319238_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85d2fde5-8ab1-4824-b6e2-1ea9fe319238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_567e7135-ab8f-485f-94b4-a80c914d678e" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_567e7135-ab8f-485f-94b4-a80c914d678e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_32a8785c-fef5-4a28-9de9-b9922d04d5d3" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_32a8785c-fef5-4a28-9de9-b9922d04d5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:to="loc_srt_OwnershipDomain_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:to="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_a014ffd6-eb70-4694-81e0-6b07cbcec11e" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_a014ffd6-eb70-4694-81e0-6b07cbcec11e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferHealthSolutionsLLCMember_afcaf025-07ed-481e-b28c-25f0f0f16b94" xlink:href="thc-20221231.xsd#thc_ConiferHealthSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:to="loc_thc_ConiferHealthSolutionsLLCMember_afcaf025-07ed-481e-b28c-25f0f0f16b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9e80e1aa-e571-4174-afc3-95936390e5f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:to="loc_us-gaap_SegmentDomain_9e80e1aa-e571-4174-afc3-95936390e5f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:to="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_a946bcd0-a493-4bba-b743-2059a286dd44" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:to="loc_thc_AmbulatoryCareMember_a946bcd0-a493-4bba-b743-2059a286dd44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember_858f1de9-7493-4fb1-8cad-78ef8bb611c3" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:to="loc_thc_HospitalOperationsSegmentMember_858f1de9-7493-4fb1-8cad-78ef8bb611c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" xlink:type="extended" id="i8c4232819e69458eac3913dea2c49ae4_SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40a7d402-c8b0-4d47-8399-6fd465d27567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40a7d402-c8b0-4d47-8399-6fd465d27567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aa5ea237-f025-4790-ab8d-33b6a9af008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aa5ea237-f025-4790-ab8d-33b6a9af008b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0ae6919-8b2b-45f3-996a-d3b412534f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0ae6919-8b2b-45f3-996a-d3b412534f69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1e722f29-e0b3-41f3-91eb-03576382fce8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1e722f29-e0b3-41f3-91eb-03576382fce8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6e9caa32-f6f0-41ca-83f9-17bb15e27f83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6e9caa32-f6f0-41ca-83f9-17bb15e27f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_183532fd-a3dc-4979-9c21-ee41fda58b8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6e9caa32-f6f0-41ca-83f9-17bb15e27f83" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_183532fd-a3dc-4979-9c21-ee41fda58b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_9aa9e760-b934-4aa8-85a0-7feb16168698_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:to="loc_us-gaap_TypeOfAdoptionMember_9aa9e760-b934-4aa8-85a0-7feb16168698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_0ceeebd0-efaf-48f3-b24a-66c424c9fe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_0ceeebd0-efaf-48f3-b24a-66c424c9fe75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_d58b5d13-f8d0-4d00-a133-74e3fcaf05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_d58b5d13-f8d0-4d00-a133-74e3fcaf05f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails" xlink:type="extended" id="i340cc743778d44c09e89bc16242556c3_SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7a38a449-0983-43d7-b261-ca9fb528c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7a38a449-0983-43d7-b261-ca9fb528c800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_f7c8ae55-09c1-4769-a79d-84225e3560f8" xlink:href="thc-20221231.xsd#thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_f7c8ae55-09c1-4769-a79d-84225e3560f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_f7dd535f-026a-4e14-bd09-d3524f630da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_f7dd535f-026a-4e14-bd09-d3524f630da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_8bc82ca3-251b-41dd-8b59-34bf5d19f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_DeferredRevenue_8bc82ca3-251b-41dd-8b59-34bf5d19f498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_690b0f94-ad3f-436c-9e53-56bd0462c05f" xlink:href="thc-20221231.xsd#thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_690b0f94-ad3f-436c-9e53-56bd0462c05f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4333e345-0716-4ec0-9627-70b9567d2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4333e345-0716-4ec0-9627-70b9567d2d71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_c794ad5f-04f2-43ef-bd1a-dee347b8bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_c794ad5f-04f2-43ef-bd1a-dee347b8bcc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_05b0d318-a429-434f-b434-d9cd4f5b472a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_05b0d318-a429-434f-b434-d9cd4f5b472a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EquityMethodInvestmentCashManagedAffiliatesMember_563d3db1-a9c3-48db-8af2-9a663d43bd04" xlink:href="thc-20221231.xsd#thc_EquityMethodInvestmentCashManagedAffiliatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:to="loc_thc_EquityMethodInvestmentCashManagedAffiliatesMember_563d3db1-a9c3-48db-8af2-9a663d43bd04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_301bac71-50f5-4dcb-9e18-36a1cf4983b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_301bac71-50f5-4dcb-9e18-36a1cf4983b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5a67d061-be1c-4ed8-a768-bca97bc91526_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:to="loc_us-gaap_SegmentDomain_5a67d061-be1c-4ed8-a768-bca97bc91526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:to="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember_ac67b6da-c5c2-42d9-920c-5666ea1d2b27" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:to="loc_thc_HospitalOperationsSegmentMember_ac67b6da-c5c2-42d9-920c-5666ea1d2b27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_da80d14d-14f7-4b5c-a0b0-5547de35a4d8" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:to="loc_thc_AmbulatoryCareMember_da80d14d-14f7-4b5c-a0b0-5547de35a4d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsAndAmbulatoryCareMember_93a508f3-2558-4451-87a5-015af1f4ad0a" xlink:href="thc-20221231.xsd#thc_HospitalOperationsAndAmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:to="loc_thc_HospitalOperationsAndAmbulatoryCareMember_93a508f3-2558-4451-87a5-015af1f4ad0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_196b003f-3494-4f61-b3d7-d7f5d25297fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_196b003f-3494-4f61-b3d7-d7f5d25297fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AccruedCompensationAndBenefitsMember_bee1bd15-fb5d-476d-835d-73c4a97021f9" xlink:href="thc-20221231.xsd#thc_AccruedCompensationAndBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_196b003f-3494-4f61-b3d7-d7f5d25297fe" xlink:to="loc_thc_AccruedCompensationAndBenefitsMember_bee1bd15-fb5d-476d-835d-73c4a97021f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended" id="if9da87cc401d4c90877c00734808ea8c_SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36697c74-f8f1-460a-9224-375dc0dd1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36697c74-f8f1-460a-9224-375dc0dd1bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankOverdrafts_43c6a7aa-ef95-4e3f-ade5-64e051c730c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_BankOverdrafts_43c6a7aa-ef95-4e3f-ade5-64e051c730c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e3ec4240-a026-4553-ab16-97d6702f40fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e3ec4240-a026-4553-ab16-97d6702f40fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_JointVentureOwnershipPercentage_f63b9e47-6bbb-43a7-91c1-36c77ff6a9f9" xlink:href="thc-20221231.xsd#thc_JointVentureOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_thc_JointVentureOwnershipPercentage_f63b9e47-6bbb-43a7-91c1-36c77ff6a9f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementPaymentForExecution_b666274e-69da-4a43-b6e5-d1acf3cc3890" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementPaymentForExecution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_thc_SharePurchaseAgreementPaymentForExecution_b666274e-69da-4a43-b6e5-d1acf3cc3890" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ec8f1cf2-5456-4569-91e9-9d8484be6930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_NotesPayable_ec8f1cf2-5456-4569-91e9-9d8484be6930" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_9f543292-c808-4a9d-a1c2-53f2e41e0a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_9f543292-c808-4a9d-a1c2-53f2e41e0a68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_254be143-0967-4492-bd85-432ce2c01c51" xlink:href="thc-20221231.xsd#thc_GainLossFromPurchaseOfNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_254be143-0967-4492-bd85-432ce2c01c51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8aefefc3-cad8-4d3e-9928-126814fb4856_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8aefefc3-cad8-4d3e-9928-126814fb4856_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ec6e2f4a-3f69-488b-a637-fcba1e8958fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ec6e2f4a-3f69-488b-a637-fcba1e8958fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_02a3c50d-d04d-41eb-95d9-da13d97400d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6e2f4a-3f69-488b-a637-fcba1e8958fe" xlink:to="loc_us-gaap_AccountsPayableMember_02a3c50d-d04d-41eb-95d9-da13d97400d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d2c188ad-983c-4038-a558-7a093871997b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:to="loc_dei_EntityDomain_d2c188ad-983c-4038-a558-7a093871997b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_afbaeeb2-9d55-43d3-aca7-89fa755912f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:to="loc_dei_EntityDomain_afbaeeb2-9d55-43d3-aca7-89fa755912f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaptiveInsuranceSubsidiariesMember_6a8c9967-36cc-401d-bd50-fa694603eeac" xlink:href="thc-20221231.xsd#thc_CaptiveInsuranceSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_afbaeeb2-9d55-43d3-aca7-89fa755912f1" xlink:to="loc_thc_CaptiveInsuranceSubsidiariesMember_6a8c9967-36cc-401d-bd50-fa694603eeac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ec27180-a3f9-4a39-88df-900abbf21812_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ec27180-a3f9-4a39-88df-900abbf21812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ecc4f16-c603-4a6b-b299-8d6c41d2a613" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ecc4f16-c603-4a6b-b299-8d6c41d2a613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_2b7dd2c0-ffce-4c62-9bdd-16d351a58516" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ecc4f16-c603-4a6b-b299-8d6c41d2a613" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_2b7dd2c0-ffce-4c62-9bdd-16d351a58516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_53a0ee44-3ad5-460d-ab14-4d48c4196f1c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:to="loc_srt_OwnershipDomain_53a0ee44-3ad5-460d-ab14-4d48c4196f1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ea53e2c0-20b3-4bd9-99ca-7079cefd1f99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:to="loc_srt_OwnershipDomain_ea53e2c0-20b3-4bd9-99ca-7079cefd1f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_a5eb07eb-a80c-4bdd-b5fb-d93ccc3104e6" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ea53e2c0-20b3-4bd9-99ca-7079cefd1f99" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_a5eb07eb-a80c-4bdd-b5fb-d93ccc3104e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_acca1937-7c8a-4114-982f-51012334bc61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_acca1937-7c8a-4114-982f-51012334bc61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_6f43ab37-d5f5-49d9-9f6c-8e25f9a8a32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_6f43ab37-d5f5-49d9-9f6c-8e25f9a8a32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_a1388415-de88-45a5-a7db-4f6b8f3b1c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_6f43ab37-d5f5-49d9-9f6c-8e25f9a8a32f" xlink:to="loc_us-gaap_PutOptionMember_a1388415-de88-45a5-a7db-4f6b8f3b1c9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails" xlink:type="extended" id="i3e8390ea218c4baf9e1e78096ba3616b_SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_f4b3f853-ba1b-4c29-b186-eb60391a20ff" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_f4b3f853-ba1b-4c29-b186-eb60391a20ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_63a6abf9-c7bf-4276-81f5-0762c2a577cc" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_63a6abf9-c7bf-4276-81f5-0762c2a577cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersAndHospitals_8cea0c82-7da5-4097-8a15-55fdf1e1d095" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersAndHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NumberOfSurgicalCentersAndHospitals_8cea0c82-7da5-4097-8a15-55fdf1e1d095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_d375f29f-4d83-4946-911f-e7dc0c3aa812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_d375f29f-4d83-4946-911f-e7dc0c3aa812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PercentageInvesteeResultsReflected_125c8afa-c9da-4cb7-884a-18f5c2d7ccd9" xlink:href="thc-20221231.xsd#thc_PercentageInvesteeResultsReflected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_PercentageInvesteeResultsReflected_125c8afa-c9da-4cb7-884a-18f5c2d7ccd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0ae83aee-1d2f-4682-b6f6-73bf1add39ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_AssetsCurrent_0ae83aee-1d2f-4682-b6f6-73bf1add39ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_4719bdec-8fc8-43e5-8041-03f7bbc83d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_AssetsNoncurrent_4719bdec-8fc8-43e5-8041-03f7bbc83d7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dc44a887-16d6-4809-9a1c-149d697a0b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_LiabilitiesCurrent_dc44a887-16d6-4809-9a1c-149d697a0b8f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b2b7c66b-01ee-4341-9ad1-f6d6bc84be46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b2b7c66b-01ee-4341-9ad1-f6d6bc84be46" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_089ffcc3-41f2-4410-94c4-62229b75f5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_MinorityInterest_089ffcc3-41f2-4410-94c4-62229b75f5a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7a6afa5-5e60-4dd9-81bd-51ccfa7dcdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7a6afa5-5e60-4dd9-81bd-51ccfa7dcdd1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_90926d3f-30f2-4f16-ba9b-ef1e6ee8d2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_ProfitLoss_90926d3f-30f2-4f16-ba9b-ef1e6ee8d2c0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetIncomeLossAttributableToInvestee_dd9ecb08-f352-4e61-aeb3-ec57f35eb557" xlink:href="thc-20221231.xsd#thc_NetIncomeLossAttributableToInvestee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NetIncomeLossAttributableToInvestee_dd9ecb08-f352-4e61-aeb3-ec57f35eb557" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ca718d71-b31a-438d-b93c-173f8ce64e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ca718d71-b31a-438d-b93c-173f8ce64e60" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30dedc88-2ae4-46b7-8fbd-29e65f283632_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:to="loc_us-gaap_SegmentDomain_30dedc88-2ae4-46b7-8fbd-29e65f283632_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bbac8ade-3ea9-4213-b57a-a8350d7f05fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:to="loc_us-gaap_SegmentDomain_bbac8ade-3ea9-4213-b57a-a8350d7f05fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_5ca7a69f-fea7-4980-bd77-96b82c2f1f70" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bbac8ade-3ea9-4213-b57a-a8350d7f05fb" xlink:to="loc_thc_AmbulatoryCareMember_5ca7a69f-fea7-4980-bd77-96b82c2f1f70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5c44327a-9cb6-49e9-8194-bd0e892d72c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5c44327a-9cb6-49e9-8194-bd0e892d72c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1dd71b81-7b46-4df3-84cd-1c30ab27bf25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1dd71b81-7b46-4df3-84cd-1c30ab27bf25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TexasHealthVenturesGroupLlcMember_d9bd67c7-6a78-41dc-9e49-f522930fe67a" xlink:href="thc-20221231.xsd#thc_TexasHealthVenturesGroupLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1dd71b81-7b46-4df3-84cd-1c30ab27bf25" xlink:to="loc_thc_TexasHealthVenturesGroupLlcMember_d9bd67c7-6a78-41dc-9e49-f522930fe67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0be6aa24-df6d-41d5-9113-c60b7b410074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0be6aa24-df6d-41d5-9113-c60b7b410074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_8ca28417-0425-430d-8dc8-91f8f4f89a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_8ca28417-0425-430d-8dc8-91f8f4f89a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_157a8f62-7b99-4fc2-8516-0bf762e5dada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_8ca28417-0425-430d-8dc8-91f8f4f89a49" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_157a8f62-7b99-4fc2-8516-0bf762e5dada" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended" id="i6039c4a8f4bb472fb45f98cd7f9951bb_SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3c7c860-cdde-4dec-bc73-af05f4b8868c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3c7c860-cdde-4dec-bc73-af05f4b8868c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_7ea7a318-09af-42c1-b13f-b335b27ba1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:to="loc_us-gaap_InterestCostsCapitalized_7ea7a318-09af-42c1-b13f-b335b27ba1ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff048ed8-ac46-45c6-b1b3-326476a163be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff048ed8-ac46-45c6-b1b3-326476a163be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_e37ccab5-1464-423d-99e6-141e28f56abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_e37ccab5-1464-423d-99e6-141e28f56abf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a82b9e57-2c46-4fc9-bdb9-5ba2dbbd6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_us-gaap_EquipmentMember_a82b9e57-2c46-4fc9-bdb9-5ba2dbbd6db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NewlyConstructedHospitalsMember_ab04a505-45c6-4d98-9024-e897b5bcd3e2" xlink:href="thc-20221231.xsd#thc_NewlyConstructedHospitalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_thc_NewlyConstructedHospitalsMember_ab04a505-45c6-4d98-9024-e897b5bcd3e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_88d004c0-e7cd-4b55-bd5e-890d3d8bf257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_us-gaap_ConstructionInProgressMember_88d004c0-e7cd-4b55-bd5e-890d3d8bf257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:to="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98f92b42-a704-4ce3-b697-f45f6002c9ee_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:to="loc_srt_RangeMember_98f92b42-a704-4ce3-b697-f45f6002c9ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:to="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b01dc84a-a436-4129-a272-85da93cd3ce9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:to="loc_srt_MinimumMember_b01dc84a-a436-4129-a272-85da93cd3ce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8eaf1c07-3f7e-4f6b-86d6-87d06d4d64aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:to="loc_srt_MaximumMember_8eaf1c07-3f7e-4f6b-86d6-87d06d4d64aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended" id="ifa7e5d8a62d6463595af4143c04043ae_SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_be4f01ca-6f0f-4f90-b142-2d6833c63aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_be4f01ca-6f0f-4f90-b142-2d6833c63aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeOperatingLeaseNumberOfRenewalOptions_34997266-3705-411d-b01f-2829f9113b06" xlink:href="thc-20221231.xsd#thc_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_thc_LesseeOperatingLeaseNumberOfRenewalOptions_34997266-3705-411d-b01f-2829f9113b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de3e321d-6659-4b04-9739-0e19a1aab0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de3e321d-6659-4b04-9739-0e19a1aab0ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_01c4aef4-3c39-495d-a5d9-180905f49adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_01c4aef4-3c39-495d-a5d9-180905f49adc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b84aeebb-53bb-409f-b385-229c50d390ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b84aeebb-53bb-409f-b385-229c50d390ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndBuildingMember_e0eaf35a-e814-44e7-ae82-076cd574a7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_us-gaap_LandAndBuildingMember_e0eaf35a-e814-44e7-ae82-076cd574a7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_262b9f7e-fa7a-409f-813f-fd15aa1c22f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_us-gaap_EquipmentMember_262b9f7e-fa7a-409f-813f-fd15aa1c22f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MedicalEquipmentMember_b046a14d-9d3d-4b3a-887c-9fb09463e133" xlink:href="thc-20221231.xsd#thc_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_thc_MedicalEquipmentMember_b046a14d-9d3d-4b3a-887c-9fb09463e133" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ComputerAndTelecommunicationEquipmentMember_7f31343f-8694-4c81-ae64-f6713bf4fb97" xlink:href="thc-20221231.xsd#thc_ComputerAndTelecommunicationEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_thc_ComputerAndTelecommunicationEquipmentMember_7f31343f-8694-4c81-ae64-f6713bf4fb97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:to="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0323cc08-6c0a-4bfc-a6b8-6a04b109f980_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:to="loc_srt_RangeMember_0323cc08-6c0a-4bfc-a6b8-6a04b109f980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:to="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_330fd5e0-9df3-47a7-9978-f224d213298f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:to="loc_srt_MinimumMember_330fd5e0-9df3-47a7-9978-f224d213298f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5bc6130c-c8f3-40da-92c4-14e0881bc0c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:to="loc_srt_MaximumMember_5bc6130c-c8f3-40da-92c4-14e0881bc0c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended" id="ic5ee2d4d5d7641dba26c057208c7fc2a_SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ba135ceb-df14-41a3-a2bf-700177f99ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_05a5df19-f831-41ed-824a-5e3c558c7070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ba135ceb-df14-41a3-a2bf-700177f99ba9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_05a5df19-f831-41ed-824a-5e3c558c7070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ba135ceb-df14-41a3-a2bf-700177f99ba9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_468113fd-bad1-4150-802e-8c5660989e15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_468113fd-bad1-4150-802e-8c5660989e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a00495c-c332-4035-80e8-a374de3da342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a00495c-c332-4035-80e8-a374de3da342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ac46e334-de8a-4dd4-84cd-88b1f33f8561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a00495c-c332-4035-80e8-a374de3da342" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ac46e334-de8a-4dd4-84cd-88b1f33f8561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:to="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4dbf2711-eb4b-4279-8842-0f83b25ff685_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:to="loc_srt_RangeMember_4dbf2711-eb4b-4279-8842-0f83b25ff685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:to="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3377f5f8-f656-4f17-b29b-bb98e076e3a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:to="loc_srt_MinimumMember_3377f5f8-f656-4f17-b29b-bb98e076e3a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c5cc73f-55a3-4354-916c-f15f52af8162" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:to="loc_srt_MaximumMember_0c5cc73f-55a3-4354-916c-f15f52af8162" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EQUITYNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails" xlink:type="extended" id="ifacf024ecd1e4e14b64997070f3dfafc_EQUITYNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa0ce773-38d0-4145-bf56-56576b21d325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa0ce773-38d0-4145-bf56-56576b21d325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8459065c-bea3-4932-b6a8-8780e93c6020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8459065c-bea3-4932-b6a8-8780e93c6020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:to="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ad6bccc-313b-400b-9394-107a214bdd0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:to="loc_us-gaap_EquityComponentDomain_5ad6bccc-313b-400b-9394-107a214bdd0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ceeacb79-ca59-49cb-8a37-f8a0fbedfef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:to="loc_us-gaap_EquityComponentDomain_ceeacb79-ca59-49cb-8a37-f8a0fbedfef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4702361d-b917-46a6-ad8d-c57643f941f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ceeacb79-ca59-49cb-8a37-f8a0fbedfef1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4702361d-b917-46a6-ad8d-c57643f941f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_88fdafbc-85d1-4dff-a79c-637951ca7d12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:to="loc_us-gaap_SegmentDomain_88fdafbc-85d1-4dff-a79c-637951ca7d12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:to="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_c038deb2-5c1c-4fc8-9993-1ac81d5e4b3d" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:to="loc_thc_HospitalOperationsMember_c038deb2-5c1c-4fc8-9993-1ac81d5e4b3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_00a833ff-382c-4a58-bcd1-56f4a025c85e" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:to="loc_thc_AmbulatoryCareMember_00a833ff-382c-4a58-bcd1-56f4a025c85e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails" xlink:type="extended" id="i4653a4ff889e4b69b41ec19f5f7994e5_ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:to="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a32c2a2b-aaa9-498c-8522-d717111135bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a32c2a2b-aaa9-498c-8522-d717111135bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_11f45025-d692-40ba-bc5a-0a99a6123151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_11f45025-d692-40ba-bc5a-0a99a6123151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:to="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4e23aeff-30fe-4ab6-89e0-731036f7de86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:to="loc_us-gaap_AccountsPayableCurrent_4e23aeff-30fe-4ab6-89e0-731036f7de86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a0a38043-6fce-4a02-a22b-ecf15f126d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a0a38043-6fce-4a02-a22b-ecf15f126d70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_70da8c78-c793-447b-9a0f-87eb04df2c4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:to="loc_us-gaap_ReceivableTypeDomain_70da8c78-c793-447b-9a0f-87eb04df2c4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_64d574ef-85e1-4a98-b147-b6baca125e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:to="loc_us-gaap_ReceivableTypeDomain_64d574ef-85e1-4a98-b147-b6baca125e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaProviderFeeProgramMember_c1174602-c31a-45ff-b1ad-6fce169223ed" xlink:href="thc-20221231.xsd#thc_CaliforniaProviderFeeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_64d574ef-85e1-4a98-b147-b6baca125e29" xlink:to="loc_thc_CaliforniaProviderFeeProgramMember_c1174602-c31a-45ff-b1ad-6fce169223ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0ec178fe-a39b-4f4f-b92e-3027fce823dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0ec178fe-a39b-4f4f-b92e-3027fce823dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7528b817-c924-47d7-9020-aede959e82a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7528b817-c924-47d7-9020-aede959e82a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_37574417-5e6f-49ea-a325-419d86c102ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherAssetsMember_37574417-5e6f-49ea-a325-419d86c102ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3c3102d9-33cf-4138-a97e-2857b2017dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3c3102d9-33cf-4138-a97e-2857b2017dfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_3123ca41-2c37-4374-8883-f1f41850741d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_3123ca41-2c37-4374-8883-f1f41850741d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLEAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails" xlink:type="extended" id="ia6778c7177cc477da6d82ceb24eafe7d_ACCOUNTSRECEIVABLEAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d5fb7ce-4358-4d1e-aeb0-f2fccbbac869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationHealthCareCostsGross_ae46c78d-38f4-4a71-96f8-671a759633d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d5fb7ce-4358-4d1e-aeb0-f2fccbbac869" xlink:to="loc_us-gaap_HealthCareOrganizationHealthCareCostsGross_ae46c78d-38f4-4a71-96f8-671a759633d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d5fb7ce-4358-4d1e-aeb0-f2fccbbac869" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_c11698cf-bdd2-43b6-926c-0912f8206f55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:to="loc_us-gaap_ReceivableTypeDomain_c11698cf-bdd2-43b6-926c-0912f8206f55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:to="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SelfPayPatientsMember_28c2e8c8-bf16-42a1-bb66-0f99502a54bd" xlink:href="thc-20221231.xsd#thc_SelfPayPatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:to="loc_thc_SelfPayPatientsMember_28c2e8c8-bf16-42a1-bb66-0f99502a54bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CharityCarePatientsMember_e0b3357e-b42d-42f3-a285-b808c4e88113" xlink:href="thc-20221231.xsd#thc_CharityCarePatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:to="loc_thc_CharityCarePatientsMember_e0b3357e-b42d-42f3-a285-b808c4e88113" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails" xlink:type="extended" id="i11d4ac1187a4458d96f202493763ff7c_CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_715d6ac2-25ad-4202-9462-4f37e3a9c873" xlink:href="thc-20221231.xsd#thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_715d6ac2-25ad-4202-9462-4f37e3a9c873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_317e132d-c423-4ada-871a-b3ad4d632271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_317e132d-c423-4ada-871a-b3ad4d632271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_87f7eeb4-7153-4e8d-967d-0c7b1dcfcb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_210a759f-e051-4f4a-b75b-98cb1ef28674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_210a759f-e051-4f4a-b75b-98cb1ef28674" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_996b0793-ffb5-4a77-905d-315995ca6460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_996b0793-ffb5-4a77-905d-315995ca6460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca2b96af-a52d-4e12-9ca3-57c10eb9376b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c578464d-dae2-4bda-8b63-71539243ed29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c578464d-dae2-4bda-8b63-71539243ed29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f32b64ae-44bf-408d-aec2-14bcc6600546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f32b64ae-44bf-408d-aec2-14bcc6600546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_863af800-cc51-44e5-8f26-740e0d605dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9c523a68-7a41-4cf6-a089-bcfc1e2ed8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8de5f272-8919-4162-a116-3c2de85e2273_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:to="loc_us-gaap_SegmentDomain_8de5f272-8919-4162-a116-3c2de85e2273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:to="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsAndOtherMember_1cb2688c-c43e-4d92-bab2-f34af2b7b205" xlink:href="thc-20221231.xsd#thc_HospitalOperationsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:to="loc_thc_HospitalOperationsAndOtherMember_1cb2688c-c43e-4d92-bab2-f34af2b7b205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_fad6018d-aaf9-43e3-ad2a-1af24517c14d" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:to="loc_thc_AmbulatoryCareMember_fad6018d-aaf9-43e3-ad2a-1af24517c14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_55244e27-e928-4141-8de6-620228a282ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_55244e27-e928-4141-8de6-620228a282ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember_9e50bf23-13b0-4ab0-8ee5-fba46f817270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:to="loc_us-gaap_ShortTermContractWithCustomerMember_9e50bf23-13b0-4ab0-8ee5-fba46f817270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember_2942a23c-c535-43f3-b3cd-a5ffd3786459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:to="loc_us-gaap_LongTermContractWithCustomerMember_2942a23c-c535-43f3-b3cd-a5ffd3786459" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCESConiferSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails" xlink:type="extended" id="i1d2b564423ce4e1aaa77d9327dea93d6_CONTRACTBALANCESConiferSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerAssetNetCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_282359dc-2dc1-43f3-a899-92c8ef043213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_282359dc-2dc1-43f3-a899-92c8ef043213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_bcff5114-fcfe-4d8d-9dfc-8439ab18c3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncreaseDecreaseInContractWithCustomerReceivable_69a2a8ef-c1c7-4013-9733-28ebd2e33fa4" xlink:href="thc-20221231.xsd#thc_IncreaseDecreaseInContractWithCustomerReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:to="loc_thc_IncreaseDecreaseInContractWithCustomerReceivable_69a2a8ef-c1c7-4013-9733-28ebd2e33fa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dd3142cc-3c5d-4c7b-b0fa-017eb8442624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dd3142cc-3c5d-4c7b-b0fa-017eb8442624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b7c0c6df-5430-48c7-89a6-864f21b5e0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6a1421f1-a72d-4dff-9664-86b769c33652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6a1421f1-a72d-4dff-9664-86b769c33652" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd0dc900-135b-4a5c-aac7-27deaaabb98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd0dc900-135b-4a5c-aac7-27deaaabb98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6bf90c68-80f7-4df3-8ec1-75e32744abdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9e7367f4-abad-4088-8563-dddde6115f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9e7367f4-abad-4088-8563-dddde6115f8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2e50e8b2-d783-47b2-a48f-602badc61314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2e50e8b2-d783-47b2-a48f-602badc61314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3bfdf4d-3f82-4392-96ac-5d4d0639e239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_75b1fab8-b77b-429e-862a-e39d021ae14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4ddab808-a51d-4554-a011-94127ff47819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4ddab808-a51d-4554-a011-94127ff47819" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0018dd6f-100e-4896-a905-a735daf0aa6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:to="loc_us-gaap_SegmentDomain_0018dd6f-100e-4896-a905-a735daf0aa6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93fb1829-a212-4a42-b496-647fda5790a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:to="loc_us-gaap_SegmentDomain_93fb1829-a212-4a42-b496-647fda5790a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_3d6cc060-998d-4b2b-80cf-1bbdee367356" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93fb1829-a212-4a42-b496-647fda5790a2" xlink:to="loc_thc_ConiferSegmentMember_3d6cc060-998d-4b2b-80cf-1bbdee367356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_1bc7e557-a823-43ed-9644-6945e48eaa3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_1bc7e557-a823-43ed-9644-6945e48eaa3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember_34a0372c-3cea-421f-bf49-cb1017e656cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:to="loc_us-gaap_ShortTermContractWithCustomerMember_34a0372c-3cea-421f-bf49-cb1017e656cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember_7a0f6ca2-1b5f-4de7-8b62-b3babf5a929d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:to="loc_us-gaap_LongTermContractWithCustomerMember_7a0f6ca2-1b5f-4de7-8b62-b3babf5a929d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ASSETSANDLIABILITIESHELDFORSALENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails" xlink:type="extended" id="i73ef08140cab481ab8f243d7829ddbd5_ASSETSANDLIABILITIESHELDFORSALENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsForSale_ce127bb3-be20-4914-9984-1d0fe0ca7fa8" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_thc_NumberOfHospitalsForSale_ce127bb3-be20-4914-9984-1d0fe0ca7fa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties_1aee10ee-3855-4b3c-a326-1088e3fba465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_us-gaap_GainLossOnSaleOfProperties_1aee10ee-3855-4b3c-a326-1088e3fba465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_af85e75d-ba22-47ab-83ca-867db5b95f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_us-gaap_AssetImpairmentCharges_af85e75d-ba22-47ab-83ca-867db5b95f99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MiamiAreaHospitalsMember_604b7770-36c2-4e3a-9d88-1c3047e6c87e" xlink:href="thc-20221231.xsd#thc_MiamiAreaHospitalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:to="loc_thc_MiamiAreaHospitalsMember_604b7770-36c2-4e3a-9d88-1c3047e6c87e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UrgentCareCentersMember_2fe2b035-b3f7-40c0-ba56-a3d2d0695803" xlink:href="thc-20221231.xsd#thc_UrgentCareCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:to="loc_thc_UrgentCareCentersMember_2fe2b035-b3f7-40c0-ba56-a3d2d0695803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhiladelphiaBuildingMember_6b2f0e5f-c0cc-406a-9a8c-e72f7302a13b" xlink:href="thc-20221231.xsd#thc_PhiladelphiaBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:to="loc_thc_PhiladelphiaBuildingMember_6b2f0e5f-c0cc-406a-9a8c-e72f7302a13b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f71a205e-a633-4ab1-9f55-e770d20d1871_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f71a205e-a633-4ab1-9f55-e770d20d1871_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4a37ee8-2184-4462-9975-e2c533f4e490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4a37ee8-2184-4462-9975-e2c533f4e490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e7fd63e4-83c4-4a35-949b-4032f07b675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e7fd63e4-83c4-4a35-949b-4032f07b675c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails" xlink:type="extended" id="ic991c7ae4f3e4610bea9e00b0f086104_ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_94530bdd-8b88-478e-b36e-9ed26adc56cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_94530bdd-8b88-478e-b36e-9ed26adc56cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties_d3970a1b-efdb-4bf3-b826-9281adec9daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:to="loc_us-gaap_GainLossOnSaleOfProperties_d3970a1b-efdb-4bf3-b826-9281adec9daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8cf34503-95d6-4b30-935d-7417ac5a52ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8cf34503-95d6-4b30-935d-7417ac5a52ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_44e1ec95-e05d-4a13-bdfa-30d752558513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_44e1ec95-e05d-4a13-bdfa-30d752558513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MiamiAreaHospitalsMember_be132ae5-9352-4094-b7b4-e254bdfe1314" xlink:href="thc-20221231.xsd#thc_MiamiAreaHospitalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_44e1ec95-e05d-4a13-bdfa-30d752558513" xlink:to="loc_thc_MiamiAreaHospitalsMember_be132ae5-9352-4094-b7b4-e254bdfe1314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_12cab580-3d90-4238-82fe-78c0c43e92fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_12cab580-3d90-4238-82fe-78c0c43e92fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ad6bcebf-8853-4ece-ba07-383626ab9746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ad6bcebf-8853-4ece-ba07-383626ab9746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_65f9a6a9-fba0-4382-ba27-79f0f83e7595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ad6bcebf-8853-4ece-ba07-383626ab9746" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_65f9a6a9-fba0-4382-ba27-79f0f83e7595" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails" xlink:type="extended" id="if25d18b997f34434b3644d5c3daa7b78_IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2051da6a-7616-4111-983b-41404287a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_NumberOfReportableSegments_2051da6a-7616-4111-983b-41404287a84b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_3f5e2fd2-c631-46f9-aa0c-03e55861fd87" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_3f5e2fd2-c631-46f9-aa0c-03e55861fd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_c4e3a3b6-fd78-4ec6-b367-f6700168460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_RestructuringCosts_c4e3a3b6-fd78-4ec6-b367-f6700168460d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_33ed76a6-c8b4-4b8f-9015-df5894376cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_AssetImpairmentCharges_33ed76a6-c8b4-4b8f-9015-df5894376cab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6416d8cb-9fd3-4f06-aad0-08cd3be80096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6416d8cb-9fd3-4f06-aad0-08cd3be80096" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_12dfbb97-bf34-4457-9064-5fd5ec80cf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_AssetsNoncurrent_12dfbb97-bf34-4457-9064-5fd5ec80cf7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_fa5e0302-9e02-4764-801f-f2df185373c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_fa5e0302-9e02-4764-801f-f2df185373c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_7412dcd7-7f12-41ed-91e1-cd865d358d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_BusinessExitCosts1_7412dcd7-7f12-41ed-91e1-cd865d358d67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_5bbbe00a-a24b-4304-9655-3885019c3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_OtherRestructuringCosts_5bbbe00a-a24b-4304-9655-3885019c3749" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_032aa671-89c6-40da-97d6-bf2221c6666c" xlink:href="thc-20221231.xsd#thc_BusinessCombinationAcquisitionRelatedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_032aa671-89c6-40da-97d6-bf2221c6666c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fe97525c-2538-494b-832b-2fe1c4649ed2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fe97525c-2538-494b-832b-2fe1c4649ed2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_9740a534-cae5-4c2d-a30f-48424d2f33a5" xlink:href="thc-20221231.xsd#thc_HospitalBuildingsAndMedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:to="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_9740a534-cae5-4c2d-a30f-48424d2f33a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BuildingsSubjectToImpairmentChargesMember_c51e9c6d-00f8-4bd8-bd8f-6626a77e57b7" xlink:href="thc-20221231.xsd#thc_BuildingsSubjectToImpairmentChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:to="loc_thc_BuildingsSubjectToImpairmentChargesMember_c51e9c6d-00f8-4bd8-bd8f-6626a77e57b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b9e6b529-f807-406a-8836-da7cd89bd165_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b9e6b529-f807-406a-8836-da7cd89bd165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2ff46d6d-ed54-424b-998c-86bbbd0f0536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2ff46d6d-ed54-424b-998c-86bbbd0f0536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_0f035ebc-47ec-47cd-9cfd-9c455f55adf9" xlink:href="thc-20221231.xsd#thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:to="loc_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_0f035ebc-47ec-47cd-9cfd-9c455f55adf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_USPIManagementEquityPlanMember_bbf7df28-b253-48ef-88a6-342972b6b163" xlink:href="thc-20221231.xsd#thc_USPIManagementEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:to="loc_thc_USPIManagementEquityPlanMember_bbf7df28-b253-48ef-88a6-342972b6b163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0940c5bb-fbb3-40ac-bc93-8f34e1244f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:to="loc_us-gaap_SegmentDomain_0940c5bb-fbb3-40ac-bc93-8f34e1244f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:to="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_4d233f59-9505-4ad7-af42-6119b24a9755" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:to="loc_thc_HospitalOperationsMember_4d233f59-9505-4ad7-af42-6119b24a9755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_1d262456-cca7-4ce9-8350-8fc8de8bde90" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:to="loc_thc_AmbulatoryCareMember_1d262456-cca7-4ce9-8350-8fc8de8bde90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_1a64a762-6abf-495d-bce2-e172dfcdc417" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:to="loc_thc_ConiferSegmentMember_1a64a762-6abf-495d-bce2-e172dfcdc417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63506acf-a375-4c0d-9b45-83115da5915e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63506acf-a375-4c0d-9b45-83115da5915e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827117f1-f421-4cd3-a9ea-86832851e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827117f1-f421-4cd3-a9ea-86832851e7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_08d9b377-e8c7-46e8-94ea-86728befb441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827117f1-f421-4cd3-a9ea-86832851e7ca" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_08d9b377-e8c7-46e8-94ea-86728befb441" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/LEASESNarrativeDetails" xlink:type="extended" id="iea8c185b4571462a9ccc51fd487f61e0_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_dfccdc19-19c7-4db5-bde5-a938816454f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_dfccdc19-19c7-4db5-bde5-a938816454f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties_2dcd70b7-4205-49ac-9047-df0a8f0eb6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_GainLossOnSaleOfProperties_2dcd70b7-4205-49ac-9047-df0a8f0eb6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_97c1237d-acdd-44f2-83fe-b2ac7ac67256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_97c1237d-acdd-44f2-83fe-b2ac7ac67256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e76c2efd-19b3-44bb-a586-61af2e789105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_OperatingLeaseLiability_e76c2efd-19b3-44bb-a586-61af2e789105" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:to="loc_us-gaap_SegmentDomain_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_edc049f3-6bc9-41ec-82ea-2b48eebfe2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:to="loc_us-gaap_SegmentDomain_edc049f3-6bc9-41ec-82ea-2b48eebfe2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember_93c01182-99d0-4e90-bbcd-df02c83975fa" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_edc049f3-6bc9-41ec-82ea-2b48eebfe2dd" xlink:to="loc_thc_HospitalOperationsSegmentMember_93c01182-99d0-4e90-bbcd-df02c83975fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails" xlink:type="extended" id="ic77408d2952d4ebaac967898276ee8da_LONGTERMDEBTScheduleofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aca33a63-ce4a-46bf-b0fe-1b51b7f67978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_aca33a63-ce4a-46bf-b0fe-1b51b7f67978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeasesAndMortgageNotes_05579a26-a2ae-49ac-b7ea-ff4681e430a6" xlink:href="thc-20221231.xsd#thc_FinanceLeasesAndMortgageNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_thc_FinanceLeasesAndMortgageNotes_05579a26-a2ae-49ac-b7ea-ff4681e430a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5b000d14-4806-4bb8-b307-a87f32193a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5b000d14-4806-4bb8-b307-a87f32193a01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_4e8dcaee-95ce-4295-ba7f-b1e41c060c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_4e8dcaee-95ce-4295-ba7f-b1e41c060c99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a5557e03-8d2c-456a-85bf-7b0e2ad28fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a5557e03-8d2c-456a-85bf-7b0e2ad28fe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_59cd7e40-f2d6-4762-ac77-87895eae985e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_59cd7e40-f2d6-4762-ac77-87895eae985e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8d0302e-cdec-4376-8067-fd6e5244d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8d0302e-cdec-4376-8067-fd6e5244d6ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_218b9e0c-9ec0-4abe-9e70-fe5e534889ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_218b9e0c-9ec0-4abe-9e70-fe5e534889ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2872371d-7cd4-42a7-b333-0de2b62f7206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2872371d-7cd4-42a7-b333-0de2b62f7206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a1bfa273-f152-43c8-8c4c-ce32d1364052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2872371d-7cd4-42a7-b333-0de2b62f7206" xlink:to="loc_us-gaap_SeniorNotesMember_a1bfa273-f152-43c8-8c4c-ce32d1364052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:to="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61b3604e-8c42-40a7-9cc1-32a30781b0e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61b3604e-8c42-40a7-9cc1-32a30781b0e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_9d07deaf-f781-41a9-b8a3-875e69010948" xlink:href="thc-20221231.xsd#thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_9d07deaf-f781-41a9-b8a3-875e69010948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_25a7dde7-a0c4-4eb8-ae8a-f28a2a4a5364" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_25a7dde7-a0c4-4eb8-ae8a-f28a2a4a5364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_53c8b159-c2dc-4286-895a-dd5745703630" xlink:href="thc-20221231.xsd#thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_53c8b159-c2dc-4286-895a-dd5745703630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_e880ff25-7c65-45e0-bf19-c3430317105c" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_e880ff25-7c65-45e0-bf19-c3430317105c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a0f7346a-e9ad-4ea2-b010-d812aa5d1b6d" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a0f7346a-e9ad-4ea2-b010-d812aa5d1b6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_18f708f9-684e-4758-9d9f-af66fec31ce0" xlink:href="thc-20221231.xsd#thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_18f708f9-684e-4758-9d9f-af66fec31ce0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_0d13aa86-90c8-4b9f-8739-8e84d7b674d3" xlink:href="thc-20221231.xsd#thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_0d13aa86-90c8-4b9f-8739-8e84d7b674d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_8ac6013c-2369-4ab2-88b1-175a879d7f19" xlink:href="thc-20221231.xsd#thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_8ac6013c-2369-4ab2-88b1-175a879d7f19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_0b91d60e-da48-4a91-8186-06b658c5210f" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_0b91d60e-da48-4a91-8186-06b658c5210f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_e55ca27d-d91b-4c84-8ef5-2d3ddc81f11e" xlink:href="thc-20221231.xsd#thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_e55ca27d-d91b-4c84-8ef5-2d3ddc81f11e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_4f22dee0-26fe-4a74-a62c-10ba0555184e" xlink:href="thc-20221231.xsd#thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_4f22dee0-26fe-4a74-a62c-10ba0555184e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_de5ba8af-ce94-47d7-b71f-d929766807fa" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_de5ba8af-ce94-47d7-b71f-d929766807fa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_7bf3a912-1fe3-4333-97a8-f5fb137ff307" xlink:href="thc-20221231.xsd#thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_7bf3a912-1fe3-4333-97a8-f5fb137ff307" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails" xlink:type="extended" id="iff3273f00782439e80e14add53ea5729_LONGTERMDEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7cebfecd-5714-4bec-827a-b59c920ba558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7cebfecd-5714-4bec-827a-b59c920ba558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4121804b-9015-40b0-8a19-55428f9be78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4121804b-9015-40b0-8a19-55428f9be78d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d35a7550-fc88-44bd-9415-db33d1dd60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d35a7550-fc88-44bd-9415-db33d1dd60f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4bd29d1c-0f27-40e9-a265-bb1916ca4b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4bd29d1c-0f27-40e9-a265-bb1916ca4b4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe149197-2c42-4ba7-8f1f-483db732c971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe149197-2c42-4ba7-8f1f-483db732c971" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_c21b3b77-3561-4642-9ba6-eeefb1636fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_RepaymentsOfDebt_c21b3b77-3561-4642-9ba6-eeefb1636fe0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_969450a5-bbfd-4a90-a1de-3b72017fdf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_969450a5-bbfd-4a90-a1de-3b72017fdf7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_fd5f88e5-a63d-4fc2-8755-d58c92967041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_fd5f88e5-a63d-4fc2-8755-d58c92967041" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_5a644088-fde4-45cc-ad39-6185aea08697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_5a644088-fde4-45cc-ad39-6185aea08697" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_372df8f8-bafb-48fb-b3d1-f5560e7f9358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_372df8f8-bafb-48fb-b3d1-f5560e7f9358" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_7b9c1b7b-fb80-4024-b9f3-1a3e0c4e004d" xlink:href="thc-20221231.xsd#thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_7b9c1b7b-fb80-4024-b9f3-1a3e0c4e004d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_eacdb605-54db-4bc5-b839-4cd2502cae66" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_eacdb605-54db-4bc5-b839-4cd2502cae66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_637572bf-080d-47db-b46f-f2b394e3f8a7" xlink:href="thc-20221231.xsd#thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_637572bf-080d-47db-b46f-f2b394e3f8a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_bd8261f0-c104-4ad3-89eb-b0702fe23f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_bd8261f0-c104-4ad3-89eb-b0702fe23f79" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_88072c11-b7ab-4c6e-9ad2-b421dedc8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_88072c11-b7ab-4c6e-9ad2-b421dedc8c2d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f5428a0b-c2c7-4446-8eca-00b6f8ec4fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f5428a0b-c2c7-4446-8eca-00b6f8ec4fc6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1427f-adc2-4251-871f-84d05eda85a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1427f-adc2-4251-871f-84d05eda85a8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentBasisSpreadOnCreditSpread_27e52ec6-8fc5-4dcc-ac4c-caf309c14b63" xlink:href="thc-20221231.xsd#thc_DebtInstrumentBasisSpreadOnCreditSpread"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentBasisSpreadOnCreditSpread_27e52ec6-8fc5-4dcc-ac4c-caf309c14b63" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1220393a-0051-4f88-82ea-0bcef2493feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1220393a-0051-4f88-82ea-0bcef2493feb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_ddc2208d-d1af-456a-a3f2-bca4690d3d0b" xlink:href="thc-20221231.xsd#thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_ddc2208d-d1af-456a-a3f2-bca4690d3d0b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_42609ec6-ea88-4dab-868a-48f1d150b643" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_42609ec6-ea88-4dab-868a-48f1d150b643" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_866eb20f-e94d-4592-ad41-0cb1127f8cce" xlink:href="thc-20221231.xsd#thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_866eb20f-e94d-4592-ad41-0cb1127f8cce" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_0dfe5ad0-53a1-4043-89a0-61e39d967196" xlink:href="thc-20221231.xsd#thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_0dfe5ad0-53a1-4043-89a0-61e39d967196" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_fb508cc0-651c-4ee2-a876-f853a90ed0fa" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantMaximumSecuredDebtRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_fb508cc0-651c-4ee2-a876-f853a90ed0fa" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_b013fa74-a3d9-45e8-9911-c5e24c014cd8" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantsOfSecuredDebtRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_b013fa74-a3d9-45e8-9911-c5e24c014cd8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_934a9cc2-d2d3-4082-a868-8e74e80e1d3e" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_934a9cc2-d2d3-4082-a868-8e74e80e1d3e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantThresholdLimit_6a9935e7-6d96-4fc4-9020-29a7225714bf" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantThresholdLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilityCovenantThresholdLimit_6a9935e7-6d96-4fc4-9020-29a7225714bf" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_d69a1e4b-9053-47fb-884e-e5f2ae8560b7" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_d69a1e4b-9053-47fb-884e-e5f2ae8560b7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_327c0c3b-c3e6-4fe7-b0f2-6966cfde3281" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_327c0c3b-c3e6-4fe7-b0f2-6966cfde3281" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f8f36436-5a44-4c1a-8771-dd6b27afafe6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f8f36436-5a44-4c1a-8771-dd6b27afafe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7770abd5-a704-4391-b499-4900a417823c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:to="loc_us-gaap_SeniorNotesMember_7770abd5-a704-4391-b499-4900a417823c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3b2de195-2f50-4380-9be2-3ab49c33aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:to="loc_us-gaap_LineOfCreditMember_3b2de195-2f50-4380-9be2-3ab49c33aedc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_eea78846-3aee-47c3-87f6-5178b55c90ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:to="loc_us-gaap_LetterOfCreditMember_eea78846-3aee-47c3-87f6-5178b55c90ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ea3ba17-8c3c-4da1-b331-06878a6d368e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6ea3ba17-8c3c-4da1-b331-06878a6d368e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_7e7a2d72-00aa-470d-9a9d-4906ea1a6804" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_7e7a2d72-00aa-470d-9a9d-4906ea1a6804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a802306d-ec3e-449f-adf6-aad2fb685d23" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a802306d-ec3e-449f-adf6-aad2fb685d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_36fe3eef-c0b5-430c-90e7-916dba53a00e" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_36fe3eef-c0b5-430c-90e7-916dba53a00e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_3160c4cd-bef3-4a60-8c64-cf5992a727ea" xlink:href="thc-20221231.xsd#thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_3160c4cd-bef3-4a60-8c64-cf5992a727ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_73036362-935a-4879-bf7f-f3ba02475900" xlink:href="thc-20221231.xsd#thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_73036362-935a-4879-bf7f-f3ba02475900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_ee53421e-78db-4f30-bffe-a86153773a42" xlink:href="thc-20221231.xsd#thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_ee53421e-78db-4f30-bffe-a86153773a42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_19cb30a1-3842-4c81-8fae-d2e54701e4a8" xlink:href="thc-20221231.xsd#thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_19cb30a1-3842-4c81-8fae-d2e54701e4a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_2283de75-8d3e-49a2-88c5-e5bcdd183d10" xlink:href="thc-20221231.xsd#thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_2283de75-8d3e-49a2-88c5-e5bcdd183d10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_c7dd7060-9b84-4706-8a0f-dc8ca037a793" xlink:href="thc-20221231.xsd#thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_c7dd7060-9b84-4706-8a0f-dc8ca037a793" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9ba24084-db73-43e0-8b66-87a37ea281eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:to="loc_us-gaap_CreditFacilityDomain_9ba24084-db73-43e0-8b66-87a37ea281eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:to="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_4d2892f4-6f4f-45fb-86e4-6936e2a01db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:to="loc_us-gaap_LetterOfCreditMember_4d2892f4-6f4f-45fb-86e4-6936e2a01db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cbbff366-410b-470d-b93d-16be3ba1c69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cbbff366-410b-470d-b93d-16be3ba1c69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_11d1d5a8-5400-4d12-ab27-190841a26ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:to="loc_us-gaap_VariableRateDomain_11d1d5a8-5400-4d12-ab27-190841a26ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:to="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_57d2b7f8-0a64-4747-bffc-f45048db2133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:to="loc_us-gaap_BaseRateMember_57d2b7f8-0a64-4747-bffc-f45048db2133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4c6b7a7c-110b-4269-9fd9-28bce48973b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4c6b7a7c-110b-4269-9fd9-28bce48973b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56bc39ea-5de0-43e7-9dca-ef0dc2a80752_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:to="loc_srt_RangeMember_56bc39ea-5de0-43e7-9dca-ef0dc2a80752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:to="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5479067-451e-41fa-b0dd-a3a7288f989e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:to="loc_srt_MinimumMember_e5479067-451e-41fa-b0dd-a3a7288f989e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_64403c3c-c522-4317-8ad6-c4dc2b65cfd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:to="loc_srt_MaximumMember_64403c3c-c522-4317-8ad6-c4dc2b65cfd3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GUARANTEESDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GUARANTEESDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/GUARANTEESDetails" xlink:type="extended" id="iae0def369d3d4bb7b3e080881baf8009_GUARANTEESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteeObligationPeriod_23e8b0f6-b133-44f0-8637-02129696d229" xlink:href="thc-20221231.xsd#thc_GuaranteeObligationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_thc_GuaranteeObligationPeriod_23e8b0f6-b133-44f0-8637-02129696d229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CommitmentPeriod_3f949596-ed4e-400d-8795-85a0430b8370" xlink:href="thc-20221231.xsd#thc_CommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_thc_CommitmentPeriod_3f949596-ed4e-400d-8795-85a0430b8370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_715abc77-a2cd-4ac4-866c-151371faf103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_715abc77-a2cd-4ac4-866c-151371faf103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesFairValueDisclosure_730acf48-ebc2-41bb-bd94-a02960efc665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_us-gaap_GuaranteesFairValueDisclosure_730acf48-ebc2-41bb-bd94-a02960efc665" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_17f11c4f-79e0-4b69-9644-166aa86e274e" xlink:href="thc-20221231.xsd#thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_17f11c4f-79e0-4b69-9644-166aa86e274e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_bb4fa570-770c-43ca-8d1e-7236935a27a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_bb4fa570-770c-43ca-8d1e-7236935a27a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeGuaranteeMember_bb3d684b-7cd7-4458-a098-6ee7a7945cbe" xlink:href="thc-20221231.xsd#thc_IncomeGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_thc_IncomeGuaranteeMember_bb3d684b-7cd7-4458-a098-6ee7a7945cbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeOfBusinessRevenueMember_56c65d10-ecaf-4f39-805b-ab39cb50e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeOfBusinessRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_us-gaap_GuaranteeOfBusinessRevenueMember_56c65d10-ecaf-4f39-805b-ab39cb50e6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeAndRevenueCollectionGuaranteeMember_9b2dd702-3f33-4395-a57a-7c5bb5ea5b94" xlink:href="thc-20221231.xsd#thc_IncomeAndRevenueCollectionGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_thc_IncomeAndRevenueCollectionGuaranteeMember_9b2dd702-3f33-4395-a57a-7c5bb5ea5b94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteedInvesteesOfThirdPartiesMember_1d9b6577-8f9e-452d-a13d-2b88385460ee" xlink:href="thc-20221231.xsd#thc_GuaranteedInvesteesOfThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_thc_GuaranteedInvesteesOfThirdPartiesMember_1d9b6577-8f9e-452d-a13d-2b88385460ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c43343c-ab27-49df-9f7b-9d150eb60e9d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:to="loc_srt_RangeMember_3c43343c-ab27-49df-9f7b-9d150eb60e9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:to="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_594ea296-fbe9-4ae5-827d-bd88bb559261" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:to="loc_srt_MinimumMember_594ea296-fbe9-4ae5-827d-bd88bb559261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_15bcf84c-2991-4c52-bc16-52174bcb40a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:to="loc_srt_MaximumMember_15bcf84c-2991-4c52-bc16-52174bcb40a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5bd4c122-6a7d-4485-9ff9-be35b7c169ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5bd4c122-6a7d-4485-9ff9-be35b7c169ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb618e72-a5cd-4fcc-981c-27500a113c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb618e72-a5cd-4fcc-981c-27500a113c6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c4b12c24-448f-4f19-9ed1-2a42d85eb182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb618e72-a5cd-4fcc-981c-27500a113c6e" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c4b12c24-448f-4f19-9ed1-2a42d85eb182" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails" xlink:type="extended" id="i7a13b15410e940b39db193a39e448078_EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6a3c6cfc-f8a9-4b20-951c-e4ac22a60f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6a3c6cfc-f8a9-4b20-951c-e4ac22a60f82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_b7e071ee-21b2-4d59-ba2a-0011f8d542cc" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_b7e071ee-21b2-4d59-ba2a-0011f8d542cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d2b13464-67af-4e16-b252-1d2e544e2566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d2b13464-67af-4e16-b252-1d2e544e2566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8dc4ea58-0b7b-4d25-b9fe-7ff317930574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8dc4ea58-0b7b-4d25-b9fe-7ff317930574" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e74d40a7-0c29-451b-b2e7-dbf1dbcf419b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e74d40a7-0c29-451b-b2e7-dbf1dbcf419b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f0378e-6f21-4f55-8bfe-fe6bc27a04e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f0378e-6f21-4f55-8bfe-fe6bc27a04e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d314de73-cc88-4cfb-a742-e858d2cd8087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d314de73-cc88-4cfb-a742-e858d2cd8087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a3b1021-c1e5-4991-b2d9-3f84531cd889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a3b1021-c1e5-4991-b2d9-3f84531cd889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2bc6eaf3-4f1d-4ed2-8f81-81082e54d541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2bc6eaf3-4f1d-4ed2-8f81-81082e54d541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedRestrictedStockUnitMember_9df10afd-a02c-4700-bb37-7d6ddce711f6" xlink:href="thc-20221231.xsd#thc_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:to="loc_thc_PerformanceBasedRestrictedStockUnitMember_9df10afd-a02c-4700-bb37-7d6ddce711f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d4e9a98e-228c-4786-8061-10bc7209a04a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:to="loc_srt_RangeMember_d4e9a98e-228c-4786-8061-10bc7209a04a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:to="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e8004557-a11c-423b-9f12-a70f3f2d0dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:to="loc_srt_MinimumMember_e8004557-a11c-423b-9f12-a70f3f2d0dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5eb34a01-1af3-468e-9efb-e34f4e340e22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:to="loc_srt_MaximumMember_5eb34a01-1af3-468e-9efb-e34f4e340e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d3c8698c-882c-4e50-8c56-ca14041bb43d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:to="loc_us-gaap_VestingDomain_d3c8698c-882c-4e50-8c56-ca14041bb43d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8317b828-5833-458d-8cd6-b4f9c8c490a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:to="loc_us-gaap_VestingDomain_8317b828-5833-458d-8cd6-b4f9c8c490a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingMember_7f9e57d5-427c-4551-b74f-30014a8a5628" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8317b828-5833-458d-8cd6-b4f9c8c490a6" xlink:to="loc_thc_PerformanceBasedVestingMember_7f9e57d5-427c-4551-b74f-30014a8a5628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_097acaf3-11e6-4cc3-a8ab-a088484d3777_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:to="loc_us-gaap_PlanNameDomain_097acaf3-11e6-4cc3-a8ab-a088484d3777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc53fcba-11ab-4661-b608-2acb98be6da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:to="loc_us-gaap_PlanNameDomain_cc53fcba-11ab-4661-b608-2acb98be6da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_StockIncentivePlan2019Member_1edd4e3c-9a40-483f-b3ef-6948afd52aa4" xlink:href="thc-20221231.xsd#thc_StockIncentivePlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc53fcba-11ab-4661-b608-2acb98be6da0" xlink:to="loc_thc_StockIncentivePlan2019Member_1edd4e3c-9a40-483f-b3ef-6948afd52aa4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails" xlink:type="extended" id="id428ebf3c9044505b4a86f0abed5794b_EMPLOYEEBENEFITPLANSStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11b4b687-c512-44b5-975d-17d673730094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11b4b687-c512-44b5-975d-17d673730094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27d5e9af-3fd0-4356-802d-c16517fe722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27d5e9af-3fd0-4356-802d-c16517fe722e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3ffbfc67-0dfa-46c5-8af4-7c46b2beb3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3ffbfc67-0dfa-46c5-8af4-7c46b2beb3b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_662e5b90-558f-40b9-85a4-2f913495c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcadf2c8-38c3-49a6-8ded-c5d65d9fdd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcadf2c8-38c3-49a6-8ded-c5d65d9fdd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05af1f27-3817-4082-8a39-3cd0b962cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05af1f27-3817-4082-8a39-3cd0b962cb8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d3113fd0-d566-4de6-82e9-91c9e1c9a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d3113fd0-d566-4de6-82e9-91c9e1c9a1a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19899134-aeb3-425b-8f95-6190da97b7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ffef342e-7edd-4b2c-a1ff-db3ac16a090d" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ffef342e-7edd-4b2c-a1ff-db3ac16a090d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1df0ccd-dae6-4004-8c0e-0a1f9669be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ffef342e-7edd-4b2c-a1ff-db3ac16a090d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1df0ccd-dae6-4004-8c0e-0a1f9669be9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba65649e-0231-4311-b333-8016548434a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba65649e-0231-4311-b333-8016548434a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a51a0e8e-3cdb-4c44-9b7b-d06236138958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba65649e-0231-4311-b333-8016548434a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a51a0e8e-3cdb-4c44-9b7b-d06236138958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb705d86-94ff-4c9b-92c6-4dfdba4f4152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb705d86-94ff-4c9b-92c6-4dfdba4f4152" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7d3003b-4284-4220-94fe-faf403247793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7d3003b-4284-4220-94fe-faf403247793" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:to="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8bd0611c-c33f-4b15-8712-5eb385dc040c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8bd0611c-c33f-4b15-8712-5eb385dc040c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_959746e6-2f0d-4d57-9789-7a3a40481e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_959746e6-2f0d-4d57-9789-7a3a40481e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_375d7a6b-fa26-4cc8-8051-528f6d5bfd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_959746e6-2f0d-4d57-9789-7a3a40481e1b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_375d7a6b-fa26-4cc8-8051-528f6d5bfd66" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails" xlink:type="extended" id="i5a830ebc19414059823726bd31b1e143_EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b50244d5-0131-44ff-acaf-17e317a8fd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b50244d5-0131-44ff-acaf-17e317a8fd03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24c5627b-2433-4975-896b-3ab19d91e3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24c5627b-2433-4975-896b-3ab19d91e3e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_af7e75a0-ece6-4d86-80b7-83e4cdf745c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_af7e75a0-ece6-4d86-80b7-83e4cdf745c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0d182566-6510-4993-a1cb-7328816118ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0d182566-6510-4993-a1cb-7328816118ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_08ae1d7b-de81-4c3d-b6c6-148da02a4dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_08ae1d7b-de81-4c3d-b6c6-148da02a4dab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a34825ab-4234-45c8-86b0-2cf57d3d4fe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a34825ab-4234-45c8-86b0-2cf57d3d4fe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3561eafa-fe4f-4c9e-a504-b078bb6e8013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3561eafa-fe4f-4c9e-a504-b078bb6e8013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0e70ba34-2813-479f-b283-44f0cc3f13e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3561eafa-fe4f-4c9e-a504-b078bb6e8013" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0e70ba34-2813-479f-b283-44f0cc3f13e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ExercisePriceRangeOneMember_257c37c0-ccf3-4c3c-9bc5-eca0b6e913ca" xlink:href="thc-20221231.xsd#thc_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:to="loc_thc_ExercisePriceRangeOneMember_257c37c0-ccf3-4c3c-9bc5-eca0b6e913ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ExercisePriceRangeSecondMember_7ca97502-79f6-4418-9c61-91140d6789ca" xlink:href="thc-20221231.xsd#thc_ExercisePriceRangeSecondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:to="loc_thc_ExercisePriceRangeSecondMember_7ca97502-79f6-4418-9c61-91140d6789ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02723178-806f-4d48-b904-e248504cc4cf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:to="loc_srt_RangeMember_02723178-806f-4d48-b904-e248504cc4cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:to="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eca92ff3-4f41-4194-a6c3-fbfb3fe4a59f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:to="loc_srt_MinimumMember_eca92ff3-4f41-4194-a6c3-fbfb3fe4a59f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_343c5f54-7a98-4f77-90a4-a67e688bef48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:to="loc_srt_MaximumMember_343c5f54-7a98-4f77-90a4-a67e688bef48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails" xlink:type="extended" id="ib5c63e12c7d6498abc4dc8d1811330e3_EMPLOYEEBENEFITPLANSEmployeeOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_6933a46b-2d6e-4cc4-a76a-60b639e549b6" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_6933a46b-2d6e-4cc4-a76a-60b639e549b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_53dab31b-865f-4ec8-8eef-c15c80af8b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_us-gaap_SharePrice_53dab31b-865f-4ec8-8eef-c15c80af8b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28fd3551-c7a8-4bd6-b1a3-fcba422d2e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28fd3551-c7a8-4bd6-b1a3-fcba422d2e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:to="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d652eba1-851b-4a47-89d4-66747b84cbc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d652eba1-851b-4a47-89d4-66747b84cbc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4fae33c-3af6-43e0-aba9-4f8856758abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4fae33c-3af6-43e0-aba9-4f8856758abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_64688035-383d-4930-b2be-fccca06cb6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4fae33c-3af6-43e0-aba9-4f8856758abd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_64688035-383d-4930-b2be-fccca06cb6ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:to="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dc39337b-8788-42bf-91e9-4007d40930c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dc39337b-8788-42bf-91e9-4007d40930c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CurrentEmployeesMember_9c270d40-a76d-4c54-98c2-af24701b58d2" xlink:href="thc-20221231.xsd#thc_CurrentEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:to="loc_thc_CurrentEmployeesMember_9c270d40-a76d-4c54-98c2-af24701b58d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FormerEmployeesMember_fdb3b8a4-1b55-411d-8ef1-2c79786d0246" xlink:href="thc-20221231.xsd#thc_FormerEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:to="loc_thc_FormerEmployeesMember_fdb3b8a4-1b55-411d-8ef1-2c79786d0246" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails" xlink:type="extended" id="id0211a5e439444f3aa41cf690da4b16f_EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d28b5e0f-b00b-446a-bcae-f626fe31e261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d28b5e0f-b00b-446a-bcae-f626fe31e261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18b6c2ad-d54e-4d60-96b7-9e38c6aa1366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18b6c2ad-d54e-4d60-96b7-9e38c6aa1366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f02182be-4299-4e03-ba3d-6269a8ea07ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f02182be-4299-4e03-ba3d-6269a8ea07ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3fd5c86f-1600-4921-9a23-ee1e5d37fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3fd5c86f-1600-4921-9a23-ee1e5d37fffa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f61ac2e4-8dc6-4ad5-a8d9-c4a0a5f7c9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a87f77da-f255-43cf-a9ce-0c70c5500b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a87f77da-f255-43cf-a9ce-0c70c5500b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c0be320-d430-4eb9-8117-85e9eea46462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c0be320-d430-4eb9-8117-85e9eea46462" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ebe9bf8e-ebda-40f4-8d95-7971f99d28a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ebe9bf8e-ebda-40f4-8d95-7971f99d28a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0005b9eb-dc5e-42aa-878d-170ffd86c2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0005b9eb-dc5e-42aa-878d-170ffd86c2e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3db1ce98-a09a-44c4-a4d0-66e58a52179a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_efbfadb4-393d-47d5-975d-650910210843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3a68f4f-787d-4880-a61f-ccd7c1337cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3a68f4f-787d-4880-a61f-ccd7c1337cc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_574b5001-30f8-41db-b5c2-a9ae476c3ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_574b5001-30f8-41db-b5c2-a9ae476c3ad3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_b99b3313-8cd8-4c06-84ea-cbd1067ab4f1" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_b99b3313-8cd8-4c06-84ea-cbd1067ab4f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_82b57fab-45f8-4cca-b378-c721c894cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_82b57fab-45f8-4cca-b378-c721c894cf84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c01bb65b-8b9f-429c-a5ca-c97016887a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c01bb65b-8b9f-429c-a5ca-c97016887a75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_558aeea8-7553-4a18-bd4a-38b3cbbea6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_558aeea8-7553-4a18-bd4a-38b3cbbea6bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_734a5774-c5f7-496c-af2a-c0b3b01a3ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:to="loc_us-gaap_VestingDomain_734a5774-c5f7-496c-af2a-c0b3b01a3ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:to="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_cddb8cec-9f4e-4e88-b919-b53aa5fa960b" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_cddb8cec-9f4e-4e88-b919-b53aa5fa960b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingFourYearFromGrantDateMember_5d3620a5-cdf2-4e73-8200-a81fe155b136" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingFourYearFromGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingFourYearFromGrantDateMember_5d3620a5-cdf2-4e73-8200-a81fe155b136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_e3aad0e8-aa7e-4581-9c19-0e58cc33b540" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_e3aad0e8-aa7e-4581-9c19-0e58cc33b540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_1ced8f4f-0569-46dc-b69d-7fc6589b2a77" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_1ced8f4f-0569-46dc-b69d-7fc6589b2a77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_9cd7baac-53ff-4e03-9065-e7c00a2350f5" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingOverAThreeYearPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_9cd7baac-53ff-4e03-9065-e7c00a2350f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingMember_ca4a78a9-da97-44e5-8a50-d50c3b329d78" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingMember_ca4a78a9-da97-44e5-8a50-d50c3b329d78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingMember_7b92b99f-250f-4e28-8a2b-2118fe707652" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingMember_7b92b99f-250f-4e28-8a2b-2118fe707652" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EightQuarterVestingPeriodMember_63ded0ef-f325-49df-a6e0-5aeed20ec6a4" xlink:href="thc-20221231.xsd#thc_EightQuarterVestingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_EightQuarterVestingPeriodMember_63ded0ef-f325-49df-a6e0-5aeed20ec6a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ElevenQuarterVestingPeriodMember_a4740b4c-2762-4af4-b82f-06f96e993571" xlink:href="thc-20221231.xsd#thc_ElevenQuarterVestingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_ElevenQuarterVestingPeriodMember_a4740b4c-2762-4af4-b82f-06f96e993571" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_946d32bf-0dfc-4f08-9243-69589b824407" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnFourthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_946d32bf-0dfc-4f08-9243-69589b824407" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_c3966723-ffff-40c9-b163-64145b8443bc" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnThirdAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_c3966723-ffff-40c9-b163-64145b8443bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingOneYearFromGrantDateMember_dc73b4b3-8471-44fb-936d-f9ae3681d677" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingOneYearFromGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingOneYearFromGrantDateMember_dc73b4b3-8471-44fb-936d-f9ae3681d677" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingOnFourthAnniversaryMember_6b481dc8-e75f-42af-a9d2-d84f2043236b" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingOnFourthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingOnFourthAnniversaryMember_6b481dc8-e75f-42af-a9d2-d84f2043236b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingOnFourthAnniversaryMember_a01b5951-9287-475f-b94c-a5069ac6ba06" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingOnFourthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingOnFourthAnniversaryMember_a01b5951-9287-475f-b94c-a5069ac6ba06" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingAndSettledImmediatelyMember_18b002d1-230c-4c68-b8df-d548f5b89d38" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingAndSettledImmediatelyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingAndSettledImmediatelyMember_18b002d1-230c-4c68-b8df-d548f5b89d38" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afba0f6c-7819-49db-9d22-9dace6c0591d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afba0f6c-7819-49db-9d22-9dace6c0591d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NonExecutiveChairmanMember_bedc29a2-8019-4006-91e6-00422b3b3761" xlink:href="thc-20221231.xsd#thc_NonExecutiveChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_thc_NonExecutiveChairmanMember_bedc29a2-8019-4006-91e6-00422b3b3761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SeniorOfficerMember_853018bc-eefd-4488-9d4c-bbeb9c62a3e9" xlink:href="thc-20221231.xsd#thc_SeniorOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_thc_SeniorOfficerMember_853018bc-eefd-4488-9d4c-bbeb9c62a3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NonEmployeeDirectorsMember_6841521f-67c0-4f4b-984d-917510811b0a" xlink:href="thc-20221231.xsd#thc_NonEmployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_thc_NonEmployeeDirectorsMember_6841521f-67c0-4f4b-984d-917510811b0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_fbb2e32b-d9b1-4ba3-990c-e2f83ce06e11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_srt_DirectorMember_fbb2e32b-d9b1-4ba3-990c-e2f83ce06e11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_992deb01-0ec2-40e4-9184-09dca5b4ed90_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:to="loc_srt_RangeMember_992deb01-0ec2-40e4-9184-09dca5b4ed90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:to="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a578382d-436e-4077-adc9-9eae9a5b9691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:to="loc_srt_MinimumMember_a578382d-436e-4077-adc9-9eae9a5b9691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2fef015e-3798-4d98-ba07-0246a74a8e34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:to="loc_srt_MaximumMember_2fef015e-3798-4d98-ba07-0246a74a8e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c6b1ea5-f482-4070-b543-e4bdfac457e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c6b1ea5-f482-4070-b543-e4bdfac457e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedRestrictedStockUnitMember_cc244992-aead-4317-9172-6c52c2235c52" xlink:href="thc-20221231.xsd#thc_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:to="loc_thc_PerformanceBasedRestrictedStockUnitMember_cc244992-aead-4317-9172-6c52c2235c52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0513bb0d-96ad-41c7-81f0-8ffccd032264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0513bb0d-96ad-41c7-81f0-8ffccd032264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdditionalProratedRestrictedStockUnitsMember_0c091d01-cf57-4884-a766-8a33b308b56d" xlink:href="thc-20221231.xsd#thc_AdditionalProratedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:to="loc_thc_AdditionalProratedRestrictedStockUnitsMember_0c091d01-cf57-4884-a766-8a33b308b56d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails" xlink:type="extended" id="i78965a768b354ac68ae867f52ad3e73d_EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f78890c-7cc3-4300-8455-3e8153f1c614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f78890c-7cc3-4300-8455-3e8153f1c614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_92d228ca-ceb5-4f83-a564-64ff2cf18222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_92d228ca-ceb5-4f83-a564-64ff2cf18222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ebad1359-21f9-4b8b-8c19-2a6ef38d6e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ebad1359-21f9-4b8b-8c19-2a6ef38d6e05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5737c756-b0c2-4159-8258-8ed495c00aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5737c756-b0c2-4159-8258-8ed495c00aa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1987d143-024f-4851-8cbd-e5bf6549a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1987d143-024f-4851-8cbd-e5bf6549a7b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05ce3769-6b23-4bc2-a213-56eef24c0163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05ce3769-6b23-4bc2-a213-56eef24c0163" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:to="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7dc8e38-efd5-4942-bfa5-0095962bae34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7dc8e38-efd5-4942-bfa5-0095962bae34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f976baa-d1f1-49e1-9560-c89e17d9ab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f976baa-d1f1-49e1-9560-c89e17d9ab8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_141c373f-a5d8-4c75-9b9c-3b2f6dfc0085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f976baa-d1f1-49e1-9560-c89e17d9ab8d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_141c373f-a5d8-4c75-9b9c-3b2f6dfc0085" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails" xlink:type="extended" id="ib6c4349cf9df40919dba6a71b5870f78_EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_0e4dbb7e-a358-43d8-9073-b3ca54e86dda" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_0e4dbb7e-a358-43d8-9073-b3ca54e86dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4d4061f-398e-4b21-9954-4f81a0ebae2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4d4061f-398e-4b21-9954-4f81a0ebae2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_e16aaf97-28e6-43ca-96f8-c44536b2f93a" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_e16aaf97-28e6-43ca-96f8-c44536b2f93a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_1c1b87bc-0c16-4f02-a224-f6eb5d71414f" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_1c1b87bc-0c16-4f02-a224-f6eb5d71414f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_247d2774-c405-4665-adcd-fc801756c9be" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_247d2774-c405-4665-adcd-fc801756c9be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_258ced15-c69a-4c91-8df5-d508a9981d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_258ced15-c69a-4c91-8df5-d508a9981d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85bed044-ac82-4e6d-b3c2-1ea6f8fb31ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85bed044-ac82-4e6d-b3c2-1ea6f8fb31ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f247a895-dc00-42e5-a656-cf6fb925f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f247a895-dc00-42e5-a656-cf6fb925f7a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6527004c-6702-440d-9da5-f39ebbab60b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6527004c-6702-440d-9da5-f39ebbab60b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c229da71-2c91-45a9-b013-3ae6744efc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84977e0a-43b2-4e13-a02d-acda0eecc5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84977e0a-43b2-4e13-a02d-acda0eecc5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22285e9f-81af-4e03-811f-8956d95f21b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22285e9f-81af-4e03-811f-8956d95f21b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b53e754b-7ce0-471c-85c1-9c1b5be930bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b53e754b-7ce0-471c-85c1-9c1b5be930bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d823475d-11bc-4674-883f-b4ca0d1cf3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d823475d-11bc-4674-883f-b4ca0d1cf3d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9894d5e9-95d7-44c8-b244-4345568afbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20f88f2-cdc6-44cc-8f29-26179954aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20f88f2-cdc6-44cc-8f29-26179954aadf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_66962277-0b7e-4ed4-8b90-4437b9cb6569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_66962277-0b7e-4ed4-8b90-4437b9cb6569" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_f79d7eb1-cbb0-4e87-8449-00c0e98f90fa" xlink:href="thc-20221231.xsd#thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_f79d7eb1-cbb0-4e87-8449-00c0e98f90fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CommonStockSharesOutstandingAndEligibleToBeSold_928878fd-d2c0-4ecc-8ed0-59bef461aead" xlink:href="thc-20221231.xsd#thc_CommonStockSharesOutstandingAndEligibleToBeSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_CommonStockSharesOutstandingAndEligibleToBeSold_928878fd-d2c0-4ecc-8ed0-59bef461aead" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e0ff3d7-17df-471c-aa71-d6da4075e707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e0ff3d7-17df-471c-aa71-d6da4075e707" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ef8c5ea9-f1fe-497f-9579-cac64c2eed89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ef8c5ea9-f1fe-497f-9579-cac64c2eed89" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b4bb6876-702d-41f1-a5ca-f3bc200dd490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:to="loc_us-gaap_PlanNameDomain_b4bb6876-702d-41f1-a5ca-f3bc200dd490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:to="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2015USPIManagementEquityPlanMember_00bb4b55-9ae5-434a-ab21-391fa8d5576c" xlink:href="thc-20221231.xsd#thc_A2015USPIManagementEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:to="loc_thc_A2015USPIManagementEquityPlanMember_00bb4b55-9ae5-434a-ab21-391fa8d5576c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2020USPIManagementEquityPlanMember_cd62958e-f0f3-4909-8ab8-63a4213e6e86" xlink:href="thc-20221231.xsd#thc_A2020USPIManagementEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:to="loc_thc_A2020USPIManagementEquityPlanMember_cd62958e-f0f3-4909-8ab8-63a4213e6e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_USPIManagementEquityPlanMember_975c5123-57f0-4906-865e-a9fda03f8334" xlink:href="thc-20221231.xsd#thc_USPIManagementEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:to="loc_thc_USPIManagementEquityPlanMember_975c5123-57f0-4906-865e-a9fda03f8334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d14d640b-1598-4821-bfa9-f5e25d5c1daf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:to="loc_srt_RangeMember_d14d640b-1598-4821-bfa9-f5e25d5c1daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:to="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e3ba938c-711b-4308-9b8b-a0d993131eaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:to="loc_srt_MinimumMember_e3ba938c-711b-4308-9b8b-a0d993131eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e671e25-0acd-45ae-a9c0-7e23288be0de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:to="loc_srt_MaximumMember_6e671e25-0acd-45ae-a9c0-7e23288be0de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2db07d01-5ced-4ae4-9c27-1eca74f90553_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2db07d01-5ced-4ae4-9c27-1eca74f90553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c2068a5e-0289-4613-b7ad-0d88795aa2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:to="loc_us-gaap_StockOptionMember_c2068a5e-0289-4613-b7ad-0d88795aa2da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a862b7b3-afb9-49d4-a1e9-b9025dfc03c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a862b7b3-afb9-49d4-a1e9-b9025dfc03c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvotingCommonStockMember_599f6c9a-ae61-45bd-9e5f-861b1963b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:to="loc_us-gaap_NonvotingCommonStockMember_599f6c9a-ae61-45bd-9e5f-861b1963b2c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_587b981d-8e4f-4cd9-9b6e-be07a4972b94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:to="loc_us-gaap_VestingDomain_587b981d-8e4f-4cd9-9b6e-be07a4972b94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:to="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_980096da-0a34-4f29-9573-6491b3550f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_980096da-0a34-4f29-9573-6491b3550f34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_590fcc63-d484-4278-a185-b78ee7711442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_590fcc63-d484-4278-a185-b78ee7711442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_fcbfd081-1ffb-4b9e-8a5e-24fc738d045d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_fcbfd081-1ffb-4b9e-8a5e-24fc738d045d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationAwardTrancheFourMember_e9374304-2e41-4cce-91db-7ca31e21ea84" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_thc_ShareBasedCompensationAwardTrancheFourMember_e9374304-2e41-4cce-91db-7ca31e21ea84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_18a38717-ce76-4a2b-b41a-9901cb9a67a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_18a38717-ce76-4a2b-b41a-9901cb9a67a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e09a61c0-48fd-42d8-854c-842c298b051f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e09a61c0-48fd-42d8-854c-842c298b051f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember_2a58799f-c527-4459-a203-cc65cd2b7d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e09a61c0-48fd-42d8-854c-842c298b051f" xlink:to="loc_us-gaap_NonqualifiedPlanMember_2a58799f-c527-4459-a203-cc65cd2b7d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_33be6197-8225-4185-bc00-dc2e54c56b1e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:to="loc_dei_EntityDomain_33be6197-8225-4185-bc00-dc2e54c56b1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3b26f37d-69ec-488c-a7e4-aea4f5f20c95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:to="loc_dei_EntityDomain_3b26f37d-69ec-488c-a7e4-aea4f5f20c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_8aff949c-d5b9-4dcb-96cd-e78bf90e0a70" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3b26f37d-69ec-488c-a7e4-aea4f5f20c95" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_8aff949c-d5b9-4dcb-96cd-e78bf90e0a70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails" xlink:type="extended" id="ib6d94c30e0234ca3aad0b48bf6b46098_EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32f2e7c8-e493-4908-8e80-f3fa72e8b15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32f2e7c8-e493-4908-8e80-f3fa72e8b15b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20903147-f71b-4c30-8e9d-2f911c38c5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20903147-f71b-4c30-8e9d-2f911c38c5c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_67a3ce1f-d781-42d8-9c40-83d2f0ee611b" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_67a3ce1f-d781-42d8-9c40-83d2f0ee611b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_78b43673-b973-4c94-97b4-2b6f8f94d401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_78b43673-b973-4c94-97b4-2b6f8f94d401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_72d945b6-5910-4da0-b59a-484ecc4579ca" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_72d945b6-5910-4da0-b59a-484ecc4579ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_fe89f18f-a911-4a02-8352-3c49b4f81457" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_fe89f18f-a911-4a02-8352-3c49b4f81457" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a829dfd7-4534-4468-a267-dca31699bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a829dfd7-4534-4468-a267-dca31699bdec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_682fad93-4926-4edb-9689-c35129f00b86" xlink:href="thc-20221231.xsd#thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_682fad93-4926-4edb-9689-c35129f00b86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:to="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75ce1814-048f-4649-9f4e-6c9e1a73a992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75ce1814-048f-4649-9f4e-6c9e1a73a992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90b6d222-c4f0-4a27-be2b-c9959c79ac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90b6d222-c4f0-4a27-be2b-c9959c79ac4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e7c4f0f8-015d-44a6-ae08-6a181260c110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90b6d222-c4f0-4a27-be2b-c9959c79ac4c" xlink:to="loc_us-gaap_EmployeeStockMember_e7c4f0f8-015d-44a6-ae08-6a181260c110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:to="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e85da090-c87c-492c-ba0b-996a6a45da45_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:to="loc_srt_RangeMember_e85da090-c87c-492c-ba0b-996a6a45da45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:to="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d405836f-585c-43ef-a172-d96878bd65d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:to="loc_srt_MinimumMember_d405836f-585c-43ef-a172-d96878bd65d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab794ec2-3a4f-4a52-8b76-01844a7a02d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:to="loc_srt_MaximumMember_ab794ec2-3a4f-4a52-8b76-01844a7a02d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" xlink:type="extended" id="i5c386bc7953044069faaa16c9ba40ae5_EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_44ec0f32-e42f-4380-899f-4ac8a0007291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_44ec0f32-e42f-4380-899f-4ac8a0007291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_f1e9132b-078f-4ef9-abb2-92122ebb84a3" xlink:href="thc-20221231.xsd#thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_f1e9132b-078f-4ef9-abb2-92122ebb84a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_25325f4d-56e3-4fda-a25f-8c263b1d8efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_25325f4d-56e3-4fda-a25f-8c263b1d8efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_b1ab2774-54cd-4abf-a25d-6d1ecc494853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_b1ab2774-54cd-4abf-a25d-6d1ecc494853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7824b2f3-146f-45b1-becd-e77f9b2fddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7824b2f3-146f-45b1-becd-e77f9b2fddc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_bdcd5496-1de9-48c3-9079-2c3ddc293abb" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_bdcd5496-1de9-48c3-9079-2c3ddc293abb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_39f685b5-5da2-4397-a525-98f3869ea392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_835daac5-cbc8-41cd-997b-f92e121053e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_835daac5-cbc8-41cd-997b-f92e121053e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_7f04127f-de7c-4fc4-83e9-9c5390ad56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_7f04127f-de7c-4fc4-83e9-9c5390ad56f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_02dbdc83-9171-4935-9d03-804dc0fb28e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_02dbdc83-9171-4935-9d03-804dc0fb28e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6daa45ce-7914-46fa-af6d-244e0518d493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6daa45ce-7914-46fa-af6d-244e0518d493" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_91c82210-ab97-49e1-923b-4293a9d6a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_de3d1531-95d0-448f-911b-19bd0c4b1eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_de3d1531-95d0-448f-911b-19bd0c4b1eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_3a4a9248-6ae8-4046-92f8-a6728dae8091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_3a4a9248-6ae8-4046-92f8-a6728dae8091" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e54d94b-8b7f-40d6-8575-918ebd13b372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e54d94b-8b7f-40d6-8575-918ebd13b372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_5f32196b-a7a4-4413-be43-ed77a416741a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_5f32196b-a7a4-4413-be43-ed77a416741a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_015038dd-6751-4fc7-a3f0-b7ee855bd305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_015038dd-6751-4fc7-a3f0-b7ee855bd305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_b3e54845-ff0e-4a04-a8a9-59880003a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_b3e54845-ff0e-4a04-a8a9-59880003a0f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_778c3094-9ade-4623-92d6-f1c19336ccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_778c3094-9ade-4623-92d6-f1c19336ccc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_37c53514-ce35-4668-9107-8286ddfdb3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_24cdb0d1-db10-41fa-97e0-0e6956243c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_24cdb0d1-db10-41fa-97e0-0e6956243c23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_c18473ff-825a-4655-91b9-8deef8da98b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_c18473ff-825a-4655-91b9-8deef8da98b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6cf5ac23-7cf8-4913-b57e-d358894827d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6cf5ac23-7cf8-4913-b57e-d358894827d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_772e9aa0-6e35-4278-9cae-f52e0676a55f" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_772e9aa0-6e35-4278-9cae-f52e0676a55f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_6e005fd5-ffc7-41fc-bee7-7433ee596be6" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_6e005fd5-ffc7-41fc-bee7-7433ee596be6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_40f409e1-c8bc-4ccf-b327-79fe735cceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_40f409e1-c8bc-4ccf-b327-79fe735cceaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_636f2977-b227-426c-a994-09b75df84449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_636f2977-b227-426c-a994-09b75df84449" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_8bbb2f4e-3a79-4509-a381-7ff09e42e6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_8bbb2f4e-3a79-4509-a381-7ff09e42e6a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_20b2ec4d-2dcd-4fb0-9ba6-9e26a79d9c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_20b2ec4d-2dcd-4fb0-9ba6-9e26a79d9c32" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_8469eae5-2399-4842-a3db-3ac2015d661d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_8469eae5-2399-4842-a3db-3ac2015d661d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f0eba70a-92d3-47fb-9a6a-1218f1de3a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_d7773e03-c8f8-4e84-a3b4-53d425986e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_d7773e03-c8f8-4e84-a3b4-53d425986e4c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e38e303a-153c-40c3-a8da-06163e9789ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e38e303a-153c-40c3-a8da-06163e9789ea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0138decc-bc8b-4198-af03-78f44afbec2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0138decc-bc8b-4198-af03-78f44afbec2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1d9afa21-be53-4aee-bfe8-59c019c92c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1d9afa21-be53-4aee-bfe8-59c019c92c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_138c6367-b0e7-4d84-abde-3b46f7694285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_138c6367-b0e7-4d84-abde-3b46f7694285" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSAssetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails" xlink:type="extended" id="i811615fdcbc7486dbea32193c30d6c20_EMPLOYEEBENEFITPLANSAssetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_daae4740-d759-4bfd-b218-81aff443939b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_daae4740-d759-4bfd-b218-81aff443939b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage_13052398-21ca-4da8-8a17-88d4add350b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage_13052398-21ca-4da8-8a17-88d4add350b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fdf32864-2017-4eac-abce-b6b91bba2ef7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fdf32864-2017-4eac-abce-b6b91bba2ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_908c8d85-a840-42f0-bd23-b48f8e9cf679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_908c8d85-a840-42f0-bd23-b48f8e9cf679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_59ab9bc6-9756-4849-a69a-6412279ba0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_908c8d85-a840-42f0-bd23-b48f8e9cf679" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_59ab9bc6-9756-4849-a69a-6412279ba0df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_7f0419c9-1063-41ff-83bc-23f2f8112ed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_7f0419c9-1063-41ff-83bc-23f2f8112ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_cf8edf7d-468f-434c-b41b-36f56cb61c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_cf8edf7d-468f-434c-b41b-36f56cb61c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_669fd390-a39c-48ae-b3ac-e32f832d0e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_669fd390-a39c-48ae-b3ac-e32f832d0e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_2b2b342d-4eef-4946-8cd5-418e22d55278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_2b2b342d-4eef-4946-8cd5-418e22d55278" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanAlternativeInvestmentsMember_c9092708-4351-4583-967d-edb245537470" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanAlternativeInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_thc_DefinedBenefitPlanAlternativeInvestmentsMember_c9092708-4351-4583-967d-edb245537470" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" xlink:type="extended" id="i17df503fdb324b038b77819c6d42b21d_EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e407ace0-2296-4d5b-a478-2fb186e09b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e407ace0-2296-4d5b-a478-2fb186e09b93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_25994716-cd2a-4d67-94e1-94ef13e7bc4d" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanExpectedFutureBenefitPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_25994716-cd2a-4d67-94e1-94ef13e7bc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_aca2c59d-a584-4023-b653-3f6a7e95646e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_aca2c59d-a584-4023-b653-3f6a7e95646e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_de8a0c76-c6a9-4ade-bd78-0fddd5b4852e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_de8a0c76-c6a9-4ade-bd78-0fddd5b4852e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_4e0ce694-e531-40fb-9d9d-1a208043fab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_4e0ce694-e531-40fb-9d9d-1a208043fab7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_53ce44fb-389a-4ced-ae3e-ad46fc5d4980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_53ce44fb-389a-4ced-ae3e-ad46fc5d4980" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_88fd89ac-0a5c-4894-b9fd-f0b34eebceba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_88fd89ac-0a5c-4894-b9fd-f0b34eebceba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_0baded5d-486e-4ef6-a33e-658262b8846d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_0baded5d-486e-4ef6-a33e-658262b8846d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_91a61bc1-07b5-4eae-b430-3c3f655299bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_91a61bc1-07b5-4eae-b430-3c3f655299bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_68b2cd5c-d7e5-4acd-abcd-9c285ad8e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_68b2cd5c-d7e5-4acd-abcd-9c285ad8e6a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e4286542-ba3d-4f0e-9b20-44dd227796e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e4286542-ba3d-4f0e-9b20-44dd227796e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1c23e2c6-6126-4a51-9055-ef8933d2531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1c23e2c6-6126-4a51-9055-ef8933d2531e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_63410ac7-3eba-4a69-8e49-423405951f29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_63410ac7-3eba-4a69-8e49-423405951f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a737c767-ec9e-4540-b922-7f79fe286889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a737c767-ec9e-4540-b922-7f79fe286889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ec0f587d-4fbf-4742-8dc4-64249e2fa6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a737c767-ec9e-4540-b922-7f79fe286889" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ec0f587d-4fbf-4742-8dc4-64249e2fa6ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eca8a3d7-c9a1-4eb6-b605-9d684079107c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eca8a3d7-c9a1-4eb6-b605-9d684079107c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_180fa476-fca5-44c4-93ac-50030e516a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_180fa476-fca5-44c4-93ac-50030e516a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_363f17ee-24be-4ca0-b608-3777004043bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_363f17ee-24be-4ca0-b608-3777004043bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ae212fec-2a34-4570-b46f-d3191003c3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ae212fec-2a34-4570-b46f-d3191003c3fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b143e961-b9fb-413d-b4fb-21876eec19ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b143e961-b9fb-413d-b4fb-21876eec19ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bccedf1b-b3a9-48da-8547-f1ca9d9104f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bccedf1b-b3a9-48da-8547-f1ca9d9104f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_82ddc117-408a-462f-9de2-fc882bffaac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_82ddc117-408a-462f-9de2-fc882bffaac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_82bb3d56-72f0-4c8c-bd0c-14dbada24654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_82bb3d56-72f0-4c8c-bd0c-14dbada24654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1d3d414b-eefa-4242-ae6a-0db979fa1620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1d3d414b-eefa-4242-ae6a-0db979fa1620" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_bc33226b-9826-4511-ad1d-ad25553605c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_PrivateEquityFundsMember_bc33226b-9826-4511-ad1d-ad25553605c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_a54436e4-8d74-47fb-beeb-261956a1d328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_a54436e4-8d74-47fb-beeb-261956a1d328" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_6d3847a5-95c1-4edc-97a0-75c9429a80f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_HedgeFundsMember_6d3847a5-95c1-4edc-97a0-75c9429a80f5" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#PROPERTYANDEQUIPMENTComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails" xlink:type="extended" id="ie4165ad532184453931da874c99d3813_PROPERTYANDEQUIPMENTComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1fab53a2-7e9d-4985-9931-ff3b6a0fb6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1fab53a2-7e9d-4985-9931-ff3b6a0fb6b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6d963a89-5016-4fcc-9c37-9195f4fc2fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6d963a89-5016-4fcc-9c37-9195f4fc2fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2e8f76a4-3a67-43e6-a809-92d11c460e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2e8f76a4-3a67-43e6-a809-92d11c460e1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_306e1c0a-8963-4681-8a79-31c9ddcdc4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_306e1c0a-8963-4681-8a79-31c9ddcdc4e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_58efded8-4d9d-443b-9289-51cf21668ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_58efded8-4d9d-443b-9289-51cf21668ca3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_69064c7c-30e9-4dd8-8cdf-2b084d6f3a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_Depreciation_69064c7c-30e9-4dd8-8cdf-2b084d6f3a53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_ae2f0a95-f18a-4458-97f4-fc49e5e5fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_LandMember_ae2f0a95-f18a-4458-97f4-fc49e5e5fd3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_18856845-fa29-4030-a647-ad4cb83fda88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_18856845-fa29-4030-a647-ad4cb83fda88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_253c25d9-0555-4333-97ab-0ae784ef5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_ConstructionInProgressMember_253c25d9-0555-4333-97ab-0ae784ef5b52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f6fff71a-8b2c-4b45-8ae8-5e89091b995b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_EquipmentMember_f6fff71a-8b2c-4b45-8ae8-5e89091b995b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails" xlink:type="extended" id="if9c406f0708a497b8de763ad53f7e3a1_GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:to="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_d707581b-52e4-4b7f-89f2-e51591329efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillGross_d707581b-52e4-4b7f-89f2-e51591329efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a7517270-7d2a-433c-b559-09867fad381d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a7517270-7d2a-433c-b559-09867fad381d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07ee9400-2309-4849-9cfb-a8b842dcd064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_Goodwill_07ee9400-2309-4849-9cfb-a8b842dcd064" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_ab5b8e78-fa93-46ba-b2e7-8796e9bfa0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTransfers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillTransfers_ab5b8e78-fa93-46ba-b2e7-8796e9bfa0d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_4c79ce55-d218-470c-93db-c6aafdec2e4e" xlink:href="thc-20221231.xsd#thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_4c79ce55-d218-470c-93db-c6aafdec2e4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_97232052-f6ce-46cf-a6f5-c6bee675ee85" xlink:href="thc-20221231.xsd#thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_97232052-f6ce-46cf-a6f5-c6bee675ee85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_4bc2ebf4-73c0-4003-8b2f-6d6d0d768d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_9b5a91a8-c820-4c42-8140-c7ba08dda59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dfe81df7-4253-4720-9510-3a3e548a471f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7e61fd47-ecad-42ba-aff6-ebf8699d55e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:to="loc_us-gaap_SegmentDomain_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:to="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_c4e6c7d2-6d4c-4768-b38c-4dd09fbf1966" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:to="loc_thc_HospitalOperationsMember_c4e6c7d2-6d4c-4768-b38c-4dd09fbf1966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_d248cc6e-a7f6-4b13-97b7-3ecf126b2b6d" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:to="loc_thc_AmbulatoryCareMember_d248cc6e-a7f6-4b13-97b7-3ecf126b2b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7e6bd213-6489-4462-8ab1-c0027edaadab" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:to="loc_thc_ConiferSegmentMember_7e6bd213-6489-4462-8ab1-c0027edaadab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" xlink:type="extended" id="iac82fd1981ee4921a75e2bb53d583664_GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b4c5530-fb17-4349-81e4-f2594fc4185c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b4c5530-fb17-4349-81e4-f2594fc4185c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8f38dd12-9827-40a7-9ddb-6e27e282acdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8f38dd12-9827-40a7-9ddb-6e27e282acdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1e02104-2306-4640-bea7-1e7eff03bfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1e02104-2306-4640-bea7-1e7eff03bfe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b9dd7633-8e88-42cb-af34-3163deab5ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b9dd7633-8e88-42cb-af34-3163deab5ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0f6a8c7c-6b36-4585-9fe8-c35919e30e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b9dd7633-8e88-42cb-af34-3163deab5ee0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0f6a8c7c-6b36-4585-9fe8-c35919e30e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_111a31af-e04e-4815-9176-a60fd31c98a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_111a31af-e04e-4815-9176-a60fd31c98a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_625ef0a3-135c-4a1f-84f7-4abc9c1e117a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_625ef0a3-135c-4a1f-84f7-4abc9c1e117a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af333e70-13bf-4551-b74e-1dc5b5a3cd15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af333e70-13bf-4551-b74e-1dc5b5a3cd15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_04244177-0c72-45cd-b8da-12fc11fb8a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_04244177-0c72-45cd-b8da-12fc11fb8a9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_4e99c947-2fc6-419f-8343-282ef3dad09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_4e99c947-2fc6-419f-8343-282ef3dad09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_f0ee6d30-e2d8-4174-a00e-530d1ecf2644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_f0ee6d30-e2d8-4174-a00e-530d1ecf2644" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_68346af3-654e-4cd2-8071-2767b0793f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_TradeNamesMember_68346af3-654e-4cd2-8071-2767b0793f2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_485c0bb0-0e7a-4c82-97a5-49e50bf442da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_485c0bb0-0e7a-4c82-97a5-49e50bf442da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_58bb7376-9093-4736-a11c-383756e6f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:to="loc_us-gaap_TradeNamesMember_58bb7376-9093-4736-a11c-383756e6f6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_45a3c957-0cf2-4772-93f4-56a8644b1188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_45a3c957-0cf2-4772-93f4-56a8644b1188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5860d1ba-e473-4071-9208-fddcae9523d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5860d1ba-e473-4071-9208-fddcae9523d9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETSScheduleofOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails" xlink:type="extended" id="i7027596c4a9a4cf78debe960bc551460_OTHERASSETSScheduleofOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d8d5a29a-b088-43f4-9d8a-f634d0ad8d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d8d5a29a-b088-43f4-9d8a-f634d0ad8d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d986bc6d-8adf-426b-8aba-7362ac7264f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d986bc6d-8adf-426b-8aba-7362ac7264f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_47a4fd4e-7d9f-4cd3-9716-ff55c86fd1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_47a4fd4e-7d9f-4cd3-9716-ff55c86fd1f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ReceivablesFromGovernmentProgramsCurrent_48d7f46a-2f74-40d8-b026-edb1c8f0848b" xlink:href="thc-20221231.xsd#thc_ReceivablesFromGovernmentProgramsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_thc_ReceivablesFromGovernmentProgramsCurrent_48d7f46a-2f74-40d8-b026-edb1c8f0848b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent_f558bbc7-f429-41cb-a128-f9f4c8a58786" xlink:href="thc-20221231.xsd#thc_PhysicianAndGroupCoverageGuaranteesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent_f558bbc7-f429-41cb-a128-f9f4c8a58786" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_e4de5317-5c7f-4e42-85bb-974f02e24d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_OtherReceivables_e4de5317-5c7f-4e42-85bb-974f02e24d11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_d9ccb39f-d585-4783-99da-69c98a882d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_d9ccb39f-d585-4783-99da-69c98a882d1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_947ce986-5fc9-426c-852f-b0d293277bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_OtherAssetsCurrent_947ce986-5fc9-426c-852f-b0d293277bc0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9ff04a45-3196-4f42-a5ae-0a6946733636_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:to="loc_us-gaap_ReceivableTypeDomain_9ff04a45-3196-4f42-a5ae-0a6946733636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_676f175a-2a7e-4fd2-8c5e-8a52ba410cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:to="loc_us-gaap_ReceivableTypeDomain_676f175a-2a7e-4fd2-8c5e-8a52ba410cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaProviderFeeProgramMember_f6c24ea2-2548-4e50-ad11-ac44f8174201" xlink:href="thc-20221231.xsd#thc_CaliforniaProviderFeeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_676f175a-2a7e-4fd2-8c5e-8a52ba410cde" xlink:to="loc_thc_CaliforniaProviderFeeProgramMember_f6c24ea2-2548-4e50-ad11-ac44f8174201" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" xlink:type="extended" id="i1236aa73171648199aabf390b5debb93_ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8adb7c41-ced9-45af-b7ac-0a1646ef2183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_StockholdersEquity_8adb7c41-ced9-45af-b7ac-0a1646ef2183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax_4e448b74-6579-4229-b7f4-4f19072b675f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax_4e448b74-6579-4229-b7f4-4f19072b675f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e6153505-04ca-4fc7-9c98-44ed46395d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e6153505-04ca-4fc7-9c98-44ed46395d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb8c8cdf-0461-4836-95c9-9093f0831de1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:to="loc_us-gaap_EquityComponentDomain_cb8c8cdf-0461-4836-95c9-9093f0831de1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:to="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_eac7500c-c5f4-4cf9-a858-1849d34ee015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_eac7500c-c5f4-4cf9-a858-1849d34ee015" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_987bfa1a-f51f-4387-ab04-3bf8f58009f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_987bfa1a-f51f-4387-ab04-3bf8f58009f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_dc3d6d57-6f47-4cda-81a3-60873c6b2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_dc3d6d57-6f47-4cda-81a3-60873c6b2d18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_41fb5e1a-ad77-4c66-a58a-06958b92ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_41fb5e1a-ad77-4c66-a58a-06958b92ed12" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails" xlink:type="extended" id="i1277b78bafd24042b880b89d5afe4106_NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac9f05-cf50-428e-958f-0f1999f4a021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21368ca6-59ee-4b40-8a44-c05ead8adad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac9f05-cf50-428e-958f-0f1999f4a021" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21368ca6-59ee-4b40-8a44-c05ead8adad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac9f05-cf50-428e-958f-0f1999f4a021" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0fcaa24a-2426-48d3-9b0c-1480dd159f39_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:to="loc_srt_ConsolidationItemsDomain_0fcaa24a-2426-48d3-9b0c-1480dd159f39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:to="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9c548abe-60e0-428f-a0c3-fc357adf2692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:to="loc_us-gaap_OperatingSegmentsMember_9c548abe-60e0-428f-a0c3-fc357adf2692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_edfe64bd-762f-4711-96d8-f6a4bb8afb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:to="loc_us-gaap_IntersegmentEliminationMember_edfe64bd-762f-4711-96d8-f6a4bb8afb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_79e7ebce-460e-43c3-b450-67500ad0664d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:to="loc_us-gaap_SegmentDomain_79e7ebce-460e-43c3-b450-67500ad0664d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:to="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_4f390127-ada1-4a39-bbbc-3e6e9825741f" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:to="loc_thc_HospitalOperationsMember_4f390127-ada1-4a39-bbbc-3e6e9825741f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_014c6767-dffa-41da-90b7-b730ec87a6fe" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:to="loc_thc_AmbulatoryCareMember_014c6767-dffa-41da-90b7-b730ec87a6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_c6e3f473-21f6-4185-9ca3-1c44f3b42d56" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:to="loc_thc_ConiferSegmentMember_c6e3f473-21f6-4185-9ca3-1c44f3b42d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_58e12b3e-ae46-4499-874a-f46775bd98ff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:to="loc_srt_ProductsAndServicesDomain_58e12b3e-ae46-4499-874a-f46775bd98ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:to="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceExcludingPhysicianPracticesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:to="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MedicareMember_6e160291-79c5-4235-97a2-a69abe5ec231" xlink:href="thc-20221231.xsd#thc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_MedicareMember_6e160291-79c5-4235-97a2-a69abe5ec231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceMedicaidMember_c3f0c990-81d1-445b-9e9a-0837e0c49a34" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceMedicaidMember_c3f0c990-81d1-445b-9e9a-0837e0c49a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceManagedCareMember_a8dff0a6-145c-4ff3-a457-0f2957da2ef6" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceManagedCareMember_a8dff0a6-145c-4ff3-a457-0f2957da2ef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceSelfpayMember_45fc00d0-95d3-486c-9719-9307a6b2f61c" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceSelfpayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceSelfpayMember_45fc00d0-95d3-486c-9719-9307a6b2f61c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceIndemnityAndOtherMember_f519106a-e5d2-4466-888b-fdf18f28a63e" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceIndemnityAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceIndemnityAndOtherMember_f519106a-e5d2-4466-888b-fdf18f28a63e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherRevenuesMember_81ed5be7-8285-4b6f-beba-195ef641de6e" xlink:href="thc-20221231.xsd#thc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:to="loc_thc_OtherRevenuesMember_81ed5be7-8285-4b6f-beba-195ef641de6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:to="loc_us-gaap_SubsegmentsDomain_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_e1d68e91-7b54-4738-bfcb-4640b6a1c809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:to="loc_us-gaap_SubsegmentsDomain_e1d68e91-7b54-4738-bfcb-4640b6a1c809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_26e42f32-71a4-4a6b-b76f-b6b2ae8a5ccf" xlink:href="thc-20221231.xsd#thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_e1d68e91-7b54-4738-bfcb-4640b6a1c809" xlink:to="loc_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_26e42f32-71a4-4a6b-b76f-b6b2ae8a5ccf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails" xlink:type="extended" id="i02dcdf5b58204932876025ea0db9419a_NETOPERATINGREVENUESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9db1ada7-50e7-462d-ae61-4bcf6621a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e23e180-2c06-4a98-b4aa-04a6b644fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9db1ada7-50e7-462d-ae61-4bcf6621a38b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e23e180-2c06-4a98-b4aa-04a6b644fba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9db1ada7-50e7-462d-ae61-4bcf6621a38b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:to="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_35e0c1c1-9e68-4544-96c8-93fb25565ba3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:to="loc_srt_RestatementDomain_35e0c1c1-9e68-4544-96c8-93fb25565ba3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b5f6ac34-6225-417a-bb91-d890338972ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:to="loc_srt_RestatementDomain_b5f6ac34-6225-417a-bb91-d890338972ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_3d8423ca-d6ca-4730-946f-f5d480b0028f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_b5f6ac34-6225-417a-bb91-d890338972ac" xlink:to="loc_srt_RestatementAdjustmentMember_3d8423ca-d6ca-4730-946f-f5d480b0028f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails" xlink:type="extended" id="i9c5e6b3b34554bcdad8c31a036184151_NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_df5757de-11b2-4dad-b435-68b7cadd580d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5058e43f-5dbe-495a-aba0-f200cdd0a213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_df5757de-11b2-4dad-b435-68b7cadd580d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5058e43f-5dbe-495a-aba0-f200cdd0a213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_df5757de-11b2-4dad-b435-68b7cadd580d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:to="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_905b611b-5639-441d-8538-6d91a6a3ceaf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:to="loc_srt_ProductsAndServicesDomain_905b611b-5639-441d-8538-6d91a6a3ceaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:to="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_d5248216-8044-4f9e-be89-3f19a1580e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_d5248216-8044-4f9e-be89-3f19a1580e38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareManagementFeesMember_e6bbbf3f-fa76-4ed0-b48c-ac231f3ec323" xlink:href="thc-20221231.xsd#thc_HealthCareManagementFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:to="loc_thc_HealthCareManagementFeesMember_e6bbbf3f-fa76-4ed0-b48c-ac231f3ec323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareOtherSourcesMember_a7cf59d2-e671-442a-ac9d-e3f407e6f580" xlink:href="thc-20221231.xsd#thc_HealthCareOtherSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:to="loc_thc_HealthCareOtherSourcesMember_a7cf59d2-e671-442a-ac9d-e3f407e6f580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_03730994-c8aa-47b1-ac21-b5891931b5c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:to="loc_us-gaap_SegmentDomain_03730994-c8aa-47b1-ac21-b5891931b5c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d990b7c8-50b9-415a-912f-7a57f34fb6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:to="loc_us-gaap_SegmentDomain_d990b7c8-50b9-415a-912f-7a57f34fb6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_1151f57c-edeb-4362-ba66-674fba449202" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d990b7c8-50b9-415a-912f-7a57f34fb6c8" xlink:to="loc_thc_AmbulatoryCareMember_1151f57c-edeb-4362-ba66-674fba449202" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails" xlink:type="extended" id="i0ba2208de6194254988ac82a4902b221_NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6e98668e-c47c-4296-adba-ff24c7a0c633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c932225-23ff-490c-910f-f1572e5acfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6e98668e-c47c-4296-adba-ff24c7a0c633" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c932225-23ff-490c-910f-f1572e5acfdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6e98668e-c47c-4296-adba-ff24c7a0c633" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ffd5f925-6d2f-44ee-8e72-0a3657aabb85_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:to="loc_srt_NameOfMajorCustomerDomain_ffd5f925-6d2f-44ee-8e72-0a3657aabb85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:to="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TenetHealthcareCorpMember_d6da2031-9097-4adf-a343-16cd1551cec0" xlink:href="thc-20221231.xsd#thc_TenetHealthcareCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:to="loc_thc_TenetHealthcareCorpMember_d6da2031-9097-4adf-a343-16cd1551cec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCustomersMember_76fc499d-eb40-4b07-b878-8b0138f1c8bb" xlink:href="thc-20221231.xsd#thc_OtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:to="loc_thc_OtherCustomersMember_76fc499d-eb40-4b07-b878-8b0138f1c8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6fa0c7bf-692a-4367-9c0c-9883375e21fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:to="loc_us-gaap_SegmentDomain_6fa0c7bf-692a-4367-9c0c-9883375e21fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1edf5853-60a7-43cb-91ca-5759d371094f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:to="loc_us-gaap_SegmentDomain_1edf5853-60a7-43cb-91ca-5759d371094f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_94e6fa3a-e3d2-4cd8-91cb-a6556adcdcd5" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1edf5853-60a7-43cb-91ca-5759d371094f" xlink:to="loc_thc_ConiferSegmentMember_94e6fa3a-e3d2-4cd8-91cb-a6556adcdcd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12cbf85d-1a73-4fd5-83ce-9501014c413c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:to="loc_srt_ProductsAndServicesDomain_12cbf85d-1a73-4fd5-83ce-9501014c413c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:to="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareClientContractsRevenueCycleServicesMember_8866a06c-8f97-45f4-a9c1-557810986979" xlink:href="thc-20221231.xsd#thc_HealthCareClientContractsRevenueCycleServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:to="loc_thc_HealthCareClientContractsRevenueCycleServicesMember_8866a06c-8f97-45f4-a9c1-557810986979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareClientContractsOtherServicesMember_d9ef7e64-6a59-430f-b863-84661cf2c546" xlink:href="thc-20221231.xsd#thc_HealthCareClientContractsOtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:to="loc_thc_HealthCareClientContractsOtherServicesMember_d9ef7e64-6a59-430f-b863-84661cf2c546" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails" xlink:type="extended" id="i7f5c8311012e44d195db25ab91054670_NETOPERATINGREVENUESPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_965c0a06-3650-4ba2-aa59-fdcb431be171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_965c0a06-3650-4ba2-aa59-fdcb431be171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1b4dd067-eb26-4003-8d93-147d535ed261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1b4dd067-eb26-4003-8d93-147d535ed261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_86ea2a6a-9397-4f01-b485-789c83f29f2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:to="loc_us-gaap_SegmentDomain_86ea2a6a-9397-4f01-b485-789c83f29f2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:to="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7c19c060-4b4e-477b-8865-8fe5bc73c52c" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:to="loc_thc_ConiferSegmentMember_7c19c060-4b4e-477b-8865-8fe5bc73c52c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_936d52fa-6325-49bd-9f23-a13bc059887f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_936d52fa-6325-49bd-9f23-a13bc059887f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails_1" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails_1" xlink:type="extended" id="ic7df48e1ae86425c9872bc5a94c596cf_NETOPERATINGREVENUESPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_965c0a06-3650-4ba2-aa59-fdcb431be171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_965c0a06-3650-4ba2-aa59-fdcb431be171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1b4dd067-eb26-4003-8d93-147d535ed261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1b4dd067-eb26-4003-8d93-147d535ed261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_86ea2a6a-9397-4f01-b485-789c83f29f2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:to="loc_us-gaap_SegmentDomain_86ea2a6a-9397-4f01-b485-789c83f29f2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:to="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7c19c060-4b4e-477b-8865-8fe5bc73c52c" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:to="loc_thc_ConiferSegmentMember_7c19c060-4b4e-477b-8865-8fe5bc73c52c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INSURANCEPropertyInsuranceDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails" xlink:type="extended" id="i8492e821db6640e58cf78df1c37e5f61_INSURANCEPropertyInsuranceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceAnnualCoverageLimit_922d57be-f3e9-4d32-9630-9dcb1419641b" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceAnnualCoverageLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceAnnualCoverageLimit_922d57be-f3e9-4d32-9630-9dcb1419641b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceMaximumCoveragePerIncident_66f40c3f-8a01-4dbd-9e73-26d559c925a5" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceMaximumCoveragePerIncident"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceMaximumCoveragePerIncident_66f40c3f-8a01-4dbd-9e73-26d559c925a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceDeductiblePercentage_f8c968a2-7b93-4dbc-b74d-a56aba29053b" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceDeductiblePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceDeductiblePercentage_f8c968a2-7b93-4dbc-b74d-a56aba29053b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceDeductible_4b8a92dc-d7ef-40d7-b9ab-45b77ae65233" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceDeductible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceDeductible_4b8a92dc-d7ef-40d7-b9ab-45b77ae65233" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CybersecurityIncidentPreTaxEffect_a5eaf86f-41a6-4f40-bda7-12cc889f9c2c" xlink:href="thc-20221231.xsd#thc_CybersecurityIncidentPreTaxEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_CybersecurityIncidentPreTaxEffect_a5eaf86f-41a6-4f40-bda7-12cc889f9c2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_760eacdb-5265-490b-ae29-46fa094514f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_us-gaap_InsuranceRecoveries_760eacdb-5265-490b-ae29-46fa094514f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48af2f5b-797a-44da-abfa-75c426318644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48af2f5b-797a-44da-abfa-75c426318644" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_6dd445a2-231d-48b4-8ed5-11d00e76484e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:to="loc_us-gaap_CatastrophicEventDomain_6dd445a2-231d-48b4-8ed5-11d00e76484e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:to="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FloodMember_6de38ca5-2718-4ecc-982e-ec9b71af6ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FloodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_us-gaap_FloodMember_6de38ca5-2718-4ecc-982e-ec9b71af6ce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarthquakeMember_9d6ba4ed-8f10-427f-b3fb-7b6379c6943a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarthquakeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_us-gaap_EarthquakeMember_9d6ba4ed-8f10-427f-b3fb-7b6379c6943a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_WindstormsMember_b0243586-0eb6-49bd-b085-cd68bbdf10f9" xlink:href="thc-20221231.xsd#thc_WindstormsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_WindstormsMember_b0243586-0eb6-49bd-b085-cd68bbdf10f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FireAndOtherPerilsMember_14e3a51c-20eb-4b31-ab82-101eb985d558" xlink:href="thc-20221231.xsd#thc_FireAndOtherPerilsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_FireAndOtherPerilsMember_14e3a51c-20eb-4b31-ab82-101eb985d558" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FloodEarthquakeAndWindstormMember_babe05f3-0301-4b8e-9c27-8455900963ab" xlink:href="thc-20221231.xsd#thc_FloodEarthquakeAndWindstormMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_FloodEarthquakeAndWindstormMember_babe05f3-0301-4b8e-9c27-8455900963ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaEarthquakeMember_edcd0ed4-6ded-46ab-9889-06e610352efa" xlink:href="thc-20221231.xsd#thc_CaliforniaEarthquakeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_CaliforniaEarthquakeMember_edcd0ed4-6ded-46ab-9889-06e610352efa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FloodsAndWindstormsMember_2348cbfd-0058-4798-84e1-3508f2503b44" xlink:href="thc-20221231.xsd#thc_FloodsAndWindstormsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_FloodsAndWindstormsMember_2348cbfd-0058-4798-84e1-3508f2503b44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NewMadridFaultEarthquakesMember_9b643cec-d3ad-475b-889d-8841541d55cd" xlink:href="thc-20221231.xsd#thc_NewMadridFaultEarthquakesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_NewMadridFaultEarthquakesMember_9b643cec-d3ad-475b-889d-8841541d55cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCatastrophicEventsMember_0bf5a2d6-2f9f-41b6-a663-70c914ae803c" xlink:href="thc-20221231.xsd#thc_OtherCatastrophicEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_OtherCatastrophicEventsMember_0bf5a2d6-2f9f-41b6-a663-70c914ae803c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2124a144-38d4-408e-b5e9-af0e9562fd15_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:to="loc_srt_ProductsAndServicesDomain_2124a144-38d4-408e-b5e9-af0e9562fd15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3bad834f-1f01-4c6e-814a-b9bac09c0ac7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:to="loc_srt_ProductsAndServicesDomain_3bad834f-1f01-4c6e-814a-b9bac09c0ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceRecoveriesMember_94555ce3-80fc-4e97-8cf1-7189486306f1" xlink:href="thc-20221231.xsd#thc_InsuranceRecoveriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3bad834f-1f01-4c6e-814a-b9bac09c0ac7" xlink:to="loc_thc_InsuranceRecoveriesMember_94555ce3-80fc-4e97-8cf1-7189486306f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_569a5503-7dfc-4630-a247-10ba9ebca3f8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_569a5503-7dfc-4630-a247-10ba9ebca3f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d9043606-40b3-44ad-b54c-784d6c0eda43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d9043606-40b3-44ad-b54c-784d6c0eda43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_612402fd-34d1-4b52-bfcc-0ff317ae426f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_d9043606-40b3-44ad-b54c-784d6c0eda43" xlink:to="loc_srt_ScenarioForecastMember_612402fd-34d1-4b52-bfcc-0ff317ae426f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INSURANCEProfessionalandGeneralLiabilityReservesDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails" xlink:type="extended" id="i5d654c997d4842f4bccc01bca668de26_INSURANCEProfessionalandGeneralLiabilityReservesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_3b1b9ea2-d131-4bc7-8f6f-b796906be9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_us-gaap_SelfInsuranceReserve_3b1b9ea2-d131-4bc7-8f6f-b796906be9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_0fc824ae-bcbd-424b-b051-bd973b7a7406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_0fc824ae-bcbd-424b-b051-bd973b7a7406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_35287f4a-2e16-49e9-ba2d-0d02a3a4d5ec" xlink:href="thc-20221231.xsd#thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_35287f4a-2e16-49e9-ba2d-0d02a3a4d5ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36beb541-bcee-470e-b1e8-4d58e7507a77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36beb541-bcee-470e-b1e8-4d58e7507a77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fcd971b6-9d64-4e09-b035-0f5f45149f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fcd971b6-9d64-4e09-b035-0f5f45149f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProfessionalAndGeneralLiabilityReservesMember_cbddef51-1b6c-421c-a65f-2350bb37d3e6" xlink:href="thc-20221231.xsd#thc_ProfessionalAndGeneralLiabilityReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fcd971b6-9d64-4e09-b035-0f5f45149f32" xlink:to="loc_thc_ProfessionalAndGeneralLiabilityReservesMember_cbddef51-1b6c-421c-a65f-2350bb37d3e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_71716ccf-428d-4f32-a116-802741d78068_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_71716ccf-428d-4f32-a116-802741d78068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cf6175bf-ce17-4b08-9fb8-75cf2bf24e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cf6175bf-ce17-4b08-9fb8-75cf2bf24e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_789fc6ae-78b4-4cbc-91d8-868e77012616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cf6175bf-ce17-4b08-9fb8-75cf2bf24e60" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_789fc6ae-78b4-4cbc-91d8-868e77012616" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CLAIMSANDLAWSUITSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails" xlink:type="extended" id="i2a038285c4b14c0ba71546660eb1186d_CLAIMSANDLAWSUITSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_d6223033-f804-4d20-a07a-9ccdb460db06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_d6223033-f804-4d20-a07a-9ccdb460db06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims_3b4904a1-dc73-41f1-8e57-e3844b44ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankruptcyClaimsAmountPaidToSettleClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:to="loc_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims_3b4904a1-dc73-41f1-8e57-e3844b44ff3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:to="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:to="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_63faf760-bbd8-4a56-9d4d-64f83d99a184_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:to="loc_srt_LitigationCaseTypeDomain_63faf760-bbd8-4a56-9d4d-64f83d99a184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e4ec3279-cdf8-4c70-8a51-98230ab74f27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:to="loc_srt_LitigationCaseTypeDomain_e4ec3279-cdf8-4c70-8a51-98230ab74f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherMattersMember_3c1d0d11-013d-412e-8f3a-be45901471a5" xlink:href="thc-20221231.xsd#thc_OtherMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e4ec3279-cdf8-4c70-8a51-98230ab74f27" xlink:to="loc_thc_OtherMattersMember_3c1d0d11-013d-412e-8f3a-be45901471a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CLAIMSANDLAWSUITSReconciliationsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails" xlink:type="extended" id="i308b688b366e4f479ec7632ae43c996b_CLAIMSANDLAWSUITSReconciliationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b5484caf-0ee8-435e-84b9-65d80058398a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5484caf-0ee8-435e-84b9-65d80058398a" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4530b6da-ef82-4021-872d-44fc5463286a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4530b6da-ef82-4021-872d-44fc5463286a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_4e731499-e8f6-4f5b-8862-a307b243aa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_4e731499-e8f6-4f5b-8862-a307b243aa57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_90a00305-3392-4876-a2a8-dc8e58120a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_90a00305-3392-4876-a2a8-dc8e58120a80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LossContingencyAccrualOther_f7e8f3df-4694-46ee-a505-13e1ea6e2d67" xlink:href="thc-20221231.xsd#thc_LossContingencyAccrualOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_thc_LossContingencyAccrualOther_f7e8f3df-4694-46ee-a505-13e1ea6e2d67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f3667702-8d04-4425-a6a1-fcc5f261db32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5484caf-0ee8-435e-84b9-65d80058398a" xlink:to="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:to="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_adcd2a66-edda-40a5-9136-c60a42fe13b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:to="loc_us-gaap_LitigationStatusDomain_adcd2a66-edda-40a5-9136-c60a42fe13b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_aa59c6b8-e922-457a-8685-eb5ee661b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:to="loc_us-gaap_LitigationStatusDomain_aa59c6b8-e922-457a-8685-eb5ee661b6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_216dd745-da15-443a-9be6-db521ee97745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_aa59c6b8-e922-457a-8685-eb5ee661b6a4" xlink:to="loc_us-gaap_PendingLitigationMember_216dd745-da15-443a-9be6-db521ee97745" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails" xlink:type="extended" id="i07c51026993746a3b7e36c4e686e46ea_REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_44fc094a-c69c-4efc-a21f-40e39a06eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_44fc094a-c69c-4efc-a21f-40e39a06eac8" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_JointVentureOwnershipPercentage_67705ffa-95c3-4c55-82fc-df1d958a2de4" xlink:href="thc-20221231.xsd#thc_JointVentureOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_JointVentureOwnershipPercentage_67705ffa-95c3-4c55-82fc-df1d958a2de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_22790636-2576-4e93-98ad-10f80ae41857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_22790636-2576-4e93-98ad-10f80ae41857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_88bbf279-12c6-467c-84a8-01bb297b1a92" xlink:href="thc-20221231.xsd#thc_PurchasedEquityInJointVenturePercentageOfTotalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_88bbf279-12c6-467c-84a8-01bb297b1a92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_2c66a8bc-2a29-4c15-add8-fe57aeac102e" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_2c66a8bc-2a29-4c15-add8-fe57aeac102e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementPaymentForExecution_5c1f08e2-9737-49b5-838a-43f33acb198b" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementPaymentForExecution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementPaymentForExecution_5c1f08e2-9737-49b5-838a-43f33acb198b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementNumberOfMonthlyPayments_26f9f1cf-3308-46a2-ae5a-1359ad862dca" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementNumberOfMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementNumberOfMonthlyPayments_26f9f1cf-3308-46a2-ae5a-1359ad862dca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementMonthlyPayment_314166d4-1f63-4506-8a9d-89dd88a69130" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementMonthlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementMonthlyPayment_314166d4-1f63-4506-8a9d-89dd88a69130" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c10fec58-cc81-4ffe-b65c-8dfb7c747365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c10fec58-cc81-4ffe-b65c-8dfb7c747365" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_4d2b1f21-abb7-42cf-ab25-6e117df66525" xlink:href="thc-20221231.xsd#thc_GainLossFromPurchaseOfNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_4d2b1f21-abb7-42cf-ab25-6e117df66525" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4ce6aa03-8930-47fa-b766-607bbe2cd956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4ce6aa03-8930-47fa-b766-607bbe2cd956" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_683b1449-e0fb-4f25-9e24-80ae1f074c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_683b1449-e0fb-4f25-9e24-80ae1f074c22" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_44fc094a-c69c-4efc-a21f-40e39a06eac8" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0940e19b-0354-4fd6-acd1-a0fec3e7e2b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0940e19b-0354-4fd6-acd1-a0fec3e7e2b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_8a9b446f-ad18-493f-82d0-e108456be537" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0940e19b-0354-4fd6-acd1-a0fec3e7e2b0" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_8a9b446f-ad18-493f-82d0-e108456be537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ed64c770-1cc4-48e8-9306-da27ec0bfad3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:to="loc_srt_OwnershipDomain_ed64c770-1cc4-48e8-9306-da27ec0bfad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9f2f051f-0cf4-4612-8480-1b8568db6225" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:to="loc_srt_OwnershipDomain_9f2f051f-0cf4-4612-8480-1b8568db6225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_4dc65d45-7b2e-44b9-a26b-4c43b6385999" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9f2f051f-0cf4-4612-8480-1b8568db6225" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_4dc65d45-7b2e-44b9-a26b-4c43b6385999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_32442704-d38d-4db3-8bdc-42bf03785a67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_32442704-d38d-4db3-8bdc-42bf03785a67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_d7e6a9f5-4b8e-49e0-afcd-87a18dfc044e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_d7e6a9f5-4b8e-49e0-afcd-87a18dfc044e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_f334d5af-dcc9-49e9-8b4f-f0bd009d54ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_d7e6a9f5-4b8e-49e0-afcd-87a18dfc044e" xlink:to="loc_us-gaap_PutOptionMember_f334d5af-dcc9-49e9-8b4f-f0bd009d54ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f41de0e-2cba-4749-a959-2ae50b9e0599_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:to="loc_srt_RangeMember_8f41de0e-2cba-4749-a959-2ae50b9e0599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_065e93c0-5289-4004-bd90-c4b1e9a668d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:to="loc_srt_RangeMember_065e93c0-5289-4004-bd90-c4b1e9a668d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_249431b5-1ca4-4a86-abf6-569d05c2204b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_065e93c0-5289-4004-bd90-c4b1e9a668d9" xlink:to="loc_srt_MaximumMember_249431b5-1ca4-4a86-abf6-569d05c2204b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails" xlink:type="extended" id="iaab7f42cee1d4833bd7e9206cfc86d05_REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_a97b3e89-d147-44ff-b674-139e09d3157a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_a97b3e89-d147-44ff-b674-139e09d3157a" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ca7f7fd7-75b7-4155-8b13-c42822a14f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ca7f7fd7-75b7-4155-8b13-c42822a14f81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_dee7890f-be1f-4f86-9bab-f7ec049a7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_dee7890f-be1f-4f86-9bab-f7ec049a7d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_f5c778c8-b4e7-4cc8-9fc0-3c3fe518ec98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_f5c778c8-b4e7-4cc8-9fc0-3c3fe518ec98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e9b6b9bf-b0d7-4871-9bf9-edbcc3eac8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e9b6b9bf-b0d7-4871-9bf9-edbcc3eac8e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_fb6af18d-f582-4c82-b416-8a8c65f7ed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_fb6af18d-f582-4c82-b416-8a8c65f7ed5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7e1210af-aef9-4da5-9f58-3d73c8a9a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_a97b3e89-d147-44ff-b674-139e09d3157a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a78e41d-2796-474c-9be5-dba758cbd156_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:to="loc_us-gaap_EquityComponentDomain_6a78e41d-2796-474c-9be5-dba758cbd156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b22d1641-033f-4c5d-90a0-b688b2d586ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:to="loc_us-gaap_EquityComponentDomain_b22d1641-033f-4c5d-90a0-b688b2d586ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RedeemableNoncontrollingInterestMember_89320e61-4d75-4cea-911f-5d50d6b02f9c" xlink:href="thc-20221231.xsd#thc_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b22d1641-033f-4c5d-90a0-b688b2d586ca" xlink:to="loc_thc_RedeemableNoncontrollingInterestMember_89320e61-4d75-4cea-911f-5d50d6b02f9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails" xlink:type="extended" id="if14ff3947ee947da8a048f20eedabc71_REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_35ed9da0-a5fb-4fe6-a109-b5197d65bc79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_35ed9da0-a5fb-4fe6-a109-b5197d65bc79" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_00997585-87c8-43bc-a2aa-638f13b98a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_00997585-87c8-43bc-a2aa-638f13b98a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_82935491-02b6-4e49-bb06-5b5af28c3345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_82935491-02b6-4e49-bb06-5b5af28c3345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_35ed9da0-a5fb-4fe6-a109-b5197d65bc79" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cafdec35-1413-42a3-a26a-ed59a87bd9f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:to="loc_us-gaap_SegmentDomain_cafdec35-1413-42a3-a26a-ed59a87bd9f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:to="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_fd7c9d8b-86f2-4148-b2da-09b8952445c8" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:to="loc_thc_HospitalOperationsMember_fd7c9d8b-86f2-4148-b2da-09b8952445c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_3503faee-fffc-40ef-86aa-1e692e410b31" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:to="loc_thc_AmbulatoryCareMember_3503faee-fffc-40ef-86aa-1e692e410b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_18e52f11-f101-4ac4-a958-b8b2e2abae39" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:to="loc_thc_ConiferSegmentMember_18e52f11-f101-4ac4-a958-b8b2e2abae39" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i6ef25bcf865f4acc8450c863ea0f8307_INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_85241afa-7fd8-4697-8c70-a5cf114c7133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_85241afa-7fd8-4697-8c70-a5cf114c7133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_32594556-f385-4a31-b172-8667e6d3f15f" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_32594556-f385-4a31-b172-8667e6d3f15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_0a757b2f-71d2-44e2-940c-329a67146afc" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_0a757b2f-71d2-44e2-940c-329a67146afc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_6db52d51-d9d3-43d3-a634-5c0bcbd0e4ea" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_6db52d51-d9d3-43d3-a634-5c0bcbd0e4ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cab9a488-844b-4640-9eec-6b736114f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cab9a488-844b-4640-9eec-6b736114f55f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_eeafbb1f-cd23-4b03-ba2f-b550a9d2efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_eeafbb1f-cd23-4b03-ba2f-b550a9d2efdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_42cf43f7-a177-4f01-862c-17d38b70a1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_42cf43f7-a177-4f01-862c-17d38b70a1e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f7356023-cc5e-4a8e-ae94-275b82474b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f7356023-cc5e-4a8e-ae94-275b82474b3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d7201023-7095-4915-b740-2bcf81f98544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7c7fff71-1483-465a-80cc-cebf8048931e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7c7fff71-1483-465a-80cc-cebf8048931e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_818e8e5b-e745-43b8-aa45-41e112bf27d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_818e8e5b-e745-43b8-aa45-41e112bf27d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d6bf6d32-3042-472a-8afd-b71ad9677ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d6bf6d32-3042-472a-8afd-b71ad9677ebf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_af36acae-3177-4c36-8681-26107bb570ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_6151a8f0-dbd8-4617-9b24-007341887287_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_6151a8f0-dbd8-4617-9b24-007341887287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_d9f7a463-d882-472e-aa39-acfd61a3abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_d9f7a463-d882-472e-aa39-acfd61a3abc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_d3f24a71-3f1a-41c6-9ad2-7c0ea26b14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_d9f7a463-d882-472e-aa39-acfd61a3abc3" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_d3f24a71-3f1a-41c6-9ad2-7c0ea26b14b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESNOLandTaxCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails" xlink:type="extended" id="i837c1170099b4d42a3e924289954ded3_INCOMETAXESNOLandTaxCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_85039606-f775-4b3e-9b71-caad82faf32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_85039606-f775-4b3e-9b71-caad82faf32f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7f114465-54e2-4021-a1be-68edea9aae92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7f114465-54e2-4021-a1be-68edea9aae92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OperatingLossCarryforwardsSubjectToExpiration_342326f1-42e4-4041-9c57-3283f4ff758e" xlink:href="thc-20221231.xsd#thc_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_thc_OperatingLossCarryforwardsSubjectToExpiration_342326f1-42e4-4041-9c57-3283f4ff758e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OperatingLossCarryforwardsNotSubjectToExpiration_110403fe-90ff-4722-aa75-0c7fca0a3874" xlink:href="thc-20221231.xsd#thc_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_thc_OperatingLossCarryforwardsNotSubjectToExpiration_110403fe-90ff-4722-aa75-0c7fca0a3874" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_8210d0b9-c826-4f0a-b459-111f1a34f535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_8210d0b9-c826-4f0a-b459-111f1a34f535" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_651aca0a-c178-477c-bcac-54502f799136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_651aca0a-c178-477c-bcac-54502f799136" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6fef20d3-dbc5-4db3-bbb4-a43cffff5991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:to="loc_us-gaap_DomesticCountryMember_6fef20d3-dbc5-4db3-bbb4-a43cffff5991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f991c0b9-834b-43bf-84e5-500cade7f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f991c0b9-834b-43bf-84e5-500cade7f298" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended" id="ibddabd8ef12843d1b8953f138dafda57_FAIRVALUEMEASUREMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e410cea4-9df9-463a-a791-00ffe00e86d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_us-gaap_AssetImpairmentCharges_e410cea4-9df9-463a-a791-00ffe00e86d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AssetsHeldforuseLongLivedFairValueDisclosure_a53e245e-a27d-4c60-ab62-0b2d5738960e" xlink:href="thc-20221231.xsd#thc_AssetsHeldforuseLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_thc_AssetsHeldforuseLongLivedFairValueDisclosure_a53e245e-a27d-4c60-ab62-0b2d5738960e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_000f674d-7b4c-413d-85c3-4360fd79d3d1" xlink:href="thc-20221231.xsd#thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_000f674d-7b4c-413d-85c3-4360fd79d3d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b647c2ee-dfc9-4314-92d1-53108cab4337_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b647c2ee-dfc9-4314-92d1-53108cab4337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90f88e84-63e8-4cbc-8c4c-106626fe29dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90f88e84-63e8-4cbc-8c4c-106626fe29dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_927c54ef-c3e4-4cd5-8658-1652d8b4f56a" xlink:href="thc-20221231.xsd#thc_HospitalBuildingsAndMedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90f88e84-63e8-4cbc-8c4c-106626fe29dd" xlink:to="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_927c54ef-c3e4-4cd5-8658-1652d8b4f56a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cc16b756-4c28-40d7-bff5-e4d7c201591f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cc16b756-4c28-40d7-bff5-e4d7c201591f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ede29c27-ed9a-4ccb-8b0f-fe46bf44ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ede29c27-ed9a-4ccb-8b0f-fe46bf44ef29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_999b6cb9-e40e-4499-aa5a-2f4ed67f3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_999b6cb9-e40e-4499-aa5a-2f4ed67f3d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aa920b1-46a7-4a20-bf8b-033979511cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aa920b1-46a7-4a20-bf8b-033979511cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ef90b112-a6cf-46c1-b8fd-04f7c0ed350e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aa920b1-46a7-4a20-bf8b-033979511cd7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ef90b112-a6cf-46c1-b8fd-04f7c0ed350e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i8e6ff9593b51424d98fdad7fffa981f2_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_127ea661-3a27-47ba-bff7-1cd117aa9734" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_127ea661-3a27-47ba-bff7-1cd117aa9734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersInDevelopmentStage_a04ce85a-b05b-408d-8838-fdd10ddc9216" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersInDevelopmentStage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfSurgicalCentersInDevelopmentStage_a04ce85a-b05b-408d-8838-fdd10ddc9216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_572c8533-2b2b-4fd0-8e0f-cbe783fda34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_572c8533-2b2b-4fd0-8e0f-cbe783fda34a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ceada531-12e5-48d1-aa8c-d6eba6070054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_Goodwill_ceada531-12e5-48d1-aa8c-d6eba6070054" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_c17c6d01-a69a-4263-a607-8789ce845522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_c17c6d01-a69a-4263-a607-8789ce845522" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersAcquired_87041673-56f1-4355-adef-9fc594ff39d3" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfSurgicalCentersAcquired_87041673-56f1-4355-adef-9fc594ff39d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c8912395-b923-44d2-831c-0228fde64d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c8912395-b923-44d2-831c-0228fde64d82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_ae3980d7-05dd-43b6-8f5a-ad19e0d567d0" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersRecordedUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_ae3980d7-05dd-43b6-8f5a-ad19e0d567d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCenters_cbfb1b7c-7e73-44f3-8019-6482143a6e66" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfAmbulatorySurgeryCenters_cbfb1b7c-7e73-44f3-8019-6482143a6e66" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_5e6d3b50-764b-4edb-a41b-7896f2c7ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_5e6d3b50-764b-4edb-a41b-7896f2c7ec25" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberofHospitals_0072037e-36e8-40b1-8d71-df666cd40168" xlink:href="thc-20221231.xsd#thc_NumberofHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberofHospitals_0072037e-36e8-40b1-8d71-df666cd40168" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_47fca748-7a85-4c8d-ab73-fbc4a15e4060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_47fca748-7a85-4c8d-ab73-fbc4a15e4060" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_21a0218b-79e8-4b94-8bd7-a6772421bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_21a0218b-79e8-4b94-8bd7-a6772421bf00" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_9544d6b1-331b-4fcd-9d50-849b872b0b0e" xlink:href="thc-20221231.xsd#thc_BusinessCombinationAcquisitionRelatedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_9544d6b1-331b-4fcd-9d50-849b872b0b0e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_dd74515b-87ef-40b1-8f85-f9f71e3621e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_dd74515b-87ef-40b1-8f85-f9f71e3621e7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb87877d-633c-4840-a6a9-70e62a6cf404_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb87877d-633c-4840-a6a9-70e62a6cf404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedUrologyGroupMember_713a7330-f70d-4395-9fe3-bfdc944ecab6" xlink:href="thc-20221231.xsd#thc_UnitedUrologyGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:to="loc_thc_UnitedUrologyGroupMember_713a7330-f70d-4395-9fe3-bfdc944ecab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_01e32d57-ae22-4bcf-ae1b-4ee9d786282b" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_01e32d57-ae22-4bcf-ae1b-4ee9d786282b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4c535a0-56f9-403b-8fef-fef17a7c43e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4c535a0-56f9-403b-8fef-fef17a7c43e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2022AcquisitionMember_84cafad3-c4cf-4ba6-b82e-6b727e76c063" xlink:href="thc-20221231.xsd#thc_A2022AcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_thc_A2022AcquisitionMember_84cafad3-c4cf-4ba6-b82e-6b727e76c063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_73d6b472-a0d1-4da0-ab66-6f6b6e6f24ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_73d6b472-a0d1-4da0-ab66-6f6b6e6f24ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2021SCDCentersMember_9092a5e4-fab4-4f99-b68e-62b46c702aeb" xlink:href="thc-20221231.xsd#thc_A2021SCDCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_thc_A2021SCDCentersMember_9092a5e4-fab4-4f99-b68e-62b46c702aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2020SCDCentersMember_37e6673b-33ae-4582-8ffc-77e1b529c362" xlink:href="thc-20221231.xsd#thc_A2020SCDCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_thc_A2020SCDCentersMember_37e6673b-33ae-4582-8ffc-77e1b529c362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_64d845ed-3930-4778-91e8-9912131c793c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:to="loc_us-gaap_SegmentDomain_64d845ed-3930-4778-91e8-9912131c793c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de23a515-db9e-41a2-b118-63f879863125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:to="loc_us-gaap_SegmentDomain_de23a515-db9e-41a2-b118-63f879863125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_54389af6-89ba-443d-aca4-58d313c93fbe" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_de23a515-db9e-41a2-b118-63f879863125" xlink:to="loc_thc_AmbulatoryCareMember_54389af6-89ba-443d-aca4-58d313c93fbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails" xlink:type="extended" id="i381bb51b2f064347a8cbb2d4e0ba4866_ACQUISITIONSPurchasePriceAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8425ce94-a7f4-4d02-89a4-f3037113fc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8425ce94-a7f4-4d02-89a4-f3037113fc3f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f6030bdc-cd27-455e-bc84-eef46d3d2bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f6030bdc-cd27-455e-bc84-eef46d3d2bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3ad2e793-8e08-48aa-889c-91e6bd0c031b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3ad2e793-8e08-48aa-889c-91e6bd0c031b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6bf9683c-93c3-4b55-9f7b-6b685cc55105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6bf9683c-93c3-4b55-9f7b-6b685cc55105" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f5ae1bcf-e0d8-461b-846c-35a270576ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_Goodwill_f5ae1bcf-e0d8-461b-846c-35a270576ab3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_70cf3194-9641-4965-858d-25e6c192fbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_70cf3194-9641-4965-858d-25e6c192fbf5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_a8f5698f-6178-4008-8d08-aad197a28e8e" xlink:href="thc-20221231.xsd#thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_a8f5698f-6178-4008-8d08-aad197a28e8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_95edea12-7bab-4ed3-890d-d3ff415911bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_95edea12-7bab-4ed3-890d-d3ff415911bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_115a4f64-518b-471e-b570-a67e0d4e1b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_115a4f64-518b-471e-b570-a67e0d4e1b7c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_b5d335b3-e00a-4537-89dc-ca1767fc7396" xlink:href="thc-20221231.xsd#thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_b5d335b3-e00a-4537-89dc-ca1767fc7396" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_f64e2c50-fa76-4cf5-9646-6f46220f875d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_f64e2c50-fa76-4cf5-9646-6f46220f875d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c803fd1e-1201-4115-861d-7074320ec813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c803fd1e-1201-4115-861d-7074320ec813" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_ed9b137f-0766-4e36-9b2d-79fd5d5d2529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_ed9b137f-0766-4e36-9b2d-79fd5d5d2529" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8425ce94-a7f4-4d02-89a4-f3037113fc3f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b641dd0-1be1-473e-9ac8-600efe207471_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b641dd0-1be1-473e-9ac8-600efe207471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a218b845-5457-474e-b387-da763e7c19ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a218b845-5457-474e-b387-da763e7c19ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_90617011-d7eb-4edb-8ee3-587cb1159e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a218b845-5457-474e-b387-da763e7c19ad" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_90617011-d7eb-4edb-8ee3-587cb1159e7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails" xlink:type="extended" id="ic70e1f2a17924be58b79f2e64274dffe_ACQUISITIONSProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5076327d-263e-4c6e-8d0b-7c48c07ff992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5076327d-263e-4c6e-8d0b-7c48c07ff992" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_d72ecee0-315f-446e-81d5-3d853a7d9980" xlink:href="thc-20221231.xsd#thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_d72ecee0-315f-446e-81d5-3d853a7d9980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b936a1aa-8dfc-4a8e-9ea7-7920f498ec06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b936a1aa-8dfc-4a8e-9ea7-7920f498ec06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_61d7979f-a2ab-4d85-b1c7-69de22e04439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_61d7979f-a2ab-4d85-b1c7-69de22e04439" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7a5fca-8da8-4b7c-8e55-ccdb382df464_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7a5fca-8da8-4b7c-8e55-ccdb382df464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3915019b-5e44-4bf7-a5e6-7a707413ad1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3915019b-5e44-4bf7-a5e6-7a707413ad1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2021SCDCentersMember_5b910a38-d09f-4c50-833b-3d7c208d377e" xlink:href="thc-20221231.xsd#thc_A2021SCDCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3915019b-5e44-4bf7-a5e6-7a707413ad1d" xlink:to="loc_thc_A2021SCDCentersMember_5b910a38-d09f-4c50-833b-3d7c208d377e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i93c70c86f7f041c28a7fc14b9dd8c842_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsOperatedBySubsidiaries_e507061c-6c74-47e1-b0c6-440be9363550" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsOperatedBySubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfHospitalsOperatedBySubsidiaries_e507061c-6c74-47e1-b0c6-440be9363550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d2709665-95ac-45e6-a5a9-f280b7fac1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d2709665-95ac-45e6-a5a9-f280b7fac1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfImagingCentersTransferred_f4d89dc9-edb3-4b2e-9f2f-62e9dacaa3cd" xlink:href="thc-20221231.xsd#thc_NumberOfImagingCentersTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfImagingCentersTransferred_f4d89dc9-edb3-4b2e-9f2f-62e9dacaa3cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_175524e5-f1c6-48be-9650-d825c49a185b" xlink:href="thc-20221231.xsd#thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_175524e5-f1c6-48be-9650-d825c49a185b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCentersConsolidated_59d93899-35ac-430e-91b3-42dc6f11e271" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCentersConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfAmbulatorySurgeryCentersConsolidated_59d93899-35ac-430e-91b3-42dc6f11e271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_9de84387-a9bf-47f0-b3e3-591c6e476c06" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_9de84387-a9bf-47f0-b3e3-591c6e476c06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsConsolidated_c82d6614-aec0-4e4c-9b6b-a89b50b17041" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfSurgicalHospitalsConsolidated_c82d6614-aec0-4e4c-9b6b-a89b50b17041" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfUrgentCareCentersSold_3223b134-9eab-4d1a-83e0-891315050353" xlink:href="thc-20221231.xsd#thc_NumberOfUrgentCareCentersSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfUrgentCareCentersSold_3223b134-9eab-4d1a-83e0-891315050353" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_de070bf0-20c7-4792-a015-c6a9fb333b6d" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_de070bf0-20c7-4792-a015-c6a9fb333b6d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5a5788e8-e888-4835-93df-361452b81316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5a5788e8-e888-4835-93df-361452b81316" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_20e5a49c-6b80-4aaf-a09d-8f8b9d8df2de" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_20e5a49c-6b80-4aaf-a09d-8f8b9d8df2de" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:to="loc_us-gaap_SegmentDomain_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:to="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_dec04320-7027-4203-9d3a-981b75f2dcf9" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_HospitalOperationsMember_dec04320-7027-4203-9d3a-981b75f2dcf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_59c66ef0-e06c-48ac-92c4-84d48d832d70" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_AmbulatoryCareMember_59c66ef0-e06c-48ac-92c4-84d48d832d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UrgentCareCentersMember_d535c928-c6a2-468a-a7c1-8c36d435137e" xlink:href="thc-20221231.xsd#thc_UrgentCareCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_UrgentCareCentersMember_d535c928-c6a2-468a-a7c1-8c36d435137e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_0f6a581c-a699-43bf-be70-5adfa6df2638" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_ConiferSegmentMember_0f6a581c-a699-43bf-be70-5adfa6df2638" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f75655-5bdb-4d02-bab6-e64ee2bc3904_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f75655-5bdb-4d02-bab6-e64ee2bc3904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_7d28a771-4cc8-4284-89dd-d727738f5f6b" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_7d28a771-4cc8-4284-89dd-d727738f5f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_c8dcb4ac-9d8e-49d3-a2aa-232e13860800" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_c8dcb4ac-9d8e-49d3-a2aa-232e13860800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0168da10-9749-40ab-ac2c-ec3b3abe42e3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:to="loc_srt_OwnershipDomain_0168da10-9749-40ab-ac2c-ec3b3abe42e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:to="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_06b0c493-4cad-4f88-890b-c9f044a72cca" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_06b0c493-4cad-4f88-890b-c9f044a72cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferHealthSolutionsLLCMember_7413ca0d-6354-4ec0-a2bc-5d94824bc9ad" xlink:href="thc-20221231.xsd#thc_ConiferHealthSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:to="loc_thc_ConiferHealthSolutionsLLCMember_7413ca0d-6354-4ec0-a2bc-5d94824bc9ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATIONReconcilingItemsDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails" xlink:type="extended" id="i12036825aca544309e16bc2ce823bc6d_SEGMENTINFORMATIONReconcilingItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c0de8f28-68f8-4b07-861a-f7e05ce9fbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_Assets_c0de8f28-68f8-4b07-861a-f7e05ce9fbc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_177b64a6-36af-4f90-b24c-d759b4082538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_177b64a6-36af-4f90-b24c-d759b4082538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f183902-00a5-4005-bc06-81a03486d01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f183902-00a5-4005-bc06-81a03486d01b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8817e129-f268-40b6-8026-093b81189773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8817e129-f268-40b6-8026-093b81189773" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_45cbe9d6-cfcb-4de1-87bd-e17d71c70262" xlink:href="thc-20221231.xsd#thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_45cbe9d6-cfcb-4de1-87bd-e17d71c70262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_45bc2533-3c1f-4dc3-a732-65901897427e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_45bc2533-3c1f-4dc3-a732-65901897427e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:href="thc-20221231.xsd#thc_AdjustedSegmentEBITDAAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_183f6ce1-fc5f-4c3c-b046-89bc46c331dc" xlink:href="thc-20221231.xsd#thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeLossFromDivestedAndClosedBusinesses_52c010ff-7377-440a-a315-85409b29ec83" xlink:href="thc-20221231.xsd#thc_IncomeLossFromDivestedAndClosedBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_IncomeLossFromDivestedAndClosedBusinesses_52c010ff-7377-440a-a315-85409b29ec83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5adb7f3d-bb64-4b12-aec1-6b163416366b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_1e387cb4-6a96-437a-9ab4-0e83709093a8" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_1e387cb4-6a96-437a-9ab4-0e83709093a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c643e001-95a5-4d0f-9671-951eb552c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c643e001-95a5-4d0f-9671-951eb552c8ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ca0a3e53-15d9-428f-9b65-6fb73e3c1f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_InterestExpense_ca0a3e53-15d9-428f-9b65-6fb73e3c1f15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc164a6b-ff7d-49ac-b046-8f849c724a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc164a6b-ff7d-49ac-b046-8f849c724a4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_806a34ff-dd39-4e4b-aaab-ee1179164456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_806a34ff-dd39-4e4b-aaab-ee1179164456" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_1bcd2a2b-819b-4ad2-8a74-43a44d106bce" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_1bcd2a2b-819b-4ad2-8a74-43a44d106bce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ebab4b3-b2f7-4887-bfab-6b9d4bc2df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ebab4b3-b2f7-4887-bfab-6b9d4bc2df0f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:to="loc_us-gaap_SegmentDomain_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:to="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_ab2242d9-8b4a-4117-9de5-e935c339d72e" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:to="loc_thc_HospitalOperationsMember_ab2242d9-8b4a-4117-9de5-e935c339d72e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_9aa57c72-4636-49d3-b4c9-e2fb933fceba" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:to="loc_thc_AmbulatoryCareMember_9aa57c72-4636-49d3-b4c9-e2fb933fceba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7634a9d1-f7e6-41a3-981f-21d10468b321" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:to="loc_thc_ConiferSegmentMember_7634a9d1-f7e6-41a3-981f-21d10468b321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0fc00c04-b8c3-42a0-bfc9-62ab00724386_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:to="loc_srt_ConsolidationItemsDomain_0fc00c04-b8c3-42a0-bfc9-62ab00724386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:to="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e0e2f3f0-c0ee-4189-b2a2-bbaffdfab094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:to="loc_us-gaap_OperatingSegmentsMember_e0e2f3f0-c0ee-4189-b2a2-bbaffdfab094" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_beaf860d-0e2e-4a37-b61e-3b2420cbf22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:to="loc_us-gaap_IntersegmentEliminationMember_beaf860d-0e2e-4a37-b61e-3b2420cbf22e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aa85f972-642c-4d91-a024-435b4ba29d2b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_aa85f972-642c-4d91-a024-435b4ba29d2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TenetHealthcareCorpMember_6c3ce7fe-793e-4b29-9c24-75adb1eb1043" xlink:href="thc-20221231.xsd#thc_TenetHealthcareCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:to="loc_thc_TenetHealthcareCorpMember_6c3ce7fe-793e-4b29-9c24-75adb1eb1043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCustomersMember_79227b7d-1c29-4007-bd9f-f3ec158b3ddb" xlink:href="thc-20221231.xsd#thc_OtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:to="loc_thc_OtherCustomersMember_79227b7d-1c29-4007-bd9f-f3ec158b3ddb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:definitionLink xlink:role="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended" id="idf277bbe9d2b4cc6822065918f384012_SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e667de48-98a4-4603-9aa5-2e378a8d07e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e667de48-98a4-4603-9aa5-2e378a8d07e6" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9797b7ec-ca4f-47b7-a251-8359fea85187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9797b7ec-ca4f-47b7-a251-8359fea85187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0949ae8f-41df-4e76-a6e5-687e7002c468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0949ae8f-41df-4e76-a6e5-687e7002c468" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_bbe710b5-b072-4647-8589-24e45c4c560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_bbe710b5-b072-4647-8589-24e45c4c560c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_2d716ecd-f163-4173-8069-c0251eb20b7d" xlink:href="thc-20221231.xsd#thc_ValuationAllowancesAndReservesReservesOfBusinessesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_2d716ecd-f163-4173-8069-c0251eb20b7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9f143201-1b5d-45d7-b966-2f4b18c14c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e667de48-98a4-4603-9aa5-2e378a8d07e6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_92712bdc-c2bc-414c-bd5d-149b4ff3a360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_92712bdc-c2bc-414c-bd5d-149b4ff3a360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_805ee2cd-e4f7-427f-89e5-8566179a3186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_805ee2cd-e4f7-427f-89e5-8566179a3186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_85094cc9-a7c0-459c-9b86-0abc9d9d30d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_805ee2cd-e4f7-427f-89e5-8566179a3186" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_85094cc9-a7c0-459c-9b86-0abc9d9d30d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>thc-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5eb22bb-8cdc-4927-ae5c-e13f3ca3c3e1,g:f5e96eef-6bc4-43e3-b34d-7345446e971c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a2cb14d3-5fe8-459a-bdbd-c7c7e3f51a7a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_cf40f573-cdd2-474e-a898-15686ff63cbe_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_02934f82-a3ee-453e-bd50-84a0bc9c7590_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0f482d2a-a9a1-40ce-b981-55ca36284e36_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_31988bf5-3163-49fc-bd45-d12de0589412_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_22610c7f-4a4f-47eb-bd62-1525235159ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6420a1ce-2f8f-406a-85cf-0665c27a23a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_b8bbd144-cfcf-4474-9efb-dead2c54ed3f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c25b96c8-b44f-4217-8811-c6434c59123c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_46f343b4-d47b-4bf8-aa5a-14648c8cbd2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCarePatientServiceSelfpayMember_0382fe05-b222-44c2-84b8-68b4068eeda9_terseLabel_en-US" xlink:label="lab_thc_HealthCarePatientServiceSelfpayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uninsured</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceSelfpayMember_label_en-US" xlink:label="lab_thc_HealthCarePatientServiceSelfpayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Self-pay [Member]</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceSelfpayMember_documentation_en-US" xlink:label="lab_thc_HealthCarePatientServiceSelfpayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Self-pay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceSelfpayMember" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceSelfpayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCarePatientServiceSelfpayMember" xlink:to="lab_thc_HealthCarePatientServiceSelfpayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_6370eaee-a004-4572-ab67-f5582f52cbd0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0d7e0c88-194a-4543-bf71-b0ce5df6c0f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d88a6ada-2606-475e-a975-fe111b9584e6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_d66bcaa2-8ca5-4482-b444-aaef7fa169e2_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_55749632-4150-4461-a408-1f3850dd93be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Net Benefit Costs and Assumptions Used for Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseRightOfUseAsset_fbda5bb0-fbfd-4f92-a49d-c099f318f3fd_totalLabel_en-US" xlink:label="lab_thc_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased assets</link:label>
    <link:label id="lab_thc_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_thc_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_thc_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_thc_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseRightOfUseAsset" xlink:href="thc-20221231.xsd#thc_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseRightOfUseAsset" xlink:to="lab_thc_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PropertyInsuranceMaximumCoveragePerIncident_171cdf04-cde9-4b24-a38c-72f66030a73e_terseLabel_en-US" xlink:label="lab_thc_PropertyInsuranceMaximumCoveragePerIncident" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property insurance coverage</link:label>
    <link:label id="lab_thc_PropertyInsuranceMaximumCoveragePerIncident_label_en-US" xlink:label="lab_thc_PropertyInsuranceMaximumCoveragePerIncident" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Maximum Coverage Per Incident</link:label>
    <link:label id="lab_thc_PropertyInsuranceMaximumCoveragePerIncident_documentation_en-US" xlink:label="lab_thc_PropertyInsuranceMaximumCoveragePerIncident" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Maximum Coverage Per Incident</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceMaximumCoveragePerIncident" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceMaximumCoveragePerIncident"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PropertyInsuranceMaximumCoveragePerIncident" xlink:to="lab_thc_PropertyInsuranceMaximumCoveragePerIncident" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f72da78b-c300-4a49-9cb9-dad71bdf960c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6fc4c7e8-aeb3-4003-8ea0-554d4ca1f96c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarthquakeMember_87b1f74e-33b3-4d6a-9000-959338404450_terseLabel_en-US" xlink:label="lab_us-gaap_EarthquakeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earthquakes</link:label>
    <link:label id="lab_us-gaap_EarthquakeMember_label_en-US" xlink:label="lab_us-gaap_EarthquakeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earthquake [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarthquakeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarthquakeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarthquakeMember" xlink:to="lab_us-gaap_EarthquakeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_122b976a-692d-4106-a096-8de48610a4aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage margin on variable rate (percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e15e98be-721f-44da-bc46-af847dbc3a39_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cd05aea1-9817-484d-88ad-160585f0616b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1aaeec63-e09d-4400-8b82-a3307f7b333b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PhiladelphiaBuildingMember_fa762c61-14be-4b7d-aafd-4fc09cfc8048_terseLabel_en-US" xlink:label="lab_thc_PhiladelphiaBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philadelphia Building</link:label>
    <link:label id="lab_thc_PhiladelphiaBuildingMember_label_en-US" xlink:label="lab_thc_PhiladelphiaBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philadelphia Building [Member]</link:label>
    <link:label id="lab_thc_PhiladelphiaBuildingMember_documentation_en-US" xlink:label="lab_thc_PhiladelphiaBuildingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Philadelphia Building</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhiladelphiaBuildingMember" xlink:href="thc-20221231.xsd#thc_PhiladelphiaBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PhiladelphiaBuildingMember" xlink:to="lab_thc_PhiladelphiaBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53ee05ca-75c8-40f2-b20d-5b74773297a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1d1e6041-052d-4752-a6b1-9054cd153c52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, operating leases (percentage)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_c3e2152c-9a0f-4f45-a162-8d38fad86bbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_f00cf26f-ec90-48dc-98c5-c708a2ab8abf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_b2acdc99-01be-4431-8d30-d8424a84369f_terseLabel_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_documentation_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearTwo" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_thc_LesseeLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_81ad5948-1c11-4976-aa7d-bf4820f34b9e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_614f9261-e129-4852-849e-d831d07cbc04_terseLabel_en-US" xlink:label="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospitals to which segment of the entity provides revenue cycle services</link:label>
    <link:label id="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_label_en-US" xlink:label="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Hospitals to which Segment of the Entity Provides Revenue Cycle Services</link:label>
    <link:label id="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_documentation_en-US" xlink:label="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of Tenet and non-Tenet Hospitals to which a segment of the entity provides revenue cycle services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" xlink:to="lab_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_StockIncentivePlan2019Member_4c940315-0bca-41a1-9bc4-4203c7436d38_terseLabel_en-US" xlink:label="lab_thc_StockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Incentive Plan</link:label>
    <link:label id="lab_thc_StockIncentivePlan2019Member_label_en-US" xlink:label="lab_thc_StockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2019 [Member]</link:label>
    <link:label id="lab_thc_StockIncentivePlan2019Member_documentation_en-US" xlink:label="lab_thc_StockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_StockIncentivePlan2019Member" xlink:href="thc-20221231.xsd#thc_StockIncentivePlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_StockIncentivePlan2019Member" xlink:to="lab_thc_StockIncentivePlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_fcc73a2d-1635-483d-a2d2-45f9bfd1dce6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_044df43d-8177-431e-bd2f-1f7e78dc77c7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e719a37c-626a-460a-bd81-0862f0380e4d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1794fd0e-e77f-4227-b4e5-d69e5b679a78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_RedeemableNoncontrollingInterestMember_689a865f-a1ca-49ff-ad4c-00e11d8326cc_terseLabel_en-US" xlink:label="lab_thc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_thc_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_thc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_thc_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_thc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to redeemable noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RedeemableNoncontrollingInterestMember" xlink:href="thc-20221231.xsd#thc_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_RedeemableNoncontrollingInterestMember" xlink:to="lab_thc_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8fa62d9b-5026-4a44-99c4-a1bc7cbd20f3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_859c98d5-7519-48f5-b54f-083c7af817c6_terseLabel_en-US" xlink:label="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% due 2030</link:label>
    <link:label id="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_label_en-US" xlink:label="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Seven Five Percent Senior Secured Note Due 2030 [Member]</link:label>
    <link:label id="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_documentation_en-US" xlink:label="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Seven Five Percent Senior Secured Note Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" xlink:href="thc-20221231.xsd#thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" xlink:to="lab_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_96a741a7-928f-4b35-86e2-c0cca6c4e491_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_103fbcae-a0af-42d8-b7af-8860b072e0e1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_59532465-27f7-41b5-a6cc-0bb46d2609f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ffc9ccd3-b8b1-46fd-90e8-7ee6e79fc135_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information About Stock Options by Range of Exercise Prices</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_646241b6-ed62-416a-943a-76af8b93348c_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities from discontinued operations, excluding income taxes</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b0e08959-de36-4eea-ba94-964e956e424a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_ccf04950-9f5f-4560-bd2f-33adc5a4a0ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_577dba6b-4429-4bc3-a6c4-506901d1a668_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_abb32db5-b549-4095-9130-3618804c8575_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_da64ae37-2845-4635-b144-5e374626c28a_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on issued but undrawn letters of credit (percentage)</link:label>
    <link:label id="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_label_en-US" xlink:label="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Issued But Undrawn Letters Of Credit</link:label>
    <link:label id="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_documentation_en-US" xlink:label="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Issued But Undrawn Letters Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" xlink:href="thc-20221231.xsd#thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" xlink:to="lab_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_99885e11-f85f-4ac5-ac74-88d1be69e3ee_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_bd91e0a5-7ff4-4ae5-821d-82867c187376_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_b9d4b107-4171-4dbb-874d-19cf8bcf1967_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Unrecognized Tax Benefits That Have Impacted Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1b2d07c2-82e9-47b4-abe3-c42b00709e2c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CharityCarePatientsMember_d50caf4f-06a3-4eb7-8ab7-4ee7e10efac6_terseLabel_en-US" xlink:label="lab_thc_CharityCarePatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charity care patients</link:label>
    <link:label id="lab_thc_CharityCarePatientsMember_label_en-US" xlink:label="lab_thc_CharityCarePatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charity Care Patients [Member]</link:label>
    <link:label id="lab_thc_CharityCarePatientsMember_documentation_en-US" xlink:label="lab_thc_CharityCarePatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents charity care patients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CharityCarePatientsMember" xlink:href="thc-20221231.xsd#thc_CharityCarePatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CharityCarePatientsMember" xlink:to="lab_thc_CharityCarePatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_26d2aa7a-ec08-418b-8289-5bceb49b7767_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AdjustedSegmentEBITDAAbstract_d12aee1d-c028-4b46-b1ac-56ceda67d10e_terseLabel_en-US" xlink:label="lab_thc_AdjustedSegmentEBITDAAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Segment EBITDA [Abstract]</link:label>
    <link:label id="lab_thc_AdjustedSegmentEBITDAAbstract_label_en-US" xlink:label="lab_thc_AdjustedSegmentEBITDAAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Segment EBITDA [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedSegmentEBITDAAbstract" xlink:href="thc-20221231.xsd#thc_AdjustedSegmentEBITDAAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract" xlink:to="lab_thc_AdjustedSegmentEBITDAAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fd947ee2-22f3-4925-bcad-1db728327128_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b17a4114-5e83-4197-bf06-9d3957789dc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7bb410a0-1bf1-4940-af93-2766f6c0ef38_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of DMC Pension Plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_58e70d3c-0329-4609-bd71-aabddce8b7df_terseLabel_en-US" xlink:label="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% due 2030</link:label>
    <link:label id="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_label_en-US" xlink:label="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Two Five Percent Senior Secured First Lien Note, Due 2030 [Member]</link:label>
    <link:label id="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_documentation_en-US" xlink:label="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Two Five Percent Senior Secured First Lien Note, Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" xlink:to="lab_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bb62a9d7-b874-4df1-b8a7-74c7fdc3af8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1a804ee5-a0e4-4726-84dc-2aa14de5bacf_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_47ab626e-ec1c-4bef-9c96-844c754994e2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_3dbccac1-58fe-4319-a61c-85b09092a8a4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized contract costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_49cc6eea-d44e-47ed-8731-f153605df205_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_b3c04bdb-13d0-4e5a-8007-5c051954fdbb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_c6909267-0127-4fe2-81c7-d74d3031c39b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_69942a6d-33f3-442c-8a07-86a6323c9f34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_67f448ac-121f-4bc5-9b5f-399a01ffbc3f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HospitalOperationsMember_a184fd23-66f6-44a4-a0d2-9db5b5aad48a_terseLabel_en-US" xlink:label="lab_thc_HospitalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations</link:label>
    <link:label id="lab_thc_HospitalOperationsMember_label_en-US" xlink:label="lab_thc_HospitalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations [Member]</link:label>
    <link:label id="lab_thc_HospitalOperationsMember_documentation_en-US" xlink:label="lab_thc_HospitalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Hospital Operations a reportable segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HospitalOperationsMember" xlink:to="lab_thc_HospitalOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_25f44e73-cfd6-4681-9348-82bb4af75f41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_cdae9ef1-b707-467f-98e1-65259de6d631_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_23b660da-ad49-4a4d-9996-f6095a158b9b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7038a72f-b0dd-4640-8496-7aa74bb86252_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_3ef5d422-aa2f-4c13-9a92-ed23f758f070_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_bacd8487-7409-4f75-b1a8-a3a70b852973_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for defined benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_a550f5eb-b06a-4c6c-a899-178d75a56404_terseLabel_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Next Twelve Months</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_documentation_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2cadf40b-c66e-4747-b8b9-00d47bd38e7e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c150cee3-0599-4299-8d08-8029a1b4ffbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_d267cc91-28ed-429d-8572-c3ac6f88e148_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_3bc018db-e96a-4806-9b57-6496b4599274_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_22b92ac4-0477-44f7-bb7a-7d3166fce580_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_0198d0bd-8a5d-4156-bffc-73fb9b24b638_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of facilities and other assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AuditInformationAbstract_label_en-US" xlink:label="lab_thc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_thc_AuditInformationAbstract_documentation_en-US" xlink:label="lab_thc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AuditInformationAbstract" xlink:href="thc-20221231.xsd#thc_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AuditInformationAbstract" xlink:to="lab_thc_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_563ea8c8-79d5-408c-8cf3-8439b86ac924_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SERP</link:label>
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Employee Retirement Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:to="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_308eb398-63fb-4660-9021-cb82fd465a09_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_7c22c97a-63cc-4a3f-b964-f1e559e3a4a8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Debt Security [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:to="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ea38a547-35ad-4c49-a03e-8d9aa6114734_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities&#160;</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankOverdrafts_047c8d01-b92d-4c3a-9bd5-3adff785e8e4_terseLabel_en-US" xlink:label="lab_us-gaap_BankOverdrafts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book overdrafts classified as accounts payable</link:label>
    <link:label id="lab_us-gaap_BankOverdrafts_label_en-US" xlink:label="lab_us-gaap_BankOverdrafts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankOverdrafts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankOverdrafts" xlink:to="lab_us-gaap_BankOverdrafts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_797ae69f-2477-4ee3-b6e3-ea5d81a8be0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years), operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b93a0c6b-7b7c-43f7-9b64-2c48ebdc0304_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_76fcb8c9-42ee-464d-a33c-474eda3ff450_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, purchase accounting adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c4049633-c042-44ba-9905-cb6223392a5c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCarePatientServiceMedicaidMember_ec26ad73-094b-4588-a96d-7e0f8697eb91_verboseLabel_en-US" xlink:label="lab_thc_HealthCarePatientServiceMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceMedicaidMember_label_en-US" xlink:label="lab_thc_HealthCarePatientServiceMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Medicaid [Member]</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceMedicaidMember_documentation_en-US" xlink:label="lab_thc_HealthCarePatientServiceMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceMedicaidMember" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCarePatientServiceMedicaidMember" xlink:to="lab_thc_HealthCarePatientServiceMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_28a1acdf-2796-4748-adaf-834e0c8b6593_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f307899-0b27-4290-a596-744cf131deee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ecd4077a-a85c-464d-9f51-acfbb96f36cc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9586855e-1fe6-412f-9787-690be1ab6263_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_4a6b7dea-b3c8-4c6b-b3a4-e4caf86ed024_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1afb9fa7-68e8-4552-a8be-6ba68c63c0bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated_2e4ecf14-6309-4b87-a068-ebca95265263_terseLabel_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ambulatory surgery centers consolidated</link:label>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated_label_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ambulatory Surgery Centers Consolidated</link:label>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated_documentation_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ambulatory Surgery Centers Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCentersConsolidated" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCentersConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfAmbulatorySurgeryCentersConsolidated" xlink:to="lab_thc_NumberOfAmbulatorySurgeryCentersConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f3d623fe-d2bb-4f7c-8964-802258e6b688_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1638a672-64b1-4d29-9f0c-5d20355051f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_f5a6e296-43b5-4b4d-8046-681f7b23b51b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_ad68b690-2716-49ab-aa87-1758c1e14aea_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ec148b9d-0bfe-4924-b7ee-47546375f05b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c7ae3709-a2d6-440c-baa5-f064868cd6f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wtd. Avg. Exercise&#160;Price Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments_6cbbba13-e022-422e-b9c8-f0dc4cf7d659_terseLabel_en-US" xlink:label="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments of share purchase agreement</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments_label_en-US" xlink:label="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Number Of Monthly Payments</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments_documentation_en-US" xlink:label="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Number Of Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementNumberOfMonthlyPayments" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementNumberOfMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SharePurchaseAgreementNumberOfMonthlyPayments" xlink:to="lab_thc_SharePurchaseAgreementNumberOfMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_5e81419f-7820-46bb-98ad-ccd36d025c4a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_f1f057d5-af58-4bb8-b0a0-177e1023bac2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bcdb2ea-8e21-461f-b84a-abe639b0aa6d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ef66e2c1-6d11-4c68-a280-b3858529316c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90a276ee-7cc1-47fc-bb44-269744703eaf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_d2a6b765-e9a7-4a1c-9f16-10c868e529d1_terseLabel_en-US" xlink:label="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_label_en-US" xlink:label="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</link:label>
    <link:label id="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_documentation_en-US" xlink:label="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:href="thc-20221231.xsd#thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:to="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69977996-62bb-49d3-9280-bad9376250bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da134529-80c5-45dc-be25-2ea97c04afa0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_6c9aee22-08a9-4bf0-a35a-ac3b224b9f7e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_7443d9f2-6382-4343-af27-1a7211714e18_terseLabel_en-US" xlink:label="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</link:label>
    <link:label id="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Income (Loss) from Equity Method Investments</link:label>
    <link:label id="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_documentation_en-US" xlink:label="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" xlink:href="thc-20221231.xsd#thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" xlink:to="lab_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_1ab8d4ea-8aa8-4c29-bdc7-b934c26d7d9f_negatedTerseLabel_en-US" xlink:label="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior-year provision to return adjustments and other changes in deferred&#160;taxes</link:label>
    <link:label id="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_label_en-US" xlink:label="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Prior Year Income Taxes and Change in Deferred Taxes</link:label>
    <link:label id="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_documentation_en-US" xlink:label="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense (benefit) as reported in the income statement for the current period and the expected income tax expense or benefit computed attributable to revisions of previously reported income tax expense and other changes in deferred taxes, net of valuation allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" xlink:href="thc-20221231.xsd#thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" xlink:to="lab_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e641414a-7088-4a11-9e70-b98dd3b2efff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_82baa959-2ec4-461a-9536-1f5099ae6ddf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock_36d13dbf-b309-4ed6-bde0-5e4db2f3a304_terseLabel_en-US" xlink:label="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of DMC Pension Plan Assets Measured at Fair Value on a Recurring Basis Aggregated by the Level in the Fair Value Hierarchy</link:label>
    <link:label id="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" xlink:href="thc-20221231.xsd#thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_777661b8-5c6a-4f5c-985f-63137e07bf95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5529166a-0b44-482e-a93e-b34b959008f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Opening and Closing Balances of Contracts Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_2616ef83-4fe6-42a5-870a-be57330d01ca_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f3e549fc-2d29-433e-9feb-0193b2db5ae1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_e52262f9-90ec-4ab1-bf2a-51cea71d0048_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based payment award options outstanding percentage</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of a certain classification of awards in a stock based compensation plan to the total of a particular category of awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SeniorOfficerMember_178baa68-e758-4bcf-8e45-dfec8a0e8a70_terseLabel_en-US" xlink:label="lab_thc_SeniorOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Officer</link:label>
    <link:label id="lab_thc_SeniorOfficerMember_label_en-US" xlink:label="lab_thc_SeniorOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Officer [Member]</link:label>
    <link:label id="lab_thc_SeniorOfficerMember_documentation_en-US" xlink:label="lab_thc_SeniorOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SeniorOfficerMember" xlink:href="thc-20221231.xsd#thc_SeniorOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SeniorOfficerMember" xlink:to="lab_thc_SeniorOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_0e455586-886c-4a4c-bf8b-095896b443ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LossContingencyAccrualOther_8c9041ca-0008-43e0-83b6-12d2ab6fe99e_terseLabel_en-US" xlink:label="lab_thc_LossContingencyAccrualOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_thc_LossContingencyAccrualOther_label_en-US" xlink:label="lab_thc_LossContingencyAccrualOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Other</link:label>
    <link:label id="lab_thc_LossContingencyAccrualOther_documentation_en-US" xlink:label="lab_thc_LossContingencyAccrualOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LossContingencyAccrualOther" xlink:href="thc-20221231.xsd#thc_LossContingencyAccrualOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LossContingencyAccrualOther" xlink:to="lab_thc_LossContingencyAccrualOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6828a7ed-e584-486d-85d7-8e84a191bb17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_f7fbcaa6-15ec-4e82-a39a-208747e000d3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share available to Tenet Healthcare Corporation common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_07c384b3-d3a5-4d50-b0c2-932654ca5d3d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_9401847a-bda7-4be7-8806-c30bb8b8bd39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California provider fee program receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_f8d421ca-c29f-428c-b9c5-19159a8eb2f9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_d4d85f33-f36e-4ea0-8d08-50b8bf5220d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f14f534c-5aa5-4dae-a838-7f94fcf8ab70_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities held as available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_6f5f9150-381d-400d-9fa4-9b6af6002484_terseLabel_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold limit of unused borrowing availability under the revolving credit facility (less than)</link:label>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_label_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit</link:label>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_documentation_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the unused borrowing availability threshold limit for the line of credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" xlink:to="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingOnFourthAnniversaryMember_573d8c06-eefe-4325-9c4a-51cc0c4edfef_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting On Fourth Anniversary</link:label>
    <link:label id="lab_thc_TimeBasedVestingOnFourthAnniversaryMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting On Fourth Anniversary [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingOnFourthAnniversaryMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting On Fourth Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingOnFourthAnniversaryMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingOnFourthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingOnFourthAnniversaryMember" xlink:to="lab_thc_TimeBasedVestingOnFourthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_8056f640-11c4-46d2-a236-ec9b52df98b4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Available to Common Shareholders (Numerator)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_e052ec1e-bca1-4854-9dbd-4f2d08a82054_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8cc5c64-ad69-4cd5-84e8-28418329d38a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5d833906-18ef-4046-bec3-6931c938d27e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_8593f784-2ada-4efc-a499-5a0299222b90_terseLabel_en-US" xlink:label="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss included in other non-operating income, net</link:label>
    <link:label id="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization of Net Actuarial Gain (Loss) Arising During Period, before Tax</link:label>
    <link:label id="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_documentation_en-US" xlink:label="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before tax of amortization of net actuarial gain (loss) that has been recognized in other non-operating income (expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" xlink:href="thc-20221231.xsd#thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_8e4e6cda-b1f6-4c41-a7ad-3d9454a28b22_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_38cf96bb-55cf-41ce-99ac-2b05dcab3dc9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_f0f48af4-be15-4044-a21a-465f448a7d9a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_757f0697-c38c-4f56-b612-778bc048bb1d_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivateEquityFundsMember_9deaee04-4f4a-49ae-82d8-c6a6dbabfff6_terseLabel_en-US" xlink:label="lab_us-gaap_PrivateEquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private equity securities</link:label>
    <link:label id="lab_us-gaap_PrivateEquityFundsMember_label_en-US" xlink:label="lab_us-gaap_PrivateEquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivateEquityFundsMember" xlink:to="lab_us-gaap_PrivateEquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_0462b034-d348-497e-a33f-3324e7657c1e_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_d4c05bd6-c984-4f08-a583-e080c63e4b72_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_da9aabc3-6711-4dc0-b094-626878ba8749_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_d8da3ed2-942b-402c-84ce-d591cda11b0e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_864c9414-10b9-4e85-96f5-580e81b1e8aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCenters_f7571644-6020-4cb0-8b20-65e48442bb42_terseLabel_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ambulatory surgery centers</link:label>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCenters_label_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ambulatory Surgery Centers</link:label>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCenters_documentation_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of ambulatory surgery centers acquired by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCenters" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfAmbulatorySurgeryCenters" xlink:to="lab_thc_NumberOfAmbulatorySurgeryCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_af35584d-6407-4552-a410-59a0b58b981f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and sales of business and noncontrolling interest, net</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_4372daec-8d30-46fb-940f-765b349105ee_netLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and sales of businesses and noncontrolling interests, net</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cd0b9e52-86ed-4e3e-90af-e2ec1d15d311_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes For Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_67e468d7-e506-47fd-99f2-a23ddd4dc769_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0366f2ad-0da6-407b-9b8b-79ecb8ffd3ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_325c32d1-f0e9-4b00-9a03-3b47b128962a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ConiferSegmentMember_b9ce40d4-f1ee-42b0-abec-23ce33db3807_verboseLabel_en-US" xlink:label="lab_thc_ConiferSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conifer Segment</link:label>
    <link:label id="lab_thc_ConiferSegmentMember_ac3f7945-ad14-4b8a-9687-c7b7731e460b_terseLabel_en-US" xlink:label="lab_thc_ConiferSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conifer</link:label>
    <link:label id="lab_thc_ConiferSegmentMember_label_en-US" xlink:label="lab_thc_ConiferSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conifer Segment [Member]</link:label>
    <link:label id="lab_thc_ConiferSegmentMember_documentation_en-US" xlink:label="lab_thc_ConiferSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Conifer, a reportable segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ConiferSegmentMember" xlink:to="lab_thc_ConiferSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_43d6b6bc-065e-40ab-8451-971bc1294655_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ba64254d-dc8e-4c4f-8495-43292590af65_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_46e0c678-1078-4303-a389-b6c46141afb5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_022dec16-a0ae-4458-b71d-1b5d23f26801_terseLabel_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities &#8211; Current Advances from Medicare</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_739bf29b-fd1b-4b30-ae33-983360a30ca0_verboseLabel_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability &#8211; Current Deferred Revenue</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_label_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability, Net, Current [Roll Forward]</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_documentation_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability, Net, Current [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:to="lab_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_b64d9e80-c2c2-4e53-8670-2efe6dfb95f2_terseLabel_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Plan</link:label>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_label_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonqualifiedPlanMember" xlink:to="lab_us-gaap_NonqualifiedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_baf9ce0a-b478-4a8e-b77f-96afec51d23f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PaymentsForRestructuringAndLitigationCosts_f8fbeff9-d83f-4e61-836f-19415b198f60_negatedLabel_en-US" xlink:label="lab_thc_PaymentsForRestructuringAndLitigationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements</link:label>
    <link:label id="lab_thc_PaymentsForRestructuringAndLitigationCosts_label_en-US" xlink:label="lab_thc_PaymentsForRestructuringAndLitigationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring and Litigation Costs</link:label>
    <link:label id="lab_thc_PaymentsForRestructuringAndLitigationCosts_documentation_en-US" xlink:label="lab_thc_PaymentsForRestructuringAndLitigationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments against reserves for restructuring charges and litigation costs, which may include attorneys' fees and other litigation costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PaymentsForRestructuringAndLitigationCosts" xlink:href="thc-20221231.xsd#thc_PaymentsForRestructuringAndLitigationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PaymentsForRestructuringAndLitigationCosts" xlink:to="lab_thc_PaymentsForRestructuringAndLitigationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2e56957f-3455-4be1-bb7f-2262436286f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upper range of stock exercise price range (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CommitmentPeriod_08034bb5-7561-46a8-933f-5c71e287b9da_terseLabel_en-US" xlink:label="lab_thc_CommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment period</link:label>
    <link:label id="lab_thc_CommitmentPeriod_label_en-US" xlink:label="lab_thc_CommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Period</link:label>
    <link:label id="lab_thc_CommitmentPeriod_documentation_en-US" xlink:label="lab_thc_CommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the commitment period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CommitmentPeriod" xlink:href="thc-20221231.xsd#thc_CommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CommitmentPeriod" xlink:to="lab_thc_CommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_b74636f2-56eb-4935-bd9c-4450e8951494_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individual Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AdditionalProratedRestrictedStockUnitsMember_b7737ee2-193b-4ac8-a467-c02a652fce14_terseLabel_en-US" xlink:label="lab_thc_AdditionalProratedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Prorated Restricted Stock Units</link:label>
    <link:label id="lab_thc_AdditionalProratedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_thc_AdditionalProratedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Prorated Restricted Stock Units [Member]</link:label>
    <link:label id="lab_thc_AdditionalProratedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_thc_AdditionalProratedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Prorated Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdditionalProratedRestrictedStockUnitsMember" xlink:href="thc-20221231.xsd#thc_AdditionalProratedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AdditionalProratedRestrictedStockUnitsMember" xlink:to="lab_thc_AdditionalProratedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_7fa324b8-d0a8-4369-89bc-a32da61031a2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_2bd8ccbd-1cd5-4eaf-94a5-df245899a1b8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ae70527a-b377-47ea-acd5-32a3bf844550_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity&#160;</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96babef5-aa8f-4f14-b90c-499de8a7b16e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e06702ab-3b85-44af-9de8-1ee053521d1c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dba3d7ac-4ad2-4074-b71b-395be67a38a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bb37220b-d3af-4d18-87fb-f7b2f8137468_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b749dafd-b086-4c1e-8729-818e96f90d06_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit, net of valuation allowance and federal tax impact, associated with NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_11bd267b-689f-4b6e-acff-b9dacf4a7a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_39e1a36d-377a-4128-908a-a028c92dd595_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant income</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PerformanceBasedRestrictedStockUnitMember_14ec8d03-b063-4263-8e29-4bde2e4c1c62_terseLabel_en-US" xlink:label="lab_thc_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Unit</link:label>
    <link:label id="lab_thc_PerformanceBasedRestrictedStockUnitMember_label_en-US" xlink:label="lab_thc_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Unit [Member]</link:label>
    <link:label id="lab_thc_PerformanceBasedRestrictedStockUnitMember_documentation_en-US" xlink:label="lab_thc_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedRestrictedStockUnitMember" xlink:href="thc-20221231.xsd#thc_PerformanceBasedRestrictedStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PerformanceBasedRestrictedStockUnitMember" xlink:to="lab_thc_PerformanceBasedRestrictedStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_ba2bf0c7-ce8e-4bb3-90a0-c19e9f3b9af7_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_294061a6-a525-44b4-bb7e-db27f0ca8241_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c05aa241-bd15-40b6-bb6e-139e37029940_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dc935ac0-5512-4d6a-af62-933f24940a2f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a3121874-7671-4cc8-a32e-294342599add_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_449831da-71fd-4ebb-a592-f40376d20b54_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2bbc1ff4-2b55-4bff-a153-0b9afe2d3587_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21ea4de8-23e8-4318-8f09-e5fb7e9e9f06_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_476448b1-8a39-4793-a30c-83aaf7a291e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_7a255e48-5b93-4aee-8c92-e0d3db546b61_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_a6e0b7ce-355e-4686-9a9d-3b150a91c445_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions paid to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_73fe60f4-ed54-46df-aa86-5773a4c8ec3b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cdddbe24-1ac7-4638-8841-3f667739a220_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_52806190-93bd-49ec-9311-a140fbed1f9e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Price Paid per Share (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_eec247f2-6c5c-486a-90b9-2ef2ec8b05c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_01d10dab-f2d7-45fc-b6b8-eccbde697f9d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4a726e10-0bc3-4ff9-b42f-0f741b8af876_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_f425cd57-7cc9-45bd-bf6f-990bf10604fd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_e9511a3a-16db-42e7-9c8c-a1453399fd21_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_91a93d7c-3f9c-4bc3-907a-94fb30098623_terseLabel_en-US" xlink:label="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term receivables and other assets</link:label>
    <link:label id="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Receivables and Other Assets, Noncurrent</link:label>
    <link:label id="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the land held for expansion, other long-term receivables and other assets which are classified as noncurrent as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" xlink:href="thc-20221231.xsd#thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" xlink:to="lab_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c28f57fc-4ea8-4ef6-aa89-3fda3a8a0e1e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_6301826e-9523-491d-929a-b9a9a5e17f3b_terseLabel_en-US" xlink:label="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="thc-20221231.xsd#thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_dd81975c-cd51-44d7-8583-326e2058fd93_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5daf8a4-483a-46ba-9138-37663fd8db15_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d99a4e3c-f67b-4a50-a631-6befd3df1c56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ProfessionalAndGeneralLiabilityReservesMember_6fd8d625-2bf2-4181-8f9f-a6ceeb56a4d5_terseLabel_en-US" xlink:label="lab_thc_ProfessionalAndGeneralLiabilityReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and General Liability Reserves</link:label>
    <link:label id="lab_thc_ProfessionalAndGeneralLiabilityReservesMember_label_en-US" xlink:label="lab_thc_ProfessionalAndGeneralLiabilityReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional And General Liability Reserves [Member]</link:label>
    <link:label id="lab_thc_ProfessionalAndGeneralLiabilityReservesMember_documentation_en-US" xlink:label="lab_thc_ProfessionalAndGeneralLiabilityReservesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Professional and General Liability Reserves in reference to the Balance Sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProfessionalAndGeneralLiabilityReservesMember" xlink:href="thc-20221231.xsd#thc_ProfessionalAndGeneralLiabilityReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ProfessionalAndGeneralLiabilityReservesMember" xlink:to="lab_thc_ProfessionalAndGeneralLiabilityReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73aa52d7-0729-433f-b9bf-6ed7819120e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contribution to the plan for 2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8b726bfb-9086-469c-8d07-44aec1d5564a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_15049d6b-39ed-47ce-b78e-edd40656f992_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_8e2ccf1b-d8a1-42f7-80e1-d36bdd915bb7_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CybersecurityIncidentPreTaxEffect_04812abd-1462-4b89-b0ec-144d74f050f2_terseLabel_en-US" xlink:label="lab_thc_CybersecurityIncidentPreTaxEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybersecurity incident, pre-tax effect</link:label>
    <link:label id="lab_thc_CybersecurityIncidentPreTaxEffect_label_en-US" xlink:label="lab_thc_CybersecurityIncidentPreTaxEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybersecurity Incident, Pre-Tax Effect</link:label>
    <link:label id="lab_thc_CybersecurityIncidentPreTaxEffect_documentation_en-US" xlink:label="lab_thc_CybersecurityIncidentPreTaxEffect" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybersecurity Incident, Pre-Tax Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CybersecurityIncidentPreTaxEffect" xlink:href="thc-20221231.xsd#thc_CybersecurityIncidentPreTaxEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CybersecurityIncidentPreTaxEffect" xlink:to="lab_thc_CybersecurityIncidentPreTaxEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ComputerAndTelecommunicationEquipmentMember_ddf55b06-09fb-4196-b274-5c9a8a86b2c2_terseLabel_en-US" xlink:label="lab_thc_ComputerAndTelecommunicationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Telecommunication Equipment</link:label>
    <link:label id="lab_thc_ComputerAndTelecommunicationEquipmentMember_label_en-US" xlink:label="lab_thc_ComputerAndTelecommunicationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Telecommunication Equipment [Member]</link:label>
    <link:label id="lab_thc_ComputerAndTelecommunicationEquipmentMember_documentation_en-US" xlink:label="lab_thc_ComputerAndTelecommunicationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Telecommunication Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ComputerAndTelecommunicationEquipmentMember" xlink:href="thc-20221231.xsd#thc_ComputerAndTelecommunicationEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ComputerAndTelecommunicationEquipmentMember" xlink:to="lab_thc_ComputerAndTelecommunicationEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_69d515a9-69f9-47c6-85b6-b7c2e751186b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt incurred in acquisition of surgical centers</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e5b2550d-73e3-437b-810a-7d6f187de400_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to Tenet Healthcare Corporation common shareholders</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fe88a528-f06b-4530-95f0-61b15ac4de5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility , maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_74b72ba7-fd25-431d-95ca-dfa04ad52987_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, contract liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f5c4b11e-17ad-4770-a5d6-bbc49f7b198d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesAbstract_8d709d99-91b7-4ee0-8d3e-dd1d087efff7_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:label id="lab_us-gaap_GuaranteesAbstract_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract" xlink:to="lab_us-gaap_GuaranteesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_33602c3a-6eca-47f4-a087-63f6d376f899_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b0cad055-a078-483d-9895-a0edce3c2b50_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76988629-38e7-433a-a311-a5655b139330_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5a2ccbe7-2e80-4ce9-ad17-0027153c5277_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total earnings (loss) per share, Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OtherRevenuesMember_a7f3165c-e108-4f73-b822-7d2d27b4eb1b_terseLabel_en-US" xlink:label="lab_thc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_thc_OtherRevenuesMember_label_en-US" xlink:label="lab_thc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_thc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_thc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherRevenuesMember" xlink:href="thc-20221231.xsd#thc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OtherRevenuesMember" xlink:to="lab_thc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_e9b7a0b8-8d4c-4ad4-bb09-75f8073659c7_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GUARANTEES</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock" xlink:to="lab_us-gaap_GuaranteesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9d2fff83-f630-40fb-a6dd-2807a4d8052f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_InsuranceRecoveriesMember_f18e9c2b-c1fd-4f68-ace9-675ba423d436_terseLabel_en-US" xlink:label="lab_thc_InsuranceRecoveriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:label id="lab_thc_InsuranceRecoveriesMember_label_en-US" xlink:label="lab_thc_InsuranceRecoveriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries [Member]</link:label>
    <link:label id="lab_thc_InsuranceRecoveriesMember_documentation_en-US" xlink:label="lab_thc_InsuranceRecoveriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceRecoveriesMember" xlink:href="thc-20221231.xsd#thc_InsuranceRecoveriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_InsuranceRecoveriesMember" xlink:to="lab_thc_InsuranceRecoveriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_35785638-7a51-4775-a61b-283852eba9b3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_c69ca9cb-701d-4dc9-849f-7015c99ddc70_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_20df72b7-8955-4b92-bdd7-d0542bb11b36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9ab5b0f8-4d6c-4a3b-bea9-6f2e59e33b02_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_5d165479-44af-4b96-a7d0-c215f1a55a69_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_c1a4fafa-d756-4c2d-a807-f51163c6f0c0_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use lease assets and obligations</link:label>
    <link:label id="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_label_en-US" xlink:label="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-Use Lease Liability And Obligations</link:label>
    <link:label id="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_documentation_en-US" xlink:label="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-Use Lease Liability And Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" xlink:href="thc-20221231.xsd#thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" xlink:to="lab_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_60475c00-ba6c-48f9-8d0c-2f39932a7654_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) adjustments recorded in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_InsuranceCoverageLineItems_aa47a92f-3ab3-4f94-b98b-1b64dd73d691_terseLabel_en-US" xlink:label="lab_thc_InsuranceCoverageLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance coverage</link:label>
    <link:label id="lab_thc_InsuranceCoverageLineItems_label_en-US" xlink:label="lab_thc_InsuranceCoverageLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageLineItems" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_InsuranceCoverageLineItems" xlink:to="lab_thc_InsuranceCoverageLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_658cd0ac-bf61-4b75-8a52-24cc3b74120e_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_b9570b11-9c48-42da-be71-3b6f964ee94e_terseLabel_en-US" xlink:label="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities, long-term investments and other assets</link:label>
    <link:label id="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_label_en-US" xlink:label="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Marketable Securities Long Term Investments and Other Assets</link:label>
    <link:label id="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_documentation_en-US" xlink:label="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (trading, held-to-maturity, or available-for-sale) during the period. Sale of long term investments and the sale of other assets not otherwise defined in the taxonomy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" xlink:href="thc-20221231.xsd#thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" xlink:to="lab_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f6619b92-df95-4cc2-a40c-182935d7f09d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_c7112e82-ef61-4bcf-8f7c-cb9e97784bfe_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CurrentEmployeesMember_02ba9fa0-66dc-465f-bdd4-8939ce9aa5a4_terseLabel_en-US" xlink:label="lab_thc_CurrentEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Employees</link:label>
    <link:label id="lab_thc_CurrentEmployeesMember_label_en-US" xlink:label="lab_thc_CurrentEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Employees [Member]</link:label>
    <link:label id="lab_thc_CurrentEmployeesMember_documentation_en-US" xlink:label="lab_thc_CurrentEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current employees of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CurrentEmployeesMember" xlink:href="thc-20221231.xsd#thc_CurrentEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CurrentEmployeesMember" xlink:to="lab_thc_CurrentEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bce1e075-c1f2-4dcb-a931-a26511707602_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd28528e-afe2-41e8-b051-8f361c8a05e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in cash from operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndBuildingMember_99075131-2871-4e4f-915c-9be09887f75a_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_LandAndBuildingMember_label_en-US" xlink:label="lab_us-gaap_LandAndBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndBuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndBuildingMember" xlink:to="lab_us-gaap_LandAndBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2db5f2f2-33b3-41bc-b9af-b470f781b69f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_e4cdb229-279a-4ce2-93a6-3a64aede95ae_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_df870e11-eafc-44a2-bb56-680538697406_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_cf21ee3e-6ff0-465f-8ca4-1610924823ea_terseLabel_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Asset &#8211; Unbilled Revenue</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_label_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset, Net, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_documentation_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" xlink:to="lab_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_84472851-6d0e-4ac7-82af-ad10bc84e78b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_223ceef2-d194-4575-ab19-fe4f374b5041_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9e02ac74-1ea4-457e-8678-835205979eb3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7f4a6c74-2fbc-42cb-9da3-cad459b6772f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_6e6c406f-6e10-444a-8411-c87e3911af71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure_b26ecf1b-a866-475d-b6bc-99dd0b95d798_terseLabel_en-US" xlink:label="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held-for-use, long lived, fair value</link:label>
    <link:label id="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure_label_en-US" xlink:label="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-use, Long Lived, Fair Value Disclosure</link:label>
    <link:label id="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure_documentation_en-US" xlink:label="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-use, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AssetsHeldforuseLongLivedFairValueDisclosure" xlink:href="thc-20221231.xsd#thc_AssetsHeldforuseLongLivedFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AssetsHeldforuseLongLivedFairValueDisclosure" xlink:to="lab_thc_AssetsHeldforuseLongLivedFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_f78cc77d-7dc3-49c5-9222-08e1aa099173_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals for retained insurance risks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTransfers_ca9a810f-c70d-4ec1-90c1-49a1c7e8a2ab_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill transferred</link:label>
    <link:label id="lab_us-gaap_GoodwillTransfers_label_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTransfers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTransfers" xlink:to="lab_us-gaap_GoodwillTransfers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_19b72a81-33bc-4da1-8d70-5435c4b7784f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_59aab77f-628a-4bdd-8209-825bb66e8dad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_2c28f6c9-7dbc-4894-863d-94680560a573_terseLabel_en-US" xlink:label="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice expense, portion related to adverse developments in prior years</link:label>
    <link:label id="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_label_en-US" xlink:label="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice Loss Contingency, Adverse Developments In Prior Years</link:label>
    <link:label id="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_documentation_en-US" xlink:label="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice Loss Contingency, Adverse Developments In Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" xlink:href="thc-20221231.xsd#thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" xlink:to="lab_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6fa12d59-f715-4e98-a201-93747d78f82f_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4ff6a0d7-69ec-4c15-8014-061ef67b0dd3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3eb17d05-ad44-4603-9d67-8c837da521a3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_067a0453-99af-467f-a6fd-830614ff5cb1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7516658e-cab7-41e0-a387-4fb39f05d7ff_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NewMadridFaultEarthquakesMember_d6236590-6588-4f0c-9ef9-ac6865caf08f_terseLabel_en-US" xlink:label="lab_thc_NewMadridFaultEarthquakesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Madrid Fault Earthquakes</link:label>
    <link:label id="lab_thc_NewMadridFaultEarthquakesMember_label_en-US" xlink:label="lab_thc_NewMadridFaultEarthquakesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Madrid Fault Earthquakes [Member]</link:label>
    <link:label id="lab_thc_NewMadridFaultEarthquakesMember_documentation_en-US" xlink:label="lab_thc_NewMadridFaultEarthquakesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Madrid Fault Earthquakes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NewMadridFaultEarthquakesMember" xlink:href="thc-20221231.xsd#thc_NewMadridFaultEarthquakesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NewMadridFaultEarthquakesMember" xlink:to="lab_thc_NewMadridFaultEarthquakesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51aacc00-5018-4cd2-b692-841b05294482_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_42ef82a1-097a-4ae4-847b-88ab5533902c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_a6949cd8-4548-4377-a815-8cc0b7ff9235_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables (doubtful accounts and adjustments)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f1a4ed8a-a6e8-4eda-8184-aa32218f0fb9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecurities_da904487-e8e5-4486-8869-a98b451164c4_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock</link:label>
    <link:label id="lab_us-gaap_DilutiveSecurities_label_en-US" xlink:label="lab_us-gaap_DilutiveSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities" xlink:to="lab_us-gaap_DilutiveSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_35b43561-38f8-4e88-a74a-d7db1d12e472_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9fa9a668-0b58-4e35-afe9-fd22d7cc6aac_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_05edf9de-27c6-4470-aa6c-aeca5e41ae72_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_ca71601c-5912-42ab-a8ad-4e4253f6bdbb_terseLabel_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% due September 2024</link:label>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_label_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent, Six Hundred Million, Senior Secured Note, Due September 2024 [Member]</link:label>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_documentation_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent, Six Hundred Million, Senior Secured Note, Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" xlink:to="lab_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_UnitedSurgicalPartnersInternationalMember_1c5c4f2b-ef5d-45a6-98ad-534cdb1676e1_terseLabel_en-US" xlink:label="lab_thc_UnitedSurgicalPartnersInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Surgical Partners International</link:label>
    <link:label id="lab_thc_UnitedSurgicalPartnersInternationalMember_label_en-US" xlink:label="lab_thc_UnitedSurgicalPartnersInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Surgical Partners International [Member]</link:label>
    <link:label id="lab_thc_UnitedSurgicalPartnersInternationalMember_documentation_en-US" xlink:label="lab_thc_UnitedSurgicalPartnersInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to United Surgical Partners International, Inc., acquired by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_UnitedSurgicalPartnersInternationalMember" xlink:to="lab_thc_UnitedSurgicalPartnersInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f02bd0aa-f330-41c1-ab28-5bcd816ae264_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PercentageInvesteeResultsReflected_09be0cf1-31c1-41d5-8ddc-37d8c3a71190_terseLabel_en-US" xlink:label="lab_thc_PercentageInvesteeResultsReflected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of investee results reflected on date of acquisition</link:label>
    <link:label id="lab_thc_PercentageInvesteeResultsReflected_label_en-US" xlink:label="lab_thc_PercentageInvesteeResultsReflected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Investee Results Reflected</link:label>
    <link:label id="lab_thc_PercentageInvesteeResultsReflected_documentation_en-US" xlink:label="lab_thc_PercentageInvesteeResultsReflected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of the investee's results accounted for under the equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PercentageInvesteeResultsReflected" xlink:href="thc-20221231.xsd#thc_PercentageInvesteeResultsReflected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PercentageInvesteeResultsReflected" xlink:to="lab_thc_PercentageInvesteeResultsReflected" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_397d30e0-4f10-497c-a514-1ce39901266b_terseLabel_en-US" xlink:label="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% due 2025</link:label>
    <link:label id="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_label_en-US" xlink:label="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Two Five Percent Senior Secured Note Due 2025 [Member]</link:label>
    <link:label id="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_documentation_en-US" xlink:label="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Two Five Percent Senior Secured Note Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" xlink:href="thc-20221231.xsd#thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" xlink:to="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_04eaf604-dc19-4428-82dd-63e1587fe9ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_bf13aacb-bdde-4cdd-ad4b-338e20ef044d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING STANDARDS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_008695cc-70cf-453a-aaae-ff247606e691_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_a7feea08-3aa8-48ef-8db0-2b575f6916d6_terseLabel_en-US" xlink:label="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement amount of payment</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_label_en-US" xlink:label="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount Of Payment for Minority Interest</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_documentation_en-US" xlink:label="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount Of Payment for Minority Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" xlink:to="lab_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9a932ab8-6d89-40d9-b62d-0079a95b70d0_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantThresholdLimit_fcc0b462-f416-48ec-a23a-81760b064a70_terseLabel_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantThresholdLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold limit of revolving credit facility</link:label>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantThresholdLimit_label_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantThresholdLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Threshold Limit</link:label>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantThresholdLimit_documentation_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantThresholdLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold limit for the line of credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantThresholdLimit" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantThresholdLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LineOfCreditFacilityCovenantThresholdLimit" xlink:to="lab_thc_LineOfCreditFacilityCovenantThresholdLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_e05e9144-fe5c-441c-9697-0699a1f9c469_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_d416a858-d444-4e06-8a96-69b68252d432_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period, days to be exercised before termination</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Vesting Period</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Exercise Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermContractWithCustomerMember_2c05aeb1-58a3-47e6-a4cf-d0f3c86e9642_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Contract with Customer</link:label>
    <link:label id="lab_us-gaap_ShortTermContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_ShortTermContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Contract with Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermContractWithCustomerMember" xlink:to="lab_us-gaap_ShortTermContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_f0cc5dd2-638f-4eb9-b8c6-783f37d9d301_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_676bb689-ecbc-4386-9d6b-1d4d55292170_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5de16c4e-55cf-4e00-9a5f-9afc3a54b7cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_ae7a33f2-1f47-428a-968e-460de8106de8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for borrowing under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_5690d91a-7f2b-4423-943c-84f071d960cb_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance fee, based on face amount (percentage)</link:label>
    <link:label id="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_label_en-US" xlink:label="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance Fee, Based on Face Amount, Percentage</link:label>
    <link:label id="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_documentation_en-US" xlink:label="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the issuance fee, expressed as a percentage of the face amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" xlink:href="thc-20221231.xsd#thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" xlink:to="lab_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_fce2e441-3d62-467d-b1ec-c8906db5b7d0_terseLabel_en-US" xlink:label="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical hospitals operated by subsidiaries</link:label>
    <link:label id="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_label_en-US" xlink:label="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Hospitals Operated By Subsidiaries</link:label>
    <link:label id="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_documentation_en-US" xlink:label="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Hospitals Operated By Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" xlink:to="lab_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bc4d7636-d1d2-4132-ac2b-ae86b6fa9d79_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2a800c17-5c18-4890-85e6-d359754c50e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_65001cc9-6392-4c74-a5ad-c8619d445172_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_56f249fd-2ab0-45a7-8ffc-fd44ee2b01c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_47d5604e-9c3a-4bc1-999c-02fc32096cf4_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill at end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_4d84a30f-b29f-4397-a374-99298fee26d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseLiabilitiesPaymentsDueAbstract_055ee5ea-f00c-413a-b6bf-1095b4ba1e6e_terseLabel_en-US" xlink:label="lab_thc_LeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_thc_LeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_thc_LeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities, Payments, Due [Abstract]</link:label>
    <link:label id="lab_thc_LeaseLiabilitiesPaymentsDueAbstract_documentation_en-US" xlink:label="lab_thc_LeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities, Payments, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilitiesPaymentsDueAbstract" xlink:href="thc-20221231.xsd#thc_LeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_thc_LeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_c5527e1a-7664-456e-9dac-a50faf83f70a_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled On Fourth Anniversary</link:label>
    <link:label id="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled On Fourth Anniversary [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled On Fourth Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnFourthAnniversaryMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnFourthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingSettledOnFourthAnniversaryMember" xlink:to="lab_thc_TimeBasedVestingSettledOnFourthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9cdaab2-359c-4a53-abdc-1f1daeb2dd44_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5d8fea97-1e66-47bb-96a4-f3dbbd2b19cb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_f3e5d6b9-3313-4042-969b-69cdb4295046_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument payment</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_BuildingsSubjectToImpairmentChargesMember_01185b51-82bc-4d21-afb2-570dfc0aa8f2_terseLabel_en-US" xlink:label="lab_thc_BuildingsSubjectToImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Subject To Impairment Charges</link:label>
    <link:label id="lab_thc_BuildingsSubjectToImpairmentChargesMember_label_en-US" xlink:label="lab_thc_BuildingsSubjectToImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Subject To Impairment Charges [Member]</link:label>
    <link:label id="lab_thc_BuildingsSubjectToImpairmentChargesMember_documentation_en-US" xlink:label="lab_thc_BuildingsSubjectToImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Subject To Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BuildingsSubjectToImpairmentChargesMember" xlink:href="thc-20221231.xsd#thc_BuildingsSubjectToImpairmentChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_BuildingsSubjectToImpairmentChargesMember" xlink:to="lab_thc_BuildingsSubjectToImpairmentChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d04f42cb-4185-4f65-baef-6245873a9309_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_abe538d6-afa4-452b-bd8a-4f477d6327a3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3c7e53b5-414d-49a6-b705-780ec8633438_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_412b9455-da9c-4086-820f-268d024c9d51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b440a7b9-e97f-4a63-9700-2702a464ed23_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1ac1e4d3-260a-465d-bdce-fb2d6e532aeb_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c2503dd2-71f8-4eb8-9884-d74810df7c5f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_55609729-3b7b-4b32-8292-e32a565a21f2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e6d82d59-0cf6-4b65-a63f-bcbf86a794b9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PropertyInsuranceDeductible_ce51b8b2-e4a5-4e65-ba7f-c6628ae09792_terseLabel_en-US" xlink:label="lab_thc_PropertyInsuranceDeductible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance deductible</link:label>
    <link:label id="lab_thc_PropertyInsuranceDeductible_label_en-US" xlink:label="lab_thc_PropertyInsuranceDeductible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Deductible</link:label>
    <link:label id="lab_thc_PropertyInsuranceDeductible_documentation_en-US" xlink:label="lab_thc_PropertyInsuranceDeductible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Deductible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceDeductible" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceDeductible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PropertyInsuranceDeductible" xlink:to="lab_thc_PropertyInsuranceDeductible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_1d45ef64-0976-4d89-8bfc-8f470e51d2ed_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_fd1e1a1f-db10-414b-9312-385a7a32a3a0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charitable contribution carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2822a366-4427-47b5-9366-eb629b489721_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.05 par value; authorized 262,500,000 shares; 156,462,456 shares issued at December&#160;31,&#160;2022 and 155,520,691 shares issued at December&#160;31,&#160;2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8ad0d860-eb22-4b9c-8a3c-daaf2aab0ff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ba809069-d962-4605-bb70-6f058617761f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_325be90b-d680-43db-966f-fe6f9ac45ac5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock_31332147-b5de-41da-9723-1a7f05dd257a_terseLabel_en-US" xlink:label="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related To Leases</link:label>
    <link:label id="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="thc-20221231.xsd#thc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_thc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_1a831e72-c080-4314-a9f1-be4c68c48406_verboseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.875% Senior Notes due 2031</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_583cd684-c14a-4b47-9956-ddc58b478fe1_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseLiability_b312f9d3-5563-4223-8e68-52172e8e065a_totalLabel_en-US" xlink:label="lab_thc_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_thc_LeaseLiability_label_en-US" xlink:label="lab_thc_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_thc_LeaseLiability_documentation_en-US" xlink:label="lab_thc_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiability" xlink:href="thc-20221231.xsd#thc_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseLiability" xlink:to="lab_thc_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfSurgicalCentersAcquired_d31510d2-291b-4390-887f-1489afb41a1b_terseLabel_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical centers acquired</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersAcquired_label_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers Acquired</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersAcquired_documentation_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersAcquired" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfSurgicalCentersAcquired" xlink:to="lab_thc_NumberOfSurgicalCentersAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_b471e521-9144-4dfa-a5d9-66287ceb49ee_terseLabel_en-US" xlink:label="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% due 2027</link:label>
    <link:label id="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_label_en-US" xlink:label="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Two Five Percent Senior Secured Note, Due 2027 [Member]</link:label>
    <link:label id="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_documentation_en-US" xlink:label="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% Senior Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" xlink:href="thc-20221231.xsd#thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" xlink:to="lab_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_d720f895-f416-4e11-93d7-68ab56a808ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals for General and Professional Liability Risks</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_280d9c64-8596-4de0-a4b7-6daec747b48d_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liability</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ea82ecac-1a03-4ceb-af43-ff8fd3e42ab0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liability</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_0d6effb5-0df1-4b84-8557-2f989e7e388e_terseLabel_en-US" xlink:label="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outpatient centers recorded not using equity method</link:label>
    <link:label id="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_label_en-US" xlink:label="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Outpatient Centers Recorded Not Using Equity Method</link:label>
    <link:label id="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_documentation_en-US" xlink:label="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of outpatient centers in which they are not recorded using the equity method of accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" xlink:to="lab_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a89d0d31-4ade-4a63-bcce-9551b46bf41c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be3e2435-22e2-4b2c-b8dd-146ab33a86a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_a0e60f84-d043-4ad0-9871-c99401cf2031_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d2614a8a-ce04-44e4-a9c4-4ffad51babf3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign pretax loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_69d04125-f43c-4769-b4e2-41452c2c02f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e2f1dba5-19e5-4773-82f2-eaeb412668af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_ba1d93ed-cd51-4ada-a01c-9e48af5494ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_3fd0749e-cdf0-44ef-9fc5-48e442c73537_terseLabel_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities &#8211; Long-Term Advances from Medicare</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_63b34215-c971-4e2e-9359-920752969f22_verboseLabel_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability &#8211; Long-Term Deferred Revenue</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_label_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability, Net, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_documentation_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability, Net, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:to="lab_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfOutpatientFacilitiesOperated_52d08f01-ca79-4871-8aac-495b6080cf9c_terseLabel_en-US" xlink:label="lab_thc_NumberOfOutpatientFacilitiesOperated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outpatient facilities operated</link:label>
    <link:label id="lab_thc_NumberOfOutpatientFacilitiesOperated_label_en-US" xlink:label="lab_thc_NumberOfOutpatientFacilitiesOperated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Outpatient Facilities Operated</link:label>
    <link:label id="lab_thc_NumberOfOutpatientFacilitiesOperated_documentation_en-US" xlink:label="lab_thc_NumberOfOutpatientFacilitiesOperated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Outpatient Facilities Operated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientFacilitiesOperated" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientFacilitiesOperated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfOutpatientFacilitiesOperated" xlink:to="lab_thc_NumberOfOutpatientFacilitiesOperated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a604f0a1-2e4f-4c8a-87de-7137f2ae3e0a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_291b6111-9b32-4083-9be8-1fe7e438d3fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_96f66741-96e1-4ee1-a705-c253f337aec7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_7df82d43-b736-4994-92e2-ded53530defe_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_12bf5ae4-0efd-4772-ab89-e49c04c901d1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2ab65a71-5aa0-4df5-8d90-41fa2a0eb7e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_b2c49335-cb54-4911-9f4a-7b3fc0fbb1f7_terseLabel_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Two</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_documentation_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" xlink:to="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ccdc4e1a-a596-4fe8-911d-e9f53c1b7c31_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_639e7d2d-7ed5-4fd3-a715-95a05dc8d353_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_c18a790e-f152-4f7a-bab6-7ac6edd0d85e_terseLabel_en-US" xlink:label="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received cash payments</link:label>
    <link:label id="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_label_en-US" xlink:label="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Government Assistance, Including Contributions From Affiliates</link:label>
    <link:label id="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_documentation_en-US" xlink:label="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Government Assistance, Including Contributions From Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" xlink:href="thc-20221231.xsd#thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" xlink:to="lab_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0f4d3c43-72e6-4832-aab1-8cf309166845_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_f06cdd4e-4f9f-4746-bc0f-18dc3f8080f1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_cc6ce1c8-91b2-4656-8d47-97ed5fd02f36_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1d4636e-6801-4ed4-a50e-95613148bb1f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc3aa0bd-e2a0-4569-880f-65019df5b506_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_c07d9ecf-c3a2-4ef9-baa2-b12b192ea7e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SharePurchaseAgreementMonthlyPayment_da3899ac-2df3-4372-a216-8935fb23b199_terseLabel_en-US" xlink:label="lab_thc_SharePurchaseAgreementMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement, monthly payment</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementMonthlyPayment_label_en-US" xlink:label="lab_thc_SharePurchaseAgreementMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Monthly Payment</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementMonthlyPayment_documentation_en-US" xlink:label="lab_thc_SharePurchaseAgreementMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Monthly Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementMonthlyPayment" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementMonthlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SharePurchaseAgreementMonthlyPayment" xlink:to="lab_thc_SharePurchaseAgreementMonthlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_cbac9c60-28b7-4111-8382-bb24a0b86a43_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e33e243f-338d-4e63-9d61-7ffd61f2621d_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d622d27-e372-4a96-9824-735a7dd73a4a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod_070a4960-845d-42e1-8679-56551622c196_terseLabel_en-US" xlink:label="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost report filing period after end of annual cost reporting period</link:label>
    <link:label id="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod_label_en-US" xlink:label="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Filing Period after End of Annual Cost Reporting Period</link:label>
    <link:label id="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod_documentation_en-US" xlink:label="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the cost report filing period after the end of the annual cost reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" xlink:href="thc-20221231.xsd#thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" xlink:to="lab_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d62e35ef-89b9-4766-be79-b02ad0551da4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a505b564-df06-476b-a975-0a32ada9e1c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wtd. Avg Remaining Life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HospitalOperationsSegmentMember_e9c1aa9d-c88d-4e3e-a860-2a0ed898c0b7_terseLabel_en-US" xlink:label="lab_thc_HospitalOperationsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations</link:label>
    <link:label id="lab_thc_HospitalOperationsSegmentMember_label_en-US" xlink:label="lab_thc_HospitalOperationsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations Segment [Member]</link:label>
    <link:label id="lab_thc_HospitalOperationsSegmentMember_documentation_en-US" xlink:label="lab_thc_HospitalOperationsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HospitalOperationsSegmentMember" xlink:to="lab_thc_HospitalOperationsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4a50629c-99e5-49d0-a728-8a76f6f3bada_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_252e762a-6c92-4af0-94f2-a991ae6b69b5_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8f002963-b088-4f8f-8b0f-28838c5c0a8d_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxAssetsReconciliationAbstract_50d27913-ed0b-4f61-8f97-76a676c3f45d_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxAssetsReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the deferred tax assets and liabilities</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsReconciliationAbstract_label_en-US" xlink:label="lab_thc_DeferredTaxAssetsReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Reconciliation [Abstract]</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsReconciliationAbstract_documentation_en-US" xlink:label="lab_thc_DeferredTaxAssetsReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Reconciliation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsReconciliationAbstract" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxAssetsReconciliationAbstract" xlink:to="lab_thc_DeferredTaxAssetsReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e96b9a9b-f6c0-4d10-bcf8-34e89c76d9ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing price at which shares are purchased by participant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_3735ae6f-5d7e-4248-b65a-5525dd5855ec_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused commitment fee (percentage)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_154f7fba-ff4c-4c81-872a-3e36ebb92fd6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later Years</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_bf58fd16-876a-4b8a-8012-b0ec0269e9b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_536743a3-d916-42b4-a1d4-cfb59efc8968_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including finance lease obligations</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-Term Debt and Capital Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d4d72eb0-c097-4d78-8b2c-f759f4b69035_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae2ff4cd-d0df-4487-917a-4aeeb320a99a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_565e3ddc-5de6-4e4b-83de-7ecca4a5f1b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized issue costs and note discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_b58f8547-96ae-4a32-8c6d-79c8276c396d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliations Of Legal Settlements And Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_2e0fa301-ccc2-4c90-9f2a-f7849124408c_terseLabel_en-US" xlink:label="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.750% due 2023</link:label>
    <link:label id="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_label_en-US" xlink:label="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Seven Five Percent Senior Unsecured Note, Due 2023 [Member]</link:label>
    <link:label id="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_documentation_en-US" xlink:label="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 6.75 percent senior notes, due 2023 issued by the reporting entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" xlink:href="thc-20221231.xsd#thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" xlink:to="lab_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_cd58cdff-28c2-4e3d-8908-227c939cc8e4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_492e419c-590b-4a39-ae83-cd697581b28e_terseLabel_en-US" xlink:label="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental period</link:label>
    <link:label id="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_label_en-US" xlink:label="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period In Which The Advanced Rated Is Increased And Limit On Certain Eligible Accounts Receivable Are Raised</link:label>
    <link:label id="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_documentation_en-US" xlink:label="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period In Which The Advanced Rated Is Increased And Limit On Certain Eligible Accounts Receivable Are Raised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" xlink:href="thc-20221231.xsd#thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" xlink:to="lab_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_4920bb40-e9ee-4deb-a775-640e0ee4361a_terseLabel_en-US" xlink:label="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related transaction costs</link:label>
    <link:label id="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_label_en-US" xlink:label="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Acquisition Related Transaction Costs</link:label>
    <link:label id="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_documentation_en-US" xlink:label="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of acquisition-related transaction costs incurred to effect a business combination which costs have been expensed during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts" xlink:href="thc-20221231.xsd#thc_BusinessCombinationAcquisitionRelatedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts" xlink:to="lab_thc_BusinessCombinationAcquisitionRelatedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_909f2b58-74f8-4909-b456-527b6b3e28de_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_b1188aae-f6c7-42a5-80df-813c131d2b9c_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled On Third Anniversary</link:label>
    <link:label id="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled On Third Anniversary [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled On Third Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnThirdAnniversaryMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnThirdAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingSettledOnThirdAnniversaryMember" xlink:to="lab_thc_TimeBasedVestingSettledOnThirdAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_c084b685-5ec2-4d7a-9b1a-452ab35bc278_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled on Second Anniversary</link:label>
    <link:label id="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled on Second Anniversary [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Settled on Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnSecondAnniversaryMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingSettledOnSecondAnniversaryMember" xlink:to="lab_thc_TimeBasedVestingSettledOnSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d012a9c3-357a-4677-93be-8f5cfbd8a502_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_e392f40f-c5e5-436c-882e-18913b0cf454_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_c74e42d3-c447-4f44-9e21-7df519444699_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_902d037f-445b-437c-8989-75905f3d4d2d_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, wages and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember_8b40ba42-0863-4fb2-b5fc-63a71e859675_terseLabel_en-US" xlink:label="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember_label_en-US" xlink:label="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments [Member]</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember_documentation_en-US" xlink:label="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanAlternativeInvestmentsMember" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanAlternativeInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DefinedBenefitPlanAlternativeInvestmentsMember" xlink:to="lab_thc_DefinedBenefitPlanAlternativeInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6887b803-266d-475f-a05b-6cbe05bc9beb_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument payment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7a75fabb-b6f7-4b5e-b363-36b826c434df_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_b4ecb812-8c76-4c0d-98c8-b2016a245a4d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligations Assumptions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_19d91cc9-594c-4c9d-b065-a957ed199b92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCareOtherSourcesMember_83aca080-bd38-4e40-bd2f-6f35cee3aba9_terseLabel_en-US" xlink:label="lab_thc_HealthCareOtherSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from other sources</link:label>
    <link:label id="lab_thc_HealthCareOtherSourcesMember_label_en-US" xlink:label="lab_thc_HealthCareOtherSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Other Sources [Member]</link:label>
    <link:label id="lab_thc_HealthCareOtherSourcesMember_documentation_en-US" xlink:label="lab_thc_HealthCareOtherSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Other Sources [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareOtherSourcesMember" xlink:href="thc-20221231.xsd#thc_HealthCareOtherSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCareOtherSourcesMember" xlink:to="lab_thc_HealthCareOtherSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_ee180277-a0e2-40f3-b513-6ddbcdc64c23_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self insurance reserve</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserve" xlink:to="lab_us-gaap_SelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember_da988ea7-4d07-4062-a194-cff05067b5ce_terseLabel_en-US" xlink:label="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting On Fourth Anniversary</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember_label_en-US" xlink:label="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting On Fourth Anniversary [Member]</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember_documentation_en-US" xlink:label="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting On Fourth Anniversary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingOnFourthAnniversaryMember" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingOnFourthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PerformanceBasedVestingOnFourthAnniversaryMember" xlink:to="lab_thc_PerformanceBasedVestingOnFourthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_346a0501-a5d4-4631-8a10-89360109f563_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_a3c64a8d-8bd4-42dc-9eac-ec3e3052bece_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:to="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_BaylorUniversityMedicalCenterMember_2e30d543-6d81-4e70-85db-cd78124111a7_terseLabel_en-US" xlink:label="lab_thc_BaylorUniversityMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baylor University Medical Center</link:label>
    <link:label id="lab_thc_BaylorUniversityMedicalCenterMember_label_en-US" xlink:label="lab_thc_BaylorUniversityMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baylor University Medical Center [Member]</link:label>
    <link:label id="lab_thc_BaylorUniversityMedicalCenterMember_documentation_en-US" xlink:label="lab_thc_BaylorUniversityMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Baylor University Medical Center.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_BaylorUniversityMedicalCenterMember" xlink:to="lab_thc_BaylorUniversityMedicalCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ec1233be-3395-427e-8d61-7476c605b80c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour_ddb705d7-6355-428f-8aa0-01f86e6a9e53_terseLabel_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour_documentation_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFour" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_acf01208-4eee-483c-b886-e02de701f029_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5aea2b9-49c9-4e59-8d4c-c1bb8877bf4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_419d77e9-852f-430c-9c11-6b8a5def3e73_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ccfe6fb-62b0-40ae-96bf-bd619bb0d005_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_cb391522-830d-4d0b-bdff-4238c520c8f1_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net patient service revenues</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_996fd401-e379-41f0-9978-bcc1094ec671_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0d45bdc2-65cb-4d6b-a0c3-cea71c632097_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_21a4a895-286f-4aff-b019-7d21e0200df4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5237f111-5233-403f-992d-ac233141e245_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9dc604c0-ba81-4d0c-b77b-832188a32568_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_9bff58e8-9e83-4de2-baa6-9757ff0f1ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9cffc8d3-23d4-4191-a013-97db8310bbfb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_13e40fa9-dcf3-4eca-a449-12cd3527faa2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests acquired and other disclosures</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22f142d8-dc8a-4105-834d-3eff4404f31b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_8fe3d0cc-ffac-43b2-988b-33551a4b7a7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts available to Tenet Healthcare Corporation common shareholders</link:label>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Amounts Attributable to Parent, Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6640b37d-8a14-4fdd-ac7b-8d7840e342f2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations, before discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_e16c484e-0776-4708-8ff5-ac1f5fff1365_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_128aad39-835e-4293-ad60-648912b8b8c5_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software costs</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_USPIManagementEquityPlanMember_87a8da6c-89e4-4480-8118-687f80ea6e5c_terseLabel_en-US" xlink:label="lab_thc_USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USPI Management Equity Plan</link:label>
    <link:label id="lab_thc_USPIManagementEquityPlanMember_label_en-US" xlink:label="lab_thc_USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USPI Management Equity Plan [Member]</link:label>
    <link:label id="lab_thc_USPIManagementEquityPlanMember_documentation_en-US" xlink:label="lab_thc_USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USPI Management Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_USPIManagementEquityPlanMember" xlink:href="thc-20221231.xsd#thc_USPIManagementEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_USPIManagementEquityPlanMember" xlink:to="lab_thc_USPIManagementEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_87bd31d7-4d2e-4f7a-b16e-e5a3d8ec9ec2_negatedLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax loss (income) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_93b90d91-53da-4809-9a1c-73b64de6554f_terseLabel_en-US" xlink:label="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_label_en-US" xlink:label="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefits Paid or Employer Contribution</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_documentation_en-US" xlink:label="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of payments made or employer contribution in a defined benefit pension plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" xlink:to="lab_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AmbulatoryCareMember_1caf411c-354f-4dde-abcc-b91928478117_terseLabel_en-US" xlink:label="lab_thc_AmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ambulatory Care</link:label>
    <link:label id="lab_thc_AmbulatoryCareMember_8a1fdf2e-c038-4e0d-a4ac-b9d6682e2c57_verboseLabel_en-US" xlink:label="lab_thc_AmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ambulatory Care</link:label>
    <link:label id="lab_thc_AmbulatoryCareMember_label_en-US" xlink:label="lab_thc_AmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ambulatory Care [Member]</link:label>
    <link:label id="lab_thc_AmbulatoryCareMember_documentation_en-US" xlink:label="lab_thc_AmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Ambulatory Care as a reportable segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AmbulatoryCareMember" xlink:to="lab_thc_AmbulatoryCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxAssetsMedicareAdvancePayments_3b870384-086a-46de-996a-4794074abd26_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxAssetsMedicareAdvancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare advance payments</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsMedicareAdvancePayments_label_en-US" xlink:label="lab_thc_DeferredTaxAssetsMedicareAdvancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Medicare Advance Payments</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsMedicareAdvancePayments_documentation_en-US" xlink:label="lab_thc_DeferredTaxAssetsMedicareAdvancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Medicare Advance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsMedicareAdvancePayments" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsMedicareAdvancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxAssetsMedicareAdvancePayments" xlink:to="lab_thc_DeferredTaxAssetsMedicareAdvancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CaptiveInsuranceSubsidiariesMember_30f6a551-de39-4cdc-b53f-d3679941552e_terseLabel_en-US" xlink:label="lab_thc_CaptiveInsuranceSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captive Insurance Subsidiaries</link:label>
    <link:label id="lab_thc_CaptiveInsuranceSubsidiariesMember_label_en-US" xlink:label="lab_thc_CaptiveInsuranceSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captive Insurance Subsidiaries [Member]</link:label>
    <link:label id="lab_thc_CaptiveInsuranceSubsidiariesMember_documentation_en-US" xlink:label="lab_thc_CaptiveInsuranceSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents activity related to captive insurance subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaptiveInsuranceSubsidiariesMember" xlink:href="thc-20221231.xsd#thc_CaptiveInsuranceSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CaptiveInsuranceSubsidiariesMember" xlink:to="lab_thc_CaptiveInsuranceSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c4097c80-9b12-4f80-9bc3-e3ae70cbe212_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_16551066-e247-4261-83e7-3f2588585833_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4dade465-2ebf-4cad-9374-6605ec200317_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfUrgentCareCentersSold_3d0e3327-8b35-4371-8e56-735f6d945130_terseLabel_en-US" xlink:label="lab_thc_NumberOfUrgentCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of urgent care centers sold</link:label>
    <link:label id="lab_thc_NumberOfUrgentCareCentersSold_label_en-US" xlink:label="lab_thc_NumberOfUrgentCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Urgent Care Centers Sold</link:label>
    <link:label id="lab_thc_NumberOfUrgentCareCentersSold_documentation_en-US" xlink:label="lab_thc_NumberOfUrgentCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Urgent Care Centers Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfUrgentCareCentersSold" xlink:href="thc-20221231.xsd#thc_NumberOfUrgentCareCentersSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfUrgentCareCentersSold" xlink:to="lab_thc_NumberOfUrgentCareCentersSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_daa36b41-cba5-43ef-adf4-a0bec03a687c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Axis]</link:label>
    <link:label id="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_label_en-US" xlink:label="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:to="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FloodEarthquakeAndWindstormMember_67b846e5-db85-482d-adea-48fe841fa47e_terseLabel_en-US" xlink:label="lab_thc_FloodEarthquakeAndWindstormMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floods, Earthquakes and Windstorms</link:label>
    <link:label id="lab_thc_FloodEarthquakeAndWindstormMember_label_en-US" xlink:label="lab_thc_FloodEarthquakeAndWindstormMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flood Earthquake And Windstorm [Member]</link:label>
    <link:label id="lab_thc_FloodEarthquakeAndWindstormMember_documentation_en-US" xlink:label="lab_thc_FloodEarthquakeAndWindstormMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overflowing of a body of water, sudden movement of the earth's crust and localized violently destructive windstorm characterized by a funnel shaped cloud.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FloodEarthquakeAndWindstormMember" xlink:href="thc-20221231.xsd#thc_FloodEarthquakeAndWindstormMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FloodEarthquakeAndWindstormMember" xlink:to="lab_thc_FloodEarthquakeAndWindstormMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_d2f65691-761b-48a4-bd91-c1017645553b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_A2020USPIManagementEquityPlanMember_0ad0928b-8fec-4f5d-9f57-88371d37f41e_terseLabel_en-US" xlink:label="lab_thc_A2020USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 USPI Management Equity Plan</link:label>
    <link:label id="lab_thc_A2020USPIManagementEquityPlanMember_label_en-US" xlink:label="lab_thc_A2020USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 USPI Management Equity Plan [Member]</link:label>
    <link:label id="lab_thc_A2020USPIManagementEquityPlanMember_documentation_en-US" xlink:label="lab_thc_A2020USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 USPI Management Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2020USPIManagementEquityPlanMember" xlink:href="thc-20221231.xsd#thc_A2020USPIManagementEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_A2020USPIManagementEquityPlanMember" xlink:to="lab_thc_A2020USPIManagementEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfHospitalsForSale_d6bea472-2028-4458-8500-deb7d8fbfad3_terseLabel_en-US" xlink:label="lab_thc_NumberOfHospitalsForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospitals for sale</link:label>
    <link:label id="lab_thc_NumberOfHospitalsForSale_label_en-US" xlink:label="lab_thc_NumberOfHospitalsForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Hospitals For Sale</link:label>
    <link:label id="lab_thc_NumberOfHospitalsForSale_documentation_en-US" xlink:label="lab_thc_NumberOfHospitalsForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Hospitals For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsForSale" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfHospitalsForSale" xlink:to="lab_thc_NumberOfHospitalsForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent_e3bcc1cf-165d-446c-8e6d-e78f639552c6_terseLabel_en-US" xlink:label="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent_label_en-US" xlink:label="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician And Group Coverage Guarantees Current</link:label>
    <link:label id="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent_documentation_en-US" xlink:label="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician And Group Coverage Guarantees Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent" xlink:href="thc-20221231.xsd#thc_PhysicianAndGroupCoverageGuaranteesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent" xlink:to="lab_thc_PhysicianAndGroupCoverageGuaranteesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1f8ad942-6133-461a-b00b-152c6ea8c3d3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_fcebca54-abf3-4d12-b285-59efd411d917_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_07d270dd-50ef-4168-aa2a-bf982ba2a336_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-patient receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax_1c952a2e-7ebe-4289-abcf-d54fbee1f284_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit (expense) allocated to adjustments for defined benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_945f7d6b-1084-4cfa-b2a6-5a83b192a921_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, total</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncomeTaxExpenseBenefitCARESAct_86460aec-4996-4472-8a4b-186be29e853e_terseLabel_en-US" xlink:label="lab_thc_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_thc_IncomeTaxExpenseBenefitCARESAct_label_en-US" xlink:label="lab_thc_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), CARES Act</link:label>
    <link:label id="lab_thc_IncomeTaxExpenseBenefitCARESAct_documentation_en-US" xlink:label="lab_thc_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxExpenseBenefitCARESAct" xlink:href="thc-20221231.xsd#thc_IncomeTaxExpenseBenefitCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncomeTaxExpenseBenefitCARESAct" xlink:to="lab_thc_IncomeTaxExpenseBenefitCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_3d8e4c17-e1c7-410d-89a7-5abd72f5e40c_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Evenly On The Third And Fourth Anniversary</link:label>
    <link:label id="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Evenly On The Third And Fourth Anniversary [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Evenly On The Third And Fourth Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" xlink:to="lab_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9eaf8d-0fc7-49f0-8271-826f12108243_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fe20a2f-a548-42c3-90e2-0829e2c90a38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8b476b2d-6bfe-4f3e-ad74-98769c5105be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d1c9f720-844b-4ab9-9a73-0b132f5686d8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares and dilutive securities outstanding (in thousands):</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_9fb712f9-f8b5-4cd4-9879-a793e7ce4d5a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred social security tax payments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Severance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_45e80407-7e8c-4180-97ef-d0528af53d31_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0c5b06c7-865e-498b-b662-1bd59eab7e62_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories of supplies, at cost</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_62f33092-27b6-4ecc-979e-1ac790b41bfb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6a78a778-32c1-42b3-bab3-1d614c016f8b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_8e8c4826-3d4e-448f-9f14-063683d084c1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business acquisitions</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1f7a30a8-106d-4b05-8dbd-08c902c5ffbf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_6c5edeca-459f-4f8d-8d0e-5a77056fa008_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period, number of quarterly periods</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Quarterly Periods</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Quarterly Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_dd582532-b5e0-49c5-bb47-ef89c3f15373_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3b4b6e4b-6db2-4bcc-89a1-45cd8a6b1e67_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_08e3ad7d-2f4a-4c02-805d-df6418ffeab5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_253a6bd3-f385-4ded-80f4-b990396702f6_negatedNetLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1445e0f5-36e0-4f2c-ad25-4d8c648e22e8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f1a426b7-d5ce-4599-9546-8f237dcd3d48_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f84e2951-b2bb-47f5-bdee-ff8152942f71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_a804e01c-6793-4d9e-841b-01ca1578ec91_periodStartLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation reserve, Balances at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4bcd60f8-9d4c-4f0c-95d0-05e3260c7e44_periodEndLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation reserve, Balances at End of Period</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfImagingCentersTransferred_3ddc0e1e-3fb2-4e83-9cec-eb446f2cfcf0_terseLabel_en-US" xlink:label="lab_thc_NumberOfImagingCentersTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of imaging centers transferred</link:label>
    <link:label id="lab_thc_NumberOfImagingCentersTransferred_label_en-US" xlink:label="lab_thc_NumberOfImagingCentersTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Imaging Centers Transferred</link:label>
    <link:label id="lab_thc_NumberOfImagingCentersTransferred_documentation_en-US" xlink:label="lab_thc_NumberOfImagingCentersTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Imaging Centers Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfImagingCentersTransferred" xlink:href="thc-20221231.xsd#thc_NumberOfImagingCentersTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfImagingCentersTransferred" xlink:to="lab_thc_NumberOfImagingCentersTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_fe638956-433c-435a-b880-f4db86776fef_negatedLabel_en-US" xlink:label="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cost reports and settlements receivable and valuation allowances</link:label>
    <link:label id="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_label_en-US" xlink:label="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cost Report Settlements Receivable (Payable) and Valuation Allowances</link:label>
    <link:label id="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_documentation_en-US" xlink:label="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cost report settlements receivable (payable) and valuation allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" xlink:href="thc-20221231.xsd#thc_NetCostReportSettlementsReceivablePayableandValuationAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" xlink:to="lab_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bbcffb95-9d29-49c1-bede-465b34245aa2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plans assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_22789805-a4b9-4cb7-b3cb-176ea72ead25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_119752e8-6501-4bb9-b72c-9499ee5185c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains from the sale of investments and long-lived assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ReceivablesFromGovernmentProgramsCurrent_627f7d1e-a95c-464a-891a-c81ade07657a_terseLabel_en-US" xlink:label="lab_thc_ReceivablesFromGovernmentProgramsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from other government programs</link:label>
    <link:label id="lab_thc_ReceivablesFromGovernmentProgramsCurrent_label_en-US" xlink:label="lab_thc_ReceivablesFromGovernmentProgramsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from government programs Current</link:label>
    <link:label id="lab_thc_ReceivablesFromGovernmentProgramsCurrent_documentation_en-US" xlink:label="lab_thc_ReceivablesFromGovernmentProgramsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from government programs Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ReceivablesFromGovernmentProgramsCurrent" xlink:href="thc-20221231.xsd#thc_ReceivablesFromGovernmentProgramsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ReceivablesFromGovernmentProgramsCurrent" xlink:to="lab_thc_ReceivablesFromGovernmentProgramsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_cb345422-f861-4dd7-b4c2-e3e38bf42312_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests in equity of consolidated subsidiaries</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_26128ea4-85de-4d7a-a00a-5de8f823f41f_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_70b6bc9a-4458-49ae-844e-ea3293863a3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0d348f5a-d8ed-4cc2-a972-80ed0e81b91a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Long Term Debt Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4e0838ac-0ee1-47f6-a00f-05b4cbdf3572_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_54857815-9391-4205-af4e-435b581f6d05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of other borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_ce39f923-5801-4eac-9c36-266da4c38750_verboseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims, Lawsuits, and Regulatory Proceedings</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d426b047-8474-4588-8b54-1957f53ce19b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c35b3b96-bded-44d1-9678-b1969c461d16_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_742b4595-e0cb-4e25-b0bd-379325196a3f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_b6df73b2-31e7-4188-89fa-f0351d54eaa4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2acb1db5-388f-463a-99b5-279705e97193_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FinanceLeaseCost_05322085-8dfe-4e36-8bea-7a4f35a1a799_totalLabel_en-US" xlink:label="lab_thc_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease expense</link:label>
    <link:label id="lab_thc_FinanceLeaseCost_label_en-US" xlink:label="lab_thc_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_thc_FinanceLeaseCost_documentation_en-US" xlink:label="lab_thc_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeaseCost" xlink:href="thc-20221231.xsd#thc_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FinanceLeaseCost" xlink:to="lab_thc_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_5a448185-a196-4788-92a6-0a506469b848_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible goodwill</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_b2de9c1e-2498-4dda-9ce8-c5dde9b2df2d_terseLabel_en-US" xlink:label="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired during the year and purchase price allocation adjustments</link:label>
    <link:label id="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period And Purchase Accounting Adjustments</link:label>
    <link:label id="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period And Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" xlink:href="thc-20221231.xsd#thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" xlink:to="lab_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_f21c3d62-7b2e-47d9-bba6-2140ae0ca586_terseLabel_en-US" xlink:label="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, subfacility maximum available capacity</link:label>
    <link:label id="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_label_en-US" xlink:label="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Subfacility for Standby Letters of Credit Maximum Available Capacity</link:label>
    <link:label id="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_documentation_en-US" xlink:label="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum available capacity under the subfacility for standby letters of credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" xlink:to="lab_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_6edc0e1e-9e92-45ac-a06e-a495adf86e0b_terseLabel_en-US" xlink:label="lab_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Professional and General Liablity Insurance [Abstract]</link:label>
    <link:label id="lab_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_label_en-US" xlink:label="lab_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Professional and General Liablity Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract" xlink:href="thc-20221231.xsd#thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract" xlink:to="lab_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_d5748865-e6fc-425c-8a49-6c5ee1f27bcd_terseLabel_en-US" xlink:label="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% due 2028</link:label>
    <link:label id="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_label_en-US" xlink:label="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Two Five Percent Senior Unsecured Note Due 2028 [Member]</link:label>
    <link:label id="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_documentation_en-US" xlink:label="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Two Five Percent Senior Unsecured Note Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" xlink:to="lab_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive_bead5b55-5e94-40b3-ac3c-757ce174c542_terseLabel_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Five</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive_documentation_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFive" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_thc_LesseeLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_f8602f81-75f0-4d7b-98c8-9292e6c4d03b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_ca64f93b-4cef-4c5e-8ec8-a895a0cc6efc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCOUNTS RECEIVABLE</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesTextBlock" xlink:to="lab_us-gaap_FinancingReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_d4b4b09f-bb38-4e9c-9ca3-fcdfaca2fa46_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of estimated obligation</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9943361e-e84c-4480-a0be-da29adc1c096_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities, Including Any Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_6f3b4ad2-06e5-429c-b899-528010d44a4e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_0b6174e0-17a6-424a-b1ea-e865ab8b6089_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_8e1a3eb1-fc6a-4f06-9d7a-bdd504c16762_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt retirement</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_b8f4e2e3-946b-4fcf-a532-984a488d265f_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_b39be0c3-6079-4723-b347-26a63f81d726_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_83f776e6-3a97-4a15-9a6b-840339e0f71c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCarePatientServiceManagedCareMember_5333daa8-b543-4b61-97ae-937e5b90356c_terseLabel_en-US" xlink:label="lab_thc_HealthCarePatientServiceManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceManagedCareMember_label_en-US" xlink:label="lab_thc_HealthCarePatientServiceManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Managed Care [Member]</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceManagedCareMember_documentation_en-US" xlink:label="lab_thc_HealthCarePatientServiceManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Managed Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceManagedCareMember" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCarePatientServiceManagedCareMember" xlink:to="lab_thc_HealthCarePatientServiceManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_f59ed1a9-9b62-41e1-a184-18a2f689f597_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_813c718b-6336-4be4-9e68-1dce94e57e97_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7b4aa0f0-daa1-4bbb-8c20-3c4f3ab5a0ab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of businesses or joint venture interests, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6c6e91ea-4120-435e-a3f6-3cd4db0acb05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FireAndOtherPerilsMember_50b81b8d-8f25-4593-96f5-10996ce4c858_terseLabel_en-US" xlink:label="lab_thc_FireAndOtherPerilsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fires and Other Perils</link:label>
    <link:label id="lab_thc_FireAndOtherPerilsMember_label_en-US" xlink:label="lab_thc_FireAndOtherPerilsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fire And Other Perils [Member]</link:label>
    <link:label id="lab_thc_FireAndOtherPerilsMember_documentation_en-US" xlink:label="lab_thc_FireAndOtherPerilsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxidation process that releases energy in the form of light and heat (flames) and often creates smoke and other perils.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FireAndOtherPerilsMember" xlink:href="thc-20221231.xsd#thc_FireAndOtherPerilsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FireAndOtherPerilsMember" xlink:to="lab_thc_FireAndOtherPerilsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cc19c129-99b3-4601-8ee5-f577f06ec7bf_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b11734d3-f12b-4133-bd6e-3c28b29f9912_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_49086ab2-a4a4-4512-8216-ee4a234bb825_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_dac62645-eb57-41fa-8035-97dc2b6fd6dd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information regarding other intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3e1a244e-91e7-406d-b002-855d5942a3c7_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, at cost, less accumulated amortization ($1,428 at December&#160;31,&#160;2022 and $1,374 at December&#160;31,&#160;2021)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c16e4ea-5198-4680-a70e-f8d28d22fd45_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;Book Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_105a7aff-83db-4eba-b15f-aaece9db94d9_terseLabel_en-US" xlink:label="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of the long-term debt instrument as a percentage of carrying value</link:label>
    <link:label id="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_label_en-US" xlink:label="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Debt Instrument as Percentage of Carrying Value</link:label>
    <link:label id="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_documentation_en-US" xlink:label="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated fair value of the long-term debt instrument as a percentage of carrying value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" xlink:href="thc-20221231.xsd#thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" xlink:to="lab_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a25cbe41-5595-4999-b402-109aca7b5a34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests_01117b9d-ce56-4c85-95c7-f8d3c7094b69_terseLabel_en-US" xlink:label="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from purchase of noncontrolling interests</link:label>
    <link:label id="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests_label_en-US" xlink:label="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Purchase Of Noncontrolling Interests</link:label>
    <link:label id="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests_documentation_en-US" xlink:label="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Purchase Of Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests" xlink:href="thc-20221231.xsd#thc_GainLossFromPurchaseOfNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests" xlink:to="lab_thc_GainLossFromPurchaseOfNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_83ca2628-fd2c-4201-ab67-8e5475544af1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities&#160;</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6a8bff26-3b0b-4f0e-a3d9-656ee06344b4_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_37d7ec6a-4bea-4e2e-8011-98095db820be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b08197bb-31f7-4c1a-a8a5-4e249e34520d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_186e9dd8-eedb-4dda-9337-f2e3e6b9d340_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_125b8838-6bde-4399-93f1-eba43b950eff_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7aa6b9cb-2114-4e52-a3f2-0d4f8b77a576_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfSurgicalHospitalsConsolidated_e3fcd08c-54a9-44fb-ac5f-e16b8353a035_terseLabel_en-US" xlink:label="lab_thc_NumberOfSurgicalHospitalsConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical hospitals consolidated</link:label>
    <link:label id="lab_thc_NumberOfSurgicalHospitalsConsolidated_label_en-US" xlink:label="lab_thc_NumberOfSurgicalHospitalsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Hospitals Consolidated</link:label>
    <link:label id="lab_thc_NumberOfSurgicalHospitalsConsolidated_documentation_en-US" xlink:label="lab_thc_NumberOfSurgicalHospitalsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Hospitals Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsConsolidated" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfSurgicalHospitalsConsolidated" xlink:to="lab_thc_NumberOfSurgicalHospitalsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d45d38b9-e63a-4e64-95c9-a4e596df51bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_40fd6330-d22f-4e62-bf3d-18cec6ba72b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS AND LIABILITIES HELD FOR SALE</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_02861772-5229-4ce3-9d36-1da07e8d5060_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits which, if recognized, would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_757e9675-da0a-4c2b-a07d-203c601cbc0a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0e5a86b8-13e1-425c-81cc-b8abdb6663f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period from the date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TenetHealthcareCorpMember_3547ea53-5279-4638-ab1c-d866e64a3eb8_verboseLabel_en-US" xlink:label="lab_thc_TenetHealthcareCorpMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenet</link:label>
    <link:label id="lab_thc_TenetHealthcareCorpMember_label_en-US" xlink:label="lab_thc_TenetHealthcareCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenet Healthcare Corp [Member]</link:label>
    <link:label id="lab_thc_TenetHealthcareCorpMember_documentation_en-US" xlink:label="lab_thc_TenetHealthcareCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenet Healthcare Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TenetHealthcareCorpMember" xlink:href="thc-20221231.xsd#thc_TenetHealthcareCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TenetHealthcareCorpMember" xlink:to="lab_thc_TenetHealthcareCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_68a8b853-c9a4-4680-ba1f-66ab48fdee4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ad9e4cf7-7f31-4775-ac21-e5e676657d15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lower range of stock exercise price range (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6c790073-6aeb-4827-9573-c50b88fc5c09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9a8066ba-70e7-4671-befc-f907219da156_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_25508d07-8176-41fa-baa7-58c7fb9b111f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_ad4acf4f-1444-4173-b2a9-9ec43d99fbdf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCareClientContractsOtherServicesMember_2d726834-74cb-43e4-8213-b993f433c0b4_terseLabel_en-US" xlink:label="lab_thc_HealthCareClientContractsOtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Client Contracts - Other Services</link:label>
    <link:label id="lab_thc_HealthCareClientContractsOtherServicesMember_label_en-US" xlink:label="lab_thc_HealthCareClientContractsOtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Client Contracts - Other Services [Member]</link:label>
    <link:label id="lab_thc_HealthCareClientContractsOtherServicesMember_documentation_en-US" xlink:label="lab_thc_HealthCareClientContractsOtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Client Contracts - Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareClientContractsOtherServicesMember" xlink:href="thc-20221231.xsd#thc_HealthCareClientContractsOtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCareClientContractsOtherServicesMember" xlink:to="lab_thc_HealthCareClientContractsOtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f711d38d-9f63-4d9b-8cbf-0cffb9d76f90_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b0947634-9eca-487a-a996-5e9f41bbb6d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years), finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1554a271-af39-4fe6-864c-a51eb24c6917_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_3b2324c1-1dcd-448d-89f4-5bda9aad4298_negatedLabel_en-US" xlink:label="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired charitable contribution carryforward</link:label>
    <link:label id="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_label_en-US" xlink:label="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Expired Charitable Contributions Carryforward, Amount</link:label>
    <link:label id="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_documentation_en-US" xlink:label="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Expired Charitable Contributions Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" xlink:href="thc-20221231.xsd#thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" xlink:to="lab_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_127bc8ba-3d3d-4471-944f-75e79b67b7e4_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_55442745-15d4-4bea-a7db-e0b2fc3eb381_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_a360e0e1-85e4-4971-b4ac-2f673904b1c4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_aee5dada-51cd-48b1-b0b9-8839a8653648_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_801959cc-bab1-4cef-8220-edee77b27934_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0554cdda-cbc4-40ff-b972-3b6ceda4242c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fad3203f-4533-48c6-85c2-764981214e3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized to be issued under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_227e18bd-171a-40e4-b32c-cae516f9571e_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and general liability reserves</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration_38e16d72-4ac6-4259-b352-e1421c21ad0e_terseLabel_en-US" xlink:label="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="thc-20221231.xsd#thc_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_thc_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_6f154fe6-abc4-4295-ac19-a3b91592cfc9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated With Exit or Disposal Activities</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EightQuarterVestingPeriodMember_f4ffe8f6-7510-4e6f-979e-1170439c20ba_terseLabel_en-US" xlink:label="lab_thc_EightQuarterVestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Quarter Vesting Period</link:label>
    <link:label id="lab_thc_EightQuarterVestingPeriodMember_label_en-US" xlink:label="lab_thc_EightQuarterVestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Quarter Vesting Period [Member]</link:label>
    <link:label id="lab_thc_EightQuarterVestingPeriodMember_documentation_en-US" xlink:label="lab_thc_EightQuarterVestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Quarter Vesting Period [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EightQuarterVestingPeriodMember" xlink:href="thc-20221231.xsd#thc_EightQuarterVestingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EightQuarterVestingPeriodMember" xlink:to="lab_thc_EightQuarterVestingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_814d4bdc-dd33-4e19-97dc-22e57b8fdc60_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_1f6f2616-5b56-42d0-beba-db151a7ac3c3_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_953efeef-cc14-4691-88e1-55439f1ac03f_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments under guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_f250e997-f0e7-4562-abb8-9676e7ad6ff9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative net actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d550124f-6c27-447a-ba96-aa4300d3b1bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation Between Reported Income Tax Expense (Benefit) and Income Taxes Calculated by the Statutory Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9632679b-30af-44c7-98e3-a92ab47f354f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FinanceLeaseExpenseAbstract_9ccf9646-8ff5-49c4-94ec-2853d10978fd_terseLabel_en-US" xlink:label="lab_thc_FinanceLeaseExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense:</link:label>
    <link:label id="lab_thc_FinanceLeaseExpenseAbstract_label_en-US" xlink:label="lab_thc_FinanceLeaseExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Expense [Abstract]</link:label>
    <link:label id="lab_thc_FinanceLeaseExpenseAbstract_documentation_en-US" xlink:label="lab_thc_FinanceLeaseExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeaseExpenseAbstract" xlink:href="thc-20221231.xsd#thc_FinanceLeaseExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FinanceLeaseExpenseAbstract" xlink:to="lab_thc_FinanceLeaseExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_79b50fb7-a984-4d8b-a5ea-0764f9c0197c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_VariableAndShorttermLeaseCosts_17786bd5-a164-40ef-be51-537e630c958a_terseLabel_en-US" xlink:label="lab_thc_VariableAndShorttermLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable and short term-lease expense</link:label>
    <link:label id="lab_thc_VariableAndShorttermLeaseCosts_label_en-US" xlink:label="lab_thc_VariableAndShorttermLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-term Lease, Costs</link:label>
    <link:label id="lab_thc_VariableAndShorttermLeaseCosts_documentation_en-US" xlink:label="lab_thc_VariableAndShorttermLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-term Lease, Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_VariableAndShorttermLeaseCosts" xlink:href="thc-20221231.xsd#thc_VariableAndShorttermLeaseCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_VariableAndShorttermLeaseCosts" xlink:to="lab_thc_VariableAndShorttermLeaseCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_57c0424f-ce83-4f0b-baf4-b817481035c5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_652def1f-a4d4-4af0-a713-95b24ad18b17_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization of intangibles with finite useful lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_24ed0d94-e0ad-4c34-b40b-93f7123b28da_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of secured debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_84dd7661-a2a2-4cbf-9d71-87d568ff7df0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d10bcf6-f4f5-405b-b9da-269a383461cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e42b994-8748-4734-9ee0-a69ec9c3df4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_e2f2819a-2a69-408b-ad00-a271576d0743_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration conveyed in the acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_e3f2bc97-1980-49a6-999e-349a31beda91_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_6c4a1303-cd7c-44b8-a697-89984f6d612b_terseLabel_en-US" xlink:label="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.500% due 2025</link:label>
    <link:label id="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_label_en-US" xlink:label="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Zero Percent Senior Unsecured Note, Due 2025 [Member]</link:label>
    <link:label id="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_documentation_en-US" xlink:label="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Zero Percent Senior Unsecured Note, Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" xlink:href="thc-20221231.xsd#thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" xlink:to="lab_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_3f5f6143-3e08-431c-b1a5-2b2b741ef093_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3cf20d47-f2aa-4cf8-a874-e70e7e34e719_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4195ae03-f514-4a56-8217-1b35f4ebbd92_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_12f6bc04-099b-4ea3-b7b3-db7b20ead707_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCareManagementFeesMember_a51584d9-938a-45f1-9ca3-0361b3436714_terseLabel_en-US" xlink:label="lab_thc_HealthCareManagementFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_thc_HealthCareManagementFeesMember_label_en-US" xlink:label="lab_thc_HealthCareManagementFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Management Fees [Member]</link:label>
    <link:label id="lab_thc_HealthCareManagementFeesMember_documentation_en-US" xlink:label="lab_thc_HealthCareManagementFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Management Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareManagementFeesMember" xlink:href="thc-20221231.xsd#thc_HealthCareManagementFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCareManagementFeesMember" xlink:to="lab_thc_HealthCareManagementFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_a4200976-990d-44b1-9668-57c6ed0e30d6_verboseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ConiferHealthSolutionsLLCMember_037508a8-910b-47a6-84a6-45f531d77c85_terseLabel_en-US" xlink:label="lab_thc_ConiferHealthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conifer Health Solutions, LLC</link:label>
    <link:label id="lab_thc_ConiferHealthSolutionsLLCMember_label_en-US" xlink:label="lab_thc_ConiferHealthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conifer Health Solutions, LLC [Member]</link:label>
    <link:label id="lab_thc_ConiferHealthSolutionsLLCMember_documentation_en-US" xlink:label="lab_thc_ConiferHealthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conifer Health Solutions, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferHealthSolutionsLLCMember" xlink:href="thc-20221231.xsd#thc_ConiferHealthSolutionsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ConiferHealthSolutionsLLCMember" xlink:to="lab_thc_ConiferHealthSolutionsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_8cf69d9f-62dc-4549-93f2-83d259942d1d_terseLabel_en-US" xlink:label="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business days after notice for reimbursement of drawings</link:label>
    <link:label id="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_label_en-US" xlink:label="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Business Days After Notice for Reimbursement of Drawings</link:label>
    <link:label id="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_documentation_en-US" xlink:label="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of business days after notice, for reimbursement of amount drawn under the facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" xlink:href="thc-20221231.xsd#thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" xlink:to="lab_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread_8c8fb0c7-fa8b-4d30-8bf1-36b86efe465f_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on credit spread</link:label>
    <link:label id="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread_label_en-US" xlink:label="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Credit Spread</link:label>
    <link:label id="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread_documentation_en-US" xlink:label="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Credit Spread</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentBasisSpreadOnCreditSpread" xlink:href="thc-20221231.xsd#thc_DebtInstrumentBasisSpreadOnCreditSpread"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentBasisSpreadOnCreditSpread" xlink:to="lab_thc_DebtInstrumentBasisSpreadOnCreditSpread" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_4a40be31-3282-4483-844b-d9843a791b68_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Interest in Corporate Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:to="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7f6c32c9-0b21-4a39-b2c8-276e38306264_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashSurrenderValueOfLifeInsurance_3359a755-1feb-4dbb-841e-8173b163154c_terseLabel_en-US" xlink:label="lab_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash surrender value of life insurance policies</link:label>
    <link:label id="lab_us-gaap_CashSurrenderValueOfLifeInsurance_label_en-US" xlink:label="lab_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Surrender Value of Life Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueOfLifeInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:to="lab_us-gaap_CashSurrenderValueOfLifeInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_4a0823b1-1a49-42e5-b37f-bd029a5a0e8a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_af3d3de2-14a9-4f7b-86ec-e25a59ef6e14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_42903053-3580-42e6-9d3f-7d900efee9d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_3791dbb9-005e-4674-bfc9-4d37a22e5d62_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_36816914-c4f4-4e8d-9a32-193e14dd1b14_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ef0083a1-6077-4f8a-8246-0fd81340b8b0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7dac472e-602c-442d-bfe1-302a9ccf63be_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HospitalOperationsAndAmbulatoryCareMember_c41eb408-4c2c-4aec-b621-2ca96bb52093_terseLabel_en-US" xlink:label="lab_thc_HospitalOperationsAndAmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations And Ambulatory Care</link:label>
    <link:label id="lab_thc_HospitalOperationsAndAmbulatoryCareMember_label_en-US" xlink:label="lab_thc_HospitalOperationsAndAmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations And Ambulatory Care [Member]</link:label>
    <link:label id="lab_thc_HospitalOperationsAndAmbulatoryCareMember_documentation_en-US" xlink:label="lab_thc_HospitalOperationsAndAmbulatoryCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations And Ambulatory Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsAndAmbulatoryCareMember" xlink:href="thc-20221231.xsd#thc_HospitalOperationsAndAmbulatoryCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HospitalOperationsAndAmbulatoryCareMember" xlink:to="lab_thc_HospitalOperationsAndAmbulatoryCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_786b5d49-fdcc-4d86-a5fa-ff004475b7ea_terseLabel_en-US" xlink:label="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.250% due 2027</link:label>
    <link:label id="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_label_en-US" xlink:label="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Two Five Zero Percent Senior Secured Second Lien Note, Due 2027 [Member]</link:label>
    <link:label id="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_documentation_en-US" xlink:label="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Two Five Zero Percent Senior Secured Second Lien Note, Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" xlink:href="thc-20221231.xsd#thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" xlink:to="lab_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_60c56cf9-4c92-440f-9e46-55cb02e48fc5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_1a90d90f-da7d-4786-97c5-325558f0c003_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_0f3ca9ff-5fb8-4931-ab46-552b3e7022d0_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_3bbafc01-3e88-4e6f-9546-74cc0c494e7c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later years</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bb29110f-c988-48db-a160-b868967a5186_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Numerators and Denominators of our Basic and Diluted Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c77987c7-bd9d-4dc1-8b0c-9f7143cb2108_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_WindstormsMember_55c8bbcd-432b-4b37-9641-5a6fd920db94_terseLabel_en-US" xlink:label="lab_thc_WindstormsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Windstorms</link:label>
    <link:label id="lab_thc_WindstormsMember_label_en-US" xlink:label="lab_thc_WindstormsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Windstorms [Member]</link:label>
    <link:label id="lab_thc_WindstormsMember_documentation_en-US" xlink:label="lab_thc_WindstormsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Localized violently destructive windstorm characterized by a funnel shaped cloud.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_WindstormsMember" xlink:href="thc-20221231.xsd#thc_WindstormsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_WindstormsMember" xlink:to="lab_thc_WindstormsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_eb1309f5-cc33-4f09-be7c-a977ef56b8be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between reported income tax expense (benefit) and income taxes calculated by the statutory federal income tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_2687d5e8-912f-45c3-8cbb-b30981a7ce5b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_fd73fea5-84ab-4231-b899-e904e849bf00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_1d5bb58f-2046-49b4-bdb9-764719328d2e_negatedLabel_en-US" xlink:label="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains on sales, consolidation and deconsolidation of facilities</link:label>
    <link:label id="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_dcf8c01e-32b9-41d5-918a-26e3f2a85815_negatedTerseLabel_en-US" xlink:label="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains on sales, consolidation and deconsolidation of facilities</link:label>
    <link:label id="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_a930a60e-a4fe-4873-86a9-de8604a8b713_terseLabel_en-US" xlink:label="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on sales, consolidation and deconsolidation of facilities</link:label>
    <link:label id="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_label_en-US" xlink:label="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Gain on Sale, Consolidation, And Deconsolidation Of Facilities</link:label>
    <link:label id="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_documentation_en-US" xlink:label="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of net gain for the period due to sales, consolidation and deconsolidation of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:to="lab_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NonEmployeeDirectorsMember_6cae6945-2118-4cd8-843b-a740ca4e5ecd_terseLabel_en-US" xlink:label="lab_thc_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Directors</link:label>
    <link:label id="lab_thc_NonEmployeeDirectorsMember_label_en-US" xlink:label="lab_thc_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Directors [Member]</link:label>
    <link:label id="lab_thc_NonEmployeeDirectorsMember_documentation_en-US" xlink:label="lab_thc_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents activity related to non-employee directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NonEmployeeDirectorsMember" xlink:href="thc-20221231.xsd#thc_NonEmployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NonEmployeeDirectorsMember" xlink:to="lab_thc_NonEmployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_18f1d787-021d-4859-9ec5-e7c375811d9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d5c6102d-fa50-4e9a-a19d-a61c96b6666f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation increase rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b0ad2343-e4f0-41a6-827a-a66468cf7f0f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b323b41a-d697-4f4d-b908-d9f10ae16f44_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a1e97e42-0ef6-4459-b945-fc85883c964a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_UnitedUrologyGroupMember_4962af59-cddf-4aba-abc5-3b2508858e66_terseLabel_en-US" xlink:label="lab_thc_UnitedUrologyGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Urology Group</link:label>
    <link:label id="lab_thc_UnitedUrologyGroupMember_label_en-US" xlink:label="lab_thc_UnitedUrologyGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Urology Group [Member]</link:label>
    <link:label id="lab_thc_UnitedUrologyGroupMember_documentation_en-US" xlink:label="lab_thc_UnitedUrologyGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Urology Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedUrologyGroupMember" xlink:href="thc-20221231.xsd#thc_UnitedUrologyGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_UnitedUrologyGroupMember" xlink:to="lab_thc_UnitedUrologyGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f64f7d41-0b42-45b3-92b6-e17e7914def3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_8a30e822-6fb3-4a21-bd14-2213e0c37eb5_terseLabel_en-US" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice expense</link:label>
    <link:label id="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_label_en-US" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:to="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_946944a9-322d-470a-9b3e-0c7e714a3c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_a59fdeaa-61bd-4c5b-a774-6e4647a4e2fe_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_077b053f-6ad6-4e03-aa79-e48b3f5d4c34_terseLabel_en-US" xlink:label="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.500% due 2025</link:label>
    <link:label id="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_label_en-US" xlink:label="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Five Zero Percent Senior Secured Note, Due 2025 [Member]</link:label>
    <link:label id="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_documentation_en-US" xlink:label="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Five Zero Percent Senior Secured Note, Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" xlink:href="thc-20221231.xsd#thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" xlink:to="lab_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d5711db6-01ef-4fdb-a38d-5c8c1a846473_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility, maximum borrowing capacity (up to)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_dedf24a6-2623-47bc-9987-0db5e87c4312_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d21aca8f-a9fa-4dbe-bc02-8c9ba0b91025_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5d31376d-d122-4384-b250-2ba7b24d1226_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5544531e-6287-4a27-8d46-3740acf0e738_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_A2020SCDCentersMember_d153ff9f-b300-4d11-8572-33cbde49e071_terseLabel_en-US" xlink:label="lab_thc_A2020SCDCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 SCD Centers</link:label>
    <link:label id="lab_thc_A2020SCDCentersMember_label_en-US" xlink:label="lab_thc_A2020SCDCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 SCD Centers [Member]</link:label>
    <link:label id="lab_thc_A2020SCDCentersMember_documentation_en-US" xlink:label="lab_thc_A2020SCDCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 SCD Centers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2020SCDCentersMember" xlink:href="thc-20221231.xsd#thc_A2020SCDCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_A2020SCDCentersMember" xlink:to="lab_thc_A2020SCDCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_2833518f-1fd8-4203-9e31-fbac134a3dc5_terseLabel_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ambulatory surgery centers noncontrolling interests</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_label_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers Recorded Using Equity Method</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_documentation_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers Recorded Using Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersRecordedUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" xlink:to="lab_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_370b9e27-dcb6-44d7-851f-cd909ee34a5c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and fixed-asset differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_74c833b3-c698-4e80-9430-45f39adbeafa_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_228ef3f8-44b4-4de7-8398-56be690cdc2c_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value per employee per year</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Maximum Fair Market Value of Shares Per Employee</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum fair market value of shares which an employee can purchase in an year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TexasHealthVenturesGroupLlcMember_32916d14-edc1-4e55-9c8b-9db2d1d11d1d_terseLabel_en-US" xlink:label="lab_thc_TexasHealthVenturesGroupLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas Health Ventures Group, LLC</link:label>
    <link:label id="lab_thc_TexasHealthVenturesGroupLlcMember_label_en-US" xlink:label="lab_thc_TexasHealthVenturesGroupLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas Health Ventures Group Llc [Member]</link:label>
    <link:label id="lab_thc_TexasHealthVenturesGroupLlcMember_documentation_en-US" xlink:label="lab_thc_TexasHealthVenturesGroupLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent the information pertaining to the Texas Health Ventures Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TexasHealthVenturesGroupLlcMember" xlink:href="thc-20221231.xsd#thc_TexasHealthVenturesGroupLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TexasHealthVenturesGroupLlcMember" xlink:to="lab_thc_TexasHealthVenturesGroupLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_9a6541b8-8b95-410e-b5c6-188e9361bb5e_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions_357da449-3ca6-4cf7-bf77-b18eb0faf2dc_terseLabel_en-US" xlink:label="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="thc-20221231.xsd#thc_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_thc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d44c83cb-67e8-4f4b-a3f3-8bf452b3bb94_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3e64fc87-476e-44c3-bd4e-5ac8651fbfc7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_398e4c11-2605-430e-b85f-5f3e9212dced_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberofHospitals_e1d78467-ec06-419a-825b-844d9a90930a_terseLabel_en-US" xlink:label="lab_thc_NumberofHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospitals</link:label>
    <link:label id="lab_thc_NumberofHospitals_label_en-US" xlink:label="lab_thc_NumberofHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Hospitals</link:label>
    <link:label id="lab_thc_NumberofHospitals_documentation_en-US" xlink:label="lab_thc_NumberofHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of hospitals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberofHospitals" xlink:href="thc-20221231.xsd#thc_NumberofHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberofHospitals" xlink:to="lab_thc_NumberofHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d833932-0ee5-4cc1-a2de-c42bf3822c0f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_39d5ff57-9560-4ca2-9a81-7bf90e7a74f0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions due to a lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73e71128-3d8a-4a6a-9aae-f243eed31c6e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (income)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5dd5b06a-4eb5-4210-ab99-c9e7dacb7978_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_94003fce-1b71-4466-9fcb-3c937201197e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9e67cdb3-3501-4c0d-82ed-0f94ad02a39e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost, less accumulated depreciation and amortization ($6,201 at December&#160;31,&#160;2022 and $5,960 at December&#160;31,&#160;2021)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_43015d74-e2e4-4b89-a595-edd4ec5633ae_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c9ce8d8b-3a97-4caa-97f9-d547836c61eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_2879efb8-274a-40e9-8680-a792fa18d4d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_4dc72b96-2bfe-412a-af6b-307ef4ff72fe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_889d71b8-0cf9-462d-9521-01c9d439a0ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_37fbd957-11f0-4e9f-9ad1-ff5b5fe80b3f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1ef21e27-8443-4546-9f2b-bb5d7fdd55bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_b5608940-0628-46f0-ab65-5f85081ed2e4_terseLabel_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Next Twelve Months</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_documentation_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" xlink:to="lab_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities_86b0b8ed-c512-4fa7-bb40-5327cbdcc8d3_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities_label_en-US" xlink:label="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other Long Term Liabilities</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities_documentation_en-US" xlink:label="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of the estimated future tax reductions attributable to the difference between the tax basis and the generally accepted accounting principle basis of a company's other long-term liabilities which will decrease future taxable income when such basis difference reverses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsOtherLongTermLiabilities" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsOtherLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxAssetsOtherLongTermLiabilities" xlink:to="lab_thc_DeferredTaxAssetsOtherLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_60b068af-49d0-48d1-8860-a8d09e2776c2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation increase rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_c11d00f2-bb21-4beb-96de-2f781f589ac7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_668170e0-7f0d-4606-86bb-b2e226de3606_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2bcf2f5d-c31c-4ab0-9fc9-a2664f51e8c0_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_88630632-afac-49ec-b982-863d96564865_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0e5177a8-01e6-410a-9b98-4d8a299aa4a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_d39911e8-277c-4ab9-b8a9-028b0ed89e54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7ae23487-8dd3-4365-90eb-694c4a9e5697_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7ca013a3-8752-489e-93dc-862b27af904b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_345e4b90-c791-4f54-b718-77d5c4ce7040_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_1ab2cb6b-6a88-4b9c-a645-a5dc73bcdd2d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock in treasury, at cost, 54,215,871 shares at December&#160;31,&#160;2022 and 48,331,649 shares at December&#160;31,&#160;2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCareClientContractsRevenueCycleServicesMember_2e24a4ad-0225-4566-a5d3-9cac580fb452_terseLabel_en-US" xlink:label="lab_thc_HealthCareClientContractsRevenueCycleServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Client Contracts - Revenue Cycle Services</link:label>
    <link:label id="lab_thc_HealthCareClientContractsRevenueCycleServicesMember_label_en-US" xlink:label="lab_thc_HealthCareClientContractsRevenueCycleServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Client Contracts - Revenue Cycle Services [Member]</link:label>
    <link:label id="lab_thc_HealthCareClientContractsRevenueCycleServicesMember_documentation_en-US" xlink:label="lab_thc_HealthCareClientContractsRevenueCycleServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care - Client Contracts - Revenue Cycle Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareClientContractsRevenueCycleServicesMember" xlink:href="thc-20221231.xsd#thc_HealthCareClientContractsRevenueCycleServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCareClientContractsRevenueCycleServicesMember" xlink:to="lab_thc_HealthCareClientContractsRevenueCycleServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0388dfb7-dce1-4846-b3f9-d0412dd88248_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable_43fc3f05-d6ea-44ff-bf56-97b563bca90b_verboseLabel_en-US" xlink:label="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease)</link:label>
    <link:label id="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable_label_en-US" xlink:label="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Contract with Customer, Receivable</link:label>
    <link:label id="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable_documentation_en-US" xlink:label="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Contract with Customer, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncreaseDecreaseInContractWithCustomerReceivable" xlink:href="thc-20221231.xsd#thc_IncreaseDecreaseInContractWithCustomerReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncreaseDecreaseInContractWithCustomerReceivable" xlink:to="lab_thc_IncreaseDecreaseInContractWithCustomerReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_9945fcc3-51d2-4425-84b8-d5cce7fd7c1c_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Share Amount</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_901e3fee-6098-4e2c-b90e-b54c91a2e6db_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseLiabilityUndiscountedExcessAmount_dd764d81-8101-48f0-ba15-bbdfd0f973d0_terseLabel_en-US" xlink:label="lab_thc_LeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_thc_LeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_thc_LeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_thc_LeaseLiabilityUndiscountedExcessAmount_documentation_en-US" xlink:label="lab_thc_LeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityUndiscountedExcessAmount" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_thc_LeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_afa4c95c-d60c-49a8-826c-746eb5e97078_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_789dacb7-082d-428b-a60b-cea3760aba5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d2dd35d1-d61c-4381-b0f0-a57c39826660_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_22e08788-a35d-4973-a719-2446689de255_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_560ca872-bf61-40af-b7ac-8c57143e0224_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_16ffec73-f930-47dc-8075-565667740226_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0c1bfa4e-ec49-4946-97fd-47dd2bd5504b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2b39ea9c-2d0f-431e-b9db-6e5a05560f73_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_f1963af0-4ecc-4a79-85a8-527cf070b5f7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SERP and DMC Pension Plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OperatingLossCarryforwardsSubjectToExpiration_7eac064b-5422-4013-94da-b266080c25f3_terseLabel_en-US" xlink:label="lab_thc_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_thc_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_thc_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_thc_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_thc_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="thc-20221231.xsd#thc_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_thc_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c3f9cc29-3755-4e05-a759-90b686fdc2d1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_3d8a5038-2bf9-4848-8912-c8ff6810245f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_24f1641f-7743-4aec-8757-416cf6c33561_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_78eee4f8-e8cf-4d31-99c3-2b5a0c3c6711_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_c3c06bd5-746d-4a34-afce-1797011663fd_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_404f8bb8-6f8d-41db-be57-0dec86e3ed05_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfSurgicalCentersAndHospitals_329d4d64-a1f5-4b54-a424-0fbadd8f5604_verboseLabel_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersAndHospitals" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outpatient centers</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersAndHospitals_label_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersAndHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers And Hospitals</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersAndHospitals_documentation_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersAndHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of surgical centers and hospitals operated by subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersAndHospitals" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersAndHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfSurgicalCentersAndHospitals" xlink:to="lab_thc_NumberOfSurgicalCentersAndHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_188424e3-c889-487c-be2f-e01569340cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_adf079bd-d4e8-480a-b734-b6bf0d58d1c5_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan obligations</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0400f233-7435-45ae-a835-79e515d8fac4_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liability</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_79961d5e-d376-4bcc-8945-abc99b93c134_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan obligations</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_8b5f2bda-ee36-4175-a448-4c4133499f5c_negatedTerseLabel_en-US" xlink:label="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously held equity method investments</link:label>
    <link:label id="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_label_en-US" xlink:label="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Previously Held Investments in Unconsolidated Affiliates</link:label>
    <link:label id="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_documentation_en-US" xlink:label="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Previously Held Investments in Unconsolidated Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" xlink:href="thc-20221231.xsd#thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" xlink:to="lab_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree_f4f6e106-0d15-40bf-a302-e5cef53e2045_terseLabel_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree_documentation_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearThree" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_thc_LesseeLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_eae9ac60-f612-4415-b7bc-82975138e885_terseLabel_en-US" xlink:label="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities advance payments</link:label>
    <link:label id="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_label_en-US" xlink:label="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Recoupment Of Advance Payments</link:label>
    <link:label id="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_documentation_en-US" xlink:label="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Recoupment Of Advance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" xlink:href="thc-20221231.xsd#thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" xlink:to="lab_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_895be2c8-cd07-4c5b-b494-b069bf3c6636_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3a623d7d-304b-4634-99bd-6e9b57f3b408_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at beginning of period&#160;</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3ef96d79-9dd3-49fc-99eb-b81ed4adf934_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at end of period&#160;</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_022ed551-564d-4a74-a266-699e96fa0efc_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f3b8ce3-e3b9-4c46-98b7-59456dd467c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1429b0e3-451d-4b26-a63d-b514711e9424_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_e1809831-6944-4bcc-966d-fc29a5111f60_terseLabel_en-US" xlink:label="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee obligations for consolidated subsidiaries</link:label>
    <link:label id="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_label_en-US" xlink:label="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee Obligation Carry Value Consolidated Subsidiaries</link:label>
    <link:label id="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_documentation_en-US" xlink:label="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees which pertains to the entity's consolidated subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" xlink:href="thc-20221231.xsd#thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" xlink:to="lab_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_70e0a677-ede9-4a22-97e7-2a477a7ae3ad_terseLabel_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance due to changes in expected realizability of deferred tax assets</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_label_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Change In Amount Attributable To Changes In Expected Realizability of Deferred Tax Assets</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_documentation_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of change in the period, in the valuation allowance attributable due to changes in expected realizability of deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" xlink:to="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_d382054a-cf07-48fa-a16c-4a97c1a7eae5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_020399bd-4418-43e9-874e-a778778eb920_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AccruedCompensationAndBenefitsMember_6bed8080-135c-46a2-a8f1-8063d417c042_terseLabel_en-US" xlink:label="lab_thc_AccruedCompensationAndBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation And Benefits</link:label>
    <link:label id="lab_thc_AccruedCompensationAndBenefitsMember_label_en-US" xlink:label="lab_thc_AccruedCompensationAndBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation And Benefits [Member]</link:label>
    <link:label id="lab_thc_AccruedCompensationAndBenefitsMember_documentation_en-US" xlink:label="lab_thc_AccruedCompensationAndBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation And Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AccruedCompensationAndBenefitsMember" xlink:href="thc-20221231.xsd#thc_AccruedCompensationAndBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AccruedCompensationAndBenefitsMember" xlink:to="lab_thc_AccruedCompensationAndBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f25c775b-f0bb-42dd-b3e7-cf2ff47972a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_025dcab1-15e3-4641-a59f-9607d9a87e1d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_fdf31189-1d29-415c-846d-a1453dab6b19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals_6f6f91c8-1129-4878-941a-c77e20029ab4_terseLabel_en-US" xlink:label="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue generated by general hospitals</link:label>
    <link:label id="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals_label_en-US" xlink:label="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Net Operating Revenues Generated By General Hospitals</link:label>
    <link:label id="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals_documentation_en-US" xlink:label="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net operating revenues generated by the entity's general hospitals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" xlink:href="thc-20221231.xsd#thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" xlink:to="lab_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_81517b3c-147f-497e-9d37-87d91a39d087_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FloodsAndWindstormsMember_9efa1d53-a143-4793-a725-127274fff8d0_terseLabel_en-US" xlink:label="lab_thc_FloodsAndWindstormsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floods And Windstorms</link:label>
    <link:label id="lab_thc_FloodsAndWindstormsMember_label_en-US" xlink:label="lab_thc_FloodsAndWindstormsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floods And Windstorms [Member]</link:label>
    <link:label id="lab_thc_FloodsAndWindstormsMember_documentation_en-US" xlink:label="lab_thc_FloodsAndWindstormsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floods And Windstorms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FloodsAndWindstormsMember" xlink:href="thc-20221231.xsd#thc_FloodsAndWindstormsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FloodsAndWindstormsMember" xlink:to="lab_thc_FloodsAndWindstormsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfBuildings_f6d2cea6-0215-48b5-acf9-899ed4846b71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of buildings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfBuildings_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfBuildings" xlink:to="lab_us-gaap_ProceedsFromSaleOfBuildings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_325ded41-3ed5-4906-846d-75ffd2a2fd16_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GuaranteedInvesteesOfThirdPartiesMember_f0473ab9-901a-4466-8c33-b1918481a7f0_terseLabel_en-US" xlink:label="lab_thc_GuaranteedInvesteesOfThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Investees of Third Parties</link:label>
    <link:label id="lab_thc_GuaranteedInvesteesOfThirdPartiesMember_label_en-US" xlink:label="lab_thc_GuaranteedInvesteesOfThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Investees Of Third Parties [Member]</link:label>
    <link:label id="lab_thc_GuaranteedInvesteesOfThirdPartiesMember_documentation_en-US" xlink:label="lab_thc_GuaranteedInvesteesOfThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the guarantees of indebtedness and other obligations to our investees to third parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteedInvesteesOfThirdPartiesMember" xlink:href="thc-20221231.xsd#thc_GuaranteedInvesteesOfThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GuaranteedInvesteesOfThirdPartiesMember" xlink:to="lab_thc_GuaranteedInvesteesOfThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_0b9615d8-f4f2-435a-b200-87dd579d9275_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_02649d7b-a071-4de6-91b5-b22c24bea191_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Asset Allocations by Asset Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseLiabilityCurrent_22789cf8-9919-4ba3-a005-1be7d2b448d9_terseLabel_en-US" xlink:label="lab_thc_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current obligations</link:label>
    <link:label id="lab_thc_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_thc_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_thc_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_thc_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityCurrent" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseLiabilityCurrent" xlink:to="lab_thc_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_63464ad2-842d-4d15-ab21-9ad65e954a36_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_e531c69e-84bb-4076-81af-b772a31e16f7_terseLabel_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% due July 2024</link:label>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_label_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent Senior Secured Note Due July 2024 [Member]</link:label>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_documentation_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent Senior Secured Note Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" xlink:to="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_51ca569c-dd69-44c6-a05a-5f93811df4b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_712db1fb-13e9-420d-8d37-c42aa0c14e65_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic&#160;Value</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_7a5128e6-ab7e-45fc-b5f4-00c7697efc6d_terseLabel_en-US" xlink:label="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest purchased during period through issuance of equity (in shares)</link:label>
    <link:label id="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_label_en-US" xlink:label="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased During Period Through Issuance Of Equity, Shares</link:label>
    <link:label id="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_documentation_en-US" xlink:label="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased During Period Through Issuance Of Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" xlink:href="thc-20221231.xsd#thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" xlink:to="lab_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8c906d26-b78c-47cd-9e9f-fe00a06bd143_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_53c1f0eb-9e7d-4dd2-bd31-173ec28dfd14_terseLabel_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Three</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_documentation_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" xlink:to="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_079c57a5-a002-408e-99e5-b2e2593ed26b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_efcd9c92-a5bd-427e-bfbd-13faa3cda0a9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_ffe1a5c4-c5f5-45a0-9d46-a3c276835fc1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_29f1861f-0e8b-4fa9-9596-2febddd777e3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_431c1330-bc27-47c8-9eaf-7b6f37a9c524_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary information about outstanding stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_a0568808-e615-4b16-a7e8-f04a96a5f682_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_5580b5e5-a536-419a-baf8-e6b0c237503b_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Three Year Period from Grant Date</link:label>
    <link:label id="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Ratably Over Three Year Period From Grant Date [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Ratably Over Three Year Period From Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" xlink:to="lab_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_22b06f58-5db5-45e2-9d14-a681d15c3d66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_91daaee1-a852-4b28-98e6-aa844b258e19_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets&#160;</link:label>
    <link:label id="lab_us-gaap_Assets_31ed8b8f-f64a-4ba0-a5a7-581d969a8616_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6b9714f9-d7d5-4e8b-bf76-055e119e1dd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ScheduleOfGrantFundsTableTextBlock_f75c7046-2d61-48ae-9fdf-4260eb2bd21b_terseLabel_en-US" xlink:label="lab_thc_ScheduleOfGrantFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Grant Funds Received And Grant Income</link:label>
    <link:label id="lab_thc_ScheduleOfGrantFundsTableTextBlock_label_en-US" xlink:label="lab_thc_ScheduleOfGrantFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Grant Funds [Table Text Block]</link:label>
    <link:label id="lab_thc_ScheduleOfGrantFundsTableTextBlock_documentation_en-US" xlink:label="lab_thc_ScheduleOfGrantFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Grant Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfGrantFundsTableTextBlock" xlink:href="thc-20221231.xsd#thc_ScheduleOfGrantFundsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ScheduleOfGrantFundsTableTextBlock" xlink:to="lab_thc_ScheduleOfGrantFundsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenOptionContractsWrittenTypeAxis_f76edf75-dd45-469e-a6ec-9f87348d6db8_terseLabel_en-US" xlink:label="lab_us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Option Contracts Written Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OpenOptionContractsWrittenTypeAxis_label_en-US" xlink:label="lab_us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Option Contracts Written Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:to="lab_us-gaap_OpenOptionContractsWrittenTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_7c40c83d-7b21-41c7-93fc-977805c408b8_terseLabel_en-US" xlink:label="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting Over A Three Year Period</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_label_en-US" xlink:label="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting Over A Three Year Period [Member]</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_documentation_en-US" xlink:label="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting Over A Three Year Period [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingOverAThreeYearPeriodMember" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingOverAThreeYearPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PerformanceBasedVestingOverAThreeYearPeriodMember" xlink:to="lab_thc_PerformanceBasedVestingOverAThreeYearPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationAwardTrancheFourMember_be81e0da-bc4d-4149-9591-8135cb514600_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four</link:label>
    <link:label id="lab_thc_ShareBasedCompensationAwardTrancheFourMember_label_en-US" xlink:label="lab_thc_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Award, Tranche Four [Member]</link:label>
    <link:label id="lab_thc_ShareBasedCompensationAwardTrancheFourMember_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Award, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationAwardTrancheFourMember" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationAwardTrancheFourMember" xlink:to="lab_thc_ShareBasedCompensationAwardTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a3c263fb-29a1-4c76-88f9-9ae363d6f47d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_48fbdc58-012e-4ccc-a2bd-e60ec09886b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_2c4dd2ce-28ad-4541-b8b5-cc512a963083_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_eae46f1b-7346-49ac-984b-3d1ac9b6e7a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common stock authorized to be repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_580bea14-3c8e-4586-835d-4ea283923f7d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a8a0e795-9fbe-4ef7-8241-d385e27f3136_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c438e62-e44d-4699-8004-f0cc4134809d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations, before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_e0cbda57-36cc-4157-a6c1-cbe949d54d2b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_3c8e48f9-b8c2-49f4-b58a-d55263b51e80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock_34b60156-8810-406a-ae0b-a7be1f869480_terseLabel_en-US" xlink:label="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Funded Status of Plans, the Amounts included in the Consolidated Balance Sheets and Assumptions Used for Projected Benefit Obligations</link:label>
    <link:label id="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status Amounts Recognized in Balance Sheet and Assumptions Used for Projected Benefit Obligations [Table Text Block]</link:label>
    <link:label id="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock_documentation_en-US" xlink:label="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of funded status of plans, the amounts included in the Consolidated Balance Sheets and the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" xlink:href="thc-20221231.xsd#thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" xlink:to="lab_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_6cd3ce67-52e8-4767-85b9-acd991c8d28e_terseLabel_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% due 2028</link:label>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_label_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent Senior Secured Note, Due 2028 [Member]</link:label>
    <link:label id="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_documentation_en-US" xlink:label="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Two Five Percent Senior Secured Note, Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" xlink:to="lab_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_492aaafa-0423-4e84-adaf-d2778b7bf2cc_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3404ca75-abbf-4582-a0af-0c9209d6ac77_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_e3f57a98-6f3b-49bd-ace1-ef69600b0e9a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_f5a8d8de-500d-4d92-ba74-7d16b6265856_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CaliforniaProviderFeeProgramMember_04518717-cc39-4328-b31d-0bdecdd92fd7_terseLabel_en-US" xlink:label="lab_thc_CaliforniaProviderFeeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California's Provider Fee Program</link:label>
    <link:label id="lab_thc_CaliforniaProviderFeeProgramMember_label_en-US" xlink:label="lab_thc_CaliforniaProviderFeeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Provider Fee Program [Member]</link:label>
    <link:label id="lab_thc_CaliforniaProviderFeeProgramMember_documentation_en-US" xlink:label="lab_thc_CaliforniaProviderFeeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents activity related to California's provider fee program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaProviderFeeProgramMember" xlink:href="thc-20221231.xsd#thc_CaliforniaProviderFeeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CaliforniaProviderFeeProgramMember" xlink:to="lab_thc_CaliforniaProviderFeeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_17bf9ccc-6f05-4d7d-99e2-b742abe7f571_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite holding period for shares issued under the plan</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Requisite Holding Period of Shares</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the requisite holding period for shares issued under plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_8b0389a5-f578-4b31-b7a0-9cea1bf7f97f_periodStartLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross, at beginning of period</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_2fdf9ebe-86fc-46cf-bb35-fa0f2dc992a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross, at end of period</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e7f73509-47cc-4738-9896-ced7c7796adc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_aa8cc04a-d20c-4af6-b43b-a1cbef6e685d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4a8325a4-587c-4626-9204-be51bd180f4b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive net income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eed6d0c3-2cfb-4075-96b9-8493ab1e641f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_37d596b2-6294-433c-a13b-e7b4fa8189bf_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_94a869be-03f3-42a4-be3e-a5a3b127951f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8023968d-ecf0-4152-8695-fe8859a88c73_netLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_81968d8d-aa03-461a-af46-756246145b73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfHospitalsOperated_4fb41265-d2cc-4def-b3e6-7ae22421e174_terseLabel_en-US" xlink:label="lab_thc_NumberOfHospitalsOperated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acute care and specialty hospitals operated</link:label>
    <link:label id="lab_thc_NumberOfHospitalsOperated_label_en-US" xlink:label="lab_thc_NumberOfHospitalsOperated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Hospitals Operated</link:label>
    <link:label id="lab_thc_NumberOfHospitalsOperated_documentation_en-US" xlink:label="lab_thc_NumberOfHospitalsOperated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Hospitals Operated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsOperated" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsOperated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfHospitalsOperated" xlink:to="lab_thc_NumberOfHospitalsOperated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2c00abfb-57c7-4f31-a326-f60e089cb70f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in the Consolidated Balance Sheets consist of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_ace533a7-ac9a-44a4-84a6-a77f23be8874_terseLabel_en-US" xlink:label="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible litigation costs</link:label>
    <link:label id="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_label_en-US" xlink:label="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Litigation</link:label>
    <link:label id="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_documentation_en-US" xlink:label="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" xlink:href="thc-20221231.xsd#thc_IncomeTaxReconciliationNondeductibleExpenseLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" xlink:to="lab_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_0da40190-1219-4a2a-bd65-507fe5dfdbe7_terseLabel_en-US" xlink:label="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contract assets that meet the conditions for unconditional right to payment (percentage)</link:label>
    <link:label id="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_label_en-US" xlink:label="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Percentage To Be Reclassified To Receivable Within 90 Days</link:label>
    <link:label id="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_documentation_en-US" xlink:label="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Percentage To Be Reclassified To Receivable Within 90 Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" xlink:href="thc-20221231.xsd#thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" xlink:to="lab_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_1f988c03-64a6-4534-9a3f-02e02679bffc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FloodMember_9dd7e89b-c7ce-47eb-8e1d-1092463c14eb_terseLabel_en-US" xlink:label="lab_us-gaap_FloodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floods</link:label>
    <link:label id="lab_us-gaap_FloodMember_label_en-US" xlink:label="lab_us-gaap_FloodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flood [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FloodMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FloodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FloodMember" xlink:to="lab_us-gaap_FloodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_c047568a-3983-449f-8858-3ffe1099cc22_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_155c563f-11e9-4a61-9635-e45fdd5e7a3a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CatastrophicEventDomain_49501042-b7a9-4aa3-a4d7-9c9a212e8a01_terseLabel_en-US" xlink:label="lab_us-gaap_CatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Domain]</link:label>
    <link:label id="lab_us-gaap_CatastrophicEventDomain_label_en-US" xlink:label="lab_us-gaap_CatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CatastrophicEventDomain" xlink:to="lab_us-gaap_CatastrophicEventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_07358e6b-1542-4ac6-9fea-4b72e8f3d627_terseLabel_en-US" xlink:label="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.250% due 2029</link:label>
    <link:label id="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_label_en-US" xlink:label="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Two Five Zero Percent Senior Unsecured Note Due 2029 [Member]</link:label>
    <link:label id="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_documentation_en-US" xlink:label="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Two Five Zero Percent Senior Unsecured Note Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" xlink:href="thc-20221231.xsd#thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" xlink:to="lab_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_5ae4d1e1-994f-4a83-b471-4876a9458585_totalLabel_en-US" xlink:label="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_label_en-US" xlink:label="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payments</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_documentation_en-US" xlink:label="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the aggregate amount of the benefits expected to be paid in future years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanExpectedFutureBenefitPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments" xlink:to="lab_thc_DefinedBenefitPlanExpectedFutureBenefitPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_be9e579b-b87c-430f-8aac-190ef2685b74_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_a01d0f75-989c-4b46-a09d-5ad6379cf478_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_2e5ada89-0aff-4ecf-bedc-c2379dfb7523_verboseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inter-segment eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_59b6f434-a138-4108-ba21-f455c64e6885_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inter-segment eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NonExecutiveChairmanMember_0569fdf6-649f-4061-9c93-2aa8f1370523_terseLabel_en-US" xlink:label="lab_thc_NonExecutiveChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Executive Chairman</link:label>
    <link:label id="lab_thc_NonExecutiveChairmanMember_label_en-US" xlink:label="lab_thc_NonExecutiveChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Executive Chairman [Member]</link:label>
    <link:label id="lab_thc_NonExecutiveChairmanMember_documentation_en-US" xlink:label="lab_thc_NonExecutiveChairmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Executive Chairman</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NonExecutiveChairmanMember" xlink:href="thc-20221231.xsd#thc_NonExecutiveChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NonExecutiveChairmanMember" xlink:to="lab_thc_NonExecutiveChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e35d0888-9e17-4da8-af2f-1e0462186b50_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Years Thereafter</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SelfPayPatientsMember_8c17889a-bf28-4656-bbe2-60ac756b0fa2_terseLabel_en-US" xlink:label="lab_thc_SelfPayPatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uninsured patients</link:label>
    <link:label id="lab_thc_SelfPayPatientsMember_label_en-US" xlink:label="lab_thc_SelfPayPatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Patients [Member]</link:label>
    <link:label id="lab_thc_SelfPayPatientsMember_documentation_en-US" xlink:label="lab_thc_SelfPayPatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SelfPayPatientsMember" xlink:href="thc-20221231.xsd#thc_SelfPayPatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SelfPayPatientsMember" xlink:to="lab_thc_SelfPayPatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c7d95d1f-3f60-4935-a785-6e6750fe69e1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests&#160;</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_580fe6c0-e2ae-4879-9175-82a0f39634b6_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxAssetsInterestExpenseLimitation_3ddb6180-d30e-4c96-9bd5-744c9bc15571_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxAssetsInterestExpenseLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense limitation</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsInterestExpenseLimitation_label_en-US" xlink:label="lab_thc_DeferredTaxAssetsInterestExpenseLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense Limitation</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsInterestExpenseLimitation_documentation_en-US" xlink:label="lab_thc_DeferredTaxAssetsInterestExpenseLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsInterestExpenseLimitation" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsInterestExpenseLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxAssetsInterestExpenseLimitation" xlink:to="lab_thc_DeferredTaxAssetsInterestExpenseLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5a45315f-20a7-4309-a836-fbab008d615e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_75be9458-97bb-4d03-bcd3-ec72db87908c_terseLabel_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Five</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_documentation_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" xlink:to="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingOneYearFromGrantDateMember_704727e4-b4aa-42cd-bf75-68574c46687f_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingOneYearFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, One Year From Grant Date</link:label>
    <link:label id="lab_thc_TimeBasedVestingOneYearFromGrantDateMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingOneYearFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, One Year From Grant Date [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingOneYearFromGrantDateMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingOneYearFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, One Year From Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingOneYearFromGrantDateMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingOneYearFromGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingOneYearFromGrantDateMember" xlink:to="lab_thc_TimeBasedVestingOneYearFromGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a095020b-0aca-4915-8bb8-8acd2d861289_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_fea269b3-cbfc-4f2f-8322-9e1be80c4ba9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_d6e9a788-2e87-4b03-8a74-8c1a46c9e853_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OtherMattersMember_83c8d0ad-8e90-4ab8-9d17-9045bdcb5b18_terseLabel_en-US" xlink:label="lab_thc_OtherMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Matters</link:label>
    <link:label id="lab_thc_OtherMattersMember_label_en-US" xlink:label="lab_thc_OtherMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Matters [Member]</link:label>
    <link:label id="lab_thc_OtherMattersMember_documentation_en-US" xlink:label="lab_thc_OtherMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherMattersMember" xlink:href="thc-20221231.xsd#thc_OtherMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OtherMattersMember" xlink:to="lab_thc_OtherMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_767713c1-a586-4963-b808-a045bddf2f63_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d3711645-c318-4177-9e4c-657472f9086e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_1bfca6ac-126c-41a1-940b-02b3623c75b2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_70508e2b-649f-4bef-ab86-00ac6af39501_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock_0213beb3-2a9c-4e8e-ad09-35430338c237_terseLabel_en-US" xlink:label="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Costs for Charity Care and Self-Pay Patients</link:label>
    <link:label id="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock_label_en-US" xlink:label="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Cost for Charity Care [Table Text Block]</link:label>
    <link:label id="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock_documentation_en-US" xlink:label="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated costs for providing charity care to patients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" xlink:href="thc-20221231.xsd#thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" xlink:to="lab_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_c63aefe8-f152-4bd3-a7fb-3f489a1c929f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ASSETS</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_e3d01d75-45b7-40cd-80f2-43d0d036503e_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt ratio</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_label_en-US" xlink:label="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants of Secured Debt Ratio</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_documentation_en-US" xlink:label="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the secured debt ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantsOfSecuredDebtRatio" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantsOfSecuredDebtRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentCovenantsOfSecuredDebtRatio" xlink:to="lab_thc_DebtInstrumentCovenantsOfSecuredDebtRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingMember_1644fc39-6bba-4ea7-8854-b0ab1f824c29_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vesting</link:label>
    <link:label id="lab_thc_TimeBasedVestingMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingMember" xlink:to="lab_thc_TimeBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_14f15a37-5996-4748-8ebb-106d1545a894_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares held in treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_b8d8fa1b-e660-4c41-b47e-104ad0c8bc1b_terseLabel_en-US" xlink:label="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_label_en-US" xlink:label="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments And Other Assets Abstract [Abstract]</link:label>
    <link:label id="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_documentation_en-US" xlink:label="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments And Other Assets Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" xlink:href="thc-20221231.xsd#thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" xlink:to="lab_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8dc27e91-0dce-4d06-adfa-7032e59d6af0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities &#8211; long-term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_19ad088d-e2df-4f55-9c4e-84f3e3555b16_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_0ef44f30-106f-4059-96a8-72fc361180c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_10efa24d-8bf3-432d-9dcc-b9c540677cc3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves related to discontinued operations and restructuring charges</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenOptionContractsWrittenTypeDomain_59dc279b-dfbd-4250-bd18-be15231998bd_terseLabel_en-US" xlink:label="lab_us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Option Contracts Written Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OpenOptionContractsWrittenTypeDomain_label_en-US" xlink:label="lab_us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Option Contracts Written Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:to="lab_us-gaap_OpenOptionContractsWrittenTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_45a6b7ba-ce9d-4005-9019-2d79be32af5e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases due to tax positions taken in prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_fdc5cf8b-89ff-413f-a216-49ce0379c40a_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_e4e71849-3d09-4dfe-a171-e81abb4f0585_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_37a28234-a6b7-4bc6-98c0-0cba758afe59_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_8cb211f8-414d-4f04-8f63-87654cb8799c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5b0ff54d-0ad9-485e-9ca7-c10128553815_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock_5fa6990c-3795-42be-9704-d9a4b1b17c97_terseLabel_en-US" xlink:label="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments and Other Assets</link:label>
    <link:label id="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Other Noncurrent Assets [Table Text Block]</link:label>
    <link:label id="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure for investments and other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" xlink:href="thc-20221231.xsd#thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" xlink:to="lab_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncomeGuaranteeMember_6cfab02d-3f5b-414a-8e32-0ebcb1287119_terseLabel_en-US" xlink:label="lab_thc_IncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Guarantee</link:label>
    <link:label id="lab_thc_IncomeGuaranteeMember_label_en-US" xlink:label="lab_thc_IncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Guarantee [Member]</link:label>
    <link:label id="lab_thc_IncomeGuaranteeMember_documentation_en-US" xlink:label="lab_thc_IncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the income guarantee agreements provided to certain physicians.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeGuaranteeMember" xlink:href="thc-20221231.xsd#thc_IncomeGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncomeGuaranteeMember" xlink:to="lab_thc_IncomeGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncomeAndRevenueCollectionGuaranteeMember_b8d46d4b-6099-48ec-b683-817c4ef5d17d_terseLabel_en-US" xlink:label="lab_thc_IncomeAndRevenueCollectionGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income and Revenue Collection Guarantee</link:label>
    <link:label id="lab_thc_IncomeAndRevenueCollectionGuaranteeMember_label_en-US" xlink:label="lab_thc_IncomeAndRevenueCollectionGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income And Revenue Collection Guarantee [Member]</link:label>
    <link:label id="lab_thc_IncomeAndRevenueCollectionGuaranteeMember_documentation_en-US" xlink:label="lab_thc_IncomeAndRevenueCollectionGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the income and revenue collection guarantees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeAndRevenueCollectionGuaranteeMember" xlink:href="thc-20221231.xsd#thc_IncomeAndRevenueCollectionGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncomeAndRevenueCollectionGuaranteeMember" xlink:to="lab_thc_IncomeAndRevenueCollectionGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_8a9b27ad-172b-4745-812a-34177124f912_terseLabel_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later years</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due After Year Five</link:label>
    <link:label id="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_documentation_en-US" xlink:label="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Liability, Payments, Due After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_6ed2efb3-4169-495a-8b97-02068aac1aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_39d23aff-42e5-4c00-9cfd-68aeb2d86c89_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4f5a2925-0463-4268-a26a-d6144f1c40ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4f15a380-c49e-425a-bec7-f4055fec380f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_71389f60-4625-4e6c-974d-8283782908e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_326c9817-574c-44e5-9775-2987a364f9ce_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_63a26252-1a51-4e0d-b5c7-0793651281d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_00be30bc-6692-4f1a-b46e-75381a47be87_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retirement Plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_a4fa5358-f468-4375-b021-5d5719d7f140_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average asset allocations by asset category</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableMember_6c1c145b-87dd-421a-aa37-ac96b0705529_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_632ff1fd-3af8-4e87-bc85-48b3a61e9b98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfSurgicalCentersInDevelopmentStage_dde50646-9e1d-4124-add5-08e4ad0a325c_terseLabel_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersInDevelopmentStage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ambulatory surgery centers development stage</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersInDevelopmentStage_label_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersInDevelopmentStage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers In Development Stage</link:label>
    <link:label id="lab_thc_NumberOfSurgicalCentersInDevelopmentStage_documentation_en-US" xlink:label="lab_thc_NumberOfSurgicalCentersInDevelopmentStage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Centers In Development Stage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersInDevelopmentStage" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersInDevelopmentStage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfSurgicalCentersInDevelopmentStage" xlink:to="lab_thc_NumberOfSurgicalCentersInDevelopmentStage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a3ff12a9-e410-4224-8633-4f5b355c8106_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for defined benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_d0c3ab22-537b-43af-a251-652fbbafb50b_terseLabel_en-US" xlink:label="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, tax benefit and issuance of common stock</link:label>
    <link:label id="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_label_en-US" xlink:label="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued And Share-Based Compensation Expense, Value, Share-Based Payment Arrangement, After Forfeiture</link:label>
    <link:label id="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_documentation_en-US" xlink:label="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued And Share-Based Compensation Expense, Value, Share-Based Payment Arrangement, After Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" xlink:href="thc-20221231.xsd#thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" xlink:to="lab_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ElevenQuarterVestingPeriodMember_8ece87cf-c2b9-4be1-9abc-e38b126fb135_terseLabel_en-US" xlink:label="lab_thc_ElevenQuarterVestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eleven Quarter Vesting Period</link:label>
    <link:label id="lab_thc_ElevenQuarterVestingPeriodMember_label_en-US" xlink:label="lab_thc_ElevenQuarterVestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eleven Quarter Vesting Period [Member]</link:label>
    <link:label id="lab_thc_ElevenQuarterVestingPeriodMember_documentation_en-US" xlink:label="lab_thc_ElevenQuarterVestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eleven Quarter Vesting Period [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ElevenQuarterVestingPeriodMember" xlink:href="thc-20221231.xsd#thc_ElevenQuarterVestingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ElevenQuarterVestingPeriodMember" xlink:to="lab_thc_ElevenQuarterVestingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_bf39f68a-cd99-46e8-b030-de9b54d63f0f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_09eb8475-f6e4-4a77-91ce-ca8b4eaae3e4_terseLabel_en-US" xlink:label="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets transferred between segments</link:label>
    <link:label id="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_label_en-US" xlink:label="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Transfer Of Assets, Percentage Of Total Assets</link:label>
    <link:label id="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_documentation_en-US" xlink:label="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Transfer Of Assets, Percentage Of Total Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" xlink:href="thc-20221231.xsd#thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" xlink:to="lab_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3a0deb5a-a119-4204-a70c-f75dd03097dc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e09b82c1-9ff6-47a1-9953-33dad645e002_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_320b0355-7a8f-4395-8ed8-b479856b0ecc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Expected to be Recognized in the Future Related to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_8c2f1a57-d6e8-48a1-a1ed-7e0934c6313d_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ff0f16a9-cf91-4bea-815f-6a65f8bda2d7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2e588edd-029a-4cb0-804e-574982132cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_514bb4f4-2bcf-4868-9598-3a96fff98f9d_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_40f73deb-8370-487b-b8b3-1d9fc5e190df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_a1ffcb38-ac5b-4110-b24a-2a2d9535b9db_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized customer contract costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41c6c429-3ffc-48ff-af78-1807ad7669a4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c354a59d-7808-4012-8cbd-8adc9cf13070_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAndReceivablesNet_349f35e5-be74-4b19-9f93-72765fc2c767_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAndReceivablesNet_37a21084-ad41-4fbb-b111-f1799f00e27d_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAndReceivablesNet_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments and Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:to="lab_us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_3c64fc18-0beb-4b25-954c-3ae70347bf71_terseLabel_en-US" xlink:label="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Care Hospitals And Related Outpatient Facilities</link:label>
    <link:label id="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_label_en-US" xlink:label="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Care Hospitals And Related Outpatient Facilities [Member]</link:label>
    <link:label id="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_documentation_en-US" xlink:label="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Care Hospitals And Related Outpatient Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" xlink:href="thc-20221231.xsd#thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" xlink:to="lab_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7a21243e-e0b5-4f2b-9f56-349b3866c287_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_870b37bf-5177-47a2-892c-01eac6e7a83b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_21386a62-1016-4bbe-b37e-a417f27b04a3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_MedicareMember_1c7cd2a4-25d3-490a-a073-c38ea22e7932_verboseLabel_en-US" xlink:label="lab_thc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_thc_MedicareMember_label_en-US" xlink:label="lab_thc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_thc_MedicareMember_documentation_en-US" xlink:label="lab_thc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information about Medicare services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MedicareMember" xlink:href="thc-20221231.xsd#thc_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_MedicareMember" xlink:to="lab_thc_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_97730753-9fe6-4061-8ae0-959573bacac5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and investigation costs</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_c25cb695-19dd-406d-9cd4-b82f7a6f49ba_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and investigation costs</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_5f7c6440-1009-4ed5-9b3b-a31b3a821de1_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and investigation costs</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a2eba907-01ab-4cdb-a7fc-7021421872aa_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1a5592bf-4786-499d-9fa2-6ee59618c487_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FinanceLeasesAndMortgageNotes_a42c5a13-ea20-4d93-9459-aa2bd868cc29_terseLabel_en-US" xlink:label="lab_thc_FinanceLeasesAndMortgageNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases, mortgages and other notes</link:label>
    <link:label id="lab_thc_FinanceLeasesAndMortgageNotes_label_en-US" xlink:label="lab_thc_FinanceLeasesAndMortgageNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases And Mortgage Notes</link:label>
    <link:label id="lab_thc_FinanceLeasesAndMortgageNotes_documentation_en-US" xlink:label="lab_thc_FinanceLeasesAndMortgageNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases And Mortgage Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeasesAndMortgageNotes" xlink:href="thc-20221231.xsd#thc_FinanceLeasesAndMortgageNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FinanceLeasesAndMortgageNotes" xlink:to="lab_thc_FinanceLeasesAndMortgageNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_5c4112bd-084a-47a5-aaf5-6288a6d1c85b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_256a0133-a9b7-488e-b34c-f9676b4b70a3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Information Related to Lease Expense, Terms and Discount Rates, and Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b10142bf-a265-4829-82d0-0726d5d0b66d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5a379303-683a-4929-b5e4-c34d450e9629_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ad170689-2fc3-466e-b458-8e4006f5d8b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Classified as Held for Sale and Components of Business that have Been Disposed of or have Been Classified as Held for Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_70364cb2-c560-4456-97c6-d4852afe1502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_432314c6-e000-47ff-9395-128abb951405_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Facility</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_92cc0da0-a2cb-4d78-9daa-50f50f2ff8f9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8096ff21-8867-40e3-9dec-d52d971062ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_7ad2c140-0c9c-48da-89ed-1cd354ba22cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Repurchase Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_53ae44fc-ebb1-4bb2-88a5-385abf7589b7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f8ae5485-8c4f-49c5-ac75-846a4f5f0c7e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_d29759e6-523f-491a-b903-1723cc1f7235_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Shares Purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_b8579861-bd57-4adc-9c3e-d5d333a19b45_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_79ebe2a0-117b-4d4d-8d6b-1a0153943864_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other intangible assets with indefinite lives</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_e1ae8157-f453-4361-81aa-090c0f850c90_terseLabel_en-US" xlink:label="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_e7996118-1f7d-4f37-a746-89f3d8b11a17_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use lease assets and obligations</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_label_en-US" xlink:label="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Right-of-Use Lease Assets And Obligations</link:label>
    <link:label id="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_documentation_en-US" xlink:label="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Right-of-Use Lease Assets And Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" xlink:to="lab_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cede1f45-445b-4228-8009-3b84a2708e99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_91328f00-42ea-469e-8e7f-4c862af638b4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9d93ea41-3b29-418d-b1cf-77f420209da0_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net&#160;</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_57f440c8-30a5-4e22-8011-5bdec71b6bdb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1c603805-f8b7-4fd6-85ac-3b56da471d64_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California provider fee program receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_1f151f40-5a49-4e00-9c19-5e490bff2423_terseLabel_en-US" xlink:label="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_label_en-US" xlink:label="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments and Other Assets</link:label>
    <link:label id="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_documentation_en-US" xlink:label="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from investments and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" xlink:href="thc-20221231.xsd#thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" xlink:to="lab_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5d5576d0-8b64-4fd1-8eee-450bf8779263_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_38f25080-7389-47c8-8b86-4478b2cfffbe_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_51ceef66-d839-42bb-bdcf-e7b344158771_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_617d9b8e-095e-419b-b8fb-309d57caec8d_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b19bc622-4efe-4c34-9081-292b6a737e86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_b60b93ff-5acb-4b68-816e-ef2e841ea7bd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates, net of distributions received</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d74e96a-e528-48fb-b822-e0999defd190_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9de43434-5392-4f80-b366-efc6ca160c01_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_4946a373-3cbc-47e4-b111-29b5d7170350_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_51a90573-f8b1-4a84-945c-89f2ba4d909a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_62610548-37b8-4a42-86b7-92a118e9a9a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a4e421f0-6ed2-4a15-9e21-e8c65c5f9c1c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseLiabilityPaymentsDue_f0809082-0a86-46d5-9fc1-736683a32175_totalLabel_en-US" xlink:label="lab_thc_LeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_thc_LeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_thc_LeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Payments Due</link:label>
    <link:label id="lab_thc_LeaseLiabilityPaymentsDue_documentation_en-US" xlink:label="lab_thc_LeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityPaymentsDue" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseLiabilityPaymentsDue" xlink:to="lab_thc_LeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationHealthCareCostsGross_5040e1a6-d903-4772-aed8-95ddb5cc35a1_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated costs of caring</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationHealthCareCostsGross_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Expenses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:to="lab_us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_1a9fff3a-2d72-4a6a-bff0-0ea8ad4cb413_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_InsuranceCoverageTable_fa3a9533-5fae-44cb-a969-f5087408bf7d_terseLabel_en-US" xlink:label="lab_thc_InsuranceCoverageTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage [Table]</link:label>
    <link:label id="lab_thc_InsuranceCoverageTable_label_en-US" xlink:label="lab_thc_InsuranceCoverageTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage [Table]</link:label>
    <link:label id="lab_thc_InsuranceCoverageTable_documentation_en-US" xlink:label="lab_thc_InsuranceCoverageTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance coverage used by the entity to manage financial risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageTable" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_InsuranceCoverageTable" xlink:to="lab_thc_InsuranceCoverageTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6c488a4d-3117-464e-991a-1aa7d22088bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_3d74a159-539b-4810-9860-ea96f908fa57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_44496122-6261-4513-8d10-35f40c3895d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_f664ac7e-7b21-482a-bba0-6fea0fa8f61a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_fdfcf9e2-3515-49f4-b4e3-b42735deff19_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ExercisePriceRangeOneMember_9a07a54e-10d6-42a3-a3bc-1933374dd8a3_terseLabel_en-US" xlink:label="lab_thc_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$18.99 to $20.609</link:label>
    <link:label id="lab_thc_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_thc_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_thc_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_thc_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information related to options for exercise prices per share of stock options outstanding and exercisable within the first range of prices.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ExercisePriceRangeOneMember" xlink:href="thc-20221231.xsd#thc_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ExercisePriceRangeOneMember" xlink:to="lab_thc_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1357636d-11ee-4e80-8f23-a773b3381180_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_6af6695d-d36f-4adc-b978-4cb594e81e1f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8ee174eb-70de-40b3-9007-5d29aa690a22_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_64aadbe0-b4ba-4187-b04c-e917af056527_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_c3836ef7-3c7d-4d0f-8b41-32036ada27b6_terseLabel_en-US" xlink:label="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Business Center in Republic of Philippines</link:label>
    <link:label id="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_label_en-US" xlink:label="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Business Center In The Republic Of Philippines [Member]</link:label>
    <link:label id="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_documentation_en-US" xlink:label="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Business Center In The Republic Of Philippines [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" xlink:href="thc-20221231.xsd#thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" xlink:to="lab_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f23f981e-c6f9-42bc-a391-99a57b4af6d0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OtherCatastrophicEventsMember_e8fb1ef4-6127-48ab-893b-35c133cd85c7_terseLabel_en-US" xlink:label="lab_thc_OtherCatastrophicEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fires and Certain Other Covered Losses</link:label>
    <link:label id="lab_thc_OtherCatastrophicEventsMember_label_en-US" xlink:label="lab_thc_OtherCatastrophicEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Catastrophic Events [Member]</link:label>
    <link:label id="lab_thc_OtherCatastrophicEventsMember_documentation_en-US" xlink:label="lab_thc_OtherCatastrophicEventsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other catastrophic events including but not limited to fires and other perils.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCatastrophicEventsMember" xlink:href="thc-20221231.xsd#thc_OtherCatastrophicEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OtherCatastrophicEventsMember" xlink:to="lab_thc_OtherCatastrophicEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0887358c-90cc-47ee-9ec6-c63126b2d637_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d02c966c-3fde-43d4-bace-305d163c2f21_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2561bf09-3b6e-4033-9420-a86b52e28f99_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_a7bff6b7-86e2-45d6-8eb2-55a710f133f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_7ea30a08-7405-4618-83be-6f066060198c_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_eaf6bc22-ea92-4fa9-b59e-f5cf40a2016f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Shares (Denominator)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_25a0535f-7b15-4d1e-8612-20e80744159d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial losses</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_0927fbec-028c-421b-aa51-5e39e95483ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_MedicalEquipmentMember_d8535549-4c83-45d7-b0bb-5889a98b0ec4_terseLabel_en-US" xlink:label="lab_thc_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment</link:label>
    <link:label id="lab_thc_MedicalEquipmentMember_label_en-US" xlink:label="lab_thc_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_thc_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_thc_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MedicalEquipmentMember" xlink:href="thc-20221231.xsd#thc_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_MedicalEquipmentMember" xlink:to="lab_thc_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_781c0d44-f975-4e41-9f3b-2a475bd7307a_terseLabel_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later Years</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal After Year Five</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_documentation_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb8a24a-6793-4ded-b47d-1aa925dc75d2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b561edf9-8231-4dec-bba2-77c1240687d0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND OTHER INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4ae5d43a-b23d-4908-892c-d6f4a77b2c44_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_daa96d33-28db-4c5b-98fc-9baeaa1f754c_terseLabel_en-US" xlink:label="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Items</link:label>
    <link:label id="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_label_en-US" xlink:label="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves, Reserves of Businesses Sold</link:label>
    <link:label id="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_documentation_en-US" xlink:label="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, related to a business sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" xlink:href="thc-20221231.xsd#thc_ValuationAllowancesAndReservesReservesOfBusinessesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" xlink:to="lab_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_549ee6b9-adf4-4aaa-8f28-50215638f665_terseLabel_en-US" xlink:label="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.250% due 2029</link:label>
    <link:label id="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_label_en-US" xlink:label="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Two Five Zero Percent Senior Secured Note, Due 2029 [Member]</link:label>
    <link:label id="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_documentation_en-US" xlink:label="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Two Five Zero Percent Senior Secured Note, Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" xlink:href="thc-20221231.xsd#thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" xlink:to="lab_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_dfcee95d-3c3c-4b2a-84b5-316110a927a1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_032b3742-47a4-4282-9b21-ba5b14847d36_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9a5cac85-47dc-4435-b5ea-7e5901b4d393_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_99386d6c-c784-4f0e-893a-9eb78fafc124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e32f0b87-1a92-4af1-88d8-df3ae4ba5186_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_6049fdb3-21ba-4763-9bc3-fd9a8fd857d2_terseLabel_en-US" xlink:label="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.875% due 2031</link:label>
    <link:label id="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_label_en-US" xlink:label="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Eight Seven Five Percent Senior Unsecured Note, Due 2031 [Member]</link:label>
    <link:label id="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_documentation_en-US" xlink:label="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Eight Seven Five Percent Senior Unsecured Note, Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" xlink:href="thc-20221231.xsd#thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" xlink:to="lab_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_17394fc5-062d-481d-83a7-2e191d3dceb5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0d5e9bd8-00f4-446a-9116-78699d097c38_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_479eecfe-e6bd-4335-b7d6-5d8e151ff07a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3d80c993-f639-4612-9ecc-8a2bae2a5e5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of awards exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_195e9c8c-435f-481b-a50d-ef95b3126613_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of common stock allocated to plan</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Allocated Shares, Percent</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Number Of Allocated Shares, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638c36b1-a771-412e-94c5-82deb4d930b7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afd60d2b-4450-4319-b3d8-f36b2b013471_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8fb01263-bb02-463f-b26f-9141c947e7e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_30832188-3836-459d-996e-d1e8ef248547_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GUARANTEES</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems" xlink:to="lab_us-gaap_GuaranteeObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_5186a93b-61df-42ed-9918-28ed4662c541_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes for continuing operations</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_ad6ef9eb-dece-4600-945e-ff7f49f4b1ef_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_78f1e708-340c-43be-ad03-0a372e856624_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_83d5cb7d-59c6-404d-a9ae-1869ed20afac_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_11818b84-7b20-4e0c-a246-7b07e4dd5cb3_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_16690976-0b00-48b6-8bc5-2d9889c6bda9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember_e80a1f94-85b1-4cc8-a6b9-76c4a3485f55_terseLabel_en-US" xlink:label="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting And Settled Immediately</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember_label_en-US" xlink:label="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting And Settled Immediately [Member]</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember_documentation_en-US" xlink:label="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting And Settled Immediately</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingAndSettledImmediatelyMember" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingAndSettledImmediatelyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PerformanceBasedVestingAndSettledImmediatelyMember" xlink:to="lab_thc_PerformanceBasedVestingAndSettledImmediatelyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a3149963-50f8-4087-a74b-f55b389cb794_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HospitalOperationsAndOtherMember_665e73be-738e-4fdc-ac79-67d0c2f33ecc_terseLabel_en-US" xlink:label="lab_thc_HospitalOperationsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations And Other</link:label>
    <link:label id="lab_thc_HospitalOperationsAndOtherMember_label_en-US" xlink:label="lab_thc_HospitalOperationsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations And Other [Member]</link:label>
    <link:label id="lab_thc_HospitalOperationsAndOtherMember_documentation_en-US" xlink:label="lab_thc_HospitalOperationsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Operations And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsAndOtherMember" xlink:href="thc-20221231.xsd#thc_HospitalOperationsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HospitalOperationsAndOtherMember" xlink:to="lab_thc_HospitalOperationsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_A2015USPIManagementEquityPlanMember_e76142c5-071b-449b-a600-e6b15a474f77_terseLabel_en-US" xlink:label="lab_thc_A2015USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 USPI Management Equity Plan</link:label>
    <link:label id="lab_thc_A2015USPIManagementEquityPlanMember_label_en-US" xlink:label="lab_thc_A2015USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 USPI Management Equity Plan [Member]</link:label>
    <link:label id="lab_thc_A2015USPIManagementEquityPlanMember_documentation_en-US" xlink:label="lab_thc_A2015USPIManagementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 USPI Management Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2015USPIManagementEquityPlanMember" xlink:href="thc-20221231.xsd#thc_A2015USPIManagementEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_A2015USPIManagementEquityPlanMember" xlink:to="lab_thc_A2015USPIManagementEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_SharePurchaseAgreementPaymentForExecution_c1004062-8d49-41e1-bddd-8406458a3fc1_terseLabel_en-US" xlink:label="lab_thc_SharePurchaseAgreementPaymentForExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement, payment for execution</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementPaymentForExecution_label_en-US" xlink:label="lab_thc_SharePurchaseAgreementPaymentForExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Payment For Execution</link:label>
    <link:label id="lab_thc_SharePurchaseAgreementPaymentForExecution_documentation_en-US" xlink:label="lab_thc_SharePurchaseAgreementPaymentForExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Payment For Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementPaymentForExecution" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementPaymentForExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_SharePurchaseAgreementPaymentForExecution" xlink:to="lab_thc_SharePurchaseAgreementPaymentForExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_3dfe8b83-7036-4934-981f-5bdbae3f0c71_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_14283c1e-b834-44bb-a3e7-cd7fafdf1726_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_95f3665f-2024-47ac-9ac6-de6310af4f37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on consolidations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_48b49f01-6bc5-4740-84a2-0256b9539462_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plans</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ExercisePriceRangeSecondMember_bc5ab007-e7e6-4baa-beb8-df4f749f01f6_terseLabel_en-US" xlink:label="lab_thc_ExercisePriceRangeSecondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$20.61 to $35.430</link:label>
    <link:label id="lab_thc_ExercisePriceRangeSecondMember_label_en-US" xlink:label="lab_thc_ExercisePriceRangeSecondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Second [Member]</link:label>
    <link:label id="lab_thc_ExercisePriceRangeSecondMember_documentation_en-US" xlink:label="lab_thc_ExercisePriceRangeSecondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information related to options for exercise prices per share of stock options outstanding and exercisable within the second range of prices.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ExercisePriceRangeSecondMember" xlink:href="thc-20221231.xsd#thc_ExercisePriceRangeSecondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ExercisePriceRangeSecondMember" xlink:to="lab_thc_ExercisePriceRangeSecondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember_1364150a-ea29-4451-bde7-898ad42ea3cb_terseLabel_en-US" xlink:label="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash&#8209;Managed Affiliates</link:label>
    <link:label id="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember_label_en-US" xlink:label="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Cash Managed Affiliates [Member]</link:label>
    <link:label id="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember_documentation_en-US" xlink:label="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Cash Managed Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EquityMethodInvestmentCashManagedAffiliatesMember" xlink:href="thc-20221231.xsd#thc_EquityMethodInvestmentCashManagedAffiliatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EquityMethodInvestmentCashManagedAffiliatesMember" xlink:to="lab_thc_EquityMethodInvestmentCashManagedAffiliatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_be7135a8-21e9-44cf-bf36-17188366ccc2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income available to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_097d0804-edc1-4107-881d-8d58bbfb4cfb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLAIMS AND LAWSUITS</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_72774363-2dce-4a65-9c08-d38ec61cb5f1_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ca031626-2e79-441a-ae4a-1a143d4241b6_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2f6a88a8-e7ab-466f-b137-78aa5b3af863_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4df845cd-88f5-4f2e-9c41-f206bc03156e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to Tenet Healthcare Corporation common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_bf7d929c-73be-4abb-bcde-e95382f1c9c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5b65a2b0-da83-41e7-9716-a6f161003f24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_54c83eea-694f-4e4e-95df-ea120eea1bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_55b9e0bd-52ad-4c96-8d8f-25afa8f4980e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_3e610a98-1bf0-46f7-adfc-c91d620429b6_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and general liability reserves</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_fbada126-2d62-4375-982a-f9f03d5e1059_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesFairValueDisclosure_c41c155d-6b3d-4e27-8a06-bc242c8e3d7f_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_GuaranteesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesFairValueDisclosure" xlink:to="lab_us-gaap_GuaranteesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b051f14d-c309-4b3c-b498-230ea383e2b9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases for items received but not yet paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_afe2f345-7ca2-4971-bdca-72dd226a2b69_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_e1d574e9-c6f3-4a3e-bb73-ec1886a635e4_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_0980497a-6cfa-4ebe-90fc-90abf5febfbe_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0b7f9e6e-11c8-4fb3-86b1-ba8da298e08a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_9b238fff-7974-4171-b950-0107c235d24d_verboseLabel_en-US" xlink:label="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of frozen plans</link:label>
    <link:label id="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_label_en-US" xlink:label="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Frozen Non Qualified Defined Benefit Pension Plans</link:label>
    <link:label id="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_documentation_en-US" xlink:label="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of frozen non-qualified benefit pension plans of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" xlink:href="thc-20221231.xsd#thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" xlink:to="lab_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_45f05e8b-887d-46d6-9894-73ceb4c9ab74_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_f93085c2-39d7-4cac-a040-cc1c22ab1ebc_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property (percentage)</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_label_en-US" xlink:label="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants Asset Value as Percentage of Consolidated Net Tangible Assets for Properties to be Defined as Principal Property</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_documentation_en-US" xlink:label="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the hospital asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" xlink:to="lab_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_eedfe8ad-bbf1-4adb-8469-5d7803926c2d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_14359b0e-aa8a-47d2-8663-104335447c9d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_2fb14e0d-0e19-4b2b-83ff-ea20457f6bf9_verboseLabel_en-US" xlink:label="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment and restructuring charges, and acquisition-related costs</link:label>
    <link:label id="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_7f7cf4e7-3970-4186-b63f-a8f595cdb295_terseLabel_en-US" xlink:label="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment and restructuring charges, and acquisition-related costs</link:label>
    <link:label id="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_351434a8-848d-499f-a716-f60cb4bb15a6_negatedLabel_en-US" xlink:label="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment and restructuring charges, and acquisition-related costs</link:label>
    <link:label id="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_label_en-US" xlink:label="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Settlement Impairment Provisions and Acquisition Cost</link:label>
    <link:label id="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_documentation_en-US" xlink:label="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period and acquisition-related costs. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:to="lab_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_e4e5accb-f96f-45ee-8e07-6109bf723dbb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d035250c-d587-4054-8f89-1ab1ff8a2de4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income available to Tenet Healthcare Corporation common shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_7a177a59-a06b-4fac-9bbb-f4522c1691ed_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_7e26ba0c-9355-4461-91c7-c54ed68c2377_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:to="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7fcc50ae-a5ea-43d3-9af2-53dad7ad7ecb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_05628677-99f9-418d-93ce-2c53867ea691_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_98ca65cf-5933-4ead-a942-c8b6972c434c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_391f8bde-dd34-4350-9ddf-9ffa1d6984d6_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_A2022AcquisitionMember_dd70c15f-a796-4e7e-afa6-61266ce4f6fc_terseLabel_en-US" xlink:label="lab_thc_A2022AcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Acquisition</link:label>
    <link:label id="lab_thc_A2022AcquisitionMember_label_en-US" xlink:label="lab_thc_A2022AcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Acquisition [Member]</link:label>
    <link:label id="lab_thc_A2022AcquisitionMember_documentation_en-US" xlink:label="lab_thc_A2022AcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2022AcquisitionMember" xlink:href="thc-20221231.xsd#thc_A2022AcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_A2022AcquisitionMember" xlink:to="lab_thc_A2022AcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8551fbc2-20e4-4caf-a9d1-da51cb8edba6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_82c6e221-371c-4755-bb11-607e9fc44d3a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationAxis_c94427a9-8025-4278-b717-e058515b026a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis" xlink:to="lab_us-gaap_ContractWithCustomerDurationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_e8ab3c85-2a1f-4fc9-8e8f-05909cbf6a9c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermContractWithCustomerMember_1c309835-7c93-4a5b-b9dc-5b0e9cf3ed3b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Contract with Customer</link:label>
    <link:label id="lab_us-gaap_LongTermContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_LongTermContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Contract with Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermContractWithCustomerMember" xlink:to="lab_us-gaap_LongTermContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_eab8fc4f-0f59-4013-ab17-65a176118bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_fd4ee0c0-6ed7-487b-85eb-0dc858dc2eaa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_f64377da-af22-4735-a65d-0d75823fbe0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preliminary Purchase Price Allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_a1d8718b-9906-4c7b-a56b-e3390423508a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5b2081fe-31c3-43a0-a7f8-12b42dbf41fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_614720be-4af0-41a9-b3e7-662618bccd08_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_0bb1a577-05fe-479f-abf5-7ba101a11fb6_terseLabel_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ambulatory surgery centers operated by subsidiaries</link:label>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_label_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ambulatory Surgery Centers Operated By Subsidiaries</link:label>
    <link:label id="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_documentation_en-US" xlink:label="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ambulatory Surgery Centers Operated By Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" xlink:to="lab_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProperties_aa9ff345-e7d5-4316-8659-d6b931f7ca58_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of properties</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProperties_c4765293-e1ab-47c6-8d50-9c66fe598785_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProperties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of properties</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfProperties_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfProperties" xlink:to="lab_us-gaap_GainLossOnSaleOfProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_7bfdb644-5006-4984-8166-21a6ce572009_terseLabel_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_label_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset, Net, Current [Roll Forward]</link:label>
    <link:label id="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_documentation_en-US" xlink:label="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerAssetNetCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" xlink:to="lab_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2b82d80c-46fb-47fc-9771-63d819c0cc67_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_764cf285-734e-40ab-8b4b-3a4becd93dba_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_0d066645-5c5a-4022-8ab3-4408f271d74b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_db0d2522-fe39-41b1-8126-c2eee6838748_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Location of Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_06267d18-06b9-4eb0-a8a7-00c30cbe4c6d_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9ad00616-dd70-4039-b1a5-4856a33b787e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Amortization of Intangibles with Finite Useful Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_OtherCustomersMember_e50e029e-e4cd-45e6-833b-367dba032cfd_verboseLabel_en-US" xlink:label="lab_thc_OtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customers</link:label>
    <link:label id="lab_thc_OtherCustomersMember_98ec3a84-daaf-413a-86df-42d468e65d7f_terseLabel_en-US" xlink:label="lab_thc_OtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other clients</link:label>
    <link:label id="lab_thc_OtherCustomersMember_label_en-US" xlink:label="lab_thc_OtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:label id="lab_thc_OtherCustomersMember_documentation_en-US" xlink:label="lab_thc_OtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to other customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCustomersMember" xlink:href="thc-20221231.xsd#thc_OtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_OtherCustomersMember" xlink:to="lab_thc_OtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_169dcc22-e790-47cb-8dca-eee05e621e41_terseLabel_en-US" xlink:label="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased equity In joint venture, percentage of total shares (percentage)</link:label>
    <link:label id="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_label_en-US" xlink:label="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Equity In Joint Venture, Percentage Of Total Shares</link:label>
    <link:label id="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_documentation_en-US" xlink:label="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Equity In Joint Venture, Percentage Of Total Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PurchasedEquityInJointVenturePercentageOfTotalShares" xlink:href="thc-20221231.xsd#thc_PurchasedEquityInJointVenturePercentageOfTotalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PurchasedEquityInJointVenturePercentageOfTotalShares" xlink:to="lab_thc_PurchasedEquityInJointVenturePercentageOfTotalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0f5ef3af-53cd-47d1-a93f-119812bfb86f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NewlyConstructedHospitalsMember_7a769324-f55c-4384-a5ee-478dd5e66e85_terseLabel_en-US" xlink:label="lab_thc_NewlyConstructedHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newly Constructed Hospitals</link:label>
    <link:label id="lab_thc_NewlyConstructedHospitalsMember_label_en-US" xlink:label="lab_thc_NewlyConstructedHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newly Constructed Hospitals [Member]</link:label>
    <link:label id="lab_thc_NewlyConstructedHospitalsMember_documentation_en-US" xlink:label="lab_thc_NewlyConstructedHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to newly constructed hospitals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NewlyConstructedHospitalsMember" xlink:href="thc-20221231.xsd#thc_NewlyConstructedHospitalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NewlyConstructedHospitalsMember" xlink:to="lab_thc_NewlyConstructedHospitalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage_8ab1e1e2-6a4a-4493-8849-70e2970beba7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b806ad9c-5f57-4a30-93d3-613e803c6173_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PropertyInsuranceAnnualCoverageLimit_e6f68fe3-7e87-4974-b4b9-ed7c77879d59_terseLabel_en-US" xlink:label="lab_thc_PropertyInsuranceAnnualCoverageLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance coverage, aggregate limit</link:label>
    <link:label id="lab_thc_PropertyInsuranceAnnualCoverageLimit_label_en-US" xlink:label="lab_thc_PropertyInsuranceAnnualCoverageLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Annual Coverage Limit</link:label>
    <link:label id="lab_thc_PropertyInsuranceAnnualCoverageLimit_documentation_en-US" xlink:label="lab_thc_PropertyInsuranceAnnualCoverageLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Annual Coverage Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceAnnualCoverageLimit" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceAnnualCoverageLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PropertyInsuranceAnnualCoverageLimit" xlink:to="lab_thc_PropertyInsuranceAnnualCoverageLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_da872959-28d6-45ac-9e66-3d77f4c5d552_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e0b17acc-cc17-49e8-85a7-f08dd4e0fb30_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d584d4f6-250c-4fee-b638-aae87729656b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_f41dad88-c2c8-47a1-bad8-f52bb884156c_negatedTerseLabel_en-US" xlink:label="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests in equity of consolidated subsidiaries</link:label>
    <link:label id="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_label_en-US" xlink:label="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Purchase Price Allocation, Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries</link:label>
    <link:label id="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_documentation_en-US" xlink:label="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of acquisition costs of a business combination allocated to redeemable noncontrolling interests in equity of consolidated subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" xlink:href="thc-20221231.xsd#thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" xlink:to="lab_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_dcf1f356-e31d-43cb-b89b-da62768d3bfe_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_49a919e2-7081-4afc-be3c-518564a87a9d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeOfBusinessRevenueMember_2053ab61-cc7a-49ca-873d-8382cf7160fe_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeOfBusinessRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee of Business Revenue</link:label>
    <link:label id="lab_us-gaap_GuaranteeOfBusinessRevenueMember_label_en-US" xlink:label="lab_us-gaap_GuaranteeOfBusinessRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee of Business Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeOfBusinessRevenueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeOfBusinessRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeOfBusinessRevenueMember" xlink:to="lab_us-gaap_GuaranteeOfBusinessRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_944e96fe-7ed0-492f-a7f7-88a0abd03382_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term rate of return on assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_d3bb5012-ac3b-40bf-9a86-cfcac551b65f_terseLabel_en-US" xlink:label="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price (in dollars per share)</link:label>
    <link:label id="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Weighted Average Price Per Share Employee Stock Purchase Plan</link:label>
    <link:label id="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents value per share for stock issued during the period as a result of employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" xlink:href="thc-20221231.xsd#thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" xlink:to="lab_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_69df9967-0fa2-4667-9a3f-fd9bf320d49f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets&#160;</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_93247a01-9d0b-406a-b4a6-54e69acb82e2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NetIncomeLossAttributableToInvestee_333454cd-8320-42dc-9584-270f56e6acc3_terseLabel_en-US" xlink:label="lab_thc_NetIncomeLossAttributableToInvestee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to the investees</link:label>
    <link:label id="lab_thc_NetIncomeLossAttributableToInvestee_label_en-US" xlink:label="lab_thc_NetIncomeLossAttributableToInvestee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Loss Attributable to Investee</link:label>
    <link:label id="lab_thc_NetIncomeLossAttributableToInvestee_documentation_en-US" xlink:label="lab_thc_NetIncomeLossAttributableToInvestee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of net income (loss) attributable to the investee reported by the equity method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetIncomeLossAttributableToInvestee" xlink:href="thc-20221231.xsd#thc_NetIncomeLossAttributableToInvestee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NetIncomeLossAttributableToInvestee" xlink:to="lab_thc_NetIncomeLossAttributableToInvestee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_8177a680-1dc6-488d-91be-e86489ce9bee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payments, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_53e73285-ec8c-4e5a-892b-8f57698875c4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities advance payments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e2a42e51-189d-47dd-82d5-414c91554f06_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationDomain_d9ae3bb7-4a10-4096-8bab-c354049e1368_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerDurationDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerDurationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Duration [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain" xlink:to="lab_us-gaap_ContractWithCustomerDurationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6a41d192-d273-4ffe-8a1a-0ee250506cad_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d28cd805-2dae-4333-96bd-5ca1bf1bcc2c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Assets by Reportable Segment to Consolidated Assets</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c4dedbaf-2ced-4d4d-bb1a-b3981595d4ef_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions paid to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_659a50ef-439f-4cb3-9b17-0623c0dc2393_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_TimeBasedVestingFourYearFromGrantDateMember_7d9498b6-6ef8-4c15-a65c-ada00138cf88_terseLabel_en-US" xlink:label="lab_thc_TimeBasedVestingFourYearFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Four Year From Grant Date</link:label>
    <link:label id="lab_thc_TimeBasedVestingFourYearFromGrantDateMember_label_en-US" xlink:label="lab_thc_TimeBasedVestingFourYearFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Four Year From Grant Date [Member]</link:label>
    <link:label id="lab_thc_TimeBasedVestingFourYearFromGrantDateMember_documentation_en-US" xlink:label="lab_thc_TimeBasedVestingFourYearFromGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Vesting, Four Year From Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingFourYearFromGrantDateMember" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingFourYearFromGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_TimeBasedVestingFourYearFromGrantDateMember" xlink:to="lab_thc_TimeBasedVestingFourYearFromGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_4820c63a-0baf-4cdc-aec9-ff9a765d2b73_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_96d565e6-a703-44b8-9a4a-45dd65688ce1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_97eb96c1-6f38-4e7c-b19b-6f4584c21069_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e1c28d1e-46d2-4c38-93b6-f8698098c50a_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in valuation and qualifying accounts</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9da796b0-9b08-4d51-befb-294173d650f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6cf97328-79a2-454f-a8b4-92810b0086cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_5c25a3a0-691e-496a-bb73-aa52fc859476_terseLabel_en-US" xlink:label="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_label_en-US" xlink:label="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service, Excluding Physician Practices [Member]</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_documentation_en-US" xlink:label="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service, Excluding Physician Practices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceExcludingPhysicianPracticesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" xlink:to="lab_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_da8701d9-488b-45dd-b7f5-294ae95ee465_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base earnings elected to be withheld each quarter by eligible employees to purchase shares of the entity's common stock</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Contribution by Eligible Employees Percent</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of eligible earnings that can be contributed by the employees towards the quarterly purchase of the entity's common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_052cbc43-cdac-4021-b23a-72cc16dba4a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_441c5475-3ef4-4223-8a8e-c3472543d426_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt to EBITDA ratio</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_label_en-US" xlink:label="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Covenant Secured Debt To EBITDA Ratio</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_documentation_en-US" xlink:label="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the ratio for secured debt to EBITDA required to be maintained under financial covenants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" xlink:to="lab_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7e770b78-e2bc-4d20-890b-a363f21a1b2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_JointVentureOwnershipPercentage_89745076-f077-42a6-9245-31b967690c5d_verboseLabel_en-US" xlink:label="lab_thc_JointVentureOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_thc_JointVentureOwnershipPercentage_491f674f-56d9-47c5-b377-1369002ca3a1_terseLabel_en-US" xlink:label="lab_thc_JointVentureOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership (as a percentage)</link:label>
    <link:label id="lab_thc_JointVentureOwnershipPercentage_label_en-US" xlink:label="lab_thc_JointVentureOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Ownership Percentage</link:label>
    <link:label id="lab_thc_JointVentureOwnershipPercentage_documentation_en-US" xlink:label="lab_thc_JointVentureOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the joint venture ownership percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_JointVentureOwnershipPercentage" xlink:href="thc-20221231.xsd#thc_JointVentureOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_JointVentureOwnershipPercentage" xlink:to="lab_thc_JointVentureOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfHospitalsOperatedBySubsidiaries_f9c74b93-f8c4-481a-af42-84cd06779a74_terseLabel_en-US" xlink:label="lab_thc_NumberOfHospitalsOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospitals owned by subsidiaries</link:label>
    <link:label id="lab_thc_NumberOfHospitalsOperatedBySubsidiaries_label_en-US" xlink:label="lab_thc_NumberOfHospitalsOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Hospitals Operated by Subsidiaries</link:label>
    <link:label id="lab_thc_NumberOfHospitalsOperatedBySubsidiaries_documentation_en-US" xlink:label="lab_thc_NumberOfHospitalsOperatedBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of hospitals operated by subsidiaries of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsOperatedBySubsidiaries" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsOperatedBySubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfHospitalsOperatedBySubsidiaries" xlink:to="lab_thc_NumberOfHospitalsOperatedBySubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_27851114-840d-411b-bad7-02dcdb44df1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM DEBT AND LEASE OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_be2052ec-d702-4597-ae4d-1abd91153cd1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, tax benefit and issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_57a5fa2c-cab1-4a60-ac69-a4946bc1e8a8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d149972b-9946-44bb-8751-9a3d219c77ce_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government obligations</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_816b1ef8-2934-4cdf-964b-1876360f139f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_90240492-de5f-4441-8ccc-46dce55bd2c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember_ce4620ff-abf7-456e-b0b6-1ef236e75845_terseLabel_en-US" xlink:label="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity and other</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember_label_en-US" xlink:label="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Indemnity And Other [Member]</link:label>
    <link:label id="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember_documentation_en-US" xlink:label="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service - Indemnity And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceIndemnityAndOtherMember" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceIndemnityAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HealthCarePatientServiceIndemnityAndOtherMember" xlink:to="lab_thc_HealthCarePatientServiceIndemnityAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_556ae643-a692-4031-ab18-5ac677673d38_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at Beginning of&#160;Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_529701ab-1793-4215-b602-95d437c52756_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at End&#160;of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_14b928be-2408-4ccd-a976-2f6def376d50_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_0d9de0d5-5076-4486-9c5e-41df1d2669fb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finance Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_10bf7120-aa1e-4381-afc5-7c5662e6465e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_66f7e78f-fa70-42a4-bc05-f4d07e23d8a9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock_64f335cb-5916-47c0-80d6-4bc357baea47_terseLabel_en-US" xlink:label="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INSURANCE</link:label>
    <link:label id="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Professional and General Liability Insurance Disclosure [Text Block]</link:label>
    <link:label id="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock_documentation_en-US" xlink:label="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This entire disclosure represents information pertaining to property and professional and general liability insurance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" xlink:href="thc-20221231.xsd#thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" xlink:to="lab_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_6ef70f81-aad8-4f14-83fc-b0f510d7c2ac_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Stock Exchange</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_72bd057c-8dcb-4d9d-b765-e5335c83cc5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e8b76bc0-428f-42db-9e2f-6fb543984351_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_f37244a8-64f8-42d1-9785-4a5859996646_terseLabel_en-US" xlink:label="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases (sales) of businesses and noncontrolling interests, net</link:label>
    <link:label id="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_label_en-US" xlink:label="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid-In Capital, Purchase (Sale) of Joint Venture Interest</link:label>
    <link:label id="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_documentation_en-US" xlink:label="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the net (decrease) increase in additional paid-in capital resulting from the purchase and sales of businesses and joint venture interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" xlink:href="thc-20221231.xsd#thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" xlink:to="lab_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_46bfe416-1dbd-443d-8983-5f8c4a862ad7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Other Significant Reconciling Items From Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_bffbb0d0-838a-42b4-8e2f-a923e7041a77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Purchase Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_4f12448e-8cb9-4b74-963b-0a9358d996e9_terseLabel_en-US" xlink:label="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="thc-20221231.xsd#thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_76076aec-0f50-4403-9a0c-706883a72e42_terseLabel_en-US" xlink:label="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA&#160;</link:label>
    <link:label id="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_label_en-US" xlink:label="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings before Interest Tax Depreciation and Amortization</link:label>
    <link:label id="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_documentation_en-US" xlink:label="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the net income with interest, taxes, depreciation, and amortization added back to it, used to analyze and compare profitability between companies and industries because it eliminates the effects of financing and accounting decisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:href="thc-20221231.xsd#thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:to="lab_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_20c36266-999c-4994-85d9-b263477affa4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final purchase price allocations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherDebt_17c911c7-9025-447b-8cf8-b2574b35d1e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from other borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt" xlink:to="lab_us-gaap_ProceedsFromOtherDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_065b8664-7af3-4a75-8eee-705d4b87ed44_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet_3202e64c-e790-49f0-a4db-338d063dff98_totalLabel_en-US" xlink:label="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset (liability)</link:label>
    <link:label id="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets (Liabilities), Net</link:label>
    <link:label id="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet" xlink:href="thc-20221231.xsd#thc_DeferredIncomeTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet" xlink:to="lab_thc_DeferredIncomeTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1cfbf190-187b-4143-95d1-d61bf75b25a6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_135e8f4a-57a5-431e-a624-5de1fac4eee5_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3069a195-c0af-4dea-8b37-290d06c9f5d1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_20e9b6f1-5c86-466b-9c75-b5b9811e7673_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_d1f44561-6843-4ace-beb0-230b4af580e2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CaliforniaEarthquakeMember_85763400-ac7a-4ead-8639-c96b6dc156d0_terseLabel_en-US" xlink:label="lab_thc_CaliforniaEarthquakeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Earthquake</link:label>
    <link:label id="lab_thc_CaliforniaEarthquakeMember_label_en-US" xlink:label="lab_thc_CaliforniaEarthquakeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Earthquake [Member]</link:label>
    <link:label id="lab_thc_CaliforniaEarthquakeMember_documentation_en-US" xlink:label="lab_thc_CaliforniaEarthquakeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Earthquake</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaEarthquakeMember" xlink:href="thc-20221231.xsd#thc_CaliforniaEarthquakeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CaliforniaEarthquakeMember" xlink:to="lab_thc_CaliforniaEarthquakeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_247f3527-fa16-480f-ad95-1100b5a3ce18_terseLabel_en-US" xlink:label="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill related to assets held for sale and disposed</link:label>
    <link:label id="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_label_en-US" xlink:label="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Related To Assets Held For Sale And Disposed Or Deconsolidated Facility</link:label>
    <link:label id="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_documentation_en-US" xlink:label="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Related To Assets Held For Sale And Disposed Or Deconsolidated Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" xlink:href="thc-20221231.xsd#thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" xlink:to="lab_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_4fa96b18-eab2-4f44-8ca9-25fb22e0868b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_93ef5685-9393-4ead-a5d9-f074889c2862_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation costs, pretax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6c601517-7b78-4b16-9071-2784895c3983_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_733aa9cb-fdf7-45f7-bfe1-05f2fdbdf5a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_42c7b531-d007-4cf1-b4b1-c70a8ba70004_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9200f30-9d5e-4c96-8285-200c89d32e07_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_186a32c5-02aa-4914-9467-3aa773862735_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_b58e5d19-2271-4f36-b290-4ed0829660e0_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_2ca9422e-ac0b-4aab-9676-7d7f756b8ab8_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase obligation due to change of control percentage of principal</link:label>
    <link:label id="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_label_en-US" xlink:label="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Obligation Due to Change of Control Percentage of Principal</link:label>
    <link:label id="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_documentation_en-US" xlink:label="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of the principal amount at which the entity is obligated to offer to repurchase the debt instrument due to a change in control.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" xlink:href="thc-20221231.xsd#thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" xlink:to="lab_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7c51fd9-b821-48c2-93c6-cc6b38d29664_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues&#160;</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea5b4d8e-9cdb-4b64-ae5c-e030d4f75251_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_MiamiAreaHospitalsMember_400f2172-86e4-4ea7-9c7a-86beeef3752d_terseLabel_en-US" xlink:label="lab_thc_MiamiAreaHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miami-Area Hospitals</link:label>
    <link:label id="lab_thc_MiamiAreaHospitalsMember_label_en-US" xlink:label="lab_thc_MiamiAreaHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miami-Area Hospitals [Member]</link:label>
    <link:label id="lab_thc_MiamiAreaHospitalsMember_documentation_en-US" xlink:label="lab_thc_MiamiAreaHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miami-Area Hospitals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MiamiAreaHospitalsMember" xlink:href="thc-20221231.xsd#thc_MiamiAreaHospitalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_MiamiAreaHospitalsMember" xlink:to="lab_thc_MiamiAreaHospitalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_78aa9a49-8c37-4802-9cf6-de2b1070745a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c12fc224-270e-44e9-b4db-cc1bcdae2a0c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_0efe8c54-2847-4c2c-be3f-7eb48f06d1d3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs capitalized related to construction projects</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_2a012a9d-b6ee-419f-ac3d-8cb013b22252_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e66b4ba-dcc7-4821-93b5-95385cf474bf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets and Liabilities Held for Sale</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fda99b20-b5ca-41f5-b719-00843710e63b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ed0110ab-dc3e-447c-9014-f47ce4628c5e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, finance leases (percentage)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_eb8b4da8-2826-4be1-a3a5-4497aee3a3f7_terseLabel_en-US" xlink:label="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outpatient centers recorded using equity method</link:label>
    <link:label id="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_label_en-US" xlink:label="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Outpatient Centers Recorded Using Equity Method</link:label>
    <link:label id="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_documentation_en-US" xlink:label="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of outpatient centers in which they are recorded using the equity method of accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" xlink:to="lab_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_cda8177c-a4c0-4d32-b014-943a7785347d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTRACT BALANCES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c49cbabb-0110-4d36-9cc8-039a1098e9d5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET OPERATING REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f7327929-8b45-4e33-8c20-1dd68b0a4ead_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold_eeb77e8e-562e-4d29-af55-3c66d52346c9_terseLabel_en-US" xlink:label="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding vested shares eligible to be sold (in shares)</link:label>
    <link:label id="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold_label_en-US" xlink:label="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding And Eligible To Be Sold</link:label>
    <link:label id="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold_documentation_en-US" xlink:label="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding And Eligible To Be Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CommonStockSharesOutstandingAndEligibleToBeSold" xlink:href="thc-20221231.xsd#thc_CommonStockSharesOutstandingAndEligibleToBeSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_CommonStockSharesOutstandingAndEligibleToBeSold" xlink:to="lab_thc_CommonStockSharesOutstandingAndEligibleToBeSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_23bcecef-5e52-4657-9dbc-9edbe5204ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_745a4d71-77bd-4cac-b0e0-3cf045bf79e2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_8a5abb69-9f83-4ebb-b0ff-276133488bec_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3dd68118-4d96-4470-8b2c-654ba0324441_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0171cc47-9a22-4e54-8af7-04d7c5c898a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_098dcfb6-4a5f-4883-8d1d-88ac9976f3a1_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod_ff03ce0c-4097-42a9-9eac-9bd525a9938d_terseLabel_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax valuation allowance due to a change in tax accounting method</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod_label_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Change In Tax Accounting Method</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod_documentation_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Change In Tax Accounting Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" xlink:to="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_22dba243-4628-445f-a4e1-3e4a8b68b50f_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_717e3f29-0e33-4743-b53c-99c649e6e587_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_23fc0747-0977-435b-9beb-a1b6b864af6e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_64309519-e4ed-48c6-bacc-2ff9bb32068d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity&#160;</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f5f69053-e8ff-4d39-81c1-5c2bd433e685_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_87a34d1e-0069-4e09-a612-99952ba7732d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Dollar Value of Shares That May Yet be Purchased Under the Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_e4c6db6d-70a6-43d4-b282-314392dd8dd1_negatedLabel_en-US" xlink:label="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories and other current assets</link:label>
    <link:label id="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_label_en-US" xlink:label="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories and Other Assets, Current</link:label>
    <link:label id="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_documentation_en-US" xlink:label="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the aggregate value of all inventory held by the reporting entity and other current assets not otherwise defined in the taxonomy, associated with underlying transactions that are classified as operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" xlink:href="thc-20221231.xsd#thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" xlink:to="lab_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount_514621c9-7e5f-4639-befc-fd7065d82e02_terseLabel_en-US" xlink:label="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive stock options, restricted stock units, and deferred compensation units (in dollars per share)</link:label>
    <link:label id="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount_label_en-US" xlink:label="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Dilutive Securities Per Share Amount</link:label>
    <link:label id="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount_documentation_en-US" xlink:label="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Dilutive Securities Per Share Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectOfDilutiveSecuritiesPerShareAmount" xlink:href="thc-20221231.xsd#thc_EffectOfDilutiveSecuritiesPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EffectOfDilutiveSecuritiesPerShareAmount" xlink:to="lab_thc_EffectOfDilutiveSecuritiesPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_625b8b9a-b969-4609-96d8-0e5b482e7f64_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_c6771fe5-a750-43b5-9859-6275e265a0a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination acquisition noncontrolling interest, fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_b52b4ef0-4678-4678-9439-ae14cd0d6210_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_3eb9da79-726a-4895-9719-df596132b329_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities and equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9b0b812e-4163-4fc6-b376-cd35cfad578c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued interest and penalties on unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_842d327b-c056-4e6d-9039-98e8bf35178d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3b3539d6-edb1-43b9-88c7-eae7c4d1089e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_08407dc2-6b05-4365-a32d-28bee7c7fe96_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e13c7a63-7a76-4db3-bd84-1bee4c727b3a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total earnings (loss) per share, Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_07ad60fa-877f-4212-b443-2f5b188059c3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_UrgentCareCentersMember_763551e8-5c51-4eef-a841-b4f7b43c152c_terseLabel_en-US" xlink:label="lab_thc_UrgentCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Urgent Care Centers</link:label>
    <link:label id="lab_thc_UrgentCareCentersMember_label_en-US" xlink:label="lab_thc_UrgentCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Urgent Care Centers [Member]</link:label>
    <link:label id="lab_thc_UrgentCareCentersMember_documentation_en-US" xlink:label="lab_thc_UrgentCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Urgent Care Centers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UrgentCareCentersMember" xlink:href="thc-20221231.xsd#thc_UrgentCareCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_UrgentCareCentersMember" xlink:to="lab_thc_UrgentCareCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_2e235ecb-a081-428c-99cd-bbad72b15b1f_terseLabel_en-US" xlink:label="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare advances and grants received by unconsolidated affiliates, net of recoupment</link:label>
    <link:label id="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_label_en-US" xlink:label="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Grants From Affiliates, Net Of Recoupment</link:label>
    <link:label id="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_documentation_en-US" xlink:label="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Grants From Affiliates, Net Of Recoupment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" xlink:href="thc-20221231.xsd#thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" xlink:to="lab_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_d4d0514b-60eb-4b8b-828a-ebd93ba07005_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvotingCommonStockMember_36e5856d-ea00-407b-bb30-379253d4cdd4_terseLabel_en-US" xlink:label="lab_us-gaap_NonvotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvoting Common Stock</link:label>
    <link:label id="lab_us-gaap_NonvotingCommonStockMember_label_en-US" xlink:label="lab_us-gaap_NonvotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvoting Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvotingCommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvotingCommonStockMember" xlink:to="lab_us-gaap_NonvotingCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40b5a9b2-5d2d-4329-819a-941816104ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_5819e27d-3810-47fd-bf4d-e2b9138eaf6f_terseLabel_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold limit of unused borrowing availability under the revolving credit facility, number of consecutive days</link:label>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_label_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit, Number Of Consecutive Days</link:label>
    <link:label id="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_documentation_en-US" xlink:label="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit, Number Of Consecutive Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" xlink:to="lab_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_0350b888-aeac-48f8-89b1-6fe5cf5ac2bb_negatedTerseLabel_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance due to changes based on expiration or worthlessness of unutilized state net operating loss carryovers</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_label_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Expiration Or Worthlessness Of Unutilized State Net Operating Loss Carryovers</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_documentation_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Expiration Or Worthlessness Of Unutilized State Net Operating Loss Carryovers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" xlink:to="lab_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_c2c2e031-bd8e-4366-ac03-c8bd03b35bc0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_15b9d07b-a599-407c-b39c-bd07eb9d0a49_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent (percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_99d52976-a2b3-4727-926e-e03a84309050_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of subsidiary</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_e053095e-638f-480f-86d9-305497eab989_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_91299b64-0356-4612-82af-e9b329005f72_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a7b493d8-ffb4-40fe-92d8-420e9775c0e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14e766e8-262e-4d1a-a09b-a204fadf9c95_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_3587be20-8e33-499e-b91e-f11eb51ded5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_761669f9-bcd0-46bd-ac5e-70dbe0f87804_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2471d7b4-271e-4009-ada3-0b81c3e745f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_88afa9bd-9cd1-4ecb-90c2-3a7d8d90ca0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_945bf156-a8a5-49a1-9611-a8dc8827e1b0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_15bd811a-6752-4dad-b195-d20571e54c06_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_0074525d-97e7-4eae-a7a2-d141da2c9263_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other impairment charges</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_99f2e6bb-14ad-44e7-a3bf-b47de31fbfa9_terseLabel_en-US" xlink:label="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future recoveries</link:label>
    <link:label id="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_label_en-US" xlink:label="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Recoveries from Accounts Assigned to Conifer</link:label>
    <link:label id="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_documentation_en-US" xlink:label="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents estimated future recoveries from accounts assigned to Conifer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" xlink:href="thc-20221231.xsd#thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" xlink:to="lab_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_bcbd80c2-a54e-493b-98ff-d8e82ece6e8e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bf1c9fba-5f38-4d1a-9d83-568ff2e514ac_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_655042aa-31d3-4c6b-9cc0-1a9ba755cb6c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LeaseLiabilityNoncurrent_e2c03694-edef-4582-a1d8-fcc06a55ffc6_terseLabel_en-US" xlink:label="lab_thc_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_thc_LeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_thc_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_thc_LeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_thc_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityNoncurrent" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LeaseLiabilityNoncurrent" xlink:to="lab_thc_LeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c3ca5630-a237-410d-82bc-05a2c5ff527e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3f23d052-55e5-4d73-ba2f-f03e269daf95_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_b651b600-bb45-4eb1-a1ac-5252552aa25c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized federal and state tax benefits and reserves for interest and penalties, which may decrease in the next 12 months</link:label>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_label_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2326d5b6-17e3-42ff-94f4-bb2776a07e91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_0a630b32-45fb-418e-9e48-6bf6aa3bbfe6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense) related to items of other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_e87ac34f-da4b-4536-8657-330664864ba3_terseLabel_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance due to limitations on deductions of interest expense</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_label_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Due To Interest Expense Limitations</link:label>
    <link:label id="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_documentation_en-US" xlink:label="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Due To Interest Expense Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" xlink:to="lab_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1da74bf4-0587-4ca8-97c0-5ad2561c488c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgeFundsMember_1cf07b14-cdae-475d-bb48-fcf5db0e999c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge funds</link:label>
    <link:label id="lab_us-gaap_HedgeFundsMember_label_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgeFundsMember" xlink:to="lab_us-gaap_HedgeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_5525d985-67f7-4d0e-8c45-ccacc73afd1f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9f9a35d9-1441-4ecb-bc6b-cda2a4094037_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b7746f07-8278-430e-8d71-9f6a34a5aa88_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_aab4daf9-9a27-4e4d-99fc-542b7decf90e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_63c77879-3fb9-4492-9ca0-37a8cec44a47_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual right to receive shares of common stock for a stock based award (in shares)</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Convertible in Number of Shares</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares of common stock into which a share-based award can be converted in the future.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_31864061-7770-4c6c-924b-a64037bad7ad_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_0b545cbb-d57e-4a41-915b-d5a3983f2ff6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Unconsolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRecoveries_9baf4c84-ebed-489d-bf40-0a641cdca97b_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries" xlink:to="lab_us-gaap_InsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_fe233949-9a72-49e7-a777-a6d6e1e1862a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d0ac6f92-7040-4a1c-a2e6-a3038ad4823a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e6f0ea6c-13fc-459d-8666-19980e20318d_terseLabel_en-US" xlink:label="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Deferred Tax Assets and Liabilities and the Corresponding Amounts Reported in the Accompanying Consolidated Balance Sheets</link:label>
    <link:label id="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classification of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label id="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of classification of deferred tax assets and liabilities recognized in the entity's statement of financial position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="thc-20221231.xsd#thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_7c67d9b9-e577-4772-9e2e-585f8979cfdd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options&#160;Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_16429623-246a-4bb9-8dd7-c781b33a1dc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bf27b572-f54a-4164-9bcf-2c5dcd23ad26_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status of plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6d1a5432-1d86-425d-97f7-503ff44f4c5e_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_662468f5-ebcc-4dd4-8c22-8c3e4f807198_terseLabel_en-US" xlink:label="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% due 2026</link:label>
    <link:label id="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_label_en-US" xlink:label="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Eight Seven Five Percent Senior Secured Note, Due 2026 [Member]</link:label>
    <link:label id="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_documentation_en-US" xlink:label="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Eight Seven Five Percent Senior Secured Note, Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" xlink:href="thc-20221231.xsd#thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" xlink:to="lab_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_GuaranteeObligationPeriod_ea82376e-cca0-4a47-8969-524da2ff0ece_terseLabel_en-US" xlink:label="lab_thc_GuaranteeObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee obligation period</link:label>
    <link:label id="lab_thc_GuaranteeObligationPeriod_label_en-US" xlink:label="lab_thc_GuaranteeObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee Obligation, Period</link:label>
    <link:label id="lab_thc_GuaranteeObligationPeriod_documentation_en-US" xlink:label="lab_thc_GuaranteeObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the period of the guarantee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteeObligationPeriod" xlink:href="thc-20221231.xsd#thc_GuaranteeObligationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_GuaranteeObligationPeriod" xlink:to="lab_thc_GuaranteeObligationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_971d06fe-843d-4c63-812d-432347160d35_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sources of Net Operating Revenues Less Provisions for Doubtful Accounts and Implicit Price Concessions</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b88bd84b-d206-444c-9c5d-40176083c542_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, gross, total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7a346ef3-3365-49d2-a59b-3392c85a9a98_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_5f30b220-374e-483f-bab4-714dd4d7367c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_58bd4a18-092e-4605-a54d-b519905949d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_0c5b83a6-c1a5-4b26-b638-cfe1e37b0c23_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0ab0ab9b-d3c7-4d92-9dba-2432c1553b07_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PerformanceBasedVestingMember_b2406d56-1906-49ba-a64e-90aacee995e2_terseLabel_en-US" xlink:label="lab_thc_PerformanceBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based vesting</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingMember_label_en-US" xlink:label="lab_thc_PerformanceBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting [Member]</link:label>
    <link:label id="lab_thc_PerformanceBasedVestingMember_documentation_en-US" xlink:label="lab_thc_PerformanceBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Vesting [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingMember" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PerformanceBasedVestingMember" xlink:to="lab_thc_PerformanceBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_a0995dc7-514d-4c0d-92c0-6daf9957a366_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_5f1bbe05-f6ae-4c14-aa09-d842224b5711_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_FormerEmployeesMember_f7a2a6ef-4108-4a77-b7f9-e195c447ff8b_terseLabel_en-US" xlink:label="lab_thc_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Employees</link:label>
    <link:label id="lab_thc_FormerEmployeesMember_label_en-US" xlink:label="lab_thc_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Employees [Member]</link:label>
    <link:label id="lab_thc_FormerEmployeesMember_documentation_en-US" xlink:label="lab_thc_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the former employees of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FormerEmployeesMember" xlink:href="thc-20221231.xsd#thc_FormerEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_FormerEmployeesMember" xlink:to="lab_thc_FormerEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8f41bda5-d9ed-44c8-82ca-00e38e552287_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive stock options, restricted stock units and deferred compensation units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_9e077304-2c9d-46ae-9417-e6cbcc9723dc_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_dd74302a-dfe4-4c23-a67a-de1761cc0edb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Benefit Costs Assumptions:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_c37453b5-8d7d-42f7-adbc-1550499b9d0a_terseLabel_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Four</link:label>
    <link:label id="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_documentation_en-US" xlink:label="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" xlink:to="lab_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_259c8fc1-94dc-407e-b27d-5c6910af5ff6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f4e900d1-99b6-4437-9fa8-eb186f6f613d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2c886adf-ca2b-4cba-8dc9-5906d3801f2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5acdd9d0-2baa-4d73-b054-9ba4e41cfa10_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_PropertyInsuranceDeductiblePercentage_6bc9ba6d-da41-45f2-a660-c0cf3466f339_verboseLabel_en-US" xlink:label="lab_thc_PropertyInsuranceDeductiblePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance deductible (percentage)</link:label>
    <link:label id="lab_thc_PropertyInsuranceDeductiblePercentage_label_en-US" xlink:label="lab_thc_PropertyInsuranceDeductiblePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Insurance, Deductible, Percentage</link:label>
    <link:label id="lab_thc_PropertyInsuranceDeductiblePercentage_documentation_en-US" xlink:label="lab_thc_PropertyInsuranceDeductiblePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of risk retained by the entity before the insurance arrangement begins to provide coverage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceDeductiblePercentage" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceDeductiblePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_PropertyInsuranceDeductiblePercentage" xlink:to="lab_thc_PropertyInsuranceDeductiblePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_A2021SCDCentersMember_57c900ec-1f89-406e-ad41-41859415e47e_terseLabel_en-US" xlink:label="lab_thc_A2021SCDCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 SCD Centers</link:label>
    <link:label id="lab_thc_A2021SCDCentersMember_label_en-US" xlink:label="lab_thc_A2021SCDCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 SCD Centers [Member]</link:label>
    <link:label id="lab_thc_A2021SCDCentersMember_documentation_en-US" xlink:label="lab_thc_A2021SCDCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 SCD Centers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2021SCDCentersMember" xlink:href="thc-20221231.xsd#thc_A2021SCDCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_A2021SCDCentersMember" xlink:to="lab_thc_A2021SCDCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_7771dcd9-2b97-4b0e-816a-4c3a6a399f07_terseLabel_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected payment for vested securities and termination of plan</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_label_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Payment For Repurchase Of Vested Options And Plan Termination</link:label>
    <link:label id="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_documentation_en-US" xlink:label="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Payment For Repurchase Of Vested Options And Plan Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" xlink:to="lab_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_cefac2b0-b16a-42a7-98f6-6949ccdbffee_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_ea67ea4c-5e83-43f7-b63f-39bcb42194c3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4a35eccb-4fb1-4b62-a8e4-7ed8d2797fa0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_HospitalBuildingsAndMedicalEquipmentMember_b3fef878-3ed7-4efb-9bef-9c8a3cb3c188_terseLabel_en-US" xlink:label="lab_thc_HospitalBuildingsAndMedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Buildings and Medical Equipment</link:label>
    <link:label id="lab_thc_HospitalBuildingsAndMedicalEquipmentMember_label_en-US" xlink:label="lab_thc_HospitalBuildingsAndMedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Buildings and Medical Equipment [Member]</link:label>
    <link:label id="lab_thc_HospitalBuildingsAndMedicalEquipmentMember_documentation_en-US" xlink:label="lab_thc_HospitalBuildingsAndMedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital Buildings and Medical Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalBuildingsAndMedicalEquipmentMember" xlink:href="thc-20221231.xsd#thc_HospitalBuildingsAndMedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_HospitalBuildingsAndMedicalEquipmentMember" xlink:to="lab_thc_HospitalBuildingsAndMedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8781f38d-de93-4180-bbb0-8d29b1fd054c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense at statutory federal rate of 21%</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af6212ff-4762-4dc1-8c91-a7cc7459884b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_IncomeLossFromDivestedAndClosedBusinesses_ee9c405d-1105-4700-8d61-9030b1cd6c7a_terseLabel_en-US" xlink:label="lab_thc_IncomeLossFromDivestedAndClosedBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from divested and closed businesses</link:label>
    <link:label id="lab_thc_IncomeLossFromDivestedAndClosedBusinesses_label_en-US" xlink:label="lab_thc_IncomeLossFromDivestedAndClosedBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Divested And Closed Businesses</link:label>
    <link:label id="lab_thc_IncomeLossFromDivestedAndClosedBusinesses_documentation_en-US" xlink:label="lab_thc_IncomeLossFromDivestedAndClosedBusinesses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents income (loss) from divested or closed businesses, specifically those related to the Company's health plan businesses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeLossFromDivestedAndClosedBusinesses" xlink:href="thc-20221231.xsd#thc_IncomeLossFromDivestedAndClosedBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_IncomeLossFromDivestedAndClosedBusinesses" xlink:to="lab_thc_IncomeLossFromDivestedAndClosedBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_c5cf085b-401e-4011-a73f-7cedc233a300_terseLabel_en-US" xlink:label="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum secured debt covenant ratio</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_label_en-US" xlink:label="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Secured Debt Ratio</link:label>
    <link:label id="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_documentation_en-US" xlink:label="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Secured Debt Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantMaximumSecuredDebtRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" xlink:to="lab_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_01dbb41f-b921-42e7-9679-7d053553d42f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_630797a9-56ef-4898-8d66-7a9dc777aed8_negatedLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_85f68f79-1c27-43e8-868d-bd252b7db6cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_28d72267-69b1-400d-b016-7ba460ed1fe7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_450f4b6e-382e-4982-b27e-118400023f49_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_8c00dc03-13db-48a5-b4d6-d8a437dece9d_terseLabel_en-US" xlink:label="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims_4322e059-9540-4cc6-97f1-7518a6211742_verboseLabel_en-US" xlink:label="lab_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bankruptcy claims, amount paid to settle claims</link:label>
    <link:label id="lab_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims_label_en-US" xlink:label="lab_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bankruptcy Claims, Amount Paid to Settle Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankruptcyClaimsAmountPaidToSettleClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims" xlink:to="lab_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>thc-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5eb22bb-8cdc-4927-ae5c-e13f3ca3c3e1,g:f5e96eef-6bc4-43e3-b34d-7345446e971c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tenethealth.com/role/CoverPage" xlink:type="simple" xlink:href="thc-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_97ce930d-0e6b-4f68-8356-91cf067a2c83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97ce930d-0e6b-4f68-8356-91cf067a2c83" xlink:to="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939fed3d-6f0f-45ff-8b59-4e8d0f0a7b44" xlink:to="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e57aa4f6-d43c-4c5d-851a-8ba29fb732e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:to="loc_us-gaap_CommonStockMember_e57aa4f6-d43c-4c5d-851a-8ba29fb732e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0c9f3b5f-97c1-437d-aa26-25c7edf45212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_56439ad1-2c97-4bd1-a936-4070b43d55cd" xlink:to="loc_us-gaap_SeniorNotesMember_0c9f3b5f-97c1-437d-aa26-25c7edf45212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:to="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_f8a443c9-db12-4849-a8d0-e34e9e2a3870" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_2f5474c7-c6db-4f01-a348-2071d8285f45" xlink:to="loc_dei_ExchangeDomain_f8a443c9-db12-4849-a8d0-e34e9e2a3870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_6ce8205f-f2d1-48dd-914b-89d071b477d7" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_f8a443c9-db12-4849-a8d0-e34e9e2a3870" xlink:to="loc_exch_XNYS_6ce8205f-f2d1-48dd-914b-89d071b477d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_12acc7e6-3ab0-4d21-970b-ab47e8dbc97c" xlink:to="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_48222c14-e26e-488d-9376-5dce4cc49214" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentType_48222c14-e26e-488d-9376-5dce4cc49214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7dfb063a-307b-4bf0-b348-599d1aad709b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentAnnualReport_7dfb063a-307b-4bf0-b348-599d1aad709b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_75e3a9ee-21e5-4f7c-8fd3-9b839008de86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentPeriodEndDate_75e3a9ee-21e5-4f7c-8fd3-9b839008de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2c8fff9b-8d4e-4d4f-b265-2643839baca3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_CurrentFiscalYearEndDate_2c8fff9b-8d4e-4d4f-b265-2643839baca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_240d2dd9-e77e-4a5e-9533-f49f4891f702" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentTransitionReport_240d2dd9-e77e-4a5e-9533-f49f4891f702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_12ffb49a-756d-4f3e-b7c1-6645138dc456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityFileNumber_12ffb49a-756d-4f3e-b7c1-6645138dc456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aeaa21bd-430d-4aa6-860d-95471fbd22c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityRegistrantName_aeaa21bd-430d-4aa6-860d-95471fbd22c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8931b7c4-4486-40e0-931f-ea867ea6e5e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8931b7c4-4486-40e0-931f-ea867ea6e5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_11b07015-edb2-41f9-b0b4-edbc83ede8e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityTaxIdentificationNumber_11b07015-edb2-41f9-b0b4-edbc83ede8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b4eca46a-e3f5-40be-a898-ded0c01e1928" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressAddressLine1_b4eca46a-e3f5-40be-a898-ded0c01e1928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e883a23b-b794-40f1-a357-565925e2aa9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressCityOrTown_e883a23b-b794-40f1-a357-565925e2aa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_883ad68a-8fda-46a9-b809-09f94774ddb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressStateOrProvince_883ad68a-8fda-46a9-b809-09f94774ddb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5a903e20-5a1c-4d07-9b58-85e48b4dd5f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityAddressPostalZipCode_5a903e20-5a1c-4d07-9b58-85e48b4dd5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a33a1313-b0ed-43d0-9a34-7492b1818496" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_CityAreaCode_a33a1313-b0ed-43d0-9a34-7492b1818496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c44977c6-53f5-44be-bcc1-44bd5fc3e1bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_LocalPhoneNumber_c44977c6-53f5-44be-bcc1-44bd5fc3e1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4e4a9434-8d4d-46a0-91fc-474c1315bebf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_Security12bTitle_4e4a9434-8d4d-46a0-91fc-474c1315bebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d43dbdee-66aa-48b5-a77a-d01cf41f7a90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_TradingSymbol_d43dbdee-66aa-48b5-a77a-d01cf41f7a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e8ead6d-1e71-427f-a601-9b9704d81ca2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_SecurityExchangeName_5e8ead6d-1e71-427f-a601-9b9704d81ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bdeb5db1-a806-43ef-91ad-f8eb3bfd98e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bdeb5db1-a806-43ef-91ad-f8eb3bfd98e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a2e60719-16e3-44e4-b8a8-301dad5ceccb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityVoluntaryFilers_a2e60719-16e3-44e4-b8a8-301dad5ceccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_097f5b36-22a0-4462-9c2b-46780acc41c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityCurrentReportingStatus_097f5b36-22a0-4462-9c2b-46780acc41c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7826db75-1b2c-4c1c-b8b1-97fc4ba64c0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityInteractiveDataCurrent_7826db75-1b2c-4c1c-b8b1-97fc4ba64c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b7b61c41-569b-46bb-b975-a62bf7136061" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityFilerCategory_b7b61c41-569b-46bb-b975-a62bf7136061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_96fd80ee-e8d0-4efa-8a7b-c435d6258aef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntitySmallBusiness_96fd80ee-e8d0-4efa-8a7b-c435d6258aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c48d5b7a-4aec-4351-b382-b75e98356577" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityEmergingGrowthCompany_c48d5b7a-4aec-4351-b382-b75e98356577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_7832080e-3918-4771-a047-5c16968e164a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_7832080e-3918-4771-a047-5c16968e164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bc2cc840-bb7d-4a3b-a0a4-3d05d407f7cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityShellCompany_bc2cc840-bb7d-4a3b-a0a4-3d05d407f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_030b5d16-82f3-484a-ab3d-fb4e93a4692f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityPublicFloat_030b5d16-82f3-484a-ab3d-fb4e93a4692f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dc71a592-f6e7-43f4-b5b1-698eefbe5cbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dc71a592-f6e7-43f4-b5b1-698eefbe5cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e164d9db-544f-43ea-8640-05f2d379cbb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e164d9db-544f-43ea-8640-05f2d379cbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_200274f3-58df-43de-a692-378d9de5a9a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_EntityCentralIndexKey_200274f3-58df-43de-a692-378d9de5a9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_74e9ba97-db4e-4e46-abdc-b4a3a32222a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_AmendmentFlag_74e9ba97-db4e-4e46-abdc-b4a3a32222a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e84c836a-414f-4068-a082-4be83cb93278" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentFiscalYearFocus_e84c836a-414f-4068-a082-4be83cb93278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_35f13f65-c55d-478e-90fe-db3ef70c113b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8813b30f-3e4a-4373-bb18-7aa9836e019a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_35f13f65-c55d-478e-90fe-db3ef70c113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/AuditInformation" xlink:type="simple" xlink:href="thc-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_thc_AuditInformationAbstract_5efb57d4-3a07-4893-b485-d38f45c16920" xlink:href="thc-20221231.xsd#thc_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_64bf0d15-f548-4f4e-99ed-bd09dc6541ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AuditInformationAbstract_5efb57d4-3a07-4893-b485-d38f45c16920" xlink:to="loc_dei_AuditorName_64bf0d15-f548-4f4e-99ed-bd09dc6541ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_2c92b825-8fe1-4abb-a07f-142d1e3c2af4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AuditInformationAbstract_5efb57d4-3a07-4893-b485-d38f45c16920" xlink:to="loc_dei_AuditorLocation_2c92b825-8fe1-4abb-a07f-142d1e3c2af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_2c148a5a-8f98-42b8-aede-f92b36835d4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AuditInformationAbstract_5efb57d4-3a07-4893-b485-d38f45c16920" xlink:to="loc_dei_AuditorFirmId_2c148a5a-8f98-42b8-aede-f92b36835d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f81da6d3-4277-4845-b219-a90fb829600f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f81da6d3-4277-4845-b219-a90fb829600f" xlink:to="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ba5042c-254d-4edb-9417-9d3f0094a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ba5042c-254d-4edb-9417-9d3f0094a1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ab4b434c-2927-4d78-ac16-d72565df56b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ab4b434c-2927-4d78-ac16-d72565df56b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4b5c757c-62eb-41e4-8028-d526098a7703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:to="loc_us-gaap_InventoryNet_4b5c757c-62eb-41e4-8028-d526098a7703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_68a886d0-e333-4892-af2c-593b0f25b390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:to="loc_us-gaap_OtherAssetsCurrent_68a886d0-e333-4892-af2c-593b0f25b390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7732a9e7-87e6-426b-a011-1c25a1491874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37e8c0de-0ad6-4cbb-852f-2bc847726dd2" xlink:to="loc_us-gaap_AssetsCurrent_7732a9e7-87e6-426b-a011-1c25a1491874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_756dbbdf-7d38-4f68-91a7-d108943db268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_756dbbdf-7d38-4f68-91a7-d108943db268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_75198f05-e600-406c-a196-cd582d22f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_75198f05-e600-406c-a196-cd582d22f2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_6ad6faed-d7b1-4acd-9c4f-f813f142a82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_6ad6faed-d7b1-4acd-9c4f-f813f142a82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_22a12105-5dbf-4fba-a606-cd8ad8dc0f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_Goodwill_22a12105-5dbf-4fba-a606-cd8ad8dc0f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c2ad5177-63c0-494d-a792-a0bb8826bdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c2ad5177-63c0-494d-a792-a0bb8826bdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2b65c703-89c5-47b7-9739-03bd9a6f4976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65ee7496-3b90-42b2-bbc7-585ee0a43890" xlink:to="loc_us-gaap_Assets_2b65c703-89c5-47b7-9739-03bd9a6f4976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f81da6d3-4277-4845-b219-a90fb829600f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c77cb2cc-4f34-498c-9b62-cad6a981a6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c77cb2cc-4f34-498c-9b62-cad6a981a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3ddfb3bc-d5bd-43f6-a759-33a9126a0991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_AccountsPayableCurrent_3ddfb3bc-d5bd-43f6-a759-33a9126a0991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_adc268a5-9c12-4239-8b38-5642efd9e916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_adc268a5-9c12-4239-8b38-5642efd9e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_ce3395d1-396e-4661-9e9d-9e1518e4cc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_ce3395d1-396e-4661-9e9d-9e1518e4cc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_455454b3-2346-4943-94dd-a3f0898b1b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_InterestPayableCurrent_455454b3-2346-4943-94dd-a3f0898b1b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b4442687-ebcc-424f-b608-9750f3d3bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b4442687-ebcc-424f-b608-9750f3d3bc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_654ee83d-1bb8-4282-8556-7dc7d3daac49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_654ee83d-1bb8-4282-8556-7dc7d3daac49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b2b454ac-6f81-4180-970c-93869b429b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_94ff187f-cc0f-43ac-8fd5-5c5c674c5e76" xlink:to="loc_us-gaap_LiabilitiesCurrent_b2b454ac-6f81-4180-970c-93869b429b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ecd7dcd3-522f-4932-bb33-ff1b4c8d8850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ecd7dcd3-522f-4932-bb33-ff1b4c8d8850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_2ee2db99-b816-44f3-a6fd-f08b540f17b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_2ee2db99-b816-44f3-a6fd-f08b540f17b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_a24f46db-42fa-409c-80b1-926560bf80c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_a24f46db-42fa-409c-80b1-926560bf80c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b0a63619-ea24-4370-b665-eecc3f2a6460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b0a63619-ea24-4370-b665-eecc3f2a6460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_09148f3a-82e2-47a5-ab72-26d921669262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_09148f3a-82e2-47a5-ab72-26d921669262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0bff4a62-8b6d-4a79-9a74-948358676fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0bff4a62-8b6d-4a79-9a74-948358676fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68aac7cc-832e-415f-8799-979cc1772bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_Liabilities_68aac7cc-832e-415f-8799-979cc1772bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1812f120-8bda-42a0-bbb2-1065366fc00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1812f120-8bda-42a0-bbb2-1065366fc00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_e7c00e2e-fe37-40ae-895a-f64d7db68273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_e7c00e2e-fe37-40ae-895a-f64d7db68273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_34957077-9720-4a05-a7b4-d560e49677d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_34957077-9720-4a05-a7b4-d560e49677d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_34957077-9720-4a05-a7b4-d560e49677d4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_12e0382b-14c7-4715-bea0-90df237e1369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:to="loc_us-gaap_CommonStockValue_12e0382b-14c7-4715-bea0-90df237e1369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cbb28f98-7767-4948-8b74-b7b3c9b758b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cbb28f98-7767-4948-8b74-b7b3c9b758b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b2fe8576-37dc-4e4c-821e-6931def715e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b2fe8576-37dc-4e4c-821e-6931def715e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71381f40-a97d-48fb-9291-1f1f36eafa99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71381f40-a97d-48fb-9291-1f1f36eafa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_e7397f72-13ea-4a8e-a13e-ebfb652bc61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:to="loc_us-gaap_TreasuryStockCommonValue_e7397f72-13ea-4a8e-a13e-ebfb652bc61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c5ec86c9-627e-45fd-a2f2-5eba1d4afa82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee5a02ea-b606-459d-9707-4f688f1955f8" xlink:to="loc_us-gaap_StockholdersEquity_c5ec86c9-627e-45fd-a2f2-5eba1d4afa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0e927963-484e-4a6a-b8c8-aa0e1508861c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_34957077-9720-4a05-a7b4-d560e49677d4" xlink:to="loc_us-gaap_MinorityInterest_0e927963-484e-4a6a-b8c8-aa0e1508861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_975f52d3-6030-4389-a6c1-d9918d937f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_34957077-9720-4a05-a7b4-d560e49677d4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_975f52d3-6030-4389-a6c1-d9918d937f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_525ed259-02bd-43e9-a699-71af9675daca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1ace8a57-9ddb-4adf-b808-c003710aa615" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_525ed259-02bd-43e9-a699-71af9675daca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_96e3276f-32f9-4b73-b4e0-417342f37355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_96e3276f-32f9-4b73-b4e0-417342f37355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_772fe906-d165-4155-a9a7-af32f19789dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_772fe906-d165-4155-a9a7-af32f19789dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5164cb71-07ee-4780-a243-e42f742401e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5164cb71-07ee-4780-a243-e42f742401e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2eb8ba96-4934-4869-a428-03b152b74381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2eb8ba96-4934-4869-a428-03b152b74381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8c18a9d8-452e-42a2-af97-df9ca30663dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:to="loc_us-gaap_CommonStockSharesIssued_8c18a9d8-452e-42a2-af97-df9ca30663dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_6b599b48-946e-4372-a032-751cf94fc21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_be87dc2c-0780-4d4d-af80-3c57f4e644a3" xlink:to="loc_us-gaap_TreasuryStockCommonShares_6b599b48-946e-4372-a032-751cf94fc21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_609c1731-1214-4b9e-b261-6a3c2ee5e351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_609c1731-1214-4b9e-b261-6a3c2ee5e351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_7605ca8c-cc88-41ec-b152-d1e6adfe34aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_7605ca8c-cc88-41ec-b152-d1e6adfe34aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8d51ca02-2087-472f-8101-a719f21c6e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8d51ca02-2087-472f-8101-a719f21c6e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_d14fac5c-9a5f-412a-9e81-1c9f230569d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:to="loc_us-gaap_LaborAndRelatedExpense_d14fac5c-9a5f-412a-9e81-1c9f230569d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_507573ac-3b7a-44a7-91dd-5022a67a12dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:to="loc_us-gaap_SuppliesExpense_507573ac-3b7a-44a7-91dd-5022a67a12dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_01e44f9a-6056-4fdf-97bf-b4337f54449f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_01e44f9a-6056-4fdf-97bf-b4337f54449f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9be19a91-5f5d-4269-a74a-b5e0ed8eb228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9be19a91-5f5d-4269-a74a-b5e0ed8eb228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_c1448849-b9f3-4a08-baed-d948a4b75aa6" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_c1448849-b9f3-4a08-baed-d948a4b75aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_be4d16f2-63fc-456a-8939-7350177e407c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_32f8c6ff-148a-410f-ac18-6cb574e81854" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_be4d16f2-63fc-456a-8939-7350177e407c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_27a9c9fa-7831-43a5-abf1-60f56ac9b5a3" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_27a9c9fa-7831-43a5-abf1-60f56ac9b5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_beec1031-e64a-419a-8279-a493cdffc799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_OperatingIncomeLoss_beec1031-e64a-419a-8279-a493cdffc799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_30f29e6d-b265-4e20-b165-34dca57d970c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_InterestExpense_30f29e6d-b265-4e20-b165-34dca57d970c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a8142391-4ee7-4b33-8eec-ee161c256e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a8142391-4ee7-4b33-8eec-ee161c256e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_67f1a167-a54f-499b-83d9-01042870f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_67f1a167-a54f-499b-83d9-01042870f52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7398fb12-351a-4e7e-914e-178308a68017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7398fb12-351a-4e7e-914e-178308a68017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_993ac0b7-9465-4bdc-acc0-d8516cf4d656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_993ac0b7-9465-4bdc-acc0-d8516cf4d656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9585aeee-74be-42c0-bba7-fb9cd764c5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9585aeee-74be-42c0-bba7-fb9cd764c5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_24f4165f-d9d1-4e94-8f2b-2707be8ffa86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_24f4165f-d9d1-4e94-8f2b-2707be8ffa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_b73f538a-d623-46f3-b753-fe8c4c66ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_24f4165f-d9d1-4e94-8f2b-2707be8ffa86" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_b73f538a-d623-46f3-b753-fe8c4c66ad74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f8b1544c-51bf-4e21-8f43-3307370525ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_24f4165f-d9d1-4e94-8f2b-2707be8ffa86" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f8b1544c-51bf-4e21-8f43-3307370525ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a152b6f-a4ef-44e4-a6e6-2b897bd7936c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_ProfitLoss_6a152b6f-a4ef-44e4-a6e6-2b897bd7936c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0ecfb7b8-c849-4a2d-90cc-fc1e2d10c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0ecfb7b8-c849-4a2d-90cc-fc1e2d10c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a768ad7e-932d-4ccc-b2d1-3fa2f7600114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a768ad7e-932d-4ccc-b2d1-3fa2f7600114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_0ff4cbd8-31b6-4e07-98e1-ff1d20f8ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_0ff4cbd8-31b6-4e07-98e1-ff1d20f8ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_b94b3171-7e82-490e-ad77-a827f68661f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_0ff4cbd8-31b6-4e07-98e1-ff1d20f8ede5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_b94b3171-7e82-490e-ad77-a827f68661f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0be28457-b28c-466e-a2d0-33ed487eb780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_0ff4cbd8-31b6-4e07-98e1-ff1d20f8ede5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0be28457-b28c-466e-a2d0-33ed487eb780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a49a1e0d-768e-4b8f-9ac0-185e614f3cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_0ff4cbd8-31b6-4e07-98e1-ff1d20f8ede5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a49a1e0d-768e-4b8f-9ac0-185e614f3cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_393e8e8f-7947-46d5-afdf-c49be049510b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_393e8e8f-7947-46d5-afdf-c49be049510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_49a8f9c3-abbb-43b8-ad13-cb7ba769d5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393e8e8f-7947-46d5-afdf-c49be049510b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_49a8f9c3-abbb-43b8-ad13-cb7ba769d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1369ad2e-7d53-42be-b88e-f432dcb71344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_49a8f9c3-abbb-43b8-ad13-cb7ba769d5d6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1369ad2e-7d53-42be-b88e-f432dcb71344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c087dbff-5f4d-4510-a4a4-26b12bbd2eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_49a8f9c3-abbb-43b8-ad13-cb7ba769d5d6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c087dbff-5f4d-4510-a4a4-26b12bbd2eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b9e6383b-15d8-4b4a-a6f9-e5e97c81da9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_49a8f9c3-abbb-43b8-ad13-cb7ba769d5d6" xlink:to="loc_us-gaap_EarningsPerShareBasic_b9e6383b-15d8-4b4a-a6f9-e5e97c81da9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_23adec2d-b472-4545-a84c-0d66775290ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393e8e8f-7947-46d5-afdf-c49be049510b" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_23adec2d-b472-4545-a84c-0d66775290ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ed1dc5c8-bcb5-4ce9-9f88-d5e8b6972bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_23adec2d-b472-4545-a84c-0d66775290ed" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ed1dc5c8-bcb5-4ce9-9f88-d5e8b6972bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_132b5d09-7a6e-49de-a835-7e4766b6b24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_23adec2d-b472-4545-a84c-0d66775290ed" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_132b5d09-7a6e-49de-a835-7e4766b6b24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_757bfa8d-633e-4c0d-aea0-7bba7bb5234f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_23adec2d-b472-4545-a84c-0d66775290ed" xlink:to="loc_us-gaap_EarningsPerShareDiluted_757bfa8d-633e-4c0d-aea0-7bba7bb5234f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0aa76dc5-8c1d-4117-9c58-7da7c45533d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53718369-5043-41dd-bc59-48345e2e4bd1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0aa76dc5-8c1d-4117-9c58-7da7c45533d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3360a0f0-039b-482c-9754-60de7f9671a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0aa76dc5-8c1d-4117-9c58-7da7c45533d4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3360a0f0-039b-482c-9754-60de7f9671a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9352f10e-1ad1-42ff-b993-f25ecb601fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0aa76dc5-8c1d-4117-9c58-7da7c45533d4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9352f10e-1ad1-42ff-b993-f25ecb601fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS_1"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a8c3ad9f-f110-48c1-b870-5b5dc988c680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_ProfitLoss_a8c3ad9f-f110-48c1-b870-5b5dc988c680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_45bde141-cef9-42cf-8637-1ce0cf28c02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_45bde141-cef9-42cf-8637-1ce0cf28c02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_3f6b6027-613d-420c-b1e4-582f33e2442f" xlink:href="thc-20221231.xsd#thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:to="loc_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax_3f6b6027-613d-420c-b1e4-582f33e2442f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_0b5e278a-057e-4a70-b6eb-c6039216dbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_0b5e278a-057e-4a70-b6eb-c6039216dbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_752ec587-975e-4ce4-849c-eb51224aedf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_752ec587-975e-4ce4-849c-eb51224aedf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_40822834-14b9-430f-9d32-16cf2ff71b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_8582585d-750a-457e-8c6b-77801d0709c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_40822834-14b9-430f-9d32-16cf2ff71b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_75227baf-a1cc-479a-98e0-bacff03a5402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_75227baf-a1cc-479a-98e0-bacff03a5402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3449a191-b463-43bf-beca-d29df2984595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3449a191-b463-43bf-beca-d29df2984595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5c7b84c4-c8b5-4bd8-85c1-e1c4194669cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5c7b84c4-c8b5-4bd8-85c1-e1c4194669cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8365b9fc-9511-4eb2-805b-c5b4b7e574fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8365b9fc-9511-4eb2-805b-c5b4b7e574fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8a94df4-c540-4704-a49b-965305a70530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4b2ccb6-0395-42b0-a3e6-f07c549a64f0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8a94df4-c540-4704-a49b-965305a70530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ec099b75-6ee8-4fa4-806a-beab1a8d995f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ec099b75-6ee8-4fa4-806a-beab1a8d995f" xlink:to="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_181f012c-fe46-4f60-b829-438a90dd8a30" xlink:to="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95f1b25e-3d6c-4788-a4a8-adaa64e61e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_CommonStockMember_95f1b25e-3d6c-4788-a4a8-adaa64e61e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c835fdf8-73a7-461a-9726-a4c0ef848ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c835fdf8-73a7-461a-9726-a4c0ef848ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89962624-af91-478d-a840-4a51142a78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89962624-af91-478d-a840-4a51142a78c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d73827ee-fa0d-43a6-bcdd-6bedba488aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_RetainedEarningsMember_d73827ee-fa0d-43a6-bcdd-6bedba488aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_bfd25d76-0a5d-47d4-aff2-cfbaa00bbf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_TreasuryStockCommonMember_bfd25d76-0a5d-47d4-aff2-cfbaa00bbf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f7645b0a-5565-44fb-92d5-565fe58a3e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0dfc0a1b-e673-4f26-9215-d12ea272e316" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f7645b0a-5565-44fb-92d5-565fe58a3e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4dd1af8-94e1-40cc-9518-36d4da84389a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36d702a4-7017-4d7f-93cd-2d7c7d108f29" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4dd1af8-94e1-40cc-9518-36d4da84389a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_24887111-7fc3-42ce-b212-2ad33ef9182e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4dd1af8-94e1-40cc-9518-36d4da84389a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_24887111-7fc3-42ce-b212-2ad33ef9182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6df73be1-28f6-44e3-8ccc-994584984b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ea41768d-b944-4153-8fea-1a9d5aacdf19" xlink:to="loc_us-gaap_StatementLineItems_6df73be1-28f6-44e3-8ccc-994584984b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6df73be1-28f6-44e3-8ccc-994584984b1c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3a656702-f094-4e92-9150-4abec5cb277d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3a656702-f094-4e92-9150-4abec5cb277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e056628-6542-47a7-943e-4f9fe795a32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e056628-6542-47a7-943e-4f9fe795a32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_66b2a37a-6ada-4856-9ce8-229e41eedc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_66b2a37a-6ada-4856-9ce8-229e41eedc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_dc33c66d-bbe4-41c3-b41a-5f33aa6733cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_dc33c66d-bbe4-41c3-b41a-5f33aa6733cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dfc4912a-e16d-4b80-b563-fb8556e156a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dfc4912a-e16d-4b80-b563-fb8556e156a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_7d41f641-073f-4bca-b3e7-323e8e255e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_7d41f641-073f-4bca-b3e7-323e8e255e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_0289902d-9ff2-422b-ab4e-d675f1dafa69" xlink:href="thc-20221231.xsd#thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest_0289902d-9ff2-422b-ab4e-d675f1dafa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f3a02b90-a7d1-48d9-b05d-31cc030be9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f3a02b90-a7d1-48d9-b05d-31cc030be9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d94599f3-4c01-481c-9ca6-23b29073a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d94599f3-4c01-481c-9ca6-23b29073a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5fa265fd-9002-4764-80f0-8c58e768b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5fa265fd-9002-4764-80f0-8c58e768b4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_c2c57aae-f5d8-4835-9c58-2cd4ef5ca2b8" xlink:href="thc-20221231.xsd#thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture_c2c57aae-f5d8-4835-9c58-2cd4ef5ca2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4adf2e8a-6a05-4381-b7a7-7c6fdca56093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4adf2e8a-6a05-4381-b7a7-7c6fdca56093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40c9904-0d07-40b7-8bf9-edd4f8ef0a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ca6775fd-33dd-4e82-9074-9ccf46e33b59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40c9904-0d07-40b7-8bf9-edd4f8ef0a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="thc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f8fe5664-7a27-42f2-ac7a-760b087ac171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_ProfitLoss_f8fe5664-7a27-42f2-ac7a-760b087ac171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3eb00b19-8f2b-4de0-9dcb-f705d75498d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3eb00b19-8f2b-4de0-9dcb-f705d75498d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f26c2d07-d558-4208-b348-59b9b9b61e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f26c2d07-d558-4208-b348-59b9b9b61e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_29ba1e92-c3e1-4d19-be27-2ded4d622b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_ShareBasedCompensation_29ba1e92-c3e1-4d19-be27-2ded4d622b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_77c8d2e6-d68a-4e8e-86d2-feb6595a8d24" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_77c8d2e6-d68a-4e8e-86d2-feb6595a8d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_16f9d4a8-f8ae-47a0-a20b-550bd74a90e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_16f9d4a8-f8ae-47a0-a20b-550bd74a90e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_bf3205ba-ffbe-409b-a2e3-98b7a477b28c" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_bf3205ba-ffbe-409b-a2e3-98b7a477b28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3559efbe-4c1d-4a93-a416-0553ec48626a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3559efbe-4c1d-4a93-a416-0553ec48626a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_60fa4a63-1d7e-4ffa-8137-9f83f9f0b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_60fa4a63-1d7e-4ffa-8137-9f83f9f0b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8e821e7c-632e-4e63-9d96-2a6440ccd3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8e821e7c-632e-4e63-9d96-2a6440ccd3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9d24f3f8-38c8-4db6-a069-890ac76ee962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9d24f3f8-38c8-4db6-a069-890ac76ee962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_93e2fc21-459d-404f-acf3-9168b3624035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_93e2fc21-459d-404f-acf3-9168b3624035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ad6c8401-f86b-423a-8e7f-c917a25cce7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ad6c8401-f86b-423a-8e7f-c917a25cce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c34d9a87-336e-420d-9480-6857a90ee792" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe05bfaf-5671-42fa-92c7-8753798ebc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe05bfaf-5671-42fa-92c7-8753798ebc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_67283c06-80b9-491d-9cb3-ca908356f400" xlink:href="thc-20221231.xsd#thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:to="loc_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent_67283c06-80b9-491d-9cb3-ca908356f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_608ecc75-8daa-41ec-a477-a51a6390f4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_608ecc75-8daa-41ec-a477-a51a6390f4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50b5522b-efa2-4cc4-b329-15728259b092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50b5522b-efa2-4cc4-b329-15728259b092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0d9a5e96-ea92-4ff6-9d08-73c4cd07306e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa49a73d-e373-484f-95dd-e501f6089f3d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0d9a5e96-ea92-4ff6-9d08-73c4cd07306e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PaymentsForRestructuringAndLitigationCosts_f533c790-dd1e-4a7b-a82b-2adc45937d03" xlink:href="thc-20221231.xsd#thc_PaymentsForRestructuringAndLitigationCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_thc_PaymentsForRestructuringAndLitigationCosts_f533c790-dd1e-4a7b-a82b-2adc45937d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_3d6f6938-9027-4315-91e9-901e1eacb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_3d6f6938-9027-4315-91e9-901e1eacb6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4df867dc-7268-408f-b555-3fa1c15bf447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4df867dc-7268-408f-b555-3fa1c15bf447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3db9fc9-4729-4380-96e6-e05e7ca72f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3db9fc9-4729-4380-96e6-e05e7ca72f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_577345ef-526d-4eb0-9616-f54f510b6b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_577345ef-526d-4eb0-9616-f54f510b6b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_a09e0d9a-7ab9-47c9-8090-f65402ccd985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_a09e0d9a-7ab9-47c9-8090-f65402ccd985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_fd4ddcdb-0a1a-4647-88cd-616fdda6f723" xlink:href="thc-20221231.xsd#thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets_fd4ddcdb-0a1a-4647-88cd-616fdda6f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_867a6d4a-f474-45d0-83ec-8e3a88f4cffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_867a6d4a-f474-45d0-83ec-8e3a88f4cffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_188636cd-d17f-47eb-a3fa-f9a4b058a642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_188636cd-d17f-47eb-a3fa-f9a4b058a642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_526dc13b-5a19-45e3-956f-b0248320ee73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22b95652-5816-49f8-a6ee-95aae5fdf26d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_526dc13b-5a19-45e3-956f-b0248320ee73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_83a66332-3752-48c0-8f8c-90473f5998b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_83a66332-3752-48c0-8f8c-90473f5998b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_871f9fca-fd1d-4e8d-b72d-68a0d413923e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_871f9fca-fd1d-4e8d-b72d-68a0d413923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_f915609d-9d3d-49f0-b80a-2b4a1476bd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_f915609d-9d3d-49f0-b80a-2b4a1476bd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_9de66361-e2eb-4ea5-b041-4076406d26f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_9de66361-e2eb-4ea5-b041-4076406d26f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f972a8d-a54a-448b-9803-00cae4b7a898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f972a8d-a54a-448b-9803-00cae4b7a898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_86b1c7b5-9b3c-44d5-a3db-3f53b0cfb722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_86b1c7b5-9b3c-44d5-a3db-3f53b0cfb722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_eec8eb31-e91c-45c3-aadf-ec8f2b48d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_eec8eb31-e91c-45c3-aadf-ec8f2b48d59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_3c28e683-21b8-4be5-b504-96dd5252050a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_3c28e683-21b8-4be5-b504-96dd5252050a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e5fd67a1-cc03-4a7f-96ad-6828bd71a2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e5fd67a1-cc03-4a7f-96ad-6828bd71a2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_6a97d9ad-074a-4b84-85d0-ab57b950499f" xlink:href="thc-20221231.xsd#thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment_6a97d9ad-074a-4b84-85d0-ab57b950499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8c34f70b-5f22-4ba5-ac6d-84519cb01c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8c34f70b-5f22-4ba5-ac6d-84519cb01c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a128d2b-8a12-4fda-8437-13ab1b3dfcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2df6874b-d960-4967-8cee-7a9715e7e894" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a128d2b-8a12-4fda-8437-13ab1b3dfcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_930f567e-c28d-4ee5-b1a6-e9776437978a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_930f567e-c28d-4ee5-b1a6-e9776437978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_604cf67a-f824-4e73-bd34-17fb847ca427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_604cf67a-f824-4e73-bd34-17fb847ca427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4537ac32-459a-4c16-a246-84a6c987beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4537ac32-459a-4c16-a246-84a6c987beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_180b0473-a41d-41f4-8c64-04744e3f6605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f098d678-3e92-4101-aaa7-86f6f27d8e86" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_180b0473-a41d-41f4-8c64-04744e3f6605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f25d4d7b-81bc-40f5-ae22-ae5381df97ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_180b0473-a41d-41f4-8c64-04744e3f6605" xlink:to="loc_us-gaap_InterestPaidNet_f25d4d7b-81bc-40f5-ae22-ae5381df97ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_545b49c4-3cb3-4cc9-8dc2-dc0accfaadd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_180b0473-a41d-41f4-8c64-04744e3f6605" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_545b49c4-3cb3-4cc9-8dc2-dc0accfaadd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ebaa5be1-3507-465e-b1f1-5cf082310264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_91a37e3b-2300-413f-96c5-59ee410951df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ebaa5be1-3507-465e-b1f1-5cf082310264" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_91a37e3b-2300-413f-96c5-59ee410951df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EQUITY" xlink:type="simple" xlink:href="thc-20221231.xsd#EQUITY"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_09272361-657b-4842-a8e6-a84eec430b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d20c2987-e9e6-4c56-8f4e-25fce2f83d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_09272361-657b-4842-a8e6-a84eec430b79" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d20c2987-e9e6-4c56-8f4e-25fce2f83d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLE"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_e4866ff8-9ed3-4073-932b-18605a841f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock_b2f095c4-3aa5-49a6-9507-9ff6350f5b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_e4866ff8-9ed3-4073-932b-18605a841f0c" xlink:to="loc_us-gaap_FinancingReceivablesTextBlock_b2f095c4-3aa5-49a6-9507-9ff6350f5b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCES" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c8633d16-eae2-4b91-81d2-5e9b4616817f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4cfc32f4-11e6-40bd-82bc-f341d0f6a792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c8633d16-eae2-4b91-81d2-5e9b4616817f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4cfc32f4-11e6-40bd-82bc-f341d0f6a792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE" xlink:type="simple" xlink:href="thc-20221231.xsd#ASSETSANDLIABILITIESHELDFORSALE"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6b55d8ac-f0b5-4575-b745-d1cbcb78e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7dbe68df-4fd8-438c-a868-95018aab376e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6b55d8ac-f0b5-4575-b745-d1cbcb78e02e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7dbe68df-4fd8-438c-a868-95018aab376e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS" xlink:type="simple" xlink:href="thc-20221231.xsd#IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_b255f2a3-8759-4b15-a58e-2fc48169d590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_47aa7ce3-b138-4d46-bf96-7ece578d2813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_b255f2a3-8759-4b15-a58e-2fc48169d590" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_47aa7ce3-b138-4d46-bf96-7ece578d2813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASES" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5b2bd602-5560-4587-bebc-03ac944e7eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_6e909ccd-e9ba-4ece-b678-f0e49f7b83e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5b2bd602-5560-4587-bebc-03ac944e7eaa" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_6e909ccd-e9ba-4ece-b678-f0e49f7b83e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b746e24b-165e-45ae-bb82-9b532357d97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5b2bd602-5560-4587-bebc-03ac944e7eaa" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b746e24b-165e-45ae-bb82-9b532357d97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBT" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBT"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_fc32d150-28e0-405f-b017-2e7565e48f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3d30a9e7-05ad-4feb-a222-4405d0a83100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_fc32d150-28e0-405f-b017-2e7565e48f31" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3d30a9e7-05ad-4feb-a222-4405d0a83100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GUARANTEES" xlink:type="simple" xlink:href="thc-20221231.xsd#GUARANTEES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GUARANTEES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract_551e5565-b7f0-4bd8-8c27-ca3f7d3c4ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesTextBlock_1de88d7b-2023-4add-a16f-2d08bfc39846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_551e5565-b7f0-4bd8-8c27-ca3f7d3c4ea5" xlink:to="loc_us-gaap_GuaranteesTextBlock_1de88d7b-2023-4add-a16f-2d08bfc39846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9daef8f2-f52e-4102-92ac-a1d34e2abd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e926919a-6646-4210-8ee3-cbf8be9f0a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9daef8f2-f52e-4102-92ac-a1d34e2abd12" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e926919a-6646-4210-8ee3-cbf8be9f0a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_eb817f32-a007-475f-acea-b001647cad47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="thc-20221231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34782627-da36-4c5c-9c64-c48e801284fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7ccfb0cc-4a31-47cc-82ef-f34da46d6cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34782627-da36-4c5c-9c64-c48e801284fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7ccfb0cc-4a31-47cc-82ef-f34da46d6cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d157beed-7bf1-4cf2-96f0-b0b1f7d175cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4b61e437-e5d4-4c50-b51a-5deb5f5e7b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d157beed-7bf1-4cf2-96f0-b0b1f7d175cd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4b61e437-e5d4-4c50-b51a-5deb5f5e7b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETS" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/OTHERASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_65fa2224-46d0-45df-bdd5-726e7ca98b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_6349bca3-7cf8-49d1-9ba8-e94f8b2ec6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_65fa2224-46d0-45df-bdd5-726e7ca98b79" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_6349bca3-7cf8-49d1-9ba8-e94f8b2ec6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_213a0c30-17bd-4744-a71e-247ecccfa62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_c4bcc9a8-0bf2-4cca-bca0-39fd273d3abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_213a0c30-17bd-4744-a71e-247ecccfa62e" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_c4bcc9a8-0bf2-4cca-bca0-39fd273d3abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUES" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4912413a-ca07-4636-bfbe-e153ece4109d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7cc07682-e7a9-4d3c-9d72-7c4a1679466d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4912413a-ca07-4636-bfbe-e153ece4109d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7cc07682-e7a9-4d3c-9d72-7c4a1679466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INSURANCE" xlink:type="simple" xlink:href="thc-20221231.xsd#INSURANCE"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INSURANCE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_3a5fac84-1eb6-41c1-b5e9-b86ab4790bc7" xlink:href="thc-20221231.xsd#thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock_fc8af6ea-434b-48d8-aa16-4a2b6f49d5f5" xlink:href="thc-20221231.xsd#thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_3a5fac84-1eb6-41c1-b5e9-b86ab4790bc7" xlink:to="loc_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock_fc8af6ea-434b-48d8-aa16-4a2b6f49d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITS" xlink:type="simple" xlink:href="thc-20221231.xsd#CLAIMSANDLAWSUITS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CLAIMSANDLAWSUITS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6afffadb-8959-45c2-9fdd-9be787ece976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f90d0528-dffd-4322-9d4f-7189437b425b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6afffadb-8959-45c2-9fdd-9be787ece976" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f90d0528-dffd-4322-9d4f-7189437b425b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_c1d07c3a-f326-4699-b62e-1d8ea7a9abfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_39eee8d9-4572-456c-b986-b8752f715820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c1d07c3a-f326-4699-b62e-1d8ea7a9abfc" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_39eee8d9-4572-456c-b986-b8752f715820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b032388-c9d9-4d0a-843c-e6b56303b961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_41a4b6d5-84dd-4f53-9d81-61f8ae76f9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b032388-c9d9-4d0a-843c-e6b56303b961" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_41a4b6d5-84dd-4f53-9d81-61f8ae76f9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE" xlink:type="simple" xlink:href="thc-20221231.xsd#EARNINGSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88f40831-4371-4400-b2a6-15b177618abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0791d189-bb97-4679-a21d-4c3c7691593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88f40831-4371-4400-b2a6-15b177618abe" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0791d189-bb97-4679-a21d-4c3c7691593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="thc-20221231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9fc94d70-a870-43d2-9678-bb8e01deea7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ef4763f4-4241-4298-be0d-331ef836318b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9fc94d70-a870-43d2-9678-bb8e01deea7d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ef4763f4-4241-4298-be0d-331ef836318b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a736ff9e-eedc-4b42-b2b7-4c66f830c815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d67bae5b-d6e9-4c24-81ef-996c07f6740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a736ff9e-eedc-4b42-b2b7-4c66f830c815" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d67bae5b-d6e9-4c24-81ef-996c07f6740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cc703bf0-eb64-4cf7-813c-92abf9f552d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5d01bba8-d1b9-4b5a-a67a-aa6989c754c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cc703bf0-eb64-4cf7-813c-92abf9f552d8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5d01bba8-d1b9-4b5a-a67a-aa6989c754c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/RECENTACCOUNTINGSTANDARDS" xlink:type="simple" xlink:href="thc-20221231.xsd#RECENTACCOUNTINGSTANDARDS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/RECENTACCOUNTINGSTANDARDS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_1bf4bbfb-d3c1-4034-b014-fcdb1a4fcf44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5fdc5a46-0214-4be1-8b01-d9339e8730cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_1bf4bbfb-d3c1-4034-b014-fcdb1a4fcf44" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5fdc5a46-0214-4be1-8b01-d9339e8730cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="thc-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_a51f3a38-b992-493c-a878-44921fa9ee06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_da44ab9f-714d-4d39-895f-866106e3f9d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_a51f3a38-b992-493c-a878-44921fa9ee06" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_da44ab9f-714d-4d39-895f-866106e3f9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6899ab6a-57d2-4dd4-9a92-57081ea7ef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6899ab6a-57d2-4dd4-9a92-57081ea7ef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7d6d7515-ec5a-463b-9bd0-431930be6e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_UseOfEstimates_7d6d7515-ec5a-463b-9bd0-431930be6e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_76c3fb7b-6903-427d-a9de-f3ea3a12df2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_76c3fb7b-6903-427d-a9de-f3ea3a12df2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c92d1296-cadb-4549-b29f-371a1afdcc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c92d1296-cadb-4549-b29f-371a1afdcc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9e95084d-bef9-4ff2-bfdf-19de520eb1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9e95084d-bef9-4ff2-bfdf-19de520eb1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7f9ddfe8-b5e3-4469-b5a8-ed3bad18165f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7f9ddfe8-b5e3-4469-b5a8-ed3bad18165f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_fec039a6-5292-455b-90ba-672aee52423e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_fec039a6-5292-455b-90ba-672aee52423e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a57865a8-c3ca-4bdb-9e49-7127024a0b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a57865a8-c3ca-4bdb-9e49-7127024a0b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_96207eb6-ce3e-4867-b8a6-e5d26b1f9077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_96207eb6-ce3e-4867-b8a6-e5d26b1f9077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9a4b58a0-95ae-43e1-bb3a-e3bd0f890757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9a4b58a0-95ae-43e1-bb3a-e3bd0f890757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_485934c5-31f8-44e7-a24f-72e38f75ad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_485934c5-31f8-44e7-a24f-72e38f75ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_13a584cb-9a53-437e-bc12-d39ec3fc1d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_13a584cb-9a53-437e-bc12-d39ec3fc1d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d3ec2dfb-b690-4672-90de-5630ea9d0cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d3ec2dfb-b690-4672-90de-5630ea9d0cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_2113c095-b02f-4d41-bf85-281c94e87118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_2113c095-b02f-4d41-bf85-281c94e87118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3e8432b6-eebe-4635-9963-e378306680dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3ba5ec4-2833-48c2-87db-f2f71c0403a6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3e8432b6-eebe-4635-9963-e378306680dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8d286e22-f41a-49a3-a450-8876ff367aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfGrantFundsTableTextBlock_bb76031e-06c8-4d49-9348-f836dfc3c773" xlink:href="thc-20221231.xsd#thc_ScheduleOfGrantFundsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8d286e22-f41a-49a3-a450-8876ff367aa0" xlink:to="loc_thc_ScheduleOfGrantFundsTableTextBlock_bb76031e-06c8-4d49-9348-f836dfc3c773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_5f989d8a-d7ec-4839-acfc-f6b0b4b4054b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8d286e22-f41a-49a3-a450-8876ff367aa0" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_5f989d8a-d7ec-4839-acfc-f6b0b4b4054b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EQUITYTables" xlink:type="simple" xlink:href="thc-20221231.xsd#EQUITYTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ceb8c687-b6ef-4949-a609-75964ca641bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_87801801-0279-4430-bccd-57ceacb4a180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ceb8c687-b6ef-4949-a609-75964ca641bb" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_87801801-0279-4430-bccd-57ceacb4a180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLETables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_bfa87eb1-2b7b-44f4-9cda-6de3b594af92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4702bc50-a1b9-472c-9699-e1e1d72eee81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_bfa87eb1-2b7b-44f4-9cda-6de3b594af92" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4702bc50-a1b9-472c-9699-e1e1d72eee81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_c2852f6c-4d75-4d67-8425-f6d409e58023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_bfa87eb1-2b7b-44f4-9cda-6de3b594af92" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_c2852f6c-4d75-4d67-8425-f6d409e58023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock_661544e4-bb78-47c3-8ae4-eef8231022ac" xlink:href="thc-20221231.xsd#thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_bfa87eb1-2b7b-44f4-9cda-6de3b594af92" xlink:to="loc_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock_661544e4-bb78-47c3-8ae4-eef8231022ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESTables" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCESTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c2c7640-bcff-4ead-afbb-f62758883772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9249ffb7-753d-46f4-91b1-21459c5ed681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c2c7640-bcff-4ead-afbb-f62758883772" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9249ffb7-753d-46f4-91b1-21459c5ed681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALETables" xlink:type="simple" xlink:href="thc-20221231.xsd#ASSETSANDLIABILITIESHELDFORSALETables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f8434c82-cc02-42f2-a6a4-3bc25d8282ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6109aaaa-5714-42b6-911f-0aff8a99ba25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f8434c82-cc02-42f2-a6a4-3bc25d8282ec" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6109aaaa-5714-42b6-911f-0aff8a99ba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESTables" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36f02453-affd-47e4-a768-0bd970b10c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AssetsAndLiabilitiesLesseeTableTextBlock_f087e445-eb82-415c-b292-5eabc45d88b4" xlink:href="thc-20221231.xsd#thc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36f02453-affd-47e4-a768-0bd970b10c58" xlink:to="loc_thc_AssetsAndLiabilitiesLesseeTableTextBlock_f087e445-eb82-415c-b292-5eabc45d88b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_af19f4d3-8d38-4c16-b36d-724af7a78e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36f02453-affd-47e4-a768-0bd970b10c58" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_af19f4d3-8d38-4c16-b36d-724af7a78e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_cd46160a-83f2-4bc2-a28a-ffd6bdebdccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36f02453-affd-47e4-a768-0bd970b10c58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_cd46160a-83f2-4bc2-a28a-ffd6bdebdccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_c930fa44-5028-43fc-b578-d5b4ee94948a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36f02453-affd-47e4-a768-0bd970b10c58" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_c930fa44-5028-43fc-b578-d5b4ee94948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTTables" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_d230d19d-f6db-4257-a6dc-cadb5075bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7c88a908-d661-4f72-a19d-70a3fbea445f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_d230d19d-f6db-4257-a6dc-cadb5075bc67" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7c88a908-d661-4f72-a19d-70a3fbea445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_b67b66c4-f0ed-46c3-b947-2252efd522d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_d230d19d-f6db-4257-a6dc-cadb5075bc67" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_b67b66c4-f0ed-46c3-b947-2252efd522d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d86dad8b-027b-4d5a-a33a-1d501c975b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d86dad8b-027b-4d5a-a33a-1d501c975b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_58ecfacc-e42c-4b6a-a819-05f54c2f99e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_58ecfacc-e42c-4b6a-a819-05f54c2f99e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bc2c0668-131e-4615-82a0-f725430f4718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bc2c0668-131e-4615-82a0-f725430f4718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_dedf07c4-c2ea-4b2a-81e9-93578c7ceba0" xlink:href="thc-20221231.xsd#thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_dedf07c4-c2ea-4b2a-81e9-93578c7ceba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_ef76fcbb-7e36-4616-bc82-eed778ffe3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_ef76fcbb-7e36-4616-bc82-eed778ffe3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock_aeb2d897-f0d3-49b6-af05-0b6725ea38f1" xlink:href="thc-20221231.xsd#thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock_aeb2d897-f0d3-49b6-af05-0b6725ea38f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_7fc91522-a10e-42fd-bbcd-b5833d4c82dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_7fc91522-a10e-42fd-bbcd-b5833d4c82dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_ec3f1426-95e1-476b-a849-513356224bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_ec3f1426-95e1-476b-a849-513356224bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock_8af583c9-99ca-480d-a88a-a70e780f47ad" xlink:href="thc-20221231.xsd#thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock_8af583c9-99ca-480d-a88a-a70e780f47ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_68f6acea-a175-4c10-b919-c6920f8914d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d9fe27-6527-4ec4-9162-cc8ab5a961f1" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_68f6acea-a175-4c10-b919-c6920f8914d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="thc-20221231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1a9fd34-7b91-459b-9ef0-609ab223a1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3aea0ec1-6d46-4b7e-9d11-b25a037102af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1a9fd34-7b91-459b-9ef0-609ab223a1c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3aea0ec1-6d46-4b7e-9d11-b25a037102af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f777df8e-e266-425f-9e54-3d1335f21d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b3f1fd8f-d8be-4566-9170-092c5b252032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f777df8e-e266-425f-9e54-3d1335f21d7c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b3f1fd8f-d8be-4566-9170-092c5b252032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_57d803b5-b528-4e92-b3dd-759792c8df56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f777df8e-e266-425f-9e54-3d1335f21d7c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_57d803b5-b528-4e92-b3dd-759792c8df56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_224808c0-53ad-47f0-8d51-8fff3342a6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f777df8e-e266-425f-9e54-3d1335f21d7c" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_224808c0-53ad-47f0-8d51-8fff3342a6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETSTables" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETSTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/OTHERASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9773a42f-ae78-4809-860f-5e9048226521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_25dfca21-1235-4a4d-b40e-8293d409c611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9773a42f-ae78-4809-860f-5e9048226521" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_25dfca21-1235-4a4d-b40e-8293d409c611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock_f9a00cc2-b2e4-4527-97bd-28fcc28b3844" xlink:href="thc-20221231.xsd#thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9773a42f-ae78-4809-860f-5e9048226521" xlink:to="loc_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock_f9a00cc2-b2e4-4527-97bd-28fcc28b3844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_eba8d7f6-7575-446a-9b00-dd7d1ad2cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_718a9f20-1bbe-42a3-b61c-ee0766ab1c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_eba8d7f6-7575-446a-9b00-dd7d1ad2cc21" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_718a9f20-1bbe-42a3-b61c-ee0766ab1c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESTables" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebbe4138-9d6a-4187-8fc4-c6cad0ba0a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_749b9eea-4f78-4152-af45-0e5039e7a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebbe4138-9d6a-4187-8fc4-c6cad0ba0a77" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_749b9eea-4f78-4152-af45-0e5039e7a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_c6b95354-af6f-4896-bb79-9264dd4f3d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebbe4138-9d6a-4187-8fc4-c6cad0ba0a77" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_c6b95354-af6f-4896-bb79-9264dd4f3d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSTables" xlink:type="simple" xlink:href="thc-20221231.xsd#CLAIMSANDLAWSUITSTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f915215e-032f-4bea-a7a0-974c4adc3125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_1fe967f0-8f27-4733-8840-ea8e2920a748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f915215e-032f-4bea-a7a0-974c4adc3125" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_1fe967f0-8f27-4733-8840-ea8e2920a748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_35c3e2c3-e2e4-4d1c-b01d-3a6b18b16336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_bdbe3d12-92c2-4b4f-8bf4-0a9aa61ced63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_35c3e2c3-e2e4-4d1c-b01d-3a6b18b16336" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_bdbe3d12-92c2-4b4f-8bf4-0a9aa61ced63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8c286722-99ee-41d7-b867-4ad98be29ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_809cd87b-3efb-4dce-ab2d-af29103b71ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c286722-99ee-41d7-b867-4ad98be29ba6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_809cd87b-3efb-4dce-ab2d-af29103b71ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_94f8dc43-75e9-4a91-bf39-d4d59021bbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c286722-99ee-41d7-b867-4ad98be29ba6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_94f8dc43-75e9-4a91-bf39-d4d59021bbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cc54f29a-252c-47c0-a1b3-253c634bac54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c286722-99ee-41d7-b867-4ad98be29ba6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cc54f29a-252c-47c0-a1b3-253c634bac54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9f330d0d-36ee-4c53-8ab2-82ab8af4533d" xlink:href="thc-20221231.xsd#thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c286722-99ee-41d7-b867-4ad98be29ba6" xlink:to="loc_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9f330d0d-36ee-4c53-8ab2-82ab8af4533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_b6c74c9c-7818-4b3f-9cce-841272205a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c286722-99ee-41d7-b867-4ad98be29ba6" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_b6c74c9c-7818-4b3f-9cce-841272205a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables" xlink:type="simple" xlink:href="thc-20221231.xsd#EARNINGSPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1ce701c4-79da-4aea-a5cd-5a5e2c30d581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_de683f52-8efc-42d9-827c-099993c19bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ce701c4-79da-4aea-a5cd-5a5e2c30d581" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_de683f52-8efc-42d9-827c-099993c19bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cfd03285-fec0-403f-8b14-8c28e13533d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c3b465b2-c842-4294-84b1-2bb7c08e8245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cfd03285-fec0-403f-8b14-8c28e13533d8" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c3b465b2-c842-4294-84b1-2bb7c08e8245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_57008364-d7f7-482c-b4fb-24fdf904cdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cfd03285-fec0-403f-8b14-8c28e13533d8" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_57008364-d7f7-482c-b4fb-24fdf904cdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f7b08969-6a6e-4a73-8b77-2896238c0429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_55e814c1-b34b-46e0-9e97-b431bfe49ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f7b08969-6a6e-4a73-8b77-2896238c0429" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_55e814c1-b34b-46e0-9e97-b431bfe49ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_a8a06943-d317-4a55-9a78-89a69f5aa395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f7b08969-6a6e-4a73-8b77-2896238c0429" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_a8a06943-d317-4a55-9a78-89a69f5aa395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3fde69a2-20fc-4c96-aee5-f7cbae8dcf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3fde69a2-20fc-4c96-aee5-f7cbae8dcf16" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_85d2fde5-8ab1-4824-b6e2-1ea9fe319238" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_567e7135-ab8f-485f-94b4-a80c914d678e" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_567e7135-ab8f-485f-94b4-a80c914d678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_32a8785c-fef5-4a28-9de9-b9922d04d5d3" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a41f8e0-9a76-43c1-8bff-f6809b161a80" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_32a8785c-fef5-4a28-9de9-b9922d04d5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_7a5bcdd7-ff2a-4409-aeb4-d89a93895a78" xlink:to="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_a014ffd6-eb70-4694-81e0-6b07cbcec11e" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_a014ffd6-eb70-4694-81e0-6b07cbcec11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferHealthSolutionsLLCMember_afcaf025-07ed-481e-b28c-25f0f0f16b94" xlink:href="thc-20221231.xsd#thc_ConiferHealthSolutionsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e775546b-5ba1-47fa-8c08-7a094ee0ad1f" xlink:to="loc_thc_ConiferHealthSolutionsLLCMember_afcaf025-07ed-481e-b28c-25f0f0f16b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9e80e1aa-e571-4174-afc3-95936390e5f3" xlink:to="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_a946bcd0-a493-4bba-b743-2059a286dd44" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:to="loc_thc_AmbulatoryCareMember_a946bcd0-a493-4bba-b743-2059a286dd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember_858f1de9-7493-4fb1-8cad-78ef8bb611c3" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a0bce58-a024-4259-8375-d573a92d469c" xlink:to="loc_thc_HospitalOperationsSegmentMember_858f1de9-7493-4fb1-8cad-78ef8bb611c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c1c4888-805f-4689-8df4-d1cd534dcee7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_3dc579c1-32e3-4ee8-810b-fca620b127e5" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_3dc579c1-32e3-4ee8-810b-fca620b127e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_ea8b3577-bb19-4ea1-924f-3241b557f8cc" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_ea8b3577-bb19-4ea1-924f-3241b557f8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsOperated_8496aaa7-1ac0-48c0-a9e4-eaecc15d1512" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsOperated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfHospitalsOperated_8496aaa7-1ac0-48c0-a9e4-eaecc15d1512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientFacilitiesOperated_7961c09a-f0de-4394-b332-77c2835a9066" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientFacilitiesOperated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_NumberOfOutpatientFacilitiesOperated_7961c09a-f0de-4394-b332-77c2835a9066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1d2e204a-34c1-478e-a3ee-a65de1ed73dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1d2e204a-34c1-478e-a3ee-a65de1ed73dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_fa4b5b73-8f35-486c-9bcd-1d43c21f2d5d" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03bf682b-2a85-4c48-ae4a-dc82198333de" xlink:to="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_fa4b5b73-8f35-486c-9bcd-1d43c21f2d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae772392-0e5b-4a5f-9e34-c4dbf8a2aaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae772392-0e5b-4a5f-9e34-c4dbf8a2aaf5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6e9caa32-f6f0-41ca-83f9-17bb15e27f83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1e722f29-e0b3-41f3-91eb-03576382fce8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6e9caa32-f6f0-41ca-83f9-17bb15e27f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_183532fd-a3dc-4979-9c21-ee41fda58b8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6e9caa32-f6f0-41ca-83f9-17bb15e27f83" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_183532fd-a3dc-4979-9c21-ee41fda58b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9aa9e760-b934-4aa8-85a0-7feb16168698" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_0ceeebd0-efaf-48f3-b24a-66c424c9fe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_0ceeebd0-efaf-48f3-b24a-66c424c9fe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_d58b5d13-f8d0-4d00-a133-74e3fcaf05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f404d6ea-fb22-4406-a292-092c5eabede8" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_d58b5d13-f8d0-4d00-a133-74e3fcaf05f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4ea4c90d-ca82-4b05-b4d1-2b7460e2c50b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40a7d402-c8b0-4d47-8399-6fd465d27567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40a7d402-c8b0-4d47-8399-6fd465d27567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aa5ea237-f025-4790-ab8d-33b6a9af008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aa5ea237-f025-4790-ab8d-33b6a9af008b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0ae6919-8b2b-45f3-996a-d3b412534f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_191369a2-5d9d-4614-98bf-3f33a1f7f165" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0ae6919-8b2b-45f3-996a-d3b412534f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96d23d2d-1d82-448e-aa6b-02b9afafae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96d23d2d-1d82-448e-aa6b-02b9afafae88" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_05b0d318-a429-434f-b434-d9cd4f5b472a" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EquityMethodInvestmentCashManagedAffiliatesMember_563d3db1-a9c3-48db-8af2-9a663d43bd04" xlink:href="thc-20221231.xsd#thc_EquityMethodInvestmentCashManagedAffiliatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:to="loc_thc_EquityMethodInvestmentCashManagedAffiliatesMember_563d3db1-a9c3-48db-8af2-9a663d43bd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_301bac71-50f5-4dcb-9e18-36a1cf4983b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7809705a-7510-46ab-8e44-b4891179d36c" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_301bac71-50f5-4dcb-9e18-36a1cf4983b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5a67d061-be1c-4ed8-a768-bca97bc91526" xlink:to="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember_ac67b6da-c5c2-42d9-920c-5666ea1d2b27" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:to="loc_thc_HospitalOperationsSegmentMember_ac67b6da-c5c2-42d9-920c-5666ea1d2b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_da80d14d-14f7-4b5c-a0b0-5547de35a4d8" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:to="loc_thc_AmbulatoryCareMember_da80d14d-14f7-4b5c-a0b0-5547de35a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsAndAmbulatoryCareMember_93a508f3-2558-4451-87a5-015af1f4ad0a" xlink:href="thc-20221231.xsd#thc_HospitalOperationsAndAmbulatoryCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5c5e8d50-392a-4ea3-98fb-05e465daf031" xlink:to="loc_thc_HospitalOperationsAndAmbulatoryCareMember_93a508f3-2558-4451-87a5-015af1f4ad0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_196b003f-3494-4f61-b3d7-d7f5d25297fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f0b6d2d1-51fc-48f8-85da-ff0f8200b07b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_196b003f-3494-4f61-b3d7-d7f5d25297fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AccruedCompensationAndBenefitsMember_bee1bd15-fb5d-476d-835d-73c4a97021f9" xlink:href="thc-20221231.xsd#thc_AccruedCompensationAndBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_196b003f-3494-4f61-b3d7-d7f5d25297fe" xlink:to="loc_thc_AccruedCompensationAndBenefitsMember_bee1bd15-fb5d-476d-835d-73c4a97021f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8aced14-0208-4080-9121-55ce8c09c0ba" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7a38a449-0983-43d7-b261-ca9fb528c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7a38a449-0983-43d7-b261-ca9fb528c800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_f7c8ae55-09c1-4769-a79d-84225e3560f8" xlink:href="thc-20221231.xsd#thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates_f7c8ae55-09c1-4769-a79d-84225e3560f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_f7dd535f-026a-4e14-bd09-d3524f630da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_f7dd535f-026a-4e14-bd09-d3524f630da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_8bc82ca3-251b-41dd-8b59-34bf5d19f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_DeferredRevenue_8bc82ca3-251b-41dd-8b59-34bf5d19f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_690b0f94-ad3f-436c-9e53-56bd0462c05f" xlink:href="thc-20221231.xsd#thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments_690b0f94-ad3f-436c-9e53-56bd0462c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4333e345-0716-4ec0-9627-70b9567d2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4333e345-0716-4ec0-9627-70b9567d2d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_c794ad5f-04f2-43ef-bd1a-dee347b8bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b53dfe1-c601-4ca5-8c73-86445d52bedb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_c794ad5f-04f2-43ef-bd1a-dee347b8bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0ac6d87-7c54-4b2f-89d0-9ceb2a8ef54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod_f760a244-abf3-402c-ba83-6ef891ad0919" xlink:href="thc-20221231.xsd#thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0ac6d87-7c54-4b2f-89d0-9ceb2a8ef54a" xlink:to="loc_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod_f760a244-abf3-402c-ba83-6ef891ad0919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c766b7a-12cb-4f74-86ec-849c945b1033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c766b7a-12cb-4f74-86ec-849c945b1033" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ec6e2f4a-3f69-488b-a637-fcba1e8958fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8aefefc3-cad8-4d3e-9928-126814fb4856" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ec6e2f4a-3f69-488b-a637-fcba1e8958fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_02a3c50d-d04d-41eb-95d9-da13d97400d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6e2f4a-3f69-488b-a637-fcba1e8958fe" xlink:to="loc_us-gaap_AccountsPayableMember_02a3c50d-d04d-41eb-95d9-da13d97400d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_afbaeeb2-9d55-43d3-aca7-89fa755912f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d2c188ad-983c-4038-a558-7a093871997b" xlink:to="loc_dei_EntityDomain_afbaeeb2-9d55-43d3-aca7-89fa755912f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaptiveInsuranceSubsidiariesMember_6a8c9967-36cc-401d-bd50-fa694603eeac" xlink:href="thc-20221231.xsd#thc_CaptiveInsuranceSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_afbaeeb2-9d55-43d3-aca7-89fa755912f1" xlink:to="loc_thc_CaptiveInsuranceSubsidiariesMember_6a8c9967-36cc-401d-bd50-fa694603eeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ecc4f16-c603-4a6b-b299-8d6c41d2a613" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3ec27180-a3f9-4a39-88df-900abbf21812" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ecc4f16-c603-4a6b-b299-8d6c41d2a613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_2b7dd2c0-ffce-4c62-9bdd-16d351a58516" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ecc4f16-c603-4a6b-b299-8d6c41d2a613" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_2b7dd2c0-ffce-4c62-9bdd-16d351a58516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ea53e2c0-20b3-4bd9-99ca-7079cefd1f99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_53a0ee44-3ad5-460d-ab14-4d48c4196f1c" xlink:to="loc_srt_OwnershipDomain_ea53e2c0-20b3-4bd9-99ca-7079cefd1f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_a5eb07eb-a80c-4bdd-b5fb-d93ccc3104e6" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ea53e2c0-20b3-4bd9-99ca-7079cefd1f99" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_a5eb07eb-a80c-4bdd-b5fb-d93ccc3104e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_6f43ab37-d5f5-49d9-9f6c-8e25f9a8a32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_acca1937-7c8a-4114-982f-51012334bc61" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_6f43ab37-d5f5-49d9-9f6c-8e25f9a8a32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_a1388415-de88-45a5-a7db-4f6b8f3b1c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_6f43ab37-d5f5-49d9-9f6c-8e25f9a8a32f" xlink:to="loc_us-gaap_PutOptionMember_a1388415-de88-45a5-a7db-4f6b8f3b1c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_6a8d18a4-786c-49a5-8cc6-9256f045b305" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36697c74-f8f1-460a-9224-375dc0dd1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36697c74-f8f1-460a-9224-375dc0dd1bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankOverdrafts_43c6a7aa-ef95-4e3f-ade5-64e051c730c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_BankOverdrafts_43c6a7aa-ef95-4e3f-ade5-64e051c730c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e3ec4240-a026-4553-ab16-97d6702f40fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e3ec4240-a026-4553-ab16-97d6702f40fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_JointVentureOwnershipPercentage_f63b9e47-6bbb-43a7-91c1-36c77ff6a9f9" xlink:href="thc-20221231.xsd#thc_JointVentureOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_thc_JointVentureOwnershipPercentage_f63b9e47-6bbb-43a7-91c1-36c77ff6a9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementPaymentForExecution_b666274e-69da-4a43-b6e5-d1acf3cc3890" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementPaymentForExecution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_thc_SharePurchaseAgreementPaymentForExecution_b666274e-69da-4a43-b6e5-d1acf3cc3890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ec8f1cf2-5456-4569-91e9-9d8484be6930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_NotesPayable_ec8f1cf2-5456-4569-91e9-9d8484be6930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_9f543292-c808-4a9d-a1c2-53f2e41e0a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_9f543292-c808-4a9d-a1c2-53f2e41e0a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_254be143-0967-4492-bd85-432ce2c01c51" xlink:href="thc-20221231.xsd#thc_GainLossFromPurchaseOfNoncontrollingInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d75eda15-1323-4912-8920-0087cdffcacf" xlink:to="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_254be143-0967-4492-bd85-432ce2c01c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8da051e2-4cb8-4937-8c58-bed042c214ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8da051e2-4cb8-4937-8c58-bed042c214ea" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bbac8ade-3ea9-4213-b57a-a8350d7f05fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30dedc88-2ae4-46b7-8fbd-29e65f283632" xlink:to="loc_us-gaap_SegmentDomain_bbac8ade-3ea9-4213-b57a-a8350d7f05fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_5ca7a69f-fea7-4980-bd77-96b82c2f1f70" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bbac8ade-3ea9-4213-b57a-a8350d7f05fb" xlink:to="loc_thc_AmbulatoryCareMember_5ca7a69f-fea7-4980-bd77-96b82c2f1f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1dd71b81-7b46-4df3-84cd-1c30ab27bf25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5c44327a-9cb6-49e9-8194-bd0e892d72c6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1dd71b81-7b46-4df3-84cd-1c30ab27bf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TexasHealthVenturesGroupLlcMember_d9bd67c7-6a78-41dc-9e49-f522930fe67a" xlink:href="thc-20221231.xsd#thc_TexasHealthVenturesGroupLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1dd71b81-7b46-4df3-84cd-1c30ab27bf25" xlink:to="loc_thc_TexasHealthVenturesGroupLlcMember_d9bd67c7-6a78-41dc-9e49-f522930fe67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_8ca28417-0425-430d-8dc8-91f8f4f89a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0be6aa24-df6d-41d5-9113-c60b7b410074" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_8ca28417-0425-430d-8dc8-91f8f4f89a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_157a8f62-7b99-4fc2-8516-0bf762e5dada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_8ca28417-0425-430d-8dc8-91f8f4f89a49" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_157a8f62-7b99-4fc2-8516-0bf762e5dada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_afac84b7-edd2-45eb-a4c6-e758b134a5f7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_f4b3f853-ba1b-4c29-b186-eb60391a20ff" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod_f4b3f853-ba1b-4c29-b186-eb60391a20ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_63a6abf9-c7bf-4276-81f5-0762c2a577cc" xlink:href="thc-20221231.xsd#thc_NumberOfOutpatientCentersRecordedUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod_63a6abf9-c7bf-4276-81f5-0762c2a577cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersAndHospitals_8cea0c82-7da5-4097-8a15-55fdf1e1d095" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersAndHospitals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NumberOfSurgicalCentersAndHospitals_8cea0c82-7da5-4097-8a15-55fdf1e1d095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_d375f29f-4d83-4946-911f-e7dc0c3aa812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_d375f29f-4d83-4946-911f-e7dc0c3aa812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PercentageInvesteeResultsReflected_125c8afa-c9da-4cb7-884a-18f5c2d7ccd9" xlink:href="thc-20221231.xsd#thc_PercentageInvesteeResultsReflected"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_PercentageInvesteeResultsReflected_125c8afa-c9da-4cb7-884a-18f5c2d7ccd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0ae83aee-1d2f-4682-b6f6-73bf1add39ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_AssetsCurrent_0ae83aee-1d2f-4682-b6f6-73bf1add39ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_4719bdec-8fc8-43e5-8041-03f7bbc83d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_AssetsNoncurrent_4719bdec-8fc8-43e5-8041-03f7bbc83d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dc44a887-16d6-4809-9a1c-149d697a0b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_LiabilitiesCurrent_dc44a887-16d6-4809-9a1c-149d697a0b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b2b7c66b-01ee-4341-9ad1-f6d6bc84be46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b2b7c66b-01ee-4341-9ad1-f6d6bc84be46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_089ffcc3-41f2-4410-94c4-62229b75f5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_MinorityInterest_089ffcc3-41f2-4410-94c4-62229b75f5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7a6afa5-5e60-4dd9-81bd-51ccfa7dcdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7a6afa5-5e60-4dd9-81bd-51ccfa7dcdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_90926d3f-30f2-4f16-ba9b-ef1e6ee8d2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_ProfitLoss_90926d3f-30f2-4f16-ba9b-ef1e6ee8d2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetIncomeLossAttributableToInvestee_dd9ecb08-f352-4e61-aeb3-ec57f35eb557" xlink:href="thc-20221231.xsd#thc_NetIncomeLossAttributableToInvestee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_thc_NetIncomeLossAttributableToInvestee_dd9ecb08-f352-4e61-aeb3-ec57f35eb557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ca718d71-b31a-438d-b93c-173f8ce64e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cd7ad657-1228-4087-aa2f-d2196e52d398" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ca718d71-b31a-438d-b93c-173f8ce64e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38b04e09-8a52-489e-9680-2105fdc479e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38b04e09-8a52-489e-9680-2105fdc479e4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ff048ed8-ac46-45c6-b1b3-326476a163be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_e37ccab5-1464-423d-99e6-141e28f56abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_e37ccab5-1464-423d-99e6-141e28f56abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a82b9e57-2c46-4fc9-bdb9-5ba2dbbd6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_us-gaap_EquipmentMember_a82b9e57-2c46-4fc9-bdb9-5ba2dbbd6db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NewlyConstructedHospitalsMember_ab04a505-45c6-4d98-9024-e897b5bcd3e2" xlink:href="thc-20221231.xsd#thc_NewlyConstructedHospitalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_thc_NewlyConstructedHospitalsMember_ab04a505-45c6-4d98-9024-e897b5bcd3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_88d004c0-e7cd-4b55-bd5e-890d3d8bf257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f3d1841-a0c9-49e3-82bf-5d3737335c96" xlink:to="loc_us-gaap_ConstructionInProgressMember_88d004c0-e7cd-4b55-bd5e-890d3d8bf257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:to="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98f92b42-a704-4ce3-b697-f45f6002c9ee" xlink:to="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b01dc84a-a436-4129-a272-85da93cd3ce9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:to="loc_srt_MinimumMember_b01dc84a-a436-4129-a272-85da93cd3ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8eaf1c07-3f7e-4f6b-86d6-87d06d4d64aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c37f066-9eca-41a0-a676-8ce9ca6afbd9" xlink:to="loc_srt_MaximumMember_8eaf1c07-3f7e-4f6b-86d6-87d06d4d64aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7c388d4-88de-43b0-9468-9bfd72ad3421" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3c7c860-cdde-4dec-bc73-af05f4b8868c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3c7c860-cdde-4dec-bc73-af05f4b8868c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_7ea7a318-09af-42c1-b13f-b335b27ba1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa6843e6-f705-4ec5-ae75-ec80344f5e35" xlink:to="loc_us-gaap_InterestCostsCapitalized_7ea7a318-09af-42c1-b13f-b335b27ba1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0cc78406-b632-4cff-b5c8-17854ca67370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0cc78406-b632-4cff-b5c8-17854ca67370" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b84aeebb-53bb-409f-b385-229c50d390ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndBuildingMember_e0eaf35a-e814-44e7-ae82-076cd574a7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_us-gaap_LandAndBuildingMember_e0eaf35a-e814-44e7-ae82-076cd574a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_262b9f7e-fa7a-409f-813f-fd15aa1c22f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_us-gaap_EquipmentMember_262b9f7e-fa7a-409f-813f-fd15aa1c22f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MedicalEquipmentMember_b046a14d-9d3d-4b3a-887c-9fb09463e133" xlink:href="thc-20221231.xsd#thc_MedicalEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_thc_MedicalEquipmentMember_b046a14d-9d3d-4b3a-887c-9fb09463e133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ComputerAndTelecommunicationEquipmentMember_7f31343f-8694-4c81-ae64-f6713bf4fb97" xlink:href="thc-20221231.xsd#thc_ComputerAndTelecommunicationEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6686571e-40c2-4dc0-9650-5f1ffa32fb83" xlink:to="loc_thc_ComputerAndTelecommunicationEquipmentMember_7f31343f-8694-4c81-ae64-f6713bf4fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:to="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0323cc08-6c0a-4bfc-a6b8-6a04b109f980" xlink:to="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_330fd5e0-9df3-47a7-9978-f224d213298f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:to="loc_srt_MinimumMember_330fd5e0-9df3-47a7-9978-f224d213298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5bc6130c-c8f3-40da-92c4-14e0881bc0c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e158bee-9e2e-4b71-b053-6791971aa503" xlink:to="loc_srt_MaximumMember_5bc6130c-c8f3-40da-92c4-14e0881bc0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_848a7891-0731-4f5f-889f-4ce798a7caaf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_be4f01ca-6f0f-4f90-b142-2d6833c63aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_be4f01ca-6f0f-4f90-b142-2d6833c63aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeOperatingLeaseNumberOfRenewalOptions_34997266-3705-411d-b01f-2829f9113b06" xlink:href="thc-20221231.xsd#thc_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_thc_LesseeOperatingLeaseNumberOfRenewalOptions_34997266-3705-411d-b01f-2829f9113b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de3e321d-6659-4b04-9739-0e19a1aab0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de3e321d-6659-4b04-9739-0e19a1aab0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_01c4aef4-3c39-495d-a5d9-180905f49adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2c5c262-7777-45e8-8acc-061f7733b2a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_01c4aef4-3c39-495d-a5d9-180905f49adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2e4ca823-6f98-4f64-92ec-0d8ceff52cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e4ca823-6f98-4f64-92ec-0d8ceff52cca" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a00495c-c332-4035-80e8-a374de3da342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_468113fd-bad1-4150-802e-8c5660989e15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a00495c-c332-4035-80e8-a374de3da342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ac46e334-de8a-4dd4-84cd-88b1f33f8561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a00495c-c332-4035-80e8-a374de3da342" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ac46e334-de8a-4dd4-84cd-88b1f33f8561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:to="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4dbf2711-eb4b-4279-8842-0f83b25ff685" xlink:to="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3377f5f8-f656-4f17-b29b-bb98e076e3a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:to="loc_srt_MinimumMember_3377f5f8-f656-4f17-b29b-bb98e076e3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c5cc73f-55a3-4354-916c-f15f52af8162" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a40c5dc-76ac-45e9-a4b1-ef8a7a4be86a" xlink:to="loc_srt_MaximumMember_0c5cc73f-55a3-4354-916c-f15f52af8162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ba135ceb-df14-41a3-a2bf-700177f99ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eea99c0a-94ca-4a6c-a1da-e8ce712a613f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ba135ceb-df14-41a3-a2bf-700177f99ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_05a5df19-f831-41ed-824a-5e3c558c7070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ba135ceb-df14-41a3-a2bf-700177f99ba9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_05a5df19-f831-41ed-824a-5e3c558c7070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7f9d0b3-a098-481c-bfea-839f06c61908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals_a1908298-310d-4a6b-ad35-e945575d2115" xlink:href="thc-20221231.xsd#thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7f9d0b3-a098-481c-bfea-839f06c61908" xlink:to="loc_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals_a1908298-310d-4a6b-ad35-e945575d2115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EQUITYNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6bfc96e5-aab6-4240-9ff5-91e9095574b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6bfc96e5-aab6-4240-9ff5-91e9095574b8" xlink:to="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ceeacb79-ca59-49cb-8a37-f8a0fbedfef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ad6bccc-313b-400b-9394-107a214bdd0a" xlink:to="loc_us-gaap_EquityComponentDomain_ceeacb79-ca59-49cb-8a37-f8a0fbedfef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4702361d-b917-46a6-ad8d-c57643f941f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ceeacb79-ca59-49cb-8a37-f8a0fbedfef1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4702361d-b917-46a6-ad8d-c57643f941f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_88fdafbc-85d1-4dff-a79c-637951ca7d12" xlink:to="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_c038deb2-5c1c-4fc8-9993-1ac81d5e4b3d" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:to="loc_thc_HospitalOperationsMember_c038deb2-5c1c-4fc8-9993-1ac81d5e4b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_00a833ff-382c-4a58-bcd1-56f4a025c85e" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3cec7657-1681-4ca1-8174-bc3c0098beaf" xlink:to="loc_thc_AmbulatoryCareMember_00a833ff-382c-4a58-bcd1-56f4a025c85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6c9b03ad-858d-4957-8758-ce239ac95cad" xlink:to="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa0ce773-38d0-4145-bf56-56576b21d325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa0ce773-38d0-4145-bf56-56576b21d325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8459065c-bea3-4932-b6a8-8780e93c6020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_2f9d21f2-8349-4a25-90dc-9f1daf2f62e8" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8459065c-bea3-4932-b6a8-8780e93c6020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EQUITYShareRepurchaseProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89027ff2-5776-4466-8342-5b08d3a5a8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ecf24aad-fb00-479a-be4a-6c17f330f54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89027ff2-5776-4466-8342-5b08d3a5a8ce" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ecf24aad-fb00-479a-be4a-6c17f330f54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9e02fcad-a731-409e-8f37-0883ce46afea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89027ff2-5776-4466-8342-5b08d3a5a8ce" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9e02fcad-a731-409e-8f37-0883ce46afea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_09f53aa7-8978-489f-827e-74f17467d61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89027ff2-5776-4466-8342-5b08d3a5a8ce" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_09f53aa7-8978-489f-827e-74f17467d61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_5597aa7f-ddb1-4598-bca2-870ee7834215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89027ff2-5776-4466-8342-5b08d3a5a8ce" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_5597aa7f-ddb1-4598-bca2-870ee7834215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLEComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_5f34d5eb-1491-4bcc-a686-38ffa534c62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_fce6f02c-35ff-4793-9a7c-5f00bc3e0514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_5f34d5eb-1491-4bcc-a686-38ffa534c62e" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_fce6f02c-35ff-4793-9a7c-5f00bc3e0514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_c733623a-c03f-4d5c-8b17-20f2efd399c9" xlink:href="thc-20221231.xsd#thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_5f34d5eb-1491-4bcc-a686-38ffa534c62e" xlink:to="loc_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer_c733623a-c03f-4d5c-8b17-20f2efd399c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_f1f5aaa6-c8a4-4eba-a074-a745f27672e6" xlink:href="thc-20221231.xsd#thc_NetCostReportSettlementsReceivablePayableandValuationAllowances"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_5f34d5eb-1491-4bcc-a686-38ffa534c62e" xlink:to="loc_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances_f1f5aaa6-c8a4-4eba-a074-a745f27672e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cf4c489b-beed-4b1c-95db-1764fb3bedc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_5f34d5eb-1491-4bcc-a686-38ffa534c62e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cf4c489b-beed-4b1c-95db-1764fb3bedc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_940fb2cc-4687-4599-b30b-f00237459b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_940fb2cc-4687-4599-b30b-f00237459b3f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_64d574ef-85e1-4a98-b147-b6baca125e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_70da8c78-c793-447b-9a0f-87eb04df2c4d" xlink:to="loc_us-gaap_ReceivableTypeDomain_64d574ef-85e1-4a98-b147-b6baca125e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaProviderFeeProgramMember_c1174602-c31a-45ff-b1ad-6fce169223ed" xlink:href="thc-20221231.xsd#thc_CaliforniaProviderFeeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_64d574ef-85e1-4a98-b147-b6baca125e29" xlink:to="loc_thc_CaliforniaProviderFeeProgramMember_c1174602-c31a-45ff-b1ad-6fce169223ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0ec178fe-a39b-4f4f-b92e-3027fce823dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7528b817-c924-47d7-9020-aede959e82a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7528b817-c924-47d7-9020-aede959e82a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_37574417-5e6f-49ea-a325-419d86c102ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherAssetsMember_37574417-5e6f-49ea-a325-419d86c102ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3c3102d9-33cf-4138-a97e-2857b2017dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3c3102d9-33cf-4138-a97e-2857b2017dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_3123ca41-2c37-4374-8883-f1f41850741d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c4ec9d30-af3e-4845-9c40-b8bbfcf12ffe" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_3123ca41-2c37-4374-8883-f1f41850741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aaa4a182-7d84-4315-94e7-e6ab1af42b6e" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:to="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a32c2a2b-aaa9-498c-8522-d717111135bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a32c2a2b-aaa9-498c-8522-d717111135bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_11f45025-d692-40ba-bc5a-0a99a6123151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0aee3cd5-6c1b-42f4-ac97-7341a56a3f67" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_11f45025-d692-40ba-bc5a-0a99a6123151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c407c79-3c6a-430b-8247-23aafd591818" xlink:to="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4e23aeff-30fe-4ab6-89e0-731036f7de86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:to="loc_us-gaap_AccountsPayableCurrent_4e23aeff-30fe-4ab6-89e0-731036f7de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a0a38043-6fce-4a02-a22b-ecf15f126d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f9ed2a88-35c1-4038-b411-1ef45fb97355" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a0a38043-6fce-4a02-a22b-ecf15f126d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCOUNTSRECEIVABLEAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_7a3e7ae8-9fb7-476e-8ca1-768e7d4b35b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract_7a3e7ae8-9fb7-476e-8ca1-768e7d4b35b0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c11698cf-bdd2-43b6-926c-0912f8206f55" xlink:to="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SelfPayPatientsMember_28c2e8c8-bf16-42a1-bb66-0f99502a54bd" xlink:href="thc-20221231.xsd#thc_SelfPayPatientsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:to="loc_thc_SelfPayPatientsMember_28c2e8c8-bf16-42a1-bb66-0f99502a54bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CharityCarePatientsMember_e0b3357e-b42d-42f3-a285-b808c4e88113" xlink:href="thc-20221231.xsd#thc_CharityCarePatientsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_84075511-2a94-429c-a5cd-cb7ee0ca174b" xlink:to="loc_thc_CharityCarePatientsMember_e0b3357e-b42d-42f3-a285-b808c4e88113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d5fb7ce-4358-4d1e-aeb0-f2fccbbac869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0486f2eb-8439-47c9-86cf-42f7c8d4688b" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d5fb7ce-4358-4d1e-aeb0-f2fccbbac869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationHealthCareCostsGross_ae46c78d-38f4-4a71-96f8-671a759633d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d5fb7ce-4358-4d1e-aeb0-f2fccbbac869" xlink:to="loc_us-gaap_HealthCareOrganizationHealthCareCostsGross_ae46c78d-38f4-4a71-96f8-671a759633d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81e7a077-efc6-4b5b-a36a-8f65fc64ed79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81e7a077-efc6-4b5b-a36a-8f65fc64ed79" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8de5f272-8919-4162-a116-3c2de85e2273" xlink:to="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsAndOtherMember_1cb2688c-c43e-4d92-bab2-f34af2b7b205" xlink:href="thc-20221231.xsd#thc_HospitalOperationsAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:to="loc_thc_HospitalOperationsAndOtherMember_1cb2688c-c43e-4d92-bab2-f34af2b7b205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_fad6018d-aaf9-43e3-ad2a-1af24517c14d" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_635e166b-be1b-41f1-a948-1031c53ec181" xlink:to="loc_thc_AmbulatoryCareMember_fad6018d-aaf9-43e3-ad2a-1af24517c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_55244e27-e928-4141-8de6-620228a282ee" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember_9e50bf23-13b0-4ab0-8ee5-fba46f817270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:to="loc_us-gaap_ShortTermContractWithCustomerMember_9e50bf23-13b0-4ab0-8ee5-fba46f817270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember_2942a23c-c535-43f3-b3cd-a5ffd3786459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ce9798e9-6b9b-4ce0-a8ec-3773ca5fc8a3" xlink:to="loc_us-gaap_LongTermContractWithCustomerMember_2942a23c-c535-43f3-b3cd-a5ffd3786459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e2345d5-9654-4cd7-aff5-90c718df89a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_715d6ac2-25ad-4202-9462-4f37e3a9c873" xlink:href="thc-20221231.xsd#thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days_715d6ac2-25ad-4202-9462-4f37e3a9c873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_317e132d-c423-4ada-871a-b3ad4d632271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_317e132d-c423-4ada-871a-b3ad4d632271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_87f7eeb4-7153-4e8d-967d-0c7b1dcfcb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_87f7eeb4-7153-4e8d-967d-0c7b1dcfcb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_210a759f-e051-4f4a-b75b-98cb1ef28674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8f69b77c-d93a-4a5a-9ea4-9ca00d8403bd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_210a759f-e051-4f4a-b75b-98cb1ef28674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_996b0793-ffb5-4a77-905d-315995ca6460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_996b0793-ffb5-4a77-905d-315995ca6460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca2b96af-a52d-4e12-9ca3-57c10eb9376b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca2b96af-a52d-4e12-9ca3-57c10eb9376b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c578464d-dae2-4bda-8b63-71539243ed29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_625d4984-3ef9-4946-8966-fd82075238e1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c578464d-dae2-4bda-8b63-71539243ed29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a963b96f-0406-4d28-aff0-5106d4944702" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f32b64ae-44bf-408d-aec2-14bcc6600546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f32b64ae-44bf-408d-aec2-14bcc6600546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_863af800-cc51-44e5-8f26-740e0d605dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_863af800-cc51-44e5-8f26-740e0d605dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9c523a68-7a41-4cf6-a089-bcfc1e2ed8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_a568e47b-d82f-47b1-b488-66f0c93cf853" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9c523a68-7a41-4cf6-a089-bcfc1e2ed8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCESConiferSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d6b75225-6c8b-43a0-a7df-137d2e6f0c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d6b75225-6c8b-43a0-a7df-137d2e6f0c76" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93fb1829-a212-4a42-b496-647fda5790a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0018dd6f-100e-4896-a905-a735daf0aa6a" xlink:to="loc_us-gaap_SegmentDomain_93fb1829-a212-4a42-b496-647fda5790a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_3d6cc060-998d-4b2b-80cf-1bbdee367356" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93fb1829-a212-4a42-b496-647fda5790a2" xlink:to="loc_thc_ConiferSegmentMember_3d6cc060-998d-4b2b-80cf-1bbdee367356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_1bc7e557-a823-43ed-9644-6945e48eaa3a" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember_34a0372c-3cea-421f-bf49-cb1017e656cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:to="loc_us-gaap_ShortTermContractWithCustomerMember_34a0372c-3cea-421f-bf49-cb1017e656cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember_7a0f6ca2-1b5f-4de7-8b62-b3babf5a929d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_ffd95b28-4b96-45e1-9670-14679b9acadb" xlink:to="loc_us-gaap_LongTermContractWithCustomerMember_7a0f6ca2-1b5f-4de7-8b62-b3babf5a929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1397a1e1-7194-4fae-b1f9-37097b8af80f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerAssetNetCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_282359dc-2dc1-43f3-a899-92c8ef043213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_282359dc-2dc1-43f3-a899-92c8ef043213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_bcff5114-fcfe-4d8d-9dfc-8439ab18c3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_bcff5114-fcfe-4d8d-9dfc-8439ab18c3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncreaseDecreaseInContractWithCustomerReceivable_69a2a8ef-c1c7-4013-9733-28ebd2e33fa4" xlink:href="thc-20221231.xsd#thc_IncreaseDecreaseInContractWithCustomerReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward_6819f299-117a-44ff-9c17-14e45a5328da" xlink:to="loc_thc_IncreaseDecreaseInContractWithCustomerReceivable_69a2a8ef-c1c7-4013-9733-28ebd2e33fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dd3142cc-3c5d-4c7b-b0fa-017eb8442624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dd3142cc-3c5d-4c7b-b0fa-017eb8442624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b7c0c6df-5430-48c7-89a6-864f21b5e0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b7c0c6df-5430-48c7-89a6-864f21b5e0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6a1421f1-a72d-4dff-9664-86b769c33652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward_97ab2616-3aed-4db0-bfaf-579c1dd0bbba" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6a1421f1-a72d-4dff-9664-86b769c33652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd0dc900-135b-4a5c-aac7-27deaaabb98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd0dc900-135b-4a5c-aac7-27deaaabb98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6bf90c68-80f7-4df3-8ec1-75e32744abdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6bf90c68-80f7-4df3-8ec1-75e32744abdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9e7367f4-abad-4088-8563-dddde6115f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward_bf0d61ff-110b-4baf-8691-c39cd3bb98cd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9e7367f4-abad-4088-8563-dddde6115f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:href="thc-20221231.xsd#thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2e50e8b2-d783-47b2-a48f-602badc61314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2e50e8b2-d783-47b2-a48f-602badc61314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3bfdf4d-3f82-4392-96ac-5d4d0639e239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3bfdf4d-3f82-4392-96ac-5d4d0639e239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_75b1fab8-b77b-429e-862a-e39d021ae14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward_f9441b92-2bed-4a9a-93a7-aa92681b4cbf" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_75b1fab8-b77b-429e-862a-e39d021ae14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4ddab808-a51d-4554-a011-94127ff47819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73047a1c-fbaf-4387-932b-bc3a38288ec8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4ddab808-a51d-4554-a011-94127ff47819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CONTRACTBALANCESContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d285fde0-7852-48ef-8dfc-0874e877ee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_31c2299b-513b-4fe5-a6da-8db97813ec4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d285fde0-7852-48ef-8dfc-0874e877ee0d" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_31c2299b-513b-4fe5-a6da-8db97813ec4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_bea402c0-df82-40b7-9f8c-47f86afdd115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d285fde0-7852-48ef-8dfc-0874e877ee0d" xlink:to="loc_us-gaap_CapitalizedContractCostNet_bea402c0-df82-40b7-9f8c-47f86afdd115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ASSETSANDLIABILITIESHELDFORSALENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1619f130-de97-4485-8c1d-2a5b39345f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1619f130-de97-4485-8c1d-2a5b39345f43" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_daf3a40a-1b01-430c-9cfe-a77f1d2bb65f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MiamiAreaHospitalsMember_604b7770-36c2-4e3a-9d88-1c3047e6c87e" xlink:href="thc-20221231.xsd#thc_MiamiAreaHospitalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:to="loc_thc_MiamiAreaHospitalsMember_604b7770-36c2-4e3a-9d88-1c3047e6c87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UrgentCareCentersMember_2fe2b035-b3f7-40c0-ba56-a3d2d0695803" xlink:href="thc-20221231.xsd#thc_UrgentCareCentersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:to="loc_thc_UrgentCareCentersMember_2fe2b035-b3f7-40c0-ba56-a3d2d0695803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhiladelphiaBuildingMember_6b2f0e5f-c0cc-406a-9a8c-e72f7302a13b" xlink:href="thc-20221231.xsd#thc_PhiladelphiaBuildingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0b5db74-3211-4aaa-ba38-a07bc576ee0c" xlink:to="loc_thc_PhiladelphiaBuildingMember_6b2f0e5f-c0cc-406a-9a8c-e72f7302a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f71a205e-a633-4ab1-9f55-e770d20d1871" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4a37ee8-2184-4462-9975-e2c533f4e490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4a37ee8-2184-4462-9975-e2c533f4e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e7fd63e4-83c4-4a35-949b-4032f07b675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_63ca07bf-3820-4489-982a-c4641ea5e220" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e7fd63e4-83c4-4a35-949b-4032f07b675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9505044b-8f90-428c-b113-efc4af8a9cae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsForSale_ce127bb3-be20-4914-9984-1d0fe0ca7fa8" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_thc_NumberOfHospitalsForSale_ce127bb3-be20-4914-9984-1d0fe0ca7fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties_1aee10ee-3855-4b3c-a326-1088e3fba465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_us-gaap_GainLossOnSaleOfProperties_1aee10ee-3855-4b3c-a326-1088e3fba465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_af85e75d-ba22-47ab-83ca-867db5b95f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ec7bb872-cb36-4220-a2b9-e8aa171079cf" xlink:to="loc_us-gaap_AssetImpairmentCharges_af85e75d-ba22-47ab-83ca-867db5b95f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_157ea682-8595-4877-a5e6-8f37728abe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_157ea682-8595-4877-a5e6-8f37728abe0b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_44e1ec95-e05d-4a13-bdfa-30d752558513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8cf34503-95d6-4b30-935d-7417ac5a52ef" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_44e1ec95-e05d-4a13-bdfa-30d752558513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MiamiAreaHospitalsMember_be132ae5-9352-4094-b7b4-e254bdfe1314" xlink:href="thc-20221231.xsd#thc_MiamiAreaHospitalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_44e1ec95-e05d-4a13-bdfa-30d752558513" xlink:to="loc_thc_MiamiAreaHospitalsMember_be132ae5-9352-4094-b7b4-e254bdfe1314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ad6bcebf-8853-4ece-ba07-383626ab9746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_12cab580-3d90-4238-82fe-78c0c43e92fa" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ad6bcebf-8853-4ece-ba07-383626ab9746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_65f9a6a9-fba0-4382-ba27-79f0f83e7595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ad6bcebf-8853-4ece-ba07-383626ab9746" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_65f9a6a9-fba0-4382-ba27-79f0f83e7595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42435191-d863-41aa-a82c-cbf667156fb2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_94530bdd-8b88-478e-b36e-9ed26adc56cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_94530bdd-8b88-478e-b36e-9ed26adc56cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties_d3970a1b-efdb-4bf3-b826-9281adec9daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cf404b6-4d2a-4188-997f-f5edaee90c6a" xlink:to="loc_us-gaap_GainLossOnSaleOfProperties_d3970a1b-efdb-4bf3-b826-9281adec9daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_907a0cd2-31b9-4f92-b91a-cfa3446b8c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_907a0cd2-31b9-4f92-b91a-cfa3446b8c3d" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe97525c-2538-494b-832b-2fe1c4649ed2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_9740a534-cae5-4c2d-a30f-48424d2f33a5" xlink:href="thc-20221231.xsd#thc_HospitalBuildingsAndMedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:to="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_9740a534-cae5-4c2d-a30f-48424d2f33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BuildingsSubjectToImpairmentChargesMember_c51e9c6d-00f8-4bd8-bd8f-6626a77e57b7" xlink:href="thc-20221231.xsd#thc_BuildingsSubjectToImpairmentChargesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d951325-c80e-434b-b1fb-ab61e4003121" xlink:to="loc_thc_BuildingsSubjectToImpairmentChargesMember_c51e9c6d-00f8-4bd8-bd8f-6626a77e57b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b9e6b529-f807-406a-8836-da7cd89bd165" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2ff46d6d-ed54-424b-998c-86bbbd0f0536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2ff46d6d-ed54-424b-998c-86bbbd0f0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_0f035ebc-47ec-47cd-9cfd-9c455f55adf9" xlink:href="thc-20221231.xsd#thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:to="loc_thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember_0f035ebc-47ec-47cd-9cfd-9c455f55adf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_USPIManagementEquityPlanMember_bbf7df28-b253-48ef-88a6-342972b6b163" xlink:href="thc-20221231.xsd#thc_USPIManagementEquityPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0a4a7524-4bcb-4a9a-b6f1-c9fbf3ca9ae9" xlink:to="loc_thc_USPIManagementEquityPlanMember_bbf7df28-b253-48ef-88a6-342972b6b163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0940c5bb-fbb3-40ac-bc93-8f34e1244f97" xlink:to="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_4d233f59-9505-4ad7-af42-6119b24a9755" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:to="loc_thc_HospitalOperationsMember_4d233f59-9505-4ad7-af42-6119b24a9755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_1d262456-cca7-4ce9-8350-8fc8de8bde90" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:to="loc_thc_AmbulatoryCareMember_1d262456-cca7-4ce9-8350-8fc8de8bde90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_1a64a762-6abf-495d-bce2-e172dfcdc417" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eebd5ef2-1b93-4e20-b6cc-ea806f3abb91" xlink:to="loc_thc_ConiferSegmentMember_1a64a762-6abf-495d-bce2-e172dfcdc417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827117f1-f421-4cd3-a9ea-86832851e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63506acf-a375-4c0d-9b45-83115da5915e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827117f1-f421-4cd3-a9ea-86832851e7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_08d9b377-e8c7-46e8-94ea-86728befb441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827117f1-f421-4cd3-a9ea-86832851e7ca" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_08d9b377-e8c7-46e8-94ea-86728befb441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_56df7302-3f73-4258-ba4e-15f1b18767b6" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2051da6a-7616-4111-983b-41404287a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_NumberOfReportableSegments_2051da6a-7616-4111-983b-41404287a84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_3f5e2fd2-c631-46f9-aa0c-03e55861fd87" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_3f5e2fd2-c631-46f9-aa0c-03e55861fd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_c4e3a3b6-fd78-4ec6-b367-f6700168460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_RestructuringCosts_c4e3a3b6-fd78-4ec6-b367-f6700168460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_33ed76a6-c8b4-4b8f-9015-df5894376cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_AssetImpairmentCharges_33ed76a6-c8b4-4b8f-9015-df5894376cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6416d8cb-9fd3-4f06-aad0-08cd3be80096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6416d8cb-9fd3-4f06-aad0-08cd3be80096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_12dfbb97-bf34-4457-9064-5fd5ec80cf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_AssetsNoncurrent_12dfbb97-bf34-4457-9064-5fd5ec80cf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_fa5e0302-9e02-4764-801f-f2df185373c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_fa5e0302-9e02-4764-801f-f2df185373c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_7412dcd7-7f12-41ed-91e1-cd865d358d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_BusinessExitCosts1_7412dcd7-7f12-41ed-91e1-cd865d358d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_5bbbe00a-a24b-4304-9655-3885019c3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_us-gaap_OtherRestructuringCosts_5bbbe00a-a24b-4304-9655-3885019c3749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_032aa671-89c6-40da-97d6-bf2221c6666c" xlink:href="thc-20221231.xsd#thc_BusinessCombinationAcquisitionRelatedTransactionCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_9991f833-f2f4-4d5b-b55e-dd8fe2e0b08f" xlink:to="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_032aa671-89c6-40da-97d6-bf2221c6666c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESBalanceSheetComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9259fcc-7665-401a-bab9-e8caeb1da131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9259fcc-7665-401a-bab9-e8caeb1da131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_953f30d7-071e-40e4-b789-80a48c254975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_953f30d7-071e-40e4-b789-80a48c254975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseRightOfUseAsset_a78e3c14-acc0-4514-ad68-29d5e8c72932" xlink:href="thc-20221231.xsd#thc_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_thc_LeaseRightOfUseAsset_a78e3c14-acc0-4514-ad68-29d5e8c72932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_32da82a3-2c53-4ef2-9506-6f0d45ec085a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_32da82a3-2c53-4ef2-9506-6f0d45ec085a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0263b7a6-a377-48c1-b100-24452941695b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0263b7a6-a377-48c1-b100-24452941695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bf1e9803-422f-4748-8a56-bf4df91a6bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseLiability_bf1e9803-422f-4748-8a56-bf4df91a6bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c979163c-5b07-4fbb-a769-e04064fb908b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c979163c-5b07-4fbb-a769-e04064fb908b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_33d733cc-a7c2-46b9-ad75-cdc6e9d55f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_33d733cc-a7c2-46b9-ad75-cdc6e9d55f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1ef91257-472d-4078-919c-50b0f88108d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseLiability_1ef91257-472d-4078-919c-50b0f88108d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiability_8373c4ee-7566-4527-b6a0-0f864bc5013f" xlink:href="thc-20221231.xsd#thc_LeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_thc_LeaseLiability_8373c4ee-7566-4527-b6a0-0f864bc5013f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4c44c113-5106-4e3f-8179-a2ef853d0deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4c44c113-5106-4e3f-8179-a2ef853d0deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1fc84a79-020d-47b6-a606-954f2edc7835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1fc84a79-020d-47b6-a606-954f2edc7835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6d02ff75-7879-4c9f-bef4-489e1a5291db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6d02ff75-7879-4c9f-bef4-489e1a5291db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2b122774-496b-49f5-a9c4-9675470dc27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2b122774-496b-49f5-a9c4-9675470dc27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0e9f1c37-33bb-4395-922a-4a4ba1b9eff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0e9f1c37-33bb-4395-922a-4a4ba1b9eff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_902dfacf-4e5a-4c4e-9b01-802d5ab69811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_77e96e1c-5c08-4230-b518-2499927fe4a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_902dfacf-4e5a-4c4e-9b01-802d5ab69811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0bdd37b4-4c34-4300-9069-52916ed04e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_us-gaap_OperatingLeaseCost_0bdd37b4-4c34-4300-9069-52916ed04e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeaseExpenseAbstract_bb846e3e-217c-4e4a-b1d0-a5b31f93b107" xlink:href="thc-20221231.xsd#thc_FinanceLeaseExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_thc_FinanceLeaseExpenseAbstract_bb846e3e-217c-4e4a-b1d0-a5b31f93b107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7164c907-9148-4ed9-98f5-14e25189571a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_FinanceLeaseExpenseAbstract_bb846e3e-217c-4e4a-b1d0-a5b31f93b107" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7164c907-9148-4ed9-98f5-14e25189571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_7d953559-1b9d-4b30-ab7c-52b9b3e2bb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_FinanceLeaseExpenseAbstract_bb846e3e-217c-4e4a-b1d0-a5b31f93b107" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_7d953559-1b9d-4b30-ab7c-52b9b3e2bb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeaseCost_bab27f76-f589-4892-9a41-807b6076e39b" xlink:href="thc-20221231.xsd#thc_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_FinanceLeaseExpenseAbstract_bb846e3e-217c-4e4a-b1d0-a5b31f93b107" xlink:to="loc_thc_FinanceLeaseCost_bab27f76-f589-4892-9a41-807b6076e39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_VariableAndShorttermLeaseCosts_2df3baaa-c870-467b-89d8-f5c1208b0e08" xlink:href="thc-20221231.xsd#thc_VariableAndShorttermLeaseCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_thc_VariableAndShorttermLeaseCosts_2df3baaa-c870-467b-89d8-f5c1208b0e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f75e2571-6254-4508-a795-86d11c0a56c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_us-gaap_LeaseCost_f75e2571-6254-4508-a795-86d11c0a56c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab65db11-8f09-4f24-afa1-1dce559acdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab65db11-8f09-4f24-afa1-1dce559acdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_64f9521d-f36d-45e9-b2d2-dc497b59ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_64f9521d-f36d-45e9-b2d2-dc497b59ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5b28940d-7815-4f14-bc2b-0370a340ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5b28940d-7815-4f14-bc2b-0370a340ed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_e7c3e96a-699a-4da3-9512-d672d0235da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8a7441c-8295-4486-8ff7-55d401b3ef5a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_e7c3e96a-699a-4da3-9512-d672d0235da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2e9b4ed7-6a11-49d8-b4c3-aa20c36404c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_e1bf9d68-99e9-4259-827f-01adc100384a" xlink:href="thc-20221231.xsd#thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2e9b4ed7-6a11-49d8-b4c3-aa20c36404c0" xlink:to="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_e1bf9d68-99e9-4259-827f-01adc100384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_58ab291b-305a-4f42-9960-3185674c3e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_e1bf9d68-99e9-4259-827f-01adc100384a" xlink:to="loc_us-gaap_OperatingLeasePayments_58ab291b-305a-4f42-9960-3185674c3e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_5e872596-a90e-4f5a-8725-6455dd967b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_e1bf9d68-99e9-4259-827f-01adc100384a" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_5e872596-a90e-4f5a-8725-6455dd967b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_fdd3be76-2eb3-4c63-b5f8-5b3becd73c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_e1bf9d68-99e9-4259-827f-01adc100384a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_fdd3be76-2eb3-4c63-b5f8-5b3becd73c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5908e417-eecb-4002-b627-779e7cf467d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2e9b4ed7-6a11-49d8-b4c3-aa20c36404c0" xlink:to="loc_us-gaap_LeaseCostAbstract_5908e417-eecb-4002-b627-779e7cf467d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_33f1ae86-325b-4d32-9861-8ffec7a7990e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5908e417-eecb-4002-b627-779e7cf467d0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_33f1ae86-325b-4d32-9861-8ffec7a7990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5f1009c3-18f7-43ae-91ea-30d7f0417ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5908e417-eecb-4002-b627-779e7cf467d0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5f1009c3-18f7-43ae-91ea-30d7f0417ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESScheduleofLeaseMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_49959945-06f2-40ba-ab3c-a32b5074ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49959945-06f2-40ba-ab3c-a32b5074ad74" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_254650be-2089-4388-92c0-0ee9a680c864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_254650be-2089-4388-92c0-0ee9a680c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e639e7de-2ba1-4002-a322-9cd397c497f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e639e7de-2ba1-4002-a322-9cd397c497f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3d09caa2-2f47-4623-8ac9-04863ca24bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3d09caa2-2f47-4623-8ac9-04863ca24bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_866025d5-37cb-42aa-8ed3-62672e246e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_866025d5-37cb-42aa-8ed3-62672e246e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7cf4ed2b-63fd-45ad-b7a3-ae7af6041503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7cf4ed2b-63fd-45ad-b7a3-ae7af6041503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0484809d-b193-429d-bb6a-8d611f930380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0484809d-b193-429d-bb6a-8d611f930380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d37570cf-827e-479a-bf5e-ca0129e2a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d37570cf-827e-479a-bf5e-ca0129e2a54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ee03d79-c885-492b-92b1-c4d082a3404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ee03d79-c885-492b-92b1-c4d082a3404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5b135fa9-e65a-4090-b74e-1de38c9a3e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_OperatingLeaseLiability_5b135fa9-e65a-4090-b74e-1de38c9a3e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2e4f1eba-fc06-4615-85ec-23902eb3f03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2e4f1eba-fc06-4615-85ec-23902eb3f03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1d45c16-ca0a-45e2-a263-8b7799d5d636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bc541076-5191-4f10-8a71-5b9253f99a4b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1d45c16-ca0a-45e2-a263-8b7799d5d636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49959945-06f2-40ba-ab3c-a32b5074ad74" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d598871a-fd8f-4016-a19d-5a21ad06f237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d598871a-fd8f-4016-a19d-5a21ad06f237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d3043043-294d-48d0-8775-ef1dc5440648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d3043043-294d-48d0-8775-ef1dc5440648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4237ede6-c8cd-4e95-b5ef-e34880a75c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4237ede6-c8cd-4e95-b5ef-e34880a75c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4748567e-8c81-49bd-9a35-a4c2f7b6d204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4748567e-8c81-49bd-9a35-a4c2f7b6d204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_794a3483-0ac4-4854-8aca-745e40794e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_794a3483-0ac4-4854-8aca-745e40794e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_bb52ad94-8844-4504-a25e-1d43e5598090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_bb52ad94-8844-4504-a25e-1d43e5598090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d8553f01-3cf3-43ee-8630-19c51e4fa0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d8553f01-3cf3-43ee-8630-19c51e4fa0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3627581c-9737-47a1-97dc-fd3123ee46d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3627581c-9737-47a1-97dc-fd3123ee46d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_57fea984-41bc-4d36-a26b-41badc52c3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiability_57fea984-41bc-4d36-a26b-41badc52c3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_3fde7c77-0ff8-47b7-bf5a-c662293aecad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_3fde7c77-0ff8-47b7-bf5a-c662293aecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4be612af-eb21-41ef-95b4-5d2c6676f288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1bfef288-eac8-4707-ab40-0f6e56d34728" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4be612af-eb21-41ef-95b4-5d2c6676f288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:href="thc-20221231.xsd#thc_LeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49959945-06f2-40ba-ab3c-a32b5074ad74" xlink:to="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_6b4a81f6-1286-4806-9172-063deebdf19b" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths_6b4a81f6-1286-4806-9172-063deebdf19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_1ad8d837-fbef-4ec7-80c7-085f3ac55497" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearTwo_1ad8d837-fbef-4ec7-80c7-085f3ac55497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearThree_ca5c7bd6-3664-4bad-b13d-c50bb21421b5" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearThree_ca5c7bd6-3664-4bad-b13d-c50bb21421b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFour_16896e62-b571-49d4-940e-8b2d56c1c175" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFour_16896e62-b571-49d4-940e-8b2d56c1c175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFive_23c7abc0-4037-4bca-b2d6-bfd64eecb3d9" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueYearFive_23c7abc0-4037-4bca-b2d6-bfd64eecb3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_8eef6702-bc41-44ac-83db-1e7fa1603e2d" xlink:href="thc-20221231.xsd#thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive_8eef6702-bc41-44ac-83db-1e7fa1603e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityPaymentsDue_1f25b32d-1367-4162-97ce-ee5eb29ae609" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LeaseLiabilityPaymentsDue_1f25b32d-1367-4162-97ce-ee5eb29ae609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityUndiscountedExcessAmount_cd099f3c-3123-4006-bd71-458a1399962b" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LeaseLiabilityUndiscountedExcessAmount_cd099f3c-3123-4006-bd71-458a1399962b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiability_11f8af32-1cda-44e5-8599-51f263af473c" xlink:href="thc-20221231.xsd#thc_LeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LeaseLiability_11f8af32-1cda-44e5-8599-51f263af473c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityCurrent_5b349813-0e7a-4673-9bf8-5e32a2e5a65a" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LeaseLiabilityCurrent_5b349813-0e7a-4673-9bf8-5e32a2e5a65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LeaseLiabilityNoncurrent_fc66317b-7c9f-453f-a04e-ca133c795a25" xlink:href="thc-20221231.xsd#thc_LeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LeaseLiabilitiesPaymentsDueAbstract_587bfbf5-72b8-4a1f-854d-18b93769c631" xlink:to="loc_thc_LeaseLiabilityNoncurrent_fc66317b-7c9f-453f-a04e-ca133c795a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6c9d089c-bf3c-4ff8-af05-8e19137363ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c9d089c-bf3c-4ff8-af05-8e19137363ce" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_edc049f3-6bc9-41ec-82ea-2b48eebfe2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30aa18ae-7e76-401e-a7dc-5b4213b4a2a9" xlink:to="loc_us-gaap_SegmentDomain_edc049f3-6bc9-41ec-82ea-2b48eebfe2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsSegmentMember_93c01182-99d0-4e90-bbcd-df02c83975fa" xlink:href="thc-20221231.xsd#thc_HospitalOperationsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_edc049f3-6bc9-41ec-82ea-2b48eebfe2dd" xlink:to="loc_thc_HospitalOperationsSegmentMember_93c01182-99d0-4e90-bbcd-df02c83975fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2d988ceb-039e-414e-85ea-0d0dbf8c7356" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfBuildings_dfccdc19-19c7-4db5-bde5-a938816454f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfBuildings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_ProceedsFromSaleOfBuildings_dfccdc19-19c7-4db5-bde5-a938816454f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfProperties_2dcd70b7-4205-49ac-9047-df0a8f0eb6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfProperties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_GainLossOnSaleOfProperties_2dcd70b7-4205-49ac-9047-df0a8f0eb6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_97c1237d-acdd-44f2-83fe-b2ac7ac67256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_97c1237d-acdd-44f2-83fe-b2ac7ac67256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e76c2efd-19b3-44bb-a586-61af2e789105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_acf5e89f-a966-4777-b872-a3ab1ace0030" xlink:to="loc_us-gaap_OperatingLeaseLiability_e76c2efd-19b3-44bb-a586-61af2e789105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_c968d808-5e08-4793-a213-d7b41cb1270d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_c968d808-5e08-4793-a213-d7b41cb1270d" xlink:to="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2872371d-7cd4-42a7-b333-0de2b62f7206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_218b9e0c-9ec0-4abe-9e70-fe5e534889ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2872371d-7cd4-42a7-b333-0de2b62f7206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a1bfa273-f152-43c8-8c4c-ce32d1364052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2872371d-7cd4-42a7-b333-0de2b62f7206" xlink:to="loc_us-gaap_SeniorNotesMember_a1bfa273-f152-43c8-8c4c-ce32d1364052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:to="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_61b3604e-8c42-40a7-9cc1-32a30781b0e4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_9d07deaf-f781-41a9-b8a3-875e69010948" xlink:href="thc-20221231.xsd#thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_9d07deaf-f781-41a9-b8a3-875e69010948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_25a7dde7-a0c4-4eb8-ae8a-f28a2a4a5364" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member_25a7dde7-a0c4-4eb8-ae8a-f28a2a4a5364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_53c8b159-c2dc-4286-895a-dd5745703630" xlink:href="thc-20221231.xsd#thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member_53c8b159-c2dc-4286-895a-dd5745703630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_e880ff25-7c65-45e0-bf19-c3430317105c" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_e880ff25-7c65-45e0-bf19-c3430317105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a0f7346a-e9ad-4ea2-b010-d812aa5d1b6d" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a0f7346a-e9ad-4ea2-b010-d812aa5d1b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_18f708f9-684e-4758-9d9f-af66fec31ce0" xlink:href="thc-20221231.xsd#thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_18f708f9-684e-4758-9d9f-af66fec31ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_0d13aa86-90c8-4b9f-8739-8e84d7b674d3" xlink:href="thc-20221231.xsd#thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member_0d13aa86-90c8-4b9f-8739-8e84d7b674d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_8ac6013c-2369-4ab2-88b1-175a879d7f19" xlink:href="thc-20221231.xsd#thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member_8ac6013c-2369-4ab2-88b1-175a879d7f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_0b91d60e-da48-4a91-8186-06b658c5210f" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member_0b91d60e-da48-4a91-8186-06b658c5210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_e55ca27d-d91b-4c84-8ef5-2d3ddc81f11e" xlink:href="thc-20221231.xsd#thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member_e55ca27d-d91b-4c84-8ef5-2d3ddc81f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_4f22dee0-26fe-4a74-a62c-10ba0555184e" xlink:href="thc-20221231.xsd#thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_4f22dee0-26fe-4a74-a62c-10ba0555184e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_de5ba8af-ce94-47d7-b71f-d929766807fa" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_de5ba8af-ce94-47d7-b71f-d929766807fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_7bf3a912-1fe3-4333-97a8-f5fb137ff307" xlink:href="thc-20221231.xsd#thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ea4e76c5-dfe8-4d91-b227-b7f0333b75ef" xlink:to="loc_thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member_7bf3a912-1fe3-4333-97a8-f5fb137ff307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_68ebcd8d-1998-4402-af06-eb6d71dd2f46" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aca33a63-ce4a-46bf-b0fe-1b51b7f67978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_aca33a63-ce4a-46bf-b0fe-1b51b7f67978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FinanceLeasesAndMortgageNotes_05579a26-a2ae-49ac-b7ea-ff4681e430a6" xlink:href="thc-20221231.xsd#thc_FinanceLeasesAndMortgageNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_thc_FinanceLeasesAndMortgageNotes_05579a26-a2ae-49ac-b7ea-ff4681e430a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5b000d14-4806-4bb8-b307-a87f32193a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5b000d14-4806-4bb8-b307-a87f32193a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_4e8dcaee-95ce-4295-ba7f-b1e41c060c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_4e8dcaee-95ce-4295-ba7f-b1e41c060c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a5557e03-8d2c-456a-85bf-7b0e2ad28fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a5557e03-8d2c-456a-85bf-7b0e2ad28fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_59cd7e40-f2d6-4762-ac77-87895eae985e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_59cd7e40-f2d6-4762-ac77-87895eae985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8d0302e-cdec-4376-8067-fd6e5244d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f1c0d33-a49d-4843-b12e-38b552f1252f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8d0302e-cdec-4376-8067-fd6e5244d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTScheduleofDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6092119d-17de-4c95-9372-9c98bab6590c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6092119d-17de-4c95-9372-9c98bab6590c" xlink:to="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f8f36436-5a44-4c1a-8771-dd6b27afafe6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7770abd5-a704-4391-b499-4900a417823c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:to="loc_us-gaap_SeniorNotesMember_7770abd5-a704-4391-b499-4900a417823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3b2de195-2f50-4380-9be2-3ab49c33aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:to="loc_us-gaap_LineOfCreditMember_3b2de195-2f50-4380-9be2-3ab49c33aedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_eea78846-3aee-47c3-87f6-5178b55c90ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a383a65-877a-4cc6-b28e-b901c4b4fae4" xlink:to="loc_us-gaap_LetterOfCreditMember_eea78846-3aee-47c3-87f6-5178b55c90ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ea3ba17-8c3c-4da1-b331-06878a6d368e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_7e7a2d72-00aa-470d-9a9d-4906ea1a6804" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member_7e7a2d72-00aa-470d-9a9d-4906ea1a6804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a802306d-ec3e-449f-adf6-aad2fb685d23" xlink:href="thc-20221231.xsd#thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member_a802306d-ec3e-449f-adf6-aad2fb685d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_36fe3eef-c0b5-430c-90e7-916dba53a00e" xlink:href="thc-20221231.xsd#thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member_36fe3eef-c0b5-430c-90e7-916dba53a00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_3160c4cd-bef3-4a60-8c64-cf5992a727ea" xlink:href="thc-20221231.xsd#thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member_3160c4cd-bef3-4a60-8c64-cf5992a727ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_73036362-935a-4879-bf7f-f3ba02475900" xlink:href="thc-20221231.xsd#thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member_73036362-935a-4879-bf7f-f3ba02475900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_ee53421e-78db-4f30-bffe-a86153773a42" xlink:href="thc-20221231.xsd#thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member_ee53421e-78db-4f30-bffe-a86153773a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_19cb30a1-3842-4c81-8fae-d2e54701e4a8" xlink:href="thc-20221231.xsd#thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member_19cb30a1-3842-4c81-8fae-d2e54701e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_2283de75-8d3e-49a2-88c5-e5bcdd183d10" xlink:href="thc-20221231.xsd#thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member_2283de75-8d3e-49a2-88c5-e5bcdd183d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_c7dd7060-9b84-4706-8a0f-dc8ca037a793" xlink:href="thc-20221231.xsd#thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57e68f1-81e6-4fa4-93b9-6223d4235240" xlink:to="loc_thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member_c7dd7060-9b84-4706-8a0f-dc8ca037a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9ba24084-db73-43e0-8b66-87a37ea281eb" xlink:to="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_4d2892f4-6f4f-45fb-86e4-6936e2a01db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:to="loc_us-gaap_LetterOfCreditMember_4d2892f4-6f4f-45fb-86e4-6936e2a01db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cbbff366-410b-470d-b93d-16be3ba1c69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dab05dcb-89a9-4917-9e1b-a2ddac233211" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cbbff366-410b-470d-b93d-16be3ba1c69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_11d1d5a8-5400-4d12-ab27-190841a26ec8" xlink:to="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_57d2b7f8-0a64-4747-bffc-f45048db2133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:to="loc_us-gaap_BaseRateMember_57d2b7f8-0a64-4747-bffc-f45048db2133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4c6b7a7c-110b-4269-9fd9-28bce48973b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a3e0c4bd-db3f-407f-9248-67718c0d84e8" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4c6b7a7c-110b-4269-9fd9-28bce48973b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_56bc39ea-5de0-43e7-9dca-ef0dc2a80752" xlink:to="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5479067-451e-41fa-b0dd-a3a7288f989e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:to="loc_srt_MinimumMember_e5479067-451e-41fa-b0dd-a3a7288f989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_64403c3c-c522-4317-8ad6-c4dc2b65cfd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9df307a2-6719-4fe0-9ef0-ff7710434777" xlink:to="loc_srt_MaximumMember_64403c3c-c522-4317-8ad6-c4dc2b65cfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e411595b-9430-4283-8dfd-88da40c7c7d0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7cebfecd-5714-4bec-827a-b59c920ba558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7cebfecd-5714-4bec-827a-b59c920ba558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4121804b-9015-40b0-8a19-55428f9be78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4121804b-9015-40b0-8a19-55428f9be78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d35a7550-fc88-44bd-9415-db33d1dd60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d35a7550-fc88-44bd-9415-db33d1dd60f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4bd29d1c-0f27-40e9-a265-bb1916ca4b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4bd29d1c-0f27-40e9-a265-bb1916ca4b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe149197-2c42-4ba7-8f1f-483db732c971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe149197-2c42-4ba7-8f1f-483db732c971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_c21b3b77-3561-4642-9ba6-eeefb1636fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_RepaymentsOfDebt_c21b3b77-3561-4642-9ba6-eeefb1636fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_969450a5-bbfd-4a90-a1de-3b72017fdf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_969450a5-bbfd-4a90-a1de-3b72017fdf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_fd5f88e5-a63d-4fc2-8755-d58c92967041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_fd5f88e5-a63d-4fc2-8755-d58c92967041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_5a644088-fde4-45cc-ad39-6185aea08697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_5a644088-fde4-45cc-ad39-6185aea08697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_372df8f8-bafb-48fb-b3d1-f5560e7f9358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_372df8f8-bafb-48fb-b3d1-f5560e7f9358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_7b9c1b7b-fb80-4024-b9f3-1a3e0c4e004d" xlink:href="thc-20221231.xsd#thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal_7b9c1b7b-fb80-4024-b9f3-1a3e0c4e004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_eacdb605-54db-4bc5-b839-4cd2502cae66" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity_eacdb605-54db-4bc5-b839-4cd2502cae66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_637572bf-080d-47db-b46f-f2b394e3f8a7" xlink:href="thc-20221231.xsd#thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised_637572bf-080d-47db-b46f-f2b394e3f8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_bd8261f0-c104-4ad3-89eb-b0702fe23f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_bd8261f0-c104-4ad3-89eb-b0702fe23f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_88072c11-b7ab-4c6e-9ad2-b421dedc8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_88072c11-b7ab-4c6e-9ad2-b421dedc8c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f5428a0b-c2c7-4446-8eca-00b6f8ec4fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_f5428a0b-c2c7-4446-8eca-00b6f8ec4fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1427f-adc2-4251-871f-84d05eda85a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8db1427f-adc2-4251-871f-84d05eda85a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentBasisSpreadOnCreditSpread_27e52ec6-8fc5-4dcc-ac4c-caf309c14b63" xlink:href="thc-20221231.xsd#thc_DebtInstrumentBasisSpreadOnCreditSpread"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentBasisSpreadOnCreditSpread_27e52ec6-8fc5-4dcc-ac4c-caf309c14b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1220393a-0051-4f88-82ea-0bcef2493feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1220393a-0051-4f88-82ea-0bcef2493feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_ddc2208d-d1af-456a-a3f2-bca4690d3d0b" xlink:href="thc-20221231.xsd#thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings_ddc2208d-d1af-456a-a3f2-bca4690d3d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_42609ec6-ea88-4dab-868a-48f1d150b643" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio_42609ec6-ea88-4dab-868a-48f1d150b643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_866eb20f-e94d-4592-ad41-0cb1127f8cce" xlink:href="thc-20221231.xsd#thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit_866eb20f-e94d-4592-ad41-0cb1127f8cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_0dfe5ad0-53a1-4043-89a0-61e39d967196" xlink:href="thc-20221231.xsd#thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage_0dfe5ad0-53a1-4043-89a0-61e39d967196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_fb508cc0-651c-4ee2-a876-f853a90ed0fa" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantMaximumSecuredDebtRatio"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio_fb508cc0-651c-4ee2-a876-f853a90ed0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_b013fa74-a3d9-45e8-9911-c5e24c014cd8" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantsOfSecuredDebtRatio"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantsOfSecuredDebtRatio_b013fa74-a3d9-45e8-9911-c5e24c014cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_934a9cc2-d2d3-4082-a868-8e74e80e1d3e" xlink:href="thc-20221231.xsd#thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty_934a9cc2-d2d3-4082-a868-8e74e80e1d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantThresholdLimit_6a9935e7-6d96-4fc4-9020-29a7225714bf" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantThresholdLimit"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilityCovenantThresholdLimit_6a9935e7-6d96-4fc4-9020-29a7225714bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_d69a1e4b-9053-47fb-884e-e5f2ae8560b7" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit_d69a1e4b-9053-47fb-884e-e5f2ae8560b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_327c0c3b-c3e6-4fe7-b0f2-6966cfde3281" xlink:href="thc-20221231.xsd#thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_775b9063-1c37-49c9-84b1-12fe753715f1" xlink:to="loc_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays_327c0c3b-c3e6-4fe7-b0f2-6966cfde3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#LONGTERMDEBTFutureMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_f4e1751a-6146-457c-bccd-4afa383696ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_f4e1751a-6146-457c-bccd-4afa383696ea" xlink:to="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_e25c477f-a985-4bb5-9493-3c980661d6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_e25c477f-a985-4bb5-9493-3c980661d6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_4505cf84-65e0-4059-9a6f-8aed1b62490d" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths_4505cf84-65e0-4059-9a6f-8aed1b62490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_4d8eed7b-0670-4446-95a8-75a006c0170c" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo_4d8eed7b-0670-4446-95a8-75a006c0170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_531217a5-0ff3-4095-b3f7-4b54cb4a9d48" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree_531217a5-0ff3-4095-b3f7-4b54cb4a9d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_b131f446-83ec-4f47-86f2-30b8f6e8ba21" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour_b131f446-83ec-4f47-86f2-30b8f6e8ba21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_dab17344-43cf-4420-847d-3cf2c3bcbb65" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive_dab17344-43cf-4420-847d-3cf2c3bcbb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_eb1a366c-c977-4e92-8035-6d444469b8a1" xlink:href="thc-20221231.xsd#thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_25cd21d9-08a4-4d1d-b0fb-3a423354a98e" xlink:to="loc_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive_eb1a366c-c977-4e92-8035-6d444469b8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GUARANTEESDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GUARANTEESDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GUARANTEESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract_1af9453e-3ebd-4af6-87b9-115930ba8d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_1af9453e-3ebd-4af6-87b9-115930ba8d65" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_bb4fa570-770c-43ca-8d1e-7236935a27a7" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeGuaranteeMember_bb3d684b-7cd7-4458-a098-6ee7a7945cbe" xlink:href="thc-20221231.xsd#thc_IncomeGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_thc_IncomeGuaranteeMember_bb3d684b-7cd7-4458-a098-6ee7a7945cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeOfBusinessRevenueMember_56c65d10-ecaf-4f39-805b-ab39cb50e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeOfBusinessRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_us-gaap_GuaranteeOfBusinessRevenueMember_56c65d10-ecaf-4f39-805b-ab39cb50e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeAndRevenueCollectionGuaranteeMember_9b2dd702-3f33-4395-a57a-7c5bb5ea5b94" xlink:href="thc-20221231.xsd#thc_IncomeAndRevenueCollectionGuaranteeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_thc_IncomeAndRevenueCollectionGuaranteeMember_9b2dd702-3f33-4395-a57a-7c5bb5ea5b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteedInvesteesOfThirdPartiesMember_1d9b6577-8f9e-452d-a13d-2b88385460ee" xlink:href="thc-20221231.xsd#thc_GuaranteedInvesteesOfThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_d25b3f13-f7a4-475b-b4db-7694a70a0d84" xlink:to="loc_thc_GuaranteedInvesteesOfThirdPartiesMember_1d9b6577-8f9e-452d-a13d-2b88385460ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3c43343c-ab27-49df-9f7b-9d150eb60e9d" xlink:to="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_594ea296-fbe9-4ae5-827d-bd88bb559261" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:to="loc_srt_MinimumMember_594ea296-fbe9-4ae5-827d-bd88bb559261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_15bcf84c-2991-4c52-bc16-52174bcb40a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3981bcf-0bcb-43f0-ba50-5ce31617ba0e" xlink:to="loc_srt_MaximumMember_15bcf84c-2991-4c52-bc16-52174bcb40a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb618e72-a5cd-4fcc-981c-27500a113c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5bd4c122-6a7d-4485-9ff9-be35b7c169ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb618e72-a5cd-4fcc-981c-27500a113c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c4b12c24-448f-4f19-9ed1-2a42d85eb182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb618e72-a5cd-4fcc-981c-27500a113c6e" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c4b12c24-448f-4f19-9ed1-2a42d85eb182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_6cc99399-263a-472a-87a7-abb5cbf472e4" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteeObligationPeriod_23e8b0f6-b133-44f0-8637-02129696d229" xlink:href="thc-20221231.xsd#thc_GuaranteeObligationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_thc_GuaranteeObligationPeriod_23e8b0f6-b133-44f0-8637-02129696d229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CommitmentPeriod_3f949596-ed4e-400d-8795-85a0430b8370" xlink:href="thc-20221231.xsd#thc_CommitmentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_thc_CommitmentPeriod_3f949596-ed4e-400d-8795-85a0430b8370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_715abc77-a2cd-4ac4-866c-151371faf103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_715abc77-a2cd-4ac4-866c-151371faf103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesFairValueDisclosure_730acf48-ebc2-41bb-bd94-a02960efc665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_us-gaap_GuaranteesFairValueDisclosure_730acf48-ebc2-41bb-bd94-a02960efc665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_17f11c4f-79e0-4b69-9644-166aa86e274e" xlink:href="thc-20221231.xsd#thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_b6f62bd8-b21d-47c9-918e-a0f544b8b389" xlink:to="loc_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries_17f11c4f-79e0-4b69-9644-166aa86e274e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeafcdb4-eae8-427c-a448-f298fba28526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeafcdb4-eae8-427c-a448-f298fba28526" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d314de73-cc88-4cfb-a742-e858d2cd8087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a3b1021-c1e5-4991-b2d9-3f84531cd889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a3b1021-c1e5-4991-b2d9-3f84531cd889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2bc6eaf3-4f1d-4ed2-8f81-81082e54d541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2bc6eaf3-4f1d-4ed2-8f81-81082e54d541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedRestrictedStockUnitMember_9df10afd-a02c-4700-bb37-7d6ddce711f6" xlink:href="thc-20221231.xsd#thc_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3952c47-2ee1-4e71-b31a-cd477ca77d02" xlink:to="loc_thc_PerformanceBasedRestrictedStockUnitMember_9df10afd-a02c-4700-bb37-7d6ddce711f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d4e9a98e-228c-4786-8061-10bc7209a04a" xlink:to="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e8004557-a11c-423b-9f12-a70f3f2d0dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:to="loc_srt_MinimumMember_e8004557-a11c-423b-9f12-a70f3f2d0dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5eb34a01-1af3-468e-9efb-e34f4e340e22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35c28c4b-2c63-42c2-9f13-92829c65a4e6" xlink:to="loc_srt_MaximumMember_5eb34a01-1af3-468e-9efb-e34f4e340e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8317b828-5833-458d-8cd6-b4f9c8c490a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d3c8698c-882c-4e50-8c56-ca14041bb43d" xlink:to="loc_us-gaap_VestingDomain_8317b828-5833-458d-8cd6-b4f9c8c490a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingMember_7f9e57d5-427c-4551-b74f-30014a8a5628" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8317b828-5833-458d-8cd6-b4f9c8c490a6" xlink:to="loc_thc_PerformanceBasedVestingMember_7f9e57d5-427c-4551-b74f-30014a8a5628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc53fcba-11ab-4661-b608-2acb98be6da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_097acaf3-11e6-4cc3-a8ab-a088484d3777" xlink:to="loc_us-gaap_PlanNameDomain_cc53fcba-11ab-4661-b608-2acb98be6da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_StockIncentivePlan2019Member_1edd4e3c-9a40-483f-b3ef-6948afd52aa4" xlink:href="thc-20221231.xsd#thc_StockIncentivePlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc53fcba-11ab-4661-b608-2acb98be6da0" xlink:to="loc_thc_StockIncentivePlan2019Member_1edd4e3c-9a40-483f-b3ef-6948afd52aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cda8dca1-1364-47cc-ab54-b3a1701e5f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6a3c6cfc-f8a9-4b20-951c-e4ac22a60f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6a3c6cfc-f8a9-4b20-951c-e4ac22a60f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_b7e071ee-21b2-4d59-ba2a-0011f8d542cc" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_b7e071ee-21b2-4d59-ba2a-0011f8d542cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d2b13464-67af-4e16-b252-1d2e544e2566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d2b13464-67af-4e16-b252-1d2e544e2566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8dc4ea58-0b7b-4d25-b9fe-7ff317930574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8dc4ea58-0b7b-4d25-b9fe-7ff317930574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e74d40a7-0c29-451b-b2e7-dbf1dbcf419b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e74d40a7-0c29-451b-b2e7-dbf1dbcf419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f0378e-6f21-4f55-8bfe-fe6bc27a04e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e139641b-2686-4747-b510-04cd469178c7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f0378e-6f21-4f55-8bfe-fe6bc27a04e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_36101a94-0c06-4f2e-bfa9-915d9ac127a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_36101a94-0c06-4f2e-bfa9-915d9ac127a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:to="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_959746e6-2f0d-4d57-9789-7a3a40481e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8bd0611c-c33f-4b15-8712-5eb385dc040c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_959746e6-2f0d-4d57-9789-7a3a40481e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_375d7a6b-fa26-4cc8-8051-528f6d5bfd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_959746e6-2f0d-4d57-9789-7a3a40481e1b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_375d7a6b-fa26-4cc8-8051-528f6d5bfd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7f889f4-7c07-4738-9a8a-cb2a9534fe6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11b4b687-c512-44b5-975d-17d673730094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11b4b687-c512-44b5-975d-17d673730094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27d5e9af-3fd0-4356-802d-c16517fe722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27d5e9af-3fd0-4356-802d-c16517fe722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3ffbfc67-0dfa-46c5-8af4-7c46b2beb3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3ffbfc67-0dfa-46c5-8af4-7c46b2beb3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_662e5b90-558f-40b9-85a4-2f913495c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22f387e9-1557-48c3-80de-edf5c6661c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_662e5b90-558f-40b9-85a4-2f913495c0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcadf2c8-38c3-49a6-8ded-c5d65d9fdd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcadf2c8-38c3-49a6-8ded-c5d65d9fdd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05af1f27-3817-4082-8a39-3cd0b962cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05af1f27-3817-4082-8a39-3cd0b962cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d3113fd0-d566-4de6-82e9-91c9e1c9a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d3113fd0-d566-4de6-82e9-91c9e1c9a1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19899134-aeb3-425b-8f95-6190da97b7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ecc73cb-17c0-4f8e-bb46-13169ab1ba6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19899134-aeb3-425b-8f95-6190da97b7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ffef342e-7edd-4b2c-a1ff-db3ac16a090d" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ffef342e-7edd-4b2c-a1ff-db3ac16a090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1df0ccd-dae6-4004-8c0e-0a1f9669be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ffef342e-7edd-4b2c-a1ff-db3ac16a090d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1df0ccd-dae6-4004-8c0e-0a1f9669be9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba65649e-0231-4311-b333-8016548434a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba65649e-0231-4311-b333-8016548434a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a51a0e8e-3cdb-4c44-9b7b-d06236138958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba65649e-0231-4311-b333-8016548434a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a51a0e8e-3cdb-4c44-9b7b-d06236138958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb705d86-94ff-4c9b-92c6-4dfdba4f4152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb705d86-94ff-4c9b-92c6-4dfdba4f4152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7d3003b-4284-4220-94fe-faf403247793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0280fb4-d72b-4998-9ff5-3138795ddc50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7d3003b-4284-4220-94fe-faf403247793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b15c540c-e80c-468e-9c61-a007bd8f2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b15c540c-e80c-468e-9c61-a007bd8f2c6e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3561eafa-fe4f-4c9e-a504-b078bb6e8013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a34825ab-4234-45c8-86b0-2cf57d3d4fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3561eafa-fe4f-4c9e-a504-b078bb6e8013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0e70ba34-2813-479f-b283-44f0cc3f13e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3561eafa-fe4f-4c9e-a504-b078bb6e8013" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0e70ba34-2813-479f-b283-44f0cc3f13e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9d7095ac-1d5e-43ea-8344-e9c17aa8a7c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ExercisePriceRangeOneMember_257c37c0-ccf3-4c3c-9bc5-eca0b6e913ca" xlink:href="thc-20221231.xsd#thc_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:to="loc_thc_ExercisePriceRangeOneMember_257c37c0-ccf3-4c3c-9bc5-eca0b6e913ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ExercisePriceRangeSecondMember_7ca97502-79f6-4418-9c61-91140d6789ca" xlink:href="thc-20221231.xsd#thc_ExercisePriceRangeSecondMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1f8830b6-a13a-4072-8e82-6da4376e0080" xlink:to="loc_thc_ExercisePriceRangeSecondMember_7ca97502-79f6-4418-9c61-91140d6789ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_02723178-806f-4d48-b904-e248504cc4cf" xlink:to="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eca92ff3-4f41-4194-a6c3-fbfb3fe4a59f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:to="loc_srt_MinimumMember_eca92ff3-4f41-4194-a6c3-fbfb3fe4a59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_343c5f54-7a98-4f77-90a4-a67e688bef48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b83a220-38d9-40dd-ad82-a86cc53df876" xlink:to="loc_srt_MaximumMember_343c5f54-7a98-4f77-90a4-a67e688bef48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_80abe9c2-cb46-4e66-9455-234ad0f65d25" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b50244d5-0131-44ff-acaf-17e317a8fd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b50244d5-0131-44ff-acaf-17e317a8fd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24c5627b-2433-4975-896b-3ab19d91e3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24c5627b-2433-4975-896b-3ab19d91e3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a5e413f4-66ce-471e-974c-a4eccdf904e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_af7e75a0-ece6-4d86-80b7-83e4cdf745c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_af7e75a0-ece6-4d86-80b7-83e4cdf745c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0d182566-6510-4993-a1cb-7328816118ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0d182566-6510-4993-a1cb-7328816118ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_08ae1d7b-de81-4c3d-b6c6-148da02a4dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_0039e5e7-5f0d-4976-8943-f7d2cc042d6c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_08ae1d7b-de81-4c3d-b6c6-148da02a4dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f71fb5-e43d-4153-9aa0-0aa3c825a4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f71fb5-e43d-4153-9aa0-0aa3c825a4f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:to="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4fae33c-3af6-43e0-aba9-4f8856758abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d652eba1-851b-4a47-89d4-66747b84cbc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4fae33c-3af6-43e0-aba9-4f8856758abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_64688035-383d-4930-b2be-fccca06cb6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4fae33c-3af6-43e0-aba9-4f8856758abd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_64688035-383d-4930-b2be-fccca06cb6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:to="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_dc39337b-8788-42bf-91e9-4007d40930c7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CurrentEmployeesMember_9c270d40-a76d-4c54-98c2-af24701b58d2" xlink:href="thc-20221231.xsd#thc_CurrentEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:to="loc_thc_CurrentEmployeesMember_9c270d40-a76d-4c54-98c2-af24701b58d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FormerEmployeesMember_fdb3b8a4-1b55-411d-8ef1-2c79786d0246" xlink:href="thc-20221231.xsd#thc_FormerEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dfc78420-7296-42df-a0d9-b84d37c736e4" xlink:to="loc_thc_FormerEmployeesMember_fdb3b8a4-1b55-411d-8ef1-2c79786d0246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92c2811f-69ee-44f5-8367-073a2eaaed48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_6933a46b-2d6e-4cc4-a76a-60b639e549b6" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage_6933a46b-2d6e-4cc4-a76a-60b639e549b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_53dab31b-865f-4ec8-8eef-c15c80af8b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_us-gaap_SharePrice_53dab31b-865f-4ec8-8eef-c15c80af8b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28fd3551-c7a8-4bd6-b1a3-fcba422d2e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8379b43a-0f25-4709-9316-2fb7aae2dc61" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28fd3551-c7a8-4bd6-b1a3-fcba422d2e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5716710a-d76d-4620-b0d5-a930d056e61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5716710a-d76d-4620-b0d5-a930d056e61c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_734a5774-c5f7-496c-af2a-c0b3b01a3ca7" xlink:to="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_cddb8cec-9f4e-4e88-b919-b53aa5fa960b" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember_cddb8cec-9f4e-4e88-b919-b53aa5fa960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingFourYearFromGrantDateMember_5d3620a5-cdf2-4e73-8200-a81fe155b136" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingFourYearFromGrantDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingFourYearFromGrantDateMember_5d3620a5-cdf2-4e73-8200-a81fe155b136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_e3aad0e8-aa7e-4581-9c19-0e58cc33b540" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnSecondAnniversaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingSettledOnSecondAnniversaryMember_e3aad0e8-aa7e-4581-9c19-0e58cc33b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_1ced8f4f-0569-46dc-b69d-7fc6589b2a77" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember_1ced8f4f-0569-46dc-b69d-7fc6589b2a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_9cd7baac-53ff-4e03-9065-e7c00a2350f5" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingOverAThreeYearPeriodMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingOverAThreeYearPeriodMember_9cd7baac-53ff-4e03-9065-e7c00a2350f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingMember_ca4a78a9-da97-44e5-8a50-d50c3b329d78" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingMember_ca4a78a9-da97-44e5-8a50-d50c3b329d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingMember_7b92b99f-250f-4e28-8a2b-2118fe707652" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingMember_7b92b99f-250f-4e28-8a2b-2118fe707652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EightQuarterVestingPeriodMember_63ded0ef-f325-49df-a6e0-5aeed20ec6a4" xlink:href="thc-20221231.xsd#thc_EightQuarterVestingPeriodMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_EightQuarterVestingPeriodMember_63ded0ef-f325-49df-a6e0-5aeed20ec6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ElevenQuarterVestingPeriodMember_a4740b4c-2762-4af4-b82f-06f96e993571" xlink:href="thc-20221231.xsd#thc_ElevenQuarterVestingPeriodMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_ElevenQuarterVestingPeriodMember_a4740b4c-2762-4af4-b82f-06f96e993571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_946d32bf-0dfc-4f08-9243-69589b824407" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnFourthAnniversaryMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingSettledOnFourthAnniversaryMember_946d32bf-0dfc-4f08-9243-69589b824407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_c3966723-ffff-40c9-b163-64145b8443bc" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingSettledOnThirdAnniversaryMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingSettledOnThirdAnniversaryMember_c3966723-ffff-40c9-b163-64145b8443bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingOneYearFromGrantDateMember_dc73b4b3-8471-44fb-936d-f9ae3681d677" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingOneYearFromGrantDateMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingOneYearFromGrantDateMember_dc73b4b3-8471-44fb-936d-f9ae3681d677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TimeBasedVestingOnFourthAnniversaryMember_6b481dc8-e75f-42af-a9d2-d84f2043236b" xlink:href="thc-20221231.xsd#thc_TimeBasedVestingOnFourthAnniversaryMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_TimeBasedVestingOnFourthAnniversaryMember_6b481dc8-e75f-42af-a9d2-d84f2043236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingOnFourthAnniversaryMember_a01b5951-9287-475f-b94c-a5069ac6ba06" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingOnFourthAnniversaryMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingOnFourthAnniversaryMember_a01b5951-9287-475f-b94c-a5069ac6ba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedVestingAndSettledImmediatelyMember_18b002d1-230c-4c68-b8df-d548f5b89d38" xlink:href="thc-20221231.xsd#thc_PerformanceBasedVestingAndSettledImmediatelyMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_56c2cd9c-92df-4454-b9c6-c13e64852884" xlink:to="loc_thc_PerformanceBasedVestingAndSettledImmediatelyMember_18b002d1-230c-4c68-b8df-d548f5b89d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_afba0f6c-7819-49db-9d22-9dace6c0591d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NonExecutiveChairmanMember_bedc29a2-8019-4006-91e6-00422b3b3761" xlink:href="thc-20221231.xsd#thc_NonExecutiveChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_thc_NonExecutiveChairmanMember_bedc29a2-8019-4006-91e6-00422b3b3761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SeniorOfficerMember_853018bc-eefd-4488-9d4c-bbeb9c62a3e9" xlink:href="thc-20221231.xsd#thc_SeniorOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_thc_SeniorOfficerMember_853018bc-eefd-4488-9d4c-bbeb9c62a3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NonEmployeeDirectorsMember_6841521f-67c0-4f4b-984d-917510811b0a" xlink:href="thc-20221231.xsd#thc_NonEmployeeDirectorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_thc_NonEmployeeDirectorsMember_6841521f-67c0-4f4b-984d-917510811b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_fbb2e32b-d9b1-4ba3-990c-e2f83ce06e11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ea3c93ee-e52c-4bd8-9122-c40b206bee6c" xlink:to="loc_srt_DirectorMember_fbb2e32b-d9b1-4ba3-990c-e2f83ce06e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_992deb01-0ec2-40e4-9184-09dca5b4ed90" xlink:to="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a578382d-436e-4077-adc9-9eae9a5b9691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:to="loc_srt_MinimumMember_a578382d-436e-4077-adc9-9eae9a5b9691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2fef015e-3798-4d98-ba07-0246a74a8e34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18848288-4848-42e1-9a21-a39b3e6f16c1" xlink:to="loc_srt_MaximumMember_2fef015e-3798-4d98-ba07-0246a74a8e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8c6b1ea5-f482-4070-b543-e4bdfac457e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PerformanceBasedRestrictedStockUnitMember_cc244992-aead-4317-9172-6c52c2235c52" xlink:href="thc-20221231.xsd#thc_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:to="loc_thc_PerformanceBasedRestrictedStockUnitMember_cc244992-aead-4317-9172-6c52c2235c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0513bb0d-96ad-41c7-81f0-8ffccd032264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0513bb0d-96ad-41c7-81f0-8ffccd032264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdditionalProratedRestrictedStockUnitsMember_0c091d01-cf57-4884-a766-8a33b308b56d" xlink:href="thc-20221231.xsd#thc_AdditionalProratedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8697e7dd-4a51-4c45-b717-395322e2fc1a" xlink:to="loc_thc_AdditionalProratedRestrictedStockUnitsMember_0c091d01-cf57-4884-a766-8a33b308b56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93545bad-748c-4fa3-a135-038787a8cab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d28b5e0f-b00b-446a-bcae-f626fe31e261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d28b5e0f-b00b-446a-bcae-f626fe31e261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18b6c2ad-d54e-4d60-96b7-9e38c6aa1366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18b6c2ad-d54e-4d60-96b7-9e38c6aa1366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f02182be-4299-4e03-ba3d-6269a8ea07ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f02182be-4299-4e03-ba3d-6269a8ea07ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3fd5c86f-1600-4921-9a23-ee1e5d37fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3fd5c86f-1600-4921-9a23-ee1e5d37fffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f61ac2e4-8dc6-4ad5-a8d9-c4a0a5f7c9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bc05960-80c5-4437-a32d-7aa77e2250fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f61ac2e4-8dc6-4ad5-a8d9-c4a0a5f7c9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a87f77da-f255-43cf-a9ce-0c70c5500b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a87f77da-f255-43cf-a9ce-0c70c5500b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c0be320-d430-4eb9-8117-85e9eea46462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c0be320-d430-4eb9-8117-85e9eea46462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ebe9bf8e-ebda-40f4-8d95-7971f99d28a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ebe9bf8e-ebda-40f4-8d95-7971f99d28a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0005b9eb-dc5e-42aa-878d-170ffd86c2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0005b9eb-dc5e-42aa-878d-170ffd86c2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3db1ce98-a09a-44c4-a4d0-66e58a52179a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_951741dd-8616-44b7-a6c3-958385ecdb20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3db1ce98-a09a-44c4-a4d0-66e58a52179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_512e8756-6600-447b-88d9-ac7242b773db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_efbfadb4-393d-47d5-975d-650910210843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_efbfadb4-393d-47d5-975d-650910210843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3a68f4f-787d-4880-a61f-ccd7c1337cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3a68f4f-787d-4880-a61f-ccd7c1337cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_574b5001-30f8-41db-b5c2-a9ae476c3ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_574b5001-30f8-41db-b5c2-a9ae476c3ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_b99b3313-8cd8-4c06-84ea-cbd1067ab4f1" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods_b99b3313-8cd8-4c06-84ea-cbd1067ab4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_82b57fab-45f8-4cca-b378-c721c894cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_82b57fab-45f8-4cca-b378-c721c894cf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c01bb65b-8b9f-429c-a5ca-c97016887a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c01bb65b-8b9f-429c-a5ca-c97016887a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_558aeea8-7553-4a18-bd4a-38b3cbbea6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_a58ad7c8-8448-474d-93ce-8040a8308c27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_558aeea8-7553-4a18-bd4a-38b3cbbea6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00600064-9a27-489d-8c08-893af0fba4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00600064-9a27-489d-8c08-893af0fba4da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:to="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f976baa-d1f1-49e1-9560-c89e17d9ab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a7dc8e38-efd5-4942-bfa5-0095962bae34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f976baa-d1f1-49e1-9560-c89e17d9ab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_141c373f-a5d8-4c75-9b9c-3b2f6dfc0085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f976baa-d1f1-49e1-9560-c89e17d9ab8d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_141c373f-a5d8-4c75-9b9c-3b2f6dfc0085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d532dd-60c7-474b-99a3-6a009a47e4e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f78890c-7cc3-4300-8455-3e8153f1c614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6f78890c-7cc3-4300-8455-3e8153f1c614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_92d228ca-ceb5-4f83-a564-64ff2cf18222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_92d228ca-ceb5-4f83-a564-64ff2cf18222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ebad1359-21f9-4b8b-8c19-2a6ef38d6e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ebad1359-21f9-4b8b-8c19-2a6ef38d6e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5737c756-b0c2-4159-8258-8ed495c00aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5737c756-b0c2-4159-8258-8ed495c00aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1987d143-024f-4851-8cbd-e5bf6549a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1987d143-024f-4851-8cbd-e5bf6549a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05ce3769-6b23-4bc2-a213-56eef24c0163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afb43fdb-e34f-48ce-a5a3-0eb26457747d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05ce3769-6b23-4bc2-a213-56eef24c0163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19a8dd75-985c-4208-8774-a555ed6a36e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19a8dd75-985c-4208-8774-a555ed6a36e9" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b4bb6876-702d-41f1-a5ca-f3bc200dd490" xlink:to="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2015USPIManagementEquityPlanMember_00bb4b55-9ae5-434a-ab21-391fa8d5576c" xlink:href="thc-20221231.xsd#thc_A2015USPIManagementEquityPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:to="loc_thc_A2015USPIManagementEquityPlanMember_00bb4b55-9ae5-434a-ab21-391fa8d5576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2020USPIManagementEquityPlanMember_cd62958e-f0f3-4909-8ab8-63a4213e6e86" xlink:href="thc-20221231.xsd#thc_A2020USPIManagementEquityPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:to="loc_thc_A2020USPIManagementEquityPlanMember_cd62958e-f0f3-4909-8ab8-63a4213e6e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_USPIManagementEquityPlanMember_975c5123-57f0-4906-865e-a9fda03f8334" xlink:href="thc-20221231.xsd#thc_USPIManagementEquityPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89accb78-bc76-4728-8edd-5cf1922e08b8" xlink:to="loc_thc_USPIManagementEquityPlanMember_975c5123-57f0-4906-865e-a9fda03f8334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d14d640b-1598-4821-bfa9-f5e25d5c1daf" xlink:to="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e3ba938c-711b-4308-9b8b-a0d993131eaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:to="loc_srt_MinimumMember_e3ba938c-711b-4308-9b8b-a0d993131eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e671e25-0acd-45ae-a9c0-7e23288be0de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23a4bb50-f7b8-4916-89a5-44d032f25cec" xlink:to="loc_srt_MaximumMember_6e671e25-0acd-45ae-a9c0-7e23288be0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2db07d01-5ced-4ae4-9c27-1eca74f90553" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c2068a5e-0289-4613-b7ad-0d88795aa2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:to="loc_us-gaap_StockOptionMember_c2068a5e-0289-4613-b7ad-0d88795aa2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a862b7b3-afb9-49d4-a1e9-b9025dfc03c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a862b7b3-afb9-49d4-a1e9-b9025dfc03c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvotingCommonStockMember_599f6c9a-ae61-45bd-9e5f-861b1963b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d66b771d-1844-4b4e-9c37-8ceaaf11274a" xlink:to="loc_us-gaap_NonvotingCommonStockMember_599f6c9a-ae61-45bd-9e5f-861b1963b2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_587b981d-8e4f-4cd9-9b6e-be07a4972b94" xlink:to="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_980096da-0a34-4f29-9573-6491b3550f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_980096da-0a34-4f29-9573-6491b3550f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_590fcc63-d484-4278-a185-b78ee7711442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_590fcc63-d484-4278-a185-b78ee7711442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_fcbfd081-1ffb-4b9e-8a5e-24fc738d045d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_fcbfd081-1ffb-4b9e-8a5e-24fc738d045d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationAwardTrancheFourMember_e9374304-2e41-4cce-91db-7ca31e21ea84" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2e3e36c-4448-430e-8c36-4ff9661cc584" xlink:to="loc_thc_ShareBasedCompensationAwardTrancheFourMember_e9374304-2e41-4cce-91db-7ca31e21ea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e09a61c0-48fd-42d8-854c-842c298b051f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_18a38717-ce76-4a2b-b41a-9901cb9a67a5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e09a61c0-48fd-42d8-854c-842c298b051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember_2a58799f-c527-4459-a203-cc65cd2b7d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e09a61c0-48fd-42d8-854c-842c298b051f" xlink:to="loc_us-gaap_NonqualifiedPlanMember_2a58799f-c527-4459-a203-cc65cd2b7d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3b26f37d-69ec-488c-a7e4-aea4f5f20c95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_33be6197-8225-4185-bc00-dc2e54c56b1e" xlink:to="loc_dei_EntityDomain_3b26f37d-69ec-488c-a7e4-aea4f5f20c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_8aff949c-d5b9-4dcb-96cd-e78bf90e0a70" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3b26f37d-69ec-488c-a7e4-aea4f5f20c95" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_8aff949c-d5b9-4dcb-96cd-e78bf90e0a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_d299bcd8-8880-482b-8f10-8f1b9f565987" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_0e4dbb7e-a358-43d8-9073-b3ca54e86dda" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent_0e4dbb7e-a358-43d8-9073-b3ca54e86dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4d4061f-398e-4b21-9954-4f81a0ebae2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4d4061f-398e-4b21-9954-4f81a0ebae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_e16aaf97-28e6-43ca-96f8-c44536b2f93a" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod_e16aaf97-28e6-43ca-96f8-c44536b2f93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_1c1b87bc-0c16-4f02-a224-f6eb5d71414f" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination_1c1b87bc-0c16-4f02-a224-f6eb5d71414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_247d2774-c405-4665-adcd-fc801756c9be" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares_247d2774-c405-4665-adcd-fc801756c9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_258ced15-c69a-4c91-8df5-d508a9981d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_258ced15-c69a-4c91-8df5-d508a9981d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85bed044-ac82-4e6d-b3c2-1ea6f8fb31ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85bed044-ac82-4e6d-b3c2-1ea6f8fb31ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f247a895-dc00-42e5-a656-cf6fb925f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f247a895-dc00-42e5-a656-cf6fb925f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6527004c-6702-440d-9da5-f39ebbab60b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6527004c-6702-440d-9da5-f39ebbab60b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c229da71-2c91-45a9-b013-3ae6744efc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72e8e6a1-dc12-4e32-843a-2e0a0fdabc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c229da71-2c91-45a9-b013-3ae6744efc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84977e0a-43b2-4e13-a02d-acda0eecc5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84977e0a-43b2-4e13-a02d-acda0eecc5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22285e9f-81af-4e03-811f-8956d95f21b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22285e9f-81af-4e03-811f-8956d95f21b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b53e754b-7ce0-471c-85c1-9c1b5be930bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b53e754b-7ce0-471c-85c1-9c1b5be930bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d823475d-11bc-4674-883f-b4ca0d1cf3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d823475d-11bc-4674-883f-b4ca0d1cf3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9894d5e9-95d7-44c8-b244-4345568afbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4a8cdda-0362-4b83-8c60-567789206a33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9894d5e9-95d7-44c8-b244-4345568afbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20f88f2-cdc6-44cc-8f29-26179954aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20f88f2-cdc6-44cc-8f29-26179954aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_66962277-0b7e-4ed4-8b90-4437b9cb6569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_66962277-0b7e-4ed4-8b90-4437b9cb6569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_f79d7eb1-cbb0-4e87-8449-00c0e98f90fa" xlink:href="thc-20221231.xsd#thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares_f79d7eb1-cbb0-4e87-8449-00c0e98f90fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CommonStockSharesOutstandingAndEligibleToBeSold_928878fd-d2c0-4ecc-8ed0-59bef461aead" xlink:href="thc-20221231.xsd#thc_CommonStockSharesOutstandingAndEligibleToBeSold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_thc_CommonStockSharesOutstandingAndEligibleToBeSold_928878fd-d2c0-4ecc-8ed0-59bef461aead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e0ff3d7-17df-471c-aa71-d6da4075e707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e0ff3d7-17df-471c-aa71-d6da4075e707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ef8c5ea9-f1fe-497f-9579-cac64c2eed89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_a734d1e4-432f-447f-b052-52e3c23fce55" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ef8c5ea9-f1fe-497f-9579-cac64c2eed89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32fa600a-3844-4484-9696-d490a3645084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32fa600a-3844-4484-9696-d490a3645084" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:to="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90b6d222-c4f0-4a27-be2b-c9959c79ac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75ce1814-048f-4649-9f4e-6c9e1a73a992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90b6d222-c4f0-4a27-be2b-c9959c79ac4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e7c4f0f8-015d-44a6-ae08-6a181260c110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90b6d222-c4f0-4a27-be2b-c9959c79ac4c" xlink:to="loc_us-gaap_EmployeeStockMember_e7c4f0f8-015d-44a6-ae08-6a181260c110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:to="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e85da090-c87c-492c-ba0b-996a6a45da45" xlink:to="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d405836f-585c-43ef-a172-d96878bd65d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:to="loc_srt_MinimumMember_d405836f-585c-43ef-a172-d96878bd65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab794ec2-3a4f-4a52-8b76-01844a7a02d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32978ff8-68cb-482a-82f2-562218d590fb" xlink:to="loc_srt_MaximumMember_ab794ec2-3a4f-4a52-8b76-01844a7a02d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f137a927-c03e-49d2-b020-6b196aecf217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32f2e7c8-e493-4908-8e80-f3fa72e8b15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32f2e7c8-e493-4908-8e80-f3fa72e8b15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20903147-f71b-4c30-8e9d-2f911c38c5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20903147-f71b-4c30-8e9d-2f911c38c5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_67a3ce1f-d781-42d8-9c40-83d2f0ee611b" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent_67a3ce1f-d781-42d8-9c40-83d2f0ee611b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_78b43673-b973-4c94-97b4-2b6f8f94d401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_78b43673-b973-4c94-97b4-2b6f8f94d401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_72d945b6-5910-4da0-b59a-484ecc4579ca" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares_72d945b6-5910-4da0-b59a-484ecc4579ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_fe89f18f-a911-4a02-8352-3c49b4f81457" xlink:href="thc-20221231.xsd#thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee_fe89f18f-a911-4a02-8352-3c49b4f81457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a829dfd7-4534-4468-a267-dca31699bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a829dfd7-4534-4468-a267-dca31699bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_682fad93-4926-4edb-9689-c35129f00b86" xlink:href="thc-20221231.xsd#thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcb53a42-96a3-448d-9feb-44e6df8120ee" xlink:to="loc_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan_682fad93-4926-4edb-9689-c35129f00b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2779f0e9-e4ad-4fef-94ff-9fa117b7d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2779f0e9-e4ad-4fef-94ff-9fa117b7d65c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0138decc-bc8b-4198-af03-78f44afbec2f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1d9afa21-be53-4aee-bfe8-59c019c92c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1d9afa21-be53-4aee-bfe8-59c019c92c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_138c6367-b0e7-4d84-abde-3b46f7694285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_19b3703b-921c-4511-a3a6-1180081ab713" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_138c6367-b0e7-4d84-abde-3b46f7694285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91dbebb2-aab1-4fc2-b5f7-8b121d073570" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_44ec0f32-e42f-4380-899f-4ac8a0007291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_44ec0f32-e42f-4380-899f-4ac8a0007291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_f1e9132b-078f-4ef9-abb2-92122ebb84a3" xlink:href="thc-20221231.xsd#thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans_f1e9132b-078f-4ef9-abb2-92122ebb84a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_25325f4d-56e3-4fda-a25f-8c263b1d8efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_25325f4d-56e3-4fda-a25f-8c263b1d8efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_b1ab2774-54cd-4abf-a25d-6d1ecc494853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_b1ab2774-54cd-4abf-a25d-6d1ecc494853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7824b2f3-146f-45b1-becd-e77f9b2fddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7824b2f3-146f-45b1-becd-e77f9b2fddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_bdcd5496-1de9-48c3-9079-2c3ddc293abb" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution_bdcd5496-1de9-48c3-9079-2c3ddc293abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_39f685b5-5da2-4397-a525-98f3869ea392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fda7ac3f-778a-4dfd-9386-13847bbb56b6" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_39f685b5-5da2-4397-a525-98f3869ea392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_835daac5-cbc8-41cd-997b-f92e121053e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_835daac5-cbc8-41cd-997b-f92e121053e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_7f04127f-de7c-4fc4-83e9-9c5390ad56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_7f04127f-de7c-4fc4-83e9-9c5390ad56f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_02dbdc83-9171-4935-9d03-804dc0fb28e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_02dbdc83-9171-4935-9d03-804dc0fb28e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6daa45ce-7914-46fa-af6d-244e0518d493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6daa45ce-7914-46fa-af6d-244e0518d493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_91c82210-ab97-49e1-923b-4293a9d6a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2bab6b55-20e7-48b1-b006-d011d319f11b" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_91c82210-ab97-49e1-923b-4293a9d6a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_de3d1531-95d0-448f-911b-19bd0c4b1eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_de3d1531-95d0-448f-911b-19bd0c4b1eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_3a4a9248-6ae8-4046-92f8-a6728dae8091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_97113df4-e480-4b2a-becf-80df6de2c35b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_3a4a9248-6ae8-4046-92f8-a6728dae8091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e54d94b-8b7f-40d6-8575-918ebd13b372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e54d94b-8b7f-40d6-8575-918ebd13b372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_5f32196b-a7a4-4413-be43-ed77a416741a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_5f32196b-a7a4-4413-be43-ed77a416741a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_015038dd-6751-4fc7-a3f0-b7ee855bd305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_ed89e3ba-f83a-47ca-8128-d55bc9c8e09b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_015038dd-6751-4fc7-a3f0-b7ee855bd305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_b3e54845-ff0e-4a04-a8a9-59880003a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_b3e54845-ff0e-4a04-a8a9-59880003a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_778c3094-9ade-4623-92d6-f1c19336ccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_83693495-2b2e-432f-985a-60b9806e1d9d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_778c3094-9ade-4623-92d6-f1c19336ccc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_37c53514-ce35-4668-9107-8286ddfdb3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_37c53514-ce35-4668-9107-8286ddfdb3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_24cdb0d1-db10-41fa-97e0-0e6956243c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_24cdb0d1-db10-41fa-97e0-0e6956243c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_c18473ff-825a-4655-91b9-8deef8da98b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_c18473ff-825a-4655-91b9-8deef8da98b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6cf5ac23-7cf8-4913-b57e-d358894827d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6cf5ac23-7cf8-4913-b57e-d358894827d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_772e9aa0-6e35-4278-9cae-f52e0676a55f" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_772e9aa0-6e35-4278-9cae-f52e0676a55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_6e005fd5-ffc7-41fc-bee7-7433ee596be6" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_dae61cd0-21f9-4a7e-a156-a066462f4396" xlink:to="loc_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag_6e005fd5-ffc7-41fc-bee7-7433ee596be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_40f409e1-c8bc-4ccf-b327-79fe735cceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_40f409e1-c8bc-4ccf-b327-79fe735cceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_636f2977-b227-426c-a994-09b75df84449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_636f2977-b227-426c-a994-09b75df84449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_8bbb2f4e-3a79-4509-a381-7ff09e42e6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b946aa4f-789f-4bab-85c1-a6ed44068adb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_8bbb2f4e-3a79-4509-a381-7ff09e42e6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_20b2ec4d-2dcd-4fb0-9ba6-9e26a79d9c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_20b2ec4d-2dcd-4fb0-9ba6-9e26a79d9c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_8469eae5-2399-4842-a3db-3ac2015d661d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_8469eae5-2399-4842-a3db-3ac2015d661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f0eba70a-92d3-47fb-9a6a-1218f1de3a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f0eba70a-92d3-47fb-9a6a-1218f1de3a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_d7773e03-c8f8-4e84-a3b4-53d425986e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_d7773e03-c8f8-4e84-a3b4-53d425986e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e38e303a-153c-40c3-a8da-06163e9789ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74aa6c1d-2618-417a-a07b-112ad1bd0d78" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e38e303a-153c-40c3-a8da-06163e9789ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSAssetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_713b5a3c-5831-4527-acc8-fd4cbe24ec85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_713b5a3c-5831-4527-acc8-fd4cbe24ec85" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_908c8d85-a840-42f0-bd23-b48f8e9cf679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_fdf32864-2017-4eac-abce-b6b91bba2ef7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_908c8d85-a840-42f0-bd23-b48f8e9cf679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_59ab9bc6-9756-4849-a69a-6412279ba0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_908c8d85-a840-42f0-bd23-b48f8e9cf679" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_59ab9bc6-9756-4849-a69a-6412279ba0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7f0419c9-1063-41ff-83bc-23f2f8112ed5" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_cf8edf7d-468f-434c-b41b-36f56cb61c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_cf8edf7d-468f-434c-b41b-36f56cb61c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_669fd390-a39c-48ae-b3ac-e32f832d0e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_669fd390-a39c-48ae-b3ac-e32f832d0e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_2b2b342d-4eef-4946-8cd5-418e22d55278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_2b2b342d-4eef-4946-8cd5-418e22d55278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanAlternativeInvestmentsMember_c9092708-4351-4583-967d-edb245537470" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanAlternativeInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1ffd20f4-47bb-4b70-99b5-7228f197c399" xlink:to="loc_thc_DefinedBenefitPlanAlternativeInvestmentsMember_c9092708-4351-4583-967d-edb245537470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_301ae232-498c-4dd3-a3b2-7d5b8245efe6" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_daae4740-d759-4bfd-b218-81aff443939b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_daae4740-d759-4bfd-b218-81aff443939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage_13052398-21ca-4da8-8a17-88d4add350b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb49c9ca-52b4-4494-abfd-5f31bfc562d3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage_13052398-21ca-4da8-8a17-88d4add350b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a07688db-7982-4bf5-96dc-eb24d26da3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a07688db-7982-4bf5-96dc-eb24d26da3b0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a737c767-ec9e-4540-b922-7f79fe286889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_63410ac7-3eba-4a69-8e49-423405951f29" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a737c767-ec9e-4540-b922-7f79fe286889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ec0f587d-4fbf-4742-8dc4-64249e2fa6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a737c767-ec9e-4540-b922-7f79fe286889" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ec0f587d-4fbf-4742-8dc4-64249e2fa6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eca8a3d7-c9a1-4eb6-b605-9d684079107c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_180fa476-fca5-44c4-93ac-50030e516a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_180fa476-fca5-44c4-93ac-50030e516a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_363f17ee-24be-4ca0-b608-3777004043bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_363f17ee-24be-4ca0-b608-3777004043bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ae212fec-2a34-4570-b46f-d3191003c3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd508213-e26e-448b-8770-4f91c5124115" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ae212fec-2a34-4570-b46f-d3191003c3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b143e961-b9fb-413d-b4fb-21876eec19ff" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bccedf1b-b3a9-48da-8547-f1ca9d9104f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bccedf1b-b3a9-48da-8547-f1ca9d9104f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_82ddc117-408a-462f-9de2-fc882bffaac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_82ddc117-408a-462f-9de2-fc882bffaac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_82bb3d56-72f0-4c8c-bd0c-14dbada24654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_82bb3d56-72f0-4c8c-bd0c-14dbada24654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1d3d414b-eefa-4242-ae6a-0db979fa1620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1d3d414b-eefa-4242-ae6a-0db979fa1620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_bc33226b-9826-4511-ad1d-ad25553605c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_PrivateEquityFundsMember_bc33226b-9826-4511-ad1d-ad25553605c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_a54436e4-8d74-47fb-beeb-261956a1d328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_a54436e4-8d74-47fb-beeb-261956a1d328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_6d3847a5-95c1-4edc-97a0-75c9429a80f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c4df6ed4-c1de-4a22-9c1b-ef77f9773088" xlink:to="loc_us-gaap_HedgeFundsMember_6d3847a5-95c1-4edc-97a0-75c9429a80f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0758af8e-8308-48b6-92e2-854e1b8c52ff" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e407ace0-2296-4d5b-a478-2fb186e09b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e407ace0-2296-4d5b-a478-2fb186e09b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_25994716-cd2a-4d67-94e1-94ef13e7bc4d" xlink:href="thc-20221231.xsd#thc_DefinedBenefitPlanExpectedFutureBenefitPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_thc_DefinedBenefitPlanExpectedFutureBenefitPayments_25994716-cd2a-4d67-94e1-94ef13e7bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_aca2c59d-a584-4023-b653-3f6a7e95646e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_aca2c59d-a584-4023-b653-3f6a7e95646e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_de8a0c76-c6a9-4ade-bd78-0fddd5b4852e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_de8a0c76-c6a9-4ade-bd78-0fddd5b4852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_4e0ce694-e531-40fb-9d9d-1a208043fab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_4e0ce694-e531-40fb-9d9d-1a208043fab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_53ce44fb-389a-4ced-ae3e-ad46fc5d4980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_53ce44fb-389a-4ced-ae3e-ad46fc5d4980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_88fd89ac-0a5c-4894-b9fd-f0b34eebceba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_88fd89ac-0a5c-4894-b9fd-f0b34eebceba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_0baded5d-486e-4ef6-a33e-658262b8846d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_2a37617d-f728-4978-b248-8b735ac35581" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_0baded5d-486e-4ef6-a33e-658262b8846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b02e3cb-4836-4ca4-b754-c29ee5f2fbf2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_91a61bc1-07b5-4eae-b430-3c3f655299bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_91a61bc1-07b5-4eae-b430-3c3f655299bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_68b2cd5c-d7e5-4acd-abcd-9c285ad8e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_68b2cd5c-d7e5-4acd-abcd-9c285ad8e6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e4286542-ba3d-4f0e-9b20-44dd227796e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e4286542-ba3d-4f0e-9b20-44dd227796e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1c23e2c6-6126-4a51-9055-ef8933d2531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3e13af7b-90f3-4c63-a7d2-b20193b6822e" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1c23e2c6-6126-4a51-9055-ef8933d2531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#PROPERTYANDEQUIPMENTComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2e16ba0e-0252-406c-aacb-7ec37e1edda4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2e16ba0e-0252-406c-aacb-7ec37e1edda4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec5e4afc-2b2e-4a4c-b3fd-97cc132f5512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_ae2f0a95-f18a-4458-97f4-fc49e5e5fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_LandMember_ae2f0a95-f18a-4458-97f4-fc49e5e5fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_18856845-fa29-4030-a647-ad4cb83fda88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_18856845-fa29-4030-a647-ad4cb83fda88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_253c25d9-0555-4333-97ab-0ae784ef5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_ConstructionInProgressMember_253c25d9-0555-4333-97ab-0ae784ef5b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f6fff71a-8b2c-4b45-8ae8-5e89091b995b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_541776ee-c9c8-4163-9fc1-8227cafb6460" xlink:to="loc_us-gaap_EquipmentMember_f6fff71a-8b2c-4b45-8ae8-5e89091b995b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_666245d6-0a02-4a8e-9601-c202f32159f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1fab53a2-7e9d-4985-9931-ff3b6a0fb6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1fab53a2-7e9d-4985-9931-ff3b6a0fb6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6d963a89-5016-4fcc-9c37-9195f4fc2fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6d963a89-5016-4fcc-9c37-9195f4fc2fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2e8f76a4-3a67-43e6-a809-92d11c460e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2e8f76a4-3a67-43e6-a809-92d11c460e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_306e1c0a-8963-4681-8a79-31c9ddcdc4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_306e1c0a-8963-4681-8a79-31c9ddcdc4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_58efded8-4d9d-443b-9289-51cf21668ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_58efded8-4d9d-443b-9289-51cf21668ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_69064c7c-30e9-4dd8-8cdf-2b084d6f3a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3ed873ca-65ea-4005-8b69-0940b5b5f5ab" xlink:to="loc_us-gaap_Depreciation_69064c7c-30e9-4dd8-8cdf-2b084d6f3a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_35caf1b9-89d2-4940-bdd3-8a2147e72c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_35caf1b9-89d2-4940-bdd3-8a2147e72c56" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_26c1bc2f-8a1e-43cb-97e6-edfbd166fce2" xlink:to="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_c4e6c7d2-6d4c-4768-b38c-4dd09fbf1966" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:to="loc_thc_HospitalOperationsMember_c4e6c7d2-6d4c-4768-b38c-4dd09fbf1966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_d248cc6e-a7f6-4b13-97b7-3ecf126b2b6d" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:to="loc_thc_AmbulatoryCareMember_d248cc6e-a7f6-4b13-97b7-3ecf126b2b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7e6bd213-6489-4462-8ab1-c0027edaadab" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f9009cb9-5ace-47c6-9ded-557a572f53e5" xlink:to="loc_thc_ConiferSegmentMember_7e6bd213-6489-4462-8ab1-c0027edaadab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_fe8d27b5-496b-4880-bc5c-423d22fd3fe5" xlink:to="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:to="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_d707581b-52e4-4b7f-89f2-e51591329efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillGross_d707581b-52e4-4b7f-89f2-e51591329efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a7517270-7d2a-433c-b559-09867fad381d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a7517270-7d2a-433c-b559-09867fad381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07ee9400-2309-4849-9cfb-a8b842dcd064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_Goodwill_07ee9400-2309-4849-9cfb-a8b842dcd064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_ab5b8e78-fa93-46ba-b2e7-8796e9bfa0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTransfers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillTransfers_ab5b8e78-fa93-46ba-b2e7-8796e9bfa0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_4c79ce55-d218-470c-93db-c6aafdec2e4e" xlink:href="thc-20221231.xsd#thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility_4c79ce55-d218-470c-93db-c6aafdec2e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_97232052-f6ce-46cf-a6f5-c6bee675ee85" xlink:href="thc-20221231.xsd#thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments_97232052-f6ce-46cf-a6f5-c6bee675ee85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_4bc2ebf4-73c0-4003-8b2f-6d6d0d768d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillGross_4bc2ebf4-73c0-4003-8b2f-6d6d0d768d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_9b5a91a8-c820-4c42-8140-c7ba08dda59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_9b5a91a8-c820-4c42-8140-c7ba08dda59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dfe81df7-4253-4720-9510-3a3e548a471f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9b549d35-027a-4395-8bce-e6e6900d3ae8" xlink:to="loc_us-gaap_Goodwill_dfe81df7-4253-4720-9510-3a3e548a471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7e61fd47-ecad-42ba-aff6-ebf8699d55e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c80831e3-e5c2-4d9e-ba26-7200e5b4a523" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7e61fd47-ecad-42ba-aff6-ebf8699d55e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cac72199-e9e9-44ed-aa64-6f9057bb88c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cac72199-e9e9-44ed-aa64-6f9057bb88c1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af333e70-13bf-4551-b74e-1dc5b5a3cd15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_04244177-0c72-45cd-b8da-12fc11fb8a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_04244177-0c72-45cd-b8da-12fc11fb8a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_4e99c947-2fc6-419f-8343-282ef3dad09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_4e99c947-2fc6-419f-8343-282ef3dad09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_f0ee6d30-e2d8-4174-a00e-530d1ecf2644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_f0ee6d30-e2d8-4174-a00e-530d1ecf2644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_68346af3-654e-4cd2-8071-2767b0793f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2151ac65-252e-4896-8486-a988e4112929" xlink:to="loc_us-gaap_TradeNamesMember_68346af3-654e-4cd2-8071-2767b0793f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_485c0bb0-0e7a-4c82-97a5-49e50bf442da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_58bb7376-9093-4736-a11c-383756e6f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:to="loc_us-gaap_TradeNamesMember_58bb7376-9093-4736-a11c-383756e6f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_45a3c957-0cf2-4772-93f4-56a8644b1188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_45a3c957-0cf2-4772-93f4-56a8644b1188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5860d1ba-e473-4071-9208-fddcae9523d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_875baf76-1fb4-499b-8cf6-8274e7dce348" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5860d1ba-e473-4071-9208-fddcae9523d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_be7b8d14-2f30-4bc8-a0cf-54913181d380" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b4c5530-fb17-4349-81e4-f2594fc4185c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b4c5530-fb17-4349-81e4-f2594fc4185c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8f38dd12-9827-40a7-9ddb-6e27e282acdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8f38dd12-9827-40a7-9ddb-6e27e282acdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1e02104-2306-4640-bea7-1e7eff03bfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d1355070-e00e-45fb-bb5c-01c200ec804d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1e02104-2306-4640-bea7-1e7eff03bfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b9dd7633-8e88-42cb-af34-3163deab5ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b9dd7633-8e88-42cb-af34-3163deab5ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0f6a8c7c-6b36-4585-9fe8-c35919e30e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b9dd7633-8e88-42cb-af34-3163deab5ee0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0f6a8c7c-6b36-4585-9fe8-c35919e30e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_111a31af-e04e-4815-9176-a60fd31c98a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_111a31af-e04e-4815-9176-a60fd31c98a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_625ef0a3-135c-4a1f-84f7-4abc9c1e117a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bd214aa2-3700-4578-bba8-75f23507614b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_625ef0a3-135c-4a1f-84f7-4abc9c1e117a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33b54cbc-253e-4a3e-9b24-d03d82341aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33b54cbc-253e-4a3e-9b24-d03d82341aa9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8276defc-3482-468a-b3bf-46e5d04d9160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8276defc-3482-468a-b3bf-46e5d04d9160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6419f2da-41f8-43d9-b5c8-436359366aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6419f2da-41f8-43d9-b5c8-436359366aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7e0dc53c-7b54-4086-ba24-0ba0a434120d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7e0dc53c-7b54-4086-ba24-0ba0a434120d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0afc82a5-1ba3-4abb-82a4-8069db2e7789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0afc82a5-1ba3-4abb-82a4-8069db2e7789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_41fac28e-b7df-4e9d-b22c-6757a5da527b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_41fac28e-b7df-4e9d-b22c-6757a5da527b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8be1040f-55b1-468d-a5de-0e77a1ae0f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8be1040f-55b1-468d-a5de-0e77a1ae0f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_db0e3f76-4e9e-4179-82a1-d39d318dcfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c056eed7-02a7-4f56-8880-b9a41622de63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_db0e3f76-4e9e-4179-82a1-d39d318dcfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7a118887-c3c3-479d-9a5f-bf9a2ec2d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33b54cbc-253e-4a3e-9b24-d03d82341aa9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7a118887-c3c3-479d-9a5f-bf9a2ec2d8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETSScheduleofOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0253f38c-64ca-44b4-803b-d1c67a8ea931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2215fca2-cff1-4444-be57-6480b616c752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0253f38c-64ca-44b4-803b-d1c67a8ea931" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2215fca2-cff1-4444-be57-6480b616c752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0253f38c-64ca-44b4-803b-d1c67a8ea931" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_676f175a-2a7e-4fd2-8c5e-8a52ba410cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9ff04a45-3196-4f42-a5ae-0a6946733636" xlink:to="loc_us-gaap_ReceivableTypeDomain_676f175a-2a7e-4fd2-8c5e-8a52ba410cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaProviderFeeProgramMember_f6c24ea2-2548-4e50-ad11-ac44f8174201" xlink:href="thc-20221231.xsd#thc_CaliforniaProviderFeeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_676f175a-2a7e-4fd2-8c5e-8a52ba410cde" xlink:to="loc_thc_CaliforniaProviderFeeProgramMember_f6c24ea2-2548-4e50-ad11-ac44f8174201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c05e0713-f600-401a-a0af-c61c475d60c1" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d8d5a29a-b088-43f4-9d8a-f634d0ad8d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d8d5a29a-b088-43f4-9d8a-f634d0ad8d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d986bc6d-8adf-426b-8aba-7362ac7264f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d986bc6d-8adf-426b-8aba-7362ac7264f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_47a4fd4e-7d9f-4cd3-9716-ff55c86fd1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_47a4fd4e-7d9f-4cd3-9716-ff55c86fd1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ReceivablesFromGovernmentProgramsCurrent_48d7f46a-2f74-40d8-b026-edb1c8f0848b" xlink:href="thc-20221231.xsd#thc_ReceivablesFromGovernmentProgramsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_thc_ReceivablesFromGovernmentProgramsCurrent_48d7f46a-2f74-40d8-b026-edb1c8f0848b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent_f558bbc7-f429-41cb-a128-f9f4c8a58786" xlink:href="thc-20221231.xsd#thc_PhysicianAndGroupCoverageGuaranteesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_thc_PhysicianAndGroupCoverageGuaranteesCurrent_f558bbc7-f429-41cb-a128-f9f4c8a58786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_e4de5317-5c7f-4e42-85bb-974f02e24d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_OtherReceivables_e4de5317-5c7f-4e42-85bb-974f02e24d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_d9ccb39f-d585-4783-99da-69c98a882d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_d9ccb39f-d585-4783-99da-69c98a882d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_947ce986-5fc9-426c-852f-b0d293277bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_992ea301-3142-4ea9-b29d-5de5da5ebac4" xlink:to="loc_us-gaap_OtherAssetsCurrent_947ce986-5fc9-426c-852f-b0d293277bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_50212ee7-c61b-4fa5-bda7-aba2bf4a1f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:href="thc-20221231.xsd#thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_50212ee7-c61b-4fa5-bda7-aba2bf4a1f07" xlink:to="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f3cc53f6-4077-43a5-ad5a-5ecee7c8ed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f3cc53f6-4077-43a5-ad5a-5ecee7c8ed6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8fd5cfb9-30d9-4840-9c63-54b97edc5cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_EquityMethodInvestments_8fd5cfb9-30d9-4840-9c63-54b97edc5cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_948ae6d6-8c51-42cc-8df5-564c92ecefc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_LongTermInvestments_948ae6d6-8c51-42cc-8df5-564c92ecefc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueOfLifeInsurance_197b1d11-5d8c-4a39-be96-0f1eef22d8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueOfLifeInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_CashSurrenderValueOfLifeInsurance_197b1d11-5d8c-4a39-be96-0f1eef22d8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_689d9ca1-d23c-4a56-832c-1b4adee63b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_689d9ca1-d23c-4a56-832c-1b4adee63b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_17827bd1-cadb-4919-8ab2-63f9066b7f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_17827bd1-cadb-4919-8ab2-63f9066b7f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca53e6f0-6d01-42d6-b81e-d8ac77f676f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca53e6f0-6d01-42d6-b81e-d8ac77f676f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_e3f70500-ab87-4095-9f8b-163c01397130" xlink:href="thc-20221231.xsd#thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent_e3f70500-ab87-4095-9f8b-163c01397130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_d9afb470-008d-49b8-b2b5-495b52b6bb17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract_25063300-de4f-45d4-9ef7-097a80c104e2" xlink:to="loc_us-gaap_LongTermInvestmentsAndReceivablesNet_d9afb470-008d-49b8-b2b5-495b52b6bb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_19ed4e84-d0af-4499-8c46-ea5dc87cc179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_19ed4e84-d0af-4499-8c46-ea5dc87cc179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb8c8cdf-0461-4836-95c9-9093f0831de1" xlink:to="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_eac7500c-c5f4-4cf9-a858-1849d34ee015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_eac7500c-c5f4-4cf9-a858-1849d34ee015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_987bfa1a-f51f-4387-ab04-3bf8f58009f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_987bfa1a-f51f-4387-ab04-3bf8f58009f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_dc3d6d57-6f47-4cda-81a3-60873c6b2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_dc3d6d57-6f47-4cda-81a3-60873c6b2d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_41fb5e1a-ad77-4c66-a58a-06958b92ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8aaeba97-dc84-4674-a1c7-815fe8309ccd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_41fb5e1a-ad77-4c66-a58a-06958b92ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7f3f83cd-119f-4e54-857a-f9c68e0b3ef5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8adb7c41-ced9-45af-b7ac-0a1646ef2183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_StockholdersEquity_8adb7c41-ced9-45af-b7ac-0a1646ef2183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax_4e448b74-6579-4229-b7f4-4f19072b675f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax_4e448b74-6579-4229-b7f4-4f19072b675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e6153505-04ca-4fc7-9c98-44ed46395d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f4cd6f82-9d4a-4ac7-a3f7-b76624e948ef" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e6153505-04ca-4fc7-9c98-44ed46395d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_12f8ce18-98c6-45bf-8b6e-90dd31904ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_12f8ce18-98c6-45bf-8b6e-90dd31904ae8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_0fcaa24a-2426-48d3-9b0c-1480dd159f39" xlink:to="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9c548abe-60e0-428f-a0c3-fc357adf2692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:to="loc_us-gaap_OperatingSegmentsMember_9c548abe-60e0-428f-a0c3-fc357adf2692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_edfe64bd-762f-4711-96d8-f6a4bb8afb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_08c35d21-44c4-4210-92bc-ffd4dd012a44" xlink:to="loc_us-gaap_IntersegmentEliminationMember_edfe64bd-762f-4711-96d8-f6a4bb8afb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_79e7ebce-460e-43c3-b450-67500ad0664d" xlink:to="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_4f390127-ada1-4a39-bbbc-3e6e9825741f" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:to="loc_thc_HospitalOperationsMember_4f390127-ada1-4a39-bbbc-3e6e9825741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_014c6767-dffa-41da-90b7-b730ec87a6fe" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:to="loc_thc_AmbulatoryCareMember_014c6767-dffa-41da-90b7-b730ec87a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_c6e3f473-21f6-4185-9ca3-1c44f3b42d56" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7b69ab8e-7788-486a-9a16-f4dd654718c7" xlink:to="loc_thc_ConiferSegmentMember_c6e3f473-21f6-4185-9ca3-1c44f3b42d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_58e12b3e-ae46-4499-874a-f46775bd98ff" xlink:to="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceExcludingPhysicianPracticesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:to="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MedicareMember_6e160291-79c5-4235-97a2-a69abe5ec231" xlink:href="thc-20221231.xsd#thc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_MedicareMember_6e160291-79c5-4235-97a2-a69abe5ec231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceMedicaidMember_c3f0c990-81d1-445b-9e9a-0837e0c49a34" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceMedicaidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceMedicaidMember_c3f0c990-81d1-445b-9e9a-0837e0c49a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceManagedCareMember_a8dff0a6-145c-4ff3-a457-0f2957da2ef6" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceManagedCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceManagedCareMember_a8dff0a6-145c-4ff3-a457-0f2957da2ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceSelfpayMember_45fc00d0-95d3-486c-9719-9307a6b2f61c" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceSelfpayMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceSelfpayMember_45fc00d0-95d3-486c-9719-9307a6b2f61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCarePatientServiceIndemnityAndOtherMember_f519106a-e5d2-4466-888b-fdf18f28a63e" xlink:href="thc-20221231.xsd#thc_HealthCarePatientServiceIndemnityAndOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_HealthCarePatientServiceExcludingPhysicianPracticesMember_bd488ed1-0e83-4928-84a5-7ec9573809e0" xlink:to="loc_thc_HealthCarePatientServiceIndemnityAndOtherMember_f519106a-e5d2-4466-888b-fdf18f28a63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherRevenuesMember_81ed5be7-8285-4b6f-beba-195ef641de6e" xlink:href="thc-20221231.xsd#thc_OtherRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c073b6fc-867c-4223-b714-9f27793c6d11" xlink:to="loc_thc_OtherRevenuesMember_81ed5be7-8285-4b6f-beba-195ef641de6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_e1d68e91-7b54-4738-bfcb-4640b6a1c809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_d1cfdd3b-797f-4845-8c0e-bfb260b3dadc" xlink:to="loc_us-gaap_SubsegmentsDomain_e1d68e91-7b54-4738-bfcb-4640b6a1c809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_26e42f32-71a4-4a6b-b76f-b6b2ae8a5ccf" xlink:href="thc-20221231.xsd#thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_e1d68e91-7b54-4738-bfcb-4640b6a1c809" xlink:to="loc_thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember_26e42f32-71a4-4a6b-b76f-b6b2ae8a5ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac9f05-cf50-428e-958f-0f1999f4a021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed4141a2-8541-4d48-ab30-f49b2db0e936" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac9f05-cf50-428e-958f-0f1999f4a021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21368ca6-59ee-4b40-8a44-c05ead8adad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac9f05-cf50-428e-958f-0f1999f4a021" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21368ca6-59ee-4b40-8a44-c05ead8adad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50980a6e-6160-46fe-ac1d-fe1de62d976b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50980a6e-6160-46fe-ac1d-fe1de62d976b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:to="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b5f6ac34-6225-417a-bb91-d890338972ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_35e0c1c1-9e68-4544-96c8-93fb25565ba3" xlink:to="loc_srt_RestatementDomain_b5f6ac34-6225-417a-bb91-d890338972ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_3d8423ca-d6ca-4730-946f-f5d480b0028f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_b5f6ac34-6225-417a-bb91-d890338972ac" xlink:to="loc_srt_RestatementAdjustmentMember_3d8423ca-d6ca-4730-946f-f5d480b0028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9db1ada7-50e7-462d-ae61-4bcf6621a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4bb66cba-e951-4b77-8e8b-680913404720" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9db1ada7-50e7-462d-ae61-4bcf6621a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e23e180-2c06-4a98-b4aa-04a6b644fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9db1ada7-50e7-462d-ae61-4bcf6621a38b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e23e180-2c06-4a98-b4aa-04a6b644fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0bdb4deb-d218-404b-8242-6f4d2a20db10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0bdb4deb-d218-404b-8242-6f4d2a20db10" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:to="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_905b611b-5639-441d-8538-6d91a6a3ceaf" xlink:to="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_d5248216-8044-4f9e-be89-3f19a1580e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_d5248216-8044-4f9e-be89-3f19a1580e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareManagementFeesMember_e6bbbf3f-fa76-4ed0-b48c-ac231f3ec323" xlink:href="thc-20221231.xsd#thc_HealthCareManagementFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:to="loc_thc_HealthCareManagementFeesMember_e6bbbf3f-fa76-4ed0-b48c-ac231f3ec323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareOtherSourcesMember_a7cf59d2-e671-442a-ac9d-e3f407e6f580" xlink:href="thc-20221231.xsd#thc_HealthCareOtherSourcesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f4b1a09-a6a2-4549-9f1a-b52196aa68aa" xlink:to="loc_thc_HealthCareOtherSourcesMember_a7cf59d2-e671-442a-ac9d-e3f407e6f580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d990b7c8-50b9-415a-912f-7a57f34fb6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03730994-c8aa-47b1-ac21-b5891931b5c3" xlink:to="loc_us-gaap_SegmentDomain_d990b7c8-50b9-415a-912f-7a57f34fb6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_1151f57c-edeb-4362-ba66-674fba449202" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d990b7c8-50b9-415a-912f-7a57f34fb6c8" xlink:to="loc_thc_AmbulatoryCareMember_1151f57c-edeb-4362-ba66-674fba449202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_df5757de-11b2-4dad-b435-68b7cadd580d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de71e7a6-b685-4822-ab0c-f6a86a85ad16" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_df5757de-11b2-4dad-b435-68b7cadd580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5058e43f-5dbe-495a-aba0-f200cdd0a213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_df5757de-11b2-4dad-b435-68b7cadd580d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5058e43f-5dbe-495a-aba0-f200cdd0a213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c4e22a1c-e2fc-4af7-91c9-cd60fd880312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c4e22a1c-e2fc-4af7-91c9-cd60fd880312" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ffd5f925-6d2f-44ee-8e72-0a3657aabb85" xlink:to="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TenetHealthcareCorpMember_d6da2031-9097-4adf-a343-16cd1551cec0" xlink:href="thc-20221231.xsd#thc_TenetHealthcareCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:to="loc_thc_TenetHealthcareCorpMember_d6da2031-9097-4adf-a343-16cd1551cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCustomersMember_76fc499d-eb40-4b07-b878-8b0138f1c8bb" xlink:href="thc-20221231.xsd#thc_OtherCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f6fad1b8-1593-4214-8e48-abc559fb6087" xlink:to="loc_thc_OtherCustomersMember_76fc499d-eb40-4b07-b878-8b0138f1c8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1edf5853-60a7-43cb-91ca-5759d371094f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6fa0c7bf-692a-4367-9c0c-9883375e21fb" xlink:to="loc_us-gaap_SegmentDomain_1edf5853-60a7-43cb-91ca-5759d371094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_94e6fa3a-e3d2-4cd8-91cb-a6556adcdcd5" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1edf5853-60a7-43cb-91ca-5759d371094f" xlink:to="loc_thc_ConiferSegmentMember_94e6fa3a-e3d2-4cd8-91cb-a6556adcdcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_12cbf85d-1a73-4fd5-83ce-9501014c413c" xlink:to="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareClientContractsRevenueCycleServicesMember_8866a06c-8f97-45f4-a9c1-557810986979" xlink:href="thc-20221231.xsd#thc_HealthCareClientContractsRevenueCycleServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:to="loc_thc_HealthCareClientContractsRevenueCycleServicesMember_8866a06c-8f97-45f4-a9c1-557810986979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HealthCareClientContractsOtherServicesMember_d9ef7e64-6a59-430f-b863-84661cf2c546" xlink:href="thc-20221231.xsd#thc_HealthCareClientContractsOtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8be15679-8f85-4b18-95a1-70b341792223" xlink:to="loc_thc_HealthCareClientContractsOtherServicesMember_d9ef7e64-6a59-430f-b863-84661cf2c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6e98668e-c47c-4296-adba-ff24c7a0c633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_201f5c05-61a0-48c9-ae02-7906ecac200e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6e98668e-c47c-4296-adba-ff24c7a0c633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c932225-23ff-490c-910f-f1572e5acfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6e98668e-c47c-4296-adba-ff24c7a0c633" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c932225-23ff-490c-910f-f1572e5acfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1f95c215-48d6-4960-8028-4d447caea806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1f95c215-48d6-4960-8028-4d447caea806" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_86ea2a6a-9397-4f01-b485-789c83f29f2a" xlink:to="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7c19c060-4b4e-477b-8865-8fe5bc73c52c" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c20af98e-3b70-4c3b-bf6f-23a138fb9938" xlink:to="loc_thc_ConiferSegmentMember_7c19c060-4b4e-477b-8865-8fe5bc73c52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_936d52fa-6325-49bd-9f23-a13bc059887f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_936d52fa-6325-49bd-9f23-a13bc059887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9e5ba7a4-0653-4314-88b6-7d57c4010004" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_965c0a06-3650-4ba2-aa59-fdcb431be171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_965c0a06-3650-4ba2-aa59-fdcb431be171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1b4dd067-eb26-4003-8d93-147d535ed261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_429091e1-9e34-41f5-988d-912289a24e31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1b4dd067-eb26-4003-8d93-147d535ed261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails_1" xlink:type="simple" xlink:href="thc-20221231.xsd#NETOPERATINGREVENUESPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INSURANCEPropertyInsuranceDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_a5d66711-113d-4bc3-859c-1abcea9591b6" xlink:href="thc-20221231.xsd#thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_a5d66711-113d-4bc3-859c-1abcea9591b6" xlink:to="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_6dd445a2-231d-48b4-8ed5-11d00e76484e" xlink:to="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FloodMember_6de38ca5-2718-4ecc-982e-ec9b71af6ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FloodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_us-gaap_FloodMember_6de38ca5-2718-4ecc-982e-ec9b71af6ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarthquakeMember_9d6ba4ed-8f10-427f-b3fb-7b6379c6943a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarthquakeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_us-gaap_EarthquakeMember_9d6ba4ed-8f10-427f-b3fb-7b6379c6943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_WindstormsMember_b0243586-0eb6-49bd-b085-cd68bbdf10f9" xlink:href="thc-20221231.xsd#thc_WindstormsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_WindstormsMember_b0243586-0eb6-49bd-b085-cd68bbdf10f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FireAndOtherPerilsMember_14e3a51c-20eb-4b31-ab82-101eb985d558" xlink:href="thc-20221231.xsd#thc_FireAndOtherPerilsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_FireAndOtherPerilsMember_14e3a51c-20eb-4b31-ab82-101eb985d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FloodEarthquakeAndWindstormMember_babe05f3-0301-4b8e-9c27-8455900963ab" xlink:href="thc-20221231.xsd#thc_FloodEarthquakeAndWindstormMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_FloodEarthquakeAndWindstormMember_babe05f3-0301-4b8e-9c27-8455900963ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CaliforniaEarthquakeMember_edcd0ed4-6ded-46ab-9889-06e610352efa" xlink:href="thc-20221231.xsd#thc_CaliforniaEarthquakeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_CaliforniaEarthquakeMember_edcd0ed4-6ded-46ab-9889-06e610352efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_FloodsAndWindstormsMember_2348cbfd-0058-4798-84e1-3508f2503b44" xlink:href="thc-20221231.xsd#thc_FloodsAndWindstormsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_FloodsAndWindstormsMember_2348cbfd-0058-4798-84e1-3508f2503b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NewMadridFaultEarthquakesMember_9b643cec-d3ad-475b-889d-8841541d55cd" xlink:href="thc-20221231.xsd#thc_NewMadridFaultEarthquakesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_NewMadridFaultEarthquakesMember_9b643cec-d3ad-475b-889d-8841541d55cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCatastrophicEventsMember_0bf5a2d6-2f9f-41b6-a663-70c914ae803c" xlink:href="thc-20221231.xsd#thc_OtherCatastrophicEventsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_9b70f4b2-d0f1-4806-aa79-fe639ee2ffcb" xlink:to="loc_thc_OtherCatastrophicEventsMember_0bf5a2d6-2f9f-41b6-a663-70c914ae803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3bad834f-1f01-4c6e-814a-b9bac09c0ac7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2124a144-38d4-408e-b5e9-af0e9562fd15" xlink:to="loc_srt_ProductsAndServicesDomain_3bad834f-1f01-4c6e-814a-b9bac09c0ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceRecoveriesMember_94555ce3-80fc-4e97-8cf1-7189486306f1" xlink:href="thc-20221231.xsd#thc_InsuranceRecoveriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3bad834f-1f01-4c6e-814a-b9bac09c0ac7" xlink:to="loc_thc_InsuranceRecoveriesMember_94555ce3-80fc-4e97-8cf1-7189486306f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d9043606-40b3-44ad-b54c-784d6c0eda43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_569a5503-7dfc-4630-a247-10ba9ebca3f8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d9043606-40b3-44ad-b54c-784d6c0eda43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_612402fd-34d1-4b52-bfcc-0ff317ae426f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_d9043606-40b3-44ad-b54c-784d6c0eda43" xlink:to="loc_srt_ScenarioForecastMember_612402fd-34d1-4b52-bfcc-0ff317ae426f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_fafe5d33-774a-4bbf-90c5-f7bc8dcdb0b0" xlink:to="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceAnnualCoverageLimit_922d57be-f3e9-4d32-9630-9dcb1419641b" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceAnnualCoverageLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceAnnualCoverageLimit_922d57be-f3e9-4d32-9630-9dcb1419641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceMaximumCoveragePerIncident_66f40c3f-8a01-4dbd-9e73-26d559c925a5" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceMaximumCoveragePerIncident"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceMaximumCoveragePerIncident_66f40c3f-8a01-4dbd-9e73-26d559c925a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceDeductiblePercentage_f8c968a2-7b93-4dbc-b74d-a56aba29053b" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceDeductiblePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceDeductiblePercentage_f8c968a2-7b93-4dbc-b74d-a56aba29053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyInsuranceDeductible_4b8a92dc-d7ef-40d7-b9ab-45b77ae65233" xlink:href="thc-20221231.xsd#thc_PropertyInsuranceDeductible"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_PropertyInsuranceDeductible_4b8a92dc-d7ef-40d7-b9ab-45b77ae65233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_CybersecurityIncidentPreTaxEffect_a5eaf86f-41a6-4f40-bda7-12cc889f9c2c" xlink:href="thc-20221231.xsd#thc_CybersecurityIncidentPreTaxEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_thc_CybersecurityIncidentPreTaxEffect_a5eaf86f-41a6-4f40-bda7-12cc889f9c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_760eacdb-5265-490b-ae29-46fa094514f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_us-gaap_InsuranceRecoveries_760eacdb-5265-490b-ae29-46fa094514f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48af2f5b-797a-44da-abfa-75c426318644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_1089eb34-e3cf-4564-8dcf-17b738520ce7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48af2f5b-797a-44da-abfa-75c426318644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INSURANCEProfessionalandGeneralLiabilityReservesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_102c9ccf-2e99-4860-a43d-d01db0c8f301" xlink:href="thc-20221231.xsd#thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract_102c9ccf-2e99-4860-a43d-d01db0c8f301" xlink:to="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fcd971b6-9d64-4e09-b035-0f5f45149f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_36beb541-bcee-470e-b1e8-4d58e7507a77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fcd971b6-9d64-4e09-b035-0f5f45149f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ProfessionalAndGeneralLiabilityReservesMember_cbddef51-1b6c-421c-a65f-2350bb37d3e6" xlink:href="thc-20221231.xsd#thc_ProfessionalAndGeneralLiabilityReservesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fcd971b6-9d64-4e09-b035-0f5f45149f32" xlink:to="loc_thc_ProfessionalAndGeneralLiabilityReservesMember_cbddef51-1b6c-421c-a65f-2350bb37d3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cf6175bf-ce17-4b08-9fb8-75cf2bf24e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71716ccf-428d-4f32-a116-802741d78068" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cf6175bf-ce17-4b08-9fb8-75cf2bf24e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_789fc6ae-78b4-4cbc-91d8-868e77012616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cf6175bf-ce17-4b08-9fb8-75cf2bf24e60" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_789fc6ae-78b4-4cbc-91d8-868e77012616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:href="thc-20221231.xsd#thc_InsuranceCoverageLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageTable_bac851c7-28c1-4df6-984d-c4e0d9ed1e88" xlink:to="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_3b1b9ea2-d131-4bc7-8f6f-b796906be9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_us-gaap_SelfInsuranceReserve_3b1b9ea2-d131-4bc7-8f6f-b796906be9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_0fc824ae-bcbd-424b-b051-bd973b7a7406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredNet_0fc824ae-bcbd-424b-b051-bd973b7a7406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_35287f4a-2e16-49e9-ba2d-0d02a3a4d5ec" xlink:href="thc-20221231.xsd#thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_InsuranceCoverageLineItems_53c56345-8c24-47ab-834f-cbd158ceca1a" xlink:to="loc_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears_35287f4a-2e16-49e9-ba2d-0d02a3a4d5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CLAIMSANDLAWSUITSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94d91e4d-2dff-41a7-a3e8-eac0e2b87161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94d91e4d-2dff-41a7-a3e8-eac0e2b87161" xlink:to="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:to="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e4ec3279-cdf8-4c70-8a51-98230ab74f27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_63faf760-bbd8-4a56-9d4d-64f83d99a184" xlink:to="loc_srt_LitigationCaseTypeDomain_e4ec3279-cdf8-4c70-8a51-98230ab74f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherMattersMember_3c1d0d11-013d-412e-8f3a-be45901471a5" xlink:href="thc-20221231.xsd#thc_OtherMattersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e4ec3279-cdf8-4c70-8a51-98230ab74f27" xlink:to="loc_thc_OtherMattersMember_3c1d0d11-013d-412e-8f3a-be45901471a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_905096fd-dc28-4049-94ce-53c0330b8bb7" xlink:to="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_d6223033-f804-4d20-a07a-9ccdb460db06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_d6223033-f804-4d20-a07a-9ccdb460db06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims_3b4904a1-dc73-41f1-8e57-e3844b44ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankruptcyClaimsAmountPaidToSettleClaims"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dafcf922-98b8-49c8-8746-8dab1bb7cc73" xlink:to="loc_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims_3b4904a1-dc73-41f1-8e57-e3844b44ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#CLAIMSANDLAWSUITSReconciliationsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bb31a552-fe9a-4903-9675-367658a0c181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bb31a552-fe9a-4903-9675-367658a0c181" xlink:to="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:to="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_aa59c6b8-e922-457a-8685-eb5ee661b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_adcd2a66-edda-40a5-9136-c60a42fe13b7" xlink:to="loc_us-gaap_LitigationStatusDomain_aa59c6b8-e922-457a-8685-eb5ee661b6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_216dd745-da15-443a-9be6-db521ee97745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_aa59c6b8-e922-457a-8685-eb5ee661b6a4" xlink:to="loc_us-gaap_PendingLitigationMember_216dd745-da15-443a-9be6-db521ee97745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b5484caf-0ee8-435e-84b9-65d80058398a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bb5affbe-bc58-4a0a-8017-e8ea9cb86d59" xlink:to="loc_us-gaap_LossContingenciesLineItems_b5484caf-0ee8-435e-84b9-65d80058398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5484caf-0ee8-435e-84b9-65d80058398a" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4530b6da-ef82-4021-872d-44fc5463286a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4530b6da-ef82-4021-872d-44fc5463286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_4e731499-e8f6-4f5b-8862-a307b243aa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_4e731499-e8f6-4f5b-8862-a307b243aa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_90a00305-3392-4876-a2a8-dc8e58120a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_90a00305-3392-4876-a2a8-dc8e58120a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_LossContingencyAccrualOther_f7e8f3df-4694-46ee-a505-13e1ea6e2d67" xlink:href="thc-20221231.xsd#thc_LossContingencyAccrualOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_thc_LossContingencyAccrualOther_f7e8f3df-4694-46ee-a505-13e1ea6e2d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f3667702-8d04-4425-a6a1-fcc5f261db32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_9118da94-6681-4aa1-806e-75c6fc4f2d66" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f3667702-8d04-4425-a6a1-fcc5f261db32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_f66632fb-5c3e-492b-a3f8-75445a024571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f66632fb-5c3e-492b-a3f8-75445a024571" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0940e19b-0354-4fd6-acd1-a0fec3e7e2b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1bed90b2-d268-4cf1-b4a6-fc37d90bc63d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0940e19b-0354-4fd6-acd1-a0fec3e7e2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_8a9b446f-ad18-493f-82d0-e108456be537" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0940e19b-0354-4fd6-acd1-a0fec3e7e2b0" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_8a9b446f-ad18-493f-82d0-e108456be537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9f2f051f-0cf4-4612-8480-1b8568db6225" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ed64c770-1cc4-48e8-9306-da27ec0bfad3" xlink:to="loc_srt_OwnershipDomain_9f2f051f-0cf4-4612-8480-1b8568db6225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_4dc65d45-7b2e-44b9-a26b-4c43b6385999" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9f2f051f-0cf4-4612-8480-1b8568db6225" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_4dc65d45-7b2e-44b9-a26b-4c43b6385999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_d7e6a9f5-4b8e-49e0-afcd-87a18dfc044e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenOptionContractsWrittenTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeAxis_32442704-d38d-4db3-8bdc-42bf03785a67" xlink:to="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_d7e6a9f5-4b8e-49e0-afcd-87a18dfc044e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_f334d5af-dcc9-49e9-8b4f-f0bd009d54ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OpenOptionContractsWrittenTypeDomain_d7e6a9f5-4b8e-49e0-afcd-87a18dfc044e" xlink:to="loc_us-gaap_PutOptionMember_f334d5af-dcc9-49e9-8b4f-f0bd009d54ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_065e93c0-5289-4004-bd90-c4b1e9a668d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8f41de0e-2cba-4749-a959-2ae50b9e0599" xlink:to="loc_srt_RangeMember_065e93c0-5289-4004-bd90-c4b1e9a668d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_249431b5-1ca4-4a86-abf6-569d05c2204b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_065e93c0-5289-4004-bd90-c4b1e9a668d9" xlink:to="loc_srt_MaximumMember_249431b5-1ca4-4a86-abf6-569d05c2204b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_44fc094a-c69c-4efc-a21f-40e39a06eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0c576350-b7ba-4f1a-b794-8a378dc58ccb" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_44fc094a-c69c-4efc-a21f-40e39a06eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_44fc094a-c69c-4efc-a21f-40e39a06eac8" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_JointVentureOwnershipPercentage_67705ffa-95c3-4c55-82fc-df1d958a2de4" xlink:href="thc-20221231.xsd#thc_JointVentureOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_JointVentureOwnershipPercentage_67705ffa-95c3-4c55-82fc-df1d958a2de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_22790636-2576-4e93-98ad-10f80ae41857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_22790636-2576-4e93-98ad-10f80ae41857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_88bbf279-12c6-467c-84a8-01bb297b1a92" xlink:href="thc-20221231.xsd#thc_PurchasedEquityInJointVenturePercentageOfTotalShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_PurchasedEquityInJointVenturePercentageOfTotalShares_88bbf279-12c6-467c-84a8-01bb297b1a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_2c66a8bc-2a29-4c15-add8-fe57aeac102e" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_2c66a8bc-2a29-4c15-add8-fe57aeac102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementPaymentForExecution_5c1f08e2-9737-49b5-838a-43f33acb198b" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementPaymentForExecution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementPaymentForExecution_5c1f08e2-9737-49b5-838a-43f33acb198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementNumberOfMonthlyPayments_26f9f1cf-3308-46a2-ae5a-1359ad862dca" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementNumberOfMonthlyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementNumberOfMonthlyPayments_26f9f1cf-3308-46a2-ae5a-1359ad862dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementMonthlyPayment_314166d4-1f63-4506-8a9d-89dd88a69130" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementMonthlyPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_SharePurchaseAgreementMonthlyPayment_314166d4-1f63-4506-8a9d-89dd88a69130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c10fec58-cc81-4ffe-b65c-8dfb7c747365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c10fec58-cc81-4ffe-b65c-8dfb7c747365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_4d2b1f21-abb7-42cf-ab25-6e117df66525" xlink:href="thc-20221231.xsd#thc_GainLossFromPurchaseOfNoncontrollingInterests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_thc_GainLossFromPurchaseOfNoncontrollingInterests_4d2b1f21-abb7-42cf-ab25-6e117df66525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4ce6aa03-8930-47fa-b766-607bbe2cd956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4ce6aa03-8930-47fa-b766-607bbe2cd956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_683b1449-e0fb-4f25-9e24-80ae1f074c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_3ded6961-a08f-42a2-b0ac-fd92fbfef069" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_683b1449-e0fb-4f25-9e24-80ae1f074c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_b0b787b7-ca3e-45ff-9580-24224f07770c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_b0b787b7-ca3e-45ff-9580-24224f07770c" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b22d1641-033f-4c5d-90a0-b688b2d586ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a78e41d-2796-474c-9be5-dba758cbd156" xlink:to="loc_us-gaap_EquityComponentDomain_b22d1641-033f-4c5d-90a0-b688b2d586ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RedeemableNoncontrollingInterestMember_89320e61-4d75-4cea-911f-5d50d6b02f9c" xlink:href="thc-20221231.xsd#thc_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b22d1641-033f-4c5d-90a0-b688b2d586ca" xlink:to="loc_thc_RedeemableNoncontrollingInterestMember_89320e61-4d75-4cea-911f-5d50d6b02f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_a97b3e89-d147-44ff-b674-139e09d3157a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_4605e6a4-85ab-40dd-a569-0d9f70aea2ce" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_a97b3e89-d147-44ff-b674-139e09d3157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_a97b3e89-d147-44ff-b674-139e09d3157a" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ca7f7fd7-75b7-4155-8b13-c42822a14f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ca7f7fd7-75b7-4155-8b13-c42822a14f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_dee7890f-be1f-4f86-9bab-f7ec049a7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_dee7890f-be1f-4f86-9bab-f7ec049a7d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_f5c778c8-b4e7-4cc8-9fc0-3c3fe518ec98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_f5c778c8-b4e7-4cc8-9fc0-3c3fe518ec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e9b6b9bf-b0d7-4871-9bf9-edbcc3eac8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e9b6b9bf-b0d7-4871-9bf9-edbcc3eac8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_fb6af18d-f582-4c82-b416-8a8c65f7ed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_fb6af18d-f582-4c82-b416-8a8c65f7ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7e1210af-aef9-4da5-9f58-3d73c8a9a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9f2cb514-0215-4cf9-a7f0-e8fa8716550b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7e1210af-aef9-4da5-9f58-3d73c8a9a8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_100cbadb-118e-4f93-ab69-e81ecc6b9ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_100cbadb-118e-4f93-ab69-e81ecc6b9ecf" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cafdec35-1413-42a3-a26a-ed59a87bd9f0" xlink:to="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_fd7c9d8b-86f2-4148-b2da-09b8952445c8" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:to="loc_thc_HospitalOperationsMember_fd7c9d8b-86f2-4148-b2da-09b8952445c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_3503faee-fffc-40ef-86aa-1e692e410b31" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:to="loc_thc_AmbulatoryCareMember_3503faee-fffc-40ef-86aa-1e692e410b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_18e52f11-f101-4ac4-a958-b8b2e2abae39" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8f1362bb-50b8-4184-9c4e-b3a6949e3837" xlink:to="loc_thc_ConiferSegmentMember_18e52f11-f101-4ac4-a958-b8b2e2abae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_35ed9da0-a5fb-4fe6-a109-b5197d65bc79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_033a534a-74c2-492f-ae60-8a5f37b13f6e" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_35ed9da0-a5fb-4fe6-a109-b5197d65bc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_35ed9da0-a5fb-4fe6-a109-b5197d65bc79" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_00997585-87c8-43bc-a2aa-638f13b98a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_00997585-87c8-43bc-a2aa-638f13b98a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_82935491-02b6-4e49-bb06-5b5af28c3345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9fcbcb00-5cf8-4656-a0ab-331bb68fc6ec" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_82935491-02b6-4e49-bb06-5b5af28c3345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESProvisionandDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_361c8856-2f6d-48ab-be3f-cb0f9cb889ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad7f8916-fdfc-4c88-bf3e-3d28806cf392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_361c8856-2f6d-48ab-be3f-cb0f9cb889ed" xlink:to="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad7f8916-fdfc-4c88-bf3e-3d28806cf392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_278c1020-9a8a-4789-92e2-7309d8f29426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad7f8916-fdfc-4c88-bf3e-3d28806cf392" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_278c1020-9a8a-4789-92e2-7309d8f29426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8ccf9437-3c48-42f1-ab4b-9e4bde57f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_278c1020-9a8a-4789-92e2-7309d8f29426" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8ccf9437-3c48-42f1-ab4b-9e4bde57f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1461d65b-7cb2-4793-93e8-4b03e81bf473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_278c1020-9a8a-4789-92e2-7309d8f29426" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1461d65b-7cb2-4793-93e8-4b03e81bf473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddef5a64-20bb-44b9-9689-304c91143e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_278c1020-9a8a-4789-92e2-7309d8f29426" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddef5a64-20bb-44b9-9689-304c91143e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6e043d50-eb7d-481f-a355-5b5fe4a387ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad7f8916-fdfc-4c88-bf3e-3d28806cf392" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6e043d50-eb7d-481f-a355-5b5fe4a387ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c97105f0-1b74-4920-ab61-97fd93b19fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6e043d50-eb7d-481f-a355-5b5fe4a387ad" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c97105f0-1b74-4920-ab61-97fd93b19fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d28a8c45-5df9-4f8b-ae7a-db46ce5bfa45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6e043d50-eb7d-481f-a355-5b5fe4a387ad" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d28a8c45-5df9-4f8b-ae7a-db46ce5bfa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_cf8ef705-a2d1-432b-a30e-656c7b85b822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6e043d50-eb7d-481f-a355-5b5fe4a387ad" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_cf8ef705-a2d1-432b-a30e-656c7b85b822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7afd96ec-0915-4c9b-8edb-cd86e55459d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad7f8916-fdfc-4c88-bf3e-3d28806cf392" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7afd96ec-0915-4c9b-8edb-cd86e55459d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESFederalTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_67a61926-1c79-4803-9ce7-8896dc862bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_292ccc26-e5c4-467a-b6bf-f984cb245bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_67a61926-1c79-4803-9ce7-8896dc862bba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_292ccc26-e5c4-467a-b6bf-f984cb245bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_67a61926-1c79-4803-9ce7-8896dc862bba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ef031eeb-fd70-4adb-82d9-e8e7f1268a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ef031eeb-fd70-4adb-82d9-e8e7f1268a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ddc58e11-12e3-4b34-8cfc-b91fd97de85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ddc58e11-12e3-4b34-8cfc-b91fd97de85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_7d6faa78-433f-4b1e-878f-23e43be2b573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_7d6faa78-433f-4b1e-878f-23e43be2b573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_79db098a-acad-445b-a957-8a38f1ad7dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_79db098a-acad-445b-a957-8a38f1ad7dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_f3b2c16f-63c2-4e9d-b1aa-9cd2f3958c59" xlink:href="thc-20221231.xsd#thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_f3b2c16f-63c2-4e9d-b1aa-9cd2f3958c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_043eda26-25fd-4721-9589-20af8bd26f00" xlink:href="thc-20221231.xsd#thc_IncomeTaxReconciliationNondeductibleExpenseLitigation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation_043eda26-25fd-4721-9589-20af8bd26f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_2c65601e-91dd-45af-9eda-9fbc7dfca796" xlink:href="thc-20221231.xsd#thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount_2c65601e-91dd-45af-9eda-9fbc7dfca796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a94dc1b8-410e-4809-b3f2-88dc84c68f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a94dc1b8-410e-4809-b3f2-88dc84c68f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d543d936-7f20-4f55-b1be-8ae9eeaa3f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d543d936-7f20-4f55-b1be-8ae9eeaa3f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_b25c75f9-984f-4ad0-a34a-0b2a1a9a6fc0" xlink:href="thc-20221231.xsd#thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes_b25c75f9-984f-4ad0-a34a-0b2a1a9a6fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_dea46084-01e8-44f1-aad5-6b557e0f91cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_dea46084-01e8-44f1-aad5-6b557e0f91cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b6e31306-f33f-42ed-bb81-4f57625f8539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5194f75f-74ee-44d3-a714-e4c3b3c5ab01" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b6e31306-f33f-42ed-bb81-4f57625f8539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eeff918e-5eca-4855-a232-61d66be0e082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeTaxExpenseBenefitCARESAct_e6a4da66-a095-4a36-8378-d4c29cd004a9" xlink:href="thc-20221231.xsd#thc_IncomeTaxExpenseBenefitCARESAct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eeff918e-5eca-4855-a232-61d66be0e082" xlink:to="loc_thc_IncomeTaxExpenseBenefitCARESAct_e6a4da66-a095-4a36-8378-d4c29cd004a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod_5a677950-1d6c-482e-b219-e50b90a33877" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eeff918e-5eca-4855-a232-61d66be0e082" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod_5a677950-1d6c-482e-b219-e50b90a33877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d1c16f0e-c62e-42dc-a273-0b3cb2206281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8110166f-808e-4b43-be70-81c97f7f3fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1c16f0e-c62e-42dc-a273-0b3cb2206281" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8110166f-808e-4b43-be70-81c97f7f3fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8110166f-808e-4b43-be70-81c97f7f3fc6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_86bec622-022d-427f-b002-c61789fde8da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_86bec622-022d-427f-b002-c61789fde8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_8d2ac0f3-4324-491b-a49a-ff51f18abaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_8d2ac0f3-4324-491b-a49a-ff51f18abaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsMedicareAdvancePayments_65186990-9089-4111-98ac-924f846bc6cb" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsMedicareAdvancePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_thc_DeferredTaxAssetsMedicareAdvancePayments_65186990-9089-4111-98ac-924f846bc6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_318c84ee-a702-4f98-8a3c-ccf7084c24dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_318c84ee-a702-4f98-8a3c-ccf7084c24dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsOtherLongTermLiabilities_2eff1d0f-9458-4107-a5dc-1424902f9df7" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsOtherLongTermLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_thc_DeferredTaxAssetsOtherLongTermLiabilities_2eff1d0f-9458-4107-a5dc-1424902f9df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_27db1b1d-fb33-4648-a5b0-0762b1e09b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_27db1b1d-fb33-4648-a5b0-0762b1e09b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_4e1e5456-c9dd-40b3-bb43-a9c343adc20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_4e1e5456-c9dd-40b3-bb43-a9c343adc20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsInterestExpenseLimitation_e4da9b14-d8f1-49af-b4d0-0a6012a502de" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsInterestExpenseLimitation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_thc_DeferredTaxAssetsInterestExpenseLimitation_e4da9b14-d8f1-49af-b4d0-0a6012a502de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f0614f1b-7337-403b-aebe-51a2d3a91de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f0614f1b-7337-403b-aebe-51a2d3a91de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ee57a4cf-ee79-4659-ad41-803755ec21ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ee57a4cf-ee79-4659-ad41-803755ec21ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_afcba92d-47a6-4409-92c7-03a82423d28d" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations_afcba92d-47a6-4409-92c7-03a82423d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1c49cf88-a06e-42ee-bdbe-e2b405e2fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1c49cf88-a06e-42ee-bdbe-e2b405e2fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3a8049b8-7cc4-484f-8d3e-b8c57371ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3a8049b8-7cc4-484f-8d3e-b8c57371ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0dc96e2b-1915-455c-8ce7-8dbce8b9c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0dc96e2b-1915-455c-8ce7-8dbce8b9c82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_90157e2c-d0d1-47e7-9ecc-b563ff798a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d7628fba-0645-4269-95ec-ba753f3ce26b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_90157e2c-d0d1-47e7-9ecc-b563ff798a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8110166f-808e-4b43-be70-81c97f7f3fc6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c4b9cdfa-bdb5-49dc-9882-f0f8cb7dfaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c4b9cdfa-bdb5-49dc-9882-f0f8cb7dfaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_07aab559-bdf0-4778-92a4-8cc70041f28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_07aab559-bdf0-4778-92a4-8cc70041f28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_77ed42db-288f-476b-8e68-4567f49d0c43" xlink:href="thc-20221231.xsd#thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets_77ed42db-288f-476b-8e68-4567f49d0c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_56dc2457-dc1e-4aea-97bd-d672a1af1fc7" xlink:href="thc-20221231.xsd#thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations_56dc2457-dc1e-4aea-97bd-d672a1af1fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2d6b6e85-daba-4cd7-993f-856a02684017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2d6b6e85-daba-4cd7-993f-856a02684017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7b8c98b2-417d-4834-aaea-4080b93ae689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7b8c98b2-417d-4834-aaea-4080b93ae689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b9d4fc3e-a38f-466b-90a8-20d90fce34ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e6fed3e0-dfec-4299-942c-219dfbcfb6b8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_b9d4fc3e-a38f-466b-90a8-20d90fce34ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredTaxAssetsReconciliationAbstract_9baaa32c-e5c0-4019-9ea5-4f6b7e57a21b" xlink:href="thc-20221231.xsd#thc_DeferredTaxAssetsReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1c16f0e-c62e-42dc-a273-0b3cb2206281" xlink:to="loc_thc_DeferredTaxAssetsReconciliationAbstract_9baaa32c-e5c0-4019-9ea5-4f6b7e57a21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_22b0a8b3-ed94-4beb-bb8f-34004bbddf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_DeferredTaxAssetsReconciliationAbstract_9baaa32c-e5c0-4019-9ea5-4f6b7e57a21b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_22b0a8b3-ed94-4beb-bb8f-34004bbddf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_238b229e-fa49-4407-a98d-53dcd197ab74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_DeferredTaxAssetsReconciliationAbstract_9baaa32c-e5c0-4019-9ea5-4f6b7e57a21b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_238b229e-fa49-4407-a98d-53dcd197ab74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet_70161c2a-a365-48cf-ac75-f2968b692329" xlink:href="thc-20221231.xsd#thc_DeferredIncomeTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_DeferredTaxAssetsReconciliationAbstract_9baaa32c-e5c0-4019-9ea5-4f6b7e57a21b" xlink:to="loc_thc_DeferredIncomeTaxAssetsLiabilitiesNet_70161c2a-a365-48cf-ac75-f2968b692329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_22948f6d-69ff-40d8-952c-d2a91287eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22948f6d-69ff-40d8-952c-d2a91287eb13" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_d9f7a463-d882-472e-aa39-acfd61a3abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_6151a8f0-dbd8-4617-9b24-007341887287" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_d9f7a463-d882-472e-aa39-acfd61a3abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_d3f24a71-3f1a-41c6-9ad2-7c0ea26b14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_d9f7a463-d882-472e-aa39-acfd61a3abc3" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_d3f24a71-3f1a-41c6-9ad2-7c0ea26b14b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5caa9ef1-85aa-42dc-bdd7-4655b02bf993" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_85241afa-7fd8-4697-8c70-a5cf114c7133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_85241afa-7fd8-4697-8c70-a5cf114c7133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_32594556-f385-4a31-b172-8667e6d3f15f" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations_32594556-f385-4a31-b172-8667e6d3f15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_0a757b2f-71d2-44e2-940c-329a67146afc" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers_0a757b2f-71d2-44e2-940c-329a67146afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_6db52d51-d9d3-43d3-a634-5c0bcbd0e4ea" xlink:href="thc-20221231.xsd#thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets_6db52d51-d9d3-43d3-a634-5c0bcbd0e4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cab9a488-844b-4640-9eec-6b736114f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cab9a488-844b-4640-9eec-6b736114f55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_eeafbb1f-cd23-4b03-ba2f-b550a9d2efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_eeafbb1f-cd23-4b03-ba2f-b550a9d2efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_42cf43f7-a177-4f01-862c-17d38b70a1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_42cf43f7-a177-4f01-862c-17d38b70a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f7356023-cc5e-4a8e-ae94-275b82474b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f7356023-cc5e-4a8e-ae94-275b82474b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d7201023-7095-4915-b740-2bcf81f98544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_614cd6a8-5b4e-4aba-b874-41f28478bb78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d7201023-7095-4915-b740-2bcf81f98544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7c7fff71-1483-465a-80cc-cebf8048931e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7c7fff71-1483-465a-80cc-cebf8048931e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_818e8e5b-e745-43b8-aa45-41e112bf27d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_818e8e5b-e745-43b8-aa45-41e112bf27d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d6bf6d32-3042-472a-8afd-b71ad9677ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25ae52f0-40c9-447a-b7ff-df745d725d34" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d6bf6d32-3042-472a-8afd-b71ad9677ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_af36acae-3177-4c36-8681-26107bb570ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#INCOMETAXESNOLandTaxCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_866151b7-0140-432c-850d-014784b45c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_866151b7-0140-432c-850d-014784b45c89" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b5a1059c-1a9d-48c3-ba6c-51e2b650aa48" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6fef20d3-dbc5-4db3-bbb4-a43cffff5991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:to="loc_us-gaap_DomesticCountryMember_6fef20d3-dbc5-4db3-bbb4-a43cffff5991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f991c0b9-834b-43bf-84e5-500cade7f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a6e89b18-db9b-4622-8267-8b344bc1c078" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f991c0b9-834b-43bf-84e5-500cade7f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_37725d4d-26eb-41e8-83a1-1bbdbc111a6e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_85039606-f775-4b3e-9b71-caad82faf32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_85039606-f775-4b3e-9b71-caad82faf32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7f114465-54e2-4021-a1be-68edea9aae92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7f114465-54e2-4021-a1be-68edea9aae92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OperatingLossCarryforwardsSubjectToExpiration_342326f1-42e4-4041-9c57-3283f4ff758e" xlink:href="thc-20221231.xsd#thc_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_thc_OperatingLossCarryforwardsSubjectToExpiration_342326f1-42e4-4041-9c57-3283f4ff758e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OperatingLossCarryforwardsNotSubjectToExpiration_110403fe-90ff-4722-aa75-0c7fca0a3874" xlink:href="thc-20221231.xsd#thc_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_thc_OperatingLossCarryforwardsNotSubjectToExpiration_110403fe-90ff-4722-aa75-0c7fca0a3874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_8210d0b9-c826-4f0a-b459-111f1a34f535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_8210d0b9-c826-4f0a-b459-111f1a34f535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_651aca0a-c178-477c-bcac-54502f799136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ec206f3-e3c7-4ecb-97cd-64f498e086ea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_651aca0a-c178-477c-bcac-54502f799136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#EARNINGSPERCOMMONSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d4c98870-2ae0-4613-9dc8-b11de95c3707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_64656101-d5ea-4bfd-9a99-deaaa22ab1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4c98870-2ae0-4613-9dc8-b11de95c3707" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_64656101-d5ea-4bfd-9a99-deaaa22ab1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5f636a96-8092-47c8-9a51-8943646e29da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_64656101-d5ea-4bfd-9a99-deaaa22ab1b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_5f636a96-8092-47c8-9a51-8943646e29da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities_a6f04085-a86b-48dc-a8f6-5b802f70c3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_64656101-d5ea-4bfd-9a99-deaaa22ab1b3" xlink:to="loc_us-gaap_DilutiveSecurities_a6f04085-a86b-48dc-a8f6-5b802f70c3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c9b42cc0-1efc-4b4e-a9c3-229c5d501a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_64656101-d5ea-4bfd-9a99-deaaa22ab1b3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c9b42cc0-1efc-4b4e-a9c3-229c5d501a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_49061291-08e8-451f-b35e-de0dd8a7dfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4c98870-2ae0-4613-9dc8-b11de95c3707" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_49061291-08e8-451f-b35e-de0dd8a7dfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63b1ed9c-fef7-4339-9726-97b47820dd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_49061291-08e8-451f-b35e-de0dd8a7dfa0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63b1ed9c-fef7-4339-9726-97b47820dd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac08e8ea-58c0-4dba-8067-8fb4ce0c7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_49061291-08e8-451f-b35e-de0dd8a7dfa0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac08e8ea-58c0-4dba-8067-8fb4ce0c7e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e380b6b6-9e6c-4cc5-956d-330aeb63313c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_49061291-08e8-451f-b35e-de0dd8a7dfa0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e380b6b6-9e6c-4cc5-956d-330aeb63313c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_4c44bc33-70fd-4dc7-be6e-4bb805914899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4c98870-2ae0-4613-9dc8-b11de95c3707" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_4c44bc33-70fd-4dc7-be6e-4bb805914899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bae1028e-be7e-414c-9dba-fcee0a6d4de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_4c44bc33-70fd-4dc7-be6e-4bb805914899" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bae1028e-be7e-414c-9dba-fcee0a6d4de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EffectOfDilutiveSecuritiesPerShareAmount_8be9f8ce-1a43-45e5-9dfb-ae5ac500be98" xlink:href="thc-20221231.xsd#thc_EffectOfDilutiveSecuritiesPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_4c44bc33-70fd-4dc7-be6e-4bb805914899" xlink:to="loc_thc_EffectOfDilutiveSecuritiesPerShareAmount_8be9f8ce-1a43-45e5-9dfb-ae5ac500be98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_884e53cc-051c-4c25-bce4-9951f12463d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_4c44bc33-70fd-4dc7-be6e-4bb805914899" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_884e53cc-051c-4c25-bce4-9951f12463d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bbb19a08-570a-46a2-b198-dba5e3418347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bbb19a08-570a-46a2-b198-dba5e3418347" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90f88e84-63e8-4cbc-8c4c-106626fe29dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b647c2ee-dfc9-4314-92d1-53108cab4337" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90f88e84-63e8-4cbc-8c4c-106626fe29dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_927c54ef-c3e4-4cd5-8658-1652d8b4f56a" xlink:href="thc-20221231.xsd#thc_HospitalBuildingsAndMedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90f88e84-63e8-4cbc-8c4c-106626fe29dd" xlink:to="loc_thc_HospitalBuildingsAndMedicalEquipmentMember_927c54ef-c3e4-4cd5-8658-1652d8b4f56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cc16b756-4c28-40d7-bff5-e4d7c201591f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ede29c27-ed9a-4ccb-8b0f-fe46bf44ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ede29c27-ed9a-4ccb-8b0f-fe46bf44ef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_999b6cb9-e40e-4499-aa5a-2f4ed67f3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f15d21a5-049e-48e0-bb06-c7b96073cd61" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_999b6cb9-e40e-4499-aa5a-2f4ed67f3d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aa920b1-46a7-4a20-bf8b-033979511cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b80df4b2-4f89-4e12-b0e1-ec14fb6170fc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aa920b1-46a7-4a20-bf8b-033979511cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ef90b112-a6cf-46c1-b8fd-04f7c0ed350e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aa920b1-46a7-4a20-bf8b-033979511cd7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ef90b112-a6cf-46c1-b8fd-04f7c0ed350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ebeb52c2-cbe0-4231-ae60-1e87392587a1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e410cea4-9df9-463a-a791-00ffe00e86d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_us-gaap_AssetImpairmentCharges_e410cea4-9df9-463a-a791-00ffe00e86d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AssetsHeldforuseLongLivedFairValueDisclosure_a53e245e-a27d-4c60-ab62-0b2d5738960e" xlink:href="thc-20221231.xsd#thc_AssetsHeldforuseLongLivedFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_thc_AssetsHeldforuseLongLivedFairValueDisclosure_a53e245e-a27d-4c60-ab62-0b2d5738960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_000f674d-7b4c-413d-85c3-4360fd79d3d1" xlink:href="thc-20221231.xsd#thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a0ae64-96c3-4589-8939-f1ba6429cf3c" xlink:to="loc_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue_000f674d-7b4c-413d-85c3-4360fd79d3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cab627ab-892b-45b5-8ae9-839c4a9c1a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cab627ab-892b-45b5-8ae9-839c4a9c1a5e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_eb87877d-633c-4840-a6a9-70e62a6cf404" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedUrologyGroupMember_713a7330-f70d-4395-9fe3-bfdc944ecab6" xlink:href="thc-20221231.xsd#thc_UnitedUrologyGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:to="loc_thc_UnitedUrologyGroupMember_713a7330-f70d-4395-9fe3-bfdc944ecab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_01e32d57-ae22-4bcf-ae1b-4ee9d786282b" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2432c5ef-2196-444a-9043-06e25668e86c" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_01e32d57-ae22-4bcf-ae1b-4ee9d786282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4c535a0-56f9-403b-8fef-fef17a7c43e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2022AcquisitionMember_84cafad3-c4cf-4ba6-b82e-6b727e76c063" xlink:href="thc-20221231.xsd#thc_A2022AcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_thc_A2022AcquisitionMember_84cafad3-c4cf-4ba6-b82e-6b727e76c063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_73d6b472-a0d1-4da0-ab66-6f6b6e6f24ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_73d6b472-a0d1-4da0-ab66-6f6b6e6f24ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2021SCDCentersMember_9092a5e4-fab4-4f99-b68e-62b46c702aeb" xlink:href="thc-20221231.xsd#thc_A2021SCDCentersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_thc_A2021SCDCentersMember_9092a5e4-fab4-4f99-b68e-62b46c702aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2020SCDCentersMember_37e6673b-33ae-4582-8ffc-77e1b529c362" xlink:href="thc-20221231.xsd#thc_A2020SCDCentersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d05ab6bc-fb58-421d-aff3-76c0ace1d177" xlink:to="loc_thc_A2020SCDCentersMember_37e6673b-33ae-4582-8ffc-77e1b529c362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de23a515-db9e-41a2-b118-63f879863125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_64d845ed-3930-4778-91e8-9912131c793c" xlink:to="loc_us-gaap_SegmentDomain_de23a515-db9e-41a2-b118-63f879863125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_54389af6-89ba-443d-aca4-58d313c93fbe" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_de23a515-db9e-41a2-b118-63f879863125" xlink:to="loc_thc_AmbulatoryCareMember_54389af6-89ba-443d-aca4-58d313c93fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b99978c8-d208-4d65-9f23-c269daed9956" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_127ea661-3a27-47ba-bff7-1cd117aa9734" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries_127ea661-3a27-47ba-bff7-1cd117aa9734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersInDevelopmentStage_a04ce85a-b05b-408d-8838-fdd10ddc9216" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersInDevelopmentStage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfSurgicalCentersInDevelopmentStage_a04ce85a-b05b-408d-8838-fdd10ddc9216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_572c8533-2b2b-4fd0-8e0f-cbe783fda34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_572c8533-2b2b-4fd0-8e0f-cbe783fda34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ceada531-12e5-48d1-aa8c-d6eba6070054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_Goodwill_ceada531-12e5-48d1-aa8c-d6eba6070054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_c17c6d01-a69a-4263-a607-8789ce845522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_c17c6d01-a69a-4263-a607-8789ce845522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersAcquired_87041673-56f1-4355-adef-9fc594ff39d3" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfSurgicalCentersAcquired_87041673-56f1-4355-adef-9fc594ff39d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c8912395-b923-44d2-831c-0228fde64d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c8912395-b923-44d2-831c-0228fde64d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_ae3980d7-05dd-43b6-8f5a-ad19e0d567d0" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalCentersRecordedUsingEquityMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod_ae3980d7-05dd-43b6-8f5a-ad19e0d567d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCenters_cbfb1b7c-7e73-44f3-8019-6482143a6e66" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCenters"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberOfAmbulatorySurgeryCenters_cbfb1b7c-7e73-44f3-8019-6482143a6e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_5e6d3b50-764b-4edb-a41b-7896f2c7ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_5e6d3b50-764b-4edb-a41b-7896f2c7ec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberofHospitals_0072037e-36e8-40b1-8d71-df666cd40168" xlink:href="thc-20221231.xsd#thc_NumberofHospitals"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_NumberofHospitals_0072037e-36e8-40b1-8d71-df666cd40168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_47fca748-7a85-4c8d-ab73-fbc4a15e4060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_47fca748-7a85-4c8d-ab73-fbc4a15e4060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_21a0218b-79e8-4b94-8bd7-a6772421bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_21a0218b-79e8-4b94-8bd7-a6772421bf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_9544d6b1-331b-4fcd-9d50-849b872b0b0e" xlink:href="thc-20221231.xsd#thc_BusinessCombinationAcquisitionRelatedTransactionCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_thc_BusinessCombinationAcquisitionRelatedTransactionCosts_9544d6b1-331b-4fcd-9d50-849b872b0b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_dd74515b-87ef-40b1-8f85-f9f71e3621e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecde3b98-fec6-4c97-aefb-951a201d40ce" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_dd74515b-87ef-40b1-8f85-f9f71e3621e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16bf1afb-3336-486a-b8e9-7add6e48745e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16bf1afb-3336-486a-b8e9-7add6e48745e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a218b845-5457-474e-b387-da763e7c19ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b641dd0-1be1-473e-9ac8-600efe207471" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a218b845-5457-474e-b387-da763e7c19ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_90617011-d7eb-4edb-8ee3-587cb1159e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a218b845-5457-474e-b387-da763e7c19ad" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_90617011-d7eb-4edb-8ee3-587cb1159e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8425ce94-a7f4-4d02-89a4-f3037113fc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e480301-4800-4333-be49-2dcc2a75cd51" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8425ce94-a7f4-4d02-89a4-f3037113fc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8425ce94-a7f4-4d02-89a4-f3037113fc3f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f6030bdc-cd27-455e-bc84-eef46d3d2bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f6030bdc-cd27-455e-bc84-eef46d3d2bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3ad2e793-8e08-48aa-889c-91e6bd0c031b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3ad2e793-8e08-48aa-889c-91e6bd0c031b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6bf9683c-93c3-4b55-9f7b-6b685cc55105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6bf9683c-93c3-4b55-9f7b-6b685cc55105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f5ae1bcf-e0d8-461b-846c-35a270576ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_Goodwill_f5ae1bcf-e0d8-461b-846c-35a270576ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_70cf3194-9641-4965-858d-25e6c192fbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_70cf3194-9641-4965-858d-25e6c192fbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_a8f5698f-6178-4008-8d08-aad197a28e8e" xlink:href="thc-20221231.xsd#thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates_a8f5698f-6178-4008-8d08-aad197a28e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_95edea12-7bab-4ed3-890d-d3ff415911bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_95edea12-7bab-4ed3-890d-d3ff415911bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_115a4f64-518b-471e-b570-a67e0d4e1b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_115a4f64-518b-471e-b570-a67e0d4e1b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_b5d335b3-e00a-4537-89dc-ca1767fc7396" xlink:href="thc-20221231.xsd#thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries_b5d335b3-e00a-4537-89dc-ca1767fc7396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_f64e2c50-fa76-4cf5-9646-6f46220f875d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_f64e2c50-fa76-4cf5-9646-6f46220f875d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c803fd1e-1201-4115-861d-7074320ec813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c803fd1e-1201-4115-861d-7074320ec813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_ed9b137f-0766-4e36-9b2d-79fd5d5d2529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f29f5cdb-62e8-437c-af16-432052e8407b" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_ed9b137f-0766-4e36-9b2d-79fd5d5d2529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#ACQUISITIONSProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9f75246-45d0-4637-9766-621a286f6353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9f75246-45d0-4637-9766-621a286f6353" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3915019b-5e44-4bf7-a5e6-7a707413ad1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d7a5fca-8da8-4b7c-8e55-ccdb382df464" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3915019b-5e44-4bf7-a5e6-7a707413ad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_A2021SCDCentersMember_5b910a38-d09f-4c50-833b-3d7c208d377e" xlink:href="thc-20221231.xsd#thc_A2021SCDCentersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3915019b-5e44-4bf7-a5e6-7a707413ad1d" xlink:to="loc_thc_A2021SCDCentersMember_5b910a38-d09f-4c50-833b-3d7c208d377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a365c49c-cfa5-4e41-8f5f-26562553571b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5076327d-263e-4c6e-8d0b-7c48c07ff992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5076327d-263e-4c6e-8d0b-7c48c07ff992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_d72ecee0-315f-446e-81d5-3d853a7d9980" xlink:href="thc-20221231.xsd#thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments_d72ecee0-315f-446e-81d5-3d853a7d9980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b936a1aa-8dfc-4a8e-9ea7-7920f498ec06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b936a1aa-8dfc-4a8e-9ea7-7920f498ec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_61d7979f-a2ab-4d85-b1c7-69de22e04439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3bc42b19-c86b-47f2-9b5f-c916122221e4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_61d7979f-a2ab-4d85-b1c7-69de22e04439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b6c970a2-6137-4b02-87f7-442f79de9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b6c970a2-6137-4b02-87f7-442f79de9cd8" xlink:to="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2a4c5da2-f9bc-4fa9-8c88-86b986cad75a" xlink:to="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_dec04320-7027-4203-9d3a-981b75f2dcf9" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_HospitalOperationsMember_dec04320-7027-4203-9d3a-981b75f2dcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_59c66ef0-e06c-48ac-92c4-84d48d832d70" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_AmbulatoryCareMember_59c66ef0-e06c-48ac-92c4-84d48d832d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UrgentCareCentersMember_d535c928-c6a2-468a-a7c1-8c36d435137e" xlink:href="thc-20221231.xsd#thc_UrgentCareCentersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_UrgentCareCentersMember_d535c928-c6a2-468a-a7c1-8c36d435137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_0f6a581c-a699-43bf-be70-5adfa6df2638" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ed377bfc-56a2-4fa7-bdd5-1f46d848345c" xlink:to="loc_thc_ConiferSegmentMember_0f6a581c-a699-43bf-be70-5adfa6df2638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c4f75655-5bdb-4d02-bab6-e64ee2bc3904" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_7d28a771-4cc8-4284-89dd-d727738f5f6b" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_7d28a771-4cc8-4284-89dd-d727738f5f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_BaylorUniversityMedicalCenterMember_c8dcb4ac-9d8e-49d3-a2aa-232e13860800" xlink:href="thc-20221231.xsd#thc_BaylorUniversityMedicalCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aebdf822-0a89-451c-ac0e-891718cf3806" xlink:to="loc_thc_BaylorUniversityMedicalCenterMember_c8dcb4ac-9d8e-49d3-a2aa-232e13860800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0168da10-9749-40ab-ac2c-ec3b3abe42e3" xlink:to="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_UnitedSurgicalPartnersInternationalMember_06b0c493-4cad-4f88-890b-c9f044a72cca" xlink:href="thc-20221231.xsd#thc_UnitedSurgicalPartnersInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:to="loc_thc_UnitedSurgicalPartnersInternationalMember_06b0c493-4cad-4f88-890b-c9f044a72cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferHealthSolutionsLLCMember_7413ca0d-6354-4ec0-a2bc-5d94824bc9ad" xlink:href="thc-20221231.xsd#thc_ConiferHealthSolutionsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_0f83e7c5-8666-4433-9fe3-0d370195b518" xlink:to="loc_thc_ConiferHealthSolutionsLLCMember_7413ca0d-6354-4ec0-a2bc-5d94824bc9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9d606f76-af6a-495f-8912-639e6ae9baab" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsOperatedBySubsidiaries_e507061c-6c74-47e1-b0c6-440be9363550" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsOperatedBySubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfHospitalsOperatedBySubsidiaries_e507061c-6c74-47e1-b0c6-440be9363550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d2709665-95ac-45e6-a5a9-f280b7fac1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d2709665-95ac-45e6-a5a9-f280b7fac1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfImagingCentersTransferred_f4d89dc9-edb3-4b2e-9f2f-62e9dacaa3cd" xlink:href="thc-20221231.xsd#thc_NumberOfImagingCentersTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfImagingCentersTransferred_f4d89dc9-edb3-4b2e-9f2f-62e9dacaa3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_175524e5-f1c6-48be-9650-d825c49a185b" xlink:href="thc-20221231.xsd#thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets_175524e5-f1c6-48be-9650-d825c49a185b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfAmbulatorySurgeryCentersConsolidated_59d93899-35ac-430e-91b3-42dc6f11e271" xlink:href="thc-20221231.xsd#thc_NumberOfAmbulatorySurgeryCentersConsolidated"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfAmbulatorySurgeryCentersConsolidated_59d93899-35ac-430e-91b3-42dc6f11e271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_9de84387-a9bf-47f0-b3e3-591c6e476c06" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries_9de84387-a9bf-47f0-b3e3-591c6e476c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfSurgicalHospitalsConsolidated_c82d6614-aec0-4e4c-9b6b-a89b50b17041" xlink:href="thc-20221231.xsd#thc_NumberOfSurgicalHospitalsConsolidated"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfSurgicalHospitalsConsolidated_c82d6614-aec0-4e4c-9b6b-a89b50b17041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfUrgentCareCentersSold_3223b134-9eab-4d1a-83e0-891315050353" xlink:href="thc-20221231.xsd#thc_NumberOfUrgentCareCentersSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfUrgentCareCentersSold_3223b134-9eab-4d1a-83e0-891315050353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_de070bf0-20c7-4792-a015-c6a9fb333b6d" xlink:href="thc-20221231.xsd#thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest_de070bf0-20c7-4792-a015-c6a9fb333b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5a5788e8-e888-4835-93df-361452b81316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5a5788e8-e888-4835-93df-361452b81316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_20e5a49c-6b80-4aaf-a09d-8f8b9d8df2de" xlink:href="thc-20221231.xsd#thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_024c633e-8868-4e6c-8054-e727d49de46f" xlink:to="loc_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices_20e5a49c-6b80-4aaf-a09d-8f8b9d8df2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SEGMENTINFORMATIONReconcilingItemsDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c14390df-afa3-40cf-b801-75f2d9275973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c14390df-afa3-40cf-b801-75f2d9275973" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6b6e9778-1b2a-4d7e-9ee0-fbc4a3a68052" xlink:to="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_HospitalOperationsMember_ab2242d9-8b4a-4117-9de5-e935c339d72e" xlink:href="thc-20221231.xsd#thc_HospitalOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:to="loc_thc_HospitalOperationsMember_ab2242d9-8b4a-4117-9de5-e935c339d72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AmbulatoryCareMember_9aa57c72-4636-49d3-b4c9-e2fb933fceba" xlink:href="thc-20221231.xsd#thc_AmbulatoryCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:to="loc_thc_AmbulatoryCareMember_9aa57c72-4636-49d3-b4c9-e2fb933fceba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ConiferSegmentMember_7634a9d1-f7e6-41a3-981f-21d10468b321" xlink:href="thc-20221231.xsd#thc_ConiferSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b54fc728-dbae-4101-a02f-593a339a142a" xlink:to="loc_thc_ConiferSegmentMember_7634a9d1-f7e6-41a3-981f-21d10468b321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_0fc00c04-b8c3-42a0-bfc9-62ab00724386" xlink:to="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e0e2f3f0-c0ee-4189-b2a2-bbaffdfab094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:to="loc_us-gaap_OperatingSegmentsMember_e0e2f3f0-c0ee-4189-b2a2-bbaffdfab094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_beaf860d-0e2e-4a37-b61e-3b2420cbf22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_06a57c28-f098-4b60-afb4-08ae20d1e678" xlink:to="loc_us-gaap_IntersegmentEliminationMember_beaf860d-0e2e-4a37-b61e-3b2420cbf22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_aa85f972-642c-4d91-a024-435b4ba29d2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_TenetHealthcareCorpMember_6c3ce7fe-793e-4b29-9c24-75adb1eb1043" xlink:href="thc-20221231.xsd#thc_TenetHealthcareCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:to="loc_thc_TenetHealthcareCorpMember_6c3ce7fe-793e-4b29-9c24-75adb1eb1043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_OtherCustomersMember_79227b7d-1c29-4007-bd9f-f3ec158b3ddb" xlink:href="thc-20221231.xsd#thc_OtherCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_83ed8757-13b6-4d3c-819b-abbcc1d3b474" xlink:to="loc_thc_OtherCustomersMember_79227b7d-1c29-4007-bd9f-f3ec158b3ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ba5887dc-ae47-4a96-b796-66f81548a2ee" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c0de8f28-68f8-4b07-861a-f7e05ce9fbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_Assets_c0de8f28-68f8-4b07-861a-f7e05ce9fbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_177b64a6-36af-4f90-b24c-d759b4082538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_177b64a6-36af-4f90-b24c-d759b4082538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f183902-00a5-4005-bc06-81a03486d01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f183902-00a5-4005-bc06-81a03486d01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8817e129-f268-40b6-8026-093b81189773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8817e129-f268-40b6-8026-093b81189773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_45cbe9d6-cfcb-4de1-87bd-e17d71c70262" xlink:href="thc-20221231.xsd#thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_45cbe9d6-cfcb-4de1-87bd-e17d71c70262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_45bc2533-3c1f-4dc3-a732-65901897427e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_45bc2533-3c1f-4dc3-a732-65901897427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:href="thc-20221231.xsd#thc_AdjustedSegmentEBITDAAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f47350a4-a7aa-404f-9513-ca4a0fb9cee4" xlink:to="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_183f6ce1-fc5f-4c3c-b046-89bc46c331dc" xlink:href="thc-20221231.xsd#thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_183f6ce1-fc5f-4c3c-b046-89bc46c331dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_IncomeLossFromDivestedAndClosedBusinesses_52c010ff-7377-440a-a315-85409b29ec83" xlink:href="thc-20221231.xsd#thc_IncomeLossFromDivestedAndClosedBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_IncomeLossFromDivestedAndClosedBusinesses_52c010ff-7377-440a-a315-85409b29ec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5adb7f3d-bb64-4b12-aec1-6b163416366b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5adb7f3d-bb64-4b12-aec1-6b163416366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_1e387cb4-6a96-437a-9ab4-0e83709093a8" xlink:href="thc-20221231.xsd#thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost_1e387cb4-6a96-437a-9ab4-0e83709093a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c643e001-95a5-4d0f-9671-951eb552c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c643e001-95a5-4d0f-9671-951eb552c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ca0a3e53-15d9-428f-9b65-6fb73e3c1f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_InterestExpense_ca0a3e53-15d9-428f-9b65-6fb73e3c1f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc164a6b-ff7d-49ac-b046-8f849c724a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc164a6b-ff7d-49ac-b046-8f849c724a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_806a34ff-dd39-4e4b-aaab-ee1179164456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_806a34ff-dd39-4e4b-aaab-ee1179164456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_1bcd2a2b-819b-4ad2-8a74-43a44d106bce" xlink:href="thc-20221231.xsd#thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities_1bcd2a2b-819b-4ad2-8a74-43a44d106bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ebab4b3-b2f7-4887-bfab-6b9d4bc2df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thc_AdjustedSegmentEBITDAAbstract_1da327fb-71dd-4c8b-b699-0766dbf9c798" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ebab4b3-b2f7-4887-bfab-6b9d4bc2df0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="thc-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:presentationLink xlink:role="http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_75bf7c49-5e94-4aec-b568-07840d720aba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_75bf7c49-5e94-4aec-b568-07840d720aba" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_805ee2cd-e4f7-427f-89e5-8566179a3186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_92712bdc-c2bc-414c-bd5d-149b4ff3a360" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_805ee2cd-e4f7-427f-89e5-8566179a3186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_85094cc9-a7c0-459c-9b86-0abc9d9d30d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_805ee2cd-e4f7-427f-89e5-8566179a3186" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_85094cc9-a7c0-459c-9b86-0abc9d9d30d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e667de48-98a4-4603-9aa5-2e378a8d07e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_da9ae9e6-3adf-41fb-b56d-3fb0c868b2b0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e667de48-98a4-4603-9aa5-2e378a8d07e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e667de48-98a4-4603-9aa5-2e378a8d07e6" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9797b7ec-ca4f-47b7-a251-8359fea85187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9797b7ec-ca4f-47b7-a251-8359fea85187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0949ae8f-41df-4e76-a6e5-687e7002c468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0949ae8f-41df-4e76-a6e5-687e7002c468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_bbe710b5-b072-4647-8589-24e45c4c560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_bbe710b5-b072-4647-8589-24e45c4c560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_2d716ecd-f163-4173-8069-c0251eb20b7d" xlink:href="thc-20221231.xsd#thc_ValuationAllowancesAndReservesReservesOfBusinessesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold_2d716ecd-f163-4173-8069-c0251eb20b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9f143201-1b5d-45d7-b966-2f4b18c14c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_087f6c7f-72d6-4aa1-985d-4cf1a89e5551" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9f143201-1b5d-45d7-b966-2f4b18c14c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 ,$# 2(  A$! Q$!_\0
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M_&[?_;FG9_U?D''YUYG:!3?6^_[OFKGZ9%>W_&31)+[0X-3A7+6;_O/]P_\
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J+23N344458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
MB5!.1PT*&@H    -24A$4@   H8   %+" (   #$=MK9  !?54E$051X7NR]
M>5@45_[H??]]W_?>]]YG9&9^\YN9S$PDB>"2F!@3%O=]W]>XQ)A-C4OB NY+
MU,0MB>S(OB\--"";**L(HH*(@LB.@"BR"?2^<$]5*S:GNZNKNZN[JYOOY_D^
M/@)5ITY7=]>GSJESON=_#       P +^!_X+      #, 2@9     %@!*!D
M    6 $H&0    !8 2@9     %@!*!D     6 $H&0    !8 2@9     %@!
M*!D     6 $H&0    !8 2@9     %@!*!D     6 $H&0    !8 2@9
M %@!*!D     6 $H&0    !8 2@9     %@!*!D     6 $H&0    !8 2@9
M     %@!*!D     6 $H&0    !8 2@9     %@!*!D     6 $H&0    !8
M 2@9     %@!*!D     6 $H&0    !8 2@9     %@!*!D     6 $H&0
M  !8 2@9     %@!*!D     6 $H&0    !8 2@9     %@!*!D     6 $H
M&0    !8 2@9     %@!*!D     6 $H&0    !8 2@9     %@!*!D
M6 $H&0    !8 2@9     %@!*!D     6 $H&0    !8 2@9     %@!*!D
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MD ^2HLN[.O S"P  8#Y R19&MTBXH_@FL2CA,,O&Q7B@<_A9>L(S/@\_Q0
M &8"E&Q)5'9WS;R10G16JP@&0H^PX8:OR+TFE$KQ$PT  & .0,D60T;K4[OD
M&,@!PFR@^YNC]^_@YQH  , <@)(M ^\GC_X6'P8CJYF/F* _QX4F/VW SS@
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M"Z72+I&PJ;\/M3736Y]Z/ZG8>Z]P87;:Z*1H)&E"SPGAK)Y=34Y3SGL.*U(
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M-MR(O\8&+\Q.]Z]YW,BF_)&=(F%(W9,9UZ\J1G'C-3=]Q 3]/2ZTLJ<;KR@
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M/XH3G/?<Z#WS"D#) ##,L68E1\:7?SS=Q\[!3,.JB44;W;[],?E6<1.JC'1
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MB]:'4XSM,GN\>?"D_DMG=B5KO8[9.7IF:5CQ4.LC [.'O:-7_%7=!I>!DNG
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MQR1%"Z7,]_X!=! 71^L]XKJ?''3=[SI*]KP&+Q<P)F*QC,\7\_AB]"^=U9P
MII#*Y *AA$>>?/0?J<&=$*8$-8$&*R\42:R['61A2FY_V3]IH;_.SZCT#7M'
MK]V'4M5^ LJZ.CY(C'S.A_MZ\R N"#%$R?WD[&1I%8P&  " 15B8DA'AG#)R
M^3!<GT8*.T?/J 0UV8+0K=J\&RGWNSKP/P F09SE9:"2T>Z2XFB\7    /-A
M>4H6BB1KOHZQHYSFP60XN'\ZZTI%E9HEV2]5E,4WUN&_!4R"*.57 Y4\<.@]
M4<8EO%P   #S87E*1MPK:QTW29\9;/H%:B@OW1BINIAV14]70(WZ\5^ L1'&
MNAJH9-DA6V'T/KQ<    \V&12AXP[3BO463RD+W'TK&)&=(!>6I+DZ:)4H!1
M$09_K]]ZR8,A/6@K\/L2+Q<  ,!\6*J2>_N$"]>%F2SE_2@RUX]G +Y \DNA
M0&*-<UO9#]]CE<35("434Y/_6"R'MP\  -9@J4I&W+[7/&ZRZ;JOT8%&.WLF
M:9BI#)@2N5C /S]3Y&*0DH4NMKQ?ILI%,&8>  "V8,%*1OSA4VC*[NM1#NZ?
M3/>]56S$C#\ '62][;P3$_@'<,OJ% *T^XE/!_HTIDT%   P,9:M9*%(NG%;
MO.E&7Y/Y0YSF!Y17/L>K I@065M5O\O[1+H/%='2#\+HA\?(NUKPT@$  ,R$
M92MY@,QD.VE!@$YIR@T,.P?/:4N"JNM@1K+9D%9FBPU[D-S_-H%7-5XZ  "
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MC"*5RA:L#5,^XE>[N/A&P###VI0\0%Z2/IOM9\II462XH2_5B7,Y H$$KQ#
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MX-^09  (@B0#0! D&0""(,D $ 1)!H @2#( !$&2 2 (D@P 09!D  B") -
M$"09 ((@R0 0!$D&@"!(,@ $09(!( B2# !!D&0 "((D T 0)!D @B#) ! $
M20: ($@R  1!D@$@")(, $&09  (@B0#0! D&0""(,D $ 1)!H @2#( !$&2
M 2 (D@P 09!D  B") - $"09 ((@R0 0!$D&@"!(,@ $09(!( B2# !!D&0
M"((D T 0)!D @B#) ! $20: ($@R  1!D@$@")(, $&09  (@B0#0! D&0""
;(,D $(1? ?0LL%#^+\)\     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MK%#&L2+]U4X%3#Z?K3@16-+#TJ/\."CZ*QI4KUJW\6;EZNXZBBBNHQ"BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>logos.jpg
<TEXT>
begin 644 logos.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ('#.4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5W-?)2BX2<7NC^I,/B*>*HQKTG>,E=?,****DZ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#GU+_P%_Y![2'\R/<J*\-_X;<^"'_0_P!G_P" MS_\;H_X;<^"'_0_V?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*BNKJ"QM9KFYFCM[:%&DEFE8*B*!DLQ/   R2:_-K]KW]O2Z\:->^#?AM>26
M7A[!BO=<B)2:^'=(N 4CZ@MU?V7[WI8'+ZV85.2DM.KZ+^NQC5JQI*\CVO\
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M4 %%%% !1110!]Y_\$IO^1@^(O\ UZV7_H<U?HG7YV?\$IO^1@^(O_7K9?\
MH<U?HG7Y'G__ ",:GR_)'NX7^$@HHHKYXZPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&T,=3]I0E=?BO5#J***X#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAIW$MCID@Q]H[B20?W/1?XNIX^]C5JQHQYI'K99EF(S;$+#X9:]7T2[LY_X
M?LPW?Q"^SZ]XC66P\-\/%"#MEO1GMW5/]KJ>WJ/MG2-'LM TVWT_3;6*RLK=
M0D4$*A50>PJVJA%"J J@8  X%+7S-?$3KRO+;L?T;DV1X7):/)15Y/>3W?\
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ML#P5(!!&"*VJ_'G]G7]I/Q#^SWXE\^R+7_A^[=?[1TB1L)*!QO0_P2 =&[\
MY%?K'\/?B#H?Q1\(Z?XE\/78O-+O4W(Q&'1@<,CK_"RG((]NXP:_&\XR:KE=
M2^]-[/\ 1^?YGZYE.;4\RA;::W7ZKR_(Z.BBBOG3WPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@@]017=3FZ<U-=#Q,?@Z>886IA:FTE;_ "?R>I^3U%=;\6/!A^'_ ,1-=T$
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MX*/J_P!#JP6\CH:***_/#U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Q_P#:ROKBP^!FO-;3R0-(\$+M&Q4LC2J&4X[$$@CN#BOSL>OT
M,_:]_P"2$ZS_ -=[;_T<E?GI)7ZOPJO]AE_B?Y(_$N-&_P"TH+^XOSD5W[U!
M)5AN]025]D?$Q*DU?:_[&_PK\'^,OA'-?Z[X:TS5KT:G-$+B[MED?:$C(7)'
M09/YU\4RU^@'["7_ "1.?_L+S_\ H$5?+\25)T\!S0;3NMOF?9\*TX5<RY:D
M4URO?7L>D']GOX:'KX%T+_P!3_"D_P"&>?AE_P!")H/_ ( I_A7H=%?E/US$
M_P#/R7WL_8_J.%_Y]1_\!7^1^-WQ*LX--^(7BBTM84M[:WU2ZBBAC&%1%F<*
MH'8  "N7>NO^*_\ R4[Q?_V&+S_T>]<B]?T%0UI1;[(_F>MI6FEW?YD3=Z93
MVZTRM2H"&FUT_@+X<^(_BAKT>C^&=*GU2];EA$,)$O3?(Y^5%]R17VU\(_\
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MLO\ L)77_H0KX[BO_D7K_$OR9]=PO_OS_P +_-'TQ1117X^?JX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5%GXF\/^(8DPM[;O:3$#^.,@J3[E9,?\ KYCK[M_;+T,:I\'S>A<OIM]#/N
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M]!.\_P"_[_XU]1?\%,O^3C+;_L!6O_HR:ODVOV;*HKZC1TZ(^?K_ ,21Z?\
ML^Z[J4WQ[^&L<FH73HWB;3596G8@@W4>01FOTT_:._;0\&_  3:6I_X2/Q=L
MRND6<@ @)&0;B3GRP0<[<%B,< '-?D1HVL7OA[6+'5=-N'L]1L9X[JVN(_O1
M2HP9''N& /X5!=74]]=37-S-)<7,SM)+-*Q9W8G)9B>223DDUCC,II8ZO"I5
M?NQ6RZCIUY4XM1W9[/\ %W]L3XH?&*>:/4/$$NCZ0Y(72=&9K: +Z,0=TG_
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M;0@C=(WL,@ =R0.]?J[\,?AGH?PE\'V7AS0+?RK2W&7E?'F7$A^])(0.6/Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BL7Q-XT\/\ @NU%SX@US3=#MSTD
MU&[C@4_0N1FO*=<_;7^"^@NR2^-K>ZE'1;&UN+@'IT9(RO?UK.52$/B:1VT,
M#BL5K0I2EZ)O\CW"BOF]_P#@H)\&EN$B&LZ@Z,,F9=-FVKUX.1G\AWK5TO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+\O0_%.-,F6'JK,:*]V?Q>4N_P _S]2I\?M-&K?!GQ? 5W;;!Y^F?]7B3/\
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M?AQ\1/&FM^)]2UOQ3!?ZM=R7D\=K=VRQ*[L6(4-;D@9/<GZUWG[(/Q??XT?
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MXHUC4N0 "Q"C. !GL*V:*Y,1C<1BDHUIN21<:<(?"K!1117$:!1110 4444
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MNM(NMTVEZ@1Q<0@]&]'7(##U((X(K]2R7/89E^YJKEJ+[GZ?Y'YIG&2RR_\
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M-1G'56TO;I_74K?LD_'8_'KX3VNIWS1CQ#I[_8=41 %#2* 5E [!U(;C@-N
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M4*<DW'==O4_/[_@J3_R'OA[_ ->U[_Z'#7T5^PE_R:IX'_[?O_2ZXKJOC/\
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M&78^I..BCNQP!W-?6OP^_P""9_BO6;>*Y\7>(['PX&&XV=G$;R9?9FW*@/\
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M:OU!K\OO^"D'_)PEO_V!+;_T9-7FYA_!^9]YP5_R-?\ MU_H?+%?8W_!,?\
MY*UXI_[ 9_\ 2B*OCFOL;_@F/_R5KQ3_ -@,_P#I1%7B83^/$_5^)/\ D48C
MT_5'Z15^*GQ__P"2\?$C_L9=2_\ 2J2OVKK\5/C_ /\ )>/B1_V,NI?^E4E>
MIF7P1/SS@/\ WFO_ (5^9P5?H'_P2Y_Y /Q"_P"OFR_]!FK\_*_0/_@ES_R
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M2]7_ )*R^04445R'U(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBI5(N+04445].<1^U'[)/CB3XA?LZ>!]7GD,MTMB+*=V.6:2!FA+-[GR]W_
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M7W'_ ,%4O^2@>!O^P9-_Z-KX<K]BR7_D7TO1_FSP,1_%D%?O+\._^2?^&?\
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MY'C3_L/I_-*_;:OJ\Z_@8;_#^D3P\N_B5O7_ #/SX_X*[?\ (N_#3_KZO_\
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MT?\ Z *][BA4HX?"JC\%G;TM&QXG#3J2Q&)=;XKJ_K>5SX)_X*D_\A[X>_\
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M;Z3$,"KD9\I'D4 'K\QX+&O<E266X1X2]ZM72WKI_7F>9&H\9B%7M:$#Q?\
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MC#J/C#XVKX#@G;^Q/#,46;:-LK+>31K(TA ZE4=$ _AP_P#>-?4'P)_X)O\
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M,MXJ2^[0^2*MV.DWNI0WTUI;2W$5C!]IN6C4D0Q;TCWMZ#=(BY]6%5*^K/\
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M=_\ RDWW_P 8KZ#V]+^=?>C\5_L?,O\ H&G_ . 2_P CWJBO!?\ ANKX'?\
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ML_L?,O\ H&G_ . 2_P CWJBO!?\ ANKX'?\ 0[_^4F^_^,4?\-U? [_H=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$S[.Z<#@4M%%?*']0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF(G7M;FZ'H4X>S@H]C\J_P#@IE_R<9;?]@*U_P#1DU?)M?67_!3+_DXRV_[
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M/S17] U%'^M7_3C_ ,F_^U#ZC_>_#_@G\_-%?T#44?ZU?]./_)O_ +4/J/\
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M<;N=/EC^4X^\-O\ 6OA#X?RM;_$+PO*APZ:I:LI]Q,M?HG#</]CQ$N^GX?\
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M/P[^U%\3/!W[0%GI?BGQIJ3Z+I_B(66I6UPRA! MQY<NX8Z!<G\.O>OU+!#
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MNB?$Y!6C7QF+JPV;37WR/@G_ (*D_P#(>^'O_7M>_P#H<-?17["7_)JG@?\
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M-)7Z+?MM_'*T^"'P'UR=9U77];ADTO2H=WSF212KR@>D:$MGIG8#]X5^=/\
MP3=_Y.T\,?\ 7K??^DTE?7972E'+\34>S6GR3_S/!QLT\51@MT_S:/V3K\6_
M^<B7_=5/_<O7[25^+?\ SD2_[JI_[EZRR+_E_P#X2\S_ .77J?M)1117RQ[8
M5^)/["/_ "=I\._^OJ?_ -)IJ_;:OQ)_81_Y.T^'?_7U/_Z335]7DW^[8O\
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MX/\ XW1_P[&\!_\ 0U>(OS@_^-T?4*_8/]<<H_G?_@+/SMT#_D/:;_U\Q_\
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M*W%M>:S,)8R#U!A553(.05=25((/(KZ;@@CM88X88UAAC4(D<:A550,  #H
M*]S#X#53J/0_),ZXR4J<\-@8M2=TY/1KO9=_-VMV)****]P_(PHHHH ****
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MYQG 'E#!^N!ZU\+?MA?M]7OQ\TN3PCX2LKC0?!C.K74ET0+K4-IRH<*2$C!
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MA'S1OCGRWP <="%.#MP?8Z^;?VG?VOKW]FWQ3I6F2^!CKUAJ5H;B#4/[5^S
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M3C^''BR\EO- O-1\(SR')@M6$]J">I$;_,/H' '85YN/^"6 R,_$[C_L ?\
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M-T_3?BA_P4(^+=WJVIR^3I6G1%[FZCC*V6DVHRWE1KGYI&P< DLQY)P"0_\
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MR6MV]!U*9ZKD<E2:_6JL3QIX+T;XA^%]1\.^(+&/4M'U"+RI[>3H1G(((Y#
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MA8Y\P.3[!9"?PK]L:^+SS 4\#7C&BK1:_'K^AZ.&JNI%N6X4445\V=84444
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MU+V6'C9?B_5A7D/[5WC5/!'P+\23>9LNM1B_LRW&<%FFRK8]Q'YC?\!KUTG
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MU:#2]%TZZU749SB.ULX6ED;Z*HS7Z/>#?^":_P /-%D277]7UCQ(ZGF'>MK
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M(E=W PC ?>D;GWK+%4I5J?)'<]'A[,J.58Y8FNFXV:TWU^:/QMKZW_X)F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=6QT^W6D<V/^^@?0?E7UU'BFHE:M33]';\-3AE@E]EGX(T5^XO\ PSS\*_\
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MU;ZAX>\&^(->L!HUO$;K3-+GN8@XDE)7<B$9 (XSW%?,G_#//Q5_Z)GXP_\
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M#AJ82$M8Z'\_=%?NCJ?P1^'6M3>=J'@'PO?RY)\RZT:VD;G&>60^@_*J]O\
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MK_?Z'^*/YGZ)FG^XUO\ "_R/S$^&?@V;XA_$/PYX:@#;]4OX;5F7JB,X#O\
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MI*X7!R<\8.:5U>QI[.?+S\KMM?S->BN"_P"%_P#PO_Z*1X1_\'MK_P#'*/\
MA?\ \+_^BD>$?_![:_\ QRI]I#N='U/$_P#/J7W,[VBN"_X7_P#"_P#Z*1X1
M_P#![:__ !RK^@_&#P'XHU6#2]%\;>'=7U*?=Y5G8:M!/-)M4LVU%<DX4$G
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M.OU522.HK5I7OL5*,HNTE8****9(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!'<6\5Y;RP3Q)/!*I22*10RNI&""#P01VK\=OVP_V
M=;C]G_XG3QV<#_\ ")ZNSW.DS<D(N07@)_O1E@.>JE3U)Q^QM>=_'GX*Z/\
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M<=OWCR8 [8K\I_V._P!KB\_9]UXZ/K1FOO VH2@W$*DL]C(>//B7_P!"4?>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK X>:A%.HIW]V/25NVFG8^9P>#@\;7@Y2M!QM[TNJOWUU[A1117R!]6%%%%
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M-&<K(C %6![@@@UMA*C<73EO'0\SB3!TZ>(CCL/_  JZYEY/JOOU^=NA\O\
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M3[<XG(1B8YHA_$1N(('/RK@'G'-C%-TGR?TCZ#AB>%IYE"6*:2L[-[*72_\
M6]C0^'__  37\$:7I-N_BW5M3US5F0&9+.46]LC8Y"C:7.#QN+#/H*ZG6?\
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M+<W$BPQ1BVN 6=B !S'W)%>+_P#!4S_DD/A/_L.C_P!)Y:_.WX=_\E \,_\
M83M?_1JU]GEN24,;A/K$Y-/7:W3Y'GUL1*G4Y$C]Y:***^,/0"BBB@".XG2U
M@DFE;9%&I=F] !DFO$?^&W/@A_T/]G_X"W/_ ,;KV'Q%_P B_J?_ %ZR_P#H
M!K\"J^GR7*Z.9*HZLFN6VUNM_)]CBQ%:5&W*MS]XO 'Q%\.?%+PZFN^%M4CU
M?27D:%;F-'0%U.&&& /'TKI*^7?^"</_ ";-9?\ 83N__0A7U%7B8RC'#XBI
M1CM%M'33DYP4GU"BBBN,T"BBB@ HHHH **** "BBB@ HHHH **** /CW_AZ+
M\*_^A?\ &'_@%:?_ "37T7\&_BYH_P </ -EXNT*VOK33;N26-(M1C1)@8W*
M-D([#JIQSTK\,*_73_@GG_R:SX;_ .OJ]_\ 2AZ^WSK*<-@<,JM%.]TM_)GF
MX>O.I/ED?25%%%?$'I!1110 4444 >2?M!?M,>%_V;[/1;GQ-8:O?)JTDL<
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M?_D44?\ M[_TJ1A>._\ D1_$/_8.N/\ T4U?BR>E?M-X[_Y$?Q#_ -@ZX_\
M135^+-?4<'_PZWJOU/G.,/XE#TE^@RFTZFU^@GPD!K5"U3-434C<A/6HVJ1N
MM1MWJR2-JB:I6J-J9(^SL;C4[VWL[2"2YNKB18H88E+/([$!54#J22!BOU\_
M98^!<7P'^%=GI4RHVOWQ%YJLRX.9B!B,'NJ#"CWW'^*OFK_@G]^S0TTT/Q1\
M26VV-"RZ%:RK]X]&NB/0<JGOENRD_>]?EG$^:JO/ZE1?NQ^+S?;Y?GZ'Z9PW
MECHP^N55[TMO)=_G^7J%%%%? GW(4444 %%%% !1110!G^(/^0#J7_7M)_Z
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MJMC9P6R$LL,:Q@MU( Q4]%%?*GTVP4444 %%%% !7QM_P3=_Y /Q(_[#B_\
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M>+C\*\'B9T.B>GFMT_N/8P.)6+P\*W5K7R?5?>%%%%<!W!1110 5\;?MD?\
M)R_[.G_8<B_]+;6OLFOA_P#;X\3VO@GXU? _Q%?1S2V6D7S7\\=NH,C1Q7-O
M(P4$@%B%.,D#/<5]!D47+'1BMVI?^DL\+.I*."<GLG'_ -*1]P45\C?\/-OA
M=_T ?%W_ (!VO_R37M'P&_:(\.?M#Z3JFH^'++5+*#3IUMY5U2*.-F9EW KL
MD?(QZD5QU\KQF&INK6I.,5U.NCF6$Q$U3I5$Y/H>HT445Y9Z04444 %%%% !
M1110 4444 %%%% !7D?[6O\ R;?X_P#^P:W_ *$M>N5Y=^T]H]_X@^ /C?3M
M+L;C4M0N-/9(;6TB:665MR\*B@DGV K*K_#EZ,]#+FHXVBWMS1_-'A/_  3'
M_P"22^*O^PV?_1$5?8]?*/\ P3M\%^(/!/PQ\2VOB+0M2T"ZFU@RQPZI9R6S
MNGD1C<%=02,@C/M7U=6.%35&*9Z?$4HSS6O*+NK_ *(*_-W_ (*<?\E:\+?]
M@,?^E$M?I%7P#_P42^&?B_QM\3_#=UX=\*:WK]K#HXBDGTO3IKE$?SY#M+(I
M ."#CWK+')NBTCT.$:D*>:PE-V5I;^A]W>'_ /D Z;_U[1_^@"OSC_9ATNSU
MC]N'Q5;W]I!>VYNM78Q7$2R)D2M@X(Q7Z/:'&\.BZ>CJR.MO&K*PP00HR"*_
M,/3=+^,/P?\ VA/%7C/PO\-=;U29]1U!(&N]!O)K>2*69OG!C"YR,$$-CGO4
M8K1TY-:)G7PVO:4L=1C)*4H65W;74_2O_A7_ (7_ .A;TC_P!B_^)H_X5_X7
M_P"A;TC_ , 8O_B:^*O^&M/VG_\ HC7_ ):VJ?\ QVC_ (:T_:?_ .B-?^6M
MJG_QVK^M4OY7]QR_ZO9C_P _8?\ @Q'V]I_A'0M)NEN;'1=/L[E00LUO:QQN
M,C!P0,]*D\1^(+'PGX?U'6M4G6VT[3[>2ZN)F_AC12S'\ATKXL\/_M4?M+:A
MKVFVM]\(/LUE-<QQSS?\(SJ:>7&S@,VXRX& 2<GBNS_;]UCQOK'@_3_ W@WP
MMKVM0ZH?M.J7>EZ;/<1K$C#RX=Z*1EG&XCJ B]FJ_K$?9RG!;>1RK(Z_URCA
M\14C:?523LEOK^7=GQ;??$#Q;\6OCG>?$FV\)W/BJ6VOX[M=-CM9KB"&-/\
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M:6"*<9P<9]#6N,3="27]:GG<,3C3S>A*;LM?_26?1GP _P"2#_#?_L6M-_\
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M6?\ !4S_ ))#X3_[#H_])Y:_.WX=_P#)0/#/_83M?_1JU^B7_!4S_DD/A/\
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MOL[G4+RXOK@ZE=*9KF5I'P&&!DDFOR=UFXCNM8OIXFWQ23R.C8(R"Q(-??\
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MLUH,\^:P/S?\!&6_#WKN:^,/VAOB./'7C)K2SE\S2=+W00E3\LDF?WDGN"0
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M^'[?V>K[79X>*_BL^IO^'F7Q=_Y]O#?_ ( 2?_':/^'F7Q=_Y]O#?_@!)_\
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MCEF/9>NU>BCWR3]OB\5A\AH1HT8WD_ZNSS:=.>*DY2>A^7$O[#/QRATTWS>
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MT^UALK&UC6*"WMT"1QH!@*H'  %6J**_/6VW=GWB22L@HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  59U*1M7^'-AO811P7TY3! +,T*YST)POX9]Z]M_P""</\ R;-9?]A.[_\
M0A7EO_!57PK//H?@#Q)&C&WM;BZT^9L<!I51X_IQ%)]?PKAPLE'/I7_FE^3-
M9_[K\D?GA#-);R+)$[12*<JZ$@CZ&KO_  D6J_\ 03O/^_[_ .->J?LA^(=
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MG_!+/_DD/BS_ +#I_P#2>*OM.O"SG_?ZOK^ATX?^%$****\8Z HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:;=PWMI*,I-"X93[?7VJ[7ZC'BK$2BI*$6GZ_YGY5+ *$G&5TT?BU_PQ_\
M&;_HGFL?]^U_^*K8L_V%_CE?,1'X#G3 R3-?VD0_\>E%?L;13?%&*Z0C^/\
MF3]2AW9^3VC_ /!-SXR:DP%Q;:)I()QNO-1# <]?W2O]?PKT/P[_ ,$J_$EQ
ML.O>.]+T_P#O+IUG)==N0"YB[^WO[5^CU%<E3B+'SV:7HO\ .YHL)21\=^$_
M^"8?PVTCRY-<UG7?$$R_>C$L=M W_ 54N/\ ONO<?!/[+?PH^'K12:+X%TB.
MXCP4N;N'[7,I]0\Q9@?H17J=%>36S'%XC^)5;^>GW(WC1IQVB(JA%"J J@8
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MUN;>1XRC%&&1E3R#7PK^SE_P3;GAOK77OBL\?EQ,)(_#=K*'#D?\_$JG&/\
M80G/=NH/W_:VL-E;16]O%'!;PH(XXHE"HB@8"@#@ #C KY[/*F G.,<(M5HV
MMO+U]?SZ=>&C52;J'F7[2WP9A^/'P@UGPOF.+46 NM.GD^[%=1Y*$GL&!9"?
M1S7XLZYHE_X:UB]TG5+26PU*RF:WN+:9=KQ2*<,I'J"*_?BOFS]JK]B[0_V@
MHVUO2YHM \;1QA%OBG[B\4#Y4N !G(' D&2!P0P  UR/-HX)NA7^!]>S_P B
M<30=3WH[GS#^RS_P4&F^&^BV7A+X@VUUJVA6B"&RU:U >YM8P,+&ZDCS$4<
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MK#<V\BRP3(LD<B]&4C((^H-?@!'&\TBQQJSNQ"JJC))/0 5^V7[+FO7GB/\
M9[\!7FH6]Q;7J:7':RI=1M'(6AS#N(;GYO+W9[A@>]?+YQD]/+J<*E.3=W;6
MQV8?$.LVFCY>_P""K/\ R+_PY_Z^K[_T"&OEW]B/_DZ;P!_U]3?^D\M?7/\
MP4X\(:]XLT/P FAZ)J.LM!<WAE73[22<Q@K#@ML!QG!Z^E?-G[&_PQ\8Z'^T
MMX&OM2\)ZYI]E#<S&6YNM-FBC0&WE +,R@#D@<^M?09?4@LE<6U?EG^IRU4_
MK%_-'ZWT445^:'L!7XE?M1_\G&?$C_L.W?\ Z,-?MK7XY_M*?"KQKJOQ^^(-
MY9>#]?O+2?6KJ2*XM],G>.13(2&5@N"#ZBOL^&)1C7J<SMI^IY^,3<58^N?^
M"6?_ "2'Q9_V'3_Z3Q5]IU\@?\$T_"VM>%/A3XHM];TB_P!'N)-:,B1:A;/
M[+Y$0W . 2,@C/M7U_7B9PU+'U6N_P"AT8?^%$****\<Z HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK3]':.]\4S)JMTN&6RAR+=3_ +1ZO^@]C7NUO;Q6D$<$$20PQJ%2.-0JJ!T
M Z"OT7*>$:E1JKF'NQ_E6[]7T_/T/S'.>-*=).CEOO2_F>R]%U^>GJ<]X#^'
MNC?#O1Q8:1;["V#-<28,L[#NS?G@#@9X%=+117ZO2I4Z$%3I1M%;)'X[6K5,
M14=6K)RD]VPHHHK4Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<\5_#O
MPYXVCQK.DV]Y)C GQLE7Z.N&_#.*\<\4?LBV4Y>7P_K4MJ>HM[]/,7/IO7!
M_ U]#45X^,RC X_6O23??9_>M3V\#G689=98>JTNVZ^YW1\3Z]^SKXZT,L1I
M2ZE$O_+2PE63/T4X;_QVN$U/P_JFBMMU'3;RP;TNH'C/_CP%?HG2,H92K $$
M8(/>OD<1P5AIZT*KCZI/_(^TP_'F+@K8BC&7HW'_ #/S=HK]"KWP;X?U+/VO
M0M-NL]?.M(WSW[BLR3X3^#)G+MX6TD$_W;1%'Y 5Y,N"<0G[M9/Y-?YGLPX]
MP[7OT)+T:?\ D?!%%??,/PK\&V^=OA;1SG^_91M_,&MFQ\.Z3I;!K/2[.T;U
M@MT0_H*<.":S^.NEZ)O_ "%/CZ@OX=!OU:7Z,^"M'\!^(_$#+_9VA:A=J?XX
M[9RGXMC _.O1?#O[+?C#5]KZA]DT6(]?/E$DF/94R/P)%?8-%>UA^#,'3=Z\
MY3_!?J_Q/!Q/'6.J*U"G&'XO]%^!XWX1_9=\*Z"R3:F\^O7*\XG_ '<.?78O
M)^A8BO7+#3[72K2.ULK:&TMHQA(8$"(OT X%6**^RPF PN!CRX:FH_G\WNSX
M?&9CB\PES8JHY>NWR6R^04445WGG!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>thc-20221231_g1.jpg
<TEXT>
begin 644 thc-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2/V17AI9@  34T *@    @ "0 +  (
M   F   (A@$2  ,    !  $   $Q  (    F   (K $R  (    4   (TE$0
M  $    ! 0   %$1  0    !   N(U$2  0    !   N(X=I  0    !   (
MYNH<  <   @,    >@  $6H<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0
M5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-  R,#(S.C R
M.C X(#$S.C(Y.C$R   &D ,  @   !0  !% D 0  @   !0  !%4DI$  @
M  ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P  " P   DT
M !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                ,C R,SHP,CHP
M." Q,SHR,SHS.  R,#(S.C R.C X(#$S.C(S.C,X      8! P #     0 &
M   !&@ %     0  $;@!&P %     0  $< !*  #     0 "   " 0 $
M 0  $<@" @ $     0  $B4         8     $   !@     ?_8_]L 0P (
M!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R B+",<'"@W
M*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\
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M"WLQRC22;2P';T_F142DUH-(33KJ-EQT); 8 @-^!Z>GX5I5#OU&@HI#"B@
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M,,@_44*-T#9#'&KF.0W2E$;Y5SSCN1]<#K700+^[#%0&8<\4ADM%( HH **
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M_P!*P)8S:7+[]IZ[2."W?'N?3Z528F/\T;PN#@D@-VXJ0''TK5.Y-A JH@5
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MV:*S*"B@ HH *P=2MC;S;PP$+-N^8\9Y./QH 6U<F_2-002V_.?;G]*W:;W
M**0!10 44 %% !10 44 %% !10 44 %% #7C21=KKD57BT^"&Y^T*#YF,9)I
MWTL!:HI %% !10 5%/"L\6QO7(..AH I6EG(EV978A%Y"XZMC&?RK2IO<2"B
MD,** "B@ J,SPK.L!EC$S#(C+#<1ZXH DHH ** &EU#A"P#'H,\FG4 %% !1
M0 44 %% !10 44 %% !10 44 %% !10 44 %8T^AF7Q)#J0N"(% :2#'WI5!
M5&SUP S<?2@!?[&N5D5UU:[*AL^6S?+C(X]3P.Y[\YIKZ!+(K!M8OQF+RP5D
MP1RIW9]3M_4XQ0 V?0;J9\?VW?)$8V4A'P<G&#GVP?S[5=T_3I+&2=WOKBY\
MUMV)3D+]* )9;,RWL<V_"+C<F.I&<?S-4[[1'O9IG&J7T*RJ5,<<F%&0!D?E
M0 ITB<NK?VK> *%& PYP&Z_BV?\ @(IR:3*IYU&[8 +C,AZALG],#\^I- %>
M30[N29&&M7J1A&#A6Y9B<@^V!QQ_^N671[B6W6/^U;N-]NUG1L$]?\?_ !T?
MB +!H\T$P?\ M6]D4,#LD?(ZY/X'I^/TK5H ** "B@ HH ** "B@ HH ** "
MB@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** /
M_]D _^$QY&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&
M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z
M9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871O
M<E1O;VP^5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-#PO
M>&UP.D-R96%T;W)4;V]L/CQX;7 Z0W)E871E1&%T93XR,#(S+3 R+3 X5#$S
M.C(S.C,X/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\+W)D
M9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L
M0P # @(# @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+
M"Q 6$!$3%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M_\  $0@'U@T  P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$
M!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B
M<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ
M\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$
M +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&Q
MP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY
M^O_:  P# 0 "$0,1 #\ _5.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBF23)" 7=4!. 6.* 'T5!+>P0[?,F1=Q
MP,FI@P."#D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %8_BC_D&C_?'\C6Q6/XH_Y!H_ZZ#^
M1H Y0UN^&;R5K@V[.3%M)"GL>/\ Z]856])N/LVH0/G W;3]#P?YT =O2T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>SEV#F1M4E8W_"667I+_ -\C_&E'BJQ/>0?\!H]G+L',C9HK'_X2FQ_O2?\
M?-'_  E-C_>D_P"^:/9R[#NC8HK'_P"$IL?[TG_?-'_"4V/]Z3_OFG[.78+H
MV**Q_P#A*;'^])_WS1_PE-C_ 'I/^^:/9R[!=&Q16/\ \)38_P!Z3_OFC_A*
M;'^])_WS1[.78+HV**Q_^$IL?[TG_?-'_"4V/]Z3_OFCV<NP71L45C_\)38_
MWI/^^:/^$IL?[TG_ 'S1[.78+HV**Q_^$IL?[TG_ 'S1_P )38_WI/\ OFCV
M<NP71L45C_\ "4V/]Z3_ +YH_P"$IL?[TG_?-+V<NP71L45C_P#"46']Y_\
MOBG?\)-I_P#SU;_O@_X4<DNP71JTM4+?6+6ZAFDB8NL(W-\I'K_@:K?\)/9^
MDO\ WS_]>I::T8S8HK'_ .$FL_27_OG_ .O1_P )-9^DO_?/_P!>D!L45C_\
M)-9^DO\ WS_]>C_A)K/TE_[Y_P#KT ;%%8__  DUGZ2_]\__ %Z/^$FL_27_
M +Y_^O0!L45C_P#"36?I+_WS_P#7H_X2:S])?^^?_KT ;%%8_P#PDUGZ2_\
M?/\ ]>C_ (2:S])?^^?_ *] &Q16/_PDUGZ2_P#?/_UZ/^$FL_27_OG_ .O0
M!L45C_\ "36?I+_WS_\ 7H_X2:S])?\ OG_Z] &Q16/_ ,)-9^DO_?/_ ->C
M_A)K/TE_[Y_^O0!L45C_ /"36?I+_P!\_P#UZ/\ A)K/TE_[Y_\ KT ;%%8_
M_"36?I+_ -\__7H_X2:S])?^^?\ Z] &Q16/_P )-9^DO_?/_P!>C_A)K/TE
M_P"^?_KT ;%%8_\ PDUGZ2_]\_\ UZ/^$FL_27_OG_Z] &Q16/\ \)-9^DO_
M 'S_ /7H_P"$FL_27_OG_P"O0!L45C_\)-9^DO\ WS_]>C_A)K/TE_[Y_P#K
MT ;%%8__  DUGZ2_]\__ %Z/^$FL_27_ +Y_^O0!L45C_P#"36?I+_WS_P#7
MH_X2:S])?^^?_KT ;%%8_P#PDUGZ2_\ ?/\ ]>C_ (2:S])?^^?_ *] &Q16
M/_PDUGZ2_P#?/_UZ/^$FL_27_OG_ .O0!L45C_\ "36?I+_WS_\ 7H_X2:S]
M)?\ OG_Z] &Q16/_ ,)-9^DO_?/_ ->C_A)K/TE_[Y_^O0!L45C_ /"36?I+
M_P!\_P#UZ/\ A)K/TE_[Y_\ KT ;%%8__"36?I+_ -\__7H_X2:S])?^^?\
MZ] &O2UC_P#"36?I+^7_ ->K=]J46GPI)*KD,<!5P30!=HK&_P"$IM/^><W_
M 'R/\:/^$JM/^><W_?(_QH V:*QO^$JM/^><W_?(_P :/^$JM/\ GG-_WR/\
M: -FBL;_ (2JT_YYS?\ ?(_QH_X2JT_YYS?]\C_&@#9HK&_X2JT_YYS?]\C_
M !H_X2JT_P"><W_?(_QH V:*QO\ A*K3_GG-_P!\C_&C_A*K3_GG-_WR/\:
M-FBL;_A*K3_GG-_WR/\ &C_A*K3_ )YS?]\C_&@#9K(\3_\ (-'^^/ZTW_A*
MK3_GG-_WR/\ &J.KZY;W]F88TD5BP.6 Q_.@##HHHH [G3;K[;913'@L.?J.
M#5JL7PO-OL73/*/^A%;- "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#<\/G_ $#5?^N7
M]&K+K2\/_P#'CJG_ %Q_HU9M>;6_B,Z(;!1116)84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 ?A72I"=9T.)<^4\1^\W0X&/Y&N:K
M?\-W D2:UE?<&'RKST[XH P,;>/3CBBGSQF.9U,9BP?N'J/:F4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &[X3D(N)TQ\K*"?P/_UZZ6N;\)LOFW (
MP^ 0?;O724 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2=Z,UQWCCXB6_A;_ $:W5;K4&&?+S\L?H6Q_+^5 &SXBLI[Z"-8S&L0.
MYV<XQ_\ 6KEI$TRW;;-KNG(^>5\\''ZUY9K'B34_$$A>^NY)N_E[L(OT4<"L
MSZ?I5QJ2BK(EP3/;8=)6^!-E?VE]WQ!,&-5+BUFM9-DT;1MZ$5X]'(T;!D8H
MRG(93@CWX_G7:>'?B7=V>+75U_M.P)P3)S+'[@]_Q_2MHUY+<GV?8ZCKTYHJ
MU=6L36\-Y9RBYL)AF.4=1['W_P *JUVQDI*Z,;6T"BBBJ$%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5L^$_\ D*G_ *YM_,5C5L^$_P#D*G_KFW\Q6=3X&5'<SJ***\I'2%%%%, H
MHHI"9KVS!?#-[G_GH/\ V6L"MV'_ )%>\_ZZK_-:PJ[\/\)C/<****ZC,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHI,#;\/_\ 'EJG_7'^C5F5I^'_ /CRU3_KC_1J
MS*\VM\;.B&P4445D6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*TJ %HHJG=ZK;63%99</C.T DT 7**JVNI6]YD0R;B!DC!JQYB[@NX;CR!0
MZBFK(K D,"!QQ3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCNV[ .?K5^WNDN41X\M&PR&_I0!/124M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMUPZD&DAF>"1)8G:.1#E70X(]P1WKZ7U;1;/7+5K>^MX[B(_WAR/<'J#[BO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ J]HMT+748F.2#\IP?7C-4:/\
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MGE@.IQ7GV3G/>E+%N22?QH ] W#CD"H7O[:/AKB)3Z%Q7#&1F !8D+P/:FT
M>@JP90001ZBG5Q^A:D+&YVR.5@<8]@:ZY75U#*05/<4 .HJ%KN%<[I57!P=Q
MQ4JL&4$'(/((H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M6KVOV[3YHNY&1CU'-7:2C9W \V961BK#:PZ@\4E=GKFAKJ2B2,A)E'IP?:N,
MKTZ=131S./*%%%%:DA1110 4444@+2W%MH>F7&L7J[XH3MBB[R2=A^?]:\GU
MO7+SQ!?R7=[*99&X"_PJ/[JCL*[#XLWQBN--TA#B*WA\UAZNV1S^ _\ 'J\_
M_EZ5Y<Y.4KG5%61-;6LU],L-O$\\SG"I&"S'\*Z%?AKXE>(2#2VVXS@RQ@_E
MNS7J/PW\*0:'H<%TT:M>W<8D>3N%/(4>@QC/O788XYJ"KGR_>V-SIMPT%U!)
M;S+U212#3M-U.YTB\CNK.9H9XSD,OZ@^WUKWSQKX4@\4:1+&R#[9&I>WEQ\P
M8<[<^AQS^?:OGKI0!ZAXBCB^(WA)-9M(PNJ6(*SPJ/O+U(^G\0_$=:\OKM_A
M'JSV/B@6>[]U>1LI'^TH+*?T(_&D^(_@E]%UE)K*!GL[U\1HBYV2'^ #W[?B
M.U S%\'>&W\4:U%;?<MD_>3R=E08S^?3\<UZ;J5TD\J10*([2!1'"@Z!1P*A
MTO24\'Z$FGJ0;ZY DO)%.?HH/IS_ #]:AKLHT_M,YIRZ!111789A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M ^&9K>5)4.&0[A7+?%#15M]3AU>W7%KJ W-C^&4?>'XXS]<UTU6Q8Q^(-'NM
M&F*@R#?;NW1)!R/P_H37-6AS*YI"5F>+T5)<VTMG<RV\R-'-&Q1T;J"#@BHZ
MX#I#\/QHHJQINGS:M?P6=NF^:9PBK]3_ "ZY/I0!UG@."/1K'4/$URH*6BF*
MV5OXYF&./H#^I]*Y!FEOKHL=TT\SYXZLS'^9)_6NL\?:A#9BS\.V#;K33A^\
M8?\ +68\L3[CG\2:G^%N@K=:A)K%RO\ HECRF>CRD< ?3K^*T =I#IR^'=#L
M=)7;YJ+YLY'0R'D_X?3%04^:9KB9Y7.6<Y-,H)"BBB@#5T'43:W"P.P$$A.<
M]B<8/Z8JCK&EG3;K;R8FY1C_ "_"H/>N@T_4DU6+['>+OD8$"3'7@_D<5I3F
MX,B4;G+T5+=0_9[J6+=NV.5W>N#45>FG<YPHHHI@%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M128&WX?_ ./+5/\ KC_1JS*T_#__ !Y:I_UQ_HU9E>;6^-G1#8****R+"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%C&JQ(H('+8Y- &%I&@R22B>Z7:@.0C=6^H]*Z51M4 # %+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ****3 V_#_\ QY:I_P!<?Z-696GX?_X\M4_ZX_T:LRO-K?&SHAL%%%%9
M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ)5VJ !@#TZ4M+0 E+110 4444 %%%% !1110 4444 %%%% !1110 44E&:
M%HI-P]:* %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444F!M^'_\ CRU3_KC_ $:LRM/P_P#\>6J?]<?Z
M-697FUOC9T0V"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *O:&6&J6^W!Y[_3FJ-7M#8+JMN2,Y)'7V- "Z['Y>J3X
MZ'!ZYZ@50K1\0 #5I\?[)/Y"LZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.XNI+>*/!M9'"R;>IY_E@4I7@^6X+74H>$]/W%KMCP"45<>W6NG7I354*H
M ]!3JYI2YG=FB5D+1125)0M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M-9E12S':
M,D^@H K:E?+I]LTK<MT5?4UQ4LK32-(YW.QR2:MZOJ1U&Z+<^4O"K_6J- !1
M110!+;W4MI)OB<HWJ*FOM4N-0;]Z^$[(O JI10 >W:E9BW+'<?>DHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $KGO$FJ8_T2,]?]8?Z5J:MJ TZV9^LC?*B^]<6SL[,S,69CDL>YH 2BBB@
MHHHH **** "BBB@ HHHH **** -WPI_K[C_=%=-7,^%/]?<?[HKIJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Q_%,9?26(_A=6_I_6MBJ&MJ'TNY!Z;"?RYJHNTD)['!T445ZQR
MA1110 4444 %%%.CC>5MJ(SMZ*,FE=#&T5/]AN<9^SRX_P!PU ?E;!X/I1=
M%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6WX1_Y"<G_7(_S%8E;/A/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
M2RK#&SN<*HR33ZR/$TFS32N<;W"_U_I0!SVJ:@VH71D/"CY5'H*J444 %%%%
M !1110 4444 %%%% !1110 4444 ;OA3_7W'^Z*Z:N9\*?Z^X_W1734 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS'@\?T_&L+>RVV*OS&!11R.M%=1F%%%%, HHHH **** "BBB@ HHHH ****
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MC![@BM6#Q9=(Q,D<<@]N,5Q5:<I.Z-8R2T.NS2 ]JP;CQ= L>88G=_1N *-
MUB:_N)OM$B;< JN,$?2L/9RM<OF6QOY%&:S=3UB&PAD'F#S]F47W[?A7.:?K
MMS'?J\TC2(YVLIZ?4"B--R7,',CKS>0K="W+CSB,A?:I@<U2ATV./4I+S&7=
M0!GMUS_2KM9LH6BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8'BR3]W;IV)+?EC_&M[-<OXIFW7T: \+'G\
MR?\ ZU &+1110 4444 %%%% !1110 4444 %%%% !1110!N^%/\ 77'^Z*Z:
MN8\*G_2IQZI_6NGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M657G5OC9T0V"BBBL2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %)FEJ.XF6"%Y&^ZBEC0!DZUKALV>"-"
M9"OWST&?:N6Z]33YIGN)&>1BSMU)IE !1110 4444 %%%% !1110 4444 %%
M%% !1110!M^%/^/R;_KG_45U%<OX4_X_)O\ KG_45U% !1110 4444 %%%%
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M$Y 7'S #D_EG\JYS\<UYDOB9T1V"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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M.TQ/,2.#@\+^)_0&N^U"\:^O)9C_ !'Y?9>U;T8\TKF51Z%>BBBO1.<****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^'_UJPJ*/J\0YV;FS1?^?FX_[Y_^QHV:+_S]7'_?/_V-8=%'U>(<[-S9HO\
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M]ZB=&,8WN-2;,^^ 6\N OW1(P'YU#2LQ9B6.23DTE<9L%%%%, HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN
M8UFAD1P64C! /-2US6K>(3,LD%N,(>#)Z^N!0!AMC<VW(7/&>N*2BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH VO"^5O9/E8@IC<!P.:ZFN>\*K(%
MG; \HG&>^1704 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &'XLM_,L5ES@Q-G\^/YXKD*[/Q
M5($TI@?XG _K_2N,KOH?"83W"BBBNDS"I[C31XD\.WNDG'G@>?;$_P!\=OQZ
M?B:@J2WN&M9XY4.'4Y%9U(\T;%)V9Q_P^N$DO+_P_>DQP:E&8OFZI,OW3]>O
MX@5RM]9RZ=>3VLZ[)H7,;KZ$''Y5V?Q&T=M-U2VUZPW1PW;"3*_\LIAR?SQG
MZYJ+QM GB#2K'Q/;* TP$%ZB]$E QGZ$?R7UKR]M&=2[G%9/!'!_*MVU\=:_
M9PB*/59]@X&\AB![;@2/SK"HH*+.H:E=ZK-YUY<RW4F,;I'+$#TYZ"JU%7]!
MT>;Q!JUM80#YY6Y;'W0.2Q^@R:0CO/AOIO\ 96B7FL2#;-<?Z/;Y_N_Q-^?_
M *#6EVZ8K4NK7SFBL-/A8VEF@C0+STZG-2VWAF9E\R[D2VB')).3_@*[J?+"
M.ISRO)F=9V,]]*(X4+'N>@'XUHR^%;Q%!5HY#W 8@_K3[S5H+&U^R::2 ?OS
M=S_GUK'CN)86)CD>,GJ58C/UK3WY:K0C1&NOA6Y"YDFAC'NQILGA>Z"AH7CG
M'^R<'_"L=F+,2Q+,>I)S3X;B2W8M%(\3'J4;'\J=JG<+HNW'A^^MUW&'S!_T
MSYQ^'6L]E*,58%6'4'J*M0ZM>6^2MS)]&.X?D:WKK34UP6MUYJ(-@\W!Y_SU
M%3S2A\063V.6ZTY$:1@JJ68]%49)K=FU33(9C&E@DJ1\+)QR?Q'ZTLGB&WBA
M,EK;K%=2<-D< ?AU_P ^E/GD]HA9%>S\.32 2W3+;0CD[C\V/Z?C4ZQZ+=3>
M0@DB?.U9<G#'\_Z5C75Y/>-NGE:0]@>@_#M^%0T<LGN[!=(USX7O?.90%V \
M2%N"/I4I\.0P_+<:C##)W7C^I%9+WMQ(NUYY&7IM+DC\JAI\LWNPNC>O-833
M(Q::=MVK]Z7KD_UK)N[^>^8&>1I,=.P'X=*KT4XPBA-L****U$%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(#1M->O+-419=T2# 1
M@#QZ9Z_K5S7K>-?L]RB>69TW,!TSP?ZUA5T>CR-JFDW-M(VXQ8*.W;VS^'ZU
MQUH*UT;0>IB>WX4445QHU"BBBF 4444 %%%% !1110 4444 :.A7PLKSYE++
M(-ORC)SGC\*B\16'V.^,BC]U-\Z^Q[BK/AR.*2^PZ%G4;U(/3'_ZZJ:]>R7F
MH.CC8L3&,+GCZ_C_ "Q6]&_,9SV,VBC_ /74]E9R7\ZQ1*2W?T ]:[VTE=F'
MH6[/P_<WUN)H]BHW3<Q!/..U4;BWDM9FBE79(O45T6H7RZ7;I86Q8/'C,F<8
M[_CUJ1K6V\10Q2>:(KI5^?;^&<C_ #UKDC7?-KL:\FARM%/N(6MYI(G&&1BI
M_"F5V)W1D%%%%, HHHH **** "BBB@ HHHH **** "BBB@ &0P(."#D'N*I^
M/-#_ .$DT==8MTS?V:[;E%ZO'V;ZC^6?2KE6M.OFT^Z60#<GW74]&4]16%2'
M.KE1ERL\H\/Z+/XAU6"QML;Y#RW9%[L?8"O6KW[/8V\&F60VV=J-@_VF[L?7
MFG6^DZ;X32\DTT[IK\[E;_GC'_='XY_R*H5C1I_:9<Y=$%%%%=ID%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(.IN>&3\M^/6
M'_&L.MOPS_R_?]<36)6<?CD/H@HHHK404444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%6]*MUNM1MXGP49N0>_?'Z?K2D[*X
M$VEZ'-J)WD^3 .LC?TJYJU]$((K*U8F",?,P_B/^?YT:Y?2M.]J!Y4$? 0<9
M]_I657F3J.;.B,;!1116984444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "JN]E4<9.,UMW$UOX=A>*/,EZZ\OC[HK+T__ )"%
ML.O[Q>/QIWB++:S<=_N_^@BM:<5*6I$G9&;1117IG.%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5);
MW,MK)OB=HV]5_D:CHI,#7M?$MQ'YGVA1=*W\+8&/IQ_3_P"O<>"TUZVS:K';
M72<F,  D>G&.,XYKG*V_"LZ1WCHRDLZX5NPZ\?C_ $KGG%17-$M.^YBLC1L5
M<%64X(/8TE6=261;^<2L'D#<L!@'\*K5O'9$=0HHJ[I-B=1O4B/W!R^/3_Z_
M2B3Y5<+7+7ANTEDU".54/EQY+,>G2M_7M/EU&SCCB4,WF G)P ,'FM**)88P
MB*%4< "EYS7FRJ.4N9'1&-E8S]&TLZ9:[&PTK'+LI./:K-]=+8VLD[ D(,X]
M:L55N;%;J:"1N?*8G:>0>".GKTJ+W=Y%6ML5[>S-]#'+?1Q2N"63'0 XZUHJ
MH10JC ' %*.*6E>X!1110,**** "BBB@ KG/&WC"#PCIOFD++=RY$,). <=S
M[#_/K715\[^.-=?Q!XEN[@N6AC8Q0^@13P1]3D_C0,S=8UF]UR\:YOIWGE)/
MWC@+[ =A5*I]/L9M2OK>TMUW33.L:#MDGC\OZ5[[X6\"Z;X8M4$<*3W>/GN9
M%RQ/MG[H^E SY[H_SZ5]/WNGVVI0-#=V\=Q$W5)%#"O%/B1X)3PO>17%GG[!
M<' 4G)C<?PY]#U'?@T :_P /?B1+#<1:7JLIEA8A(;ECRA[*Q[CW[?3IZX.E
M?+'UYKW#P;XMFO/!]K=2 3S6\GV:;<<$X'!^N"/QS32OH)Z';TM9^FZQ#JD;
M&/<K+U1NM7Z&G%V9-[BT444AA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1F06UPC;H2-HP> ?_KC^5<]7ITG>!SRW"BBBMB0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH .:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCE0HW\_I458EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 .CD:*1'4X93N!]Q6O'XFG+*'CB;G!.#T_.L:B@"]XBL4M;Q'B
M3$4J@_+TSG_]59-=):R-+X>N?M"J8HU(B+=<_P#UCBN;KT*,N:)SR5F%%%%=
M! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6[X4N3'=208&)!NW=\CM6%716?_ !*]!-VD06X?Y=TG
M4@G@C\/Y5C5?NV[E1W,.]9VO)S)CS-[;L=,YYJ&K<6FW-Q:O<K'F)>_K]*J5
M:ML3YA78^&+'[-8B5AAYCN]]O;_/O7,:;9M?7L42@$9RV>FWO_GWKOU4*H &
M .E<V(EM%&L%U%I:**XC8****8!1110 444F: "BN%\:?$^V\/RO9V*+>7R\
M,2?W<9]"1U/L/SKRS5O&6M:T[&YU"8H>?+B;8GTVCC\Z!GT=29KY9\QM^[>0
M_7=GFMK2?&FMZ*ZFWU"8H/\ EE,Q=/R.?TQ0%CZ&NV?[+,8N9 AV_P"]CBOE
MVO;_  7\3+;Q%(EG=HMGJ#<*/X)#[>A]C7E?C+1SH?B6^M<8C\PR1?[C<C^>
M/J* 1H_"XQCQMI_F8Z2;<_WMAQ_6O?*^7K&\ET^\AN8&V30N)$8=B.17N_A?
MXA:7XBMHQ)/'9WN!OMY6V\^JD]1F@#JJXCXO-'_PB#[C\WGQ[/\ >Y_IFNHO
MM=T_383-=7L$" 9RT@Y^@[GZ5XM\0_&__"5WD<-N&33[<G9GAI">K'T]A]:
M1R&/R%>D?#7=_P (OKF?N"6+;]<\_P!*\WY_KQ7KGAZQ.B^";&!QB:]<W4@_
MV2!M_0 U<%>2%+8MZ7=?8[^"3=M7< V/3/-=^CJZA@00>XKS;K3Q<2JH D;
MZ ,>*[:E+G=T<\9<IZ/FEKA])UN73YOG)DA8_,K'./<5U]KJ%O=(&BF5L]L\
M_E7'*FX&T9)EFBDS1FLRA:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY!&>C.JG\Q2;LKC-F\_T/0;.!!Q<#S&/KT//YC\JR*U/$%P7OS#P(X0%51]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHYI;A1116Q(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ"22?05TD/PU\231"1=+8*1D!Y44_D6S7H?PH\*Q:=HJ:I(@:\N@2C'^"/.
M!]<9_*N^K,JY\Q:EI5YH]QY-[;26TN,[9%QD>H]:BM;N:QN8Y[>1H9XSE74X
M*_2OHOQ-X<MO$VERVEPHW8)CEQ\T;8X(/\_:OG*XMWM9Y(9%VR1L49?0@X-
M'KNCZTGC/1&N\*NI6H"W*#^-<</C\_IS[4S_ #S7%?#?5#IOBRT0G]S='[/(
MN>#NX'_CV*]0ET&SBD9#J<<94XVLHR/;K771J:6D83CK=&)16T-#LS_S%H?R
M'_Q5+_8-G_T%H?T_^*K?VD?Z1G9F)16W_8-G_P!!:']/_BJ/[!L_^@M#^G_Q
M5'M(A9F)16W_ &#9_P#06A_3_P"*H_L&S_Z"\/Z?_%4_:1#E8OA7_CZN?^N1
M_G6'75Z1I\-C]HF2]2Y7RRK;>B]_4URE3!\TFQO1(****W)"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -SP__
M ,@_5?\ KE_1JRZU/#__ "#]5_ZY?T:LNO,J_&SHAL%%%%9%A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5I^'H))-1211\L>2Q^
MH(K,K9\--YDMQ;, T4L?(S@^G\C2 R=6:-M2N&A;?&S[@WUY/ZYJI3I,>8VT
M%5R<!NHIM>O'9'*PHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%2VMLUY<1PI]YSC_&D]%<"6QT]KW>Y=88(QF29SA5'6L/5OB58Z0Q@
MT2U6ZE7@WER#C/\ LKP?QX_&LWXC>*?M$QT.Q;986IVRLIQYT@ZY]0#^H[\5
MPU>;4J.3T.F,;+4Z*[^(7B&\8LVIS1_[,.$'_CH%,M_'GB&UDW)JMP3Z2D./
MR(J[H/PRUK7K=+A4CM(&&5>X8@L/4  G\ZL:M\)=;TRW:6+R;U5Y9;=B&_(C
MG\*Q+T+^E_%%+QEBUVRCE4\?:[=<2+[D=_PQ]#72W%G']F2\LYUO+&3E)D[>
MQ]_\^U>,,I1BK*593@JPP0>_T-=-X&\7/X=O_(N&,FEW!VSPDY"YXWCWZ9]1
M^%:PJ.+)E!-';45;U*R-C=M&#NC/S(V<AE/0U4KTHOF5SFM8****H04?A12J
MI9@J@ECT %)@;>EZA%>VCV-ZZJNW$3MV/^?ZBNKAC6*%$0811@8Z5QVF:'=R
M7,3M$8T4ACYG'<5V:GIVKSZO+?W6;P'50UB^;3[&25/O_=7ZFKK&N,US56U2
MZ$4?,*-\F!R3TS44X\\AR=D7=#FGU+5GNI(U90NTGLO3&/?BNG7I5'1]._LV
MS6(G<^=S$>M7J4Y*4M-AQO;46BBBH*"BBB@!*\+^+6GM9>+YIL82ZC25?3@;
M3_Z#^M>ZUP?Q>T$ZIX?6^C7=-8MN('4QG ;\N#^!H&>)_P Z^D/"NO0^(M!M
MKV-P6*[95_NN!\P/^>XKYOK3T'Q)J'ANY,UC.8RW#(>4;ZC_ ":!GTIFL/QE
MKT7A[P_=W+L!(R&.)>[.1P/PZ_@:\W_X75JGD@"QLQ+C[WSX_+/]:X[7?$6H
M>)+H3W\YE9>$4#:J#V Z4"L9M=G\)[0R>*#>'_5V<$DI/N1MQ^3'\JXRO5O!
M^F_V#X.$KC;=:FV_Z1#[OY\G_@55%<SL$G9$OBS1_P#A+?#IE1=VIZ>"R@=9
M8^X^OI]/>O)/>O9=/O'L+I)DZKU'J.X-<5\1O#*:5?KJ%FO_ !+KT[EQT1^Z
M^W<__JK2K3Y7=;&<)7./KJOA[X977M6\^Y7_ (EUGB68GHQ_A7\?Y ^M<W9V
M<VH745O C23RL%1!U)/^3^M>PK81>&]'AT:W8,R_/<RK_'(<9_ ?T'I40CSN
MQ<I60:C?-J%X\QX!X4>BCI56BBO32LK(Y-W<****H HHHH *='&\TBHB,[$\
M!1DTVND\(1IMN'P#("!TY K.I+EC<:5V:FA37$MF4N5*2QG;R,$C (K2%(OT
MI:\MN[N=*%HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 444F: %HJO/J%O;3+'+*(W89 ;
M/\ZDDN(H5!DD1 > 68"@"2BJW]I6G_/U#_W\%*-0M6Z7,)_X&* +%%0?;;?_
M )[Q?]]BC[=;_P#/Q%_WV* )Z*K?VC:?\_,/_?P4AU2S'_+U%_WV* +5%4_[
M8LO^?E/P-,_MVQ S]H'_ 'R?\* +]%5(-4MKF.5XI-ZQC+84\=?;VJM_PD5C
MU\UO^^#0!J45E?\ "2V7]Y_^^:/^$ELO[S_]\T :M%97_"2V7]Y_^^:/^$DL
MO[S_ /?- &K168OB*Q;K*R_5#4BZ[8D9^T#_ +Y/^% %^BJ']N6/_/P/R/\
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MRH2/RIK<3.&U*7SM0N7SD&1L'VS5:BBO5CHDCF"BBBJ$%%%% !1110 4444
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M515F92BWJ<M16OJ&@F&'[3:RK-;8R<D9'^/\ZR*[(R4E=&35@HHHJQ!1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M35BUE'XF4]D%%%%:DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV/PW\,KJFH/J5VO_ !+K$AVR.)).JK[^OY>M8:^&;]O$ T;RO],\SRRO\/\
MO?3'.?2O5+B"#1;&#1[(Y@M_]9)WDD[L?Q_SQ7)"+F[&TI61%>WCWUQ),_5N
M@[ >E0445ZBT5D<O4****8!1110 4444 %%%% !1110 4444 ;OA%W^W2H/N
M&/)_ C'\ZZVN<\'QKY-Q(/O[@OX8KI*\VM\;.B&P4445B6%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DD6%
M&=SM51DDTKN(U+,=JCDDUR6LZPVH-Y<?RP*>G][WH ?JVO/>;H83L@]>A;Z^
ME9%%% !1110 4444 %%%% !1110 4444 %%%% &U9J8?#MTY(7S&P/?D#_&L
M7Z5N,'O/#:"+EHG^=5].?\16'0 4444 %%%% !1110 4444 %%%%(#;L%&J:
M/-9!6#QC<NUL!CDD9_&N=92C,K JRG!!&"*V_#]S+%?+&@+(_P!\ 9X]:J>(
M%5-6GV,K9.X[1T/I77AY:M&4^YG4445W&)O6N&\+S_[,H_F/\:R:U;#'_",7
M@_Z:C^:UE5Y53XV=,=D%%%%04%%%% !1110 4444 %%%% !1110 444^&%[B
M18XU+.QP * &44^:&2WD:.1"CKU!IE !11BM2U\/W%U;B7*)D952>30!ET4N
M#DCN#BD[>U !3XH7FD5(U+NW0"NBTWP^BK!<22,S8#[<#&3@U0CMI["]N9[6
M)7BA8_> Z>V?YCTH HOI]PDR1-$RNYPN>];EOX9BDMD\QFCF!^;:P/?_  K9
M\O[1"GF(.@.W.<'K4H7VH X^ZT6X%T4AB<QLWR%B,\=373V-DEC;K&BX[M[F
MK..:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K.UY]NDW)_P!G'Z@5HUC^*)!'I3+C_6.J_KG^E5'62$]CC.]%
M%%>JCE"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#AU.1[^U,JPTEII.G2ZGJ3;;6/A47[TK>@_SV]J .GM)(K]6O4;:QB\M]PP
M>O7\:XNZU+P]IK;+K6XY)>A6V0R<_4 BN \4>.-0\3.4=_LMB.$M(CA !TSC
M[Q_R,5SWZ?I5*3CL+E3W/5X_%'A68[3J%Q#_ +4D!(_05IVUA;ZI&9-+O[?4
M% R5C8!Q]5_QKQ7Z?X5);W4MK,LT$K0RIRLD;$,/H15JK-=1>S1ZW)&T+E)%
M*,.H88IM4?"?CB/Q&T>F:R52].$M[U1@L>RM[Y_ ^QK3N;9[.9XI!AU//O[U
MV4ZBGZF#BXD5%%%;DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %)1574;Y+"V:5OF/ "YZT
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M\ML9QG/%0UT$4EMKUJQ=9(YH(QF9N@_7GO7/UR-.+LS8****0PHHHH ****
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M(4'T')_SZ5K3CS2,YNR*-%%%>F<J"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 S:T/_ )!FJ_\ 7(?R:L6MK0_^0;JP_P"F0_DU8M91^)E/
M9!1116I(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!MZ#_ ,@_5/\ KF/Y-696GH/_ "#]4_ZYC^35F5YE7XV=
M$-@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"6VNI;.3?#(T9]NA^M:UW:Q>((5G@=4O%7#Q9
MY;'^>OO6)3X9I+>021L4<="*<9.+NA/7<AGM9;4@31-%GIO&,U%6]!X@?:8[
MR-+F(]<@9']/\]:K:SI:6VVYMFWVLAXQ_#[5W0K<SLS&4;&5111709A1113
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -;PW9BZ
MU)6=-\<8W<] >U=H.E8?A.V:.Q>5ACS&R/H./YYK<KS:LN:1T05D+1116)84
M444 %%%% $-S<+;0O*^=J#)P,UP^JZF^J7&]OE1>$7TKO&4,"",J>"*\_P!2
MM19WTT*_=5L#Z=1^E=-"U]3*I<K4445WF(444?SH **** "BBB@ HHHH ***
M* "BBB@ HHHH *58VD8*H+,3@*.]:OAW2QJ%TS2KF",<^Y["NIM]*M+60O'
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M0 4444 %%%% !1110!CZIHDFH72N)]L>.C9.#[#I67J'AU[*W,RR>;@\@+C
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MPNGN1Q^=0UD6%%%% !1110 4NTM@ 9R<=*2NC\-V$;6WVAQD[\K^ (_J?RH
MAT739;35@)T(*QEAW'84R&!_$=X[2XB\M IV#//./Z_E6A>//:V-Y<39\V3]
MVB@_=7H,?F33_#EFL%B)<'?+R?H"<?Y]Z .:ELWBOFM00T@8*"._-=%I.FK8
MWDWER"7 "GU4]?\ "M$6L<4AE2)3*3DL.ISUJ58U7<0J@L<G QGZT /HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%%)@S<T,?\2K5#W\O_ -E:L.MW0_\ D$ZI_P!<_P#V4UA5E#XF4]D%%%%;
M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &WH/_(/U3_KF/Y-696GH/\ R#]4_P"N8_DU9E>95^-G1#8****R
M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?;VK:C3YG=DSET1%1117H'.%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444F#-W0_^03JG_7/_P!E-85;NA_\@G5/^N?_ +*:PJRA\4BG
ML@HHHK8D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5HJU_9=Y_P ^TG_?-']EWG_/M)_WS0!5HJU_9=Y_S[2?]\T?V7>?\^TG_?-
M%6BK7]EWG_/M)_WS1_9=Y_S[2?\ ?- %6BK7]EWG_/M)_P!\T?V7>?\ /M)_
MWS0!5JQI_P#Q_P!MD\>:O\Q3O[+O/^?:3_OFE&EWBL#]FEX]%H$'B12-8GW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6EX;_ .0U;_\  O\ T$UFUI>&_P#D-6__
M  +_ -!-14^%C6Z([[_C]N/^NC?S-0U-??\ 'Y<?]=&_G4->2=(4444QA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXWM?"KO9:4JW>HJ2LUT_*1'T4=R/\YZ#SG4];O\ 6)O,O;N6Y8G.'8[1]!G
M%4NM=/X-\!WGBYVD#_9K)#M:9AG)]%&>3^@KS6W)W9U62.8^GXU9L-3O-+F$
MMG<S6T@_BB<K_P#K%>PQ_!G1!"%:>\9\??WJ/TVUPOC3X<77A6/[5%)]LL,X
M,F,-'GC##TZ#([TAZ&UH/Q#M/$*PZ=XGB1H_,5TN%.U&8=!(HX(_3U'&:O\
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MHHH **** "BBB@ HHHH *V-7/_$KTP>J'^0K'K9UKC3]+_ZY_P!%H QJ***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\5S&
M+3U4=6D'/<8!.?TK;KG_ !-JJP*UJJ!Y'3EF'"@\<>]:4U>2)EL<M)(\KEG9
MG<]68Y--H_6BO4\CF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *T_#:YUB#VW?^@FLRM3PS_R&(OHW\C6=3X6-;HAO
M?^/R?_KHW\ZAJ:\_X_)_^NC?SJ&O*.D****8PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBBD)FOX8_Y"#_\ 7,_S%8%;_AC_ )"#_P#7,_S%8%=F'W9C,***
M*[3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M0,W=#_Y!.J?]<_\ V4UA5NZ'_P @C5/]P_\ H)K"K*'Q2*>R"BBBMB0HHHH
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M#2XZ\]A0(X3'M_2E5F1@58JPY!4\@^O%?0*_#?PYY(C_ ++C*_WM[[OSSFN
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M_P!:CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K8UH_Z#I?_ %RS^BUCUL:[C[-IP':+^@H QZ*** "BBB@"]HL/G:I
M,9 .X_A_]?%5]8F:ZU:X.,GS-@'T.!_*KOAV0QZFHQG<I!]N^?TJ*TCBL]2O
M;B0$V]B))#GKA<X_'_"MJ+Y;LSEKH8GBOQ,/!=K]BL]K:S,F9)<9\A3Z>_\
M^OTKRJ::2YE>6:1I9&.YI'.XD^N34VJ:A-JVH7%Y.VZ:=R[>@SV^@'%7O"OA
M^3Q/KEO8H2B-EI)!_"@Y)^O8>Y%9.3D[LT2Y49D%M-=2".&)Y9/[D:EC^0IU
MU97%DP6X@E@8]%D0J?UKZ2T?0[+0K-;:RMTAC4<X'+>Y/<U8O+"WU&W>"ZA2
M>%NJ2*"*0[GB'P_OXKK[;X=O6Q::DN(V/_+.8?=/XX'X@4O@O4Y/!_BJ?3K\
MF.WF;[//VVL"=K_@3U]&S5?Q]X4_X0_6HS:LPM)OWL!SRA'5<^W'/N*O>*(Q
MXN\.V_B.!1]L@ @U!%X.1]U\?YZCTH N_%KPX;>ZBUB-,"8B*YV]!(!P?Q'^
M>:\ZKV7P3JD'C;PK/IE^V^:*,02Y/+)_ _U!_49/6O)]:TB?0=2N+&X&)(6V
M[NS#J"/J,'\:!E*BBB@9H^'=%F\1:Q;6$/!E;YF_N*.2WX#^@KZ-L+>"SMTM
M;9 D-N!$JCH,#I7#?#'PO)HFAR:H\.Z_NU_=JW!6/M^?7\J[VUA^SP*AY;&6
M;U;N:"2:BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 (37#^(IC-J\V>BX4>V /ZUUVI7:V-K),W)4<#U/85P#,9&+,<L
MQR2>]=6'CJY&4WT$HHHKN,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "M7PS_R&(OHW\C656KX9_Y#$7T;^1K.I\+*
MCN07G_'Y/_UT;^=0U->?\?D__71OYU#7E'2%%%%, HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBBD)FOX8_Y"#_\ 7,_S%8%;_AC_ )"#_P#7,_S%8%=F'W9C
M,****[3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (1<G_E\AI?^$5;_ )_(:RJ*/;3[AR(U/^$9"_>OH1_GZTA\.Q+UU* ?C_\
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MKD]DP)CSNA<_QH>A_I^%8U>\_$CPG_PDFC&2!-U_:Y>(=W'\2?CQ^(KP;_\
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ME!7'IV_2I:"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<;9N:?.;F$R  1,V(QT^4<9_0U:IL<8C554851@ 4^D(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* ,;Q3;F;3?,!/[
MI@VT=^W]:XT=*])90V0>0>U</KFFMI]\V !%(24KKP\_LF,UU,ZBBBNTR"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*U?#/_(8C^C?R-95:OAG_D,1?1OY5G4^%E1W(+S_ (^YO]]OYU#4MU_Q]3?[
M[?SJ*O*.D****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(3-?PQ_R$'_
M .N9_F*P*W_#'_(0?_KF?YBL"NS#[LQF%%%%=IF%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &WH/_(/U3_KF/Y-696GH/_(/
MU3_KF/Y-697F5?C9T0V"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"_9ZW<6BLC8GC/\,AS^56KK38=<C^T616.<</">!6-3ED:-MRDJPZ$'!IQE
M*+T$TF;>FZ;_ &"LEY=LN\+M1%[U4B\07D,CMO$@8D[7&0/\*SWD:1MSL7;U
M;FFT2DY.[$HV-23Q)>. %\N+O\J_XYH_X2.]W;MR@8^[M&*RZ*11>76KU00+
MAN6SR ?YU?CN(-<LTM;J8QW.[<K8 #'GT^OZ5A4?2FFUL(OS>%[Z/.U4E_W&
MQ_.LZYM9[&;;*K1R+\W;BIH;B6#/ERNF>NUB*V)/$BS8#V:M&?O*QSG]*W5=
M[26AGR'RI^VM\+1K6D6?Q%TV',]N%LM82,9^7.(I3[ D*?9D]*^.>YK]=KSP
MS8ZM9SV<EM'/I&HV[P7=K(QVNC#&/K@FOS"^-/PMO?@_\0-0\/W0=[93YME<
M,,>?;L3L;Z\%3[J:QE:]T:(X:BBMKP7X/U+Q]XJTSP_I,7G7^H2B&,<[5'5G
M;'15 +$^@/I4C/??V*_A.OB#Q1/XXU2'=I.@MBU5AQ-=D#:1_N AOJR5]@S3
M/<3/*YR[')JCX;\*:=\._">E^%-('^A:;'M:3&&FE/+R-[EB3Z<X'&,6Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!T;&-U93AE.1QG!K5UM_MNCVEXZA9B^PD>G/^
M'ZUD5IZ9JXM86MIT\RV?@^V>OUJHRY7<35S$]:*WY- MKQF-A=*6SD1R=AZ9
MZU0N-!OK?.8&<>J?-_*O1C5C+J<[BT9]%+@@D$8(X-)6I(4444 %%%% !111
M2%Z$U]I:^*O#TVEMC[9#F:T9O[P'*_CS^?M7CSQM'(T;J5=25*L,$$=C7KT$
MSV\R2QG#J<BN=^)GA]6\O7[-/W%R=MR@_@DZ9_'^?UK@K0Y7='33E?0X"C_/
M%+79?#?PVFI7SZI>+_Q+[$ASG_EI(.0O\C^7K7.:G5>&]'_X1/PRJR+MU+4
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^
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M8E2=SOU^Z*6HX)X[F(21MN1NA%/4@C(.17G:G2+1113 **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !2@E2".N<@^E)12 S?B-H_P#;&EPZ[ N9X0(;M0.H[-^N,^X]*P_
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MGOD'(_*I1TI:"1!TI:0T+0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M%HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -W0!_Q+=4/;R_Z-656
MMH/_ ""M3_W/Z&LFO,J_&SHAL%%%%9%A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &GX?E?^T8XMW[LDL5[9VG
M!JOJRR+J-QY@8$N2-WIGC]*JJQ4@J2&'(*GD'UK<UZ$W5I!>[&C? 1HV_'_Z
M_P"= &%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!);W#VLZ2IPZG
M(K7>.V\0Q2%(Q!?*N?EZ-6)6AH,R0ZE&7QA@5SZ9IJ3B[H3U1D,K(Q5AM8'!
M!['TI*O:Q9RV=]+Y@)#L65\?>SS5&O5C+F5SEZA1115 %%%% !1110 4444
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MK7]EW?\ S[2?]\FC^R[O_GVD_P"^30!5HJU_9=W_ ,^TG_?)H_LN[_Y]I/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** -[0?^05J?^Y_0UDUK:#_ ,@K4_\
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M*JS*OWMHSBO0K.%;>UBC3.Q5 &1@UR5Y:6-*:UN2@8I:**XC<**** "BBB@
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MBHRT-X/0=1116)H%%)1N% "T444 %%%% !1110 4444 %%%% !1110 4444
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M ,<7_"C_ (2+4?\ GX_\<7_"LVBCEAV"[-+_ (2+4?\ GX_\<7_"M.'5KMM
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M:R;X7,;8QD59_MR__P"?E_TJC14.*;U0[LO?VY?_ //R_P"E']N7_P#S\O\
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MO3/]:OZ@L>J:7]O2)HI5.&S_ !=!QZX_QK@_A?<&31-?M6/[M?+F7V8Y!/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=!X7_P"/^3_KD?YBN?KLP_4RGT"BBBNTR"BBB@ HHHH **** "BBB@ HHHH
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M/*HS\TB2@<=P "*\SAL;FX7=%;RRCU6,FK$>FZI8S+)':W=O*IRCK$ZL/<$
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M9K@[0W^Z,$D>]:VH?!W6+6$O;S6UV<<QJQ5C],C!_.O:(XUBC5$4(BC"JHP
M!V%.YH$?+MQ;RV<TD,T;131DJR.,$?A6KX5\37'A;5$N83O@;Y9H<\2+W_'T
M/M7H'QFT&+[';ZM&NV=7$,I'\2D':3],8_&O)OPQZ4%;GM.I0P_N;JU;?9W*
M"6(_7''ZU3_6JG@>Z-_X&DB<Y:QN=J>R-@X_,FK=>C1ES1.62LPHHHK<@***
M* "BBB@ HHHH **** "MFW_Y%6Z_Z[C_ -EK&K9M_P#D5;K_ *[C_P!EK*IT
M]2HF-1116A""BBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI ;VL?\>.
MF?\ 7'^@K)K6UC_CQTO_ *XC^0K)KR'N=2"BBB@84444 %%%% !1110 4444
M %%%% !1110 4444 %%%%(3-CPO_ ,?\G_7(_P Q7/UT'A?_ (_Y/^N1_F*Y
M^NS#]3*84445VF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ;V@_\@K4_P#<_H:R:UM!_P"05J?^Y_0UDUY=7XV=$-@HHHK,
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** )+>8V\R2#!*L& (XKJK>\AU:QG\M )G0AX^,YQCKWKD:EM
M5D:=%B+"1C@;3@T +=6<UDP29"C$9Z@_RJ&MGQ1(6OXTW9"Q]/3).?TK&H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***VM/\K3=):]EB220OB/=^7^/Y4:O1 8Z1M(V$5F
M/HHS4ZZ;=R=+:7_O@BK4GBB7RSY%O'!*WWI!SG]*JMXAU!E(^T?^.*/Z5NJ,
MV9\Z-"'2X=/M_M&H\<_+"#U--_MVSM8W:SM&CG88W-T'ZUB37$MPVZ65I6QU
M8YJ.MXT$MS-R?0?-,]Q(7D=G8]2QR:91172DEL2%%%%,04444 %%%% !1110
M 4444 %%%% !1110 4444 %=-X4F::WG@8Y2,@JI]\Y'TKF:V_#[%;'5"#@B
M+@]QPU8UDG!W+CN>7>/_  J?"^ML(E(L;C]Y >P&>4_#/Y8KE_KUKWK5+"#Q
MUX;>TE9$O4.8W;^&0#@_0\Y_&O"KFUEL[B6WGC:.:-BCH1R".U>;).+LSI3N
M7O#NA3^(]7@L(!@R'YWQPBCJQ_#\^!7K&HR0PI!868VV=HHC3'<CJ?K[^YJA
MX7T/_A$-!WRKMU:_7+Y_Y91_W?KW^OTIU==&'VF8SET"BBBNPQ"BBBF 4444
M %%%% !1110 4444 %%%%)@;GB#_ )!ND_\ 7+^BUAUN>(/^0;I/_7+^BUAU
MG3^$J6X4445J2%%%% !115_0[=;C4HO,_P!7'EV_#G^=3)V5Q[F=XG\1+X)T
M]8+?:VLW*9W$9$"'OCU]OQ^OD\TTES,\TSM+*YW,[G<Q)[DGK5WQ!K$FNZU=
MW\F29G++GJ%_A7\!BCP_H\FO:S:6$1VM,^"V/NKU8^^ #Q[5Y3DY.[.I)117
MLM/NM2F\JTMY;F3KLA0N?KQVJS?>'-5TV(RW6G7,$0ZN\3!1^.*^A]'T2ST*
MQCM;*%8HE S_ 'F/JQ[FKK)N4JPRIZ@]Z0[GRU[8KN?A[\0)M#NH[&_E,FFR
M' 9N3"3W_P!WU';KZYE^*G@V#0;B'4+*/RK6X8J\2_=1\=O0$9X]JX#]:!GU
M.I&T<YI<UYYX3UZZOO!=E<+,PGLY3;2<YW #*Y]>"*Z#3_%:-A+I-A_OH./R
MJU3DU=&?,D['1YHS6)>^*;:%<09G?\0H^IK&F\37LT;*"D>>Z#D?C51HSEJ)
MR1U5YJ5M9?ZZ95/]WJ?R%9R>++-I-K"15_OD UR3.TC%G8LQZL>3^=-KH6'C
M;4SYV=VVNV"*&-RN#Z D_E574/$UO;Q_N#Y\AZ8!P/<UQPHIJA%:ASLFNKJ6
M]F,LSEV_E]/:H:**Z$DMB HHHJA!1110 5M6G_(KWO\ UU'\UK%K:M/^16O?
M^NH_FM95.GJ4C%%6[/37O%>5G2"VC&7GE.$4?6C3;,7DQWMY<$:[Y9#P%4=>
M:Y[5EU;X@2,EB%T[PY;'"S3MLC8 \N>Y/Z#V-95:O)[J*C&^Y:U+QYH&CL8[
M.VDUB93@R2-LB_#U'X8]ZR&^+FH*Q$.F:;&G93$Q/Z,*@;3/!NCY6ZU.\U:8
M<$6481/S/4?0TW^T/!#*%.EZD@SRRR@G\BU<7-)[LVY4C0MOBLDI U'1+:1>
M[VQ,; ?CG/YBNDTV?2O$T;/I%R?.49:SN/E<#V]1]":XY/"_AO7&"Z/K;6MR
MWW;?4DV[CZ!P /RR:P=5T/5?".H)]I1[693NCGC;Y21W##_/YU49RCU!QBST
MF2-H6974HR]0W&*;2^'?$"^-M,?S%5-8M%S)M&/.3^\!Z_Y[TE>A3GSJYSRC
MRL***/>M20HH_6B@ HHHH **** "BBB@ HHHH **** "BIK>TFNVQ#&TA[[1
MP*N_\(]>JH+B.('IOD J'.*W8[,S**U/^$;O^"J*RG^)7&/YTPZ+(C;6N[17
M_NM, :GVD>X^5]C.HK0GT"]A7=Y/F+ZQD-56ULY;J<0QJ2_<'MZYJN:+6XK,
MGL8H=2M[G2KHXM[Q-F?[K_PD?C_2O+G\'ZR+Z>UCTZXF>)RC-'&2OY]*[[7/
M&&E^$V:WMHEU34T^\S']S$?0^I_SD5F_:/''B2%KJ2Z;2[$#<99'%M&J^N?O
M8]^:\ZI)2E='1"Z6IS#> _$"KG^R;C'LN:R;S3;O39/+N[::V?\ NS(5/ZUM
M7'B;1=(FV7?Q:T.WN 2"D>KARI[@X;C\<5UF@ZY?:Y$T6F^(O#OCJT ^>VAO
M(YF..O(X_,FLS0\PKT;X2^&9+J:XUDJO^CADMO,^Z92.2?8 C\_:EU#X>P:Y
M)G2HY-*O@P,VFWF<*N<%T/=1GMG\.E7V^(=IX/U:+1;2W$^E6:B%Y ?WA<$[
MF'8\YX[G/(H \_\ $VCZEH^K2QZFC?:9"9#)G(DR<E@>_-4+&^FTV[BNK:0Q
M3Q$,CKU'^?ZU[3X^ALO%'@>6^MF2=85$\,J^@(W#VXSD>H&>E>(4"/9H[Z/Q
M+HUMJ\*!7D(BGC':0?X_U%87Q;\1RM):Z(C\1HLMR%Z,^/E7\.OXCTIWP9N/
M.DU*P?F,B.X4>A5L'\^/RK(N-%D\7?$;4H)&,<*7#F>0_P $:':3GZ  ?7FK
M<G**3)C&S,OPSX.GUZ*2[FF2PTN'F6\EZ?11W/\ C^!]%@L_#'@C3UO)[38&
M_P!4]VH>YFQW5#]WMSQ[@51&M6K6<VLO$$T'3'\G3;(<">8=';_/')Z@UYKJ
MVK7FO:C)=W;F6>0^G3T"CT]O\:@L[RZ^*^KZM=K::-8+$TAVQ@J9)#].P_6M
M5O$5WX7VR^(]?>>]QD:;911\>S':/YCZFL":1?AOH\=M;JI\1WL8:68#)MHR
M>%'N<?G^%06_ANP\/VZ:IXIDDFNI_GBTU6)DD)[N<Y'/^>U &A>?$R\\03".
MQ\.P7;+]U9HVN&^N !C_ #Z5<DU;Q1J6P7_A&SNX@,!7MR"![;F.*YJY^(FJ
MW6VTTF&/2K<G:EO91C<?QQDGZ 59M?#?CC4_WAEOX@>=UQ=LA_(MG]* .U\-
MZY8:&)([G0KGPZ)FW.[HS0$]/O\ 1?T%>:>-M#U+3=6GO+U%>.\D:1+B$[HF
MW'( /]#77:?I?C[3LF&]2\"]89KA9<^WS?XBMVSU&._M7TCQ'HQTKSSM#*/]
M'=CTVL,A&SSUZ^YH \L\%Z:VK>*=,MQROG+(_P!%^8_H*]7.6T6\O0/EO]0:
M1?= -BGZ$1@_C61X?\%3^$[C4SOW75TXL;*4==C?,\GX+S]4-=1XB2*WT:S@
M@ 6*-@B#L H(%:4_B1G/8YKL****].YS%K3;XV%RLF-R$;74]&4]17G_ (]\
M+CP[J@EMAG3KK]Y P_A]4^HS^1%=M6E8W-G-;BUU&%;BWC<31!AG:Z]/\^Y]
M:YJU/FU1I"5M&97A'1!X1T(SRKLU6_7IWBBZX]B?YX]*?^//6IKR[DOKAYI/
MO-T'H/2H:TIT^2/F3)\S->ZT>*2W-S8/YL2C+1M]Y*R*O:/J!T^\5B?W3?+)
MD9&WUJ;6M,2S,<\!+6TW(XX'M24G%\K%NKHRZNW.G^1I]M=!BPE)!7'3T_E5
M+Z"MK7U=H-.VY,;1#"KZX&?S%5*5FD"U,6M[4S_Q*=+7_8)_E5*STN9;RW^T
MVLAB9PK @CN.OMR*O^(I-US%:I'M$0PNTYSD#C';I7/7DG9(TIIK4QZU/#;.
M-44+]TJV[Z8_QQ3;?P_>W'.P1#L9#_2NEL=-BL478BB3:%9AWQ7(;#M0MGO+
M1X4?RR^!N]!FDDM7:^@F! "HRMZG.,?RJW10!$T*LV2H)P5_ ]:D%+10 4SR
MUWEMJ[C_ !8YI])0 4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %8_BF0KI+ #[S '^?\ 2MBN4\77GF7$=NIX
M0;F'O_G^=:TX\TD1)V1S]%%%>F<X4444 %%%% !6EH*B6ZE@)QY\+Q _4?\
MUJS:EM;AK6XCF7[R-N%1-7BT-/4\?EB>"5XI!MD1BK*>H(."*Z'X>ZM'H_BR
MQGF;; Q,3L>@## )]LXJW\3M'&G>(FNX1_HM^OGH?]H_?'Y\_C7(5Y1V+8^J
M**\3\,?%B^T.V2UNX?[0MTX1B^V11Z9Q\V/?\ZV-0^-@\DK9:9B7'#SR?*#]
M .?S%!)?^,VK1PZ/;:>KCSYY?,*YZ*H/)_''Y&O':M:KJMUK5])=WDS33R=6
M/8#H!Z#VJ"&&2XF2*)"\LC!44=R> *3*/2_A_"UOX)OYGX6YN0B#U"@$G^8_
M"K]7+JSCT73;#28SD6D0#MZN>6/^?6J=>E1C:)RR=V%%%%;D!1110 4444 %
M%%% !1110 5LV_\ R*MU_P!=Q_[+6-6S;_\ (JW7_7<?^RUE4Z>I43&HHHK0
MA!1113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444AG0:Y\MKIP["+'Z"L>
MMG7O^/;3O^N7]!6-7DO<Z4%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%%(1L>%_^/^3_ *Y'^8KGZZ#PO_Q_R?\ 7(_S%<_79A^IC,****[3
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M OVAK9Q@S2MR,@<G:">/?GI@U=2\;1:Y&L.G^&;K5;=!M4.K>4 .GR*"./\
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MTZBD,04M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOZ"L>MC7O]1I_P#UR'\A6/7D=3I04444#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHI ;'A?_C_D_P"N1_F*P_L\O_/)_P#ODU=L+^33IC+$%+%=
MIW#W!_I5_P#X2B[_ .></_?)_P :UIU/9]")1N8?V>7_ )Y/_P!\FC[/+_SR
M?_ODUN?\)1=_W(?^^3_C1_PE%W_<A_[Y/^-;?6'V)Y##^SR_\\G_ .^31]GE
M_P">3_\ ?)K<_P"$HN_[D/\ WR?\:/\ A*+O^Y#_ -\G_&CZP^P<AA_9Y?\
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MO/L&AE_9Y?\ GD__ 'R:/L\O_/)_^^36I_PE5[Z1?]\__7H_X2J]](O^^?\
MZ]%Y]@T,O[/+_P \G_[Y-'V>7_GD_P#WR:U/^$JO?2+_ +Y_^O2KXKO1U6(_
M\!/^-%Y]@T,K[/+_ ,\G_P"^31]GE_YY/_WR:U_^$LO/^></Y'_&C_A++S_G
MG#^1_P :5Y]@T*FGPI:^?>W:,MM:1F9MPQG .!7D.NZS<>(-4GOKAOWDK<+U
M"KV4>PKU3QUK4UWX#O&<(K2SI#\@/3(;^E>.5Q5)-RU.B"26A=T71[K7M1AL
MK1-\TA[G 4#J3["O7-)^#NCVMNOVYY;V?'S$-Y:@^P'/YFLSX*:<%M]0OFC(
M=RL:,1CY>IQ^./RKT'7I[R#1[I].A\^]"$1("!\QXSSQQU_"LRF>9>(M8TGP
M!<3V7AZV4ZDW$UU(?,\D8^ZN>_\ DYZ#SJZO9[^=Y[F=YYF.6DD;)/XULR>"
M?$,E]Y;Z7=-/(Q.]EX)ZDE^GXYK73X?6VFLG]NZ[:6!X+6\3&27'ICM]<&@9
MQ5'J1^E>NZ;J/PZL(EC3[/,<8WW%K)(3[Y9>/PQ2ZKX*\->++5Y-!N;:"^4;
ME6%_E/H&3J/J /QH \\\-^+]1\+S9MI2\!/[RVDY1OP['W'ZUZ9#-:>(]-_M
M/3 0F<3VW\43?X5Y!J&FW.D736UY ]O,G57&/Q]_PK?^'?B%_#_B2WW-BVN6
M$,RYP,$X#?@?TS51E*#T(E%,[K[/+_SR?_ODTHM9FZ0R'_@)K<U#7[ZQO)8?
MW9"G@[>QY'Z57_X2J]](O^^?_KUWJ4WK8Y[(L:)#)'I>I!XV0E. RD9X-97V
M:;_GD_\ WR:N?\)5>^D?_?-(/%%__?3_ +X%<\J,Y.YHI)*Q4^S3?\\G_P"^
M31]FF_YY/_WR:M_\)3?_ -Y/^^*/^$IO_P"\G_?%3["8^9%3[--_SR?_ +Y-
M'V:;_GD__?)JW_PE-_\ WD_[XH_X2F__ +R?]\4>PF',BI]FF_YY/_WR:/LT
MW_/)_P#ODU;_ .$IO_[R?]\4?\)3?_WD_P"^*/83#F14^S3?\\G_ .^31]FF
M_P">3_\ ?)JW_P )3?\ ]Y/^^*/^$IO_ .\G_?%'L)AS(J?9IO\ GD__ 'R:
M/LTW_/)_^^35O_A*;_\ O)_WQ1_PE-__ 'D_[XH]A,.9%3[--_SR?_ODT?9I
MO^>3_P#?)JW_ ,)3?_WD_P"^*3_A*+[/WT_[XH]A,.9%-XWCQO1ES_>&*;6S
MKTK3V.G2-RTB%C^2UC5AUL6%%%% PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH VM-7_B0WY4Y;NIZ  #_P"O6+6UX9EW336S[3%(N2I[G@5CR*4D
M92NT@XV^E #:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH */PHJ2"![J58XUWL3@ ?G2 T?$;&2
MSTV1CEVB.6[GA?\ $UA5N^*F FMD#\I'S&/X<_X_TK"KTZ/P(YI;A1116Q(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5MZ!_R#]6_P"N
M/_LK5B5MZ!_R#]6_ZX_^RM6-7X2H_$C$HHHK4D****8!1110 4444 %%%% !
M1110 4444 %%%% !11128S;U_P#Y!^D_]<?Z+6)6UKW_ "#]*_ZY?T6L6LZ?
MP@]PHHHK404444 %'ZT44 5/'>EG7O"\>H1C==Z;\DGJ8CW_  _EFO+:]JTJ
M\2UN?WHWV\H\N5",@J?_ -=>8>,?#K>&=<FM,%K=OWD#_P!Y#T_+I^%>95AR
MR.F$KJQB4?Y]***R-0KJOASH"ZUKZS3C_0K(>?*2,@X^ZOXD?D#7+*I9@%!9
MB<  9S[5[%IVE+X3\.0:;Q]LG_?73#U[+^ _D?6JC'F:1$G9#KZZ-[>2SMGY
MCP/0=A5>BBO422T1R!1115 %%%% !1110 4444 %%%% !1110 5TGA\ Z3)G
M_GY3_P!"6N;K<T^0P^'+N1?O+,K#\"M85OA+CN>/>,F=O%FL%^OVJ0?AN./T
MQ5/151M8L!*!Y7VB/=NZ8W#/X5TWQ4TT6OB);Z,?Z/?Q"9?0,!AA_(_C7&\C
MH>>HKS>IU(^IE(Q3JX;P+\1K/6K.&UOIUM]10!3YI $ON#Z^H]:[62>.&)I)
M)%CC49+,< #US3),KQB$;PKK DQC[))Q[[3C]<5\X5Z;\3OB!;:E:MI.FR^=
M$Q_?SK]T@$$*I[C/4^U>94#Z'=_!QBOB:Y'_ "S-HY?/3&Y?\_G74WMP;N[E
MFSC>V1[>E8GPUL38>']4U-QAKDBUA/MU8C\__':UH\!UST!%=5".CD85'JD8
M7Q5U$VL>G:+&<)'']HF'J[9P#].3^->>^OK76?%)7_X3:^W#"E8]I_V?+4?S
MS7)<^O-<SU=S>*LCV7X;^ ;:ST^#5;Z)9[N91)$K@%8E/0@>I&#[9]<UZ%M[
M8XJ#3Y(WT^V:,CRS$I7'3;@8JS2$>??$?P#:WVFSZE8PK!>PJ7<1C"RJ.3D?
MWAZ]_P L>,=*^H[B1(X)6EQY:J2V?3'-?+?ZT#/0?A3J1FDO]%D/[J>/SH@>
M@D7T^H_]!K=KBOACO_X3?3MG;S,_3RVS7<W&/M$N.FXX_.NO#MZHQJ$=%%%=
MIB%%%% $/BNX-EX!NRN UU<)"?I]['Z'\Z\GKUKQ+:G4? =^BC=):S)< 8[?
M=/Z;J\FZ>]>54^)G5#8[+XE;K671-.'$=II\>!_M'AC_ ..BN-Z<"NR^(*_;
M[+P_JZ\I<62Q,?1T/S?JWZ5QO2H+/HCP+I<>E>$]-B1=K20K,Y[EG&XY]>N/
MPK?KD/AIXBBUKPW;6^]1=6:"&1,\X'"L/8C'XUU^:"1&7=UYKXS_ &])I=%\
M,^#=%3*V]YJ&H7T@!X+*R;#CO@3D5]>Z_K=OX?TJ>^N6PD:_*N>7;LH]R:^5
M/VRM-D\=?!;PYXKB7S+C2+LPW>T?<64!6;V!=(O^^A0!\1\]^M?HO^Q#X<M=
M'^!=CJ$*I]IU:[N+B=QRQV2-$H/T$><>Y/>OSHK[3_85^,>GQZ3<> -4NDMK
MU)VN=,\Q@HF5L%XA_M!@6 ZD,W]V@#[$'2D)I16-XN\7:3X%\/WVMZU=I9:?
M:1F221SR>.%4?Q,3P%')/2@#\SOVF/#EKX4^.GB_3K-52W%TMPJ)]U?-B24J
M/0 R$8]J\_T/5I]!UJPU2V.+BRN([F,^CHP8?J!6M\1_&DWQ$\=ZYXDG3RWU
M&Z>98\Y\M,X1,]]JA1GVJ;X6^#Y/B!\1?#OA^-"XOKQ(Y?:('=(WX(&/X4 ?
M?WC_ $=KSXD&UA&'O&A''8LH!/Z$UOMIL/B+XCW=S(O_ !+-'1%;(X9DZ+_W
MUN_[YIT4HN/%VO\ B389H[(_9+10,^9/@( /7G_T,5NV_A\Z'X>CMI;B&W:1
MO/O;J9PH>0\D9]!_04TKO4;V*;K<:S?2/&A=W;..P'8'VZ5LWFGVDVF2Z"Q!
MEN86W/V$F,@_7(S^ K.B\6>'M+T][7^VXQ(QR9H8V;'3I@$56L[C2KRX5K'7
M;62<-E5E/EDG/OU-=$I*>G0Q46M3D;^UDUGP"$=3_:&@3M#*AY/E$_T(Q_P$
MUI?#7PS-9VZ:UY7FWLP9+*)FP@&,-*_MU_/U(K;UC3WT?QE:WOD^;8:VOV.\
M@'*AR  ?\^C>M9'Q/\5"QC3P]II\M4C5+AH^H7'RQY^G)]C]:YC9%76?%&D:
M5?.\<:^)=:;AKNX&8$/]U%[@>WYU>\SQ+<6RWFN:ZGARR;[D2J%D(] HY_7/
MM63:Q6WPYTN&]NHTN/$5TF^"&0?+;J?XB/[WZ]NQKBM1U*[UB[:YNYGN9G/W
MFY_ =L4#/1H_'NCZ3(-FHZYJC@X+22!4/X'!_2GWGQ$\,>((EAU72[A^,"5D
M0LGN&!!'X5Y@UO+&I9HG51W*G%,_E0,]7\-V=O"TRZ%J$>M:1,/](TFZ.V4+
MW*AL9/Y ^O>N0\9>&Y?!VM0S6;NEM*?-M9>0R$$':2>ZG'^>G-0SR6TRRQ.T
M4J'*NC88$>F*]#TW7E^(>CMH6J2+'JB_/9W3# =@/NM[D9^O7&0*!&9XZC36
MM+TKQ+$JH]TOD72KP!*N1G\0#^ %;GPC']J:3JVFO(519(YD]B<@_P#H(K&A
MMIH/AOK=E<QLDMG?I\K=F.U2!_GO73?!73FATW4+TCB:58T^B@DG_P >_2C;
M43V/1+2SCLX1'&H4#J<8R?4U/2%@BY8[1ZDX%+[YX]:-7J2+169)X@LXY61F
M;*G!(&15?_A*K?\ YXR?I_C0,VZ*P&\50\X@<GZ@4^RU:ZU:1TACCB"]78DD
M?3WH UY+A(Y%CSF1NB9Y-2"H(;9+<$J,N?O.>I^M8MYKES-=M!9)O"Y7.,DG
MU'I0!T.:6L>UT^\N(U-Y<,O/*QGDXY&3VY]*UUZ4 +1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4E+24 &:Y[Q9';M"DV1]HR%7!Y(Y[5L:E<&ULYY1C<JDC)QSB
MO/SD\Y)KHHP;=S.4N@E%%%>@8!1110 4444 %%%% !5Q;.'Q!I-QHUT0JR_-
M;R'_ )9R#H1_GU'>J=*K%6# D$8Y'45$X\RL-.S/*+ZQFTV\FM;A#'/"Q1U/
MJ*@KTWXA:&->TL:Y;(/M=LH2\1>ZC^/\/Y?[M<EX)\+MXGUA8Y/ELH/WES)T
MP@[9]3R/S->4TT[,ZU+2YU?PZT0:-IDFO7"?Z3,#'9HPZ#H7_P ]OK6FS%F+
M$Y).235O4[Q;J<+$NRVB 2) , *..E4Z]"C#D1S2E=A111700%%%% !1110
M4444 %%%% !1110 5LV__(JW7_7<?^RUC5LV_P#R*MU_UW'_ ++653IZE1,:
MBBBM"$%%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112&;^N_ZBP_ZY#^
M0K(K7U[_ %&G_P#7$?R%9%>1U.E!1110,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI,#4O_P#D
M6;/_ *ZG^;5AUN7_ /R+-G_UU/\ -JPZ]&A\!SRW"BBBN@@**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH FO--DU[PIJFG0+ON/EGB3.-S
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MEW$S7$TDK?>=B36UHN8]+N)K9%DNE8@COC K"P1UX- "4444 %%%% !1110
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M51@#.>*=0!'%;K#%Y8R5Z?,<TD%K';+MBC6,?[(J:B@!*6BB@ HHHH ****
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M7,V<(HQD<^N0/>M?7]?\-?8[:VU61_$=]:_*+BW4QY'HS@_,/<9KF/%7B_\
MM",:7I:FST.#Y8X4X\W_ &G[GUY_'FN7H*.P;QAH*\1>$K;8.GF7!)_]!J]I
M'BOPM#J$-U_95SHUS&<K-:3&1>^<@XX/<8/6N*M]+O+J,R0VD\R#JR1L0/R%
M5F4JQ##!!P0>"*!'N5W';:TC:AI,T=W >76/[RGZ=1]*RJ\OT?6KS0;U;FRF
M,,JGD=F'HP[CVKU>RU*W\5Z0=4MD\JY0A;JW'\+?WA['_'T-==*K]EF$X]2"
MBCWHKM,0HHHH **** "BBB@ HHHH **** "BBBDP-_5_^0;I/_7+^BUD5KZO
M_P @W2?^N7]%K(KR'NSJ6P4444#"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@">SO9K&3S(6VMC!R,@CTK=U32Y=2C@N(D F91O4\$\=?\^M<W_GB
MNIT?5$OC'$4831Q\MG@] >_?CM0!D?\ ".WW_/)?^^Q_C2'P_?C_ )8@_1U_
MQJ#5M3FDU"=HI)HDS@*25Q@8/'UJI]ON?^?B4'_?-=$:#:N9<YH_V!?_ //#
M_P ?7_&C^P;_ /YX?^/K_C6?_:-W_P _4W_?P_XT?VE=_P#/U-_W\;_&G]7?
M</:%_P#L.^'_ "[G_OH?XTQM(O5_Y=I/P&:J?VE>9S]JF_&0_P"-2?VU?#_E
MZD_,4?5Y=PYR7^R[S_GVE_[Y-*-)O#Q]FD_[YJ/^W[_I]I;\A_A2?VU?-R;F
M3/Y4>PD'M"<:+?-_R[M^E+_8=]_S[M^8_P :JMK%\XP;F4#V;%,_M*\_Y^Y_
M^_C?XT?5Y![1%TZ+>CG[.WYBD_L>]_Y]GJHNJ7BG(NIL^[D_UI_]M7W_ #\R
M?G1]7D'.6%T6];@6[?B0*=_8-]_SP/\ WTO^-4VU:]?DW4H^CD4W^T[S_GZG
M_P"_A_QH^KR#G+_]@W__ #P_\?7_ !H_L"__ .>'_CZ_XU0_M*[_ .?J?_OX
M?\:3^TKO_GZF_P"_A_QH^KL.<TE\/7Q_Y9*/^!C_ !I1X=OL_<4?\#%9?V^Z
M_P"?B7_OX::UY<-UFD/_  ,T_J[[A[0V/^$;O#VC_P"^J=_PC%Y_>A'_  (_
MX5AF>5NLC'ZMFF4_J[[B]H=!_P (O==Y(?\ OH_X4G_",3@\S0#_ ($?\*P*
M*/J_F'M#?/AUE^]=P+_P*@Z'"O+ZA OXC_&L"C\:/J_F'M#>_L>TQ_R%8/\
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M/&VJ>'-2&9[.7"2@$+-&>4D7V*D'VY'4&OOSQMXY;4V;3--8P:3&=I*\-/\
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M(5Z2C^\O^?Z&H^GM7=3FIJZ,''E84445J2%;-O\ \BK=?]=Q_P"RUC5M6O\
MR*UW_P!=A_[+653IZE1,6BBBM"$%%%%,84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1112&;NN?ZNQ_P"N(K*K6U[[EC_UQ%9->1U.E!1110,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHI,#4O\ _D6;/_KJ?YM6'6Y?_P#(LV?_ %U/\VK#KT:'P'/+<****Z"
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"#QEIW]N^#?-4
M;KG3&+<=3$?O?R!_X#7E->TZ3=K:78\Q=T,@\N13R"IX->7^+O#[>&M=GL^3
M#]^%O[T9Z?X?45YM6/+(Z:;NB/P_XHU#PQ=&:QFVAO\ 61MRCCW']>OOS7:K
M\;KORL'2X3+C[WFG&?IC^M>:T5B:&SXD\7:EXJF5KV4>6OW(8^$7W [GW//\
MJV[AO^$?^&]M%'\MSK$K22MW\I. OTZ?F:XNNR\>?-HGA1DSY7V!0/3=A=WZ
MT <;7I7PM\"V^IPG5]0C$T08I!"XRK8ZL1W&> /K7FGTKZ"^',D4G@O3/+(
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MF4>W'K7AOQ7T6+2?$QE@79'=Q^<0!P'R0<?4C/XUV&@_&+3[YUBU&!M/<_\
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M/AWP[>>)M16TM%&<;GD8G:B^I_SS7K^B_#_2_">GWSSW4DJS6S1W,CX5-G?
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M/R_F:J,>9I$R=D2W$QN;B24]78M^=1T45ZJTT.0****8!1110 4444 %%%%
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MI32YG9";L>:Z_JAUK7+Z];(\Z1F ;J%SA1^ Q6?77_$CP\NEZJE]:K_H%_\
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M"ST/X8^%?[ T-;B9,7EX!(_JJ_PK^N?Q]J[,>] Z4M!(4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****0=4=!XBX:S4]1$*QZV?$G_'Q;?]<A
M_.L:O'ZG6%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBBDP-2_\ ^19L_P#KJ?YM6'6Y?_\
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M])FNS.L>"I/E.@7D*]VCN6)_(MBGIX7\.^(,+HNLO:W9^[:ZD-NX^@8<?S-
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MZ1?]\G_&C_A++[TB_P"^3_C6-11[.'8.9FS_ ,)9?>D7_?)_QH_X2R^](O\
MOD_XUC44>SAV#F9L_P#"67WI%_WR?\:/^$LOO2+_ +Y/^-8U%'LX=@YF;/\
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M?>D7_?)_QH_X2R^](O\ OD_XUC44>SAV#F9M#Q9>]UA_[Y/^-)_PEE]Z1?\
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M_P \UQ&J_$[6]0^2WF73K8<+%:KM(_X%U_E7-W]]/JEW+=7,C332MN9F]?\
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MU'1X=UH^+?#)GF.[4K$A)F[R(>C'^OT/K17ITY\ZN<TH\KL%;=K_ ,BK>?\
M78?S2L2MNU_Y%6\_Z[#^:45.GJ$3$HHHK0A!1113&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444@ZHZ'Q)_Q\6W_7(?SK&K9\2?\?%M_P!<A_.L:O'ZG6%%
M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBBDP-2__ .19L_\ KJ?YM6'6Y?\ _(LV?_74_P V
MK#KT:'P'/+<****Z" HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA1116I(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _NCEOT!KU?6K@7.J7#CH&V@^N!C/Z5T8>_,9U L4@U"UN-*O.;6\7;[J_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'NW<_7/]:HUZ%&/+$YIN["NA\-R_9[&_E(W! &*^N 37/5T&DV\MOH^HLZ%
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MA727/P6U6.'=#>6LSCG8=RY/H#C_  KF-="CI?Q4U2WQ'J,<.J6_\2RJ%?\
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M_LM.IT]01BT445H0@HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5;VRB&./I@ 5XM#/);RI+#(T<J'<DB'!4]B"#UKUOP_KH\9:&\TFU=4L@!,
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M7T.$HHK9\(^'9/%&M0V:Y6$?O)I.R(.OXGH/<US&NQV/PWT4:3I\VO7"?OI
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M_2C^U/!4WROHU_:C^]#.6(_!FKC?THH$=K_PA>DZ\I/A[65DGQQ9WWR2'Z'
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MX]Z]'7XE>&VBW_VDHXR08GS^6VD(Z.ZN([6&6:1@D<:%V8]@!G-?+\S"29V
MV@L2%].:] \>?$X:Y:OI^EJT5FW^MF<8:09Z =E]?7V[\GX=\,WWB:Z,-HF$
M3_6S2'"1CW/].](I&A\-X7F\:Z9L!^5F8GT78?\ Z_YUWMXP>[F(Z%V/ZU+I
M/A[0?AK;C4+V\9[ET*!V&"V<9"(.>W7^586H?&)8G*:5I,,2#I)<#D_\!7&/
MS-:TY\AG*/,:56])A%QJ5O&>07!/T'/]*X\_%_6V^]!8L/0PG_XJM/1_BQ:?
M:$?4=*CB=3GS[0XQVR5/7\_PK=U[JUB/9G'>--1;5O%6I3L<CSF1/]U3M'\J
MH:/8'5-4L[-3M,\JQ;O3) S72^)/!OGPW.LZ+=+JFG,[.X3(DAR<_,O4@>OI
MSTKG=#OQI.M65VPW+!,CL/4!N?T!KC-SZ1L;&'3;.&UMHQ'!$H1%'8"K%,MY
MX[B%)8G$D;J&5E.00>AI^1ZTR3B/BOH,6I>&Y+P*!=6>'1NY4D!E^G?ZBO#Z
M]X^*6K1:;X3N8F8>;=8BC7/)Y!)_ ?S%>#T%=#T7X779N-(UO3W.555N4'H1
MPW\EKIK/R+ZWN-+OOFM+H;3_ ++=F'OD?H*YOX/:9)=?VS.O&8!;JQZ$MD_I
MC]16U+;R0S&.1&5P<;>^?;UKII6E%Q9C/=,\MU[19_#VJ3V-R/GB/# <.O9A
M[$5V'PU\/QQ[]?O4S!;G;;(W\<G][Z#^?TKKM<\%MXQLK076;.]MF"F8K]^(
MGD?4=1[_ %-,U&XAQ%9VB"*SME\N*,=.._Y_C^9K.%/FE8J4M"M<3/<S/+(<
MNYR34=%%>BNQS;A1115 %%%% !1110 4444 %%%% !1110 4444 /2:2..1%
M<JL@PRCO6M8:+']E-S?N8(6'R =>O7I61%(89E=2-R-N'&>:Z/Q4P\ZW0'HI
M.WTYKDK2<=NII!7W&ZD]K%HT=O:S>8J28/J>OY\XK&5VC)VL5/\ LG%-]/Y]
MZ*XM3<4GYB>M)110 4444 %%%% !1110 4444 %%%% &OHB-)8ZFJC<S18 _
M!JD6"TT&*)IH?/O6&<$@A3_2LZRU*?3]_DL%WXSD9Z9_QJ":9[B0R2,7<]2Q
MIJ32LB;:W);^^>_N&D;('\*Y^Z/2J]%%(H**** "I+>,33QHQ.UF"G YY-1U
MIZ#:2RWL<RK^ZC/S,1QT_G0(L:WJ#Z;=6UM;X2*+#D _>Y/!_7\Z\N^)NBC3
M]<^W0+BTU!?.0@=&_B'USS^-=YK4T5SJ4TD1)0G!SWQQQ5?4-+'BKP[<:8<?
M:X?W]J3W8=5^AY'XUTRI^XFC.,M3E?AO$=+74-<O'\K28HF@D3;DSEL?(!W/
M3_.<8GB;Q==^)) AQ:V$?$-G#PB =.F,G'_UL5K?$2X&EQZ=X;MSB"PA5I<?
MQRL,EC^!S_P(UQ?^>*Y3</7/:CV[^E>S> ?AO:6-C!?:E EU>2@.L<@W)$".
M/E/4^YKNWLX98/)>&-X?^>;*"OY4PN?+W_ZZZCPQXR?2T.GZDOV_1I?ED@D^
M8Q\\LA[8ZX_EUKJ/B5\.[>QLY-6TN(0+&<SVZ_=P>-RCM[C_  .?+_;'X4 >
MQVNK1Z%JUA9ZHZZCI4Q\S3-3E&YHR1C:S?CU^GX>8^*=.O=,UZ\AU#YKEI"[
M2#HX8YW#V-=!X=D_X2+P7JVD2_--8K]MM2>H ^^/U_\ 'J-<?_A)? =AJC_/
M?:?)]CF<]60\J3^GXDT >K^#+"/3_"NEQ1@ - DC8[LPW$_F36V*X?X7>*H=
M6T.+3Y) +VS39L)Y:,<*P^@P/PKN,T$C)HTN(WBD4/&ZE64]"".17S)J5J+'
M4KJV4[EAE>,'Z$BOH3Q9XFM_"^DRW4S*9B"L$7>1\<#'IZU\Z22--(\CMN9B
M6+>I/>@:-SP'<M:^,-*=3]Z81GZ-\I_]"KJ/&\$?A/0;C38R!<:G>R3N!VA5
MCL'_ *"?SK"^&FG?;_%EJ[<0VH:YD8\  # /YD50\8^(&\2>(+J]Y$.=D(/:
M,=/SZ_4F@HV+G-Q\*;1F/-OJ+(F?[I4DC\S7(0S26TT<L3&*6-@R.IP5(.00
M:]-UGP^+#X0VZRC;.DB71]V=L?\ H+_I7E] 'ML&L?\ "3^&]/U+I*,PS@=G
M&,_GC/XU%%*\$BR(VUE.0:P/A=,TWA_7;<\K&\4J_5L@_P#H-;GT%!!W&FSR
M7%JDDOEY;D>6<\>].OK&/4+=HI5RK?F#ZBLSPQ"L=O*?F$I;YE.>G8UN4; <
M%?:/<6=T8=K3<;@R G(]ZBO=.GT_9YZ[=XR.17H&T;LXYZ9J*>UBN%Q)&LG;
MYA73&NUN9<AYW6MX;N1#?A/)\UI. XZIZFFZKIHCU;[-:*3N .WKM)_I75:;
MIJ:;:K$G+=6;')-:U*BY?4F,7<M)&%S@!<^@Q3AQ10*X#<6BBBF 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'VQ(TC>BC-6%BM;&Q;4=3F^SV*GC^]*WHH[GC]/;-<9K7Q0O[H-;Z4HTJR'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?I616)I/Q1L=+D?R?#T5M'(,.+>; /U7;@UNZ;K6@>))!'9736-V_P!VVNN
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M+_\ Y%FS_P"NI_FU8=>C0^ YY;A111700%%%% !1110 4444 %%%% !1110
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M7<G4/!6AW#',B*\!]<*2H_0"FUZ=.7-%,Y)*S"BBBM20HHHH **** "BBB@
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MOO+_ %JA14%'?07$5Q&'B<.OM4M<YX=TU6\N\67E2P,>W';U_&NBH 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,K7M)_M*$%!^^C^[[^HKBY
M(VC9E<$,O!S7I%9^I:';ZEEF79-VD7@_C6].IRZ,SE&^IPM%6-0L9-/N6AD.
M6'(([BJ]>@G=71@%-\0$KX!UHH.2T08_[.]?\_C3JO6-JNJ6>HZ8Y %W 54G
MLX^[_C^%8UE>#+CN>*=^>>:[J69O _@N&.!MFKZRN^20<-%#V ]"<_J?05QU
MG8M-J4-FZE7>9867N"6 (_6NB^)]TUQXQNX^B6ZI"@]%"@_S)KS4=1RGZ5U'
MAOP:+ZS;5-5N!IFCQGF9OO2GIA!C\,\^P/:IX-\/KXBUI8ICY=E"IFN7SC:B
M]>??@?F:=XP\4-XBO@L*^1IMN/+MK=1A50<9(]3^G2F,U9/'UMHJF#PWID5D
M@&/M<ZAYV]_0?3D5C7/C?7[IBSZO=+_USD,8_P#'<5C1QO-(J(K.[$!549)/
M;'K7;:;\']:OH%EF:WLMW(25B7^I ! H$8]C\0/$%BRE-3FEQU6;$@/YYK=;
MQ=I'C3RX/$=J+.Z V1ZE;=N>C ]L_7KVZUF^(?AGK/A^W:=TCO+91EGMR3M]
MR#@_E7*?SH Z:\\ WUEKUEIY99;>\<+!>1\QNIQD^W!SC^?6N_\ &'B>U\ :
M3!I&D1JMVR?+W\I?[Q]6/_US[X7PGU^5II].N@)K*VC:[C=N?(*G!(] 0Q_/
MW-<+K.IS:_JUS>2@M)<29"CG Z #Z# H JW-Q+>7#S3R-+,YRSR'+$_7O6EH
M_A/5]=PUC8RRQG_EH0$3_OH\5TL.BZ9X&LXKK6XEO]7F7?#IN?DC'K)U_P Y
M'/;"UKQQK&O,1+=M#!T6WMSL0#TP.OXYH&:3?"_5HL":ZT^!^Z27."/TJ.Z^
M&.O0Q&2*"*]C[M;3!OYX)KD^3WS4]G?7.GRB2UGEMY!_'$Y4_F* /0?!_BJ?
MSE\/>(%D3<=D$TZD/$W93GL>Q_#ITV[JUDL[AX9!AU/;I]1[5R&G^.XM6B6Q
M\36ZZA;?=6\50)H?<$#GW[_7I7H>L6ZR:587<=Q]L&P1FX'_ "T&/E8^_7/N
M:Z*-1Q=F8374Q:***] P04444 2VMU)9S++$VQU[^OM6Y)%!XDA,D6(;Y1\R
M=G'^>]<]3XI7@D62-BKJ>"*RE"^JW*3[A)$\,C)(I60'E2.<TRNA62#Q);B.
M3;!?J/E;L_M6'<VTEI,T4JE77KG^=$97T>XK=414445J(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-6SXD_X^+;_KD/YUC5X_4ZPHHHI@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444@-2__ .19L_\
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M])L8-(L3BVM_O/WDDZEC^/\ G@53_'%%9>S7-S%<SM8****V)"BBB@ HHHH
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M$14'HHQ3Z\QN[NCI0M%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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MK7Q>\<>(YF?4?%NM71;DHU]($_!0=H_ "N4M[>6[GB@@B>:>5E2.*-2S.Q.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHI!U.A\2?\?%M_UR'\ZQJV/$G_ !\6W_7(?SK'KQ^IUA1113 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH$S6_YE6;_KL/YBL&M[_F5Y?^NP_I6#7?0^$QGN%%%%=)F%%%%
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MLH/O_G\ZM:YI45FOGQR8$AXBQ0!CT444 %%%% !1110 4444 %%%% !1110
M4Z.-II%1!EF.T"FULZ1'%I]J^HW!&/NQC/4_Y_K1OH(?-)'X=LRL;+)?2<$_
MW17.R2/+(SNQ9V.2S=32W$SW$SRR'+N<FF5Z5.GR(YY.X4445L2%%%% !111
M0 4444 %%%% !1110 4444 %6+O3$\5:#-I3D"ZB_?6CMV89^7Z'^OM5>G12
MM#*DB':ZG(85G4CS1L5%\K/(IHGMY'BD1DDC)5E88((X(--KT+XE>'UNH8_$
M-F@"2$)=QJ/N/_>^AX'Y>M>?(C2.JJI9B0%5>I/I7EM6T.I.Z-GP?X;D\4:U
M%:#Y;<?//)_=0=?Q/0?6O2_'NO+I'A(K9CR?M9^RP!?X85&"1]>GT(J/1]''
M@_P^+(\:E> /<NO\([)^']37/_%9F%OX?7'[KR'(],Y7(_E5\K4>9DWN['GV
M-S8 R2> .]=KI'@VRT>VCU+Q3/\ 98&&Z&Q4GS9?J!R!_DXQR>%+.W\-Z,_B
M?4(UEEW>7I]NW\<G]\^P/Y8/M7*ZKJUUK5[)=W<K2S.<DMT'L!V'TJ"SMKCX
MJ16*F+1=$M;.(<!I4!)'T7&#^)K/_P"%J:VQ^9;-ESDJ8!C^=<I9V<^H7"P6
ML,EQ*QP(XU+'\A6\WPW\2+#YITM]N,X$B%O^^=V?TH OKXTTC5ODUKP];?-U
MN+#]TZ^^._YUU/@?28])U9;[0[X:CHUUB&XB;Y9H3U4L.^#QGC@GZUY/<6\M
MI,\4\3PRKP4D4@C\*MZ'KEYX=U".[LI-CJ?F7^%U]".X- 'J<WQ:72=7N;#4
MM.9##*T9E@<'(!Z[2!QWZ]ZP/%OAN#Q?-+K?AR6.[#*#<6JC;*K=V"G'48_$
M$C.:H>.K2'6K6'Q38@B"Z(CN8B<F*4#'7T..OT]:Y33=2NM'O([JTF:"XC.0
MR_J".X]C0!692I(<%3W#<5[58W$FI:+X=N\YN)8UC+-W9"!D_CG\ZXW7+>V\
M::'+K]E$MOJ=MC^T+>/HPQ_K%_ST!STR?4/!^DBS\,Z3',@:6.$/\P^ZS?,1
M^M5&7*[DRU-Y%PH!.3W-.I*6H ****8!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %(>U+2'M0!SWB]?]'MFXR'(_E6_$ L: ;0
M  /EZ?A7-^+Q*6@ 5O)4$[L<;C_G]:K:=XGEM8TBEC$J*-H*G#5T<CE35C+F
MM)F_KEB-0L9$ S(HW)CKGTKAB"C8^Z5/Y5Z,C>9&&]1FN5\56;QW2W&%$;C;
MP.X]:=&=O=8275"0ZY;QJMPULKWS*(99,<F,'/7\:\O\?^%U\/ZFMQ;#.FW?
M[R%AT3U0_3/%=IT^M7K>&TUK3WTG4LFUD(>-@<%&'/![?_7]ZNI15KQ%&7<Y
MCX:^'UL;=O$-XGW<I9QM_$W0O]!T'X^U;<DKS2-(YR['<3ZU:U*[2X=(H$$5
MI OEPQKT"@8Z53K6C#D5WN3*7,PHHHK<@7)XP<?C57QSHO\ PDVAC4X%SJ%B
MN)U YDC]?J.?U]JLU9TZ^;3[I91\R]&7L1WK&I3YEH5%M,\9^M:OAGP_-XDU
MB&QBRH8YDDQD(@/)_P ^H]:UO'WA8:'JBW%FF[3KS+P;1]T]T_#M[?2M#4=O
M@'PK_9R%5UO4TWW+#K#$>B9]^1^)]J\SK9G6C*\=:]%JE]%8V(":58+Y,"CH
MV."_X^OI]34_POTLZAXLMYF7,%HIGD8]!@8'XYP?P-<HD;22*B*69CA5 Y)[
M#%>W^#M'A\)V5MIL@!O;L;[I_3*G:GX?X^M.U]A-V/'/B!XHFT7X._$SQ*K[
M;VZB6RC8'YE\^01M@^P<$>FW-? -?>OQ(\-RZQ\#_B3H07-[8)'>J .T$@:3
M _W4/YU\%4"/I[]@WP!9^)/'^K^(KR-)_P"P8(_L\;\[9IBP$GU"QO\ B0>P
MK[Y'2O@?]@OQ]9^'/'VL^';R58#KT$9MW8@!IH2Y"?5ED?'^Z!U(K[X!H 3'
M-?GU^W1\/[+PG\3;+6;"*.VBUVV:::-  #<(P#OC_:#(3ZG<>]?H-FOS[_;J
M\?6?BCXGV.BV,JS)H-LT,\B$$">0AG3(Z[0$!]#N'44 ?-GO7Z6_"OQ%)XP^
M#?@C69G,MQ)8?9I9&.2[0DQEC[DH3^-?FEUK])_@]H#^$_@AX&TJ9=DWV(WC
MIW4SN9L'W_>$?A6U+XT1+8Z:BBBO11SA1113 *L6-]-I\XEB;'8KV(]#5>BD
MTGHQF_<V4&N0M=68"7'_ "TASW]?\]:P64JQ5@0P."#U!]/K4EM=2V<RRQ-L
M<=_Z5N210^)+<RQ8AOT'S)V<#^E8ZT_0?Q'/44Z2-H9&1U*.IY4]J;6Q(444
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI
M#-_Q%\S6C>L(K(K7\0?\N?\ UQ%9%>1U.E!1110,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH$
M:W_,KR_]=A_2L&M[_F5Y?^NW^%8-=]#X3&>X4445TF84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444@-W4/^17L?^NG_P 56%6[
MJ'_(KV/_ %T_^*K"K.GL7+H%%%%:D!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %;7BS_C_ (?^N(_F:Q:VO%G_ !_P
M_P#7$?S-8R^*(U\)BT445L(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH /0_Y%:VDZS/%,D$C+
M+%(X!\WG'/7_ #Z5DU-9%!>0&3[GF+NSTQD9K.<4TQIZESQ!;K;ZI(J1B-"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,#H<P>)H,?+#?HOX-_\ 6K"F@DMYFBD4K(IP5IL<C1.KHQ5E.00:WHY(?$D
MAF(BOD'R28X?_/I^-8ZT]MBOB.?HJ6ZMI+.9HI5*NOKW]ZBK9.ZNB0HHHI@%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(9O\ B#_E
MS_ZY"LBM?Q!_RY_]<1617D=3I04444#"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -1FQX7D_Z
M[?X5AUMO_P BRW_7?^E8E=]#X3">X4445TF84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444@-W4/^17L?\ KI_\56%6[J'_ "*]
MC_UT_P#BJPJSI[%RZ!1116I 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<],8I* "BI[2REOI-D2Y/4D\ #U)K-UCQEH7AUFAC5M8O%ZA&VQ*?3=W_#-
M%NBN2G^+FJG(MK2RM$[!8B3^.31#\7-64XN;:RNT[J\1!_ @_P!#0!UM%5-(
M\::%X@98I5;1[QN%W-NB8_[V./QQ6G>6,MC)LE7&>0PY!^AH KT444 %%%%
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M%<7$EU*9)7+L>YJ.BNB%.,=C-R;"BBBM!!1113 **** "BBB@ HHHH ****
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M 'NBC\^?^ U[K7)_#3PX= \.1-*NVZN\32>H!'RK^ _4FNMH)"BBB@04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHI7&%%%%%Q!1113 **** "BBBD!NZA_R*]C_ -=/_BJPJW;_ /Y%BQ_ZZ?\
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M/[P'K_GO713K-:2,94^J$HHHKO,0HHHH **** "BBB@ HHHH **** "BBB@
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M>_CKQ"KYSMCU*9%Z_P!U6 _2NM\)_M=_$WPO(HEUP:[:?Q6NK0K,KCW?A_\
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M0WIIQ:(L>IQC:!]0RC%>,^W^>U=IXL<:/X/\/:3'P9X_MT_'WBWW<_@2/P%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD^IY[]2:9711I\JN]S.4KA111700%%%% !1110 4444 %%%% !1110 4444
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MG^?^!4GV_1>UC)G_ #[UAT4>S07-K^T-)_Z![?\ ?7_UZ/[1TG_H'M_WU_\
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MJ:5_T#S^E,_MFQ[:5&1[L/\ "L:BCV:"YL_VW9?] F$_\"'_ ,31_;=E_P!
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M\Q_\36-11[.(<S-G^V[+_H$P_F/_ (FC^V[+_H$P_F/_ (FL:BCV<0YF;/\
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MKITRYX99_P!W@^P9E;Z@5P_C7Q /%GC+7M;">6-2U"XO-A_A\R1GQ^&ZNF^
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M\7K)[/5=*SRBV*Q @<$JS9_]"%,^%^BK)>SZS<)FUL1\F?XI2.!^'7\5K?\
M'5H_B#PD;O[UUI\Q=L#DQMU_7'X+5<KM<F^MCF/ "^?8^)K=/]=)ISE5_O8[
M?K^M<?6[X%U@:'XGL;ASB!CY,OIM;C)]@<'\*@\5Z*?#_B"\L<8C5R8B>Z'E
M?T(J2C7^%^M1:-XJC\]@D-PA@9VZ*205S^*X_&O>AT%?*]=OX?\ BOJNC6Z6
M]PJ:C"HPIE)60>VX=?Q!H ]QKR?XT:U'--9:7&P=X_WTH],C"C\LG\15/4_C
M/J-U"8[.SALF;K(6,C#Z< 9^H->?S3R74SRS.TDLAW,['DD]2:!$=>J^#(V@
M^'Z%^DUXSI] ,']5->7V\#W4T<,2%Y)&"(HZDG@"O9KZV32K*PTJ,Y6SB"LP
M[N>6/Y\_C6M-<TD14>A2HHHKTSF"BBB@ HHHH ****5T 4444P"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHI +XDT?\ X3+0"%&[5K$%XO65.I7Z
M^GOCUKR..-Y)5C52TC,%" <DG@#'KFO<?#,/F:@)/,$?D@N<CJ,8/\ZB;POI
M.GZ_-XDB990PS%;J/E$QSEOZ_4D^E>;4A[WNG1&6FH:1X$&F^";C2S.+?4;Y
M/WDN['S]D^G8@>I]:\6N[66QNI;>9#'-$Q1T/4$=:]UO?%#SVB1PAHI2/G;M
M^%8VM^#;;QK>6>I"5;9U(2_']Y0.&'OVY['VI.G**NQJ:N9_PC\([F_MRZ3@
M96V5OR+_ ,P/Q]J]6%8VEW*1ZG)8PA4MHH4$*+T  !_]F_2MD5#5BKW%HHHI
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,FJ'XUZD&G%6.-Z/4**,T9K00449HS0 449HS0 449HS0 449HS0 449HS0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=L'S8Z>,2N/^6LW\3'Z9_,GVK5TG3;CP3X)N-<$+'4;P+%$V/^/>-NCGW/\
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M2].U%%%>DCE"BBBF 4444 %%%% !1110 4444 ;4O_(JQ?\ 7;_&L6MJ8_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_C;EOU_G6M)7FB*FQ3]:***](Y@HHHI@%%%% !1110 4444 %%%% !1110
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MMNS_ .15O/\ KL/YI653IZE1,2BBBM.A""BBBF,**** "BBB@ HHHH ****
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MK>UQF-/8M]X_[R@X*U2CS.Q,G9'KEY]FA\BSL8EM]/LXEMK:&/A4C4;0![8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD&!#<]!(<= X'/\ M#/\=?+&?4_G7ZGS:?8>(-)U#0M8@6ZTC4H3;W$+>A&
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MD^]=%&%WS,QJ2Z#:***] P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9G 4?@.OZ5Y114%%[6M:N]?U![R\E\R9NG& H] .PJDD;2.%4%F8[0HZG/\
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MZ@0%4W:-N/!!SZTDVE7)O);BVN_L_F8W+Y8(..,\FL76;\B^1&;-X1;:YAN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6=K=U!;V+_: 61_E"J>2?:M&J
M&J:6FJ0A')1EY5QV]:<;75Q/8X5\;CC.WL&.:=JVCKXPT)K(X_M&U!>UD;^(
M=T)]_P# ]JTIO"]]#N*HL@7NK#G\ZS8WEM+A6&Y)8SD9'(/^%>A)1J*R,%>.
MI#X7T,^#=$,DR[=7OA\V>L,?4#V/<^_TK4\.JO\ :D;M]V-6?\A5.ZNI+VX>
M:4Y=OR'M5O0)ECU2(-]UP4/XCI4JGR08<W,SQ>^NGOKR>YD_UDTC2-]2<FM;
MP/ID6K^+-.M9@&B:0NRGD,%4M@_7;^M9NK:>^E:I=V;_ 'H)6C)]<$\U:\+Z
MP-!\065\02D+_./]D@AOT->>=1])K]T4M16US%=V\<T+K)%(H967H0:DR*9)
MP7QBTN*Z\-K>$ 36LB[6_P!EC@C\\'\*\5KU[XR>((8=-BTF-PUQ,XDD4?PH
MO(!^IQ^5>0T#/2OAO<&X\*:Q:DY%O,DRY[;A@_\ H-:=9_P]M39>#]1NFX-Y
M.L:<=0G?\R1^%:%=U"_*<]3<MZ79_;KQ8V.V,?.[=@HZURFKQ:I\2=4;[!'Y
M.C6N8XI93LB51U8GN3[<XQTKM]-CMDT;5)KR7R+79MDD4X.W'S $=R#CCGI7
ME_BGQE+KF+.T3[#H\7RPVL8V@CU;'4_RS^)PK2YI6-*:T+\FD^$-#&V]U*ZU
M>X!YCL5"QY[\GK^!K2;Q]X>_L?\ LI-'NHK#.2D4VTM_O$'YL^^?T%>=?7TY
MHK U.S73?!VLX6UU"\T><\ 7BAH_S'3ZDUGZM\/]:TN51':OJ$#C<D]DK2JP
M_ 9'XUSG_P"NND\(>.K[PK<*JL;BP8_O+9CQSW7T/\Z .>FMY;60QS1O%(.J
MNI4C\#3[.^N--NDN+:5H9XSE9%."*^@+_2])\?:''(P66&9,PSJ!OC/L>Q!Z
MC\Z\$U;39='U*YLI_P#6P.4)'0^A'L1S^- CU30M<C\:Z6\Q58]6M1F=%&!*
MO3>!_GG\*;7G7A#6FT#Q%978;;&) DH]4/!'ZY_"O4M8M19ZE/$HPN<K]#S7
M90DW[K,)QZHI4445V&04444 %%%% !1110 4444 %%%% !1110 4444 26]Q
M):3++$VQUZ&MR2*'Q) 98ML-^B_,G9@/\_A7/T^">2UF66)BCJ<YK*4+ZK<:
M?1B2*T;LKJ58'!4]0?2FUT++#XEMRZ[8;]%^8=G _I_*L"2-X9&212CJ<%3V
MIQGS;[@UU-G_ %WA7GGR)>/S_P#LJQ*V](_?Z-J<##"HOF?C@G_V45B5-/1M
M#84445L2%%%% !1110 4444 %%%% !1110 4444 %%%7;729IX3.Y2WMUY,T
MQVJ!ZU$I*.['OL4J*+C6_#5@Q6;5_/<?PV\18?@<8/YU%#XF\+7!VC4KB ],
MRP$C]!67MHE<C):*OQZ6+R SZ==0:C$.IA8$CVQZU192K%2""."#UK6,E+9D
MM-"44458@HHHH **** "BBB@ HHHH **** "BBB@ HHHI,#8G_Y%>V_Z^/\
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M@ HHHH **** "BBB@ HHHH **** "K\=U9EH+V:SAEU>TC>WM;QXP9(HWQO
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MV@_WV[L?7_ZYJE7H48<JNSEE*["BBBND@**** "BBB@ HHHH **** "BBB@
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MID5ZD8\D;'&_>9B_%#4C8Z?I^B1':&3[3< ?Q$\*#],']*\Z[^IKKOBHS_\
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MVYN &Y^@Q^M>7*3D[LZHI(X\=OZ4GXU['X7\&^$K.-%FOK'5[W^(M.C*#Z!
M?YYKH=2^'V@:I"R-I\,#$8$EL/+*^XQQ^=27<\$L-0N=+N%N+.>2WF7H\9P?
M_KBO4?#/BN'QHOV2[5+;657*2+PLX'\CC^N*XGQ+X'O]!UD6,44EXL@WP/%&
M6+K]!W'?_P"O4NG^ ?%"31W%MITL,L9#H[.B%2._)%-2<7=$M)H[=XVCD9&7
M:RG!4]O:FUM:E8WEY:VEY):-%<O&!<0K\VQQQVSQ6,P*D@\&O2A-25SE:<1*
M***U$%%%% !1110 4444 %%%% !1110 4444F!L3_P#(KVW_ %\?_%5CULW
M_P"*6M?><_\ LU8U9PZ^I3Z!1116I(4444 %%%% !1110 4444 %%%% !111
M2 OV;6=]9MIVIQB:SW"5<\[6!S^O]3ZFK<WB222&9%C6-C\L3 #Y%[C]!6+1
M67LX\UV5S/8****U)"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
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M=S$HK9_MZVXSI5O^G^%+_;UIWTF#]!_[+3YI=@LNYBT5M_V]9_\ 0)A_,?\
MQ-(=>M>VE6_Y#_XFCFE_*%EW,6BMH:]:]]*M_P A_P#$TO\ ;]I_T";?]/\
MXFCFE_*&G<Q,T5M_\)!:_P#0)M_T_P#B:/[>M/\ H$P?F/\ XFCFE_*&G<Q*
M*VO[=L^^DP_F/_B:/[<L_P#H$P_F/_B:.:7\H67<S;"\DL+I)H^2IY7U'<5S
MOQ6\.J)H=>M%W6UT )MH^Z^.&/U_F/>N]T[4++4+R. Z9"@;/S<'L3TVTL]Q
M9:I]JT2XM5BMI"T7RD8SGJ!C@^GOBN:K>3VU-(^Z>1^!O$$6D:A):WH#Z7?+
MY-RC'@ \!_PS^1JAXH\.R^&=8ELGRZ?>BDQ_K$/0_P">]0Z]HL_A_5KBPN?O
MQ' ;'#+V8?S^M=9I;#QYX7_LJ0@ZSIJE[1F/,T?>/\,#\A[URFQP=>G?#[11
MH&D/K=PO^EW*^7:H?X4/5_Q_E]:Y;P/X3;Q%K!6Y#)96OSW+,".G\/U//X9K
MU:;Q%:R$*=.CD1!M3<1PO; QQ6D(N3O8F3,$DDDGDT5M?VY9_P#0)A_,?_$T
M?VY9_P#0)A_,?_$UW\TND3GL8M;?AK]R+ZY/_+*+/\S_ .RTG]N6?_0)A_,?
M_$T^/Q';Q*ZQZ;&BOPP5@ ?K\M1/FDK6&K(X[XC:"NK:>NOVR 3Q@1WB <^@
M?_/MZ5P6CZ3<:YJ4%E;)OFE; '8#N3[#^E>W1>(+5=\9TZ..*4;9 I!!7OD8
MYZFJ.C>'=/\  LUQ=P?Z7+=-^X!X,<77&?KW[X'O7+*G)2M;<V4E8;=0V^DV
M,&D69S;VP^=^\DG\3'WZ_P"15*MK^W;/OI4/_?0_^)H_MVR_Z!,/YC_XFNN-
MXJRB8O5W;,6BML:_:K]W2H%/KQ_\30WB./\ AT^W'U _PJN:7\HM.YB?7BBM
MO_A)CVLK<?A6SH]U=WJM)<0QP)QLVH03^9J95)1W0<J?4Y>UTF[O,&*!L'^)
MAM'YFM >'X;3#7]['%W\M3DGZ9_P-1ZQJ][]LGA\QH45L!5X^G/7]:R"Q8DD
MYYR::YIJ[=AZ(Z19M*T7$\#-<RL/E7=DC_"J4WBB[D>39MC4@A5'..>N?7_.
M*Q_\^E%-4UUU%S,?+/+.VZ21G;KEF)IG8T45JDEL3J%%%% !11118 IR.T;9
M5BI]13:*5D!2\?:'_P )%I(UFV7-]:*%ND4<NG9OJ/Y9]*XGPEX;?Q-J\=MG
MR[9!OGF[(@Z_GT'UKTW3[XV%P),;T((=#T93U%7[&/2O"BO#I\ DCNG:6?//
MRGHH]AGI]?6N"=*7-H;QGIJ><_$ZXN%UY=.:'[-8V<2I;0CE=A ^;\2/T ]:
MZGP=H;>$]!^W3+MU._7"9ZQ1\''U/'Z>E;4T>F^)'M[G58U,]B_G)@<.ISA#
MZC../8>]7K.]'B);BTN1M8_/$P'W?_U9_4THP<7>6R&Y7V.;HITB&.1D/53@
MXIM>BCG"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 6]-M8;F5O/N%MT49R>IKJ(VM=4M7LVN?M4A&[<1@]>U<94]E>/8W23
MI@LO8_E7/4IN6MRHRMH7]4T"6R\R2/+P(H.YNO/!IFCW=T&^RPS&)'.XE4W$
M=N./I^5=5#<0ZEI^^0!8Y$)96/0=#2V=K;:;"JQ!55CPW=B??O6'M7:TEJ:<
MNMT36\/D1A=[OZM(V34U4?[27[1<P':LL8R S<,,9'TI;35K>YLQ<&01IG:V
MXXVGTS7/RO<TNB]12*=R@TM(84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 )7)>+((X[R)U4"5U)?WZ"NNKE/&$&VX@F#<LI7!]O_
M -=;4G::(GL<_1117I'..CD:&19$.UU((/N*POB=H:W,<'B"U3Y9<172KT63
M& WT/3\NYK;J[I\D,RS6-VN^SNU\J13VST-<]:',KHN$N5GBM%:?B309_#>L
M3V,WS;#E)/[Z'HWY?R-9E><=1;TC2Y]:U*WL;8;IIFVCT'J3[ 9/X5Z_>1P:
M;:VVE6G_ ![6:[<_WG_B8^^?YFL?P'HH\-Z*VJW"XO[U=ENIZQQ_WOJ?Z#U-
M6\[N3R3R:ZZ,/M,QJ2Z(*6DHKN.<Q/BI8FYATO64'$D?V>;V9<D9^O/Y5Y[_
M (=Z]G6Q37]&OM'<@/,OF0,W:1>1_+^=>-2PO#,\4BE)$.TJPZ$'H:\J<>63
M1UQ=T>O_  M\6/=:+/:7JE8=.CS]L8_)L[*Q]0/T'MSS/C+XH7FL326VF226
M5BIV[U.V27GJ3U ]OS]*B\72'PWX<TWP["?+DDC%W>D<%G/13],?H*XG]*@H
M[;Q>'TKP[H&A0J3)+$+R95ZO(Y.T?GN'Y5K:'\/=-T"Q34_%,Z1@C*VK,<#V
M..2?]D?K6WK36&@3CQ1=[9Y/LT<-A!_M%3D_KU[<^HKR?6]=O?$5\UW>S&21
MN%7HJ#T4=A0,]'N_BYIFGQ_9]*TMFA7A>1 H^@4'C\JSA\9+AFP^FJ4/9;J0
M'\^U>=JI=@JC<Q.  .M79M!U.WA\Z73KN*+&?,>!@OYXH ].TOXFZ7?CRI9+
MC368<BY_TF ^S$_-C\0*=K7PVM/$5NUS810V-T5W));MOM9_ICE?Y#WKR']:
MZ3P;XVNO"MVJEVFTYV_>P9[=V7T/TZ_E0!K_  XEN-$\5SZ+>QM"+I&BEB;L
MP!*G^8!']ZNDEC,,KQM]Y25/X5TEY<:!?W6DW5S)&)Y,2V5TWRYP<[=WXXVG
M^=9.N64MI?RLX^21V=6'0Y.<?A73AW9V9A4[F?1117>8A3XH7FD"1HSN>BJ,
MFI+&SDU"X6&/J>I/0#UK$\4?$!-'\S3=!*[U.V:^/))[A/;W_+UK"I5Y-"XQ
MYCHKC38M.C#ZE?6VGJ>0LSC<?H.]4&USPO&VUM=R?]FVD(_E7G6CZ)J7B[4V
MCA+32GYY;B9N$']YC_2NADN?#'@_,5O;CQ#J2GYIIB!;JWL/XOU^M<;K3>MS
M;D1V5G;6&K9_LS5+>[?^YG8WY=:ANK&XLV*S1,GOCC\ZXFX^*6OR#;;RP6,7
M01V]NH _/-,MOBCXCMV&Z^6=?[LL2'/Y ']:N->2W$Z9V5%9NE_$?3=480ZQ
M8BRD;C[5:YVCW*]1]>?PK=O-/-O''/'(EQ:2#,<\9R#73"K&6ADXM%2BBBMR
M HHHH **** "BBBDP-^]\K7M/:[3='<VZ_.I[KU_Q_*L"KVDZH=-E?*"6*0;
M70]_\\U/K&GPQPP7EJ"+>;^'/W6]/Y_E6,7[-V>Q3UU,JBCIQ16Y(4444 %%
M%% !1110 4444@"IK6SFO7VP1F0^W0?4U+8VD<L<MS<RK;V4"[Y9F/0>GUZ?
MYXJ"Q\9"XM;_ %-(OLFA:?\ )%".)+J4]-QZXZ<>_.<&L*E;ET1<8MEC5/[/
M\*VJW.L3[G;_ %=K#]]__K?YSVJCI7BG4-6M9M1F:/0/#UN<'R5#2S-_<!(Z
M^X'7CW'G\;7OCKQ1$)Y"T]W+M)'1$Z\>P&?R_&K_ ,0-:2ZU!=*LALTO3?W,
M4:]&8<,Q]3G(S^/<UQ2FY;FZBD6O$OQ0U+5B8;&1].L5X7:Y,K#U9^OY?F:P
MM!\-ZAXJO'2W&57YIKF5B$C'J3_GI571-(GUS5+:PMP#+,VT,>BCJ6/L "?P
MKIO&'B"'3[?_ (1S1F\K3[<[9Y4/S7$G\1)';/ZCZ5F6223^%?"G[N*W/B._
M7AI93MMP?0#N/P/UJ-_BOK"KY=G'9V,0X6.&$8'YUA^&_"][XFNFBME$<48S
M-<2':D:^Y_/C^76NADU+PSX3S#8V8\07R\-=77^I!_V5Z'G_ /73 ET[XK>(
MV;_40WRCJ!"V?_'35ZXO]/\ %C?Z1/J'AO4V^XT\SM Q[#+=/3M^-8-Q\4O$
M$ORPW$5I%C CMX5 'TSD_K3;?XH>(83B2[CNDQS'- A!^N #^M K$>I7'B;P
M3J'D2WUU">J,)2\4@]1G@_C6]H_Q.BU!E@U^W5@>!?6ZX9?=AZ?3\C3T\>:3
MXNT[^R]=M%L,_P"KNK?E8F[$#JOZUR7B;PG=^&I8V=DN;.7F"[B^Y(#_ "/M
M^6:$W'8+)GIE[8&U\N2.19[64;HYHSD$=JJUSGPU\2^7<?V'>-OLKHXB)_Y9
M2=L>Q_G^-=/<6[6MQ)"_WD8@_P"->A2J<ZL]SGE'E9'111709A1110 4444
M%%%% !1110 4444F!M7'_(K6G_78_P#LU8M;5Q_R*UI_UV/_ +-6+6<.OJ4^
M@4445J2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5OYUCUE3V*84445J2%%%% !1110 4444 %%%% !1110 4444 %%%% !1112
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M,6<84222'N9'+?EZ5:HI:XKWW-M@HHHH&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+12 85W<D
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M^I!THW"O+/#_ ,9D6!(M8M9'E48^T6P'S>Y4D8_"K>J?&C3XX"+"SGN)NQG
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MT>.;8 3R71"OXGTS0!]<?&'XJ:5\(?!-[KNHR(9U0I96A/S7,Y'RH!Z9ZGL
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M)/4^Y]ZDGN);A@99'E(&!O.<5%6M./*M=R6[[!1116I(4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP/4,#R".0>16NO3%&X4 ?DW\8OAW+\*_B1K?AIY&FBM)08)FZR0NH>-C[[6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[4\(:=\T=OI\J>9QF:?C=GWR?Y^U>0T#.I^&^@Q>(/%$45PH>W@0SNAZ,%(
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M>B8!1110 4444 %%%% !1110 4444 %%%%)@;5Q_R*UI_P!=C_[-6+6U<?\
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M8&K0M\._&D.H6B[]*N\L(UZ-&WWD^H/3\*[K4+.WOKFV%NP-CJFFR6,;KT!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $-86L>'WO-K02;0I/[MC\HSUQZ9K>I,4XR<=4)J
MYQHMXKRPN-"U9=D<HQ&W7:V>"/H>1]*YK2;>V^%BQ27WE3ZG>3^6-IXBMPWS
M/^(Y_+T->F:AIL.I0F.5,_W7[K]*\[^*7AZ>[T6#4F3==6)\F9L??C)RK?@3
M_P"/&JDU+WEN$=#F=09_ _Q'>X_Y8I/YOUB?K]>"1]16;X[T4:+XDN4CQ]FG
M_P!(@*]"C<C'MG(_"M?6E_X2KP/8ZJOS7NF?Z+<CN8_X6_SZMZ4+_P 5AX#V
M@>9J>B#</62 _P"&/_'?>H+.('RG(X/7_/O7H?A_XQ7FGVZ6^HV_V\*,"97V
MO^.<[C[UYY10!Z?JGQJ>2!DT_3O*E8<23ON _P" @<_G7F]]?7&I7<MU=3-/
M/(<M(QR3_@/:H** +&G:?+JE_;V< W2S.(U].3C)_P ]*]QN=171[?\ LNS7
M$5O$L"/W&!S_ $_&N*^%^D"SANM?G7_5@PVH(ZN0=S?@./Q/I6TS%F+$Y).2
M:Z*,.;5F,Y="Y830R136%ZOF6-TNR1?3T(].U)]AMO#6EIH]DV]0=\\V,&1C
MZ_I^0JG175[)<W,9<SM8****V)"BBB@ HHHH **** )K.W-W=10CJ[8SZ5Q'
MQ*UTZIKSV<1Q9:?F")1TW#AC]<C'T%>B^&\?VHK8W%59@!U)P:\0ED::1W<Y
M=B68^I/6N"O+WK&]-:7$2-II B*69CA549)/8?G7LOA7X2V-C;QS:L@O+MAD
MQ9Q''[<?>/UXKSWX<P1W'C72UD *AV<9_O*C,OZ@5]!US&K.=O/A]H%]"8WT
MR&/T:$;&'OD5Y!XX\$S>#[Y-K&>QF)\F8CG/=6]_YU]!5QGQ:ACE\&W#. 7C
MEC9/KNQ_(F@#PI248%3M8'(/<5[%IVJ'Q-X7L]3<YNHF^SW!]6'1C]1C\Z\=
MKT;X7R-)H'B"$_ZM&A=?J2V?_015PERR0I*Z-?\ #%%%%>H<B"BBBF 4444
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M3MCJW0_(17T)\8/@%:?&7PSHVEZKJBP>)=-=7_M)5W$PL_[V,_WOEY&>Z@\
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M'Z<]:^B]'\%Z1HMNL5O8PL<8,LJAG;ZD_P!./:F:UX(TC7+=HYK**)\86>%
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M;DEY0.P8XQ_LJIX)Q7C*J78!023QQR: /T9_9_OIM6_9W\"W,[;Y4BGM@?\
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M6,'YUC (;V/)K.\46KQWXE,:K&X&&7J3WS[U@I<U35E[(Q:***Z^ID%%%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHH"DD8ZDT ;?B#Y+/3(S]Y8N1^"
M_P"%8E;7BM=M]"@/ A Q^)_^M6+65+X2I;A1116I(4444 %%%% !1]>E%%(!
M[RO(J*S%E487/:F444+R ****8!1110!8AOIH;62V5ML4AR?\^]5Z**226PP
MHHHIB"MK5!]HT'3I^FS,?^?^^:Q:VX?W_A:<'DPRY7VY'^)K&II9E(Q****V
M(04444#"BBB@#7TW7C8VQ1XQ-(A_=,W8$C(S^%5=4U!;R1%AC$-M&-L<:@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M Y!'6DHKT;+L8%W4-4FU(1"0X"+C Z$^M4J**(I+1"O<****H HHHH ****
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MQKI OU &?Z5I3=I(B2NC2HHHKU#E"BBB@ HHHH **** "BBB@ HHHH ****
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MKP&WU&PF,,R=LCH0<<J1@@]P0:/"?A?4?&WB73M"TB W&HWTPABCS@9/4MZ
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M:0V.!N(6MYY(F.61BIQ[&HZGO;=[2ZDB=@[*>6!SGOG]:@KKCLF9];!1115
M%%%% !1110 4444 %%%% !1110 4444 %:OAE-VKQ'^ZK']"/ZUE5M^$U_TZ
M5ST6(_S%95/A8UN9=\XDO;AQR&D8_F:@HHK1; PHHHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****0'0ZX@N-%L;@D-( JEA[CI^=<]6OH
MNHIQ8W*B2VD^4?[))X_#^54M3LQ87TL )95(P3U.1FLJ?NMP93UU*M%%%;$A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5T^CXN=
M FCDR\8)79"IWCO^)Y%<Q5K3]2ETV;S(CUX96Z'ZUE4CS+0J+L6H5;4+;[+"
M?)O+63[19/)V8?PGV()!QZGVK@?B)HZ&:'7;6(QVU\2)HSUAG&=ZM[Y!_$&O
M4X9K?7@&B"VE\A#[MH)...O&1TK.U*QM]0@GBN$\NRU$B*X4C_47(P$DQ[D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'4G@O^I'Y^U;,DC32,[-EV.2:Z:,+N[,:DNB&T445WF 4444P"BBB@ HHHH
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M_=?D?F.E8EYHUY99,D)*_P!Y>17>TFVMHUI1,W!'FWZ45WEWHMI>9+Q!6/\
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MO/2@&:&O7"VL'D1#8\P&0HQMC'"KCMZX]S7/=.*VKK0M3O+B2:2-2SGGYQ^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>9A4ET)OMD__ #VD_P"^S1]LG_Y[R?\ ?9_QJ&BNSE1D3?;)_P#GO)_WV?\
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M:X$=)]&:UK%MH.FS7MRVV*(9P.K'L![FO!=9U[4_'&L1*Y9VD?9;VR'Y4R>
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML;H>? 1TP>J_@?TQ7-QX5U+C<,C(]>:]AU+2AXL\/3:=Q]MM\S6C'U[K^/\
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M_M-Z#_/TVG44%=DI<Q8M=&NKJ/S HCBQGS)#M7'K4$DFBV[;9]?LU?TC._\
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M\<;;F_;<N>H7HO\ 5OQJ*NJA'[3,*CZ!1117<8A115W2;$7UXJOQ"GSR-G
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M'V-8]?4%Y9Q:A;RVUQ$LUO(NUD89!KYR\3:.= UZ]L,EEA?"LW4J0"N??!%
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MSS]:M5RG@OQH/$'G65VBVVJVI*RQ \-C@E?QZCM75BI&+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Y:)>V[Q2#*L/3I[UQV
MH>'[FP+,%\V%1_K%Z_B*[BDZ]N*TC4<"7%,\UHK4\0:>;._<I$5A;D$#CW_6
MLNO1C)25SG>CL%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<;4;GY;/38S<R-[C.T?7(S_P&NC^&VGW&N:YJGB.:/>ZL_D@]#(W)Q[ ''_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:+KE[X?O4N[.9HI1]X=G'HP[BNE\4:9::]HX\2:7$(26V7]JO_+*0]6'L?\
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M 4444 %%%% !5BQOI=/N!+$1G&"&Z$57HI-75F,VO^$JN6X:"W8>FT_XT?\
M"11M_K-/MW_#_P"M6+16?LX]@YF;?]O6>.=)@_,?_$T?VMIDGW],53_L$?\
MUJQ**/9H?,S:^V:(W6RF'T8__%4;M#E_@GA_,_U-8M%+V?F%S:^S:&W_ "]S
MK_P'_P"QI?[,TJ0?N]19?]]?_K"L2C\*?(^C87-K^P;,]-5A_$#_ .*H7PUY
M@_=7UO(.W./Y5B_YZ44<LOY@T[&U_P (G=]IH&'^\?\ "HV\+WR]%1O]U_\
M&LG]*D2XECP$E=?3#$?UHY9KJ+3L7CX=U$?\N^?^!K_C4;Z'?1];9S_NX/\
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M=%?/_P -]'.L>+;,$9BMS]HD],+TS_P(K7T!0#%HHHH$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'>*+%H;TSA2(Y
M.^?XL5V-5K^QCU"W:*1<@]#Z'UK2$N25R9*Z//:*GO+.2QN7AD'S \'U]Z@K
MTT[JYS!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX[G=\OL':O-/BE?6VJ?$[Q?>695K.XUB\FA9<8*-,Y7&.V"*M_!BWN+KXO\
M@B.U&;C^VK-D.,XQ,A)^@QD_2@#[=\8>#KKPC?".4^;:R9\F91PX]#Z-5[X:
M7ZQZ\VF7'SV>I1-;RIVS@X/U[?\  JZ[4/%%EX@UC5?#.L;5@:<QVMTH_P!6
MX. #]#W_  KBM)T6\T7Q]IUA.I$\5Y&25.0R[L[A[$9H&85[8R6>I7%DWS21
M2M"0.I(;%>[ZYJSVRM9@?O=BJTH'(! R/QXKS_3]*36OBK>'K;6UT]Q*W;Y&
M[_\  L5TE]<F\O)INS,2/IV_2MZ,>9W9G49!1117H'.%%%%, HHHH *S_B':
MF]\'Z==J,FSG:)QZ!^<_F%'XUH5=L;:/5K.]TJ9@L=Y&54GHKCE3^?\ (5A6
MCS0+B[,X;6O^29^'PG0W$Q?_ ']S8_2OGS]NKQ$\?BKPQX0A?%CH^F+,T8Z&
M60E23[A(UP?]IO6OHO2[234/!>N:'*I6]TN?[4B'K\ORN/P&?Q:OE[]N.QD_
MX6W8:JOSVFJ:1;SPOCC@LI'UX!_X$*\TZ3YW^E?IG^RO\*K'X;_"C2ITA7^V
M-:MX[^^N,#>2ZADCS_=12!CIG<>]?F7V/?BOU?\ @=XPM/''PG\+ZK:R*^ZQ
MCAF4=4FC4)(I^C*?J"#WIB.Y%<7\7OACIWQ:\"ZCH&H1IYDB%[2X(RUO.!\C
MJ>W/!QU4D=Z[2LWQ)X@LO"N@ZCK&I3""PL8&N)I">BJ"3@=SQ@#N3B@#\?9H
M7M9GAE4I)&Q1E/8C@BO:?V0=>73_ (Q6VBW7[S2O$5I/IEY"WW75HV9<CUW*
M%^C&O'=6U!]6U2\OI%V/<S/,RCH"S$D?K7J/[*.CSZS\?O":0#BWG>ZD;&0J
MI$Y.?K@#\10!YSJWANYT_P 67GA^)&NKR&]DL$2,9:219"@  ZDD<5][^#?A
MY_PKWP7H'PZT\H^JW#+>:Q/'R&N& )&>ZJ /P537F'P&\&V>N_$;QI\8M4B6
M32(=6NY-&C88%Q<R2LP<>R!A@^IR#\AKZ;^&^BR0P7/B+4V_TR^!DW2<;(LY
M)YZ _P @*3V U6U*TT'5M$\,VR?NY8W#_P"RH1L9]R0:P9%\N1E]"16'X3O7
M\4?$N;5GSY$(DFYXVH%VH/KR/UK<D?S)'?&"Q)_.NS#WU,JA;TV:',MI=*)+
M*Z7RI4/3D8S_ )_I7E7B;0)?#>LSV,F653NBD_OH>C?X^X->D>H[4OB31O\
MA,/#S*B[M5L1NAQUE3NOU]/<#U-%>G]I!3ET/(:U?#.@3>)-9AL8LJ&.Z23'
MW$'5O\]R*R\$-CG.>@ZUZYX;T7_A#_#X1QC5;X;Y?6),<)_C[GV%<L8N3LC:
M3LC0O/+N)[>PLE5+6W AA7MQP3^-:FN3QV&EQ:>&+2[5W<<8SR?Q-8UCJ)L<
M%+>%W'(>0$D?K@5LZ\\5YI,%X$8,6"K\QPO7/'X5V-<LDNASWNFSFZ***ZS,
M**** "BBB@ HHHH **** "BBB@ HHHH *NS:78>++2W@U)BDEFWF)(#R\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1112 Y+Q=$%O(I!D%DP3]#6#ZUO^+PWVJ#
M/W=IQ]<\_IBL"O3I? CFEN%%%%;$A1110 4444 %%%% !1110 4444 %%%%
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MH'04"84M%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"2,$[#V/M70V_A6UCC42%I64DY4[0?;%:2JQB[,2BV<A6AI^AW.H,"%\J/\
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MZ,AS^!]#[4 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K'\0:2VH1K)%@2Q\XQRP],UL4F*:DXNZ$U<\V96C8
MJP(8=<C%)7=:AH=MJ$RRR!@P&#M.,_6N9U;0)=-4RAA+#W;&",^HKT(55+?<
MYW%HRZ*,45N2%%%% !1110 4444@"M[POIIDG^U.K!4^YQPW4=?:L)5+,% R
MQ. *]!L+,6-G%"O.Q<$^I[G\ZYZ\N561<5=E@=.>M+24M>>= 4444P"BBB@
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M70:7Q%;DE?,,8^_&?]O;M)XP &ZYK9\5:\NMWR"VB%KIUJ@M[.V0 +%&H
M' Z#CZ#M0(R9))+J9G=FEED8L23DLQYS[\UVGBG'A7PQ9>'D.+NX_P!*ORIY
MSQM3_/I[U!X!TR&%KGQ#?K_H&FC>H[23?PJ/H2#]2M9^EV5WX^\6$2,=]Q)Y
MD\@Z1H/3Z# 'X4@.I^&NC_V7IL^O3K^^DS#:*?\ QYA_+\#ZUJ$DG)Y-7=3G
MB+1VMLHCL[5?*B5>F!QFJ5>C1ARQ.:<KL*R_B4S+X5T1 /D:65F^HX'\S6I4
M7BBQ.L>![E%&9K"47"@=2F"&_F3^%*O\(Z>YY/7MWP?1%\(Y7[S7#EOKP/Y
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M" ;L8W8'%>?548[;FL=3D5M;>>^GLB/)(D98I!SWZ$=ZT-'AM]'NY?M-RJ7
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M]ZZSXO:D'UJ#2X@L=O9QY,:C WL,YQ]"/S-<#Z&@!8XVED5$4N[':JJ,DGT
MK6/@_7%CWG2;S;C/^I;/Y8KV#X>^#8?#VE07,L2MJ,Z!Y)&&2@(^X/3'>NOQ
MTH"Y\M,K1L492K@XVD8(-:?AWQ+>^&;Y;JRDQG&^)ON2#T/^(Y%>N_$KP;!K
MFDS7T,:IJ%LA<,!CS% R5/X=*\.H ^E]!UNV\0:5!?6K$QR#E6ZHPZJ?<5HU
MX_\ !?6&AU.[TQF_=31^<B^CJ0#^8/\ XZ*]?%!(M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-Y&TGVJ2BF E+112 ****8#64-C(!QR,BEI:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *3-+6=KVK1Z'I-W?2C<D*;@N<;CT _/'YT
M8GC3QO9>$UQY:W&HR)A(O1?5CV'MWKQG7/%FJ>(9"UY=.T>>(4.V-?HH_F<F
MJ6I:E/K%]->73EYIFW,>P]@/TQ[59\/Z!=^)-22SM%^=N6=ONHOJ:16QFC/:
M@,1C&?7@U[7IOP>T:W@7[4TUY+CEB^U<^P'^-9?B3X-P_9WFT>9_.49^SSD,
M']@W8_7-,#D-%\?WMA']DU%1JVF/P]O<_,P'JK'I_+CM3O$WA>VALH]:T21I
M])D;#*?OVS?W6_Q^G)X)Y=XWB=D=61U)5E8<@]P:Z3P#KB:;JWV&Z DTV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M CM_OG_>?KGW'Z]:!$C_  GUZ,9=;9?]Z<"NB\ _#F\TK7%O]0$)CA0F+RI
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M$]K$RYMX3Y\O'&U2,#\3@?C7.<UWGG-X%\$HB$QZQK'SEEX:*'M]"<_J>XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *1J6B@#B?$EC):Z@\A)*2_,K>_I65
MZUW.M:4-4A5=Y1D.1QD'V-<.\9B8HPVE3@@]J]"C-25CGDK,2BBBN@@****
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MRI9:;;V"XAB"'NW<_C5H4M%1J]64%%%% !1110 4444 %%%% !1110 4444
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MMEO+V9I?]I8V*@?3A37)7^(UI;'->*/$ESXHU)[F?Y8A\L,'\,2]@/?CGU_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>2&,5K$-TTH&< ] /<X./H3STKV >'_#/A/3_,FM;.WB48,MPH9F/U/)/L*
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MVBR:KH]Y!<-YNKZ* RSGK<6IY!/N!G/NI]:P[EO[?^&<4S_-<:3/Y08]?*?
M _#('_ : /:-'U*/6-+M;V+B.>,.!Z9'(_ \?A5RN*^$=PTW@V-6Y$4TB+]"
M0W_LQKM*"1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH :5S6!X@T.(P/<P@1N@W,.@(Q_.NAJ*XA2X
MA>.1=R,,$549.+T)DDSSFBE;&XX&!GO25ZJU5SF"BBBF 4444 %%%% !1110
M 444^*&29L1QM(?15)I7L RBIFL[B,9>"11[H16[K&@PP6/VB$F,QJN5ZAO?
M]?TK-U$FD/E;)O"-QNADA$6W;R9!WST!_6NBK&\+VPATM7[RL6_#H/Y5L5Y]
M2SD['1'86BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M0L[?4+26WNHEGM
MY!AT?H1U_P _2K--ZYR*0')6OB-EU(R2<6K@+Y8_A4=#^O-<-#X?7PW\5+*
MC%I),);<CIM;.T?@>/PKK==LEL=1D1%VQMAE_K^N:J:U:/K&APW-N-VJZ.XN
M(!W= 02OOT'X@>M=-2"Y5*)E"33LSSRZTB?6O'%UIZDB6:^D4ENWSG)/X9/X
M5>\?:W'+<QZ)8G9I>G?NE5?XW'#,?4YR ?J>]=BMG%:>++_Q'!@VTVE27\+>
MC[0&_'N?]ZO(F)9B2<G/)KG-A,$\ 9)XP!7HWASX.W%_;I<:G<&T5QD0(H+X
M]\\ ^W-8OPOTN+4_%UOYP#I;HT^UNY' _(D'\*][7H*!L\PU+X)P>0QL=0D$
MH'"W"@JWL2,8^N#7F.J:7<Z+?2VEY$89XSAE/3Z@]Q[U].UYG\:M-B.G6&H!
M0)UE\@G^\K*6Y^FT_G0(\TT'7+GP[JD-]:G$D9PR] ZYY4^QKUK4A!<);W]H
M<VEXGFI['C(_6O%?\YKU/P3<&\\![&/-I=E%_P!T@-_-C6M*3C)(B:NBUZU3
M^(5K<:I9^%M/M@&>X>0 <XW J 3[#)JY6G>:Q9^'=!M-2OH]]S;M(+./.&<L
M,''H.3D^GKP#TU_A,J>YDZQX;N8]*71+&:+2=#M^;O4+@A/M$G?CN.._'&.U
M<NUGX*TOY9;S4-6D'>W0(GZX_F:P?$'B:_\ $UT9[V8LN<QPKPD?L!_7K]:R
MZX3I.P%UX(F^5[+5H0?XUD5L?F:E'@G2M<4G0-;CGG(XM+U?+D/T/?\ +'O7
M%4+E6!!*D'(*\'/:@9:U+2[O2+MK:]@>WG7JKCJ/;L16YX+\3KI,K:=?CS]&
MO/W<\+=$S@;QZ$=\>GJ!6CH?B:'Q1:QZ'XA;S%;BVU _ZR%^P8]P3W/X^HY?
M7M%N/#^J3V-T/WD9X8=&4]"/8B@#T[PK8-INJZKX2O)&EL9E%S;MG[\9(W+^
M(X./0^M=?X;M7E^TZK.I6>_(95;@QP@8C7V..3[M7'>%Y7U2+P;J/WKB"2:Q
ME;^\HC<KGZ!?S->F"@@!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BDS1F@!:*3<*,T +124M !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !124M !1244 +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<2130L5=&!X((Y!_&OT=_97^/9^,?A22RU1U'BC2E5;KHHN8SPLP Z9(PP'
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M%%%% !7!?&;X[>!?V>_"L/B3X@:\GA[1IKI+**X:WFG+S,K,J!(D=B=J.>F
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MQF_: \5Z]K-QK^9].TZ.Y"226^3MDD<@[$8Y*11A0%VG.#M&M_P7$COV\/\
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M[97_ "EL^%'_ &&/"_\ Z6)74?\ !#/_ )K9V_Y G_M_7+_ME?\ *6WX4?\
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M*LI&""#U!% 'RC^S?_P4N^$'[0E]9Z(U[-X+\5W!V1Z3KI5$G<_PPW .QR>
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M9$8W'!\S%?I;X;^&MA^P?^R'XRMO"ES?>(T\-Z=J6N6S:B$,DDPB:0!]@4;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWQZ\&:)<ZQ::'%:+=26L+S_9+JUN7GADE5>5C8,J[AP"F#@L,_2'['O_  4
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MY=>-OAEJ>]9]-M%DE\JV=@QMKA44LAC;_5S888 SR60_K;MHV_G0!^:NO?\
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MT#,2H^]C%?I;^SG\$M._9W^"_A?P!IDWVJ/2;;;/=[=AN;AV,DTN,DC=([$
MDX&!VKTG;VI5Z4 ?CI^TW\,_B7^PG^V3>?'#P3H,VL>$-3OI]2\Z*!WM$^T[
MC=6=QLSY?+.R$X&-A'*E1ZQ;_P#!1;XO_M9:1)X-^"'PAO-$US4XS;S^)KJ^
M-Q:Z6K</)O\ )1%(!.&8Y!QA&.!7Z9,N<GO1@F@#\A_^"7/@&7X1_M_?%CP7
M=70NY="T/5-,%T0%^T"+4K-1)C)QN5=V,G&?:F_\%O/F^)WPRQS_ ,2>Z_\
M1RU^O6WVHQ0 M? '_!3C]BWQ+\8I]$^*WPTADN/''AZ!8+G3[4[+B[@C<R12
M0G/,T3,W'5E( .556^_QT]*\E_:&_:@\!?LP:7H.I>/+^XL;36;TV,#6MNT[
M*0C.TC(OS;%PH)4,<NO')( /B;X=_P#!7G4="TFT\,_$CX3>(Y/B%;QB!X=,
MB\LWD@&-Y@D >)B0<@!AD''H/DO_ (*':M\6_B-JW@OXF_%#0/\ A"K/Q%'>
M6GA[PI*S>?8V=N8&,DP(!#R-<\EE5CY?W54(*_6E?V^/V>VTA]2'Q8\/?9T7
M<8S,PF/&>(=OF$^P7-?G?\=/&MW_ ,%2OVL/!_A3P!IM\WP\\- I<:K<1F,)
M!)(C75TX_P"6881HD:GYF*+T+%5 /U ;X:Z7\5OV<[3P3XAA=M,UGPW!87*X
MVNFZ!1N'HZMAAZ%17YK?"_Q+\?/^"6_B#6O#.N^!+KXA?"R^NC<PWNFA_)#D
M!?.BE57$+,JC?#*.J@@X^9OUT@ACMX8XHD6.)%"HB#"JHZ #TQ3Z /SNM_\
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MZ'5Q)NOH2F3*K/%'GYL@[00/[QYQ^??[90_XVV?"C_L,>&/_ $L2OUZP:-M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>thc-20221231_g2.jpg
<TEXT>
begin 644 thc-20221231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-_P!J?]K[]FC]
MB7X57'QL_:I^,>C^"_#5O((A?:K*Q>YF()$,$,8:6XE(#$1Q([D*3C )'B_@
MK_@L-^SQXN\"+\9=0^!WQST#X>R6_P!JA^(>N_!O54TI[7&1=GRHY)X[8KAO
MM$D2Q!?F+!<FOR#_ &J_B3??\%/O^#M+P+^R?\;7-_\ #?X8>,FTO0_"M[\U
MHXTW3I-3NC)$?E<W-U;%7)'SQ+%&<A!7]%9C0IY10;<8VXXQZ4 >??LX_M3_
M  *_:Q^#47[0?P'\>6VM^#+F^U"VL_$"92WN/L5U+;3RHS8S%YD,F'X#* PX
M->/>!_\ @KS^R;\;/$GB/P_^RSIGCSXPP>$;DVOB/7_ACX(NM1TJTN -Q@2]
M8)!=2;<-MMWE)# C.:^!O^#EC4%_X)?_ /!'.T_90_92N)_#^A?%/XN:G;ZC
M'8#R%L]+O[C4-8N]/A\O'EPM-(D(08!@#QD%6(K[&_X-VOA'X4^#W_!&OX&:
M7X6TZ&%M<\+'7]4FC0!KF[OIY+AW<_Q, ZQ@GHL:KT44 >X_LB?\% /V2_VY
MK#6I/V;OBS#JVI>&+UK/Q7X9U"PN-.UC0KE69&BO+"[CCN("'1TRR;2R, 3M
M->0?MD_\%U?^">_[ 'Q27X.?M:^+O%WA'7)K,7EE%<> M1GAO+8R21K/#-#$
M\<B%HI!PV?EY K\FO^"D?Q6\0_\ !/C_ (.TO!'Q=^"5Q)IJ?$.Z\*1>--.L
MB4BU.TU%X]-O8Y(UX<NL*S#(/[]$D^\ :^SO^"_'[ O_  \%O?C#X#\-Z+]K
M\9>#?V>]!\6^!Q''NE>^LM8UMI+= .2T]LUQ JYQODC)^[0!^I'@OQCX8^(G
M@[2?B!X*UF'4M&UW3(-0TC4+9LQW5K-&LD4J'NK(RL/8U\C>*?\ @OC_ ,$U
M?#'[6EQ^P]#\4?$&L?$RW\3GPZ/#V@>"-1O?.U(2>6]O'+'"8V*2!D9@VU61
M\D;3CXF_X-WO^"LNL>(?^",/B7X6-/%K'Q1^"EY;>%/ ^CW<N6U9M6G^S^'8
MF[^7]LE-HV ?+AME8]Z^3?%_P,T?]FK_ (.R?@K\#=&U.74%\.W'A2WO=6N!
MB;4[QM#22ZOI?66XN'EG<]WE8T ?L/%_P7M_X)^W7[16K?LCZ7/\2]0^)NB3
MW,.I>!M*^$FM7>I1O;H9)@(8;9FD"H"^4W K@@D$&O6?V._^"F7[#W[>NHZW
MX>_9;^/5CK^N>&F9?$/AB]TZ[TS5M-*R>6YELKZ*&=563Y&?85#$*3D@5^)'
MPU^+_@#X$_\ !XU\2OB3\3-2N[31[.\UA;B:QTBZOI0S^'T50(;6.25\DC[J
MG'>O6_\ @EE^QU^U/^T-_P '%'Q'_P""K6@? KQC\-_@K_:^N36%YXST"XT:
M;Q0MU9-91+%:W"I,ZR2G[:S%-JF(!B)"%H _;;XG_$GP9\&_AMX@^+GQ'UN+
M3/#_ (7T6ZU;7-1F/R6UI;Q-+-(?941C^%'PN^)?@OXS_#3P]\7OAOK<>I>'
MO%.B6NK:'J$/W;FTN(EFBD'^\CJ<>]?%?_!=?P3\</VQOV=]:_X)O?LNZP;;
MQ5XN\$:IXI\32QH6;^R--56MM/R"-DFH:DUK;J2>88KPX8(17S=_P9[?M]2_
M';]BO7?V(_'^K,WB?X,ZCG1XKE_WLV@WDCO&N&Y8P7(GB/9$DMUXXH ^P_VB
M/^"XW[!7[*?[16G?LG_';6/'&B_$#67M5T+PXOPZU.YEU07,[06[6S00NLXD
ME1HU*$Y92O4$5JS?\%H?^"?OAOXSZ-^SS\8_B3XB^&/C'Q$4_L#2/BK\/=9\
M.+J 9MBM%<7UK';D%\("9!ECMZ\5^1O_  <C:_I7A3_@Y._9/\4:[<-#8Z;H
M7@2ZO94A>0I%'XPU-W8(@+,0H)PH)/0 FK__  <-?M#_  N_X+G?%WX-_L*_
M\$M=+N_BSX^\+ZGJNH^(]2T_29K2VT2VE%M T<T]VD81 ZJTKG"(4C4DNVT
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M\A^&/C74M=TN;1_$=K()-"N]8L[V&YM9$>8&339OM$2;5EWQ]5,P+!3]E_\
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M'^QM\'/!/P;O&6U_:@TR-M?BMY\R:3X8AB63Q&CLN"& /]D[Q]RXU&)N0#0
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M_A)\4/!OQP^%/ACXT_#K4)+OP]XO\/66MZ%=RV[Q--9W<"3P.4<!D)CD4E6
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M6U<2VYDV@D1OAH7(!(CF<@$@"OIBB@#\:/\ @@Y^VKJ__!*S]G^\_P""9?\
MP58^'GBCX1:WX,\27T_@;Q+KGAZZFT/6;"ZF:>2*"_MXY(&9+E[AP^_8ZRJ
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M5+BTG9" _P"[N(8B\9VL5#(<9-?0M% 'XZ?\&_WQB\4?\$DOA+XS_P"";/\
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M4_&=K+]OUZ_@O]/:W$1O)TC9EAN[*6.W",<E+>3LU?T944 ?@5_P=7?$F?\
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MI_&M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3
MW_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?"YT'[5Y(U_^U"OV8P?V7A_LPD-WYW[KR/XJ_4:B@#E/@1\(?#/[/GP/\&_
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MW_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.&PK=Z^1XH_X4JN'R2.V(;=3RH4[.HGY3;A2])R:V/,S#]_*&$7V]9?X%O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\^_:A^*=Q\(?@IK'B?2=S:M<1K8:%#&,
MO)>SGRX@H[E22^.X0UZ#7AWCG_B]7[7^@?#Q#YNB_#>S&O:THY5]2E&VTC;_
M &D7]Z/8M7S?%6,Q&&RET,+*U:O)4J;[2GHY?]PX<U1^4&<&8U9T\-R4W:<V
MHQ]7U_[=5Y?(] ^ 'PLMO@O\'M"^',6UIK"R!OY5.?-NG)>9\]\R,V/; [5V
M-%%>U@<'A\NP5/"8>-H4XJ,5V459+[D==&E"A2C3@K**27H@HHHKJ- HHHH
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M %%%% !1110 4444 %%0ZAJ%AI-A/JNJWT-K:VL+2W-S<2A(XHU!+.S' 50
M22> !4D4L<T:S0R*Z.H9'4Y# ]"#WH =1110 4444 %%%% !1110!X7_ ,$]
M_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?
MXK\3:3X+\,:CXOUZX\JRTNRENKN3^['&A9OQP*\N_8N\,ZM_PKB^^,7BVWV:
MY\0M5DUN\#=8K=R1;1 _W%BPR^GF54_;&O;OQLOA7]F?0[ETNO'>LJ-5:(X:
M'2[8B:Y?(Z$X4#/7YA7L]C96FFV4.G6%ND,%O$L<$48PJ(HP% [   5\C3_X
M5N+I3WIX./*O^OU5)R^<*7*EY5I(\R/^TYFW]FDK?]O2U?W1M_X$R6BBBOKC
MTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*?Q>OAVV&J,FS9L-UL\TKL^7&[&..E=710 4444 %%%% 'A?_!/?_DB>K?\
M8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNDD[J2W333V.C#UZ>)H1JPV:_I/S6S\PHHHKO-@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">_
M_)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV[1_PQT7WN\O1H****^N/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
M)$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '+?&WXGZ;\&OA5KGQ*U3:RZ78L\$+'_73GY8H_\
M@4C*OXUSW[)WPPU+X8_!NRC\4%G\0:[/)K'B2>0?.][<'>P;W4;4/NI/>N5^
M,!_X7K^TMX;^!%O^]T/PB$\2>+P.4DF'%G;-]2=Y4\%6SVKW2OD,!_PL<35L
M<]:6&3HT_.;LZTOE:%-/=.-1=3S*/^U8^=;[-/W(^NCF_EI'U4@HHHKZ\],*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#R']KKP'K]WX7T[XU_#RWW>*? %T=3T
M]5'-W:XQ=6IQR5>,$X')*X'WJ]$^'7CS0/B?X&TOX@>%[CS;#5K-+B D\KD<
MHWHRME2.Q4BMH@$8(R#U%?./@KQ_X0_8T^+7B7X._$/7X=*\':JK>(/!UU/N
M*6WF/MN+,!03P_S(H'0$]6KXK,:]'AG/EF%62AAL3:%5MI1A5BOW=1MZ)3BO
M9R;ZQI+N>57E# 8SVTG:G4TEV4DO=D_5>Z_2)]'45Y5X;_;>_94\5:DNE:5\
M9]-29FVJ;^&:T0G_ 'YT1?UKU.&:&XA2XMY5DCD4,CHV0P/(((ZBOH\NSC*,
MX@YX#$4ZR6[A.,TO7E;L=U#%8;%)NC-22[-/\AU%%%>D;A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>
MK?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/S;-,+AXX7#QI1ULM^[ZM^;>K"BBBO3.@**** "BBB@ HHHH **** "BBB@
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M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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M[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO
M_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?U44445^:GP(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKVWY816D(7^S'?>3E+4_<,-@XT9NI.7-4>\GV[);)>2^;;U"BBBO>.P****
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M?*YQDJPQQ2?"WXT_#WXR2>(XO &J3W3>$_%%UX>UP3V$T AO[?:98U,BJ)%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG*4E'1/7E4=>KM=/R<IX,EAL3&MBYJ7*[I*]F^EVTONMJ.HHHK^G#[\****
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M_511117\UGX&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _*O_@YH_P":)_\ <R?^XNORKK]_O^"FG_!,O_AXO_PA/_%[/^$._P"$
M._M+_F6_[0^U_:_LO_3S#Y>S[-_M;M_;'/RK_P 0R_\ U>Q_YC?_ .^5?J?#
M?$F2X#):5"O5Y9QYKKED]Y-K5)K9GZ-D.?93@LJIT:U2TE>ZM)[R;Z)K9GY5
MT5^JG_$,O_U>Q_YC?_[Y4?\ $,O_ -7L?^8W_P#OE7N?ZW\._P#/_P#\EG_\
MB>O_ *T9%_S^_P#)9?\ R)^JE%%%?B!^1!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E
M)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\'^)OC[Q=^T=XWO/V>O@AK,ECHM@_E^/?&=J?]0IZV-LW1IF&0S#[HR.
MQ%6_C=\3?&'Q/\:O^S%\!-4-OJ+1AO&?BB+E-!M&ZQH1UN7&0 #E?8Y9/3?A
M?\,/!WP>\$V?@'P+I8M;"S3C/+S.?O2R-_$['DG\!@  ?%8RM6XJQ<\OPLG'
M"TWRUJB=G.2WHTVMDMJLUM_#B^;F</*JRGF-1T:;M36DI+J_Y8O_ -*?_;JU
MO:?X??#[PC\+?"%EX&\#Z/'8Z;81;((8QR3W=CU9B>2QY)-;-%%?84*%'"T8
MT:,5&$4DDE9)+1));)+9'IPA"G!1BK);(****U*"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **@U/4]-T33I]8UG48+2TM86EN;JZF6..&-1EG9F("J "23P!7
M+_%6]^+]]X-L=1_9XF\+W6HS:K8R2R>(I9C:2Z:TJFX:-X,GS#$24/*Y[&KA
M!SDEM?J]BH0<Y);7ZO8N^)OBU\-?!GC;P]\-_%7C73[#7O%DEPGAS2KB<+-J
M#01^9*(U[[4P3]0.I JMI?@KQ]9?&/5O'U]\6;N[\-WVB6UI8>#'TV%8;"ZC
M>1I+I9U'F.9%95V-P,'DC:%Z*YT?2+W4+75KS2K:6[LM_P!CNI8%:2#>-K[&
M(RNX<'&,CK5FJYXQC:*W5G>SZ]--.GGOK9V*YU&-H]59WL^O333IY[ZV8444
M5D9A1110 4444 %%%% !1110 4444 %%%5M8U?3/#^D76O:W?1VME8VSW%W<
MS-A(8D4L[L>P"@DGVIQC*4E&*NV*4HPBY2=DBS17S7^P'^WOIG[8FK^-]!N[
M:.RO=$UJ2XT.VQM>;1W;;"[#O(K##GH/,3UKZ4KU,ZR7,>'\QG@<=#DJ1M=>
MJ37X,\K(\[RWB++88_ 3YZ4[V?HVG^*"BBBO*/6"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#YB_X*"?%7]G/XB?#+XP_L1?%.RT74=>F^!%_P"+
M++P]X@A@FCU*UV7\8E@BDR7DMI[2-V8+F,RPL#GD?,G_  2<\'W?[!O[:GQK
M_8Y^&7QJOM9_9H\%?#32/%J'Q1K GM_AOKEV\DESHRWDI^2(VR/>-&[?ND:-
MF^9WDD^^?VA/V6OV>OVJ?!=UX$_: ^#WASQ597%C/:POK>B6]U+9B5"C26[S
M(QAD .0ZX((![5?\)_L^_ OP+\+/^%'^$O@[X7T_P>T)BE\,6F@6T>GS*<;M
M]NJ"-]Q +97D\F@#X>3_ (*E?\$MOVG/BUI7[0'QG_;T^$FF>!OAMJDU]\-_
M!VI>.[$7FHZHB/"=?O+7S#(K(CRI96I7>@D>XD7S7A2W;\5=(C\$?\%X_P!G
MW]O26"XM_ OQH^ =[\.K+4]0MFMULM7$[:S907 D ,$MS"SQQQMAFD@9,;L
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MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@
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MNOU4_P"#FC_FB?\ W,G_ +BZ_*NOVKA#_DG:'_;W_I<C]9X7_P"1%1_[>_\
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M 7B31X5XRPG#&<NG"IF'-[-4ZGM(QE%>YSR<()2J.\$H\R;4;2;;2];KT3X
M:!^U!;:\_C#]GGX8>%=4F%NUO_;7B[6C%;6#L>?W$),[D@$;@ N-P!8YV^5^
M*O$FF^#_  Y>^)]7DVV]E;M+)SRV!PH]R< >Y%=K_P $:?VMI/%_C7Q5\$O'
MLT U+5F_M;0;C8JM(J#$MID#+!%(D0=0/--?EOT7_"O/.(\RQ/&JPM.M@LL:
MYE4YK2J3B[."C;F=%6J33DE%.,M=C[+QL\0<ER;ZKPG/$SHXK,+\KI\MXPBU
M=2<D^557>$6HMR:DDUN?5&H?&G5(O T_PM\>6^LZAXW;26L]>N/ASI5QLM;J
M2(@RVTDP4IC<&5CG!P><5X]X!_8RCM?%UA\1;7X':]K_ (BTZZCN=.\6_%KQ
M[/=W$,R,'63R(2H#!@&SM/(XK[$HK^GXSXS52O&EF]3#TJLFW##PA2]UWM!S
MDJL[6=GRN"?9;'YA5P'#%=4)8C+X5ZE))*5:4JFJM[RBN2-[JZ;3:[F59:?X
MBU/P:-*\57\5OJ=Q8M%>76C.R+'(RD%X2WS+C.03R"*X_2OV6OA);7:ZGXCL
M+[Q%>CK>>(=1DN6/U4D(?Q6O1:*Y\7P[DN9.E+'4(UG35HNHE/YV=US>=KG?
M0S3'X536'J.FI/7E?+\M-;>5[%72-$T70+,:?H6D6ME;K]V"TMUC0?\  5 %
M6J**]>G3ITH*$$DELEHE\CBE*4Y.4G=L****LD**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH YSXN_$_P ,?!;X8ZY\5O&5QY>FZ#ITEW<X(#2;1\L:YZL[
M;44=V8"OP9^+OQ/\3_&GXG:Y\5O&5QYFI:]J,EW<X)*Q[C\L:YZ*B[44=E4"
MOVA_;@_92\3_ +8?PQL_A3I7QA_X1+35U%;O5=NAF]:^V#]U&?W\6U58ER/F
MRP0\;>?E'_AP/_U=C_Y8G_W=7]">#W$O ?"&7UL5F6*Y<35=K>SJ2Y81V5XP
M:]YZNSV4>J/YS\9^&./^,LPHX7+,(YX6DKW]I2CS3EN[2FG:*T5TM7*VC/SI
MK]%O^"'_ .T]_P A?]E3Q3J/_/35O"OF-]/M-NOZ2@#_ *;&C_AP/_U=C_Y8
MG_W=71_"+_@BMXG^"WQ.T/XK>#?VN?+U+0=1CN[;/@4A9-I^:-L7W*NNY&'=
M6(K[KC?C[PQXMX:KY=+'>])7@_95M)QUB_X??1_W6SX'@7P]\4N#^*,/F4<
M^2+M-*K1UA+22_B;VU7]Y(^\Z***_D$_LH**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5O^Q[UG_T
MI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@
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MUXI^!O\ PJ7XG^/KW4M1OO# TO7O%&C1C3+FYG:#RI;R%8B1;2,VZ10I(0D
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M$@W?ZU%P6]?0UZ!\%/%/PE^-'@B'X@>"/ +6-E+<21)%JWAX6<X9#M8F-U!
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MKXI\=^*KJ*6_O+>TC*6]K&L$44%M;1;G*PP11H6=G8,[%CZ]10!X->?\$_O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2
M)ZM_V/>L_P#I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJ
MW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/
M_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]
MTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\__:._:B^!7[)W
M@"?XC_';XA6&B6207#V5K-.IN]2DAA>9X+2#.^XE\M&;8@) 4DX ) !Z!17!
M_ O]I[X ?M+:??7WP.^+&B^(I-):)-<TZQO5-YI,DJEHX[NV.);5V4$A954D
M D9'-9[?ME_LLK\5O^%(GXZ>'_\ A)AK T=M/%YE%U,IO&G&;'E"\*?,+4OY
MQ7G9CF@#TRBBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
M8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\R/\
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MQ7X<\#>'+OQ;XMU>&PTVPA,MY>3G"1)TW'';FO./^&Y_V1_^B]:#_P!_G_\
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M)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /+/\ A[5_P3I_Z.DT3_P#N_\
MXS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF3]FW_HWOP/\ ^$G9_P#QNC_AF3]F
MW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\ ^,T?\/:O^"=/_1TF
MB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\ ^$G9_P#Q
MN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\ 1TFB?^ =W_\ &:]3_P"&
M9/V;?^C>_ __ (2=G_\ &Z/^&9/V;?\ HWOP/_X2=G_\;H \L_X>U?\ !.G_
M *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\ X9D_9M_Z-[\#
M_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /*H_^"M__  3GE7<O[4>C
M 9Q\UA>+_.&G?\/:O^"=/_1TFB?^ =W_ /&:R/V$/@%\"?$7P=U2^\0?!7PE
M?3IXUU>))KSPW:RNL:W!"H"T9(4#@#H*]J_X9D_9M_Z-[\#_ /A)V?\ \;H
M\L_X>U?\$Z?^CI-$_P# .[_^,T?\/:O^"=/_ $=)HG_@'=__ !FO4_\ AF3]
MFW_HWOP/_P"$G9__ !NC_AF3]FW_ *-[\#_^$G9__&Z /+/^'M7_  3I_P"C
MI-$_\ [O_P",T?\ #VK_ ()T_P#1TFB?^ =W_P#&:]3_ .&9/V;?^C>_ _\
MX2=G_P#&Z/\ AF3]FW_HWOP/_P"$G9__ !N@#RS_ (>U?\$Z?^CI-$_\ [O_
M .,T?\/:O^"=/_1TFB?^ =W_ /&:]3_X9D_9M_Z-[\#_ /A)V?\ \;H_X9D_
M9M_Z-[\#_P#A)V?_ ,;H \L_X>U?\$Z?^CI-$_\  .[_ /C-'_#VK_@G3_T=
M)HG_ (!W?_QFO4_^&9/V;?\ HWOP/_X2=G_\;H_X9D_9M_Z-[\#_ /A)V?\
M\;H \L_X>U?\$Z?^CI-$_P# .[_^,T?\/:O^"=/_ $=)HG_@'=__ !FO4_\
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M-$_\ [O_ .,T?\/:O^"=/_1TFB?^ =W_ /&:]3_X9D_9M_Z-[\#_ /A)V?\
M\;H_X9D_9M_Z-[\#_P#A)V?_ ,;H \JC_P""M_\ P3GE7<O[4>C 9Q\UA>+_
M #AIW_#VK_@G3_T=)HG_ (!W?_QFLC]A#X!? GQ%\'=4OO$'P5\)7TZ>-=7B
M2:\\-VLKK&MP0J M&2% X Z"O:O^&9/V;?\ HWOP/_X2=G_\;H \L_X>U?\
M!.G_ *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\ X9D_9M_Z
M-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /+/\ A[5_P3I_Z.DT
M3_P#N_\ XS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF3]FW_HWOP/\ ^$G9_P#Q
MNC_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\ ^,T?\/:O
M^"=/_1TFB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\
M^$G9_P#QN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\ 1TFB?^ =W_\
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ML_X>U?\ !.G_ *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\
MX9D_9M_Z-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /+/\ A[5_
MP3I_Z.DT3_P#N_\ XS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF3]FW_HWOP/\
M^$G9_P#QNC_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\
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M^"=/_1TFB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\
M^$G9_P#QN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\ 1TFB?^ =W_\
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ML_X>U?\ !.G_ *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\
MX9D_9M_Z-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /+/\ A[5_
MP3I_Z.DT3_P#N_\ XS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF3]FW_HWOP/\
M^$G9_P#QNC_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\
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MWX'_ /"3L_\ XW0!Y9_P]J_X)T_]'2:)_P" =W_\9H_X>U?\$Z?^CI-$_P#
M.[_^,UZG_P ,R?LV_P#1O?@?_P ).S_^-T?\,R?LV_\ 1O?@?_PD[/\ ^-T
M>6?\/:O^"=/_ $=)HG_@'=__ !FC_A[5_P $Z?\ HZ31/_ .[_\ C->I_P##
M,G[-O_1O?@?_ ,).S_\ C='_  S)^S;_ -&]^!__  D[/_XW0!Y9_P /:O\
M@G3_ -'2:)_X!W?_ ,9H_P"'M7_!.G_HZ31/_ .[_P#C->I_\,R?LV_]&]^!
M_P#PD[/_ .-T?\,R?LV_]&]^!_\ PD[/_P"-T >6?\/:O^"=/_1TFB?^ =W_
M /&:/^'M7_!.G_HZ31/_  #N_P#XS7J?_#,G[-O_ $;WX'_\).S_ /C='_#,
MG[-O_1O?@?\ \).S_P#C= 'EG_#VK_@G3_T=)HG_ (!W?_QFC_A[5_P3I_Z.
MDT3_ , [O_XS7J?_  S)^S;_ -&]^!__  D[/_XW1_PS)^S;_P!&]^!__"3L
M_P#XW0!Y9_P]J_X)T_\ 1TFB?^ =W_\ &:/^'M7_  3I_P"CI-$_\ [O_P",
MUZG_ ,,R?LV_]&]^!_\ PD[/_P"-T?\ #,G[-O\ T;WX'_\ "3L__C= 'E0_
MX*W_ /!.<R&(?M1Z-D#))L+S'Y^3BG?\/:O^"=/_ $=)HG_@'=__ !FLCP/\
M O@3<?MV>.O#MQ\%?"3Z?;^"M,EM[%_#=J88I&=MSJACVJQ[D#)KVK_AF3]F
MW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\ ^,T?\/:O^"=/_1TF
MB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\ ^$G9_P#Q
MN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\ 1TFB?^ =W_\ &:]3_P"&
M9/V;?^C>_ __ (2=G_\ &Z/^&9/V;?\ HWOP/_X2=G_\;H \L_X>U?\ !.G_
M *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\ X9D_9M_Z-[\#
M_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /+/\ A[5_P3I_Z.DT3_P#
MN_\ XS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF3]FW_HWOP/\ ^$G9_P#QNC_A
MF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\ ^,T?\/:O^"=/
M_1TFB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\ ^$G9
M_P#QN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\ 1TFB?^ =W_\ &:]3
M_P"&9/V;?^C>_ __ (2=G_\ &Z/^&9/V;?\ HWOP/_X2=G_\;H \L_X>U?\
M!.G_ *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\ X9D_9M_Z
M-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /+/\ A[5_P3I_Z.DT
M3_P#N_\ XS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF3]FW_HWOP/\ ^$G9_P#Q
MNC_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P  [O\ ^,T?\/:O
M^"=/_1TFB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\
M^$G9_P#QN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\ 1TFB?^ =W_\
M&:]3_P"&9/V;?^C>_ __ (2=G_\ &Z/^&9/V;?\ HWOP/_X2=G_\;H \L_X>
MU?\ !.G_ *.DT3_P#N__ (S1_P /:O\ @G3_ -'2:)_X!W?_ ,9KU/\ X9D_
M9M_Z-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z /*A_P5O\ ^"<Y
MD,0_:CT;(&2387F/S\G%._X>U?\ !.G_ *.DT3_P#N__ (S61X'^ 7P)N/V[
M/'7AVX^"OA)]/M_!6F2V]B_ANU,,4C.VYU0Q[58]R!DU[5_PS)^S;_T;WX'_
M /"3L_\ XW0!Y9_P]J_X)T_]'2:)_P" =W_\9H_X>U?\$Z?^CI-$_P# .[_^
M,UZG_P ,R?LV_P#1O?@?_P ).S_^-T?\,R?LV_\ 1O?@?_PD[/\ ^-T >6?\
M/:O^"=/_ $=)HG_@'=__ !FC_A[5_P $Z?\ HZ31/_ .[_\ C->I_P##,G[-
MO_1O?@?_ ,).S_\ C='_  S)^S;_ -&]^!__  D[/_XW0!Y9_P /:O\ @G3_
M -'2:)_X!W?_ ,9H_P"'M7_!.G_HZ31/_ .[_P#C->I_\,R?LV_]&]^!_P#P
MD[/_ .-T?\,R?LV_]&]^!_\ PD[/_P"-T >6?\/:O^"=/_1TFB?^ =W_ /&:
M/^'M7_!.G_HZ31/_  #N_P#XS7J?_#,G[-O_ $;WX'_\).S_ /C='_#,G[-O
M_1O?@?\ \).S_P#C= 'EG_#VK_@G3_T=)HG_ (!W?_QFC_A[5_P3I_Z.DT3_
M , [O_XS7J?_  S)^S;_ -&]^!__  D[/_XW1_PS)^S;_P!&]^!__"3L_P#X
MW0!C_ ?]M+]E[]IS7;[PS\!_C!IWB._TZT%U>VUI#,C10E@F\^8BY&X@<>M>
MH5S_ (.^$WPK^'EW-?\ @#X:>']"GN(Q'<3:/HT%J\J Y"L8T!89YP:Z"@ H
MHHH **** "BBB@ J*]LK/4K.73M1M(KBWN(FCG@FC#I(C##*RG@@@D$'@@U+
M10 D<:1(L42!54 *JC  ]!2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%,N;B.UMY+J57*QH781QL[$ 9X502Q]@"3VKP/\ 9"_X*$> ?VQOCA\8_@?X
M/^%_BWP[>_!C6=.TO79?%M@EI)>SW<,LRM%"'9UB\N-6#2;682#Y%QR >_T5
M\J_M<_\ !2SQM\ O'.M?#_\ 9_\ V#/BM\<+KP?;1S>.K_P+;6T5GHK20K<+
M:+)<2*UY>>1)%,;:W1V5)HBQ!<"O3_V'?VUO@;_P4'_9LT']J3]GK5+R;P_K
MHEC:TU2V$%[IUU$YCGM+F(,P26-P00&92,,K,K*Q .W^%OPI\(_![P[/X7\%
MPSI:7&I7%](+B<R-YTS[W.3VST':NDKS+P'^TA#XXM_B/KUGX#U&;1O OB^?
MP_IMUI"O>W&OS6]O;FZ:&!(P4\J\EGLR"S#?:2NQ1>G-_P#!/C]NOP'_ ,%$
M_P!GY_VC/AMX$U_PYI)\3ZGHT&F^)XHX[X-97!@=Y8XG=8B64_)N8CN<T >X
MT5\0>-/^"R?CFQ^('B+PQ\'O^"57[2/Q'T#0M>NM+M/'/A3PO:'2M9>WE:&6
M:SDGN$,T'F(ZK*!M;;D$@U]!_L*?M<:+^W7^RUX7_:J\-?#;7_">F>+$N9-.
MT;Q-Y'VQ8H;F6W$K""1TVR&(NA#'*,I[T >N4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !13+FXCM;>2ZE5RL:%V$<;.Q &>%4$L?8 D]J\#_9"
M_P""A'@']L;XX?&/X'^#_A?XM\.WOP8UG3M+UV7Q;8):27L]W#+,K10AV=8O
M+C5@TFUF$@^1<<@'O]%?*O[7/_!2SQM\ O'.M?#_ /9__8,^*WQPNO!]M'-X
MZO\ P+;6T5GHK20K<+:+)<2*UY>>1)%,;:W1V5)HBQ!<"O3_ -AW]M;X&_\
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M,OVC?A#X<^._P9\5P:YX6\6:1#J6A:K; A9[>50RDJP#(P^ZR, RL"K $$4
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M_!C6=.TO79?%M@EI)>SW<,LRM%"'9UB\N-6#2;682#Y%QR >_P!%?*O[7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX)3?\$S?$?C+XKZ1;R^*S)K_ ,0O&NB:/,'B.M7\LEW_ &7:D</M)@LHRO\
MK'0, -X%8W[2O[.?_!8WQ[^UN_QP^"/Q9_9UM_"GA^)H/AYX<\>:!K=_)I+.
MC)-J#?9I88VO9D9H_,(;R82T4142SM-V/@;]F?\ ;\^)/@_0=%_;@^-GP^\1
MW!^+6G>(/$5CX'TJZT_3;?1-,B^UV%G:13"266=M7AM)IGFDP859!G:%8 ]H
M_9+^#NJ? 3]G'PE\+O$E_'>Z[9:9]H\5:C$/EO\ 6KEVNM1N_P#MM>37$O\
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MO?#VH:H5>\M72"SN$U&V$P:6,E[>0*YB8M@2CU#]A#]D7PE^PA^R3X*_9/\
M!.LR:E8^$;"5'U%[80"ZN9[B6ZN95B4D0HT\\K+$&;8I5=S;<D ]<HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O@C_ ()C?\I9/^"@7_8]^"/_
M %'J^]I#((V,2AFP=JLV 3VR<''Y5\E?L3?L<?M+_L_?ML_M"?M,_$^;P-/H
MWQUUS1]233M!UR\ENM#.G6#6:1GS;.-+KS%V,6S%L(. ^1@ ^@?C-\4_A[^S
M5\+M:^*GB'2V6W@D\Q--T>S#WFLZA,RQP6MO$N#/=W$S1Q1K]YW=1GO7S?\
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M!@ 6(.?2/^#9#P-X]\ _\$4?@Y8>/[6>VEU&+5]4TJSN,[H=/NM5NY[8C/\
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MTSRRO@ ;I&P ,"@#TRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(_\ 4>K[VD,@C8Q*&;!VJS8!/;)P<?E7R5^Q-^QQ^TO^S]^VS^T)^TS\3YO
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M'>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444$A068X ZDT %%?.7QH_X*7?!3X8ZQ-X:\(Z==>*[ZV<I/)83+%:(P."
MHF;.\^Z*R_[5<WX$_P""L?PTUK5(['Q]\-=3T*"1@OVVTO5O4C_VG79&V/\
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MSCK7[4_C_P"#WBGQ7X4\-I#)XA?PE)8FYLHY9XH$D\JZN(?,7?*@.PL0,G&
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M 7[(,W[>&O?%K3_^%5Q>%XM?C\4P;GCN+*55,/EH!O:61G2-8L;S(X3;NXH
M]7HKYL\*?\%%(;#XC?#WP%^TC^SKXI^%$7Q>E:W^&NI^)[^RGCO+X1>>FEWH
MMI7_ +/OY(=SQPN71S&\8D\Q?+/TG0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !!I5M?6%]\++6WO;&\@66&XA=75XW1@5=64D%2"""0:Y/QE^WCXW_:%^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MITW]B'XJ>)_B/J'A,^)]*@T+4?#L=G>Z2'EC-RL]YJD"KAX9%*/M?*\*002
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MH **** "BBB@ HHHH S7\8^$(G,<GBK3593AE:^C!!].M)_PFO@W_H;=,_\
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MZK+&48 C."IY4^H/(J2FPHT42QO,TA50#(X&6/J< #)]@!3J "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*5BRV'VDG@#I7J=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677552864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-7293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TENET HEALTHCARE CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-2557091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">14201 Dallas Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">893-2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,274,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s definitive proxy statement for the 2023 annual meeting of shareholders are incorporated by reference into Part&#160;III of this Form&#160;10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000070318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock | New York Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.05 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">THC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember', window );">6.875% Senior Notes due 2031 | New York Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.875% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">THC31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672696176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">DELOITTE & TOUCHE LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Dallas, Texas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677707632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">$ 2,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories of supplies, at cost</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets&#160;</a></td>
<td class="nump">5,981<span></span>
</td>
<td class="nump">7,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAndReceivablesNet', window );">Investments and other assets</a></td>
<td class="nump">3,147<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, at cost, less accumulated depreciation and amortization ($6,201 at December&#160;31,&#160;2022 and $5,960 at December&#160;31,&#160;2021)</a></td>
<td class="nump">6,462<span></span>
</td>
<td class="nump">6,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,123<span></span>
</td>
<td class="nump">9,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, at cost, less accumulated amortization ($1,428 at December&#160;31,&#160;2022 and $1,374 at December&#160;31,&#160;2021)</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets&#160;</a></td>
<td class="nump">27,156<span></span>
</td>
<td class="nump">27,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveCurrent', window );">Professional and general liability reserves</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities&#160;</a></td>
<td class="nump">4,476<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="nump">14,934<span></span>
</td>
<td class="nump">15,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveNoncurrent', window );">Professional and general liability reserves</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Defined benefit plan obligations</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities &#8211; long-term</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities&#160;</a></td>
<td class="nump">22,548<span></span>
</td>
<td class="nump">23,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests in equity of consolidated subsidiaries</a></td>
<td class="nump">2,149<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.05 par value; authorized 262,500,000 shares; 156,462,456 shares issued at December&#160;31,&#160;2022 and 155,520,691 shares issued at December&#160;31,&#160;2021</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,778<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(803)<span></span>
</td>
<td class="num">(1,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Common stock in treasury, at cost, 54,215,871 shares at December&#160;31,&#160;2022 and 48,331,649 shares at December&#160;31,&#160;2021</a></td>
<td class="num">(2,660)<span></span>
</td>
<td class="num">(2,410)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests&#160;</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity&#160;</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity&#160;</a></td>
<td class="nump">$ 27,156<span></span>
</td>
<td class="nump">$ 27,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAndReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAndReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675718288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Property and equipment, accumulated depreciation and amortization</a></td>
<td class="nump">$ 6,201<span></span>
</td>
<td class="nump">$ 5,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets, accumulated amortization</a></td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">$ 1,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized (in shares)</a></td>
<td class="nump">262,500,000<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, number of shares issued (in shares)</a></td>
<td class="nump">156,462,456<span></span>
</td>
<td class="nump">155,520,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common stock, number of shares held in treasury (in shares)</a></td>
<td class="nump">54,215,871<span></span>
</td>
<td class="nump">48,331,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675580944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 19,174<span></span>
</td>
<td class="nump">$ 19,485<span></span>
</td>
<td class="nump">$ 17,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries, wages and benefits</a></td>
<td class="nump">8,844<span></span>
</td>
<td class="nump">8,878<span></span>
</td>
<td class="nump">8,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">3,328<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses, net</a></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost', window );">Impairment and restructuring charges, and acquisition-related costs</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and investigation costs</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities', window );">Net gains on sales, consolidation and deconsolidation of facilities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">2,871<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(890)<span></span>
</td>
<td class="num">(923)<span></span>
</td>
<td class="num">(1,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations, before income taxes</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations, before discontinued operations</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Income (loss) from operations</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income available to noncontrolling interests</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income available to Tenet Healthcare Corporation common shareholders</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Amounts available to Tenet Healthcare Corporation common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations, net of tax</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income available to Tenet Healthcare Corporation common shareholders</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 8.56<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Total earnings (loss) per share, Basic (in dollars per share)</a></td>
<td class="nump">3.84<span></span>
</td>
<td class="nump">8.55<span></span>
</td>
<td class="nump">3.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">3.78<span></span>
</td>
<td class="nump">8.43<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Total earnings (loss) per share, Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares and dilutive securities outstanding (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">106,929<span></span>
</td>
<td class="nump">106,833<span></span>
</td>
<td class="nump">105,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">110,516<span></span>
</td>
<td class="nump">108,571<span></span>
</td>
<td class="nump">106,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain for the period due to sales, consolidation and deconsolidation of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period and acquisition-related costs. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677440096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Adjustments for defined benefit plans</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax', window );">Amortization of net actuarial loss included in other non-operating income, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on debt securities held as available-for-sale</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss) before income taxes</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Income tax benefit (expense) related to items of other comprehensive income (loss)</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive net income</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income to noncontrolling interests</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income available to Tenet Healthcare Corporation common shareholders</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of amortization of net actuarial gain (loss) that has been recognized in other non-operating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670430192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 437<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 4,760<span></span>
</td>
<td class="num">$ (257)<span></span>
</td>
<td class="num">$ (2,513)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (2,414)<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions paid to noncontrolling interests</a></td>
<td class="num">(152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of redeemable noncontrolling interests</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest', window );">Purchases (sales) of businesses and noncontrolling interests, net</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense, tax benefit and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture', window );">Stock-based compensation expense, tax benefit and issuance of common stock</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">4,844<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(2,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,414)<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions paid to noncontrolling interests</a></td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of redeemable noncontrolling interests</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest', window );">Purchases (sales) of businesses and noncontrolling interests, net</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense, tax benefit and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture', window );">Stock-based compensation expense, tax benefit and issuance of common stock</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(1,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,410)<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions paid to noncontrolling interests</a></td>
<td class="num">(229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of redeemable noncontrolling interests</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest', window );">Purchases (sales) of businesses and noncontrolling interests, net</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense, tax benefit and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture', window );">Stock-based compensation expense, tax benefit and issuance of common stock</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4,778<span></span>
</td>
<td class="num">$ (181)<span></span>
</td>
<td class="num">$ (803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,660)<span></span>
</td>
<td class="nump">$ 1,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the net (decrease) increase in additional paid-in capital resulting from the purchase and sales of businesses and joint venture interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued And Share-Based Compensation Expense, Value, Share-Based Payment Arrangement, After Forfeiture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675056176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost', window );">Impairment and restructuring charges, and acquisition-related costs</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and investigation costs</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities', window );">Net gains on sales, consolidation and deconsolidation of facilities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from early extinguishment of debt</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Equity in earnings of unconsolidated affiliates, net of distributions received</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Pre-tax loss (income) from discontinued operations</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gains from the sale of investments and long-lived assets</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in cash from operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent', window );">Inventories and other current assets</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, contract liabilities and other current liabilities</a></td>
<td class="num">(898)<span></span>
</td>
<td class="num">(584)<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PaymentsForRestructuringAndLitigationCosts', window );">Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities from discontinued operations, excluding income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">3,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(762)<span></span>
</td>
<td class="num">(658)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchases of businesses or joint venture interests, net of cash acquired</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(1,220)<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sales of facilities and other assets</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets', window );">Proceeds from sales of marketable securities, long-term investments and other assets</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of marketable securities and equity investments</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other items, net</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(808)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of borrowings under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from borrowings under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Repayments of other borrowings</a></td>
<td class="num">(2,851)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(3,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from other borrowings</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">2,872<span></span>
</td>
<td class="nump">3,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Distributions paid to noncontrolling interests</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit', window );">Proceeds from sale of noncontrolling interests</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Purchases of noncontrolling interests</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment', window );">Medicare advances and grants received by unconsolidated affiliates, net of recoupment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other items, net</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="num">(936)<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,506)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,364<span></span>
</td>
<td class="nump">2,446<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">2,364<span></span>
</td>
<td class="nump">2,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid, net of capitalized interest</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(937)<span></span>
</td>
<td class="num">(962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income tax payments, net</a></td>
<td class="num">$ (161)<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the aggregate value of all inventory held by the reporting entity and other current assets not otherwise defined in the taxonomy, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain for the period due to sales, consolidation and deconsolidation of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PaymentsForRestructuringAndLitigationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments against reserves for restructuring charges and litigation costs, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PaymentsForRestructuringAndLitigationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Grants From Affiliates, Net Of Recoupment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (trading, held-to-maturity, or available-for-sale) during the period. Sale of long term investments and the sale of other assets not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period and acquisition-related costs. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow resulting from the sale of an interest in a corporate unit during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInterestInCorporateUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676556048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as &#8220;Tenet,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) is a diversified healthcare services company headquartered in Dallas, Texas. Our care delivery network includes our subsidiary USPI Holding Company, Inc. (&#8220;USPI&#8221;), which had indirect ownership interests in 442 ambulatory surgery centers and 24&#160;surgical hospitals at December&#160;31,&#160;2022. We hold noncontrolling interests in 158 of these facilities, which are recorded using the equity method of accounting. We also operated 61 acute care and specialty hospitals, 109 other outpatient facilities, a network of employed physicians and a Global Business Center (&#8220;GBC&#8221;) in Manila, Philippines at December&#160;31,&#160;2022. In addition, we operate Conifer Health Solutions,&#160;LLC, in which we own an interest of approximately 76%, through our Conifer Holdings,&#160;Inc. subsidiary (&#8220;Conifer&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June&#160;30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (&#8220;Baylor&#8221;) in USPI for $406&#160;million, which increased our ownership interest in USPI&#8217;s voting shares from 95% to 100%. See Note&#160;18 for additional information about this transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business consists of our Hospital Operations and other (&#8220;Hospital Operations&#8221;) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#8209;hospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of USPI, which holds indirect ownership interests in and manages ambulatory surgery centers and surgical hospitals. Our Conifer segment provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements include the accounts of Tenet and its wholly owned and majority&#8209;owned subsidiaries. We eliminate intercompany accounts and transactions in consolidation, and we include the results of operations of businesses that are newly acquired in purchase transactions from their dates of acquisition. We account for significant investments in other affiliated companies using the equity method. We also utilize the equity method when we have the ability to exercise significant influence over the affiliated company, despite not holding a significant percentage of its ownership interest. Unless otherwise indicated, all financial and statistical data included in these notes to our Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in&#160;millions (except per&#8209;share amounts).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, &#8220;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU&#160;2020-06&#8221;), effective as of January&#160;1,&#160;2022 using the modified retrospective method. Among other amendments, ASU&#160;2020-06 changed the accounting for diluted earnings&#8209;per&#8209;share for convertible instruments and contracts that may be settled in cash or stock. ASU&#160;2020-06 eliminated an entity&#8217;s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer&#8217;s election. Additionally, ASU&#160;2020-06 requires that the if&#8209;converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU&#160;2020-06, diluted weighted average shares outstanding increased by approximately three million shares and diluted earnings per share available to Tenet common shareholders decreased by $0.01 for the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1,&#160;2020, we adopted ASU 2016&#8209;13, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU 2016&#8209;13&#8221;), using the modified retrospective transition approach as of the period of adoption. The amendments in this ASU required a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Upon adoption of ASU 2016&#8209;13 on January&#160;1,&#160;2020, we recorded a cumulative effect adjustment to increase accumulated deficit by $14 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior-year amounts have been reclassified to conform to the current&#8209;year presentation. Due to their increased significance, net gains from the sale of investments and long-lived assets are presented separately in the operating activities section of the accompanying Consolidated Statements of Cash Flows. In prior periods, this activity was included in other items, net within the operating activities section.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID&#8209;19 pandemic has impacted all three segments of our business, as well as our patients, communities and employees, to varying degrees since March&#160;2020. Throughout this time, federal, state and local authorities have undertaken several actions designed to assist healthcare providers in providing care to COVID&#8209;19 and other patients and to mitigate the adverse economic impact of the pandemic. Among other things, federal legislation (collectively, the &#8220;COVID Acts&#8221;) authorized aggregate grant payments of $178&#160;billion to be distributed through the Public Health and Social Services Emergency Fund (&#8220;PRF&#8221;) to healthcare providers who experienced lost revenues and increased expenses as a result of the COVID&#8209;19 pandemic. The COVID Acts also revised the Medicare accelerated payment program (&#8220;MAPP&#8221;) and permitted employers to defer payroll Social Security tax payments in 2020. Our participation in these programs and the related accounting policies are summarized below.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Income&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in the table below, we received cash payments from the PRF and state and local grant programs during the years ended December&#160;31,&#160;2022, 2021 and 2020. Grant funds received by our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate are included in cash flows from operating activities in our consolidated statements of cash flows. Grant funds received by unconsolidated affiliates for which we provide cash management services (&#8220;Cash&#8209;Managed Affiliates&#8221;) are included in cash flows from financing activities.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funds received from COVID-19 relief programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#8209;Managed Affiliates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To receive distributions, providers must agree to certain terms and conditions, including, among other things, that the funds would be used for lost revenues and unreimbursed pandemic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related costs as defined by the U.S.&#160;Department of Health and Human Services (&#8220;HHS&#8221;), and that the providers will not seek collection of out</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pocket payments from a COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">network provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by the Secretary of HHS. PRF funds not utilized by the established deadlines, generally 12 to 18&#160;months after receipt, will be recouped by HHS.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize grant payments as income when there is reasonable assurance that we have complied with the conditions associated with the grant. The estimates we use to recognize grant income could change materially in the future based on our operating performance or fluctuations in the severity of COVID&#8209;19 outbreaks at individual locations, as well as the government&#8217;s grant compliance guidance.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes grant </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income recognized by our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Ambulatory Care segments, which is presented in grant income, and grant income recognized through our unconsolidated affiliates, which is presented in equity in earnings of unconsolida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ted affiliates, in each case in our consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income recognized from COVID-19 relief programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in grant income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in equity in earnings of unconsolidated affiliates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unconsolidated affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022 and 2021, we had remaining deferred grant payment balances of $7 million and $5 million, respectively, which amounts were recorded in other current liabilities in the accompanying Consolidated Balance Sheets for those periods.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Accelerated Payment Program (MAPP)&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, when a healthcare facility is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the MAPP. The COVID Acts revised the MAPP to disburse payments to healthcare providers more quickly and to allow recipients to retain the advance payments for one year from the date of receipt before recoupment commenced through offsets of Medicare claims payments. Recipients were also permitted to repay the advance payments at any time. Our Hospital Operations and Ambulatory Care segments both received advance payments from the MAPP following its expansion under the COVID Acts in the year ended December&#160;31,&#160;2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 and 2021.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes MAPP advances received in prior periods that were repaid or recouped during the years ended December&#160;31,&#160;2022 and 2021. No advances were repaid or recouped during the year ended December&#160;31,&#160;2020. Advances to our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate were recouped through a reduction of their respective Medicare claims payments and, together with any repayments, are presented in cash flows from operating activities in our consolidated statements of cash flows. Advance payments to our Cash&#8209;Managed Affiliates were recouped through a reduction of those affiliates&#8217; Medicare claims payments and, together with any repayments, are presented in cash flows from financing activities.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAPP advances repaid or recouped:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#8209;Managed Affiliates</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, all of the remaining MAPP advances we received were fully repaid or recouped, which resulted in no outstanding liability at December&#160;31,&#160;2022. In the accompanying Consolidated Balance Sheets, advances totaling $880&#160;million were included in contract liabilities at December&#160;31,&#160;2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferral of Employment Tax Payments&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts permitted employers to defer payment of the 6.2%&#160;employer Social Security tax beginning March&#160;27,&#160;2020 through December&#160;31,&#160;2020. Deferred tax amounts were required to be paid in equal amounts over two years beginning in December&#160;2021. We made a payment of $128&#160;million in December&#160;2021 and remitted the second and final payment of $128&#160;million in December&#160;2022, which resulted in no outstanding liability at December&#160;31,&#160;2022. At December&#160;31,&#160;2021, deferred Social Security tax payments totaling $128&#160;million were included in accrued compensation and benefits in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translation of Foreign Currencies</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formed our GBC in the Philippines during the year ended December&#160;31,&#160;2019. The GBC&#8217;s accounts are measured in its local currency (the Philippine peso) and then translated into U.S.&#160;dollars. All assets and liabilities denominated in foreign currency are translated using the current rate of exchange at the balance sheet date. Results of operations denominated in foreign currency are translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders&#8217; equity.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Revenues</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net operating revenues in the period in which we satisfy our performance obligations under contracts by transferring services to our customers. Net operating revenues are recognized in the amounts we expect to be entitled to, which are the transaction prices allocated for the distinct services. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact with Uninsured Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Patient Service Revenues&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third&#8209;party payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third&#8209;party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when (1)&#160;services are provided, and (2)&#160;we do not believe the patient requires additional services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our patient service performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in FASB Accounting Standards Codification (&#8220;ASC&#8221;) 606&#8209;10&#8209;50&#8209;14(a) and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments recognized for third&#8209;party payers, discounts provided to uninsured patients in accordance with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and estimated implicit price concessions related primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop&#8209;loss payments). Because Medicare requires that a hospital&#8217;s gross charges be the same for all patients (regardless of payer category), gross charges are what hospitals charge all patients prior to the application of discounts and allowances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the traditional fee&#8209;for&#8209;service (&#8220;FFS&#8221;) Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost&#8209;based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense reimbursement, which are based on our hospitals&#8217; cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule&#160;interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements with third&#8209;party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and our historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#8209;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#8217;s bill is subject to adjustment on a patient&#8209;by&#8209;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the years ended December&#160;31,&#160;2022, 2021 or 2020. In addition, on a corporate&#8209;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We know of no claims, disputes or unsettled matters with any payer that would materially affect our revenues for which we have not adequately provided in the accompanying Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, patients who are covered by third&#8209;party payers are responsible for related co&#8209;pays, co&#8209;insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co&#8209;pays, co&#8209;insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#8209;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self&#8209;pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such as: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients; the volume of patients through our emergency departments; the increased burden of co&#8209;pays, co&#8209;insurance amounts and deductibles to be made by patients with insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record implicit price concessions, primarily related to uninsured patients and patients with co&#8209;pays, co&#8209;insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co&#8209;pays, co&#8209;insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (&#8220;EMTALA&#8221;). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non&#8209;emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1)&#160;we are unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2)&#160;a&#160;determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3)&#160;under physician orders we provide services to patients that require immediate treatment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per&#8209;diem amount for services received, subject to a cap. Except for the per&#8209;diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Patient advocates from our Eligibility and Enrollment Services program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conifer Revenues&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment recognizes revenue from its contracts when Conifer&#8217;s performance obligations are satisfied, which is generally as services are rendered. Revenue is recognized in an amount that reflects the consideration to which Conifer expects to be entitled.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, Conifer assesses the services specified in its contracts with customers and identifies a performance obligation for each distinct contracted service. Conifer identifies the performance obligations and considers all the services provided under the contract. Conifer generally considers the following distinct services as separate performance obligations:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue cycle management services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">value&#8209;based care services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient communication and engagement services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consulting services; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other client&#8209;defined projects.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer&#8217;s contracts generally consist of fixed&#8209;price, volume&#8209;based or contingency&#8209;based fees. Conifer&#8217;s long&#8209;term contracts typically provide for Conifer to deliver recurring monthly services over a multi&#8209;year period. The contracts are typically priced such that Conifer&#8217;s monthly fee to its customer represents the value obtained by the customer in the month for those services. Such multi&#8209;year service contracts may have upfront fees related to transition or integration work performed by Conifer to set up the delivery for the ongoing services. Such transition or integration work typically does not result in a separately identifiable obligation; thus, the fees and expenses related to such work are deferred and recognized over the life of the related contractual service period. For contracts in which the amortization period of the asset is one year or less, we have elected to apply the practical expedient provided by FASB ASC 340&#8209;40&#8209;25&#8209;4 and expense these costs as incurred.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for fixed&#8209;priced contracts is typically recognized at the time of billing unless evidence suggests that the revenue is earned or Conifer&#8217;s obligations are fulfilled in a different pattern. Revenue for volume&#8209;based contracts is typically recognized as the services are being performed at the contractually billable rate, which is generally a percentage of collections or a percentage of client net patient revenue.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $858 million and $2.364 billion at December&#160;31,&#160;2022 and 2021, respectively. At December&#160;31,&#160;2022 and 2021, our book overdrafts were $266 million and $226 million, respectively, which were classified as accounts payable. At December&#160;31,&#160;2022 and 2021, $140 million and $188 million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our insurance&#8209;related subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, 2021 and 2020, we had $196 million, $95 million and $93&#160;million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $191&#160;million, $88&#160;million and $85&#160;million, respectively, were included in accounts payable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we acquired all of Baylor&#8217;s 5% voting ownership interest in USPI. We paid $11&#160;million from cash on hand and recognized a liability of $377&#160;million, the present value of the liability on the acquisition date, for the remainder of the purchase price. We recorded reductions in redeemable noncontrolling interest of $365&#160;million for the carrying value of Baylor&#8217;s ownership interest and $23&#160;million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares on the acquisition date. This has been reflected as noncash financing activity in the accompanying Consolidated Statement of Cash Flows for the year ended December&#160;31,&#160;2022. Payments made subsequent to the transaction&#8217;s close are reflected as cash activity within the financing section of our consolidated statements of cash flows. See Note&#160;18 for additional information about this transaction.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify investments in debt securities as either available&#8209;for&#8209;sale, held&#8209;to&#8209;maturity or as part of a trading portfolio. Our policy is to classify investments in debt securities that may be needed for cash requirements as &#8220;available&#8209;for&#8209;sale.&#8221; At December&#160;31,&#160;2022, we had no significant investments in debt securities classified as either held&#8209;to&#8209;maturity or trading. We carry debt securities classified as available&#8209;for&#8209;sale at fair value. We report their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss). We periodically evaluate available-for-sale securities in unrealized loss positions for credit impairment, using both qualitative and quantitative criteria. In the event a security is deemed to be impaired as the result of a credit loss, we record a loss in our consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry equity securities at fair value, and we report their unrealized gains and losses in other non-operating income, net, in our consolidated statements of operations. If the equity security does not have a readily determinable fair value, the carrying value of the security is adjusted only when there is a price change that is observable from a transaction of an identical or similar investment. We include realized gains or losses in our consolidated statements of operations based on the specific identification method.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Unconsolidated Affiliates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control 308 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (158 of 466 at December&#160;31,&#160;2022), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations. In the years ended December&#160;31,&#160;2021 and 2020, equity in earnings of unconsolidated affiliates included $14&#160;million and $17&#160;million, respectively, from PRF grants recognized by our Ambulatory Care segment&#8217;s unconsolidated affiliates. No additional revenue was recognized from PRF grants by unconsolidated affiliates during the year ended December&#160;31,&#160;2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information for equity method investees is included in the following table. For investments acquired during the reported periods, amounts below include 100% of the investee&#8217;s results beginning on the date of our acquisition of the investment.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(866)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to the investees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity method investment that contributed the most to our equity in earnings of unconsolidated affiliates during the years ended December&#160;31,&#160;2022, 2021 and 2020 was Texas Health Ventures Group, LLC (&#8220;THVG&#8221;), which is operated by USPI. THVG represented $89 million, $107&#160;million and $85&#160;million of total equity in earnings of unconsolidated affiliates of $216 million, $218&#160;million and $169&#160;million in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions and improvements to property and equipment exceeding established minimum amounts with a useful life greater than one year are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. We use the straight&#8209;line method of depreciation for buildings, building improvements and equipment. The estimated useful life for buildings and improvements is primarily 15 to 40 years, and for equipment <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b">three</span> to 15 years. Newly constructed hospitals are usually depreciated over 50 years. Interest costs related to construction projects are capitalized. In the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, capitalized interest was $8 million, $4 million and $5 million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long&#8209;lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of an impairment charge only if the carrying value of the long&#8209;lived assets exceeds their fair value. The fair value of the asset is estimated based on third&#8209;party appraisals, established market values of comparable assets or internally developed estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. Estimates require our subjective judgments and take into account assumptions about revenue and expense growth rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of asset and presume stable, improving or, in some cases, declining results, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report long&#8209;lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception of the contract. Our right&#8209;of&#8209;use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right&#8209;of&#8209;use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. We use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. For our Hospital Operations and Conifer segments, we estimate our incremental borrowing rates for our portfolio of leases using documented rates included in our recent equipment finance leases or, if applicable, recent secured debt issuances that correspond to various lease terms. We also give consideration to information obtained from our bankers, our secured debt fair value and publicly available data for instruments with similar characteristics. For our Ambulatory Care segment, we estimate an incremental borrowing rate for each center by </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing historical and projected financial data, estimating a hypothetical credit rating using publicly available market data and adjusting the market data to reflect the effects of collateralization.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are primarily for real estate, including off&#8209;campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. Our real estate lease agreements typically have initial terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8">five</span> to 10 years, and our equipment lease agreements typically have initial terms of three years. We do not record leases with an initial term of 12 months or less (short&#8209;term leases) in our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our real estate leases may include one or more options to renew, with renewals that can extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce">five</span> to 10 years. The exercise of lease renewal options is at our sole discretion. In general, we do not consider renewal options to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of our right&#8209;of&#8209;use assets and lease liabilities. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of our medical equipment leases have terms of three years with a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life, typically ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076">five</span> to seven years. Similarly, some of our leases of information technology and telecommunications assets include a transfer of title and, therefore, have useful lives of 15 years.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the right&#8209;of&#8209;use asset or liability balances. Our lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the practical expedient that allows lessees to choose to not separate lease and non&#8209;lease components by class of underlying asset and are applying this expedient to all relevant asset classes. We have also elected the practical expedient package to not reassess at adoption (1)&#160;expired or existing contracts for whether they are or contain a lease, (2)&#160;the lease classification of any existing leases or (3)&#160;initial indirect costs for existing leases.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of costs over the fair value of assets of businesses acquired. Goodwill and other intangible assets acquired in purchase business combinations and determined to have indefinite useful lives are not amortized, but instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level when events occur that require an evaluation to be performed or at least annually. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value. Estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consist of capitalized software costs, which are amortized on a straight&#8209;line basis over the estimated useful life of the software, which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e">three</span> to 15 years, costs of acquired management and other contract service rights, most of which have indefinite lives, and miscellaneous intangible assets.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accruals for General and Professional Liability Risks</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income/losses expected in future years;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The carryforward period associated with the deferred tax assets and liabilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&#160;the more likely than not recognition threshold is satisfied; (2)&#160;the position is ultimately settled through negotiation or litigation; or (3)&#160;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily operate acute care hospitals and related healthcare facilities. Our Hospital Operations segment generated 76%, 80% and 81% of our net operating revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Major decisions, including capital resource allocations, are made at the consolidated level, not at the market or hospital level. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs Associated with Exit or Disposal Activities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize costs associated with exit (including restructuring) or disposal activities when they are incurred and can be measured at fair value, rather than at the date of a commitment to an exit or disposal plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676381184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text">EQUITY<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our noncontrolling interests balances at December&#160;31,&#160;2022 and 2021 in the accompanying Consolidated Statements of Changes in Equity were comprised of $132 million and $128 million, respectively, from our Hospital Operations segment, and $1.185&#160;billion and $898 million, respectively, from our Ambulatory Care segment.&#160;Our net income attributable to noncontrolling interests for the years ended December&#160;31,&#160;2022, 2021 and 2020 were comprised of $21 million, $21 million and $14 million, respectively, from our Hospital Operations segment, and $221 million, $205 million and $169 million, respectively, from our Ambulatory Care segment.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;22,&#160;2022, we announced that our board of directors had authorized the repurchase of up to $1&#160;billion of our common stock through a share repurchase program that expires on December&#160;31,&#160;2024. Under the program, shares can be purchased in the open market or through privately negotiated transactions in a manner consistent with applicable securities laws </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations, including pursuant to a Rule 10b5-1 plan maintained by the Company, at times and in amounts based on market conditions and other factors.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes transactions completed under the repurchase program:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Dollar Value of Shares That May Yet be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception through October&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November&#160;1 through November&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;1 through December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inception through December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,889</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,889</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672692688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract', window );"><strong>Accounts Receivable Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">ACCOUNTS RECEIVABLE</a></td>
<td class="text">ACCOUNTS RECEIVABLE<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of accounts receivable are shown in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated future recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cost reports and settlements receivable and valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts that are pursued for collection through Conifer&#8217;s business offices are maintained on our hospitals&#8217; books and reflected in patient accounts receivable. Patient accounts receivable, including billed accounts and certain unbilled accounts, as well as estimated amounts due from third&#8209;party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. Estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital&#8217;s eligibility for Medicaid disproportionate share hospital payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in various provider fee programs, which help reduce the amount of uncompensated care from indigent patients and those covered by Medicaid. The following table summarizes the amount and classification of assets and liabilities in the accompanying Consolidated Balance Sheets related to California&#8217;s provider fee program:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated costs for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured patients</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity care patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt 0 13pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196816<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672692560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT BALANCES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">CONTRACT BALANCES</a></td>
<td class="text">CONTRACT BALANCES<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hospital Operations Segment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment&#8217;s contract assets were included in other current assets in the accompanying Consolidated Balance Sheets at December&#160;31,&#160;2022 or 2021. Approximately 88% of our Hospital Operations segment&#8217;s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, our Hospital Operations segment received advance payments from the MAPP following its expansion under the COVID Acts in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Hospital Operations segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract assets and contract liabilities, as well as their classification in our consolidated balance sheets, for our Hospital Operations segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ambulatory Care Segment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment also received advance payments from the MAPP following its expansion in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Ambulatory Care segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conifer Segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of Conifer&#8217;s receivables, contract asset, and current and long&#8209;term contract liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Asset &#8211;<br/>Unbilled Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Current<br/>Deferred Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Long-Term<br/>Deferred Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the opening and closing balances of Conifer&#8217;s contract assets and contract liabilities are primarily related to prepayments for those clients who are billed in advance, changes in estimates related to metric&#8209;based services, and up&#8209;front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment&#8217;s receivables and contract assets were reported as part of other current assets in the accompanying Consolidated Balance Sheets, and its current and long&#8209;term contract liabilities were reported as part of contract liabilities and contract liabilities&#160;&#8211;&#160;long&#8209;term, respectively, in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both of the years ended December&#160;31,&#160;2022 and 2021, Conifer recognized $56&#160;million of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those clients who are billed in advance, changes in estimates related to metric&#8209;based services, and up&#8209;front integration services that are recognized over the service period.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized amortization expense related to deferred contract setup costs of $4&#160;million in each of the years ended December&#160;31,&#160;2022, 2021 and 2020. At December&#160;31,&#160;2022 and 2021, the unamortized customer contract costs were $24&#160;million and $23&#160;million, respectively, and were presented as part of investments and other assets in the accompanying Consolidated Balance Sheets.</span></div>NET OPERATING REVENUES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.</span><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our sources of net operating revenues from continuing operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues from hospitals and related outpatient facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inter-segment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:0.1%"/><td style="width:2.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.646%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Primarily physician practices revenues.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for prior&#8209;year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020 by $10&#160;million, $26 million and $6&#160;million, respectively. Estimated cost report settlements and valuation allowances were included in accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Ambulatory Care segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Conifer segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes Conifer&#8217;s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume&#8209; or contingency&#8209;based contracts, variable&#8209;based escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer&#8217;s contract with Catholic Health Initiatives (&#8220;CHI&#8221;), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed&#8209;fee revenue related to remaining performance obligations. Conifer&#8217;s contract term with CHI ends December&#160;31,&#160;2032.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681230400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES HELD FOR SALE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">ASSETS AND LIABILITIES HELD FOR SALE</a></td>
<td class="text">ASSETS AND LIABILITIES HELD FOR SALE<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the sale of five Miami&#8209;area hospitals and certain related operations (the &#8220;Miami Hospitals&#8221;) held by our Hospital Operations segment in August&#160;2021, resulting in our recognition of a pre&#8209;tax gain on sale of $406 million in the year ended December&#160;31,&#160;2021. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June&#160;30, 2021, we completed the sale of the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments, and we also completed the separate sale of a Philadelphia&#8209;area building held by our Hospital Operations segment. We recorded a gain related to the sale of the urgent care centers of $14 million and a gain of $2 million related to the sale of the building in Philadelphia in 2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains related to the sales described above were included in net gains on sales, consolidation and deconsolidation of facilities in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2021. No impairment charge was incurred during the years ended December&#160;31,&#160;2022, 2021 or 2020 related to planned divestitures.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents amounts included in income from continuing operations, before income taxes, related to significant components of our business that were recently disposed of:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.72pt;text-indent:-6.73pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miami Hospitals (includes a $406 million gain on sale in 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681401696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract', window );"><strong>Restructuring Costs and Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS</a></td>
<td class="text">IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized impairment charges on long&#8209;lived assets in 2022, 2021 and 2020 because the fair values of those assets or groups of assets indicated that the carrying amount was not recoverable. The fair value estimates were derived from third&#8209;party appraisals, established market values of comparable assets, or internally developed estimates of future net cash flows. These fair value estimates can change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the future financial results of the facilities, how the facilities are operated in the future, changes in healthcare industry trends and regulations, and the nature of the ultimate disposition of the assets. In certain cases, these fair value estimates assume the highest and best use of facility assets in the future to a marketplace participant is other than as a medical facility. In these cases, the estimates are based on the fair value of the real property and equipment if utilized other than as a medical facility. The impairment recognized does not include the costs of closing the facilities or other future operating costs, which could be substantial. Accordingly, the ultimate net cash realized from the facilities, should we choose to sell them, could be significantly less than their impaired value.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility&#8217;s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our continuing operations consisted of three reportable segments &#8211; Hospital Operations, Ambulatory Care and Conifer.&#160;Our segments are reporting units used to perform our goodwill impairment analysis. We completed our annual impairment tests for goodwill as of October&#160;1,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost&#8209;effective structure, such as the establishment of support operations at our GBC. Certain restructuring and acquisition&#8209;related costs are based on estimates. Changes in estimates are recognized as they occur.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December&#160;31,&#160;2022</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we recorded impairment and restructuring charges and acquisition&#8209;related costs of $226&#160;million, consisting of $118&#160;million of restructuring charges, $94&#160;million of impairment charges and $14&#160;million of acquisition&#8209;related costs. Impairment charges included $82&#160;million for the write&#8209;down of certain buildings and medical equipment located in one of our markets to their estimated fair values, which assets are part of our Hospital Operations segment. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#8217; long&#8209;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included decreased revenues and lower patient volumes due to the pandemic and competition, as well as higher labor costs as a result of the pandemic. As a result, we updated the estimate of the fair value of the hospitals&#8217; long&#8209;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#8209;lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals&#8217; assets held and used for which impairment charges were recorded was $167&#160;million at December&#160;31,&#160;2022. Impairment charges for the year ended December&#160;31,&#160;2022 were comprised of $86&#160;million from our Hospital Operations segment, $6&#160;million from our Ambulatory Care segment and $2&#160;million from our Conifer segment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges consisted of $27&#160;million of employee severance costs, $16&#160;million related to the transition of various administrative functions to our GBC, $32&#160;million of contract and lease termination fees, and $43&#160;million of other restructuring costs. Acquisition&#8209;related costs consisted of $14&#160;million of transaction costs.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December&#160;31,&#160;2021</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021, we recorded impairment and restructuring charges and acquisition&#8209;related costs of $85 million, consisting of $57 million of restructuring charges, $8 million of impairment charges and $20 million of acquisition&#8209;related costs. Restructuring charges consisted of $14 million of employee severance costs, $19 million related to the transition of various administrative functions to our GBC and $24&#160;million of other restructuring costs. Our impairment charges for the year ended December&#160;31,&#160;2021, comprised of $5&#160;million from our Ambulatory Care segment and $3&#160;million from our Conifer segment, primarily consisted of charges to reduce the carrying value of certain management contract intangible assets held by our Ambulatory Care segment to their estimated fair value. Acquisition&#8209;related costs consisted of $20&#160;million of transaction costs.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December&#160;31,&#160;2020</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2020, we recorded impairment and restructuring charges and acquisition&#8209;related costs of $290 million, consisting of $92 million of impairment charges, $184 million of restructuring charges and $14 million of acquisition&#8209;related costs. Impairment charges included $76 million for the write&#8209;down of hospital buildings to their estimated fair values, which assets are part of our Hospital Operations segment. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#8217; long&#8209;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. As a result, we updated the estimate of the fair value of the hospitals&#8217; long&#8209;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#8209;lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals&#8217; assets held and used for which impairment charges were recorded was $483 million at December&#160;31,&#160;2020. We also recorded $16 million of other impairment charges. Restructuring charges consisted of $65 million of employee severance costs, $50 million related to the transitioning of various administrative functions to our GBC, $23 million of charges due to the termination of the USPI management equity plan, $14&#160;million of contract and lease termination fees, and $32&#160;million of other restructuring costs. Acquisition&#8209;related costs consisted of $14&#160;million of transaction costs. Our impairment charges for the year ended December&#160;31,&#160;2020 were comprised of $79&#160;million from our Hospital Operations segment, $12&#160;million from our Ambulatory Care segment and $1&#160;million from our Conifer segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681530448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our right&#8209;of&#8209;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1">Investments and other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost, less</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated depreciation and amortization</span></div></div></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and short term-lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average lease terms and discount rates for operating and finance leases are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow and other information related to leases is included in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31,&#160;2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $147 million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $69&#160;million from the sale of these buildings, included in other operating expenses, net in the accompanying Consolidated Statement of Operations, and we recognized right-of-use assets and operating lease obligations of $103&#160;million, in each case in the three months ended March&#160;31,&#160;2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our right&#8209;of&#8209;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1">Investments and other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost, less</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated depreciation and amortization</span></div></div></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and short term-lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average lease terms and discount rates for operating and finance leases are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow and other information related to leases is included in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31,&#160;2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $147 million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $69&#160;million from the sale of these buildings, included in other operating expenses, net in the accompanying Consolidated Statement of Operations, and we recognized right-of-use assets and operating lease obligations of $103&#160;million, in each case in the three months ended March&#160;31,&#160;2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677476832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-Term Debt and Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM DEBT</a></td>
<td class="text">LONG-TERM DEBT<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our long&#8209;term debt included in the accompanying Consolidated Balance Sheets:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750% due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.125% due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.875% due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured first lien notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% due July 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% due September 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.500% due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.875% due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.250% due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.125% due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured second lien notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.250% due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases, mortgages and other notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized issue costs and note discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes and Senior Unsecured Notes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2021, we redeemed approximately $1.100 billion of the then&#8209;outstanding $1.870&#160;billion aggregate principal amount of our 4.625% senior secured first lien notes due July 2024 (&#8220;July 2024 Senior Secured First Lien Notes&#8221;) in advance of their maturity date. We paid $1.113&#160;billion to redeem the notes, which was primarily funded with the proceeds from the sale of the Miami Hospitals in August&#160;2021. During the three months ended December&#160;31,&#160;2022, we repurchased an additional $14&#160;million of the aggregate remaining principal amount of our July 2024 Senior Secured First Lien Notes through multiple open&#8209;market transactions. In total, we paid $13&#160;million from cash on hand during the three&#8209;month period to repurchase the notes. In connection with these transactions, we recorded aggregate gains from early extinguishment of debt of less than $1&#160;million during the three months ended December&#160;31,&#160;2022, and a loss of $20&#160;million in the three months ended September&#160;30,&#160;2021. The loss recognized in 2021 primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31,&#160;2022, we also repurchased $11&#160;million of the then $600&#160;million aggregate principal amount outstanding of our 4.625% senior secured first lien notes due September 2024 in advance of their maturity date. We made aggregate payments of $11&#160;million from cash on hand through multiple open&#8209;market transactions to repurchase these notes. In connection with these repurchases, we recognized aggregate gains of less than $1&#160;million during the three months ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;15, 2022, we issued $2.000&#160;billion aggregate principal amount of 6.125% senior secured first lien notes, which will mature on June&#160;15, 2030 (the &#8220;2030&#160;Senior Secured First Lien Notes&#8221;). We pay interest on the 2030&#160;Senior Secured First Lien Notes semi&#8209;annually in arrears on June&#160;15 and December&#160;15 of each year, which payments commenced in December&#160;2022. As further discussed below, we used a substantial portion of the issuance proceeds from the 2030&#160;Senior Secured First Lien Notes, after payment of fees and expenses, to finance the redemption of our 6.750% senior unsecured notes due 2023 (the &#8220;2023&#160;Senior Unsecured Notes&#8221;).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a series of open&#8209;market transactions during the six months ended June&#160;30,&#160;2022, we repurchased $124&#160;million aggregate principal amount outstanding of our 2023&#160;Senior Unsecured Notes using cash on hand. Following the issuance of our 2030&#160;Senior Secured First Lien Notes, we used a substantial portion of the proceeds to redeem the then-remaining $1.748&#160;billion aggregate principal outstanding of the 2023&#160;Senior Unsecured Notes in advance of their maturity date. In total, we paid $1.933&#160;billion during the six months ended June&#160;30,&#160;2022 to retire all $1.872&#160;billion aggregate principal amount </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding of our 2023&#160;Senior Unsecured Notes, and we recorded aggregate losses from early extinguishment of debt of $71&#160;million, primarily related to the difference between the purchase prices and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;23, 2022, we redeemed all $700&#160;million aggregate principal amount outstanding of our 7.500% senior secured first lien notes due 2025 in advance of their maturity date. We paid $730&#160;million from cash on hand to redeem the notes. In connection with the redemption, we recorded a loss from early extinguishment of debt of $38&#160;million in the three months ended March&#160;31,&#160;2022, primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;1, 2021, we issued $1.450 billion aggregate principal amount of 4.375% senior secured first lien notes, which will mature on January&#160;15, 2030 (the &#8220;2030&#160;Senior Secured First Lien Notes&#8221;). We will pay interest on the 2030&#160;Senior Secured First Lien Notes semi&#8209;annually in arrears on January&#160;15 and July&#160;15 of each year, which payments commended in July&#160;2022. We used the net proceeds from the issuance of the 2030&#160;Senior Secured First Lien Notes, after payment of fees and expenses, to finance the acquisition of a group of ambulatory surgery centers in December 2021 and for general corporate purposes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;2, 2021, we issued $1.400&#160;billion aggregate principal amount of 4.250% senior secured first lien notes, which will mature on June&#160;1, 2029 (the &#8220;2029&#160;Senior Secured First Lien Notes&#8221;). We pay interest on the 2029&#160;Senior Secured First Lien Notes semi&#8209;annually in arrears on June&#160;1 and December&#160;1 of each year, which payments commenced in December 2021. The proceeds from the sale of the 2029&#160;Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $1.410 billion aggregate principal amount then outstanding of our 5.125% senior secured second lien notes due 2025 (the &#8220;2025 Senior Secured Second Lien Notes&#8221;) in advance of their maturity date for approximately $1.428 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $31&#160;million in the three months ended June&#160;30,&#160;2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we retired all $478&#160;million aggregate principal amount outstanding of our 7.000% senior unsecured notes due 2025 in advance of their maturity date. We paid approximately $495&#160;million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $23 million in the three months ended March&#160;31,&#160;2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#8209;off of associated unamortized issuance costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our senior secured notes are guaranteed by certain of our wholly owned domestic hospital company subsidiaries and secured by a pledge of the capital stock and other ownership interests of those subsidiaries on either a first lien or second lien basis, as indicated in the table above. All of our senior secured notes and the related subsidiary guarantees are our and the subsidiary guarantors&#8217; senior secured obligations. All of our senior secured notes rank equally in right of payment with all of our other senior secured indebtedness. Our senior secured notes rank senior to any subordinated indebtedness that we or such subsidiary guarantors may incur; they are effectively senior to our and such subsidiary guarantors&#8217; existing and future unsecured indebtedness and other liabilities to the extent of the value of the collateral securing the notes and the subsidiary guarantees; they are effectively subordinated to our and such subsidiary guarantors&#8217; obligations under our senior secured revolving credit facility (as&#160;amended to date, the &#8220;Credit Agreement&#8221;) to the extent of the value of the collateral securing borrowings thereunder; and they are structurally subordinated to all obligations of our non&#8209;guarantor subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures setting forth the terms of our senior secured notes contain provisions governing our ability to redeem the notes and the terms by which we may do so. At our option, we may redeem our senior secured notes, in whole or in part, at any time at a redemption price equal to 100% of the principal amount of the notes redeemed plus the make&#8209;whole premium set forth in the related indenture, together with accrued and unpaid interest thereon, if any, to the redemption date. Certain series of the senior secured notes may also be redeemed, in whole or in part, at certain redemption prices set forth in the applicable indentures, together with accrued and unpaid interest. In addition, we may be required to purchase for cash all or any part of each series of our senior secured notes upon the occurrence of a change of control (as defined in the applicable indentures) for a cash purchase price of 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our senior unsecured notes are general unsecured senior debt obligations that rank equally in right of payment with all of our other unsecured senior indebtedness, but are effectively subordinated to our senior secured notes described above, the obligations of our subsidiaries and any obligations under our Credit Agreement to the extent of the value of the collateral. We may redeem any series of our senior unsecured notes, in whole or in part, at any time at a redemption price equal </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to 100% of the principal amount of the notes redeemed, plus&#160;a make&#8209;whole premium specified in the applicable indenture, if any, together with accrued and unpaid interest to the redemption date.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement provides for revolving loans in an aggregate principal amount of up to $1.500 billion with a $200&#160;million subfacility for standby letters of credit. We amended our Credit Agreement in April 2020 to increase our borrowing availability in response to the COVID-19 pandemic. This amendment, among other things, (1)&#160;increased the aggregate revolving credit commitments from the previous limit of $1.500 billion to $1.900 billion (the &#8220;Increased Commitments&#8221;), subject to borrowing availability, and (2)&#160;increased the advance rate and raise limits on certain eligible accounts receivable in the calculation of the borrowing base, in each case, for an incremental period of 364&#160;days. In April 2021, we amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April&#160;2022 and reduce the interest rate margins. In March&#160;2022, we further amended our Credit Agreement to, among other things, (1)&#160;decrease the aggregate revolving credit commitments from the previous Increased Commitments to aggregate revolving credit commitments not to exceed $1.500&#160;billion, subject to borrowing availability, (2)&#160;extend the scheduled maturity date to March&#160;16,&#160;2027, and (3)&#160;replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) and Daily&#160;Simple&#160;SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At December&#160;31,&#160;2022, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.500&#160;billion was available for borrowing at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding revolving loans accrue interest depending on the type of loan at either (a)&#160;a base rate plus an applicable margin ranging from 0.25% to 0.75% per annum or (b)&#160;Term SOFR, Daily Simple SOFR or the Euro Interbank Offered Rate (EURIBOR) (each, as defined in the Credit Agreement) plus an applicable margin ranging from 1.25% to 1.75% per annum and (in the case of Term SOFR and Daily Simple SOFR only) a credit spread adjustment of 0.10%, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible inventory and accounts receivable, including self&#8209;pay accounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the Credit Agreement continue to be guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and secured by a first&#8209;priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letter of Credit Facility</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a letter of credit facility (as amended to date, the &#8220;LC Facility&#8221;) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200&#160;million. The scheduled maturity date of the LC Facility is September&#160;12,&#160;2024. Obligations under the LC Facility are guaranteed and secured by a first&#8209;priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal&#8209;ranking basis with our senior secured first lien notes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within three business days after notice thereof accrue interest at a base rate plus a margin of 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured&#8209;debt&#8209;to&#8209;EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit accrues at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. The LC Facility is subject to an effective maximum secured debt covenant of 4.25 to 1.00. At December&#160;31,&#160;2022, we had $116&#160;million of standby letters of credit outstanding under the LC&#160;Facility and were in compliance with all applicable covenants and conditions.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenants</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The indentures governing our senior secured notes contain covenants that, among other things, restrict our ability and the ability of our subsidiaries to incur liens, consummate asset sales, enter into sale and lease&#8209;back transactions or consolidate, merge or sell all or substantially all of our or their assets, other than in certain transactions between one or more of our wholly owned subsidiaries. These restrictions, however, are subject to a number of exceptions and qualifications. In particular, there are no restrictions on our ability or the ability of our subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities). In addition, the indentures governing our senior secured notes contain a covenant that neither we nor any of our </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries will incur secured debt, unless at the time of and after giving effect to the incurrence of such debt, the aggregate amount of all such secured debt (including the aggregate principal amount of senior secured notes outstanding and any outstanding borrowings under our Credit Agreement at such time) does not exceed the amount that would cause the secured debt ratio (as defined in the indentures) to exceed 4.00 to 1.00.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The indentures governing our senior unsecured notes contain covenants and conditions that have, among other requirements, limitations on (1)&#160;liens on &#8220;principal properties&#8221; and (2)&#160;sale and lease&#8209;back transactions with respect to principal properties. A principal property is defined in the senior unsecured notes indentures as a hospital that has an asset value on our books in excess of 5% of our consolidated net tangible assets, as defined in such indentures. The above limitations do not apply, however, to (1)&#160;debt that is not secured by principal properties or (2)&#160;debt that is secured by principal properties if the aggregate of such secured debt does not exceed 15%&#160;of our consolidated net tangible assets, as further described in the indentures. The senior unsecured notes indentures also prohibit the consolidation, merger or sale of all or substantially all assets unless no event of default would result after giving effect to such transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our Credit Agreement contains customary covenants for an asset&#8209;backed facility, including a minimum fixed charge coverage ratio to be met if the designated excess availability under the revolving credit facility falls below $150 million, as well as limits on debt, asset sales and prepayments of certain other debt. The Credit Agreement also includes a provision, which we believe is customary in receivables&#8209;backed credit facilities, that gives our lenders the right to require that proceeds of collections of substantially all of our consolidated accounts receivable be applied directly to repay outstanding loans and other amounts that are due and payable under the Credit Agreement at any time that unused borrowing availability under the revolving credit facility is less than $150 million for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODY4_dfdfd5fb-468c-4e0d-afdb-50499803685f">three</span> consecutive business days or if an event of default has occurred and is continuing thereunder. In that event, we would seek to re&#8209;borrow under the Credit Agreement to satisfy our operating cash requirements. Our ability to borrow under the Credit Agreement is subject to conditions that we believe are customary in revolving credit facilities, including that no events of default then exist.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Maturities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future long&#8209;term debt maturities, including finance lease obligations were as follows as of December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.658%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including finance lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676523888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GUARANTEES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">GUARANTEES</a></td>
<td class="text">GUARANTEES<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our policy on physician relocation and recruitment, we provide income guarantee agreements to certain physicians who agree to relocate to fill a community need in the service area of one of our hospitals and commit to remain in practice in the area for a specified period of time. Under such agreements, we are required to make payments to the physicians in excess of the amounts they earn in their practices up to the amount of the income guarantee. The income guarantee periods are typically 12 months. If a physician does not fulfill his or her commitment period to the community, which is typically three years subsequent to the guarantee period, we seek recovery of the income guarantee payments from the physician on a prorated basis. We also provide revenue collection guarantees to hospital&#8209;based physician groups providing certain services at our hospitals with terms generally ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkyNA_42d833b7-adcf-4193-8432-f964517997d1">one</span> to three years.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital&#8209;based physician groups providing certain services at our hospitals was $164 million. We had a total liability of $143 million recorded for these guarantees included in other current liabilities in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $102&#160;million. Of the total, $25&#160;million relates to the obligations of consolidated subsidiaries, which obligations were recorded in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI https://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636758331856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options and restricted stock units (&#8220;RSUs&#8221;) to certain of our employees and directors pursuant to our stock incentive plans. Stock options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years&#160;from the date of grant. An RSU is a contractual right to receive one share of our common stock in the future, and the fair value of the RSU is based on our share price on the grant date. Typically, stock options and time&#8209;based RSUs vest one&#8209;third on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_0c2fc9bb-b93d-4b06-840f-178792b3529d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_1d18318b-f1d8-462d-93f9-2c3eaf3de351">three</span></span> anniversary dates of the grant; however, certain special retention awards may have different vesting terms. Shares underlying vested RSUs are generally distributed to participants (settled) immediately after the vesting date. In addition, grants of RSUs to our non&#8209;employee directors as part of their annual compensation vest immediately and are settled on the third anniversary of the date of grant, while initial grants to directors vest immediately but settle upon separation from the board. Compensation cost is measured by the fair value of the awards on their grant dates and is recognized over the requisite service period of the awards, whether or not the awards had any intrinsic value during the period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also grant performance&#8209;based RSUs that vest subject to the achievement of specified performance goals within a specified time frame. The performance&#8209;based RSUs may contain provisions that increase or decrease the number of RSUs that ultimately vest, depending upon the level of achievement. For certain of our performance&#8209;based awards, the number of options or RSUs that ultimately vest is also subject to adjustment based on the achievement of a market&#8209;based condition. These adjustments generally range from 0% to 200% of the number of RSUs initially granted. The fair value of awards that contain a market&#8209;based condition is estimated using a discrete model to analyze the fair value of the subject shares. The discrete model utilizes multiple stock paths, through the use of a Monte Carlo simulation, which paths are then analyzed to determine the fair value of the subject shares.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our stock&#8209;based compensation plans, awards granted under the plan vest and may be exercised as determined by the human resources committee of our board of directors. In the event of a change in control, the human resources committee of our board of directors may, at its sole discretion without obtaining shareholder approval, accelerate the vesting or performance periods of the awards.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, assuming outstanding performance&#8209;based stock options and RSUs for which performance has not yet been determined will achieve target performance, approximately 9.5&#160;million shares of common stock were available under our 2019 Stock Incentive Plan for future stock option grants and other equity incentive awards, including RSUs. The accompanying Consolidated Statements of Operations include pre-tax compensation costs related to our stock&#8209;based compensation arrangements of $56&#160;million for each of the years ended December&#160;31,&#160;2022 and 2021, respectively, and $44&#160;million for the year ended December&#160;31,&#160;2020.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg<br/>Remaining Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock options were granted during the years ended December&#160;31,&#160;2022, 2021 or 2020. There were 60,051, 391,533 and 987,471 stock options exercised during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The stock options exercised in 2022 had an aggregate intrinsic value of approximately $4 million, and options exercised during 2021 and 2020 both had aggregate intrinsic values of approximately $15&#160;million. All outstanding options were vested and exercisable at December&#160;31,&#160;2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about our outstanding stock options at December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding and Exercisable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range&#160;of&#160;Exercise&#160;Prices&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise&#160;Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.99 to $20.609</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.61 to $35.430</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, 42.3% of all our outstanding options were held by current employees and 57.7% were held by former employees. All of our outstanding options were in&#8209;the&#8209;money, that is, they had exercise price less than the $48.79 market price of our common stock on December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs related to our stock-based compensation arrangements for the years ended December&#160;31,&#160;2021 and 2020 included $1 million and $2 million, respectively, of expense related to our stock options. We did not recognize any expense related to our stock options during the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Grant Date&#160;Fair<br/>Value&#160;Per&#160;Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310,296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,520,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, we granted an aggregate of 641,205&#160;RSUs. Of these, 237,381 will vest ratably over a three&#8209;year period from the grant date, 53,716 RSUs that were scheduled to vest ratably over 11 quarterly periods, 9,215 will vest ratably over a four&#8209;year period from the grant date, 4,608 will vest on the second anniversary of the grant date, and 6,170 will vest evenly on the third and fourth anniversaries of the grant date. We also granted 35,482&#160;RSUs to our non&#8209;employee directors for the 2022-2023 board service year, which units vested and will settle as described above. In November 2022, we granted 7,325 to a non-executive member of the board of directors for their service as chairman of the board through the end of 2023. Unlike our normal grants to board members, these RSUs will vest on December&#160;31,&#160;2023 if the grantee serves as chairman through that date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we granted 287,308&#160;performance&#8209;based RSUs during the year ended December&#160;31,&#160;2022; the vesting of these RSUs is contingent on our achievement of specified performance goals for the years 2022 to 2024. Provided the goals are achieved, the performance&#8209;based RSUs will vest on the third anniversary of the grant date. The actual number of performance&#8209;based RSUs that could vest will range from 0% to 200% of the 287,308&#160;units granted, depending on our level of achievement with respect to the performance goals.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021 we granted 561,788 RSUs that vest based on the passage of time. The granted RSUs vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">263,180 RSUs vest and settle ratably over a three&#8209;year period from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">189,215 RSUs vest and settle ratably over eight quarterly periods from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">53,341 RSUs vest and settle on the fourth anniversary of the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">33,351 RSUs vest and settle on the third anniversary of the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">14,192 RSUs vested on December&#160;31,&#160;2021 and settled in January 2022; and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">8,509 RSUs, one-third of which vest and settle on the second anniversary of the grant date and the remainder of which vest and settle on the fourth anniversary.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021 we granted 298,492 performance-based RSUs which vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">244,259 RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2023;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">53,341 RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2025; and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">892 RSUs vested and settled immediately as a result of our level of achievement with respect to performance&#8209;based RSUs granted in 2018.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual number of performance&#8209;based RSUs that could vest will range from 0% to 200% of the 297,600 RSUs which did not vest immediately, depending upon our level of achievement with respect to the performance goals. During the year ended December&#160;31,&#160;2021, we also granted 39,738 RSUs to our non&#8209;employee directors. These consisted of 36,681 RSUs for the 2021&#8209;2022 board service year, 1,372 for an initial grant to a new member of our board of directors and 1,685 for a pro&#8209;rata annual grant to the same new member. While RSUs granted to our board of directors vest immediately, annual grants settle on the third anniversary of the grant date and initial grants settle upon separation from the board.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2020 we granted 1,084,883 RSUs that vest based on the passage of time. The granted RSUs vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">607,198 RSUs vest and settle ratably over a three&#8209;year period from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">359,713 RSUs vest and settle ratably over 11 quarterly periods from the grant date;</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">104,167 RSUs vest and settle ratably over a four-year period from the grant date; and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">13,805 RSUs vest and settle on the third anniversary of the grant date.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2020 we granted 579,413 performance-based RSUs which vest as follows:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">499,285 RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2022 and</span></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">80,128 RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2023, all of which were subsequently forfeited.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual number of performance&#8209;based RSUs that could vest will range from 0% to 200% of the 499,285 remaining RSUs granted, depending upon our level of achievement with respect to the performance goals. In May&#160;2020, we made an annual grant of 103,434 RSUs to our non&#8209;employee directors for the 2020-2021 board service year, which units vested immediately and will settle in shares of our common stock on the third anniversary of the date of the grant.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the aforementioned aggregate numbers of time-based RSUs granted in 2022, 2021 and 2020 were 53,716, 189,215 and 359,713 RSUs, respectively, awarded to our former Executive Chairman. The RSUs granted in 2022 and 2020 were each scheduled to vest ratably over 11 quarterly periods, while the RSUs granted in 2021 were schedule to vest ratably over eight quarterly periods. Additionally, in the aforementioned aggregate number of performance-based RSUs granted in 2022 were 53,716 RSUs awarded to our former Executive Chairman. The unvested portion of these grants vested in October&#160;2022 in accordance with the disability provisions of the stock incentive plan.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs related to our stock-based compensation arrangements for the years ended December&#160;31,&#160;2022, 2021 and 2020 included $45 million, $42 million and $30 million of expense related to our RSUs, respectively. At December&#160;31,&#160;2022, there were $33 million of total unrecognized compensation costs related to RSUs. These costs are expected to be recognized over a weighted average period of 1.8 years.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of the performance-based RSU grants, the number of units that will ultimately vest is subject to adjustment based on the achievement of a market-based condition. The fair value of these RSUs is estimated through the use of a Monte Carlo simulation. Significant inputs used in our valuation of these RSUs included the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6% - 68.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2% - 79.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0% - 1.7% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 0.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2%</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USPI Management Equity Plan</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 USPI Management Equity Plan</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, USPI adopted the USPI Holding Company, Inc. 2015 Stock Incentive Plan (&#8220;2015 USPI Management Equity Plan&#8221;) under which it granted non-qualified options to purchase nonvoting shares of USPI&#8217;s outstanding common stock to eligible plan participants, allowing the recipient to participate in incremental growth in the value of USPI from the applicable grant date. Under the 2015 USPI Management Equity Plan, the total pool of options consisted of approximately 10% of USPI&#8217;s fully diluted outstanding common stock. Options had an exercise price equal to the estimated fair market value of USPI&#8217;s common stock on the date of grant. The option awards were structured such that they had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg0Mzg_74a46396-62a0-44d1-87da-e5a77de5ca2f">three</span> or four year vesting period in which half of the award vested in equal pro-rata amounts over the applicable vesting period and the remaining half vested at the end of the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg2MjE_fd2aa8ae-54d5-4b8a-b36d-1b3d0bc214ae">three</span> or four year period. Any unvested awards were forfeited upon the participant&#8217;s termination of service with USPI, and vested options were required to have been exercised within 90 days of termination. Once an award was exercised and the requisite holding period met, the participant was eligible to sell the underlying shares to USPI at their estimated fair market value. Payment for USPI&#8217;s purchase of any eligible nonvoting common shares could be made in cash or in shares of Tenet&#8217;s common stock.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the 2015 USPI Management Equity Plan and all unvested options granted under the plan were terminated in accordance with the terms of the plan. USPI repurchased all vested options and all shares of USPI stock acquired upon exercise of an option for approximately $35&#160;million.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 USPI Management Equity Plan</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, USPI adopted the USPI Holding Company, Inc. Restricted Stock Plan (&#8220;USPI Management Equity Plan&#8221;) to replace the terminated 2015 USPI Management Equity Plan. Under the USPI Management Equity Plan, USPI grants RSUs representing a contractual right to receive one share of USPI&#8217;s non&#8209;voting common stock in the future. The vesting of RSUs granted under the plan varies based on the terms of the underlying award agreement. Once the requisite holding period is met, during specified times, the participant can sell the underlying shares to USPI at their estimated fair market value. At our sole discretion, the purchase of any non&#8209;voting common shares can be made in cash or in shares of Tenet&#8217;s common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity under USPI&#8217;s management equity plan during the years ended December&#160;31,&#160;2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Grant Date&#160;Fair<br/>Value&#160;Per&#160;Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception of Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,588)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">922,840</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPI did not make any grants under the USPI Management Equity Plan during the year ended December&#160;31,&#160;2022. During the year ended December&#160;31,&#160;2021, USPI granted 76,990 RSUs under its management equity plan. Twenty&#160;percent of these RSUs vests on each of the first and second anniversaries of the grant date, and the remaining 60% vests on the third </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary of the grant date. In 2020, USPI granted 2,556,333 RSUs, 20% of which vest in each of the first three&#160;years on the anniversary of the grant date with the remaining 40% vesting on the fourth anniversary of the grant date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2022 and 2021, USPI paid $11 million and $9 million, respectively, to repurchase portions of the non&#8209;voting common stock shares issued under the USPI management equity plan. No shares were repurchased during the year ended December&#160;31,&#160;2020. At December&#160;31,&#160;2022, there were 98,374 outstanding vested shares of non&#8209;voting common stock eligible to be sold to USPI.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, 922,840 RSUs were outstanding under USPI&#8217;s management equity plan, all of which are expected to vest. The accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020 included $11 million, $13 million and $12 million, respectively, of pre-tax compensation costs related to USPI&#8217;s management equity plans.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee stock purchase plan under which we are currently authorized to issue up to 4,070,363 shares of common stock to our eligible employees. As of December&#160;31,&#160;2022, there were approximately 2.6&#160;million&#160;shares available for issuance under our employee stock purchase plan. Under the terms of the plan, eligible employees may elect to have between 1%&#160;and 10% of their base earnings withheld each quarter to purchase shares of our common stock. Shares are purchased at a price equal to 95% of the closing price on the last day of the quarter. The plan requires a one&#8209;year holding period for all shares issued. The holding period does not apply upon termination of employment. Under the plan, no individual may purchase, in any year, shares with a fair market value in excess of $25,000. The plan is currently not considered to be compensatory.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued the following numbers of shares under our employee stock purchase plan:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Retirement Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our employees, upon qualification, are eligible to participate in our defined contribution 401(k)&#160;plans. Under the plans, employees may contribute a portion of their eligible compensation, which we may match with employer contributions at our discretion. Employer matching contributions will vary depending on which of our subsidiaries employs the participant and whether the employee is covered under a collective bargaining agreement. Plan expenses, primarily related to our contributions to the plans, were $86 million, $98 million and $119 million for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively. Such amounts are reflected in salaries, wages and benefits in the accompanying Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain three frozen non&#8209;qualified defined benefit pension plans (&#8220;SERPs&#8221;) that provide supplemental retirement benefits to certain of our current and former executives. These plans are not funded, and plan obligations for these plans are paid from our working capital. Pension benefits are generally based on years of service and compensation. Upon completing the acquisition of Vanguard Health Systems, Inc. on October&#160;1,&#160;2013, we assumed a frozen qualified defined benefit plan (&#8220;DMC Pension Plan&#8221;) covering substantially all of the employees of our Detroit market that were hired prior to June&#160;1,&#160;2003. The benefits paid under the DMC Pension Plan are primarily based on years of service and final average earnings. During the year ended December&#160;31,&#160;2019, the Society of Actuaries issued a new mortality base table (Pri&#8209;2012), which we incorporated into the estimates of our defined benefit plan obligations beginning December&#160;31,&#160;2019. During the year ended December 31,&#160;2020, the Society of Actuaries issued the MP-2020 mortality improvement scale, which we incorporated into the estimates of our defined benefit plan obligations at December 31,&#160;2020. During the year ended December 31,&#160;2021, the Society of Actuaries issued the MP&#8209;2021 mortality improvement scale, which we incorporated into the estimates of our defined benefit plan obligations at December&#160;31,&#160;2022 and&#160;2021.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet impact, as well as the benefit obligations, funded status and rate assumptions associated with the SERPs and the DMC Pension Plan based on actuarial valuations prepared:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,002)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plans assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status of plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(354)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(446)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The accumulated benefit obligation at December&#160;31,&#160;2022 and 2021 was approximately $1.002 billion and $1.311 billion, respectively.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the Consolidated Balance Sheets consist of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SERP Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMC Pension Plan Assumptions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit costs and related assumptions are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SERP Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Census date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMC Pension Plan Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term rate of return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Census date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the current year are based on assumptions determined at the valuation date of the prior year for the SERPs and the DMC Pension Plan.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded gain (loss) adjustments of $72&#160;million, $61 million and $(32)&#160;million in other comprehensive income in the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, to recognize changes in the funded status of our SERPs and the DMC Pension Plan. Changes in the funded status are recorded as a direct increase or decrease to shareholders&#8217; equity through accumulated other comprehensive loss. Net actuarial gains (losses) of $63&#160;million, $50&#160;million and $(41)&#160;million were recognized during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, and the amortization of net actuarial loss of $9&#160;million, $11&#160;million and $9&#160;million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively, were recognized in other comprehensive income. Actuarial gains affecting the benefit obligation during the years ended December&#160;31,&#160;2022, 2021 and 2020 are primarily attributable to changes in the discount rate utilized for the SERP and DMC Pension Plan. Cumulative net actuarial losses totaled $222 million, $294&#160;million and $355 million as of December&#160;31,&#160;2022, 2021 and 2020, respectively. There were no unrecognized prior service costs at December&#160;31,&#160;2022, 2021 and 2020 that had not yet been recognized as components of net periodic benefit cost.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop the expected long&#8209;term rate of return on plan assets assumption, the DMC Pension Plan considers the current level of expected returns on risk&#8209;free investments (primarily government bonds), the historical level of risk premium associated with the other asset classes in which the portfolio is invested and the expectations for future returns on each asset class. The expected return for each asset class is then weighted based on the target asset allocation to develop the expected long&#8209;term rate of return on assets assumption for the portfolio.</span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average asset allocations by asset category as of December&#160;31,&#160;2022, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DMC Pension Plan assets are invested in public commingled vehicles, segregated separately managed accounts, and private commingled vehicles, all of which are managed by professional investment management firms. The objective for all asset categories is to maximize total return without assuming undue risk exposure. The DMC Pension Plan maintains a well&#8209;diversified asset allocation that meets these objectives. The DMC Pension Plan assets are largely comprised of cash and cash equivalents, including but not limited to money market funds and repurchase agreements secured by U.S. Treasury or federal agency obligations, equity securities, including but not limited to the publicly traded shares of U.S. companies with various market capitalizations in addition to international and convertible securities, debt securities including, but not limited to, </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">domestic and foreign government obligations, corporate bonds, and mortgage&#8209;backed securities, and alternative investments. Alternative investments is a broadly defined asset category with the objective of diversifying the overall portfolio, complementing traditional equity and fixed&#8209;income securities and improving the overall performance consistency of the portfolio. Alternative investments may include, but are not limited to, diversified hedge funds in the form of professionally managed pooled limited partnership investments and investments in private markets via professionally managed pooled limited partnership interests.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each investment account, the DMC Pension Plan investment managers are responsible for monitoring and reacting to economic indicators, such as gross domestic product, consumer price index and U.S. monetary policy that may affect the performance of their account. The performance of all managers and the aggregate asset allocation are formally reviewed on a quarterly basis. The current asset allocation objective is to maintain a certain percentage within each asset class allowing for deviation within the established range for each asset class. The portfolio is rebalanced on an as&#8209;needed basis to keep these allocations within the accepted ranges.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as quoted prices for similar assets, interest rates and yield curves. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the DMC Pension Plan assets measured at fair value on a recurring basis as of December&#160;31,&#160;2022 and 2021, aggregated by the level in the fair value hierarchy within which those measurements are determined.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future benefit payments to be made from the SERPs and the DMC Pension Plan, a portion of which will be funded from plan assets, for the next five years and in the aggregate for the five years thereafter:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.975%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending&#160;December&#160;31,&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Five Years Thereafter</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The SERP and DMC Pension Plan obligations of $354&#160;million at December&#160;31,&#160;2022 are classified in the accompanying Consolidated Balance Sheet as an other current liability of $23 million and defined benefit plan obligations of $331&#160;million based on an estimate of the expected payment patterns. We expect to make total contributions to the plans of approximately $23&#160;million for the year ending December&#160;31,&#160;2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675734128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of property and equipment are shown in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,663&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net property and equipment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation and amortization and impairment write&#8209;downs related to assets held and used. We recognized depreciation expense of $669 million, $667 million and $685 million in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677704656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND OTHER INTANGIBLE ASSETS<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year and purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill transferred from Ambulatory Care segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill related to assets held for sale and disposed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at end of period:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year and purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill transferred to Hospital Operations segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill related to assets held for sale and disposed or deconsolidated facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accumulated impairment losses related to the goodwill in our Ambulatory Care and Conifer segments at December&#160;31,&#160;2022 and 2021.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information regarding other intangible assets:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,428)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,424</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets with indefinite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,374)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future amortization of intangibles with finite useful lives as of December&#160;31,&#160;2022 was as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized amortization expense of $172&#160;million, $188 million and $172 million in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676632464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">OTHER ASSETS</a></td>
<td class="text">OTHER ASSETS<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of other current assets in the accompanying Consolidated Balance Sheets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California provider fee program receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from other government programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guarantees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-patient receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of investments and other assets in the accompanying Consolidated Balance Sheets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments in unconsolidated healthcare entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California provider fee program receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term receivables and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments and other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,147</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676494432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated other comprehensive loss was comprised of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for defined benefit plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) allocated to the adjustments for our defined benefit plans and unrealized gains on investments were approximately&#160;$18&#160;million and $(1)&#160;million, respectively, for the year ended December&#160;31,&#160;2022, and the income tax expense allocated to the adjustments for our defined benefit plans was $14&#160;million for the year ended December&#160;31,&#160;2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676494432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET OPERATING REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">NET OPERATING REVENUES</a></td>
<td class="text">CONTRACT BALANCES<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hospital Operations Segment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment&#8217;s contract assets were included in other current assets in the accompanying Consolidated Balance Sheets at December&#160;31,&#160;2022 or 2021. Approximately 88% of our Hospital Operations segment&#8217;s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, our Hospital Operations segment received advance payments from the MAPP following its expansion under the COVID Acts in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Hospital Operations segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract assets and contract liabilities, as well as their classification in our consolidated balance sheets, for our Hospital Operations segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ambulatory Care Segment</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment also received advance payments from the MAPP following its expansion in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Ambulatory Care segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conifer Segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of Conifer&#8217;s receivables, contract asset, and current and long&#8209;term contract liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Asset &#8211;<br/>Unbilled Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Current<br/>Deferred Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Long-Term<br/>Deferred Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the opening and closing balances of Conifer&#8217;s contract assets and contract liabilities are primarily related to prepayments for those clients who are billed in advance, changes in estimates related to metric&#8209;based services, and up&#8209;front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment&#8217;s receivables and contract assets were reported as part of other current assets in the accompanying Consolidated Balance Sheets, and its current and long&#8209;term contract liabilities were reported as part of contract liabilities and contract liabilities&#160;&#8211;&#160;long&#8209;term, respectively, in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both of the years ended December&#160;31,&#160;2022 and 2021, Conifer recognized $56&#160;million of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those clients who are billed in advance, changes in estimates related to metric&#8209;based services, and up&#8209;front integration services that are recognized over the service period.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized amortization expense related to deferred contract setup costs of $4&#160;million in each of the years ended December&#160;31,&#160;2022, 2021 and 2020. At December&#160;31,&#160;2022 and 2021, the unamortized customer contract costs were $24&#160;million and $23&#160;million, respectively, and were presented as part of investments and other assets in the accompanying Consolidated Balance Sheets.</span></div>NET OPERATING REVENUES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.</span><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our sources of net operating revenues from continuing operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues from hospitals and related outpatient facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inter-segment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:0.1%"/><td style="width:2.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.646%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Primarily physician practices revenues.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for prior&#8209;year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020 by $10&#160;million, $26 million and $6&#160;million, respectively. Estimated cost report settlements and valuation allowances were included in accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Ambulatory Care segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Conifer segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes Conifer&#8217;s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume&#8209; or contingency&#8209;based contracts, variable&#8209;based escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer&#8217;s contract with Catholic Health Initiatives (&#8220;CHI&#8221;), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed&#8209;fee revenue related to remaining performance obligations. Conifer&#8217;s contract term with CHI ends December&#160;31,&#160;2032.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636758271072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INSURANCE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract', window );"><strong>Property and Professional and General Liablity Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock', window );">INSURANCE</a></td>
<td class="text">INSURANCE<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property Insurance</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April&#160;1, 2022 through March 31, 2023, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub&#8209;limits of $100 million for floods, $200&#160;million for earthquakes and a per&#8209;occurrence sub&#8209;limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values up to a maximum of $25 million for California earthquakes, $25 million for floods and named windstorms, and 2% of insured values for New Madrid fault earthquakes, with a maximum per&#8209;claim deductible of $25&#160;million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $5 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also purchase cyber liability insurance from third parties. In April&#160;2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information (the &#8220;Cybersecurity Incident&#8221;). We estimate that the Cybersecurity Incident had an adverse pre&#8209;tax impact of approximately $100&#160;million during the year ended December&#160;31,&#160;2022. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have filed a claim within our policy limits. Insurance recoveries of $14&#160;million related to this claim were received during the year ended December&#160;31,&#160;2022, $6&#160;million of which were recorded as net operating revenues.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional and General Liability Reserves</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are self&#8209;insured for the majority of our professional and general liability claims, and we purchase insurance from third&#8209;parties to cover catastrophic claims. At both December&#160;31,&#160;2022 and 2021, the aggregate current and long&#8209;term professional and general liability reserves in the accompanying Consolidated Balance Sheets was $1.045 billion. These reserves include the reserves recorded by our captive insurance subsidiaries and our self&#8209;insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial insurance we purchase is subject to per&#8209;claim and policy period aggregate limits. If the policy period aggregate limit of any of our policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay other material claims applicable to that policy period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malpractice expense of $276 million, $355 million and $320 million was included in other operating expenses, net, in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, of which $74&#160;million, $131&#160;million and $120&#160;million, respectively, related to adverse claims development for prior years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This entire disclosure represents information pertaining to property and professional and general liability insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636758271072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CLAIMS AND LAWSUITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CLAIMS AND LAWSUITS</a></td>
<td class="text">CLAIMS AND LAWSUITSWe operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or &#8220;whistleblower&#8221; lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment&#8209;related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties associated with these matters, especially those involving governmental agencies, and the indeterminate damages sought in some cases, we are unable to predict the ultimate liability we may incur from these matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Investigation of Detroit Medical Center</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detroit Medical Center (&#8220;DMC&#8221;) is subject to an ongoing investigation commenced in October&#160;2017 by the U.S.&#160;Attorney&#8217;s Office for the Eastern District of Michigan and the Civil Division of the U.S. Department of Justice (&#8220;DOJ&#8221;) for potential violations of the Stark law, the Medicare and Medicaid anti&#8209;kickback and antifraud and abuse amendments codified under Section 1128B(b) of the Social Security Act, and the federal False Claims Act related to DMC&#8217;s employment of nurse practitioners and physician assistants (&#8220;Mid&#8209;Level Practitioners&#8221;) from 2006 through 2017. As previously disclosed, a media report was published in August&#160;2017 alleging that 14&#160;Mid&#8209;Level Practitioners were terminated by DMC earlier in 2017 due to compliance concerns. The DOJ issued a civil investigative demand to DMC for documents and interrogatories in September&#160;2021. In January&#160;2023, we reached a settlement in principle with the DOJ to resolve this matter, subject to certain conditions, and were fully reserved for such potential settlement at December&#160;31,&#160;2022.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, certain of the entities that purchased the operations of Hahnemann University Hospital and St.&#160;Christopher&#8217;s Hospital for Children in Philadelphia from us commenced Chapter&#160;11 bankruptcy proceedings. In the three months ended December&#160;31,&#160;2021, we established a reserve of $23&#160;million for certain obligations related to the sale of the hospitals and the subsequent bankruptcy proceedings of the buyers. In the six months ended June&#160;30,&#160;2022, we made advance payments of approximately $1&#160;million. In the three months ended September&#160;30,&#160;2022, the bankruptcy court approved a final settlement among the parties, and we made the remaining $22&#160;million in payments to fully resolve this matter.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor and privacy laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New claims or inquiries may be initiated against us from time to time. These matters could (1)&#160;require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2)&#160;cause us to incur substantial expenses, (3)&#160;require significant time and attention from our management, and (4)&#160;cause us to close or sell hospitals or otherwise modify the way we conduct business.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances&#160;at<br/>Beginning<br/>of&#160;Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Litigation&#160;and<br/>Investigation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash<br/>Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances&#160;at<br/>End&#160;of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636797187408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES</a></td>
<td class="text">REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our put/call agreement (the &#8220;Baylor Put/Call Agreement&#8221;) with Baylor contained put and call options with respect to the 5% ownership interest Baylor held in USPI until June&#160;30,&#160;2022. The Baylor Put/Call Agreement gave Baylor the option to annually put up to one-third of its total shares in USPI (the &#8220;Baylor Shares&#8221;) over a period of three years beginning in 2021. We had the right to call the difference between the number of shares Baylor put each year and the maximum number of shares it could have put. Based on the nature of the Baylor Put/Call Agreement, Baylor&#8217;s minority interest in USPI was classified as a redeemable noncontrolling interest in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2021. During the years ended December&#160;31,&#160;2022 and 2021, we recognized accretion totaling $102&#160;million and $8&#160;million, respectively, and a corresponding decrease in additional paid-in capital related to Baylor&#8217;s minority interest in USPI.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares for that year (66.6% in total). In June 2022, we entered into an agreement with Baylor (the &#8220;Share Purchase Agreement&#8221;) to complete the purchase of the Baylor Shares we called in 2021 and 2022 and to accelerate the acquisition of the remaining Baylor Shares eligible to be put/called in 2023. Under the terms of the Share Purchase Agreement, we agreed to pay Baylor $406&#160;million to buy its entire 5% voting ownership interest in USPI. We paid $11&#160;million upon execution of the Share Purchase Agreement and are obligated to make 35 additional non-interest bearing monthly payments of approximately $11&#160;million, which payments commenced in August&#160;2022. We recorded the present value of the purchase price as a liability on our balance sheet, with an offset to redeemable noncontrolling interest of $365&#160;million for the carrying amount of the shares and $23&#160;million to additional paid&#8209;in capital for the difference between the carrying value and present value of the purchase price for the shares. At December&#160;31,&#160;2022, we had liabilities of $135&#160;million recorded in other current liabilities and $190&#160;million in other long-term liabilities in the accompanying Consolidated Balance Sheet for the purchase of these shares.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases and sales of businesses and noncontrolling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at end of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676520368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for continuing operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the amount of reported income tax expense (benefit) and the amount computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is presented below. Foreign pre-tax loss was $8 million, $5 million and $13 million for the years ended December&#160;31,&#160;2022, 2021 and&#160;2020, respectively.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory federal rate of 21%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired charitable contribution carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior-year provision to return adjustments and other changes in deferred&#160;taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the business interest expense disallowance rules took effect in 2022, resulting in a larger amount of interest disallowance compared to prior years. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID Acts included a significant number of tax provisions applicable to individuals and businesses. For businesses, the COVID Acts made changes to the U.S. tax code relating to, among other things: (1) the business interest expense disallowance rules for 2019 and 2020; (2) net operating loss rules; (3) charitable contribution limitations; and (4) the realization of corporate alternative minimum tax credits. As a result of the change in the business interest expense disallowance rules, we recorded an income tax benefit of $88 million during the year ended December&#160;31,&#160;2020 to decrease the valuation allowance for interest expense carryforwards due to the additional deduction of interest expense.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we filed an application with the Internal Revenue Service (&#8220;IRS&#8221;) to change our method of accounting for certain capitalized costs on our 2019 tax return. This change in tax accounting method resulted in additional interest expense being allowed on the 2019 and 2020 tax returns. We reduced our valuation allowance by an additional $126&#160;million in the year ended December&#160;31,&#160;2020 related to the change in accounting method.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. The following table discloses those significant components of our deferred tax assets and liabilities, including any valuation allowance:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and fixed-asset differences</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves related to discontinued operations and restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables (doubtful accounts and adjustments)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare advance payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for retained insurance risks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use lease assets and obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,358</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the deferred tax assets and liabilities and the corresponding amounts reported in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(198)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, the valuation allowance increased by $120&#160;million, including an increase of $123&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $2 million due to changes in the expected realizability of deferred tax assets. The balance in the valuation allowance as of December&#160;31,&#160;2022 was $177 million. During the year ended December&#160;31,&#160;2021, the valuation allowance increased by $2 million, including an increase of $2&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $2&#160;million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $2&#160;million due to changes in the expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December&#160;31,&#160;2021 was $57 million. During the year ended December&#160;31,&#160;2020, the valuation allowance decreased by $226 million, including a decrease of $211 million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $14 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance as of December&#160;31,&#160;2020 was $55&#160;million. Deferred tax assets relating to interest expense limitations under Internal Revenue Code Section 163(j) have a full valuation allowance because the interest expense carryovers are not expected to be utilized in the foreseeable future.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with FASB ASC 740-10-25, which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The following table summarizes the total changes in unrecognized tax benefits in continuing operations during the years ended December&#160;31,&#160;2022, 2021 and 2020. There were no such changes in discontinued operations. The additions and reductions for tax positions include the impact of items for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductions. Such amounts include unrecognized tax benefits that have impacted deferred tax assets and liabilities at December&#160;31,&#160;2022, 2021 and 2020.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:85.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to a lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to a lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to tax positions taken in prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits as of December&#160;31,&#160;2022 was $34&#160;million, of which $32&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December&#160;31,&#160;2022, there was no change in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December&#160;31,&#160;2021 was $34&#160;million, of which $32&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. Income tax expense in the year ended December&#160;31,&#160;2021 included expense of $3&#160;million in continuing operations attributable to an increase in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December&#160;31,&#160;2020 was $31&#160;million, of which $29&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December&#160;31,&#160;2020, there was no change in our estimated liabilities for uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Approximately $1 million of interest and penalties related to accrued liabilities for uncertain tax positions are included in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2022. Total accrued interest or penalties on unrecognized tax benefits as of December&#160;31,&#160;2022 was $1 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS has completed audits of our tax returns for all tax years ended on or before December&#160;31,&#160;2007. All disputed issues with respect to these audits have been resolved and all related tax assessments (including interest) have been paid. Our tax returns for years ended after December&#160;31,&#160;2007 and USPI&#8217;s tax returns for years ended after December&#160;31,&#160;2018 remain subject to audit by the IRS.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, no significant changes in unrecognized federal and state tax benefits are expected in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, our carryforwards available to offset future taxable income consisted of (1)&#160;federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $100 million pre&#8209;tax, $40 million of which expires in 2024 to 2037 and $60 million of which has no expiration date, (2) charitable contribution carryforwards of approximately $45&#160;million expiring in 2025 through 2027 and (3)&#160;state NOL carryforwards of approximately $3.106&#160;billion expiring in 2023 through 2042 for which the associated deferred tax benefit, net of valuation allowance and federal tax impact, is $42&#160;million. Our ability to utilize NOL carryforwards to reduce future taxable income may be limited under Section&#160;382 of the Internal Revenue Code if certain ownership changes in our company occur during a rolling three&#8209;year period. These ownership changes include purchases of common stock under share repurchase programs, the offering of stock by us, the purchase or sale of our stock by 5%&#160;shareholders, as defined in the Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5%&#160;shareholders result in aggregate increases that exceed 50 percentage points during the three&#8209;year period, then Section&#160;382 imposes an annual limitation on the amount of our taxable income that may be offset by the NOL&#160;carryforwards or tax credit carryforwards at the time of ownership change.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636758331856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER COMMON SHARE</a></td>
<td class="text">EARNINGS PER COMMON SHARE<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in&#160;millions and weighted average shares are expressed in thousands.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Available to Common Shareholders (Numerator)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Shares<br/>(Denominator)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per-Share<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units and deferred compensation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units and deferred compensation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted loss per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, our convertible instruments consisted of an agreement related to the ownership interest in a Hospital Operations segment joint venture and RSUs issued under the USPI Management Equity Plan. Prior to our purchase of all of the shares underlying the Baylor Put/Call Agreement in June&#160;2022, that agreement was also included in our convertible instruments. Additional information about the RSUs issued under the USPI Management Equity Plan and our purchase of the shares underlying the Baylor Put/Call Agreement is included in Notes 10 and 18, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636758190112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non&#8209;financial assets and liabilities. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Recurring Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non&#8209;financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long&#8209;lived assets held and used, long&#8209;lived assets held for sale and goodwill. As discussed in Note 6, we recognized an impairment charge of $82&#160;million to write down certain long&#8209;lived assets located in one of our markets to their estimated fair value during the year ended December&#160;31,&#160;2022. Based on our evaluation, we estimated the fair value of the long&#8209;lived assets to be $167&#160;million. The inputs used to establish this fair value are considered to be Level&#160;2 inputs, which include inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long&#8209;term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit&#160;Agreement are considered to be Level 2 inputs. At December&#160;31,&#160;2022 and 2021, the estimated fair value of our long&#8209;term debt was approximately 92.8% and 103.3%, respectively, of the carrying value of the debt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675734128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2022, we acquired controlling ownership interests in 19 fully operational ambulatory surgery centers and three centers then in development from United Urology Group. We paid $104 million, net of cash acquired, for our ownership interests in these facilities and recognized goodwill of $316 million. The aggregate acquisition date fair value of the non&#8209;controlling interests in the facilities we acquired was $223 million. The acquisition of these facilities provided us with access to new markets and further diversified our ambulatory care services portfolio.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired controlling interests in an additional 11 ambulatory surgery centers through a series of transactions during the year ended December&#160;31,&#160;2022. We paid an aggregate purchase price of $65 million, net of cash acquired, for these facilities. During 2022, we also acquired controlling interests in 23 ambulatory surgery centers in which we previously owned a noncontrolling interest for an aggregate purchase price of $65 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, subsidiaries of USPI acquired ownership interests in 86 ambulatory surgery centers and related ambulatory support services (collectively, the &#8220;2021 SCD Centers&#8221;) from Surgical Center Development&#160;#3,&#160;LLC and Surgical Center Development&#160;#4,&#160;LLC (&#8220;SCD&#8221;). Of these, we acquired controlling interests in 15 ambulatory surgery centers, noncontrolling interests in 57 centers and interests in 14 centers still in the development stage. The newly acquired facilities augmented our Ambulatory Care segment&#8217;s existing musculoskeletal service line and expanded the number of markets it serves. We made a cash payment of $1.125 billion, net of cash acquired, to acquire these facilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the 2021 SCD Centers, we paid an aggregate purchase price of $74 million to acquire controlling interests in 11 outpatient businesses and various physician practices during the year ended December&#160;31,&#160;2021. During 2021, we also acquired controlling interests in three surgical hospitals and two ambulatory surgery centers in which we previously owned a noncontrolling interest for $21 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2020, USPI acquired controlling interests in 45 ambulatory surgery centers (collectively, the &#8220;2020 SCD Centers&#8221;) from SurgCenter Development and physician owners. The fair value of the consideration conveyed for the 2020 SCD Centers was $1.115&#160;billion, consisting of a cash payment of $1.097&#160;billion, fully funded using cash on hand, and the assumption of $18&#160;million of center&#8209;level debt.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the 2020 SCD Centers, we acquired ownership interests in 10 outpatient businesses (all of which are in our Ambulatory Care segment), and various physician practices during the year ended December&#160;31,&#160;2020.&#160;The aggregate purchase price for these acquisitions was $80&#160;million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values.&#160;The excess of the purchase price allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2022 are preliminary. We are in process of assessing working capital balances as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying consolidated financial statements are subject to adjustment once the assessments and valuation work are completed and evaluated. Such adjustments will be recorded as soon as practical and within the measurement period as defined by the accounting literature. During the year ended December&#160;31,&#160;2022, we adjusted the initial purchase allocation of certain acquisitions completed in 2021 based on the results of completed valuations. These adjustments resulted in a net increase in goodwill of $7&#160;million. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary or final purchase price allocations for all the acquisitions made during the years ended December&#160;31,&#160;2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously held equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests in equity of consolidated subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains on consolidations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the facilities described above are included in our Ambulatory Care segment. The majority of the goodwill generated from our 2022 acquisitions will not be deductible for income tax purposes; however, the majority of the goodwill generated from our 2021 and 2020 transactions will be. The goodwill generated from these transactions can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. Approximately $14&#160;million, $20&#160;million and $14 million in transaction costs related to prospective and closed acquisitions were expensed during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively, and are included in impairment and restructuring charges, and acquisition&#8209;related costs in the accompanying Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2021, we recognized gains totaling $23&#160;million associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests. No such gains or losses were recognized in the years ended December&#160;31,&#160;2022 or 2020.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro Forma Information - Unaudited</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain pro forma information for Tenet as if the 2021 SCD Centers acquisition had occurred at the beginning of the year ended December&#160;31,&#160;2020:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share available to Tenet Healthcare Corporation </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676377056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business consists of our Hospital Operations segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#8209;hospitals and physician practices. At December&#160;31,&#160;2022, our subsidiaries operated 61&#160;hospitals serving primarily urban and suburban communities in nine&#160;states, including the new acute care hospital we opened in September&#160;2022 in South Carolina. On April&#160;1, 2021, we transferred 24&#160;imaging centers from our Ambulatory Care segment to our Hospital Operations segment. The total assets associated with the imaging centers transferred to our Hospital Operations segment constituted less than 1% of our consolidated total assets at March&#160;31,&#160;2021. Also in April&#160;2021, we completed the sale of the majority of the urgent care centers then held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, we completed the sale of the Miami Hospitals in August&#160;2021, all of which were held by our Hospital Operations segment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ambulatory Care segment is comprised of the operations of USPI. At December&#160;31,&#160;2022, USPI had ownership interests in 442 ambulatory surgery centers (300 consolidated) and 24 surgical hospitals (eight consolidated) in 35&#160;states. In April&#160;2021, we completed the sale of 40&#160;urgent care centers then held by our Ambulatory Care segment to an unaffiliated urgent care provider and, as noted above, transferred 24&#160;imaging centers from our Ambulatory Care segment to our Hospital Operations segment. Effective June&#160;30,&#160;2022, we purchased all of the shares previously held by Baylor in USPI for $406&#160;million, which increased our ownership interest in USPI&#8217;s voting shares from 95% to 100%. See Note&#160;18 for additional information about this transaction.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment provides revenue cycle management and value&#8209;based care services to hospitals, health systems, physician practices, employers and other clients. At December&#160;31,&#160;2022, Conifer provided services to approximately 660&#160;Tenet and non&#8209;Tenet hospitals and other clients nationwide. We have entered into an agreement documenting the terms and conditions of various services Conifer provides to Tenet hospitals (&#8220;RCM Agreement&#8221;), as well as an agreement documenting certain administrative services our Hospital Operations segment provides to Conifer. In March 2021, we entered into a month&#8209;to&#8209;month agreement amending the RCM Agreement effective January&#160;1,&#160;2021 (&#8220;Amended RCM Agreement&#8221;) to update certain terms and conditions related to the revenue cycle management services Conifer provides to Tenet hospitals. We believe the pricing terms for the services provided under the Amended RCM Agreement are commercially reasonable and consistent with estimated third&#8209;party terms. At December&#160;31,&#160;2022, we owned approximately 76% of Conifer Health Solutions, LLC, which is Conifer&#8217;s principal subsidiary.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Consolidated Balance Sheets and Consolidated Statements of Operations, as applicable:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other clients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Conifer revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-segment eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA&#160;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from divested and closed businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations, before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676302288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING STANDARDS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING STANDARDS</a></td>
<td class="text">RECENT ACCOUNTING STANDARDS<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB issued ASU 2022&#8209;03, &#8220;Fair Value Measurement (Topic 820) &#8211; Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&#8221; (&#8220;ASU 2022&#8209;03&#8221;) in June&#160;2022. Through ASU 2022&#8209;03 the FASB clarified that an entity should measure the fair value of an equity security subject to contractual sale restriction the same way it measures an identical equity security that is not subject to such a restriction. Under this approach the contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, should not affect its fair value. ASU 2022&#8209;03 also enhanced the disclosure requirements related to these instruments. The ASU is effective for public entities for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years, and early adoption is permitted. For non&#8209;investment companies, ASU 2022&#8209;03 will be applied prospectively with adjustments resulting from the initial adoption recognized in earnings and disclosed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in ASU 2022&#8209;03 primarily affect the RSUs granted to our non&#8209;employee directors as part of their annual compensation, which vest immediately but cannot be sold until a three&#8209;year holding period has lapsed. Upon adoption, we expect to recognize an immaterial amount of incremental stock compensation expense related to these awards.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2021, the FASB issued ASU 2021-08, &#8220;Business Combinations (Topic 805) &#8211; Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221; (&#8220;ASU 2021-08&#8221;). The standard addresses diversity in practice related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 &#8211; Revenue from Contracts with Customers as if the acquirer had originated the contracts, as opposed to at their fair value on the acquisition date. ASU 2021-08 is effective for us beginning in 2023, with early adoption permitted. We are currently evaluating the impact of this standard to our financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span id="ia7d2f0a090874865a638f33e23b84948_25466"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 1, we adopted ASU&#160;2020-06 effective January&#160;1,&#160;2022 and adopted ASU 2016&#8209;13 effective January&#160;1,&#160;2020. We applied the modified retrospective transition approach as of the period of adoption for both ASU&#160;2020-06 and ASU 2016&#8209;13.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676331824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</a></td>
<td class="text"><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II&#8212;VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at<br/>Beginning<br/>of&#160;Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Costs&#160;and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at<br/>End&#160;of<br/>Period</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.586%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes amounts recorded in discontinued operations.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636679318992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements include the accounts of Tenet and its wholly owned and majority&#8209;owned subsidiaries. We eliminate intercompany accounts and transactions in consolidation, and we include the results of operations of businesses that are newly acquired in purchase transactions from their dates of acquisition. We account for significant investments in other affiliated companies using the equity method. We also utilize the equity method when we have the ability to exercise significant influence over the affiliated company, despite not holding a significant percentage of its ownership interest. Unless otherwise indicated, all financial and statistical data included in these notes to our Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in&#160;millions (except per&#8209;share amounts).</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, &#8220;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU&#160;2020-06&#8221;), effective as of January&#160;1,&#160;2022 using the modified retrospective method. Among other amendments, ASU&#160;2020-06 changed the accounting for diluted earnings&#8209;per&#8209;share for convertible instruments and contracts that may be settled in cash or stock. ASU&#160;2020-06 eliminated an entity&#8217;s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer&#8217;s election. Additionally, ASU&#160;2020-06 requires that the if&#8209;converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU&#160;2020-06, diluted weighted average shares outstanding increased by approximately three million shares and diluted earnings per share available to Tenet common shareholders decreased by $0.01 for the year ended December&#160;31,&#160;2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1,&#160;2020, we adopted ASU 2016&#8209;13, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU 2016&#8209;13&#8221;), using the modified retrospective transition approach as of the period of adoption. The amendments in this ASU required a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Upon adoption of ASU 2016&#8209;13 on January&#160;1,&#160;2020, we recorded a cumulative effect adjustment to increase accumulated deficit by $14 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior-year amounts have been reclassified to conform to the current&#8209;year presentation. Due to their increased significance, net gains from the sale of investments and long-lived assets are presented separately in the operating activities section of the accompanying Consolidated Statements of Cash Flows. In prior periods, this activity was included in other items, net within the operating activities section.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text">We formed our GBC in the Philippines during the year ended December&#160;31,&#160;2019. The GBC&#8217;s accounts are measured in its local currency (the Philippine peso) and then translated into U.S.&#160;dollars. All assets and liabilities denominated in foreign currency are translated using the current rate of exchange at the balance sheet date. Results of operations denominated in foreign currency are translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Net Operating Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Revenues</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net operating revenues in the period in which we satisfy our performance obligations under contracts by transferring services to our customers. Net operating revenues are recognized in the amounts we expect to be entitled to, which are the transaction prices allocated for the distinct services. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact with Uninsured Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Patient Service Revenues&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third&#8209;party payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third&#8209;party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when (1)&#160;services are provided, and (2)&#160;we do not believe the patient requires additional services.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our patient service performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in FASB Accounting Standards Codification (&#8220;ASC&#8221;) 606&#8209;10&#8209;50&#8209;14(a) and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments recognized for third&#8209;party payers, discounts provided to uninsured patients in accordance with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and estimated implicit price concessions related primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop&#8209;loss payments). Because Medicare requires that a hospital&#8217;s gross charges be the same for all patients (regardless of payer category), gross charges are what hospitals charge all patients prior to the application of discounts and allowances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the traditional fee&#8209;for&#8209;service (&#8220;FFS&#8221;) Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost&#8209;based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense reimbursement, which are based on our hospitals&#8217; cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule&#160;interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements with third&#8209;party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and our historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#8209;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#8217;s bill is subject to adjustment on a patient&#8209;by&#8209;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the years ended December&#160;31,&#160;2022, 2021 or 2020. In addition, on a corporate&#8209;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We know of no claims, disputes or unsettled matters with any payer that would materially affect our revenues for which we have not adequately provided in the accompanying Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, patients who are covered by third&#8209;party payers are responsible for related co&#8209;pays, co&#8209;insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co&#8209;pays, co&#8209;insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#8209;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self&#8209;pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such as: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients; the volume of patients through our emergency departments; the increased burden of co&#8209;pays, co&#8209;insurance amounts and deductibles to be made by patients with insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record implicit price concessions, primarily related to uninsured patients and patients with co&#8209;pays, co&#8209;insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co&#8209;pays, co&#8209;insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (&#8220;EMTALA&#8221;). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non&#8209;emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1)&#160;we are unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2)&#160;a&#160;determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3)&#160;under physician orders we provide services to patients that require immediate treatment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per&#8209;diem amount for services received, subject to a cap. Except for the per&#8209;diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Patient advocates from our Eligibility and Enrollment Services program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conifer Revenues&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Conifer segment recognizes revenue from its contracts when Conifer&#8217;s performance obligations are satisfied, which is generally as services are rendered. Revenue is recognized in an amount that reflects the consideration to which Conifer expects to be entitled.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, Conifer assesses the services specified in its contracts with customers and identifies a performance obligation for each distinct contracted service. Conifer identifies the performance obligations and considers all the services provided under the contract. Conifer generally considers the following distinct services as separate performance obligations:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue cycle management services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">value&#8209;based care services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient communication and engagement services;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consulting services; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other client&#8209;defined projects.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conifer&#8217;s contracts generally consist of fixed&#8209;price, volume&#8209;based or contingency&#8209;based fees. Conifer&#8217;s long&#8209;term contracts typically provide for Conifer to deliver recurring monthly services over a multi&#8209;year period. The contracts are typically priced such that Conifer&#8217;s monthly fee to its customer represents the value obtained by the customer in the month for those services. Such multi&#8209;year service contracts may have upfront fees related to transition or integration work performed by Conifer to set up the delivery for the ongoing services. Such transition or integration work typically does not result in a separately identifiable obligation; thus, the fees and expenses related to such work are deferred and recognized over the life of the related contractual service period. For contracts in which the amortization period of the asset is one year or less, we have elected to apply the practical expedient provided by FASB ASC 340&#8209;40&#8209;25&#8209;4 and expense these costs as incurred.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for fixed&#8209;priced contracts is typically recognized at the time of billing unless evidence suggests that the revenue is earned or Conifer&#8217;s obligations are fulfilled in a different pattern. Revenue for volume&#8209;based contracts is typically recognized as the services are being performed at the contractually billable rate, which is generally a percentage of collections or a percentage of client net patient revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $858 million and $2.364 billion at December&#160;31,&#160;2022 and 2021, respectively. At December&#160;31,&#160;2022 and 2021, our book overdrafts were $266 million and $226 million, respectively, which were classified as accounts payable. At December&#160;31,&#160;2022 and 2021, $140 million and $188 million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our insurance&#8209;related subsidiaries.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31,&#160;2022, 2021 and 2020, we had $196 million, $95 million and $93&#160;million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $191&#160;million, $88&#160;million and $85&#160;million, respectively, were included in accounts payable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we acquired all of Baylor&#8217;s 5% voting ownership interest in USPI. We paid $11&#160;million from cash on hand and recognized a liability of $377&#160;million, the present value of the liability on the acquisition date, for the remainder of the purchase price. We recorded reductions in redeemable noncontrolling interest of $365&#160;million for the carrying value of Baylor&#8217;s ownership interest and $23&#160;million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares on the acquisition date. This has been reflected as noncash financing activity in the accompanying Consolidated Statement of Cash Flows for the year ended December&#160;31,&#160;2022. Payments made subsequent to the transaction&#8217;s close are reflected as cash activity within the financing section of our consolidated statements of cash flows. See Note&#160;18 for additional information about this transaction.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify investments in debt securities as either available&#8209;for&#8209;sale, held&#8209;to&#8209;maturity or as part of a trading portfolio. Our policy is to classify investments in debt securities that may be needed for cash requirements as &#8220;available&#8209;for&#8209;sale.&#8221; At December&#160;31,&#160;2022, we had no significant investments in debt securities classified as either held&#8209;to&#8209;maturity or trading. We carry debt securities classified as available&#8209;for&#8209;sale at fair value. We report their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss). We periodically evaluate available-for-sale securities in unrealized loss positions for credit impairment, using both qualitative and quantitative criteria. In the event a security is deemed to be impaired as the result of a credit loss, we record a loss in our consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry equity securities at fair value, and we report their unrealized gains and losses in other non-operating income, net, in our consolidated statements of operations. If the equity security does not have a readily determinable fair value, the carrying value of the security is adjusted only when there is a price change that is observable from a transaction of an identical or similar investment. We include realized gains or losses in our consolidated statements of operations based on the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments in Unconsolidated Affiliates</a></td>
<td class="text">We control 308 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (158 of 466 at December&#160;31,&#160;2022), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations. In the years ended December&#160;31,&#160;2021 and 2020, equity in earnings of unconsolidated affiliates included $14&#160;million and $17&#160;million, respectively, from PRF grants recognized by our Ambulatory Care segment&#8217;s unconsolidated affiliates. No additional revenue was recognized from PRF grants by unconsolidated affiliates during the year ended December&#160;31,&#160;2022.<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information for equity method investees is included in the following table. For investments acquired during the reported periods, amounts below include 100% of the investee&#8217;s results beginning on the date of our acquisition of the investment.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(866)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to the investees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity method investment that contributed the most to our equity in earnings of unconsolidated affiliates during the years ended December&#160;31,&#160;2022, 2021 and 2020 was Texas Health Ventures Group, LLC (&#8220;THVG&#8221;), which is operated by USPI. THVG represented $89 million, $107&#160;million and $85&#160;million of total equity in earnings of unconsolidated affiliates of $216 million, $218&#160;million and $169&#160;million in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions and improvements to property and equipment exceeding established minimum amounts with a useful life greater than one year are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. We use the straight&#8209;line method of depreciation for buildings, building improvements and equipment. The estimated useful life for buildings and improvements is primarily 15 to 40 years, and for equipment <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b">three</span> to 15 years. Newly constructed hospitals are usually depreciated over 50 years. Interest costs related to construction projects are capitalized. In the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, capitalized interest was $8 million, $4 million and $5 million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long&#8209;lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of an impairment charge only if the carrying value of the long&#8209;lived assets exceeds their fair value. The fair value of the asset is estimated based on third&#8209;party appraisals, established market values of comparable assets or internally developed estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. Estimates require our subjective judgments and take into account assumptions about revenue and expense growth rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of asset and presume stable, improving or, in some cases, declining results, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report long&#8209;lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">We determine if an arrangement is a lease at inception of the contract. Our right&#8209;of&#8209;use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right&#8209;of&#8209;use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. We use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. For our Hospital Operations and Conifer segments, we estimate our incremental borrowing rates for our portfolio of leases using documented rates included in our recent equipment finance leases or, if applicable, recent secured debt issuances that correspond to various lease terms. We also give consideration to information obtained from our bankers, our secured debt fair value and publicly available data for instruments with similar characteristics. For our Ambulatory Care segment, we estimate an incremental borrowing rate for each center by <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing historical and projected financial data, estimating a hypothetical credit rating using publicly available market data and adjusting the market data to reflect the effects of collateralization.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are primarily for real estate, including off&#8209;campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. Our real estate lease agreements typically have initial terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8">five</span> to 10 years, and our equipment lease agreements typically have initial terms of three years. We do not record leases with an initial term of 12 months or less (short&#8209;term leases) in our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our real estate leases may include one or more options to renew, with renewals that can extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce">five</span> to 10 years. The exercise of lease renewal options is at our sole discretion. In general, we do not consider renewal options to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of our right&#8209;of&#8209;use assets and lease liabilities. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of our medical equipment leases have terms of three years with a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life, typically ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076">five</span> to seven years. Similarly, some of our leases of information technology and telecommunications assets include a transfer of title and, therefore, have useful lives of 15 years.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the right&#8209;of&#8209;use asset or liability balances. Our lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the practical expedient that allows lessees to choose to not separate lease and non&#8209;lease components by class of underlying asset and are applying this expedient to all relevant asset classes. We have also elected the practical expedient package to not reassess at adoption (1)&#160;expired or existing contracts for whether they are or contain a lease, (2)&#160;the lease classification of any existing leases or (3)&#160;initial indirect costs for existing leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of costs over the fair value of assets of businesses acquired. Goodwill and other intangible assets acquired in purchase business combinations and determined to have indefinite useful lives are not amortized, but instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level when events occur that require an evaluation to be performed or at least annually. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value. Estimates of fair value are based on third&#8209;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consist of capitalized software costs, which are amortized on a straight&#8209;line basis over the estimated useful life of the software, which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e">three</span> to 15 years, costs of acquired management and other contract service rights, most of which have indefinite lives, and miscellaneous intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Accruals for General and Professional Liability Risks</a></td>
<td class="text">We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in our consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income/losses expected in future years;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The carryforward period associated with the deferred tax assets and liabilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&#160;the more likely than not recognition threshold is satisfied; (2)&#160;the position is ultimately settled through negotiation or litigation; or (3)&#160;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">We primarily operate acute care hospitals and related healthcare facilities. Our Hospital Operations segment generated 76%, 80% and 81% of our net operating revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Major decisions, including capital resource allocations, are made at the consolidated level, not at the market or hospital level. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Costs Associated With Exit or Disposal Activities</a></td>
<td class="text">We recognize costs associated with exit (including restructuring) or disposal activities when they are incurred and can be measured at fair value, rather than at the date of a commitment to an exit or disposal plan.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB issued ASU 2022&#8209;03, &#8220;Fair Value Measurement (Topic 820) &#8211; Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&#8221; (&#8220;ASU 2022&#8209;03&#8221;) in June&#160;2022. Through ASU 2022&#8209;03 the FASB clarified that an entity should measure the fair value of an equity security subject to contractual sale restriction the same way it measures an identical equity security that is not subject to such a restriction. Under this approach the contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, should not affect its fair value. ASU 2022&#8209;03 also enhanced the disclosure requirements related to these instruments. The ASU is effective for public entities for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years, and early adoption is permitted. For non&#8209;investment companies, ASU 2022&#8209;03 will be applied prospectively with adjustments resulting from the initial adoption recognized in earnings and disclosed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in ASU 2022&#8209;03 primarily affect the RSUs granted to our non&#8209;employee directors as part of their annual compensation, which vest immediately but cannot be sold until a three&#8209;year holding period has lapsed. Upon adoption, we expect to recognize an immaterial amount of incremental stock compensation expense related to these awards.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2021, the FASB issued ASU 2021-08, &#8220;Business Combinations (Topic 805) &#8211; Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221; (&#8220;ASU 2021-08&#8221;). The standard addresses diversity in practice related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 &#8211; Revenue from Contracts with Customers as if the acquirer had originated the contracts, as opposed to at their fair value on the acquisition date. ASU 2021-08 is effective for us beginning in 2023, with early adoption permitted. We are currently evaluating the impact of this standard to our financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span id="ia7d2f0a090874865a638f33e23b84948_25466"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 1, we adopted ASU&#160;2020-06 effective January&#160;1,&#160;2022 and adopted ASU 2016&#8209;13 effective January&#160;1,&#160;2020. We applied the modified retrospective transition approach as of the period of adoption for both ASU&#160;2020-06 and ASU 2016&#8209;13.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670429776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ScheduleOfGrantFundsTableTextBlock', window );">Schedule of Grant Funds Received And Grant Income</a></td>
<td class="text">As detailed in the table below, we received cash payments from the PRF and state and local grant programs during the years ended December&#160;31,&#160;2022, 2021 and 2020. Grant funds received by our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate are included in cash flows from operating activities in our consolidated statements of cash flows. Grant funds received by unconsolidated affiliates for which we provide cash management services (&#8220;Cash&#8209;Managed Affiliates&#8221;) are included in cash flows from financing activities.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funds received from COVID-19 relief programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#8209;Managed Affiliates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income recognized from COVID-19 relief programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in grant income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in equity in earnings of unconsolidated affiliates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unconsolidated affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>Advance payments to our Cash&#8209;Managed Affiliates were recouped through a reduction of those affiliates&#8217; Medicare claims payments and, together with any repayments, are presented in cash flows from financing activities.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAPP advances repaid or recouped:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#8209;Managed Affiliates</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text">For investments acquired during the reported periods, amounts below include 100% of the investee&#8217;s results beginning on the date of our acquisition of the investment.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(866)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to the investees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ScheduleOfGrantFundsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Grant Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ScheduleOfGrantFundsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672670800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Share Repurchase Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes transactions completed under the repurchase program:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Dollar Value of Shares That May Yet be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception through October&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November&#160;1 through November&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;1 through December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inception through December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,889</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,889</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681539168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract', window );"><strong>Accounts Receivable Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Components of Accounts Receivable</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of accounts receivable are shown in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated future recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cost reports and settlements receivable and valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Schedule of Location of Assets and Liabilities</a></td>
<td class="text">The following table summarizes the amount and classification of assets and liabilities in the accompanying Consolidated Balance Sheets related to California&#8217;s provider fee program:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock', window );">Schedule of Estimated Costs for Charity Care and Self-Pay Patients</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated costs for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured patients</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charity care patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt 0 13pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated costs for providing charity care to patients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681484416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT BALANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Opening and Closing Balances of Contracts Assets and Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract assets and contract liabilities, as well as their classification in our consolidated balance sheets, for our Hospital Operations segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Current Advances from Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liabilities &#8211; Long-Term Advances from Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening and closing balances of Conifer&#8217;s receivables, contract asset, and current and long&#8209;term contract liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Asset &#8211;<br/>Unbilled Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Current<br/>Deferred Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract Liability &#8211;<br/>Long-Term<br/>Deferred Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31,&#160;2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681365376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES HELD FOR SALE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Assets and Liabilities Classified as Held for Sale and Components of Business that have Been Disposed of or have Been Classified as Held for Sale</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents amounts included in income from continuing operations, before income taxes, related to significant components of our business that were recently disposed of:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.72pt;text-indent:-6.73pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miami Hospitals (includes a $406 million gain on sale in 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670587424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related To Leases</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our right&#8209;of&#8209;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1">Investments and other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"><div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost, less</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated depreciation and amortization</span></div></div></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Additional Information Related to Lease Expense, Terms and Discount Rates, and Cash Flow Information</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Component of Lease Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and short term-lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average lease terms and discount rates for operating and finance leases are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow and other information related to leases is included in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Finance Lease Liability Maturity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670461184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-Term Debt and Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our long&#8209;term debt included in the accompanying Consolidated Balance Sheets:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750% due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.125% due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.875% due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured first lien notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% due July 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% due September 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.500% due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.875% due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.250% due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.125% due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured second lien notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.250% due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases, mortgages and other notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized issue costs and note discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Future Long Term Debt Maturities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future long&#8209;term debt maturities, including finance lease obligations were as follows as of December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.658%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including finance lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670085936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg<br/>Remaining Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information About Stock Options by Range of Exercise Prices</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about our outstanding stock options at December&#160;31,&#160;2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding and Exercisable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range&#160;of&#160;Exercise&#160;Prices&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise&#160;Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.99 to $20.609</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.61 to $35.430</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Grant Date&#160;Fair<br/>Value&#160;Per&#160;Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310,296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,520,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity under USPI&#8217;s management equity plan during the years ended December&#160;31,&#160;2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Grant Date&#160;Fair<br/>Value&#160;Per&#160;Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inception of Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,588)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">922,840</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions</a></td>
<td class="text">Significant inputs used in our valuation of these RSUs included the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6% - 68.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2% - 79.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0% - 1.7% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 0.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2%</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Employee Stock Purchase Plan Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued the following numbers of shares under our employee stock purchase plan:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock', window );">Schedule of Reconciliation of Funded Status of Plans, the Amounts included in the Consolidated Balance Sheets and Assumptions Used for Projected Benefit Obligations</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet impact, as well as the benefit obligations, funded status and rate assumptions associated with the SERPs and the DMC Pension Plan based on actuarial valuations prepared:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,002)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plans assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status of plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(354)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(446)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The accumulated benefit obligation at December&#160;31,&#160;2022 and 2021 was approximately $1.002 billion and $1.311 billion, respectively.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the Consolidated Balance Sheets consist of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SERP Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMC Pension Plan Assumptions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Components of Net Benefit Costs and Assumptions Used for Net Periodic Benefit Costs</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit costs and related assumptions are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SERP Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Census date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMC Pension Plan Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term rate of return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation increase rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frozen</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Census date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Weighted-Average Asset Allocations by Asset Category</a></td>
<td class="text"><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted&#8209;average asset allocations by asset category as of December&#160;31,&#160;2022, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of DMC Pension Plan Assets Measured at Fair Value on a Recurring Basis Aggregated by the Level in the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the DMC Pension Plan assets measured at fair value on a recurring basis as of December&#160;31,&#160;2022 and 2021, aggregated by the level in the fair value hierarchy within which those measurements are determined.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Estimated Future Benefit Payments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future benefit payments to be made from the SERPs and the DMC Pension Plan, a portion of which will be funded from plan assets, for the next five years and in the aggregate for the five years thereafter:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.975%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending&#160;December&#160;31,&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Five Years Thereafter</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of funded status of plans, the amounts included in the Consolidated Balance Sheets and the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676390576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of property and equipment are shown in the table below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,663&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net property and equipment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681693424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year and purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill transferred from Ambulatory Care segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill related to assets held for sale and disposed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at end of period:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year and purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill transferred to Hospital Operations segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill related to assets held for sale and disposed or deconsolidated facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at beginning of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Other Intangible Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information regarding other intangible assets:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,428)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,424</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with indefinite useful lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets with indefinite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,374)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization of Intangibles with Finite Useful Lives</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future amortization of intangibles with finite useful lives as of December&#160;31,&#160;2022 was as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680968416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of other current assets in the accompanying Consolidated Balance Sheets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California provider fee program receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from other government programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guarantees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-patient receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock', window );">Schedule of Investments and Other Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of investments and other assets in the accompanying Consolidated Balance Sheets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments in unconsolidated healthcare entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California provider fee program receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term receivables and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments and other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,147</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681484416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated other comprehensive loss was comprised of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for defined benefit plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677749632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET OPERATING REVENUES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Sources of Net Operating Revenues Less Provisions for Doubtful Accounts and Implicit Price Concessions</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows our sources of net operating revenues from continuing operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues from hospitals and related outpatient facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uninsured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inter-segment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:0.1%"/><td style="width:2.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.646%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Primarily physician practices revenues.</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Ambulatory Care segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the composition of net operating revenues for our Conifer segment:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue cycle services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; Tenet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services &#8211; other customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Revenue Expected to be Recognized in the Future Related to Performance Obligations</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes Conifer&#8217;s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume&#8209; or contingency&#8209;based contracts, variable&#8209;based escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer&#8217;s contract with Catholic Health Initiatives (&#8220;CHI&#8221;), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed&#8209;fee revenue related to remaining performance obligations. Conifer&#8217;s contract term with CHI ends December&#160;31,&#160;2032.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Later Years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676442176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CLAIMS AND LAWSUITS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of Reconciliations Of Legal Settlements And Related Costs</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing operations:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances&#160;at<br/>Beginning<br/>of&#160;Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Litigation&#160;and<br/>Investigation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash<br/>Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances&#160;at<br/>End&#160;of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676442176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Schedule of Changes in Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases and sales of businesses and noncontrolling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at end of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675397840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes For Continuing Operations</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for continuing operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation Between Reported Income Tax Expense (Benefit) and Income Taxes Calculated by the Statutory Federal Income Tax Rate</a></td>
<td class="text">Foreign pre-tax loss was $8 million, $5 million and $13 million for the years ended December&#160;31,&#160;2022, 2021 and&#160;2020, respectively.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory federal rate of 21%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired charitable contribution carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior-year provision to return adjustments and other changes in deferred&#160;taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>A change in the business interest expense disallowance rules took effect in 2022, resulting in a larger amount of interest disallowance compared to prior years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities, Including Any Valuation Allowance</a></td>
<td class="text">The following table discloses those significant components of our deferred tax assets and liabilities, including any valuation allowance:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and fixed-asset differences</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves related to discontinued operations and restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables (doubtful accounts and adjustments)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare advance payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for retained insurance risks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use lease assets and obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,358</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Reconciliation of the Deferred Tax Assets and Liabilities and the Corresponding Amounts Reported in the Accompanying Consolidated Balance Sheets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the deferred tax assets and liabilities and the corresponding amounts reported in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(198)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Changes in Unrecognized Tax Benefits That Have Impacted Deferred Tax Assets and Liabilities</a></td>
<td class="text">The following table summarizes the total changes in unrecognized tax benefits in continuing operations during the years ended December&#160;31,&#160;2022, 2021 and 2020. There were no such changes in discontinued operations. The additions and reductions for tax positions include the impact of items for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductions. Such amounts include unrecognized tax benefits that have impacted deferred tax assets and liabilities at December&#160;31,&#160;2022, 2021 and 2020.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:85.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to a lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to a lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to tax positions taken in prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance At December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of classification of deferred tax assets and liabilities recognized in the entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681484416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Numerators and Denominators of our Basic and Diluted Earnings Per Common Share</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in&#160;millions and weighted average shares are expressed in thousands.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Available to Common Shareholders (Numerator)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Shares<br/>(Denominator)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per-Share<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units and deferred compensation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for basic loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options, restricted stock units and deferred compensation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders for diluted loss per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672692560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Preliminary Purchase Price Allocation</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary or final purchase price allocations for all the acquisitions made during the years ended December&#160;31,&#160;2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously held equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests in equity of consolidated subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains on consolidations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain pro forma information for Tenet as if the 2021 SCD Centers acquisition had occurred at the beginning of the year ended December&#160;31,&#160;2020:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to Tenet Healthcare Corporation common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share available to Tenet Healthcare Corporation </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680669440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Schedule of Reconciliation of Assets by Reportable Segment to Consolidated Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Consolidated Balance Sheets and Consolidated Statements of Operations, as applicable:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Other Significant Reconciling Items From Segments to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations total prior to inter-segment eliminations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other clients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Conifer revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-segment eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of unconsolidated affiliates:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambulatory Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conifer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA&#160;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from divested and closed businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment and restructuring charges, and acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and investigation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sales, consolidation and deconsolidation of facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations, before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636679467072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>healthcare_facility </div>
<div>hospital</div>
</th>
<th class="th"><div>Jun. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfHospitalsOperated', window );">Number of acute care and specialty hospitals operated | hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod', window );">Number of outpatient centers recorded using equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfOutpatientFacilitiesOperated', window );">Number of outpatient facilities operated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=thc_ConiferHealthSolutionsLLCMember', window );">Conifer Health Solutions, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries', window );">Number of surgical hospitals operated by subsidiaries | hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod', window );">Number of outpatient centers recorded using equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest', window );">Share purchase agreement amount of payment | $</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfHospitalsOperated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Hospitals Operated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfHospitalsOperated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of outpatient centers in which they are recorded using the equity method of accounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfOutpatientCentersRecordedUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfOutpatientFacilitiesOperated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Outpatient Facilities Operated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfOutpatientFacilitiesOperated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surgical Hospitals Operated By Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount Of Payment for Minority Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=thc_ConiferHealthSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=thc_ConiferHealthSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675433392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">110,516<span></span>
</td>
<td class="nump">108,571<span></span>
</td>
<td class="nump">106,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Increase (decrease) accumulated deficit</a></td>
<td class="num">$ (803)<span></span>
</td>
<td class="num">$ (1,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Increase (decrease) accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671215728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Pandemic (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates', window );">Received cash payments</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments', window );">Contract liabilities advance payments</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=thc_AccruedCompensationAndBenefitsMember', window );">Accrued Compensation And Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments', window );">Deferred social security tax payments</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates', window );">Received cash payments</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments', window );">Contract liabilities advance payments</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates', window );">Received cash payments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments', window );">Contract liabilities advance payments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndAmbulatoryCareMember', window );">Hospital Operations And Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=thc_EquityMethodInvestmentCashManagedAffiliatesMember', window );">Cash&#8209;Managed Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates', window );">Received cash payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=thc_EquityMethodInvestmentCashManagedAffiliatesMember', window );">Cash&#8209;Managed Affiliates | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments', window );">Contract liabilities advance payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Unconsolidated affiliates | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Recoupment Of Advance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Government Assistance, Including Contributions From Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=thc_AccruedCompensationAndBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=thc_AccruedCompensationAndBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndAmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndAmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=thc_EquityMethodInvestmentCashManagedAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=thc_EquityMethodInvestmentCashManagedAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676471856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Net Operating Revenues (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod', window );">Cost report filing period after end of annual cost reporting period</a></td>
<td class="text">5 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cost report filing period after the end of the annual cost reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636679249072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">$ 2,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases for items received but not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase and sales of business and noncontrolling interest, net</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GainLossFromPurchaseOfNoncontrollingInterests', window );">Loss from purchase of noncontrolling interests</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementPaymentForExecution', window );">Share purchase agreement, payment for execution</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Debt instrument payment</a></td>
<td class="nump">$ 377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_JointVentureOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=thc_CaptiveInsuranceSubsidiariesMember', window );">Captive Insurance Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankOverdrafts', window );">Book overdrafts classified as accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases for items received but not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_GainLossFromPurchaseOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Purchase Of Noncontrolling Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_GainLossFromPurchaseOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_JointVentureOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the joint venture ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_JointVentureOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementPaymentForExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Payment For Execution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementPaymentForExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=thc_CaptiveInsuranceSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=thc_CaptiveInsuranceSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671223504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Investments in Unconsolidated Affiliates (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>healthcare_facility</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PercentageInvesteeResultsReflected', window );">Percentage of investee results reflected on date of acquisition</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 5,981<span></span>
</td>
<td class="nump">7,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="num">(4,476)<span></span>
</td>
<td class="num">(5,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(1,317)<span></span>
</td>
<td class="num">(1,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">19,174<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">17,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Unconsolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="num">(479)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="num">(878)<span></span>
</td>
<td class="num">(855)<span></span>
</td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(644)<span></span>
</td>
<td class="num">(659)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">2,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NetIncomeLossAttributableToInvestee', window );">Net income attributable to the investees</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=thc_TexasHealthVenturesGroupLlcMember', window );">Texas Health Ventures Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod', window );">Number of outpatient centers recorded not using equity method | healthcare_facility</a></td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod', window );">Number of outpatient centers recorded using equity method | healthcare_facility</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersAndHospitals', window );">Number of outpatient centers | healthcare_facility</a></td>
<td class="nump">466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care | Unconsolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NetIncomeLossAttributableToInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) attributable to the investee reported by the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NetIncomeLossAttributableToInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of outpatient centers in which they are not recorded using the equity method of accounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfOutpatientCentersRecordedUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of outpatient centers in which they are recorded using the equity method of accounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfOutpatientCentersRecordedUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalCentersAndHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of surgical centers and hospitals operated by subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalCentersAndHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PercentageInvesteeResultsReflected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the investee's results accounted for under the equity method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PercentageInvesteeResultsReflected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=thc_TexasHealthVenturesGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=thc_TexasHealthVenturesGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671021744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_NewlyConstructedHospitalsMember', window );">Newly Constructed Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized related to construction projects</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_NewlyConstructedHospitalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_NewlyConstructedHospitalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636679439408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>renewal_option</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Real estate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Real estate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_MedicalEquipmentMember', window );">Medical Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_MedicalEquipmentMember', window );">Medical Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_MedicalEquipmentMember', window );">Medical Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_ComputerAndTelecommunicationEquipmentMember', window );">Computer And Telecommunication Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_ComputerAndTelecommunicationEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_ComputerAndTelecommunicationEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677599456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Other Intangible Assets (Details) - Capitalized software costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Goodwill and Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676614560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals', window );">Revenue generated by general hospitals</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net operating revenues generated by the entity's general hospitals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670411680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Noncontrolling interests balance</a></td>
<td class="nump">$ 2,459<span></span>
</td>
<td class="nump">$ 2,054<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Noncontrolling interests balance</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interests | Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Noncontrolling interests balance</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interests | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Noncontrolling interests balance</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671580800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - Share Repurchase Programs (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of common stock authorized to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Total Number of Shares Purchased</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">5,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average Price Paid per Share (in dollars per shares)</a></td>
<td class="nump">$ 41.81<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42.74<span></span>
</td>
<td class="nump">$ 42.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Maximum Dollar Value of Shares That May Yet be Purchased Under the Program</a></td>
<td class="nump">$ 925<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636681313184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE - Components (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract', window );"><strong>Accounts Receivable Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">$ 2,746<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer', window );">Estimated future recoveries</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances', window );">Net cost reports and settlements receivable and valuation allowances</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net&#160;</a></td>
<td class="nump">$ 2,943<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents estimated future recoveries from accounts assigned to Conifer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NetCostReportSettlementsReceivablePayableandValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cost report settlements receivable (payable) and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NetCostReportSettlementsReceivablePayableandValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670578832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Other current assets</a></td>
<td class="nump">$ 2,943<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember', window );">California's Provider Fee Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Other current assets</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember', window );">California's Provider Fee Program | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Other current assets</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember', window );">California's Provider Fee Program | Investments and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember', window );">California's Provider Fee Program | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Other current liabilities</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember', window );">California's Provider Fee Program | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670676208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE - Allowance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts receivable and allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationHealthCareCostsGross', window );">Estimated costs of caring</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_SelfPayPatientsMember', window );">Uninsured patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts receivable and allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationHealthCareCostsGross', window );">Estimated costs of caring</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CharityCarePatientsMember', window );">Charity care patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts receivable and allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationHealthCareCostsGross', window );">Estimated costs of caring</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationHealthCareCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126943116&amp;loc=d3e5919-115623<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126943116&amp;loc=d3e5910-115623<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationHealthCareCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_SelfPayPatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_SelfPayPatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CharityCarePatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CharityCarePatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671318144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days', window );">Percentage of contract assets that meet the conditions for unconditional right to payment (percentage)</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at end of period</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at end of period</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at beginning of period</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at end of period</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndOtherMember', window );">Hospital Operations And Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at end of period</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Increase (decrease)</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndOtherMember', window );">Hospital Operations And Other | Short-term Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="num">(876)<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="num">(876)<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndOtherMember', window );">Hospital Operations And Other | Long-term Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care | Short-term Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care | Long-term Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liabilities &#8211; Current Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liabilities &#8211; Long-Term Advances from Medicare</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability, Net, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability, Net, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Percentage To Be Reclassified To Receivable Within 90 Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670844592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT BALANCES - Conifer Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward', window );"><strong>Contract Asset &#8211; Unbilled Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at end of period</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liability &#8211; Current Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at end of period</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liability &#8211; Long-Term Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at beginning of period</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at end of period</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward', window );"><strong>Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent', window );">Balance at end of period</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_IncreaseDecreaseInContractWithCustomerReceivable', window );">Increase (decrease)</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward', window );"><strong>Contract Asset &#8211; Unbilled Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at end of period</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Increase (decrease)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liability &#8211; Current Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at beginning of period</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at end of period</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liability &#8211; Long-Term Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at beginning of period</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance at end of period</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract liabilities advance payments</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer Segment | Short-term Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liability &#8211; Current Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liability &#8211; Long-Term Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer Segment | Long-term Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward', window );"><strong>Contract Liability &#8211; Current Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward', window );"><strong>Contract Liability &#8211; Long-Term Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease)</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ChangeInContractWithCustomerAssetNetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset, Net, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ChangeInContractWithCustomerAssetNetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset, Net, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability, Net, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability, Net, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_IncreaseDecreaseInContractWithCustomerReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Contract with Customer, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_IncreaseDecreaseInContractWithCustomerReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675715600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT BALANCES - Contract Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortized customer contract costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Unamortized contract costs</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677769200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>hospital</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Current Assets and Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 92,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Current Assets and Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_MiamiAreaHospitalsMember', window );">Miami-Area Hospitals | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Current Assets and Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfHospitalsForSale', window );">Number of hospitals for sale | hospital</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperties', window );">Gain (loss) on sale of properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_UrgentCareCentersMember', window );">Urgent Care Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Current Assets and Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperties', window );">Gain (loss) on sale of properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_PhiladelphiaBuildingMember', window );">Philadelphia Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Current Assets and Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperties', window );">Gain (loss) on sale of properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfHospitalsForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Hospitals For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfHospitalsForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_MiamiAreaHospitalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_MiamiAreaHospitalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_UrgentCareCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_UrgentCareCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_PhiladelphiaBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_PhiladelphiaBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677599456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES HELD FOR SALE - Significant Components (Details) - Miami-Area Hospitals - Disposal Group, Disposed of by Sale, Not Discontinued Operations - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperties', window );">Gain (loss) on sale of properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_MiamiAreaHospitalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=thc_MiamiAreaHospitalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672536096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost', window );">Impairment and restructuring charges, and acquisition-related costs</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring charges</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Other impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Lease termination costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessCombinationAcquisitionRelatedTransactionCosts', window );">Acquisition-related transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individual Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessCombinationAcquisitionRelatedTransactionCosts', window );">Acquisition-related transaction costs</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring charges</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember', window );">Global Business Center in Republic of Philippines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring charges</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_HospitalBuildingsAndMedicalEquipmentMember', window );">Hospital Buildings and Medical Equipment | Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_BuildingsSubjectToImpairmentChargesMember', window );">Buildings Subject To Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_BusinessCombinationAcquisitionRelatedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of acquisition-related transaction costs incurred to effect a business combination which costs have been expensed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_BusinessCombinationAcquisitionRelatedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period and acquisition-related costs. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=thc_USPIManagementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=thc_USPIManagementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_HospitalBuildingsAndMedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_HospitalBuildingsAndMedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_BuildingsSubjectToImpairmentChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=thc_BuildingsSubjectToImpairmentChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671203136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Balance Sheet Components (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, long-term</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Investments and other assets<span></span>
</td>
<td class="text">Investments and other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Current portion of long-term debt<span></span>
</td>
<td class="text">Current portion of long-term debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term debt, net of current portion<span></span>
</td>
<td class="text">Long-term debt, net of current portion<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670688176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_FinanceLeaseExpenseAbstract', window );"><strong>Finance lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_FinanceLeaseCost', window );">Total finance lease expense</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_VariableAndShorttermLeaseCosts', window );">Variable and short term-lease expense</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years), operating leases</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years), finance leases</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, operating leases (percentage)</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, finance leases (percentage)</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_FinanceLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Expense [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_FinanceLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_VariableAndShorttermLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable And Short-term Lease, Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_VariableAndShorttermLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636679330832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflows from finance leases</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflows from finance leases</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670846704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Lease Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Later years</a></td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current obligations</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Later years</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: Current obligations</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive', window );">Later years</a></td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiabilityCurrent', window );">Less: Current obligations</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities, Payments, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Payments Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Liability, Payments, Due After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Liability, Payments, Due Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Liability, Payments, Due Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Liability, Payments, Due Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Liability, Payments, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Liability, Payments, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670616000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Net proceeds from sale of buildings</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperties', window );">Gain on sale of properties</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672258160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM DEBT - Schedule of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_FinanceLeasesAndMortgageNotes', window );">Finance leases, mortgages and other notes</a></td>
<td class="nump">$ 453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issue costs and note discounts</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">15,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current portion</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="nump">14,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.125% due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.875% due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% due July 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% due September 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.500% due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.875% due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.250% due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.125% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.250% due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_FinanceLeasesAndMortgageNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Leases And Mortgage Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_FinanceLeasesAndMortgageNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636662455456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 23, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (109,000,000)<span></span>
</td>
<td class="num">$ (74,000,000)<span></span>
</td>
<td class="num">$ (316,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal', window );">Repurchase obligation due to change of control percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty', window );">Asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentCovenantsOfSecuredDebtRatio', window );">Secured debt ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty', window );">Asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% due July 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,870,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt instrument payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,113,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,000,000<span></span>
</td>
<td class="nump">770,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% due September 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.125% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt instrument payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,872,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,872,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.500% due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt instrument payment</a></td>
<td class="nump">$ 730,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.250% due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,410,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayments of secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,428,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.500% due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt instrument payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised', window );">Incremental period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Letter of Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity', window );">Line of credit facility, subfacility maximum available capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit facility, maximum borrowing capacity (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Amount available for borrowing under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LineOfCreditFacilityCovenantThresholdLimit', window );">Threshold limit of revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit', window );">Threshold limit of unused borrowing availability under the revolving credit facility (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays', window );">Threshold limit of unused borrowing availability under the revolving credit facility, number of consecutive days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused commitment fee (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused commitment fee (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Base rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage margin on variable rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Base rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage margin on variable rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentBasisSpreadOnCreditSpread', window );">Basis spread on credit spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage margin on variable rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Credit Agreement | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage margin on variable rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit Facility | Letter of Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit facility, maximum borrowing capacity (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio', window );">Secured debt to EBITDA ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit', window );">Interest rate on issued but undrawn letters of credit (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage', window );">Issuance fee, based on face amount (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio', window );">Maximum secured debt covenant ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit Facility | Letter of Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused commitment fee (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit Facility | Letter of Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused commitment fee (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings', window );">Number of business days after notice for reimbursement of drawings | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit Facility | Letter of Credit Facility | Base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT AND LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage margin on variable rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentBasisSpreadOnCreditSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread On Credit Spread</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentBasisSpreadOnCreditSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentCovenantMaximumSecuredDebtRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Maximum Secured Debt Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentCovenantMaximumSecuredDebtRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the ratio for secured debt to EBITDA required to be maintained under financial covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the hospital asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentCovenantsOfSecuredDebtRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the secured debt ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentCovenantsOfSecuredDebtRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Issued But Undrawn Letters Of Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the issuance fee, expressed as a percentage of the face amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the principal amount at which the entity is obligated to offer to repurchase the debt instrument due to a change in control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LineOfCreditFacilityCovenantThresholdLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold limit for the line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LineOfCreditFacilityCovenantThresholdLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the unused borrowing availability threshold limit for the line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit, Number Of Consecutive Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum available capacity under the subfacility for standby letters of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of business days after notice, for reimbursement of amount drawn under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period In Which The Advanced Rated Is Increased And Limit On Certain Eligible Accounts Receivable Are Raised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677714544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM DEBT - Future Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt, including finance lease obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total</a></td>
<td class="nump">$ 15,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">3,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive', window );">Later Years</a></td>
<td class="nump">$ 8,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Repayments Of Principal After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Repayments Of Principal In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670774480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GUARANTEES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeGuaranteeMember', window );">Income Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GuaranteeObligationPeriod', window );">Guarantee obligation period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_CommitmentPeriod', window );">Commitment period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_GuaranteeOfBusinessRevenueMember', window );">Guarantee of Business Revenue | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GuaranteeObligationPeriod', window );">Guarantee obligation period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_GuaranteeOfBusinessRevenueMember', window );">Guarantee of Business Revenue | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GuaranteeObligationPeriod', window );">Guarantee obligation period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeAndRevenueCollectionGuaranteeMember', window );">Income and Revenue Collection Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum potential amount of future payments under guarantees</a></td>
<td class="nump">$ 164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeAndRevenueCollectionGuaranteeMember', window );">Income and Revenue Collection Guarantee | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesFairValueDisclosure', window );">Liability for guarantees</a></td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_GuaranteedInvesteesOfThirdPartiesMember', window );">Guaranteed Investees of Third Parties</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum potential amount of future payments under guarantees</a></td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_GuaranteedInvesteesOfThirdPartiesMember', window );">Guaranteed Investees of Third Parties | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>GUARANTEES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries', window );">Guarantee obligations for consolidated subsidiaries</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_CommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the commitment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_CommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees which pertains to the entity's consolidated subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_GuaranteeObligationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of the guarantee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_GuaranteeObligationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of guarantee, including, but not limited to, financial standby letter of credit, fair value guarantee, guarantee of collection of scheduled contractual cash flows from financial assets, and contracts that contingently require the guarantor to make payments or perform services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12201-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_GuaranteeOfBusinessRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_GuaranteeOfBusinessRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeAndRevenueCollectionGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=thc_IncomeAndRevenueCollectionGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=thc_GuaranteedInvesteesOfThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=thc_GuaranteedInvesteesOfThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671248816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Share-based Compensation Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="nump">$ 44,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_StockIncentivePlan2019Member', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance under the plan (in shares)</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period from the date of grant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares', window );">Contractual right to receive shares of common stock for a stock based award (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="nump">$ 42,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Minimum | Performance-based vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Maximum | Performance-based vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember', window );">Performance Based Restricted Stock Unit | Minimum | Performance-based vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember', window );">Performance Based Restricted Stock Unit | Maximum | Performance-based vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares of common stock into which a share-based award can be converted in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=thc_StockIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=thc_StockIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_PerformanceBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680718976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Wtd. Avg Remaining Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">520,998<span></span>
</td>
<td class="nump">912,531<span></span>
</td>
<td class="nump">1,960,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(60,051)<span></span>
</td>
<td class="num">(391,533)<span></span>
</td>
<td class="num">(987,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">460,947<span></span>
</td>
<td class="nump">520,998<span></span>
</td>
<td class="nump">912,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Wtd. Avg. Exercise&#160;Price Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 23.90<span></span>
</td>
<td class="nump">$ 22.51<span></span>
</td>
<td class="nump">$ 20.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">28.26<span></span>
</td>
<td class="nump">20.66<span></span>
</td>
<td class="nump">17.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 23.33<span></span>
</td>
<td class="nump">$ 23.90<span></span>
</td>
<td class="nump">$ 22.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Wtd. Avg Remaining Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of awards exercised</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670764944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Options&#160;Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">460,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 23.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$18.99 to $20.609</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Options&#160;Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">293,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 19.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$18.99 to $20.609 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Summary information about outstanding stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of stock exercise price range (in dollars per share)</a></td>
<td class="nump">18.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$18.99 to $20.609 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Summary information about outstanding stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of stock exercise price range (in dollars per share)</a></td>
<td class="nump">$ 20.609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$20.61 to $35.430</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Options&#160;Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">167,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 29.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$20.61 to $35.430 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Summary information about outstanding stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of stock exercise price range (in dollars per share)</a></td>
<td class="nump">20.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$20.61 to $35.430 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Summary information about outstanding stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of stock exercise price range (in dollars per share)</a></td>
<td class="nump">$ 35.430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=thc_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=thc_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=thc_ExercisePriceRangeSecondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=thc_ExercisePriceRangeSecondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670569552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Employee Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="nump">$ 44,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 48.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Current Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage', window );">Share based payment award options outstanding percentage</a></td>
<td class="nump">42.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Former Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage', window );">Share based payment award options outstanding percentage</a></td>
<td class="nump">57.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a certain classification of awards in a stock based compensation plan to the total of a particular category of awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=thc_CurrentEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=thc_CurrentEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=thc_FormerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=thc_FormerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636669853200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>quarter </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>quarter </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>quarter </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember', window );">Performance Based Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,171,202<span></span>
</td>
<td class="nump">2,095,206<span></span>
</td>
<td class="nump">1,463,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,205<span></span>
</td>
<td class="nump">900,018<span></span>
</td>
<td class="nump">1,767,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,187,384)<span></span>
</td>
<td class="num">(765,814)<span></span>
</td>
<td class="num">(825,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,605)<span></span>
</td>
<td class="num">(58,208)<span></span>
</td>
<td class="num">(310,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520,418<span></span>
</td>
<td class="nump">2,171,202<span></span>
</td>
<td class="nump">2,095,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the beginning of the period (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.51<span></span>
</td>
<td class="nump">$ 25.87<span></span>
</td>
<td class="nump">$ 25.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.79<span></span>
</td>
<td class="nump">58.61<span></span>
</td>
<td class="nump">27.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.18<span></span>
</td>
<td class="nump">30.51<span></span>
</td>
<td class="nump">25.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.58<span></span>
</td>
<td class="nump">37.60<span></span>
</td>
<td class="nump">32.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.36<span></span>
</td>
<td class="nump">$ 40.51<span></span>
</td>
<td class="nump">$ 25.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,205<span></span>
</td>
<td class="nump">900,018<span></span>
</td>
<td class="nump">1,767,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=thc_NonExecutiveChairmanMember', window );">Non Executive Chairman | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">7,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="nump">7,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=thc_NonEmployeeDirectorsMember', window );">Non Employee Directors | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,681<span></span>
</td>
<td class="nump">35,482<span></span>
</td>
<td class="nump">39,738<span></span>
</td>
<td class="nump">103,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,681<span></span>
</td>
<td class="nump">35,482<span></span>
</td>
<td class="nump">39,738<span></span>
</td>
<td class="nump">103,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember', window );">Time Based Vesting, Three Year Period from Grant Date | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,381<span></span>
</td>
<td class="nump">263,180<span></span>
</td>
<td class="nump">607,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,381<span></span>
</td>
<td class="nump">263,180<span></span>
</td>
<td class="nump">607,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingFourYearFromGrantDateMember', window );">Time Based Vesting, Four Year From Grant Date | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnSecondAnniversaryMember', window );">Time Based Vesting, Settled on Second Anniversary | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember', window );">Time Based Vesting, Evenly On The Third And Fourth Anniversary | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingOverAThreeYearPeriodMember', window );">Performance Based Vesting Over A Three Year Period | Performance Based Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingOverAThreeYearPeriodMember', window );">Performance Based Vesting Over A Three Year Period | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,259<span></span>
</td>
<td class="nump">499,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,259<span></span>
</td>
<td class="nump">499,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember', window );">Performance-based vesting | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,600<span></span>
</td>
<td class="nump">298,492<span></span>
</td>
<td class="nump">579,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,600<span></span>
</td>
<td class="nump">298,492<span></span>
</td>
<td class="nump">579,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember', window );">Performance-based vesting | Minimum | Performance Based Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember', window );">Performance-based vesting | Minimum | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember', window );">Performance-based vesting | Maximum | Performance Based Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember', window );">Performance-based vesting | Maximum | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingMember', window );">Time-vesting | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,788<span></span>
</td>
<td class="nump">1,084,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,788<span></span>
</td>
<td class="nump">1,084,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingMember', window );">Time-vesting | Director | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingMember', window );">Time-vesting | Director | Additional Prorated Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_EightQuarterVestingPeriodMember', window );">Eight Quarter Vesting Period | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods', window );">Award vesting period, number of quarterly periods | quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_ElevenQuarterVestingPeriodMember', window );">Eleven Quarter Vesting Period | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods', window );">Award vesting period, number of quarterly periods | quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnFourthAnniversaryMember', window );">Time Based Vesting, Settled On Fourth Anniversary | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnThirdAnniversaryMember', window );">Time Based Vesting, Settled On Third Anniversary | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,351<span></span>
</td>
<td class="nump">13,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,351<span></span>
</td>
<td class="nump">13,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingOneYearFromGrantDateMember', window );">Time Based Vesting, One Year From Grant Date | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_TimeBasedVestingOnFourthAnniversaryMember', window );">Time Based Vesting On Fourth Anniversary | Senior Officer | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingOnFourthAnniversaryMember', window );">Performance Based Vesting On Fourth Anniversary | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,341<span></span>
</td>
<td class="nump">80,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,341<span></span>
</td>
<td class="nump">80,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingAndSettledImmediatelyMember', window );">Performance Based Vesting And Settled Immediately | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Quarterly Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=thc_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=thc_NonExecutiveChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=thc_NonExecutiveChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=thc_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=thc_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingFourYearFromGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingFourYearFromGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingOverAThreeYearPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_PerformanceBasedVestingOverAThreeYearPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_PerformanceBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=thc_AdditionalProratedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=thc_AdditionalProratedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_EightQuarterVestingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_EightQuarterVestingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_ElevenQuarterVestingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_ElevenQuarterVestingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingSettledOnThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingOneYearFromGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingOneYearFromGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_TimeBasedVestingOnFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_TimeBasedVestingOnFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=thc_SeniorOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=thc_SeniorOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingOnFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_PerformanceBasedVestingOnFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_PerformanceBasedVestingAndSettledImmediatelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_PerformanceBasedVestingAndSettledImmediatelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680707072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">39.60%<span></span>
</td>
<td class="nump">65.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility , maximum</a></td>
<td class="nump">68.10%<span></span>
</td>
<td class="nump">79.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636660531120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares', window );">Contractual right to receive shares of common stock for a stock based award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,171,202<span></span>
</td>
<td class="nump">2,095,206<span></span>
</td>
<td class="nump">1,463,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,205<span></span>
</td>
<td class="nump">900,018<span></span>
</td>
<td class="nump">1,767,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,187,384)<span></span>
</td>
<td class="num">(765,814)<span></span>
</td>
<td class="num">(825,727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,605)<span></span>
</td>
<td class="num">(58,208)<span></span>
</td>
<td class="num">(310,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520,418<span></span>
</td>
<td class="nump">2,171,202<span></span>
</td>
<td class="nump">2,095,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.51<span></span>
</td>
<td class="nump">$ 25.87<span></span>
</td>
<td class="nump">$ 25.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.79<span></span>
</td>
<td class="nump">58.61<span></span>
</td>
<td class="nump">27.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.18<span></span>
</td>
<td class="nump">30.51<span></span>
</td>
<td class="nump">25.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.58<span></span>
</td>
<td class="nump">37.60<span></span>
</td>
<td class="nump">32.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.36<span></span>
</td>
<td class="nump">$ 40.51<span></span>
</td>
<td class="nump">$ 25.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember', window );">2015 USPI Management Equity Plan | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod', window );">Vesting period, days to be exercised before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember', window );">2015 USPI Management Equity Plan | Equity Option | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination', window );">Expected payment for vested securities and termination of plan</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember', window );">2015 USPI Management Equity Plan | Equity Option | Tranche One | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember', window );">2015 USPI Management Equity Plan | Equity Option | Tranche Two | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember', window );">2015 USPI Management Equity Plan | Minimum | Equity Option | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent', window );">Percent of common stock allocated to plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember', window );">2015 USPI Management Equity Plan | Maximum | Equity Option | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_A2020USPIManagementEquityPlanMember', window );">2020 USPI Management Equity Plan | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares', window );">Contractual right to receive shares of common stock for a stock based award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494,882<span></span>
</td>
<td class="nump">2,025,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,990<span></span>
</td>
<td class="nump">2,556,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(369,691)<span></span>
</td>
<td class="num">(388,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,351)<span></span>
</td>
<td class="num">(218,576)<span></span>
</td>
<td class="num">(531,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,840<span></span>
</td>
<td class="nump">1,494,882<span></span>
</td>
<td class="nump">2,025,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.13<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.13<span></span>
</td>
<td class="nump">34.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.13<span></span>
</td>
<td class="nump">34.13<span></span>
</td>
<td class="nump">34.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares', window );">Noncontrolling interest purchased during period through issuance of equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,990<span></span>
</td>
<td class="nump">2,556,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Restricted Stock Units | Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Restricted Stock Units | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Restricted Stock Units | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Restricted Stock Units | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Restricted Stock Units | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember', window );">USPI Management Equity Plan | Nonvoting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Wtd. Avg. Grant Date&#160;Fair Value&#160;Per&#160;Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_CommonStockSharesOutstandingAndEligibleToBeSold', window );">Outstanding vested shares eligible to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_CommonStockSharesOutstandingAndEligibleToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares, Outstanding And Eligible To Be Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_CommonStockSharesOutstandingAndEligibleToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest Repurchased During Period Through Issuance Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares of common stock into which a share-based award can be converted in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award, Number Of Allocated Shares, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Exercise Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Payment For Repurchase Of Vested Options And Plan Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=thc_A2015USPIManagementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=thc_A2020USPIManagementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=thc_A2020USPIManagementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=thc_USPIManagementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=thc_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=thc_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670193712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be issued under the plan (in shares)</a></td>
<td class="nump">4,070,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance under the plan (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of closing price at which shares are purchased by participant</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares', window );">Requisite holding period for shares issued under the plan</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee', window );">Fair market value per employee per year</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares (in shares)</a></td>
<td class="nump">98,498<span></span>
</td>
<td class="nump">89,865<span></span>
</td>
<td class="nump">254,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan', window );">Weighted average price (in dollars per share)</a></td>
<td class="nump">$ 54.19<span></span>
</td>
<td class="nump">$ 63.01<span></span>
</td>
<td class="nump">$ 19.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent', window );">Base earnings elected to be withheld each quarter by eligible employees to purchase shares of the entity's common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent', window );">Base earnings elected to be withheld each quarter by eligible employees to purchase shares of the entity's common stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of eligible earnings that can be contributed by the employees towards the quarterly purchase of the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum fair market value of shares which an employee can purchase in an year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the requisite holding period for shares issued under plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents value per share for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672469952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution expense</a></td>
<td class="nump">$ 86,000,000<span></span>
</td>
<td class="nump">$ 98,000,000<span></span>
</td>
<td class="nump">$ 119,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Projected benefit obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Beginning obligations</a></td>
<td class="num">(1,313,000,000)<span></span>
</td>
<td class="num">(1,429,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="num">(37,000,000)<span></span>
</td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="num">(47,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gain</a></td>
<td class="nump">265,000,000<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution', window );">Benefits paid</a></td>
<td class="nump">83,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Ending obligations</a></td>
<td class="num">(1,002,000,000)<span></span>
</td>
<td class="num">(1,313,000,000)<span></span>
</td>
<td class="num">(1,429,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Fair value of plans assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning plan assets</a></td>
<td class="nump">867,000,000<span></span>
</td>
<td class="nump">869,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Gain (loss) on plan assets</a></td>
<td class="num">(161,000,000)<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(60,000,000)<span></span>
</td>
<td class="num">(86,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending plan assets</a></td>
<td class="nump">648,000,000<span></span>
</td>
<td class="nump">867,000,000<span></span>
</td>
<td class="nump">869,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status of plans</a></td>
<td class="num">(354,000,000)<span></span>
</td>
<td class="num">(446,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">1,002,000,000.000<span></span>
</td>
<td class="nump">1,311,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the Consolidated Balance Sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liability</a></td>
<td class="num">(23,000,000)<span></span>
</td>
<td class="num">(25,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other long-term liability</a></td>
<td class="num">(331,000,000)<span></span>
</td>
<td class="num">(421,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">222,000,000<span></span>
</td>
<td class="nump">294,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest costs</a></td>
<td class="nump">37,000,000<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(42,000,000)<span></span>
</td>
<td class="num">(53,000,000)<span></span>
</td>
<td class="num">(48,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (income)</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="num">$ (6,000,000)<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag', window );">Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</a></td>
<td class="text">Interest costs<span></span>
</td>
<td class="text">Interest costs<span></span>
</td>
<td class="text">Interest costs<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag', window );">Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</a></td>
<td class="text">Expected return on plan assets<span></span>
</td>
<td class="text">Expected return on plan assets<span></span>
</td>
<td class="text">Expected return on plan assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Costs Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Gain (loss) adjustments recorded in other comprehensive income (loss)</a></td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="nump">$ 61,000,000<span></span>
</td>
<td class="num">$ (32,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net actuarial losses</a></td>
<td class="nump">63,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="num">(41,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss</a></td>
<td class="num">(9,000,000)<span></span>
</td>
<td class="num">(11,000,000)<span></span>
</td>
<td class="num">(9,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Cumulative net actuarial losses</a></td>
<td class="nump">222,000,000<span></span>
</td>
<td class="nump">294,000,000<span></span>
</td>
<td class="nump">355,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Unrecognized prior service costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember', window );">SERP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans', window );">Number of frozen plans | plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Accumulated Benefit Obligations Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Compensation increase rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Costs Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Compensation increase rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Fair value of plans assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning plan assets</a></td>
<td class="nump">$ 867,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending plan assets</a></td>
<td class="nump">$ 648,000,000<span></span>
</td>
<td class="nump">$ 867,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Accumulated Benefit Obligations Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.51%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Costs Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.53%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Long-term rate of return on assets</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of payments made or employer contribution in a defined benefit pension plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of frozen non-qualified benefit pension plans of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680712272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Asset Allocations (Details) - Pension Plan<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Weighted-average asset allocations by asset category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage', window );">Actual</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Weighted-average asset allocations by asset category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage', window );">Actual</a></td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Weighted-average asset allocations by asset category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target</a></td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage', window );">Actual</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Alternative investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Weighted-average asset allocations by asset category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage', window );">Actual</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment to total investment within defined benefit plan asset category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=thc_DefinedBenefitPlanAlternativeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=thc_DefinedBenefitPlanAlternativeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636662252400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Fair Value of Assets and Future Benefit Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">$ 648<span></span>
</td>
<td class="nump">$ 867<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>SERP and DMC Pension Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DefinedBenefitPlanExpectedFutureBenefitPayments', window );">Total</a></td>
<td class="nump">822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">Five Years Thereafter</a></td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the Consolidated Balance Sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Benefit plan obligations</a></td>
<td class="num">(354)<span></span>
</td>
<td class="num">(446)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liability</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Defined benefit plan obligations</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contribution to the plan for 2023</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | U.S. government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Private equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Real estate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Hedge funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | U.S. government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | Private equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | Real estate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;1 | Hedge funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | U.S. government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | Private equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | Real estate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;2 | Hedge funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | U.S. government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | Private equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | Real estate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Level&#160;3 | Hedge funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Retirement Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of DMC Pension Plan assets</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DefinedBenefitPlanExpectedFutureBenefitPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate amount of the benefits expected to be paid in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DefinedBenefitPlanExpectedFutureBenefitPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_PrivateEquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_PrivateEquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670422032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Components (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Components of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease assets</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">12,663<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(6,201)<span></span>
</td>
<td class="num">(5,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Net property and equipment</a></td>
<td class="nump">6,462<span></span>
</td>
<td class="nump">6,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">$ 685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Components of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Components of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">6,646<span></span>
</td>
<td class="nump">6,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Components of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Components of property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 4,748<span></span>
</td>
<td class="nump">$ 4,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671222368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 9,261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill at end of period</a></td>
<td class="nump">10,123,000,000<span></span>
</td>
<td class="nump">$ 9,261,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross, at beginning of period</a></td>
<td class="nump">5,238,000,000<span></span>
</td>
<td class="nump">5,375,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="num">(2,430,000,000)<span></span>
</td>
<td class="num">(2,430,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">2,808,000,000<span></span>
</td>
<td class="nump">2,945,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill transferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility', window );">Goodwill related to assets held for sale and disposed</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="num">(178,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments', window );">Goodwill acquired during the year and purchase price allocation adjustments</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross, at end of period</a></td>
<td class="nump">5,236,000,000<span></span>
</td>
<td class="nump">5,238,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="num">(2,430,000,000)<span></span>
</td>
<td class="num">(2,430,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill at end of period</a></td>
<td class="nump">2,806,000,000<span></span>
</td>
<td class="nump">2,808,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">2,430,000,000<span></span>
</td>
<td class="nump">2,430,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">5,848,000,000<span></span>
</td>
<td class="nump">5,258,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill transferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility', window );">Goodwill related to assets held for sale and disposed</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="num">(33,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments', window );">Goodwill acquired during the year and purchase price allocation adjustments</a></td>
<td class="nump">866,000,000<span></span>
</td>
<td class="nump">664,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill at end of period</a></td>
<td class="nump">6,712,000,000<span></span>
</td>
<td class="nump">5,848,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">605,000,000<span></span>
</td>
<td class="nump">605,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill at end of period</a></td>
<td class="nump">605,000,000<span></span>
</td>
<td class="nump">605,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Acquired During Period And Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Related To Assets Held For Sale And Disposed Or Deconsolidated Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636662392320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,428)<span></span>
</td>
<td class="num">(1,374)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total other intangible assets with indefinite lives</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">2,871<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net&#160;Book Value</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total other intangible assets with indefinite lives</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total other intangible assets with indefinite lives</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total other intangible assets with indefinite lives</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,751<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,206)<span></span>
</td>
<td class="num">(1,165)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671257024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated future amortization of intangibles with finite useful lives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 710<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Later Years</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636679192240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ASSETS - Schedule of Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts receivable and allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">California provider fee program receivables</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ReceivablesFromGovernmentProgramsCurrent', window );">Receivables from other government programs</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PhysicianAndGroupCoverageGuaranteesCurrent', window );">Guarantees</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Non-patient receivables</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember', window );">California's Provider Fee Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts receivable and allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">California provider fee program receivables</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PhysicianAndGroupCoverageGuaranteesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Physician And Group Coverage Guarantees Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PhysicianAndGroupCoverageGuaranteesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ReceivablesFromGovernmentProgramsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables from government programs Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ReceivablesFromGovernmentProgramsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=thc_CaliforniaProviderFeeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680716896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ASSETS - Schedule of Investments and Other Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract', window );"><strong>Investments and other assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total investments</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueOfLifeInsurance', window );">Cash surrender value of life insurance policies</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits Assets, Noncurrent</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">California provider fee program receivables</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent', window );">Other long-term receivables and other assets</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAndReceivablesNet', window );">Investments and other assets</a></td>
<td class="nump">$ 3,147<span></span>
</td>
<td class="nump">$ 3,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments And Other Assets Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the land held for expansion, other long-term receivables and other assets which are classified as noncurrent as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashSurrenderValueOfLifeInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashSurrenderValueOfLifeInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAndReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAndReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672201136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax', window );">Tax benefit (expense) allocated to adjustments for defined benefit plans</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Adjustments for defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (181)<span></span>
</td>
<td class="num">$ (233)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670642784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET OPERATING REVENUES - Net Operating Revenue By Source (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 19,174<span></span>
</td>
<td class="nump">$ 19,485<span></span>
</td>
<td class="nump">$ 17,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">15,061<span></span>
</td>
<td class="nump">15,982<span></span>
</td>
<td class="nump">14,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Total | Acute Care Hospitals And Related Outpatient Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">13,847<span></span>
</td>
<td class="nump">14,759<span></span>
</td>
<td class="nump">13,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Medicare | Acute Care Hospitals And Related Outpatient Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">2,615<span></span>
</td>
<td class="nump">2,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Medicaid | Acute Care Hospitals And Related Outpatient Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Managed care | Acute Care Hospitals And Related Outpatient Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">9,730<span></span>
</td>
<td class="nump">9,985<span></span>
</td>
<td class="nump">9,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Uninsured | Acute Care Hospitals And Related Outpatient Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Indemnity and other | Acute Care Hospitals And Related Outpatient Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Hospital Operations | Other Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Inter-segment eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="num">$ (451)<span></span>
</td>
<td class="num">$ (482)<span></span>
</td>
<td class="num">$ (528)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCarePatientServiceExcludingPhysicianPracticesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCarePatientServiceExcludingPhysicianPracticesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCarePatientServiceMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCarePatientServiceMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCarePatientServiceManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCarePatientServiceManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCarePatientServiceSelfpayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCarePatientServiceSelfpayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCarePatientServiceIndemnityAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCarePatientServiceIndemnityAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675723264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET OPERATING REVENUES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 19,174<span></span>
</td>
<td class="nump">$ 19,485<span></span>
</td>
<td class="nump">$ 17,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672473264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 19,174<span></span>
</td>
<td class="nump">$ 19,485<span></span>
</td>
<td class="nump">$ 17,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenues | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=thc_HealthCareManagementFeesMember', window );">Management fees | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=thc_HealthCareOtherSourcesMember', window );">Revenue from other sources | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCareManagementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCareManagementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCareOtherSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCareOtherSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671585312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET OPERATING REVENUES - Net Operating Revenue Composition, Conifer Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 19,174<span></span>
</td>
<td class="nump">$ 19,485<span></span>
</td>
<td class="nump">$ 17,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=thc_TenetHealthcareCorpMember', window );">Tenet | Conifer | Health Care - Client Contracts - Revenue Cycle Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=thc_TenetHealthcareCorpMember', window );">Tenet | Conifer | Health Care - Client Contracts - Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=thc_OtherCustomersMember', window );">Other Customers | Conifer | Health Care - Client Contracts - Revenue Cycle Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=thc_OtherCustomersMember', window );">Other Customers | Conifer | Health Care - Client Contracts - Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=thc_TenetHealthcareCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=thc_TenetHealthcareCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCareClientContractsRevenueCycleServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCareClientContractsRevenueCycleServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_HealthCareClientContractsOtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_HealthCareClientContractsOtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=thc_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=thc_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677567392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET OPERATING REVENUES - Performance Obligation (Details) - Conifer<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 5,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 2,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672080992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INSURANCE - Property Insurance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_CybersecurityIncidentPreTaxEffect', window );">Cybersecurity incident, pre-tax effect</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,174<span></span>
</td>
<td class="nump">$ 19,485<span></span>
</td>
<td class="nump">$ 17,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceAnnualCoverageLimit', window );">Insurance coverage, aggregate limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=thc_InsuranceRecoveriesMember', window );">Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_FloodMember', window );">Floods | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceMaximumCoveragePerIncident', window );">Property insurance coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_EarthquakeMember', window );">Earthquakes | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceMaximumCoveragePerIncident', window );">Property insurance coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductiblePercentage', window );">Insurance deductible (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_WindstormsMember', window );">Windstorms | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceMaximumCoveragePerIncident', window );">Property insurance coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FireAndOtherPerilsMember', window );">Fires and Other Perils | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceMaximumCoveragePerIncident', window );">Property insurance coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FloodEarthquakeAndWindstormMember', window );">Floods, Earthquakes and Windstorms | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductiblePercentage', window );">Insurance deductible (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_CaliforniaEarthquakeMember', window );">California Earthquake | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductible', window );">Insurance deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FloodsAndWindstormsMember', window );">Floods And Windstorms | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductible', window );">Insurance deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_NewMadridFaultEarthquakesMember', window );">New Madrid Fault Earthquakes | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductiblePercentage', window );">Insurance deductible (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductible', window );">Insurance deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_OtherCatastrophicEventsMember', window );">Fires and Certain Other Covered Losses | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PropertyInsuranceDeductible', window );">Insurance deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_CybersecurityIncidentPreTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cybersecurity Incident, Pre-Tax Effect</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_CybersecurityIncidentPreTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_InsuranceCoverageLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_InsuranceCoverageLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PropertyInsuranceAnnualCoverageLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Insurance, Annual Coverage Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PropertyInsuranceAnnualCoverageLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PropertyInsuranceDeductible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Insurance, Deductible</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PropertyInsuranceDeductible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PropertyInsuranceDeductiblePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of risk retained by the entity before the insurance arrangement begins to provide coverage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PropertyInsuranceDeductiblePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PropertyInsuranceMaximumCoveragePerIncident">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Insurance, Maximum Coverage Per Incident</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PropertyInsuranceMaximumCoveragePerIncident</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=thc_InsuranceRecoveriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=thc_InsuranceRecoveriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_FloodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_FloodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_EarthquakeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_EarthquakeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_WindstormsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_WindstormsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FireAndOtherPerilsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FireAndOtherPerilsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FloodEarthquakeAndWindstormMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FloodEarthquakeAndWindstormMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_CaliforniaEarthquakeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_CaliforniaEarthquakeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FloodsAndWindstormsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_FloodsAndWindstormsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_NewMadridFaultEarthquakesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_NewMadridFaultEarthquakesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_OtherCatastrophicEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=thc_OtherCatastrophicEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680894768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INSURANCE - Professional and General Liability Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears', window );">Malpractice expense, portion related to adverse developments in prior years</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other Operating Expense, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredNet', window );">Malpractice expense</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=thc_ProfessionalAndGeneralLiabilityReservesMember', window );">Professional and General Liability Reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_InsuranceCoverageLineItems', window );"><strong>Insurance coverage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_InsuranceCoverageLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_InsuranceCoverageLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Malpractice Loss Contingency, Adverse Developments In Prior Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs associated with malpractice claims and insurance premiums incurred during an accounting period, less insurance recoveries and returns of previously paid premiums.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126943116&amp;loc=d3e5870-115623<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126943371&amp;loc=d3e8578-115644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=thc_ProfessionalAndGeneralLiabilityReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=thc_ProfessionalAndGeneralLiabilityReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676379280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CLAIMS AND LAWSUITS - Narrative (Details) - Other Matters - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Reserve of estimated obligation</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims', window );">Bankruptcy claims, amount paid to settle claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankruptcyClaimsAmountPaidToSettleClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount paid to settle bankruptcy claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56015-112765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankruptcyClaimsAmountPaidToSettleClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=thc_OtherMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=thc_OtherMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680812544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CLAIMS AND LAWSUITS - Reconciliations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and investigation costs</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Claims, Lawsuits, and Regulatory Proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation reserve, Balances at Beginning of Period</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and investigation costs</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Cash Payments</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_LossContingencyAccrualOther', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation reserve, Balances at End of Period</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_LossContingencyAccrualOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Accrual, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_LossContingencyAccrualOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670734896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Interests acquired and other disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Accretion of redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">$ 1,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Interests acquired and other disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase and sales of business and noncontrolling interest, net</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_GainLossFromPurchaseOfNoncontrollingInterests', window );">Loss from purchase of noncontrolling interests</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Interests acquired and other disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest', window );">Share purchase agreement amount of payment</a></td>
<td class="nump">406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementPaymentForExecution', window );">Share purchase agreement, payment for execution</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementNumberOfMonthlyPayments', window );">Number of monthly payments of share purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementMonthlyPayment', window );">Share purchase agreement, monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Interests acquired and other disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_JointVentureOwnershipPercentage', window );">Joint venture ownership (as a percentage)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International | Put Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Interests acquired and other disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_PurchasedEquityInJointVenturePercentageOfTotalShares', window );">Purchased equity In joint venture, percentage of total shares (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3333<span></span>
</td>
<td class="nump">0.666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_GainLossFromPurchaseOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Purchase Of Noncontrolling Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_GainLossFromPurchaseOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_JointVentureOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the joint venture ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_JointVentureOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_PurchasedEquityInJointVenturePercentageOfTotalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Equity In Joint Venture, Percentage Of Total Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_PurchasedEquityInJointVenturePercentageOfTotalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount Of Payment for Minority Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Monthly Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementNumberOfMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Number Of Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementNumberOfMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementPaymentForExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Payment For Execution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementPaymentForExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672095216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balances at beginning of period&#160;</a></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions paid to noncontrolling interests</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Accretion of redeemable noncontrolling interests</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balances at end of period&#160;</a></td>
<td class="nump">2,149<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=thc_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balances at beginning of period&#160;</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions paid to noncontrolling interests</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Accretion of redeemable noncontrolling interests</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchases and sales of businesses and noncontrolling interests, net</a></td>
<td class="num">(175)<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balances at end of period&#160;</a></td>
<td class="nump">$ 2,149<span></span>
</td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="nump">$ 1,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=thc_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=thc_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672474880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">$ 2,149<span></span>
</td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income available to redeemable noncontrolling interests</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income available to redeemable noncontrolling interests</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income available to redeemable noncontrolling interests</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income available to redeemable noncontrolling interests</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680819504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Provision and Deferred Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670675504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Federal Tax Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign pretax loss</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation between reported income tax expense (benefit) and income taxes calculated by the statutory federal income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax expense at statutory federal rate of 21%</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal income tax benefit</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Tax benefit attributable to noncontrolling interests</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible goodwill</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount', window );">Nondeductible executive compensation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation', window );">Nondeductible litigation costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount', window );">Expired charitable contribution carryforward</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation tax benefit</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes', window );">Prior-year provision to return adjustments and other changes in deferred&#160;taxes</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other items</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Expired Charitable Contributions Carryforward, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_IncomeTaxReconciliationNondeductibleExpenseLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to litigation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_IncomeTaxReconciliationNondeductibleExpenseLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense (benefit) as reported in the income statement for the current period and the expected income tax expense or benefit computed attributable to revisions of previously reported income tax expense and other changes in deferred taxes, net of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636676290192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_IncomeTaxExpenseBenefitCARESAct', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod', window );">Increase (decrease) in deferred tax valuation allowance due to a change in tax accounting method</a></td>
<td class="num">$ (126)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_IncomeTaxExpenseBenefitCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_IncomeTaxExpenseBenefitCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Change In Tax Accounting Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636672046080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges', window );">Reserves related to discontinued operations and restructuring charges</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Receivables (doubtful accounts and adjustments)</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxAssetsMedicareAdvancePayments', window );">Medicare advance payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance', window );">Accruals for retained insurance risks</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxAssetsOtherLongTermLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits', window );">Benefit plans</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accrued liabilities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxAssetsInterestExpenseLimitation', window );">Interest expense limitation</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations', window );">Right-of-use lease assets and obligations</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other items</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">$ (55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and fixed-asset differences</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets', window );">Investments and other assets</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations', window );">Right-of-use lease assets and obligations</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other items</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities, gross, total</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities, total</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredTaxAssetsReconciliationAbstract', window );"><strong>Reconciliation of the deferred tax assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_DeferredIncomeTaxAssetsLiabilitiesNet', window );">Net deferred tax asset (liability)</a></td>
<td class="num">$ (198)<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredIncomeTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredIncomeTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxAssetsInterestExpenseLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Expense Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxAssetsInterestExpenseLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxAssetsMedicareAdvancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Medicare Advance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxAssetsMedicareAdvancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxAssetsOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of the estimated future tax reductions attributable to the difference between the tax basis and the generally accepted accounting principle basis of a company's other long-term liabilities which will decrease future taxable income when such basis difference reverses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxAssetsOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxAssetsReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Reconciliation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxAssetsReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Right-of-Use Lease Assets And Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-Use Lease Liability And Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671078048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Valuation Allowances and Unrecognized Tax Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance against deferred tax assets</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="num">$ (226,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations', window );">Increase (decrease) in valuation allowance due to limitations on deductions of interest expense</a></td>
<td class="nump">123,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="num">(211,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers', window );">Decrease in valuation allowance due to changes based on expiration or worthlessness of unutilized state net operating loss carryovers</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets', window );">Increase (decrease) in valuation allowance due to changes in expected realizability of deferred tax assets</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="num">(14,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">177,000,000<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Changes in unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits which, if recognized, would impact effective tax rate</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase (decrease) unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Total accrued interest and penalties on unrecognized tax benefits</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Changes in unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions due to a lapse of statute of limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases due to tax positions taken in prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="nump">$ 31,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of change in the period, in the valuation allowance attributable due to changes in expected realizability of deferred tax assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Expiration Or Worthlessness Of Unutilized State Net Operating Loss Carryovers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Due To Interest Expense Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680744304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - NOL and Tax Credit Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Unrecognized federal and state tax benefits and reserves for interest and penalties, which may decrease in the next 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax benefit, net of valuation allowance and federal tax impact, associated with NOL carryforwards</a></td>
<td class="nump">74,000,000<span></span>
</td>
<td class="nump">$ 99,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">3,106,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax benefit, net of valuation allowance and federal tax impact, associated with NOL carryforwards</a></td>
<td class="nump">$ 42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636677716912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER COMMON SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Net Income Available to Common Shareholders (Numerator)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share</a></td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted Average Shares (Denominator)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in shares)</a></td>
<td class="nump">106,929<span></span>
</td>
<td class="nump">106,833<span></span>
</td>
<td class="nump">105,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive stock options, restricted stock units and deferred compensation units (in shares)</a></td>
<td class="nump">3,587<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in shares)</a></td>
<td class="nump">110,516<span></span>
</td>
<td class="nump">108,571<span></span>
</td>
<td class="nump">106,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Per-Share Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 8.56<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_EffectOfDilutiveSecuritiesPerShareAmount', window );">Effect of dilutive stock options, restricted stock units, and deferred compensation units (in dollars per share)</a></td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.05)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 3.78<span></span>
</td>
<td class="nump">$ 8.43<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_EffectOfDilutiveSecuritiesPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Dilutive Securities Per Share Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_EffectOfDilutiveSecuritiesPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680655616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AssetsHeldforuseLongLivedFairValueDisclosure', window );">Assets held-for-use, long lived, fair value</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue', window );">Estimated fair value of the long-term debt instrument as a percentage of carrying value</a></td>
<td class="nump">92.80%<span></span>
</td>
<td class="nump">103.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_AssetsHeldforuseLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Held-for-use, Long Lived, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_AssetsHeldforuseLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated fair value of the long-term debt instrument as a percentage of carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636671701424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>surgery_center</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>surgery_center</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>surgical_center</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>hospital </div>
<div>surgery_center</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>business </div>
<div>hospital </div>
<div>quarter</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>business</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,123<span></span>
</td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, purchase accounting adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessCombinationAcquisitionRelatedTransactionCosts', window );">Acquisition-related transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">$ 5,258<span></span>
</td>
<td class="nump">6,712<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">5,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individual Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Business combination acquisition noncontrolling interest, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessCombinationAcquisitionRelatedTransactionCosts', window );">Acquisition-related transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gains on consolidations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individual Business Acquisitions | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersAcquired', window );">Number of surgical centers acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration conveyed in the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod', window );">Number of ambulatory surgery centers noncontrolling interests | surgery_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of business acquisitions | business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberofHospitals', window );">Number of hospitals | hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_UnitedUrologyGroupMember', window );">United Urology Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries', window );">Number of ambulatory surgery centers operated by subsidiaries | surgery_center</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_UnitedUrologyGroupMember', window );">United Urology Group | 2022 Acquisition | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersInDevelopmentStage', window );">Number of ambulatory surgery centers development stage | surgery_center</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire businesses</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Business combination acquisition noncontrolling interest, fair value</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfAmbulatorySurgeryCenters', window );">Number of ambulatory surgery centers | hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International | 2021 SCD Centers | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersInDevelopmentStage', window );">Number of ambulatory surgery centers development stage | surgery_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersAcquired', window );">Number of surgical centers acquired | surgery_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod', window );">Number of ambulatory surgery centers noncontrolling interests | surgery_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfAmbulatorySurgeryCenters', window );">Number of ambulatory surgery centers | surgery_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember', window );">United Surgical Partners International | 2020 SCD Centers | Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalCentersAcquired', window );">Number of surgical centers acquired | surgical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration conveyed in the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Debt incurred in acquisition of surgical centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_BusinessCombinationAcquisitionRelatedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of acquisition-related transaction costs incurred to effect a business combination which costs have been expensed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_BusinessCombinationAcquisitionRelatedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfAmbulatorySurgeryCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of ambulatory surgery centers acquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfAmbulatorySurgeryCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ambulatory Surgery Centers Operated By Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalCentersAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surgical Centers Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalCentersAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalCentersInDevelopmentStage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surgical Centers In Development Stage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalCentersInDevelopmentStage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalCentersRecordedUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surgical Centers Recorded Using Equity Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalCentersRecordedUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberofHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of hospitals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberofHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_UnitedUrologyGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_UnitedUrologyGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=thc_A2022AcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=thc_A2022AcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=thc_A2021SCDCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=thc_A2021SCDCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=thc_A2020SCDCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=thc_A2020SCDCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636675153424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Purchase Price Allocation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Final purchase price allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 10,123<span></span>
</td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(1,220)<span></span>
</td>
<td class="num">$ (1,177)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individual Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Final purchase price allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates', window );">Previously held equity method investments</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities', window );">Long-term liabilities</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries', window );">Redeemable noncontrolling interests in equity of consolidated subsidiaries</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interests</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(1,220)<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gains on consolidations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition costs of a business combination allocated to redeemable noncontrolling interests in equity of consolidated subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Previously Held Investments in Unconsolidated Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636662375808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Pro Forma Information (Details) - 2021 SCD Centers - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net operating revenues</a></td>
<td class="nump">$ 19,627<span></span>
</td>
<td class="nump">$ 17,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income available to Tenet Healthcare Corporation common shareholders</a></td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted earnings per share available to Tenet Healthcare Corporation common shareholders (in dollars per share)</a></td>
<td class="nump">$ 8.66<span></span>
</td>
<td class="nump">$ 3.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Pro Forma Income (Loss) from Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=thc_A2021SCDCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=thc_A2021SCDCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636670638592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>hospital</div>
</th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>hospital </div>
<div>state </div>
<div>surgery_center</div>
</th>
<th class="th"><div>Jun. 29, 2022</div></th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>imaging_center</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=thc_ConiferHealthSolutionsLLCMember', window );">Conifer Health Solutions, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember', window );">Baylor University Medical Center | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest', window );">Share purchase agreement amount of payment | $</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfHospitalsOperatedBySubsidiaries', window );">Number of hospitals owned by subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfImagingCentersTransferred', window );">Number of imaging centers transferred | imaging_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets', window );">Percentage of assets transferred between segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage of subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfAmbulatorySurgeryCentersConsolidated', window );">Number of ambulatory surgery centers consolidated | surgery_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries', window );">Number of surgical hospitals operated by subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfSurgicalHospitalsConsolidated', window );">Number of surgical hospitals consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_UrgentCareCentersMember', window );">Urgent Care Centers | United Surgical Partners International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfUrgentCareCentersSold', window );">Number of urgent care centers sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices', window );">Number of hospitals to which segment of the entity provides revenue cycle services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfAmbulatorySurgeryCentersConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ambulatory Surgery Centers Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfAmbulatorySurgeryCentersConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfHospitalsOperatedBySubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of hospitals operated by subsidiaries of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfHospitalsOperatedBySubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of Tenet and non-Tenet Hospitals to which a segment of the entity provides revenue cycle services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfImagingCentersTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Imaging Centers Transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfImagingCentersTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalHospitalsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surgical Hospitals Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalHospitalsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surgical Hospitals Operated By Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NumberOfUrgentCareCentersSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Urgent Care Centers Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NumberOfUrgentCareCentersSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Reporting, Transfer Of Assets, Percentage Of Total Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount Of Payment for Minority Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=thc_ConiferHealthSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=thc_ConiferHealthSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_BaylorUniversityMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=thc_UnitedSurgicalPartnersInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_UrgentCareCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_UrgentCareCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636660229488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Reconciling Items (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 27,156<span></span>
</td>
<td class="nump">$ 27,579<span></span>
</td>
<td class="nump">$ 27,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">19,174<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">17,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">3,469<span></span>
</td>
<td class="nump">3,483<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedSegmentEBITDAAbstract', window );"><strong>Adjusted Segment EBITDA [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">3,469<span></span>
</td>
<td class="nump">3,483<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_IncomeLossFromDivestedAndClosedBusinesses', window );">Income (loss) from divested and closed businesses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(841)<span></span>
</td>
<td class="num">(855)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost', window );">Impairment and restructuring charges, and acquisition-related costs</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and investigation costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(890)<span></span>
</td>
<td class="num">(923)<span></span>
</td>
<td class="num">(1,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from early extinguishment of debt</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities', window );">Gains on sales, consolidation and deconsolidation of facilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations, before income taxes</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Inter-segment eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="num">(451)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">15,682<span></span>
</td>
<td class="nump">17,173<span></span>
</td>
<td class="nump">18,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedSegmentEBITDAAbstract', window );"><strong>Adjusted Segment EBITDA [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">(722)<span></span>
</td>
<td class="num">(739)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember', window );">Hospital Operations | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">15,061<span></span>
</td>
<td class="nump">15,982<span></span>
</td>
<td class="nump">14,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">10,557<span></span>
</td>
<td class="nump">9,473<span></span>
</td>
<td class="nump">8,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedSegmentEBITDAAbstract', window );"><strong>Adjusted Segment EBITDA [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember', window );">Ambulatory Care | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedSegmentEBITDAAbstract', window );"><strong>Adjusted Segment EBITDA [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization', window );">Adjusted EBITDA&#160;</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer | Operating segments | Tenet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember', window );">Conifer | Operating segments | Other clients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues&#160;</a></td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the net income with interest, taxes, depreciation, and amortization added back to it, used to analyze and compare profitability between companies and industries because it eliminates the effects of financing and accounting decisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_AdjustedSegmentEBITDAAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_AdjustedSegmentEBITDAAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_IncomeLossFromDivestedAndClosedBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents income (loss) from divested or closed businesses, specifically those related to the Company's health plan businesses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_IncomeLossFromDivestedAndClosedBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain for the period due to sales, consolidation and deconsolidation of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period and acquisition-related costs. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_HospitalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_AmbulatoryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=thc_ConiferSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=thc_TenetHealthcareCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=thc_TenetHealthcareCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=thc_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=thc_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139636680725472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details) - Valuation allowance for deferred tax assets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in valuation and qualifying accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning of&#160;Period</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Costs and Expenses</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold', window );">Other Items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at End&#160;of Period</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thc_ValuationAllowancesAndReservesReservesOfBusinessesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, related to a business sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thc_ValuationAllowancesAndReservesReservesOfBusinessesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>thc-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:thc="http://www.tenethealth.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="thc-20221231.xsd" xlink:type="simple"/>
    <context id="i462e90434397417b94ea400ab3e98d19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3cddf06bd574be2ad2b6db4f6c58e08_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i466f81b830d4456980895fd2849bc045_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i1338325429bf43b1917d2b7a451f60b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8962e91413c44e4eaa374cf217033203_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8317271c934402ebe8d6b8414e1b396_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaaeed20294de403f864897b4800c3076_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73837e4f8db9412e8f899038e1d69a38_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9537d740a09d4c659577fa85ae658fbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d874170404f42828e4c20e8b8df0183_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9554f40adca348fcb6728bf86c3ecdf7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9d0733ad43146a38ea0933fae539a08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a99224736d148eb923d186edf1422a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia89adc45b1f04cc7b5b5f7802b70f646_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia34520ac68b949658c3caaf22edd6880_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idfc3c23664d14313871878cccfd836b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68dbb9be4d814d51ad51baa9ef64725a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacc7f69df573459097fdcb5d09e4778c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73a3605c2b39491ba943fd1edfc38e57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3a3a91f53e143f88c4008add5713b37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d8b2757ba2949ca8cd949137ff2242f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4961643c307a4f6f870dcae12b32be64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic970d8adef764f56901b3449b235a580_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8cd4726c880f4e148d4569ab39f1d407_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id96beba9c82c45c1bc21607c1ff74f2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23b513def6714ccda59af687a753af25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4668e92bb57b48e5b60535088433640e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3357e2680a954c2f9e9a7ea6681fe6ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00199680d78144a79e385f52ad262816_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id44ff96f5e0b4207bd89a9ce5dd47a7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b9a7228a28d48dd8f40b5100d81ac6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a4aa1e6e88f4448ac550047af2e16de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic697b5296a55464da1d3d7ed92f77ab2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92aac1e9ae304c2c9a6e91a2b9279e3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb9e8ae8287042d59710ebc9811fd7fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6deeb898cc694b44af79dd598642335b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63be1af82c5a4ce08a55c20e64768dd2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i141f2bcca31f4b0380c3b5e8254e8c6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58f75f50cbee4ce2a41dfe51c9ce7596_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b2f751698934015b40a39f68b1a7b32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78e1ff00656b4675b1053c1131354580_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b72ce7a7f084592ab6d37729017b52f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i239bd2934060423182e137ce4439d676_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i328d8102d6f44cfa952a21bd7c09daba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffe4a381bd734a65ad42049eb3bae264_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i314717058c7b4b6fb0a8169f1a019fe3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:ConiferHealthSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id03e28a327e64655b42d061b206c91d2_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i647dc680b9224e41a241261103ccd5aa_I20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="i20f7c47ed3f1432b9993a85a212b93bc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6364b905b4f448f180aff1eec2cae8f0_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i2045a695149b44b7a235414628a53b37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibaaaa5abc7244245b9b67813cd3b395d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7f8148fcad34b6ba60172409bbf6668_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18501b1020814804b2eec3c3a49eda56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64a68ee2c5334eff95979103621be27a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8eeb9cc68a96448383cd633e3217c1f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9377069d70814572a175b579ec7a281d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab64915969534cf4956bafb8271dc248_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f1a1807f7c64edaa3db3ee3ca10ea53_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iece489c88064416a8f8ac688d1f70c95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">thc:EquityMethodInvestmentCashManagedAffiliatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa94d45bb7994110803e7156298da109_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndAmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c1b5e8fa8eb4e95875735d34c47d58a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:AccruedCompensationAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50ac87d72391498b913cf175b99fcea9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:AccruedCompensationAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87503b31cf9b44539e4e33a5a506f23a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i453df43ed989465c83339dfbcbbf1f2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd85c2d1a1374a65b8654ba74a6f38c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:CaptiveInsuranceSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe6626659d434b6cb1b41cc1706a572b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:CaptiveInsuranceSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2743e63d59e4952888f44efdbce4683_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i747d501e6e0f41bd9ca9f27f5b091c1a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26aedf0885e647e29e1d889e0703be3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4465885b467846d392b87babc57179d9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if85eb793e6b84363968e6ff370cb8b75_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9feb05943d7e4d72a6e4c70948071b28_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">thc:TexasHealthVenturesGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4437bef5e9b44a32b53fb9a7a5f9b32e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">thc:TexasHealthVenturesGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i084834af07f94533b36d44d59a7a2b21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">thc:TexasHealthVenturesGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1c80f6e03094431a9b9dc5696c76170_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic99a8eb5ba464ce4815b2681aa41727f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e67596c4fbd48eea8785f354f1d98d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibed3bfef5ee649f29df0916da65a65ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5343d74439bf454aab6dd66ea2a9f13d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:NewlyConstructedHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i49e69c97f00a4fd4be24bc4f694c6383_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if2a82f5c5f0b4bdea97702ea376fa880_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc879355fab3418bb4e9b23bb6b58cd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccd9ce39a7dc448ba011235d835f9e2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd1c5b7f55b147fe81cec433ecb2800a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4130035b4ffb4b2b9759276d80640702_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52e0390579564677a1312d0789221786_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14ddaa71294141e9be1093eec432aaaa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5df7801e84484df0aaf96468dbac66e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i997032dafb7b429994fd8eec46ba466e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie118b0f2118146a497e17cce3c5da1f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2f9829aeea0346f490db02486d0b9fa4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:ComputerAndTelecommunicationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae5ba870f1f4485e81af6c8bba7c493d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26d9b425fef84906a67c577eb496f953_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42ad7bcccdb04247a3b2e90bbacf26bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc1386fd3cb640aba64d28e810f688ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9047828c01704885a5dbf35dedddc704_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4595fd3300594bae87dfb53d46c07c84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b651d49dfde4a238741f373ca58bc2c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7868d9c4a59e48619659d721cc78888e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i844a37e3831a44668dbcdd0ebafe40b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15bd4ee78bbe42988676a562c194f442_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e5985c976394f5390431764b17623d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56dd31502d3d4194884bb9c9caf6d2ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34c7defbef2a4e3b8612d7aba82bf5c3_I20221022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2022-10-22</instant>
        </period>
    </context>
    <context id="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2022-10-22</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="iede14df2bae641aaae79e4148970642b_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i2c7906fd4dea427ab980615c8e378f98_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2022-10-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71e77f1a3cc942158bce2e26449d46fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24938975183a4055b12b952f44b451eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cc28a960d044d118475b47b836ac7d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9b5eb45d8444ba8ad4d24f039012736_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9971ae1d4d574f25af6bab80f8bcaf5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice05b8f807e4403893fdf7bd5fcacb5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib366e77f27444ed6a3e8856060b9bf21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if78de6460b114c0bab0a7b968955449f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51ac1ea0fa6641af836d8e80f2703fcb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:SelfPayPatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic549de21b71e42098463117277ec3417_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:SelfPayPatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1e4506f61374f2e92951abf71b05057_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:SelfPayPatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied775d7b43794f9a9cfcd968393ab2cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CharityCarePatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48b47f6e27bd4b2da194704a14b97d77_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CharityCarePatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib25b38307f82433581aafb23c9f00d50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CharityCarePatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4166bca0f2b4df8b36ff5398d99c789_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25cf6de3bc994080bc0ff271d5f1e7c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7db4f9aeba2e456da8757c9a02d08c78_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c71cd81b16644ba893aa7255b08d6e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5123a758f7de455b8800a2a9ce940c2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a580d8694214bf884a09da9b2b1dbd8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4384be4a2dd447d87643cd3c2f0798d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e977fd989cb4d9390f31035ca2e4a2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4b7db85097147a3877bb4389f2984a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib165a084700643e1b139d15df43a3b15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib51529c7491145d285a730665f73c23d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id7b8ec068ae246cdbc6cfb42f8a12fc4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2366c9010b2e49cba43c03549f1d2ddf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c3e3d1b5bee4eeb8147e32baf77ae89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if536ced15ef94662b44301934aa1dae0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a0b252636e347bfa5ded4fff8ef5797_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fabc80fff1241c29e2540d687490e0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71a467f2558648978a9d48e2d2e603ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6cf46e0abc954d2a9519b9c790945c68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96ad47d7e3c04f468af3c2713771b904_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4885c05ba74d4161a50b941fc56a1043_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7afbba7a6c6f4934b189f3870051beac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4e58b05cbc648e891cb8eb0308a9bd3_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9198bb96b0c34619839a103e26656c5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:UrgentCareCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b88533462e34354956300ca036d5a16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:PhiladelphiaBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2caa1d0849c540b493559deb02c5baae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5c6f743bc7c41a9a1958950899659b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2dd5c058d4484de28c384ae0497a9cb0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i216cf3ae855e4607889370b5a9466471_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic05fae90132d4c549fb7d1d0e2284c2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">thc:MiamiAreaHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87e348ef2f5949cfb83ccab43bf831b1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:HospitalBuildingsAndMedicalEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i533053ff136948178e655a762abff3e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:BuildingsSubjectToImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i194ea9513fe545cda7f1fc401e373fc3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied9bab022f5344008a846ed40a785dfc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:GlobalBusinessCenterInTheRepublicOfPhilippinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87faa7579d7f4b91a4f182929ca4f1b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b84189bf5024247805cd0d9a5e0ea47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:GlobalBusinessCenterInTheRepublicOfPhilippinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70ed061cd6934306b4066e74ce365959_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie66efb75ed1542c3a0342c08477760c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:HospitalBuildingsAndMedicalEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idca9108158cb459d9c536f451843cd7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">thc:BuildingsSubjectToImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47f5b56532644469acafb2fdf2a8344a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22277913b4384752915cdfe34322cd7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:GlobalBusinessCenterInTheRepublicOfPhilippinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8169667563aa498e92398dfb1b02ac01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59a09d299f6d4fce883b3595bf918a30_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i622ee28e9f1e42d7aff972d73252f4c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifae6361bfece4d29965dd05a7c7809e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8a7e36b94de4011b826c46271390423_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4fb3c83283242f6bee137da54776fec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20c821a80a1b41029dc25c50b51dfcea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8871456e17fc4ba49fffcdcb23ed7b71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i989bb5295fc74ba1aa10f7543aab0c09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b09f2c0b00a46fd93e77c46515311ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0da8add6a93946079dd9bfbe6ba2763c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57788fd689bc47bd813aec1a0ef11ee5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id060c1c1b2764c1bb2759e725cf12295_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifde641ba54514fa09690f87fa89673d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i697cb82b913848f2b26b5f92fc37e35e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i461c58e253f64f09a6ac5dc3c2784b82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5404c8f217424e06babd62544ad4b7b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i558c5a218dd0455d853b5f0e68d8b7c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4afeea9e0df44876bc52904d8d7057fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id17f96184b5f4ebd8db51025fe3377c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5599a9535d841a28d1c1e4b3ced46aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d9b9cf6618c4aa6afd0b5bc92c8b85d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa72f8375f37499d86f928b68dff6f53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i186d8e5c6032427baa46b10be1424d87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fba8ba8429243958c7942852541472e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0cb767709934643ac30a4e91dd1c63f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3540a60419084118bc740136b6cb62d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="i7488113b2f8a4008a0c1e41e64bbaa8d_D20210910-20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="i49c0fd70eca44c388aba457549bc1bde_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95369c42fa7c411bb4958a0409bc9c80_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5db931c86fe147d399a5218e8787b348_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5426987ed148420cbbfa4a0f0d7a191f_I20220615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="ifa8cce4fc2f848a2857f83e50a08eb16_I20220615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="id84fa693c2024155b0b1075bd91a66e2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac8320d1db684d2e978228570390fbbc_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i0b4c256aea654f0e81f827e0120eeca0_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i774268ee073042e296346aebdcefdf00_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38e3f3971b45492ebda95c4159ea5bed_I20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="i7daa6cd1b7be473ba7d7f3897a209175_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="ic0d2bb14dafb425e9e73ab20986d8aba_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="i216bb1419f01411cbe289ef91b5d9301_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="ia74c040bcaea4ecfa1841b613ea39e5b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd0319d75b304db7a61ce7e8160119f5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6f3bda72356c4c8a90a164544fdb3419_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">thc:SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58fa2d207abf4c7d930128ada13635f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d1634d5e5c74227b8cb258fc3071474_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i85c9953574604a679693fb09557caf2c_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ib14f1fc180e441e2a02f1e6258051ea9_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ied39b398e82143dbad504e93ddad6c70_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie79724e46f9345fbb6283e854762c21b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbde1cbd711b43aab8f621cc2b3b071d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4470e4393114d6aa39323d7ec6f963f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4d759b6ae6a43f7a40e0ef19d9f025e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i339dc68a43b14d1cb043fb9d9e7bc4bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5976155b721e4588af99404df30450c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i289e59d55e724f6d816c0df9b3f788d7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icee7731e045f45ceb6027185e10efdf4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i807623c3e0804c008f81fdd3f1dfa3fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03c60d6ea9404c3ab4509a64a435d111_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f2bd835c2ea41418922c21a022a0229_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i13f604ea7a86499fbbfbc12bc96eb817_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f47cf0048e74feb8f6625b5de6e4a56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7c8eda4b4d14ac49c4e91d6e7cb0cbc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:IncomeGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibfd7a9c8341e4fbb98014f10cc135b7a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:GuaranteeOfBusinessRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2f0abb0a0e4a43e4bd6e824ef8f0e3b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:GuaranteeOfBusinessRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0fdd924a274f443fa92ca5c6423bdc2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:IncomeAndRevenueCollectionGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3bc6670142a4e808c1316df2aec4f4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:IncomeAndRevenueCollectionGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43dba714bb6f47bcba5217f722e33680_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:GuaranteedInvesteesOfThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0e89a0a42d34e7386bbd6bcb26e395d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">thc:GuaranteedInvesteesOfThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8c4f60c37dd4423b655206fe804e2a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id54c892934f94ec9a1653dda6b70f552_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2aefe441942b4b1b9964978feb391a61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:StockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f70438f4b824837b203d53a4d4992cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7b77940692a4f7db126c0242c3c5ac4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0107ed011a3a46fdb613b444b95af318_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73a77c00b16741cd82fbfa2cd2e6aeef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c48ee9db11e4626a720073e3d52765c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8332ac81ea994fa080bd2c74aea55433_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c680273422d4752955e73ac5d10bd49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd0038bf48844cf2b84aed399a6f80ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3031d28ff1b47d48f762be70d952bc5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa66aa2f15ca430daa47cd0bdc598c56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82dd3f9e68e54d33b184fd6660d2b3e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">thc:ExercisePriceRangeSecondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6525986e7cec4246bf79c66a19a22c42_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:CurrentEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd5b8bc126dd41e49f8d133ce6a2f7e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:FormerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic33f32827498430ea95e37c4de25591c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf2c425940604ce3bb5200984c22a581_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b0698fef50b441a8809d814d5874bd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9447e0acfdc8411fa545539e357b1624_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ae413ceda20471eaa9654d788c7e9c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:ElevenQuarterVestingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d49db19071d4e76af718a4ebfcd2551_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingFourYearFromGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ica37af9eadb64144b4a83ab54b2eb4e1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc78025992d2498693e0cfe01b80263d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifdc06daccd6f4843bb75db0eba6fda8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd952e84dcc743b9af382bfd56d539a6_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonExecutiveChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i792b9ba8d6434e31ba4998b638861429_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOverAThreeYearPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib31c3d8b7cdb4518b73e55dc7378d317_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba5b2544884b47d884c4199111051b50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:EightQuarterVestingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9364d349beee475faa3c8ae75ca39b99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0f6dfe4070b40479c568783e37dbdb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82745fe1a5c149759ae2bb2ebd18c99f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingOneYearFromGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b0e586f41214b669d46af8983e496a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:SeniorOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingOnFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67cb4a48480947cb934f8e6e7be5a3ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83afe2783741410d8c56a323ae90b6c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOverAThreeYearPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieec7c07bedae422fb1e0fa272c435e3d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOnFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02d9270641be4b258d8e9d251500ed2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingAndSettledImmediatelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ffe68638d7b4f33a12f20c24c63eaca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77704bd6df014d42ad1974f3065e00bb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iddd4d4aa649e490fa03c3693ab1d3b6d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5c513a239cd415cadbc7d515e826c84_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25b782905e1e4e0eac9049059657f1b5_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i459d2687d88148ecb61b4fae2a62863b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4dab5b2fbdc143c39fa76b787542f0df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:AdditionalProratedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46ba779d997746cb97b06efbf30d887e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie91ba56fa1e847e8a1c73049e8ae86f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:ElevenQuarterVestingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icdc7d548925b41349d858624f9963b63_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingFourYearFromGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf51d35f981442c99167b2d957e6c469_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:TimeBasedVestingSettledOnThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49aa4fd04a47497b9c081da63e6815a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40882d4788cd4504ab064fa6891d0693_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOverAThreeYearPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0aafc61192254d9d93ce6bc583456021_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingOnFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cf2066a73d3442da2799d558b87a606_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d78c92def194c19a4adbbb2259e22c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30fc1015621a4924bfbb26ae78a46dad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">thc:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc3d6bba1c884c478022a01b2e6cb3bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">thc:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i0a793f59564d4a279d849edac266ccd2_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i22e72837fb0e4ccaa451831a1f7d7152_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i575d1fb3905042bda466ba37322c7021_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i4992fa411a47474cb9b7e672161cc2b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2020USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87721822e7c147bfa5fc199473a92a04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29275879e7484df887acacaddf98d599_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8295862c62a64157b42db6f146e8c12d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fc0d268ac814aaf82dd4c2c38f45afc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48e7b2eaecfe4b418364da6c80616cdd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib640db27bdcd4bb98e4be184ed784de6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36a0e4afed9c4d62a3cab9875677e71b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff0a68e5520c4a67b603ea61aabf6d5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ee76bd3ebc94aee84000b9861cc8925_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id872956450094631a6e69b7b3b22b116_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7aeb8c24eb5e4d1fb3cc39f11508af94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4c2a4e8b3584f25ba9995590bb44105_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f26d7b1bb2e411482df40eeb64c6fe2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">thc:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a5b35347f794fff83ccb6182bcfaefe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib60161593b56431198752c72b64076ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf31acec6aff4c96ae0465cc5661d7d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i726bb4f7600248c880398c7ae29152c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b599704099d4411946c2b6a61490067_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i67d8fd82832242d3874ce46a1f5bda4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5e2d35b46364527900ac62fe853f500_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98ed17ca8f424eddbb76511ce975b7d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4dea6f1094954116a3f68cf961f8ae89_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ced06d52d0948f2b33cd7c96c19ac99_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i826c719c694345cbbd09a505858f05cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5f1bdfc3e69496d9d0b8fad4f514056_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f46c6a3f87c4ea9a9fc91235eb3ce6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9911fb6980184642b2b91df127e81577_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e71186460e94813b374c45bf631f9e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1714de0eddf4a14b7a6a4d8e217cf42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8494255e124249a0a3eeafe8a1ec5580_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39222fbfc5de44bcbd66b5dd47d6c432_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7214f3a35494e78a472ea44db915760_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f659dcb43db4e5299ae2bd34817319b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a0335a3b4cd4570916a79350e8b8301_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8470639b4b74ccb87974669a576a9a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7db9aaa63ebf4a2c9985af6bf21ba265_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b14503d12cd4ff1a8738f04383e21c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">thc:DefinedBenefitPlanAlternativeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i804714da76e641858c08fb5432ea37ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a67fa33749c43db986a0beb057d4ac7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i454a85da8698479a8e723e2cce4a6296_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6628865c9e54cb59a13c1563d995f42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80a91a77e3d24e61a737e24af4f558eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e8ac7ec5a3745248b611c964292857b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49284b149a704d88bdc9d6e996c457e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e2b5e26a8054b03b96aa3a7fbeb79ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b9ca9d71ea74bd0a7deec85ce36524a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1e43f8ced2d426988a867fc0f0b14c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12b87a25e42b480aac87219815bac866_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic93c45adbd6e4f78b04ad5d1b90243b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i285ab10c7ac148e38a100d1ad2af2744_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia94c4bf4ebf248dc96407cf574d23a82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i166be3168d7f4ac7b806eb76ded856f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a9280afba054c2f84e6e536996e9a74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44f9676a3338438bbcb6a0fc6b10f019_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ae60f4fa3854826b47d1a2b21ed0e58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5b28459d0dc443289dbd7f5a11180a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6d79b4c21364b1e8d5b7aafdc463a8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2315eeff4c34c5b9d914e09c1031bdd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89da8ec516bc4c688a3f2e4138bd9130_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i042c29b651e9422c9c3b8fc7734703e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78f58b7435b945b38eab242b75e7de88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9461354d8d8d47dd881117ff98a3af8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3c31677d6754a34bd494423b74a602e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2286f8106dae40a78e46d44361f52c75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice9ea6ae06b14e35bad5e2ca1e409fde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6af6470ab1cb4bff9fe84140822865d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if199fa14f8c442b6b5a44ca21380346d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f72100695fc4f70b93df4bc5ca16207_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1bdcec982d2405ab478007ab8e9cf72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cea09136b94497abde3744de16ffbb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5d7173e0e014de1934a570e1112af04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb5bb9664ade472286428ea8e0f32595_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b2c8dfd6d53454598ef5cc59f8493f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6833358c1d6741f7a2f16c63211b57f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c06dc18705542b1b0f4578035465c35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d50cbc9ad614ba59c37a5e12995c52a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia55523ac8a4c49a4b496cb9c6bc21731_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc6551b57d1e4468b0725e4877eb3d2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if415ffa4ddcd4d20b4d45d7405511cef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4631c47e1f244bdd9e1c8d3c5f70454a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa63b9feebb74020bb298b5272d2cb91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i686e590299944c6c873a2b143fb8bc32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i800184fe85bb47b5a889821fbb17e7e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i585ae55410ba4bf0b908db0bc2194a89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ea4687cc2d24bd4be9ac86b4b9f8bed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e833d841f1a420ba5b7b46bc27b98cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6531ba19db2c480e8abe335385484440_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccc97a4820c542d4bf607e57b51505a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8cbfe439eef4938941ac808a39e48b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaadb2472f2014a5b80d77c42eb1bf932_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibac9538659da4c918abe6bc8330da9fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if54ea2398cb64048a475a0c8781dcff2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0650b7b45a99449c9af4ff648257c831_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife8dd83765da4cd98415083bc755446e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i016c96b25eea4c4e852f3cb7e72aedf8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">thc:A2015USPIManagementEquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e2fd93f349c4e4c9ddc4ef367845986_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibfbf92bb89634290b801e88029d92389_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b511b7a489f423484bdb8a101ff9a36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bb29332c7e349048cbb4839508b6add_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib43e7382c8b743a7b9f53c2d06e8305a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ca722478f4d4353be6a7b1b4eb2b7e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4086403e4e54685aed1e1243c892e5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11c9ffc9de624831af0a297d262e7276_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if474534dcafd415d9534dbb0774b811e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i476176f776be4198873c2255c05882ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i694630452a604fb9ad2d2c6646397326_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8655e44515147ea8a7957f6e984603a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccb013137715473a8be5f4a83d7293f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7d0c6d3c86d49d0bae4aa0dd4b382e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0abd09d196974cba90b5e722e01a984c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38e94e8fb0af4f14add5061334e930e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6cce08bda3d542f198b8d18a883aec5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i865db5ff099a45238d86047cb5bf3f0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fbb8dc0a34648caadf9b08b028a9c30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedac06e53ae3427382872dc1d8f25c8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58b58c9b298645b8821390d35d437e25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83eeaae00cd442549c9edcc2dc638e9e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib133b5b1591e4a4ea142acbda1961911_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">thc:CaliforniaProviderFeeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1bb12b1893946248b9ab7b6cb8bc7dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72ff1d80e6bf43d59f82710f6d9d3b3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70d397b0d9a54755805ebf13b24f0c3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id48b6bbe6ee04e76973e637b31dbb932_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5d591ea7d794a6bbfc70c45fa0ea665_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic533c479212f454fa40f5a81863983fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic480b7e478a9472e9d85fba3eb9c12f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfc722d0c2684b039bc615d08fdc3ffb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1c70f5ebc6e458cac8a2f6abf815c4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie964e8e69c1c4105a086707420629f2c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id74f5e2d7ec046868cdc2f7fbd355aee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iabec11c9436644b39b5f21992e4be853_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61aba57deafe4c6ba34e913edce4fa4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i46b470daff964cccbcf39b25959c3e24_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3950c1618554de69021cc2cc1a79848_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib396f0f65807418887a0c0af3e39a1e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceSelfpayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1d6b8d0b42e425ba69ee9e7f0d7a8b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceSelfpayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9029942b52174f9f9c8908a424dc17c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceSelfpayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5aeeeee831ed476884676b44fd6cfe29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceIndemnityAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib14df2a1821346edbbccbb2de64905eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceIndemnityAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id127fd2a48b9468fb152d68215c3a4ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceIndemnityAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8650d876760f4a5db3ab633b09d01bc4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceExcludingPhysicianPracticesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide258a1d885e4c0f89deb490aea7e041_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceExcludingPhysicianPracticesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26398e525b5346e4b152c794c73a6fe5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCarePatientServiceExcludingPhysicianPracticesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">thc:AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedb3ce9661bd4d238e03107f7d28b516_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie5ea9fc470eb4780a32a6b0b1b1a2a41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8eff462dc0034c218f3464becc79363a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie464e81a78ca4b5bbc82e4f831a2f8fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2a6e909d5f7146e6b2f3799ec1c792e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8fc34a3116b48039c40d17002cd0211_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3ce7b2af81a45cebea65cf46c0e002e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id6e55bb2a3404d37ac0446903cd6f0ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4bd925e775946d38f284ce1b8382ffb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cc1bcf836fb4be6bef17a04e3599061_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5a76387d9429414d8b35662237a46f7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27b36c3b506c460a83c8be8982727090_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1253b20e6f0b4e17802a597aa8a7b59f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia925e5b318a2405589428d1271dec1b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9db4542a137447f59a1e7ac2c89d14d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i530018987e3745d5abf91b8e5524fc98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4b993383ef88460483182c2003d1d78f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc1fb9caa7fb44fcbd2a4b49ddce2861_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0781fa826249423991780dca7297e0a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81914a8262974e3fbb3a025471f7eee8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54151a0b57be4cb78257f73d921ec0ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43649916a8a24c10835bd3035c29605c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareManagementFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i00fd6a31e00d4b11bd3304b198958511_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareManagementFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc3991fafc3d4efdacdf716c9d96c74c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareManagementFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28f3ed824e4544e3b60697a39097ec3c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareOtherSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic43074c6c14b4410b81097a344a99a4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareOtherSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44f1c997f82e4683bf9f1bfddca5dcbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareOtherSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8393dff26a4a4be89907f8a207404638_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i323ccc8d9dff4644a7abebc08a38004c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i235f4a13d11d4df9becc252ef1dc9c7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d3ba16a76c64bd5ad24f4df995e560f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20a93e729edc44dfbafaaf36efb815da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26388ca5abe346d88976ab4e56da4f3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsRevenueCycleServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60c5cfbf30434593a6d78c97172bba64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c20159d864c4b41ba379ff416d148ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28537df01b624afa95022a135cf7d691_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24675d2632254bb2b6bc89b632413541_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08f286017ca94e2bb6ddcf0fcc89ef42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4058f3d61484fcba0d030ec4ee43320_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:HealthCareClientContractsOtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7cd6c10c8c74700867918c05b8d066e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8235d44217a459cb42567e761b66f1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5607340778f848eeba9562ba40506527_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib32381cae0dc40e8971f9588ae25f535_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3fe036fe195e4e7d9cf7c4783fa3b8d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a8a661109d44f82ab8d85b5e23bfda3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09cf92dc60274d8584d52ce10bbca397_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibecd81c658874986bbada79239873a72_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:FloodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i28407917ddcc4c2ea22b7337ab6cbb6f_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:EarthquakeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd1758863eb749acbb352959ab071117_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:WindstormsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8b5076fba4c4fdb855d3ab34e6a97b2_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:FireAndOtherPerilsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0e926b75dbf3452ca4435e4d0c5a4087_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:FloodEarthquakeAndWindstormMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id85b713fc7a9441c8397ecba316b3238_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:CaliforniaEarthquakeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i76790a90cfa941e4bff3a5ae92dff3aa_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:FloodsAndWindstormsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f6d901dd264433fbda22d0ff499fce6_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:NewMadridFaultEarthquakesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9cfc47e9f41b4cc8881d17b072c28e6d_D20220401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">thc:OtherCatastrophicEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a5585dec099491a811760ed0c015749_D20220401-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i946e83f23eab48c0977d5cc62313d926_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">thc:InsuranceRecoveriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i929d5f3206d1415988b40ae29b248818_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:ProfessionalAndGeneralLiabilityReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a00e93147d34604be1c56fdcf1740bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">thc:ProfessionalAndGeneralLiabilityReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bae571ac5a8443d9f4f6d6619c6e742_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ce8af9e8c2243dab9e653703111fd49_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46385a1111194a8589fc66d33d240d12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99278a7c32f64fa0b070b36593467a59_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">thc:OtherMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6592cd4d757a46e2a3d6e589962ea2da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">thc:OtherMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia222bd0504b649a38f78d78bec2b6c91_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">thc:OtherMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icbe65d466f4f469d80f697fa5ae26073_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40b3d4d738e04be3bf00f293d9edb4f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic63f979e7be145bc9c86e0f440b39a75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a2ea7fb5d834e519c54544ff665cc9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1acbe1c3a707444594718d1fb713a4dd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9b94c1f135f64a488e17326f4496bb5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb5fa32817764caa8f2f7644c58ca52b_D20210101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OpenOptionContractsWrittenTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia73487c1fdc34b30b87fbe06f5951834_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:BaylorUniversityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4951aea584a14d4b873b83530d333b3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i082e53fec105442d97f902da195a0d31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibea644fa13c540e892499ab2838c341d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0254fa58d5da4b66af614eec6e6b07a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">thc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1d91a903a1a481fa20d8e476407ae20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i99a33773dbfe4b1c9e0db6630258d6d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7e5bdf39f78442c999f04f849962c0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58845e096d6e4053baf993f0b5480e65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife847cb48ff64445b52e24dff42ab345_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i016ade91fd494b2092c70d023aa6b142_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f311af9ca5b443ca38ce68247b5b1c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3ceb05ff4044a7c839c70944244e25e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie394bb97475d441db6f2d7fdbb59def8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54b3f987c4664d6586d2dc3ce06561df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4fe8572ea6c491aa3b643277fd661f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i019176855e2e4e78a448696e0f58e777_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4aaed855090043789ca397a60d4a8565_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedUrologyGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="id8d3a9179b7641f5bd9df2620d60173e_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedUrologyGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2022AcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i64a492066cbd4c4a85b96cb84a3068f3_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedUrologyGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2022AcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ie6616fd0402041209d851e0632005bb6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48e686e617164f8788dbef7579035ca2_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib58f6ac4316f4317ab753edc02419bea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7bc2ab83971e4498a02f300ccab65006_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2020SCDCentersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia66fc1c0750d4afda6c0d81b93a363b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2020SCDCentersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8d5d769fdb2494fa847d0ee04defa5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if07cf50792f1459db9cc6eaf83c40b5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i335893427cf548deb9b34f0425efb1a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14390acae25c4ac79d2ac8ce44d91a68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d080dd82b644853b823fde9301748b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a110926660a4054af849fa472768d12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">thc:A2021SCDCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i201297e314ab451088f2cc2cd5577ad8_I20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="i1c476cd298284a1bafde8fdd47d49539_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:HospitalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i86001c59573247b08eeb42c93d75f6f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:AmbulatoryCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82e19c7717074970a71b4dccde90bc0b_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">thc:UnitedSurgicalPartnersInternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:UrgentCareCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ia18d9a3de8e841b08ffc82230780dc95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7ceaf5394f94012b9da3e04b6ed796c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4376608b69a145f2998cf8f78326c6d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:TenetHealthcareCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4247e435c1a48c9abfb49f3a445ea67_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id6bdb8fda770486f97297332c7c0c2e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bd670b142c346aba126a22c475f14a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">thc:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">thc:ConiferSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa722f7986ca4c518e3bcdca37e64012_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7fb31be8d6de4e44a3f930dc03031843_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6544cc6587346acb00b26c710bc7751_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i133c13b23a124143877c18e0c045ff74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b95f4641f134e5c9fffaae2b5ca01e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000070318</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="hospital">
        <measure>thc:hospital</measure>
    </unit>
    <unit id="healthcare_facility">
        <measure>thc:healthcare_facility</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>thc:segment</measure>
    </unit>
    <unit id="renewal_option">
        <measure>thc:renewal_option</measure>
    </unit>
    <unit id="day">
        <measure>thc:day</measure>
    </unit>
    <unit id="quarter">
        <measure>thc:quarter</measure>
    </unit>
    <unit id="plan">
        <measure>thc:plan</measure>
    </unit>
    <unit id="surgery_center">
        <measure>thc:surgery_center</measure>
    </unit>
    <unit id="business">
        <measure>thc:business</measure>
    </unit>
    <unit id="surgical_center">
        <measure>thc:surgical_center</measure>
    </unit>
    <unit id="state">
        <measure>thc:state</measure>
    </unit>
    <unit id="imaging_center">
        <measure>thc:imaging_center</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN18yLTEtMS0xLTI5MzcxMA_9e75c0e3-1f42-448f-93fb-dbca6995e37c">0000070318</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN180LTEtMS0xLTI5MzcxMA_b3198b1f-9578-4bc1-a041-ff1548138be8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN18xMi0xLTEtMS0yOTM3MTA_89da6d9e-924b-4095-81fa-9f064930c671">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80L2ZyYWc6ZGY2ODllZTMyNjdlNDc3ODkyZTVjYTA0OTM1NmYzNmIvdGFibGU6OTcyMWYzN2RjNmY0NGE4MjgzYmI2NTg4ZjlmNzg4ZjcvdGFibGVyYW5nZTo5NzIxZjM3ZGM2ZjQ0YTgyODNiYjY1ODhmOWY3ODhmN18xMy0xLTEtMS0yOTM3MTA_30839a6c-5c1d-4710-89ed-b54ba7d5c1dc">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7e67596c4fbd48eea8785f354f1d98d8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iccd9ce39a7dc448ba011235d835f9e2f_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i52e0390579564677a1312d0789221786_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i997032dafb7b429994fd8eec46ba466e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iae5ba870f1f4485e81af6c8bba7c493d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872">http://fasb.org/us-gaap/2022#LongTermInvestmentsAndReceivablesNet</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1">http://fasb.org/us-gaap/2022#LongTermInvestmentsAndReceivablesNet</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays
      contextRef="ib7c8eda4b4d14ac49c4e91d6e7cb0cbc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODY4_dfdfd5fb-468c-4e0d-afdb-50499803685f">P3D</thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays>
    <thc:GuaranteeObligationPeriod
      contextRef="ibfd7a9c8341e4fbb98014f10cc135b7a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkyNA_42d833b7-adcf-4193-8432-f964517997d1">P1Y</thc:GuaranteeObligationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_0c2fc9bb-b93d-4b06-840f-178792b3529d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_1d18318b-f1d8-462d-93f9-2c3eaf3de351">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg0Mzg_74a46396-62a0-44d1-87da-e5a77de5ca2f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg2MjE_fd2aa8ae-54d5-4b8a-b36d-1b3d0bc214ae">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZmJmMmE5OTM5YTA4NDYzZTk1NDJjNWEyMzYzNDkwYmIvdGFibGVyYW5nZTpmYmYyYTk5MzlhMDg0NjNlOTU0MmM1YTIzNjM0OTBiYl8xLTEtMS0xLTM1MTY3OQ_d3d3768e-10a2-46fd-b72b-535f0ee710ef"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZmJmMmE5OTM5YTA4NDYzZTk1NDJjNWEyMzYzNDkwYmIvdGFibGVyYW5nZTpmYmYyYTk5MzlhMDg0NjNlOTU0MmM1YTIzNjM0OTBiYl8yLTEtMS0xLTM1MTY3OQ_c1274d87-7681-4a4a-991b-44675e8010b2"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ife8dd83765da4cd98415083bc755446e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZTNiZTFmMDJhMDU5NGIwNmE4NGNjMDE4NGM2ZmVkNWYvdGFibGVyYW5nZTplM2JlMWYwMmEwNTk0YjA2YTg0Y2MwMTg0YzZmZWQ1Zl8yLTEtMS0xLTM1MTY3Nw_ad452b51-c1a3-4a0b-8e20-31ef0c5106ff"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i016c96b25eea4c4e852f3cb7e72aedf8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl80MTI1L2ZyYWc6MDk1ZjAyNDVhYTA5NDE5ZmI1M2ZhYmRiMjJmNDFmMDEvdGFibGU6ZTNiZTFmMDJhMDU5NGIwNmE4NGNjMDE4NGM2ZmVkNWYvdGFibGVyYW5nZTplM2JlMWYwMmEwNTk0YjA2YTg0Y2MwMTg0YzZmZWQ1Zl8zLTEtMS0xLTM1MTY3Nw_bf576d78-663e-4d37-87ef-5e26c73ae846"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ic7cd6c10c8c74700867918c05b8d066e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzItMS0xLTEtMjkzNzEw_5cf46639-be82-4299-9806-daa669b4346f">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="id8235d44217a459cb42567e761b66f1d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzMtMS0xLTEtMjkzNzEw_976cf519-85aa-4c45-96c5-eadb9210aaea">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i5607340778f848eeba9562ba40506527_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzQtMS0xLTEtMjkzNzEw_f3f579ad-8616-44e1-9831-ad38615a3039">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ib32381cae0dc40e8971f9588ae25f535_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzUtMS0xLTEtMjkzNzEw_b749ec2f-8b4e-4d1c-ae52-765857c43fec">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i3fe036fe195e4e7d9cf7c4783fa3b8d6_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzYtMS0xLTEtMjkzNzEw_8ab62ad8-4d13-4c1a-bea1-bb8d3ea9fbde">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i2a8a661109d44f82ab8d85b5e23bfda3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDQvZnJhZzpiMmNkYmJiZGI3MDE0YzFhYThiZTQxNGM0ODlhOTAzOS90YWJsZTpjOWI3NmZiNDQwZGM0NTUyOWQwNTZkYmQ2MGQyZTFhZC90YWJsZXJhbmdlOmM5Yjc2ZmI0NDBkYzQ1NTI5ZDA1NmRiZDYwZDJlMWFkXzctMS0xLTEtMjkzNzEw_e64c5f1e-d47c-4da5-b811-85c155561009"
      xsi:nil="true"/>
    <thc:PurchasedEquityInJointVenturePercentageOfTotalShares
      contextRef="i9b94c1f135f64a488e17326f4496bb5a_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTkvZnJhZzo3OGRhOTE5MDFmNDU0NjI2ODg4YzJhN2U5ZjA2ZTQwYi90ZXh0cmVnaW9uOjc4ZGE5MTkwMWY0NTQ2MjY4ODhjMmE3ZTlmMDZlNDBiXzYz_aea51f89-a345-4830-a438-197415caca2c"
      unitRef="number">0.3333</thc:PurchasedEquityInJointVenturePercentageOfTotalShares>
    <dei:DocumentType
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl80LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjMzN2E1Y2I3NDg5YjRkYzBiNTg3OGI1YTFmMDI5NmQ2XzEw_517d708d-5208-4055-8790-f5c8ef5dc243">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl82LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmUxYWQ0MDg3YTdjZDQwN2NiODk4ODFkMjNlOGE3ZTNjXzQ_31f6eb14-82c2-49d0-aca5-749d4889b1dd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl82LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmUxYWQ0MDg3YTdjZDQwN2NiODk4ODFkMjNlOGE3ZTNjXzExOA_9d385f38-8552-4c69-956d-731d278eb3ee">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl82LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmUxYWQ0MDg3YTdjZDQwN2NiODk4ODFkMjNlOGE3ZTNjXzExOA_c19bd108-f921-4370-87e6-2f56f5e013e8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl84LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmY4M2UwM2ZmMGRmMDQ4NjY4MTU2MmY4NDUzMGY2ZmQzXzU_ca7020bb-613c-4cdb-bbe5-493c3482cf3b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo2ZWVjZWNlNDU5Y2E0NGM4YTgzOWRiNzY4MjUwNmZlZF8yOA_b6cfa303-2ff4-4da1-ad37-ea31bcaf2860">1-7293</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xMy0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjpjY2IwNjIzNGI3YmY0Nzc5YjA4YjIzNGJhMzg5Y2E0MF81_600c9cb7-748b-4ea0-8a7b-32d548dbc90d">TENET HEALTHCARE CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xNi0xLTEtMS0zMDQ4MTc_ce0dd766-a127-41f1-bac8-5e9e86806ee3">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xNi01LTEtMS0zMDQ4MTk_c667cd8a-e495-4bee-8d05-10cd00e53505">95-2557091</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8xOS0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo1NjkyZDFlZWE5MGI0ZTkwYWY4OTUwNTEwZGZlMDdmNl81_004f1891-aa7e-4aed-8813-f8f171b87fe6">14201 Dallas Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo3MjAwN2I1YTI1MTg0NjU4YTUyOGYxZWZiYWYxNGQ5Yl81_ed2bf061-65da-4977-a46b-2625aa1db030">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo3MjAwN2I1YTI1MTg0NjU4YTUyOGYxZWZiYWYxNGQ5Yl85_db894590-3641-45e7-8966-b0d2bd844fea">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMC0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjo3MjAwN2I1YTI1MTg0NjU4YTUyOGYxZWZiYWYxNGQ5Yl8xMw_be549490-886a-444d-9739-ce1b9539d174">75254</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMy0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjpkNmI4ZTA2YTZiMGU0OTJhOGMxNDczMjk0Nzk1NGZjYl82_ddfc7706-fa5f-4e20-aa9e-a0fa5e542e67">469</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6YjUzZjcwM2Q3YWU1NDRjNmFhZGRjZTY1NmQzM2JhOTYvdGFibGVyYW5nZTpiNTNmNzAzZDdhZTU0NGM2YWFkZGNlNjU2ZDMzYmE5Nl8yMy0wLTEtMS0zMDAxNDAvdGV4dHJlZ2lvbjpkNmI4ZTA2YTZiMGU0OTJhOGMxNDczMjk0Nzk1NGZjYl8xMA_ac35b66b-4580-42f7-852d-b164f146244f">893-2200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18xLTEtMS0xLTMwNDgyMQ_426522df-1a6d-48e6-b75f-d000641f1a50">Common stock, $0.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18xLTMtMS0xLTMwNDgyNQ_d7ed16e9-b14c-4185-80e3-3915e7f6ad86">THC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2b08bd8a49c2477e8f2841eca52d6cb2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18xLTUtMS0xLTMwNDgyNQ_1bca8b05-9aa5-451c-a616-5c24d8dd8937">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18yLTEtMS0xLTMwNDgyNw_adffa69b-96a9-4f2c-9fb5-8b666f0998cf">6.875% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18yLTMtMS0xLTMwNDgzMA_db621103-48d8-4fdd-b2f4-8621323e72ad">THC31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia528ee1ad4ff44589cedb69c13685f6e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MDUyMmFlZWIzZGRmNDJiYWJiZDhiMjBiNmJjYTU5ZjcvdGFibGVyYW5nZTowNTIyYWVlYjNkZGY0MmJhYmJkOGIyMGI2YmNhNTlmN18yLTUtMS0xLTMwNDgzMg_23c8829f-55f0-482a-89ae-d742449458bf">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN18zLTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmM1Nzg1M2I2ZTYwMDRjOWRiNWExYzMxMzI2ZmQzNmZlXzEyNQ_782ae3e9-1cb6-4755-b6f0-96a6db6512d4">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN181LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjcyNDM0YmQ5MThlNTRhZjBhZWUzYmEzNDIyNTg2ZmI1XzE0NQ_4ef27d4c-de19-4952-8f88-429b91ebcb41">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN183LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmViMDUzNTFkYWZlNTQ5NDY4NmIzN2JiODc5ODQ0NjljXzI0OA_77c683bd-ce84-453f-a431-486a49adb0fc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MjExMzRmY2U4NDBkNDE1ZWJlNjU0NTdiMTAyMjk4MzcvdGFibGVyYW5nZToyMTEzNGZjZTg0MGQ0MTVlYmU2NTQ1N2IxMDIyOTgzN185LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOmM4NmYzYjQ2YTMyYjQzYTI5ZGZiZGNlOTczOWE3YTU4XzIwNA_792ac5c0-3970-439b-81e3-a223ae1bf898">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6ZTdjMDJmNzY1ODg5NDI4NWExYjI2ODViYzI2YzAyMjIvdGFibGVyYW5nZTplN2MwMmY3NjU4ODk0Mjg1YTFiMjY4NWJjMjZjMDIyMl8wLTAtMS0xLTM2NTM3NS90ZXh0cmVnaW9uOjhkZjBjMDljNmM0MDQ0YmY5Mzk5YzhhYmEwZDU3N2Y2XzU_c05fe4b1-3a66-43e3-af1d-23044d4c4ee3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6ODdhMDIxOWMzMWRiNDJjMjhjNjM5YmRkZTU4ZWVkZjUvdGFibGVyYW5nZTo4N2EwMjE5YzMxZGI0MmMyOGM2MzliZGRlNThlZWRmNV8wLTEtMS0xLTM2NTM4Mi90ZXh0cmVnaW9uOjk3NTAyMGI4MDBhNDQ3NTU4ZmY3ZmQ4MGM1YTU2YTY4XzMx_fd6b7938-a910-4214-82f1-708652adb5bc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6ODdhMDIxOWMzMWRiNDJjMjhjNjM5YmRkZTU4ZWVkZjUvdGFibGVyYW5nZTo4N2EwMjE5YzMxZGI0MmMyOGM2MzliZGRlNThlZWRmNV8wLTMtMS0xLTM2NTM4Mi90ZXh0cmVnaW9uOjA4YjgzZjE0M2UxZjQxYTdiNTE0ODNjZTMzYTUwOWJhXzI5_a9acc481-a34c-4868-918b-8895e3730a11">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M18yLTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjJmY2E0ZTg2NDBiODQ2Yzg5NWFjNmEyNzM3YTAyNGZlXzM0MA_ecc65ccb-115b-4b9a-81da-3e546afb7108">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M180LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjBhMjA5MWUzNTQ2ZDRlNDJhZWM2OTg0NzI4ZWVlNmZjXzExNQ_249786c0-e798-4fff-80c7-2502f732221e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="if3cddf06bd574be2ad2b6db4f6c58e08_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M182LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjc4MWJjOTk1NGI4MjQ1Mzk5YzBhMTA3ZTI4NmJmNWNkXzMyMg_3c23f456-9605-4c7a-9578-3ab9860e35f5"
      unitRef="usd">5600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i466f81b830d4456980895fd2849bc045_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M182LTAtMS0xLTMwMDE0MC90ZXh0cmVnaW9uOjc4MWJjOTk1NGI4MjQ1Mzk5YzBhMTA3ZTI4NmJmNWNkXzQ1OA_c2acd828-95f4-4e8b-9ddf-107463c2e928"
      unitRef="shares">102274102</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zODcyL2ZyYWc6YmJmMzU5M2M1ZTkyNDUzMGExZTI4ZDE3ODM1NmZiMzQvdGFibGU6MTQ1YTkxNGY5ZjM0NGFiYmIwMmJiY2JiYWUxYzc0ODMvdGFibGVyYW5nZToxNDVhOTE0ZjlmMzQ0YWJiYjAyYmJjYmJhZTFjNzQ4M18xMC0wLTEtMS0zMDQ4NTM_b6eb5070-c68c-47a6-b968-067d89f0c916">Portions of the Registrant&#x2019;s definitive proxy statement for the 2023 annual meeting of shareholders are incorporated by reference into Part&#160;III of this Form&#160;10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjAvZnJhZzpjYzAyZDE2N2M2YzY0Y2Y5ODFkMjBmYzFiYzExZTAzNC90ZXh0cmVnaW9uOmNjMDJkMTY3YzZjNjRjZjk4MWQyMGZjMWJjMTFlMDM0XzI3NDg3NzkxNzk3MzU_36167ca0-99bf-4bee-9989-4465c04e0903">DELOITTE &amp; TOUCHE LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjAvZnJhZzpjYzAyZDE2N2M2YzY0Y2Y5ODFkMjBmYzFiYzExZTAzNC90ZXh0cmVnaW9uOmNjMDJkMTY3YzZjNjRjZjk4MWQyMGZjMWJjMTFlMDM0XzI3NDg3NzkxNzk3Mzc_ce82c216-5a91-4fba-ac6e-5473195b2dd1">Dallas, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQtMi0xLTEtMjkzNzEw_f89fe412-6e50-45d4-ba40-92be20c1bdbd"
      unitRef="usd">858000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQtNC0xLTEtMjkzNzEw_124cf15b-329d-416a-b5cf-441ab00e2df0"
      unitRef="usd">2364000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzUtMi0xLTEtMjkzNzEw_03ce3369-4d9f-41ef-ae0a-122a4f7f6f59"
      unitRef="usd">2943000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzUtNC0xLTEtMjkzNzEw_b06f2afe-587c-4ad7-892b-6bd72c740635"
      unitRef="usd">2770000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzYtMi0xLTEtMjkzNzEw_029f8895-dae0-428e-966a-8ab60f076a42"
      unitRef="usd">405000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzYtNC0xLTEtMjkzNzEw_a5415587-08c9-440e-860b-a04da0500f78"
      unitRef="usd">384000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzktMi0xLTEtMjkzNzEw_06a82de7-a67c-4e0a-9110-5923481c1f5b"
      unitRef="usd">1775000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzktNC0xLTEtMjkzNzEw_053a7f53-f2eb-44d6-a25a-39f4adbc1d03"
      unitRef="usd">1557000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEwLTItMS0xLTI5MzcxMA_2a60524c-d77f-4e61-bbc8-66ddef4c9928"
      unitRef="usd">5981000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEwLTQtMS0xLTI5MzcxMA_bd40a4a5-6039-4238-bb56-714502b27be1"
      unitRef="usd">7075000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestmentsAndReceivablesNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzExLTItMS0xLTI5MzcxMA_faec8d66-a82b-43c8-b17d-f1784ceb9593"
      unitRef="usd">3147000000</us-gaap:LongTermInvestmentsAndReceivablesNet>
    <us-gaap:LongTermInvestmentsAndReceivablesNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzExLTQtMS0xLTI5MzcxMA_3025b71c-76a3-4ee4-9cbf-bce109c43b4f"
      unitRef="usd">3254000000</us-gaap:LongTermInvestmentsAndReceivablesNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEyLTItMS0xLTI5MzcxMA_d6594ff1-2bd5-49f9-9d3e-7c03b46b782e"
      unitRef="usd">19000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEyLTQtMS0xLTI5MzcxMA_69982a7d-7ca2-4f76-8378-84dc33b9f87b"
      unitRef="usd">65000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjdjMmU3OThjMTJiZDQ4YTVhNmFmN2JkYTg3ODM1N2ZkXzg1_ad634166-591f-4462-a1d2-1f5f3f14bac7"
      unitRef="usd">6201000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjdjMmU3OThjMTJiZDQ4YTVhNmFmN2JkYTg3ODM1N2ZkXzk4_4fbbaee0-93f5-4eee-8b8b-7374e9cb26ba"
      unitRef="usd">5960000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTItMS0xLTI5MzcxMA_060f8149-431c-42dd-bdc5-b81c48c1dcea"
      unitRef="usd">6462000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzEzLTQtMS0xLTI5MzcxMA_ec1d321a-5b18-4270-b898-f52b68b7504e"
      unitRef="usd">6427000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Goodwill
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE0LTItMS0xLTI5MzcxMA_ba3af743-cb5c-4bc8-afb9-e09e88668a45"
      unitRef="usd">10123000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE0LTQtMS0xLTI5MzcxMA_38b67bd6-e67d-426f-9492-31154d36570e"
      unitRef="usd">9261000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjBlNTU0ZjlhNGNiMTQ1ZTZhNDFiOTA0ZmUxYzQ2Y2MyXzcw_9efff27e-4128-4cd8-9412-cd14b6f64ac1"
      unitRef="usd">1428000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjBlNTU0ZjlhNGNiMTQ1ZTZhNDFiOTA0ZmUxYzQ2Y2MyXzgz_e10fe331-8111-4e78-9c54-ad5a0c74805c"
      unitRef="usd">1374000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTItMS0xLTI5MzcxMA_c5d89e1b-08e2-42b4-849c-d325dd3d4b75"
      unitRef="usd">1424000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE1LTQtMS0xLTI5MzcxMA_36812eed-7d97-4dc4-a815-77cc5b87ebe7"
      unitRef="usd">1497000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE2LTItMS0xLTI5MzcxMA_de55177f-a1ab-492c-bcdd-6b071c98d9ce"
      unitRef="usd">27156000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE2LTQtMS0xLTI5MzcxMA_70028934-5158-4c5a-a0eb-f170e8ac4123"
      unitRef="usd">27579000000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE5LTItMS0xLTI5MzcxMA_dce00e54-f35d-46de-a3fe-061712df42cd"
      unitRef="usd">145000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzE5LTQtMS0xLTI5MzcxMA_59b2d614-91b8-44d2-b114-c594e8643ebd"
      unitRef="usd">135000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIwLTItMS0xLTI5MzcxMA_a1293e14-5559-495d-b378-f16b7e55ed72"
      unitRef="usd">1504000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIwLTQtMS0xLTI5MzcxMA_abaf3296-c442-451b-aba7-90c7e5518eac"
      unitRef="usd">1300000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIxLTItMS0xLTI5MzcxMA_876ddf55-568b-4169-a01a-9b7e234a0336"
      unitRef="usd">778000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIxLTQtMS0xLTI5MzcxMA_f31649db-6019-4f25-91d9-7887111bb6f3"
      unitRef="usd">896000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIyLTItMS0xLTI5MzcxMA_e16e71bf-4985-4cad-a9a0-3cbc16d6c988"
      unitRef="usd">255000000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIyLTQtMS0xLTI5MzcxMA_73074958-f68f-400e-91d0-44b48f0fc649"
      unitRef="usd">254000000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIzLTItMS0xLTI5MzcxMA_aae3975b-493e-4549-bb11-0adc14cd396e"
      unitRef="usd">213000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzIzLTQtMS0xLTI5MzcxMA_c9e6225b-4dc8-4f7c-b392-10f698604654"
      unitRef="usd">203000000</us-gaap:InterestPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI1LTItMS0xLTI5MzcxMA_39eb322d-d3b3-441d-98c6-00d0565abf90"
      unitRef="usd">110000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI1LTQtMS0xLTI5MzcxMA_88f0db4d-b356-491f-a2e3-d496dc982256"
      unitRef="usd">959000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI2LTItMS0xLTI5MzcxMA_21453353-a7cc-42ab-b6a4-1305f97ed462"
      unitRef="usd">1471000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI2LTQtMS0xLTI5MzcxMA_50b863ca-8837-4235-aac8-a40b83b39a53"
      unitRef="usd">1362000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI3LTItMS0xLTI5MzcxMA_4c07aa23-6f88-43ee-a206-7ba68611698f"
      unitRef="usd">4476000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI3LTQtMS0xLTI5MzcxMA_0c6b83ea-d9c7-4415-81d3-f4d5d3e6a5f0"
      unitRef="usd">5109000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI4LTItMS0xLTI5MzcxMA_10fc9f5d-7101-49fd-89b2-749f231b7918"
      unitRef="usd">14934000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI4LTQtMS0xLTI5MzcxMA_461c24c4-d564-4ae5-86e7-a65b7d28a4ec"
      unitRef="usd">15511000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:SelfInsuranceReserveNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI5LTItMS0xLTI5MzcxMA_cd60d506-2b06-44c4-b215-f851ac1e6636"
      unitRef="usd">790000000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzI5LTQtMS0xLTI5MzcxMA_e71a2d50-34e1-4422-bc92-640f184f09bc"
      unitRef="usd">791000000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMwLTItMS0xLTI5MzcxMA_374c57e6-99ce-4210-8d2c-7cdfa23f00c4"
      unitRef="usd">331000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMwLTQtMS0xLTI5MzcxMA_ffac478e-ed83-4961-b9ce-3132656942bd"
      unitRef="usd">421000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMxLTItMS0xLTI5MzcxMA_e6d3239d-3a0e-4d20-b8ef-cf7b3896f835"
      unitRef="usd">217000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMxLTQtMS0xLTI5MzcxMA_f5c0950a-6bf6-4cc3-817b-c787c953aaa5"
      unitRef="usd">36000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMyLTItMS0xLTI5MzcxMA_6e2e29c6-f55c-43b7-83c6-2a72f2487a05"
      unitRef="usd">13000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMyLTQtMS0xLTI5MzcxMA_894eadb7-1ea0-4d46-af4c-15d805430414"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMzLTItMS0xLTI5MzcxMA_b5f0ed00-b607-41b6-81bb-7c555572e2c0"
      unitRef="usd">1787000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzMzLTQtMS0xLTI5MzcxMA_97c74a27-98ad-4511-869b-7692330e9ba7"
      unitRef="usd">1439000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM0LTItMS0xLTI5MzcxMA_d3023ba1-b68a-4f3c-ac0c-6f2637035b5e"
      unitRef="usd">22548000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM0LTQtMS0xLTI5MzcxMA_ac707d53-5ae5-4819-a48c-e57311cc59bb"
      unitRef="usd">23322000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM1LTItMS0xLTI5MzcxMA_f565bbee-aae3-4326-9201-9cf08666e143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM1LTQtMS0xLTI5MzcxMA_df3ae751-ac11-43fb-af7d-cba84b074365"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM2LTItMS0xLTI5MzcxMA_f02b14a1-bdb2-4020-844d-8924128ff8e3"
      unitRef="usd">2149000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM2LTQtMS0xLTI5MzcxMA_cd926cf3-0597-4e54-8ab0-e0a28da9947f"
      unitRef="usd">2203000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzE5_200ed232-971d-4219-8310-148b26dce011"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzE5_ad46615e-b321-447f-af39-205f54f7e236"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzQ0_6912a276-b253-40a0-a80f-6f4f67273327"
      unitRef="shares">262500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzQ0_9dd4c4a8-0837-4fdc-b17f-f14ee36a305e"
      unitRef="shares">262500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1XzU1_7d051568-4bed-4f0a-97df-5f8c8e4eaadc"
      unitRef="shares">156462456</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmFjMjc2YjJhNTljZDQ4MDlhNDhiZWFlYjU0N2IzYzU1Xzgy_d0e3fecb-918c-4f8d-a08c-182b53859bd5"
      unitRef="shares">155520691</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTItMS0xLTI5MzcxMA_2865bb36-e0e2-49a0-af26-a34d275d2e63"
      unitRef="usd">8000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzM5LTQtMS0xLTI5MzcxMA_728dc95c-144c-4f5a-8841-fa73c83c088a"
      unitRef="usd">8000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQwLTItMS0xLTI5MzcxMA_51cc1b07-cac9-43a6-ab42-d33a4446c38c"
      unitRef="usd">4778000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQwLTQtMS0xLTI5MzcxMA_0cc6ddcc-c0c5-4b7e-b076-7d204bbea4ad"
      unitRef="usd">4877000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQxLTItMS0xLTI5MzcxMA_5bf058ab-0bac-4469-8e0b-8c6a4fb499da"
      unitRef="usd">-181000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQxLTQtMS0xLTI5MzcxMA_ef7948f0-cf67-495a-9e66-e29ef693adcb"
      unitRef="usd">-233000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQyLTItMS0xLTI5MzcxMA_5dce8b94-6144-4079-bae6-40adf4cc74d2"
      unitRef="usd">-803000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQyLTQtMS0xLTI5MzcxMA_34c537bf-aeae-491a-a082-8b2d5a2a25f9"
      unitRef="usd">-1214000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmYxNDZkN2FlZjQ1MDRhMjM4NTA1ODJjZjg0YzQ5YjIyXzQw_053bf07b-d6ed-4ecc-bd29-e5b2506878b3"
      unitRef="shares">54215871</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmYxNDZkN2FlZjQ1MDRhMjM4NTA1ODJjZjg0YzQ5YjIyXzYx_d2314124-5dbe-48f0-ae78-658aaebe5a67"
      unitRef="shares">48331649</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTItMS0xLTI5MzcxMA_cde7e6fd-3dd5-447d-bff7-8fe354014abd"
      unitRef="usd">2660000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQzLTQtMS0xLTI5MzcxMA_b4f9fe03-803d-40bf-ae32-32e749485901"
      unitRef="usd">2410000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ0LTItMS0xLTI5MzcxMA_5fc1bcaa-f017-49b1-8a9b-2ff09066461c"
      unitRef="usd">1142000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ0LTQtMS0xLTI5MzcxMA_ff7b0877-5672-4eb8-8951-8a9cfbf04862"
      unitRef="usd">1028000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ1LTItMS0xLTI5MzcxMA_abbeb338-48ed-4f60-b021-eb2179c105ee"
      unitRef="usd">1317000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ1LTQtMS0xLTI5MzcxMA_1bd2ef7c-91be-427c-91cd-04c7dc2ad7d6"
      unitRef="usd">1026000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ2LTItMS0xLTI5MzcxMA_5da74a43-4824-4947-bdc0-23da79968b5a"
      unitRef="usd">2459000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ2LTQtMS0xLTI5MzcxMA_f81ddcee-9c0e-44f7-96cf-5ef2964e517b"
      unitRef="usd">2054000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ3LTItMS0xLTI5MzcxMA_59935e50-3a45-4f65-a762-f56d87777b0f"
      unitRef="usd">27156000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNjkvZnJhZzowZGNjOGUzMGFjZmY0YjE3OWYzMjg4NGM4ZDhmM2MzNy90YWJsZTo5YjVkNGIxYzlmNTc0Zjg3YjZiOTlmNjJhMDE4MGUyZC90YWJsZXJhbmdlOjliNWQ0YjFjOWY1NzRmODdiNmI5OWY2MmEwMTgwZTJkXzQ3LTQtMS0xLTI5MzcxMA_3feb32bf-79f9-42db-821d-db08985758e1"
      unitRef="usd">27579000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzItMS0xLTEtMjkzNzEw_a0a5defb-0789-4ed1-93e3-5740e82286d6"
      unitRef="usd">19174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzItMy0xLTEtMjkzNzEw_edd1ec78-1eae-491f-897b-6023e17f43f3"
      unitRef="usd">19485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzItNS0xLTEtMjkzNzEw_26bba0fc-33ba-4c10-85a4-e78379be3037"
      unitRef="usd">17640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMtMS0xLTEtMjkzNzEw_ddc7d2c7-32f4-4c24-b6d3-670571f36698"
      unitRef="usd">194000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMtMy0xLTEtMjkzNzEw_1ef38e4e-eda1-4d37-bd8d-a83f460a6016"
      unitRef="usd">191000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMtNS0xLTEtMjkzNzEw_45966650-8759-449f-9ccb-3b982a486b12"
      unitRef="usd">882000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQtMS0xLTEtMjkzNzEw_d893e43c-226e-4740-b704-c2f1fbabb8ee"
      unitRef="usd">216000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQtMy0xLTEtMjkzNzEw_c10c02a3-cb95-422c-a2d0-34ec3f7ed81c"
      unitRef="usd">218000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQtNS0xLTEtMjkzNzEw_8de7f276-b1d3-422c-8ec1-ef16696b399a"
      unitRef="usd">169000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzYtMS0xLTEtMjkzNzEw_18665c36-149c-4f7a-af50-de35de4af3d9"
      unitRef="usd">8844000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzYtMy0xLTEtMjkzNzEw_e9372136-bd0f-4670-9405-95433d6b44ce"
      unitRef="usd">8878000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzYtNS0xLTEtMjkzNzEw_99fd425f-be04-450e-8c64-b830b00d2e6e"
      unitRef="usd">8418000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:SuppliesExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzctMS0xLTEtMjkzNzEw_712c52b0-ff55-4a98-adb6-7a4021a326db"
      unitRef="usd">3273000000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzctMy0xLTEtMjkzNzEw_65b04504-21b5-48c3-91db-61e9c44652e2"
      unitRef="usd">3328000000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzctNS0xLTEtMjkzNzEw_9f25471d-87ed-48f7-912c-6850ab76df36"
      unitRef="usd">2982000000</us-gaap:SuppliesExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzgtMS0xLTEtMjkzNzEw_b17e8efb-374d-45c4-9f5b-5eae2f81951a"
      unitRef="usd">3998000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzgtMy0xLTEtMjkzNzEw_24e6f296-c537-4d70-9d14-0d1de057b570"
      unitRef="usd">4206000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzgtNS0xLTEtMjkzNzEw_59a10dd5-5039-4fb0-b492-9147c2163f9f"
      unitRef="usd">4125000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzktMS0xLTEtMjkzNzEw_1e6a6af7-95ef-40dc-86ba-91a9b6805277"
      unitRef="usd">841000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzktMy0xLTEtMjkzNzEw_d1fe4e62-edf9-4fcf-86e7-327bdbe2f570"
      unitRef="usd">855000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzktNS0xLTEtMjkzNzEw_6d61feca-824c-44df-b8e8-d8b995b3cbbe"
      unitRef="usd">857000000</us-gaap:DepreciationDepletionAndAmortization>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEwLTEtMS0xLTI5MzcxMA_9040f636-603d-46be-b253-0e51bad10363"
      unitRef="usd">226000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEwLTMtMS0xLTI5MzcxMA_b2826baa-7065-4b13-9dbc-a612e7242f22"
      unitRef="usd">85000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEwLTUtMS0xLTI5MzcxMA_e732c9ba-2b4d-496a-9d7a-aa54a1edbb12"
      unitRef="usd">290000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzExLTEtMS0xLTI5MzcxMA_f16593a1-fe9c-4435-ab8c-a9ae4a9822a2"
      unitRef="usd">-70000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzExLTMtMS0xLTI5MzcxMA_dc2c2bc2-8d28-4e09-ae17-cced409cd029"
      unitRef="usd">-116000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzExLTUtMS0xLTI5MzcxMA_27cd80e4-dc4c-4634-8e5b-855e0ca60f2c"
      unitRef="usd">-44000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEyLTEtMS0xLTI5MzcxMA_e4cbbbcb-3087-4be4-95d6-ed49593a1b13"
      unitRef="usd">1000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEyLTMtMS0xLTI5MzcxMA_5799ee88-fcd7-48f7-b8ad-5b994dcc2c7a"
      unitRef="usd">445000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEyLTUtMS0xLTI5MzcxMA_851babaf-a944-4a6a-90ca-a1c178c9bbaa"
      unitRef="usd">14000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <us-gaap:OperatingIncomeLoss
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEzLTEtMS0xLTI5MzcxMA_a6a527a2-cb7d-401d-8454-9e08a5dcde11"
      unitRef="usd">2333000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEzLTMtMS0xLTI5MzcxMA_b16bbba3-48b1-41aa-a36d-4864a4239562"
      unitRef="usd">2871000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzEzLTUtMS0xLTI5MzcxMA_fc07fc2b-402e-4259-9ebf-1f3ffb9ede5d"
      unitRef="usd">1989000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE0LTEtMS0xLTI5MzcxMA_ae9a92dc-2cac-494b-8f7a-b5c967ffb2d3"
      unitRef="usd">890000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE0LTMtMS0xLTI5MzcxMA_af5908fe-7854-4580-bc2e-f51786058311"
      unitRef="usd">923000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE0LTUtMS0xLTI5MzcxMA_12933246-b18f-46a8-9b79-6aa1fce6c773"
      unitRef="usd">1003000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE1LTEtMS0xLTI5MzcxMA_86491642-3fe4-4916-95db-fe576582583e"
      unitRef="usd">10000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE1LTMtMS0xLTI5MzcxMA_646b2d36-6722-46f0-801a-c4fa7e67399f"
      unitRef="usd">14000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE1LTUtMS0xLTI5MzcxMA_bc496db4-6922-4346-a311-f5662709fad2"
      unitRef="usd">1000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE2LTEtMS0xLTI5MzcxMA_6e446645-1fb9-4067-ba34-de6dd9a2d94c"
      unitRef="usd">-109000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE2LTMtMS0xLTI5MzcxMA_53f2961a-3aaf-4c74-bb28-c08480c7570e"
      unitRef="usd">-74000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE2LTUtMS0xLTI5MzcxMA_a4ec7580-1370-47fe-aea8-9bfa9cf4682e"
      unitRef="usd">-316000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE3LTEtMS0xLTI5MzcxMA_6c3f0775-c1b7-4a0e-8d15-6b6d116c49cf"
      unitRef="usd">1344000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE3LTMtMS0xLTI5MzcxMA_52e1b004-5838-4e8b-aaee-6bd0e8a8631f"
      unitRef="usd">1888000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE3LTUtMS0xLTI5MzcxMA_0cb029d3-8773-438b-9eb1-5cc760ebe2ec"
      unitRef="usd">671000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE4LTEtMS0xLTI5MzcxMA_22781c6a-0c0d-4aee-88fc-e3312ac9aed7"
      unitRef="usd">344000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE4LTMtMS0xLTI5MzcxMA_50f987a9-38c0-4655-986b-2391f53a38c2"
      unitRef="usd">411000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE4LTUtMS0xLTI5MzcxMA_faa0ec47-535f-4259-a308-839ef3b6c814"
      unitRef="usd">-97000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE5LTEtMS0xLTI5MzcxMA_668d85a3-6860-4242-92ec-ddd8a5b40867"
      unitRef="usd">1000000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE5LTMtMS0xLTI5MzcxMA_48531a71-a49c-4af2-848b-ca6affaf2548"
      unitRef="usd">1477000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzE5LTUtMS0xLTI5MzcxMA_19621fe4-ee57-423a-8328-edb4411e4fb5"
      unitRef="usd">768000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIxLTEtMS0xLTI5MzcxMA_a21ae71e-5d3e-4cd9-8365-fd49bdf47b69"
      unitRef="usd">1000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIxLTMtMS0xLTI5MzcxMA_114ca079-263e-484d-890a-d611b1fa26bf"
      unitRef="usd">-1000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIxLTUtMS0xLTI5MzcxMA_6a11d6e3-cd1f-435e-8a93-d925a4184390"
      unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIzLTEtMS0xLTI5MzcxMA_353efe94-beec-4a0a-a84f-2a04da28f871"
      unitRef="usd">1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIzLTMtMS0xLTI5MzcxMA_4df2f948-970b-40fd-993d-9c6c3dd37c1a"
      unitRef="usd">-1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzIzLTUtMS0xLTI5MzcxMA_48c834d2-1979-4af4-b48d-6f80def59e00"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI0LTEtMS0xLTI5MzcxMA_f1f60ffa-8cc3-48fa-b438-b4120e662a00"
      unitRef="usd">1001000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI0LTMtMS0xLTI5MzcxMA_bd63172c-a5c9-47d7-980c-70f5d9f05651"
      unitRef="usd">1476000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI0LTUtMS0xLTI5MzcxMA_9775d24d-a203-4d18-9e19-c9f0fd41e7c9"
      unitRef="usd">768000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI1LTEtMS0xLTI5MzcxMA_b5803b8d-92ff-45a9-aeb8-90560ac099f8"
      unitRef="usd">590000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI1LTMtMS0xLTI5MzcxMA_1adb3e13-396c-4b65-8133-ce5482087f3f"
      unitRef="usd">562000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI1LTUtMS0xLTI5MzcxMA_04e48ecd-84c7-4f00-94ea-e045f0b42d9a"
      unitRef="usd">369000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI2LTEtMS0xLTI5MzcxMA_9e231260-c63e-4101-a51b-f73544232f09"
      unitRef="usd">411000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI2LTMtMS0xLTI5MzcxMA_809bb537-a042-4911-9d50-a110435fb9d9"
      unitRef="usd">914000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI2LTUtMS0xLTI5MzcxMA_4369b44c-d41a-4ea9-b8c5-8da8d18d02ee"
      unitRef="usd">399000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI4LTEtMS0xLTI5MzcxMA_4f52ac0d-b341-41c9-866a-5f93ca5d2c8f"
      unitRef="usd">410000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI4LTMtMS0xLTI5MzcxMA_d089b4a0-2065-432d-ae0c-700e49d5ffbd"
      unitRef="usd">915000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI4LTUtMS0xLTI5MzcxMA_d29977a9-b704-4966-8cd8-162917154967"
      unitRef="usd">399000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI5LTEtMS0xLTI5MzcxMA_4b8d5531-406e-4bfb-9a6c-ab85599df622"
      unitRef="usd">1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI5LTMtMS0xLTI5MzcxMA_8bbea286-de81-422b-afef-c3354fb0ed50"
      unitRef="usd">-1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzI5LTUtMS0xLTI5MzcxMA_51016837-a7cd-4b97-913e-61962b565e3a"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMwLTEtMS0xLTI5MzcxMA_06c71abd-2f57-4bcd-9ed0-56ca97a04636"
      unitRef="usd">411000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMwLTMtMS0xLTI5MzcxMA_eaae9c9f-e725-47fa-88e1-73bbb5e1181c"
      unitRef="usd">914000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMwLTUtMS0xLTI5MzcxMA_d8db9f56-900c-481b-9f9d-73ad236d1a52"
      unitRef="usd">399000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMzLTEtMS0xLTI5MzcxMA_16b47b03-f30f-4991-9974-31f180b8bafd"
      unitRef="usdPerShare">3.83</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMzLTMtMS0xLTI5MzcxMA_9819ede3-f051-46ba-bb6a-cb7c04d4c909"
      unitRef="usdPerShare">8.56</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzMzLTUtMS0xLTI5MzcxMA_2e88de55-111c-416b-b464-b5f58d8b82f1"
      unitRef="usdPerShare">3.80</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM0LTEtMS0xLTI5MzcxMA_40e14091-e5ad-4320-9344-daca65c3dbe3"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM0LTMtMS0xLTI5MzcxMA_25db87be-eb14-497e-96b3-aa6373c825e9"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM0LTUtMS0xLTI5MzcxMA_82742840-7bc9-4c89-a123-160c55dd314d"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM1LTEtMS0xLTI5MzcxMA_f57f7fea-e473-4120-bbc0-70dd3a94b35b"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM1LTMtMS0xLTI5MzcxMA_e25606ae-e63b-4497-b791-199213941832"
      unitRef="usdPerShare">8.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM1LTUtMS0xLTI5MzcxMA_9cf75b35-ee9e-4a93-b022-bbef6060b9c2"
      unitRef="usdPerShare">3.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM3LTEtMS0xLTI5MzcxMA_d5f846ca-0ed3-451b-8f83-200ca8f24c09"
      unitRef="usdPerShare">3.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM3LTMtMS0xLTI5MzcxMA_5610d9a4-fb3e-434d-a9e5-aed39241a30c"
      unitRef="usdPerShare">8.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM3LTUtMS0xLTI5MzcxMA_a04c3da4-44e2-4428-a8dd-eac89df250dd"
      unitRef="usdPerShare">3.75</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM4LTEtMS0xLTI5MzcxMA_165cbdcc-614e-44f8-ac88-0409db9aede9"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM4LTMtMS0xLTI5MzcxMA_df1578d8-8054-4a3b-b511-9b47e07d47ef"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM4LTUtMS0xLTI5MzcxMA_4a045fa6-2a61-4982-8ff8-b00a62aca5de"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM5LTEtMS0xLTI5MzcxMA_75c501b2-f76d-4aff-9ec5-f3130b3fb0bd"
      unitRef="usdPerShare">3.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM5LTMtMS0xLTI5MzcxMA_ae354540-c4ae-486c-a7d9-4a0824d4bbb7"
      unitRef="usdPerShare">8.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzM5LTUtMS0xLTI5MzcxMA_48e361dc-5022-4449-b184-499f14b492c0"
      unitRef="usdPerShare">3.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQxLTEtMS0xLTI5MzcxMA_7186b51e-3d15-4863-8e53-9366d63d87e3"
      unitRef="shares">106929000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQxLTMtMS0xLTI5MzcxMA_b00ae0c9-0772-4d04-9112-4b110b499bda"
      unitRef="shares">106833000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQxLTUtMS0xLTI5MzcxMA_0d611576-4ae6-4932-9916-083bd7f59e8e"
      unitRef="shares">105010000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQyLTEtMS0xLTI5MzcxMA_b20b4f66-8bdf-4430-a723-9756a9f59573"
      unitRef="shares">110516000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQyLTMtMS0xLTI5MzcxMA_2bd7a172-70f9-49ad-91eb-15b515040412"
      unitRef="shares">108571000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzIvZnJhZzpmNTZjNGQ5N2JjNzA0MWIyODE1ZGNiMDI1N2NjZWY5NC90YWJsZTo5NDY4NTNhYjM4Zjc0NGZmYTcwN2JiYzNjMTNhNzRmYy90YWJsZXJhbmdlOjk0Njg1M2FiMzhmNzQ0ZmZhNzA3YmJjM2MxM2E3NGZjXzQyLTUtMS0xLTI5MzcxMA_3438ce58-17e4-4c7f-8b8c-e52faa8711ca"
      unitRef="shares">106263000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzItMS0xLTEtMjkzNzEw_62d175d5-4548-4cd5-a852-469c13814622"
      unitRef="usd">1001000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzItMy0xLTEtMjkzNzEw_3553c7ca-a087-4443-b154-ee6bd14ec8b4"
      unitRef="usd">1476000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzItNS0xLTEtMjkzNzEw_85c5af83-fe2a-4249-8fc1-3bca363341f2"
      unitRef="usd">768000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzQtMS0xLTEtMjkzNzEw_105531e6-f1ce-40f8-b93f-cf3a065881d9"
      unitRef="usd">-63000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzQtMy0xLTEtMjkzNzEw_fa180081-3fae-4f2a-a91d-846ba9160ba8"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzQtNS0xLTEtMjkzNzEw_0843b516-d345-41a6-b35e-f2f146d96893"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzUtMS0xLTEtMjkzNzEw_c9dbc30d-4fad-4695-924c-ec83c362dc2c"
      unitRef="usd">9000000</thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax>
    <thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzUtMy0xLTEtMjkzNzEw_a7e61fe8-e30c-449c-9aff-3c01fa106ad4"
      unitRef="usd">11000000</thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax>
    <thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzUtNS0xLTEtMjkzNzEw_d54b813c-0299-4143-bb03-34e0c397dbc4"
      unitRef="usd">9000000</thc:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzYtMS0xLTEtMjkzNzEw_48245b0d-1a8d-4aab-8de1-3b85b2347023"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzYtMy0xLTEtMjkzNzEw_8a612136-5673-4562-b9ea-4cf428c0269f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzYtNS0xLTEtMjkzNzEw_8fe371ed-344d-467e-86b6-73f248ff6a36"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzgtMS0xLTEtMjkzNzEw_cf06adeb-1ec4-4075-b7ec-31ba14c6b2b0"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzgtMy0xLTEtMjkzNzEw_5c3e101a-4156-4e09-97a4-87618d153290"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzgtNS0xLTEtMjkzNzEw_88b30270-3664-4d08-aa99-7c6c2763770c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzktMS0xLTEtMjkzNzEw_32f0fa9e-2afb-474a-8008-f8d749b4da0e"
      unitRef="usd">69000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzktMy0xLTEtMjkzNzEw_71caeef5-6232-46ff-9563-fa42ac73081e"
      unitRef="usd">62000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzktNS0xLTEtMjkzNzEw_ba6781f0-9e52-4edd-8649-481235814d63"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEwLTEtMS0xLTI5MzcxMA_9741f417-2cdb-4982-a1e0-6e4ae078a77e"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEwLTMtMS0xLTI5MzcxMA_b04b17ba-821c-4864-b3b2-9e0da57893fc"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEwLTUtMS0xLTI5MzcxMA_d008f604-63b9-45a4-8c04-111c33ea9dfe"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzExLTEtMS0xLTI5MzcxMA_b4f97309-8816-4438-af2e-808e0b8e5efa"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzExLTMtMS0xLTI5MzcxMA_864e6efe-72a5-4be7-9603-a86e8b9f8254"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzExLTUtMS0xLTI5MzcxMA_6a437ad0-df76-4d67-8be2-859c44d1bc81"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEyLTEtMS0xLTI5MzcxMA_2c8af8c2-4025-410d-a513-82cdbed14a42"
      unitRef="usd">1053000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEyLTMtMS0xLTI5MzcxMA_cc6fdc15-2677-492f-b8ed-52c1883ab019"
      unitRef="usd">1524000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEyLTUtMS0xLTI5MzcxMA_2d98883d-639a-4e13-b0a5-8be2264d95d7"
      unitRef="usd">744000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEzLTEtMS0xLTI5MzcxMA_bf884d77-d289-4ab8-ab7f-450cdc86a07c"
      unitRef="usd">590000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEzLTMtMS0xLTI5MzcxMA_4c881713-4a85-4367-a7f3-b74d643a81ec"
      unitRef="usd">562000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzEzLTUtMS0xLTI5MzcxMA_73a93859-2bad-4d9b-9947-5469d53e4d6a"
      unitRef="usd">369000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzE0LTEtMS0xLTI5MzcxMA_8fc6eef1-f2b4-450b-b626-0f1198eb4176"
      unitRef="usd">463000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzE0LTMtMS0xLTI5MzcxMA_ec76dc7a-6dbc-47ad-ab06-51a86384c2a5"
      unitRef="usd">962000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzUvZnJhZzpiZDg0ZmY0ZWMwMjQ0YzdmODUzNTU5YTkwMWJkNDZjMS90YWJsZTo1NjAwZTcxNzQxNjM0N2I0OGUyMDM1Y2YyZDBhZmZkMi90YWJsZXJhbmdlOjU2MDBlNzE3NDE2MzQ3YjQ4ZTIwMzVjZjJkMGFmZmQyXzE0LTUtMS0xLTI5MzcxMA_6411b4ee-11ce-46f3-a129-c8638b40214d"
      unitRef="usd">375000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic8317271c934402ebe8d6b8414e1b396_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMS0xLTEtMjkzNzEw_3bf8645d-45f2-449f-a77b-fc9a43b93ec3"
      unitRef="shares">104197000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8317271c934402ebe8d6b8414e1b396_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMy0xLTEtMjkzNzEw_d6d74abe-5b00-4690-b9b5-31d1ffbc0c2c"
      unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaeed20294de403f864897b4800c3076_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtNS0xLTEtMjkzNzEw_d8133e86-03b8-4290-938c-d239c448780a"
      unitRef="usd">4760000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73837e4f8db9412e8f899038e1d69a38_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtNy0xLTEtMjkzNzEw_5d1a9ee5-74bc-4bf0-a3e1-9d6d9a45213a"
      unitRef="usd">-257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9537d740a09d4c659577fa85ae658fbc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtOS0xLTEtMjkzNzEw_fa2a8e39-9b4a-4fed-a1ea-5162f55bc461"
      unitRef="usd">-2513000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d874170404f42828e4c20e8b8df0183_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMTEtMS0xLTI5MzcxMA_ae537235-e363-4c24-839d-7f52a8684e7b"
      unitRef="usd">-2414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9554f40adca348fcb6728bf86c3ecdf7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMTMtMS0xLTI5MzcxMA_62e55f5b-e3a9-4360-aba9-1473827db96c"
      unitRef="usd">854000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9d0733ad43146a38ea0933fae539a08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzMtMTUtMS0xLTI5MzcxMA_310ed76f-0236-413f-bb6d-ec3094bb0fa4"
      unitRef="usd">437000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i8a99224736d148eb923d186edf1422a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzQtOS0xLTEtMjkzNzEw_d04dd257-76fc-4ffb-8664-2e68fa0dca0d"
      unitRef="usd">399000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzQtMTMtMS0xLTI5MzcxMA_30d8a9e7-007f-48e1-83b4-75396aee7a5b"
      unitRef="usd">183000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzQtMTUtMS0xLTI5MzcxMA_4003849a-ea0c-49b4-9460-f4c67bbf53fb"
      unitRef="usd">582000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzUtMTMtMS0xLTI5MzcxMA_4c09c7d3-a01c-43b2-8eed-d6a925ce0fd8"
      unitRef="usd">152000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzUtMTUtMS0xLTI5MzcxMA_1f1b3ded-f107-4242-bcfd-f36ceb725539"
      unitRef="usd">152000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia89adc45b1f04cc7b5b5f7802b70f646_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzYtNy0xLTEtMjkzNzEw_669f23c2-a511-4c0f-bc29-c07f9a8d9c21"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzYtMTUtMS0xLTI5MzcxMA_9c03397a-0758-4505-9d41-dddacca2ca14"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzctNS0xLTEtMjkzNzEw_bd210088-8009-4cbb-8ec0-0fd94358b241"
      unitRef="usd">4000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzctMTUtMS0xLTI5MzcxMA_56f2fdc1-ac40-4c76-9f6e-a659c3bfe474"
      unitRef="usd">4000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzgtNS0xLTEtMjkzNzEw_4b3c6d72-cc36-48db-a7cf-3386a4192fb7"
      unitRef="usd">27000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="ie68b1c633b694cd2bcde8f81551de72e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzgtMTMtMS0xLTI5MzcxMA_4bab163e-7bc4-4586-9342-597f16efd831"
      unitRef="usd">24000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzgtMTUtMS0xLTI5MzcxMA_54c9492f-5afc-4061-93c8-73cb1454459a"
      unitRef="usd">51000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia34520ac68b949658c3caaf22edd6880_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzktOS0xLTEtMjkzNzEw_4b482a95-affd-4a04-b847-f206c61f69d0"
      unitRef="usd">-14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfc3c23664d14313871878cccfd836b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzktMTUtMS0xLTI5MzcxMA_833facac-8d18-4a7b-9a94-3032354a6c09"
      unitRef="usd">-14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i68dbb9be4d814d51ad51baa9ef64725a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEwLTEtMS0xLTI5MzcxMA_cf3a85f1-4010-42ca-850d-91bd5906260a"
      unitRef="shares">1873000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i22b1a830147747a7b18e4b93789825a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEwLTUtMS0xLTI5MzcxMA_8f63660a-b7fd-431c-9ba8-d2a9d9bec6fe"
      unitRef="usd">61000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEwLTE1LTEtMS0yOTM3MTA_51490476-ad58-403b-b8ef-406abd493fe2"
      unitRef="usd">61000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iacc7f69df573459097fdcb5d09e4778c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTEtMS0xLTI5MzcxMA_cf394dbf-f088-47cc-a398-bd9d5241f8ee"
      unitRef="shares">106070000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iacc7f69df573459097fdcb5d09e4778c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTMtMS0xLTI5MzcxMA_31705640-bc5b-47d9-9279-d63bacf4bb09"
      unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73a3605c2b39491ba943fd1edfc38e57_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTUtMS0xLTI5MzcxMA_aabe96ea-34a1-415d-a0e4-02946dc62586"
      unitRef="usd">4844000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3a3a91f53e143f88c4008add5713b37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTctMS0xLTI5MzcxMA_2d3e32e8-302f-40a1-8098-302c71c57894"
      unitRef="usd">-281000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d8b2757ba2949ca8cd949137ff2242f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTktMS0xLTI5MzcxMA_15ccea60-9957-464d-a61a-faa6f0f788ba"
      unitRef="usd">-2128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4961643c307a4f6f870dcae12b32be64_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTExLTEtMS0yOTM3MTA_709f3223-b2ca-4fde-ab4a-bf7a6634909b"
      unitRef="usd">-2414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic970d8adef764f56901b3449b235a580_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTEzLTEtMS0yOTM3MTA_e2836a9d-6145-44f0-a9d2-97a4a3a58af9"
      unitRef="usd">909000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzExLTE1LTEtMS0yOTM3MTA_d8cd01a6-27df-422e-a1c5-7127ce50b258"
      unitRef="usd">937000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="id96beba9c82c45c1bc21607c1ff74f2d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEyLTktMS0xLTI5MzcxMA_fe263c4a-e7a3-4143-93be-a7981b68d748"
      unitRef="usd">914000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEyLTEzLTEtMS0yOTM3MTA_eb3a693b-5b7d-48ba-a260-863518abd1d1"
      unitRef="usd">226000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEyLTE1LTEtMS0yOTM3MTA_ec90db2b-f1cf-4f26-91b9-f2b12414f3b7"
      unitRef="usd">1140000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEzLTEzLTEtMS0yOTM3MTA_bc9ad593-5ffd-40f1-8a05-078017311725"
      unitRef="usd">206000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzEzLTE1LTEtMS0yOTM3MTA_a0df95da-90c5-4ed2-853a-75145460d14d"
      unitRef="usd">206000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i23b513def6714ccda59af687a753af25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE0LTctMS0xLTI5MzcxMA_381c18a5-68dd-4a12-b9f0-12902e214f9d"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE0LTE1LTEtMS0yOTM3MTA_47932c22-e586-4c44-a753-be14d3596f6b"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i4668e92bb57b48e5b60535088433640e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE1LTUtMS0xLTI5MzcxMA_a66ac215-8f1f-492f-a95f-b80fc0978254"
      unitRef="usd">11000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE1LTE1LTEtMS0yOTM3MTA_627ccc6b-df08-4cf9-9e31-81fc3a539aad"
      unitRef="usd">11000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="if864460a0a12441b8e8c1cdb8951d522_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE2LTEzLTEtMS0yOTM3MTA_a5a5244d-ffb9-48c6-9d88-9ab03712092a"
      unitRef="usd">97000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE2LTE1LTEtMS0yOTM3MTA_edf3abd3-8566-4af5-9dee-2f4f8404106d"
      unitRef="usd">97000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3357e2680a954c2f9e9a7ea6681fe6ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTEtMS0xLTI5MzcxMA_f5765252-bcf7-4200-84ee-9737c7c33a11"
      unitRef="shares">1119000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i3357e2680a954c2f9e9a7ea6681fe6ac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTMtMS0xLTI5MzcxMA_b636ff77-038e-4b45-84a7-2ae8f34c056d"
      unitRef="usd">1000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i4668e92bb57b48e5b60535088433640e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTUtMS0xLTI5MzcxMA_66709178-2fec-490a-9793-c791f8352fd5"
      unitRef="usd">44000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i00199680d78144a79e385f52ad262816_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTExLTEtMS0yOTM3MTA_fe2512a3-0b8f-49d1-8a44-bd0e0dd02bf6"
      unitRef="usd">4000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE4LTE1LTEtMS0yOTM3MTA_99d97129-3015-4c82-b2fc-8e182997a500"
      unitRef="usd">49000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id44ff96f5e0b4207bd89a9ce5dd47a7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTEtMS0xLTI5MzcxMA_3f9e1e3d-7138-4e4f-a32a-f7f53a7505aa"
      unitRef="shares">107189000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id44ff96f5e0b4207bd89a9ce5dd47a7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTMtMS0xLTI5MzcxMA_efe0db41-b46f-40b8-9d63-c641552f520b"
      unitRef="usd">8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b9a7228a28d48dd8f40b5100d81ac6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTUtMS0xLTI5MzcxMA_b8bc9e63-37c8-4780-b4b5-959a2181c648"
      unitRef="usd">4877000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a4aa1e6e88f4448ac550047af2e16de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTctMS0xLTI5MzcxMA_0b3c71ce-6483-4c25-ae4f-1c2b89ba4586"
      unitRef="usd">-233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic697b5296a55464da1d3d7ed92f77ab2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTktMS0xLTI5MzcxMA_64156fc1-0287-40ae-b25f-ab1a53b9d403"
      unitRef="usd">-1214000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92aac1e9ae304c2c9a6e91a2b9279e3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTExLTEtMS0yOTM3MTA_41024ede-8a84-489c-8805-789c75f623ab"
      unitRef="usd">-2410000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb9e8ae8287042d59710ebc9811fd7fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTEzLTEtMS0yOTM3MTA_4cb54307-9030-4ddc-9a30-ed3061ace5ea"
      unitRef="usd">1026000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzE5LTE1LTEtMS0yOTM3MTA_6568178f-ffa5-46ee-840b-a81fc2c00df6"
      unitRef="usd">2054000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i6deeb898cc694b44af79dd598642335b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIwLTktMS0xLTI5MzcxMA_9f5e8f82-c684-480d-a88c-527dfaeaef3d"
      unitRef="usd">411000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIwLTEzLTEtMS0yOTM3MTA_efc34495-a1be-4468-8856-b59a6a1d795a"
      unitRef="usd">242000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIwLTE1LTEtMS0yOTM3MTA_d3460608-68f7-46a5-b30f-dbaa748b9d59"
      unitRef="usd">653000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIxLTEzLTEtMS0yOTM3MTA_6bb2b1d7-d72e-4679-9245-a1f674065d99"
      unitRef="usd">229000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIxLTE1LTEtMS0yOTM3MTA_897d719e-3271-4cb3-ab31-ad1c6a09f5ee"
      unitRef="usd">229000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i63be1af82c5a4ce08a55c20e64768dd2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIyLTctMS0xLTI5MzcxMA_a8e3eb12-2bfc-4bca-80ed-9aca12d83651"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIyLTE1LTEtMS0yOTM3MTA_0d1bf920-ad7e-4f6f-903c-bdedab711f65"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIzLTUtMS0xLTI5MzcxMA_a16a617c-0f2f-4864-8c0e-37ddc302a08b"
      unitRef="usd">104000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzIzLTE1LTEtMS0yOTM3MTA_24997a7e-f785-4a53-9bc3-d2df2d971d35"
      unitRef="usd">104000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI0LTUtMS0xLTI5MzcxMA_bd264df9-2d21-4014-88f5-3f1c796eb945"
      unitRef="usd">-34000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="i116d350f05cd4d09b88fb5a5223f34eb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI0LTEzLTEtMS0yOTM3MTA_92812983-dfff-4409-b2e4-b184caefa5aa"
      unitRef="usd">278000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI0LTE1LTEtMS0yOTM3MTA_54ee0fbc-ba2b-4f6f-974b-913817800852"
      unitRef="usd">244000000</thc:AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i141f2bcca31f4b0380c3b5e8254e8c6a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI1LTEtMS0xLTI5MzcxMA_c79ba721-c1be-4264-bfc9-b23d1cc62ed2"
      unitRef="shares">5889000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i58f75f50cbee4ce2a41dfe51c9ce7596_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI1LTExLTEtMS0yOTM3MTA_8836eff1-2d79-4062-8c0a-8225d9b6c0f6"
      unitRef="usd">250000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI1LTE1LTEtMS0yOTM3MTA_211b54af-9690-4398-9ec6-eea9fa3c7eda"
      unitRef="usd">250000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i141f2bcca31f4b0380c3b5e8254e8c6a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI2LTEtMS0xLTI5MzcxMA_c23d939c-99b0-4fc5-8ca0-8eac90369b6f"
      unitRef="shares">947000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i41a32bf718d747cbabff2e68881d21a2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI2LTUtMS0xLTI5MzcxMA_24aeab6c-5afa-4677-8c0e-b011f5f9dcaf"
      unitRef="usd">39000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI2LTE1LTEtMS0yOTM3MTA_5ff987a3-88c7-408f-8cba-d10ffcd1cbb9"
      unitRef="usd">39000000</thc:SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5b2f751698934015b40a39f68b1a7b32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTEtMS0xLTI5MzcxMA_c8a25005-c6a7-425b-93e9-bf9085f3f782"
      unitRef="shares">102247000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b2f751698934015b40a39f68b1a7b32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTMtMS0xLTI5MzcxMA_33761491-14ff-4a0d-a205-9425b1a2d1bf"
      unitRef="usd">8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78e1ff00656b4675b1053c1131354580_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTUtMS0xLTI5MzcxMA_239d64f5-6f99-4e88-aca8-ce06e3fafb91"
      unitRef="usd">4778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b72ce7a7f084592ab6d37729017b52f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTctMS0xLTI5MzcxMA_a09983ca-f106-4356-b131-16e8de360720"
      unitRef="usd">-181000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i239bd2934060423182e137ce4439d676_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTktMS0xLTI5MzcxMA_4578bf7b-e7a9-4590-822a-b31862c5556e"
      unitRef="usd">-803000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i328d8102d6f44cfa952a21bd7c09daba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTExLTEtMS0yOTM3MTA_c7a076c9-4f33-4e3b-bd9c-e53556d3711f"
      unitRef="usd">-2660000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffe4a381bd734a65ad42049eb3bae264_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTEzLTEtMS0yOTM3MTA_da7bd692-12d1-47c6-a4fd-508163b2cf5d"
      unitRef="usd">1317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xNzgvZnJhZzphZmYwZjI4OWZmNzc0ZTIwOGEyOWVjNTg4MTEwNTA5YS90YWJsZTozMmQ4MWIwMTkyMTI0NDY2YjhmYmMxNWI2NmM2OTIwMi90YWJsZXJhbmdlOjMyZDgxYjAxOTIxMjQ0NjZiOGZiYzE1YjY2YzY5MjAyXzI3LTE1LTEtMS0yOTM3MTA_3032ab7e-2782-49e9-bfaa-af2a08293347"
      unitRef="usd">2459000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzItMS0xLTEtMjkzNzEw_aa5a5806-919c-46bd-a775-2657121a31aa"
      unitRef="usd">1001000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzItMy0xLTEtMjkzNzEw_bcce2dad-6af3-4e7f-8fcb-f78e8c3daad6"
      unitRef="usd">1476000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzItNS0xLTEtMjkzNzEw_933cccec-88a1-4095-9905-f46fa3bb1611"
      unitRef="usd">768000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQtMS0xLTEtMjkzNzEw_cf7f5faa-a7b6-46b6-b4e3-f86d37bc5640"
      unitRef="usd">841000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQtMy0xLTEtMjkzNzEw_3fa7d316-4b9a-487a-91a9-d66c5899faa8"
      unitRef="usd">855000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQtNS0xLTEtMjkzNzEw_59580f87-2b58-40da-9006-50f7e5ef0681"
      unitRef="usd">857000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUtMS0xLTEtMjkzNzEw_ef4c0831-7157-4ab5-af68-d0e230aed080"
      unitRef="usd">209000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUtMy0xLTEtMjkzNzEw_375420c7-2ab6-4131-a307-b3a8be315c16"
      unitRef="usd">250000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUtNS0xLTEtMjkzNzEw_0d1b219b-f209-4169-b7e8-9bc0211837c0"
      unitRef="usd">-128000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzYtMS0xLTEtMjkzNzEw_860e2f24-31bc-4987-955a-50ffa84ec07a"
      unitRef="usd">56000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzYtMy0xLTEtMjkzNzEw_4d282ce5-b571-4107-8331-5d26a3a93f49"
      unitRef="usd">56000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzYtNS0xLTEtMjkzNzEw_d7b0b30a-6913-4330-9465-5a218d6a93d3"
      unitRef="usd">44000000</us-gaap:ShareBasedCompensation>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzctMS0xLTEtMjkzNzEw_5e0a77ae-9d02-4e8a-a62e-a22deb901718"
      unitRef="usd">226000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzctMy0xLTEtMjkzNzEw_a08d8513-8d22-4246-b519-ce6010ae06f7"
      unitRef="usd">85000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzctNS0xLTEtMjkzNzEw_2797b63f-65c4-4f1f-a851-7a5a24c67c5a"
      unitRef="usd">290000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzgtMS0xLTEtMjkzNzEw_101de059-f1c1-4208-a819-56165747794c"
      unitRef="usd">-70000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzgtMy0xLTEtMjkzNzEw_1c424ac3-db30-4e69-9214-e1312ad919fa"
      unitRef="usd">-116000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzgtNS0xLTEtMjkzNzEw_a621709d-56aa-4e11-b05f-742822dde275"
      unitRef="usd">-44000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzktMS0xLTEtMjkzNzEw_25fef7f2-ebd4-49d8-ac5e-74c84f29e3b8"
      unitRef="usd">1000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzktMy0xLTEtMjkzNzEw_a680c122-9c92-4fdc-8f95-5963519853a7"
      unitRef="usd">445000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzktNS0xLTEtMjkzNzEw_dd742a8c-5c4a-4e99-afa6-0a1900789f1c"
      unitRef="usd">14000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEwLTEtMS0xLTI5MzcxMA_745cfbbe-3bef-4553-bc33-1b4aae203246"
      unitRef="usd">-109000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEwLTMtMS0xLTI5MzcxMA_cf387366-020e-4e4c-87fc-47e15d9bc49a"
      unitRef="usd">-74000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEwLTUtMS0xLTI5MzcxMA_e3170ac4-6074-49d0-a839-8653e2b94894"
      unitRef="usd">-316000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzExLTEtMS0xLTI5MzcxMA_ca2860a8-6be8-4ad4-ab07-fb91a1bf0da5"
      unitRef="usd">-2000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzExLTMtMS0xLTI5MzcxMA_0d11e8c4-7f73-412d-9141-2dfa8a3f703e"
      unitRef="usd">10000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzExLTUtMS0xLTI5MzcxMA_15f261b5-7418-4b42-a85a-87fb40f5a1f3"
      unitRef="usd">37000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEyLTEtMS0xLTI5MzcxMA_853e6bb3-8af1-4085-97d3-57a6dc44f42a"
      unitRef="usd">33000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEyLTMtMS0xLTI5MzcxMA_7b7a9ee1-0e7f-4741-b79b-bb79f250e3a5"
      unitRef="usd">33000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEyLTUtMS0xLTI5MzcxMA_48407eaf-d393-4df9-b519-048a5c40323c"
      unitRef="usd">38000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEzLTEtMS0xLTI5MzcxMA_79aeb125-cda1-4bca-b18b-c8efe18fbc95"
      unitRef="usd">1000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEzLTMtMS0xLTI5MzcxMA_65a36f37-2491-41d6-8d33-aa10c50bd2f2"
      unitRef="usd">-1000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzEzLTUtMS0xLTI5MzcxMA_aa11f43f-23d2-4266-8b03-1e9bdce8c289"
      unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTEtMS0xLTM1MDEzMQ_474133c9-30ad-43bf-8431-51fe03b7120c"
      unitRef="usd">117000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTMtMS0xLTM1MDEzMQ_7e7e12c2-08bc-4e36-9a65-64cafe78fd7a"
      unitRef="usd">23000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTUtMS0xLTM1MDIwMg_af34824c-3235-4c6e-ac38-8421c8c6796e"
      unitRef="usd">25000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTEtMS0xLTI5MzcxMA_d25b7c4e-f3fc-4451-9357-586b25d19d69"
      unitRef="usd">-13000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTMtMS0xLTI5MzcxMA_aec785cb-59b7-4d91-bf5a-bd7fde1b78f7"
      unitRef="usd">10000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE0LTUtMS0xLTI5MzcxMA_5e7b68cd-2432-4a5c-ab3e-c7cfe49f9963"
      unitRef="usd">4000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE2LTEtMS0xLTI5MzcxMA_f2a5ab3a-8c69-48e6-a440-ca9b807fafb9"
      unitRef="usd">140000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE2LTMtMS0xLTI5MzcxMA_69092e93-439f-49aa-b0fa-64a8dad4148f"
      unitRef="usd">197000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE2LTUtMS0xLTI5MzcxMA_6720cc13-651c-436c-af6d-de6280d86049"
      unitRef="usd">-195000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE3LTEtMS0xLTI5MzcxMA_23c5a8f4-e8a4-4078-a733-81e0dc3a9038"
      unitRef="usd">64000000</thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent>
    <thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE3LTMtMS0xLTI5MzcxMA_8bd5fd18-06db-479f-b7b0-761227292e4c"
      unitRef="usd">52000000</thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent>
    <thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE3LTUtMS0xLTI5MzcxMA_aba775a8-ac23-498e-ace8-682127127dd9"
      unitRef="usd">145000000</thc:IncreaseDecreaseInInventoriesAndOtherAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE4LTEtMS0xLTI5MzcxMA_8347e383-784d-4c9b-8c48-854762949196"
      unitRef="usd">26000000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE4LTMtMS0xLTI5MzcxMA_b94a3591-799d-4fea-aecf-7c74cccad853"
      unitRef="usd">-68000000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE4LTUtMS0xLTI5MzcxMA_5ee7aec2-416d-4174-908e-bd53becc0ca4"
      unitRef="usd">-19000000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE5LTEtMS0xLTI5MzcxMA_ed9c7e39-7b7e-491e-bec6-277288a34e0f"
      unitRef="usd">-898000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE5LTMtMS0xLTI5MzcxMA_05a32db1-12b2-48d4-a45b-5011d18aed3d"
      unitRef="usd">-584000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzE5LTUtMS0xLTI5MzcxMA_2e407e29-313d-4076-a284-224a8eb12adc"
      unitRef="usd">1302000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIwLTEtMS0xLTI5MzcxMA_888ddb0b-db7e-4cc5-b282-aea4c74ce523"
      unitRef="usd">-15000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIwLTMtMS0xLTI5MzcxMA_ffe5efc1-9209-44af-b6c9-b2bf51572f24"
      unitRef="usd">28000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIwLTUtMS0xLTI5MzcxMA_21592713-af76-4c98-895f-62c00490d455"
      unitRef="usd">221000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <thc:PaymentsForRestructuringAndLitigationCosts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIxLTEtMS0xLTI5MzcxMA_c15e8c0a-749e-4158-92d7-9772146cece7"
      unitRef="usd">214000000</thc:PaymentsForRestructuringAndLitigationCosts>
    <thc:PaymentsForRestructuringAndLitigationCosts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIxLTMtMS0xLTI5MzcxMA_9ca7bb44-3fa4-406b-9eea-3c18d9cf3e7e"
      unitRef="usd">153000000</thc:PaymentsForRestructuringAndLitigationCosts>
    <thc:PaymentsForRestructuringAndLitigationCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIxLTUtMS0xLTI5MzcxMA_36ca084a-194f-4e91-9285-ccdfdef95e0b"
      unitRef="usd">333000000</thc:PaymentsForRestructuringAndLitigationCosts>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIyLTEtMS0xLTI5MzcxMA_2aec0499-73a5-47a8-9bde-1731844c506c"
      unitRef="usd">-1000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIyLTMtMS0xLTI5MzcxMA_a22027c3-862c-4f03-9a20-58c0a3e77ba6"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIyLTUtMS0xLTI5MzcxMA_35cb8768-a425-429f-b590-9da9d7f0fa00"
      unitRef="usd">-1000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIzLTEtMS0xLTI5MzcxMA_0edabba8-d20e-435f-9535-21b2ce87a44b"
      unitRef="usd">1083000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIzLTMtMS0xLTI5MzcxMA_c4d74e15-4f07-4a6a-9ad1-389c8d4465f1"
      unitRef="usd">1568000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzIzLTUtMS0xLTI5MzcxMA_e9ce56d6-68aa-4387-98af-ae9626141a97"
      unitRef="usd">3407000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI1LTEtMS0xLTI5MzcxMA_b59497ff-5879-4867-9059-23917eac9d63"
      unitRef="usd">762000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI1LTMtMS0xLTI5MzcxMA_edfc23cf-11d2-4736-aa0b-bf4912010f04"
      unitRef="usd">658000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI1LTUtMS0xLTI5MzcxMA_2025ad87-2638-45ee-a64b-8094cc59532a"
      unitRef="usd">540000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI2LTEtMS0xLTI5MzcxMA_56bb8009-4b0d-4e40-bfdb-78560008723d"
      unitRef="usd">234000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI2LTMtMS0xLTI5MzcxMA_d3230003-f67e-4501-9493-3b220d5d7338"
      unitRef="usd">1220000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI2LTUtMS0xLTI5MzcxMA_a92e1d6a-aee2-47e3-bd0c-25adcd7b0b25"
      unitRef="usd">1177000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI3LTEtMS0xLTI5MzcxMA_67abd402-3b17-4de6-a9c6-7047c4a71298"
      unitRef="usd">210000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI3LTMtMS0xLTI5MzcxMA_2bc7f74d-8616-4971-b2c8-cc342f118127"
      unitRef="usd">1248000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI3LTUtMS0xLTI5MzcxMA_db53b767-772c-4f8e-a5bf-af8136ffef02"
      unitRef="usd">77000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI5LTEtMS0xLTI5MzcxMA_a6572935-f331-44dc-9168-869af82bdbcd"
      unitRef="usd">76000000</thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets>
    <thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI5LTMtMS0xLTI5MzcxMA_2e205491-7030-4d92-bd3c-0e82380592b6"
      unitRef="usd">31000000</thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets>
    <thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzI5LTUtMS0xLTI5MzcxMA_7e03343b-f444-47be-9178-cad844b2c522"
      unitRef="usd">59000000</thc:ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMwLTEtMS0xLTI5MzcxMA_ff54da33-0081-4a75-a4de-88f14dac4881"
      unitRef="usd">92000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMwLTMtMS0xLTI5MzcxMA_b5b3efea-2998-4d44-8cac-bb6f516085bd"
      unitRef="usd">108000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMwLTUtMS0xLTI5MzcxMA_04b7e2ac-5b9d-4948-ab4e-0f5e09bbb4f6"
      unitRef="usd">44000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMxLTEtMS0xLTI5MzcxMA_e377d0e1-d3ab-4d81-b5bd-d09354ec2313"
      unitRef="usd">6000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMxLTMtMS0xLTI5MzcxMA_1c660166-63a3-4f14-b3aa-b6a35d72dcb0"
      unitRef="usd">7000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMxLTUtMS0xLTI5MzcxMA_061a61c5-39c7-4015-9967-d94af4be1f4c"
      unitRef="usd">-17000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMyLTEtMS0xLTI5MzcxMA_ed75ba69-22d1-42c1-b694-015e1a65dd4b"
      unitRef="usd">-808000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMyLTMtMS0xLTI5MzcxMA_38e82d65-53b6-4532-84e0-7c25b6772408"
      unitRef="usd">-714000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzMyLTUtMS0xLTI5MzcxMA_95fe72a6-84f3-4a3c-80d6-c5afe661ec76"
      unitRef="usd">-1608000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM0LTEtMS0xLTI5MzcxMA_1134538b-2898-46e2-87c0-2738cf97699e"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM0LTMtMS0xLTI5MzcxMA_00e324a8-6b74-4a2e-becc-0533858d92e9"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM0LTUtMS0xLTI5MzcxMA_edd8edcc-a917-4b0c-9506-7f9c9f0e1c4e"
      unitRef="usd">740000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM1LTEtMS0xLTI5MzcxMA_920dba94-ee2f-480b-8d43-51b4369c9543"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM1LTMtMS0xLTI5MzcxMA_92a3fe13-cc25-4488-83a9-0f9b51cea3ed"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM1LTUtMS0xLTI5MzcxMA_197ef69e-2c87-47dd-a216-3dfa0c74643b"
      unitRef="usd">740000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM2LTEtMS0xLTI5MzcxMA_1834ba46-6548-46ab-aa1c-f926f2e82907"
      unitRef="usd">2851000000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM2LTMtMS0xLTI5MzcxMA_906d3b91-e39e-4e6f-810b-7a720254de7e"
      unitRef="usd">3221000000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM2LTUtMS0xLTI5MzcxMA_736e37e7-1789-46b0-82c1-9df2b9b03f6a"
      unitRef="usd">3293000000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM3LTEtMS0xLTI5MzcxMA_6413f256-f972-4ead-90a7-33ce399f51d3"
      unitRef="usd">2023000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM3LTMtMS0xLTI5MzcxMA_b96da44c-9698-4674-9010-ba9a85f1f49f"
      unitRef="usd">2872000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM3LTUtMS0xLTI5MzcxMA_ae8a403f-baab-4a6c-981f-193e6d79b8ab"
      unitRef="usd">3818000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTEtMS0xLTM1MDAwOQ_ff4c8dfb-3be4-470b-88bc-56c26f2abbe4"
      unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTMtMS0xLTM1MDAxNw_d22d80dc-86f0-4486-8361-e8be708c17b1"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTUtMS0xLTM1MDAzMA_3e6cca4f-1ceb-466b-8ccc-9e866dd23613"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTEtMS0xLTI5MzcxMA_b270913e-eb64-494b-82ef-c5f390476a96"
      unitRef="usd">24000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTMtMS0xLTI5MzcxMA_e02ca555-c125-4373-a6d0-e50b6e1d74d2"
      unitRef="usd">31000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM4LTUtMS0xLTI5MzcxMA_1be8fd14-8137-48ff-9526-3448bd32805c"
      unitRef="usd">48000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM5LTEtMS0xLTI5MzcxMA_221f6610-2e87-4e41-bf79-39e9ec1353f1"
      unitRef="usd">560000000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM5LTMtMS0xLTI5MzcxMA_8da15a7d-5bb2-4776-87e6-ac486c270eef"
      unitRef="usd">423000000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzM5LTUtMS0xLTI5MzcxMA_54fd57d7-ffab-4b57-93a9-ecc0dd95db47"
      unitRef="usd">287000000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQwLTEtMS0xLTI5MzcxMA_59fab9cb-6f44-4013-b0f6-101202f293e9"
      unitRef="usd">27000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQwLTMtMS0xLTI5MzcxMA_fb7908bf-889f-4daa-b323-35bab69db460"
      unitRef="usd">25000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQwLTUtMS0xLTI5MzcxMA_3a09137b-0afd-431a-a9d7-bfe71150a69d"
      unitRef="usd">14000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQxLTEtMS0xLTI5MzcxMA_9c06564e-32ff-4338-bf4e-4e6c1c83c2b2"
      unitRef="usd">100000000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQxLTMtMS0xLTI5MzcxMA_6bf06201-fb7e-4d11-aae2-e5b44bd4c41e"
      unitRef="usd">27000000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQxLTUtMS0xLTI5MzcxMA_c899956a-946a-4284-9d9e-06a8eb7aee38"
      unitRef="usd">39000000</us-gaap:PaymentsToMinorityShareholders>
    <thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQzLTEtMS0xLTI5MzcxMA_3c953056-0c2e-4000-b37f-1458a4de298e"
      unitRef="usd">0</thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment>
    <thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQzLTMtMS0xLTI5MzcxMA_603ee5e2-5478-4184-b51d-60bc116a7472"
      unitRef="usd">-67000000</thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment>
    <thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQzLTUtMS0xLTI5MzcxMA_a43fe32a-722b-4a16-89bd-dbbb7066d658"
      unitRef="usd">187000000</thc:ProceedsFromGrantsFromAffiliatesNetOfRecoupment>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ0LTEtMS0xLTI5MzcxMA_6301202c-bf14-48b0-a79d-86ea040e8da4"
      unitRef="usd">-46000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ0LTMtMS0xLTI5MzcxMA_23d47d80-a12a-4d21-adfb-09acda16c5b4"
      unitRef="usd">-64000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ0LTUtMS0xLTI5MzcxMA_3e7598d2-8185-4238-aabb-7f9dc8e06856"
      unitRef="usd">33000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ1LTEtMS0xLTI5MzcxMA_c3e16926-47a5-4aab-a75a-50af08236937"
      unitRef="usd">-1781000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ1LTMtMS0xLTI5MzcxMA_944eb3f5-2895-407b-953f-b4130577fd2b"
      unitRef="usd">-936000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ1LTUtMS0xLTI5MzcxMA_e0107849-4746-4c32-a2a5-7337f78eba1b"
      unitRef="usd">385000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ2LTEtMS0xLTI5MzcxMA_d18bbd83-bcff-4d14-89ad-cc26f9b74394"
      unitRef="usd">-1506000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ2LTMtMS0xLTI5MzcxMA_1ef874fc-7e08-474f-99e4-c00aff1bc129"
      unitRef="usd">-82000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ2LTUtMS0xLTI5MzcxMA_d5d4d806-cc6e-4f1f-959e-d90be07ae37d"
      unitRef="usd">2184000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ3LTEtMS0xLTI5MzcxMA_4d81fa7b-d589-4f6f-a5c1-a5f4699efc6d"
      unitRef="usd">2364000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ3LTMtMS0xLTI5MzcxMA_34091a83-f74e-4ca7-a72d-f2751a035db4"
      unitRef="usd">2446000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9d0733ad43146a38ea0933fae539a08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ3LTUtMS0xLTI5MzcxMA_0956f2a6-db19-432a-89de-8603bf7cd9ed"
      unitRef="usd">262000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ4LTEtMS0xLTI5MzcxMA_a8df6add-6f7a-4de5-986c-4db1bfcd672b"
      unitRef="usd">858000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ4LTMtMS0xLTI5MzcxMA_70c2c4a9-623c-4274-8e99-4195ef3285f0"
      unitRef="usd">2364000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzQ4LTUtMS0xLTI5MzcxMA_2252c5ef-1fb8-4959-b9a6-13c7ff35d89d"
      unitRef="usd">2446000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUwLTEtMS0xLTI5MzcxMA_15e08d9f-8937-4a2e-a03a-53160d2f2fb4"
      unitRef="usd">848000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUwLTMtMS0xLTI5MzcxMA_de7a95b4-ca27-4d9b-aecb-dfc1cfcb6b00"
      unitRef="usd">937000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUwLTUtMS0xLTI5MzcxMA_e7888eef-5cd5-4edb-8a09-fd29bdad9e96"
      unitRef="usd">962000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUxLTEtMS0xLTI5MzcxMA_e8c2d603-6eba-4c8d-9471-ea7b2f710c47"
      unitRef="usd">161000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUxLTMtMS0xLTI5MzcxMA_841ab964-c1a5-4491-ad9c-a1abbdbb76e3"
      unitRef="usd">92000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODEvZnJhZzpiMTI4MTI2MWJiYjU0NTY2YWE0OWIxM2YwNTExYTM1NC90YWJsZTpiYTU2MzZlNzQxZmU0MDBiYTgxM2MyYmVjY2ZmNDE2NS90YWJsZXJhbmdlOmJhNTYzNmU3NDFmZTQwMGJhODEzYzJiZWNjZmY0MTY1XzUxLTUtMS0xLTI5MzcxMA_687554b7-d5a5-4f10-838d-34bffa2de995"
      unitRef="usd">12000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTM5_42052dd2-c765-4dce-87d6-404420c0a835">SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as &#x201c;Tenet,&#x201d; &#x201c;we&#x201d; or &#x201c;us&#x201d;) is a diversified healthcare services company headquartered in Dallas, Texas. Our care delivery network includes our subsidiary USPI Holding Company, Inc. (&#x201c;USPI&#x201d;), which had indirect ownership interests in 442 ambulatory surgery centers and 24&#160;surgical hospitals at December&#160;31,&#160;2022. We hold noncontrolling interests in 158 of these facilities, which are recorded using the equity method of accounting. We also operated 61 acute care and specialty hospitals, 109 other outpatient facilities, a network of employed physicians and a Global Business Center (&#x201c;GBC&#x201d;) in Manila, Philippines at December&#160;31,&#160;2022. In addition, we operate Conifer Health Solutions,&#160;LLC, in which we own an interest of approximately 76%, through our Conifer Holdings,&#160;Inc. subsidiary (&#x201c;Conifer&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective June&#160;30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (&#x201c;Baylor&#x201d;) in USPI for $406&#160;million, which increased our ownership interest in USPI&#x2019;s voting shares from 95% to 100%. See Note&#160;18 for additional information about this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our business consists of our Hospital Operations and other (&#x201c;Hospital Operations&#x201d;) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#x2011;hospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of USPI, which holds indirect ownership interests in and manages ambulatory surgery centers and surgical hospitals. Our Conifer segment provides revenue cycle management and value&#x2011;based care services to hospitals, health systems, physician practices, employers and other clients. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Consolidated Financial Statements include the accounts of Tenet and its wholly owned and majority&#x2011;owned subsidiaries. We eliminate intercompany accounts and transactions in consolidation, and we include the results of operations of businesses that are newly acquired in purchase transactions from their dates of acquisition. We account for significant investments in other affiliated companies using the equity method. We also utilize the equity method when we have the ability to exercise significant influence over the affiliated company, despite not holding a significant percentage of its ownership interest. Unless otherwise indicated, all financial and statistical data included in these notes to our Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in&#160;millions (except per&#x2011;share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &#x201c;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU&#160;2020-06&#x201d;), effective as of January&#160;1,&#160;2022 using the modified retrospective method. Among other amendments, ASU&#160;2020-06 changed the accounting for diluted earnings&#x2011;per&#x2011;share for convertible instruments and contracts that may be settled in cash or stock. ASU&#160;2020-06 eliminated an entity&#x2019;s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer&#x2019;s election. Additionally, ASU&#160;2020-06 requires that the if&#x2011;converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU&#160;2020-06, diluted weighted average shares outstanding increased by approximately three million shares and diluted earnings per share available to Tenet common shareholders decreased by $0.01 for the year ended December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1,&#160;2020, we adopted ASU 2016&#x2011;13, &#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&#x201d; (&#x201c;ASU 2016&#x2011;13&#x201d;), using the modified retrospective transition approach as of the period of adoption. The amendments in this ASU required a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Upon adoption of ASU 2016&#x2011;13 on January&#160;1,&#160;2020, we recorded a cumulative effect adjustment to increase accumulated deficit by $14 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior-year amounts have been reclassified to conform to the current&#x2011;year presentation. Due to their increased significance, net gains from the sale of investments and long-lived assets are presented separately in the operating activities section of the accompanying Consolidated Statements of Cash Flows. In prior periods, this activity was included in other items, net within the operating activities section.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID&#x2011;19 pandemic has impacted all three segments of our business, as well as our patients, communities and employees, to varying degrees since March&#160;2020. Throughout this time, federal, state and local authorities have undertaken several actions designed to assist healthcare providers in providing care to COVID&#x2011;19 and other patients and to mitigate the adverse economic impact of the pandemic. Among other things, federal legislation (collectively, the &#x201c;COVID Acts&#x201d;) authorized aggregate grant payments of $178&#160;billion to be distributed through the Public Health and Social Services Emergency Fund (&#x201c;PRF&#x201d;) to healthcare providers who experienced lost revenues and increased expenses as a result of the COVID&#x2011;19 pandemic. The COVID Acts also revised the Medicare accelerated payment program (&#x201c;MAPP&#x201d;) and permitted employers to defer payroll Social Security tax payments in 2020. Our participation in these programs and the related accounting policies are summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Income&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As detailed in the table below, we received cash payments from the PRF and state and local grant programs during the years ended December&#160;31,&#160;2022, 2021 and 2020. Grant funds received by our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate are included in cash flows from operating activities in our consolidated statements of cash flows. Grant funds received by unconsolidated affiliates for which we provide cash management services (&#x201c;Cash&#x2011;Managed Affiliates&#x201d;) are included in cash flows from financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant funds received from COVID-19 relief programs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&#x2011;Managed Affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To receive distributions, providers must agree to certain terms and conditions, including, among other things, that the funds would be used for lost revenues and unreimbursed pandemic&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related costs as defined by the U.S.&#160;Department of Health and Human Services (&#x201c;HHS&#x201d;), and that the providers will not seek collection of out&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pocket payments from a COVID&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;network provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by the Secretary of HHS. PRF funds not utilized by the established deadlines, generally 12 to 18&#160;months after receipt, will be recouped by HHS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize grant payments as income when there is reasonable assurance that we have complied with the conditions associated with the grant. The estimates we use to recognize grant income could change materially in the future based on our operating performance or fluctuations in the severity of COVID&#x2011;19 outbreaks at individual locations, as well as the government&#x2019;s grant compliance guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes grant &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income recognized by our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hospital Operations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Ambulatory Care segments, which is presented in grant income, and grant income recognized through our unconsolidated affiliates, which is presented in equity in earnings of unconsolida&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ted affiliates, in each case in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant income recognized from COVID-19 relief programs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in grant income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in equity in earnings of unconsolidated affiliates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022 and 2021, we had remaining deferred grant payment balances of $7 million and $5 million, respectively, which amounts were recorded in other current liabilities in the accompanying Consolidated Balance Sheets for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Accelerated Payment Program (MAPP)&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, when a healthcare facility is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the MAPP. The COVID Acts revised the MAPP to disburse payments to healthcare providers more quickly and to allow recipients to retain the advance payments for one year from the date of receipt before recoupment commenced through offsets of Medicare claims payments. Recipients were also permitted to repay the advance payments at any time. Our Hospital Operations and Ambulatory Care segments both received advance payments from the MAPP following its expansion under the COVID Acts in the year ended December&#160;31,&#160;2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes MAPP advances received in prior periods that were repaid or recouped during the years ended December&#160;31,&#160;2022 and 2021. No advances were repaid or recouped during the year ended December&#160;31,&#160;2020. Advances to our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate were recouped through a reduction of their respective Medicare claims payments and, together with any repayments, are presented in cash flows from operating activities in our consolidated statements of cash flows. Advance payments to our Cash&#x2011;Managed Affiliates were recouped through a reduction of those affiliates&#x2019; Medicare claims payments and, together with any repayments, are presented in cash flows from financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MAPP advances repaid or recouped:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;880&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&#x2011;Managed Affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2022, all of the remaining MAPP advances we received were fully repaid or recouped, which resulted in no outstanding liability at December&#160;31,&#160;2022. In the accompanying Consolidated Balance Sheets, advances totaling $880&#160;million were included in contract liabilities at December&#160;31,&#160;2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferral of Employment Tax Payments&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID Acts permitted employers to defer payment of the 6.2%&#160;employer Social Security tax beginning March&#160;27,&#160;2020 through December&#160;31,&#160;2020. Deferred tax amounts were required to be paid in equal amounts over two years beginning in December&#160;2021. We made a payment of $128&#160;million in December&#160;2021 and remitted the second and final payment of $128&#160;million in December&#160;2022, which resulted in no outstanding liability at December&#160;31,&#160;2022. At December&#160;31,&#160;2021, deferred Social Security tax payments totaling $128&#160;million were included in accrued compensation and benefits in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Translation of Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We formed our GBC in the Philippines during the year ended December&#160;31,&#160;2019. The GBC&#x2019;s accounts are measured in its local currency (the Philippine peso) and then translated into U.S.&#160;dollars. All assets and liabilities denominated in foreign currency are translated using the current rate of exchange at the balance sheet date. Results of operations denominated in foreign currency are translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize net operating revenues in the period in which we satisfy our performance obligations under contracts by transferring services to our customers. Net operating revenues are recognized in the amounts we expect to be entitled to, which are the transaction prices allocated for the distinct services. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact with Uninsured Patients&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Patient Service Revenues&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third&#x2011;party payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third&#x2011;party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when (1)&#160;services are provided, and (2)&#160;we do not believe the patient requires additional services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our patient service performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 606&#x2011;10&#x2011;50&#x2011;14(a) and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments recognized for third&#x2011;party payers, discounts provided to uninsured patients in accordance with our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and estimated implicit price concessions related primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop&#x2011;loss payments). Because Medicare requires that a hospital&#x2019;s gross charges be the same for all patients (regardless of payer category), gross charges are what hospitals charge all patients prior to the application of discounts and allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the traditional fee&#x2011;for&#x2011;service (&#x201c;FFS&#x201d;) Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost&#x2011;based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense reimbursement, which are based on our hospitals&#x2019; cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule&#160;interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements with third&#x2011;party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and our historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#x2011;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#x2019;s bill is subject to adjustment on a patient&#x2011;by&#x2011;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the years ended December&#160;31,&#160;2022, 2021 or 2020. In addition, on a corporate&#x2011;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We know of no claims, disputes or unsettled matters with any payer that would materially affect our revenues for which we have not adequately provided in the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, patients who are covered by third&#x2011;party payers are responsible for related co&#x2011;pays, co&#x2011;insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co&#x2011;pays, co&#x2011;insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#x2011;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self&#x2011;pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such as: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients; the volume of patients through our emergency departments; the increased burden of co&#x2011;pays, co&#x2011;insurance amounts and deductibles to be made by patients with insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record implicit price concessions, primarily related to uninsured patients and patients with co&#x2011;pays, co&#x2011;insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co&#x2011;pays, co&#x2011;insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (&#x201c;EMTALA&#x201d;). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non&#x2011;emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1)&#160;we are unable to obtain verification because the patient&#x2019;s insurance company was unable to be reached or contacted, (2)&#160;a&#160;determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3)&#160;under physician orders we provide services to patients that require immediate treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per&#x2011;diem amount for services received, subject to a cap. Except for the per&#x2011;diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Patient advocates from our Eligibility and Enrollment Services program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conifer Revenues&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Conifer segment recognizes revenue from its contracts when Conifer&#x2019;s performance obligations are satisfied, which is generally as services are rendered. Revenue is recognized in an amount that reflects the consideration to which Conifer expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, Conifer assesses the services specified in its contracts with customers and identifies a performance obligation for each distinct contracted service. Conifer identifies the performance obligations and considers all the services provided under the contract. Conifer generally considers the following distinct services as separate performance obligations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;revenue cycle management services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;value&#x2011;based care services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;patient communication and engagement services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;consulting services; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;other client&#x2011;defined projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Conifer&#x2019;s contracts generally consist of fixed&#x2011;price, volume&#x2011;based or contingency&#x2011;based fees. Conifer&#x2019;s long&#x2011;term contracts typically provide for Conifer to deliver recurring monthly services over a multi&#x2011;year period. The contracts are typically priced such that Conifer&#x2019;s monthly fee to its customer represents the value obtained by the customer in the month for those services. Such multi&#x2011;year service contracts may have upfront fees related to transition or integration work performed by Conifer to set up the delivery for the ongoing services. Such transition or integration work typically does not result in a separately identifiable obligation; thus, the fees and expenses related to such work are deferred and recognized over the life of the related contractual service period. For contracts in which the amortization period of the asset is one year or less, we have elected to apply the practical expedient provided by FASB ASC 340&#x2011;40&#x2011;25&#x2011;4 and expense these costs as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue for fixed&#x2011;priced contracts is typically recognized at the time of billing unless evidence suggests that the revenue is earned or Conifer&#x2019;s obligations are fulfilled in a different pattern. Revenue for volume&#x2011;based contracts is typically recognized as the services are being performed at the contractually billable rate, which is generally a percentage of collections or a percentage of client net patient revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $858 million and $2.364 billion at December&#160;31,&#160;2022 and 2021, respectively. At December&#160;31,&#160;2022 and 2021, our book overdrafts were $266 million and $226 million, respectively, which were classified as accounts payable. At December&#160;31,&#160;2022 and 2021, $140 million and $188 million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our insurance&#x2011;related subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, 2021 and 2020, we had $196 million, $95 million and $93&#160;million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $191&#160;million, $88&#160;million and $85&#160;million, respectively, were included in accounts payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we acquired all of Baylor&#x2019;s 5% voting ownership interest in USPI. We paid $11&#160;million from cash on hand and recognized a liability of $377&#160;million, the present value of the liability on the acquisition date, for the remainder of the purchase price. We recorded reductions in redeemable noncontrolling interest of $365&#160;million for the carrying value of Baylor&#x2019;s ownership interest and $23&#160;million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares on the acquisition date. This has been reflected as noncash financing activity in the accompanying Consolidated Statement of Cash Flows for the year ended December&#160;31,&#160;2022. Payments made subsequent to the transaction&#x2019;s close are reflected as cash activity within the financing section of our consolidated statements of cash flows. See Note&#160;18 for additional information about this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify investments in debt securities as either available&#x2011;for&#x2011;sale, held&#x2011;to&#x2011;maturity or as part of a trading portfolio. Our policy is to classify investments in debt securities that may be needed for cash requirements as &#x201c;available&#x2011;for&#x2011;sale.&#x201d; At December&#160;31,&#160;2022, we had no significant investments in debt securities classified as either held&#x2011;to&#x2011;maturity or trading. We carry debt securities classified as available&#x2011;for&#x2011;sale at fair value. We report their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss). We periodically evaluate available-for-sale securities in unrealized loss positions for credit impairment, using both qualitative and quantitative criteria. In the event a security is deemed to be impaired as the result of a credit loss, we record a loss in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We carry equity securities at fair value, and we report their unrealized gains and losses in other non-operating income, net, in our consolidated statements of operations. If the equity security does not have a readily determinable fair value, the carrying value of the security is adjusted only when there is a price change that is observable from a transaction of an identical or similar investment. We include realized gains or losses in our consolidated statements of operations based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Unconsolidated Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We control 308 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (158 of 466 at December&#160;31,&#160;2022), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations. In the years ended December&#160;31,&#160;2021 and 2020, equity in earnings of unconsolidated affiliates included $14&#160;million and $17&#160;million, respectively, from PRF grants recognized by our Ambulatory Care segment&#x2019;s unconsolidated affiliates. No additional revenue was recognized from PRF grants by unconsolidated affiliates during the year ended December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information for equity method investees is included in the following table. For investments acquired during the reported periods, amounts below include 100% of the investee&#x2019;s results beginning on the date of our acquisition of the investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to the investees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity method investment that contributed the most to our equity in earnings of unconsolidated affiliates during the years ended December&#160;31,&#160;2022, 2021 and 2020 was Texas Health Ventures Group, LLC (&#x201c;THVG&#x201d;), which is operated by USPI. THVG represented $89 million, $107&#160;million and $85&#160;million of total equity in earnings of unconsolidated affiliates of $216 million, $218&#160;million and $169&#160;million in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions and improvements to property and equipment exceeding established minimum amounts with a useful life greater than one year are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. We use the straight&#x2011;line method of depreciation for buildings, building improvements and equipment. The estimated useful life for buildings and improvements is primarily 15 to 40 years, and for equipment &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b"&gt;three&lt;/span&gt; to 15 years. Newly constructed hospitals are usually depreciated over 50 years. Interest costs related to construction projects are capitalized. In the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, capitalized interest was $8 million, $4 million and $5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our long&#x2011;lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of an impairment charge only if the carrying value of the long&#x2011;lived assets exceeds their fair value. The fair value of the asset is estimated based on third&#x2011;party appraisals, established market values of comparable assets or internally developed estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. Estimates require our subjective judgments and take into account assumptions about revenue and expense growth rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of asset and presume stable, improving or, in some cases, declining results, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report long&#x2011;lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on third&#x2011;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception of the contract. Our right&#x2011;of&#x2011;use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right&#x2011;of&#x2011;use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. We use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. For our Hospital Operations and Conifer segments, we estimate our incremental borrowing rates for our portfolio of leases using documented rates included in our recent equipment finance leases or, if applicable, recent secured debt issuances that correspond to various lease terms. We also give consideration to information obtained from our bankers, our secured debt fair value and publicly available data for instruments with similar characteristics. For our Ambulatory Care segment, we estimate an incremental borrowing rate for each center by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;utilizing historical and projected financial data, estimating a hypothetical credit rating using publicly available market data and adjusting the market data to reflect the effects of collateralization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases are primarily for real estate, including off&#x2011;campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. Our real estate lease agreements typically have initial terms of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8"&gt;five&lt;/span&gt; to 10 years, and our equipment lease agreements typically have initial terms of three years. We do not record leases with an initial term of 12 months or less (short&#x2011;term leases) in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our real estate leases may include one or more options to renew, with renewals that can extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce"&gt;five&lt;/span&gt; to 10 years. The exercise of lease renewal options is at our sole discretion. In general, we do not consider renewal options to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of our right&#x2011;of&#x2011;use assets and lease liabilities. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of our medical equipment leases have terms of three years with a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life, typically ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076"&gt;five&lt;/span&gt; to seven years. Similarly, some of our leases of information technology and telecommunications assets include a transfer of title and, therefore, have useful lives of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the right&#x2011;of&#x2011;use asset or liability balances. Our lease agreements do not contain any material residual value guarantees, restrictions or covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the practical expedient that allows lessees to choose to not separate lease and non&#x2011;lease components by class of underlying asset and are applying this expedient to all relevant asset classes. We have also elected the practical expedient package to not reassess at adoption (1)&#160;expired or existing contracts for whether they are or contain a lease, (2)&#160;the lease classification of any existing leases or (3)&#160;initial indirect costs for existing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of costs over the fair value of assets of businesses acquired. Goodwill and other intangible assets acquired in purchase business combinations and determined to have indefinite useful lives are not amortized, but instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level when events occur that require an evaluation to be performed or at least annually. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value. Estimates of fair value are based on third&#x2011;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consist of capitalized software costs, which are amortized on a straight&#x2011;line basis over the estimated useful life of the software, which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e"&gt;three&lt;/span&gt; to 15 years, costs of acquired management and other contract service rights, most of which have indefinite lives, and miscellaneous intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accruals for General and Professional Liability Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income/losses expected in future years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The carryforward period associated with the deferred tax assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&#160;the more likely than not recognition threshold is satisfied; (2)&#160;the position is ultimately settled through negotiation or litigation; or (3)&#160;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We primarily operate acute care hospitals and related healthcare facilities. Our Hospital Operations segment generated 76%, 80% and 81% of our net operating revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Major decisions, including capital resource allocations, are made at the consolidated level, not at the market or hospital level. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Costs Associated with Exit or Disposal Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize costs associated with exit (including restructuring) or disposal activities when they are incurred and can be measured at fair value, rather than at the date of a commitment to an exit or disposal plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <thc:NumberOfAmbulatorySurgeryCenters
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzU0OTc1NTk5ODY1MA_b2b2ca3f-bee8-4ddd-8e2d-39a8b281b0a6"
      unitRef="hospital">442</thc:NumberOfAmbulatorySurgeryCenters>
    <thc:NumberOfSurgicalHospitalsOperatedBySubsidiaries
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTIzNzE_19600bc7-87dc-4902-8eb2-a67bf2491dbd"
      unitRef="hospital">24</thc:NumberOfSurgicalHospitalsOperatedBySubsidiaries>
    <thc:NumberOfOutpatientCentersRecordedUsingEquityMethod
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTIzODQ_82ae7aa7-ef49-4db0-8f1d-0da62de4ce23"
      unitRef="healthcare_facility">158</thc:NumberOfOutpatientCentersRecordedUsingEquityMethod>
    <thc:NumberOfHospitalsOperated
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTIzODA_322efc48-6bb9-4bd2-8b7f-11776d715cab"
      unitRef="hospital">61</thc:NumberOfHospitalsOperated>
    <thc:NumberOfOutpatientFacilitiesOperated
      contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzU0OTc1NTk5ODQ1Mg_021e9313-289c-4ba3-9c2f-f02de2975cb5"
      unitRef="healthcare_facility">109</thc:NumberOfOutpatientFacilitiesOperated>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i314717058c7b4b6fb0a8169f1a019fe3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3OTI0MTM_8667ce91-84a8-4f98-b5ee-1e5c2528f6d5"
      unitRef="number">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest
      contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MTYzMzI_fa8c3ef3-021a-4cc5-9bd4-a8c95825b1c6"
      unitRef="usd">406000000</thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i647dc680b9224e41a241261103ccd5aa_I20220629"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MTYzNDI_b3c1d141-1e18-4b2d-953e-ef3ac40f0990"
      unitRef="number">0.95</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i20f7c47ed3f1432b9993a85a212b93bc_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MTYzNDY_92a366f0-dac1-4f41-9978-3b698155d42b"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTI4_46fedbb7-8654-415b-afd4-1b6f61665148">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Consolidated Financial Statements include the accounts of Tenet and its wholly owned and majority&#x2011;owned subsidiaries. We eliminate intercompany accounts and transactions in consolidation, and we include the results of operations of businesses that are newly acquired in purchase transactions from their dates of acquisition. We account for significant investments in other affiliated companies using the equity method. We also utilize the equity method when we have the ability to exercise significant influence over the affiliated company, despite not holding a significant percentage of its ownership interest. Unless otherwise indicated, all financial and statistical data included in these notes to our Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in&#160;millions (except per&#x2011;share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &#x201c;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU&#160;2020-06&#x201d;), effective as of January&#160;1,&#160;2022 using the modified retrospective method. Among other amendments, ASU&#160;2020-06 changed the accounting for diluted earnings&#x2011;per&#x2011;share for convertible instruments and contracts that may be settled in cash or stock. ASU&#160;2020-06 eliminated an entity&#x2019;s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer&#x2019;s election. Additionally, ASU&#160;2020-06 requires that the if&#x2011;converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU&#160;2020-06, diluted weighted average shares outstanding increased by approximately three million shares and diluted earnings per share available to Tenet common shareholders decreased by $0.01 for the year ended December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1,&#160;2020, we adopted ASU 2016&#x2011;13, &#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&#x201d; (&#x201c;ASU 2016&#x2011;13&#x201d;), using the modified retrospective transition approach as of the period of adoption. The amendments in this ASU required a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Upon adoption of ASU 2016&#x2011;13 on January&#160;1,&#160;2020, we recorded a cumulative effect adjustment to increase accumulated deficit by $14 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior-year amounts have been reclassified to conform to the current&#x2011;year presentation. Due to their increased significance, net gains from the sale of investments and long-lived assets are presented separately in the operating activities section of the accompanying Consolidated Statements of Cash Flows. In prior periods, this activity was included in other items, net within the operating activities section.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDUyNzc_69806a86-621f-4593-a91b-f3c8bf16f59d"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDUyNzA_e197d08a-59c7-43c0-a54c-5777ed41a3ac"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6364b905b4f448f180aff1eec2cae8f0_I20200101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxNzU_d5b50309-1884-45fc-8b71-c74dae3e0184"
      unitRef="usd">-14000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:UseOfEstimates
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTky_ff391054-51f1-4093-b931-16483339816a">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.</us-gaap:UseOfEstimates>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMyOTg1MzUwNTg4NjE_dec1b7ad-544a-4fd2-95d8-83917c74f0c6"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <thc:ScheduleOfGrantFundsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMyOTg1MzUwMTk2OTA_908d7859-0bc3-4672-8d3a-724a2f4bf246">As detailed in the table below, we received cash payments from the PRF and state and local grant programs during the years ended December&#160;31,&#160;2022, 2021 and 2020. Grant funds received by our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate are included in cash flows from operating activities in our consolidated statements of cash flows. Grant funds received by unconsolidated affiliates for which we provide cash management services (&#x201c;Cash&#x2011;Managed Affiliates&#x201d;) are included in cash flows from financing activities.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant funds received from COVID-19 relief programs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&#x2011;Managed Affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant income recognized from COVID-19 relief programs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in grant income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in equity in earnings of unconsolidated affiliates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;Advance payments to our Cash&#x2011;Managed Affiliates were recouped through a reduction of those affiliates&#x2019; Medicare claims payments and, together with any repayments, are presented in cash flows from financing activities.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MAPP advances repaid or recouped:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;880&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&#x2011;Managed Affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</thc:ScheduleOfGrantFundsTableTextBlock>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzQtMi0xLTEtMzE0Mjcz_2bbe13a6-bbb1-4689-9532-0e2ce39debe2"
      unitRef="usd">193000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i2045a695149b44b7a235414628a53b37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzQtNC0xLTEtMzE0Mjcz_5720fb2d-92cc-4eea-9ab2-332d7c0ef855"
      unitRef="usd">142000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="ibaaaa5abc7244245b9b67813cd3b395d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzQtNi0xLTEtMzE0MzY0_a4ef707d-297b-445f-9dda-f6453443bde6"
      unitRef="usd">824000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzUtMi0xLTEtMzE0Mjcz_d46d5400-c552-408b-870f-c15903aec781"
      unitRef="usd">3000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzUtNC0xLTEtMzE0Mjcz_75642c07-f11c-451c-92ea-5d539c255f3d"
      unitRef="usd">36000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzUtNi0xLTEtMzE0MzY0_478087b0-11c2-4430-acf5-17c90e7b2baf"
      unitRef="usd">76000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzYtMi0xLTEtMzE1MTk2_45732b10-d3de-49c1-92b6-882bc3065c49"
      unitRef="usd">196000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzYtNC0xLTEtMzE1MTk2_017e16dd-8210-46f5-9b65-9030b7c7db07"
      unitRef="usd">178000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzYtNi0xLTEtMzE1MjA0_dc16be48-987c-4baa-9f38-70467064a789"
      unitRef="usd">900000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="if7f8148fcad34b6ba60172409bbf6668_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzktMi0xLTEtMzE0Mjcz_f1118d81-689e-4d1e-8c8c-b63599476c66"
      unitRef="usd">0</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i18501b1020814804b2eec3c3a49eda56_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzktNC0xLTEtMzE0Mjcz_8ed08cc9-f9f3-44d9-83b5-a9523c70a568"
      unitRef="usd">37000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates
      contextRef="i64a68ee2c5334eff95979103621be27a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo1YWNhNGVjNzZiMzc0MjUyYjUxZWEyNjQ3ZjBkZjlhZS90YWJsZXJhbmdlOjVhY2E0ZWM3NmIzNzQyNTJiNTFlYTI2NDdmMGRmOWFlXzktNi0xLTEtMzE0Mzcx_6d669259-e06e-45de-807b-d65c976779ed"
      unitRef="usd">74000000</thc:ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzEzLTItMS0xLTI5MzcxMA_9a431039-6cf0-4d4a-9d38-06e480746c57"
      unitRef="usd">190000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i2045a695149b44b7a235414628a53b37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzEzLTQtMS0xLTI5MzcxMA_c863d555-fd8e-42fb-bc72-e8110e55cb28"
      unitRef="usd">142000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ibaaaa5abc7244245b9b67813cd3b395d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzEzLTYtMS0xLTMxNDM3OQ_b7b35c52-9a0d-4b4e-8ec6-a8e2f162bedc"
      unitRef="usd">823000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE0LTItMS0xLTI5MzcxMA_e94fa5b3-9d97-436e-a130-a2da52fb30f1"
      unitRef="usd">4000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE0LTQtMS0xLTI5MzcxMA_5859e06d-80fd-4265-91b8-865b2baf461e"
      unitRef="usd">49000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE0LTYtMS0xLTMxNDM4Mg_e6eb39dc-c139-4e08-a4bf-34252997a6a3"
      unitRef="usd">59000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE1LTItMS0xLTI5MzcxMA_e36950f4-6d42-4cf3-9ee6-0f8c54b8f4d9"
      unitRef="usd">194000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE1LTQtMS0xLTI5MzcxMA_52c98d2d-e588-4838-be27-9c14a6ff21b0"
      unitRef="usd">191000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE1LTYtMS0xLTMxNTIxMQ_07ad7260-5877-4bd6-ae93-096de0134523"
      unitRef="usd">882000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i8eeb9cc68a96448383cd633e3217c1f9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE4LTItMS0xLTI5MzcxMA_af588407-ca92-4aa1-99e8-5a8aeff84e6f"
      unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i9377069d70814572a175b579ec7a281d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE4LTQtMS0xLTI5MzcxMA_fb84867b-e5ad-4423-9c64-e22258ff86b5"
      unitRef="usd">14000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="iab64915969534cf4956bafb8271dc248_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpmMWFiZjI0MzhiOTc0YzBjOWNiYjhkZGRiOTJlMjhlMi90YWJsZXJhbmdlOmYxYWJmMjQzOGI5NzRjMGM5Y2JiOGRkZGI5MmUyOGUyXzE4LTYtMS0xLTMxNDM4OQ_e1c4b463-235c-4eee-801f-cc1e35020d21"
      unitRef="usd">17000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredRevenue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MzUyNjE_d0fc2330-484e-4ec5-8326-bc2c648f9567"
      unitRef="usd">7000000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3MzUyNDY_228528a5-0ab7-42d2-a52e-ec0796012704"
      unitRef="usd">5000000</us-gaap:DeferredRevenue>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="ie620efa156d74ff2af72d1b64f123632_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzQtNi0xLTEtMzE0NDY4_569e06e8-a40e-4d46-9497-ff3265f1b0c1"
      unitRef="usd">876000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="i2045a695149b44b7a235414628a53b37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzQtOC0xLTEtMzE0NDY4_9e9eeb94-0a6c-450b-a558-255c607fdb14"
      unitRef="usd">457000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzUtNi0xLTEtMzE0NDY4_29fadc7f-2b35-4f69-8d6a-52f73f1997e7"
      unitRef="usd">4000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzUtOC0xLTEtMzE0NDY4_25e81aac-1aab-44d3-a7bf-ae23bbc03947"
      unitRef="usd">55000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzYtMS0xLTEtMzE1MjE2_4fd5aa8c-92a4-49d0-a663-9daa1a29b109"
      unitRef="usd">880000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzYtMy0xLTEtMzE0NDg3_7d90c4ef-1115-4ed6-a8c1-a4f2eefd51c6"
      unitRef="usd">512000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="i9f1a1807f7c64edaa3db3ee3ca10ea53_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzktNi0xLTEtMzE0NDY4_76a8d033-a963-4a9c-a08a-108e4d6d1b01"
      unitRef="usd">0</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments
      contextRef="iece489c88064416a8f8ac688d1f70c95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTpiNDBiMjcxZmI0MDE0ODgyYmZhMDQ4ZWU1N2FkYTlhOC90YWJsZXJhbmdlOmI0MGIyNzFmYjQwMTQ4ODJiZmEwNDhlZTU3YWRhOWE4XzktOC0xLTEtMzE0NDY4_65bbda11-c4a6-492b-9ae7-1becf5d281d6"
      unitRef="usd">104000000</thc:ContractWithCustomerLiabilityRecoupmentOfAdvancePayments>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iaa94d45bb7994110803e7156298da109_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3Mzg3MTU_f43b7a6c-7fd5-4ba0-aa86-a8d05827e0f4"
      unitRef="usd">880000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
      contextRef="i3c1b5e8fa8eb4e95875735d34c47d58a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDE0NjU_7f928a43-fd22-4a68-b085-2fafc52852ee"
      unitRef="usd">128000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
      contextRef="i50ac87d72391498b913cf175b99fcea9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE4MTI1NDU_015e0bcc-a981-4b1c-88d8-316126d006d6"
      unitRef="usd">128000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
      contextRef="i3c1b5e8fa8eb4e95875735d34c47d58a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NDE4Mzk_7f928a43-fd22-4a68-b085-2fafc52852ee"
      unitRef="usd">128000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTM2_86941d0e-198d-4cf6-9715-1010c9e3498c">We formed our GBC in the Philippines during the year ended December&#160;31,&#160;2019. The GBC&#x2019;s accounts are measured in its local currency (the Philippine peso) and then translated into U.S.&#160;dollars. All assets and liabilities denominated in foreign currency are translated using the current rate of exchange at the balance sheet date. Results of operations denominated in foreign currency are translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders&#x2019; equity.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjI2_aca28f53-ce56-4d9d-996f-d97bc8d3e91b">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize net operating revenues in the period in which we satisfy our performance obligations under contracts by transferring services to our customers. Net operating revenues are recognized in the amounts we expect to be entitled to, which are the transaction prices allocated for the distinct services. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact with Uninsured Patients&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Patient Service Revenues&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third&#x2011;party payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third&#x2011;party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when (1)&#160;services are provided, and (2)&#160;we do not believe the patient requires additional services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our patient service performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 606&#x2011;10&#x2011;50&#x2011;14(a) and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments recognized for third&#x2011;party payers, discounts provided to uninsured patients in accordance with our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and estimated implicit price concessions related primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop&#x2011;loss payments). Because Medicare requires that a hospital&#x2019;s gross charges be the same for all patients (regardless of payer category), gross charges are what hospitals charge all patients prior to the application of discounts and allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the traditional fee&#x2011;for&#x2011;service (&#x201c;FFS&#x201d;) Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost&#x2011;based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense reimbursement, which are based on our hospitals&#x2019; cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule&#160;interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements with third&#x2011;party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and our historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per&#x2011;diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient&#x2019;s bill is subject to adjustment on a patient&#x2011;by&#x2011;patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the years ended December&#160;31,&#160;2022, 2021 or 2020. In addition, on a corporate&#x2011;wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We know of no claims, disputes or unsettled matters with any payer that would materially affect our revenues for which we have not adequately provided in the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, patients who are covered by third&#x2011;party payers are responsible for related co&#x2011;pays, co&#x2011;insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co&#x2011;pays, co&#x2011;insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self&#x2011;pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self&#x2011;pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such as: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients; the volume of patients through our emergency departments; the increased burden of co&#x2011;pays, co&#x2011;insurance amounts and deductibles to be made by patients with insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record implicit price concessions, primarily related to uninsured patients and patients with co&#x2011;pays, co&#x2011;insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co&#x2011;pays, co&#x2011;insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (&#x201c;EMTALA&#x201d;). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non&#x2011;emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1)&#160;we are unable to obtain verification because the patient&#x2019;s insurance company was unable to be reached or contacted, (2)&#160;a&#160;determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3)&#160;under physician orders we provide services to patients that require immediate treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per&#x2011;diem amount for services received, subject to a cap. Except for the per&#x2011;diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Patient advocates from our Eligibility and Enrollment Services program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conifer Revenues&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Conifer segment recognizes revenue from its contracts when Conifer&#x2019;s performance obligations are satisfied, which is generally as services are rendered. Revenue is recognized in an amount that reflects the consideration to which Conifer expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, Conifer assesses the services specified in its contracts with customers and identifies a performance obligation for each distinct contracted service. Conifer identifies the performance obligations and considers all the services provided under the contract. Conifer generally considers the following distinct services as separate performance obligations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;revenue cycle management services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;value&#x2011;based care services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;patient communication and engagement services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;consulting services; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;other client&#x2011;defined projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Conifer&#x2019;s contracts generally consist of fixed&#x2011;price, volume&#x2011;based or contingency&#x2011;based fees. Conifer&#x2019;s long&#x2011;term contracts typically provide for Conifer to deliver recurring monthly services over a multi&#x2011;year period. The contracts are typically priced such that Conifer&#x2019;s monthly fee to its customer represents the value obtained by the customer in the month for those services. Such multi&#x2011;year service contracts may have upfront fees related to transition or integration work performed by Conifer to set up the delivery for the ongoing services. Such transition or integration work typically does not result in a separately identifiable obligation; thus, the fees and expenses related to such work are deferred and recognized over the life of the related contractual service period. For contracts in which the amortization period of the asset is one year or less, we have elected to apply the practical expedient provided by FASB ASC 340&#x2011;40&#x2011;25&#x2011;4 and expense these costs as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue for fixed&#x2011;priced contracts is typically recognized at the time of billing unless evidence suggests that the revenue is earned or Conifer&#x2019;s obligations are fulfilled in a different pattern. Revenue for volume&#x2011;based contracts is typically recognized as the services are being performed at the contractually billable rate, which is generally a percentage of collections or a percentage of client net patient revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <thc:CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzE5NjM5_ec7967a0-5443-41ae-a687-434f53e4ceda">P5M</thc:CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjE1_97c75515-bced-4b63-8f24-c24f4f66e16c">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $858 million and $2.364 billion at December&#160;31,&#160;2022 and 2021, respectively. At December&#160;31,&#160;2022 and 2021, our book overdrafts were $266 million and $226 million, respectively, which were classified as accounts payable. At December&#160;31,&#160;2022 and 2021, $140 million and $188 million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our insurance&#x2011;related subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, 2021 and 2020, we had $196 million, $95 million and $93&#160;million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $191&#160;million, $88&#160;million and $85&#160;million, respectively, were included in accounts payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we acquired all of Baylor&#x2019;s 5% voting ownership interest in USPI. We paid $11&#160;million from cash on hand and recognized a liability of $377&#160;million, the present value of the liability on the acquisition date, for the remainder of the purchase price. We recorded reductions in redeemable noncontrolling interest of $365&#160;million for the carrying value of Baylor&#x2019;s ownership interest and $23&#160;million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares on the acquisition date. This has been reflected as noncash financing activity in the accompanying Consolidated Statement of Cash Flows for the year ended December&#160;31,&#160;2022. Payments made subsequent to the transaction&#x2019;s close are reflected as cash activity within the financing section of our consolidated statements of cash flows. See Note&#160;18 for additional information about this transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDE1_18c3c6c9-795f-4036-826e-174a2811f018"
      unitRef="usd">858000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDIy_22b4e70e-befc-4cac-b00b-c98bbadc6ca7"
      unitRef="usd">2364000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BankOverdrafts
      contextRef="i87503b31cf9b44539e4e33a5a506f23a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDky_136a4d17-8090-474b-b001-176f6f45629a"
      unitRef="usd">266000000</us-gaap:BankOverdrafts>
    <us-gaap:BankOverdrafts
      contextRef="i453df43ed989465c83339dfbcbbf1f2b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NDk5_4350c607-3f6e-4567-93a1-157d947cccc4"
      unitRef="usd">226000000</us-gaap:BankOverdrafts>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd85c2d1a1374a65b8654ba74a6f38c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NTc0_bace8258-a8f7-432c-9bf1-9fe749927ac3"
      unitRef="usd">140000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe6626659d434b6cb1b41cc1706a572b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3NTgx_523b149d-6bd2-449c-8d3c-2b6859d54daa"
      unitRef="usd">188000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3Nzc5_180a4ed0-33f1-4c86-835f-a4ed96eadec8"
      unitRef="usd">196000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3Nzgz_141fb5bd-74db-49f4-af6d-340a04eab9bc"
      unitRef="usd">95000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3Nzkw_5b458e1b-3363-4809-a633-e63b60ad625b"
      unitRef="usd">93000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic2743e63d59e4952888f44efdbce4683_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3OTA3_ec5c2250-dc20-45e0-ab94-cdbc79b02e6b"
      unitRef="usd">191000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i747d501e6e0f41bd9ca9f27f5b091c1a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3OTEx_ee0a6410-e814-4c50-8654-7bd6d2ec7c02"
      unitRef="usd">88000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i26aedf0885e647e29e1d889e0703be3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI3OTE4_6efb4b49-7cc7-4485-abf4-572feb917239"
      unitRef="usd">85000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <thc:JointVentureOwnershipPercentage
      contextRef="i4465885b467846d392b87babc57179d9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc1NDE_a3041d17-b83f-4c34-b4a1-c08475ade0bc"
      unitRef="number">0.05</thc:JointVentureOwnershipPercentage>
    <thc:SharePurchaseAgreementPaymentForExecution
      contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc1ODg_3c73c98e-483e-4738-8078-9015aa4ec4ba"
      unitRef="usd">11000000</thc:SharePurchaseAgreementPaymentForExecution>
    <us-gaap:NotesPayable
      contextRef="if85eb793e6b84363968e6ff370cb8b75_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc2NDA_fa00cf09-2373-4de2-b998-a60f311d084a"
      unitRef="usd">377000000</us-gaap:NotesPayable>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc4MTA_f86f2f9e-3e20-4322-8a78-38933d68de21"
      unitRef="usd">365000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <thc:GainLossFromPurchaseOfNoncontrollingInterests
      contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODc4Njk_51af3758-aba1-4724-b1a8-c07412382df1"
      unitRef="usd">23000000</thc:GainLossFromPurchaseOfNoncontrollingInterests>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTYy_360d3aff-e015-446d-993d-f59d3c11fe17">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify investments in debt securities as either available&#x2011;for&#x2011;sale, held&#x2011;to&#x2011;maturity or as part of a trading portfolio. Our policy is to classify investments in debt securities that may be needed for cash requirements as &#x201c;available&#x2011;for&#x2011;sale.&#x201d; At December&#160;31,&#160;2022, we had no significant investments in debt securities classified as either held&#x2011;to&#x2011;maturity or trading. We carry debt securities classified as available&#x2011;for&#x2011;sale at fair value. We report their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss). We periodically evaluate available-for-sale securities in unrealized loss positions for credit impairment, using both qualitative and quantitative criteria. In the event a security is deemed to be impaired as the result of a credit loss, we record a loss in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We carry equity securities at fair value, and we report their unrealized gains and losses in other non-operating income, net, in our consolidated statements of operations. If the equity security does not have a readily determinable fair value, the carrying value of the security is adjusted only when there is a price change that is observable from a transaction of an identical or similar investment. We include realized gains or losses in our consolidated statements of operations based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTgz_b3552afa-572a-4715-b953-a2ccb8b5b9d2">We control 308 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (158 of 466 at December&#160;31,&#160;2022), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations. In the years ended December&#160;31,&#160;2021 and 2020, equity in earnings of unconsolidated affiliates included $14&#160;million and $17&#160;million, respectively, from PRF grants recognized by our Ambulatory Care segment&#x2019;s unconsolidated affiliates. No additional revenue was recognized from PRF grants by unconsolidated affiliates during the year ended December&#160;31,&#160;2022.&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information for equity method investees is included in the following table. For investments acquired during the reported periods, amounts below include 100% of the investee&#x2019;s results beginning on the date of our acquisition of the investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to the investees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity method investment that contributed the most to our equity in earnings of unconsolidated affiliates during the years ended December&#160;31,&#160;2022, 2021 and 2020 was Texas Health Ventures Group, LLC (&#x201c;THVG&#x201d;), which is operated by USPI. THVG represented $89 million, $107&#160;million and $85&#160;million of total equity in earnings of unconsolidated affiliates of $216 million, $218&#160;million and $169&#160;million in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <thc:NumberOfOutpatientCentersRecordedNotUsingEquityMethod
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5Mjc0_5d9778b4-b1e3-445d-a34c-04ddad964f69"
      unitRef="healthcare_facility">308</thc:NumberOfOutpatientCentersRecordedNotUsingEquityMethod>
    <thc:NumberOfOutpatientCentersRecordedUsingEquityMethod
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5NDQ5_2870b4c9-f913-4fe0-8f19-23c75ce99749"
      unitRef="healthcare_facility">158</thc:NumberOfOutpatientCentersRecordedUsingEquityMethod>
    <thc:NumberOfSurgicalCentersAndHospitals
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5NDU1_634bfd66-d647-49e8-95a6-8752ce682756"
      unitRef="healthcare_facility">466</thc:NumberOfSurgicalCentersAndHospitals>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i9377069d70814572a175b579ec7a281d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzI5ODc4_fb84867b-e5ad-4423-9c64-e22258ff86b5"
      unitRef="usd">14000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="iab64915969534cf4956bafb8271dc248_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3ODg1MjA_e1c4b463-235c-4eee-801f-cc1e35020d21"
      unitRef="usd">17000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i8eeb9cc68a96448383cd633e3217c1f9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE4MDg5MjQ_af588407-ca92-4aa1-99e8-5a8aeff84e6f"
      unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjMx_be4c1e9b-a817-44c0-b08a-d8ed67d30a38">For investments acquired during the reported periods, amounts below include 100% of the investee&#x2019;s results beginning on the date of our acquisition of the investment.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to the investees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <thc:PercentageInvesteeResultsReflected
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwMTU2_1c2d33dd-d6ac-4afc-a6c5-af71db3c47e7"
      unitRef="number">1</thc:PercentageInvesteeResultsReflected>
    <us-gaap:AssetsCurrent
      contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzItMS0xLTEtMjkzNzEw_cd1fcee8-f67c-4e6c-9203-f225a60cccfe"
      unitRef="usd">1142000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzItMy0xLTEtMjkzNzEw_aa4c09b8-b4cb-4f57-9909-cc5e86dfe0b9"
      unitRef="usd">1176000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzItNS0xLTEtMjkzNzEw_68259031-c33b-4846-9008-a6e58ba1f85e"
      unitRef="usd">1309000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzMtMS0xLTEtMjkzNzEw_d4943da6-f313-462a-91b1-48b3e2ab5a44"
      unitRef="usd">1356000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzMtMy0xLTEtMjkzNzEw_39a43c86-ea43-4ad6-bdb1-11b3e20eae05"
      unitRef="usd">1390000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzMtNS0xLTEtMjkzNzEw_bf83847f-ee4f-4256-8e72-450f976aafa9"
      unitRef="usd">1262000000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzQtMS0xLTEtMjkzNzEw_01b23d9b-640a-487c-81dd-4bd840b10bf4"
      unitRef="usd">479000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzQtMy0xLTEtMjkzNzEw_15122de7-5ad5-4fe6-b83d-87183395000a"
      unitRef="usd">495000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzQtNS0xLTEtMjkzNzEw_4f0ef794-d7ac-4c7d-a80c-490fce2ef932"
      unitRef="usd">516000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzUtMS0xLTEtMjkzNzEw_f2279f85-ea4b-46ec-a117-46e8618b9ddb"
      unitRef="usd">878000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzUtMy0xLTEtMjkzNzEw_963ff8b6-d8c3-4a30-a6c7-f7d99beafeee"
      unitRef="usd">855000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzUtNS0xLTEtMjkzNzEw_9e90ce28-70d4-4d38-a48e-f1b87c06baf9"
      unitRef="usd">866000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:MinorityInterest
      contextRef="i6b4dbb5dcadd421e8ace5e3a32883040_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzYtMS0xLTEtMjkzNzEw_4fba14d1-5379-4726-97aa-c282b2b3f455"
      unitRef="usd">644000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i1fcb17caee5f4b38a7b1cc41966cbb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzYtMy0xLTEtMjkzNzEw_83d79137-f2ad-4dad-a444-48046a62d5a7"
      unitRef="usd">659000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i3d0fc4f4d2d44e52ba14297a6d777941_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzYtNS0xLTEtMjkzNzEw_b3fa2abf-512a-4a80-8567-1c7a700e69ea"
      unitRef="usd">621000000</us-gaap:MinorityInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEwLTEtMS0xLTI5MzcxMA_97ab04bf-8008-4f5e-a787-e2ea9a720cb1"
      unitRef="usd">3360000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEwLTMtMS0xLTI5MzcxMA_a446d09c-feb8-4f47-b049-d5ac99b8c150"
      unitRef="usd">3030000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEwLTUtMS0xLTI5MzcxMA_3b45605f-af85-40cb-87f7-26a744c78c5a"
      unitRef="usd">2665000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzExLTEtMS0xLTI5MzcxMA_56c9b186-3cf8-48a9-b083-da2b50a82161"
      unitRef="usd">805000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzExLTMtMS0xLTI5MzcxMA_e2dbc956-1765-4b3f-b1db-7fb338849dd1"
      unitRef="usd">836000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzExLTUtMS0xLTI5MzcxMA_b867bc36-4b0d-423f-9414-6329550a4cc0"
      unitRef="usd">702000000</us-gaap:ProfitLoss>
    <thc:NetIncomeLossAttributableToInvestee
      contextRef="i7c6fa76a92714dc3b3b5980d5d86f5a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEyLTEtMS0xLTI5MzcxMA_d6c4fb6c-bbe1-4c43-93ec-0327b83ab102"
      unitRef="usd">453000000</thc:NetIncomeLossAttributableToInvestee>
    <thc:NetIncomeLossAttributableToInvestee
      contextRef="if3e9b9142cfb4bbe8c7d08271ea4490c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEyLTMtMS0xLTI5MzcxMA_f4e9d398-63a5-4f25-b508-c46ac4235c99"
      unitRef="usd">499000000</thc:NetIncomeLossAttributableToInvestee>
    <thc:NetIncomeLossAttributableToInvestee
      contextRef="iaa695fd8253a46bb8d1666bdaa0c6272_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90YWJsZTo3ZmI3YzBmNjg2YTE0NTE0YjM3NDFhNmYxMDdlM2YzNC90YWJsZXJhbmdlOjdmYjdjMGY2ODZhMTQ1MTRiMzc0MWE2ZjEwN2UzZjM0XzEyLTUtMS0xLTI5MzcxMA_1ab9807f-cc81-4b51-a733-3ed205d2526d"
      unitRef="usd">437000000</thc:NetIncomeLossAttributableToInvestee>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9feb05943d7e4d72a6e4c70948071b28_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNDQ3_e7573d00-cdb2-4929-8f45-2be260acecfa"
      unitRef="usd">89000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4437bef5e9b44a32b53fb9a7a5f9b32e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNDUx_7080933a-39d9-4249-8f21-476b7c1f8da8"
      unitRef="usd">107000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i084834af07f94533b36d44d59a7a2b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNDU4_0ae8a3df-30cd-4977-924b-5fd853f014ca"
      unitRef="usd">85000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNTIx_397fcaa1-0d2b-4af8-b4f2-29439d9f00dd"
      unitRef="usd">216000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNTI1_908490e5-c60e-4efb-9ed1-acaf3ca556e7"
      unitRef="usd">218000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMwNTMy_2e5d80c6-9f92-415d-a27c-f2be067e5097"
      unitRef="usd">169000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTk4_22cf3ed0-de43-401d-a637-fb0b938b3d1c">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions and improvements to property and equipment exceeding established minimum amounts with a useful life greater than one year are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. We use the straight&#x2011;line method of depreciation for buildings, building improvements and equipment. The estimated useful life for buildings and improvements is primarily 15 to 40 years, and for equipment &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDM4_8a4945e6-39ae-49f3-a683-07c2567dae6b"&gt;three&lt;/span&gt; to 15 years. Newly constructed hospitals are usually depreciated over 50 years. Interest costs related to construction projects are capitalized. In the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, capitalized interest was $8 million, $4 million and $5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our long&#x2011;lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of an impairment charge only if the carrying value of the long&#x2011;lived assets exceeds their fair value. The fair value of the asset is estimated based on third&#x2011;party appraisals, established market values of comparable assets or internally developed estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. Estimates require our subjective judgments and take into account assumptions about revenue and expense growth rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of asset and presume stable, improving or, in some cases, declining results, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report long&#x2011;lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on third&#x2011;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie1c80f6e03094431a9b9dc5696c76170_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDEw_024fe883-28c0-4840-9a30-c0f379ae7245">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic99a8eb5ba464ce4815b2681aa41727f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDE2_fab01ca7-6f90-44f1-90a6-d66325bf733d">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibed3bfef5ee649f29df0916da65a65ef_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMDQ0_f8c95bb9-9a2e-445d-bb73-68f28cbf930f">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5343d74439bf454aab6dd66ea2a9f13d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMTA1_89d9a72e-e793-4d0b-8658-ea9d55c52cc4">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InterestCostsCapitalized
      contextRef="i49e69c97f00a4fd4be24bc4f694c6383_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMjMz_3bb45361-4ca1-4e9d-ab14-5b42ccbf8c8d"
      unitRef="usd">8000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="if2a82f5c5f0b4bdea97702ea376fa880_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMjM3_76e85585-a87e-4a97-8cc4-3ffbaa10fd23"
      unitRef="usd">4000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="icc879355fab3418bb4e9b23bb6b58cd4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzMxMjQ0_4005272b-c66a-4720-8b23-cd5a53a818ba"
      unitRef="usd">5000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTQ3_cb7e4e0d-9712-4b44-8ff8-760e5a5172d5">We determine if an arrangement is a lease at inception of the contract. Our right&#x2011;of&#x2011;use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right&#x2011;of&#x2011;use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. We use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. For our Hospital Operations and Conifer segments, we estimate our incremental borrowing rates for our portfolio of leases using documented rates included in our recent equipment finance leases or, if applicable, recent secured debt issuances that correspond to various lease terms. We also give consideration to information obtained from our bankers, our secured debt fair value and publicly available data for instruments with similar characteristics. For our Ambulatory Care segment, we estimate an incremental borrowing rate for each center by &lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;utilizing historical and projected financial data, estimating a hypothetical credit rating using publicly available market data and adjusting the market data to reflect the effects of collateralization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases are primarily for real estate, including off&#x2011;campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. Our real estate lease agreements typically have initial terms of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDA1_46a39fcc-b402-4cc7-b07b-2aae9c25a1f8"&gt;five&lt;/span&gt; to 10 years, and our equipment lease agreements typically have initial terms of three years. We do not record leases with an initial term of 12 months or less (short&#x2011;term leases) in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our real estate leases may include one or more options to renew, with renewals that can extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzE4_a75bda69-a5dd-43b8-aa1b-433cc5fc96ce"&gt;five&lt;/span&gt; to 10 years. The exercise of lease renewal options is at our sole discretion. In general, we do not consider renewal options to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of our right&#x2011;of&#x2011;use assets and lease liabilities. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of our medical equipment leases have terms of three years with a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life, typically ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDU2_2c5b56e9-9c9a-4a6d-96bb-710f45ff9076"&gt;five&lt;/span&gt; to seven years. Similarly, some of our leases of information technology and telecommunications assets include a transfer of title and, therefore, have useful lives of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the right&#x2011;of&#x2011;use asset or liability balances. Our lease agreements do not contain any material residual value guarantees, restrictions or covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the practical expedient that allows lessees to choose to not separate lease and non&#x2011;lease components by class of underlying asset and are applying this expedient to all relevant asset classes. We have also elected the practical expedient package to not reassess at adoption (1)&#160;expired or existing contracts for whether they are or contain a lease, (2)&#160;the lease classification of any existing leases or (3)&#160;initial indirect costs for existing leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ifd1c5b7f55b147fe81cec433ecb2800a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDEx_47aa6705-361d-46c8-b3be-27e4c5c3aea5">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i4130035b4ffb4b2b9759276d80640702_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MDgy_a36af152-9692-4b68-856f-049061d0040e">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <thc:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MjM5_3948d8c8-8732-4082-bdb1-bdda21c4aa53"
      unitRef="renewal_option">1</thc:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i14ddaa71294141e9be1093eec432aaaa_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1MzI0_6dcfbb99-a2dd-4cac-9f60-a530c5c9c2d9">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5df7801e84484df0aaf96468dbac66e2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM1OTAz_c447b45b-496c-4235-9178-9cd3d31160d4">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie118b0f2118146a497e17cce3c5da1f7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MDYy_31488af4-7497-4264-b5fc-fddccf0af8f3">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2f9829aeea0346f490db02486d0b9fa4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM2MjE3_0fcb1391-e599-4787-a0c8-15a81e9afacc">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTcy_047ed465-9e0d-4db2-89db-a978171b225f">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of costs over the fair value of assets of businesses acquired. Goodwill and other intangible assets acquired in purchase business combinations and determined to have indefinite useful lives are not amortized, but instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level when events occur that require an evaluation to be performed or at least annually. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value. Estimates of fair value are based on third&#x2011;party appraisals, established market prices for comparable assets or internally developed estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consist of capitalized software costs, which are amortized on a straight&#x2011;line basis over the estimated useful life of the software, which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzEy_b30c627e-a768-4537-9003-2597c403430e"&gt;three&lt;/span&gt; to 15 years, costs of acquired management and other contract service rights, most of which have indefinite lives, and miscellaneous intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i26d9b425fef84906a67c577eb496f953_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzM4MzE4_a6d79890-6d7b-4912-ad05-13030cc993cf">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQzOTgwNDY2OTU2MzY_ee6228df-7514-4551-a468-9b0fd998fe7f">We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in our consolidated statements of operations.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTk0_53fa2cb1-934e-4d15-857c-ed6a2b713181">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income/losses expected in future years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The carryforward period associated with the deferred tax assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&#160;the more likely than not recognition threshold is satisfied; (2)&#160;the position is ultimately settled through negotiation or litigation; or (3)&#160;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNjE3_2618c863-5d59-41d8-8874-3ad8a551a4c8">We primarily operate acute care hospitals and related healthcare facilities. Our Hospital Operations segment generated 76%, 80% and 81% of our net operating revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Major decisions, including capital resource allocations, are made at the consolidated level, not at the market or hospital level. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQxNzMy_5aa839f9-c665-4e73-8d2b-7df224f60f0a"
      unitRef="number">0.76</thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals>
    <thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NjQwMzg_11e8c425-dff2-4937-b117-b5f6bc7eaefa"
      unitRef="number">0.80</thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals>
    <thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzEwOTk1MTE3NjQwNDY_2683d7ca-ea37-48f1-9c14-a2cfd562e4d3"
      unitRef="number">0.81</thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xODcvZnJhZzpkNGQwZTAxOTdlNmQ0MjAyYjQ4MDgwMmNlM2JiYjQ2My90ZXh0cmVnaW9uOmQ0ZDBlMDE5N2U2ZDQyMDJiNDgwODAyY2UzYmJiNDYzXzQyNTkw_1e6a41da-3056-486e-85d8-4739eed64cae">We recognize costs associated with exit (including restructuring) or disposal activities when they are incurred and can be measured at fair value, rather than at the date of a commitment to an exit or disposal plan.</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzU0MA_6e235708-323d-4734-bd63-d3541e34769c">EQUITY&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our noncontrolling interests balances at December&#160;31,&#160;2022 and 2021 in the accompanying Consolidated Statements of Changes in Equity were comprised of $132 million and $128 million, respectively, from our Hospital Operations segment, and $1.185&#160;billion and $898 million, respectively, from our Ambulatory Care segment.&#160;Our net income attributable to noncontrolling interests for the years ended December&#160;31,&#160;2022, 2021 and 2020 were comprised of $21 million, $21 million and $14 million, respectively, from our Hospital Operations segment, and $221 million, $205 million and $169 million, respectively, from our Ambulatory Care segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;22,&#160;2022, we announced that our board of directors had authorized the repurchase of up to $1&#160;billion of our common stock through a share repurchase program that expires on December&#160;31,&#160;2024. Under the program, shares can be purchased in the open market or through privately negotiated transactions in a manner consistent with applicable securities laws &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and regulations, including pursuant to a Rule 10b5-1 plan maintained by the Company, at times and in amounts based on market conditions and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes transactions completed under the repurchase program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Price Paid per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased as Part of Publicly Announced Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maximum Dollar Value of Shares That May Yet be Purchased Under the Program&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inception through October&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November&#160;1 through November&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;1 through December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inception through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,889&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,889&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42ad7bcccdb04247a3b2e90bbacf26bf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzE3Mg_3104532a-064c-4e56-ad79-d69e15a615bb"
      unitRef="usd">132000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc1386fd3cb640aba64d28e810f688ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzE3OQ_db721c2f-ec8f-4cca-b88a-b5b0740640c6"
      unitRef="usd">128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9047828c01704885a5dbf35dedddc704_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzIzOQ_e6d9367f-92ee-40c7-91cc-2b4159d6dfe2"
      unitRef="usd">1185000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4595fd3300594bae87dfb53d46c07c84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzI0Ng_ba8c0758-6b90-4abe-b5de-00479bd8f225"
      unitRef="usd">898000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i1b651d49dfde4a238741f373ca58bc2c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQwNg_ae87762e-6468-40b9-a538-44b7f2a78cb0"
      unitRef="usd">21000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i7868d9c4a59e48619659d721cc78888e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQxMA_7444ab71-3e38-45ba-a712-74fb62f7d1bb"
      unitRef="usd">21000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i844a37e3831a44668dbcdd0ebafe40b9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQxNw_9cace607-88ea-49b5-bf38-0021705cf1f9"
      unitRef="usd">14000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i15bd4ee78bbe42988676a562c194f442_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQ3Nw_b77478d5-3f1e-42e0-9d72-85a37abeb234"
      unitRef="usd">221000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i0e5985c976394f5390431764b17623d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQ4MQ_624ce6ea-35be-4e5d-996a-77805fb2b150"
      unitRef="usd">205000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i56dd31502d3d4194884bb9c9caf6d2ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzQ4OA_fc3dc2bc-4949-4554-8a01-57e824827440"
      unitRef="usd">169000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i34c7defbef2a4e3b8612d7aba82bf5c3_I20221022"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzEwOTk1MTE2MzA5MzU_32544e66-8c7c-4c49-8464-34ac0d6299b8"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90ZXh0cmVnaW9uOmJkODk5NTA1ODQyMTQ3ZDc4NzczNzc2ZWExYTYyMmQ2XzMyOTg1MzQ4OTEyMzM_9f64602b-407f-4e39-a191-0d47682832e3">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes transactions completed under the repurchase program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Price Paid per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased as Part of Publicly Announced Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maximum Dollar Value of Shares That May Yet be Purchased Under the Program&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inception through October&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November&#160;1 through November&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;1 through December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inception through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,889&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,889&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItMi0xLTEtMzA0ODYz_a71fcfde-ec4b-4698-9c69-a98234f56385"
      unitRef="shares">1800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItNC0xLTEtMzA0ODc5_2958a545-bd4a-49d2-ac0a-bff64c61c0ae"
      unitRef="usdPerShare">41.81</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ieb6c4bb6ecbc4e5a868a08038b24dcb6_D20221022-20221031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItNi0xLTEtMzA0ODg1_3c8ff3df-a1ea-484d-bfa6-c36843861c5a"
      unitRef="shares">1800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="iede14df2bae641aaae79e4148970642b_I20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzItOC0xLTEtMzA0ODY5_ee370725-7051-440a-8ffb-3687507b5b71"
      unitRef="usd">925000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtMi0xLTEtMzA0ODYz_d8d20a22-4e65-4a5c-86fc-18234ad0000e"
      unitRef="shares">4089000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtNC0xLTEtMzA0ODgx_9bf58856-8eb8-4699-b33d-f23f2a8d5088"
      unitRef="usdPerShare">42.74</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib5cbc2ef7ef14b2d94969c3ac66a0b4a_D20221101-20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtNi0xLTEtMzA0ODg3_006bcdea-556a-480c-a316-216eb67bbe1e"
      unitRef="shares">4089000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i2c7906fd4dea427ab980615c8e378f98_I20221130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtOC0xLTEtMzA0ODcz_91a90e01-f3e3-407a-be37-d89848c856f9"
      unitRef="usd">750000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtMi0xLTEtMzE3MTU1_a14765d4-7e3e-462f-8c7a-c02a875be9f2"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtNC0xLTEtMzE3MjAy_91787176-b3ee-4de4-8503-b370d953cf81"
      unitRef="usdPerShare">0</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ieb2359b40b364289a981bf17f7227a84_D20221201-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtNi0xLTEtMzE3MTcz_0c4c8fac-2171-4d06-a308-c407dd4fcf9a"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtOC0xLTEtMzE3MjI5_dd82e40b-23b1-4e7d-8d25-17e1b420c369"
      unitRef="usd">750000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtMS0xLTEtMjk2NDM3_452ce940-d958-4597-b6d0-135af3b95f2b"
      unitRef="shares">5889000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzMtMy0xLTEtMjk2NDM3_6c5a131e-4377-4bea-941d-376976fa7cad"
      unitRef="usdPerShare">42.45</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i492058fb609948eb9d26d7e2ed889605_D20221022-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTMvZnJhZzpiZDg5OTUwNTg0MjE0N2Q3ODc3Mzc3NmVhMWE2MjJkNi90YWJsZTo3ZDYzYTA2NGU1OGU0OTZlODcxNzkxZjBjNzllOTM0MS90YWJsZXJhbmdlOjdkNjNhMDY0ZTU4ZTQ5NmU4NzE3OTFmMGM3OWU5MzQxXzQtNi0xLTEtMzA0ODg5_b3ba67bb-1650-4b87-8a87-e2402f71ba87"
      unitRef="shares">5889000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:FinancingReceivablesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxODU_8c61b048-002f-43e5-8db3-4d6f09ff8630">ACCOUNTS RECEIVABLE&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of accounts receivable are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated future recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cost reports and settlements receivable and valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,770&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts that are pursued for collection through Conifer&#x2019;s business offices are maintained on our hospitals&#x2019; books and reflected in patient accounts receivable. Patient accounts receivable, including billed accounts and certain unbilled accounts, as well as estimated amounts due from third&#x2011;party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. Estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital&#x2019;s eligibility for Medicaid disproportionate share hospital payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in various provider fee programs, which help reduce the amount of uncompensated care from indigent patients and those covered by Medicaid. The following table summarizes the amount and classification of assets and liabilities in the accompanying Consolidated Balance Sheets related to California&#x2019;s provider fee program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated costs for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uninsured patients&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charity care patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 13pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;764&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancingReceivablesTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxODY_2a00b50b-1f37-4fb1-9f75-33b0620fe0d5">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of accounts receivable are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated future recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cost reports and settlements receivable and valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,770&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzMtMS0xLTEtMjkzNzEw_734483b2-7a1b-4cb7-9ebc-00191c3e785c"
      unitRef="usd">2746000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzMtMy0xLTEtMjkzNzEw_f5e7b17c-49e3-4876-8eb6-2732ee4d0ad1"
      unitRef="usd">2600000000</us-gaap:AccountsReceivableGrossCurrent>
    <thc:EstimatedFutureRecoveriesFromAccountsAssignedToConifer
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzQtMS0xLTEtMjkzNzEw_62f6c41f-d007-44c7-b28b-5461b1c42649"
      unitRef="usd">149000000</thc:EstimatedFutureRecoveriesFromAccountsAssignedToConifer>
    <thc:EstimatedFutureRecoveriesFromAccountsAssignedToConifer
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzQtMy0xLTEtMjkzNzEw_1b52eb4a-b9f9-4c0b-ae4e-17dcdc181c5e"
      unitRef="usd">137000000</thc:EstimatedFutureRecoveriesFromAccountsAssignedToConifer>
    <thc:NetCostReportSettlementsReceivablePayableandValuationAllowances
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzUtMS0xLTEtMjkzNzEw_820a439f-fb64-4ee6-a5a9-2015b57c144b"
      unitRef="usd">-48000000</thc:NetCostReportSettlementsReceivablePayableandValuationAllowances>
    <thc:NetCostReportSettlementsReceivablePayableandValuationAllowances
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzUtMy0xLTEtMjkzNzEw_52acea0a-279e-43ba-a0e0-65d83a2e4d19"
      unitRef="usd">-33000000</thc:NetCostReportSettlementsReceivablePayableandValuationAllowances>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzgtMS0xLTEtMjkzNzEw_76b13a5d-f317-476d-b2ec-fb95af29fafe"
      unitRef="usd">2943000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTowYmVhNzBmMzlkODI0YTIwYWM5NmU2YzBiNzQ2ZTkzYy90YWJsZXJhbmdlOjBiZWE3MGYzOWQ4MjRhMjBhYzk2ZTZjMGI3NDZlOTNjXzgtMy0xLTEtMjkzNzEw_9fb7ee8c-46fc-416f-b6e2-353a86d9789d"
      unitRef="usd">2770000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxOTM_749b1129-f482-49af-a7c1-40bb06d7f618">The following table summarizes the amount and classification of assets and liabilities in the accompanying Consolidated Balance Sheets related to California&#x2019;s provider fee program:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i71e77f1a3cc942158bce2e26449d46fb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzMtMS0xLTEtMjkzNzEw_24188d01-e18f-4569-b173-93e8d7a65639"
      unitRef="usd">367000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i24938975183a4055b12b952f44b451eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzMtMy0xLTEtMjkzNzEw_72c47f6e-e279-469c-baeb-4c096cc13e10"
      unitRef="usd">370000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i8cc28a960d044d118475b47b836ac7d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzQtMS0xLTEtMjkzNzEw_b081aab0-081c-4178-b3b6-e14ec663c6f5"
      unitRef="usd">197000000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="ia9b5eb45d8444ba8ad4d24f039012736_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzQtMy0xLTEtMjkzNzEw_a5538637-e834-4bc4-8de1-79675016638a"
      unitRef="usd">213000000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9971ae1d4d574f25af6bab80f8bcaf5a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzctMS0xLTEtMjkzNzEw_5d742298-b90b-48b7-b52a-b9c989abbe7d"
      unitRef="usd">145000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ice05b8f807e4403893fdf7bd5fcacb5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzctMy0xLTEtMjkzNzEw_04bc1f54-c61e-4101-a9c2-08968fbc3e5e"
      unitRef="usd">123000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ib366e77f27444ed6a3e8856060b9bf21_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzgtMS0xLTEtMjkzNzEw_cc64dedd-a3c2-48a8-8dba-e3a1c70493c4"
      unitRef="usd">63000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="if78de6460b114c0bab0a7b968955449f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTpiMDNjODUxZThlNGY0ZDJiOWJhYjFiYmJmMjY4YmIzZC90YWJsZXJhbmdlOmIwM2M4NTFlOGU0ZjRkMmI5YmFiMWJiYmYyNjhiYjNkXzgtMy0xLTEtMjkzNzEw_9b91fd58-816a-4bc2-a8b2-b91a021e89a4"
      unitRef="usd">60000000</us-gaap:LiabilitiesNoncurrent>
    <thc:ScheduleOfEstimatedCostForCharityCareTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90ZXh0cmVnaW9uOjQ2NWNkYzQyMGYzMzRlMWE4MDMyYTViOGQwOWQwZWQxXzIxOTg_952b15ca-8905-44eb-b3cd-d2dd6646e841">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated costs for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uninsured patients&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charity care patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 13pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;764&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</thc:ScheduleOfEstimatedCostForCharityCareTableTextBlock>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="i51ac1ea0fa6641af836d8e80f2703fcb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzMtMS0xLTEtMjkzNzEw_beaf9745-c4d8-48ac-bb43-bf9428624cc6"
      unitRef="usd">537000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="ic549de21b71e42098463117277ec3417_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzMtMy0xLTEtMjkzNzEw_1d44abdf-b42f-41fe-a165-ce492c64121e"
      unitRef="usd">650000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="ie1e4506f61374f2e92951abf71b05057_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzMtNS0xLTEtMjkzNzEw_56e76894-777b-43ee-afff-789bf02d8bab"
      unitRef="usd">617000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="ied775d7b43794f9a9cfcd968393ab2cf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzQtMS0xLTEtMjkzNzEw_02b48fdc-5761-481c-a9f6-06c972084c8b"
      unitRef="usd">83000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="i48b47f6e27bd4b2da194704a14b97d77_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzQtMy0xLTEtMjkzNzEw_5194e309-a29d-45d6-a1c5-a4f047be1cdc"
      unitRef="usd">97000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="ib25b38307f82433581aafb23c9f00d50_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzQtNS0xLTEtMjkzNzEw_0921d1ac-4718-4958-bc38-a42282047552"
      unitRef="usd">147000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzUtMS0xLTEtMjkzNzEw_23a9d331-3e11-473c-b6e0-4f1f3a526481"
      unitRef="usd">620000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzUtMy0xLTEtMjkzNzEw_5621e46e-d1b4-4ec8-b912-b714ab7a9514"
      unitRef="usd">747000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTYvZnJhZzo0NjVjZGM0MjBmMzM0ZTFhODAzMmE1YjhkMDlkMGVkMS90YWJsZTo1NDcxNjc4ZjZkYmY0MWU2YjQzNTUwMzZkZDkxYTQxZi90YWJsZXJhbmdlOjU0NzE2NzhmNmRiZjQxZTZiNDM1NTAzNmRkOTFhNDFmXzUtNS0xLTEtMjkzNzEw_67415fa4-af03-41a2-9574-343840e345db"
      unitRef="usd">764000000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMxNzI_c1fcca56-ae9f-4401-87d2-e316b7ad7445">CONTRACT BALANCES&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hospital Operations Segment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment&#x2019;s contract assets were included in other current assets in the accompanying Consolidated Balance Sheets at December&#160;31,&#160;2022 or 2021. Approximately 88% of our Hospital Operations segment&#x2019;s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, our Hospital Operations segment received advance payments from the MAPP following its expansion under the COVID Acts in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Hospital Operations segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening and closing balances of contract assets and contract liabilities, as well as their classification in our consolidated balance sheets, for our Hospital Operations segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Current Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Long-Term Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ambulatory Care Segment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Ambulatory Care segment also received advance payments from the MAPP following its expansion in 2020; however, no additional advances were received during the years ended December&#160;31,&#160;2022 or 2021. All remaining MAPP advances received by our Ambulatory Care segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at December&#160;31,&#160;2022. The remaining advance payments at December&#160;31,&#160;2021 were recorded as contract liabilities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Current Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Long-Term Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Conifer Segment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening and closing balances of Conifer&#x2019;s receivables, contract asset, and current and long&#x2011;term contract liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Asset &#x2013;&lt;br/&gt;Unbilled Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liability &#x2013;&lt;br/&gt;Current&lt;br/&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liability &#x2013;&lt;br/&gt;Long-Term&lt;br/&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between the opening and closing balances of Conifer&#x2019;s contract assets and contract liabilities are primarily related to prepayments for those clients who are billed in advance, changes in estimates related to metric&#x2011;based services, and up&#x2011;front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment&#x2019;s receivables and contract assets were reported as part of other current assets in the accompanying Consolidated Balance Sheets, and its current and long&#x2011;term contract liabilities were reported as part of contract liabilities and contract liabilities&#160;&#x2013;&#160;long&#x2011;term, respectively, in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In both of the years ended December&#160;31,&#160;2022 and 2021, Conifer recognized $56&#160;million of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those clients who are billed in advance, changes in estimates related to metric&#x2011;based services, and up&#x2011;front integration services that are recognized over the service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized amortization expense related to deferred contract setup costs of $4&#160;million in each of the years ended December&#160;31,&#160;2022, 2021 and 2020. At December&#160;31,&#160;2022 and 2021, the unamortized customer contract costs were $24&#160;million and $23&#160;million, respectively, and were presented as part of investments and other assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;NET OPERATING REVENUES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices.&lt;/span&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows our sources of net operating revenues from continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hospital Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net patient service revenues from hospitals and related outpatient facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uninsured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indemnity and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hospital Operations total prior to inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,061&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,485&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Primarily physician practices revenues.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments for prior&#x2011;year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December&#160;31,&#160;2022, 2021 and 2020 by $10&#160;million, $26 million and $6&#160;million, respectively. Estimated cost report settlements and valuation allowances were included in accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the composition of net operating revenues for our Ambulatory Care segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from other sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the composition of net operating revenues for our Conifer segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue cycle services &#x2013; Tenet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue cycle services &#x2013; other customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other services &#x2013; Tenet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other services &#x2013; other customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes Conifer&#x2019;s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume&#x2011; or contingency&#x2011;based contracts, variable&#x2011;based escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer&#x2019;s contract with Catholic Health Initiatives (&#x201c;CHI&#x201d;), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed&#x2011;fee revenue related to remaining performance obligations. Conifer&#x2019;s contract term with CHI ends December&#160;31,&#160;2032.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Later Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <thc:ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzE2NDkyNjc0NjY1ODk_72f0c70f-7246-4593-9a39-5441443eda0a"
      unitRef="number">0.88</thc:ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMxNzU_1a062aa3-3fbe-4b14-83f9-43a7b4a7a9e6">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening and closing balances of contract assets and contract liabilities, as well as their classification in our consolidated balance sheets, for our Hospital Operations segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Current Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Long-Term Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Current Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liabilities &#x2013; Long-Term Advances from Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening and closing balances of Conifer&#x2019;s receivables, contract asset, and current and long&#x2011;term contract liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Asset &#x2013;&lt;br/&gt;Unbilled Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liability &#x2013;&lt;br/&gt;Current&lt;br/&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract Liability &#x2013;&lt;br/&gt;Long-Term&lt;br/&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzMtMi0xLTEtMjkzNzEw_a6668f45-5566-4e82-bb73-e6f0a01bdabc"
      unitRef="usd">181000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzMtNi0xLTEtMjkzNzEw_d3b792c0-effd-40ac-963b-500e54753f97"
      unitRef="usd">876000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzItMTItMS0xLTMxNzMzNA_df9bd75f-4ca8-4f9f-9b31-58f51d0144e3"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzQtMi0xLTEtMjkzNzEw_52f3750f-29f9-4165-b15e-efd9bfadbdf3"
      unitRef="usd">185000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzQtNi0xLTEtMjkzNzEw_622706b0-71ea-4cca-a3d1-a91cca2c93dc"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic3e2f0a1a87d4b8ba046374d5cc326ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzMtMTItMS0xLTMxNzMzMg_9a31c29f-87d2-49eb-a3fd-453e96d8628c"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i25cf6de3bc994080bc0ff271d5f1e7c2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzUtMi0xLTEtMjkzNzEw_b972eda8-f7b6-475c-9d72-bf436472943b"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7db4f9aeba2e456da8757c9a02d08c78_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzUtNi0xLTEtMjkzNzEw_7fd75415-c70c-4d57-82bf-4b4474685b92"
      unitRef="usd">-876000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4c71cd81b16644ba893aa7255b08d6e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzQtMTItMS0xLTMxNTg5MQ_04a74974-bdea-41d6-b119-03638b2051a8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5123a758f7de455b8800a2a9ce940c2c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzctMi0xLTEtMjkzNzEw_4b520a72-0d5c-4143-bef6-6d6d9db5ee33"
      unitRef="usd">208000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5123a758f7de455b8800a2a9ce940c2c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzctNi0xLTEtMjkzNzEw_93bf174f-64ad-49a8-bb4d-aa3f46740cb3"
      unitRef="usd">510000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5123a758f7de455b8800a2a9ce940c2c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzYtMTItMS0xLTMxNzM0Mg_8a388a2b-e3b8-4c86-aa32-403790402477"
      unitRef="usd">819000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzgtMi0xLTEtMjkzNzEw_a6668f45-5566-4e82-bb73-e6f0a01bdabc"
      unitRef="usd">181000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzgtNi0xLTEtMjkzNzEw_d3b792c0-effd-40ac-963b-500e54753f97"
      unitRef="usd">876000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id4166bca0f2b4df8b36ff5398d99c789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzctMTItMS0xLTMxNzMzMg_df9bd75f-4ca8-4f9f-9b31-58f51d0144e3"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i8a580d8694214bf884a09da9b2b1dbd8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzktMi0xLTEtMjkzNzEw_ca96b014-7e6b-468f-9929-81833d11e5a8"
      unitRef="usd">-27000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib4384be4a2dd447d87643cd3c2f0798d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzktNi0xLTEtMjkzNzEw_1bf3bd96-0ad0-417c-96f8-2d6c40c4a878"
      unitRef="usd">366000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8e977fd989cb4d9390f31035ca2e4a2e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1YmRjNGFjZGYxMzI0MGMxOWJhMTU2ZTI4NjQ5YWMwYS90YWJsZXJhbmdlOjViZGM0YWNkZjEzMjQwYzE5YmExNTZlMjg2NDlhYzBhXzgtMTItMS0xLTMxNTkwNQ_3a106d08-abf9-481b-9210-b91133edd817"
      unitRef="usd">-819000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzMtMi0xLTEtMjkzNzEw_1eab0537-cfec-4f16-b3b2-066ba7d1c7cd"
      unitRef="usd">4000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzMtNC0xLTEtMjkzNzEw_7b2bf9c0-f1d6-4870-bdf2-9d8d649fe48b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib165a084700643e1b139d15df43a3b15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzQtMi0xLTEtMjkzNzEw_937d597c-8aee-458d-84e6-eda5e437ecd4"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib165a084700643e1b139d15df43a3b15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzQtNC0xLTEtMjkzNzEw_031303f1-3ad4-480a-8588-ccb0a349b500"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib51529c7491145d285a730665f73c23d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzUtMi0xLTEtMjkzNzEw_b50d5bb3-9ea6-4591-a9ea-5ae754980dfc"
      unitRef="usd">-4000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id7b8ec068ae246cdbc6cfb42f8a12fc4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzUtNC0xLTEtMjkzNzEw_1fc1163a-82bc-4dcc-a8c4-68148407e5de"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzctMi0xLTEtMjkzNzEw_08e8eb07-9b84-40dd-af01-64d1b2592ba8"
      unitRef="usd">93000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzctNC0xLTEtMjkzNzEw_4321cf41-a49d-4cb3-b6b3-f1a69254fe69"
      unitRef="usd">83000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzgtMi0xLTEtMjkzNzEw_1edc5237-0042-4ecb-9051-4a13fa7bad45"
      unitRef="usd">4000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzgtNC0xLTEtMjkzNzEw_9db0a74c-6f61-4fbb-8360-231b06dc8d59"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3c3e3d1b5bee4eeb8147e32baf77ae89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzktMi0xLTEtMjkzNzEw_e3513e0f-d018-46b4-8d58-1899bcbc7025"
      unitRef="usd">-89000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if536ced15ef94662b44301934aa1dae0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo1ZGVkZTM2M2RhYTg0YWQ5OGYyMTBkMmQzOWYyM2M0Mi90YWJsZXJhbmdlOjVkZWRlMzYzZGFhODRhZDk4ZjIxMGQyZDM5ZjIzYzQyXzktNC0xLTEtMjkzNzEw_0fcc8c5b-2241-4807-a652-733c19050cee"
      unitRef="usd">-83000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtMi0xLTEtMzM1NDE2_55b9c53c-8a7f-4729-862d-093a349a4955"
      unitRef="usd">28000000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtNC0xLTEtMzM1NDE2_5c2c1059-ee51-491d-9a46-8a90ccb89144"
      unitRef="usd">18000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtNi0xLTEtMzM1NDE2_d02fa899-e839-45d1-ab6b-8f3b0da23afe"
      unitRef="usd">79000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzMtOC0xLTEtMzM1NDE2_92ce6f26-94a6-4dc5-b9fb-b8bac4ec6759"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtMi0xLTEtMzM1NDE2_44bf85f3-e3d1-4806-a7a2-668137203d32"
      unitRef="usd">37000000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtNC0xLTEtMzM1NDE2_6f5c0b47-34df-444a-9571-c6a56c61df92"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtNi0xLTEtMzM1NDE2_c0c44c9c-feec-4f7d-8375-2e98261391db"
      unitRef="usd">110000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzQtOC0xLTEtMzM1NDE2_a54ed2d5-8a50-4268-a435-0cb260e839a0"
      unitRef="usd">13000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <thc:IncreaseDecreaseInContractWithCustomerReceivable
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtMi0xLTEtMzM1OTc3_7465cff8-0a2a-4117-8ab1-acdd38372f71"
      unitRef="usd">9000000</thc:IncreaseDecreaseInContractWithCustomerReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtNC0xLTEtMzM1OTc5_22b8b7a1-d801-4a4d-85b0-17321f67fe79"
      unitRef="usd">-3000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i71a467f2558648978a9d48e2d2e603ae_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtNi0xLTEtMzM1OTc5_e8080f6d-6d75-4de1-a4f9-4ea80bf27081"
      unitRef="usd">31000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6cf46e0abc954d2a9519b9c790945c68_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzUtOC0xLTEtMzM1OTc5_792e0ec9-2a30-451b-9dde-700f9c2aa2eb"
      unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
      contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctMi0xLTEtMzM1NDE2_71459604-240a-4455-a1c8-eb98f1ee8285"
      unitRef="usd">56000000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctNC0xLTEtMzM1NDE2_d22c084a-d9e4-4486-a54b-7c0dd82f1f46"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctNi0xLTEtMzM1NDE2_0578260a-d124-478c-9168-71ee066a2b75"
      unitRef="usd">56000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzctOC0xLTEtMzM1NDE2_ddd4d97b-74b9-4cd8-b0a1-4cc7b1cc1397"
      unitRef="usd">16000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtMi0xLTEtMzM1NDE2_8b838a12-4187-4017-a809-95a4514037b8"
      unitRef="usd">28000000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtNC0xLTEtMzM1NDE2_6194e6d3-1c90-4331-8249-2f4400285d2e"
      unitRef="usd">18000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtNi0xLTEtMzM1NDE2_e36f006f-6bb8-4338-a705-4caede280a74"
      unitRef="usd">79000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzgtOC0xLTEtMzM1NDE2_7bc8cf0b-ffab-45bf-94ef-463472e4d99f"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <thc:IncreaseDecreaseInContractWithCustomerReceivable
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktMi0xLTEtMzM1OTgx_9320b19e-9db9-4477-a640-b60b40bdceea"
      unitRef="usd">-28000000</thc:IncreaseDecreaseInContractWithCustomerReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktNC0xLTEtMzM1OTgx_d0e60da6-b451-4300-a19d-a471df4f46a9"
      unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4885c05ba74d4161a50b941fc56a1043_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktNi0xLTEtMzM1OTgx_1f60a66d-e7b2-4297-800b-29898bfcbe26"
      unitRef="usd">23000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7afbba7a6c6f4934b189f3870051beac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90YWJsZTo4ZWY2ZjljYzg5ZmQ0YjNlYWUwYTY1YjU5ZmVjOGZjNC90YWJsZXJhbmdlOjhlZjZmOWNjODlmZDRiM2VhZTBhNjViNTlmZWM4ZmM0XzktOC0xLTEtMzM1OTgx_297c602e-5778-4ad7-91fa-26198989a8aa"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzE2NDkyNjc0NzE2MDg_b8852964-1abd-4776-a86f-71bfc71b0197"
      unitRef="usd">56000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzE2NDkyNjc0NzE2MDg_bbb927d8-527c-43bb-bbcf-3c7e55bdb304"
      unitRef="usd">56000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzI5MTA_51cd1935-62f5-4d4c-914b-b8d080c2e578"
      unitRef="usd">4000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzI5MTA_741831ae-5633-40b2-af32-126e4a72039d"
      unitRef="usd">4000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzI5MTA_b4b65827-d396-4d3a-b0a5-82c58eef384a"
      unitRef="usd">4000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMwMzk_a25425e3-3c4c-424c-b7a4-77f86e34a32a"
      unitRef="usd">24000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8xOTkvZnJhZzo4MzJmZmI1ZTkyMDQ0MzIyOTA0NmZiOWE2NTFiMWY3Mi90ZXh0cmVnaW9uOjgzMmZmYjVlOTIwNDQzMjI5MDQ2ZmI5YTY1MWIxZjcyXzMwNDY_5c29759c-7040-42f2-ad0b-2dcd89efdb33"
      unitRef="usd">23000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI2Nzc_68d9ba38-78cd-4bb1-aba4-ba52ab8b906a">ASSETS AND LIABILITIES HELD FOR SALE&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We completed the sale of five Miami&#x2011;area hospitals and certain related operations (the &#x201c;Miami Hospitals&#x201d;) held by our Hospital Operations segment in August&#160;2021, resulting in our recognition of a pre&#x2011;tax gain on sale of $406 million in the year ended December&#160;31,&#160;2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended June&#160;30, 2021, we completed the sale of the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments, and we also completed the separate sale of a Philadelphia&#x2011;area building held by our Hospital Operations segment. We recorded a gain related to the sale of the urgent care centers of $14 million and a gain of $2 million related to the sale of the building in Philadelphia in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains related to the sales described above were included in net gains on sales, consolidation and deconsolidation of facilities in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2021. No impairment charge was incurred during the years ended December&#160;31,&#160;2022, 2021 or 2020 related to planned divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents amounts included in income from continuing operations, before income taxes, related to significant components of our business that were recently disposed of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6.72pt;text-indent:-6.73pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miami Hospitals (includes a $406 million gain on sale in 2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <thc:NumberOfHospitalsForSale
      contextRef="ia4e58b05cbc648e891cb8eb0308a9bd3_D20210801-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzM2MjY_2dc2decc-cfac-4902-aafa-47f943d15d47"
      unitRef="hospital">5</thc:NumberOfHospitalsForSale>
    <us-gaap:GainLossOnSaleOfProperties
      contextRef="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzM5MDg_d2782104-0a06-48af-88ed-f45478227438"
      unitRef="usd">406000000</us-gaap:GainLossOnSaleOfProperties>
    <us-gaap:GainLossOnSaleOfProperties
      contextRef="i9198bb96b0c34619839a103e26656c5f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzUzNTI_fbd78893-846b-4c67-95c1-7012a72ba94e"
      unitRef="usd">14000000</us-gaap:GainLossOnSaleOfProperties>
    <us-gaap:GainLossOnSaleOfProperties
      contextRef="i5b88533462e34354956300ca036d5a16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzEwOTk1MTE2MzUzNTY_8e954cd7-5f88-4fa6-a29c-c603b3b9282b"
      unitRef="usd">2000000</us-gaap:GainLossOnSaleOfProperties>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2caa1d0849c540b493559deb02c5baae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI0NTQ_29c4a45f-7e88-46d3-985b-c0d38a8df90b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib5c6f743bc7c41a9a1958950899659b0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI0NTQ_b1ee69fb-83de-454b-9ca8-93ece14f53fa"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2dd5c058d4484de28c384ae0497a9cb0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI0NTQ_d1f6e978-c6a7-4b7e-b7f1-db8a602ac3d3"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90ZXh0cmVnaW9uOjY3OTYxZjI4YTY2ZDQwNDRhYjVjNGJjMzczMTc0YTUwXzI2NzY_3215aff2-ac73-421a-92a2-acfff8c5e3e0">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents amounts included in income from continuing operations, before income taxes, related to significant components of our business that were recently disposed of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6.72pt;text-indent:-6.73pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miami Hospitals (includes a $406 million gain on sale in 2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:GainLossOnSaleOfProperties
      contextRef="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246Nzc1Y2Q5ZDM1NmJhNDk0ODljNTZjMjczMzI5MmNjZDBfMzM_d2782104-0a06-48af-88ed-f45478227438"
      unitRef="usd">406000000</us-gaap:GainLossOnSaleOfProperties>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax
      contextRef="i216cf3ae855e4607889370b5a9466471_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtMS0xLTEtMjkzNzEw_d099cfdb-aa32-461d-9027-0fe414a2926b"
      unitRef="usd">10000000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax
      contextRef="i6c8ec187f8504d5d893bf7645d40375c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtMy0xLTEtMjkzNzEw_8d260d1b-23ba-4194-b6f5-5d67bde91ce9"
      unitRef="usd">455000000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax
      contextRef="ic05fae90132d4c549fb7d1d0e2284c2b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDIvZnJhZzo2Nzk2MWYyOGE2NmQ0MDQ0YWI1YzRiYzM3MzE3NGE1MC90YWJsZTphNTQzNDE5MmQ2N2U0N2I5OWRmNzFiYzk4OWQ2MWMyMC90YWJsZXJhbmdlOmE1NDM0MTkyZDY3ZTQ3Yjk5ZGY3MWJjOTg5ZDYxYzIwXzUtNS0xLTEtMjkzNzEw_12cc410f-ff76-480f-861c-14c2a437f1ec"
      unitRef="usd">67000000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzYzMjY_aa421d1c-8b65-4b53-88b6-6dd1ba32ad8f">IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized impairment charges on long&#x2011;lived assets in 2022, 2021 and 2020 because the fair values of those assets or groups of assets indicated that the carrying amount was not recoverable. The fair value estimates were derived from third&#x2011;party appraisals, established market values of comparable assets, or internally developed estimates of future net cash flows. These fair value estimates can change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the future financial results of the facilities, how the facilities are operated in the future, changes in healthcare industry trends and regulations, and the nature of the ultimate disposition of the assets. In certain cases, these fair value estimates assume the highest and best use of facility assets in the future to a marketplace participant is other than as a medical facility. In these cases, the estimates are based on the fair value of the real property and equipment if utilized other than as a medical facility. The impairment recognized does not include the costs of closing the facilities or other future operating costs, which could be substantial. Accordingly, the ultimate net cash realized from the facilities, should we choose to sell them, could be significantly less than their impaired value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility&#x2019;s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, our continuing operations consisted of three reportable segments &#x2013; Hospital Operations, Ambulatory Care and Conifer.&#160;Our segments are reporting units used to perform our goodwill impairment analysis. We completed our annual impairment tests for goodwill as of October&#160;1,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost&#x2011;effective structure, such as the establishment of support operations at our GBC. Certain restructuring and acquisition&#x2011;related costs are based on estimates. Changes in estimates are recognized as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2022, we recorded impairment and restructuring charges and acquisition&#x2011;related costs of $226&#160;million, consisting of $118&#160;million of restructuring charges, $94&#160;million of impairment charges and $14&#160;million of acquisition&#x2011;related costs. Impairment charges included $82&#160;million for the write&#x2011;down of certain buildings and medical equipment located in one of our markets to their estimated fair values, which assets are part of our Hospital Operations segment. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#x2019; long&#x2011;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included decreased revenues and lower patient volumes due to the pandemic and competition, as well as higher labor costs as a result of the pandemic. As a result, we updated the estimate of the fair value of the hospitals&#x2019; long&#x2011;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#x2011;lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals&#x2019; assets held and used for which impairment charges were recorded was $167&#160;million at December&#160;31,&#160;2022. Impairment charges for the year ended December&#160;31,&#160;2022 were comprised of $86&#160;million from our Hospital Operations segment, $6&#160;million from our Ambulatory Care segment and $2&#160;million from our Conifer segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges consisted of $27&#160;million of employee severance costs, $16&#160;million related to the transition of various administrative functions to our GBC, $32&#160;million of contract and lease termination fees, and $43&#160;million of other restructuring costs. Acquisition&#x2011;related costs consisted of $14&#160;million of transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2021, we recorded impairment and restructuring charges and acquisition&#x2011;related costs of $85 million, consisting of $57 million of restructuring charges, $8 million of impairment charges and $20 million of acquisition&#x2011;related costs. Restructuring charges consisted of $14 million of employee severance costs, $19 million related to the transition of various administrative functions to our GBC and $24&#160;million of other restructuring costs. Our impairment charges for the year ended December&#160;31,&#160;2021, comprised of $5&#160;million from our Ambulatory Care segment and $3&#160;million from our Conifer segment, primarily consisted of charges to reduce the carrying value of certain management contract intangible assets held by our Ambulatory Care segment to their estimated fair value. Acquisition&#x2011;related costs consisted of $20&#160;million of transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&#160;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2020, we recorded impairment and restructuring charges and acquisition&#x2011;related costs of $290 million, consisting of $92 million of impairment charges, $184 million of restructuring charges and $14 million of acquisition&#x2011;related costs. Impairment charges included $76 million for the write&#x2011;down of hospital buildings to their estimated fair values, which assets are part of our Hospital Operations segment. Material adverse trends in our estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals&#x2019; long&#x2011;lived assets was not recoverable from their estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. As a result, we updated the estimate of the fair value of the hospitals&#x2019; long&#x2011;lived assets and compared it to the aggregate carrying value of those assets. Because the fair value estimates were lower than the aggregate carrying value of the long&#x2011;lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals&#x2019; assets held and used for which impairment charges were recorded was $483 million at December&#160;31,&#160;2020. We also recorded $16 million of other impairment charges. Restructuring charges consisted of $65 million of employee severance costs, $50 million related to the transitioning of various administrative functions to our GBC, $23 million of charges due to the termination of the USPI management equity plan, $14&#160;million of contract and lease termination fees, and $32&#160;million of other restructuring costs. Acquisition&#x2011;related costs consisted of $14&#160;million of transaction costs. Our impairment charges for the year ended December&#160;31,&#160;2020 were comprised of $79&#160;million from our Hospital Operations segment, $12&#160;million from our Ambulatory Care segment and $1&#160;million from our Conifer segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzE2NDkyNjc0Njc4MDA_fb0d4a2f-a12d-490f-afdc-ef6a7a4b564e"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1MzU_cf0f279b-c931-4fb6-aaac-ed96b9e66686"
      unitRef="usd">226000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <us-gaap:RestructuringCosts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NDk_68256b1e-6c5b-4099-81e0-6ec84764dcb2"
      unitRef="usd">118000000</us-gaap:RestructuringCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NTM_523df44d-abfe-4d11-8093-1f6cce703616"
      unitRef="usd">94000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NTc_a1fa849d-538a-4d2b-a808-c5de05490a9e"
      unitRef="usd">14000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="i87e348ef2f5949cfb83ccab43bf831b1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzU0OTc1NTg0NDA3Mg_37f159b1-237a-4e70-a38e-8f5e9cbdfadd"
      unitRef="usd">82000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetsNoncurrent
      contextRef="i533053ff136948178e655a762abff3e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzU0OTc1NTg0NDMyNw_9cde7868-575c-4741-a85b-947b36ad4958"
      unitRef="usd">167000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTk5OTg_b75eecd9-e0b5-4ef5-a0b6-7c11f18ecf95"
      unitRef="usd">86000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NjAwNDA_dc999893-d1cf-4d55-b87f-f8f3a49d9060"
      unitRef="usd">6000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NjAwNzM_4e44d5ad-bd90-452d-8a6c-985036ddd65e"
      unitRef="usd">2000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCosts
      contextRef="i194ea9513fe545cda7f1fc401e373fc3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NjE_06744d6d-d888-47ea-92ac-9cedbc52d686"
      unitRef="usd">27000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="ied9bab022f5344008a846ed40a785dfc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1NjU_b1335b20-235d-4bda-ad8a-0e6eaa929db2"
      unitRef="usd">16000000</us-gaap:RestructuringCosts>
    <us-gaap:BusinessExitCosts1
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzU0OTc1NTg0MTU2OQ_e1e6909b-1c4e-4872-9624-8f1abf174128"
      unitRef="usd">32000000</us-gaap:BusinessExitCosts1>
    <us-gaap:OtherRestructuringCosts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM1ODI_357b55f4-cef6-4f2a-85fd-a3fce812d967"
      unitRef="usd">43000000</us-gaap:OtherRestructuringCosts>
    <thc:BusinessCombinationAcquisitionRelatedTransactionCosts
      contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDM2Njk_35d9c4b5-d652-40cf-a861-bfa2554cc682"
      unitRef="usd">14000000</thc:BusinessCombinationAcquisitionRelatedTransactionCosts>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NTA_9b3b4eb1-8ad4-4dbf-b6fd-bb5cd65e1e4a"
      unitRef="usd">85000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <us-gaap:RestructuringCosts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NjE_a6084606-6c62-43d8-9931-e8e28f117354"
      unitRef="usd">57000000</us-gaap:RestructuringCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NjU_646f710e-3b98-4cac-9bde-16f9b4b08360"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4Njk_049453e3-6b0a-4a79-8e43-ab11e36f877a"
      unitRef="usd">20000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RestructuringCosts
      contextRef="i87faa7579d7f4b91a4f182929ca4f1b4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4NzM_754881a0-1eb7-4233-ad55-ed6f5b4152ff"
      unitRef="usd">14000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i2b84189bf5024247805cd0d9a5e0ea47_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4Nzc_fbae209c-f388-4f18-817b-e95c43dca4e4"
      unitRef="usd">19000000</us-gaap:RestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDU1MDY_1db0ec26-76c9-404c-8224-0b42bb60aa48"
      unitRef="usd">24000000</us-gaap:OtherRestructuringCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4OTE_df5e58cb-83b2-48d2-846f-630ad15ef9d8"
      unitRef="usd">5000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk4OTY_17c04c99-956b-450c-9c5c-442dd705bd41"
      unitRef="usd">3000000</us-gaap:AssetImpairmentCharges>
    <thc:BusinessCombinationAcquisitionRelatedTransactionCosts
      contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NDk5Mzk_b775109c-153f-4368-bce8-0530f4070835"
      unitRef="usd">20000000</thc:BusinessCombinationAcquisitionRelatedTransactionCosts>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyNzU_287db9b7-cc79-4731-833b-d2f7f2862967"
      unitRef="usd">290000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyNzk_5bcdfcf3-e567-42a2-a614-d6a38f856a95"
      unitRef="usd">92000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyODM_1a9d1926-440c-4f73-8071-4d75ea3682fc"
      unitRef="usd">184000000</us-gaap:RestructuringCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyODc_10dd7ab1-7250-4bee-8fdc-f6efcc38cbe8"
      unitRef="usd">14000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie66efb75ed1542c3a0342c08477760c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIyOTE_063b2379-0656-407e-b4be-da0307b8e88b"
      unitRef="usd">76000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetsNoncurrent
      contextRef="idca9108158cb459d9c536f451843cd7a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMDM_0996e90f-9ae1-4e77-aa2c-73b9d428642a"
      unitRef="usd">483000000</us-gaap:AssetsNoncurrent>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMTM_22f32a05-1f55-49a2-8d4e-2023daf314b8"
      unitRef="usd">16000000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:RestructuringCosts
      contextRef="i47f5b56532644469acafb2fdf2a8344a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMjA_c296aa50-fa67-46e1-8287-29f1d0cb9f26"
      unitRef="usd">65000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i22277913b4384752915cdfe34322cd7c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMjQ_2ec1bda4-7209-4970-8f47-3c680c0609b9"
      unitRef="usd">50000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i8169667563aa498e92398dfb1b02ac01_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMzI_c9341e6d-1787-4ce7-bebe-ee96414c7245"
      unitRef="usd">23000000</us-gaap:RestructuringCosts>
    <us-gaap:BusinessExitCosts1
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMjg_386a6934-1e86-441d-a779-702a6ad8255e"
      unitRef="usd">14000000</us-gaap:BusinessExitCosts1>
    <us-gaap:OtherRestructuringCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzMzk_0a332736-baed-44da-8641-4b1caea4be55"
      unitRef="usd">32000000</us-gaap:OtherRestructuringCosts>
    <thc:BusinessCombinationAcquisitionRelatedTransactionCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzNDM_2218792f-ec14-4505-a877-86f181fbf969"
      unitRef="usd">14000000</thc:BusinessCombinationAcquisitionRelatedTransactionCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzE2NDkyNjc0Njc5Nzk_c29931fa-7a4b-49f7-ad10-d512e6515cb6"
      unitRef="usd">79000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzEwOTk1MTE2NTIzNjg_7cd04b03-cfd7-4896-b4bb-2b711c796a2e"
      unitRef="usd">12000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMDgvZnJhZzowNDUyZWU4ZTA1Y2Q0ZThhOGIxMTQ4ODAyYjdiMjU1Ni90ZXh0cmVnaW9uOjA0NTJlZThlMDVjZDRlOGE4YjExNDg4MDJiN2IyNTU2XzE2NDkyNjc0NjgwMDY_ff49a442-27e8-4e61-9b03-a94aebc79e15"
      unitRef="usd">1000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzMQ_67568a3f-5edb-4116-bbcd-4a4a7c604ad8">LEASES&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our right&#x2011;of&#x2011;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Component of Lease Balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1"&gt;Investments and other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"&gt;&lt;div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,517&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Component of Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and short term-lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted&#x2011;average lease terms and discount rates for operating and finance leases are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flow and other information related to leases is included in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Later years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31,&#160;2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $147 million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $69&#160;million from the sale of these buildings, included in other operating expenses, net in the accompanying Consolidated Statement of Operations, and we recognized right-of-use assets and operating lease obligations of $103&#160;million, in each case in the three months ended March&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzMg_a98bae78-d2f2-431c-8582-25011050da75">LEASES&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our right&#x2011;of&#x2011;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Component of Lease Balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1"&gt;Investments and other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"&gt;&lt;div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,517&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Component of Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and short term-lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted&#x2011;average lease terms and discount rates for operating and finance leases are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flow and other information related to leases is included in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Later years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31,&#160;2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $147 million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $69&#160;million from the sale of these buildings, included in other operating expenses, net in the accompanying Consolidated Statement of Operations, and we recognized right-of-use assets and operating lease obligations of $103&#160;million, in each case in the three months ended March&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <thc:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzMw_d56be158-05d3-4ed8-9cc5-78dd196b47d3">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our right&#x2011;of&#x2011;use assets and liabilities related to leases and their classification in our Consolidated Balance Sheets at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Component of Lease Balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_790287c7-2ab1-444a-b299-0b19ce307872"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtMi0xLTEtMjkzNzEw_9136535f-5c62-44cf-b037-d9afa3d8eaf1"&gt;Investments and other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_527fe7c0-8fca-47ba-9b48-6397737267b5"&gt;&lt;div style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtMi0xLTEtMjkzNzEw_ccebda47-90fc-4041-b7a1-54b09f596f29"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_7f7899d5-2750-450e-a4b0-78747e7aaf2d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktMi0xLTEtMjkzNzEw_cb3ccfb0-0bd8-430d-bee3-049a4164787c"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_7495bc84-5bbd-4b95-9352-c1231bb94c84"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTItMS0xLTI5MzcxMA_bdbc8caa-f7f2-4886-a0e2-0f00daace5d6"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_64c190f3-af08-44eb-929d-85b549eb261f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTItMS0xLTI5MzcxMA_dffcf8a5-55c8-42ff-9243-3b2acd482509"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_2d2737f5-8d59-4564-9c8f-54908ed4628f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTItMS0xLTI5MzcxMA_367d10af-6ab0-4104-9ef3-7b7773807119"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,517&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</thc:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtNC0xLTEtMjkzNzEw_faeeec71-a98b-4f0e-a6ea-ec0513abd997"
      unitRef="usd">1129000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzMtNi0xLTEtMjkzNzEw_0d0fac12-55e4-4a4c-89c6-67ec4666926c"
      unitRef="usd">1002000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtNC0xLTEtMjkzNzEw_419850a0-bbb6-4b0b-a6cf-1124e83a28bb"
      unitRef="usd">303000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzQtNi0xLTEtMjkzNzEw_26b0e56e-d7a1-4b74-ae82-e7c3becce6ab"
      unitRef="usd">333000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <thc:LeaseRightOfUseAsset
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzUtNC0xLTEtMjkzNzEw_3cf917e7-ba69-4d17-8be8-8655f0f51463"
      unitRef="usd">1432000000</thc:LeaseRightOfUseAsset>
    <thc:LeaseRightOfUseAsset
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzUtNi0xLTEtMjkzNzEw_4e91dafe-87ed-4b8f-8545-3311b4fa252f"
      unitRef="usd">1335000000</thc:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktNC0xLTEtMjkzNzEw_c3e9dfde-17d9-4fa4-a329-4b1e3969582c"
      unitRef="usd">207000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzktNi0xLTEtMjkzNzEw_194657ec-c91d-4683-9bcc-e8c45961fd3e"
      unitRef="usd">201000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTQtMS0xLTI5MzcxMA_226b3279-ea7e-4a1c-8dd9-8063be1cc2e6"
      unitRef="usd">1046000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEwLTYtMS0xLTI5MzcxMA_e7417315-cf62-40d8-9132-b7e457f6ccb8"
      unitRef="usd">924000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzExLTQtMS0xLTI5MzcxMA_4b215c23-0607-4f80-b6c5-57138bd1e8ea"
      unitRef="usd">1253000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzExLTYtMS0xLTI5MzcxMA_84ee66e9-b1ab-44ae-bf40-d02415def7a5"
      unitRef="usd">1125000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTQtMS0xLTI5MzcxMA_2d7623c1-38e6-46e0-8237-f68f9873a547"
      unitRef="usd">99000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzEzLTYtMS0xLTI5MzcxMA_f52240d2-ac8f-41a3-abe4-8a03ca0b4d87"
      unitRef="usd">106000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTQtMS0xLTI5MzcxMA_b7fed45f-0afd-4233-a4a7-ed87079c5c8e"
      unitRef="usd">165000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE0LTYtMS0xLTI5MzcxMA_83bc44cc-d8f7-4997-b053-ce56aa8988c0"
      unitRef="usd">176000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE1LTQtMS0xLTI5MzcxMA_f6039699-a839-47e6-bdb5-2ed313df5541"
      unitRef="usd">264000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE1LTYtMS0xLTI5MzcxMA_7e9c645b-867b-46b7-a0c8-e5ee111b0fdd"
      unitRef="usd">282000000</us-gaap:FinanceLeaseLiability>
    <thc:LeaseLiability
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE2LTQtMS0xLTI5MzcxMA_25a6a275-08f3-49b0-8b79-417114a7941c"
      unitRef="usd">1517000000</thc:LeaseLiability>
    <thc:LeaseLiability
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5OGI1NWE3OGJiNDY0MWRhOTcyMmFlZjg4YzllZWI1OC90YWJsZXJhbmdlOjk4YjU1YTc4YmI0NjQxZGE5NzIyYWVmODhjOWVlYjU4XzE2LTYtMS0xLTI5MzcxMA_b4f94125-5b8a-4a9f-9545-c89fe2e42aad"
      unitRef="usd">1407000000</thc:LeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzNA_7a8d2c23-4e3e-40dd-a486-398e37872efa">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our lease expense and their classification in our Consolidated Statements of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Component of Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and short term-lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted&#x2011;average lease terms and discount rates for operating and finance leases are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flow and other information related to leases is included in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzItNi0xLTEtMjkzNzEw_b94404a8-e264-4134-b145-c6b902928d7b"
      unitRef="usd">262000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzItOC0xLTEtMjkzNzEw_401f939f-776a-4921-8818-659731a63fe4"
      unitRef="usd">241000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzItMTAtMS0xLTI5MzcxMA_4f72dd35-cc33-4d1c-999d-49d20ee35560"
      unitRef="usd">247000000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzQtNi0xLTEtMjkzNzEw_25bf90c4-06bc-41a5-940e-8ba7624af550"
      unitRef="usd">58000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzQtOC0xLTEtMjkzNzEw_d2eafec4-045e-4fa6-a60b-8dbcdf513ab0"
      unitRef="usd">71000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzQtMTAtMS0xLTI5MzcxMA_57c67c7c-2e53-4ee1-8e75-9adf7fa023e3"
      unitRef="usd">86000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzUtNi0xLTEtMjkzNzEw_4d9f4121-9a14-42d2-b546-68d10db0c1e9"
      unitRef="usd">8000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzUtOC0xLTEtMjkzNzEw_42751834-0bdf-4655-9960-d68799f31070"
      unitRef="usd">9000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzUtMTAtMS0xLTI5MzcxMA_1d7161b2-d491-4ab7-9eb3-bfe8b931a328"
      unitRef="usd">11000000</us-gaap:FinanceLeaseInterestExpense>
    <thc:FinanceLeaseCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzYtNi0xLTEtMjkzNzEw_3cb5811a-1c2a-443d-8933-09955f5d588e"
      unitRef="usd">66000000</thc:FinanceLeaseCost>
    <thc:FinanceLeaseCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzYtOC0xLTEtMjkzNzEw_0cf4194f-6a03-43e3-849a-f98db62322fa"
      unitRef="usd">80000000</thc:FinanceLeaseCost>
    <thc:FinanceLeaseCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzYtMTAtMS0xLTI5MzcxMA_768bbc44-826a-4403-9beb-72bf8be319bc"
      unitRef="usd">97000000</thc:FinanceLeaseCost>
    <thc:VariableAndShorttermLeaseCosts
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzctNi0xLTEtMjkzNzEw_a52c2757-b834-4256-8e6f-1d15e7cb59cf"
      unitRef="usd">150000000</thc:VariableAndShorttermLeaseCosts>
    <thc:VariableAndShorttermLeaseCosts
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzctOC0xLTEtMjkzNzEw_5528619a-079f-4f05-8990-0fd8494c4e39"
      unitRef="usd">171000000</thc:VariableAndShorttermLeaseCosts>
    <thc:VariableAndShorttermLeaseCosts
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzctMTAtMS0xLTI5MzcxMA_339bb2e5-c90f-4745-8de2-d3d63f556bd5"
      unitRef="usd">156000000</thc:VariableAndShorttermLeaseCosts>
    <us-gaap:LeaseCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzgtNi0xLTEtMjkzNzEw_e047a7de-be0d-4264-b416-fd0360353d09"
      unitRef="usd">478000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzgtOC0xLTEtMjkzNzEw_079fd808-e526-4d0f-b050-39513845820c"
      unitRef="usd">492000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNjQ1MmJlZGVjMWI0MDdjYTMxMWI2NWE5MTZkZDVhMC90YWJsZXJhbmdlOmU2NDUyYmVkZWMxYjQwN2NhMzExYjY1YTkxNmRkNWEwXzgtMTAtMS0xLTI5MzcxMA_7f6f7626-f75e-43d0-805f-b007aa8f6ea2"
      unitRef="usd">500000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzMtMi0xLTEtMjkzNzEw_c033cd05-2727-4f83-b496-2ee38c427d95">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzMtNC0xLTEtMjkzNzEw_e2346acc-ee72-4572-ace2-ef58543dfe19">P7Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzMtNi0xLTEtMjkzNzEw_47b50086-e8f3-4132-9a38-58bcfa369ba5">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzQtMi0xLTEtMjkzNzEw_82d8f3f7-0aeb-49a7-a869-02b6f28083dc">P5Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzQtNC0xLTEtMjkzNzEw_30bb1378-68a8-4806-983c-98a4ed15a0ac">P5Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzQtNi0xLTEtMjkzNzEw_bf192b90-cc47-4f63-ac1c-5973b88d6903">P5Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzctMi0xLTEtMjkzNzEw_38417eeb-9065-45dc-b376-12133b7951c6"
      unitRef="number">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzctNC0xLTEtMjkzNzEw_25591084-232e-4429-bd0b-26f8365b5c92"
      unitRef="number">0.051</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzctNi0xLTEtMjkzNzEw_67993d09-55f8-4f8f-baf4-7ae9df403e45"
      unitRef="number">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzgtMi0xLTEtMjkzNzEw_b82a4a3c-e770-4f84-9272-610d782b49bf"
      unitRef="number">0.059</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzgtNC0xLTEtMjkzNzEw_426a8eea-a0de-4cba-94e4-b0af7c0eb97a"
      unitRef="number">0.054</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTplNmExZjU2MzQyYWE0NTk3YjI5ZWI0MjVmYjgwYzIxNi90YWJsZXJhbmdlOmU2YTFmNTYzNDJhYTQ1OTdiMjllYjQyNWZiODBjMjE2XzgtNi0xLTEtMjkzNzEw_51eef8a6-bdbe-4a11-97c7-0a12657ebd92"
      unitRef="number">0.056</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzMtMi0xLTEtMjkzNzEw_ddd24982-0e7b-4ed5-b47a-9d48e94e713e"
      unitRef="usd">250000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzMtNC0xLTEtMjkzNzEw_dde9913f-7935-4560-89a5-e3509f10171e"
      unitRef="usd">237000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzMtNi0xLTEtMjkzNzEw_2ff5733c-6435-4b27-95ad-b9377c9d3978"
      unitRef="usd">239000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzQtMi0xLTEtMjkzNzEw_e4c355d3-16ae-48a9-9e50-6d35a792cc9a"
      unitRef="usd">14000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzQtNC0xLTEtMjkzNzEw_b15808a7-72e5-41f7-9cb2-c26b0ec39e52"
      unitRef="usd">12000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzQtNi0xLTEtMjkzNzEw_0ae8a8de-9fc2-44e7-8ff3-b7a833e17d8a"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzUtMi0xLTEtMjkzNzEw_4a34280c-9148-444e-8029-923584e7a40e"
      unitRef="usd">118000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzUtNC0xLTEtMjkzNzEw_ed6d0f73-58ed-47fe-ab92-1c116fe9699e"
      unitRef="usd">140000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzUtNi0xLTEtMjkzNzEw_bbfdee15-a346-409e-a10e-a129dad2f4bf"
      unitRef="usd">154000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzgtMi0xLTEtMjkzNzEw_bf3c3489-0e9c-4486-b5e5-e5c1fd8f2ffa"
      unitRef="usd">341000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzgtNC0xLTEtMjkzNzEw_4f9c109b-bac4-4795-b1e6-d1a2115d3ed8"
      unitRef="usd">176000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzgtNi0xLTEtMjkzNzEw_f9969e3a-4cc0-43ed-8e0d-999ad3785413"
      unitRef="usd">304000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzktMi0xLTEtMjkzNzEw_cb64ed9f-830d-47ca-86d8-a98c8cd6f1d1"
      unitRef="usd">97000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzktNC0xLTEtMjkzNzEw_5ea169ef-a4f9-49bf-af4e-06909f97dd7b"
      unitRef="usd">136000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo5ZWIzYTRhZWE0YTQ0YTZiYTBiOTIyMmQ2MTBmOTIxOC90YWJsZXJhbmdlOjllYjNhNGFlYTRhNDRhNmJhMGI5MjIyZDYxMGY5MjE4XzktNi0xLTEtMjkzNzEw_7cbb1e25-3a64-41b4-9b70-ecf825013111"
      unitRef="usd">98000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzNQ_60733ca6-ac1f-4224-b7ca-6399695daa65">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Later years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzYzNg_a4310bdb-52d5-4865-96de-59a4f5d628b1">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31,&#160;2022 are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Later years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEtMi0xLTEtMjkzNzEw_be7402c9-aac8-40ca-a368-aa38d9aff234"
      unitRef="usd">254000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEtNC0xLTEtMjkzNzEw_151c29af-8f99-4c78-967a-c40e14aa92bb"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <thc:LesseeLeaseLiabilityPaymentsNextTwelveMonths
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEtNi0xLTEtMjkzNzEw_f870d0bb-1cad-4199-a7ab-d59175e9dbbc"
      unitRef="usd">364000000</thc:LesseeLeaseLiabilityPaymentsNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzItMi0xLTEtMjkzNzEw_9e851ed1-612a-4935-9e9d-19d0dae791d2"
      unitRef="usd">229000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzItNC0xLTEtMjkzNzEw_98f72c3f-8c20-492b-a463-6d50771b4cdb"
      unitRef="usd">80000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <thc:LesseeLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzItNi0xLTEtMjkzNzEw_0667bc33-8400-4e21-a320-dca8edc9f5bb"
      unitRef="usd">309000000</thc:LesseeLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzMtMi0xLTEtMjkzNzEw_205b64f0-9dc6-45d4-919d-0f7dc482cf70"
      unitRef="usd">198000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzMtNC0xLTEtMjkzNzEw_40d9a040-67eb-4294-ade4-9c887282cb40"
      unitRef="usd">39000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <thc:LesseeLeaseLiabilityPaymentsDueYearThree
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzMtNi0xLTEtMjkzNzEw_19f41448-8777-42d8-9758-0881859922da"
      unitRef="usd">237000000</thc:LesseeLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzQtMi0xLTEtMjkzNzEw_fc484d08-3915-4412-a48f-05adeb8682fe"
      unitRef="usd">163000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzQtNC0xLTEtMjkzNzEw_a79c7c11-55e2-4333-ad29-20e5adbde766"
      unitRef="usd">14000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <thc:LesseeLeaseLiabilityPaymentsDueYearFour
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzQtNi0xLTEtMjkzNzEw_b46729d9-fb5c-480f-af49-47c713133d2b"
      unitRef="usd">177000000</thc:LesseeLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzUtMi0xLTEtMjkzNzEw_cf48d74f-f16b-4597-87e1-6073b52ab634"
      unitRef="usd">139000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzUtNC0xLTEtMjkzNzEw_c950fffb-5894-412f-98d7-d1f9b9c62c10"
      unitRef="usd">7000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <thc:LesseeLeaseLiabilityPaymentsDueYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzUtNi0xLTEtMjkzNzEw_1e5c1f8e-b53c-47ac-bdc7-2a5949a827ef"
      unitRef="usd">146000000</thc:LesseeLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzYtMi0xLTEtMjkzNzEw_da47d23d-8ef5-4897-85b5-5591e222b7fb"
      unitRef="usd">540000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzYtNC0xLTEtMjkzNzEw_eaaf46e8-e6ee-498e-bc80-6c0ffce0c205"
      unitRef="usd">75000000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <thc:LesseeLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzYtNi0xLTEtMjkzNzEw_9c3a8ed9-c072-40ec-99bc-30c4aff28961"
      unitRef="usd">615000000</thc:LesseeLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzctMi0xLTEtMjkzNzEw_75f78a90-6bdd-431e-87ca-4ec8722c80f0"
      unitRef="usd">1523000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzctNC0xLTEtMjkzNzEw_b3026c2b-4508-4f7f-bbcd-e1e45ad67fb2"
      unitRef="usd">325000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <thc:LeaseLiabilityPaymentsDue
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzctNi0xLTEtMjkzNzEw_942a4779-1777-487a-b00d-339c88490e84"
      unitRef="usd">1848000000</thc:LeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzgtMi0xLTEtMjkzNzEw_6026fb41-ceb2-4af5-82a4-9b2feaeb3031"
      unitRef="usd">270000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzgtNC0xLTEtMjkzNzEw_a360c9ab-25d8-4078-8754-757ecc41668e"
      unitRef="usd">61000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <thc:LeaseLiabilityUndiscountedExcessAmount
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzgtNi0xLTEtMjkzNzEw_49396b42-ca78-4300-93fb-81954e0ffa33"
      unitRef="usd">331000000</thc:LeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzktMi0xLTEtMjkzNzEw_5db13bd7-8bea-42fa-a76b-5f79c5f70e8b"
      unitRef="usd">1253000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzktNC0xLTEtMjkzNzEw_09183d48-81a4-473d-a0e8-e19ae7d686ae"
      unitRef="usd">264000000</us-gaap:FinanceLeaseLiability>
    <thc:LeaseLiability
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzktNi0xLTEtMjkzNzEw_bd6453c0-3fd3-4aca-9f65-e9b755e16567"
      unitRef="usd">1517000000</thc:LeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEwLTItMS0xLTI5MzcxMA_95f0f268-f858-443b-997a-996c7b83a347"
      unitRef="usd">207000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEwLTQtMS0xLTI5MzcxMA_bc1f655c-c45d-4382-8305-875982f30aa0"
      unitRef="usd">99000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <thc:LeaseLiabilityCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzEwLTYtMS0xLTI5MzcxMA_becc0edf-9bd5-45e3-9e44-07000fa10ab6"
      unitRef="usd">306000000</thc:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzExLTItMS0xLTI5MzcxMA_c55691b4-0fb6-4dbc-99e8-aca5ef4dabf6"
      unitRef="usd">1046000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzExLTQtMS0xLTI5MzcxMA_9de72f78-6ce1-4c82-a1fb-1530358e765b"
      unitRef="usd">165000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <thc:LeaseLiabilityNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90YWJsZTo2MjhmNDdkNWI4Mzg0YTZkYjM2NmYzNDUwOTNiNTQ2ZS90YWJsZXJhbmdlOjYyOGY0N2Q1YjgzODRhNmRiMzY2ZjM0NTA5M2I1NDZlXzExLTYtMS0xLTI5MzcxMA_ed6d15bd-dcbb-48f7-9aca-5cb43504b232"
      unitRef="usd">1211000000</thc:LeaseLiabilityNoncurrent>
    <us-gaap:ProceedsFromSaleOfBuildings
      contextRef="ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg2MTE_d5cdb58a-2065-4c9f-9ccd-396824f4ebc1"
      unitRef="usd">147000000</us-gaap:ProceedsFromSaleOfBuildings>
    <us-gaap:GainLossOnSaleOfProperties
      contextRef="ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg3MzA_4f46ca2d-c044-4473-b61d-1471eb6d5b73"
      unitRef="usd">69000000</us-gaap:GainLossOnSaleOfProperties>
    <us-gaap:OperatingLeaseLiability
      contextRef="i59a09d299f6d4fce883b3595bf918a30_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg5NDE_953b6c82-8d06-498f-9203-3bed691caa72"
      unitRef="usd">103000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i59a09d299f6d4fce883b3595bf918a30_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTEvZnJhZzpjMGQ0NzgxNmI0Zjc0NWYzYjg5MTVjNDE3NDQ4NWNhMS90ZXh0cmVnaW9uOmMwZDQ3ODE2YjRmNzQ1ZjNiODkxNWM0MTc0NDg1Y2ExXzEwOTk1MTE2Mjg5NDE_ba93962d-80da-4d4d-8fbc-ab7d762345bd"
      unitRef="usd">103000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE0OTcz_ef6c8a91-7be2-4c29-beb8-230e918b10d7">LONG-TERM DEBT&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows our long&#x2011;term debt included in the accompanying Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior unsecured notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.750% due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.125% due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.875% due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured first lien notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% due July 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% due September 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.500% due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.875% due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.250% due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.125% due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured second lien notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.250% due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases, mortgages and other notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized issue costs and note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes and Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;10, 2021, we redeemed approximately $1.100 billion of the then&#x2011;outstanding $1.870&#160;billion aggregate principal amount of our 4.625% senior secured first lien notes due July 2024 (&#x201c;July 2024 Senior Secured First Lien Notes&#x201d;) in advance of their maturity date. We paid $1.113&#160;billion to redeem the notes, which was primarily funded with the proceeds from the sale of the Miami Hospitals in August&#160;2021. During the three months ended December&#160;31,&#160;2022, we repurchased an additional $14&#160;million of the aggregate remaining principal amount of our July 2024 Senior Secured First Lien Notes through multiple open&#x2011;market transactions. In total, we paid $13&#160;million from cash on hand during the three&#x2011;month period to repurchase the notes. In connection with these transactions, we recorded aggregate gains from early extinguishment of debt of less than $1&#160;million during the three months ended December&#160;31,&#160;2022, and a loss of $20&#160;million in the three months ended September&#160;30,&#160;2021. The loss recognized in 2021 primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#x2011;off of associated unamortized issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31,&#160;2022, we also repurchased $11&#160;million of the then $600&#160;million aggregate principal amount outstanding of our 4.625% senior secured first lien notes due September 2024 in advance of their maturity date. We made aggregate payments of $11&#160;million from cash on hand through multiple open&#x2011;market transactions to repurchase these notes. In connection with these repurchases, we recognized aggregate gains of less than $1&#160;million during the three months ended December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;15, 2022, we issued $2.000&#160;billion aggregate principal amount of 6.125% senior secured first lien notes, which will mature on June&#160;15, 2030 (the &#x201c;2030&#160;Senior Secured First Lien Notes&#x201d;). We pay interest on the 2030&#160;Senior Secured First Lien Notes semi&#x2011;annually in arrears on June&#160;15 and December&#160;15 of each year, which payments commenced in December&#160;2022. As further discussed below, we used a substantial portion of the issuance proceeds from the 2030&#160;Senior Secured First Lien Notes, after payment of fees and expenses, to finance the redemption of our 6.750% senior unsecured notes due 2023 (the &#x201c;2023&#160;Senior Unsecured Notes&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through a series of open&#x2011;market transactions during the six months ended June&#160;30,&#160;2022, we repurchased $124&#160;million aggregate principal amount outstanding of our 2023&#160;Senior Unsecured Notes using cash on hand. Following the issuance of our 2030&#160;Senior Secured First Lien Notes, we used a substantial portion of the proceeds to redeem the then-remaining $1.748&#160;billion aggregate principal outstanding of the 2023&#160;Senior Unsecured Notes in advance of their maturity date. In total, we paid $1.933&#160;billion during the six months ended June&#160;30,&#160;2022 to retire all $1.872&#160;billion aggregate principal amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding of our 2023&#160;Senior Unsecured Notes, and we recorded aggregate losses from early extinguishment of debt of $71&#160;million, primarily related to the difference between the purchase prices and the par value of the notes, as well as the write&#x2011;off of associated unamortized issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;23, 2022, we redeemed all $700&#160;million aggregate principal amount outstanding of our 7.500% senior secured first lien notes due 2025 in advance of their maturity date. We paid $730&#160;million from cash on hand to redeem the notes. In connection with the redemption, we recorded a loss from early extinguishment of debt of $38&#160;million in the three months ended March&#160;31,&#160;2022, primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#x2011;off of associated unamortized issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;1, 2021, we issued $1.450 billion aggregate principal amount of 4.375% senior secured first lien notes, which will mature on January&#160;15, 2030 (the &#x201c;2030&#160;Senior Secured First Lien Notes&#x201d;). We will pay interest on the 2030&#160;Senior Secured First Lien Notes semi&#x2011;annually in arrears on January&#160;15 and July&#160;15 of each year, which payments commended in July&#160;2022. We used the net proceeds from the issuance of the 2030&#160;Senior Secured First Lien Notes, after payment of fees and expenses, to finance the acquisition of a group of ambulatory surgery centers in December 2021 and for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;2, 2021, we issued $1.400&#160;billion aggregate principal amount of 4.250% senior secured first lien notes, which will mature on June&#160;1, 2029 (the &#x201c;2029&#160;Senior Secured First Lien Notes&#x201d;). We pay interest on the 2029&#160;Senior Secured First Lien Notes semi&#x2011;annually in arrears on June&#160;1 and December&#160;1 of each year, which payments commenced in December 2021. The proceeds from the sale of the 2029&#160;Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $1.410 billion aggregate principal amount then outstanding of our 5.125% senior secured second lien notes due 2025 (the &#x201c;2025 Senior Secured Second Lien Notes&#x201d;) in advance of their maturity date for approximately $1.428 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $31&#160;million in the three months ended June&#160;30,&#160;2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write&#x2011;off of associated unamortized issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we retired all $478&#160;million aggregate principal amount outstanding of our 7.000% senior unsecured notes due 2025 in advance of their maturity date. We paid approximately $495&#160;million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $23 million in the three months ended March&#160;31,&#160;2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write&#x2011;off of associated unamortized issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our senior secured notes are guaranteed by certain of our wholly owned domestic hospital company subsidiaries and secured by a pledge of the capital stock and other ownership interests of those subsidiaries on either a first lien or second lien basis, as indicated in the table above. All of our senior secured notes and the related subsidiary guarantees are our and the subsidiary guarantors&#x2019; senior secured obligations. All of our senior secured notes rank equally in right of payment with all of our other senior secured indebtedness. Our senior secured notes rank senior to any subordinated indebtedness that we or such subsidiary guarantors may incur; they are effectively senior to our and such subsidiary guarantors&#x2019; existing and future unsecured indebtedness and other liabilities to the extent of the value of the collateral securing the notes and the subsidiary guarantees; they are effectively subordinated to our and such subsidiary guarantors&#x2019; obligations under our senior secured revolving credit facility (as&#160;amended to date, the &#x201c;Credit Agreement&#x201d;) to the extent of the value of the collateral securing borrowings thereunder; and they are structurally subordinated to all obligations of our non&#x2011;guarantor subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indentures setting forth the terms of our senior secured notes contain provisions governing our ability to redeem the notes and the terms by which we may do so. At our option, we may redeem our senior secured notes, in whole or in part, at any time at a redemption price equal to 100% of the principal amount of the notes redeemed plus the make&#x2011;whole premium set forth in the related indenture, together with accrued and unpaid interest thereon, if any, to the redemption date. Certain series of the senior secured notes may also be redeemed, in whole or in part, at certain redemption prices set forth in the applicable indentures, together with accrued and unpaid interest. In addition, we may be required to purchase for cash all or any part of each series of our senior secured notes upon the occurrence of a change of control (as defined in the applicable indentures) for a cash purchase price of 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our senior unsecured notes are general unsecured senior debt obligations that rank equally in right of payment with all of our other unsecured senior indebtedness, but are effectively subordinated to our senior secured notes described above, the obligations of our subsidiaries and any obligations under our Credit Agreement to the extent of the value of the collateral. We may redeem any series of our senior unsecured notes, in whole or in part, at any time at a redemption price equal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to 100% of the principal amount of the notes redeemed, plus&#160;a make&#x2011;whole premium specified in the applicable indenture, if any, together with accrued and unpaid interest to the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Credit Agreement provides for revolving loans in an aggregate principal amount of up to $1.500 billion with a $200&#160;million subfacility for standby letters of credit. We amended our Credit Agreement in April 2020 to increase our borrowing availability in response to the COVID-19 pandemic. This amendment, among other things, (1)&#160;increased the aggregate revolving credit commitments from the previous limit of $1.500 billion to $1.900 billion (the &#x201c;Increased Commitments&#x201d;), subject to borrowing availability, and (2)&#160;increased the advance rate and raise limits on certain eligible accounts receivable in the calculation of the borrowing base, in each case, for an incremental period of 364&#160;days. In April 2021, we amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April&#160;2022 and reduce the interest rate margins. In March&#160;2022, we further amended our Credit Agreement to, among other things, (1)&#160;decrease the aggregate revolving credit commitments from the previous Increased Commitments to aggregate revolving credit commitments not to exceed $1.500&#160;billion, subject to borrowing availability, (2)&#160;extend the scheduled maturity date to March&#160;16,&#160;2027, and (3)&#160;replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) and Daily&#160;Simple&#160;SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At December&#160;31,&#160;2022, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.500&#160;billion was available for borrowing at December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding revolving loans accrue interest depending on the type of loan at either (a)&#160;a base rate plus an applicable margin ranging from 0.25% to 0.75% per annum or (b)&#160;Term SOFR, Daily Simple SOFR or the Euro Interbank Offered Rate (EURIBOR) (each, as defined in the Credit Agreement) plus an applicable margin ranging from 1.25% to 1.75% per annum and (in the case of Term SOFR and Daily Simple SOFR only) a credit spread adjustment of 0.10%, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible inventory and accounts receivable, including self&#x2011;pay accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obligations under the Credit Agreement continue to be guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and secured by a first&#x2011;priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Letter of Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a letter of credit facility (as amended to date, the &#x201c;LC Facility&#x201d;) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200&#160;million. The scheduled maturity date of the LC Facility is September&#160;12,&#160;2024. Obligations under the LC Facility are guaranteed and secured by a first&#x2011;priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal&#x2011;ranking basis with our senior secured first lien notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within three business days after notice thereof accrue interest at a base rate plus a margin of 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured&#x2011;debt&#x2011;to&#x2011;EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit accrues at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. The LC Facility is subject to an effective maximum secured debt covenant of 4.25 to 1.00. At December&#160;31,&#160;2022, we had $116&#160;million of standby letters of credit outstanding under the LC&#160;Facility and were in compliance with all applicable covenants and conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The indentures governing our senior secured notes contain covenants that, among other things, restrict our ability and the ability of our subsidiaries to incur liens, consummate asset sales, enter into sale and lease&#x2011;back transactions or consolidate, merge or sell all or substantially all of our or their assets, other than in certain transactions between one or more of our wholly owned subsidiaries. These restrictions, however, are subject to a number of exceptions and qualifications. In particular, there are no restrictions on our ability or the ability of our subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities). In addition, the indentures governing our senior secured notes contain a covenant that neither we nor any of our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsidiaries will incur secured debt, unless at the time of and after giving effect to the incurrence of such debt, the aggregate amount of all such secured debt (including the aggregate principal amount of senior secured notes outstanding and any outstanding borrowings under our Credit Agreement at such time) does not exceed the amount that would cause the secured debt ratio (as defined in the indentures) to exceed 4.00 to 1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The indentures governing our senior unsecured notes contain covenants and conditions that have, among other requirements, limitations on (1)&#160;liens on &#x201c;principal properties&#x201d; and (2)&#160;sale and lease&#x2011;back transactions with respect to principal properties. A principal property is defined in the senior unsecured notes indentures as a hospital that has an asset value on our books in excess of 5% of our consolidated net tangible assets, as defined in such indentures. The above limitations do not apply, however, to (1)&#160;debt that is not secured by principal properties or (2)&#160;debt that is secured by principal properties if the aggregate of such secured debt does not exceed 15%&#160;of our consolidated net tangible assets, as further described in the indentures. The senior unsecured notes indentures also prohibit the consolidation, merger or sale of all or substantially all assets unless no event of default would result after giving effect to such transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Our Credit Agreement contains customary covenants for an asset&#x2011;backed facility, including a minimum fixed charge coverage ratio to be met if the designated excess availability under the revolving credit facility falls below $150 million, as well as limits on debt, asset sales and prepayments of certain other debt. The Credit Agreement also includes a provision, which we believe is customary in receivables&#x2011;backed credit facilities, that gives our lenders the right to require that proceeds of collections of substantially all of our consolidated accounts receivable be applied directly to repay outstanding loans and other amounts that are due and payable under the Credit Agreement at any time that unused borrowing availability under the revolving credit facility is less than $150 million for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODY4_dfdfd5fb-468c-4e0d-afdb-50499803685f"&gt;three&lt;/span&gt; consecutive business days or if an event of default has occurred and is continuing thereunder. In that event, we would seek to re&#x2011;borrow under the Credit Agreement to satisfy our operating cash requirements. Our ability to borrow under the Credit Agreement is subject to conditions that we believe are customary in revolving credit facilities, including that no events of default then exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Future Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future long&#x2011;term debt maturities, including finance lease obligations were as follows as of December&#160;31,&#160;2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Later Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE0OTc4_12ece894-ae51-4839-b81f-ca4f581f0701">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows our long&#x2011;term debt included in the accompanying Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior unsecured notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.750% due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.125% due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.875% due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured first lien notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% due July 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% due September 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.500% due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.875% due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.250% due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.125% due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured second lien notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.250% due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases, mortgages and other notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized issue costs and note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i622ee28e9f1e42d7aff972d73252f4c8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzMtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZmY2NTkyZTNmMDlmNDIzNDhhM2E4MDViYmU2MjBiZTNfNQ_53c299eb-4fee-43bc-a119-4b62584acad6"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i622ee28e9f1e42d7aff972d73252f4c8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzMtMS0xLTEtMjkzNzEw_7f8e92d8-f552-44db-bf43-53f109a5535a"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifae6361bfece4d29965dd05a7c7809e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzMtMy0xLTEtMjkzNzEw_55683043-81b3-4888-9e53-e95737704e6e"
      unitRef="usd">1872000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if8a7e36b94de4011b826c46271390423_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzUtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZWEzYjJjNzJlOTZlNGNlNmFkZjBkMWZjNDlhY2NjM2FfNQ_be54f922-5973-4c86-8523-595a6f84e24a"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if8a7e36b94de4011b826c46271390423_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzUtMS0xLTEtMjkzNzEw_6ed72f92-a903-4c5e-a136-a76d144ad61e"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id4fb3c83283242f6bee137da54776fec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzUtMy0xLTEtMjkzNzEw_88bfcd99-876b-4a04-a3a8-82122d609b42"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i20c821a80a1b41029dc25c50b51dfcea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzYtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246MzczNDAyY2JiZmIyNDNkNDlmNThkM2JjZDM4NTQ3ZDZfNQ_5d68e1c0-d4f5-4d9d-8c5d-61266cbf66d6"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i20c821a80a1b41029dc25c50b51dfcea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzYtMS0xLTEtMjkzNzEw_c1602abf-859e-4b1b-87f0-039090075e9f"
      unitRef="usd">362000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8871456e17fc4ba49fffcdcb23ed7b71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzYtMy0xLTEtMjkzNzEw_d69ba4b1-8874-42ad-9892-a4e487310bcc"
      unitRef="usd">362000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzgtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDAzZmNhMDkzYWU4NDcwNThiNWM3MzU4N2U0YzgwZjRfNQ_455ad357-c451-4baf-bd73-ac3c16410fb4"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzgtMS0xLTEtMjkzNzEw_934256e8-3ac0-48c6-9d73-ba162edda7e2"
      unitRef="usd">756000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i989bb5295fc74ba1aa10f7543aab0c09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzgtMy0xLTEtMjkzNzEw_03a2f41e-e1ea-48a5-89d4-44a2e186a6cc"
      unitRef="usd">770000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzktMC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDVkMWI2YTRhNDVkNGI2YmJlOWZhNGI2YTIxMDEzNzVfNQ_f3379321-9c31-40a3-b4ef-2707fd65341e"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzktMS0xLTEtMjkzNzEw_63f79986-c8a1-4d1d-859e-d415ba73c3ee"
      unitRef="usd">589000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0da8add6a93946079dd9bfbe6ba2763c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzktMy0xLTEtMjkzNzEw_4fc1f93e-c80f-4e4b-b4d8-14d0b90a82c5"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57788fd689bc47bd813aec1a0ef11ee5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEwLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjRlMDQxYzhiMDk3ZTQyMDBiNmE2ZTBiN2E0OWFiOWZkXzU_51a20b15-b47f-4c68-a940-fd3435a58495"
      unitRef="number">0.07500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i57788fd689bc47bd813aec1a0ef11ee5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEwLTEtMS0xLTI5MzcxMA_37af0169-7ea2-4a78-b677-1112d2f4fc2d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id060c1c1b2764c1bb2759e725cf12295_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEwLTMtMS0xLTI5MzcxMA_deb20864-2b2c-43ba-8cf4-18fa9fcbe303"
      unitRef="usd">700000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifde641ba54514fa09690f87fa89673d3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzExLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjE5NmViMWQzYmE3OTQ4MmFiMDY5OWIzNDBmNmFjZDQ0XzU_01d8dd46-0c25-47db-8359-2865035df752"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifde641ba54514fa09690f87fa89673d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzExLTEtMS0xLTI5MzcxMA_0a0bc0f2-5c93-42ad-a1bb-5150abd3735b"
      unitRef="usd">2100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i697cb82b913848f2b26b5f92fc37e35e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzExLTMtMS0xLTI5MzcxMA_59684d17-562e-4f54-b881-1a4aafeeb460"
      unitRef="usd">2100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i461c58e253f64f09a6ac5dc3c2784b82_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEyLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjNhMjQ5M2EwMjAzZDQxZDk5ZTI0NWNmOTkzMWJmZjgyXzU_fb69d99e-8dbb-4f2b-9d1f-c0fc3f7a4d54"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i461c58e253f64f09a6ac5dc3c2784b82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEyLTEtMS0xLTI5MzcxMA_46340130-bd27-4702-b9a1-e8176978bced"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5404c8f217424e06babd62544ad4b7b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEyLTMtMS0xLTI5MzcxMA_aee2ab3f-ae6b-4dcd-9a72-3ab3d641542c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i558c5a218dd0455d853b5f0e68d8b7c6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEzLTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmU4Y2NmZWY2ZWM5YzQ4NDBhY2NlZjQ4NzdmNDM2Yjk4XzU_3b4a7330-19b8-479e-b522-8f5a32fd4777"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i558c5a218dd0455d853b5f0e68d8b7c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEzLTEtMS0xLTI5MzcxMA_87a6d680-18ed-43a8-915b-de935c9bf3fa"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4afeea9e0df44876bc52904d8d7057fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzEzLTMtMS0xLTI5MzcxMA_ab14fc4b-fb7c-4058-aa24-6f1cd820a9f5"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id17f96184b5f4ebd8db51025fe3377c6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE0LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjFiYTNiYTlmZDM2NDRmMWY5MzdlYzdhZTAyZTg2YTU3XzU_955c14f8-1974-4358-8aa6-03548d0ce111"
      unitRef="number">0.04250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id17f96184b5f4ebd8db51025fe3377c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE0LTEtMS0xLTI5MzcxMA_a973d900-ffb5-403c-b8dc-1d1081f89509"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib5599a9535d841a28d1c1e4b3ced46aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE0LTMtMS0xLTI5MzcxMA_1674397f-0cbb-4b46-a6d5-0443bed0e2f9"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d9b9cf6618c4aa6afd0b5bc92c8b85d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOjc5ZjBhZjM0ZDM5OTQ5MGNhZTVmNmIzYzY4OTIwYzlkXzQ_08be3e5b-ea73-433c-be79-917bb0315657"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d9b9cf6618c4aa6afd0b5bc92c8b85d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTEtMS0xLTI5MzcxMA_b95c66b5-7754-4d18-8738-762453ce4186"
      unitRef="usd">1450000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifa72f8375f37499d86f928b68dff6f53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTMtMS0xLTI5MzcxMA_d13037dc-5363-4af0-a70e-3ca6350a23d7"
      unitRef="usd">1450000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i186d8e5c6032427baa46b10be1424d87_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTAtMS0xLTMxNjkwMS90ZXh0cmVnaW9uOjcxNzljYzVjZjcxMjQyNjE4OGU0OGMzOWRiMzYzZTBjXzEwOTk1MTE2Mjc4MTk_f29f544c-11e8-46a3-9556-db5ce1a5b7db"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i186d8e5c6032427baa46b10be1424d87_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTEtMS0xLTM0MzQwNQ_10e38e7d-b819-4392-8dec-cd64e677b404"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7fba8ba8429243958c7942852541472e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE1LTMtMS0xLTM0MzQwOQ_c1c1bc71-3557-4429-b850-243577730dba"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic0cb767709934643ac30a4e91dd1c63f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE4LTAtMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmIxYWVlNzcyMGE4MDRiZDRhODBmNTFmNGU1Yjc3MjJhXzU_cfa975ea-6304-45eb-9b7b-0da8e96806a6"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic0cb767709934643ac30a4e91dd1c63f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE4LTEtMS0xLTI5MzcxMA_d7c4f4a6-526d-4e7c-bf2d-a1e4df400e65"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3540a60419084118bc740136b6cb62d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE4LTMtMS0xLTI5MzcxMA_94680902-0f5a-491d-8264-48a66daa1f2f"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <thc:FinanceLeasesAndMortgageNotes
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE5LTEtMS0xLTI5MzcxMA_49b4c860-39fd-43c9-944c-eecf52917378"
      unitRef="usd">453000000</thc:FinanceLeasesAndMortgageNotes>
    <thc:FinanceLeasesAndMortgageNotes
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzE5LTMtMS0xLTI5MzcxMA_57abe79e-ffab-44a7-9675-4e014710eb74"
      unitRef="usd">443000000</thc:FinanceLeasesAndMortgageNotes>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIwLTEtMS0xLTI5MzcxMA_bbd13d66-2513-49ef-a787-2f6d44fd7161"
      unitRef="usd">131000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIwLTMtMS0xLTI5MzcxMA_74e3cef6-b2b5-48a3-9fa7-2a9dcb170c5a"
      unitRef="usd">151000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIxLTEtMS0xLTI5MzcxMA_a2e03732-79ef-49b8-8a9d-a12bee10c9f2"
      unitRef="usd">15079000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIxLTMtMS0xLTI5MzcxMA_a53e4089-1bc3-4fb9-b732-cea16e5de4a8"
      unitRef="usd">15646000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIyLTEtMS0xLTI5MzcxMA_10a37ee8-41ed-47c0-9181-7e19162524bf"
      unitRef="usd">145000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIyLTMtMS0xLTI5MzcxMA_b72bbf50-cd63-4fea-af7c-13528de5a57d"
      unitRef="usd">135000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIzLTEtMS0xLTI5MzcxMA_f33ab3b4-fc48-4255-a61b-1c07263ea4f5"
      unitRef="usd">14934000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTplNDkwN2VmNzY0MTE0NDExODcxZGYyOThkNzFlOTNkNi90YWJsZXJhbmdlOmU0OTA3ZWY3NjQxMTQ0MTE4NzFkZjI5OGQ3MWU5M2Q2XzIzLTMtMS0xLTI5MzcxMA_0726efa2-e7be-4c1b-b879-4e789bd0a24b"
      unitRef="usd">15511000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc0MzI_1bea6ae4-77c8-4bcb-bf49-7700044bbf5e"
      unitRef="usd">1100000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc0NjA_281133dd-6c1d-4d3f-af8e-c4dc4e74947e"
      unitRef="usd">1870000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefdcd65138ae4d1ab6955c4e14be7fd1_I20210910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEzNA_9bd230ec-51f0-4a97-84e4-a2942013c11b"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i7488113b2f8a4008a0c1e41e64bbaa8d_D20210910-20210910"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc2MzE_ff3a6ea7-2555-4169-b3b2-3be5490797ce"
      unitRef="usd">1113000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i7e404e8dede8423aa86b1c4c0e1f3f1f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc3OTg_1446c227-a3ff-416d-9014-2873572700ba"
      unitRef="usd">14000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i49c0fd70eca44c388aba457549bc1bde_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTc5MTg_d48bfb2a-6cf4-4706-bb5c-285c6ca9d6d5"
      unitRef="usd">13000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i49c0fd70eca44c388aba457549bc1bde_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTgxMTM_91561f09-9e52-40ed-8f24-8b6d9de13cd7"
      unitRef="usd">1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i95369c42fa7c411bb4958a0409bc9c80_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTgxODE_934e1f87-5d2b-446e-9a74-6df38d82dcf4"
      unitRef="usd">-20000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg0NzY_ef6011c8-a5ff-40d6-a2bf-64ce3714c679"
      unitRef="usd">11000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg0OTI_0926b00d-08dc-469b-95be-64dffc5aa56e"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b09f2c0b00a46fd93e77c46515311ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEzOQ_48a40cb2-137a-4b06-94ab-22023ad60fcb"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="i5db931c86fe147d399a5218e8787b348_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzNzc1NA_a3eb42fe-bdfe-4bbb-b568-5eb9a7f534c6"
      unitRef="usd">11000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5db931c86fe147d399a5218e8787b348_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg4MjM_5351a264-79cf-4e23-9dfc-71b0dfc6267d"
      unitRef="usd">1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5426987ed148420cbbfa4a0f0d7a191f_I20220615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTg4ODA_1262c21e-1513-489d-9cd8-8d67cb298a2a"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5426987ed148420cbbfa4a0f0d7a191f_I20220615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEyNw_d94223ea-becc-4a3a-be13-4cc68890fd2e"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifa8cce4fc2f848a2857f83e50a08eb16_I20220615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODExOQ_daaf284c-924a-4bc0-9ab0-94dcef8fc7f6"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="id84fa693c2024155b0b1075bd91a66e2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk0ODc_20ff16a6-6bd5-4210-9cd5-d94c8bb8796b"
      unitRef="usd">124000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id84fa693c2024155b0b1075bd91a66e2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk2NzE_1250244d-9031-4ae4-a4d4-b367b88034d9"
      unitRef="usd">1748000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk3NzE_44aae5a4-22b6-453e-8106-88173045a7d6"
      unitRef="usd">1933000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk4MzE_36f7daa3-fb8c-4e05-8d8d-763a047bf787"
      unitRef="usd">1872000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2bf71e3a580144318a4bfebc892fefab_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NTk5NTY_985f1602-fb12-4866-a016-0d3c9307c2b3"
      unitRef="usd">-71000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="iac8320d1db684d2e978228570390fbbc_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjAxNDg_cb072daa-77e8-4924-8140-c76abd3f6570"
      unitRef="usd">700000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iac8320d1db684d2e978228570390fbbc_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODEyMw_16753042-2888-4849-871f-bdf6d0e6faa3"
      unitRef="number">0.07500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0b4c256aea654f0e81f827e0120eeca0_D20220223-20220223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjAyODY_592e074a-e82c-4317-84ed-1e59c0022e6a"
      unitRef="usd">730000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i774268ee073042e296346aebdcefdf00_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjA0MjA_8a53b6d9-9a09-460d-b848-b4cafb297c93"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i38e3f3971b45492ebda95c4159ea5bed_I20211201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjA2NDY_03ba3092-61bd-4c15-883a-2ea036e17c0f"
      unitRef="usd">1450000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38e3f3971b45492ebda95c4159ea5bed_I20211201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjA2ODA_b1f3d4cd-d1f3-4e26-b76f-ebdeb195733a"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7daa6cd1b7be473ba7d7f3897a209175_I20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjExMjQ_e528449d-5a8b-48f4-bdeb-a6f13e4cfc4d"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7daa6cd1b7be473ba7d7f3897a209175_I20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjExNTg_eaa26c8d-04d0-4c52-b013-a3baf98da78a"
      unitRef="number">0.04250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ic0d2bb14dafb425e9e73ab20986d8aba_I20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE1MjY_8559cbe8-2f2c-4634-a735-0ffc58c3c11e"
      unitRef="usd">1410000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic0d2bb14dafb425e9e73ab20986d8aba_I20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE1ODE_ad5447c1-8c4c-40c2-951c-d0ed4329aef5"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i216bb1419f01411cbe289ef91b5d9301_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE3MjU_c4076836-d9f8-48ce-be63-169e36fe1059"
      unitRef="usd">1428000000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia74c040bcaea4ecfa1841b613ea39e5b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjE4MzU_9df8e452-6f7d-4e79-ad47-9db74ffff7ef"
      unitRef="usd">-31000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="icd0319d75b304db7a61ce7e8160119f5_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIwNjM_1e0983ee-76f5-4cdf-b306-331806acb5f3"
      unitRef="usd">478000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd0319d75b304db7a61ce7e8160119f5_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIxMTM_5869fa6d-4177-4a21-8f31-70a9d7e74bd6"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6f3bda72356c4c8a90a164544fdb3419_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIyMDU_6beb377a-574e-45ed-82d8-49c04395b54c"
      unitRef="usd">495000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6f3bda72356c4c8a90a164544fdb3419_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjIzMzk_ff59b090-8659-4e8c-944c-4d126ee203d5"
      unitRef="usd">-23000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjQwNzM_26cc5424-b263-4b26-8f5c-42db58439abe"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <thc:DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal
      contextRef="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjQ2OTQ_c6190f82-652b-43a9-bca2-6e396b666b04"
      unitRef="number">1.01</thc:DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i5f385f61e4a549d18f6b539609e43283_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE2NDkyNjc1NjUyNjU_aad2e7b9-ab01-4ead-9358-1faddbd27e03"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODUxODE_160901f3-ba1d-4e9c-92bf-327b74111b30"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <thc:LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity
      contextRef="i58fa2d207abf4c7d930128ada13635f8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzU0OTc1NTkzODE0NA_56c26c2a-c916-4f46-aac1-1c194570b20d"
      unitRef="usd">200000000</thc:LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8d1634d5e5c74227b8cb258fc3071474_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODUxOTQ_e71ccc20-f130-4336-b5d3-4d0e5c00f51c"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i85c9953574604a679693fb09557caf2c_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzUyNw_35ae8b85-fa3c-41ee-9691-44d7b0f221f0"
      unitRef="usd">1900000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <thc:PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised
      contextRef="ib14f1fc180e441e2a02f1e6258051ea9_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzc3Mw_86dd520d-8c68-4bd9-847e-0f886839dcb3">P364D</thc:PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ied39b398e82143dbad504e93ddad6c70_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3NTE5MTY_3e95f10a-7a0e-4b1d-85a9-858a1d82b9f3"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzkzNg_a8d2b112-9589-48ea-b873-9898b86e2d07"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i58fa2d207abf4c7d930128ada13635f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwMDk_b66ae070-417e-4f90-ac25-cd3d9be135c0"
      unitRef="usd">1000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwODk_1661188f-b28b-434d-89de-51f640be493e"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie79724e46f9345fbb6283e854762c21b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwMzU_beed9f72-cedb-454a-9e67-426b4e38abb3"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icbde1cbd711b43aab8f621cc2b3b071d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwMzk_7fa01c88-4b90-49d8-bb4a-62a09e9bc424"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib4470e4393114d6aa39323d7ec6f963f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNDM_52a30c2b-d649-4526-8c36-3c272cf5701b"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if4d759b6ae6a43f7a40e0ef19d9f025e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNDc_220648de-f5db-4486-9cdb-607198cdd951"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <thc:DebtInstrumentBasisSpreadOnCreditSpread
      contextRef="i339dc68a43b14d1cb043fb9d9e7bc4bd_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNTE_ce2e474a-68ca-4eaf-8b9a-598bf1e38447"
      unitRef="number">0.0010</thc:DebtInstrumentBasisSpreadOnCreditSpread>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i5976155b721e4588af99404df30450c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNTk_cf4a9a50-ad6b-4e29-8e99-27aa253a2fcf"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i289e59d55e724f6d816c0df9b3f788d7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2ODkwNjM_9ebc34a7-01e2-451e-ae0f-c63dc7edcb68"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTQzNTI_1d70a1a5-99c6-4ba9-b0dc-abcd07db7a76"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <thc:NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings
      contextRef="icee7731e045f45ceb6027185e10efdf4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIxOTY_e9772911-83e9-4a45-9bee-593be48944dc"
      unitRef="day">3</thc:NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i807623c3e0804c008f81fdd3f1dfa3fd_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIyODM_1781b243-f582-4fc5-a66c-72134fed0956"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i03c60d6ea9404c3ab4509a64a435d111_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIzNTY_8d16915c-10fb-4945-b800-600220646153"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="icee7731e045f45ceb6027185e10efdf4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTIzODg_555067ad-6daf-4639-b18a-500070a376da"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <thc:DebtInstrumentCovenantSecuredDebtToEbitdaRatio
      contextRef="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI0NTg_2cc8ba9d-d1a4-49b4-b6bc-00e32724c7a6"
      unitRef="number">3.00</thc:DebtInstrumentCovenantSecuredDebtToEbitdaRatio>
    <thc:DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit
      contextRef="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI2MDc_5a7a22f1-aae6-4310-969b-38f3ad967645"
      unitRef="number">0.0150</thc:DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit>
    <thc:DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage
      contextRef="icb0e67f8c1f94a7797a4fcc2c92d07f3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI2NDc_04e73db5-6e56-4991-b744-24db72389aab"
      unitRef="number">0.00125</thc:DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage>
    <thc:DebtInstrumentCovenantMaximumSecuredDebtRatio
      contextRef="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTI4Njg_71c50ab5-35d4-4721-b6fe-26b4c5466b70"
      unitRef="number">4.25</thc:DebtInstrumentCovenantMaximumSecuredDebtRatio>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib72f3e9f54b244d0a3ffb51d8495277f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE2OTQ5NTg_52f25054-bd30-4320-bac3-21ab78a1d4f4"
      unitRef="usd">116000000</us-gaap:LettersOfCreditOutstandingAmount>
    <thc:DebtInstrumentCovenantsOfSecuredDebtRatio
      contextRef="i6f2bd835c2ea41418922c21a022a0229_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3MDY2ODc_4a2db3fc-6db3-4761-9de7-2330dfae8e90"
      unitRef="number">4.00</thc:DebtInstrumentCovenantsOfSecuredDebtRatio>
    <thc:DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty
      contextRef="i13f604ea7a86499fbbfbc12bc96eb817_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3MDcxMTI_45d6d14d-dc3e-4e07-87ce-78703f010b07"
      unitRef="number">0.05</thc:DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty>
    <thc:DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty
      contextRef="i8f47cf0048e74feb8f6625b5de6e4a56_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzEwOTk1MTE3MDczOTY_466b6ae0-fb68-4ed2-a7ae-d0751b41b9dd"
      unitRef="number">0.15</thc:DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty>
    <thc:LineOfCreditFacilityCovenantThresholdLimit
      contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExMzQx_7ebdbc71-07cd-4304-82a9-d42c7668cdc9"
      unitRef="usd">150000000</thc:LineOfCreditFacilityCovenantThresholdLimit>
    <thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit
      contextRef="ia9b5cdc03d684d6482fb83737a2e28b0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzExODYx_ae013867-a880-4619-af56-e88611e7e246"
      unitRef="usd">150000000</thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90ZXh0cmVnaW9uOjdiMjIzZmEyZDA3ZDRhNDA4OTI5MmExOWUzNzAyMzBjXzE0OTgw_85f9437f-25da-44f4-a32a-dcf24501825a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future long&#x2011;term debt maturities, including finance lease obligations were as follows as of December&#160;31,&#160;2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Later Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMS0xLTEtMjkzNzEw_a846446f-3776-4ab7-82dc-e3f8df653c65"
      unitRef="usd">15210000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMy0xLTEtMjkzNzEw_4c1eef57-bc87-4fa7-87bb-7cf0f7b81787"
      unitRef="usd">145000000</thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths>
    <thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItNS0xLTEtMjkzNzEw_12825ed7-6b3b-4742-8eae-7b837f03dd0d"
      unitRef="usd">1463000000</thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo>
    <thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItNy0xLTEtMjkzNzEw_e1becbf3-e8af-476c-b0fd-c0192d8e8db4"
      unitRef="usd">77000000</thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree>
    <thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItOS0xLTEtMjkzNzEw_66ccde77-6e2a-444b-98a9-4859dbb64314"
      unitRef="usd">2143000000</thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour>
    <thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMTEtMS0xLTI5MzcxMA_74017115-0ee1-41ea-b166-e8d1028458ec"
      unitRef="usd">3012000000</thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive>
    <thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTQvZnJhZzo3YjIyM2ZhMmQwN2Q0YTQwODkyOTJhMTllMzcwMjMwYy90YWJsZTowYmYyNmIxMjgyODA0YTExODk5ODgwY2MyM2M5MWFhNC90YWJsZXJhbmdlOjBiZjI2YjEyODI4MDRhMTE4OTk4ODBjYzIzYzkxYWE0XzItMTMtMS0xLTI5MzcxMA_082c4a21-f88a-48dc-9536-c69fbed1c664"
      unitRef="usd">8370000000</thc:LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:GuaranteesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzE2OTU_224fb97a-e743-4f45-823d-aa9aec46023d">GUARANTEES&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with our policy on physician relocation and recruitment, we provide income guarantee agreements to certain physicians who agree to relocate to fill a community need in the service area of one of our hospitals and commit to remain in practice in the area for a specified period of time. Under such agreements, we are required to make payments to the physicians in excess of the amounts they earn in their practices up to the amount of the income guarantee. The income guarantee periods are typically 12 months. If a physician does not fulfill his or her commitment period to the community, which is typically three years subsequent to the guarantee period, we seek recovery of the income guarantee payments from the physician on a prorated basis. We also provide revenue collection guarantees to hospital&#x2011;based physician groups providing certain services at our hospitals with terms generally ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkyNA_42d833b7-adcf-4193-8432-f964517997d1"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital&#x2011;based physician groups providing certain services at our hospitals was $164 million. We had a total liability of $143 million recorded for these guarantees included in other current liabilities in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $102&#160;million. Of the total, $25&#160;million relates to the obligations of consolidated subsidiaries, which obligations were recorded in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
    <thc:GuaranteeObligationPeriod
      contextRef="i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzUzNA_f86f119c-503f-46ae-8f5d-e12ce01e4756">P12M</thc:GuaranteeObligationPeriod>
    <thc:CommitmentPeriod
      contextRef="i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzYzNg_3b524e49-8e60-46ac-b710-75ab94e43556">P3Y</thc:CommitmentPeriod>
    <thc:GuaranteeObligationPeriod
      contextRef="i2f0abb0a0e4a43e4bd6e824ef8f0e3b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzkzMA_73e9f633-e4f1-4d8d-a6e0-a80828fe0c2a">P3Y</thc:GuaranteeObligationPeriod>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="i0fdd924a274f443fa92ca5c6423bdc2e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzExNzk_ea2447ee-8731-4676-bba2-884ff8e98a5e"
      unitRef="usd">164000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuaranteesFairValueDisclosure
      contextRef="ic3bc6670142a4e808c1316df2aec4f4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzEyMTE_4e19f6d2-8129-439c-b00b-246453c95170"
      unitRef="usd">143000000</us-gaap:GuaranteesFairValueDisclosure>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="i43dba714bb6f47bcba5217f722e33680_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzE1Mjk_6c2de80a-0256-4c2c-b2b0-e5405a026fad"
      unitRef="usd">102000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <thc:GuaranteeObligationCarryValueConsolidatedSubsidiaries
      contextRef="ic0e89a0a42d34e7386bbd6bcb26e395d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMTcvZnJhZzpkMzRkNWM5Y2Y1N2M0ZDYwOGRmZDFhYTAyMTgyYjYzNS90ZXh0cmVnaW9uOmQzNGQ1YzljZjU3YzRkNjA4ZGZkMWFhMDIxODJiNjM1XzE1NDc_bd5aac32-9856-4724-a77c-92f961588abf"
      unitRef="usd">25000000</thc:GuaranteeObligationCarryValueConsolidatedSubsidiaries>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODk3_61b82d96-d268-44d3-9341-9daf48060558">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted stock options and restricted stock units (&#x201c;RSUs&#x201d;) to certain of our employees and directors pursuant to our stock incentive plans. Stock options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years&#160;from the date of grant. An RSU is a contractual right to receive one share of our common stock in the future, and the fair value of the RSU is based on our share price on the grant date. Typically, stock options and time&#x2011;based RSUs vest one&#x2011;third on each of the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_0c2fc9bb-b93d-4b06-840f-178792b3529d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzYwOQ_1d18318b-f1d8-462d-93f9-2c3eaf3de351"&gt;three&lt;/span&gt;&lt;/span&gt; anniversary dates of the grant; however, certain special retention awards may have different vesting terms. Shares underlying vested RSUs are generally distributed to participants (settled) immediately after the vesting date. In addition, grants of RSUs to our non&#x2011;employee directors as part of their annual compensation vest immediately and are settled on the third anniversary of the date of grant, while initial grants to directors vest immediately but settle upon separation from the board. Compensation cost is measured by the fair value of the awards on their grant dates and is recognized over the requisite service period of the awards, whether or not the awards had any intrinsic value during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also grant performance&#x2011;based RSUs that vest subject to the achievement of specified performance goals within a specified time frame. The performance&#x2011;based RSUs may contain provisions that increase or decrease the number of RSUs that ultimately vest, depending upon the level of achievement. For certain of our performance&#x2011;based awards, the number of options or RSUs that ultimately vest is also subject to adjustment based on the achievement of a market&#x2011;based condition. These adjustments generally range from 0% to 200% of the number of RSUs initially granted. The fair value of awards that contain a market&#x2011;based condition is estimated using a discrete model to analyze the fair value of the subject shares. The discrete model utilizes multiple stock paths, through the use of a Monte Carlo simulation, which paths are then analyzed to determine the fair value of the subject shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of our stock&#x2011;based compensation plans, awards granted under the plan vest and may be exercised as determined by the human resources committee of our board of directors. In the event of a change in control, the human resources committee of our board of directors may, at its sole discretion without obtaining shareholder approval, accelerate the vesting or performance periods of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, assuming outstanding performance&#x2011;based stock options and RSUs for which performance has not yet been determined will achieve target performance, approximately 9.5&#160;million shares of common stock were available under our 2019 Stock Incentive Plan for future stock option grants and other equity incentive awards, including RSUs. The accompanying Consolidated Statements of Operations include pre-tax compensation costs related to our stock&#x2011;based compensation arrangements of $56&#160;million for each of the years ended December&#160;31,&#160;2022 and 2021, respectively, and $44&#160;million for the year ended December&#160;31,&#160;2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg&lt;br/&gt;Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160;Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(987,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;460,947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock options were granted during the years ended December&#160;31,&#160;2022, 2021 or 2020. There were 60,051, 391,533 and 987,471 stock options exercised during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The stock options exercised in 2022 had an aggregate intrinsic value of approximately $4 million, and options exercised during 2021 and 2020 both had aggregate intrinsic values of approximately $15&#160;million. All outstanding options were vested and exercisable at December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about our outstanding stock options at December&#160;31,&#160;2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding and Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&#160;of&#160;Exercise&#160;Prices&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.99 to $20.609&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.61 to $35.430&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;460,947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, 42.3% of all our outstanding options were held by current employees and 57.7% were held by former employees. All of our outstanding options were in&#x2011;the&#x2011;money, that is, they had exercise price less than the $48.79 market price of our common stock on December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation costs related to our stock-based compensation arrangements for the years ended December&#160;31,&#160;2021 and 2020 included $1 million and $2 million, respectively, of expense related to our stock options. We did not recognize any expense related to our stock options during the year ended December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Grant Date&#160;Fair&lt;br/&gt;Value&#160;Per&#160;Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,767,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,095,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(765,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,187,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,520,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2022, we granted an aggregate of 641,205&#160;RSUs. Of these, 237,381 will vest ratably over a three&#x2011;year period from the grant date, 53,716 RSUs that were scheduled to vest ratably over 11 quarterly periods, 9,215 will vest ratably over a four&#x2011;year period from the grant date, 4,608 will vest on the second anniversary of the grant date, and 6,170 will vest evenly on the third and fourth anniversaries of the grant date. We also granted 35,482&#160;RSUs to our non&#x2011;employee directors for the 2022-2023 board service year, which units vested and will settle as described above. In November 2022, we granted 7,325 to a non-executive member of the board of directors for their service as chairman of the board through the end of 2023. Unlike our normal grants to board members, these RSUs will vest on December&#160;31,&#160;2023 if the grantee serves as chairman through that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we granted 287,308&#160;performance&#x2011;based RSUs during the year ended December&#160;31,&#160;2022; the vesting of these RSUs is contingent on our achievement of specified performance goals for the years 2022 to 2024. Provided the goals are achieved, the performance&#x2011;based RSUs will vest on the third anniversary of the grant date. The actual number of performance&#x2011;based RSUs that could vest will range from 0% to 200% of the 287,308&#160;units granted, depending on our level of achievement with respect to the performance goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2021 we granted 561,788 RSUs that vest based on the passage of time. The granted RSUs vest as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;263,180 RSUs vest and settle ratably over a three&#x2011;year period from the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;189,215 RSUs vest and settle ratably over eight quarterly periods from the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;53,341 RSUs vest and settle on the fourth anniversary of the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;33,351 RSUs vest and settle on the third anniversary of the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;14,192 RSUs vested on December&#160;31,&#160;2021 and settled in January 2022; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;8,509 RSUs, one-third of which vest and settle on the second anniversary of the grant date and the remainder of which vest and settle on the fourth anniversary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2021 we granted 298,492 performance-based RSUs which vest as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;244,259 RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;53,341 RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2025; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;892 RSUs vested and settled immediately as a result of our level of achievement with respect to performance&#x2011;based RSUs granted in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actual number of performance&#x2011;based RSUs that could vest will range from 0% to 200% of the 297,600 RSUs which did not vest immediately, depending upon our level of achievement with respect to the performance goals. During the year ended December&#160;31,&#160;2021, we also granted 39,738 RSUs to our non&#x2011;employee directors. These consisted of 36,681 RSUs for the 2021&#x2011;2022 board service year, 1,372 for an initial grant to a new member of our board of directors and 1,685 for a pro&#x2011;rata annual grant to the same new member. While RSUs granted to our board of directors vest immediately, annual grants settle on the third anniversary of the grant date and initial grants settle upon separation from the board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2020 we granted 1,084,883 RSUs that vest based on the passage of time. The granted RSUs vest as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;607,198 RSUs vest and settle ratably over a three&#x2011;year period from the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;359,713 RSUs vest and settle ratably over 11 quarterly periods from the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;104,167 RSUs vest and settle ratably over a four-year period from the grant date; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;13,805 RSUs vest and settle on the third anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2020 we granted 579,413 performance-based RSUs which vest as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;499,285 RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2022 and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:49.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;80,128 RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2023, all of which were subsequently forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actual number of performance&#x2011;based RSUs that could vest will range from 0% to 200% of the 499,285 remaining RSUs granted, depending upon our level of achievement with respect to the performance goals. In May&#160;2020, we made an annual grant of 103,434 RSUs to our non&#x2011;employee directors for the 2020-2021 board service year, which units vested immediately and will settle in shares of our common stock on the third anniversary of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the aforementioned aggregate numbers of time-based RSUs granted in 2022, 2021 and 2020 were 53,716, 189,215 and 359,713 RSUs, respectively, awarded to our former Executive Chairman. The RSUs granted in 2022 and 2020 were each scheduled to vest ratably over 11 quarterly periods, while the RSUs granted in 2021 were schedule to vest ratably over eight quarterly periods. Additionally, in the aforementioned aggregate number of performance-based RSUs granted in 2022 were 53,716 RSUs awarded to our former Executive Chairman. The unvested portion of these grants vested in October&#160;2022 in accordance with the disability provisions of the stock incentive plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation costs related to our stock-based compensation arrangements for the years ended December&#160;31,&#160;2022, 2021 and 2020 included $45 million, $42 million and $30 million of expense related to our RSUs, respectively. At December&#160;31,&#160;2022, there were $33 million of total unrecognized compensation costs related to RSUs. These costs are expected to be recognized over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For certain of the performance-based RSU grants, the number of units that will ultimately vest is subject to adjustment based on the achievement of a market-based condition. The fair value of these RSUs is estimated through the use of a Monte Carlo simulation. Significant inputs used in our valuation of these RSUs included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.6% - 68.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.2% - 79.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0% - 1.7% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1% - 0.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;USPI Management Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2015 USPI Management Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, USPI adopted the USPI Holding Company, Inc. 2015 Stock Incentive Plan (&#x201c;2015 USPI Management Equity Plan&#x201d;) under which it granted non-qualified options to purchase nonvoting shares of USPI&#x2019;s outstanding common stock to eligible plan participants, allowing the recipient to participate in incremental growth in the value of USPI from the applicable grant date. Under the 2015 USPI Management Equity Plan, the total pool of options consisted of approximately 10% of USPI&#x2019;s fully diluted outstanding common stock. Options had an exercise price equal to the estimated fair market value of USPI&#x2019;s common stock on the date of grant. The option awards were structured such that they had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg0Mzg_74a46396-62a0-44d1-87da-e5a77de5ca2f"&gt;three&lt;/span&gt; or four year vesting period in which half of the award vested in equal pro-rata amounts over the applicable vesting period and the remaining half vested at the end of the applicable &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg2MjE_fd2aa8ae-54d5-4b8a-b36d-1b3d0bc214ae"&gt;three&lt;/span&gt; or four year period. Any unvested awards were forfeited upon the participant&#x2019;s termination of service with USPI, and vested options were required to have been exercised within 90 days of termination. Once an award was exercised and the requisite holding period met, the participant was eligible to sell the underlying shares to USPI at their estimated fair market value. Payment for USPI&#x2019;s purchase of any eligible nonvoting common shares could be made in cash or in shares of Tenet&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the 2015 USPI Management Equity Plan and all unvested options granted under the plan were terminated in accordance with the terms of the plan. USPI repurchased all vested options and all shares of USPI stock acquired upon exercise of an option for approximately $35&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 USPI Management Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, USPI adopted the USPI Holding Company, Inc. Restricted Stock Plan (&#x201c;USPI Management Equity Plan&#x201d;) to replace the terminated 2015 USPI Management Equity Plan. Under the USPI Management Equity Plan, USPI grants RSUs representing a contractual right to receive one share of USPI&#x2019;s non&#x2011;voting common stock in the future. The vesting of RSUs granted under the plan varies based on the terms of the underlying award agreement. Once the requisite holding period is met, during specified times, the participant can sell the underlying shares to USPI at their estimated fair market value. At our sole discretion, the purchase of any non&#x2011;voting common shares can be made in cash or in shares of Tenet&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity under USPI&#x2019;s management equity plan during the years ended December&#160;31,&#160;2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Grant Date&#160;Fair&lt;br/&gt;Value&#160;Per&#160;Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inception of Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;922,840&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;USPI did not make any grants under the USPI Management Equity Plan during the year ended December&#160;31,&#160;2022. During the year ended December&#160;31,&#160;2021, USPI granted 76,990 RSUs under its management equity plan. Twenty&#160;percent of these RSUs vests on each of the first and second anniversaries of the grant date, and the remaining 60% vests on the third &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anniversary of the grant date. In 2020, USPI granted 2,556,333 RSUs, 20% of which vest in each of the first three&#160;years on the anniversary of the grant date with the remaining 40% vesting on the fourth anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2022 and 2021, USPI paid $11 million and $9 million, respectively, to repurchase portions of the non&#x2011;voting common stock shares issued under the USPI management equity plan. No shares were repurchased during the year ended December&#160;31,&#160;2020. At December&#160;31,&#160;2022, there were 98,374 outstanding vested shares of non&#x2011;voting common stock eligible to be sold to USPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, 922,840 RSUs were outstanding under USPI&#x2019;s management equity plan, all of which are expected to vest. The accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020 included $11 million, $13 million and $12 million, respectively, of pre-tax compensation costs related to USPI&#x2019;s management equity plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an employee stock purchase plan under which we are currently authorized to issue up to 4,070,363 shares of common stock to our eligible employees. As of December&#160;31,&#160;2022, there were approximately 2.6&#160;million&#160;shares available for issuance under our employee stock purchase plan. Under the terms of the plan, eligible employees may elect to have between 1%&#160;and 10% of their base earnings withheld each quarter to purchase shares of our common stock. Shares are purchased at a price equal to 95% of the closing price on the last day of the quarter. The plan requires a one&#x2011;year holding period for all shares issued. The holding period does not apply upon termination of employment. Under the plan, no individual may purchase, in any year, shares with a fair market value in excess of $25,000. The plan is currently not considered to be compensatory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued the following numbers of shares under our employee stock purchase plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Retirement Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our employees, upon qualification, are eligible to participate in our defined contribution 401(k)&#160;plans. Under the plans, employees may contribute a portion of their eligible compensation, which we may match with employer contributions at our discretion. Employer matching contributions will vary depending on which of our subsidiaries employs the participant and whether the employee is covered under a collective bargaining agreement. Plan expenses, primarily related to our contributions to the plans, were $86 million, $98 million and $119 million for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively. Such amounts are reflected in salaries, wages and benefits in the accompanying Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain three frozen non&#x2011;qualified defined benefit pension plans (&#x201c;SERPs&#x201d;) that provide supplemental retirement benefits to certain of our current and former executives. These plans are not funded, and plan obligations for these plans are paid from our working capital. Pension benefits are generally based on years of service and compensation. Upon completing the acquisition of Vanguard Health Systems, Inc. on October&#160;1,&#160;2013, we assumed a frozen qualified defined benefit plan (&#x201c;DMC Pension Plan&#x201d;) covering substantially all of the employees of our Detroit market that were hired prior to June&#160;1,&#160;2003. The benefits paid under the DMC Pension Plan are primarily based on years of service and final average earnings. During the year ended December&#160;31,&#160;2019, the Society of Actuaries issued a new mortality base table (Pri&#x2011;2012), which we incorporated into the estimates of our defined benefit plan obligations beginning December&#160;31,&#160;2019. During the year ended December 31,&#160;2020, the Society of Actuaries issued the MP-2020 mortality improvement scale, which we incorporated into the estimates of our defined benefit plan obligations at December 31,&#160;2020. During the year ended December 31,&#160;2021, the Society of Actuaries issued the MP&#x2011;2021 mortality improvement scale, which we incorporated into the estimates of our defined benefit plan obligations at December&#160;31,&#160;2022 and&#160;2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the balance sheet impact, as well as the benefit obligations, funded status and rate assumptions associated with the SERPs and the DMC Pension Plan based on actuarial valuations prepared:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plans assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funded status of plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The accumulated benefit obligation at December&#160;31,&#160;2022 and 2021 was approximately $1.002 billion and $1.311 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the Consolidated Balance Sheets consist of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SERP Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DMC Pension Plan Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit costs and related assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost (income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SERP Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Census date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DMC Pension Plan Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term rate of return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Census date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the current year are based on assumptions determined at the valuation date of the prior year for the SERPs and the DMC Pension Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded gain (loss) adjustments of $72&#160;million, $61 million and $(32)&#160;million in other comprehensive income in the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, to recognize changes in the funded status of our SERPs and the DMC Pension Plan. Changes in the funded status are recorded as a direct increase or decrease to shareholders&#x2019; equity through accumulated other comprehensive loss. Net actuarial gains (losses) of $63&#160;million, $50&#160;million and $(41)&#160;million were recognized during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, and the amortization of net actuarial loss of $9&#160;million, $11&#160;million and $9&#160;million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively, were recognized in other comprehensive income. Actuarial gains affecting the benefit obligation during the years ended December&#160;31,&#160;2022, 2021 and 2020 are primarily attributable to changes in the discount rate utilized for the SERP and DMC Pension Plan. Cumulative net actuarial losses totaled $222 million, $294&#160;million and $355 million as of December&#160;31,&#160;2022, 2021 and 2020, respectively. There were no unrecognized prior service costs at December&#160;31,&#160;2022, 2021 and 2020 that had not yet been recognized as components of net periodic benefit cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To develop the expected long&#x2011;term rate of return on plan assets assumption, the DMC Pension Plan considers the current level of expected returns on risk&#x2011;free investments (primarily government bonds), the historical level of risk premium associated with the other asset classes in which the portfolio is invested and the expectations for future returns on each asset class. The expected return for each asset class is then weighted based on the target asset allocation to develop the expected long&#x2011;term rate of return on assets assumption for the portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted&#x2011;average asset allocations by asset category as of December&#160;31,&#160;2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Actual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alternative investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The DMC Pension Plan assets are invested in public commingled vehicles, segregated separately managed accounts, and private commingled vehicles, all of which are managed by professional investment management firms. The objective for all asset categories is to maximize total return without assuming undue risk exposure. The DMC Pension Plan maintains a well&#x2011;diversified asset allocation that meets these objectives. The DMC Pension Plan assets are largely comprised of cash and cash equivalents, including but not limited to money market funds and repurchase agreements secured by U.S. Treasury or federal agency obligations, equity securities, including but not limited to the publicly traded shares of U.S. companies with various market capitalizations in addition to international and convertible securities, debt securities including, but not limited to, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;domestic and foreign government obligations, corporate bonds, and mortgage&#x2011;backed securities, and alternative investments. Alternative investments is a broadly defined asset category with the objective of diversifying the overall portfolio, complementing traditional equity and fixed&#x2011;income securities and improving the overall performance consistency of the portfolio. Alternative investments may include, but are not limited to, diversified hedge funds in the form of professionally managed pooled limited partnership investments and investments in private markets via professionally managed pooled limited partnership interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each investment account, the DMC Pension Plan investment managers are responsible for monitoring and reacting to economic indicators, such as gross domestic product, consumer price index and U.S. monetary policy that may affect the performance of their account. The performance of all managers and the aggregate asset allocation are formally reviewed on a quarterly basis. The current asset allocation objective is to maintain a certain percentage within each asset class allowing for deviation within the established range for each asset class. The portfolio is rebalanced on an as&#x2011;needed basis to keep these allocations within the accepted ranges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as quoted prices for similar assets, interest rates and yield curves. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the DMC Pension Plan assets measured at fair value on a recurring basis as of December&#160;31,&#160;2022 and 2021, aggregated by the level in the fair value hierarchy within which those measurements are determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;545&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future benefit payments to be made from the SERPs and the DMC Pension Plan, a portion of which will be funded from plan assets, for the next five years and in the aggregate for the five years thereafter:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ending&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Five Years Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The SERP and DMC Pension Plan obligations of $354&#160;million at December&#160;31,&#160;2022 are classified in the accompanying Consolidated Balance Sheet as an other current liability of $23 million and defined benefit plan obligations of $331&#160;million based on an estimate of the expected payment patterns. We expect to make total contributions to the plans of approximately $23&#160;million for the year ending December&#160;31,&#160;2023.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzOQ_baad0ee9-f060-4294-9632-54c982334139">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzQwNw_891a3f63-e292-41fc-869b-41d30b71beb5"
      unitRef="shares">1</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if8c4f60c37dd4423b655206fe804e2a7_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1Mzk_f91a1881-7d8c-40e2-a01c-5f9211904ccc"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id54c892934f94ec9a1653dda6b70f552_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDU_04fa562a-8804-45aa-95a1-52055c6e1b00"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2aefe441942b4b1b9964978feb391a61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI0OTQ_7499385a-8745-44e9-b6d9-d70bf6942b69"
      unitRef="shares">9500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQyMDk_1b9bd851-a26f-43f8-b665-945db758fc44"
      unitRef="usd">56000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQyMDk_6a9e8331-1bd0-470b-b5ed-59fd0641f758"
      unitRef="usd">56000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQyODI_bc212389-daf6-4b30-933b-e7458babcb5e"
      unitRef="usd">44000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODgx_f1e8204a-ad33-4cb1-b0ed-85f3230695a8">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg&lt;br/&gt;Remaining Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160;Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(987,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;460,947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8f70438f4b824837b203d53a4d4992cb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzItMi0xLTEtMjkzNzEw_5a38deda-a4f6-404e-b965-86304c7104e5"
      unitRef="shares">1960992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8f70438f4b824837b203d53a4d4992cb_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzItNC0xLTEtMjkzNzEw_18117e3a-bd64-4423-bf11-7164aed1097d"
      unitRef="usdPerShare">20.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzQtMi0xLTEtMjkzNzEw_62c2b2f9-0648-442c-abc0-cd5801e5fc15"
      unitRef="shares">987471</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzQtNC0xLTEtMjkzNzEw_1a82a9af-4968-4540-b20b-b2fc60368c3d"
      unitRef="usdPerShare">17.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzUtMi0xLTEtMjkzNzEw_dcbe1fa1-7dc7-4480-aab8-fc101c1ae15f"
      unitRef="shares">60990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzUtNC0xLTEtMjkzNzEw_f88a3ae0-0cee-4a2c-9acf-cdf68844da57"
      unitRef="usdPerShare">23.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia7b77940692a4f7db126c0242c3c5ac4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzYtMi0xLTEtMjkzNzEw_a15f24c6-6ae5-4c95-9219-77dfd1ea2e8c"
      unitRef="shares">912531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia7b77940692a4f7db126c0242c3c5ac4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzYtNC0xLTEtMjkzNzEw_0076ffbd-1cda-46ed-a68e-07623cdea1f3"
      unitRef="usdPerShare">22.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzgtMi0xLTEtMjkzNzEw_810f2bf6-9bb3-430f-aab1-30278368c8ac"
      unitRef="shares">391533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzgtNC0xLTEtMjkzNzEw_a975633f-6acc-4db8-9550-1edf54321e7a"
      unitRef="usdPerShare">20.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0107ed011a3a46fdb613b444b95af318_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEwLTItMS0xLTI5MzcxMA_5de8f5b1-1de0-43c7-b566-5d21de91a8f8"
      unitRef="shares">520998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0107ed011a3a46fdb613b444b95af318_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEwLTQtMS0xLTI5MzcxMA_8485df64-1fca-4f5b-a4a5-4bbe8af910b4"
      unitRef="usdPerShare">23.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEyLTItMS0xLTI5MzcxMA_5d7902dd-e8aa-4367-b34c-d9307c76f20a"
      unitRef="shares">60051</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzEyLTQtMS0xLTI5MzcxMA_66e77d50-8917-438f-a6e4-a5dad1c8d082"
      unitRef="usdPerShare">28.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTItMS0xLTI5MzcxMA_8685d85c-7a08-4211-8987-d30a105fd953"
      unitRef="shares">460947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTQtMS0xLTI5MzcxMA_e18ec0d4-8f55-46a9-81ff-ac255df228b0"
      unitRef="usdPerShare">23.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTYtMS0xLTI5MzcxMA_951656e4-c434-48da-99dd-1df4a5e38ed5"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZjdhNTFiNGM3YWU0YjRhOTlmZjc4ZmEwYmJlOTc4OS90YWJsZXJhbmdlOjZmN2E1MWI0YzdhZTRiNGE5OWZmNzhmYTBiYmU5Nzg5XzE0LTgtMS0xLTI5MzcxMA_933238b9-8303-41ec-81d1-d511cfabfa4e">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzNzI_34effa6d-1c10-4d3e-8b59-6ba46212fd43"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzNzI_5aa9f3fe-5e31-43b7-910e-befe79e70874"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMzNzI_ef71aecf-3271-4988-9d95-3b90ac74966d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTMzNzE_ea5ba1f5-7e7e-451f-b36d-e4158bb20b30"
      unitRef="shares">60051</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTMzNzY_e3dad0e1-e1c1-442f-88dc-24510c17f6f6"
      unitRef="shares">391533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTMzODQ_503254f7-4478-448e-967f-4c4d033a392b"
      unitRef="shares">987471</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTM2Mzg_5e5f7c63-0fdc-4b73-97b8-f87d28f7564e"
      unitRef="usd">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTM3NTA_0c9194cd-5594-4d9c-9c3c-ed43e94a4956"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTM3NTA_e4abfb60-cb74-4edf-bf7f-8f47ca2620d2"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTEx_efd64ffc-9fc5-4c83-a8c8-66bfb8d26ceb">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about our outstanding stock options at December&#160;31,&#160;2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding and Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&#160;of&#160;Exercise&#160;Prices&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.99 to $20.609&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.61 to $35.430&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;460,947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i73a77c00b16741cd82fbfa2cd2e6aeef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItMC0xLTEtMjkzNzEwL3RleHRyZWdpb246N2I0OGEwMDU3YTdjNGE1YWI3ZjkyOTFhZTY4NmVjNTJfNA_fc776dda-6e73-4cd4-a64e-2778053dac3f"
      unitRef="usdPerShare">18.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i3c48ee9db11e4626a720073e3d52765c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItMC0xLTEtMjkzNzEwL3RleHRyZWdpb246N2I0OGEwMDU3YTdjNGE1YWI3ZjkyOTFhZTY4NmVjNTJfMTA_e037fe5f-f530-4f91-835b-52ad655095bc"
      unitRef="usdPerShare">20.609</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8332ac81ea994fa080bd2c74aea55433_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItMi0xLTEtMjkzNzEw_287c4711-609d-49f5-a757-d2a8570df88c"
      unitRef="shares">293796</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1c680273422d4752955e73ac5d10bd49_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItNC0xLTEtMjkzNzEw_8bec67c8-3ad9-4d0a-85db-97bf18a67d0f">P4Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i8332ac81ea994fa080bd2c74aea55433_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzItNi0xLTEtMjkzNzEw_6a8d795e-0fe1-4eca-8705-50a6f93be9bb"
      unitRef="usdPerShare">19.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="icd0038bf48844cf2b84aed399a6f80ce_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246YjRiZDAyNTNkMTIwNDAzNzkxODFhZTMxNWU4MmQ0NjNfNA_60b9e4e6-7383-497d-96ae-a198c274ec88"
      unitRef="usdPerShare">20.61</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ie3031d28ff1b47d48f762be70d952bc5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtMC0xLTEtMjkzNzEwL3RleHRyZWdpb246YjRiZDAyNTNkMTIwNDAzNzkxODFhZTMxNWU4MmQ0NjNfMTA_11de5925-2caf-40ba-b3a8-bd6f0a45ffc4"
      unitRef="usdPerShare">35.430</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ifa66aa2f15ca430daa47cd0bdc598c56_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtMi0xLTEtMjkzNzEw_213aba94-b600-4eee-8088-f5749b0d631f"
      unitRef="shares">167151</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i82dd3f9e68e54d33b184fd6660d2b3e0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtNC0xLTEtMjkzNzEw_3b40bce5-20d4-4054-89b7-7584b6498998">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ifa66aa2f15ca430daa47cd0bdc598c56_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzMtNi0xLTEtMjkzNzEw_a1c32e64-7234-41d2-b270-84fcd5a73680"
      unitRef="usdPerShare">29.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzQtMi0xLTEtMjkzNzEw_a797ae6a-c236-4f4a-b8a2-715d6a658522"
      unitRef="shares">460947</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzQtNC0xLTEtMjkzNzEw_04a2ae8e-3ff4-4bb4-b7ae-7cf46fad688e">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToyZWIxMDlkYjY1MmE0ZmRmYjdiZTYzNGE4MDUxYjQ0Mi90YWJsZXJhbmdlOjJlYjEwOWRiNjUyYTRmZGZiN2JlNjM0YTgwNTFiNDQyXzQtNi0xLTEtMjkzNzEw_577812dd-2f07-49e8-bea4-aeb02216e1af"
      unitRef="usdPerShare">23.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage
      contextRef="i6525986e7cec4246bf79c66a19a22c42_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzM3NDc_619988c1-8241-458c-8968-4105bea993ce"
      unitRef="number">0.423</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage
      contextRef="idd5b8bc126dd41e49f8d133ce6a2f7e9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzM4MTY_37f3360b-c27e-44dd-9110-eceae7f2a433"
      unitRef="number">0.577</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage>
    <us-gaap:SharePrice
      contextRef="i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzM5NDc_7862b977-1c0a-4035-997f-add275acc373"
      unitRef="usdPerShare">48.79</us-gaap:SharePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d580d311cca41a49885bde9c25bb637_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODEyMjA_2f5a9d43-1ff7-41be-95ad-0283e053609d"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f10123f91224a3fb3876d230a73e3cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODEyMjg_d4639986-5204-40c0-a987-f4d8b26f01d9"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96161ba6b9f741c3a1858a893ce32fff_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODEyOTQ_447b6a1b-5595-4119-9fac-50f79fdead87"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODgy_0514439d-8342-4045-86cc-1c24129ef586">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Grant Date&#160;Fair&lt;br/&gt;Value&#160;Per&#160;Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,767,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,095,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(765,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,187,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,520,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity under USPI&#x2019;s management equity plan during the years ended December&#160;31,&#160;2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Grant Date&#160;Fair&lt;br/&gt;Value&#160;Per&#160;Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inception of Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31,&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;922,840&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic33f32827498430ea95e37c4de25591c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEtMi0xLTEtMjkzNzEw_3fe5ea41-009e-4b81-bf40-09373b228b21"
      unitRef="shares">1463499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic33f32827498430ea95e37c4de25591c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEtNC0xLTEtMjkzNzEw_71d8e59d-ba1e-4eec-a74e-88ea0170a0f4"
      unitRef="usdPerShare">25.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzItMi0xLTEtMjkzNzEw_14b200ce-efd8-43bd-bb1d-ae4c0ecc2b06"
      unitRef="shares">1767730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzItNC0xLTEtMjkzNzEw_22520f76-4f3d-4c0e-8c1e-44097a38df08"
      unitRef="usdPerShare">27.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzMtMi0xLTEtMjkzNzEw_f91fa4db-5f34-4ffe-a585-72342cb8d37f"
      unitRef="shares">825727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzMtNC0xLTEtMjkzNzEw_a79ec50c-ed80-4070-8937-3c653861fd8a"
      unitRef="usdPerShare">25.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzQtMi0xLTEtMjkzNzEw_2172873c-9792-4e7b-af69-63e3db85d86b"
      unitRef="shares">310296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzQtNC0xLTEtMjkzNzEw_834039fa-c063-4507-910e-d1a312d23b78"
      unitRef="usdPerShare">32.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibf2c425940604ce3bb5200984c22a581_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzUtMi0xLTEtMjkzNzEw_1002d30f-f22b-4892-8690-29e8aecd97c3"
      unitRef="shares">2095206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibf2c425940604ce3bb5200984c22a581_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzUtNC0xLTEtMjkzNzEw_150f9641-de1b-4337-9cc6-33ec63e52c7d"
      unitRef="usdPerShare">25.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzYtMi0xLTEtMjkzNzEw_bdfabc4c-8f34-4b0d-ad3e-98bc40d2ce43"
      unitRef="shares">900018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzYtNC0xLTEtMjkzNzEw_881f4ceb-7bae-47cc-b877-c5cfbc8ce5d4"
      unitRef="usdPerShare">58.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzctMi0xLTEtMjkzNzEw_d644e9d9-bbae-4c3f-be1e-6bc4e32403eb"
      unitRef="shares">765814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzctNC0xLTEtMjkzNzEw_6b228d63-7362-46e0-bcb9-e55957d317c1"
      unitRef="usdPerShare">30.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzgtMi0xLTEtMjkzNzEw_0e6aadd2-0a8d-4be1-9e75-d4a34ae8f663"
      unitRef="shares">58208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzgtNC0xLTEtMjkzNzEw_0bedeb29-3b74-45fd-93d6-b36b06c89740"
      unitRef="usdPerShare">37.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2b0698fef50b441a8809d814d5874bd9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzktMi0xLTEtMjkzNzEw_a17856bc-663f-4763-bc84-fe0c1b0f374c"
      unitRef="shares">2171202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2b0698fef50b441a8809d814d5874bd9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzktNC0xLTEtMjkzNzEw_f7b59b47-a706-4a14-86d6-68db8389cf3c"
      unitRef="usdPerShare">40.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEwLTItMS0xLTI5MzcxMA_b823e66c-cf8e-4fac-8709-ebae1470de3b"
      unitRef="shares">641205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEwLTQtMS0xLTI5MzcxMA_7931da75-ec5f-492a-8a45-4b0bffc3b75a"
      unitRef="usdPerShare">80.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzExLTItMS0xLTI5MzcxMA_06940d9a-218e-402c-9efe-eb8f11799030"
      unitRef="shares">1187384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzExLTQtMS0xLTI5MzcxMA_05c9a11c-9eee-4dd9-b2b2-51c89a08c3ba"
      unitRef="usdPerShare">37.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEyLTItMS0xLTI5MzcxMA_b67a9fbd-4de9-442f-b091-ca1cccebe68c"
      unitRef="shares">104605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEyLTQtMS0xLTI5MzcxMA_a3b7ce74-44b9-4307-93d2-9abd739b4ec2"
      unitRef="usdPerShare">53.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9447e0acfdc8411fa545539e357b1624_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEzLTItMS0xLTI5MzcxMA_3c60f95f-29b1-4a69-9605-a88bf5e3429d"
      unitRef="shares">1520418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9447e0acfdc8411fa545539e357b1624_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplNGU2Yjg0ZDI0NTE0N2E3YjEwZjA4MzBlYmUwY2YxNi90YWJsZXJhbmdlOmU0ZTZiODRkMjQ1MTQ3YTdiMTBmMDgzMGViZTBjZjE2XzEzLTQtMS0xLTI5MzcxMA_433d375d-cfe8-4829-98f1-5e2dc82c692b"
      unitRef="usdPerShare">66.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1MjY_0edfb9e2-6748-450d-b66a-cc637e398318"
      unitRef="shares">641205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1ae413ceda20471eaa9654d788c7e9c4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1MzE_4ab68ebb-76e9-49a5-a1d1-cef6742764db"
      unitRef="shares">237381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1ae413ceda20471eaa9654d788c7e9c4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMyOTg1MzQ5NjUxNDg_cb0700cd-5e1e-434b-9649-998b0294340e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQ2ODA_c01f0eaa-a11e-49e8-a0fd-72bda9e34503"
      unitRef="shares">53716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods
      contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTQ3Mjg_c09589f0-e0e4-492c-b76b-3a779fd7230a"
      unitRef="quarter">11</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5d49db19071d4e76af718a4ebfcd2551_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NDE_9ccce096-478e-4471-9113-65be97afe58b"
      unitRef="shares">9215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5d49db19071d4e76af718a4ebfcd2551_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzMyOTg1MzQ5NjUxNTE_f37bb6da-f398-403d-9467-1f21fb4df484">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ica37af9eadb64144b4a83ab54b2eb4e1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NTE_4a1f9267-283b-4359-861c-63bca91c0808"
      unitRef="shares">4608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibc78025992d2498693e0cfe01b80263d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NTY_ec3cb997-37e8-4193-9671-0e9fc36e786c"
      unitRef="shares">6170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifdc06daccd6f4843bb75db0eba6fda8b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1NzE_ef0a4750-345a-431a-bde4-6dea2712f924"
      unitRef="shares">35482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icd952e84dcc743b9af382bfd56d539a6_D20221101-20221130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTA2NTc_d052b429-0f6c-4b68-8157-848191ffd7dd"
      unitRef="shares">7325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i792b9ba8d6434e31ba4998b638861429_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI1OTM_855ff40d-ba3d-4d81-8fa1-4054e9cfbc0b"
      unitRef="shares">287308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if8c4f60c37dd4423b655206fe804e2a7_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI2NDM_f91a1881-7d8c-40e2-a01c-5f9211904ccc"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id54c892934f94ec9a1653dda6b70f552_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI2NTA_04fa562a-8804-45aa-95a1-52055c6e1b00"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i792b9ba8d6434e31ba4998b638861429_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzI2NTQ_855ff40d-ba3d-4d81-8fa1-4054e9cfbc0b"
      unitRef="shares">287308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib31c3d8b7cdb4518b73e55dc7378d317_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMTI_2e49235f-1a89-4799-b8b8-d9ba5fdddb32"
      unitRef="shares">561788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iba5b2544884b47d884c4199111051b50_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMTg_7f87dff9-6a2d-47de-a7ac-a26ad9d065c4"
      unitRef="shares">263180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iba5b2544884b47d884c4199111051b50_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzQzOTgwNDY1OTU0NjQ_e96fbe90-ef37-43a3-ab49-482ca10c2e61">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMjQ_50013ed2-b435-40b6-910b-8caa1d7a9cf6"
      unitRef="shares">189215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods
      contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY1Nw_d162953f-a7c4-4ac1-a4fb-37c04cfc013b"
      unitRef="quarter">8</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9364d349beee475faa3c8ae75ca39b99_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMzA_5d901fd6-377a-4418-a271-1fcb662a7bec"
      unitRef="shares">53341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if0f6dfe4070b40479c568783e37dbdb1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyMzY_d39e6584-8bc1-405f-8c39-429a1a29bc7f"
      unitRef="shares">33351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i82745fe1a5c149759ae2bb2ebd18c99f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyNDI_4267ad19-60bc-49f9-9d83-124fb39a97a4"
      unitRef="shares">14192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3b0e586f41214b669d46af8983e496a5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODgyNTM_20ef5ba1-eb15-4964-be6f-c8dd2cccefc4"
      unitRef="shares">8509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i67cb4a48480947cb934f8e6e7be5a3ac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODg3OTY_f29b8258-6bb9-4ab1-85bf-f0e3a6b144be"
      unitRef="shares">298492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i83afe2783741410d8c56a323ae90b6c5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODk0Nzg_0b0d0f1f-e88a-445f-bbd5-e8804e676c22"
      unitRef="shares">244259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ieec7c07bedae422fb1e0fa272c435e3d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODg4MTg_1b183440-937c-48e5-8e92-03cfbf845b4e"
      unitRef="shares">53341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i02d9270641be4b258d8e9d251500ed2c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODg4MjQ_840412a6-5c66-4eef-a2d8-a021f47ed529"
      unitRef="shares">892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4ffe68638d7b4f33a12f20c24c63eaca_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzUzMzI_e8bbfcea-c553-4015-aa8a-ebac92445d1d"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i77704bd6df014d42ad1974f3065e00bb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzUzMzg_90b63b88-14c7-4c4a-a6a8-159d7931bdac"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iddd4d4aa649e490fa03c3693ab1d3b6d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzYxNTE_512ea1ab-0a14-4a72-b0b4-6ba0d927c80f"
      unitRef="shares">297600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic5c513a239cd415cadbc7d515e826c84_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzcxNDY_6d101ae8-0e64-4a82-9706-eb59b79643f1"
      unitRef="shares">39738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i25b782905e1e4e0eac9049059657f1b5_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzcxNTA_c009fa50-a654-4c7f-951b-1b4f2b4404ce"
      unitRef="shares">36681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i459d2687d88148ecb61b4fae2a62863b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2NzcxNTQ_b8b7809a-f116-4df7-8ebe-0749b3413bd8"
      unitRef="shares">1372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4dab5b2fbdc143c39fa76b787542f0df_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTg5NTkzMA_ea76915e-7c3c-490a-ab4a-d326097464d2"
      unitRef="shares">1685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i46ba779d997746cb97b06efbf30d887e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjE0OTg_3f3bdf50-1cf0-4c30-b8ab-51c82affc002"
      unitRef="shares">1084883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie91ba56fa1e847e8a1c73049e8ae86f8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY0Mg_ee02a165-e760-4677-9166-39344c1b8bd0"
      unitRef="shares">607198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie91ba56fa1e847e8a1c73049e8ae86f8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE3MDQyNDMwMzI0OTg2_94fb6fad-3ed8-44d7-9112-b21e165f35de">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY4OA_095bcca4-c53c-4d07-8b3e-68aabc0b37a9"
      unitRef="shares">359713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods
      contextRef="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY2Nw_74d206c9-a5c6-4aa1-a641-4db9f3ba1980"
      unitRef="quarter">11</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icdc7d548925b41349d858624f9963b63_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjY5NA_05a2ce28-a112-4308-8cce-dab42a9a8e63"
      unitRef="shares">104167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icdc7d548925b41349d858624f9963b63_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE3MDQyNDMwMzI0OTkw_e880963a-be05-4c00-8282-9e95e6bc8619">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idf51d35f981442c99167b2d957e6c469_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcwMA_31ddb7dd-39ff-4b63-ad5c-95995b0e7d2e"
      unitRef="shares">13805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i49aa4fd04a47497b9c081da63e6815a1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcxMQ_6e835aa8-cb0f-4b4a-85e2-c3a2caf805ca"
      unitRef="shares">579413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i40882d4788cd4504ab064fa6891d0693_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcxNw_4f8883ef-ca30-4f75-9313-8f70a3fe488e"
      unitRef="shares">499285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0aafc61192254d9d93ce6bc583456021_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjcyMw_d4e3a449-c1c6-4e59-9593-234f0568e5ea"
      unitRef="shares">80128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4cf2066a73d3442da2799d558b87a606_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjczNw_3c537326-659d-4643-b350-7625d6600e51"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i0d78c92def194c19a4adbbb2259e22c1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjc0MQ_6a713bb1-1768-41f7-bbc7-1311113952a8"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i40882d4788cd4504ab064fa6891d0693_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjc1MA_4f8883ef-ca30-4f75-9313-8f70a3fe488e"
      unitRef="shares">499285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i30fc1015621a4924bfbb26ae78a46dad_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjc1Nw_3b8a2ada-6a30-43cc-9819-d5bef70cd6fa"
      unitRef="shares">103434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTk3NzA_c01f0eaa-a11e-49e8-a0fd-72bda9e34503"
      unitRef="shares">53716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTk3ODM_50013ed2-b435-40b6-910b-8caa1d7a9cf6"
      unitRef="shares">189215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia0866e34f68d4ed5ba36c86004410253_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjE1ODE_aea8760d-3085-4faa-aa34-7de66057a4aa"
      unitRef="shares">359713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods
      contextRef="i2dc4e62fbf694c13a87fee043fdb6db6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjE2NzY_c09589f0-e0e4-492c-b76b-3a779fd7230a"
      unitRef="quarter">11</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods
      contextRef="ide10a9ff4e144163bbe3071193b967eb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MTk4OTc_4740228e-f627-45a2-b931-15531523d05b"
      unitRef="quarter">8</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifc3d6bba1c884c478022a01b2e6cb3bc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE3MjAwMzQ_26127c72-b618-4f56-aea2-b7d11e3b30e9"
      unitRef="shares">53716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODE2Nzk_7c9e5bc9-a062-4453-b514-471220713bbb"
      unitRef="usd">45000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODE2OTM_b318a861-cbec-49c8-b26c-40c878bdd0f4"
      unitRef="usd">42000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODE2OTY_bf459dbd-f374-4ad2-8417-e46129178aed"
      unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9447e0acfdc8411fa545539e357b1624_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODMyMTU_4ef24ed8-5612-4f5b-b317-58c96006bbb6"
      unitRef="usd">33000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2ODMyMzA_f377acef-5856-471a-aabd-9794de2aacf3">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <thc:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTAy_83118a1b-d321-4ad3-87fa-d052197959f8">Significant inputs used in our valuation of these RSUs included the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.6% - 68.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.2% - 79.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0% - 1.7% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1% - 0.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</thc:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItMi0xLTEtMjkzNzEwL3RleHRyZWdpb246ZjBhOTBlOWNhMTk1NDQxOWI3ZjcyOTU1YjI0YWIxZTRfNA_d6269311-ec7d-431c-9252-bff87a49b579"
      unitRef="number">0.396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItMi0xLTEtMjkzNzEwL3RleHRyZWdpb246ZjBhOTBlOWNhMTk1NDQxOWI3ZjcyOTU1YjI0YWIxZTRfOQ_de34d799-00f8-4552-aba5-4965ebcd8b16"
      unitRef="number">0.681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItNC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDIyMDc2YTliNDNhNGQ1M2E4NTEwYWNkNzE2YWI3NjNfMTA5OTUxMTYyNzc5MA_7b285622-e7b8-42d9-80d4-c8684c654baf"
      unitRef="number">0.652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItNC0xLTEtMjkzNzEwL3RleHRyZWdpb246ZDIyMDc2YTliNDNhNGQ1M2E4NTEwYWNkNzE2YWI3NjNfMTA5OTUxMTYyNzc5Ng_fc72bfbd-e27f-479c-9544-0fd822e76d84"
      unitRef="number">0.793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzItNi0xLTEtMzYzODMyL3RleHRyZWdpb246YjFlNzRkMjZkM2RmNGJhNDk0ZjM2ZmU0MmMzZjU3MTVfNTQ5NzU1ODEzOTAy_9fcd0758-c06f-46b9-925d-2bf452ef646f"
      unitRef="number">0.547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtMi0xLTEtMjkzNzEwL3RleHRyZWdpb246MTExMzg3NjE1ZGRjNDJkY2JkNTQyOTZkNTJlOWU4ZmFfNA_5c9ee882-f89f-4708-9892-fd3dde8c07da"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtMi0xLTEtMjkzNzEwL3RleHRyZWdpb246MTExMzg3NjE1ZGRjNDJkY2JkNTQyOTZkNTJlOWU4ZmFfOQ_d4165425-2f0b-49c4-9930-e81872adfd96"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtNC0xLTEtMjkzNzEwL3RleHRyZWdpb246M2M3OWQ2ZWQ3YTBiNDE4MWJlNGIyNjA3ZjNmZWJkNjRfMTA5OTUxMTYyNzc4OA_9743a9e9-9755-4146-8673-d26b574a5b3a"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ia6b9dee23c07479d97722a8103dd20f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtNC0xLTEtMjkzNzEwL3RleHRyZWdpb246M2M3OWQ2ZWQ3YTBiNDE4MWJlNGIyNjA3ZjNmZWJkNjRfMTA5OTUxMTYyNzc5NA_abc158ce-7559-4a80-b199-f823c751dec4"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5ec3b77a810047eba602b69c09e004d0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo5MzYzNjFiZjc1MzM0Y2Q0OTk4ZDE5YmU5NmNhMzhjZS90YWJsZXJhbmdlOjkzNjM2MWJmNzUzMzRjZDQ5OThkMTliZTk2Y2EzOGNlXzQtNi0xLTEtMzYzODMyL3RleHRyZWdpb246ODBlMWY4MWVjNjEwNGFhYjkyNTg1M2I5NjQ4ODYwN2ZfNTQ5NzU1ODEzOTAw_b842ca4e-4852-46de-8207-3483671c48f6"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent
      contextRef="if57f1638bc10442baa7a4da9410fb748_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzgyMTQ_0711bdff-0038-4b78-91d3-9a3c884ac288"
      unitRef="number">0.10</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0a793f59564d4a279d849edac266ccd2_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTE5_f310fc2a-3f86-44e9-b763-b2e3e0541e92">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0a793f59564d4a279d849edac266ccd2_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTEw_37bc067b-c023-4f68-9d09-cb3f7924fde3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod
      contextRef="i22e72837fb0e4ccaa451831a1f7d7152_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzg3OTg_138c9fae-2ff5-45f4-9025-dc36342664df">P90D</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination
      contextRef="i575d1fb3905042bda466ba37322c7021_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzkzNjc_1beef6ab-26d7-4bf7-ad09-9634aa906cc3"
      unitRef="usd">35000000</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares
      contextRef="i4992fa411a47474cb9b7e672161cc2b0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzk2MzE_4e7cc2f2-225b-4428-a7df-b9b4889f7170"
      unitRef="shares">1</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItMi0xLTEtMzE5ODAx_614cf35c-2ad1-4829-bec7-d0b289563538"
      unitRef="shares">2556353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItNC0xLTEtMzI1MDQ0_d976f946-7056-40f0-bf48-db62dac1fe9a"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtMi0xLTEtMzE5ODA4_563e962d-45d2-4682-90a0-118a13d3c69f"
      unitRef="shares">531297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtNC0xLTEtMzI1MDQ2_b6f0efd5-4e00-4e3f-bea8-b148e31b6c45"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i87721822e7c147bfa5fc199473a92a04_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtMi0xLTEtMzI1MDUw_ae322bba-a770-4b68-b5c3-280796bdfcf4"
      unitRef="shares">2025056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i87721822e7c147bfa5fc199473a92a04_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtNC0xLTEtMzI1MDUw_dc7bf799-bc84-4a22-bbb9-f62d2ed5619b"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItMi0xLTEtMjkzNzEw_da7d13b3-bb20-411e-bab5-2f85b34308bc"
      unitRef="shares">76990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzItNC0xLTEtMjkzNzEw_233b34ce-8384-465e-972e-3f1d4fab2adb"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtMi0xLTEtMjkzNzEw_c6a70cc7-3654-41cf-8258-adf9954b57b5"
      unitRef="shares">388588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzMtNC0xLTEtMjkzNzEw_432712c0-2897-4717-9550-8bc0410582e0"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtMi0xLTEtMjkzNzEw_3f2dd947-64af-419d-a5d0-df20ba808882"
      unitRef="shares">218576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9c87d93f9a0246559d2e555073b129db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzQtNC0xLTEtMjkzNzEw_794b5543-3f03-4e3d-907d-752f99eb908d"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i29275879e7484df887acacaddf98d599_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzUtMi0xLTEtMjkzNzEw_e445d489-3ab5-4a8f-9087-5d5e43798f21"
      unitRef="shares">1494882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i29275879e7484df887acacaddf98d599_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzUtNC0xLTEtMjkzNzEw_b30ab49b-d28c-4b1f-84d2-31c546778bfa"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzctMi0xLTEtMjkzNzEw_1bc79e44-7569-4bf0-b41e-56b875ff5e4b"
      unitRef="shares">369691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzctNC0xLTEtMjkzNzEw_96987651-beee-4045-97de-beaad38b50cc"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzgtMi0xLTEtMjkzNzEw_badeb7fb-3f78-4e38-a9b0-e93382cc5881"
      unitRef="shares">202351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i27ff73f0ebfe47e3be751b43c331538e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzgtNC0xLTEtMjkzNzEw_8b0adba7-002c-4fa4-85b7-c48b20d1d15c"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8295862c62a64157b42db6f146e8c12d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzktMi0xLTEtMjkzNzEw_bc77ca4a-8dfe-43c8-954c-c822c624b5d4"
      unitRef="shares">922840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8295862c62a64157b42db6f146e8c12d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4MjZlZWJjZmZiODc0OTEyYjA1ZWVhM2QzM2ZiYjU4NC90YWJsZXJhbmdlOjgyNmVlYmNmZmI4NzQ5MTJiMDVlZWEzZDMzZmJiNTg0XzktNC0xLTEtMjkzNzEw_4a4db359-45ea-4860-a768-0c9f067707b2"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9fc0d268ac814aaf82dd4c2c38f45afc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNjQwODg_005e81bf-40aa-4d78-ab01-fd7eb603570a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i48e7b2eaecfe4b418364da6c80616cdd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwMjM1_fa0049b5-382e-49ae-9a4f-86b131d4bfd2"
      unitRef="shares">76990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib640db27bdcd4bb98e4be184ed784de6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTQ3OTA_b4e8b860-356e-4543-bca6-0a472bfa200e"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i36a0e4afed9c4d62a3cab9875677e71b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTQ3OTA_f982cbc0-4ed3-45a7-bd3c-2bf239643f6d"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iff0a68e5520c4a67b603ea61aabf6d5f_D20210101-20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTQ4MDY_1eb35bb9-caeb-4158-b306-08274289f019"
      unitRef="number">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4ee76bd3ebc94aee84000b9861cc8925_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjYwNg_de0b67bd-36ca-4a14-86de-7cdd50649dcd"
      unitRef="shares">2556333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id872956450094631a6e69b7b3b22b116_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwODUzMg_1019628f-0488-4ff5-9e31-2c1255610999"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7aeb8c24eb5e4d1fb3cc39f11508af94_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwODUzMg_79d41b77-3238-475d-86f9-7d418a7cbe14"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id4c2a4e8b3584f25ba9995590bb44105_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwODUzMg_fb0fbb29-ee8c-4f02-8357-93a49c501415"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i0f26d7b1bb2e411482df40eeb64c6fe2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzU0OTc1NTkwMjYyOA_99a7bc82-8f36-4cf1-97a5-8dbb84914dd0"
      unitRef="number">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i0a5b35347f794fff83ccb6182bcfaefe_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTUwODg_6d215df7-a1bb-4375-8555-539838f6ce93"
      unitRef="usd">11000000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ib60161593b56431198752c72b64076ff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwNjYz_20bc2b07-b590-478e-96a0-2c0a2d787481"
      unitRef="usd">9000000</us-gaap:PaymentsToMinorityShareholders>
    <thc:NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares
      contextRef="i05ee613b42ef4917ba2eacae648e7369_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNjQwOTc_050c1904-334e-4d52-a342-35c313569532"
      unitRef="shares">0</thc:NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares>
    <thc:CommonStockSharesOutstandingAndEligibleToBeSold
      contextRef="iaf31acec6aff4c96ae0465cc5661d7d4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwOTk1MTE2OTUzMzg_3406bd77-cc7f-4bed-a582-72a883d8a3d2"
      unitRef="shares">98374</thc:CommonStockSharesOutstandingAndEligibleToBeSold>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i726bb4f7600248c880398c7ae29152c6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEwODcx_2433deb3-f27d-444a-8fa8-dbb6db074f87"
      unitRef="shares">922840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b599704099d4411946c2b6a61490067_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMDY2_0f7ee077-5173-4f49-a483-107b1161cd6f"
      unitRef="usd">11000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67d8fd82832242d3874ce46a1f5bda4d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMDcw_da8b229c-ed3a-4a90-85db-b085e5b77738"
      unitRef="usd">13000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5e2d35b46364527900ac62fe853f500_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMDc3_ee2f40b4-ca45-44ec-a21e-a9c74e9dc321"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i98ed17ca8f424eddbb76511ce975b7d3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMjkz_cf8f48e4-4808-417f-82a6-c1340c605e04"
      unitRef="shares">4070363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i98ed17ca8f424eddbb76511ce975b7d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExMzgx_032397b4-fb99-4897-b00a-0a4a6f1a5b18"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent
      contextRef="i4dea6f1094954116a3f68cf961f8ae89_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExNTI4_ba3b061b-0266-4cbf-838b-54da9b87bf6f"
      unitRef="number">0.01</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent
      contextRef="i1ced06d52d0948f2b33cd7c96c19ac99_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExNTM1_1a49a31a-6d6c-46b0-bc8f-e9fb33bd25b4"
      unitRef="number">0.10</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExNjY0_caa4386c-be1c-4c8a-8668-9c5cc0f9e125"
      unitRef="number">0.95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares
      contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODky_26011a9c-3bce-4035-b711-d974d7843a47">P1Y</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares>
    <thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee
      contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzExOTU0_905e9e4d-1fa8-4cf4-92c0-5030a9cd6666"
      unitRef="usd">25000</thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODk1_0e00d9f9-cded-4229-906d-9d6d87a97d03">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued the following numbers of shares under our employee stock purchase plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzItMi0xLTEtMjkzNzEw_6554463a-c847-4233-891c-2dcd9a46efb0"
      unitRef="shares">98498</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i826c719c694345cbbd09a505858f05cf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzItNC0xLTEtMjkzNzEw_bed9baf6-20e6-4bb2-a111-c684431809e1"
      unitRef="shares">89865</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id5f1bdfc3e69496d9d0b8fad4f514056_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzItNi0xLTEtMjkzNzEw_16fb1601-fbfa-4f1d-9c69-e0f58a0f1263"
      unitRef="shares">254767</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan
      contextRef="i497ea6143aa14b5793a93fdee0ac4d73_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzMtMi0xLTEtMjkzNzEw_23caae4b-e822-4796-aabb-b4b9fcca56c7"
      unitRef="usdPerShare">54.19</thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan>
    <thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan
      contextRef="i826c719c694345cbbd09a505858f05cf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzMtNC0xLTEtMjkzNzEw_df3e3141-2e70-472b-8a22-ec038bbc73ca"
      unitRef="usdPerShare">63.01</thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan>
    <thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan
      contextRef="id5f1bdfc3e69496d9d0b8fad4f514056_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxOTQ1ZGMwNGQwZjY0ZjI4YjlmOWMxNTUyZTYxOGNjZC90YWJsZXJhbmdlOjE5NDVkYzA0ZDBmNjRmMjhiOWY5YzE1NTJlNjE4Y2NkXzMtNi0xLTEtMjkzNzEw_27663990-98ab-4ba1-9a06-31f14c965816"
      unitRef="usdPerShare">19.97</thc:StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNTMz_9219e843-ef4a-4196-bcb2-751b315a44dd"
      unitRef="usd">86000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNTM3_a8f031ea-4923-4430-a52d-57baf81a3edf"
      unitRef="usd">98000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNTQ0_f117c3c5-cc04-4b25-b45f-69f8528b7e4d"
      unitRef="usd">119000000</us-gaap:DefinedContributionPlanCostRecognized>
    <thc:NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans
      contextRef="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzEyNzI3_e26af8c3-3025-41cd-82ba-e3ede8e768c6"
      unitRef="plan">3</thc:NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans>
    <thc:ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTIy_44638cb4-a0b0-4b67-85ba-2277d6c35483">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the balance sheet impact, as well as the benefit obligations, funded status and rate assumptions associated with the SERPs and the DMC Pension Plan based on actuarial valuations prepared:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plans assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funded status of plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The accumulated benefit obligation at December&#160;31,&#160;2022 and 2021 was approximately $1.002 billion and $1.311 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the Consolidated Balance Sheets consist of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SERP Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DMC Pension Plan Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</thc:ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzQtMi0xLTEtMjkzNzEw_8f010291-01f5-4512-b83a-ed92519d07b5"
      unitRef="usd">1313000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzQtNC0xLTEtMjkzNzEw_6d260872-e07e-46b8-b892-a85be1909e8a"
      unitRef="usd">1429000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzYtMi0xLTEtMjkzNzEw_917a0fc0-6f7c-493e-b2ef-f6a915542dd0"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzYtNC0xLTEtMjkzNzEw_eda94d87-714f-44d0-a7d1-cc0c95180351"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzctMi0xLTEtMjkzNzEw_2e024218-a662-405e-8649-aeac93b948c0"
      unitRef="usd">-265000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzctNC0xLTEtMjkzNzEw_91f67fcd-9871-4012-9f70-99e646f65bd5"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <thc:DefinedBenefitPlanBenefitsPaidOrEmployerContribution
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzgtMi0xLTEtMjkzNzEw_1350ca81-e08f-4a44-ad13-3ab97ab610cc"
      unitRef="usd">83000000</thc:DefinedBenefitPlanBenefitsPaidOrEmployerContribution>
    <thc:DefinedBenefitPlanBenefitsPaidOrEmployerContribution
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzgtNC0xLTEtMjkzNzEw_bb1b3f3d-ec29-431e-8f10-573e36c271b2"
      unitRef="usd">110000000</thc:DefinedBenefitPlanBenefitsPaidOrEmployerContribution>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEwLTItMS0xLTI5MzcxMA_1b60fae0-9719-45a9-b020-319c5dbccc89"
      unitRef="usd">1002000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEwLTQtMS0xLTI5MzcxMA_960237d0-5b2a-4392-8901-560f13b227f8"
      unitRef="usd">1313000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEyLTItMS0xLTI5MzcxMA_38126000-c5ab-4783-b0c1-53e6ce359794"
      unitRef="usd">867000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEyLTQtMS0xLTI5MzcxMA_f1800f74-aedb-44f2-a779-950e72bfc458"
      unitRef="usd">869000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEzLTItMS0xLTI5MzcxMA_65f541b3-645d-4298-a71e-d172c42b2c4b"
      unitRef="usd">-161000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzEzLTQtMS0xLTI5MzcxMA_aabe6415-4450-4169-b191-d017b37a388f"
      unitRef="usd">62000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE0LTItMS0xLTI5MzcxMA_abdc2679-199a-459c-a365-de0aa236341c"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE0LTQtMS0xLTI5MzcxMA_1dc69d3f-4374-47e1-85bd-bcb434e741aa"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE1LTItMS0xLTI5MzcxMA_359b5405-fe68-4bd3-b9fe-489c486aee16"
      unitRef="usd">60000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE1LTQtMS0xLTI5MzcxMA_6aeb7197-0fc0-411e-b14c-42eb34e988f0"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE2LTItMS0xLTI5MzcxMA_a7a25821-42ef-4145-93dc-3d456c67f6e4"
      unitRef="usd">648000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE2LTQtMS0xLTI5MzcxMA_ceba2c12-bc4c-4724-8af1-7a597a4c13a8"
      unitRef="usd">867000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE3LTItMS0xLTI5MzcxMA_2c718ef2-314d-4cdb-b362-6acf3e440014"
      unitRef="usd">-354000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpiNDcyNGY5Y2M1ZWY0OTY4OGJlYzM0N2ViYTNiYjkxMy90YWJsZXJhbmdlOmI0NzI0ZjljYzVlZjQ5Njg4YmVjMzQ3ZWJhM2JiOTEzXzE3LTQtMS0xLTI5MzcxMA_a69c4381-e7dc-49e4-80b6-02081633b23d"
      unitRef="usd">-446000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NDE0_9ce982e7-0fd9-4ee1-9662-ba2c44f9476e"
      unitRef="usd">1002000000.000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NDIx_db4ab266-7068-49ab-85d8-58ad4beceaee"
      unitRef="usd">1311000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIwLTItMS0xLTI5MzcxMA_2ce5cc1b-4867-4fd3-bd52-6b860569a5f8"
      unitRef="usd">23000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIwLTQtMS0xLTI5MzcxMA_a5fbf446-772e-4414-9a1c-c07159a28b98"
      unitRef="usd">25000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIxLTItMS0xLTI5MzcxMA_dc692143-0166-4482-b152-389c43f4687f"
      unitRef="usd">331000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIxLTQtMS0xLTI5MzcxMA_62f413a8-c928-49b5-8273-924e38a29934"
      unitRef="usd">421000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIyLTItMS0xLTI5MzcxMA_d114f477-14c8-4cee-abb5-5628adab8d82"
      unitRef="usd">222000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzIyLTQtMS0xLTI5MzcxMA_057a050b-3e36-4e26-9aa3-4e7e45b63fb3"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i3f46c6a3f87c4ea9a9fc91235eb3ce6d_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI1LTItMS0xLTI5MzcxMA_88ae2033-c10e-4f12-be24-da6bbcae093c"
      unitRef="number">0.0575</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i9911fb6980184642b2b91df127e81577_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI1LTQtMS0xLTI5MzcxMA_d286aacb-c532-43f0-979d-79e971230785"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i3f46c6a3f87c4ea9a9fc91235eb3ce6d_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI2LTItMS0xLTI5MzcxMA_4ac0d9cd-18c7-4857-b51d-b446face6f31"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i9911fb6980184642b2b91df127e81577_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzI2LTQtMS0xLTI5MzcxMA_499bcf32-f901-4a5b-aeb0-c22522e23a74"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i3e71186460e94813b374c45bf631f9e4_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzMwLTItMS0xLTI5MzcxMA_1a1ae6fc-6556-4add-a76c-0494b806012d"
      unitRef="number">0.0551</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ia1714de0eddf4a14b7a6a4d8e217cf42_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTplZmUxODUwYWMzNTM0ODdmYmM3ZDA4MmI1ZmNlZDk2ZC90YWJsZXJhbmdlOmVmZTE4NTBhYzM1MzQ4N2ZiYzdkMDgyYjVmY2VkOTZkXzMwLTQtMS0xLTI5MzcxMA_eeabb162-2b20-4027-b239-fb2a399503a9"
      unitRef="number">0.0289</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTMx_1305fd37-8f09-42ed-9871-5c10868d2fbd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit costs and related assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost (income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SERP Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Census date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DMC Pension Plan Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term rate of return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation increase rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Frozen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Census date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMC0xLTEtMjkzNzEw_4f483039-27bc-4155-b76a-ffda72e9e3f6">Interest costs</thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag>
    <thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMC0xLTEtMjkzNzEw_6546235e-9b3a-48e8-9070-9732a68b44a6">Interest costs</thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag>
    <thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMC0xLTEtMjkzNzEw_70f7842c-e8c2-4a9c-8fb0-26721e2a1a09">Interest costs</thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtMi0xLTEtMjkzNzEw_8781c283-d7ce-449a-b214-cd7525a88026"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtNC0xLTEtMjkzNzEw_d20ef1a8-dcfc-46fa-94ef-6099b14bac8d"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzMtNi0xLTEtMjkzNzEw_f3dc9d28-5741-441a-9a2d-9f0fc2fd06ea"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanInterestCost>
    <thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMC0xLTEtMjkzNzEw_091b37a6-9a6c-43a7-8537-037162ea23bf">Expected return on plan assets</thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag>
    <thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMC0xLTEtMjkzNzEw_a83c63be-d50c-4087-9d49-c1826c34a5e3">Expected return on plan assets</thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag>
    <thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMC0xLTEtMjkzNzEw_add8dc48-a4f8-4c97-9306-a0a8d2417ca4">Expected return on plan assets</thc:DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtMi0xLTEtMjkzNzEw_e63acf81-91d8-49cb-bd86-cd3cedfff61e"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtNC0xLTEtMjkzNzEw_31a89247-cfda-4a17-aeab-87eeb8980261"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzQtNi0xLTEtMjkzNzEw_b6145e96-fc59-456b-9468-9fdc85fb85fe"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzUtMi0xLTEtMjkzNzEw_fe87caa7-9ac2-4db0-89c2-9a4ab536f449"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzUtNC0xLTEtMjkzNzEw_696d6886-365d-4b07-88d7-890bda4e0efa"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzUtNi0xLTEtMjkzNzEw_fa1489e5-7fa8-4a2d-8d65-a573c5827bc5"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzctMi0xLTEtMjkzNzEw_2c3f833e-6e08-40cf-a8b9-95105ed6217c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzctNC0xLTEtMjkzNzEw_33b36df4-8631-4ad1-87ba-f7a68543f031"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzctNi0xLTEtMjkzNzEw_914dc007-0af2-4e70-b2ea-1b11f3e39420"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEwLTItMS0xLTI5MzcxMA_d2230dc1-0990-4b71-975f-6d27f85b2603"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i8494255e124249a0a3eeafe8a1ec5580_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEwLTQtMS0xLTI5MzcxMA_d6016acf-a132-40d4-955c-a317b32a7cb0"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i39222fbfc5de44bcbd66b5dd47d6c432_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEwLTYtMS0xLTI5MzcxMA_50dbbe68-e983-4d18-8afb-08f7aed89de0"
      unitRef="number">0.0350</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ic3434152f47143f69ad506a0d0b49c1d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEyLTItMS0xLTI5MzcxMA_9e8754a5-107b-4d2f-9065-7d7efb6dadbf"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i8494255e124249a0a3eeafe8a1ec5580_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEyLTQtMS0xLTI5MzcxMA_f4bc1b7f-c73e-4221-beaa-822190589a74"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i39222fbfc5de44bcbd66b5dd47d6c432_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzEyLTYtMS0xLTI5MzcxMA_efb5e7d3-aa2d-42d1-a845-c3e25fa91a51"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ie7214f3a35494e78a472ea44db915760_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE3LTItMS0xLTI5MzcxMA_7642df62-1fbd-4260-b111-73e0d416c25a"
      unitRef="number">0.0289</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i0f659dcb43db4e5299ae2bd34817319b_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE3LTQtMS0xLTI5MzcxMA_140518a5-bcd9-4e3d-957f-a87c6cc7fe6c"
      unitRef="number">0.0253</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i7a0335a3b4cd4570916a79350e8b8301_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE3LTYtMS0xLTI5MzcxMA_6e259220-812b-4d39-ad80-2a3385a5834f"
      unitRef="number">0.0360</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ie7214f3a35494e78a472ea44db915760_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE4LTItMS0xLTI5MzcxMA_25408b24-000b-4a7b-b04a-29b09a1c2263"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i0f659dcb43db4e5299ae2bd34817319b_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE4LTQtMS0xLTI5MzcxMA_9b7d7461-0be3-40c3-ac3b-6fc41d395757"
      unitRef="number">0.0625</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i7a0335a3b4cd4570916a79350e8b8301_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo4N2EyOGQ5YmVmYTM0NWNmOGRmYTU4MmJhMTI2MDlhMy90YWJsZXJhbmdlOjg3YTI4ZDliZWZhMzQ1Y2Y4ZGZhNTgyYmExMjYwOWEzXzE4LTYtMS0xLTI5MzcxMA_9e17eec6-ec30-4c43-b0f5-978a1b92978b"
      unitRef="number">0.0625</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NzI2_bee3530d-df9e-4bbf-8bea-cdf589de281d"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NzMw_b09fcc7f-8647-4438-9059-4cce2268626e"
      unitRef="usd">61000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE0NzM3_5c4c00af-881b-4711-bed4-e30dc40f90d9"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MDA2_3260baed-c7a8-4b3d-89bd-a142c604c601"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MDEw_2840c64e-5789-442a-bf49-ec877e2a5f3b"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MDE3_aa3bf9e1-e56c-49c9-9617-40ff210b0068"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MTM0_ab124fd9-3891-4716-9913-1b960c9062f4"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MTM4_eae1fa4d-6ced-408c-865d-0df3a796a3df"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1MTQ1_2b414406-9387-4b54-bf7f-33b0d4a018f5"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDMx_7279c2df-7ccd-4adb-9ba0-e76c39463013"
      unitRef="usd">-222000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDM1_b1928d5e-edcd-4a74-b67d-23c790e538a5"
      unitRef="usd">-294000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE1NDQy_2b742573-0f1a-4b0a-84b4-e78e94dc572d"
      unitRef="usd">-355000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNTQ5MjA_73770634-416b-4fbd-8148-e64232bd03bb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNTQ5MjA_9bb1be77-c93c-4645-9a57-78acd5469ad6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzI3NDg3NzkxNTQ5MjA_d2b52b53-080a-47f6-ada9-605b6fdc2251"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTI1_acd3f092-cbdb-4ebe-8d0d-910737589c4c">&lt;div style="text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted&#x2011;average asset allocations by asset category as of December&#160;31,&#160;2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Actual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alternative investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ia8470639b4b74ccb87974669a576a9a9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzEtMi0xLTEtMjkzNzEw_1a7a6f83-c5b0-4a70-807e-033b62e1df6e"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage
      contextRef="ia8470639b4b74ccb87974669a576a9a9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzEtNC0xLTEtMjkzNzEw_7992a3e6-136e-43c4-a26c-58dd13772726"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzMtMi0xLTEtMjkzNzEw_65a33db6-715e-4b84-911e-d89110392a5e"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage
      contextRef="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzMtNC0xLTEtMjkzNzEw_0ce68801-8174-4ecc-a70f-e6bc2f93e806"
      unitRef="number">0.14</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i7db9aaa63ebf4a2c9985af6bf21ba265_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzQtMi0xLTEtMjkzNzEw_2ea0aaf3-2342-4089-82cf-3c38f81f8a63"
      unitRef="number">0.73</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage
      contextRef="i7db9aaa63ebf4a2c9985af6bf21ba265_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzQtNC0xLTEtMjkzNzEw_726bde14-d3fb-46e6-aa84-ee2a9f981930"
      unitRef="number">0.70</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i1b14503d12cd4ff1a8738f04383e21c5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzUtMi0xLTEtMjkzNzEw_017927ab-3a7e-4c2e-8859-07c16d95887a"
      unitRef="number">0.07</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage
      contextRef="i1b14503d12cd4ff1a8738f04383e21c5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTo2ZTI3ZTEzYmMwM2Q0YzYyYjFhMjZlODBhZjEwNWZiYi90YWJsZXJhbmdlOjZlMjdlMTNiYzAzZDRjNjJiMWEyNmU4MGFmMTA1ZmJiXzUtNC0xLTEtMjkzNzEw_144dbbe1-414e-4ad2-a19d-471e1b756e46"
      unitRef="number">0.15</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage>
    <thc:ScheduleOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5OTI2_4fd66ca7-bb5a-4251-a161-e26ebc91ccbb">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the DMC Pension Plan assets measured at fair value on a recurring basis as of December&#160;31,&#160;2022 and 2021, aggregated by the level in the fair value hierarchy within which those measurements are determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;545&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</thc:ScheduleOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8470639b4b74ccb87974669a576a9a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtMi0xLTEtMjkzNzEw_cc9ec3a5-a668-4612-ab07-1c69f59ea05b"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i804714da76e641858c08fb5432ea37ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtNC0xLTEtMjkzNzEw_7f8d4f8d-4284-46a9-8b26-d4f46c00ea92"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a67fa33749c43db986a0beb057d4ac7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtNi0xLTEtMjkzNzEw_9641cdc2-35d7-42a4-9021-e14efb345040"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i454a85da8698479a8e723e2cce4a6296_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEtOC0xLTEtMjkzNzEw_a393179c-7307-46f2-839a-4eee2a73ac07"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie8f29696742d4f7c924fa8a7d2d1676c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItMi0xLTEtMjkzNzEw_e64ec16a-8d7e-4a22-bef7-8b7eb45c82ac"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6628865c9e54cb59a13c1563d995f42_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItNC0xLTEtMjkzNzEw_0f250a39-e62b-447e-97fa-e1e8a656cfb9"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80a91a77e3d24e61a737e24af4f558eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItNi0xLTEtMjkzNzEw_f49ececb-1768-4e12-a999-2435bb3c7cb6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5e8ac7ec5a3745248b611c964292857b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzItOC0xLTEtMjkzNzEw_ebd495c7-7390-4c49-94c5-48c10434c44e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i49284b149a704d88bdc9d6e996c457e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtMi0xLTEtMjkzNzEw_88a0762f-5890-4737-b21c-cb1d6373ec6c"
      unitRef="usd">200000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7e2b5e26a8054b03b96aa3a7fbeb79ed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtNC0xLTEtMjkzNzEw_b2cde2e1-aee5-4ace-9db2-1e949a18c296"
      unitRef="usd">200000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b9ca9d71ea74bd0a7deec85ce36524a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtNi0xLTEtMjkzNzEw_85a0ab11-cf9a-4078-aaa6-bf0de2aaee91"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1e43f8ced2d426988a867fc0f0b14c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzQtOC0xLTEtMjkzNzEw_c7ba0b2d-b980-491d-8732-bec2e4950fe5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12b87a25e42b480aac87219815bac866_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtMi0xLTEtMjkzNzEw_8e3549ed-a3dc-4c0e-b660-018029ded696"
      unitRef="usd">249000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic93c45adbd6e4f78b04ad5d1b90243b5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtNC0xLTEtMjkzNzEw_6f8c1062-afa3-47e2-ac19-17365e541619"
      unitRef="usd">249000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i285ab10c7ac148e38a100d1ad2af2744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtNi0xLTEtMjkzNzEw_357969f8-f71e-446b-8330-a3b3a6d20cad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia94c4bf4ebf248dc96407cf574d23a82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzUtOC0xLTEtMjkzNzEw_5ee590c3-90b9-47ba-8c2e-55b2b775dbd7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i166be3168d7f4ac7b806eb76ded856f0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctMi0xLTEtMjkzNzEw_fab7f402-832e-468d-873f-621db739e679"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a9280afba054c2f84e6e536996e9a74_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctNC0xLTEtMjkzNzEw_e38a4eba-8c69-4977-baad-12c1d9262fa5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44f9676a3338438bbcb6a0fc6b10f019_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctNi0xLTEtMjkzNzEw_b12aee82-c4a5-447e-b02b-8431c5dcff2d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7ae60f4fa3854826b47d1a2b21ed0e58_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzctOC0xLTEtMjkzNzEw_f9e4a6af-340e-4097-a9e9-d45ebd35f826"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5b28459d0dc443289dbd7f5a11180a1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktMi0xLTEtMjkzNzEw_359a4192-ff47-4982-a22f-2c3cd1a60fa7"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id6d79b4c21364b1e8d5b7aafdc463a8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktNC0xLTEtMjkzNzEw_982986df-ba29-468b-8a35-de17204c1ad9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2315eeff4c34c5b9d914e09c1031bdd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktNi0xLTEtMjkzNzEw_e1d16b28-b4a0-40d6-9995-0539a037c145"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89da8ec516bc4c688a3f2e4138bd9130_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzktOC0xLTEtMjkzNzEw_887457a7-99f5-4ab1-96f9-5afcfbea6eac"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e71186460e94813b374c45bf631f9e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTItMS0xLTI5MzcxMA_bfd43554-b4d7-4d8f-8c5a-6856c7135c28"
      unitRef="usd">648000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i042c29b651e9422c9c3b8fc7734703e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTQtMS0xLTI5MzcxMA_a0c77f0e-f7ab-42dc-9f54-35474b1bf5ab"
      unitRef="usd">545000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i78f58b7435b945b38eab242b75e7de88_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTYtMS0xLTI5MzcxMA_795cbc79-ab24-4adb-a671-ec8b22ac9663"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9461354d8d8d47dd881117ff98a3af8b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTphYmMzODEzMjI0MWM0MzlkODUyNGU0N2I0MjgzODRjOS90YWJsZXJhbmdlOmFiYzM4MTMyMjQxYzQzOWQ4NTI0ZTQ3YjQyODM4NGM5XzEwLTgtMS0xLTI5MzcxMA_2d67fda8-4a5e-4043-883c-937044d46328"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib3c31677d6754a34bd494423b74a602e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtMi0xLTEtMjkzNzEw_712fab2e-340b-4c1b-a865-2df0cc78ddb3"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2286f8106dae40a78e46d44361f52c75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtNC0xLTEtMjkzNzEw_af68b784-90b4-4ee3-812b-a54823c8470d"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice9ea6ae06b14e35bad5e2ca1e409fde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtNi0xLTEtMjkzNzEw_ca8a00eb-1bf5-4ad8-abc6-1cbc9d9d2789"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6af6470ab1cb4bff9fe84140822865d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzEtOC0xLTEtMjkzNzEw_e0fe7013-0b84-4cab-9a5c-fb188475235e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if199fa14f8c442b6b5a44ca21380346d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItMi0xLTEtMjkzNzEw_8a4c3367-211f-4b21-ba14-567d63c1122c"
      unitRef="usd">242000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4f72100695fc4f70b93df4bc5ca16207_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItNC0xLTEtMjkzNzEw_a818f998-aa50-473a-ba57-bc2c97c16a7c"
      unitRef="usd">242000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id1bdcec982d2405ab478007ab8e9cf72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItNi0xLTEtMjkzNzEw_9cb33408-cead-43cf-b628-e00608041d96"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6cea09136b94497abde3744de16ffbb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzItOC0xLTEtMjkzNzEw_6da09937-3c9b-415c-8543-6d1221352198"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if5d7173e0e014de1934a570e1112af04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtMi0xLTEtMjkzNzEw_02f11322-336c-4dfe-8fac-2754e3774008"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb5bb9664ade472286428ea8e0f32595_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtNC0xLTEtMjkzNzEw_7f2f0bd6-6aad-4229-bf03-e2ec71ef3641"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b2c8dfd6d53454598ef5cc59f8493f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtNi0xLTEtMjkzNzEw_3847c489-d984-4258-89b7-eff85c7437ae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6833358c1d6741f7a2f16c63211b57f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzQtOC0xLTEtMjkzNzEw_472c5bb8-da7c-4b6e-b3a2-a36a4781b73d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c06dc18705542b1b0f4578035465c35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtMi0xLTEtMjkzNzEw_050a9c7e-f92d-4980-8ef6-85bba6ac5f2c"
      unitRef="usd">448000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d50cbc9ad614ba59c37a5e12995c52a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtNC0xLTEtMjkzNzEw_3b44fa58-8b2c-4ccc-912c-deb68b488a37"
      unitRef="usd">448000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia55523ac8a4c49a4b496cb9c6bc21731_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtNi0xLTEtMjkzNzEw_291f45b1-4411-457b-b347-724679b4c49a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc6551b57d1e4468b0725e4877eb3d2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzUtOC0xLTEtMjkzNzEw_cc0830ad-4729-4c2a-bd81-4088b8e680e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if415ffa4ddcd4d20b4d45d7405511cef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctMi0xLTEtMjkzNzEw_a6dedeb0-81b2-4f2c-8781-b30924d749fd"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4631c47e1f244bdd9e1c8d3c5f70454a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctNC0xLTEtMjkzNzEw_6c1779c6-a81b-41f2-b02d-aaf9f9dcfa5d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa63b9feebb74020bb298b5272d2cb91_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctNi0xLTEtMjkzNzEw_1194af0a-2250-4d5e-aa9c-10d5d31409e3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i686e590299944c6c873a2b143fb8bc32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzctOC0xLTEtMjkzNzEw_bf934639-3252-470e-841c-d34c7106c0c2"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i800184fe85bb47b5a889821fbb17e7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtMi0xLTEtMzI1MDU3_8e286411-db81-40ce-9c93-82411f1ff316"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i585ae55410ba4bf0b908db0bc2194a89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNC0xLTEtMzIwODgx_86b226ae-4641-4628-976c-d50aafe5089c"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ea4687cc2d24bd4be9ac86b4b9f8bed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNi0xLTEtMzIwODgx_1bc42207-5fcf-4f21-81a2-fd001c59cd29"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0e833d841f1a420ba5b7b46bc27b98cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtOC0xLTEtMzIwODgx_f03392d4-7229-49b4-ac63-c7fe0d561a55"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6531ba19db2c480e8abe335385484440_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtMi0xLTEtMjkzNzEw_f5ca4e90-2057-468a-9823-f2604c6a6a41"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccc97a4820c542d4bf607e57b51505a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNC0xLTEtMjkzNzEw_25cec06b-aafd-4a41-8df3-4108d1bb28ad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8cbfe439eef4938941ac808a39e48b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtNi0xLTEtMjkzNzEw_e31c3710-cf29-4725-a712-822f594f181d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaadb2472f2014a5b80d77c42eb1bf932_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzgtOC0xLTEtMjkzNzEw_88cbb9ef-f464-4390-be2a-7274e9b2d1dd"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1714de0eddf4a14b7a6a4d8e217cf42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktMi0xLTEtMjkzNzEw_6f4aa374-e1dc-45e0-82fd-c0edbe5efc58"
      unitRef="usd">867000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibac9538659da4c918abe6bc8330da9fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktNC0xLTEtMjkzNzEw_379b502c-85a8-4e99-b3e8-40fe8554cb92"
      unitRef="usd">784000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if54ea2398cb64048a475a0c8781dcff2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktNi0xLTEtMjkzNzEw_10417b12-9a4e-4746-b592-a1b34f5a47bd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0650b7b45a99449c9af4ff648257c831_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZToxMTFkOTEyYjJiM2Y0ZjE2OTQyYjIyNmJiYjVhMjBjNS90YWJsZXJhbmdlOjExMWQ5MTJiMmIzZjRmMTY5NDJiMjI2YmJiNWEyMGM1XzktOC0xLTEtMjkzNzEw_1fb96b20-688a-443b-8783-c5208136ee3d"
      unitRef="usd">83000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODk2_c1616679-9abe-4e25-9855-4487a50dfe06">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future benefit payments to be made from the SERPs and the DMC Pension Plan, a portion of which will be funded from plan assets, for the next five years and in the aggregate for the five years thereafter:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ending&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Five Years Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <thc:DefinedBenefitPlanExpectedFutureBenefitPayments
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMi0xLTEtMjkzNzEw_ef9e3798-29ca-436a-9ded-39fdfdf26384"
      unitRef="usd">822000000</thc:DefinedBenefitPlanExpectedFutureBenefitPayments>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItNC0xLTEtMjkzNzEw_01454eff-b215-445f-93de-a7819ab131f5"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItNi0xLTEtMjkzNzEw_91ea0193-2bf4-46fa-a8b7-ce02b023b42f"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItOC0xLTEtMjkzNzEw_c5f04477-9afa-4489-8a8a-63a6e56bf9a3"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMTAtMS0xLTI5MzcxMA_72e8a2d3-6d1c-4b6a-bd87-160db30f88f6"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMTItMS0xLTI5MzcxMA_9173279f-39e0-4643-9a75-01a5a9d8d898"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90YWJsZTpkZjgxZWJlMDEzZGU0MzgzOWUzNzlmYTQ2NGNlNDA3Yi90YWJsZXJhbmdlOmRmODFlYmUwMTNkZTQzODM5ZTM3OWZhNDY0Y2U0MDdiXzItMTQtMS0xLTI5MzcxMA_1600d0de-04e0-4bcc-bc5e-ac600d2b153f"
      unitRef="usd">398000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5NTYy_d743c679-0f51-4779-966c-0e46a10c23d8"
      unitRef="usd">-354000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5NjY2_75ecec26-2b9f-4e83-826a-3730cd7c89a4"
      unitRef="usd">23000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5NzA5_3893fe8c-d6fa-48f1-8934-6b042e5c569d"
      unitRef="usd">331000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjAvZnJhZzpiOTMzN2JiMDQ4MzU0Y2UzOTI0OTFiZDE2ZjNjZmRiZC90ZXh0cmVnaW9uOmI5MzM3YmIwNDgzNTRjZTM5MjQ5MWJkMTZmM2NmZGJkXzE5ODM1_a96edd8d-6b8a-44c1-9771-ffb3487bf5c9"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzI3MA_40a3b2ed-e424-4912-84a9-8211236a8146">PROPERTY AND EQUIPMENT&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of property and equipment are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, less accumulated depreciation and amortization and impairment write&#x2011;downs related to assets held and used. We recognized depreciation expense of $669 million, $667 million and $685 million in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzI3Mg_fa59e874-8003-4a74-b3c8-64042d86221b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of property and equipment are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e2fd93f349c4e4c9ddc4ef367845986_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzItMS0xLTEtMjkzNzEw_86cedbc1-c7c3-4e9c-b96d-64e4177bda29"
      unitRef="usd">661000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibfbf92bb89634290b801e88029d92389_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzItMy0xLTEtMjkzNzEw_0bf4a89f-c1d9-4392-94f4-f7b7da3ed699"
      unitRef="usd">635000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b511b7a489f423484bdb8a101ff9a36_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzMtMS0xLTEtMjkzNzEw_30263278-a821-4b3d-804e-94982efd6c0c"
      unitRef="usd">6646000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2bb29332c7e349048cbb4839508b6add_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzMtMy0xLTEtMjkzNzEw_dfbe3c84-3ef4-466b-8b75-3d4bebe3e754"
      unitRef="usd">6652000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib43e7382c8b743a7b9f53c2d06e8305a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzQtMS0xLTEtMjkzNzEw_4d1efc61-fb2f-4d27-ba08-9b32b9d361b3"
      unitRef="usd">195000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7ca722478f4d4353be6a7b1b4eb2b7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzQtMy0xLTEtMjkzNzEw_34bcc43a-c581-408d-94c5-89266a1809ff"
      unitRef="usd">166000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4130035b4ffb4b2b9759276d80640702_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzUtMS0xLTEtMjkzNzEw_9e30c512-d1a3-4a49-bb94-1eb848e611b5"
      unitRef="usd">4748000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4086403e4e54685aed1e1243c892e5e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzUtMy0xLTEtMjkzNzEw_46cf2499-6724-45a5-a654-04495dbf9301"
      unitRef="usd">4455000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzYtMS0xLTEtMjkzNzEw_a801e1a5-1af6-4259-a990-e8522ebdb982"
      unitRef="usd">413000000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzYtMy0xLTEtMjkzNzEw_230e2fbf-66a5-4a93-a4b9-a68d2ed17783"
      unitRef="usd">479000000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzctMS0xLTEtMjkzNzEw_48388e89-233e-459b-9664-c8bd99382227"
      unitRef="usd">12663000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzctMy0xLTEtMjkzNzEw_42faf0be-c4b1-4597-b34e-dd92edf42db6"
      unitRef="usd">12387000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzgtMS0xLTEtMjkzNzEw_38b120bb-ec7f-47de-abb0-cab7993bdc15"
      unitRef="usd">6201000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzgtMy0xLTEtMjkzNzEw_c2874965-8431-4c60-906b-b7aaa369b5c5"
      unitRef="usd">5960000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzktMS0xLTEtMjkzNzEw_647f2da3-3b55-4901-b7ab-5ad65505f54e"
      unitRef="usd">6462000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90YWJsZToyOTI0YjQxOWJmYmE0ZmNhYjFlYzc2ZmYxYTQ2M2NiNS90YWJsZXJhbmdlOjI5MjRiNDE5YmZiYTRmY2FiMWVjNzZmZjFhNDYzY2I1XzktMy0xLTEtMjkzNzEw_e16e1ba2-c65f-4d35-b012-84cac76d2f9f"
      unitRef="usd">6427000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzU0OTc1NTgxNDc1NA_2aac11f5-e209-49b3-9e69-f6b0c7074c6b"
      unitRef="usd">669000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzU0OTc1NTgxNDc2NA_c073d07e-886a-4a81-9fa3-7e683b805768"
      unitRef="usd">667000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjYvZnJhZzpkMWYzZDFmOTE3OTQ0MzI2YjNkMDdmNzNlODc4ZDdjYy90ZXh0cmVnaW9uOmQxZjNkMWY5MTc5NDQzMjZiM2QwN2Y3M2U4NzhkN2NjXzU0OTc1NTgxNDc3MQ_5c4160a4-c5fc-4e3b-a7fe-e06b2f7efe55"
      unitRef="usd">685000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc2Mg_d4bae254-95c5-43f0-9961-126fd2363790">GOODWILL AND OTHER INTANGIBLE ASSETS&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information on changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at beginning of period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired during the year and purchase price allocation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill transferred from Ambulatory Care segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill related to assets held for sale and disposed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at end of period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired during the year and purchase price allocation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill transferred to Hospital Operations segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill related to assets held for sale and disposed or deconsolidated facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no accumulated impairment losses related to the goodwill in our Ambulatory Care and Conifer segments at December&#160;31,&#160;2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information regarding other intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&#160;Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;At December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with finite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with indefinite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with finite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with indefinite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated future amortization of intangibles with finite useful lives as of December&#160;31,&#160;2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Later Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized amortization expense of $172&#160;million, $188 million and $172 million in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc2Nw_f2e5013f-ef62-43da-9770-04ee49927336">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information on changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at beginning of period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired during the year and purchase price allocation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill transferred from Ambulatory Care segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill related to assets held for sale and disposed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at end of period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired during the year and purchase price allocation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill transferred to Hospital Operations segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill related to assets held for sale and disposed or deconsolidated facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillGross
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzQtMS0xLTEtMjkzNzEw_8965be94-91fc-4363-b011-daa6a6065f84"
      unitRef="usd">5238000000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="if474534dcafd415d9534dbb0774b811e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzQtMy0xLTEtMjkzNzEw_fc25ebe7-0fba-432b-807c-cfbe6bfb512c"
      unitRef="usd">5375000000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzUtMS0xLTEtMjkzNzEw_390b327c-162c-47c4-b6f1-784f6318f604"
      unitRef="usd">2430000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="if474534dcafd415d9534dbb0774b811e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzUtMy0xLTEtMjkzNzEw_19504b72-18c3-407b-bbf5-642fb94b447a"
      unitRef="usd">2430000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzYtMS0xLTEtMjkzNzEw_1774b6c2-74e4-4f8c-9e78-6762daa19ad4"
      unitRef="usd">2808000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if474534dcafd415d9534dbb0774b811e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzYtMy0xLTEtMjkzNzEw_400d8499-fd6c-4f58-9323-88b674faccf7"
      unitRef="usd">2945000000</us-gaap:Goodwill>
    <thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMS0xLTEtMzUyMzg5_b7456b13-a892-4bfe-ab61-b73a1f932651"
      unitRef="usd">1000000</thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments>
    <thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMy0xLTEtMzUyNDE3_ca96f8c1-23f6-4e3c-abc5-a774a504d899"
      unitRef="usd">0</thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTransfers
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMS0xLTEtMjkzNzEw_d89a8e7c-c9aa-4437-a9de-4dc87d133a5e"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzctMy0xLTEtMjkzNzEw_8e668c1d-425d-4770-997b-5bdd525ef03b"
      unitRef="usd">41000000</us-gaap:GoodwillTransfers>
    <thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzgtMS0xLTEtMjkzNzEw_53725c1a-c0e7-4253-94bf-db8edf355576"
      unitRef="usd">-3000000</thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility>
    <thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzgtMy0xLTEtMjkzNzEw_0f0d023e-1dd2-48a6-a2f9-6958e9d6fad8"
      unitRef="usd">-178000000</thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility>
    <us-gaap:Goodwill
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzktMS0xLTEtMjkzNzEw_7cda4d54-4c5c-439e-933b-9d21c3a2efff"
      unitRef="usd">2806000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzktMy0xLTEtMjkzNzEw_87d9cc78-3969-45f7-b7ed-c5f96b6e2649"
      unitRef="usd">2808000000</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEyLTEtMS0xLTI5MzcxMA_6b9c07fa-2a15-4df4-8162-9d2249947fee"
      unitRef="usd">5236000000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEyLTMtMS0xLTI5MzcxMA_e6ad03b3-ee9f-46c1-98f0-77e623e8a0aa"
      unitRef="usd">5238000000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEzLTEtMS0xLTI5MzcxMA_c6089ae0-e150-4311-96a7-f00387667f3c"
      unitRef="usd">2430000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzEzLTMtMS0xLTI5MzcxMA_b18f9d59-ccc7-4ed1-a1a4-5b408f3f5707"
      unitRef="usd">2430000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE0LTEtMS0xLTI5MzcxMA_c364e171-be81-4b00-90a6-1d11f7d9c030"
      unitRef="usd">2806000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE0LTMtMS0xLTI5MzcxMA_6338afdc-2f21-4cc6-863e-1e8954869924"
      unitRef="usd">2808000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE3LTEtMS0xLTI5MzcxMA_d001a0b8-ab18-4551-a428-e935078587a3"
      unitRef="usd">5848000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE3LTMtMS0xLTI5MzcxMA_54697c5e-4a88-4697-a227-99ff9ac2812a"
      unitRef="usd">5258000000</us-gaap:Goodwill>
    <thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE4LTEtMS0xLTI5MzcxMA_225d9b0f-36d1-43e1-91a8-ac19cbdc6f7f"
      unitRef="usd">866000000</thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments>
    <thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE4LTMtMS0xLTI5MzcxMA_632ff58b-c44a-4879-a54b-af203499b957"
      unitRef="usd">664000000</thc:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTransfers
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE5LTEtMS0xLTI5MzcxMA_7885cfbe-2dec-4240-a6f8-5cb8c22a391a"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzE5LTMtMS0xLTI5MzcxMA_050d45c9-4f85-4c07-875d-9df433a9888f"
      unitRef="usd">-41000000</us-gaap:GoodwillTransfers>
    <thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIwLTEtMS0xLTI5MzcxMA_ecfdcbf9-b513-4be7-bc80-66726e271769"
      unitRef="usd">-2000000</thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility>
    <thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIwLTMtMS0xLTI5MzcxMA_f7f7c99f-8522-45b7-81d1-7b370f31f400"
      unitRef="usd">-33000000</thc:GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility>
    <us-gaap:Goodwill
      contextRef="ib165a084700643e1b139d15df43a3b15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIxLTEtMS0xLTI5MzcxMA_bd569a6c-41c7-4340-b568-afa307f8cf8e"
      unitRef="usd">6712000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzIxLTMtMS0xLTI5MzcxMA_94cc5697-bdf9-405f-a57f-d5e683587ef8"
      unitRef="usd">5848000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI0LTEtMS0xLTI5MzcxMA_341c3e60-6576-45ac-b4ed-b2d36cd59f39"
      unitRef="usd">605000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI0LTMtMS0xLTI5MzcxMA_5201891c-77e9-40d6-add2-511f759104df"
      unitRef="usd">605000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI3LTEtMS0xLTI5MzcxMA_102f36af-173d-4330-8744-ce12918f2a79"
      unitRef="usd">605000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTpkYjdiNDE2ZWI0MjU0YjRiOWEyODBiMWRlMzQyYjcyZC90YWJsZXJhbmdlOmRiN2I0MTZlYjQyNTRiNGI5YTI4MGIxZGUzNDJiNzJkXzI3LTMtMS0xLTI5MzcxMA_07c982b5-7795-406e-bf0c-868afd2f9a80"
      unitRef="usd">605000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_300d8f5c-dde9-482f-84c0-2f10c08615e5"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_5229596d-a503-4e20-8e5e-567f8beac5ba"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_6cfaf57d-d7a1-4db3-96e2-d54d47359344"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ib165a084700643e1b139d15df43a3b15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzIyMQ_aa4a56c8-68ce-4ab5-8c0f-807b708a0ed4"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc2MQ_bef24e48-b2b4-4e0d-b6dd-be8694cfccbe">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information regarding other intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&#160;Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;At December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with finite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with indefinite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with finite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets with indefinite useful lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i694630452a604fb9ad2d2c6646397326_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzItMS0xLTEtMjkzNzEw_ebf58bab-7ad8-4599-bde8-2c2a69d57321"
      unitRef="usd">1751000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i694630452a604fb9ad2d2c6646397326_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzItMy0xLTEtMjkzNzEw_e80509ea-a10b-4a00-9603-f78b1af9d5e0"
      unitRef="usd">1206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i694630452a604fb9ad2d2c6646397326_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzItNS0xLTEtMjkzNzEw_24cf702f-9377-4e10-bc75-80e3ba688a8d"
      unitRef="usd">545000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib8655e44515147ea8a7957f6e984603a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzQtMS0xLTEtMjkzNzEw_4987a70c-04b2-40dd-bc69-8f94497b2598"
      unitRef="usd">295000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib8655e44515147ea8a7957f6e984603a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzQtMy0xLTEtMjkzNzEw_28b497a6-dc3e-40e6-8fb0-ba14eaaca1e0"
      unitRef="usd">146000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib8655e44515147ea8a7957f6e984603a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzQtNS0xLTEtMjkzNzEw_8f48c87d-e838-41fc-b1d9-e56b4c8e9da6"
      unitRef="usd">149000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iccb013137715473a8be5f4a83d7293f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzUtMS0xLTEtMjkzNzEw_95d51c3c-2b33-4c56-982b-cf98da38493c"
      unitRef="usd">92000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iccb013137715473a8be5f4a83d7293f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzUtMy0xLTEtMjkzNzEw_0e415929-2cde-49a3-903d-4715f7241c39"
      unitRef="usd">76000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iccb013137715473a8be5f4a83d7293f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzUtNS0xLTEtMjkzNzEw_4509ea7b-a06e-4a4c-99b6-5ec706c79a28"
      unitRef="usd">16000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzYtMS0xLTEtMjkzNzEw_fa5277d7-8a97-48f2-a368-863eddd03d79"
      unitRef="usd">2138000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzYtMy0xLTEtMjkzNzEw_75564df8-d11e-41ea-b651-97a7fce94b4c"
      unitRef="usd">1428000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzYtNS0xLTEtMjkzNzEw_97b83bab-7731-46cf-a755-5e38d5eb5c43"
      unitRef="usd">710000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic7d0c6d3c86d49d0bae4aa0dd4b382e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTEtMS0xLTMyMDk3NA_4a2702e8-74d8-4eb0-806b-48ab623d0b39"
      unitRef="usd">105000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic7d0c6d3c86d49d0bae4aa0dd4b382e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTUtMS0xLTMyMDk3NA_dfc41ca3-3473-47da-8f71-399fc4fad443"
      unitRef="usd">105000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0abd09d196974cba90b5e722e01a984c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTEtMS0xLTMyMTAwNQ_32e45e3b-ebea-4600-8951-b65232d69b3a"
      unitRef="usd">603000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0abd09d196974cba90b5e722e01a984c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEwLTUtMS0xLTMyNTA2Nw_f8196b06-6983-4962-8630-ff89e4fc11b8"
      unitRef="usd">603000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i38e94e8fb0af4f14add5061334e930e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzExLTEtMS0xLTMyMTAwNQ_a760ee8d-e7d1-45dd-b4d0-12ea21f3a0c3"
      unitRef="usd">6000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i38e94e8fb0af4f14add5061334e930e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzExLTUtMS0xLTMyNTA2Nw_6ddd9bca-3b7f-4a3f-a948-74626981b8a0"
      unitRef="usd">6000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEyLTEtMS0xLTMyNTA2Nw_e1099713-1eee-4c84-aa6c-0170b46c271e"
      unitRef="usd">714000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEyLTUtMS0xLTMyNTA2Nw_eca4f3be-24b1-4f80-a0a1-dd45639cb734"
      unitRef="usd">714000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEzLTEtMS0xLTMyNTA3Mw_9a7dcd94-5ea8-4eb3-b868-a0bcd8f16bcf"
      unitRef="usd">2852000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEzLTMtMS0xLTMyNTA3NQ_8c35837e-e469-4ee9-a017-7e6c469ad002"
      unitRef="usd">1428000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzEzLTUtMS0xLTMyNTA3Nw_bd3a2861-9408-4fbe-965c-4f9c21b7f71a"
      unitRef="usd">1424000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6cce08bda3d542f198b8d18a883aec5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE3LTEtMS0xLTMyMTA0OQ_3a13db85-2540-446d-806a-ed2e0a9da04a"
      unitRef="usd">1770000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6cce08bda3d542f198b8d18a883aec5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE3LTMtMS0xLTMyMTA0OQ_eff4eb04-b3f2-41d9-83f2-5ee2a6ace616"
      unitRef="usd">1165000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6cce08bda3d542f198b8d18a883aec5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE3LTUtMS0xLTMyMTA0OQ_2cb2985e-262a-457e-89a0-b2d27bd7bef2"
      unitRef="usd">605000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE4LTEtMS0xLTMyMTA1NA_9516e0ae-528b-4e90-899b-1709c7e42431"
      unitRef="usd">295000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE4LTMtMS0xLTMyMTA1NA_d1ea355e-c7e1-4a0b-a299-e9a7f4cbb3f3"
      unitRef="usd">128000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0c48ef47bbb24ffb8f4b4c5a77c98096_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE4LTUtMS0xLTMyMTA1NA_eb3a272f-1658-475d-ae09-04271d641883"
      unitRef="usd">167000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i865db5ff099a45238d86047cb5bf3f0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE5LTEtMS0xLTMyMTA1NA_06192260-fbac-4402-b314-f6ddb59f5702"
      unitRef="usd">95000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i865db5ff099a45238d86047cb5bf3f0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE5LTMtMS0xLTMyMTA1NA_35ea4de1-48ed-4e17-8063-e9deb9875d0d"
      unitRef="usd">81000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i865db5ff099a45238d86047cb5bf3f0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzE5LTUtMS0xLTMyMTA1NA_dcdaecba-ddb0-4538-8d65-8abf9e0a78a4"
      unitRef="usd">14000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzIxLTEtMS0xLTMyNTA4NQ_1486e125-94f1-474f-947d-9cadf5ca4c35"
      unitRef="usd">2160000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzIxLTMtMS0xLTMyNTA4NQ_4d0b5824-1210-4d5a-99a0-e10f6f59efa0"
      unitRef="usd">1374000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzIxLTUtMS0xLTMyNTA4NQ_008cfe1e-1da6-4500-aac4-4d7955494146"
      unitRef="usd">786000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2fbb8dc0a34648caadf9b08b028a9c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI0LTEtMS0xLTMyMTA2OQ_f25f027c-0f4a-4865-99db-f780ab81abd4"
      unitRef="usd">102000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2fbb8dc0a34648caadf9b08b028a9c30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI0LTUtMS0xLTMyNTA3MA_b6f7efda-5440-4528-9c48-624f57fe3b1a"
      unitRef="usd">102000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iedac06e53ae3427382872dc1d8f25c8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI1LTEtMS0xLTMyMTA2OQ_f06005bd-9880-424e-be66-aa1d83ec0e03"
      unitRef="usd">602000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iedac06e53ae3427382872dc1d8f25c8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI1LTUtMS0xLTMyNTA3MA_37a34872-541a-41a0-b28b-d0331e3e8d4f"
      unitRef="usd">602000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i58b58c9b298645b8821390d35d437e25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI2LTEtMS0xLTMyMTA2OQ_b753f3de-6881-428a-9331-9673568ce723"
      unitRef="usd">7000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i58b58c9b298645b8821390d35d437e25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI2LTUtMS0xLTMyNTA3MA_c43d7458-e855-4f4f-ac0c-18a9baa18873"
      unitRef="usd">7000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI3LTEtMS0xLTMyNTA3MA_998e5b9a-91a4-42d0-9a84-802f416ea365"
      unitRef="usd">711000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI3LTUtMS0xLTMyNTA3MA_4ae96fad-4332-45aa-8be1-573f27f11fce"
      unitRef="usd">711000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI4LTEtMS0xLTMyNTA4Mw_11331bd0-212c-40fe-b211-bf4fed6fe120"
      unitRef="usd">2871000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI4LTMtMS0xLTMyNTA4MQ_8ca0cd51-68c2-4cfa-89eb-1e5662e943ac"
      unitRef="usd">1374000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo3NDdhZWI0NTFlNjI0YzY4OTM0NDY3NjVkMTljMWNmMC90YWJsZXJhbmdlOjc0N2FlYjQ1MWU2MjRjNjg5MzQ0Njc2NWQxOWMxY2YwXzI4LTUtMS0xLTMyNTA3OQ_55dd751e-df12-4449-9c0a-ebedcb4c2eee"
      unitRef="usd">1497000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzc1OQ_868ef784-92ae-4ee2-8432-368a84723c5a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated future amortization of intangibles with finite useful lives as of December&#160;31,&#160;2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Later Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMS0xLTEtMjkzNzEw_b0561801-2e5a-42a1-9652-f9391485f8fc"
      unitRef="usd">710000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMy0xLTEtMjkzNzEw_76fec197-1fed-4c51-9987-cce2dcf5c06e"
      unitRef="usd">141000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItNS0xLTEtMjkzNzEw_a241b5a6-f5d0-4b89-b85d-20eb02dc0fd6"
      unitRef="usd">117000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItNy0xLTEtMjkzNzEw_093e95da-6811-43bc-98bf-f99a25e1abdc"
      unitRef="usd">98000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItOS0xLTEtMjkzNzEw_91967e4b-4c31-4edc-9414-63edc14dd481"
      unitRef="usd">81000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMTEtMS0xLTI5MzcxMA_2e63b353-c09d-4440-9477-b57935a621fd"
      unitRef="usd">64000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90YWJsZTo5OTM4MzQyMjhlZWM0MDVjYjEyMTliYThmYzI0NzRhZi90YWJsZXJhbmdlOjk5MzgzNDIyOGVlYzQwNWNiMTIxOWJhOGZjMjQ3NGFmXzItMTMtMS0xLTI5MzcxMA_f8ee30be-7180-43aa-872c-b26d10894ac9"
      unitRef="usd">209000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzEwOTk1MTE2MjkzMTc_9c016977-93ad-4345-90ca-1649d5eea25f"
      unitRef="usd">172000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzY0MQ_99aa1d12-8e6a-4284-bc6a-6d7f723d6e7d"
      unitRef="usd">188000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMjkvZnJhZzphOGYwZGY2ODFkNzU0YjIyYTQwMjQ2YTZlZjg2ZDFlZS90ZXh0cmVnaW9uOmE4ZjBkZjY4MWQ3NTRiMjJhNDAyNDZhNmVmODZkMWVlXzY0OA_903c0d13-5579-4c6f-ad20-051a87bc4a31"
      unitRef="usd">172000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90ZXh0cmVnaW9uOmQ3NmUxMDdkZTNjODQwNjI5ZGIwM2NmZTVhZDg5YjhkXzMyOTg1MzQ4ODM5NjU_a97f1f9f-fc70-42ef-8baa-26a77f0de5c5">OTHER ASSETS&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of other current assets in the accompanying Consolidated Balance Sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California provider fee program receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from other government programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Guarantees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-patient receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of investments and other assets in the accompanying Consolidated Balance Sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments in unconsolidated healthcare entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash surrender value of life insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California provider fee program receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term receivables and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90ZXh0cmVnaW9uOmQ3NmUxMDdkZTNjODQwNjI5ZGIwM2NmZTVhZDg5YjhkXzMyOTg1MzQ4ODM5Njc_358f4aac-81e4-4a19-837c-a42d95d51d4c">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of other current assets in the accompanying Consolidated Balance Sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California provider fee program receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from other government programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Guarantees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-patient receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzEtMi0xLTEtMzI5ODU3_aa811ef0-5875-456f-8608-33fc66261867"
      unitRef="usd">400000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzEtNC0xLTEtMzI5ODU3_fc776c7b-03b7-4fd9-a756-11b255bb939f"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzItMi0xLTEtMzI5ODU3_5eb18d3a-ce24-4748-957b-c52c90ea19d3"
      unitRef="usd">200000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzItNC0xLTEtMzI5ODU3_9e4b5395-ebf4-4cb9-b021-a63f8b7ee67f"
      unitRef="usd">199000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i83eeaae00cd442549c9edcc2dc638e9e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtMi0xLTEtMzYyNjQy_da4e5310-6313-4390-a583-4189907b95b1"
      unitRef="usd">367000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib133b5b1591e4a4ea142acbda1961911_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtNC0xLTEtMzYyNjQ4_3030d07c-b1b7-4839-9e3c-cac540f4cab4"
      unitRef="usd">370000000</us-gaap:AccountsReceivableNetCurrent>
    <thc:ReceivablesFromGovernmentProgramsCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzMtMi0xLTEtMzI5ODU3_e9318f4a-e52e-47d0-8671-c45b732aa943"
      unitRef="usd">187000000</thc:ReceivablesFromGovernmentProgramsCurrent>
    <thc:ReceivablesFromGovernmentProgramsCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzMtNC0xLTEtMzI5ODU3_86a28e9e-d388-4ac8-bb2d-057fc71bbace"
      unitRef="usd">257000000</thc:ReceivablesFromGovernmentProgramsCurrent>
    <thc:PhysicianAndGroupCoverageGuaranteesCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtMi0xLTEtMzI5ODU3_24d6c5d0-6922-45b0-8a12-000ad313b0b5"
      unitRef="usd">143000000</thc:PhysicianAndGroupCoverageGuaranteesCurrent>
    <thc:PhysicianAndGroupCoverageGuaranteesCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzQtNC0xLTEtMzI5ODU3_07542daf-bdc1-4e62-9dbf-91f22c2671cf"
      unitRef="usd">104000000</thc:PhysicianAndGroupCoverageGuaranteesCurrent>
    <us-gaap:OtherReceivables
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzUtMi0xLTEtMzI5ODU3_dd688f72-ed33-49c8-83fb-1133def4aee8"
      unitRef="usd">390000000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzUtNC0xLTEtMzI5ODU3_30e5e054-f314-4882-9233-0fcad21c1424"
      unitRef="usd">321000000</us-gaap:OtherReceivables>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzYtMi0xLTEtMzI5ODU3_71f5ae6e-4aa4-4b91-8402-54a60d49dc9a"
      unitRef="usd">88000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzYtNC0xLTEtMzI5ODU3_1531b99d-7f30-4abc-a8d8-58d8c86a1b51"
      unitRef="usd">54000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzctMi0xLTEtMzMxNzE3_57afa752-9843-493a-9d96-9818245544db"
      unitRef="usd">1775000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo4ZGI0OGY4ZDEwODU0NmFmOTU5MzEyM2M2ODEyMjJkZS90YWJsZXJhbmdlOjhkYjQ4ZjhkMTA4NTQ2YWY5NTkzMTIzYzY4MTIyMmRlXzctNC0xLTEtMzMxNzM1_6298111f-0141-4ae0-b047-d7bc52a7c7c8"
      unitRef="usd">1557000000</us-gaap:OtherAssetsCurrent>
    <thc:InvestmentsAndOtherNoncurrentAssetsTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90ZXh0cmVnaW9uOmQ3NmUxMDdkZTNjODQwNjI5ZGIwM2NmZTVhZDg5YjhkXzMyOTg1MzQ4ODM5Njg_304e02f4-b024-4dc7-87c2-281596d4e081">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of investments and other assets in the accompanying Consolidated Balance Sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments in unconsolidated healthcare entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash surrender value of life insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California provider fee program receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term receivables and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</thc:InvestmentsAndOtherNoncurrentAssetsTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzItMS0xLTEtMjkzNzEw_7e7011ed-9b98-4f85-b9d5-cf0760ea9f94"
      unitRef="usd">30000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzItMy0xLTEtMjkzNzEw_2dd5fcb0-bf12-4e2a-b939-f746cb712f4b"
      unitRef="usd">9000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzMtMS0xLTEtMjkzNzEw_9cfb9cd0-abd9-4a59-bf36-2fe6cd3d02cf"
      unitRef="usd">1599000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzMtMy0xLTEtMjkzNzEw_99763e03-ff38-4de8-9550-413e79597e2a"
      unitRef="usd">1806000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzQtMS0xLTEtMjkzNzEw_62867fa1-82d5-4c1c-950d-3cf34a392804"
      unitRef="usd">1629000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzQtMy0xLTEtMjkzNzEw_767e1381-9c03-4a2b-bb01-fc4a4e0e3662"
      unitRef="usd">1815000000</us-gaap:LongTermInvestments>
    <us-gaap:CashSurrenderValueOfLifeInsurance
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzUtMS0xLTEtMjkzNzEw_d2d50ddb-2ab3-4578-9cfd-a1ab3d7d7985"
      unitRef="usd">37000000</us-gaap:CashSurrenderValueOfLifeInsurance>
    <us-gaap:CashSurrenderValueOfLifeInsurance
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzUtMy0xLTEtMjkzNzEw_a694691d-2d69-4c26-8b38-6c4722d7c31d"
      unitRef="usd">47000000</us-gaap:CashSurrenderValueOfLifeInsurance>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzYtMS0xLTEtMjkzNzEw_488738eb-2b88-4cc9-a58e-5369ab955f47"
      unitRef="usd">56000000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzYtMy0xLTEtMjkzNzEw_f1f7fb8f-5d4c-4dd3-9bda-ec1062d2502c"
      unitRef="usd">57000000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzctMS0xLTEtMjkzNzEw_6f4f6bfd-dedc-45e3-a519-ed22c5b45911"
      unitRef="usd">197000000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzctMy0xLTEtMjkzNzEw_395c5d87-7f6b-404d-94a8-32cd8ceea1ad"
      unitRef="usd">213000000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzgtMS0xLTEtMjkzNzEw_7ddfce40-9732-43fd-aeb6-3998d20fd013"
      unitRef="usd">1129000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzgtMy0xLTEtMjkzNzEw_8e999fc3-189f-4384-b10b-580d3c6dd2f2"
      unitRef="usd">1002000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <thc:OtherLongTermReceivablesAndOtherAssetsNoncurrent
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzktMS0xLTEtMjkzNzEw_11a13a3c-996d-422a-8838-a5e47209ad1e"
      unitRef="usd">99000000</thc:OtherLongTermReceivablesAndOtherAssetsNoncurrent>
    <thc:OtherLongTermReceivablesAndOtherAssetsNoncurrent
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzktMy0xLTEtMjkzNzEw_cc9f3a52-63c0-4717-8f8e-be999ffa7bd7"
      unitRef="usd">120000000</thc:OtherLongTermReceivablesAndOtherAssetsNoncurrent>
    <us-gaap:LongTermInvestmentsAndReceivablesNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzEwLTEtMS0xLTI5MzcxMA_b27da350-1cad-4c51-b806-6db90fb75381"
      unitRef="usd">3147000000</us-gaap:LongTermInvestmentsAndReceivablesNet>
    <us-gaap:LongTermInvestmentsAndReceivablesNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzUvZnJhZzpkNzZlMTA3ZGUzYzg0MDYyOWRiMDNjZmU1YWQ4OWI4ZC90YWJsZTo2ZmUyMmE1M2MxY2Y0ZTE5ODFkMWMwNDQ1YjE5NDQ5Zi90YWJsZXJhbmdlOjZmZTIyYTUzYzFjZjRlMTk4MWQxYzA0NDViMTk0NDlmXzEwLTMtMS0xLTI5MzcxMA_d2f8f754-580f-4fd7-a621-2777b36b52cc"
      unitRef="usd">3254000000</us-gaap:LongTermInvestmentsAndReceivablesNet>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzI2MA_2056193e-dbb0-49ab-9867-efa566362e12">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accumulated other comprehensive loss was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments for defined benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense (benefit) allocated to the adjustments for our defined benefit plans and unrealized gains on investments were approximately&#160;$18&#160;million and $(1)&#160;million, respectively, for the year ended December&#160;31,&#160;2022, and the income tax expense allocated to the adjustments for our defined benefit plans was $14&#160;million for the year ended December&#160;31,&#160;2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzI1Ng_9c000996-9934-43c4-b437-eaf73948d6d6">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accumulated other comprehensive loss was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments for defined benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="if1bb12b1893946248b9ab7b6cb8bc7dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzItMS0xLTEtMjkzNzEw_d2ed913f-2863-4d9b-8c1f-a43c1b03fe64"
      unitRef="usd">-178000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72ff1d80e6bf43d59f82710f6d9d3b3a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzItMy0xLTEtMjkzNzEw_8691986b-eb27-4048-9df6-0746a389fe1f"
      unitRef="usd">-232000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70d397b0d9a54755805ebf13b24f0c3c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzMtMS0xLTEtMjkzNzEw_5ecf9da5-6074-4843-9cfd-c5b8fd9b7018"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id48b6bbe6ee04e76973e637b31dbb932_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzMtMy0xLTEtMjkzNzEw_30d7c9dd-ede1-4397-a5fa-90dcbee350a5"
      unitRef="usd">-1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5d591ea7d794a6bbfc70c45fa0ea665_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzQtMS0xLTEtMjkzNzEw_23d1a665-d52a-4703-92a9-e09b3868173d"
      unitRef="usd">-3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic533c479212f454fa40f5a81863983fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzQtMy0xLTEtMjkzNzEw_d90086ec-b451-47d3-b035-c398abe619f4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b72ce7a7f084592ab6d37729017b52f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzUtMS0xLTEtMjkzNzEw_7fc1d64a-52e4-4005-861d-5381e8f7071a"
      unitRef="usd">-181000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a4aa1e6e88f4448ac550047af2e16de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90YWJsZTo4Nzk0MTBjNWVkNzY0MzViOGM3OGM3NWNjNmRmYjViYy90YWJsZXJhbmdlOjg3OTQxMGM1ZWQ3NjQzNWI4Yzc4Yzc1Y2M2ZGZiNWJjXzUtMy0xLTEtMjkzNzEw_4293010c-37a4-40dc-ba25-6ec85234f96d"
      unitRef="usd">-233000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzIwMQ_012e1602-1fe8-402e-a98c-6d45eaa1cfc0"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzQ5NDc4MDIzMjYyNDg_5c5c0c73-d065-4292-9d5e-62393024f8bf"
      unitRef="usd">1000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yMzgvZnJhZzowN2Q5ZTU5YzlhZGQ0MjFlYWUzYmIxNTdiZGQzOTVhNC90ZXh0cmVnaW9uOjA3ZDllNTljOWFkZDQyMWVhZTNiYjE1N2JkZDM5NWE0XzIwOA_9a3b1c58-b039-40b9-a319-f41f15b0c79f"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzI0OTQ_4604135e-b6ad-4afd-b709-539c7cfe6c07">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows our sources of net operating revenues from continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hospital Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net patient service revenues from hospitals and related outpatient facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uninsured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indemnity and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hospital Operations total prior to inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,061&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,485&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Primarily physician practices revenues.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the composition of net operating revenues for our Ambulatory Care segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from other sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the composition of net operating revenues for our Conifer segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue cycle services &#x2013; Tenet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue cycle services &#x2013; other customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other services &#x2013; Tenet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other services &#x2013; other customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic480b7e478a9472e9d85fba3eb9c12f5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzQtMi0xLTEtMjkzNzEw_2d8d1e48-87d0-4423-8a03-e0309871bbf8"
      unitRef="usd">2369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfc722d0c2684b039bc615d08fdc3ffb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzQtNC0xLTEtMjkzNzEw_170cd410-f128-4c00-b498-a53e1455e8e3"
      unitRef="usd">2615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1c70f5ebc6e458cac8a2f6abf815c4c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzQtNi0xLTEtMjkzNzEw_16d1b3f0-9a04-48ed-9b04-fb75780d51c3"
      unitRef="usd">2695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie964e8e69c1c4105a086707420629f2c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzUtMi0xLTEtMjkzNzEw_43ab7e8c-7869-4fab-b92b-92d774090e6f"
      unitRef="usd">946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id74f5e2d7ec046868cdc2f7fbd355aee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzUtNC0xLTEtMjkzNzEw_7c37a415-a752-4162-bf41-2de3a5753ffd"
      unitRef="usd">1254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabec11c9436644b39b5f21992e4be853_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzUtNi0xLTEtMjkzNzEw_769bf49d-4d21-45d6-b8e6-b6634776ce0b"
      unitRef="usd">1081000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61aba57deafe4c6ba34e913edce4fa4c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzYtMi0xLTEtMjkzNzEw_eb7f4421-739e-49ef-9ca1-897ae797c722"
      unitRef="usd">9730000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46b470daff964cccbcf39b25959c3e24_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzYtNC0xLTEtMjkzNzEw_7e6e7c6b-bc1c-42f2-8596-bb15af1af81c"
      unitRef="usd">9985000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3950c1618554de69021cc2cc1a79848_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzYtNi0xLTEtMjkzNzEw_e0fe79b4-18e0-4c10-a66d-a4e4479f9550"
      unitRef="usd">9022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib396f0f65807418887a0c0af3e39a1e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzctMi0xLTEtMjkzNzEw_4b24cdf2-72f5-4c0d-b27b-5381137cb2da"
      unitRef="usd">141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1d6b8d0b42e425ba69ee9e7f0d7a8b2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzctNC0xLTEtMjkzNzEw_62a5c2db-6c46-4f12-9cd1-7fc0f9819dc4"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9029942b52174f9f9c8908a424dc17c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzctNi0xLTEtMjkzNzEw_4fccb9a4-f1d3-48e8-96d7-435e14e75865"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aeeeee831ed476884676b44fd6cfe29_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzgtMi0xLTEtMjkzNzEw_d4db1a74-733f-4bd3-b5e2-88625fdaa30c"
      unitRef="usd">661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib14df2a1821346edbbccbb2de64905eb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzgtNC0xLTEtMjkzNzEw_8e7fd6f3-35e7-4046-b1a4-5d6b0c9f002a"
      unitRef="usd">706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id127fd2a48b9468fb152d68215c3a4ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzgtNi0xLTEtMjkzNzEw_2ccc0858-1b39-4549-9a22-73d2bbe387e5"
      unitRef="usd">658000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8650d876760f4a5db3ab633b09d01bc4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzktMi0xLTEtMjkzNzEw_792fbedb-7671-4976-b970-8769d5ad359a"
      unitRef="usd">13847000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide258a1d885e4c0f89deb490aea7e041_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzktNC0xLTEtMjkzNzEw_4fc7d32a-3fab-42d4-8812-a7f11c6a207b"
      unitRef="usd">14759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26398e525b5346e4b152c794c73a6fe5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzktNi0xLTEtMjkzNzEw_4fbd45c3-8dc0-47c5-a92e-85af0db2dc75"
      unitRef="usd">13618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedb3ce9661bd4d238e03107f7d28b516_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEwLTItMS0xLTI5MzcxMA_5c7164fb-b5e1-42e8-89f5-e48284523783"
      unitRef="usd">1214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5ea9fc470eb4780a32a6b0b1b1a2a41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEwLTQtMS0xLTI5MzcxMA_8d3ea3bc-91b1-4663-af64-c12461f4a5a2"
      unitRef="usd">1223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eff462dc0034c218f3464becc79363a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEwLTYtMS0xLTI5MzcxMA_9ba07fdf-6521-4be7-b675-2515b5184b6d"
      unitRef="usd">1172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie464e81a78ca4b5bbc82e4f831a2f8fd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzExLTItMS0xLTI5MzcxMA_97830bf3-9470-4960-8f20-c3e0c7575a03"
      unitRef="usd">15061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a6e909d5f7146e6b2f3799ec1c792e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzExLTQtMS0xLTI5MzcxMA_a277bd79-44e6-45dc-a564-184d6f89e884"
      unitRef="usd">15982000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8fc34a3116b48039c40d17002cd0211_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzExLTYtMS0xLTI5MzcxMA_b5a4a05d-05e6-4c16-83fb-a75870dfdd49"
      unitRef="usd">14790000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3ce7b2af81a45cebea65cf46c0e002e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEyLTItMS0xLTI5MzcxMA_76d722a9-0d43-493f-8707-87b897a18511"
      unitRef="usd">3248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6e55bb2a3404d37ac0446903cd6f0ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEyLTQtMS0xLTI5MzcxMA_8e98964f-8682-4a47-a269-47b51ed9627f"
      unitRef="usd">2718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4bd925e775946d38f284ce1b8382ffb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEyLTYtMS0xLTI5MzcxMA_82f79209-c171-4770-acd5-2d1ebd17b6d6"
      unitRef="usd">2072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cc1bcf836fb4be6bef17a04e3599061_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEzLTItMS0xLTI5MzcxMA_69353d35-8735-440e-bb5d-2da39808e215"
      unitRef="usd">1316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a76387d9429414d8b35662237a46f7d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEzLTQtMS0xLTI5MzcxMA_0b380f24-e242-4d13-97f1-f23cd77473a0"
      unitRef="usd">1267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27b36c3b506c460a83c8be8982727090_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzEzLTYtMS0xLTI5MzcxMA_a9e8c1ea-0c12-455d-a17c-6aee27dd1bb0"
      unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1253b20e6f0b4e17802a597aa8a7b59f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE0LTItMS0xLTI5MzcxMA_d9a18a87-6e9d-4204-b49a-474b0a227d56"
      unitRef="usd">-451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia925e5b318a2405589428d1271dec1b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE0LTQtMS0xLTI5MzcxMA_a7446614-cde1-4707-83fb-8258fcf9fbf8"
      unitRef="usd">-482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9db4542a137447f59a1e7ac2c89d14d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE0LTYtMS0xLTI5MzcxMA_f81c28e7-2e8a-493b-9dae-b432e5c46c6c"
      unitRef="usd">-528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE1LTItMS0xLTI5MzcxMA_971de4c7-e968-49df-9f80-fd18c728ea24"
      unitRef="usd">19174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE1LTQtMS0xLTI5MzcxMA_417342a0-7dd6-497d-bcde-c523670feff6"
      unitRef="usd">19485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0NTgyZjA5ZWNjNWY0ZTE1OThiN2NmNmIxM2FlZjVjMi90YWJsZXJhbmdlOjQ1ODJmMDllY2M1ZjRlMTU5OGI3Y2Y2YjEzYWVmNWMyXzE1LTYtMS0xLTI5MzcxMA_102b1194-1110-499e-97af-66581fe8ae25"
      unitRef="usd">17640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i530018987e3745d5abf91b8e5524fc98_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzg3Nw_e60e6471-bf50-4d31-81e5-6a80d2418353"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b993383ef88460483182c2003d1d78f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzg4MQ_ffc3d5e7-99ae-40fe-ae18-09dc2f88ea6e"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc1fb9caa7fb44fcbd2a4b49ddce2861_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzg4OA_08231a95-7de9-41cf-9cf7-1dbe989b8296"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0781fa826249423991780dca7297e0a1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzItMi0xLTEtMjkzNzEw_8b3ae718-cf91-4b6c-a68a-1dbef0fbf5e2"
      unitRef="usd">3115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81914a8262974e3fbb3a025471f7eee8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzItNC0xLTEtMjkzNzEw_dd57e62f-9347-462b-94a6-1233d2762404"
      unitRef="usd">2604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54151a0b57be4cb78257f73d921ec0ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzItNi0xLTEtMjkzNzEw_e61b5133-d730-48e0-8b4f-24e2ad5171f5"
      unitRef="usd">1960000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43649916a8a24c10835bd3035c29605c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzMtMi0xLTEtMjkzNzEw_46b9fb38-5f48-4830-ab09-bfe08aa32cff"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00fd6a31e00d4b11bd3304b198958511_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzMtNC0xLTEtMjkzNzEw_9b61f5c5-5882-4b0d-8fec-bb1e7516306f"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc3991fafc3d4efdacdf716c9d96c74c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzMtNi0xLTEtMjkzNzEw_790866fc-6725-4052-8dc0-0240ec6c6693"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28f3ed824e4544e3b60697a39097ec3c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzQtMi0xLTEtMjkzNzEw_39e660b5-62e6-45e0-9dbb-2508532c5bcb"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic43074c6c14b4410b81097a344a99a4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzQtNC0xLTEtMjkzNzEw_806202f9-1b9a-43fa-ac08-5e28b0b4860d"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44f1c997f82e4683bf9f1bfddca5dcbb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzQtNi0xLTEtMjkzNzEw_07def461-40cc-4b4a-9dff-e65d19cab9bd"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzUtMi0xLTEtMjkzNzEw_c4bee9a7-7ec7-48dd-be65-eab0e63fce2e"
      unitRef="usd">3248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzUtNC0xLTEtMjkzNzEw_6f089025-338b-4168-95d3-2b56dec22746"
      unitRef="usd">2718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo4YTg3MTRjNDcyNDE0OTNlYWEwZDA1YzhhZTBmYjM5Zi90YWJsZXJhbmdlOjhhODcxNGM0NzI0MTQ5M2VhYTBkMDVjOGFlMGZiMzlmXzUtNi0xLTEtMjkzNzEw_7574ec8c-c813-4865-8e69-235ec628aba6"
      unitRef="usd">2072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8393dff26a4a4be89907f8a207404638_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzItMi0xLTEtMjkzNzEw_e2abb509-fc3b-4286-a916-03f6151410c6"
      unitRef="usd">439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i323ccc8d9dff4644a7abebc08a38004c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzItNC0xLTEtMjkzNzEw_12eba280-a9b0-4868-8898-58225f832f83"
      unitRef="usd">467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i235f4a13d11d4df9becc252ef1dc9c7c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzItNi0xLTEtMjkzNzEw_29ac1db5-1b56-444e-8754-46fc5505b290"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d3ba16a76c64bd5ad24f4df995e560f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzMtMi0xLTEtMjkzNzEw_e208a42a-3724-4806-9864-da01bdd22442"
      unitRef="usd">786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20a93e729edc44dfbafaaf36efb815da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzMtNC0xLTEtMjkzNzEw_c4ed4202-0ff7-4b31-8034-03972b8e865f"
      unitRef="usd">705000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26388ca5abe346d88976ab4e56da4f3a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzMtNi0xLTEtMjkzNzEw_849df78d-7fe1-4ae6-81e9-4ca011caed63"
      unitRef="usd">700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60c5cfbf30434593a6d78c97172bba64_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzQtMi0xLTEtMjkzNzEw_6bd1d06f-c8ce-4a51-82e9-6ca2b84870e9"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c20159d864c4b41ba379ff416d148ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzQtNC0xLTEtMjkzNzEw_933e8ca1-8414-4b1b-b300-a838857c1595"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28537df01b624afa95022a135cf7d691_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzQtNi0xLTEtMjkzNzEw_14c1f50c-7deb-4ea4-8173-20cd8b4bf5da"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24675d2632254bb2b6bc89b632413541_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzUtMi0xLTEtMjkzNzEw_3320806c-b6a4-4127-9ed7-74e8a77ee409"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08f286017ca94e2bb6ddcf0fcc89ef42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzUtNC0xLTEtMjkzNzEw_f3a0ce12-43b6-422d-9945-c3db240ef71c"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4058f3d61484fcba0d030ec4ee43320_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzUtNi0xLTEtMjkzNzEw_f8310bc6-d408-4f77-a5fa-beec94bbea81"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzYtMi0xLTEtMjkzNzEw_8dee3ab4-2fc0-4125-b32f-88844a75cc3c"
      unitRef="usd">1316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzYtNC0xLTEtMjkzNzEw_46e3b57e-73d9-4a63-99f6-1ef836cd7a87"
      unitRef="usd">1267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTpmZTdlOTQyYzM5ZjI0NjZmOWU5MTgxNDUwZjM3ZGFhNS90YWJsZXJhbmdlOmZlN2U5NDJjMzlmMjQ2NmY5ZTkxODE0NTBmMzdkYWE1XzYtNi0xLTEtMjkzNzEw_965aa1f0-7d92-4f5d-9998-c02737637114"
      unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90ZXh0cmVnaW9uOjA4NGNlOTM0MzdhODRkOTg5ZDNjYzBkMjdkMTNhMmRlXzI0ODc_d6d32858-0af6-4771-b6ed-a22bcee03262">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes Conifer&#x2019;s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume&#x2011; or contingency&#x2011;based contracts, variable&#x2011;based escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer&#x2019;s contract with Catholic Health Initiatives (&#x201c;CHI&#x201d;), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed&#x2011;fee revenue related to remaining performance obligations. Conifer&#x2019;s contract term with CHI ends December&#160;31,&#160;2032.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Later Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMi0xLTEtMjkzNzEw_2b6e91e0-1d8e-4e62-8eb1-0526d1c5d054"
      unitRef="usd">5729000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic7cd6c10c8c74700867918c05b8d066e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItNC0xLTEtMjkzNzEw_5387f1d7-704f-4254-9b1b-db7bf43c094f"
      unitRef="usd">642000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id8235d44217a459cb42567e761b66f1d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItNi0xLTEtMjkzNzEw_d808a14e-1bd1-41ee-a502-e30631506223"
      unitRef="usd">565000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5607340778f848eeba9562ba40506527_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItOC0xLTEtMjkzNzEw_c2778b77-948d-4394-8bf7-6560d4093ee3"
      unitRef="usd">565000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib32381cae0dc40e8971f9588ae25f535_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMTAtMS0xLTI5MzcxMA_1555a56a-13b6-4a0f-af16-4816b85bf003"
      unitRef="usd">565000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i3fe036fe195e4e7d9cf7c4783fa3b8d6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMTItMS0xLTI5MzcxMA_d7fb3821-c39a-4c1a-a2a9-414587fbeefc"
      unitRef="usd">565000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2a8a661109d44f82ab8d85b5e23bfda3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDEvZnJhZzowODRjZTkzNDM3YTg0ZDk4OWQzY2MwZDI3ZDEzYTJkZS90YWJsZTo0MjIyZWVlZmM0YTg0YThkYjA1OTgyMDU0YjM1MjNhZi90YWJsZXJhbmdlOjQyMjJlZWVmYzRhODRhOGRiMDU5ODIwNTRiMzUyM2FmXzItMTQtMS0xLTI5MzcxMA_9299aca4-86af-4f12-b2de-e20e51c8219f"
      unitRef="usd">2827000000</us-gaap:RevenueRemainingPerformanceObligation>
    <thc:PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzI0MDg_77fbc3bb-d047-4a40-aaa2-c441d34a9276">INSURANCE&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April&#160;1, 2022 through March 31, 2023, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub&#x2011;limits of $100 million for floods, $200&#160;million for earthquakes and a per&#x2011;occurrence sub&#x2011;limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values up to a maximum of $25 million for California earthquakes, $25 million for floods and named windstorms, and 2% of insured values for New Madrid fault earthquakes, with a maximum per&#x2011;claim deductible of $25&#160;million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also purchase cyber liability insurance from third parties. In April&#160;2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information (the &#x201c;Cybersecurity Incident&#x201d;). We estimate that the Cybersecurity Incident had an adverse pre&#x2011;tax impact of approximately $100&#160;million during the year ended December&#160;31,&#160;2022. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have filed a claim within our policy limits. Insurance recoveries of $14&#160;million related to this claim were received during the year ended December&#160;31,&#160;2022, $6&#160;million of which were recorded as net operating revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Professional and General Liability Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are self&#x2011;insured for the majority of our professional and general liability claims, and we purchase insurance from third&#x2011;parties to cover catastrophic claims. At both December&#160;31,&#160;2022 and 2021, the aggregate current and long&#x2011;term professional and general liability reserves in the accompanying Consolidated Balance Sheets was $1.045 billion. These reserves include the reserves recorded by our captive insurance subsidiaries and our self&#x2011;insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial insurance we purchase is subject to per&#x2011;claim and policy period aggregate limits. If the policy period aggregate limit of any of our policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay other material claims applicable to that policy period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Malpractice expense of $276 million, $355 million and $320 million was included in other operating expenses, net, in the accompanying Consolidated Statements of Operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020, respectively, of which $74&#160;million, $131&#160;million and $120&#160;million, respectively, related to adverse claims development for prior years.&lt;/span&gt;&lt;/div&gt;</thc:PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock>
    <thc:PropertyInsuranceAnnualCoverageLimit
      contextRef="i09cf92dc60274d8584d52ce10bbca397_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzQzNA_dcdf3db6-69eb-4351-b337-aead4d807f41"
      unitRef="usd">850000000</thc:PropertyInsuranceAnnualCoverageLimit>
    <thc:PropertyInsuranceMaximumCoveragePerIncident
      contextRef="ibecd81c658874986bbada79239873a72_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzUyMw_52335d6a-a1e5-46eb-8087-bfb0e6ea3db7"
      unitRef="usd">100000000</thc:PropertyInsuranceMaximumCoveragePerIncident>
    <thc:PropertyInsuranceMaximumCoveragePerIncident
      contextRef="i28407917ddcc4c2ea22b7337ab6cbb6f_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzUzOA_af55a0dc-dd31-4279-a091-ec9300ba55fa"
      unitRef="usd">200000000</thc:PropertyInsuranceMaximumCoveragePerIncident>
    <thc:PropertyInsuranceMaximumCoveragePerIncident
      contextRef="ibd1758863eb749acbb352959ab071117_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzU5MQ_fa064aa1-3c25-4812-a004-e7de9ed593ef"
      unitRef="usd">200000000</thc:PropertyInsuranceMaximumCoveragePerIncident>
    <thc:PropertyInsuranceMaximumCoveragePerIncident
      contextRef="ie8b5076fba4c4fdb855d3ab34e6a97b2_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzc0Mw_bbd705b1-2f5c-43e2-9b00-02d486e77c83"
      unitRef="usd">850000000</thc:PropertyInsuranceMaximumCoveragePerIncident>
    <thc:PropertyInsuranceDeductiblePercentage
      contextRef="i28407917ddcc4c2ea22b7337ab6cbb6f_D20220401-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzgwNA_aaf2421f-91f7-4677-a78a-e75a27b3ed1f"
      unitRef="number">0.05</thc:PropertyInsuranceDeductiblePercentage>
    <thc:PropertyInsuranceDeductiblePercentage
      contextRef="i0e926b75dbf3452ca4435e4d0c5a4087_D20220401-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzgwNA_b2608ac1-bfb1-431c-b2a2-e87a13a12d86"
      unitRef="number">0.05</thc:PropertyInsuranceDeductiblePercentage>
    <thc:PropertyInsuranceDeductible
      contextRef="id85b713fc7a9441c8397ecba316b3238_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzg0NA_f8bf89e7-7a4a-4799-ad50-90f2c04d02ca"
      unitRef="usd">25000000</thc:PropertyInsuranceDeductible>
    <thc:PropertyInsuranceDeductible
      contextRef="i76790a90cfa941e4bff3a5ae92dff3aa_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzg3NQ_df54213b-cce2-4978-95a1-1c06d39af772"
      unitRef="usd">25000000</thc:PropertyInsuranceDeductible>
    <thc:PropertyInsuranceDeductiblePercentage
      contextRef="i5f6d901dd264433fbda22d0ff499fce6_D20220401-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzkxNQ_f1737fbc-663e-4c49-a08f-af4a6de2cc33"
      unitRef="number">0.02</thc:PropertyInsuranceDeductiblePercentage>
    <thc:PropertyInsuranceDeductible
      contextRef="i5f6d901dd264433fbda22d0ff499fce6_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzEwMDk_7595ec17-c54e-4d9f-97c6-092e940c3bc9"
      unitRef="usd">25000000</thc:PropertyInsuranceDeductible>
    <thc:PropertyInsuranceDeductible
      contextRef="i9cfc47e9f41b4cc8881d17b072c28e6d_D20220401-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzExMTc_fdf55e12-9154-448a-a251-1d3eeb00c09a"
      unitRef="usd">5000000</thc:PropertyInsuranceDeductible>
    <thc:CybersecurityIncidentPreTaxEffect
      contextRef="i1a5585dec099491a811760ed0c015749_D20220401-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzU0OTc1NTgyMDY2MA_418a8d71-609e-4f06-90e8-8d6dd13ac33d"
      unitRef="usd">100000000</thc:CybersecurityIncidentPreTaxEffect>
    <us-gaap:InsuranceRecoveries
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzEwOTk1MTE2MzQ1Nzk_c6d2b522-a778-47d3-8c1b-a7375eefed9a"
      unitRef="usd">14000000</us-gaap:InsuranceRecoveries>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i946e83f23eab48c0977d5cc62313d926_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzU0OTc1NTgyMDY3OQ_31191b36-6f78-4d7d-aafa-b5e7dbeeebab"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SelfInsuranceReserve
      contextRef="i929d5f3206d1415988b40ae29b248818_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzE0NzU_574e9b90-666c-4311-be2f-83c88e36a9e4"
      unitRef="usd">1045000000.000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="i6a00e93147d34604be1c56fdcf1740bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzE0NzU_f709f1ae-88e2-4e38-91e6-8881f75f4888"
      unitRef="usd">1045000000.000</us-gaap:SelfInsuranceReserve>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredNet
      contextRef="i5bae571ac5a8443d9f4f6d6619c6e742_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIxNDU_822b1f8d-83cd-42e6-8c41-f8d46ccfca9e"
      unitRef="usd">276000000</us-gaap:MalpracticeLossContingencyClaimsIncurredNet>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredNet
      contextRef="i2ce8af9e8c2243dab9e653703111fd49_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIxNDk_f9d3bb3f-96ed-4853-91a0-a40e64ec07a1"
      unitRef="usd">355000000</us-gaap:MalpracticeLossContingencyClaimsIncurredNet>
    <us-gaap:MalpracticeLossContingencyClaimsIncurredNet
      contextRef="i46385a1111194a8589fc66d33d240d12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIxNTY_0333cfd4-d179-4a67-98a8-172f7f080e54"
      unitRef="usd">320000000</us-gaap:MalpracticeLossContingencyClaimsIncurredNet>
    <thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIzMjI_71c5561f-f87e-4cd7-b9c7-e78a656bd9fa"
      unitRef="usd">74000000</thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears>
    <thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIzMjY_57c92c57-e7c5-49c2-b3cb-818e5b48e2e9"
      unitRef="usd">131000000</thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears>
    <thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNDcvZnJhZzo1YjRiNTY1MjY5OTQ0Nzc1YjRkNjcyM2RjNjdkNWE0YS90ZXh0cmVnaW9uOjViNGI1NjUyNjk5NDQ3NzViNGQ2NzIzZGM2N2Q1YTRhXzIzMzM_0b8d101e-9056-440e-8eb2-472e4fafe0e4"
      unitRef="usd">120000000</thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzUzMjQ_f80345d8-67de-447f-8181-37b48a62fab1">CLAIMS AND LAWSUITSWe operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or &#x201c;whistleblower&#x201d; lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment&#x2011;related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial &lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties associated with these matters, especially those involving governmental agencies, and the indeterminate damages sought in some cases, we are unable to predict the ultimate liability we may incur from these matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Investigation of Detroit Medical Center&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detroit Medical Center (&#x201c;DMC&#x201d;) is subject to an ongoing investigation commenced in October&#160;2017 by the U.S.&#160;Attorney&#x2019;s Office for the Eastern District of Michigan and the Civil Division of the U.S. Department of Justice (&#x201c;DOJ&#x201d;) for potential violations of the Stark law, the Medicare and Medicaid anti&#x2011;kickback and antifraud and abuse amendments codified under Section 1128B(b) of the Social Security Act, and the federal False Claims Act related to DMC&#x2019;s employment of nurse practitioners and physician assistants (&#x201c;Mid&#x2011;Level Practitioners&#x201d;) from 2006 through 2017. As previously disclosed, a media report was published in August&#160;2017 alleging that 14&#160;Mid&#x2011;Level Practitioners were terminated by DMC earlier in 2017 due to compliance concerns. The DOJ issued a civil investigative demand to DMC for documents and interrogatories in September&#160;2021. In January&#160;2023, we reached a settlement in principle with the DOJ to resolve this matter, subject to certain conditions, and were fully reserved for such potential settlement at December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, certain of the entities that purchased the operations of Hahnemann University Hospital and St.&#160;Christopher&#x2019;s Hospital for Children in Philadelphia from us commenced Chapter&#160;11 bankruptcy proceedings. In the three months ended December&#160;31,&#160;2021, we established a reserve of $23&#160;million for certain obligations related to the sale of the hospitals and the subsequent bankruptcy proceedings of the buyers. In the six months ended June&#160;30,&#160;2022, we made advance payments of approximately $1&#160;million. In the three months ended September&#160;30,&#160;2022, the bankruptcy court approved a final settlement among the parties, and we made the remaining $22&#160;million in payments to fully resolve this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor and privacy laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;New claims or inquiries may be initiated against us from time to time. These matters could (1)&#160;require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2)&#160;cause us to incur substantial expenses, (3)&#160;require significant time and attention from our management, and (4)&#160;cause us to close or sell hospitals or otherwise modify the way we conduct business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances&#160;at&lt;br/&gt;Beginning&lt;br/&gt;of&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Litigation&#160;and&lt;br/&gt;Investigation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&lt;br/&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances&#160;at&lt;br/&gt;End&#160;of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i99278a7c32f64fa0b070b36593467a59_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzEwOTk1MTE2NDEyOTQ_637c626d-f703-4fdc-be55-48e141c3796d"
      unitRef="usd">23000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:BankruptcyClaimsAmountPaidToSettleClaims
      contextRef="i6592cd4d757a46e2a3d6e589962ea2da_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzEwOTk1MTE2NDEzMTQ_7fd1e466-7312-4089-88b1-7f0499d66aab"
      unitRef="usd">1000000</us-gaap:BankruptcyClaimsAmountPaidToSettleClaims>
    <us-gaap:BankruptcyClaimsAmountPaidToSettleClaims
      contextRef="ia222bd0504b649a38f78d78bec2b6c91_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzEwOTk1MTE2NDEzMzg_abf82ce6-057b-4d42-9dc5-a65de867d456"
      unitRef="usd">22000000</us-gaap:BankruptcyClaimsAmountPaidToSettleClaims>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90ZXh0cmVnaW9uOjY2ZmI5Njk5MmJhMTQxZjJhYzVkYTYwZGEwZDMzMzlhXzUzMjY_fc1e38a6-7b83-4544-870d-d6b842253363">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances&#160;at&lt;br/&gt;Beginning&lt;br/&gt;of&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Litigation&#160;and&lt;br/&gt;Investigation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&lt;br/&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances&#160;at&lt;br/&gt;End&#160;of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="icbe65d466f4f469d80f697fa5ae26073_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtMS0xLTEtMjkzNzEw_86093556-2c41-4790-8caa-97d30539f48f"
      unitRef="usd">78000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtMy0xLTEtMjkzNzEw_a7a7621c-8b4c-48c5-a7b5-adeeab9b7942"
      unitRef="usd">-70000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtNS0xLTEtMjkzNzEw_a5e62dd4-3ebd-4d66-84e1-2e52b0e98727"
      unitRef="usd">100000000</us-gaap:LossContingencyAccrualPayments>
    <thc:LossContingencyAccrualOther
      contextRef="i4e6e0827e0b647f8844b9cfd952192e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtNy0xLTEtMjkzNzEw_8ba716d8-71be-4f5d-96a3-7fd2e5312cd0"
      unitRef="usd">3000000</thc:LossContingencyAccrualOther>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i40b3d4d738e04be3bf00f293d9edb4f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzMtOS0xLTEtMjkzNzEw_a97f351d-c692-4c05-9e42-e3e99e8b2a42"
      unitRef="usd">51000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic63f979e7be145bc9c86e0f440b39a75_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtMS0xLTEtMjkzNzEw_81fd9f98-40ff-4e3c-814f-7d15ca7f961c"
      unitRef="usd">26000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtMy0xLTEtMjkzNzEw_110aa061-c4a2-4f1b-a7f9-9c2852315279"
      unitRef="usd">-116000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtNS0xLTEtMjkzNzEw_f2f58924-c906-456b-b392-e502cc1d0c01"
      unitRef="usd">59000000</us-gaap:LossContingencyAccrualPayments>
    <thc:LossContingencyAccrualOther
      contextRef="i4e7e5e990bda40f7ab5e146e326ebd4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtNy0xLTEtMjkzNzEw_15826542-72c1-4fbc-9e0c-f3e6725e0236"
      unitRef="usd">-5000000</thc:LossContingencyAccrualOther>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="icbe65d466f4f469d80f697fa5ae26073_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzYtOS0xLTEtMjkzNzEw_cc18a2b5-3bfd-46c1-a418-51ba6d93deba"
      unitRef="usd">78000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i1a2ea7fb5d834e519c54544ff665cc9a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktMS0xLTEtMjkzNzEw_7b0c775f-381f-48b8-b311-a434086f0844"
      unitRef="usd">86000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktMy0xLTEtMjkzNzEw_b94ff4d2-9227-45db-bf1b-7691446fbfe8"
      unitRef="usd">-44000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktNS0xLTEtMjkzNzEw_9f742fe5-4ea2-4642-84a1-9833393c9019"
      unitRef="usd">108000000</us-gaap:LossContingencyAccrualPayments>
    <thc:LossContingencyAccrualOther
      contextRef="id92f164480ba451aa46abe634ecc5b5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktNy0xLTEtMjkzNzEw_40cd95ff-1e69-4ba2-8e75-a74ff803db7d"
      unitRef="usd">4000000</thc:LossContingencyAccrualOther>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic63f979e7be145bc9c86e0f440b39a75_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTAvZnJhZzo2NmZiOTY5OTJiYTE0MWYyYWM1ZGE2MGRhMGQzMzM5YS90YWJsZTo0MmJlMjI3YTQwMjQ0MzgwYTY1ZjFjZjFiOGVlNmIwNS90YWJsZXJhbmdlOjQyYmUyMjdhNDAyNDQzODBhNjVmMWNmMWI4ZWU2YjA1XzktOS0xLTEtMjkzNzEw_e3dbb667-1b04-4dc7-9618-10e5d046e3f7"
      unitRef="usd">26000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzE4Mzg_b272f6bc-f2a7-4850-9499-496851bf3684">REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our put/call agreement (the &#x201c;Baylor Put/Call Agreement&#x201d;) with Baylor contained put and call options with respect to the 5% ownership interest Baylor held in USPI until June&#160;30,&#160;2022. The Baylor Put/Call Agreement gave Baylor the option to annually put up to one-third of its total shares in USPI (the &#x201c;Baylor Shares&#x201d;) over a period of three years beginning in 2021. We had the right to call the difference between the number of shares Baylor put each year and the maximum number of shares it could have put. Based on the nature of the Baylor Put/Call Agreement, Baylor&#x2019;s minority interest in USPI was classified as a redeemable noncontrolling interest in the accompanying Consolidated Balance Sheet at December&#160;31,&#160;2021. During the years ended December&#160;31,&#160;2022 and 2021, we recognized accretion totaling $102&#160;million and $8&#160;million, respectively, and a corresponding decrease in additional paid-in capital related to Baylor&#x2019;s minority interest in USPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares for that year (66.6% in total). In June 2022, we entered into an agreement with Baylor (the &#x201c;Share Purchase Agreement&#x201d;) to complete the purchase of the Baylor Shares we called in 2021 and 2022 and to accelerate the acquisition of the remaining Baylor Shares eligible to be put/called in 2023. Under the terms of the Share Purchase Agreement, we agreed to pay Baylor $406&#160;million to buy its entire 5% voting ownership interest in USPI. We paid $11&#160;million upon execution of the Share Purchase Agreement and are obligated to make 35 additional non-interest bearing monthly payments of approximately $11&#160;million, which payments commenced in August&#160;2022. We recorded the present value of the purchase price as a liability on our balance sheet, with an offset to redeemable noncontrolling interest of $365&#160;million for the carrying amount of the shares and $23&#160;million to additional paid&#x2011;in capital for the difference between the carrying value and present value of the purchase price for the shares. At December&#160;31,&#160;2022, we had liabilities of $135&#160;million recorded in other current liabilities and $190&#160;million in other long-term liabilities in the accompanying Consolidated Balance Sheet for the purchase of these shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at beginning of period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions paid to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases and sales of businesses and noncontrolling interests, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at end of period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <thc:JointVentureOwnershipPercentage
      contextRef="i4465885b467846d392b87babc57179d9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzIxNTE_a3041d17-b83f-4c34-b4a1-c08475ade0bc"
      unitRef="number">0.05</thc:JointVentureOwnershipPercentage>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzIyNzI_fa2c1cd4-7da2-4142-b598-b9d4fdb129b5"
      unitRef="usd">102000000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzIyNzY_66c79483-2a00-4eac-8c04-efeaa55fe1ed"
      unitRef="usd">8000000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <thc:PurchasedEquityInJointVenturePercentageOfTotalShares
      contextRef="i1acbe1c3a707444594718d1fb713a4dd_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ1NzI_b4741191-00f3-41da-bf14-cf24f0a21e40"
      unitRef="number">0.333</thc:PurchasedEquityInJointVenturePercentageOfTotalShares>
    <thc:PurchasedEquityInJointVenturePercentageOfTotalShares
      contextRef="i9b94c1f135f64a488e17326f4496bb5a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ1NzI_d4d87930-eb7e-40ac-9f3b-dfa4a4fa5dd0"
      unitRef="number">0.333</thc:PurchasedEquityInJointVenturePercentageOfTotalShares>
    <thc:PurchasedEquityInJointVenturePercentageOfTotalShares
      contextRef="ieb5fa32817764caa8f2f7644c58ca52b_D20210101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ1ODA_01a3a2a9-bc47-49ef-882b-40fe448d1105"
      unitRef="number">0.666</thc:PurchasedEquityInJointVenturePercentageOfTotalShares>
    <thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest
      contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ2ODc_fa8c3ef3-021a-4cc5-9bd4-a8c95825b1c6"
      unitRef="usd">406000000</thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest>
    <thc:JointVentureOwnershipPercentage
      contextRef="i4465885b467846d392b87babc57179d9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ2OTg_a3041d17-b83f-4c34-b4a1-c08475ade0bc"
      unitRef="number">0.05</thc:JointVentureOwnershipPercentage>
    <thc:SharePurchaseAgreementPaymentForExecution
      contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3MDI_3c73c98e-483e-4738-8078-9015aa4ec4ba"
      unitRef="usd">11000000</thc:SharePurchaseAgreementPaymentForExecution>
    <thc:SharePurchaseAgreementNumberOfMonthlyPayments
      contextRef="ia73487c1fdc34b30b87fbe06f5951834_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3MTc_961eaa4e-2756-4f56-9e9b-dca0f394cf85">P35M</thc:SharePurchaseAgreementNumberOfMonthlyPayments>
    <thc:SharePurchaseAgreementMonthlyPayment
      contextRef="ia73487c1fdc34b30b87fbe06f5951834_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3MjE_b59586b5-6f5f-44c9-ab7a-c36329c8e74b"
      unitRef="usd">11000000</thc:SharePurchaseAgreementMonthlyPayment>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3Mzc_f86f2f9e-3e20-4322-8a78-38933d68de21"
      unitRef="usd">365000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <thc:GainLossFromPurchaseOfNoncontrollingInterests
      contextRef="icbc54f96f2704ef6838ec87ed217fae4_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3NDY_51af3758-aba1-4724-b1a8-c07412382df1"
      unitRef="usd">23000000</thc:GainLossFromPurchaseOfNoncontrollingInterests>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4951aea584a14d4b873b83530d333b3c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3NTk_d2f1afa4-9b7b-45ce-a2ad-81e8ee49c91e"
      unitRef="usd">135000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4951aea584a14d4b873b83530d333b3c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzEwOTk1MTE2MzQ3NzM_d0db0d18-e872-4f35-beef-0f32e8dae985"
      unitRef="usd">190000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90ZXh0cmVnaW9uOjQzYjQ2ZjA5NTNhMjQ2MzhhMDlkYTgxZjgwZDc5ZjY5XzE4MzU_007975d7-e25c-4e51-b5b8-895e4d890d87">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at beginning of period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions paid to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases and sales of businesses and noncontrolling interests, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at end of period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i082e53fec105442d97f902da195a0d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzItMS0xLTEtMjkzNzEw_14f12542-d044-4cd6-90b1-d38ee44ec402"
      unitRef="usd">2203000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ibea644fa13c540e892499ab2838c341d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzItMy0xLTEtMjkzNzEw_287a3218-8725-404a-af40-c4ef49e4676c"
      unitRef="usd">1952000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzMtMS0xLTEtMjkzNzEw_2370beb2-3827-415f-bf05-87fd355ff1c2"
      unitRef="usd">348000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzMtMy0xLTEtMjkzNzEw_2f40f561-64ab-4be7-86b5-0915e1826ed5"
      unitRef="usd">336000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzQtMS0xLTEtMjkzNzEw_4501abac-4be7-4978-b675-160f8cf22c0d"
      unitRef="usd">331000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzQtMy0xLTEtMjkzNzEw_b9f6c78b-058b-44a1-9b5f-05491146a077"
      unitRef="usd">217000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzUtMS0xLTEtMjkzNzEw_5085552f-1b3f-4951-a42a-7bfb2a83eb9f"
      unitRef="usd">104000000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzUtMy0xLTEtMjkzNzEw_a2e93971-9064-4354-8fc8-6a130cbdbfb1"
      unitRef="usd">11000000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzYtMS0xLTEtMjkzNzEw_2720f910-205f-4144-a1ba-8264247ce638"
      unitRef="usd">-175000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i06e26a7dbb764daa95354c0f9bb4bdbc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzYtMy0xLTEtMjkzNzEw_bf28e1c1-cea4-440b-b2d5-f3b2c2c806e8"
      unitRef="usd">121000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i0254fa58d5da4b66af614eec6e6b07a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzctMS0xLTEtMjkzNzEw_bbc93d39-000d-4a04-b493-36ad29ab0240"
      unitRef="usd">2149000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i082e53fec105442d97f902da195a0d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo5NjU3ZWQ4YTYxNDQ0MDVhOGQ1OWM0NWExNGNmNWU1MC90YWJsZXJhbmdlOjk2NTdlZDhhNjE0NDQwNWE4ZDU5YzQ1YTE0Y2Y1ZTUwXzctMy0xLTEtMjkzNzEw_7972bec6-d6ba-4646-9e5e-e68b221b52d0"
      unitRef="usd">2203000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzItMi0xLTEtMjkzNzEw_2df7ac66-3c8f-498e-b491-9a7b54e40ec4"
      unitRef="usd">233000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzItNC0xLTEtMjkzNzEw_49c9554b-0cea-413e-9748-17f2bb215800"
      unitRef="usd">297000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ib165a084700643e1b139d15df43a3b15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzMtMi0xLTEtMjkzNzEw_2dfcb320-36cf-492c-8c0d-6c3086a0e901"
      unitRef="usd">1357000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzMtNC0xLTEtMjkzNzEw_39c91927-2898-4b93-95d3-8681c40df055"
      unitRef="usd">1425000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzQtMi0xLTEtMjkzNzEw_9d40844b-c8a8-45bb-8ecb-652cc19bf0a6"
      unitRef="usd">559000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzQtNC0xLTEtMjkzNzEw_efda7773-0cd5-4f43-99e1-66e587ebddc8"
      unitRef="usd">481000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzUtMi0xLTEtMjkzNzEw_d7c8e94b-41e6-4dbc-96c5-27a665c67692"
      unitRef="usd">2149000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo3MTUxMzU4MDIwMzg0MTIxYjY3MjRjMzM0NjRhY2U5Zi90YWJsZXJhbmdlOjcxNTEzNTgwMjAzODQxMjFiNjcyNGMzMzQ2NGFjZTlmXzUtNC0xLTEtMjkzNzEw_f2d3c410-cb13-4cb8-97ef-4cd45a75513c"
      unitRef="usd">2203000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzItMi0xLTEtMjkzNzEw_48d0b94a-794b-4657-8fcd-77bf3b7ac80b"
      unitRef="usd">23000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzItNC0xLTEtMjkzNzEw_b1cd7eac-a0cf-4c43-9071-f0d29ad23123"
      unitRef="usd">24000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzItNi0xLTEtMjkzNzEw_540192bc-f4eb-4a37-9af4-3c1ef2005ad3"
      unitRef="usd">-33000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzMtMi0xLTEtMjkzNzEw_f64bf817-a6c8-4cfb-85e8-e379df42f954"
      unitRef="usd">248000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzMtNC0xLTEtMjkzNzEw_19fa791a-667e-411f-8ec7-ac6f645beac9"
      unitRef="usd">243000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzMtNi0xLTEtMjkzNzEw_b1ce9170-8ee2-45c3-a37d-f33e5144159f"
      unitRef="usd">153000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzQtMi0xLTEtMjkzNzEw_6d88d77b-902e-4036-ab10-f0c70278208d"
      unitRef="usd">77000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzQtNC0xLTEtMjkzNzEw_0f4f8c19-0fa1-4300-b9ff-bfe849fbc0d3"
      unitRef="usd">69000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzQtNi0xLTEtMjkzNzEw_42936c3d-7b3a-4bbb-8790-b53a223ab51c"
      unitRef="usd">66000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzUtMi0xLTEtMjkzNzEw_e6f95557-e808-405b-8571-149c9333812b"
      unitRef="usd">348000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzUtNC0xLTEtMjkzNzEw_d06891e2-fae6-4e7c-bf32-0fa3e768267d"
      unitRef="usd">336000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNTYvZnJhZzo0M2I0NmYwOTUzYTI0NjM4YTA5ZGE4MWY4MGQ3OWY2OS90YWJsZTo0NGRkN2E1MzU1YmE0NGM2OTU5OTU4MWM2YzIxM2JhZi90YWJsZXJhbmdlOjQ0ZGQ3YTUzNTViYTQ0YzY5NTk5NTgxYzZjMjEzYmFmXzUtNi0xLTEtMjkzNzEw_908a56fc-ceb8-4f44-a57c-bb54970e8526"
      unitRef="usd">186000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5MzU_f0bc8135-e9ea-425d-a24d-f4b6f8d76090">INCOME TAXES&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for continuing operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the amount of reported income tax expense (benefit) and the amount computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is presented below. Foreign pre-tax loss was $8 million, $5 million and $13 million for the years ended December&#160;31,&#160;2022, 2021 and&#160;2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense at statutory federal rate of 21%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible litigation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired charitable contribution carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior-year provision to return adjustments and other changes in deferred&#160;taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in the business interest expense disallowance rules took effect in 2022, resulting in a larger amount of interest disallowance compared to prior years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID Acts included a significant number of tax provisions applicable to individuals and businesses. For businesses, the COVID Acts made changes to the U.S. tax code relating to, among other things: (1) the business interest expense disallowance rules for 2019 and 2020; (2) net operating loss rules; (3) charitable contribution limitations; and (4) the realization of corporate alternative minimum tax credits. As a result of the change in the business interest expense disallowance rules, we recorded an income tax benefit of $88 million during the year ended December&#160;31,&#160;2020 to decrease the valuation allowance for interest expense carryforwards due to the additional deduction of interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we filed an application with the Internal Revenue Service (&#x201c;IRS&#x201d;) to change our method of accounting for certain capitalized costs on our 2019 tax return. This change in tax accounting method resulted in additional interest expense being allowed on the 2019 and 2020 tax returns. We reduced our valuation allowance by an additional $126&#160;million in the year ended December&#160;31,&#160;2020 related to the change in accounting method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. The following table discloses those significant components of our deferred tax assets and liabilities, including any valuation allowance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and fixed-asset differences&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves related to discontinued operations and restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables (doubtful accounts and adjustments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals for retained insurance risks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use lease assets and obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,358&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;988&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a reconciliation of the deferred tax assets and liabilities and the corresponding amounts reported in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2022, the valuation allowance increased by $120&#160;million, including an increase of $123&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $2 million due to changes in the expected realizability of deferred tax assets. The balance in the valuation allowance as of December&#160;31,&#160;2022 was $177 million. During the year ended December&#160;31,&#160;2021, the valuation allowance increased by $2 million, including an increase of $2&#160;million due to limitations on the tax deductibility of interest expense, a decrease of $2&#160;million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $2&#160;million due to changes in the expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December&#160;31,&#160;2021 was $57 million. During the year ended December&#160;31,&#160;2020, the valuation allowance decreased by $226 million, including a decrease of $211 million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized net operating loss carryovers, and a decrease of $14 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance as of December&#160;31,&#160;2020 was $55&#160;million. Deferred tax assets relating to interest expense limitations under Internal Revenue Code Section 163(j) have a full valuation allowance because the interest expense carryovers are not expected to be utilized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for uncertain tax positions in accordance with FASB ASC 740-10-25, which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The following table summarizes the total changes in unrecognized tax benefits in continuing operations during the years ended December&#160;31,&#160;2022, 2021 and 2020. There were no such changes in discontinued operations. The additions and reductions for tax positions include the impact of items for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductions. Such amounts include unrecognized tax benefits that have impacted deferred tax assets and liabilities at December&#160;31,&#160;2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing&lt;br/&gt;Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions due to a lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions due to a lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to tax positions taken in prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of unrecognized tax benefits as of December&#160;31,&#160;2022 was $34&#160;million, of which $32&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December&#160;31,&#160;2022, there was no change in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December&#160;31,&#160;2021 was $34&#160;million, of which $32&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. Income tax expense in the year ended December&#160;31,&#160;2021 included expense of $3&#160;million in continuing operations attributable to an increase in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December&#160;31,&#160;2020 was $31&#160;million, of which $29&#160;million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December&#160;31,&#160;2020, there was no change in our estimated liabilities for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Approximately $1 million of interest and penalties related to accrued liabilities for uncertain tax positions are included in the accompanying Consolidated Statement of Operations for the year ended December&#160;31,&#160;2022. Total accrued interest or penalties on unrecognized tax benefits as of December&#160;31,&#160;2022 was $1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS has completed audits of our tax returns for all tax years ended on or before December&#160;31,&#160;2007. All disputed issues with respect to these audits have been resolved and all related tax assessments (including interest) have been paid. Our tax returns for years ended after December&#160;31,&#160;2007 and USPI&#x2019;s tax returns for years ended after December&#160;31,&#160;2018 remain subject to audit by the IRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, no significant changes in unrecognized federal and state tax benefits are expected in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31,&#160;2022, our carryforwards available to offset future taxable income consisted of (1)&#160;federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of approximately $100 million pre&#x2011;tax, $40 million of which expires in 2024 to 2037 and $60 million of which has no expiration date, (2) charitable contribution carryforwards of approximately $45&#160;million expiring in 2025 through 2027 and (3)&#160;state NOL carryforwards of approximately $3.106&#160;billion expiring in 2023 through 2042 for which the associated deferred tax benefit, net of valuation allowance and federal tax impact, is $42&#160;million. Our ability to utilize NOL carryforwards to reduce future taxable income may be limited under Section&#160;382 of the Internal Revenue Code if certain ownership changes in our company occur during a rolling three&#x2011;year period. These ownership changes include purchases of common stock under share repurchase programs, the offering of stock by us, the purchase or sale of our stock by 5%&#160;shareholders, as defined in the Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5%&#160;shareholders result in aggregate increases that exceed 50 percentage points during the three&#x2011;year period, then Section&#160;382 imposes an annual limitation on the amount of our taxable income that may be offset by the NOL&#160;carryforwards or tax credit carryforwards at the time of ownership change.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NjI_bde3da50-d413-4346-82e2-0a641be63cf7">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for continuing operations for the years ended December&#160;31,&#160;2022,&#160;2021 and&#160;2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzMtMS0xLTEtMjkzNzEw_050ceada-7b12-490d-b3e0-c6eaf619d114"
      unitRef="usd">78000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzMtMy0xLTEtMjkzNzEw_19b7e15b-3816-415e-9ced-03a27dd32244"
      unitRef="usd">50000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzMtNS0xLTEtMjkzNzEw_1a2ccec8-4351-4483-990b-1a6c6cd6f836"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzQtMS0xLTEtMjkzNzEw_368dad73-90de-446a-9fe9-bdd9e637c989"
      unitRef="usd">57000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzQtMy0xLTEtMjkzNzEw_1c5a246d-2e53-4afd-8526-46e93ac6e1eb"
      unitRef="usd">111000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzQtNS0xLTEtMjkzNzEw_f0c3599e-8874-4342-829c-59120145a939"
      unitRef="usd">30000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzUtMS0xLTEtMjkzNzEw_58d67b34-d262-4074-8728-c0d99466e8e2"
      unitRef="usd">135000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzUtMy0xLTEtMjkzNzEw_f0017f14-2c09-4515-8c14-fdff819746c3"
      unitRef="usd">161000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzUtNS0xLTEtMjkzNzEw_57634492-628e-4072-95dd-eb27cd82c40c"
      unitRef="usd">30000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzctMS0xLTEtMjkzNzEw_363a20d5-9d55-4473-9c59-4bdfc3009a67"
      unitRef="usd">174000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzctMy0xLTEtMjkzNzEw_42235d9c-cc32-42a7-9788-9bdd298c635d"
      unitRef="usd">267000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzctNS0xLTEtMjkzNzEw_1c251e3d-2adb-4b76-9ded-b32e0215e70c"
      unitRef="usd">-131000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzgtMS0xLTEtMjkzNzEw_329e6608-b814-44b6-9e87-b735e0a8f4b4"
      unitRef="usd">35000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzgtMy0xLTEtMjkzNzEw_d7107460-0403-43ab-8f74-8df60e78b12d"
      unitRef="usd">-17000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzgtNS0xLTEtMjkzNzEw_560b2a86-832f-4632-9280-d41169750951"
      unitRef="usd">4000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzktMS0xLTEtMjkzNzEw_69d888d9-c694-45a4-beb0-730ca450a0dd"
      unitRef="usd">209000000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzktMy0xLTEtMjkzNzEw_f31c5ab8-f03f-41cc-8153-f2e041bf8a72"
      unitRef="usd">250000000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzktNS0xLTEtMjkzNzEw_b65bb8ee-84cf-4f41-8c73-f89bcffea072"
      unitRef="usd">-127000000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzEwLTEtMS0xLTI5MzcxMA_c973dcf7-ae34-44bc-9c60-2102fd28d4c5"
      unitRef="usd">344000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzEwLTMtMS0xLTI5MzcxMA_b466c869-3d9a-4fc7-ab4f-c17218376a00"
      unitRef="usd">411000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo5NzY5ZTU4ODg4ZTI0MWQzYjJjOWZjZGZmZDY2MTRiMi90YWJsZXJhbmdlOjk3NjllNTg4ODhlMjQxZDNiMmM5ZmNkZmZkNjYxNGIyXzEwLTUtMS0xLTI5MzcxMA_92edb48b-dc5e-4c99-89ae-f6f6794f9240"
      unitRef="usd">-97000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NTk_353a506b-c003-43e8-b826-0cfff88a4ab2">Foreign pre-tax loss was $8 million, $5 million and $13 million for the years ended December&#160;31,&#160;2022, 2021 and&#160;2020, respectively.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense at statutory federal rate of 21%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible litigation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired charitable contribution carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior-year provision to return adjustments and other changes in deferred&#160;taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;A change in the business interest expense disallowance rules took effect in 2022, resulting in a larger amount of interest disallowance compared to prior years.</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NTkyMjk_6004a7ef-d5c1-4522-890e-5ed9115bd562"
      unitRef="usd">-8000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NTkyMzQ_86f3a40e-ee39-4b2f-a6e2-9e76b9cad818"
      unitRef="usd">-5000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NTkyNDI_dff16af3-4a8b-4cd4-9b69-7e342490ea1c"
      unitRef="usd">-13000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzItMS0xLTEtMjkzNzEw_87cdd4dd-cf79-47ce-86b4-6f674191dffd"
      unitRef="usd">282000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzItMy0xLTEtMjkzNzEw_489c1012-780e-46c4-8a1d-2b839ddb0781"
      unitRef="usd">396000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzItNS0xLTEtMjkzNzEw_d08b4e46-e12d-451a-b8f2-69bf0faba379"
      unitRef="usd">141000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzMtMS0xLTEtMjkzNzEw_f64e8226-24e2-47f5-a70e-81b458252514"
      unitRef="usd">64000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzMtMy0xLTEtMjkzNzEw_b6587ebf-7769-4483-b71f-d4156d51349b"
      unitRef="usd">77000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzMtNS0xLTEtMjkzNzEw_a4bbd3b9-8ccc-417c-9a2d-82f50c552062"
      unitRef="usd">33000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzUtMS0xLTEtMjkzNzEw_314e3a71-137c-40d5-8fda-77de18382641"
      unitRef="usd">122000000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzUtMy0xLTEtMjkzNzEw_d6b4fb8b-27f1-4ffe-bca2-406221341131"
      unitRef="usd">114000000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzUtNS0xLTEtMjkzNzEw_d96e3054-2c0d-4a90-9ca4-3eed3b7eee41"
      unitRef="usd">75000000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzYtMS0xLTEtMjkzNzEw_5efaa143-b609-4af6-922e-3d5e272e6860"
      unitRef="usd">1000000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzYtMy0xLTEtMjkzNzEw_2d360be4-61ed-4b72-9302-69bb76dcf9e2"
      unitRef="usd">35000000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzYtNS0xLTEtMjkzNzEw_0dbaf4ce-fc6e-4a7b-a8ee-3cf53dbf3c1d"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzctMS0xLTEtMjkzNzEw_a3cfa0c7-5924-47ab-8a89-f11668215cb3"
      unitRef="usd">10000000</thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzctMy0xLTEtMjkzNzEw_dd6f0623-83aa-47da-90b4-982375800ebe"
      unitRef="usd">8000000</thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzctNS0xLTEtMjkzNzEw_4bcc1d58-d935-4269-bfe2-0f28b4a43207"
      unitRef="usd">6000000</thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <thc:IncomeTaxReconciliationNondeductibleExpenseLitigation
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzgtMS0xLTEtMjkzNzEw_43694f90-0138-4680-93fd-ba8bf7f7455f"
      unitRef="usd">0</thc:IncomeTaxReconciliationNondeductibleExpenseLitigation>
    <thc:IncomeTaxReconciliationNondeductibleExpenseLitigation
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzgtMy0xLTEtMjkzNzEw_44ad474d-bd33-489f-9177-02e791b03306"
      unitRef="usd">1000000</thc:IncomeTaxReconciliationNondeductibleExpenseLitigation>
    <thc:IncomeTaxReconciliationNondeductibleExpenseLitigation
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzgtNS0xLTEtMjkzNzEw_842d5382-03d0-43f6-b7ae-9547664b4611"
      unitRef="usd">0</thc:IncomeTaxReconciliationNondeductibleExpenseLitigation>
    <thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzktMS0xLTEtMjkzNzEw_5c060526-825a-497c-bdbb-be4601b71534"
      unitRef="usd">0</thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount>
    <thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzktMy0xLTEtMjkzNzEw_446a6eae-9838-4959-87ae-5edf8a2ace17"
      unitRef="usd">0</thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount>
    <thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzktNS0xLTEtMjkzNzEw_70246603-1613-4f98-b858-a5190ead751b"
      unitRef="usd">-1000000</thc:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEyLTEtMS0xLTI5MzcxMA_4e349444-e9bb-4ed3-92e8-4aae7c0b217c"
      unitRef="usd">-6000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEyLTMtMS0xLTI5MzcxMA_2cb101bd-7d1d-40e8-ad7f-2af6cb0fe7e9"
      unitRef="usd">-5000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEyLTUtMS0xLTI5MzcxMA_0c721358-687d-4782-966f-0a53a2a3302d"
      unitRef="usd">-2000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEzLTEtMS0xLTI5MzcxMA_77a15628-49f9-4f2f-b831-c52eded035cd"
      unitRef="usd">120000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEzLTMtMS0xLTI5MzcxMA_84b083da-c1f2-430e-95cb-35228cd7921c"
      unitRef="usd">2000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzEzLTUtMS0xLTI5MzcxMA_6ea7eb9e-a7b2-429d-9f4e-745d24153a49"
      unitRef="usd">-226000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE1LTEtMS0xLTI5MzcxMA_f2565c91-c1ea-47d3-999e-21d9368187eb"
      unitRef="usd">12000000</thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes>
    <thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE1LTMtMS0xLTI5MzcxMA_9c748f63-89ec-4fe9-b46a-496bdddf4ec3"
      unitRef="usd">-8000000</thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes>
    <thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE1LTUtMS0xLTI5MzcxMA_3bfc9a9f-d3e0-4969-bfb9-4a8544f72ee1"
      unitRef="usd">-14000000</thc:IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE2LTEtMS0xLTI5MzcxMA_493761c1-c7fe-4fb5-8ab4-0307b20561fa"
      unitRef="usd">7000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE2LTMtMS0xLTI5MzcxMA_d0ab72d6-c71d-42ed-bba5-4bc8fbd16c5a"
      unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE2LTUtMS0xLTI5MzcxMA_3d26e399-21df-4ac4-bfb1-344bf6936370"
      unitRef="usd">10000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE3LTEtMS0xLTI5MzcxMA_337d043a-14f6-4d90-acac-8b3522c57ffe"
      unitRef="usd">344000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE3LTMtMS0xLTI5MzcxMA_6ea2aabe-a03a-4cc9-81dd-4f54e47ef653"
      unitRef="usd">411000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZToyYTNhOGQyOTYzNDg0ODE1YmNkNzZjYWQzNWIxZGY3ZS90YWJsZXJhbmdlOjJhM2E4ZDI5NjM0ODQ4MTViY2Q3NmNhZDM1YjFkZjdlXzE3LTUtMS0xLTI5MzcxMA_74116ec6-4cf1-4f46-b57e-5d7d4cd6d346"
      unitRef="usd">-97000000</us-gaap:IncomeTaxExpenseBenefit>
    <thc:IncomeTaxExpenseBenefitCARESAct
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzU0OTc1NTgzOTk0MQ_6d5065bb-19fc-44b9-9086-940d3ccc7d40"
      unitRef="usd">-88000000</thc:IncomeTaxExpenseBenefitCARESAct>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzU0OTc1NTgzOTUwMA_d99bb7d9-c621-40d0-aa23-ce6b4699ac0e"
      unitRef="usd">-126000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NTA_93615951-af17-456e-be0c-2f53aca5cfbd">The following table discloses those significant components of our deferred tax assets and liabilities, including any valuation allowance:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and fixed-asset differences&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves related to discontinued operations and restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables (doubtful accounts and adjustments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals for retained insurance risks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use lease assets and obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,358&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;988&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzItMy0xLTEtMjkzNzEw_2392ea45-ba6a-45fb-82a9-368b1c1bf19d"
      unitRef="usd">436000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzItNy0xLTEtMjkzNzEw_122dc9be-70d6-4700-a7ee-5a4e6010a71e"
      unitRef="usd">532000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzMtMS0xLTEtMjkzNzEw_4afbb7ea-1452-4af4-9a2c-ca88c6df52d0"
      unitRef="usd">5000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzMtNS0xLTEtMjkzNzEw_c796a0ce-4017-4eee-8f10-c1bb8a6ff8e8"
      unitRef="usd">2000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzQtMS0xLTEtMjkzNzEw_24c9634c-f101-403a-8451-8a15344cd90f"
      unitRef="usd">246000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzQtNS0xLTEtMjkzNzEw_468df2a4-289c-4d7b-bcec-f40c0ba8d4a1"
      unitRef="usd">215000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <thc:DeferredTaxAssetsMedicareAdvancePayments
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzUtMS0xLTEtMjkzNzEw_8bc6a8f2-c48f-45f7-9d49-08326f01f407"
      unitRef="usd">0</thc:DeferredTaxAssetsMedicareAdvancePayments>
    <thc:DeferredTaxAssetsMedicareAdvancePayments
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzUtNS0xLTEtMjkzNzEw_0e0e45a7-5e23-43b4-ac5b-daae7f83efd1"
      unitRef="usd">209000000</thc:DeferredTaxAssetsMedicareAdvancePayments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzYtMS0xLTEtMjkzNzEw_839baf74-bddf-4096-b74d-1c7d3e2a6fe9"
      unitRef="usd">227000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzYtNS0xLTEtMjkzNzEw_00513d71-16a8-4fb0-b1d8-3e206f27e851"
      unitRef="usd">234000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzctMy0xLTEtMjkzNzEw_61fe35f8-9b99-4bed-b6b0-344e08c5cb94"
      unitRef="usd">416000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzctNy0xLTEtMjkzNzEw_4c7c06af-a655-417a-b067-9558fe65d91d"
      unitRef="usd">396000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <thc:DeferredTaxAssetsOtherLongTermLiabilities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzgtMS0xLTEtMjkzNzEw_231d9c3a-ffb9-4791-96b9-6483e9ecc56f"
      unitRef="usd">27000000</thc:DeferredTaxAssetsOtherLongTermLiabilities>
    <thc:DeferredTaxAssetsOtherLongTermLiabilities
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzgtNS0xLTEtMjkzNzEw_cb841b11-3e54-4f75-900d-7a880bc86489"
      unitRef="usd">23000000</thc:DeferredTaxAssetsOtherLongTermLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzktMS0xLTEtMjkzNzEw_9722f091-172b-404e-bf8c-1cedb11da699"
      unitRef="usd">207000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzktNS0xLTEtMjkzNzEw_1afd9016-7dd6-4377-9858-153fb9e35034"
      unitRef="usd">242000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEwLTEtMS0xLTI5MzcxMA_e500d936-361e-4c32-bda8-1dd4517098fd"
      unitRef="usd">30000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEwLTUtMS0xLTI5MzcxMA_dc1b766f-f465-4b4f-a415-2d3942b50d17"
      unitRef="usd">56000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <thc:DeferredTaxLiabilitiesInvestmentsAndOtherAssets
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzExLTMtMS0xLTI5MzcxMA_a3b4d070-d8f2-40fc-99a7-c72603db258e"
      unitRef="usd">112000000</thc:DeferredTaxLiabilitiesInvestmentsAndOtherAssets>
    <thc:DeferredTaxLiabilitiesInvestmentsAndOtherAssets
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzExLTctMS0xLTI5MzcxMA_9a3ebfe6-7001-4cb2-927e-ca6a4072d876"
      unitRef="usd">92000000</thc:DeferredTaxLiabilitiesInvestmentsAndOtherAssets>
    <thc:DeferredTaxAssetsInterestExpenseLimitation
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEyLTEtMS0xLTI5MzcxMA_366f3b89-7267-49de-8ce9-59b7ece422fd"
      unitRef="usd">133000000</thc:DeferredTaxAssetsInterestExpenseLimitation>
    <thc:DeferredTaxAssetsInterestExpenseLimitation
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEyLTUtMS0xLTI5MzcxMA_6bca50ef-1bfe-4385-9e17-69b4cdb6485d"
      unitRef="usd">10000000</thc:DeferredTaxAssetsInterestExpenseLimitation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEzLTEtMS0xLTI5MzcxMA_caa73c96-fc4c-4145-964d-862ccb712355"
      unitRef="usd">74000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzEzLTUtMS0xLTI5MzcxMA_5fa9da15-c5eb-4da3-a9ec-6bff1eba45c6"
      unitRef="usd">99000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE0LTEtMS0xLTI5MzcxMA_f63c5ea9-6707-4208-b6f4-8808f778bb7a"
      unitRef="usd">13000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE0LTUtMS0xLTI5MzcxMA_4a5ed381-9b8d-4202-b677-9a219ec1b4da"
      unitRef="usd">12000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <thc:DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTEtMS0xLTI5MzcxMA_c888966e-bd73-4eed-a6bd-6ac34b36919b"
      unitRef="usd">192000000</thc:DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations>
    <thc:DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTMtMS0xLTI5MzcxMA_2ddacf78-b546-40c0-8292-4bb521de6534"
      unitRef="usd">173000000</thc:DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations>
    <thc:DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTUtMS0xLTI5MzcxMA_828fdc49-b878-4f06-bc3a-b3153564beaa"
      unitRef="usd">208000000</thc:DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations>
    <thc:DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE1LTctMS0xLTI5MzcxMA_53f36c00-803d-4801-8290-18f14822d9b3"
      unitRef="usd">208000000</thc:DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTEtMS0xLTI5MzcxMA_b8db7fe5-b8c7-4b75-97de-10f52910bc50"
      unitRef="usd">11000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTMtMS0xLTI5MzcxMA_d012e06d-4a61-4328-8bb5-825f2d30c658"
      unitRef="usd">49000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTUtMS0xLTI5MzcxMA_595fb7e6-99d7-454b-8165-44bb49406a6b"
      unitRef="usd">48000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE2LTctMS0xLTI5MzcxMA_83bd909f-4b71-4a40-bd1e-50de9bc8dd5b"
      unitRef="usd">44000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTEtMS0xLTI5MzcxMA_aba68115-4923-40a1-9587-a252a4db5f9d"
      unitRef="usd">1165000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTMtMS0xLTI5MzcxMA_a1b3b8f6-192c-42d7-8df5-9367920b8f2b"
      unitRef="usd">1186000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTUtMS0xLTI5MzcxMA_3cbc8021-1197-4852-963e-a053f03044fd"
      unitRef="usd">1358000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE3LTctMS0xLTI5MzcxMA_b50251ca-184d-46bc-b9bc-cddfbb246e33"
      unitRef="usd">1272000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE4LTEtMS0xLTI5MzcxMA_8e1518f8-9328-41e4-b0f1-aee464629855"
      unitRef="usd">177000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE4LTUtMS0xLTI5MzcxMA_6cf3d140-7534-4237-a95f-e0e87cd666e4"
      unitRef="usd">57000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTEtMS0xLTI5MzcxMA_cb260ace-40d3-4b07-852a-68586cf37cec"
      unitRef="usd">988000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTMtMS0xLTI5MzcxMA_238fd2c2-c3b6-4b1a-a3df-fdc3282af96a"
      unitRef="usd">1186000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTUtMS0xLTI5MzcxMA_6e4a9ca6-ec93-45b3-b9bb-7fde4cf2bd04"
      unitRef="usd">1301000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTo1ZTdkYzM1ODNlMjI0YmIyYTcyMjdlOWZlNjU4NjBjMS90YWJsZXJhbmdlOjVlN2RjMzU4M2UyMjRiYjJhNzIyN2U5ZmU2NTg2MGMxXzE5LTctMS0xLTI5MzcxMA_88cb5ba7-1c6c-4d91-ac1d-23ba12bb5d43"
      unitRef="usd">1272000000</us-gaap:DeferredTaxLiabilities>
    <thc:ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5Njg_247a4472-09a0-4b1e-9098-45de22de8dae">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a reconciliation of the deferred tax assets and liabilities and the corresponding amounts reported in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</thc:ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzItMS0xLTEtMjkzNzEw_ffea5267-562d-4101-b80d-75a0b1593ab6"
      unitRef="usd">19000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzItMy0xLTEtMjkzNzEw_1c869b1b-60d6-4892-96e0-303a68fc277f"
      unitRef="usd">65000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzMtMS0xLTEtMjkzNzEw_6580dfc5-57b2-4fd9-910d-0ea13fff629a"
      unitRef="usd">217000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzMtMy0xLTEtMjkzNzEw_280d8b43-3d33-4d9a-b54b-14fe2e4b87b5"
      unitRef="usd">36000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <thc:DeferredIncomeTaxAssetsLiabilitiesNet
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzQtMS0xLTEtMjkzNzEw_f2dbec57-209e-4e9b-87f7-2ef6299c040b"
      unitRef="usd">-198000000</thc:DeferredIncomeTaxAssetsLiabilitiesNet>
    <thc:DeferredIncomeTaxAssetsLiabilitiesNet
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTpiYWE0OWFjZWVlMTk0N2VkYWU1NWY5YjFkOTczOWRhMy90YWJsZXJhbmdlOmJhYTQ5YWNlZWUxOTQ3ZWRhZTU1ZjliMWQ5NzM5ZGEzXzQtMy0xLTEtMjkzNzEw_f5d1cf13-634d-4ad1-8bae-031f10e78c4c"
      unitRef="usd">29000000</thc:DeferredIncomeTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI1NDE_e14af7ef-489f-4b63-9a10-2f58268a2ab7"
      unitRef="usd">120000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI1NzA_fee1e6ba-5613-4f14-81d4-77ee0231116c"
      unitRef="usd">123000000</thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI2NTI_bcd74dd2-b40c-4366-8aad-b5ef25d0add5"
      unitRef="usd">-1000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI3NjQ_196a18e9-c994-48db-9821-dadaf48432ab"
      unitRef="usd">-2000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI4ODQ_06ba9276-cad1-4c5e-9b67-c09160bd564d"
      unitRef="usd">177000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI5NTE_cce82b2c-6ac7-453c-9ae0-df00f2d58469"
      unitRef="usd">2000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzI5Nzk_81ab9d2b-be96-4e6e-9448-ae1492015198"
      unitRef="usd">2000000</thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMwNjE_e2168614-5a00-4191-a2aa-0cac27997854"
      unitRef="usd">-2000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMxNzI_1369ef6f-81b5-4d06-bc0e-b837bd3b7061"
      unitRef="usd">2000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMyOTk_e306fdac-13e7-4c73-abdf-5d94872894d0"
      unitRef="usd">57000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMzNjY_7ab17499-41c3-4d2d-a227-eb557b9f9854"
      unitRef="usd">-226000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzMzOTU_30916e70-61dd-45af-8278-fb466dee0a02"
      unitRef="usd">-211000000</thc:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzM0MDE_c40839a5-9db3-4e72-a2b2-9961d439ee62"
      unitRef="usd">-1000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers>
    <thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzM0MjQ_c678c5a8-db6a-4046-9387-c5f5b1704a66"
      unitRef="usd">-14000000</thc:ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzM1NTQ_d096b93c-3443-42a7-95b4-b55990d870e8"
      unitRef="usd">55000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzc5NzQ_131b1bd6-25ac-4f9b-9f9f-9c3b98df56ad">The following table summarizes the total changes in unrecognized tax benefits in continuing operations during the years ended December&#160;31,&#160;2022, 2021 and 2020. There were no such changes in discontinued operations. The additions and reductions for tax positions include the impact of items for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductions. Such amounts include unrecognized tax benefits that have impacted deferred tax assets and liabilities at December&#160;31,&#160;2022, 2021 and 2020.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing&lt;br/&gt;Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions due to a lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions due to a lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to tax positions taken in prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id1d91a903a1a481fa20d8e476407ae20_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzEtMS0xLTEtMjkzNzEw_39b89d3e-6c8b-4bfe-a5f0-6d1716c65cc5"
      unitRef="usd">31000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i99a33773dbfe4b1c9e0db6630258d6d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzItMS0xLTEtMjkzNzEw_a1980d20-d6da-45e9-8f2e-c015cb094ad1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib7e5bdf39f78442c999f04f849962c0a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzMtMS0xLTEtMjkzNzEw_1fa758c4-86c0-4b99-911f-3e900e7f77aa"
      unitRef="usd">31000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i58845e096d6e4053baf993f0b5480e65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzQtMS0xLTEtMjkzNzEw_df17000d-d38d-4cb8-a6df-50e13f02554a"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ife847cb48ff64445b52e24dff42ab345_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzUtMS0xLTEtMjkzNzEw_951d1e0d-28a8-491d-9f63-bb8753b7108f"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i016ade91fd494b2092c70d023aa6b142_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzYtMS0xLTEtMjkzNzEw_a0c3ecdd-8035-4905-8be9-e1c9e115ddb3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3f311af9ca5b443ca38ce68247b5b1c9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90YWJsZTphNDM0ODFmNmEzM2Y0ZThjYTAyOGE1ZTM1OGQyODJlMy90YWJsZXJhbmdlOmE0MzQ4MWY2YTMzZjRlOGNhMDI4YTVlMzU4ZDI4MmUzXzctMS0xLTEtMjkzNzEw_35ccc4db-a690-4b9b-8f8d-9575225f2b59"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzQ2NTQ_9772d61f-bfb4-4170-abfa-b7661addb2ec"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzQ2Njc_27e38f9b-eaf0-4298-9cfe-0c917b1b9572"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUwNDM_0ff869c8-5bf5-46e2-9c46-1275862e81a2"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUwNTY_5dd89c88-519e-4373-90bf-930b1ee4de7d"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzU0OTc1NTg0MjIzNg_7c37621a-20a0-453a-b548-f28efd39524b"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUzMjE_d9242806-d6b9-48c6-b9b4-c14363dd73bb"
      unitRef="usd">31000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzUzMzQ_f146c9e2-9600-4600-bbd9-0696b487c242"
      unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NjI1OTM_64ede91e-1086-4439-9604-b4dca9dd4f19"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzEwOTk1MTE2NjI2MDE_88412123-4b9a-4cf1-941b-1a93713eb36b"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzYyOTc_94d74741-de43-46b1-bc27-abfe0a7ca9cc"
      unitRef="usd">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if3ceb05ff4044a7c839c70944244e25e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY2NzQ_a61d7059-9f55-4ff6-bf79-0b9143b54665"
      unitRef="usd">100000000</us-gaap:OperatingLossCarryforwards>
    <thc:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="if3ceb05ff4044a7c839c70944244e25e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY2ODY_21092bdf-f130-4bed-9090-505d6ac7ee8b"
      unitRef="usd">40000000</thc:OperatingLossCarryforwardsSubjectToExpiration>
    <thc:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="if3ceb05ff4044a7c839c70944244e25e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY3MjI_84f2c940-3dbb-494f-b52f-15a0948c07ed"
      unitRef="usd">60000000</thc:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY5MDk_a65bc1df-aba8-40fb-afac-6e89f12197a1"
      unitRef="usd">45000000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <thc:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="ie394bb97475d441db6f2d7fdbb59def8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzY5ODg_60d3df74-7012-44ee-a887-349b6dcafeba"
      unitRef="usd">3106000000</thc:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie394bb97475d441db6f2d7fdbb59def8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjIvZnJhZzo1NjJiOWU3MDgyZmE0YmVjOTZkNzNlMTE2ZDlhOGZiYi90ZXh0cmVnaW9uOjU2MmI5ZTcwODJmYTRiZWM5NmQ3M2UxMTZkOWE4ZmJiXzcxMTg_278be6a9-bebd-4f58-b549-647ab9f7d57d"
      unitRef="usd">42000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90ZXh0cmVnaW9uOjgxMjVmMDE0YTY2MDQ2YzQ5YWViMzliNTc3OGU5ZWViXzEyODM_5d218721-5c55-4ef6-9637-cf8c1082afa2">EARNINGS PER COMMON SHARE&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in&#160;millions and weighted average shares are expressed in thousands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Income Available to Common Shareholders (Numerator)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Shares&lt;br/&gt;(Denominator)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Per-Share&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options, restricted stock units and deferred compensation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108,571&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for basic loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options, restricted stock units and deferred compensation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;106,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2022, our convertible instruments consisted of an agreement related to the ownership interest in a Hospital Operations segment joint venture and RSUs issued under the USPI Management Equity Plan. Prior to our purchase of all of the shares underlying the Baylor Put/Call Agreement in June&#160;2022, that agreement was also included in our convertible instruments. Additional information about the RSUs issued under the USPI Management Equity Plan and our purchase of the shares underlying the Baylor Put/Call Agreement is included in Notes 10 and 18, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90ZXh0cmVnaW9uOjgxMjVmMDE0YTY2MDQ2YzQ5YWViMzliNTc3OGU5ZWViXzEyODI_5bffb9b9-f9f3-45fa-9444-a643a7555190">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in&#160;millions and weighted average shares are expressed in thousands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Income Available to Common Shareholders (Numerator)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Shares&lt;br/&gt;(Denominator)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Per-Share&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options, restricted stock units and deferred compensation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108,571&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for basic loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options, restricted stock units and deferred compensation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders for diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;106,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzItMS0xLTEtMjkzNzEw_8d2dfb5b-dabe-4858-b4b2-b7806d92790e"
      unitRef="usd">410000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzItMy0xLTEtMjkzNzEw_0eab6586-fe3f-4343-afc7-080e111c74c4"
      unitRef="shares">106929000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzItNS0xLTEtMjkzNzEw_776fae81-8f63-45f2-9e76-6ccac3fb480a"
      unitRef="usdPerShare">3.83</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DilutiveSecurities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzMtMS0xLTEtMjkzNzEw_8cb1ab7f-45da-4296-8024-4bec56680a20"
      unitRef="usd">8000000</us-gaap:DilutiveSecurities>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzMtMy0xLTEtMjkzNzEw_73ba4f2b-c39f-486a-8762-ae063bdff0f8"
      unitRef="shares">3587000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <thc:EffectOfDilutiveSecuritiesPerShareAmount
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzMtNS0xLTEtMjkzNzEw_756a4d3b-934b-4f90-90a2-827fe9af13ac"
      unitRef="usdPerShare">-0.05</thc:EffectOfDilutiveSecuritiesPerShareAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzQtMS0xLTEtMjkzNzEw_31ed6f14-b4d3-421d-9f86-c3fd61bc81e1"
      unitRef="usd">418000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzQtMy0xLTEtMjkzNzEw_d4057300-4728-4c52-a5e5-2372fb7dddbf"
      unitRef="shares">110516000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzQtNS0xLTEtMjkzNzEw_0cfd181c-9f3a-4f56-b7b8-501c2384c868"
      unitRef="usdPerShare">3.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzYtMS0xLTEtMjkzNzEw_ee847482-d5d8-4fd9-be45-2483ab9a977d"
      unitRef="usd">915000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzYtMy0xLTEtMjkzNzEw_7304cc21-b091-4f87-ae3c-75812adc2194"
      unitRef="shares">106833000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzYtNS0xLTEtMjkzNzEw_6fcc0c85-8f44-402e-a6c5-66dbdfc4dd23"
      unitRef="usdPerShare">8.56</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DilutiveSecurities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzctMS0xLTEtMjkzNzEw_0cff3ea7-6284-41d5-97ee-8fe188301abe"
      unitRef="usd">0</us-gaap:DilutiveSecurities>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzctMy0xLTEtMjkzNzEw_55d346ec-021d-47a9-8c2b-ed184397f634"
      unitRef="shares">1738000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <thc:EffectOfDilutiveSecuritiesPerShareAmount
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzctNS0xLTEtMjkzNzEw_73fb6b8c-6a37-4b9a-af8e-fcc27741e5c4"
      unitRef="usdPerShare">-0.13</thc:EffectOfDilutiveSecuritiesPerShareAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzgtMS0xLTEtMjkzNzEw_b639470f-0b2d-4275-b249-bd7824a220e2"
      unitRef="usd">915000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzgtMy0xLTEtMjkzNzEw_75a82ab7-bc46-4b23-aadd-e3d912be584a"
      unitRef="shares">108571000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzgtNS0xLTEtMjkzNzEw_ecd9521b-69fd-4a9c-adc1-49ecdfbd3a6d"
      unitRef="usdPerShare">8.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEwLTEtMS0xLTI5MzcxMA_af0db189-d7fe-4804-966a-144d458d4c74"
      unitRef="usd">399000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEwLTMtMS0xLTI5MzcxMA_af056147-b126-4c85-8e8f-a840f73d85c5"
      unitRef="shares">105010000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEwLTUtMS0xLTI5MzcxMA_aa5eb6b9-0e31-4f48-b9c5-d07cf5dbeadd"
      unitRef="usdPerShare">3.80</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DilutiveSecurities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzExLTEtMS0xLTI5MzcxMA_d67782f2-c6ad-4145-99e3-105baae0a718"
      unitRef="usd">0</us-gaap:DilutiveSecurities>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzExLTMtMS0xLTI5MzcxMA_31d88933-5b2e-4708-b924-512c9e9c1a45"
      unitRef="shares">1253000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <thc:EffectOfDilutiveSecuritiesPerShareAmount
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzExLTUtMS0xLTI5MzcxMA_dfd71372-7333-44f6-9b60-2de6f25490af"
      unitRef="usdPerShare">-0.05</thc:EffectOfDilutiveSecuritiesPerShareAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEyLTEtMS0xLTI5MzcxMA_3eb9028a-e033-4569-a96f-c66ba9fe6716"
      unitRef="usd">399000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEyLTMtMS0xLTI5MzcxMA_7eee38e8-488d-4564-ac6a-7beb9d96091c"
      unitRef="shares">106263000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjUvZnJhZzo4MTI1ZjAxNGE2NjA0NmM0OWFlYjM5YjU3NzhlOWVlYi90YWJsZTo0NGQ2NzFiOGY1Nzg0MmMxYmEwMzQwY2NlNGJlNDVmOC90YWJsZXJhbmdlOjQ0ZDY3MWI4ZjU3ODQyYzFiYTAzNDBjY2U0YmU0NWY4XzEyLTUtMS0xLTI5MzcxMA_a04db026-b915-419e-aa45-6c2eabff561b"
      unitRef="usdPerShare">3.75</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzIwNjM_ba1bef64-2b7f-4217-892c-8d624e795a3f">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non&#x2011;financial assets and liabilities. Fair values determined by Level&#160;2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our non&#x2011;financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long&#x2011;lived assets held and used, long&#x2011;lived assets held for sale and goodwill. As discussed in Note 6, we recognized an impairment charge of $82&#160;million to write down certain long&#x2011;lived assets located in one of our markets to their estimated fair value during the year ended December&#160;31,&#160;2022. Based on our evaluation, we estimated the fair value of the long&#x2011;lived assets to be $167&#160;million. The inputs used to establish this fair value are considered to be Level&#160;2 inputs, which include inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long&#x2011;term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit&#160;Agreement are considered to be Level 2 inputs. At December&#160;31,&#160;2022 and 2021, the estimated fair value of our long&#x2011;term debt was approximately 92.8% and 103.3%, respectively, of the carrying value of the debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i87e348ef2f5949cfb83ccab43bf831b1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzEwOTk1MTE2MzczODE_37f159b1-237a-4e70-a38e-8f5e9cbdfadd"
      unitRef="usd">82000000</us-gaap:AssetImpairmentCharges>
    <thc:AssetsHeldforuseLongLivedFairValueDisclosure
      contextRef="i54b3f987c4664d6586d2dc3ce06561df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzEwOTk1MTE2Mzc4NDU_ca6ee0d4-469d-406b-af99-f3876bbe5e44"
      unitRef="usd">167000000</thc:AssetsHeldforuseLongLivedFairValueDisclosure>
    <thc:EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue
      contextRef="ie4fe8572ea6c491aa3b643277fd661f6_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzIwMDI_f27e3b42-f137-4925-874e-8f65269ffff2"
      unitRef="number">0.928</thc:EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue>
    <thc:EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue
      contextRef="i019176855e2e4e78a448696e0f58e777_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNjgvZnJhZzozNGRmMDI3MTA3YmY0MDUzYmE0MmNhYThlOTY0YWVjZi90ZXh0cmVnaW9uOjM0ZGYwMjcxMDdiZjQwNTNiYTQyY2FhOGU5NjRhZWNmXzIwMDk_c883ee81-c926-438e-b9af-d3a74145b1ed"
      unitRef="number">1.033</thc:EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzQzMTg_daa54010-846f-49c9-a450-c7f7f2bb7a9f">ACQUISITIONS&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July&#160;2022, we acquired controlling ownership interests in 19 fully operational ambulatory surgery centers and three centers then in development from United Urology Group. We paid $104 million, net of cash acquired, for our ownership interests in these facilities and recognized goodwill of $316 million. The aggregate acquisition date fair value of the non&#x2011;controlling interests in the facilities we acquired was $223 million. The acquisition of these facilities provided us with access to new markets and further diversified our ambulatory care services portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We acquired controlling interests in an additional 11 ambulatory surgery centers through a series of transactions during the year ended December&#160;31,&#160;2022. We paid an aggregate purchase price of $65 million, net of cash acquired, for these facilities. During 2022, we also acquired controlling interests in 23 ambulatory surgery centers in which we previously owned a noncontrolling interest for an aggregate purchase price of $65 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2021, subsidiaries of USPI acquired ownership interests in 86 ambulatory surgery centers and related ambulatory support services (collectively, the &#x201c;2021 SCD Centers&#x201d;) from Surgical Center Development&#160;#3,&#160;LLC and Surgical Center Development&#160;#4,&#160;LLC (&#x201c;SCD&#x201d;). Of these, we acquired controlling interests in 15 ambulatory surgery centers, noncontrolling interests in 57 centers and interests in 14 centers still in the development stage. The newly acquired facilities augmented our Ambulatory Care segment&#x2019;s existing musculoskeletal service line and expanded the number of markets it serves. We made a cash payment of $1.125 billion, net of cash acquired, to acquire these facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the 2021 SCD Centers, we paid an aggregate purchase price of $74 million to acquire controlling interests in 11 outpatient businesses and various physician practices during the year ended December&#160;31,&#160;2021. During 2021, we also acquired controlling interests in three surgical hospitals and two ambulatory surgery centers in which we previously owned a noncontrolling interest for $21 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2020, USPI acquired controlling interests in 45 ambulatory surgery centers (collectively, the &#x201c;2020 SCD Centers&#x201d;) from SurgCenter Development and physician owners. The fair value of the consideration conveyed for the 2020 SCD Centers was $1.115&#160;billion, consisting of a cash payment of $1.097&#160;billion, fully funded using cash on hand, and the assumption of $18&#160;million of center&#x2011;level debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the 2020 SCD Centers, we acquired ownership interests in 10 outpatient businesses (all of which are in our Ambulatory Care segment), and various physician practices during the year ended December&#160;31,&#160;2020.&#160;The aggregate purchase price for these acquisitions was $80&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values.&#160;The excess of the purchase price allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2022 are preliminary. We are in process of assessing working capital balances as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying consolidated financial statements are subject to adjustment once the assessments and valuation work are completed and evaluated. Such adjustments will be recorded as soon as practical and within the measurement period as defined by the accounting literature. During the year ended December&#160;31,&#160;2022, we adjusted the initial purchase allocation of certain acquisitions completed in 2021 based on the results of completed valuations. These adjustments resulted in a net increase in goodwill of $7&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preliminary or final purchase price allocations for all the acquisitions made during the years ended December&#160;31,&#160;2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Previously held equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests in equity of consolidated subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains on consolidations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the facilities described above are included in our Ambulatory Care segment. The majority of the goodwill generated from our 2022 acquisitions will not be deductible for income tax purposes; however, the majority of the goodwill generated from our 2021 and 2020 transactions will be. The goodwill generated from these transactions can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. Approximately $14&#160;million, $20&#160;million and $14 million in transaction costs related to prospective and closed acquisitions were expensed during the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively, and are included in impairment and restructuring charges, and acquisition&#x2011;related costs in the accompanying Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2021, we recognized gains totaling $23&#160;million associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests. No such gains or losses were recognized in the years ended December&#160;31,&#160;2022 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pro Forma Information - Unaudited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides certain pro forma information for Tenet as if the 2021 SCD Centers acquisition had occurred at the beginning of the year ended December&#160;31,&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in earnings of unconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share available to Tenet Healthcare Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <thc:NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries
      contextRef="i4aaed855090043789ca397a60d4a8565_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NjkzNDY_e48e6893-a858-45a8-b640-5ec42a3db68c"
      unitRef="surgery_center">19</thc:NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries>
    <thc:NumberOfSurgicalCentersInDevelopmentStage
      contextRef="id8d3a9179b7641f5bd9df2620d60173e_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NjkzNTY_fa1c81bd-a8ae-4db8-bd58-a0bca6f4a56d"
      unitRef="surgery_center">3</thc:NumberOfSurgicalCentersInDevelopmentStage>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id8d3a9179b7641f5bd9df2620d60173e_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDQ4MjI_b025705d-0877-44db-84a8-d47399b9852b"
      unitRef="usd">104000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:Goodwill
      contextRef="i64a492066cbd4c4a85b96cb84a3068f3_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDQ4OTE_34b1860d-58ef-4ad9-bb28-7a6c1e3d47b1"
      unitRef="usd">316000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i64a492066cbd4c4a85b96cb84a3068f3_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDQ5OTQ_0ecefec1-bd41-42ad-94c8-08b041e42d26"
      unitRef="usd">223000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <thc:NumberOfSurgicalCentersAcquired
      contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDUyNDg_fd758cc5-27da-47d0-8e4a-d2288a5f7fcc"
      unitRef="surgery_center">11</thc:NumberOfSurgicalCentersAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDU0MTA_2de7967e-6f18-4113-b74f-7f8bc2c57b18"
      unitRef="usd">65000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <thc:NumberOfSurgicalCentersRecordedUsingEquityMethod
      contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NzEwODU_a819d6db-771d-4b36-9e6b-42ad86b8726b"
      unitRef="surgery_center">23</thc:NumberOfSurgicalCentersRecordedUsingEquityMethod>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie6616fd0402041209d851e0632005bb6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDYwODk_39c0ce68-57bd-4792-bdaf-6130a97ce0a7"
      unitRef="usd">65000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <thc:NumberOfSurgicalCentersAcquired
      contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2MzkxMzY_af76c272-85d2-4616-9529-07354e2e1842"
      unitRef="surgery_center">86</thc:NumberOfSurgicalCentersAcquired>
    <thc:NumberOfAmbulatorySurgeryCenters
      contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2MzkzNzA_412c11d8-ad31-450a-bd4d-28fa2cc8b8e1"
      unitRef="surgery_center">15</thc:NumberOfAmbulatorySurgeryCenters>
    <thc:NumberOfSurgicalCentersRecordedUsingEquityMethod
      contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Mzk0MzA_c8a3d674-703f-46b4-8ee7-ef911dcabf9e"
      unitRef="surgery_center">57</thc:NumberOfSurgicalCentersRecordedUsingEquityMethod>
    <thc:NumberOfSurgicalCentersInDevelopmentStage
      contextRef="i48e686e617164f8788dbef7579035ca2_D20211201-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Mzk0NTk_5b0305e4-4b1a-4d8a-b2e2-2170826eafbf"
      unitRef="surgery_center">14</thc:NumberOfSurgicalCentersInDevelopmentStage>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib58f6ac4316f4317ab753edc02419bea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDIyODg_a6d171ca-9527-4abb-8794-11ef4d69b27a"
      unitRef="usd">1125000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDIzMDE_2147d2f6-1516-43c6-a895-bdb4ce99513b"
      unitRef="usd">74000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Mzk4OTU_55cb757b-d2ab-43b3-b0e1-40111199e706"
      unitRef="business">11</us-gaap:NumberOfBusinessesAcquired>
    <thc:NumberofHospitals
      contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDAwMzc_fcf86c6a-7846-4f7b-b4b2-2bca9e998a5f"
      unitRef="hospital">3</thc:NumberofHospitals>
    <thc:NumberOfSurgicalCentersAcquired
      contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM4MDA4_8a258726-ca52-4970-a6d3-c45e83acc0d5"
      unitRef="quarter">2</thc:NumberOfSurgicalCentersAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i79a82a15b1ff4884bae71a6f0ffd6dac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NDIzMTU_11d3ec2d-35e2-4a50-8152-a20af79820f1"
      unitRef="usd">21000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <thc:NumberOfSurgicalCentersAcquired
      contextRef="i7bc2ab83971e4498a02f300ccab65006_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1NjY_10e8dd83-86ab-4adc-98ae-e28c70464fda"
      unitRef="surgical_center">45</thc:NumberOfSurgicalCentersAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7bc2ab83971e4498a02f300ccab65006_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1NzM_d1c4b830-9239-49db-a406-387af825361a"
      unitRef="usd">1115000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia66fc1c0750d4afda6c0d81b93a363b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1ODY_5f68d2d6-9c98-4df8-8b52-8416dd78e9d5"
      unitRef="usd">1097000000.000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ia66fc1c0750d4afda6c0d81b93a363b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI1OTg_a9c13ce9-006a-4366-9662-1f44df486f93"
      unitRef="usd">18000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ic8d5d769fdb2494fa847d0ee04defa5b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI2MTY_782b2700-414e-4987-a297-b59cc96e3c48"
      unitRef="business">10</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ic8d5d769fdb2494fa847d0ee04defa5b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTI2MjI_b53ebe54-f3ec-42dc-a059-f07b3d1d6743"
      unitRef="usd">80000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NjI1Njc_04c2cea2-9244-42f9-91ab-8a1e9da9b9ba"
      unitRef="usd">7000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzQzMjY_36d84762-b4c3-4ecb-b598-91501ff8af17">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preliminary or final purchase price allocations for all the acquisitions made during the years ended December&#160;31,&#160;2022, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Previously held equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests in equity of consolidated subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains on consolidations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzItMS0xLTEtMjkzNzEw_1fec45be-3ce2-4cb5-ae81-48293efc83ae"
      unitRef="usd">38000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzItMy0xLTEtMjkzNzEw_8abf36af-672f-4b27-88dc-9f51c39a9357"
      unitRef="usd">59000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzItNS0xLTEtMjkzNzEw_5f93c02b-8d17-4150-867a-a6225d495720"
      unitRef="usd">67000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzMtMS0xLTEtMjkzNzEw_3a9088b6-22f1-4b1d-ad1b-7addf33d1357"
      unitRef="usd">54000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzMtMy0xLTEtMjkzNzEw_9512e570-c8de-4fd8-a8dc-425080fe4f4f"
      unitRef="usd">88000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzMtNS0xLTEtMjkzNzEw_feec70e4-41cf-4cbb-9c4f-73106fe56b25"
      unitRef="usd">63000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzQtMS0xLTEtMjkzNzEw_abcf4c5f-2468-4b55-b71a-30e16d67b627"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzQtMy0xLTEtMjkzNzEw_501fa898-b020-4850-afb5-4c65e857c9af"
      unitRef="usd">8000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzQtNS0xLTEtMjkzNzEw_e01c22b2-64dd-4eb1-bf76-80d5040c1fd8"
      unitRef="usd">14000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzUtMS0xLTEtMjkzNzEw_8f53d93f-4411-4131-9fab-3ce68a407228"
      unitRef="usd">860000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzUtMy0xLTEtMjkzNzEw_c624e8f8-53b3-4395-8035-30fc2f663b21"
      unitRef="usd">664000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzUtNS0xLTEtMjkzNzEw_5e29096f-ee7f-44ad-acd8-6bec6c562183"
      unitRef="usd">1581000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMS0xLTEtMzYyNzU2_9f4492be-f588-48bf-9181-2242f838b129"
      unitRef="usd">99000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMy0xLTEtMzYyNzU2_c1b0b0cd-71a9-48ec-a7ef-7223547aeff9"
      unitRef="usd">796000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtNS0xLTEtMzYyNzU2_59d0fa0d-2a91-48eb-b7df-d338e9679b2f"
      unitRef="usd">38000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMS0xLTEtMjkzNzEw_34454e8b-83b7-4698-871e-7c7a761e7cf6"
      unitRef="usd">207000000</thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates>
    <thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtMy0xLTEtMjkzNzEw_75c5b7b7-0684-4085-bc29-8ccc227c1e77"
      unitRef="usd">43000000</thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates>
    <thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzYtNS0xLTEtMjkzNzEw_1be1161b-d394-4419-b315-4a3b78a8ce2c"
      unitRef="usd">0</thc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzctMS0xLTEtMjkzNzEw_d99efac8-f7ec-4ed8-90b3-393be6f6cba4"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzctMy0xLTEtMjkzNzEw_256cd06d-61c2-4fbe-ae61-65fd20c54c8c"
      unitRef="usd">25000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzctNS0xLTEtMjkzNzEw_f61ea424-8635-4dde-9513-80486d88203e"
      unitRef="usd">45000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzgtMS0xLTEtMjkzNzEw_499f34c6-8176-4f97-ae1b-2094f59c4fea"
      unitRef="usd">118000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzgtMy0xLTEtMjkzNzEw_11e85226-c31a-4d22-86cf-899c7f11bddd"
      unitRef="usd">70000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzgtNS0xLTEtMjkzNzEw_3a2a46d9-71ab-48eb-b81b-72c9128d7182"
      unitRef="usd">43000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities>
    <thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzktMS0xLTEtMjkzNzEw_4bdd8819-c019-404e-9bc7-8c376c858aad"
      unitRef="usd">180000000</thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries>
    <thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzktMy0xLTEtMjkzNzEw_ed96ea76-174d-4e49-89b0-5ed1774f2d88"
      unitRef="usd">139000000</thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries>
    <thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzktNS0xLTEtMjkzNzEw_6dfb5009-9aa7-4ae5-9d3c-7803671f7ed5"
      unitRef="usd">478000000</thc:BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="if07cf50792f1459db9cc6eaf83c40b5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEwLTEtMS0xLTI5MzcxMA_33e0a8ef-e2b8-4996-a959-72ca05fd98c6"
      unitRef="usd">273000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i335893427cf548deb9b34f0425efb1a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEwLTMtMS0xLTI5MzcxMA_3d8a28f8-b71b-40e5-aa33-f5f8fd4aacbd"
      unitRef="usd">95000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i14390acae25c4ac79d2ac8ce44d91a68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEwLTUtMS0xLTI5MzcxMA_10383875-6553-4a3e-ab58-1672134b0216"
      unitRef="usd">20000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzExLTEtMS0xLTI5MzcxMA_d165e2b4-1194-485f-b60c-8371693d7091"
      unitRef="usd">234000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzExLTMtMS0xLTI5MzcxMA_19cd8ba0-ec62-4beb-aa34-2d02498b4469"
      unitRef="usd">1220000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzExLTUtMS0xLTI5MzcxMA_c24d1afb-688e-4d33-b542-7c8612b593bd"
      unitRef="usd">1177000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEyLTEtMS0xLTI5MzcxMA_ffec8b85-47e0-4106-a6a8-2df72cc25caf"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEyLTMtMS0xLTI5MzcxMA_c5d55fc3-1a41-4565-aa18-9b1894bfea2d"
      unitRef="usd">23000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo1ZjlmNzQ0Zjc1Mjc0OWU2ODQ3MmRjMDJmNjVhYzJkMi90YWJsZXJhbmdlOjVmOWY3NDRmNzUyNzQ5ZTY4NDcyZGMwMmY2NWFjMmQyXzEyLTUtMS0xLTI5MzcxMA_a1a7d95d-c18c-49c8-ba35-c7d3baaab2ed"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <thc:BusinessCombinationAcquisitionRelatedTransactionCosts
      contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM1MjU_8c542d99-eb19-41a2-b026-43aec3d51499"
      unitRef="usd">14000000</thc:BusinessCombinationAcquisitionRelatedTransactionCosts>
    <thc:BusinessCombinationAcquisitionRelatedTransactionCosts
      contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM1Mjk_6bba5c97-7beb-438e-97fc-26ac0e56c2e6"
      unitRef="usd">20000000</thc:BusinessCombinationAcquisitionRelatedTransactionCosts>
    <thc:BusinessCombinationAcquisitionRelatedTransactionCosts
      contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzM1MzY_35fe0b8f-0d07-45b4-ac39-393e29c11f00"
      unitRef="usd">14000000</thc:BusinessCombinationAcquisitionRelatedTransactionCosts>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i70ed061cd6934306b4066e74ce365959_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2NTc3NjQ_822fbf78-7489-44b9-8de1-575e61766627"
      unitRef="usd">23000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i9d080dd82b644853b823fde9301748b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Njg5NTI_609b6fbd-29e7-4469-be62-c90ec89b156d"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i80ec6aa56155485292ff1e2091e22da1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzEwOTk1MTE2Njg5NTI_cba13333-75ff-40c7-80a4-c8ff5da7f346"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90ZXh0cmVnaW9uOmQyNWY5NWY2N2ViNzQ1MjVhMjkyMTgyZGUxZjgyOGEyXzQ5NDc4MDIzNjg3NDE_7e0fca00-d421-40fe-ac38-d2795094a8f4">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides certain pro forma information for Tenet as if the 2021 SCD Centers acquisition had occurred at the beginning of the year ended December&#160;31,&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in earnings of unconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to Tenet Healthcare Corporation common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share available to Tenet Healthcare Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzItMS0xLTEtMzYyMTE3_eb51627b-d345-499b-9496-05272ada4bcc"
      unitRef="usd">19627000000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzItMy0xLTEtMzYyMTE3_dc5a13de-50b4-4ff7-8aa5-e6aab9485b8b"
      unitRef="usd">17752000000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <thc:BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments
      contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzMtMS0xLTEtMzYyMTE3_64ddcc7a-71e5-49e1-af41-edfcd921a4d6"
      unitRef="usd">258000000</thc:BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments>
    <thc:BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments
      contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzMtMy0xLTEtMzYyMTE3_e5d34352-ed5a-4e46-9916-f27acf9d848a"
      unitRef="usd">192000000</thc:BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzQtMS0xLTEtMzYyMTE3_0415ae36-4699-42f4-b191-db6ee3866173"
      unitRef="usd">941000000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzQtMy0xLTEtMzYyMTE3_4d96b1f2-8ae4-4eaa-a0f0-b36641aee45c"
      unitRef="usd">416000000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzUtMS0xLTEtMzYyMTE3_98175f0a-b6fe-42c1-a97f-019269de68fc"
      unitRef="usdPerShare">8.66</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i8a110926660a4054af849fa472768d12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzQvZnJhZzpkMjVmOTVmNjdlYjc0NTI1YTI5MjE4MmRlMWY4MjhhMi90YWJsZTo5NGVhZThmOTFmNGY0NzM3ODg4M2FkZGMzNTAzZGJlMi90YWJsZXJhbmdlOjk0ZWFlOGY5MWY0ZjQ3Mzc4ODgzYWRkYzM1MDNkYmUyXzUtMy0xLTEtMzYyMTE3_8920c611-1af1-4fdc-a735-aa918bd2fd41"
      unitRef="usdPerShare">3.92</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzI1MDI_f9a5563c-da05-4f4f-934e-d925d41b107c">SEGMENT INFORMATION&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our business consists of our Hospital Operations segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro&#x2011;hospitals and physician practices. At December&#160;31,&#160;2022, our subsidiaries operated 61&#160;hospitals serving primarily urban and suburban communities in nine&#160;states, including the new acute care hospital we opened in September&#160;2022 in South Carolina. On April&#160;1, 2021, we transferred 24&#160;imaging centers from our Ambulatory Care segment to our Hospital Operations segment. The total assets associated with the imaging centers transferred to our Hospital Operations segment constituted less than 1% of our consolidated total assets at March&#160;31,&#160;2021. Also in April&#160;2021, we completed the sale of the majority of the urgent care centers then held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, we completed the sale of the Miami Hospitals in August&#160;2021, all of which were held by our Hospital Operations segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Ambulatory Care segment is comprised of the operations of USPI. At December&#160;31,&#160;2022, USPI had ownership interests in 442 ambulatory surgery centers (300 consolidated) and 24 surgical hospitals (eight consolidated) in 35&#160;states. In April&#160;2021, we completed the sale of 40&#160;urgent care centers then held by our Ambulatory Care segment to an unaffiliated urgent care provider and, as noted above, transferred 24&#160;imaging centers from our Ambulatory Care segment to our Hospital Operations segment. Effective June&#160;30,&#160;2022, we purchased all of the shares previously held by Baylor in USPI for $406&#160;million, which increased our ownership interest in USPI&#x2019;s voting shares from 95% to 100%. See Note&#160;18 for additional information about this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Conifer segment provides revenue cycle management and value&#x2011;based care services to hospitals, health systems, physician practices, employers and other clients. At December&#160;31,&#160;2022, Conifer provided services to approximately 660&#160;Tenet and non&#x2011;Tenet hospitals and other clients nationwide. We have entered into an agreement documenting the terms and conditions of various services Conifer provides to Tenet hospitals (&#x201c;RCM Agreement&#x201d;), as well as an agreement documenting certain administrative services our Hospital Operations segment provides to Conifer. In March 2021, we entered into a month&#x2011;to&#x2011;month agreement amending the RCM Agreement effective January&#160;1,&#160;2021 (&#x201c;Amended RCM Agreement&#x201d;) to update certain terms and conditions related to the revenue cycle management services Conifer provides to Tenet hospitals. We believe the pricing terms for the services provided under the Amended RCM Agreement are commercially reasonable and consistent with estimated third&#x2011;party terms. At December&#160;31,&#160;2022, we owned approximately 76% of Conifer Health Solutions, LLC, which is Conifer&#x2019;s principal subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Consolidated Balance Sheets and Consolidated Statements of Operations, as applicable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,579&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations total prior to inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other clients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Conifer revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,485&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity in earnings of unconsolidated affiliates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;857&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from divested and closed businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment and restructuring charges, and acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and investigation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sales, consolidation and deconsolidation of facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations, before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <thc:NumberOfHospitalsOperatedBySubsidiaries
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzQyMg_54e4a860-048a-4cc3-a1f4-48e710100192"
      unitRef="hospital">61</thc:NumberOfHospitalsOperatedBySubsidiaries>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzQ4Nw_b7b2d7ef-0461-4d53-9f16-be3fa864146e"
      unitRef="state">9</us-gaap:NumberOfStatesInWhichEntityOperates>
    <thc:NumberOfImagingCentersTransferred
      contextRef="i201297e314ab451088f2cc2cd5577ad8_I20210401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzUyMA_1c9f1e54-0342-4dd7-a0e8-dfe44b03fc3c"
      unitRef="imaging_center">24</thc:NumberOfImagingCentersTransferred>
    <thc:SegmentReportingTransferOfAssetsPercentageOfTotalAssets
      contextRef="i1c476cd298284a1bafde8fdd47d49539_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzczMA_c1eb750d-3f68-4f30-aabc-f3b3b181f226"
      unitRef="number">0.01</thc:SegmentReportingTransferOfAssetsPercentageOfTotalAssets>
    <thc:NumberOfAmbulatorySurgeryCenters
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzU0OTc1NTgyNDMzNA_b2b2ca3f-bee8-4ddd-8e2d-39a8b281b0a6"
      unitRef="hospital">442</thc:NumberOfAmbulatorySurgeryCenters>
    <thc:NumberOfAmbulatorySurgeryCentersConsolidated
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwMjg_372f189b-e246-4dc1-9c0c-f97500bb3934"
      unitRef="surgery_center">300</thc:NumberOfAmbulatorySurgeryCentersConsolidated>
    <thc:NumberOfSurgicalHospitalsOperatedBySubsidiaries
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwNTA_8195e77a-deb5-46c2-b162-445e0908cf16"
      unitRef="hospital">24</thc:NumberOfSurgicalHospitalsOperatedBySubsidiaries>
    <thc:NumberOfSurgicalHospitalsConsolidated
      contextRef="ib82b8f4aa9f24143ac58ed4d2a026dbf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwNzQ_56152a7c-cb7e-4fbd-9508-3d90c304d022"
      unitRef="hospital">8</thc:NumberOfSurgicalHospitalsConsolidated>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i86001c59573247b08eeb42c93d75f6f7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEwOTU_df009046-ce98-484c-9770-e534259f08ba"
      unitRef="state">35</us-gaap:NumberOfStatesInWhichEntityOperates>
    <thc:NumberOfUrgentCareCentersSold
      contextRef="i82e19c7717074970a71b4dccde90bc0b_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTExODE_594e90f6-2a8d-4db2-8035-4c10894ce386"
      unitRef="hospital">40</thc:NumberOfUrgentCareCentersSold>
    <thc:NumberOfImagingCentersTransferred
      contextRef="i201297e314ab451088f2cc2cd5577ad8_I20210401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTEzMzE_1c9f1e54-0342-4dd7-a0e8-dfe44b03fc3c"
      unitRef="imaging_center">24</thc:NumberOfImagingCentersTransferred>
    <thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest
      contextRef="id03e28a327e64655b42d061b206c91d2_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTE1MTU_fa8c3ef3-021a-4cc5-9bd4-a8c95825b1c6"
      unitRef="usd">406000000</thc:SharePurchaseAgreementAmountOfPaymentForMinorityInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i647dc680b9224e41a241261103ccd5aa_I20220629"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTE2MTQ_b3c1d141-1e18-4b2d-953e-ef3ac40f0990"
      unitRef="number">0.95</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i20f7c47ed3f1432b9993a85a212b93bc_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzE2NDkyNjc0NTE2MjE_92a366f0-dac1-4f41-9978-3b698155d42b"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <thc:NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzEzODY_c32766d5-3bfb-412d-8633-0e9dfd459ae5"
      unitRef="hospital">660</thc:NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i314717058c7b4b6fb0a8169f1a019fe3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzIxNzY_5a760f4f-7fae-48f6-9c61-b07d26dc8ebd"
      unitRef="number">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzI0OTU_9e654d69-01a6-4679-b836-e6052c6a90a4">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Consolidated Balance Sheets and Consolidated Statements of Operations, as applicable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,579&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i476176f776be4198873c2255c05882ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzMtMS0xLTEtMjkzNzEw_e9175705-e403-408b-9e9a-2dd5583cb929"
      unitRef="usd">15682000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i11c9ffc9de624831af0a297d262e7276_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzMtMy0xLTEtMjkzNzEw_685126fd-34b0-483f-978b-92f0b161e65d"
      unitRef="usd">17173000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if474534dcafd415d9534dbb0774b811e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzMtNS0xLTEtMjkzNzEw_5861b183-1283-4db1-a558-08a7bacf9aa3"
      unitRef="usd">18048000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib165a084700643e1b139d15df43a3b15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzQtMS0xLTEtMjkzNzEw_de53536f-62da-4d4b-8f2f-4c9ee8541857"
      unitRef="usd">10557000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia4b7db85097147a3877bb4389f2984a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzQtMy0xLTEtMjkzNzEw_78cf949f-de42-43f5-ab98-73099eae7b90"
      unitRef="usd">9473000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2366c9010b2e49cba43c03549f1d2ddf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzQtNS0xLTEtMjkzNzEw_e8d11458-083f-4d9c-9c4a-8bf6eb38f542"
      unitRef="usd">8048000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7fabc80fff1241c29e2540d687490e0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzUtMS0xLTEtMjkzNzEw_b1daf8c3-5e4e-4924-a5a1-2dfe7a78b026"
      unitRef="usd">917000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5a0b252636e347bfa5ded4fff8ef5797_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzUtMy0xLTEtMjkzNzEw_7e979f77-1537-4599-bead-4cb941e1b59e"
      unitRef="usd">933000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i96ad47d7e3c04f468af3c2713771b904_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzUtNS0xLTEtMjkzNzEw_d6a22a40-c0e4-43a0-a8be-4f443b4babd6"
      unitRef="usd">1010000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1338325429bf43b1917d2b7a451f60b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzYtMS0xLTEtMjkzNzEw_08c66b8b-ce0a-46ed-8d7f-d21ad0f6859d"
      unitRef="usd">27156000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4c6583adb6404a2e9fb74d00bd953e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzYtMy0xLTEtMjkzNzEw_460be173-cbc2-4475-a7ca-abd0a97e5ab8"
      unitRef="usd">27579000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8cd4726c880f4e148d4569ab39f1d407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2YzBiMjk0YWIzMzY0MTkxYmJiZThhYzc5NjU4OWRiMy90YWJsZXJhbmdlOjZjMGIyOTRhYjMzNjQxOTFiYmJlOGFjNzk2NTg5ZGIzXzYtNS0xLTEtMjkzNzEw_d68bb19a-b60e-48e4-8d21-2c4eb894d497"
      unitRef="usd">27106000000</us-gaap:Assets>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90ZXh0cmVnaW9uOmExOWM5NGRhZDkyZDQ1MTJhODA4NTk0MTNmMjkwYmZkXzI0OTc_05937e04-1f8d-4d96-9e5a-68cd9dfa8a08">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations total prior to inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other clients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Conifer revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inter-segment eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,485&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity in earnings of unconsolidated affiliates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospital Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ambulatory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conifer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;857&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from divested and closed businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment and restructuring charges, and acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and investigation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sales, consolidation and deconsolidation of facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations, before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzMtMS0xLTEtMjkzNzEw_70fbc80f-2f0a-45c5-b5bc-47cb420a387a"
      unitRef="usd">668000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzMtMy0xLTEtMjkzNzEw_61a7916b-fcfb-4fac-ba08-c08184a83a7a"
      unitRef="usd">578000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzMtNS0xLTEtMjkzNzEw_18b8eb56-db99-4e5c-9ba9-2e26d89de335"
      unitRef="usd">467000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzQtMS0xLTEtMjkzNzEw_c368703c-4e8e-4b39-864c-60a3189797e5"
      unitRef="usd">75000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzQtMy0xLTEtMjkzNzEw_aacd3104-1eb9-4e19-9cb3-a9c035b5927a"
      unitRef="usd">66000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzQtNS0xLTEtMjkzNzEw_93b8c48f-d541-42d7-92e5-cc7472895a9a"
      unitRef="usd">51000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzUtMS0xLTEtMjkzNzEw_b55f17e8-f33d-4c2c-bd9d-a760a22bc12c"
      unitRef="usd">19000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzUtMy0xLTEtMjkzNzEw_ca8b0156-b5eb-4e7a-9d4d-56015e43cd50"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzUtNS0xLTEtMjkzNzEw_99dfa60f-2b31-45e8-bad2-595c9733bc6a"
      unitRef="usd">22000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzYtMS0xLTEtMjkzNzEw_bba46f12-6a88-4515-856a-1adcfe3f112b"
      unitRef="usd">762000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzYtMy0xLTEtMjkzNzEw_ac903541-dad1-4220-b416-2575fc60bb05"
      unitRef="usd">658000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzYtNS0xLTEtMjkzNzEw_9a8eb682-4d8e-4b0f-9719-67de8f43437c"
      unitRef="usd">540000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie464e81a78ca4b5bbc82e4f831a2f8fd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzktMS0xLTEtMjkzNzEw_96f4bce5-9320-421b-9bbd-e7c7d0698392"
      unitRef="usd">15061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a6e909d5f7146e6b2f3799ec1c792e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzktMy0xLTEtMjkzNzEw_aa7d4114-35aa-45bb-a3b9-8188d4529b75"
      unitRef="usd">15982000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8fc34a3116b48039c40d17002cd0211_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzktNS0xLTEtMjkzNzEw_d4108a16-b9f7-46f3-b559-94407073af58"
      unitRef="usd">14790000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3ce7b2af81a45cebea65cf46c0e002e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEwLTEtMS0xLTI5MzcxMA_b8ce1ddd-fb95-45df-8d8c-006018dc22f0"
      unitRef="usd">3248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6e55bb2a3404d37ac0446903cd6f0ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEwLTMtMS0xLTI5MzcxMA_b38258d2-d4ba-4eb5-81fc-3a0e7ffbb12d"
      unitRef="usd">2718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4bd925e775946d38f284ce1b8382ffb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEwLTUtMS0xLTI5MzcxMA_7126e95f-1868-4985-a607-b58375343009"
      unitRef="usd">2072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia18d9a3de8e841b08ffc82230780dc95_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEyLTEtMS0xLTI5MzcxMA_081a815a-c392-4f14-ae99-cd10c6a9e3c4"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7ceaf5394f94012b9da3e04b6ed796c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEyLTMtMS0xLTI5MzcxMA_6f40ff5e-4539-4068-84dc-afb3070bc39e"
      unitRef="usd">482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4376608b69a145f2998cf8f78326c6d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEyLTUtMS0xLTI5MzcxMA_4d1c01ab-4966-45d4-b39c-5a220220dc58"
      unitRef="usd">528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4247e435c1a48c9abfb49f3a445ea67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEzLTEtMS0xLTI5MzcxMA_6b20adc3-73b4-4adb-99c8-8bbe0e72507f"
      unitRef="usd">865000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6bdb8fda770486f97297332c7c0c2e9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEzLTMtMS0xLTI5MzcxMA_baee1e8e-24fd-4a06-8cfd-d5098a697c18"
      unitRef="usd">785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bd670b142c346aba126a22c475f14a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzEzLTUtMS0xLTI5MzcxMA_2395c878-5b10-4bb4-87a0-42fc04458ca7"
      unitRef="usd">778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cc1bcf836fb4be6bef17a04e3599061_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE0LTEtMS0xLTI5MzcxMA_6c875dab-91f1-45c4-b63b-8e8ed19c12df"
      unitRef="usd">1316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a76387d9429414d8b35662237a46f7d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE0LTMtMS0xLTI5MzcxMA_019081e9-74a2-4f38-89af-ca43301919ee"
      unitRef="usd">1267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27b36c3b506c460a83c8be8982727090_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE0LTUtMS0xLTI5MzcxMA_1e17a532-ef9c-47ca-84dc-5d1426ab46c0"
      unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1253b20e6f0b4e17802a597aa8a7b59f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE1LTEtMS0xLTI5MzcxMA_2979d74a-8608-4002-be94-a281aa4a7929"
      unitRef="usd">-451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia925e5b318a2405589428d1271dec1b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE1LTMtMS0xLTI5MzcxMA_6d27f424-664a-485e-b406-d6b4b9191b4f"
      unitRef="usd">-482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9db4542a137447f59a1e7ac2c89d14d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE1LTUtMS0xLTI5MzcxMA_aefeb727-c00a-4c4b-a6be-2325f2497c17"
      unitRef="usd">-528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE2LTEtMS0xLTI5MzcxMA_9d64db4c-4ea6-4e14-a523-a363acadd292"
      unitRef="usd">19174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE2LTMtMS0xLTI5MzcxMA_a605c4a0-ee24-480f-8485-438f1c60ad62"
      unitRef="usd">19485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE2LTUtMS0xLTI5MzcxMA_4da60c73-02e9-46b9-8891-456be8ed2009"
      unitRef="usd">17640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE5LTEtMS0xLTI5MzcxMA_52e215f2-a8e1-48ab-b656-93d6ef803c96"
      unitRef="usd">10000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE5LTMtMS0xLTI5MzcxMA_1d592820-05e6-4b71-891c-3c900effaab1"
      unitRef="usd">25000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzE5LTUtMS0xLTI5MzcxMA_2bccc380-a71d-4914-ac4e-00291b3b7e3f"
      unitRef="usd">6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIwLTEtMS0xLTI5MzcxMA_da491b0c-ba0c-4e43-8f0c-39ac9b430f49"
      unitRef="usd">206000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIwLTMtMS0xLTI5MzcxMA_2a21ddd0-75d8-4874-a306-20857fbe67d1"
      unitRef="usd">193000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIwLTUtMS0xLTI5MzcxMA_c56d8f67-bccf-4cef-95e8-202dc6d53e73"
      unitRef="usd">163000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIxLTEtMS0xLTI5MzcxMA_b557b9c8-e0c9-4117-9b87-945a43a11896"
      unitRef="usd">216000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIxLTMtMS0xLTI5MzcxMA_9736cb14-74e9-42d8-9a88-23003f4c6d95"
      unitRef="usd">218000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTphMGUxMWUwOGNmMGI0MzA1YmI4MTdlOWFkZGYxNGI5OS90YWJsZXJhbmdlOmEwZTExZTA4Y2YwYjQzMDViYjgxN2U5YWRkZjE0Yjk5XzIxLTUtMS0xLTI5MzcxMA_19f60d32-3c08-4c55-86f0-269eb7091d5e"
      unitRef="usd">169000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzgtMS0xLTEtMjkzNzEw_840cc815-fd34-4117-b4ef-50759ab2c1e7"
      unitRef="usd">1777000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzgtMy0xLTEtMjkzNzEw_daf7bd4e-61df-4909-9b4b-d4b8252c4ba3"
      unitRef="usd">1931000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzgtNS0xLTEtMjkzNzEw_892e2531-8f61-4680-86ee-6a5ad8744c6e"
      unitRef="usd">1911000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzktMS0xLTEtMjkzNzEw_efca1267-b66a-4550-b727-23334c42afdf"
      unitRef="usd">1327000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzktMy0xLTEtMjkzNzEw_8cc5f8a0-dd53-42aa-a073-aa2b9990e750"
      unitRef="usd">1197000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzktNS0xLTEtMjkzNzEw_6383ca7f-f48e-46fe-9f00-976f610e27e4"
      unitRef="usd">868000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzEwLTEtMS0xLTI5MzcxMA_5e98e01a-fdc6-4b34-9b58-6fc428c108a7"
      unitRef="usd">365000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzEwLTMtMS0xLTI5MzcxMA_99f723ec-1cd7-4f8e-951c-75077833e28f"
      unitRef="usd">355000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzEwLTUtMS0xLTI5MzcxMA_23568b43-591b-4fc0-866e-976396938f82"
      unitRef="usd">367000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzExLTEtMS0xLTI5MzcxMA_698b00f8-c8f9-4446-9da9-945852f823e5"
      unitRef="usd">3469000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzExLTMtMS0xLTI5MzcxMA_5b79446e-ffd4-4c88-a91b-cf0988a03ce4"
      unitRef="usd">3483000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzExLTUtMS0xLTI5MzcxMA_cdc119bd-1cef-4a0e-bdeb-173045fa8165"
      unitRef="usd">3146000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib9105bcf52db42479105d6f470b7132c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIwLTEtMS0xLTI5MzcxMA_4023bf90-fc5b-43b8-85c5-4474286c2dad"
      unitRef="usd">692000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib276fc70e6bc4e0582826069c3fe8dd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIwLTMtMS0xLTI5MzcxMA_19d3e4e5-f349-4825-92d3-d7bca11de28b"
      unitRef="usd">722000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia08e689284844b2ab2f30581bbeab61a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIwLTUtMS0xLTI5MzcxMA_330d3ebb-e3e1-414b-ba0f-c1e359b86fba"
      unitRef="usd">739000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i31240fb38fb94d07974dee580125b5e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIxLTEtMS0xLTI5MzcxMA_872569b3-97bf-4fde-bd9c-e0d85ae032cb"
      unitRef="usd">112000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib67e7aa5397345338cccd193f0c7b08b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIxLTMtMS0xLTI5MzcxMA_b994629e-aa49-48a1-9282-0069e7937f9d"
      unitRef="usd">95000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if07b5ba4b7a947709f59e7d23c81f138_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIxLTUtMS0xLTI5MzcxMA_68917734-d7cf-4b16-95da-7cf940b9a589"
      unitRef="usd">81000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iff38c52acd0e411f9cb996c1dc9ed494_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIyLTEtMS0xLTI5MzcxMA_d1d4f7cc-84c9-410e-a0cd-d4b1d40ad084"
      unitRef="usd">37000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iee1b2c0393f94393a945261d587a5e46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIyLTMtMS0xLTI5MzcxMA_b9ac9633-ec40-4c64-b648-6cffaf0d5b6a"
      unitRef="usd">38000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if35c7e90c95e4bef8dd4992baf8e0f2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIyLTUtMS0xLTI5MzcxMA_26c3d7a4-031a-4e96-8ae0-7b6b8d6e7c8e"
      unitRef="usd">37000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIzLTEtMS0xLTI5MzcxMA_f823d4bd-c088-48f0-bc6e-ae114e712749"
      unitRef="usd">841000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIzLTMtMS0xLTI5MzcxMA_86b5a410-e349-4e52-8617-31fbeff8a996"
      unitRef="usd">855000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzIzLTUtMS0xLTI5MzcxMA_3a5078e8-5861-4a65-9a96-4906e18e78d0"
      unitRef="usd">857000000</us-gaap:DepreciationDepletionAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI1LTEtMS0xLTI5MzcxMA_45126754-5811-4f7e-8737-28aa63447612"
      unitRef="usd">3469000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI1LTMtMS0xLTI5MzcxMA_d498012a-7cd3-4832-b602-5c9908114d22"
      unitRef="usd">3483000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI1LTUtMS0xLTI5MzcxMA_0453ad5a-ad0f-4aa9-bfdc-11829ccc0ee6"
      unitRef="usd">3146000000</thc:AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization>
    <thc:IncomeLossFromDivestedAndClosedBusinesses
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI2LTEtMS0xLTI5MzcxMA_ea19a8eb-57ab-42e6-86f2-87fa8c538583"
      unitRef="usd">0</thc:IncomeLossFromDivestedAndClosedBusinesses>
    <thc:IncomeLossFromDivestedAndClosedBusinesses
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI2LTMtMS0xLTI5MzcxMA_f864371c-e23f-4835-ad67-299ae7cc45d0"
      unitRef="usd">-1000000</thc:IncomeLossFromDivestedAndClosedBusinesses>
    <thc:IncomeLossFromDivestedAndClosedBusinesses
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI2LTUtMS0xLTI5MzcxMA_3b378113-9b63-44cf-82ba-e83105cc026e"
      unitRef="usd">20000000</thc:IncomeLossFromDivestedAndClosedBusinesses>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI3LTEtMS0xLTI5MzcxMA_363f4154-8da1-4cfb-8d37-01f21b7a7aa8"
      unitRef="usd">841000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI3LTMtMS0xLTI5MzcxMA_9e9ffc64-cbdd-4911-9b31-54bc1812490e"
      unitRef="usd">855000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI3LTUtMS0xLTI5MzcxMA_7129c831-d8cb-496b-b1d3-fdd9bcf5ce78"
      unitRef="usd">857000000</us-gaap:DepreciationDepletionAndAmortization>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI4LTEtMS0xLTI5MzcxMA_717d355f-699e-4e63-a966-64779ed9577c"
      unitRef="usd">226000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI4LTMtMS0xLTI5MzcxMA_29b28c2b-65a0-4e85-b1b5-7fcc01d402eb"
      unitRef="usd">85000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI4LTUtMS0xLTI5MzcxMA_e071357e-4255-4a4c-b941-654d7c2a482d"
      unitRef="usd">290000000</thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI5LTEtMS0xLTI5MzcxMA_d3c69c42-3ad6-4e8f-bb7d-1b18d5c91775"
      unitRef="usd">-70000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI5LTMtMS0xLTI5MzcxMA_696fae1e-43c1-4c59-b7d8-9335b6f69613"
      unitRef="usd">-116000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzI5LTUtMS0xLTI5MzcxMA_f3aa3af3-de5d-409c-a363-927ca3c36344"
      unitRef="usd">-44000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:InterestExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMwLTEtMS0xLTI5MzcxMA_6c740acf-fd3a-4301-9223-3f20bb65b237"
      unitRef="usd">890000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMwLTMtMS0xLTI5MzcxMA_c658ef81-1fe7-4c93-8983-1fc3766f7130"
      unitRef="usd">923000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMwLTUtMS0xLTI5MzcxMA_82bb2949-1219-42df-90d0-2dd97e0d5137"
      unitRef="usd">1003000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMxLTEtMS0xLTI5MzcxMA_4a34f400-e659-4508-bd50-9526f72669ab"
      unitRef="usd">-109000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMxLTMtMS0xLTI5MzcxMA_5ade9127-a914-4c16-957b-28a5cbf9428d"
      unitRef="usd">-74000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMxLTUtMS0xLTI5MzcxMA_f11970c6-07c8-410d-9f5c-c7183e384f95"
      unitRef="usd">-316000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMyLTEtMS0xLTI5MzcxMA_b328e674-e248-46a1-8546-3147d0bd19cb"
      unitRef="usd">10000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMyLTMtMS0xLTI5MzcxMA_2ee320bd-b8dc-43f4-9e1a-e9abdfd83666"
      unitRef="usd">14000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMyLTUtMS0xLTI5MzcxMA_23c5a3fc-824a-40aa-973a-882a6469256b"
      unitRef="usd">1000000</us-gaap:OtherNonoperatingIncomeExpense>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMzLTEtMS0xLTI5MzcxMA_e386feee-420b-4147-b63d-49ae905dc3b1"
      unitRef="usd">1000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMzLTMtMS0xLTI5MzcxMA_e803e0c9-d058-41d8-ac2c-29bd3c2fcfd5"
      unitRef="usd">445000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzMzLTUtMS0xLTI5MzcxMA_a3e297bb-a5ba-47b7-be4d-670a476adef3"
      unitRef="usd">14000000</thc:NetGainonSaleConsolidationAndDeconsolidationOfFacilities>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzM0LTEtMS0xLTI5MzcxMA_384fb1b6-2caa-4063-9a37-c8ee2ce6255b"
      unitRef="usd">1344000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i64259c4aaf6c466899782c25f81797e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzM0LTMtMS0xLTI5MzcxMA_d64ca949-ef94-42a7-bd4d-6d12ab460676"
      unitRef="usd">1888000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8962e91413c44e4eaa374cf217033203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yNzcvZnJhZzphMTljOTRkYWQ5MmQ0NTEyYTgwODU5NDEzZjI5MGJmZC90YWJsZTo2NDE4M2UzNTFiMjE0ZmRiYmZmYjY2NGYwOGY2NzY5Yy90YWJsZXJhbmdlOjY0MTgzZTM1MWIyMTRmZGJiZmZiNjY0ZjA4ZjY3NjljXzM0LTUtMS0xLTI5MzcxMA_13eb049e-23e8-4c0a-bf87-291e7f3732f7"
      unitRef="usd">671000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yODAvZnJhZzphN2QyZjBhMDkwODc0ODY1YTYzOGYzM2UyM2I4NDk0OC90ZXh0cmVnaW9uOmE3ZDJmMGEwOTA4NzQ4NjVhNjM4ZjMzZTIzYjg0OTQ4XzQ2MjM_242207ea-ce0a-412f-bf7b-4bff179fb8e3">RECENT ACCOUNTING STANDARDS&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FASB issued ASU 2022&#x2011;03, &#x201c;Fair Value Measurement (Topic 820) &#x2013; Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&#x201d; (&#x201c;ASU 2022&#x2011;03&#x201d;) in June&#160;2022. Through ASU 2022&#x2011;03 the FASB clarified that an entity should measure the fair value of an equity security subject to contractual sale restriction the same way it measures an identical equity security that is not subject to such a restriction. Under this approach the contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, should not affect its fair value. ASU 2022&#x2011;03 also enhanced the disclosure requirements related to these instruments. The ASU is effective for public entities for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years, and early adoption is permitted. For non&#x2011;investment companies, ASU 2022&#x2011;03 will be applied prospectively with adjustments resulting from the initial adoption recognized in earnings and disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in ASU 2022&#x2011;03 primarily affect the RSUs granted to our non&#x2011;employee directors as part of their annual compensation, which vest immediately but cannot be sold until a three&#x2011;year holding period has lapsed. Upon adoption, we expect to recognize an immaterial amount of incremental stock compensation expense related to these awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October&#160;2021, the FASB issued ASU 2021-08, &#x201c;Business Combinations (Topic 805) &#x2013; Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d; (&#x201c;ASU 2021-08&#x201d;). The standard addresses diversity in practice related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 &#x2013; Revenue from Contracts with Customers as if the acquirer had originated the contracts, as opposed to at their fair value on the acquisition date. ASU 2021-08 is effective for us beginning in 2023, with early adoption permitted. We are currently evaluating the impact of this standard to our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span id="ia7d2f0a090874865a638f33e23b84948_25466"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further discussed in Note 1, we adopted ASU&#160;2020-06 effective January&#160;1,&#160;2022 and adopted ASU 2016&#x2011;13 effective January&#160;1,&#160;2020. We applied the modified retrospective transition approach as of the period of adoption for both ASU&#160;2020-06 and ASU 2016&#x2011;13.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8yODAvZnJhZzphN2QyZjBhMDkwODc0ODY1YTYzOGYzM2UyM2I4NDk0OC90ZXh0cmVnaW9uOmE3ZDJmMGEwOTA4NzQ4NjVhNjM4ZjMzZTIzYjg0OTQ4XzQ2MTg_fa56d421-b215-4d6d-8731-5ea8d85c75b9">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FASB issued ASU 2022&#x2011;03, &#x201c;Fair Value Measurement (Topic 820) &#x2013; Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&#x201d; (&#x201c;ASU 2022&#x2011;03&#x201d;) in June&#160;2022. Through ASU 2022&#x2011;03 the FASB clarified that an entity should measure the fair value of an equity security subject to contractual sale restriction the same way it measures an identical equity security that is not subject to such a restriction. Under this approach the contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, should not affect its fair value. ASU 2022&#x2011;03 also enhanced the disclosure requirements related to these instruments. The ASU is effective for public entities for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years, and early adoption is permitted. For non&#x2011;investment companies, ASU 2022&#x2011;03 will be applied prospectively with adjustments resulting from the initial adoption recognized in earnings and disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in ASU 2022&#x2011;03 primarily affect the RSUs granted to our non&#x2011;employee directors as part of their annual compensation, which vest immediately but cannot be sold until a three&#x2011;year holding period has lapsed. Upon adoption, we expect to recognize an immaterial amount of incremental stock compensation expense related to these awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October&#160;2021, the FASB issued ASU 2021-08, &#x201c;Business Combinations (Topic 805) &#x2013; Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d; (&#x201c;ASU 2021-08&#x201d;). The standard addresses diversity in practice related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 &#x2013; Revenue from Contracts with Customers as if the acquirer had originated the contracts, as opposed to at their fair value on the acquisition date. ASU 2021-08 is effective for us beginning in 2023, with early adoption permitted. We are currently evaluating the impact of this standard to our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span id="ia7d2f0a090874865a638f33e23b84948_25466"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further discussed in Note 1, we adopted ASU&#160;2020-06 effective January&#160;1,&#160;2022 and adopted ASU 2016&#x2011;13 effective January&#160;1,&#160;2020. We applied the modified retrospective transition approach as of the period of adoption for both ASU&#160;2020-06 and ASU 2016&#x2011;13.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <dei:AuditorFirmId
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zMzcvZnJhZzpmYmJkOTUwMGU2ZmI0MDk1YmVhNjUxZmM4MDk1ZTQ4ZC90YWJsZTpiN2M2OTllNGRmYWI0Yjk0YTQ5NjhjOTFhZDNmOWIwOS90YWJsZXJhbmdlOmI3YzY5OWU0ZGZhYjRiOTRhNDk2OGM5MWFkM2Y5YjA5Xzk1LTItMS0xLTI5MzcxMC90ZXh0cmVnaW9uOmEyNDhmNWJjOTkwNzRmZDdhYjk2ZjVjYzBjOWE4MWU2XzUy_4a6b66b6-e88d-417e-af0d-5e365d652284">34</dei:AuditorFirmId>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i462e90434397417b94ea400ab3e98d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90ZXh0cmVnaW9uOmU4NmUyOTQ2Y2E2NjRlNzM5OTZhNDE1Zjk2YTAwZDk3XzEyNg_e6879f59-ffe8-4d3e-9b1d-b93cf981c81b">&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&#x2014;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In&#160;Millions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;at&lt;br/&gt;Beginning&lt;br/&gt;of&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Costs&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;at&lt;br/&gt;End&#160;of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Includes amounts recorded in discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa722f7986ca4c518e3bcdca37e64012_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtMS0xLTEtMjkzNzEw_e944dfd7-6922-414d-912c-49ed76b1cfc4"
      unitRef="usd">57000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtMy0xLTEtMjkzNzEw_076707d2-3c4d-4bea-a298-b830cd530b2e"
      unitRef="usd">120000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtNS0xLTEtMjkzNzEw_18ef484d-f6b7-4123-bd6f-4db624c7d741"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <thc:ValuationAllowancesAndReservesReservesOfBusinessesSold
      contextRef="ice14040d2bfa4aa1a9d1c96bc6e62b5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtNy0xLTEtMjkzNzEw_a42f058f-9334-42b6-8684-0775b575a1f2"
      unitRef="usd">0</thc:ValuationAllowancesAndReservesReservesOfBusinessesSold>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7fb31be8d6de4e44a3f930dc03031843_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzYtOS0xLTEtMjkzNzEw_269534b0-c28c-4082-8050-9d121dfeea34"
      unitRef="usd">177000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie6544cc6587346acb00b26c710bc7751_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctMS0xLTEtMjkzNzEw_739df74e-1c65-49ee-9d64-5a104e8f1eb4"
      unitRef="usd">55000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i133c13b23a124143877c18e0c045ff74_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctMy0xLTEtMjkzNzEw_b1c05d2d-7cd3-448f-af8f-11b5aa2650c2"
      unitRef="usd">2000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i133c13b23a124143877c18e0c045ff74_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctNS0xLTEtMjkzNzEw_ad1e3a14-a0fa-42d4-b9f5-24f8f1937186"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <thc:ValuationAllowancesAndReservesReservesOfBusinessesSold
      contextRef="i133c13b23a124143877c18e0c045ff74_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctNy0xLTEtMjkzNzEw_4e01ae7f-b813-4801-8bea-bffb5798df75"
      unitRef="usd">0</thc:ValuationAllowancesAndReservesReservesOfBusinessesSold>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa722f7986ca4c518e3bcdca37e64012_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzctOS0xLTEtMjkzNzEw_13ac5485-e5f9-4cc5-95ff-b60c1d4dcee6"
      unitRef="usd">57000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0b95f4641f134e5c9fffaae2b5ca01e5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtMS0xLTEtMjkzNzEw_47529dc1-3e3c-4924-9c24-55d1ca3d9d05"
      unitRef="usd">281000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtMy0xLTEtMjkzNzEw_d523f09e-6fdf-406f-9dd3-9cc3c16160ce"
      unitRef="usd">-226000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtNS0xLTEtMjkzNzEw_e31811c5-9e7b-4f71-838f-eaa7da757bd7"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <thc:ValuationAllowancesAndReservesReservesOfBusinessesSold
      contextRef="i5c782dc45e56483d9f39e44f9b859775_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtNy0xLTEtMjkzNzEw_15233c7f-4937-4278-8b6d-f78fdec1f37c"
      unitRef="usd">0</thc:ValuationAllowancesAndReservesReservesOfBusinessesSold>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie6544cc6587346acb00b26c710bc7751_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM5N2IwMGUzZGNmZjQ1ZDliOWM1YzY0NTliYTMwMjc2L3NlYzozOTdiMDBlM2RjZmY0NWQ5YjljNWM2NDU5YmEzMDI3Nl8zNDkvZnJhZzplODZlMjk0NmNhNjY0ZTczOTk2YTQxNWY5NmEwMGQ5Ny90YWJsZTo0OGZhNTMxOTZhYWI0MWVhODA3ZmZiMjVkMzg5ZjczNi90YWJsZXJhbmdlOjQ4ZmE1MzE5NmFhYjQxZWE4MDdmZmIyNWQzODlmNzM2XzgtOS0xLTEtMjkzNzEw_a8c4df21-94b8-4130-99c9-f13177e22428"
      unitRef="usd">55000000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>151
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MV5QN.(/EKPW@^Y40ZOF#?O/?_=+C^G]02P,$%     @ !(]15A29T=Y! P
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MO:OZV"B\B)S.:$]-T*D)GE5SB_M6XC;5M%RQ!0="E0*M]N6\Q#XX(N8&7GS
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M%,,**6TC=VH67D=W#_<*5U2R!,N9T4D*D^6W@5X&-NUK=(8->)*M-Q(?>U!
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MDJU _)H(D.BC :(%R68V*OY3AQ3Z"(%W/716N67959K]4A.'!!.<)2SBP_$
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M_,UW2W:1 Q8RSH0E,]<6SL_J6#36**Y&FO7I?[ RQZ@<G?;Q(9NH -QJOX*
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M<ST/NC*WQE^2CBJ6>)$OD894R,?0O4M0WL$?(XW+$-#S]ZO9DSCKNJ>L(JD
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MZ;=N*XE >D2-E(R'%+.E!NG[?T-=KX2_S]O2#P&AFT38;E"7;75D&K]#=UW
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M"GR'A"]"4JEM?5UD %@$(P2N0V@P:K9A$OK0Q#W.UB.MCC9>B:$!E"1<(:\
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M+*#>V[7J'>'X:S_*CU^\V-FH%AR(W_EB_J3%W[;,+"5)MD_^M<3F.3[$1,H
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MW0:L+Q7ZCTYP!_2]]_QO4$L#!!0    (  2/45:*SG;\?@8  #H/   9
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M*A&.)6P=$ .@N98I-IOB5125S)Y6]M2T1$G.RF>,&HI-# T+"].(T"2K,Q#
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M3)6E!7@^-<;7%Z2@^?[G_-]02P,$%     @ !(]15J@6#";D!@  KQ\  !D
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M?D$Y]7#Z*X'TZ/ H6F:-Y['A\E@(O6].^),(>HTG_5L*TV3UW7!]B3(,P0$
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MF4T'EY,IOID-9DDPU2].-/\D/I!.]\/OP8;M3]=%9";)B*P>;/]60$++A-C
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MMAB^)3\OM?62\P],?2!EF[6C3C#"4H>-IO.+)V.CT>C!^NI1D*BEM>GE["&
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M-"S[F QH(MX,F$7W&!$>Q2[#>WOP[9/M$V&\<M]T/GYE$X;%3K&,G[K1.#1
M51A&)[J?D/(%*&&G"GS&_H/._K^S8FW\_A'/#;C?O^+]>/86.+JCF@X5VX>9
MX)- VD_6Z$,A/5UCG(SH>1LS>KC+]!P?]S*?P[_Q()GBA\E@E(SA]6(PF8]8
MUZ-USJ+'(%%\Q(<](88 @[!/1 K?AN=)O;:/4:J'VX=1?;+[BT#L$B[%?8DC
M:_W^0ZFV]%"EA2K!S>CM6G"P!QP OR\5A'3W 1<(3]EZ]3]02P,$%     @
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M%6"%QF)R".3T-JVSQAD!H8D(\QR$A]@2Z6*A.LW^ X:(L&R8: +]J9*? 22
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MS%2-1DN%YB9-N,.AQ&,Q5_]U4-&_V@\LD@7^T]_KWQ1D7)E1SU@G3WLRV-A
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M\A]FZX?SG[=[!Z$O1MJ%7,.CGCN/'_$11/VFK7;T9]J65=M66WJYD4#0&@?
M]^L*;*IZ@PN8O]OWXO\!4$L#!!0    (  2/45:'X^<W? ,  (L'   9
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MM43M%.C_6BE[%)R#[OV=_0E02P,$%     @ !(]15K&[(&&A!0  F0\  !D
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MJ8LZ9X:G((J*"855Q@#RK='- V\8^,YA__:&L1-C.PG&:S:3S[50J)_6RF8
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MW4\''4)'H *X(I8P"ACGJ=A 1PBNT#QJ7AY&"7S]2"((V$#PZ <::I/@P"U
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MO^U1,O1Y]<PQ[V@;,Z+=MT-_?B1^>Z@EWLI425E 8([FFJ=K@C<>1H33&?"
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M*D\;L%XY%_L;,C!\U;GZ'U!+ P04    "  $CU%6L:P=*8D+  !E&P  &0
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M^$=;J>I0P"DT&M1:]6J]73TI\4:5)^)L.1>KQ6KUA+RSP<PSEG?V/3-MT^@
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MJMS]3#G#:P MP/FY4K9^( ?-RZ73?P!02P,$%     @ !(]15KQ@\S[<#@
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M%Q8Y/&^3N,AJRSKWN7I/JAZ1R3(%KA'A/+@O:!W6V.(R3!PEEE.-]64&#8
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MDJF@LD^FFD.8[E9I6EU4:/@\6R'6=V!W57A$\;A6Y8P^"IA.6SLX=XLG&]_
M_/=6LDX?6U&[Y?B*(A.$42ZJHBW#I;-'PSZ9E"5WGD,%+D-3[KO;.3INS^2[
MW?9B_=?A'_+4/''C1EE8HU0<?I+[2FB8[\+%8W]7AS38ZF-Q?RY]M^[RII4V
MM+2;T<T'P23TP=^6AZ^):ZJ7T(T(MH!IC!R.B X=>GBQJO%=\5Q9]-C^L<)'
M#=-N >87"O2[%[?!YC-I_"]02P,$%     @ !(]15BC\UM!)!0  [0P  !D
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M&WUQKCII&"<+2LJ]U;@K(6>OKF_^]G![?_OU]O.G^\M3"XUT_30)TN^\='Q
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ME;NO2X&Q3-,"W)\K93<_:(/Z;>[5OP%02P,$%     @ !(]15A@O-PO("0
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M;?)V,1#DNG"_\K[E86O!V-NS(&@7!(S;;<0H/\A:GI]69BTJF@UI=,.J\FJ
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M0S0![Q<&AY[V@3;H_X]Q_E]02P,$%     @ !(]15N(/44YG!@  :0\  !D
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M>66=+E=@BJ 4JO[RYU4=M@ 7R0X 6P%8B+MV%*+L<\<[+:.78/QI8O.3D&I
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M<5^E>\95*'NV+*8,(PIAW]%#9=TW7%VKTRT2MQ-"/_.5<7EVN]U@-((][Q)
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M4SNP*8>\7'VJ[&+:H:Y9,C*1M>!AG[78R2!J#W'.IY%S/CT<*]'FQ+B=TJ^
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M;FK$G% .,7>RNZI\\8F3B)OE3,H5B+*$.,M:6CH1EYWCT]K$W;5NI?Y>X^-
M[%>:!:5-&MXKUP8LWV'#41'<4PWIO^*\<_:_;C\E-RMQB*'+ITLXXAXV-Y.P
M/1"_B\:G-KKZ$3-NUGR$$CDV1!J#OX^?3M_E/;YJG'RURU$.:>QF2BW-M7O+
M]^25XK2^B6/G130:-ATF42<#O#!?E"4$I/>)*=5J_TB]W$N:'.!&:',"\5!Q
MRA0UB2/-%$DDCU4H(J"]^-IR%E9.W(2,B5O@%8$K$QQDMQRT9\9X< ?R>L\F
M2$.$^W?AVW'JKAQ0[!Y4 B^B$GAQ4(N[D0SX/]2C,ZD)'A[CHP]C2"JEOP4S
MO<Q;,Z]<=ZP8FF%M_5"J/AN:.,"SB[_.LLOCO]*HER=_56FYI]GM@73)O_WE
MY.+XQ=G)C'^Y/W$2M/T_29HORF[4G]#J39'/#FV\_%3802L]2V-?@ZCO$W.=
ML7NO]W&TIATUW-?L*V9(K%FD<66VI8CK:F380AH\<EUSJQ2F2=>!1W/X.H=&
MG^W"[DO/3]/+K%W7?G.S26EH>8_K^%FDVV>'6RJ0!_<J'LV/",NK+R4AZV=R
MVL'\5S;M)%T?GB.Y$5D;>J2\(."$[CIV"H4,BYYRF1]3 SL%)6)@Y.HP,]BY
M.N2^Z&)<9^;OJA02T<3[G*);9:]7PE"0C=%A,&"/^8/XCQTM3@[WH?B#-9RI
MZX@G,?TUHP'W>--UV )@\I9CI'CJQU+*0S<?*,=9/'7'9S,M*WV-&/LG^4Q_
M8T024AZ]!PMFD<'3C^G)DY,7V9Y' 9\[];W8JE=EMK\+X@9K)?]P,3 M6XTW
M,8\ M8L*2]=7 (\TB\&=YVF?:>F+*F<U6;3>FEN:;?%N>VIW+_>,3T0UZIW:
M0*>#)!UY<#TNIL="%Z^0O,.H;Z^3=&G%WGAT=:Q3Y&Y\3XX?7UNH]XD[P"=(
M#<Q.#2"#J=JW-)G7W3^E-<^<*U5RJNQBX;.#QX.,:^$$Q\2>655. P%'$SO'
M$<+Z%ADGVTMRA?80;_/4"XUC5RGRLKGL$F;W.#I&*6EN"I)C'C6E9C 9J!MD
M"5.XBW.T4H>O*;,:@9-S$G)GJ4L3P[UK4\>MD!_#L'Y8N0TY;]%NT"AF2?$E
MX$'DF,5H4HS/NM(1*]";32!,C3-*%V)/L[MVDQ6PY!IH;=UFF6@:Q32P4H7,
M:C'(^R+WF8L-"$1>%U;0MPM<5'-<P_<_;CYT7"[&NT<ZB.N0BZW7 ^X[AE3I
M6LG.4V/99G95W!J=@3FW(I2K&JACB#8LQ=9' R502(HZQ:OX@LF<PPN^H1EJ
MC_'2.5)QJWQ#J_V +B#%T&Q\ZYX*/<HE']W9*)Y;2T_J^@;L-P^[NR-T1-(Y
M&F9<>O@6<(%4R"UU^FG>?O+=\:5Q]9>J2US[\*DR]>/SR-2=^) >=]SH\2I:
M>O;9K]Z%B"1TG?9TO-:>CGNX.H(86T>_9_N$;[S(BZ+EZ'&!+=XZ*08R-W&*
MGD3Y1Q#7J3R*5T/'5=AGB:/*Q9[SR: SP[D:2K[JW%QQJ%3PR^V8#J)HF8+C
MVZ;/)FY:YUV\.+ZP3?S#=R3=MRE45R-)^0HY-H60]E>:EF%I%)2PU6PXHDOM
MTW<*&_;W<'$[OLN'!\]I88',65E)3+FD8Y$?I:\O%QW&=@RJQ.NE DL6CD99
MPF4F[B:G"^9$F;K"&?=I4U>=7;Z!3'#H.MXR[K7"38[T?5[W\7>P.W'1_\B!
M:;7;S/?'2M\XN1!F='*V][UC1H(P>S:,"]9P6G_ELN]_Z"^"UZX\U@W0T$P%
M3NB_].!3'_@Q<),:\9,.FVW]G/?Y3S]0D_/K@%=3$29!47[@/L7T1M28O[\Z
M?? $WHR/__3#!HRJWZ12H@I+>/7XZ-GY \[:TC_Z9H-#(KA UO0K6,>@M^ #
M\/VR@4V1/W "[+Y(X/WT?P%02P,$%     @ !(]15KZ_%.XU!0  MPT  !D
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MVX$^J^?8<WA]&UPQO>94B0)7! VZ)P,/=#UA:\.JHIIJL;(T(ZME1I<2:A=
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MCM^>1N!:%6PWWE:-\JRL9QUKEB7_.- % [Y?6^MWF^"@_Q5-_@)02P,$%
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M L:G>5XU'XA!^XNCT_\ 4$L#!!0    (  2/45;^3/:]]0(  $(&   9
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MR:/Q#O1]I;7;&3Y!]]N8_ -02P,$%     @ !(]15C>#(M%P!0  S@\  !D
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ME,7[GWM=X(5;:!+ ]50IN_X@!\T5?OPW4$L#!!0    (  2/458O1M?GW@,
M #H)   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;+56VV[C-A#]E8&Z
M*%K &]ULRTYM [EM=X%N$\1N^U#T@9;&%A&*U)*4G?3K.Z1DU\XZ1O>A+^)M
MYLSMD*/)5NDG4R):>*Z$--.@M+:^#$.3EU@Q<Z%JE'2R4KIBEI9Z'9I:(RN\
M4B7")(J&8<6X#&83O_>@9Q/56,$E/F@P354Q_7*-0FVG01SL-A[YNK1N(YQ-
M:K;&.=K?Z@=-JW"/4O *I>%*@L;5-+B*+Z\'3MX+_,YQ:P[FX")9*O7D%I^*
M:1 YAU!@;AT"HV&#-RB$ R(WOG28P=ZD4SR<[] _^-@IEB4S>*/$'[RPY308
M!5#@BC7"/JKM1^SB\0[F2AC_A6TKFV4!Y(VQJNJ4R8.*RW9DSUT>#A1&T1L*
M2:>0>+];0][+6V;9;*+5%K23)C0W\:%Z;7*.2U>4N=5TRDG/SNX7'^\>X6H^
MOUO,X8<%6PHT/TY"2]!.(,P[F.L6)GD#)D[@LY*V-' G"RR. 4+R:>]8LG/L
M.CF+>(OY!:1Q#Y(H2<[@I?M 4X^7OHFW0JVQ@!MEK.G!#:NY98+_C44/'C36
MC-.$R0+N;8D:KHQ!:^"6FUPHTVB$/Z^6QFJBT5^G\M-:[Y^V[J[6I:E9CM.
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M; J6EK4RTA6= X2&]9CZ7YNC _?MK#Y(X"',&_3L\QUF;Q[['=F<%9<"ZX+
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M<4U"S5F:).?4-^AKI:=P*5ED;6K2U+5GK4_GOCL/?">0SD_'89K-X+'C,,W
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M1U(3UI3$ $RMC0.<,+S6I.$%UQI=PEK"%HIS-^FQ.RR8)1JWGQ6%K%>L>;0
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MQ?!Q)I_[G%/Q+Q9V?#R??;J=?9SYD]NO8.+[=P^W7V>WG\#]W?7,GWV8@]]
M@%A(<:Z>$EF":<&$!&/@-$ <XH2] R< 9^ &)XFXA0UM+KHEQ>VP[,)TVP7O
M0!=<<$,R'C/P(8M0U&+O_X>]IQ&P!8\*BO<,9>II%3\7V1GH..^!YW@>>)@'
MX/3D75O']#(!"H6,6\K$""8\#B%%_RQAB!/,-R F+,<<)BW:P2NZZ VVVIHA
M=ZIYT%%ZG0-ZU6.=A-\+S+!ZW']=BS8PXRAE?[<]UZUDMUU2KEB7+(<A&EEB
M26*(/B)K_.LO;M_YO8VE2;' D%@#9;="V=6ICV^+=(&HC!48%AP!^<@!S"+
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MH$G^=45P2%@6(']?4"J>+[(.RH."X_\ 4$L#!!0    (  2/45:/-R@S40(
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MH/%\'LG\+]D?VEH=XF=2\?@0#".(PZ3X3W\<B#@* )SV .<0X#0#AF<">H>
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M&*$NU:, &^5@NA@]S\:#\;3[?$SS:1NG-^S7&WE(HZK1-RCI&QCIN_5]D;&
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MN&,T8$(W@-\WG*O7$]U!N<]I]@]02P,$%     @ !(]15H*=QA>O!@  6R8
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M'LA?Y N812ORQS5H'L7JS[ZOS;PVVI]MY[@JYF!'YJ",W(I4KQ2Y2><P_Q'
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MYJ)!M@N[<8NW;/""$WA^0*ZEP$R32Y% \J>!:V+M @X. 2^#7L<+B,_(P/]
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M9CE WM]0*IY/\@'J5S'S;U!+ P04    "  $CU%6^4A"-JH#  !V#0  &0
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M0[@8$:X,X/V&,7D8* ?55<O]%U!+ P04    "  $CU%6.,]%0,D"  !<!P
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M3&P_0^VG:_ABP57Y2[95;'!CD;A06J0U&!6D+*O^Z7.=AQU QS\!<&N ^U:
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M7.E:VC87^GT$PACH[S/.U7/'3%"]N.+_4$L#!!0    (  2/4591!4&,JP8
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ME<V!L)Z/&J&RS54U2U0$'IZ2EW&T.OY.6;A'4N;S6<I*6VA5[R#E'60Y,7/
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MG9&^.K?4/9)+\F6]AJEB4$-^HM B^#ML/=*6\ZYKP!1:=4Q$74?ZNMY]#>2
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MW3F?J+'33(D'FF9F76*^)%2@ A:*TCD]4P)X,P>:C625Z8QS)M7'8):Y&IW
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M^4U'J4TP9 FL1&^WH+=K0A_?IM&*,$"?Y(*74";P*B1O<XF#'X9I=;D%[N?
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MN$>7NSL=;'K5/O0T7J]M'Y3\'/W]..>"R</PCTGB L(W0Z@,\<#7.(:Q)5,
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MU=!K=SU6NH(OM-.WK]J!.G=AMRJVNQXK78$7VLG;5_! ';7:<_$<H$4*M&@
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M)5GD9;57N=&7+--RD6^SJE?H/3L\>JA>NK[;4=JZ@;%*(V&L;_NTLWV.K"A
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MLBI]?%;3[\]J4O.E(/;BH\6&6I!0&H?2!(JF7PQ*69#!4_.9C[W6U X<>XZ
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M.2C?0,M+-?G-&!++(:P1:*.'0!M9 ^U3,9\MEDZV6!>KMMRR;MTWMTC,)[&
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M(,\Z-_Z=F*^+TMW=W2Y^<5;KW?T;^Z,V[&3?B*PTUVM<WSX;CKVC2]P^.FZ
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MI/6!&PH=.$6U#-4TJAE4RRFM&9-U)V5H[Z3L#B"7Q7JV+!X]<$2+**CFHUJ
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M&H?2!)0F431S#U"R@I&GS5ZSK'FS7%;M9OO2OG/^L%7U3U_^./<*J.B TOA
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M@XHI*(U#:0)*DRB:&; 24QE$3-$4[W2A8BISK 8J\GAT)@RM5:)H9FY*364
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M^$(:<_V+-GFL8Z%PQ05-<K!4D) T>^*W/ ][ +=Y!.#E *\,J!\!U') [;V
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MI^7FK[>E-GA0^0E*2Z T J51%$UN#$)^BLR;ER-S,U2B@M(2*(U :11%DUN
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M#U8X"<0SW7Z&S*&.TG-IP/5_M,WZF@WD)ES0,#.6,PA)E/[BMPS$D8%TM-S
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MRNVF,UR@I L+#<BR06FT :VRU!+8/?%T/M]DJ9%9)]C0D5 YMF&$ J8-.RS
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ME<WR\D;0K&@?OU(A:%)<KC&*,,L-Y/,EI6)_DT]0_\MB^C]02P,$%     @
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MK45;:'6]VISAZ1LV6=!I_4>GHB6T^I=/;??(;?='+UIDFOC^6G5/^5I)NA-
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MFN1OUP2'A*D ^?F24O%\H2:H3EDG_P%02P,$%     @ !(]15C)(9=<4!0
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MGAC[H1L7BY'EZ(B PEQJ"ZS^GN$<*-5.*HY_2U.KFE,+MZ]?W;^8Y%4R3UC
M.:./9"%7(ZMOH04D.*?RCFV^09G0J?:;,RK,+]J48QT+S7,A65J*500IR8I_
M_%*"V!*XP1L"KQ1X38'_AJ!7"GKO%?BEP#=DBE0,AQA+' TYVR"N1RLW?6%@
M&K5*GV1ZW6>2J[M$Z63T]>8F?KRXO$3CZQC=W'^;WJ&+Z_OQ]=>+R>44C6>S
MZ?T,?4;CE'%)?F*S5A]CD)A0\4G=>)C%Z..'3^@#(AFZ(I2J 6)H2Q6:GL">
MEV%,BC"\-\)P/73%,KD2:)HM8%$WL%5.56+>:V(3K],QAOD)ZKE_(<_QO):
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MTX=[D8LG;GNO95AL385$)6&GW_XD(,0V,LW-9?K&1K#[UV\7:5?,]EQ\EUL
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MXPI8 -((X/N%$/IE8 SD-UB#_P!02P,$%     @ !(]15MB1XY2C!@  FS8
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MM%1/OXK\T2]T,EU)7N2FE6&&3I*96GDJ;^4S=+V22^6EP-#G8!I&H;JV\_J
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M"Q[,>)H;J,\?A9"O-WD#U7FTR?]02P,$%     @ !(]15J0$.G?L @  -@H
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MMF&S"V>F0QOYE-MGGVII3JG!Z7A\,[R>3&%XF\#-\''Z</US"I_@EDA)[(/
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M0:/TZXK@.6&J@?Q]0:G8':@.\NWJ_?\!4$L#!!0    (  2/45:<)AV";00
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MC3P;)4(PS\6/Z#OAL?&$U9WG\XZY&YES91*0-9RC0*XD*\L=EX+\L'^.F0^
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MW3M@.IN.9]/%?'9_/YG^!2;3A3-WW(4K5L#Y^VFR^ ?,/@-AXL[N)_9PX=C
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M^&.>HJLOU^@+*BAZ*LI2<<3$E<J2%G:S9OO[>GO_Q/;81T^,RI5 #S2'_%C
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M:"V2['(.- )I#/#]5 B]OC$?*/^F,/D/4$L#!!0    (  2/45;,;1+KL0,
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M+.^=94.+PE[=UD+C1= ^IGA7!VD&X/M$"'W?,+?!^O8??@502P,$%     @
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M("0PT)8F!!0%@3U,<PF3@YO8*Q((:EF'#>[:%@UVHT,6>[P%%6_!?U=+.?5
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M^_?#W1JX_WZXT[":;FE%-^/KGK.",DE>*$_ABDR5 JT(34+RR.B:<:89*+(
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MR4D2IUJ:D>$H"*;(85++86*4PTG+_F/*(Y;SM96G+,[8892\2K)V*1BQ?:6
MA/E(&$'" B2,3IKMD5>K5-'"M-;"U*R%[7(O%)"D+]:"I;PMZT9 WZPC83X2
M1I"P  FC()BBCUFMCQE^.#A#*@8)\Y$P@H0%2!@%P13%7-2*N7CS<-!8LZ\P
M+AH]]GCFS;3AX$6CQ1P[8ZT0:9(F4]O1NO\NX6A+H=-PR@&U1]*J&!D/Z1U/
M0YY9R8-U&Z_#IW"]%U/(MC.SW:4PPOL>=2C-A]((E!9 :11%4R5TXG;9^':\
M8J*4@Z3Y4!J!T@(HC:)HJG(<J1SGS>VYN6IO@3C-=GCB:0UZ2R%[/--FVZ2E
MU&PRTEKT+O'H:_'4HRI=-MMHR<CS<95LEV',JLL3\MR,DWB5Q'F:1%$Q20\+
M/Y)G^0?K@86I]<2B?>M@W1RV=T;<IK4QUA/2+..,]'2XC8/H3'4;I:60'HRV
M@49G<B']*]ML8+UY/FSF]C[82)H/I9&*IIP%GIZ_9AE="-3,4?,GW2W[%7N+
MA;$8'16)BK,D"M?L_%@(ZF9!:3Z41NRFH=5H_YI%=&^3&C%JOJ3]9)O]I^[#
M6>LWJX-!80[7.ZE08PI*(U!: *51%$T5E?2Q[.D[#'"AWA:4YD-I!$H+H#2*
MHJG*D0Z7;;1#Y@N6;:P="T6GGQR&8"FOKZCR]FX$ZG!!:3Z41BK:Z>AN,M;[
MD6891[_\A=HK-<?2D[+-IM27_7;)TZ++.:X@L Z7^+-CQML6:-R8J;WSC*3Y
M4!JQF\Z5;>MY;I9Q]#2#=DI=WB*-,L=LE"W$F"%<\Y15X_;XB;^(P7P86_F&
MGTZOVI)M9O=--I3F0VFDHAE/ZI8R4WUNW%)F=F9TZ$BGRC'Z&2>G*I-#OVI=
M3GW2GID=%P/&5Y?PW)AWH'>BH;86E$8JFFF$'T C4A1-%8\TJQRS627%4Z^Y
M8NI\HGVI5"4,J)T%I?E0&H'2 J?%(],' &UESK45TD5SS"Z:3/=Q95V1XN/G
MUA1#_3$HS8?2")06.$WC3;<*4 %5+4@7SS&[>/=Q6!AW]Z)/2!Y?+)HF^UVK
M J"F'93F0VD$2@N@-(JBJ6*1EJ$SQKL%#M0\A-)\*(U :0&41E$T53G2O'3,
MYF6GX6FR*^8@HC5:%G];BCE)R$K/L]/P=-+L*2_4MG9AWLG>XH&:E%!: *51
M%$T5CS0I'?-JN[8^2FBBO!?AM"7J9'N;8_5NCJ#F)91&H+0 2J,HFJHH:5XZ
M[[ ^SX':EU":#Z41*"V TBB*IBI'6J).5TO4T)&M^1./DEUQ<X"5Y>R1=^O!
MFD:AJW=@4"\42B-06@"E411-O3=,&JSN*P9K_VLE;M,DM$>:D[@PA^U]TQ?4
M+872 BB-HFBJ'*17ZYJ]6M/:,+?I/;KV1,\[U#R%T@B4%D!I%$53\RYM5M=L
ML[[7ZK4JK'(E43>L%^9]ZZT9J*\*I050&D715,V<W%=L]FJKN<_=\?KK5Y;F
M<3'&N"W$<="0V-QIZF,.U7< "Z7Y4!J!T@(HC:)HJJ"DX>MZ^*F/"W5_H30?
M2B-06@"E411-58YT?UWS@M%.4Q_S=21SA-XZ@GK!4!IQFRM /4^_.0H:DJ)H
MJCRDQ>N:+=[./57YD(^[A6\M:LUTZ;R@RU6A-!]*(U!: *51%$W5F'2"W7=8
MKNI"'5\HS8?2")060&D415.5(QU?U[Q<]1U].W/DWOJ:-:]CZ7=S02,2*"V
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MKR4Y?,F37?E6C&62Y\FV_+CA3#1:10'Q]X<DR8]?B@#URV'FOP-02P,$%
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M0Z*.OAK5F8]Z,Y\);1N%>@&(90#K+EIK(Z=L"D;M])KK0QLR;(A,VI HL"N
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MC,X8UR>HXP]Y+M<;.D']OI;QOU!+ P04    "  $CU%6Z9-TVOT)   S2
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MJ/%\*'3/S55BD@"3A#,D8-)RVMYEV#!X"W@DL)(;;60B>>+\V73Z<<LI&4-
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  $CU%62(F([@8)   &4P
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M9(T^L34P9E_%1 ;I$QNDB??9ARB6WUO\H6(A8_2)C=$2^+<R(H/TZ2>=]!F
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MU;L ]"ZJ=P'H7=R?E0"]B^I= 'H7U;L ]"ZJ=P'H753O M"[JMX5H'=5O2M
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MGU!+ 0(4 Q0    (  2/458'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !(]15I],JI?O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ !(]15IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  $CU%6SM0A[T<(  #Y-P  &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ !(]15F!BB1$\ @  N04  !@              ("!BQ   'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  2/45:'<)I8G <  /4A   8
M              " @?T2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  $CU%6%)G1WD$#   B"0  &               @('/&@  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ !(]15J$(=LI+"
M/"H  !@              ("!1AX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    (  2/45:/DM]"T00  !41   8              " @<<F
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  $CU%60=59
M_Z )   .9@  &               @('.*P  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ !(]15I"6,"*:"@  $C0  !@
M ("!I#4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  2/
M459D:\9L92H  )>(   8              " @71   !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  $CU%6:,1MTN\$  "'"P  &0
M        @($/:P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   (  2/45:*SG;\?@8  #H/   9              " @35P  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ !(]15CV#'+79"P  *B8
M !D              ("!ZG8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  $CU%6;:6ZW8 $  "H"@  &0              @('Z@@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  2/459*Q"M0
M:0H   LD   9              " @;&'  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ !(]15J@6#";D!@  KQ\  !D
M ("!49(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  $
MCU%6#_@7! T5  !Q2P  &0              @(%LF0  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  2/45:5Z5T,F00  'X+   9
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M970R,2YX;6Q02P$"% ,4    "  $CU%6G1=<NSH#  "F!P  &0
M    @($MX0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M  2/45;K_C8>[@L  #0F   9              " @9[D  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ !(]15OYJE%H=!P  X1$  !D
M             ("!P_   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  $CU%6L:P=*8D+  !E&P  &0              @($7^   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  2/45;==K]!.0<
M &@2   9              " @=<# 0!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ !(]15KQ@\S[<#@  *R\  !D              ("!
M1PL! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  $CU%6
M?V8?<;H$   R#0  &0              @(%:&@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    (  2/458H_-;0204  .T,   9
M      " @4L? 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ !(]15H'C)U.H"@  V1T  !D              ("!RR0! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  $CU%6&"\W"\@)  #3&
M&0              @(&J+P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    (  2/45;B#U%.9P8  &D/   9              " @:DY 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ !(]15GCDO,SE
M @  E08  !D              ("!1T ! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    "  $CU%6F80%6@XS   +J   &0
M@(%C0P$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  2/
M45:^OQ3N-04  +<-   9              " @:AV 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ !(]15NKOQT8C P  \@8  !D
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M=#0P+GAM;%!+ 0(4 Q0    (  2/459.^N5R+ 0  ,8)   9
M  " @>&1 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M!(]15H^,(+;#"P  ?20  !D              ("!1)8! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    "  $CU%6_DSVO?4"  !"!@  &0
M            @($^H@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    (  2/458W@R+1< 4  ,X/   9              " @6JE 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ !(]15B]&U^?> P
M.@D  !D              ("!$:L! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    "  $CU%6M;''F-L"   E!@  &0              @($F
MKP$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  2/45;M
M>44V7@8  )</   9              " @3BR 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ !(]15E>)SEOV @  AP8  !D
M     ("!S;@! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  2/458:;QE#N@4  %X-   9              "
M@3/1 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ !(]1
M5LWN =0W!0  H!\  !D              ("!)-<! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    "  $CU%6FE@#)44$  "C%0  &0
M        @(&2W $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   (  2/45;TMYAS%P8  #0H   9              " @0[A 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ !(]15H\W*#-1 @  ^@0
M !D              ("!7.<! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    "  $CU%6YX[$.*T%  #S)   &0              @('DZ0$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  2/45:"G<87
MKP8  %LF   9              " @<CO 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ !(]15JDBK\<Q!   ?AH  !D
M ("!KO8! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  $
MCU%6;$*@9SP$  !Y&0  &0              @($6^P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (  2/45;+]%6JA (  ' '   9
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M970V-BYX;6Q02P$"% ,4    "  $CU%6YNOQL\8#  "$%   &0
M    @($B$ ( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M  2/4583ZI:Q, ,  'T-   9              " @1\4 @!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ !(]15E$%08RK!@  OBX  !D
M             ("!AA<" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    "  $CU%6BPB7$%$%  #>(   &0              @(%H'@( >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (  2/458,_4<IH (
M )@'   9              " @? C @!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ !(]15NU^,PF$!   -1P  !D              ("!
MQR8" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  $CU%6
M<IM=HS4#  "5"   &0              @(&"*P( >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    (  2/45:/O+[XQ 8  &\N   9
M      " @>XN @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ !(]15A'KL()&!   (1,  !D              ("!Z34" 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  $CU%6$G]?7AD$  !&$
M&0              @(%F.@( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    (  2/45;OFQM460,  ' +   9              " @;8^ @!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ !(]15IRTXB$;
M!0  @AX  !D              ("!1D(" 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    "  $CU%64[(:L54#  "9#@  &0
M@(&81P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (  2/
M459*8LB%%0H  /%\   9              " @21+ @!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ !(]15B.WC?C.(0  (Y@" !D
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M=#@U+GAM;%!+ 0(4 Q0    (  2/45:-B(+B800  &\5   9
M  " @2:) @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @
M!(]15J/0H(S- P  D1,  !D              ("!OHT" 'AL+W=O<FMS:&5E
M=',O<VAE970X-RYX;6Q02P$"% ,4    "  $CU%6O)Y3.+43   G!@$ &0
M            @('"D0( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4
M Q0    (  2/45:CVOV"00,  #L,   9              " @:ZE @!X;"]W
M;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ !(]15LIW=4UO#@
ML)L  !D              ("!)JD" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX
M;6Q02P$"% ,4    "  $CU%6J_8'?],$  "'%@  &0              @(',
MMP( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (  2/458-
M1AKZ"0D  /$Z   9              " @=:\ @!X;"]W;W)K<VAE971S+W-H
M965T.3(N>&UL4$L! A0#%     @ !(]15N!/=YT* P  .PP  !D
M     ("!%L8" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4
M"  $CU%6"\RBZ2<,  !WB0  &0              @(%7R0( >&PO=V]R:W-H
M965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    (  2/45:/DOQ+:00  +X8   9
M              " @;75 @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L!
M A0#%     @ !(]15FT!%6E=!0  <1T  !D              ("!5=H" 'AL
M+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    "  $CU%6,DAEUQ0%
M  "%'0  &0              @('IWP( >&PO=V]R:W-H965T<R]S:&5E=#DW
M+GAM;%!+ 0(4 Q0    (  2/45;U;VKN:@,  -,-   9              "
M@33E @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ !(]1
M5M0KF:QX P  <PP  !D              ("!U>@" 'AL+W=O<FMS:&5E=',O
M<VAE970Y.2YX;6Q02P$"% ,4    "  $CU%6[?(10%@#  !]"@  &@
M        @(&$[ ( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M    "  $CU%6-TLAF?X#  #-$@  &@              @($4\ ( >&PO=V]R
M:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    "  $CU%6V)'CE*,&  ";
M-@  &@              @(%*] ( >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX
M;6Q02P$"% ,4    "  $CU%6I 0Z=^P"   V"@  &@              @($E
M^P( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    "  $CU%6
MLTSA-? #  #_%   &@              @(%)_@( >&PO=V]R:W-H965T<R]S
M:&5E=#$P-"YX;6Q02P$"% ,4    "  $CU%6R<E%\T$$   &&0  &@
M        @(%Q @, >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4
M    "  $CU%64!JX<\D#  !\&   &@              @('J!@, >&PO=V]R
M:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    "  $CU%6 #NGQ18'  !U
M3   &@              @('K"@, >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX
M;6Q02P$"% ,4    "  $CU%6J;YA4E8#  ";#0  &@              @($Y
M$@, >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    "  $CU%6
M:7*G8[4"  #9!P  &@              @(''%0, >&PO=V]R:W-H965T<R]S
M:&5E=#$P.2YX;6Q02P$"% ,4    "  $CU%6LH@6'XD#  !/#0  &@
M        @(&T& , >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"% ,4
M    "  $CU%6<  ,BF,&  "Z+@  &@              @(%U' , >&PO=V]R
M:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    "  $CU%6G"8=@FT$
M%   &@              @($0(P, >&PO=V]R:W-H965T<R]S:&5E=#$Q,BYX
M;6Q02P$"% ,4    "  $CU%6GF:*A4$$  "C%0  &@              @(&U
M)P, >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4    "  $CU%6
MHA^(Q40#   @#   &@              @($N+ , >&PO=V]R:W-H965T<R]S
M:&5E=#$Q-"YX;6Q02P$"% ,4    "  $CU%6GF'>'? $  !.$@  &@
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M:&5E=#$Q.2YX;6Q02P$"% ,4    "  $CU%6VCU1"I($  !)$P  &@
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M:&5E=#$R-"YX;6Q02P$"% ,4    "  $CU%6E"?F7'X'  "[10  &@
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M2P$"% ,4    "  $CU%6A>>NP'8#  !^2@  &@              @ $PA0,
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  $CU%6A:-_
M>*X"  !11P  $P              @ '>B , 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     AP"' $0E  "]BP,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>621</ContextCount>
  <ElementCount>665</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>195</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EQUITY</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - ACCOUNTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE</Role>
      <ShortName>ACCOUNTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - CONTRACT BALANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONTRACTBALANCES</Role>
      <ShortName>CONTRACT BALANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE</Role>
      <ShortName>ASSETS AND LIABILITIES HELD FOR SALE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS</Role>
      <ShortName>IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - LONG-TERM DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LONGTERMDEBT</Role>
      <ShortName>LONG-TERM DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - GUARANTEES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GUARANTEES</Role>
      <ShortName>GUARANTEES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/OTHERASSETS</Role>
      <ShortName>OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - NET OPERATING REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUES</Role>
      <ShortName>NET OPERATING REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - INSURANCE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INSURANCE</Role>
      <ShortName>INSURANCE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - CLAIMS AND LAWSUITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CLAIMSANDLAWSUITS</Role>
      <ShortName>CLAIMS AND LAWSUITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES</Role>
      <ShortName>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - EARNINGS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE</Role>
      <ShortName>EARNINGS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - RECENT ACCOUNTING STANDARDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/RECENTACCOUNTINGSTANDARDS</Role>
      <ShortName>RECENT ACCOUNTING STANDARDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EQUITYTables</Role>
      <ShortName>EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/EQUITY</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - ACCOUNTS RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables</Role>
      <ShortName>ACCOUNTS RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - CONTRACT BALANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONTRACTBALANCESTables</Role>
      <ShortName>CONTRACT BALANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/CONTRACTBALANCES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALETables</Role>
      <ShortName>ASSETS AND LIABILITIES HELD FOR SALE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/LEASES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - LONG-TERM DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LONGTERMDEBTTables</Role>
      <ShortName>LONG-TERM DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/LONGTERMDEBT</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/OTHERASSETSTables</Role>
      <ShortName>OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/OTHERASSETS</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - NET OPERATING REVENUES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUESTables</Role>
      <ShortName>NET OPERATING REVENUES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/NETOPERATINGREVENUES</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - CLAIMS AND LAWSUITS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CLAIMSANDLAWSUITSTables</Role>
      <ShortName>CLAIMS AND LAWSUITS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/CLAIMSANDLAWSUITS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables</Role>
      <ShortName>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/INCOMETAXES</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - EARNINGS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables</Role>
      <ShortName>EARNINGS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/ACQUISITIONS</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Pandemic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Pandemic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Net Operating Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Net Operating Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Investments in Unconsolidated Affiliates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Investments in Unconsolidated Affiliates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - EQUITY - Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails</Role>
      <ShortName>EQUITY - Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - EQUITY - Share Repurchase Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails</Role>
      <ShortName>EQUITY - Share Repurchase Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - ACCOUNTS RECEIVABLE - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - ACCOUNTS RECEIVABLE - Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE - Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails</Role>
      <ShortName>CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - CONTRACT BALANCES - Conifer Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails</Role>
      <ShortName>CONTRACT BALANCES - Conifer Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - CONTRACT BALANCES - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails</Role>
      <ShortName>CONTRACT BALANCES - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails</Role>
      <ShortName>ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Significant Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails</Role>
      <ShortName>ASSETS AND LIABILITIES HELD FOR SALE - Significant Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails</Role>
      <ShortName>IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - LEASES - Balance Sheet Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails</Role>
      <ShortName>LEASES - Balance Sheet Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - LEASES - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASESLeaseCostsDetails</Role>
      <ShortName>LEASES - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails</Role>
      <ShortName>LEASES - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - LEASES - Schedule of Lease Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails</Role>
      <ShortName>LEASES - Schedule of Lease Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - LONG-TERM DEBT - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails</Role>
      <ShortName>LONG-TERM DEBT - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - LONG-TERM DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails</Role>
      <ShortName>LONG-TERM DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - LONG-TERM DEBT - Future Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails</Role>
      <ShortName>LONG-TERM DEBT - Future Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - GUARANTEES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GUARANTEESDetails</Role>
      <ShortName>GUARANTEES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/GUARANTEES</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - EMPLOYEE BENEFIT PLANS - Share-based Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Share-based Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - EMPLOYEE BENEFIT PLANS - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Employee Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - EMPLOYEE BENEFIT PLANS - Asset Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Asset Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - EMPLOYEE BENEFIT PLANS - Fair Value of Assets and Future Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Fair Value of Assets and Future Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - PROPERTY AND EQUIPMENT - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - OTHER ASSETS - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails</Role>
      <ShortName>OTHER ASSETS - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - OTHER ASSETS - Schedule of Investments and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails</Role>
      <ShortName>OTHER ASSETS - Schedule of Investments and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue By Source (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails</Role>
      <ShortName>NET OPERATING REVENUES - Net Operating Revenue By Source (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - NET OPERATING REVENUES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails</Role>
      <ShortName>NET OPERATING REVENUES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails</Role>
      <ShortName>NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue Composition, Conifer Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails</Role>
      <ShortName>NET OPERATING REVENUES - Net Operating Revenue Composition, Conifer Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - NET OPERATING REVENUES - Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails</Role>
      <ShortName>NET OPERATING REVENUES - Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - INSURANCE - Property Insurance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails</Role>
      <ShortName>INSURANCE - Property Insurance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - INSURANCE - Professional and General Liability Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails</Role>
      <ShortName>INSURANCE - Professional and General Liability Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - CLAIMS AND LAWSUITS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails</Role>
      <ShortName>CLAIMS AND LAWSUITS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - CLAIMS AND LAWSUITS - Reconciliations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails</Role>
      <ShortName>CLAIMS AND LAWSUITS - Reconciliations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails</Role>
      <ShortName>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails</Role>
      <ShortName>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails</Role>
      <ShortName>REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - INCOME TAXES - Provision and Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails</Role>
      <ShortName>INCOME TAXES - Provision and Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - INCOME TAXES - Federal Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Federal Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - INCOME TAXES - Valuation Allowances and Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Valuation Allowances and Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - INCOME TAXES - NOL and Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES - NOL and Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - EARNINGS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails</Role>
      <ShortName>EARNINGS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>0000121 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>0000122 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>0000123 - Disclosure - ACQUISITIONS - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails</Role>
      <ShortName>ACQUISITIONS - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>0000124 - Disclosure - ACQUISITIONS - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails</Role>
      <ShortName>ACQUISITIONS - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>0000125 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>0000126 - Disclosure - SEGMENT INFORMATION - Reconciling Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Reconciling Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="thc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>0000127 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails</Role>
      <ShortName>SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</ParentRole>
      <Position>127</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 21 fact(s) appearing in ix:hidden were eligible for transformation: thc:GuaranteeObligationPeriod, thc:LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays, thc:PurchasedEquityInJointVenturePercentageOfTotalShares, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  thc-20221231.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 -  thc-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="thc-20221231.htm">thc-20221231.htm</File>
    <File>thc-20221231.xsd</File>
    <File>thc-20221231_cal.xml</File>
    <File>thc-20221231_def.xml</File>
    <File>thc-20221231_lab.xml</File>
    <File>thc-20221231_pre.xml</File>
    <File>thc-20221231ex10ll.htm</File>
    <File>thc-20221231ex10mm.htm</File>
    <File>thc-20221231ex10ss.htm</File>
    <File>thc-20221231ex10y.htm</File>
    <File>thc-20221231ex21.htm</File>
    <File>thc-20221231ex23.htm</File>
    <File>thc-20221231ex31a.htm</File>
    <File>thc-20221231ex31b.htm</File>
    <File>thc-20221231ex32.htm</File>
    <File>thc-20221231ex4a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>thc-20221231_g1.jpg</File>
    <File>thc-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1829">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>157
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "thc-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 51,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 1829,
    "http://xbrl.sec.gov/dei/2022": 40
   },
   "contextCount": 621,
   "dts": {
    "calculationLink": {
     "local": [
      "thc-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "thc-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "thc-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "thc-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "thc-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "thc-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 1116,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 31,
    "http://www.tenethealth.com/20221231": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 38
   },
   "keyCustom": 151,
   "keyStandard": 514,
   "memberCustom": 103,
   "memberStandard": 83,
   "nsprefix": "thc",
   "nsuri": "http://www.tenethealth.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.tenethealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - EQUITY",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.tenethealth.com/role/EQUITY",
     "shortName": "EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:InvestmentsAndOtherNoncurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - OTHER ASSETS - Schedule of Investments and Other Assets (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails",
     "shortName": "OTHER ASSETS - Schedule of Investments and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:InvestmentsAndOtherNoncurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue By Source (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
     "shortName": "NET OPERATING REVENUES - Net Operating Revenue By Source (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i8650d876760f4a5db3ab633b09d01bc4_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - NET OPERATING REVENUES - Narrative (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails",
     "shortName": "NET OPERATING REVENUES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i530018987e3745d5abf91b8e5524fc98_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory Segment (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
     "shortName": "NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i0781fa826249423991780dca7297e0a1_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - NET OPERATING REVENUES - Net Operating Revenue Composition, Conifer Segment (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
     "shortName": "NET OPERATING REVENUES - Net Operating Revenue Composition, Conifer Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i8393dff26a4a4be89907f8a207404638_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i7fabc80fff1241c29e2540d687490e0c_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - NET OPERATING REVENUES - Performance Obligation (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails",
     "shortName": "NET OPERATING REVENUES - Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i7fabc80fff1241c29e2540d687490e0c_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1a5585dec099491a811760ed0c015749_D20220401-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:CybersecurityIncidentPreTaxEffect",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - INSURANCE - Property Insurance (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails",
     "shortName": "INSURANCE - Property Insurance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1a5585dec099491a811760ed0c015749_D20220401-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:CybersecurityIncidentPreTaxEffect",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - INSURANCE - Professional and General Liability Reserves (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails",
     "shortName": "INSURANCE - Professional and General Liability Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:MalpracticeLossContingencyAdverseDevelopmentsInPriorYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i99278a7c32f64fa0b070b36593467a59_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - CLAIMS AND LAWSUITS - Narrative (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails",
     "shortName": "CLAIMS AND LAWSUITS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i99278a7c32f64fa0b070b36593467a59_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - ACCOUNTS RECEIVABLE",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE",
     "shortName": "ACCOUNTS RECEIVABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - CLAIMS AND LAWSUITS - Reconciliations (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails",
     "shortName": "CLAIMS AND LAWSUITS - Reconciliations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1a2ea7fb5d834e519c54544ff665cc9a_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestChangeInRedemptionValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
     "shortName": "REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i4951aea584a14d4b873b83530d333b3c_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i4c6583adb6404a2e9fb74d00bd953e4d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
     "shortName": "REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "icdbd34c65bd84548a9ef68c45e116904_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityNetIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails",
     "shortName": "REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i476176f776be4198873c2255c05882ac_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - INCOME TAXES - Provision and Deferred Taxes (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails",
     "shortName": "INCOME TAXES - Provision and Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - INCOME TAXES - Federal Tax Reconciliation (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails",
     "shortName": "INCOME TAXES - Federal Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i8962e91413c44e4eaa374cf217033203_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:IncomeTaxExpenseBenefitCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i8962e91413c44e4eaa374cf217033203_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:IncomeTaxExpenseBenefitCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - INCOME TAXES - Valuation Allowances and Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Valuation Allowances and Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - INCOME TAXES - NOL and Tax Credit Carryforwards (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails",
     "shortName": "INCOME TAXES - NOL and Tax Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - CONTRACT BALANCES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.tenethealth.com/role/CONTRACTBALANCES",
     "shortName": "CONTRACT BALANCES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - EARNINGS PER COMMON SHARE (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails",
     "shortName": "EARNINGS PER COMMON SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DilutiveSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000121 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i54b3f987c4664d6586d2dc3ce06561df_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "thc:AssetsHeldforuseLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i4c6583adb6404a2e9fb74d00bd953e4d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000122 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillPurchaseAccountingAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000123 - Disclosure - ACQUISITIONS - Purchase Price Allocation (Details)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
     "shortName": "ACQUISITIONS - Purchase Price Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "if07cf50792f1459db9cc6eaf83c40b5d_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000124 - Disclosure - ACQUISITIONS - Pro Forma Information (Details)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails",
     "shortName": "ACQUISITIONS - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i032814cf7eb5434e8c970ff85f7fce7b_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i314717058c7b4b6fb0a8169f1a019fe3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000125 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ib9105bcf52db42479105d6f470b7132c_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "thc:NumberOfHospitalsOperatedBySubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "hospital",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000126 - Disclosure - SEGMENT INFORMATION - Reconciling Items (Details)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails",
     "shortName": "SEGMENT INFORMATION - Reconciling Items (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i8cd4726c880f4e148d4569ab39f1d407_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "iaa722f7986ca4c518e3bcdca37e64012_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000127 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails",
     "shortName": "SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i0b95f4641f134e5c9fffaae2b5ca01e5_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE",
     "shortName": "ASSETS AND LIABILITIES HELD FOR SALE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS",
     "shortName": "IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.tenethealth.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - LONG-TERM DEBT",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.tenethealth.com/role/LONGTERMDEBT",
     "shortName": "LONG-TERM DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - GUARANTEES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.tenethealth.com/role/GUARANTEES",
     "shortName": "GUARANTEES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.tenethealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - OTHER ASSETS",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.tenethealth.com/role/OTHERASSETS",
     "shortName": "OTHER ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - NET OPERATING REVENUES",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUES",
     "shortName": "NET OPERATING REVENUES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - INSURANCE",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.tenethealth.com/role/INSURANCE",
     "shortName": "INSURANCE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - CLAIMS AND LAWSUITS",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.tenethealth.com/role/CLAIMSANDLAWSUITS",
     "shortName": "CLAIMS AND LAWSUITS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES",
     "shortName": "REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.tenethealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - EARNINGS PER COMMON SHARE",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE",
     "shortName": "EARNINGS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - ACQUISITIONS",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.tenethealth.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://www.tenethealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - RECENT ACCOUNTING STANDARDS",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://www.tenethealth.com/role/RECENTACCOUNTINGSTANDARDS",
     "shortName": "RECENT ACCOUNTING STANDARDS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS",
     "shortName": "SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "34",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:ScheduleOfGrantFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:ScheduleOfGrantFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.tenethealth.com/role/EQUITYTables",
     "shortName": "EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - ACCOUNTS RECEIVABLE (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables",
     "shortName": "ACCOUNTS RECEIVABLE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - CONTRACT BALANCES (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.tenethealth.com/role/CONTRACTBALANCESTables",
     "shortName": "CONTRACT BALANCES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALETables",
     "shortName": "ASSETS AND LIABILITIES HELD FOR SALE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.tenethealth.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - LONG-TERM DEBT (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.tenethealth.com/role/LONGTERMDEBTTables",
     "shortName": "LONG-TERM DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables",
     "shortName": "EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - OTHER ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.tenethealth.com/role/OTHERASSETSTables",
     "shortName": "OTHER ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - NET OPERATING REVENUES - (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.tenethealth.com/role/NETOPERATINGREVENUESTables",
     "shortName": "NET OPERATING REVENUES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - CLAIMS AND LAWSUITS (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSTables",
     "shortName": "CLAIMS AND LAWSUITS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables",
     "shortName": "REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://www.tenethealth.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - EARNINGS PER COMMON SHARE (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables",
     "shortName": "EARNINGS PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - ACQUISITIONS (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://www.tenethealth.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://www.tenethealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "thc:NumberOfHospitalsOperated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "hospital",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "thc:NumberOfHospitalsOperated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "hospital",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i5b80e44ad39248b78ee149633cd1af81_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Pandemic (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Pandemic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Net Operating Revenues (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Net Operating Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Investments in Unconsolidated Affiliates (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Investments in Unconsolidated Affiliates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "thc:PercentageInvesteeResultsReflected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ie1c80f6e03094431a9b9dc5696c76170_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ie1c80f6e03094431a9b9dc5696c76170_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "thc:LesseeOperatingLeaseNumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewal_option",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "thc:LesseeOperatingLeaseNumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewal_option",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i26d9b425fef84906a67c577eb496f953_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Other Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i26d9b425fef84906a67c577eb496f953_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "thc:PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - EQUITY - Noncontrolling Interests (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
     "shortName": "EQUITY - Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i42ad7bcccdb04247a3b2e90bbacf26bf_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i34c7defbef2a4e3b8612d7aba82bf5c3_I20221022",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - EQUITY - Share Repurchase Programs (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails",
     "shortName": "EQUITY - Share Repurchase Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i34c7defbef2a4e3b8612d7aba82bf5c3_I20221022",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - ACCOUNTS RECEIVABLE - Components (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails",
     "shortName": "ACCOUNTS RECEIVABLE - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
     "shortName": "ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i71e77f1a3cc942158bce2e26449d46fb_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:ScheduleOfEstimatedCostForCharityCareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationHealthCareCostsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - ACCOUNTS RECEIVABLE - Allowance (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails",
     "shortName": "ACCOUNTS RECEIVABLE - Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:ScheduleOfEstimatedCostForCharityCareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationHealthCareCostsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "thc:ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
     "shortName": "CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "thc:ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ic8317271c934402ebe8d6b8414e1b396_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ic8317271c934402ebe8d6b8414e1b396_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i4c6583adb6404a2e9fb74d00bd953e4d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - CONTRACT BALANCES - Conifer Segment (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
     "shortName": "CONTRACT BALANCES - Conifer Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i96ad47d7e3c04f468af3c2713771b904_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CapitalizedContractCostAmortization",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - CONTRACT BALANCES - Contract Costs (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails",
     "shortName": "CONTRACT BALANCES - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CapitalizedContractCostAmortization",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
     "shortName": "ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i2dd5c058d4484de28c384ae0497a9cb0_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i216cf3ae855e4607889370b5a9466471_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Significant Components (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails",
     "shortName": "ASSETS AND LIABILITIES HELD FOR SALE - Significant Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i216cf3ae855e4607889370b5a9466471_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
     "shortName": "IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - LEASES - Balance Sheet Components (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
     "shortName": "LEASES - Balance Sheet Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - LEASES - Lease Costs (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.tenethealth.com/role/LEASESLeaseCostsDetails",
     "shortName": "LEASES - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails",
     "shortName": "LEASES - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - LEASES - Schedule of Lease Maturities (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails",
     "shortName": "LEASES - Schedule of Lease Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - LEASES - Narrative (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.tenethealth.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ia908dc87eacc464da5dda4d6f359e3df_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfBuildings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:FinanceLeasesAndMortgageNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - LONG-TERM DEBT - Schedule of Debt (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails",
     "shortName": "LONG-TERM DEBT - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "thc:FinanceLeasesAndMortgageNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - LONG-TERM DEBT - Narrative (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
     "shortName": "LONG-TERM DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i5f385f61e4a549d18f6b539609e43283_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - LONG-TERM DEBT - Future Maturities (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails",
     "shortName": "LONG-TERM DEBT - Future Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:GuaranteeObligationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - GUARANTEES (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.tenethealth.com/role/GUARANTEESDetails",
     "shortName": "GUARANTEES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1bc0e704bf0e4925a168a319787e91bb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "thc:GuaranteeObligationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - EMPLOYEE BENEFIT PLANS - Share-based Compensation Plans (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Share-based Compensation Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i2aefe441942b4b1b9964978feb391a61_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - EMPLOYEE BENEFIT PLANS - Stock Options (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Options (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Employee Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1e819f2a1fb04d61bd621d90d6cff9b7_I20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i9447e0acfdc8411fa545539e357b1624_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i6c96def486284a8a8c5c631db5846d6a_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i22e72837fb0e4ccaa451831a1f7d7152_D20150101-20151231",
      "decimals": null,
      "lang": "en-US",
      "name": "thc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i98ed17ca8f424eddbb76511ce975b7d3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i98ed17ca8f424eddbb76511ce975b7d3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Employee Retirement Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i462e90434397417b94ea400ab3e98d19_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ia8470639b4b74ccb87974669a576a9a9_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - EMPLOYEE BENEFIT PLANS - Asset Allocations (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Asset Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "ia8470639b4b74ccb87974669a576a9a9_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "thc:ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - EMPLOYEE BENEFIT PLANS - Fair Value of Assets and Future Benefit Payments (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Fair Value of Assets and Future Benefit Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "thc:DefinedBenefitPlanExpectedFutureBenefitPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - PROPERTY AND EQUIPMENT - Components (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i4c6583adb6404a2e9fb74d00bd953e4d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "if474534dcafd415d9534dbb0774b811e_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - OTHER ASSETS - Schedule of Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails",
     "shortName": "OTHER ASSETS - Schedule of Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "thc-20221231.htm",
      "contextRef": "i1338325429bf43b1917d2b7a451f60b4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 195,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r975",
      "r976",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r975",
      "r976",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r975",
      "r976",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r975",
      "r976",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r975",
      "r976",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "New York Stock Exchange"
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r360",
      "r422",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r450",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r524",
      "r526",
      "r527",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r1054",
      "r1055",
      "r1187",
      "r1188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r360",
      "r422",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r450",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r524",
      "r526",
      "r527",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r1054",
      "r1055",
      "r1187",
      "r1188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r358",
      "r359",
      "r532",
      "r560",
      "r922",
      "r927",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r300",
      "r371",
      "r382",
      "r389",
      "r473",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r772",
      "r775",
      "r778",
      "r779",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r300",
      "r371",
      "r382",
      "r389",
      "r473",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r772",
      "r775",
      "r778",
      "r779",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r300",
      "r371",
      "r382",
      "r389",
      "r473",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r772",
      "r775",
      "r778",
      "r779",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r1025"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r455",
      "r945",
      "r1059",
      "r1184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r515",
      "r667",
      "r857",
      "r884",
      "r909",
      "r910",
      "r942",
      "r960",
      "r970",
      "r1056",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r515",
      "r667",
      "r857",
      "r884",
      "r909",
      "r910",
      "r942",
      "r960",
      "r970",
      "r1056",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r455",
      "r945",
      "r1059",
      "r1184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r452",
      "r859",
      "r943",
      "r969",
      "r1051",
      "r1052",
      "r1059",
      "r1183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r452",
      "r859",
      "r943",
      "r969",
      "r1051",
      "r1052",
      "r1059",
      "r1183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r515",
      "r626",
      "r667",
      "r695",
      "r696",
      "r697",
      "r856",
      "r857",
      "r884",
      "r909",
      "r910",
      "r942",
      "r960",
      "r970",
      "r1046",
      "r1056",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r515",
      "r626",
      "r667",
      "r695",
      "r696",
      "r697",
      "r856",
      "r857",
      "r884",
      "r909",
      "r910",
      "r942",
      "r960",
      "r970",
      "r1046",
      "r1056",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r358",
      "r359",
      "r532",
      "r560",
      "r928",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r384",
      "r385",
      "r409",
      "r778",
      "r779",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1020",
      "r1021"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "verboseLabel": "Revision of Prior Period, Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r301",
      "r368",
      "r369",
      "r370",
      "r374",
      "r375",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r409",
      "r476",
      "r477",
      "r735",
      "r773",
      "r778",
      "r779",
      "r780",
      "r824",
      "r850",
      "r851",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r301",
      "r368",
      "r369",
      "r370",
      "r374",
      "r375",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r409",
      "r476",
      "r477",
      "r735",
      "r773",
      "r778",
      "r779",
      "r780",
      "r824",
      "r850",
      "r851",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r668",
      "r1019",
      "r1186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r389",
      "r668",
      "r982",
      "r1019"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r367",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r389",
      "r668",
      "r982",
      "r983",
      "r1019"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r1025",
      "r1169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_A2015USPIManagementEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 USPI Management Equity Plan",
        "label": "2015 USPI Management Equity Plan [Member]",
        "terseLabel": "2015 USPI Management Equity Plan"
       }
      }
     },
     "localname": "A2015USPIManagementEquityPlanMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_A2020SCDCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 SCD Centers",
        "label": "2020 SCD Centers [Member]",
        "terseLabel": "2020 SCD Centers"
       }
      }
     },
     "localname": "A2020SCDCentersMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_A2020USPIManagementEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 USPI Management Equity Plan",
        "label": "2020 USPI Management Equity Plan [Member]",
        "terseLabel": "2020 USPI Management Equity Plan"
       }
      }
     },
     "localname": "A2020USPIManagementEquityPlanMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_A2021SCDCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 SCD Centers",
        "label": "2021 SCD Centers [Member]",
        "terseLabel": "2021 SCD Centers"
       }
      }
     },
     "localname": "A2021SCDCentersMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_A2022AcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Acquisition",
        "label": "2022 Acquisition [Member]",
        "terseLabel": "2022 Acquisition"
       }
      }
     },
     "localname": "A2022AcquisitionMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_AccruedCompensationAndBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation And Benefits [Member]",
        "label": "Accrued Compensation And Benefits [Member]",
        "terseLabel": "Accrued Compensation And Benefits"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acute Care Hospitals And Related Outpatient Facilities [Member]",
        "label": "Acute Care Hospitals And Related Outpatient Facilities [Member]",
        "terseLabel": "Acute Care Hospitals And Related Outpatient Facilities"
       }
      }
     },
     "localname": "AcuteCareHospitalsAndRelatedOutpatientFacilitiesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_AdditionalProratedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Prorated Restricted Stock Units [Member]",
        "label": "Additional Prorated Restricted Stock Units [Member]",
        "terseLabel": "Additional Prorated Restricted Stock Units"
       }
      }
     },
     "localname": "AdditionalProratedRestrictedStockUnitsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the net income with interest, taxes, depreciation, and amortization added back to it, used to analyze and compare profitability between companies and industries because it eliminates the effects of financing and accounting decisions.",
        "label": "Adjusted Earnings before Interest Tax Depreciation and Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_AdjustedSegmentEBITDAAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Segment EBITDA [Abstract]",
        "terseLabel": "Adjusted Segment EBITDA [Abstract]"
       }
      }
     },
     "localname": "AdjustedSegmentEBITDAAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the net (decrease) increase in additional paid-in capital resulting from the purchase and sales of businesses and joint venture interests.",
        "label": "Adjustments to Additional Paid-In Capital, Purchase (Sale) of Joint Venture Interest",
        "terseLabel": "Purchases (sales) of businesses and noncontrolling interests, net"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfJointVentureInterest",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_AmbulatoryCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Ambulatory Care as a reportable segment of the entity.",
        "label": "Ambulatory Care [Member]",
        "terseLabel": "Ambulatory Care",
        "verboseLabel": "Ambulatory Care"
       }
      }
     },
     "localname": "AmbulatoryCareMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related To Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_AssetsHeldforuseLongLivedFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held-for-use, Long Lived, Fair Value Disclosure",
        "label": "Assets Held-for-use, Long Lived, Fair Value Disclosure",
        "terseLabel": "Assets held-for-use, long lived, fair value"
       }
      }
     },
     "localname": "AssetsHeldforuseLongLivedFairValueDisclosure",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "thc_BaylorUniversityMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Baylor University Medical Center.",
        "label": "Baylor University Medical Center [Member]",
        "terseLabel": "Baylor University Medical Center"
       }
      }
     },
     "localname": "BaylorUniversityMedicalCenterMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_BuildingsSubjectToImpairmentChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buildings Subject To Impairment Charges",
        "label": "Buildings Subject To Impairment Charges [Member]",
        "terseLabel": "Buildings Subject To Impairment Charges"
       }
      }
     },
     "localname": "BuildingsSubjectToImpairmentChargesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Pro Forma Income (Loss) from Equity Method Investments",
        "label": "Business Acquisition, Pro Forma Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of acquisition costs of a business combination allocated to redeemable noncontrolling interests in equity of consolidated subsidiaries.",
        "label": "Business Acquisition, Purchase Price Allocation, Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries",
        "negatedTerseLabel": "Redeemable noncontrolling interests in equity of consolidated subsidiaries"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationRedeemableNoncontrollingInterestsInEquityOfConsolidatedSubsidiaries",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_BusinessCombinationAcquisitionRelatedTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of acquisition-related transaction costs incurred to effect a business combination which costs have been expensed during the period.",
        "label": "Business Combination Acquisition Related Transaction Costs",
        "terseLabel": "Acquisition-related transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedTransactionCosts",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Previously Held Investments in Unconsolidated Affiliates",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Previously Held Investments in Unconsolidated Affiliates",
        "negatedTerseLabel": "Previously held equity method investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPreviouslyHeldInvestmentsInUnconsolidatedAffiliates",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_CaliforniaEarthquakeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Earthquake",
        "label": "California Earthquake [Member]",
        "terseLabel": "California Earthquake"
       }
      }
     },
     "localname": "CaliforniaEarthquakeMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_CaliforniaProviderFeeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents activity related to California's provider fee program.",
        "label": "California Provider Fee Program [Member]",
        "terseLabel": "California's Provider Fee Program"
       }
      }
     },
     "localname": "CaliforniaProviderFeeProgramMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_CaptiveInsuranceSubsidiariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents activity related to captive insurance subsidiaries.",
        "label": "Captive Insurance Subsidiaries [Member]",
        "terseLabel": "Captive Insurance Subsidiaries"
       }
      }
     },
     "localname": "CaptiveInsuranceSubsidiariesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_ChangeInContractWithCustomerAssetNetCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Asset, Net, Current",
        "label": "Change In Contract With Customer, Asset, Net, Current [Roll Forward]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetNetCurrentRollForward",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_ChangeInContractWithCustomerAssetNetNoncurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Asset, Net, Noncurrent",
        "label": "Change In Contract With Customer, Asset, Net, Noncurrent [Roll Forward]",
        "terseLabel": "Contract Asset \u2013 Unbilled Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetNetNoncurrentRollForward",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_ChangeInContractWithCustomerLiabilityNetCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability, Net, Current [Roll Forward]",
        "label": "Change In Contract With Customer, Liability, Net, Current [Roll Forward]",
        "terseLabel": "Contract Liabilities \u2013 Current Advances from Medicare",
        "verboseLabel": "Contract Liability \u2013 Current Deferred Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNetCurrentRollForward",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability, Net, Noncurrent [Roll Forward]",
        "label": "Change In Contract With Customer, Liability, Net, Noncurrent [Roll Forward]",
        "terseLabel": "Contract Liabilities \u2013 Long-Term Advances from Medicare",
        "verboseLabel": "Contract Liability \u2013 Long-Term Deferred Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNetNoncurrentRollForward",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_CharityCarePatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents charity care patients.",
        "label": "Charity Care Patients [Member]",
        "terseLabel": "Charity care patients"
       }
      }
     },
     "localname": "CharityCarePatientsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_CommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the commitment period.",
        "label": "Commitment Period",
        "terseLabel": "Commitment period"
       }
      }
     },
     "localname": "CommitmentPeriod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_CommonStockSharesOutstandingAndEligibleToBeSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares, Outstanding And Eligible To Be Sold",
        "label": "Common Stock, Shares, Outstanding And Eligible To Be Sold",
        "terseLabel": "Outstanding vested shares eligible to be sold (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstandingAndEligibleToBeSold",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "thc_ComputerAndTelecommunicationEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer And Telecommunication Equipment",
        "label": "Computer And Telecommunication Equipment [Member]",
        "terseLabel": "Computer And Telecommunication Equipment"
       }
      }
     },
     "localname": "ComputerAndTelecommunicationEquipmentMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ConiferHealthSolutionsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conifer Health Solutions, LLC [Member]",
        "label": "Conifer Health Solutions, LLC [Member]",
        "terseLabel": "Conifer Health Solutions, LLC"
       }
      }
     },
     "localname": "ConiferHealthSolutionsLLCMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ConiferSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Conifer, a reportable segment of the entity.",
        "label": "Conifer Segment [Member]",
        "terseLabel": "Conifer",
        "verboseLabel": "Conifer Segment"
       }
      }
     },
     "localname": "ConiferSegmentMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Percentage To Be Reclassified To Receivable Within 90 Days",
        "label": "Contract With Customer, Asset, Percentage To Be Reclassified To Receivable Within 90 Days",
        "terseLabel": "Percentage of contract assets that meet the conditions for unconditional right to payment (percentage)"
       }
      }
     },
     "localname": "ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_ContractWithCustomerLiabilityRecoupmentOfAdvancePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Recoupment Of Advance Payments",
        "label": "Contract With Customer, Liability, Recoupment Of Advance Payments",
        "terseLabel": "Contract liabilities advance payments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRecoupmentOfAdvancePayments",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cost report filing period after the end of the annual cost reporting period.",
        "label": "Cost Report Filing Period after End of Annual Cost Reporting Period",
        "terseLabel": "Cost report filing period after end of annual cost reporting period"
       }
      }
     },
     "localname": "CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNetOperatingRevenuesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_CurrentEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current employees of the entity.",
        "label": "Current Employees [Member]",
        "terseLabel": "Current Employees"
       }
      }
     },
     "localname": "CurrentEmployeesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_CybersecurityIncidentPreTaxEffect": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cybersecurity Incident, Pre-Tax Effect",
        "label": "Cybersecurity Incident, Pre-Tax Effect",
        "terseLabel": "Cybersecurity incident, pre-tax effect"
       }
      }
     },
     "localname": "CybersecurityIncidentPreTaxEffect",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DebtInstrumentBasisSpreadOnCreditSpread": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread On Credit Spread",
        "label": "Debt Instrument, Basis Spread On Credit Spread",
        "terseLabel": "Basis spread on credit spread"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnCreditSpread",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_DebtInstrumentCovenantMaximumSecuredDebtRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Maximum Secured Debt Ratio",
        "label": "Debt Instrument, Covenant, Maximum Secured Debt Ratio",
        "terseLabel": "Maximum secured debt covenant ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMaximumSecuredDebtRatio",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "thc_DebtInstrumentCovenantSecuredDebtToEbitdaRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the ratio for secured debt to EBITDA required to be maintained under financial covenants.",
        "label": "Debt Instrument Covenant Secured Debt To EBITDA Ratio",
        "terseLabel": "Secured debt to EBITDA ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantSecuredDebtToEbitdaRatio",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "thc_DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the hospital asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property.",
        "label": "Debt Instrument, Covenants Asset Value as Percentage of Consolidated Net Tangible Assets for Properties to be Defined as Principal Property",
        "terseLabel": "Asset value as a percentage of consolidated net tangible assets for properties to be defined as principal property (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantsAssetValueAsPercentageOfConsolidatedNetTangibleAssetsForPropertiesToBeDefinedAsPrincipalProperty",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_DebtInstrumentCovenantsOfSecuredDebtRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the secured debt ratio.",
        "label": "Debt Instrument, Covenants of Secured Debt Ratio",
        "terseLabel": "Secured debt ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantsOfSecuredDebtRatio",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "thc_DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Issued But Undrawn Letters Of Credit",
        "label": "Debt Instrument, Interest Rate, Issued But Undrawn Letters Of Credit",
        "terseLabel": "Interest rate on issued but undrawn letters of credit (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIssuedButUndrawnLettersOfCredit",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the issuance fee, expressed as a percentage of the face amount.",
        "label": "Debt Instrument, Issuance Fee, Based on Face Amount, Percentage",
        "terseLabel": "Issuance fee, based on face amount (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceFeeBasedOnFaceAmountPercentage",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the principal amount at which the entity is obligated to offer to repurchase the debt instrument due to a change in control.",
        "label": "Debt Instrument, Repurchase Obligation Due to Change of Control Percentage of Principal",
        "terseLabel": "Repurchase obligation due to change of control percentage of principal"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseObligationDueToChangeOfControlPercentageOfPrincipal",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_DeferredIncomeTaxAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Assets (Liabilities), Net",
        "label": "Deferred Income Tax Assets (Liabilities), Net",
        "totalLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsLiabilitiesNet",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DeferredTaxAssetsInterestExpenseLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Expense Limitation",
        "label": "Deferred Tax Assets, Interest Expense Limitation",
        "terseLabel": "Interest expense limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpenseLimitation",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DeferredTaxAssetsMedicareAdvancePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Medicare Advance Payments",
        "label": "Deferred Tax Assets, Medicare Advance Payments",
        "terseLabel": "Medicare advance payments"
       }
      }
     },
     "localname": "DeferredTaxAssetsMedicareAdvancePayments",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DeferredTaxAssetsOtherLongTermLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax reductions attributable to the difference between the tax basis and the generally accepted accounting principle basis of a company's other long-term liabilities which will decrease future taxable income when such basis difference reverses.",
        "label": "Deferred Tax Assets, Other Long Term Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherLongTermLiabilities",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DeferredTaxAssetsReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Reconciliation",
        "label": "Deferred Tax Assets Reconciliation [Abstract]",
        "terseLabel": "Reconciliation of the deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsReconciliationAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Right-of-Use Lease Assets And Obligations",
        "label": "Deferred Tax Assets, Right-of-Use Lease Assets And Obligations",
        "terseLabel": "Right-of-use lease assets and obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseLeaseAssetsAndObligations",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DeferredTaxLiabilitiesInvestmentsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments and other assets.",
        "label": "Deferred Tax Liabilities, Investments and Other Assets",
        "terseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentsAndOtherAssets",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-of-Use Lease Liability And Obligations",
        "label": "Deferred Tax Liabilities, Right-of-Use Lease Liability And Obligations",
        "terseLabel": "Right-of-use lease assets and obligations"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseLeaseLiabilityAndObligations",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DefinedBenefitPlanAlternativeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Alternative Investments [Member]",
        "label": "Defined Benefit Plan, Alternative Investments [Member]",
        "terseLabel": "Alternative investments"
       }
      }
     },
     "localname": "DefinedBenefitPlanAlternativeInvestmentsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_DefinedBenefitPlanBenefitsPaidOrEmployerContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of payments made or employer contribution in a defined benefit pension plan.",
        "label": "Defined Benefit Plan, Benefits Paid or Employer Contribution",
        "terseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitsPaidOrEmployerContribution",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DefinedBenefitPlanExpectedFutureBenefitPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate amount of the benefits expected to be paid in future years.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPayments",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag",
        "label": "Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag",
        "terseLabel": "Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag",
        "label": "Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag",
        "terseLabel": "Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_EffectOfDilutiveSecuritiesPerShareAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect Of Dilutive Securities Per Share Amount",
        "label": "Effect Of Dilutive Securities Per Share Amount",
        "terseLabel": "Effect of dilutive stock options, restricted stock units, and deferred compensation units (in dollars per share)"
       }
      }
     },
     "localname": "EffectOfDilutiveSecuritiesPerShareAmount",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount",
        "terseLabel": "Nondeductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Expired Charitable Contributions Carryforward, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Expired Charitable Contributions Carryforward, Amount",
        "negatedLabel": "Expired charitable contribution carryforward"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpiredCharitableContributionsCarryforwardAmount",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_EightQuarterVestingPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eight Quarter Vesting Period [Member]",
        "label": "Eight Quarter Vesting Period [Member]",
        "terseLabel": "Eight Quarter Vesting Period"
       }
      }
     },
     "localname": "EightQuarterVestingPeriodMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ElevenQuarterVestingPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eleven Quarter Vesting Period [Member]",
        "label": "Eleven Quarter Vesting Period [Member]",
        "terseLabel": "Eleven Quarter Vesting Period"
       }
      }
     },
     "localname": "ElevenQuarterVestingPeriodMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_EquityMethodInvestmentCashManagedAffiliatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Cash Managed Affiliates",
        "label": "Equity Method Investment, Cash Managed Affiliates [Member]",
        "terseLabel": "Cash\u2011Managed Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentCashManagedAffiliatesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated fair value of the long-term debt instrument as a percentage of carrying value.",
        "label": "Estimated Fair Value of Debt Instrument as Percentage of Carrying Value",
        "terseLabel": "Estimated fair value of the long-term debt instrument as a percentage of carrying value"
       }
      }
     },
     "localname": "EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_EstimatedFutureRecoveriesFromAccountsAssignedToConifer": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents estimated future recoveries from accounts assigned to Conifer.",
        "label": "Estimated Future Recoveries from Accounts Assigned to Conifer",
        "terseLabel": "Estimated future recoveries"
       }
      }
     },
     "localname": "EstimatedFutureRecoveriesFromAccountsAssignedToConifer",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to options for exercise prices per share of stock options outstanding and exercisable within the first range of prices.",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$18.99 to $20.609"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ExercisePriceRangeSecondMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to options for exercise prices per share of stock options outstanding and exercisable within the second range of prices.",
        "label": "Exercise Price Range Second [Member]",
        "terseLabel": "$20.61 to $35.430"
       }
      }
     },
     "localname": "ExercisePriceRangeSecondMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease expense"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_FinanceLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Expense [Abstract]",
        "label": "Finance Lease Expense [Abstract]",
        "terseLabel": "Finance lease expense:"
       }
      }
     },
     "localname": "FinanceLeaseExpenseAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_FinanceLeasesAndMortgageNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Leases And Mortgage Notes",
        "label": "Finance Leases And Mortgage Notes",
        "terseLabel": "Finance leases, mortgages and other notes"
       }
      }
     },
     "localname": "FinanceLeasesAndMortgageNotes",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_FireAndOtherPerilsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxidation process that releases energy in the form of light and heat (flames) and often creates smoke and other perils.",
        "label": "Fire And Other Perils [Member]",
        "terseLabel": "Fires and Other Perils"
       }
      }
     },
     "localname": "FireAndOtherPerilsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Two Five Percent Senior Secured Note Due 2025",
        "label": "Five Point One Two Five Percent Senior Secured Note Due 2025 [Member]",
        "terseLabel": "5.125% due 2025"
       }
      }
     },
     "localname": "FivePointOneTwoFivePercentSeniorSecuredNoteDue2025Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.625% Senior Notes Due 2028 [Member]",
        "label": "Five Point One Two Five Percent Senior Secured Note, Due 2027 [Member]",
        "terseLabel": "5.125% due 2027"
       }
      }
     },
     "localname": "FivePointOneTwoFivePercentSeniorSecuredNoteDue2027Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FloodEarthquakeAndWindstormMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overflowing of a body of water, sudden movement of the earth's crust and localized violently destructive windstorm characterized by a funnel shaped cloud.",
        "label": "Flood Earthquake And Windstorm [Member]",
        "terseLabel": "Floods, Earthquakes and Windstorms"
       }
      }
     },
     "localname": "FloodEarthquakeAndWindstormMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FloodsAndWindstormsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floods And Windstorms",
        "label": "Floods And Windstorms [Member]",
        "terseLabel": "Floods And Windstorms"
       }
      }
     },
     "localname": "FloodsAndWindstormsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FormerEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the former employees of the entity.",
        "label": "Former Employees [Member]",
        "terseLabel": "Former Employees"
       }
      }
     },
     "localname": "FormerEmployeesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Eight Seven Five Percent Senior Secured Note, Due 2026",
        "label": "Four Point Eight Seven Five Percent Senior Secured Note, Due 2026 [Member]",
        "terseLabel": "4.875% due 2026"
       }
      }
     },
     "localname": "FourPointEightSevenFivePercentSeniorSecuredNoteDue2026Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Two Five Percent Senior Secured Note, Due 2028",
        "label": "Four Point Six Two Five Percent Senior Secured Note, Due 2028 [Member]",
        "terseLabel": "4.625% due 2028"
       }
      }
     },
     "localname": "FourPointSixTwoFivePercentSeniorSecuredNoteDue2028Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Two Five Percent Senior Secured Note Due 2024 [Member]",
        "label": "Four Point Six Two Five Percent Senior Secured Note Due July 2024 [Member]",
        "terseLabel": "4.625% due July 2024"
       }
      }
     },
     "localname": "FourPointSixTwoFivePercentSeniorSecuredNoteDueJuly2024Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Two Five Percent, Six Hundred Million, Senior Secured Note, Due 2024 [Member]",
        "label": "Four Point Six Two Five Percent, Six Hundred Million, Senior Secured Note, Due September 2024 [Member]",
        "terseLabel": "4.625% due September 2024"
       }
      }
     },
     "localname": "FourPointSixTwoFivePercentSixHundredMillionSeniorSecuredNoteDueSeptember2024Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Three Seven Five Percent Senior Secured Note Due 2030",
        "label": "Four Point Three Seven Five Percent Senior Secured Note Due 2030 [Member]",
        "terseLabel": "4.375% due 2030"
       }
      }
     },
     "localname": "FourPointThreeSevenFivePercentSeniorSecuredNoteDue2030Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Two Five Zero Percent Senior Secured Note, Due 2029",
        "label": "Four Point Two Five Zero Percent Senior Secured Note, Due 2029 [Member]",
        "terseLabel": "4.250% due 2029"
       }
      }
     },
     "localname": "FourPointTwoFiveZeroPercentSeniorSecuredNoteDue2029Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Two Five Zero Percent Senior Unsecured Note Due 2029",
        "label": "Four Point Two Five Zero Percent Senior Unsecured Note Due 2029 [Member]",
        "terseLabel": "4.250% due 2029"
       }
      }
     },
     "localname": "FourPointTwoFiveZeroPercentSeniorUnsecuredNoteDue2029Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_GainLossFromPurchaseOfNoncontrollingInterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) From Purchase Of Noncontrolling Interests",
        "label": "Gain (Loss) From Purchase Of Noncontrolling Interests",
        "terseLabel": "Loss from purchase of noncontrolling interests"
       }
      }
     },
     "localname": "GainLossFromPurchaseOfNoncontrollingInterests",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_GlobalBusinessCenterInTheRepublicOfPhilippinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Business Center In The Republic Of Philippines [Member]",
        "label": "Global Business Center In The Republic Of Philippines [Member]",
        "terseLabel": "Global Business Center in Republic of Philippines"
       }
      }
     },
     "localname": "GlobalBusinessCenterInTheRepublicOfPhilippinesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Acquired During Period And Purchase Accounting Adjustments",
        "label": "Goodwill, Acquired During Period And Purchase Accounting Adjustments",
        "terseLabel": "Goodwill acquired during the year and purchase price allocation adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustments",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Related To Assets Held For Sale And Disposed Or Deconsolidated Facility",
        "label": "Goodwill Related To Assets Held For Sale And Disposed Or Deconsolidated Facility",
        "terseLabel": "Goodwill related to assets held for sale and disposed"
       }
      }
     },
     "localname": "GoodwillRelatedToAssetsHeldForSaleAndDisposedOrDeconsolidatedFacility",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_GuaranteeObligationCarryValueConsolidatedSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees which pertains to the entity's consolidated subsidiaries",
        "label": "Guarantee Obligation Carry Value Consolidated Subsidiaries",
        "terseLabel": "Guarantee obligations for consolidated subsidiaries"
       }
      }
     },
     "localname": "GuaranteeObligationCarryValueConsolidatedSubsidiaries",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_GuaranteeObligationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of the guarantee.",
        "label": "Guarantee Obligation, Period",
        "terseLabel": "Guarantee obligation period"
       }
      }
     },
     "localname": "GuaranteeObligationPeriod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_GuaranteedInvesteesOfThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the guarantees of indebtedness and other obligations to our investees to third parties",
        "label": "Guaranteed Investees Of Third Parties [Member]",
        "terseLabel": "Guaranteed Investees of Third Parties"
       }
      }
     },
     "localname": "GuaranteedInvesteesOfThirdPartiesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCareClientContractsOtherServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care - Client Contracts - Other Services [Member]",
        "label": "Health Care - Client Contracts - Other Services [Member]",
        "terseLabel": "Health Care - Client Contracts - Other Services"
       }
      }
     },
     "localname": "HealthCareClientContractsOtherServicesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCareClientContractsRevenueCycleServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care - Client Contracts - Revenue Cycle Services [Member]",
        "label": "Health Care - Client Contracts - Revenue Cycle Services [Member]",
        "terseLabel": "Health Care - Client Contracts - Revenue Cycle Services"
       }
      }
     },
     "localname": "HealthCareClientContractsRevenueCycleServicesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCareManagementFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care - Management Fees [Member]",
        "label": "Health Care - Management Fees [Member]",
        "terseLabel": "Management fees"
       }
      }
     },
     "localname": "HealthCareManagementFeesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCareOtherSourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care - Other Sources [Member]",
        "label": "Health Care - Other Sources [Member]",
        "terseLabel": "Revenue from other sources"
       }
      }
     },
     "localname": "HealthCareOtherSourcesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCarePatientServiceExcludingPhysicianPracticesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care, Patient Service, Excluding Physician Practices [Member]",
        "label": "Health Care, Patient Service, Excluding Physician Practices [Member]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "HealthCarePatientServiceExcludingPhysicianPracticesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCarePatientServiceIndemnityAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care, Patient Service - Indemnity And Other [Member]",
        "label": "Health Care, Patient Service - Indemnity And Other [Member]",
        "terseLabel": "Indemnity and other"
       }
      }
     },
     "localname": "HealthCarePatientServiceIndemnityAndOtherMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCarePatientServiceManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care, Patient Service - Managed Care [Member]",
        "label": "Health Care, Patient Service - Managed Care [Member]",
        "terseLabel": "Managed care"
       }
      }
     },
     "localname": "HealthCarePatientServiceManagedCareMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCarePatientServiceMedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care, Patient Service - Medicaid [Member]",
        "label": "Health Care, Patient Service - Medicaid [Member]",
        "verboseLabel": "Medicaid"
       }
      }
     },
     "localname": "HealthCarePatientServiceMedicaidMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HealthCarePatientServiceSelfpayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care, Patient Service - Self-pay [Member]",
        "label": "Health Care, Patient Service - Self-pay [Member]",
        "terseLabel": "Uninsured"
       }
      }
     },
     "localname": "HealthCarePatientServiceSelfpayMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HospitalBuildingsAndMedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospital Buildings and Medical Equipment",
        "label": "Hospital Buildings and Medical Equipment [Member]",
        "terseLabel": "Hospital Buildings and Medical Equipment"
       }
      }
     },
     "localname": "HospitalBuildingsAndMedicalEquipmentMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HospitalOperationsAndAmbulatoryCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospital Operations And Ambulatory Care",
        "label": "Hospital Operations And Ambulatory Care [Member]",
        "terseLabel": "Hospital Operations And Ambulatory Care"
       }
      }
     },
     "localname": "HospitalOperationsAndAmbulatoryCareMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HospitalOperationsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospital Operations And Other",
        "label": "Hospital Operations And Other [Member]",
        "terseLabel": "Hospital Operations And Other"
       }
      }
     },
     "localname": "HospitalOperationsAndOtherMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HospitalOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Hospital Operations a reportable segment of the entity.",
        "label": "Hospital Operations [Member]",
        "terseLabel": "Hospital Operations"
       }
      }
     },
     "localname": "HospitalOperationsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_HospitalOperationsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospital Operations Segment [Member]",
        "label": "Hospital Operations Segment [Member]",
        "terseLabel": "Hospital Operations"
       }
      }
     },
     "localname": "HospitalOperationsSegmentMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_IncomeAndRevenueCollectionGuaranteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the income and revenue collection guarantees.",
        "label": "Income And Revenue Collection Guarantee [Member]",
        "terseLabel": "Income and Revenue Collection Guarantee"
       }
      }
     },
     "localname": "IncomeAndRevenueCollectionGuaranteeMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_IncomeGuaranteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the income guarantee agreements provided to certain physicians.",
        "label": "Income Guarantee [Member]",
        "terseLabel": "Income Guarantee"
       }
      }
     },
     "localname": "IncomeGuaranteeMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_IncomeLossFromDivestedAndClosedBusinesses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents income (loss) from divested or closed businesses, specifically those related to the Company's health plan businesses.",
        "label": "Income (Loss) From Divested And Closed Businesses",
        "terseLabel": "Income (loss) from divested and closed businesses"
       }
      }
     },
     "localname": "IncomeLossFromDivestedAndClosedBusinesses",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_IncomeTaxExpenseBenefitCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), CARES Act",
        "label": "Income Tax Expense (Benefit), CARES Act",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitCARESAct",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_IncomeTaxReconciliationNondeductibleExpenseLitigation": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to litigation",
        "label": "Income Tax Reconciliation Nondeductible Expense Litigation",
        "terseLabel": "Nondeductible litigation costs"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseLitigation",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense (benefit) as reported in the income statement for the current period and the expected income tax expense or benefit computed attributable to revisions of previously reported income tax expense and other changes in deferred taxes, net of valuation allowance.",
        "label": "Income Tax Reconciliation, Prior Year Income Taxes and Change in Deferred Taxes",
        "negatedTerseLabel": "Prior-year provision to return adjustments and other changes in deferred\u00a0taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_IncreaseDecreaseInContractWithCustomerReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Contract with Customer, Receivable",
        "label": "Increase (Decrease) In Contract with Customer, Receivable",
        "verboseLabel": "Increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerReceivable",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_IncreaseDecreaseInInventoriesAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the aggregate value of all inventory held by the reporting entity and other current assets not otherwise defined in the taxonomy, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories and Other Assets, Current",
        "negatedLabel": "Inventories and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventoriesAndOtherAssetsCurrent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_InsuranceCoverageLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Coverage [Line Items]",
        "terseLabel": "Insurance coverage"
       }
      }
     },
     "localname": "InsuranceCoverageLineItems",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails",
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_InsuranceCoverageTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance coverage used by the entity to manage financial risk.",
        "label": "Insurance Coverage [Table]",
        "terseLabel": "Insurance Coverage [Table]"
       }
      }
     },
     "localname": "InsuranceCoverageTable",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails",
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_InsuranceRecoveriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Recoveries",
        "label": "Insurance Recoveries [Member]",
        "terseLabel": "Insurance Recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveriesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_InvestmentsAndOtherNoncurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for investments and other noncurrent assets.",
        "label": "Investments and Other Noncurrent Assets [Table Text Block]",
        "terseLabel": "Schedule of Investments and Other Assets"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssetsTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_JointVentureOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the joint venture ownership percentage.",
        "label": "Joint Venture, Ownership Percentage",
        "terseLabel": "Joint venture ownership (as a percentage)",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "JointVentureOwnershipPercentage",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_LeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liabilities, Payments, Due [Abstract]",
        "label": "Lease Liabilities, Payments, Due [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "thc_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Current",
        "label": "Lease, Liability, Current",
        "terseLabel": "Less: Current obligations"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "thc_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Noncurrent",
        "label": "Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations"
       }
      }
     },
     "localname": "LeaseLiabilityNoncurrent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LeaseLiabilityPaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Payments Due",
        "label": "Lease, Liability, Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LeaseLiabilityPaymentsDue",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Undiscounted Excess Amount",
        "label": "Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-Of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "thc_LeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Liability, Payments, Due After Year Five",
        "label": "Lessee, Lease, Liability, Payments, Due After Year Five",
        "terseLabel": "Later years"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "thc_LeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Liability, Payments, Due Year Five",
        "label": "Lessee, Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "thc_LeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Liability, Payments, Due Year Four",
        "label": "Lessee, Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "thc_LeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Liability, Payments, Due Year Three",
        "label": "Lessee, Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "thc_LeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Liability, Payments, Due Year Two",
        "label": "Lessee, Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeLeaseLiabilityPaymentsNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "thc_LeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Liability, Payments, Next Twelve Months",
        "label": "Lessee, Lease, Liability, Payments, Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityPaymentsNextTwelveMonths",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_LineOfCreditFacilityCovenantThresholdLimit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold limit for the line of credit facility.",
        "label": "Line of Credit Facility, Covenant Threshold Limit",
        "terseLabel": "Threshold limit of revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantThresholdLimit",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the unused borrowing availability threshold limit for the line of credit facility.",
        "label": "Line of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit",
        "terseLabel": "Threshold limit of unused borrowing availability under the revolving credit facility (less than)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimit",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit, Number Of Consecutive Days",
        "label": "Line Of Credit Facility, Covenant Unused Borrowing Availability Threshold Limit, Number Of Consecutive Days",
        "terseLabel": "Threshold limit of unused borrowing availability under the revolving credit facility, number of consecutive days"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantUnusedBorrowingAvailabilityThresholdLimitNumberOfConsecutiveDays",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum available capacity under the subfacility for standby letters of credit.",
        "label": "Line of Credit Facility, Subfacility for Standby Letters of Credit Maximum Available Capacity",
        "terseLabel": "Line of credit facility, subfacility maximum available capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilitySubfacilityForStandbyLettersOfCreditMaximumAvailableCapacity",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Repayments Of Principal After Year Five",
        "label": "Long-Term Debt And Lease Obligations, Repayments Of Principal After Year Five",
        "terseLabel": "Later Years"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Next Twelve Months",
        "label": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Five",
        "label": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Four",
        "label": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Three",
        "label": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Two",
        "label": "Long-Term Debt And Lease Obligations, Repayments Of Principal In Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_LongTermInvestmentsAndOtherAssetsAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments And Other Assets Abstract",
        "label": "Long Term Investments And Other Assets Abstract [Abstract]",
        "terseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "LongTermInvestmentsAndOtherAssetsAbstractAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_LossContingencyAccrualOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Accrual, Other",
        "label": "Loss Contingency Accrual, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LossContingencyAccrualOther",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_MalpracticeLossContingencyAdverseDevelopmentsInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Malpractice Loss Contingency, Adverse Developments In Prior Years",
        "label": "Malpractice Loss Contingency, Adverse Developments In Prior Years",
        "terseLabel": "Malpractice expense, portion related to adverse developments in prior years"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAdverseDevelopmentsInPriorYears",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]",
        "terseLabel": "Medical Equipment"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information about Medicare services.",
        "label": "Medicare [Member]",
        "verboseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_MiamiAreaHospitalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miami-Area Hospitals",
        "label": "Miami-Area Hospitals [Member]",
        "terseLabel": "Miami-Area Hospitals"
       }
      }
     },
     "localname": "MiamiAreaHospitalsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_NetCostReportSettlementsReceivablePayableandValuationAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cost report settlements receivable (payable) and valuation allowances.",
        "label": "Net Cost Report Settlements Receivable (Payable) and Valuation Allowances",
        "negatedLabel": "Net cost reports and settlements receivable and valuation allowances"
       }
      }
     },
     "localname": "NetCostReportSettlementsReceivablePayableandValuationAllowances",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_NetGainonSaleConsolidationAndDeconsolidationOfFacilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain for the period due to sales, consolidation and deconsolidation of facilities.",
        "label": "Net Gain on Sale, Consolidation, And Deconsolidation Of Facilities",
        "negatedLabel": "Net gains on sales, consolidation and deconsolidation of facilities",
        "negatedTerseLabel": "Net gains on sales, consolidation and deconsolidation of facilities",
        "terseLabel": "Gains on sales, consolidation and deconsolidation of facilities"
       }
      }
     },
     "localname": "NetGainonSaleConsolidationAndDeconsolidationOfFacilities",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_NetIncomeLossAttributableToInvestee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) attributable to the investee reported by the equity method.",
        "label": "Net Income Loss Attributable to Investee",
        "terseLabel": "Net income attributable to the investees"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToInvestee",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_NewMadridFaultEarthquakesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Madrid Fault Earthquakes [Member]",
        "label": "New Madrid Fault Earthquakes [Member]",
        "terseLabel": "New Madrid Fault Earthquakes"
       }
      }
     },
     "localname": "NewMadridFaultEarthquakesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_NewlyConstructedHospitalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to newly constructed hospitals.",
        "label": "Newly Constructed Hospitals [Member]",
        "terseLabel": "Newly Constructed Hospitals"
       }
      }
     },
     "localname": "NewlyConstructedHospitalsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents activity related to non-employee directors",
        "label": "Non Employee Directors [Member]",
        "terseLabel": "Non Employee Directors"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_NonExecutiveChairmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Executive Chairman",
        "label": "Non Executive Chairman [Member]",
        "terseLabel": "Non Executive Chairman"
       }
      }
     },
     "localname": "NonExecutiveChairmanMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest Repurchased During Period Through Issuance Of Equity, Shares",
        "label": "Noncontrolling Interest Repurchased During Period Through Issuance Of Equity, Shares",
        "terseLabel": "Noncontrolling interest purchased during period through issuance of equity (in shares)"
       }
      }
     },
     "localname": "NoncontrollingInterestRepurchasedDuringPeriodThroughIssuanceOfEquityShares",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "thc_NumberOfAmbulatorySurgeryCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of ambulatory surgery centers acquired by the entity.",
        "label": "Number of Ambulatory Surgery Centers",
        "terseLabel": "Number of ambulatory surgery centers"
       }
      }
     },
     "localname": "NumberOfAmbulatorySurgeryCenters",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfAmbulatorySurgeryCentersConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Ambulatory Surgery Centers Consolidated",
        "label": "Number Of Ambulatory Surgery Centers Consolidated",
        "terseLabel": "Number of ambulatory surgery centers consolidated"
       }
      }
     },
     "localname": "NumberOfAmbulatorySurgeryCentersConsolidated",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Ambulatory Surgery Centers Operated By Subsidiaries",
        "label": "Number Of Ambulatory Surgery Centers Operated By Subsidiaries",
        "terseLabel": "Number of ambulatory surgery centers operated by subsidiaries"
       }
      }
     },
     "localname": "NumberOfAmbulatorySurgeryCentersOperatedBySubsidiaries",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of business days after notice, for reimbursement of amount drawn under the facility.",
        "label": "Number of Business Days After Notice for Reimbursement of Drawings",
        "terseLabel": "Number of business days after notice for reimbursement of drawings"
       }
      }
     },
     "localname": "NumberOfBusinessDaysAfterNoticeForReimbursementOfDrawings",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of frozen non-qualified benefit pension plans of the entity.",
        "label": "Number Of Frozen Non Qualified Defined Benefit Pension Plans",
        "verboseLabel": "Number of frozen plans"
       }
      }
     },
     "localname": "NumberOfFrozenNonQualifiedDefinedBenefitPensionPlans",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfHospitalsForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Hospitals For Sale",
        "label": "Number Of Hospitals For Sale",
        "terseLabel": "Number of hospitals for sale"
       }
      }
     },
     "localname": "NumberOfHospitalsForSale",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfHospitalsOperated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Hospitals Operated",
        "label": "Number Of Hospitals Operated",
        "terseLabel": "Number of acute care and specialty hospitals operated"
       }
      }
     },
     "localname": "NumberOfHospitalsOperated",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfHospitalsOperatedBySubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of hospitals operated by subsidiaries of the entity.",
        "label": "Number of Hospitals Operated by Subsidiaries",
        "terseLabel": "Number of hospitals owned by subsidiaries"
       }
      }
     },
     "localname": "NumberOfHospitalsOperatedBySubsidiaries",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of Tenet and non-Tenet Hospitals to which a segment of the entity provides revenue cycle services.",
        "label": "Number of Hospitals to which Segment of the Entity Provides Revenue Cycle Services",
        "terseLabel": "Number of hospitals to which segment of the entity provides revenue cycle services"
       }
      }
     },
     "localname": "NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfImagingCentersTransferred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Imaging Centers Transferred",
        "label": "Number of Imaging Centers Transferred",
        "terseLabel": "Number of imaging centers transferred"
       }
      }
     },
     "localname": "NumberOfImagingCentersTransferred",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfOutpatientCentersRecordedNotUsingEquityMethod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of outpatient centers in which they are not recorded using the equity method of accounting",
        "label": "Number Of Outpatient Centers Recorded Not Using Equity Method",
        "terseLabel": "Number of outpatient centers recorded not using equity method"
       }
      }
     },
     "localname": "NumberOfOutpatientCentersRecordedNotUsingEquityMethod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfOutpatientCentersRecordedUsingEquityMethod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of outpatient centers in which they are recorded using the equity method of accounting",
        "label": "Number Of Outpatient Centers Recorded Using Equity Method",
        "terseLabel": "Number of outpatient centers recorded using equity method"
       }
      }
     },
     "localname": "NumberOfOutpatientCentersRecordedUsingEquityMethod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfOutpatientFacilitiesOperated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Outpatient Facilities Operated",
        "label": "Number Of Outpatient Facilities Operated",
        "terseLabel": "Number of outpatient facilities operated"
       }
      }
     },
     "localname": "NumberOfOutpatientFacilitiesOperated",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfSurgicalCentersAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Surgical Centers Acquired",
        "label": "Number Of Surgical Centers Acquired",
        "terseLabel": "Number of surgical centers acquired"
       }
      }
     },
     "localname": "NumberOfSurgicalCentersAcquired",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfSurgicalCentersAndHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of surgical centers and hospitals operated by subsidiaries.",
        "label": "Number Of Surgical Centers And Hospitals",
        "verboseLabel": "Number of outpatient centers"
       }
      }
     },
     "localname": "NumberOfSurgicalCentersAndHospitals",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfSurgicalCentersInDevelopmentStage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Surgical Centers In Development Stage",
        "label": "Number Of Surgical Centers In Development Stage",
        "terseLabel": "Number of ambulatory surgery centers development stage"
       }
      }
     },
     "localname": "NumberOfSurgicalCentersInDevelopmentStage",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfSurgicalCentersRecordedUsingEquityMethod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Surgical Centers Recorded Using Equity Method",
        "label": "Number Of Surgical Centers Recorded Using Equity Method",
        "terseLabel": "Number of ambulatory surgery centers noncontrolling interests"
       }
      }
     },
     "localname": "NumberOfSurgicalCentersRecordedUsingEquityMethod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfSurgicalHospitalsConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Surgical Hospitals Consolidated",
        "label": "Number Of Surgical Hospitals Consolidated",
        "terseLabel": "Number of surgical hospitals consolidated"
       }
      }
     },
     "localname": "NumberOfSurgicalHospitalsConsolidated",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfSurgicalHospitalsOperatedBySubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Surgical Hospitals Operated By Subsidiaries",
        "label": "Number Of Surgical Hospitals Operated By Subsidiaries",
        "terseLabel": "Number of surgical hospitals operated by subsidiaries"
       }
      }
     },
     "localname": "NumberOfSurgicalHospitalsOperatedBySubsidiaries",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberOfUrgentCareCentersSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Urgent Care Centers Sold",
        "label": "Number Of Urgent Care Centers Sold",
        "terseLabel": "Number of urgent care centers sold"
       }
      }
     },
     "localname": "NumberOfUrgentCareCentersSold",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_NumberofHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of hospitals.",
        "label": "Number of Hospitals",
        "terseLabel": "Number of hospitals"
       }
      }
     },
     "localname": "NumberofHospitals",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Subject To Expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "terseLabel": "Operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_OtherCatastrophicEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other catastrophic events including but not limited to fires and other perils.",
        "label": "Other Catastrophic Events [Member]",
        "terseLabel": "Fires and Certain Other Covered Losses"
       }
      }
     },
     "localname": "OtherCatastrophicEventsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of amortization of net actuarial gain (loss) that has been recognized in other non-operating income (expense).",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization of Net Actuarial Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Amortization of net actuarial loss included in other non-operating income, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to other customers.",
        "label": "Other Customers [Member]",
        "terseLabel": "Other clients",
        "verboseLabel": "Other Customers"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_OtherLongTermReceivablesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestmentsAndReceivablesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the land held for expansion, other long-term receivables and other assets which are classified as noncurrent as of the balance sheet date.",
        "label": "Other Long Term Receivables and Other Assets, Noncurrent",
        "terseLabel": "Other long-term receivables and other assets"
       }
      }
     },
     "localname": "OtherLongTermReceivablesAndOtherAssetsNoncurrent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_OtherMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Matters",
        "label": "Other Matters [Member]",
        "terseLabel": "Other Matters"
       }
      }
     },
     "localname": "OtherMattersMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other Revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PaymentsForRestructuringAndLitigationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments against reserves for restructuring charges and litigation costs, which may include attorneys' fees and other litigation costs.",
        "label": "Payments for Restructuring and Litigation Costs",
        "negatedLabel": "Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements"
       }
      }
     },
     "localname": "PaymentsForRestructuringAndLitigationCosts",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_PercentageInvesteeResultsReflected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the investee's results accounted for under the equity method",
        "label": "Percentage Investee Results Reflected",
        "terseLabel": "Percentage of investee results reflected on date of acquisition"
       }
      }
     },
     "localname": "PercentageInvesteeResultsReflected",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "thc_PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net operating revenues generated by the entity's general hospitals",
        "label": "Percentage Of Net Operating Revenues Generated By General Hospitals",
        "terseLabel": "Revenue generated by general hospitals"
       }
      }
     },
     "localname": "PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_PerformanceBasedRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Restricted Stock Unit",
        "label": "Performance Based Restricted Stock Unit [Member]",
        "terseLabel": "Performance Based Restricted Stock Unit"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PerformanceBasedVestingAndSettledImmediatelyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Vesting And Settled Immediately",
        "label": "Performance Based Vesting And Settled Immediately [Member]",
        "terseLabel": "Performance Based Vesting And Settled Immediately"
       }
      }
     },
     "localname": "PerformanceBasedVestingAndSettledImmediatelyMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PerformanceBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Vesting [Member]",
        "label": "Performance Based Vesting [Member]",
        "terseLabel": "Performance-based vesting"
       }
      }
     },
     "localname": "PerformanceBasedVestingMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PerformanceBasedVestingOnFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Vesting On Fourth Anniversary [Member]",
        "label": "Performance Based Vesting On Fourth Anniversary [Member]",
        "terseLabel": "Performance Based Vesting On Fourth Anniversary"
       }
      }
     },
     "localname": "PerformanceBasedVestingOnFourthAnniversaryMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PerformanceBasedVestingOverAThreeYearPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Vesting Over A Three Year Period [Member]",
        "label": "Performance Based Vesting Over A Three Year Period [Member]",
        "terseLabel": "Performance Based Vesting Over A Three Year Period"
       }
      }
     },
     "localname": "PerformanceBasedVestingOverAThreeYearPeriodMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period In Which The Advanced Rated Is Increased And Limit On Certain Eligible Accounts Receivable Are Raised",
        "label": "Period In Which The Advanced Rated Is Increased And Limit On Certain Eligible Accounts Receivable Are Raised",
        "terseLabel": "Incremental period"
       }
      }
     },
     "localname": "PeriodInWhichTheAdvancedRatedIsIncreasedAndLimitOnCertainEligibleAccountsReceivableAreRaised",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_PhiladelphiaBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Philadelphia Building",
        "label": "Philadelphia Building [Member]",
        "terseLabel": "Philadelphia Building"
       }
      }
     },
     "localname": "PhiladelphiaBuildingMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PhysicianAndGroupCoverageGuaranteesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physician And Group Coverage Guarantees Current",
        "label": "Physician And Group Coverage Guarantees Current",
        "terseLabel": "Guarantees"
       }
      }
     },
     "localname": "PhysicianAndGroupCoverageGuaranteesCurrent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Government Assistance, Including Contributions From Affiliates",
        "label": "Proceeds From Government Assistance, Including Contributions From Affiliates",
        "terseLabel": "Received cash payments"
       }
      }
     },
     "localname": "ProceedsFromGovernmentAssistanceIncludingContributionsFromAffiliates",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ProceedsFromGrantsFromAffiliatesNetOfRecoupment": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Grants From Affiliates, Net Of Recoupment",
        "label": "Proceeds From Grants From Affiliates, Net Of Recoupment",
        "terseLabel": "Medicare advances and grants received by unconsolidated affiliates, net of recoupment"
       }
      }
     },
     "localname": "ProceedsFromGrantsFromAffiliatesNetOfRecoupment",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (trading, held-to-maturity, or available-for-sale) during the period. Sale of long term investments and the sale of other assets not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale of Marketable Securities Long Term Investments and Other Assets",
        "terseLabel": "Proceeds from sales of marketable securities, long-term investments and other assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ProfessionalAndGeneralLiabilityReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Professional and General Liability Reserves in reference to the Balance Sheet.",
        "label": "Professional And General Liability Reserves [Member]",
        "terseLabel": "Professional and General Liability Reserves"
       }
      }
     },
     "localname": "ProfessionalAndGeneralLiabilityReservesMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_PropertyInsuranceAnnualCoverageLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Insurance, Annual Coverage Limit",
        "label": "Property Insurance, Annual Coverage Limit",
        "terseLabel": "Insurance coverage, aggregate limit"
       }
      }
     },
     "localname": "PropertyInsuranceAnnualCoverageLimit",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_PropertyInsuranceDeductible": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Insurance, Deductible",
        "label": "Property Insurance, Deductible",
        "terseLabel": "Insurance deductible"
       }
      }
     },
     "localname": "PropertyInsuranceDeductible",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_PropertyInsuranceDeductiblePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of risk retained by the entity before the insurance arrangement begins to provide coverage.",
        "label": "Property Insurance, Deductible, Percentage",
        "verboseLabel": "Insurance deductible (percentage)"
       }
      }
     },
     "localname": "PropertyInsuranceDeductiblePercentage",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_PropertyInsuranceMaximumCoveragePerIncident": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Insurance, Maximum Coverage Per Incident",
        "label": "Property Insurance, Maximum Coverage Per Incident",
        "terseLabel": "Property insurance coverage"
       }
      }
     },
     "localname": "PropertyInsuranceMaximumCoveragePerIncident",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This entire disclosure represents information pertaining to property and professional and general liability insurance.",
        "label": "Property Professional and General Liability Insurance Disclosure [Text Block]",
        "terseLabel": "INSURANCE"
       }
      }
     },
     "localname": "PropertyProfessionalAndGeneralLiabilityInsuranceDisclosureTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_PropertyandProfessionalandGeneralLiablityInsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Professional and General Liablity Insurance [Abstract]",
        "terseLabel": "Property and Professional and General Liablity Insurance [Abstract]"
       }
      }
     },
     "localname": "PropertyandProfessionalandGeneralLiablityInsuranceAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "thc_PurchasedEquityInJointVenturePercentageOfTotalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased Equity In Joint Venture, Percentage Of Total Shares",
        "label": "Purchased Equity In Joint Venture, Percentage Of Total Shares",
        "terseLabel": "Purchased equity In joint venture, percentage of total shares (percentage)"
       }
      }
     },
     "localname": "PurchasedEquityInJointVenturePercentageOfTotalShares",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "thc_ReceivablesFromGovernmentProgramsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables from government programs Current",
        "label": "Receivables from government programs Current",
        "terseLabel": "Receivables from other government programs"
       }
      }
     },
     "localname": "ReceivablesFromGovernmentProgramsCurrent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redeemable noncontrolling interests.",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_RestructuringSettlementImpairmentProvisionsAndAcquisitionCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period and acquisition-related costs. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).",
        "label": "Restructuring Settlement Impairment Provisions and Acquisition Cost",
        "negatedLabel": "Impairment and restructuring charges, and acquisition-related costs",
        "terseLabel": "Impairment and restructuring charges, and acquisition-related costs",
        "verboseLabel": "Impairment and restructuring charges, and acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringSettlementImpairmentProvisionsAndAcquisitionCost",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of classification of deferred tax assets and liabilities recognized in the entity's statement of financial position.",
        "label": "Schedule of Classification of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Deferred Tax Assets and Liabilities and the Corresponding Amounts Reported in the Accompanying Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfClassificationOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_ScheduleOfEstimatedCostForCharityCareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated costs for providing charity care to patients.",
        "label": "Schedule of Estimated Cost for Charity Care [Table Text Block]",
        "terseLabel": "Schedule of Estimated Costs for Charity Care and Self-Pay Patients"
       }
      }
     },
     "localname": "ScheduleOfEstimatedCostForCharityCareTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_ScheduleOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of DMC Pension Plan Assets Measured at Fair Value on a Recurring Basis Aggregated by the Level in the Fair Value Hierarchy"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_ScheduleOfGrantFundsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Grant Funds",
        "label": "Schedule Of Grant Funds [Table Text Block]",
        "terseLabel": "Schedule of Grant Funds Received And Grant Income"
       }
      }
     },
     "localname": "ScheduleOfGrantFundsTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of funded status of plans, the amounts included in the Consolidated Balance Sheets and the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.",
        "label": "Schedule of Net Funded Status Amounts Recognized in Balance Sheet and Assumptions Used for Projected Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Funded Status of Plans, the Amounts included in the Consolidated Balance Sheets and Assumptions Used for Projected Benefit Obligations"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusAmountsRecognizedInBalanceSheetAndAssumptionsUsedForProjectedBenefitObligationsTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions",
        "label": "Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "thc_SegmentReportingTransferOfAssetsPercentageOfTotalAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting, Transfer Of Assets, Percentage Of Total Assets",
        "label": "Segment Reporting, Transfer Of Assets, Percentage Of Total Assets",
        "terseLabel": "Percentage of assets transferred between segments"
       }
      }
     },
     "localname": "SegmentReportingTransferOfAssetsPercentageOfTotalAssets",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_SelfPayPatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self-Pay Patients [Member]",
        "label": "Self-Pay Patients [Member]",
        "terseLabel": "Uninsured patients"
       }
      }
     },
     "localname": "SelfPayPatientsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SeniorOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Officer [Member]",
        "label": "Senior Officer [Member]",
        "terseLabel": "Senior Officer"
       }
      }
     },
     "localname": "SeniorOfficerMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seven Point Five Zero Percent Senior Secured Note, Due 2025",
        "label": "Seven Point Five Zero Percent Senior Secured Note, Due 2025 [Member]",
        "terseLabel": "7.500% due 2025"
       }
      }
     },
     "localname": "SevenPointFiveZeroPercentSeniorSecuredNoteDue2025Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seven Point Zero Percent Senior Unsecured Note, Due 2025 [Member]",
        "label": "Seven Point Zero Percent Senior Unsecured Note, Due 2025 [Member]",
        "terseLabel": "7.500% due 2025"
       }
      }
     },
     "localname": "SevenPointZeroPercentSeniorUnsecuredNoteDue2025Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Quarterly Periods",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Quarterly Periods",
        "terseLabel": "Award vesting period, number of quarterly periods"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfQuarterlyPeriods",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of eligible earnings that can be contributed by the employees towards the quarterly purchase of the entity's common stock.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Contribution by Eligible Employees Percent",
        "terseLabel": "Base earnings elected to be withheld each quarter by eligible employees to purchase shares of the entity's common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeesPercent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares of common stock into which a share-based award can be converted in the future.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Convertible in Number of Shares",
        "terseLabel": "Contractual right to receive shares of common stock for a stock based award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConvertibleInNumberOfShares",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum fair market value of shares which an employee can purchase in an year.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Maximum Fair Market Value of Shares Per Employee",
        "terseLabel": "Fair market value per employee per year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairMarketValueOfSharesPerEmployee",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award, Number Of Allocated Shares, Percent",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Allocated Shares, Percent",
        "terseLabel": "Percent of common stock allocated to plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAllocatedSharesPercent",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Exercise Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Vesting Period",
        "terseLabel": "Vesting period, days to be exercised before termination"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableVestingPeriod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of a certain classification of awards in a stock based compensation plan to the total of a particular category of awards.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage",
        "terseLabel": "Share based payment award options outstanding percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Payment For Repurchase Of Vested Options And Plan Termination",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Payment For Repurchase Of Vested Options And Plan Termination",
        "terseLabel": "Expected payment for vested securities and termination of plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPaymentForRepurchaseOfVestedOptionsAndPlanTermination",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the requisite holding period for shares issued under plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Requisite Holding Period of Shares",
        "terseLabel": "Requisite holding period for shares issued under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteHoldingPeriodOfShares",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_ShareBasedCompensationAwardTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Award, Tranche Four",
        "label": "Share-Based Compensation Award, Tranche Four [Member]",
        "terseLabel": "Tranche Four"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SharePurchaseAgreementAmountOfPaymentForMinorityInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Amount Of Payment for Minority Interest",
        "label": "Share Purchase Agreement, Amount Of Payment for Minority Interest",
        "terseLabel": "Share purchase agreement amount of payment"
       }
      }
     },
     "localname": "SharePurchaseAgreementAmountOfPaymentForMinorityInterest",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_SharePurchaseAgreementMonthlyPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Monthly Payment",
        "label": "Share Purchase Agreement, Monthly Payment",
        "terseLabel": "Share purchase agreement, monthly payment"
       }
      }
     },
     "localname": "SharePurchaseAgreementMonthlyPayment",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_SharePurchaseAgreementNumberOfMonthlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Number Of Monthly Payments",
        "label": "Share Purchase Agreement, Number Of Monthly Payments",
        "terseLabel": "Number of monthly payments of share purchase agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementNumberOfMonthlyPayments",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "thc_SharePurchaseAgreementPaymentForExecution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Payment For Execution",
        "label": "Share Purchase Agreement, Payment For Execution",
        "terseLabel": "Share purchase agreement, payment for execution"
       }
      }
     },
     "localname": "SharePurchaseAgreementPaymentForExecution",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued And Share-Based Compensation Expense, Value, Share-Based Payment Arrangement, After Forfeiture",
        "label": "Shares Issued And Share-Based Compensation Expense, Value, Share-Based Payment Arrangement, After Forfeiture",
        "terseLabel": "Stock-based compensation expense, tax benefit and issuance of common stock"
       }
      }
     },
     "localname": "SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Eight Seven Five Percent Senior Unsecured Note, Due 2031",
        "label": "Six Point Eight Seven Five Percent Senior Unsecured Note, Due 2031 [Member]",
        "terseLabel": "6.875% due 2031"
       }
      }
     },
     "localname": "SixPointEightSevenFivePercentSeniorUnsecuredNoteDue2031Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point One Two Five Percent Senior Secured First Lien Note, Due 2030",
        "label": "Six Point One Two Five Percent Senior Secured First Lien Note, Due 2030 [Member]",
        "terseLabel": "6.125% due 2030"
       }
      }
     },
     "localname": "SixPointOneTwoFivePercentSeniorSecuredFirstLienNoteDue2030Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point One Two Five Percent Senior Unsecured Note Due 2028",
        "label": "Six Point One Two Five Percent Senior Unsecured Note Due 2028 [Member]",
        "terseLabel": "6.125% due 2028"
       }
      }
     },
     "localname": "SixPointOneTwoFivePercentSeniorUnsecuredNoteDue2028Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 6.75 percent senior notes, due 2023 issued by the reporting entity.",
        "label": "Six Point Seven Five Percent Senior Unsecured Note, Due 2023 [Member]",
        "terseLabel": "6.750% due 2023"
       }
      }
     },
     "localname": "SixPointSevenFivePercentSeniorUnsecuredNoteDue2023Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Two Five Zero Percent Senior Secured Second Lien Note, Due 2027 [Member]",
        "label": "Six Point Two Five Zero Percent Senior Secured Second Lien Note, Due 2027 [Member]",
        "terseLabel": "6.250% due 2027"
       }
      }
     },
     "localname": "SixPointTwoFiveZeroPercentSeniorSecuredSecondLienNoteDue2027Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_StockIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2019 [Member]",
        "label": "Stock Incentive Plan 2019 [Member]",
        "terseLabel": "2019 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2019Member",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents value per share for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Weighted Average Price Per Share Employee Stock Purchase Plan",
        "terseLabel": "Weighted average price (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodWeightedAveragePricePerShareEmployeeStockPurchasePlan",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "thc_TenetHealthcareCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenet Healthcare Corp [Member]",
        "label": "Tenet Healthcare Corp [Member]",
        "verboseLabel": "Tenet"
       }
      }
     },
     "localname": "TenetHealthcareCorpMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TexasHealthVenturesGroupLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to the Texas Health Ventures Group, LLC",
        "label": "Texas Health Ventures Group Llc [Member]",
        "terseLabel": "Texas Health Ventures Group, LLC"
       }
      }
     },
     "localname": "TexasHealthVenturesGroupLlcMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, Evenly On The Third And Fourth Anniversary",
        "label": "Time Based Vesting, Evenly On The Third And Fourth Anniversary [Member]",
        "terseLabel": "Time Based Vesting, Evenly On The Third And Fourth Anniversary"
       }
      }
     },
     "localname": "TimeBasedVestingEvenlyOnTheThirdAndFourthAnniversaryMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingFourYearFromGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, Four Year From Grant Date",
        "label": "Time Based Vesting, Four Year From Grant Date [Member]",
        "terseLabel": "Time Based Vesting, Four Year From Grant Date"
       }
      }
     },
     "localname": "TimeBasedVestingFourYearFromGrantDateMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting [Member]",
        "label": "Time Based Vesting [Member]",
        "terseLabel": "Time-vesting"
       }
      }
     },
     "localname": "TimeBasedVestingMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingOnFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting On Fourth Anniversary",
        "label": "Time Based Vesting On Fourth Anniversary [Member]",
        "terseLabel": "Time Based Vesting On Fourth Anniversary"
       }
      }
     },
     "localname": "TimeBasedVestingOnFourthAnniversaryMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingOneYearFromGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, One Year From Grant Date",
        "label": "Time Based Vesting, One Year From Grant Date [Member]",
        "terseLabel": "Time Based Vesting, One Year From Grant Date"
       }
      }
     },
     "localname": "TimeBasedVestingOneYearFromGrantDateMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, Ratably Over Three Year Period From Grant Date",
        "label": "Time Based Vesting, Ratably Over Three Year Period From Grant Date [Member]",
        "terseLabel": "Time Based Vesting, Three Year Period from Grant Date"
       }
      }
     },
     "localname": "TimeBasedVestingRatablyOverThreeYearPeriodFromGrantDateMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingSettledOnFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, Settled On Fourth Anniversary",
        "label": "Time Based Vesting, Settled On Fourth Anniversary [Member]",
        "terseLabel": "Time Based Vesting, Settled On Fourth Anniversary"
       }
      }
     },
     "localname": "TimeBasedVestingSettledOnFourthAnniversaryMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingSettledOnSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, Settled on Second Anniversary",
        "label": "Time Based Vesting, Settled on Second Anniversary [Member]",
        "terseLabel": "Time Based Vesting, Settled on Second Anniversary"
       }
      }
     },
     "localname": "TimeBasedVestingSettledOnSecondAnniversaryMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_TimeBasedVestingSettledOnThirdAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Based Vesting, Settled On Third Anniversary",
        "label": "Time Based Vesting, Settled On Third Anniversary [Member]",
        "terseLabel": "Time Based Vesting, Settled On Third Anniversary"
       }
      }
     },
     "localname": "TimeBasedVestingSettledOnThirdAnniversaryMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_USPIManagementEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "USPI Management Equity Plan",
        "label": "USPI Management Equity Plan [Member]",
        "terseLabel": "USPI Management Equity Plan"
       }
      }
     },
     "localname": "USPIManagementEquityPlanMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_UnitedSurgicalPartnersInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to United Surgical Partners International, Inc., acquired by the entity.",
        "label": "United Surgical Partners International [Member]",
        "terseLabel": "United Surgical Partners International"
       }
      }
     },
     "localname": "UnitedSurgicalPartnersInternationalMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_UnitedUrologyGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Urology Group",
        "label": "United Urology Group [Member]",
        "terseLabel": "United Urology Group"
       }
      }
     },
     "localname": "UnitedUrologyGroupMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_UrgentCareCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Urgent Care Centers",
        "label": "Urgent Care Centers [Member]",
        "terseLabel": "Urgent Care Centers"
       }
      }
     },
     "localname": "UrgentCareCentersMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Change In Tax Accounting Method",
        "label": "Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Change In Tax Accounting Method",
        "terseLabel": "Increase (decrease) in deferred tax valuation allowance due to a change in tax accounting method"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangeInTaxAccountingMethod",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of change in the period, in the valuation allowance attributable due to changes in expected realizability of deferred tax assets",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount Attributable To Changes In Expected Realizability of Deferred Tax Assets",
        "terseLabel": "Increase (decrease) in valuation allowance due to changes in expected realizability of deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToChangesInExpectedRealizabilityOfDeferredTaxAssets",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Expiration Or Worthlessness Of Unutilized State Net Operating Loss Carryovers",
        "label": "Valuation Allowance, Deferred Tax Asset, Change In Amount Attributable To Expiration Or Worthlessness Of Unutilized State Net Operating Loss Carryovers",
        "negatedTerseLabel": "Decrease in valuation allowance due to changes based on expiration or worthlessness of unutilized state net operating loss carryovers"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToExpirationOrWorthlessnessOfUnutilizedStateNetOperatingLossCarryovers",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Due To Interest Expense Limitations",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Due To Interest Expense Limitations",
        "terseLabel": "Increase (decrease) in valuation allowance due to limitations on deductions of interest expense"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmountDueToInterestExpenseLimitations",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_ValuationAllowancesAndReservesReservesOfBusinessesSold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, related to a business sold.",
        "label": "Valuation Allowances and Reserves, Reserves of Businesses Sold",
        "terseLabel": "Other Items"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesReservesOfBusinessesSold",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_VariableAndShorttermLeaseCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable And Short-term Lease, Costs",
        "label": "Variable And Short-term Lease, Costs",
        "terseLabel": "Variable and short term-lease expense"
       }
      }
     },
     "localname": "VariableAndShorttermLeaseCosts",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "thc_WindstormsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Localized violently destructive windstorm characterized by a funnel shaped cloud.",
        "label": "Windstorms [Member]",
        "terseLabel": "Windstorms"
       }
      }
     },
     "localname": "WindstormsMember",
     "nsuri": "http://www.tenethealth.com/20221231",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts receivable and allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails",
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails",
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable Additional Disclosures [Abstract]",
        "terseLabel": "Accounts Receivable Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "AccountsReceivableAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r318",
      "r457",
      "r458",
      "r925"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "California provider fee program receivables",
        "terseLabel": "Other current assets",
        "totalLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEComponentsDetails",
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetNoncurrent": {
     "auth_ref": [
      "r457",
      "r869",
      "r876"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestmentsAndReceivablesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "California provider fee program receivables",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "AccountsReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r55",
      "r61",
      "r243",
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Adjustments for defined benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r338",
      "r339",
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Unrealized gains on investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r320",
      "r877",
      "r892",
      "r896"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r337",
      "r338",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r61",
      "r243",
      "r851",
      "r887",
      "r888",
      "r989",
      "r990",
      "r991",
      "r1011",
      "r1012",
      "r1013"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r53",
      "r61",
      "r243",
      "r338",
      "r339",
      "r809",
      "r810",
      "r811",
      "r812",
      "r814",
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r33",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r1011",
      "r1012",
      "r1013",
      "r1159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r374",
      "r375",
      "r376",
      "r378",
      "r389",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r704",
      "r705",
      "r706",
      "r732",
      "r733",
      "r734",
      "r735",
      "r756",
      "r757",
      "r758",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r803",
      "r804",
      "r816",
      "r817",
      "r821",
      "r822",
      "r823",
      "r824",
      "r845",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r861",
      "r862",
      "r863",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r162",
      "r169",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "negatedLabel": "Accretion of redeemable noncontrolling interests"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r699"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation costs, pretax",
        "verboseLabel": "Stock-based compensation costs"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r551",
      "r819",
      "r940",
      "r941",
      "r1000"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r121",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r89",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r263",
      "r281",
      "r314",
      "r354",
      "r430",
      "r442",
      "r448",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r762",
      "r766",
      "r793",
      "r968",
      "r1054",
      "r1055",
      "r1171"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r307",
      "r324",
      "r354",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r762",
      "r766",
      "r793",
      "r968",
      "r1054",
      "r1055",
      "r1171"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r354",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r762",
      "r766",
      "r793",
      "r1054",
      "r1055",
      "r1171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails",
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails",
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankOverdrafts": {
     "auth_ref": [
      "r41",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.",
        "label": "Bank Overdrafts",
        "terseLabel": "Book overdrafts classified as accounts payable"
       }
      }
     },
     "localname": "BankOverdrafts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BankruptcyClaimsAmountPaidToSettleClaims": {
     "auth_ref": [
      "r1170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount paid to settle bankruptcy claim.",
        "label": "Bankruptcy Claims, Amount Paid to Settle Claims",
        "verboseLabel": "Bankruptcy claims, amount paid to settle claims"
       }
      }
     },
     "localname": "BankruptcyClaimsAmountPaidToSettleClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r754",
      "r954",
      "r957"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r754",
      "r954",
      "r957"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r1156",
      "r1157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share available to Tenet Healthcare Corporation common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r1156",
      "r1157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r752",
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "verboseLabel": "Net income available to Tenet Healthcare Corporation common shareholders"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r752",
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net operating revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Noncontrolling interests",
        "terseLabel": "Business combination acquisition noncontrolling interest, fair value"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r228",
      "r229",
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration conveyed in the acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Final purchase price allocations"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Debt incurred in acquisition of surgical centers"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities",
        "negatedTerseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Gains on consolidations"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Lease termination costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases for items received but not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortized customer contract costs"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Unamortized contract costs"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r91",
      "r309",
      "r923"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r91",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r256"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r13",
      "r86"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities from discontinued operations, excluding income taxes"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashSurrenderValueOfLifeInsurance": {
     "auth_ref": [
      "r986"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermInvestmentsAndReceivablesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity.",
        "label": "Cash Surrender Value of Life Insurance",
        "terseLabel": "Cash surrender value of life insurance policies"
       }
      }
     },
     "localname": "CashSurrenderValueOfLifeInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CatastrophicEventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion.",
        "label": "Catastrophic Event [Domain]",
        "terseLabel": "Catastrophic Event [Domain]"
       }
      }
     },
     "localname": "CatastrophicEventDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r354",
      "r395",
      "r396",
      "r403",
      "r405",
      "r412",
      "r413",
      "r468",
      "r516",
      "r519",
      "r520",
      "r521",
      "r527",
      "r528",
      "r558",
      "r559",
      "r562",
      "r566",
      "r572",
      "r793",
      "r911",
      "r981",
      "r1001",
      "r1022"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r270",
      "r286"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r509",
      "r510",
      "r904",
      "r1053"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "CLAIMS AND LAWSUITS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Accruals for General and Professional Liability Risks"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r1011",
      "r1012",
      "r1159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, number of shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.05 par value; authorized 262,500,000 shares; 156,462,456 shares issued at December\u00a031,\u00a02022 and 155,520,691 shares issued at December\u00a031,\u00a02021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Provision for income taxes for continuing operations"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r333",
      "r335",
      "r344",
      "r873",
      "r881"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income available to Tenet Healthcare Corporation common shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r236",
      "r237",
      "r247",
      "r333",
      "r335",
      "r343",
      "r872",
      "r880"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r235",
      "r247",
      "r333",
      "r335",
      "r342",
      "r871",
      "r879"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive net income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r73",
      "r341",
      "r870",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r964",
      "r1038",
      "r1039"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Capitalized software costs"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r253",
      "r254",
      "r903"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r240",
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Opening and Closing Balances of Contracts Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract Assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r574",
      "r576",
      "r598"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerDurationAxis": {
     "auth_ref": [
      "r947",
      "r1059"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Axis]",
        "terseLabel": "Contract with Customer, Duration [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerDurationDomain": {
     "auth_ref": [
      "r947",
      "r1059"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Domain]",
        "terseLabel": "Contract with Customer, Duration [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r574",
      "r575",
      "r598"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Contract liabilities \u2013 long-term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract liabilities advance payments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": {
     "auth_ref": [
      "r574",
      "r577",
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss, Current",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r950",
      "r952",
      "r1185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Costs Associated With Exit or Disposal Activities"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r1004",
      "r1153",
      "r1155"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r215",
      "r729",
      "r742",
      "r1004"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current tax expense:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r1004",
      "r1153",
      "r1155"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r269",
      "r287"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r352",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r545",
      "r552",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r264",
      "r266",
      "r280",
      "r360",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r820",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Percentage margin on variable rate (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r26",
      "r266",
      "r280",
      "r556"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r259",
      "r261",
      "r529",
      "r820",
      "r938",
      "r939"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "LONG-TERM DEBT AND LEASE OBLIGATIONS"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r360",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r820",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased face amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r170",
      "r171",
      "r172",
      "r173",
      "r258",
      "r259",
      "r261",
      "r278",
      "r360",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r820",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r260",
      "r541",
      "r557",
      "r938",
      "r939"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized issue costs and note discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r1004",
      "r1154",
      "r1155"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r711",
      "r712"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "thc_DeferredIncomeTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r215",
      "r730",
      "r741",
      "r742",
      "r1004"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred tax expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r29",
      "r30",
      "r265",
      "r279",
      "r723"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred tax liabilities, gross, total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r711",
      "r712"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "thc_DeferredIncomeTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r211",
      "r214",
      "r1004"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r988"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r1004",
      "r1154",
      "r1155"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "terseLabel": "Charitable contribution carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1151"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "verboseLabel": "Deferred tax benefit, net of valuation allowance and federal tax impact, associated with NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits": {
     "auth_ref": [
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from postretirement benefits.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits",
        "terseLabel": "Benefit plans"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Severance Payments",
        "terseLabel": "Deferred social security tax payments"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Receivables (doubtful accounts and adjustments)"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges",
        "terseLabel": "Reserves related to discontinued operations and restructuring charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance",
        "terseLabel": "Accruals for retained insurance risks"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r725"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r200",
      "r1151"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred tax liabilities, total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r210",
      "r1152"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Depreciation and fixed-asset differences"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r56",
      "r61",
      "r1102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r61",
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedLabel": "Cumulative net actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r617",
      "r952"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Gain (loss) on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedLabel": "Actuarial gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r604",
      "r641",
      "r658",
      "r952",
      "r953"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Amortization of net actuarial loss",
        "terseLabel": "Amortization of net actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r604",
      "r642",
      "r659",
      "r952",
      "r953"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Unrecognized prior service costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts recognized in the Consolidated Balance Sheets consist of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Compensation increase rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r649",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Long-term rate of return on assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Compensation increase rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "negatedPeriodEndLabel": "Ending obligations",
        "negatedPeriodStartLabel": "Beginning obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r651",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Projected benefit obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Fair value of plans assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r619",
      "r628",
      "r662",
      "r950",
      "r951",
      "r952",
      "r953"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDebtSecurityMember": {
     "auth_ref": [
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Debt Security [Member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanDebtSecurityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Employee Retirement Plans",
        "verboseLabel": "Weighted-average asset allocations by asset category"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r950",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]",
        "terseLabel": "SERP and DMC Pension Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": 1.0,
       "parentTag": "thc_DefinedBenefitPlanExpectedFutureBenefitPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "Five Years Thereafter"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": 2.0,
       "parentTag": "thc_DefinedBenefitPlanExpectedFutureBenefitPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": 3.0,
       "parentTag": "thc_DefinedBenefitPlanExpectedFutureBenefitPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": 4.0,
       "parentTag": "thc_DefinedBenefitPlanExpectedFutureBenefitPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": 5.0,
       "parentTag": "thc_DefinedBenefitPlanExpectedFutureBenefitPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails": {
       "order": 6.0,
       "parentTag": "thc_DefinedBenefitPlanExpectedFutureBenefitPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r636",
      "r953"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected contribution to the plan for 2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r604",
      "r640",
      "r657",
      "r952",
      "r953"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r616",
      "r627",
      "r628",
      "r629",
      "r950",
      "r951",
      "r952"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Ending plan assets",
        "periodStartLabel": "Beginning plan assets",
        "verboseLabel": "Fair value of DMC Pension Plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r602",
      "r625",
      "r952"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status of plans",
        "verboseLabel": "Benefit plan obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]",
        "terseLabel": "Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r604",
      "r608",
      "r639",
      "r656",
      "r952",
      "r953"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "negatedLabel": "Interest cost",
        "terseLabel": "Interest costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r637",
      "r654",
      "r952",
      "r953"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost (income)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Components of net periodic benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r621",
      "r1122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage": {
     "auth_ref": [
      "r952",
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of investment to total investment within defined benefit plan asset category.",
        "label": "Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Percentage",
        "terseLabel": "Actual"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r626",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "auth_ref": [
      "r950",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "terseLabel": "Real estate securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Accumulated Benefit Obligations Assumptions"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net Periodic Benefit Costs Assumptions:"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r986"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestmentsAndReceivablesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits Assets, Noncurrent"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r89",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r425"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Per-Share Amount"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r597",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r1059"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Sources of Net Operating Revenues Less Provisions for Doubtful Accounts and Implicit Price Concessions"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r672",
      "r700",
      "r701",
      "r703",
      "r707",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r68",
      "r290"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "negatedLabel": "Pre-tax loss (income) from discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r12"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax",
        "terseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r132",
      "r139",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "ASSETS AND LIABILITIES HELD FOR SALE"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r954",
      "r957"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r345",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r392",
      "r395",
      "r403",
      "r404",
      "r405",
      "r409",
      "r779",
      "r780",
      "r874",
      "r882",
      "r933"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Total earnings (loss) per share, Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r345",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r395",
      "r403",
      "r404",
      "r405",
      "r409",
      "r779",
      "r780",
      "r874",
      "r882",
      "r933"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Total earnings (loss) per share, Diluted (in dollars per share)",
        "verboseLabel": "Earnings per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarthquakeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sudden movement of the earth's crust.",
        "label": "Earthquake [Member]",
        "terseLabel": "Earthquakes"
       }
      }
     },
     "localname": "EarthquakeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r169",
      "r300",
      "r337",
      "r338",
      "r339",
      "r368",
      "r369",
      "r370",
      "r375",
      "r385",
      "r388",
      "r411",
      "r473",
      "r573",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r778",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r814",
      "r851",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r306",
      "r354",
      "r468",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r306",
      "r354",
      "r468",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r984",
      "r1003",
      "r1026",
      "r1160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Unconsolidated affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r114",
      "r431",
      "r985"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r85",
      "r116",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments in Unconsolidated Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt retirement"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r785",
      "r786",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r543",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r786",
      "r853",
      "r854",
      "r855",
      "r938",
      "r939",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails",
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r543",
      "r628",
      "r633",
      "r786",
      "r853",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r543",
      "r628",
      "r633",
      "r786",
      "r854",
      "r938",
      "r939",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails",
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r543",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r786",
      "r855",
      "r938",
      "r939",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r543",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r853",
      "r854",
      "r855",
      "r938",
      "r939",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails",
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r790",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r830",
      "r836",
      "r967"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "thc_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r832",
      "r838"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r828",
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 1.0,
       "parentTag": "thc_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Less: Current obligations",
        "verboseLabel": "Finance lease liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Finance Lease Liability Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations",
        "verboseLabel": "Finance lease liabilities, long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Later years"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r843"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r831",
      "r838"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r827"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 2.0,
       "parentTag": "thc_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r830",
      "r836",
      "r967"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "thc_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r1163"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r841",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, finance leases (percentage)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r840",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years), finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancingReceivablesTextBlock": {
     "auth_ref": [
      "r459",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financing receivable.",
        "label": "Financing Receivables [Text Block]",
        "terseLabel": "ACCOUNTS RECEIVABLE"
       }
      }
     },
     "localname": "FinancingReceivablesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r313",
      "r497"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "terseLabel": "Other intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Later Years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r494",
      "r496",
      "r497",
      "r499",
      "r860",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated future amortization of intangibles with finite useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r127",
      "r867"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Information regarding other intangible assets",
        "verboseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r127",
      "r860"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationDetails",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FloodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overflowing of a body of water.",
        "label": "Flood [Member]",
        "terseLabel": "Floods"
       }
      }
     },
     "localname": "FloodMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Translation of Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r1000"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net gains from the sale of investments and long-lived assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfProperties": {
     "auth_ref": [
      "r1000",
      "r1040",
      "r1045"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.",
        "label": "Gain (Loss) on Sale of Properties",
        "terseLabel": "Gain (loss) on sale of properties",
        "verboseLabel": "Gain on sale of properties"
       }
      }
     },
     "localname": "GainLossOnSaleOfProperties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails",
      "http://www.tenethealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r1047"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Litigation and investigation costs",
        "negatedTerseLabel": "Litigation and investigation costs",
        "terseLabel": "Litigation and investigation costs"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r89",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss from early extinguishment of debt",
        "netLabel": "Loss from early extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r312",
      "r482",
      "r868",
      "r936",
      "r968",
      "r1027",
      "r1034"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill at end of period",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r483",
      "r490",
      "r936"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "periodEndLabel": "Goodwill, gross, at end of period",
        "periodStartLabel": "Goodwill, gross, at beginning of period"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r483",
      "r490",
      "r936"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "negatedPeriodEndLabel": "Accumulated impairment losses",
        "negatedPeriodStartLabel": "Accumulated impairment losses",
        "terseLabel": "Accumulated impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r216",
      "r1033"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, purchase accounting adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTransfers": {
     "auth_ref": [
      "r1033"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Transfers",
        "terseLabel": "Goodwill transferred"
       }
      }
     },
     "localname": "GoodwillTransfers",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of guarantee.",
        "label": "Guarantor Obligations, Nature [Axis]",
        "terseLabel": "Guarantor Obligations, Nature [Axis]"
       }
      }
     },
     "localname": "GuaranteeObligationsByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Guarantor Obligations [Line Items]",
        "terseLabel": "GUARANTEES"
       }
      }
     },
     "localname": "GuaranteeObligationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "terseLabel": "Maximum potential amount of future payments under guarantees"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Nature [Domain]",
        "terseLabel": "Guarantor Obligations, Nature [Domain]"
       }
      }
     },
     "localname": "GuaranteeObligationsNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteeOfBusinessRevenueMember": {
     "auth_ref": [
      "r147",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts that contingently require the indemnifying party (guarantor) to make payments to the indemnified party (guaranteed party) the amount by which the revenue of a specified business (or a specific portion of a business or for a specified product) for a specified period of time is less than a specified amount.",
        "label": "Guarantee of Business Revenue [Member]",
        "terseLabel": "Guarantee of Business Revenue"
       }
      }
     },
     "localname": "GuaranteeOfBusinessRevenueMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantees [Abstract]",
        "terseLabel": "Guarantees [Abstract]"
       }
      }
     },
     "localname": "GuaranteesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteesFairValueDisclosure": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of guarantee, including, but not limited to, financial standby letter of credit, fair value guarantee, guarantee of collection of scheduled contractual cash flows from financial assets, and contracts that contingently require the guarantor to make payments or perform services.",
        "label": "Guarantees, Fair Value Disclosure",
        "terseLabel": "Liability for guarantees"
       }
      }
     },
     "localname": "GuaranteesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteesTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.",
        "label": "Guarantees [Text Block]",
        "terseLabel": "GUARANTEES"
       }
      }
     },
     "localname": "GuaranteesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOrganizationHealthCareCostsGross": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported).",
        "label": "Health Care Organization, Expenses, Gross",
        "terseLabel": "Estimated costs of caring"
       }
      }
     },
     "localname": "HealthCareOrganizationHealthCareCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r1060"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Net patient service revenues"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgeFundsMember": {
     "auth_ref": [
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in registered hedge funds.",
        "label": "Hedge Funds [Member]",
        "terseLabel": "Hedge funds"
       }
      }
     },
     "localname": "HedgeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]"
       }
      }
     },
     "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]",
        "terseLabel": "Amounts available to Tenet Healthcare Corporation common shareholders"
       }
      }
     },
     "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r69",
      "r90",
      "r234",
      "r379",
      "r380",
      "r382",
      "r383",
      "r401",
      "r405"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations, net of tax",
        "verboseLabel": "Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r262",
      "r273",
      "r292",
      "r430",
      "r441",
      "r447",
      "r450",
      "r875",
      "r935"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations, before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r355",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedTerseLabel": "Foreign pretax loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r235",
      "r354",
      "r374",
      "r430",
      "r441",
      "r447",
      "r450",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r780",
      "r793",
      "r935",
      "r1054"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income from continuing operations, before discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r65",
      "r271",
      "r274",
      "r289",
      "r345",
      "r374",
      "r379",
      "r380",
      "r382",
      "r383",
      "r395",
      "r403",
      "r404",
      "r780",
      "r874"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations (in dollars per share)",
        "verboseLabel": "Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r65",
      "r289",
      "r291",
      "r345",
      "r374",
      "r379",
      "r380",
      "r382",
      "r383",
      "r395",
      "r403",
      "r404",
      "r405",
      "r780",
      "r874",
      "r882"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations (in dollars per share)",
        "totalLabel": "Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r15",
      "r290",
      "r306",
      "r748"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income (loss) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Discontinued operations:"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r235"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income (loss) from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r68",
      "r290",
      "r291",
      "r345",
      "r396",
      "r403",
      "r404",
      "r1179",
      "r1181"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r248",
      "r396",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r67",
      "r89",
      "r114",
      "r272",
      "r288",
      "r427"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedLabel": "Equity in earnings of unconsolidated affiliates, net of distributions received"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, before Income Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r954",
      "r957"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "verboseLabel": "Current Assets and Liabilities Held for Sale"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r139",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALENarrativeDetails",
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALESignificantComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r500",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r356",
      "r715",
      "r721",
      "r728",
      "r739",
      "r744",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r357",
      "r387",
      "r388",
      "r428",
      "r713",
      "r740",
      "r746",
      "r883"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails",
      "http://www.tenethealth.com/role/INCOMETAXESProvisionandDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation between reported income tax expense (benefit) and income taxes calculated by the statutory federal income tax rate"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r336",
      "r709",
      "r710",
      "r721",
      "r722",
      "r727",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1149"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r714"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Tax expense at statutory federal rate of 21%"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r1149"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount",
        "negatedTerseLabel": "Tax benefit attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r1149"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Nondeductible goodwill"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r1149"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1149"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1149"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESFederalTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "negatedTerseLabel": "Income tax payments, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, contract liabilities and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r999"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "verboseLabel": "Increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r858",
      "r999"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Increase (decrease)",
        "verboseLabel": "Increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in cash from operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r495",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Total other intangible assets with indefinite lives"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r123",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InsuranceRecoveries": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.",
        "label": "Insurance Recoveries",
        "terseLabel": "Insurance recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r120",
      "r125"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Net\u00a0Book Value",
        "verboseLabel": "Other intangible assets, at cost, less accumulated amortization ($1,428 at December\u00a031,\u00a02022 and $1,374 at December\u00a031,\u00a02021)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest costs capitalized related to construction projects"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r260",
      "r276",
      "r340",
      "r424",
      "r818"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r346",
      "r349",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Interest paid, net of capitalized interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r422",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Inter-segment eliminations",
        "verboseLabel": "Inter-segment eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r321",
      "r924",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventories of supplies, at cost"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r467",
      "r1182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r993"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries, wages and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.",
        "label": "Land and Building [Member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "LandAndBuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r1060"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r842",
      "r967"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r1167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Additional Information Related to Lease Expense, Terms and Discount Rates, and Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Later years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r843"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r1165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit Facility"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Standby letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r354",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r763",
      "r766",
      "r767",
      "r793",
      "r934",
      "r1054",
      "r1171",
      "r1172"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r268",
      "r285",
      "r968",
      "r1003",
      "r1026",
      "r1160"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r308",
      "r354",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r763",
      "r766",
      "r767",
      "r793",
      "r968",
      "r1054",
      "r1171",
      "r1172"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "negatedLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r26",
      "r27",
      "r354",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r763",
      "r766",
      "r767",
      "r793",
      "r1054",
      "r1171",
      "r1172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "negatedLabel": "Noncurrent liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion.",
        "label": "Catastrophic Event [Axis]",
        "terseLabel": "Catastrophic Event [Axis]"
       }
      }
     },
     "localname": "LiabilityForCatastropheClaimsByCatastrophicEventAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Amount available for borrowing under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Revolving credit facility, maximum borrowing capacity (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Unused commitment fee (percentage)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermContractWithCustomerMember": {
     "auth_ref": [
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which duration is classified as long-term.",
        "label": "Long-Term Contract with Customer [Member]",
        "terseLabel": "Long-term Contract with Customer"
       }
      }
     },
     "localname": "LongTermContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, net of current portion",
        "verboseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt and Lease Obligation [Abstract]",
        "terseLabel": "Long-term Debt and Lease Obligation [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Less: Current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermInvestmentsAndReceivablesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "totalLabel": "Total investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAndReceivablesNet": {
     "auth_ref": [
      "r987"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value.",
        "label": "Long-Term Investments and Receivables, Net",
        "terseLabel": "Investments and other assets",
        "totalLabel": "Investments and other assets"
       }
      }
     },
     "localname": "LongTermInvestmentsAndReceivablesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails",
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r148",
      "r149",
      "r511",
      "r512",
      "r513",
      "r1048",
      "r1050"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails",
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r511",
      "r982"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Litigation reserve, Balances at End of Period",
        "periodStartLabel": "Litigation reserve, Balances at Beginning of Period"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r1047"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "negatedLabel": "Cash Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r1047"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Reserve of estimated obligation"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MalpracticeLossContingencyClaimsIncurredNet": {
     "auth_ref": [
      "r294",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs associated with malpractice claims and insurance premiums incurred during an accounting period, less insurance recoveries and returns of previously paid premiums.",
        "label": "Malpractice Loss Contingency, Claims Incurred, Net",
        "terseLabel": "Malpractice expense"
       }
      }
     },
     "localname": "MalpracticeLossContingencyClaimsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-Term Debt and Capital Lease Obligations [Abstract]",
        "terseLabel": "Long-term debt, including finance lease obligations"
       }
      }
     },
     "localname": "MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTFutureMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r51",
      "r267",
      "r284",
      "r354",
      "r468",
      "r516",
      "r519",
      "r520",
      "r521",
      "r527",
      "r528",
      "r793"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interests",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "terseLabel": "Accretion of redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestChangeInRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions paid to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r174",
      "r238",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "netLabel": "Purchases and sales of businesses and noncontrolling interests, net",
        "terseLabel": "Purchase and sales of business and noncontrolling interest, net"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage of subsidiary",
        "verboseLabel": "Ownership percentage by parent (percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r51",
      "r70",
      "r233",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Movement in valuation and qualifying accounts"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r241",
      "r246",
      "r331",
      "r334",
      "r387",
      "r388",
      "r991"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income available to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r379",
      "r380",
      "r382",
      "r383",
      "r392",
      "r393",
      "r402",
      "r405",
      "r430",
      "r441",
      "r447",
      "r450",
      "r935"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income available to Tenet Healthcare Corporation common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Net Income Available to Common Shareholders (Numerator)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r394",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r165",
      "r241",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r303",
      "r372",
      "r373",
      "r376",
      "r377",
      "r389",
      "r390",
      "r391",
      "r462",
      "r463",
      "r474",
      "r475",
      "r736",
      "r737",
      "r738",
      "r776",
      "r782",
      "r783",
      "r784",
      "r800",
      "r801",
      "r802",
      "r825",
      "r826",
      "r846",
      "r852",
      "r864",
      "r865",
      "r866",
      "r891",
      "r892",
      "r893",
      "r894",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING STANDARDS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/RECENTACCOUNTINGSTANDARDS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest Items [Abstract]",
        "terseLabel": "Interests acquired and other disclosures"
       }
      }
     },
     "localname": "NoncontrollingInterestItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r232",
      "r573",
      "r1011",
      "r1012",
      "r1013"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonqualifiedPlanMember": {
     "auth_ref": [
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Nonqualified Plan [Member]",
        "terseLabel": "Nonqualified Plan"
       }
      }
     },
     "localname": "NonqualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvotingCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.",
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Nonvoting Common Stock"
       }
      }
     },
     "localname": "NonvotingCommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r26",
      "r266",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Debt instrument payment"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of business acquisitions"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r1024"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r1024"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenOptionContractsWrittenTypeAxis": {
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This axis is used for open option contracts written table to separate the put options from the call options.",
        "label": "Open Option Contracts Written Type [Axis]",
        "terseLabel": "Open Option Contracts Written Type [Axis]"
       }
      }
     },
     "localname": "OpenOptionContractsWrittenTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OpenOptionContractsWrittenTypeDomain": {
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This domain is used for open option contracts written table to separate the put options from the call options.",
        "label": "Open Option Contracts Written Type [Domain]",
        "terseLabel": "Open Option Contracts Written Type [Domain]"
       }
      }
     },
     "localname": "OpenOptionContractsWrittenTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r430",
      "r441",
      "r447",
      "r450",
      "r935"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r837",
      "r967"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 2.0,
       "parentTag": "thc_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESNarrativeDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: Current obligations",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations",
        "verboseLabel": "Operating lease liabilities, long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESScheduleofLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r833",
      "r838"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r827"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails": {
       "order": 1.0,
       "parentTag": "thc_LeaseRightOfUseAsset",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestmentsAndReceivablesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails",
      "http://www.tenethealth.com/role/LEASESNarrativeDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofInvestmentsandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESBalanceSheetComponentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r841",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, operating leases (percentage)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r840",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years), operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r1000",
      "r1044"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Other impairment charges"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r323",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "OTHER ASSETS"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r52",
      "r58",
      "r805",
      "r806",
      "r807"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r115",
      "r341",
      "r808",
      "r813",
      "r814",
      "r870",
      "r878",
      "r989",
      "r990"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income (loss) before income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r169",
      "r332",
      "r335",
      "r341",
      "r808",
      "r813",
      "r814",
      "r870",
      "r878",
      "r989",
      "r990"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r952",
      "r1101"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "negatedLabel": "Adjustments for defined benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r54",
      "r58",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Gain (loss) adjustments recorded in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r58",
      "r62",
      "r330",
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Net actuarial losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r59",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax",
        "verboseLabel": "Tax benefit (expense) allocated to adjustments for defined benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r59",
      "r337",
      "r341",
      "r713",
      "r745",
      "r747",
      "r808",
      "r811",
      "r814",
      "r870",
      "r878"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedLabel": "Income tax benefit (expense) related to items of other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r325",
      "r328",
      "r465"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on debt securities held as available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses, net"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other non-operating income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other Operating Expense, Net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Non-patient receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringCosts": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.",
        "label": "Other Restructuring Costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "OtherRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r994",
      "r995"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other items, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "negatedLabel": "Distributions paid to noncontrolling interests"
       }
      }
     },
     "localname": "PaymentsOfDividendsMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r76",
      "r759"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Purchases of businesses or joint venture interests, net of cash acquired",
        "negatedTerseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of marketable securities and equity investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Purchases of noncontrolling interests",
        "terseLabel": "Payments to noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "verboseLabel": "Claims, Lawsuits, and Regulatory Proceedings"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r25",
      "r602",
      "r603",
      "r625",
      "r952"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Other current liability",
        "terseLabel": "Other current liability"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r28",
      "r602",
      "r603",
      "r625",
      "r952"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Other long-term liability",
        "terseLabel": "Defined benefit plan obligations",
        "verboseLabel": "Defined benefit plan obligations"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r181",
      "r602",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r669",
      "r952",
      "r953",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r651",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r322",
      "r478",
      "r479",
      "r926"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivateEquityFundsMember": {
     "auth_ref": [
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments held in private equity funds.",
        "label": "Private Equity Funds [Member]",
        "terseLabel": "Private equity securities"
       }
      }
     },
     "localname": "PrivateEquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from sales of facilities and other assets"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from borrowings under credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from debt classified as other.",
        "label": "Proceeds from Other Debt",
        "terseLabel": "Proceeds from other borrowings"
       }
      }
     },
     "localname": "ProceedsFromOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r996",
      "r998"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other items, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfBuildings": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of buildings.",
        "label": "Proceeds from Sale of Buildings",
        "terseLabel": "Net proceeds from sale of buildings"
       }
      }
     },
     "localname": "ProceedsFromSaleOfBuildings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfInterestInCorporateUnit": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow resulting from the sale of an interest in a corporate unit during the period.",
        "label": "Proceeds from Sale of Interest in Corporate Unit",
        "terseLabel": "Proceeds from sale of noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromSaleOfInterestInCorporateUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r306",
      "r331",
      "r334",
      "r347",
      "r354",
      "r374",
      "r387",
      "r388",
      "r430",
      "r441",
      "r447",
      "r450",
      "r468",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r527",
      "r528",
      "r761",
      "r764",
      "r765",
      "r780",
      "r793",
      "r875",
      "r935",
      "r965",
      "r966",
      "r991",
      "r1054"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOTHERCOMPREHENSIVEINCOMELOSS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r1042",
      "r1164",
      "r1166"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedNetLabel": "Accumulated depreciation and amortization",
        "terseLabel": "Property and equipment, accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r1043",
      "r1166"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Net property and equipment",
        "verboseLabel": "Property and equipment, at cost, less accumulated depreciation and amortization ($6,201 at December\u00a031,\u00a02022 and $5,960 at December\u00a031,\u00a02021)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r987",
      "r1041",
      "r1163"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "totalLabel": "Total property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r906",
      "r907",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r136",
      "r311"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Components of property and equipment",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r906",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PutOptionMember": {
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.",
        "label": "Put Option [Member]",
        "terseLabel": "Put Option"
       }
      }
     },
     "localname": "PutOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails",
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r109",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Assets by Reportable Segment to Consolidated Assets"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r110",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.",
        "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Other Significant Reconciling Items From Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Changes in unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]",
        "terseLabel": "Redeemable Noncontrolling Interest, by Legal Entity [Table]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestByLegalEntityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r163",
      "r164",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interests in equity of consolidated subsidiaries"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Redeemable Noncontrolling Interest [Line Items]",
        "terseLabel": "Redeemable Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESNarrativeDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Changes in Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r997"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "terseLabel": "Debt instrument payment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "negatedLabel": "Repayments of borrowings under credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other.",
        "label": "Repayments of Other Debt",
        "negatedTerseLabel": "Repayments of other borrowings"
       }
      }
     },
     "localname": "RepaymentsOfOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "terseLabel": "Repayments of secured debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r502",
      "r503",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs and Asset Impairment Charges [Abstract]",
        "terseLabel": "Restructuring Costs and Asset Impairment Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringCostsAndAssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r174",
      "r283",
      "r891",
      "r896",
      "r968"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Increase (decrease) accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r300",
      "r368",
      "r369",
      "r370",
      "r375",
      "r385",
      "r388",
      "r473",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r778",
      "r887",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r602",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r602",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r421",
      "r422",
      "r440",
      "r445",
      "r446",
      "r452",
      "r453",
      "r455",
      "r596",
      "r597",
      "r859"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net operating revenues",
        "terseLabel": "Net operating revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/INSURANCEPropertyInsuranceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNarrativeDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r601",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Net Operating Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r587",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "CONTRACT BALANCES",
        "verboseLabel": "NET OPERATING REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCES",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r992"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r1058"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Schedule of Revenue Expected to be Recognized in the Future Related to Performance Obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r839",
      "r967"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r839",
      "r967"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLEAllowanceDetails",
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLELocationofAssetsandLiabilitiesDetails",
      "http://www.tenethealth.com/role/OTHERASSETSScheduleofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Components of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r61",
      "r1161",
      "r1162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Asset Allocations by Asset Category"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r219",
      "r220",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSProFormaInformationDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes For Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r44",
      "r170",
      "r171",
      "r172",
      "r173",
      "r258",
      "r259",
      "r261",
      "r278",
      "r938",
      "r940",
      "r1005"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Long Term Debt Maturities"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities, Including Any Valuation Allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSAssetAllocationsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Components of Net Benefit Costs and Assumptions Used for Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r139",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Classified as Held for Sale and Components of Business that have Been Disposed of or have Been Classified as Held for Sale"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ASSETSANDLIABILITIESHELDFORSALETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r1023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Numerators and Denominators of our Basic and Diluted Earnings Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation Between Reported Income Tax Expense (Benefit) and Income Taxes Calculated by the Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the details pertaining to each employee stock ownership plan.",
        "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]",
        "terseLabel": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r117",
      "r306",
      "r354",
      "r468",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r122",
      "r126",
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r936",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGuaranteeObligationsTable": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties.",
        "label": "Schedule of Guarantor Obligations [Table]",
        "terseLabel": "Schedule of Guarantor Obligations [Table]"
       }
      }
     },
     "localname": "ScheduleOfGuaranteeObligationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GUARANTEESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a long-lived asset to be held and used by an entity, the table may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.",
        "label": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "terseLabel": "Schedule of Impaired Long-Lived Assets Held and Used [Table]"
       }
      }
     },
     "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r1047",
      "r1049",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.",
        "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]",
        "terseLabel": "Schedule of Reconciliations Of Legal Settlements And Related Costs"
       }
      }
     },
     "localname": "ScheduleOfLossContingenciesByContingencyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CLAIMSANDLAWSUITSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, classified as other.",
        "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Location of Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCOUNTSRECEIVABLETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/OTHERASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/PROPERTYANDEQUIPMENTComponentsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Preliminary Purchase Price Allocation"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r111",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Purchase Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of Information About Stock Options by Range of Exercise Prices"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of Share Repurchase Activity"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization of Intangibles with Finite Useful Lives"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r1158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r455",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r505",
      "r508",
      "r936",
      "r1183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/LEASESNarrativeDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r430",
      "r433",
      "r444",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelfInsuranceReserve": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.",
        "label": "Self Insurance Reserve",
        "terseLabel": "Self insurance reserve"
       }
      }
     },
     "localname": "SelfInsuranceReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INSURANCEProfessionalandGeneralLiabilityReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfInsuranceReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Current",
        "terseLabel": "Professional and general liability reserves"
       }
      }
     },
     "localname": "SelfInsuranceReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfInsuranceReserveNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Noncurrent",
        "terseLabel": "Professional and general liability reserves"
       }
      }
     },
     "localname": "SelfInsuranceReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes",
        "verboseLabel": "6.875% Senior Notes due 2031"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage",
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails",
      "http://www.tenethealth.com/role/LONGTERMDEBTScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Series of Individual Business Acquisitions"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/ACQUISITIONSPurchasePriceAllocationDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Other Disclosures",
        "verboseLabel": "Options\u00a0Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at the end of the period (in shares)",
        "periodStartLabel": "Unvested at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at the end of the period (in dollars per share)",
        "periodStartLabel": "Unvested at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Wtd. Avg. Grant Date\u00a0Fair Value\u00a0Per\u00a0Unit",
        "verboseLabel": "Wtd. Avg. Grant Date\u00a0Fair Value\u00a0Per\u00a0Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility , maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r963"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized to be issued under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Wtd. Avg Remaining Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of awards exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited/Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Wtd. Avg. Exercise\u00a0Price Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSValuationofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Summary information about outstanding stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Lower range of stock exercise price range (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number of options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Upper range of stock exercise price range (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r1123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r962"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period from the date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of closing price at which shares are purchased by participant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRangeofExercisePricesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermContractWithCustomerMember": {
     "auth_ref": [
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which duration is classified as short-term.",
        "label": "Short-Term Contract with Customer [Member]",
        "terseLabel": "Short-term Contract with Customer"
       }
      }
     },
     "localname": "ShortTermContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r98",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Unrecognized federal and state tax benefits and reserves for interest and penalties, which may decrease in the next 12 months"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESNOLandTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r304",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r455",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r501",
      "r505",
      "r508",
      "r936",
      "r1183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESConiferSegmentDetails",
      "http://www.tenethealth.com/role/CONTRACTBALANCESHospitalOperationsandAmbulatoryCareSegmentsDetails",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillDetails",
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails",
      "http://www.tenethealth.com/role/LEASESNarrativeDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionAmbulatorySegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueCompositionConiferSegmentDetails",
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESPerformanceObligationDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.tenethealth.com/role/SEGMENTINFORMATIONReconcilingItemsDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESCOVID19PandemicDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESDescriptionofBusinessDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInvestmentsinUnconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r354",
      "r395",
      "r396",
      "r403",
      "r405",
      "r412",
      "r413",
      "r468",
      "r516",
      "r519",
      "r520",
      "r521",
      "r527",
      "r528",
      "r558",
      "r559",
      "r562",
      "r566",
      "r572",
      "r793",
      "r911",
      "r981",
      "r1001",
      "r1022"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r169",
      "r300",
      "r337",
      "r338",
      "r339",
      "r368",
      "r369",
      "r370",
      "r375",
      "r385",
      "r388",
      "r411",
      "r473",
      "r573",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r778",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r814",
      "r851",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r411",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r31",
      "r32",
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Number of shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r31",
      "r32",
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Stock-based compensation expense, tax benefit and issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r169",
      "r174",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Amount of common stock authorized to be repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Maximum Dollar Value of Shares That May Yet be Purchased Under the Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r31",
      "r32",
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r31",
      "r32",
      "r169",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r35",
      "r36",
      "r113",
      "r968",
      "r1003",
      "r1026",
      "r1160"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails",
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r232",
      "r233",
      "r245",
      "r300",
      "r301",
      "r338",
      "r368",
      "r369",
      "r370",
      "r375",
      "r385",
      "r473",
      "r573",
      "r704",
      "r705",
      "r706",
      "r734",
      "r735",
      "r778",
      "r808",
      "r809",
      "r814",
      "r851",
      "r888",
      "r889",
      "r1003",
      "r1026",
      "r1160"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Noncontrolling interests balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.tenethealth.com/role/EQUITYNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r353",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/NETOPERATINGREVENUESNetOperatingRevenueBySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r202",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Changes in Unrecognized Tax Benefits That Have Impacted Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide limited group of employees with supplemental retirement benefits, in addition to other pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Supplemental Employee Retirement Plan [Member]",
        "terseLabel": "SERP"
       }
      }
     },
     "localname": "SupplementalEmployeeRetirementPlanDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSEmployeeRetirementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r47",
      "r354",
      "r468",
      "r793"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Balances at end of period",
        "periodStartLabel": "Balances at beginning of period",
        "verboseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net income",
        "verboseLabel": "Net income available to redeemable noncontrolling interests"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESChangesinRedeemableNoncontrollingInterestsDetails",
      "http://www.tenethealth.com/role/REDEEMABLENONCONTROLLINGINTERESTSINEQUITYOFCONSOLIDATEDSUBSIDIARIESSegmentDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average Price Paid per Share (in dollars per shares)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Common stock, number of shares held in treasury (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r50",
      "r176",
      "r179"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Common stock in treasury, at cost, 54,215,871 shares at December\u00a031,\u00a02022 and 48,331,649 shares at December\u00a031,\u00a02021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r32",
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Total Number of Shares Purchased"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EQUITYShareRepurchaseProgramsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r374",
      "r375",
      "r376",
      "r378",
      "r389",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r704",
      "r705",
      "r706",
      "r732",
      "r733",
      "r734",
      "r735",
      "r756",
      "r757",
      "r758",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r803",
      "r804",
      "r816",
      "r817",
      "r821",
      "r822",
      "r823",
      "r824",
      "r845",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r861",
      "r862",
      "r863",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r502",
      "r503",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/IMPAIRMENTANDRESTRUCTURINGCHARGESANDACQUISITIONRELATEDCOSTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r932",
      "r950",
      "r1180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government obligations"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSFairValueofAssetsandFutureBenefitPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r708",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r716"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Total accrued interest and penalties on unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases due to tax positions taken in prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r1150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "terseLabel": "Reductions due to a lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r720"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits which, if recognized, would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r726"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/INCOMETAXESValuationAllowancesandUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r361",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance\u00a0at End\u00a0of Period",
        "periodStartLabel": "Balance\u00a0at Beginning of\u00a0Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Costs and Expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/LONGTERMDEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSRestrictedStockUnitsDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSSharebasedCompensationPlansDetails",
      "http://www.tenethealth.com/role/EMPLOYEEBENEFITPLANSUSPIManagementEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r1023"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Effect of dilutive stock options, restricted stock units and deferred compensation units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r394",
      "r405"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails",
      "http://www.tenethealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares and dilutive securities outstanding (in thousands):"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r392",
      "r405"
     ],
     "calculation": {
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Net income (loss) available/attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted Average Shares (Denominator)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tenethealth.com/role/EARNINGSPERCOMMONSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 16
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1074": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1075": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1076": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1077": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1078": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1079": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1080": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1081": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1082": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1083": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1084": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1085": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1086": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1087": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1088": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1089": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1090": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1091": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1092": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1093": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1094": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1095": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1096": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1097": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1098": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1099": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56015-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1186": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1187": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1188": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2599-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12201-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "16(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126943116&loc=d3e5870-115623",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126943116&loc=d3e5910-115623",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126943116&loc=d3e5919-115623",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126943371&loc=d3e8578-115644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196816",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130534-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r911": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r912": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r913": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r914": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r915": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r916": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r917": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r918": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r919": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r921": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r922": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r971": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r972": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r973": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r974": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r975": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r976": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r977": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r978": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r979": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>158
<FILENAME>0000070318-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000070318-23-000010-xbrl.zip
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MS&_WAW\<[']X\WK[X=-W^[L;[^7S@^VCIVKK<.-D[_ I;&V^>K=UM"WG^T,
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MTBWAX9>^]7$?J3]H2S?'X[%\F345YTK%UQ<(M1IB2L7U3'!*9+L2 2\L[(E
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M>&.8C>B>VEIY2L!9:PKRTQIG*N2X_&O]FTS31\,F?=H'/^O3V'__9-0?3EO
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M+F),-K,UM79IY\3&.QR7;Z/Z^T=O!J,3YN?347Z]\Z8!N(IRS.?D"U>(WD1
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M2F$V-JL (944@N A(\Z68E3UW4^L6<P86TARC2'E4ZQ<G2( C3&J5**&XF(
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MV-7 ':KTTDTC.@?7>_,E93AI0N<K:HX0.*+.P8IXD]\X^AI7B36W.9]U,4W
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M> U?R_Y@V(FCJT+^]J0U.SI8[8?\3\XD^&*[.(RYM0 I$^@>)*:*.C$CC53
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MO>0(82=4XD\#SN6?OJSA?+?%74]D\%0K(@0P1QU)()0F7( 4GE> ;-0[M1<
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MT^OTBR.7T;?83'&%PY=K&1 A-#H9G;.!:8A(7?B2^);%2'0Q^_J" P',4JX
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M!R@Z;59 S#^A7:P8:A:07_8P/1;HCY#?N67Q/M SL4=[J&+'3]F?JA(X).4
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M.BH3<4VQV-9&9[V_XR(=X#%3YWI@HCELHH+)>IZB:H!W3.TSW&L&\J\T\;3
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M.,V(RF[;=@&U[L*MH$C)(M%57?0FY3T"UMMKO4GY",3D,EN4A_"$1E\5 EA
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MN1\[V ]04?TS?O SOJ<270)VL-?PFC2Y'SW#HU:*"[QBBZ<$%W[)%E8UW<7
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M,[(WR5%T0VO=2YO,T>Q<.6=RX#M\7I31UD:%PMM?+@^G([.@M4,?U)99"5[
M)OE<)A<S9IRLX3LGRLZM*.@VR?;0L@OD%;XR+:8X'-AO<*8:I NW& L.B8$,
M1B^%K5<O4^<O&)\DMF+!?43L;L&FB$5PB$Y+T2'%.B6Q247T@</$ZSE&MA\)
M#+.HI6LA@M:"2%SF%XR3#(.RWMY_0XYI>_.!Y9@.3MX?O3[\>,?<TB+)W/?@
M0J(<\>++3I=,0--6QMDL J,!Y<%!D:=XE2V&RT$)*(OL?^;/SX2\R+51>2;=
MY/0D6*0%8BDX9NYK8 KCWP@W-*]Z"^H:,ZE2<^LAXFU14>N3K7#]SO;*^N]F
M.=P$!H([@_L$I\.D^8\PZ$&Q;:]HZ>V1?21"T%2TOK'R_'?/AC!1[I7HR7XK
MWPMKL[ZZMAL1H$\L[E?I>8XBB]\YB. %Z*[D(#*4]<P.BLFDR$^G<*E-]?'*
M4RQGI K#*)S[0 :(T2R*XH  _  /XD4]XMG#*\"C11 & R4S='-)YEZFE:#M
M$K.%L5_KA7(1#CA"JD8DS8N.[0G/AZW9!"%VI\.QF+?NCB:YP8@L@"%NMD2N
ML@@"/=8Y.85@>+1M4TV1TL1$!$U!"QD%-CPB\!XK7_SXKP55!B%B.#R@[<%<
MB6=Q%J(>;?R/X2NQAT@#_6;-XH;BDGRR+E36:!G:D ),#$7!)!/''M'[=Q7$
MH1X>!,8?FG T!3V99L7,1" %R)B18;.@Y_+:$R!;;RWOJS; K9I!)X/ >!$]
M67O*\L,%F^?V^D7$R%*.>*<YN-C*F'-BR($A":.73=WSH9H9:"O\-*4&##0<
ML_GFTP0[3:O:@'K0/![K^(M\%J/_,B3.$_LPT":O=$:QOXX3"BN1ZDM2?8S6
M8AL2K;US-(;9YO;L],*/.*H*UXCFZ;!-^%TX V->!)V(D#4_.0/92SR00S!*
MM75?IQF<DICPK>=Z+WJR+CM@O1RSA8Q0I."C._'^KI@OJ&0B+6=ESHA Q\_L
MN<\D<-$)S$NK+! ESN+S9SD_D?+.PAMJ?,H8PS]@;%9QF7)D:<(4 #X*P'/-
M4Z^T*=RV)QLR3<%@5<*90!Y'US$-I@J*K;1""G0>.-9@Y1KK%Z%HFEPT>!E<
MR!2#<^T1.OEC/XSQ;&-$58%<D?AT.J%L%!T%(R10[0;XN=0#&P_,Y@U:<M$?
M0>A32D4%&%KG!3YQ BX-G"8VSP@+#G9$40H0XHN>M:^XKDO">7AGSO=UZ2'&
M*_7VW1[K991Z01K :#_R4BLI%R19=8.NL1*Q9HX'_!(#YCU'SS)(A&!9<]=7
MHK8$!DE&CB2/@XQM3A. 809&(]_!"PJ*T0/%=!I$ZYNVMJ,!GW,"YF6*9[S!
MR ?K19) 3F9[:A=&4)+LP.0HBB!$.5=>?2&!W_,@E>$4H#F::4X>)@I2)Y<$
M;SJ+L)3!2>D>47+'0[O5(TIZ1,G"PA.+IBZE_,%7URX6RZ':*?D()#]!2>$A
M*IT,###L^/'4E,M57M63>9-G6(GN(H/^B]93AT!ABT)3@@ZL$!#$[(E6^')5
M2@19BJ@N+&AEP;,_MS'I.28K2NUF5\C#W1N;SY2XD);TDNE8#N:97*3.;-33
MF'*^[Q:6:][**I)(L&=[L)V5!F4LII*D#=5)G4J"TP(:2'N'#.OQ*OOB89-F
M@M.G2+[1JH)$(@J#7&4S+I+WQB.&%OPR+HM*PM=4,6DBQ"VX@7F_!%9MH0;I
M&F>ON86%&;M53ZD^CQ0_XW;]XHI:?=&8L^(P.B>+>)N*1+O+EV!:UKI*\/@+
M5:9%@Q07,WHC?;RR@6NL(YRWCV3AZJ*0>EJW/IAE8!/1WS8:H^1<:&WI%UW)
M+#^#P7&P&&:#Z* DK9B7"VM5\(:EHUDK=4(3=CZ4J\P@[!-Z3CXLC4\YY2 ,
M*ID./]5OM QG>R/L85I"L7!30+45!$HX=%MR,:F$1J\,[8B/-T2?=HC;CS<\
MP$!O;Z\*80DN;E[DLFO\NR <% 15(JZM ?-$KW@/P'BHEYVRMO$<]GIS\W?G
MHLDS'5D< ]L('('0K":W2(=VNGC@1XHZ(T.5SD8VZL >O5]:Z ),Z,'[UC.>
M9LJSA&E%E$$I08N8+TYX -V:SX7M!-KEK0O+HPFX$3$7KC*JC\&(G$E$,<R8
M"A@:V/ZT< F[S,_86:;WSWLJ'K4+%=C!EG!U$PM0$<#,VC68#TL,HAM\>=_I
M=8+059(5D83=VR41ADRI<%B<"$Y[M+ZZL6XACK?&TH7G:8//4WLM\%RZ+)K,
MM>)3I6IPL8<-EYRBB*09>RXB+9\[VZT#O/W[71X#2_(-^;K=M7OEZWX^LS6)
MM(^'^\?1AX\G'PX_GOUK"47R&8&*37A!<FPJQHZI5F=6<_2%E95>+HG?HOJI
MF2;S)DX?PC124(!B;_1,/EY>]0S"JL]UU.E4_<#5F?.J0&5X#M7SW;7AZO.=
MK=WGF]N;PQT]5,^'S[>3U>WMK9WAUG;R[_75M>?K.[_]8QV=*.+X#)>Z!?Z9
M [?C&C/XO40U,<JHRM\@R29JNJ@K<^LRQ4U>F;^$)'4.ID204@>\]N0K'!4*
M8]](\7$](-PPKPKCJN-,(6 B$8A9LE3$_A&6 PN31BE;&(8^U1ALE)1@J#X_
MTK"P,JQ1<.I8B.L^A*"7M$ "$(2U!"@P=J $GZ2\VV9*!PK$^VMV(=BMG".F
MH3-'YP:1[J F5#F<#0+>EXBI;D3_%Y<YEU18H^6JM^VU+!C*01AJ.U+?S!D@
MOK0PX4J6?@GRJ3<AQ]QYX8VD\\IK!".*M:!>G5;FCUFK1;8<KM&TH"T&\RP!
MMZ7D^@)O\^ $O4*R8]A@XF68QY'C'C"DR/.Q$$]+XZ$;@VDJ/(.6JL:<K%#F
M",#)PGD"UQ:G^.;E ;-RYFFFYI%H<@()XE_B*ZP=6#4I"W<Q),%)!B-I*E6)
M> #9^D '"%YP#O9(B=PM*M&P*C5_CY]+IC;3"MS?V-A<VUTF8^/MIW?[[Z.#
M_0]'9V!U?#P\/?GT\>#P])9W9WLQH C=4_OP]E^G1P='^^]O.YM%D@1XASVD
M$A,^X $F"BC!RN2>O30PL8F!7_4\L"&2VG(K><%+Z^=9#6,L+@_,>#DNZ*9-
MR.2R'S4"G!"J5W"2\;7W<:]^/J[U"N.CLL7?"*N9B$#?^ZN(504UGH&Z2W#,
MS&8E^D1"DH ]L&*7_FAXBL(3R80H@_9D<+HB*;*9[P)SCIPLR(!"R&/LQ 35
MA&AYJ,0:MM2 B0QBTQIH*(FSR#USB(3P*]&[VRRTOR <$H7U8.H3:\[-?='[
M$HCJI$ "5R.Q;?B J%@):XK304.%8M<&N%E519QRK(U9>%J(VI*/6QBPE&H&
MHLMRV%4:?$V\6XS!/:H1#H8:(F<KB5U_DP6V@9H _RP!\Z!<P]0 H7>)7#F8
M;$;_<UK2"7-&CR7*<8=17 ;O%E$"D2KCL Y#DHYD;_A)0_-.JS7/BR)QOJQ!
M9",1@'O;,EHI^QE"<<_'MKU"7EC ?D/IUK;[[ANQK6MO+JT!9[<$R%R)Y.!&
MLE]+B$#@[IVMU>[ EC'C ^-8<%!)](0-FBF>_EH @5:</+6T;80?]*)K?"/P
MO6N#3?_-8I89DATTV>E5P<&KN/Z- EI$.H?DC%RJY!U9(0>$TSQ.AVGM4@O&
MXK-+:HSZ--?AB.7Q%$,FH/]LRCK !.V(XF]NA+8D,JQ>F&^HT<G))1+ $ ,*
MO,2*Z&6\"6 PVS-GBA(2J1O6)>/[+5A=[.6X;%*KBTN-DB*HR6 [O"HF-CYM
M;&SXNBFX=4+;ASO0HZV/"L\V$/M26T8_9@BOQB#"% /H'18K%(*FGH +-\$U
MGX1E)T&=IQ_4H:"O*V/WUH8)TT9T'M'DMF,?JBI(II0V#>H*!XK<6U:X&%2:
MZK-)A>1;IB"]N@["V*,RN@_V=H_*Z%$92^S[';[[<'SRK\-K'-D%N6A>H(."
MVV* :)-_1S%IB/S&3*F'?04$Q& M9(&Z6IZDRL]96<>0ND#0!Y4)QHNQZ],G
M7G(R3M]<K8(M$HS!%*9WUE;7!S!AL)^**0SWB8L>!A];-UF@*95L,!H?EM<N
M0_74D"X+YX0C^>=H*[N4HP++SJH7=S$AO/C+%K<X_*D='4'ZK:RR!+QK2\?G
MFROKSV_7TO$NCUW;6-E:OU.GR'LW6KYE1]])FB29_D6]0#M2 %>V][VN-6_'
MU!>NQ6[W"FSO#M:W[MJTOGNG[]6N]CMUX%[H4]9*(MWKA'5,>TE.V/H::HG[
M-5+^)2=L">688#H>F>Q:6QOL]++KA^6.:(W/D$/U6R36M;W0<>RWZB^]D*?R
MBJ;U;!8_L*[U=]JI;[I0MVT<OD APIM\*&*J,DX?YNH)/'B;5C.,D9 J\EI1
MQB2;S8$?Y]Y.'<]6HG\A4)!"U=QT3C@[PO=?11;GV.U:>-C?!PS/H*$D'/%C
M_)>EX8N4%.%YW8W;[VU3,ESUON>_MU,R+@SK\6(Y<#JCP4IDR6K#Q5L@AU&3
MQZX0CB$*MW*)D2G!^J]$W))ED=%%U&=!(OAF]J_PI6DLY =9,QFV:#IS)K?8
M&,!1]1[MJ';, GA! PS]EJX)@&17> XA]),Y(N@[]M'$F=>4U<+":.Y(2\"M
MMD],1G8!V DP&S3D!N C*78LI(H2(; 8D,'$DW 452@<J F':>@]008=OS""
M4CJE$%T(UW4+=JR2B[0JL#0)@8/T=IN+YJ<[(AX[ -?MXR-1<] O+2T(46M4
M4Y0Y!H1CB8>($9>SZ)S[S2O.&T^1>,2RR=K*3?\:MSL=65944Z%)^78L'/&*
M,G4^IDIM.LO4=84NKTL"FX1+5'U)LTQ[]W3@BKM@R[Z$X[5Y;CL:]WH>C0<&
MP(RTZ[HBA6.;ICC5U(IXG:."5X4,M+B<6-RLO^JXH=?QUOE;P>E_@Y8/^>^Q
M>Q<"^/!$P: ,+,JO@/4[Q/C53=+)B[8K4X2:'2#6+!'F%R_;/H#S*W3R R_!
M-? S4+E;:ZX%A@]T'<-6ARW"&G#]!,,D:)SF1!Z>.@);>UY-#/22XH*&/9CY
M*FU-@<-FT-X*8LQ(>GBNI0+E=S=IPB<KIS^ZRR=LR*7.--)[F2>8@_(PI"=.
M^2/)E040G/NN$U3:V3.6S U4<1A/Q^O/:<7S$B\NYC6+/&>N ]Y\?T/;?6 I
MMH[@!:SE@.UU*^&%VM6%2C/.I_ W+O40>:_Y?/N#Y.>&G_*+%.O6YV4$[JUX
MERM"[<"73,(_8<I>L)<HX4PLJGGAJ&Z)  EQ.8B_);D@;$A(92P,&&BXC-),
MP%=(^M&4.9+'(03(](<Z!2E4IA9[>_@U'E-[#I)%+"LLO>OA@;F:#^,.< NL
MCU8_?C!(D@6X$G\)#L?OZ^4W6?/3[T9'LC*D5+S]:(LAJ6*.6P<21'7DRW=;
M7\AL>\0588YQVYXPT'M/4Q+0@5#AQ 9-QK/IZ6@5+)+IQ&.LDPY[0W*AIEP0
MH^R)%9\QZHJ @BW%K$V[$FZ>Z&@O!L1)+PU,X>237\1D[,R_>5-[JD5.D5Y5
M4.V9'=0@1N@G]Z*#)D-PSP*<[",/L4UY2?W%L^@LXZ-OVB$VE/8UH69]<##0
M"HL1EGGA.JH9VAS/^HEYUD)(/AG"&[ $5-7*4->6>'+@G3'UYI/?3HAH?6 J
M^ZE,&/: "H^=^>V: G)BECJO6;.)OYP37S7>BS8M.A4IWS:[B:=.(B[/,&;X
M8JO=!.S9VO-?%@\AK;"]]^O.5K@V:YLKE/U5@4ENNT[%[4MBJ+TL/(F[/S+J
MJ]27Z-#YATJ,#]IN=.<-6X&F,^,T/YY:8Q]7=1%_L4V3R/S&]IN;JVM/OCR5
M'Z7HUA;4.0(RPR)K/B.^E>G*A]$0:C^2$42*N61-R:H0-*DT(4 NGKN]_M3]
MN%,W[^V)JB:-$Q +>=U?7&^+: A6;N(=5P/.,RZ6J9'J\-H\,%U E)'F3C96
M\O*"P [(+5>:@AI\A!!P^9/HC\L/%5(2(@$9-3#ZXD+[)>663%!:*ABE1B%U
M"U &DXFX4W@KF3J%?"AV@T<&+-QOYX_<3H)CY88AGX)H!>Z9L6;A:L)..0L;
M3._B/&<3F\U5#8.I)F+C&T(R >:2Z7\7UZO?OWO8#(F8"3E2"UJN'53W50<G
MA-]CEY(0X*)C6^$P:D<=?S5X[5*\PT5*#\.-/C1&SJD::5F)OW0V4@OA;GAH
MS# ?(ASBFGUDN6A8LTQ5>(Y>YY+,M=CV;88O2>5Y;NN"Z#K#+8U-=QNVTV;D
MKO"WI99U0H6PMD^S%>98!.*6CX,Y5!\UL\$MM!^L/<F?M5%WGS:H_4<[#29-
M]<,$5+QCGB'IAHQ;DP:%.X/N^GJ?DXSYG=):G'Y23L[5QO"5UC;^AGDH_#4N
MNAM?FE^87D9>89>U>SS.)L&W3C$8'5L. !S".?E?\W7/%$SA\T&MO])\Q '#
M9U/B0.$DAFFU$99*>^E7B0NFAC&*#2JN6*LENH&%95.;H$F0IE[>93K/^ULB
M:^XHIXH\3J5R HY3R:E2\P!OL": W5="W%4R[/25$'TEQ$)IW)OJ"1Q#HA=^
M14YXG4T]E28M8$QY&C'"I67<3)C@._ )VY%A5Z4P1PAN567"AE$'&[ECO;)Y
M-793SS'5ER:<-V'F*$*=O,:LR1.4XZ;Y@_FMGX=6T=;JVI/XZ9.-I]&T&6)O
M"Z3JIG)+CP.QZN8SE\2=6Q\L3N6HNBLZ@U^ )4:.-$73N[.MHY2:..4*E#62
MC*<5T8,3_7!-7;^G8-O!\O[=E":7P@0NJ&NRC"DR>!7<_+$54T,?<7W#A/;$
M#=J06=C?/ RK\540*#TR@=+%L!C][$K0F&\L;8G\T$U8F DWA,263_3G2$>Y
M]I%)*SEY8I,B6,M?X*$RL4.,>-,5%A-1JH9M!+P="*HUU5;BO; OOZX2B!(X
M-[:NJ1$1ZKT4<_ A8&OG^>_12$]4)@:S0)NV5CM 2#[U()-C8I&J0MHDX?U#
MM$D]SH4PA\/IN@UPVMKZW73<=<]^DJ[HE8&4XU_27EF@P/K3>[]Z,6_;31J#
M>X5&[I8=@-@&N]WDN,6FI3,@9\B=&CQU23JB[#/9^[JVV3ZRY$@;#-HX/0/P
MN2('8H(@8622F64IN0=O\%.1DG$)4"FPXX8[/B7^$HE8#CP?SF^QS"?2AEV1
MG,H/;;) GENDB'NK>?5VE)H<D'+3KCK:NB9MQ,D0_1B79.595C)/<DX8O%)W
MOMT1FUI(BZBR=@8VT3A9@5/2TX*VJCXQM:72)=%B]O 9TI5Z84>;,#,SJQ@P
MU'*HNL>-Q8Q^OII;7V(97^"[FN$CFK/A3L;F%*$(LZ0TW'HXA?NARLC!F GW
M@)U3N;LL][M\$>V/RA2A'OL33?\81'\5,&^+0GK/J,D!R+U4Y7]\@$L_2N-!
M=/SFY=D__Y]!]#;%FPHZ'%?M,XCS4L&L#X,"SG#D7+R9.R17)/$^:YE13Q=A
MZ4%?]S^@40RJ@O/KIO21^(PM<2H]?D$%SWU2TG7*[7).33@ )W^,=?W1&8B8
M9!$ %RUV)B;MQF0:$5R+F/*\_X$39_P;9_99G@CJ31[ -2U_CQQXCA_D.O.%
M(J-TZ9:5:II6W(E2E1,XLY6P0L,PX+;$X]S2>#BKE?GY6 .0TVIB)297P"')
M+D*/Z^@L6(19?;L7C8M+3700W'(38TE@"L.1)SU@& ]1;L');,!(GM&5&6*3
MD1'W(B<U!&\FA\T9&8Y@8R4Z3K]H,V1+1$AA]E1B30$6QJU^2(DA%EOBJ%3"
M/B<QHJ!@:TRVQ<&E?>(,,/SC=.HTP+E&#XEL?Y'M9.&??#YZ)0]:VX55@5,T
M@8_HKZ!*RZ'0%A-7BHRP\L$]O/-Z*.7=<GU(.CAB#Q!Q"?60][Y:,0>V%^,D
M6XC2V 0=)\N,,)\21'-+CJ)'?2')#QJ$W"@F>V\'TU)A,I&>I(QO,U!^812A
MM*?BL&9(DQXN#3YME#4Z_Z_R0HFH2-.22Q0NTK*1/6A%)$,B?=.7#_2=B@TQ
M$<S=^EY!NUO7'LUA]E/DO +Y0J>*+L^TJ?$0D2XT"#^G>RV4B$QIOT\BB0I8
M KKVL&:X6_9 NV@DW@,;"$1R'O\<#_4@H*@R&*]+.BP>;*'B[:4[ZV-F?!?7
M@T1/%88:X30VV%Z8&-!-.B)$1C#LV[!VX3DA=W>"9^0<=AN;8W' =F+Z(H39
M;6M"C(A.]!+I+PT5W35BL"@C-NWH)'^=2GBBACD4)6*Y)*-.\&]O8I9&AV(E
M(O!NE'=H>U#4?D&U[:T"0\(D&"JI#"F84,-.P72E] )L^C,#DB<>OMS\)+M+
M>X@&CSG#9)6W:4 #+B,NS['N9=!UD M73"F.J !J6LZLN49F\-W#0IU),Z$#
M;G83M45,9RWA\^"+0R4]DFDH@C9D7B.9.#;F,&3T*;J>6(Y!C%@/*Y+R*<?E
MV/?;H+%M]=&0MBV >753D=4\B8@<PJ#LZJ;Z.2(>\2,OPYD<AB;G1GC'FCJ@
MP#JLV5=PB"-XD66-;E?+44N'L)(-+9JLX 25XA<A6R7\AWJSN><:/>V"?=P1
MDE =N</A2%AU8 P\J9:@?)3F<@ES8ZWJ]TB 51UM;,R1=P[F:+,=]S-,^ #M
MBJ+,L4SM-9P,,"WHI>_@,^DYND(GC+ME;!F=-;S+K07&Z'"6N [N.(0,75*.
MBS&JWW6'8SS\J"&?4_BM782"GB3ZO EN]8)>W.NE]1C,WDO-=7CZO*#6S&0"
M<Y]&M A@\":;;,F?A3N5EQ<Y#$F;,2;:?8@K5D#-(LTB-?@LL6F1*,KJZ8".
M#.(0IU-K0J \_B+,@$--?#R*TZ,H*&/0B]@Y4I@A3=80CBVX^]30>>!BW.91
MG&=5R4 0+'P:I"L];3-^8D#LG0D%V 3!;0PLDV5&-,R$8N[=#2O$";)R7M74
MD!GT>A/0XU.C9J%EY=9<BWIZ[BCVK3/]$2\2"'LR%B><[OKE\OXD;!#A]B.0
M-7)LG9EK<^[&'""QV&[J;($.9@E(#UC)P3*CFA,:'H$AE5(2'A:+8>"_ W,U
M_=%D*;+>VJZS,/B11[([-DY4KA$'CK:I8_0TXMP:8S@YK6MA?Y1WA.-F,K"X
M*+G\DM-TG9?$W((^]W_7X_G\ZMS_71CA-[=_ZR$#/61@,1L ')R\^W!X=G1V
M=/)^N:J:KNAG<+A_?/;V8/_C871Z^/'ST>U[&2R4^1?B$*_DQ/9XU/T@AK5A
M_&2N>/Q#5:65!)MG^ "D'0C:BK=Z'.[9#D,<L29+?20-T+A;2Q6#S<5Q)A!H
M23WF$()PHQ,412=[:,PW;,CO6>X+&&4J6M"CR.?H0 "-<WZXI % 25*UC6OX
M3J4VTEO. ]>2Q4JQ#_$/E!_>F2/E]^N C%HCZF6,C=N";\QXII@ X\0?==7L
MR'MU/8Q6_S9;NA1-'SB#?J\6#ZZ_0YOD_58]'CZXA]^J^0$%A<B;QQZ09M];
M;0]<^YU;-T @[^H[=4!80EEUZC&5NU--%R4,K(:"+&CKI+Z:(@B.\6I#]\#7
M_YS+;J4AEBUC;ST%S&QY"O@+QO@O"ZS6"YMUT-A0*)!1[J'!,.O#"18TV0-S
M/.QRX2?@YNA+3'46W-WB4CAJ&8A&#R,W&SL><NH0#Y_Z:HUTC\V$)2P=0;L^
M^BO(0=LWTI2=6NH2_C,]F)R62F44Q^>6219B@3L&S]0=V1J3N^H.YPY$$M48
M^:5&M79##?@!HZK8,T78US&H=;50=UTOS9;@P@_]N#3^7KI'!"=H)5K"NX+Y
M/OV5X.&<10-WR21_O68U LLBOP_WFAJC,89))Z9,D'LP6+7\=:JLJ)Q7;R*7
M['H_47YS6XFYO'5?^R@-(N3IQ[9GCHDA'B!7&VA :G0S@O6!Q_A1!2(E$QPZ
M1CPOG\ZI82\^3^=0*#8D$QQV@D1A3*DG@IG,-X\<4+-##5ZU;1-R^,IT6Q=D
MG*@6F6P[&=O578&<;)=[P"0GS3FOL>[!$WR!!B2I9#6?7%R24JVN")BP8@@0
M57KA\.QE-)1))IU+MYEZ]LH#_9:^@2WA;;Z7^?:4LI0.<S=?26B#W43%\;B#
M]<Q]D2KNI9Z"*-S\A%@@,+PF%2Y^MXSZ;#_G%"!%O\5 ]FC2YVU#-(8=VJ#H
M:B\Y(T9V:RG#-]IM;B5RRP@0Z6-/'957Y%H&$?U0GUF"KG<GE0%$H]!'1IA2
M>STUNK_VX8/_-6JQ:$-GI#0<+UYANE):P'/KLU-%Z3RTZH*IV-BR/>VE.M>!
M;83?L2U'_ B@-C0S*/@04\'=E3DJYQL=8L('L#)4O(0,:7??R3DGC1ANU^:0
M,N((%!VIBZ)TZII&3AN$:SQP=X=\&S:JYU8[:(OC%FU^BX/;"0(@XA%8>6*@
MZ:@X6N%^Y<+V'"&DEMV^G)+&+U40"FP!RAB- (OTQO0\$Z@,FV^X[E?L9MNI
M1/]+#R1V[CE\ U_>&G_2>B^\\*:(W14*M)S#P*0WQ#8P(0(NP Y?G;DGU2-!
MT:O. 7FTT]IKU]V:+:8*@CTEJ +G9OQ^Y+0-5FU4W)I;?U4(KARTD^$D3@H9
MHGL:G'D"61)$%:=1N19B\P>HW=Q)Z"0I+>_*SUJ3,A*^=LV[3.>]E>BS4+&:
M1A.U!\E%)$>173#*ZPH!T%)$GLKP"R9L] $G;].  3>>PW8MH2JAWKL>;R'!
M!!U=",$^;QO?8;97?W$&5W ;7MGK;NH[S"A)X?+')KQAH!=A','))0/_<&WW
M# S'DVWAEH\8#LP K)RF;#>YE;F;I[PAWVRB$NV+LSD0D?$F)/T-^WJ.8,L
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M/7Q7?JG V SJ_0(+(ZM* D/H \.@L!=%.KK^:0'(3ME*>9L8X7C66%L@0V7
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MH69_H=ECN?JI_KG2OFNLA#/;S#G(^^$"@,-??6$R6,L&8(O4+7-_<*2[%ST
M.7:A?JUJ#MNBVRP YVW12F83@KK".W/9,=0%A>>$V$1^@W1<%$G$?K5$^7QC
M&RE<SN]D1R]T?.[3V='QT?_'%-T?#Y'/.CHX>??A^(B"=1B@>WMR^N'H;/\X
M>H.,U^_Q]TOH0)Q=4=[EL.!E6#/H5T=X):\A7[]D7RA$C<?,!87L,PT>Q=J
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M%SS^0?) -N82>7KZ"B>FP5A-SJKS;8R#/M@\^VB2G5Q <++(/:=&![P9%DA
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M[V2.3EUNR>%KYN$C^(J#2X\=G6UG#N&&[?9RW&1O+C;A)G79TVLL^X"T78I
M3:QLT@Y-;(0(X;GG$.=P%AA1;<V$Y@+^,4]*/\+SO.Y\:[MW-, ;I,N%4@/\
MZK(%B,7:[%ID2(#=-J-.?0B7J8CI.<,924U?YH'H+\OTF1GKS9;+*4^B_QU'
M5(\X0O(F FWQ6!9;!4&GRZ<KIEE17<2<VUPDJ1 ;^K<4.27\>VR))72QRMO[
MHY1[3)I%-$?=J$/IB-SP9NBM\9[,RJ!6)'V8WFVSR1@6YMC&(W?2U6?9V+Z
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M)ZX?S18)TZ,K+,LZ'>YDB"-40*C>,]*77"1$/T1VE)T.=G":!8],'B>$^6#
M&!_N/!7U,Q@IX%Y(*?5)#I;N(LP98D_6>:5&,H"A>VR\3YTFT>=L[5)73$=3
MM_.JR"O&%Q#OKS0'KR?]*Z?A.YXS9.IP,BS%>ZH<1SA.&W:[+(GG<&FY3P27
M973F^?;QSK:I73<9=?TAI23YNXC%<S?C-IZFHUYI+D4 .;*>1>]>_[_)<G5X
MQ#9?72H%F!;96=YP_H[:];5$EZ=$HE>@YJ)#F''7/8<S2T:49LZ'H+*] !+Z
M9&W7Z3#;T#M!'L9X?Z1&Q>)9"'R6M T@0HXEV&VRP7M0U%LB/2*\MLL"_ZZ$
ML_?O)]%;FTJVT^,&D*AH-MJC>0%WK.,:Q+V;D[07X7XDIO*#P?V.273\YNC%
M$E+=5&6Q=ERR:><A8<,(-UMF<$P13DZA!<9XAA$GFV%/ @_KQQ]/U#H01<I%
MU,P6X+L5O#7 (N!M#;_S+ED++X7AWCI@]A7=@08?+8ZM2-<CK[7],Y]GK9Q;
M;QIY'+JB<_25I""J5@R;4#>VV.H6PHP*A67A'IE*2Q#R8YQR3(PT9>@N3=&$
M4F6;@2;*4^&^5^1G1%!9,:GWFG74J7^.%'3Q?TZS,IOG7":*[1N%YZ2GX^M?
M%[P<)LH,G>R8.&EPJ!S(3[F"[0?KFZ8%:$-&<+VBG6J>*AZ\&3$8SL_X?W7B
MS!OKW%H@&?V$H<HE0)OX3XI48O^.7'F2)70_/T&2_]9KA5T@@Z0;C")[_#0J
MU:?8@_ZIOS(KMK%#9IB0PRQ<;[1!+JV'PS,3IE(KAMI2+9$WEN4 R%?GU&/H
MR.9T<-MX5_VCKA*33%/P"MO6T;>T/A9[YA[4%IO8O2N]$(VTQ:&[))$B"UY>
MT)&X4/QSYMDLL]3#XRC&I+8.CNS%(=N4-N*_QU*_O:2MM0?MGD3_T'P.TKQ0
M)91L7[+&#>+@<#QR/V8\E4K5.0#/&<A<*3@<1S+L^F-%9+=7";7Y _,N87:2
M1N2U<5Q"00BSYY7_'M-@6R+-$-V'M%A(L)!+U< 3MQ.V</@K#JIGH(;B.@[>
MA?F=]5XV*9_>_4T%=L54CF$I_1"%-)RT!EW>CGO52S93J<M(::=Z'.;%>=Z]
M*UIGQ#*.Y]T *0E]JU*9P>9KW3UTU16D!KE.D,K5W"X(%28K(_;8-&DCY(8]
M*-)FW%6#;UP-?K%CZ]F5=;?G,CYVS::Q];64!^$ZY&*;^$&DX64<-(4X/8=:
M\::4LB]HO]*,LKR4X,!RIS@):"/SU.!Q!,CE_(, 9-[\$,0]L>?@YJ@_^8TD
M5]?]HF:_G<9)KC;@ "9DV1T'!0R?TI:$"3VCX!J>\G>X$K#H5F0LM+@,2W&'
MCI=H>-T,[EJ_"#96FME;'"Q%3ND7="-M*5@#:Z6(=I0$^+TI.F)(+<XD+.%;
M4T[.IW_I=WS=V<4@$F<=2O7!I9'B83L+V*Y,)E!TP;DJB&/6Y YE8CS3ZSG<
M3>@>'>I$R)U!*\#1:Y/,$?RI;CY_DMTK#J&QDL.41O!G%Z=:@3)V%7S%P-?!
M_7,V55&268W4\^QK(-=1UF)2UK+0C];S&5 7EEZ";@NJ0Z';*,J,,.VEA*Z/
MW,GCGL%>DO,,)K04:"/S8]/F.P*_%O.F 2K-,4$X'O.*1#!:<IY19QV3?@*T
MI9!6$X9& 9*VF2$]#X+]/P.J _S#00K!D^+$1A* ?,P!/XY6"[ PU:?(<862
M<XF/R?T*&.-]-3IDW6=/F1^-Z3I:LXO,A<@41X5$/<F:]#IJ^0T*;A #BIN'
MT)+D=[L@;.3+L=8#1Q)A#FPY1%AN8Z"ZD09I=,7GR3FX%AR/\)H(JO7'=Q^H
M2L Z*,RWS,A25=,=YT_RM<EP&8JD=TF :Q_Q"%S-4] "WGP[RB,T=_U-$]NR
MBENT1E9:B.X-3M2CHIF)OKTV[W[<H_)_OO<W2HI]_W+R_$!(_:=LM&*]Y,&D
MNO!/@VM/OR\_WR_M<ZX'W 7]IID<J>?_J&;70]!<*>8B&38CC!X&?V6.D_3T
M>;)80,;<#@YXH_AB$2P)OHA3D)?Z*II46%$:5$ ./FOBI^*Z+QHLR8O]OVF2
MA=A_J73BY(36>48=0ZCXZ JD?A#4Z,=#,<[*<++T[<8GS6B.X&;?1MOQ:V;\
MVP47K,$W3"CRGH]?#V(OM$:#=H/FY>/'#^"3+*J+C'8,,794JVA_;]2XLSN/
MN__9X[_I&1KLIBL/U'5U-/Z12>^$L)^35G?9JL<M*61SF25<K".8/GCJLH7P
MZO,-K9+ *=WYMX9'!LHWF'A69((QW08;AN$ 9#DO<G*BI%05.M-<IDC[LQ\4
MF&E&>Q4==QDK7Y94&ZGPJ*0K4W #L9(K10G[T+$U4Q EYK7]#XQ/Q^T+4T?M
MY:;YV;._69L[EFK3Q.!5)@4Q-YL\B&T\SA_K'$6$=+VX0DE93=B3>&.VB ]I
M)1VLM!NF0">(+PFKTAR;']W6(WP-;CYONAD;QFIKBG BJXO]/@1*2+6KVN2_
M6[CB_J-*,.=Y)FG/,Q* PN,,HRJTV6CT:HJUKA&:'T[DEME9U3)?A0[#?9$\
M9$)^PM =?Y7J-H:>E$L(AS1U[,"VE19'_ SS]/4.(I'^EF<533KR-"I-X\Q)
MV1#A$>4#RJH42S.XEZ)6.![]N#C@F<)V5!HV$GMB@4R%_I"W/HG^Z;FZ#/Y'
MS&ACK;L$XWQ'DBPI+"L:E/IS1AH:72M6\RS#225*()7WC1E");$TN8GX#)^A
MA_ YEZXX+C8+7 )A;UIS ]-)1EA55B1-L,A78OWTIF8GRBZ.W@NT6[P68*Q9
MZA"YX<3(+N4M,R3RB@Z11:I4T$_BZ8B<0O8[P2N;#: WC/>5H.A]%9UT]0HE
MS!J6.^!J=5M5G]6:_D]2=DF]'D2LCPFPXW)BF/.X7OA%EK%]5,T?Z9B' 5FO
MK**=P?9Z<-&8>*HF)+/L"AMCNZ]RE?P9@OJW 6Q$%W0#U:8:.2=#9ZQ(",,0
M*SI*Y8DU;C@.HEHY@^F-@_4J-ZR3TQ3>PIMS(WRG#=@/):\X/JU8L&(K3")H
MNF2#.KE3$>:3M\*E S/D'\I>F][@4O6-E9::5L0:5:O:._80,./":Q[[G IN
MD;!;MP<]IX9VHD@755[.WJ'ZB"F!NHT(#^KOPU!BZ-*M&+MF#DW-7&44_@ (
MU+TT#Y?NTM^7Q=A__C<ZTL__]DUS%KC.+@O@]H_N&<ZG<VC)**N!>8L5*$JX
M.,I-D$X0Y:)YS]XXTW%ZM5$5F2[I[]\) MPA_PZ36%>UTD0Z(FJ'GNP5DXAW
M#I:=S$#=%:P71+J6*X1M^2I4KR1 >8":G6?9SK: ($T@PG"C!EXX$+7\LLS
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MJ Z+9=]!ZX[L_; TRAY'D'L^"N8N1P!MOO)7MH%\$MT#(R<VM=Q:MCZ>3<^
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ML"T1@4^>X.3H:WLB=T/IBTFJ9LZ\?$$JT">S%@D)(5B&W%@Q&XF/BPP*4]+
M[ROV28*N=A=3&6K7D2;[H %A"JY127?[QO[WL'?9E>G#_!21+2@:@+6Z87D<
MS7" _:X,(['["V'$X,) XGDD$R3O7CU'Q>#JA#&U2G)6@N$GKL04NWLM^MD3
M^Z7Z),]!?#R/!,':.RG@?^'Y@0#;,YH],/^;W&3V_RXL'9*:)#@6#T?W156/
M;@L$)YUGZT:[A2E^[.\.Z?E-V&T3?"PKL/5IF<PX'%)&R\7S[,)444>DHJS5
MU70@3=QU3(ED+.XWF(U+T;>"KGG<VO!BNP9V[2^&OMG"Z_/$H'H,ZPZ#D&VB
M?M"[7UV4 D-)OFB&AFL&\,^6H17%--R67[I^_=Y3(#"7I\"U(/\+B^/(FL-A
MH3B13JN<7%KO?5(YDBM_F+8)4C)]X(2W[ _V'[+)UWJ'8WPMT^I"W"\T27GK
M.0V1#<^A+N#U7>031P\>R_/D'D6[[.8G^X+D2#IF(NF%!SPXD*_PG^G!!,YK
MDH+J0C5Z:$)X R/'%8-G#O)] XK_4706VZD6$Z,D(^#E[@1\A,85H8QLK"C3
ML-G5\-U.NBHX]U.;O,5_ERZI8!/QC4[,C%S:Q_"CT2H_(_H)>B2M-W1[X]RE
M) ] NDF9U#.M$)0@!A)GE2R!1@ ==8-WTN"2SS2N-LTQMF? "TOYW=MV0KFB
MVJC2U:N%7]N@H(?$C:,WKWGGP&U_1DD'L:@2B_<KX!N:3!J3<PYH*R>1.=2!
MX>?+5.V54@SA"=Q&TW54*BOH;Y7+Z#D^HN&ESLU/SK%EGJ+>G4Y)PH #)6^;
M,8*H(16IY1MFJE,D#,/MDM>I&K2$SK&G%JB""''X42%8H3:Q<:I$*D!#C$^D
MQ18LAM]Q@$F;'<J^<%<*'1WE+VM&>#.E10P=4SC)>;/PKNAE=%\;!GJO6+\V
MEYW)%O@<\"COK96*N";!<>U)XRR[J83^HES2PY3VJE+JXK*9=4\C/I*&,]ST
M&HWO-AG9I0$EI)8-N#[F549Z+R6NE*/T2V:M=C9,HE^RFF ^A" _$YR*(+D0
MAE 5YXQUVK"W>QZ?6XF0T,)%WRRE*KE?>\P-PFD'&+@I8&!_!QC8 0:VY^H_
M'AI%2JMF+9KH/F+<XZTU Q^@S=!73 ,NPFK*>D:.R7S#E99HXU$(!]?*TBCK
M;^E2Z *VIG:=GAS6GR4U[MH"77FY1[!>CG2YBMXK8K_HYJ5"&%WQ;0+7546.
M ;4W6=_)5$CD_B:6!8+*4@*3[B6'[U?B)Y$2I+S$5@;P'S:_H;P5Z[0)&%<3
MA2E*4C+C="7_(T7]+:T%]!L[*9>CJM"7S"HWX<^H,D3I5]66;5I"O$BOCBT;
M)9Y0GW*WE&46R K1 S;1QQ^/8R=8C!L%9QVV$1U.,Q(1D:8^7Z9P$-=OSM](
M?.&*?H;>BHEH4*H2-DU=E5X*M$:[F]I=MN&M68RXS&:^4Y&4V_L%%IMYH-D5
M-E?38.H53GGU8I7V9<5E7UHU./BVJC">QJW@OB6D(<)1ALP6/J.GZSCTR73+
M:"^S8&"&^D+.PTXSWP'M*"YF7-N2G(K*!]%(:#*\IQE(W<[KA.-X9FDP.XXC
MV1$?TJ;CN<9IVKQEV$H-T0K7M-\,=CG]"S28T6Q%Z=,U?.F&6>0%X<=( A1S
M2WQ9./TYF3P:*U-:9B*CJD/H'1^EILP)JIPWGSD 5?L'DT0G8H&" U/19PV?
M[JPK.F>81::Y ^\9KT9><0AU8=O#9!)K!/>NRP\X,U&F9NW(+>>B<4H$%%RQ
MIJ$HL2^]J"Q!0_0(99I0LF_89.9J I8?1&=$=\=9S8ER'1HER:U^DH1W- HF
M7]YD:B;1C]I,P4_?> F$^PX?VS6^0?F20W(A6UK#H7@ 'L=5+_+/..]]!+EI
M%48WID/'11#U,7HNR>PS05\6\#]8;J;6Y65:>6(X*>8PK8FDS[3N%V5U7=67
M-TZ0/D!0,H,9H(;^2\V[,R\Z.[1?,;%"(XYEB)X?V%_+7H=:YX\%)!LTO.>)
MT.I0\H8%(VP-G-)P1EK)];A:+'T2S=98"='= \:*3KH<2(&I(S)*1D7?@85
MDG6QU<D,.R:Y0<+T+M$VP5"6 9[PL_.\:$USIR1: NO"@?,ZJ(Z:>97RB-\6
M9*3QH./U3L@?G=WPO<0CBEI,Q9!U'8^?3?T23D>UO*"N6]Y:V^CJ!'SD<D)(
M'\><C)&-A^8_OM03!(/'.1JNE+&$A[&O>AO2;=2M2*V*P%.<+MYDO=#V]HS7
M9L-%W81DM_#8:O^^D:._R*2=R-$JV?-'MX)N>&?+QZX;^^8F8>][::EI9GS'
M!7UA=!P"9@(CMHJ-Q$3E[).0O&1"9LIHR!H)EAA'S(PX1@I/AB_D3 )6EI:<
MT)B&W3A$]!207QDCYWN$T'Q6:3Y?*_@N*\]:TJ.S=Z/_96ZH80$5]J'0 ^+_
M6D?G75&J7V-HBNVTVVLVO')BM2_" 8&<3F:1[(7I-%S<"'$#B._GY8(21"XB
MY' ]=>)$]$&^4>7LZ+*YMG-*G(O^W45FUY"0YDZIVSNIOJ?+8,L*!,K3_ATI
MMSMCKSMW:)MB?YS'XSN2J+@TY-E\DS *']'?'D/JUHOFRS1AH;--D <W+805
MWTKK>1J:M K+_4LJ*74M'PIW4I7UI2M58 *5VS%ZH.]4/LXPT04=S04Z)6O?
MR("[D)SB6 ) /EWJ7P^B,[2/,;-#8#W..$EJ[$C[%-\NE1XYKBJO/58?D<*-
M<?Z]23$>I]A+<QD?E1N=&'Y9Z\OX#$-BF2C'W'(/TL>&XUY0+?BLV !%@T.K
M1Q7!OOV:A6'G][V[@D@6QCU!.'OE;)&\%,GTQ,E]TY$ED@H1?M=5F67>EDG'
M\3A#F=1,NL#OP#?6Z$\*/83E6=EF5K<^I2&4&EA@-D%<H+(QHPPJ-[Z!Y<[T
M)&Y*V"@B79:^:QN/\P=FU\<X3' (0RLH#>M-%;C)9AM+'(&5(3Q0G%3STD>R
M[]WMK$F,;G56)ZG>QUJ%]?T#7-PFKD$#8'5L3^94F[&$2'3"!O+)<<,R,>5(
M+M#NNT2*PAF<Q,6_.W";,.%$&$BX$= KH/Z'(A/4IW(9"G(;_X8A%'9AB]<B
M4@48S&WC;D&^W,%%JX8N=@N-QES7@QHN^O[K)J=&#R>8OT>]()F23@X,@P\@
M)[AW/%FA&GZP ^^P)M0)EJ;!+M%Z+/.&@G*V4S5U3W7.BM!^Q:<>!J^@=)A$
MQBA6K,2AFRR@"?(>A&+7V@K"/Z$(GX>'+I1#XW;H!;!A;^A$49&&$6DS$Q#$
MWKRJ<\OS/*#A0=S+H:6F!)^6@8.'0<Y<Q)\U59(F2_119)I]29U5R]PM=9..
M@+O$^>^JL1NJL8]WU=A=-7:+2W^_#I3>6R\Y:KPWF#(PQPXLXD"=7UV!Z3Y=
MU:>43<KI2AG!,9HHWP6E?-_@'!_A5*:TNU[A#&-[A&4M)[9) <_D%J8>T,%T
MC1:H+(<G]2CD4N)AL#7B^^D&<E2O;DR4:/"L^_!COON!PC["U*XYU>I[KY&)
MLU(9T% R;EP]*51G=,T8FW.AB%FRI0&NO"B#<%=*$ Q#DS$T*Q."HB#ADBB$
ML];(MFV:>W&PB;/'.0H"615NQI[P'ES]CIH]=+RY)%-=C(&KM:.3,5<B2A3E
MK578OAB<R@N,Y,3AUH:=G)I$8K1,9U006.+>=*G'9)E)YG_D=:G%1)Y'R35+
M$M[72O*168@)X(8-WR]*80PW1?0WG9P(W7/TBE)NH=*+P5WH1DR'3:P:& ;M
MJ[V#TI6.@4=@((XX@9RIT?[Q<0-%*[7M%DK*E1A:VA.#XNBU\Z#]CO=IPGX6
MXY%",'IW02*9QH%@B3+!$\99OF3T4QTUT]+FP<%/Q(TTTCGNNY>%)F*<=)V4
MWY;YER$QH# ]6"-TA=*I0MF9?$+RU6.):9<XW]BO:4XW\X9(OI/GI0G+%!8Q
M97'1(2/HN!YNV&KC\%1AQ-27FZ4/OWIWHCCBNBLR!5.S0+3O,ASTZ_TI,%!\
MEVO>K!9]91)G)A;41U,V2;#R"Q9X)MMC="E4'P"V!*J*"/1W9(<ZKI M-"B_
MX%Q(QO-F,V*//IX/>+E%*%%J>\-4YYKZMDP1HYQQK8T.GP6:9U(3F[D67[Y8
M0LUS:P=&7=+-?/*CO2FQSVE?NM3"4Q/R]A#[C.L<U9?1[DHT&>I&B1UJ0A!-
MG5$;E-J>04NG+=LY*]<51<\&^M+*G.Y^O75[K914!TWIP5)DK;GXB21+.+=X
M5M!C[&#/)BVS\AXRK1.VX\1H7Z)NQ=VNG-YP0]56+K"&L.5H6&1^EZAGPB2M
M>=,RF,DT,A,67FI6W&9TX3Y@+6ZO78XFGN#[,^Q+ZD^@[:-VJ\&[2:?1]_.$
M<^D%1M@##'Z6 B:2&\,&,DJS86.Y^M/TE_U#SJ=B=Q)376H4U1N!=X7,[U\.
M)''\HXE+YO*]-^/;S]C_WEX*=$^(:U.9&D/NJDQ/7:_J"PY<TG+"K>^IFQGP
MJ3,7\*"V+2H-]-KCW<$HJPAC$-;^:>RY]85D)OGV&K9$E\%;;#YHN]%BSDS*
MU&;Z'\C2_7CT2M?J80S'N6 5DRQ8*CD<#1TDPU@U<9Q"VBV7E)_U=2\J))]Y
M_)0(B1"5Z-^G%,@E>MWP'C@&_9:>058"[N\/8T.L!NE(N7<L*((U7^13XL=<
M9%J/44\/%7\:$]$.5*YH>>57C>FBA<!%X(XZ7@#]L^LGI5*!-G+*O&[CC7FZ
M86J9VTSX$'#ZT#P>0]!WSB'D*VYBPLH+:[)(Z8B !_PI<\4:7#RFT1$&N%9/
MQ!N?T-7W\!3=)+%?0[0'B[Q(P1-R0>Z/',0=N[3&1UEH*]F%P58AF[^F:! M
M+1&OJO?9X^*@#<$$='#)UZ0 X&):-%HIW0II2')%_H/>&YOV+[L4<CZ,]%F/
M+\MD5L3RSD)MKD8-I#168;+#^M13. 5%EO9\P*#UCCKJ1C\&Q[RPEX5S=_!6
MG5'/'[V5&C#K]GBJ0>SP+YGH>)4W\.!@>A/S8DQ+D3/G@][JOJDPI<@][#/W
M!BP*? 3_=5V)EWL\MRG:8XA;M%4<2T34D&BGS<5:!MOB]!+TMWV1T_6"Q&8(
M=;;@8HX@=)5:$GG4U"E=8,2E*0A25/OH->-Z2O9-T)$K*P23A4F($H'JAOM[
M\&4'RR"7L;_<09]ACB$"<B=BT6A>&;U!Q]V&I7#X2+7$)F_"O&?I6,LE<<VI
M%?8/Y;''/3( EK0N,NL5.K?:2_01C 39HX(BL+Z)2?<)-8^'5=9UGF*;#X<'
MC A'K@GC52GHR>[DADP(W@AU3G4NN*)(0@P";-BVF( R7)>4#V-'VR?">,D&
MHGJLUD9O8W/6?@L%)&G.9?\SI*?KS"-T)*CE5LU^G&4BW5M%=VR#1B OX(8C
M[H:Y#$P[K?RPN([&4W9QC6X. 1K1!<?D^NYTRD-H:=&$>&_#6%-<1^=D>*_"
M%5'/LQ[/^Z6SH/O)FK&^(J"X*[W8H/+-8Q!6$3>$QRR2G\S_)G2S2V4 KQ3/
MC(!CIM,A9$ZI[/[ASXB[NXT;]M<@0N;.C(8DP.S1Q[QZ>T6VYI9[F#;256EA
MPT][F?BC)QKA6Z)C9-G&1,#8S6["3]O9#Q?D=;(GNW+^C<OY![MR_JZ<O\59
M[%_RJO"I3)<T,W)@1'+K64^QRE!(5@:S9TX(-] 0<SBD'BJ6C([/SHJYW,:K
MYWKLH%H!&^<'[0$F/>6:@T]CD?@+1%K),J.N/%@C4R'V$]ZKJ0GCNH#<L953
M2VNGY 9!8"L7@,&A^:N#1TVM-9:GHZU6^:SY@7B]:BP@A>V]/5U0NEZ&U&N'
MPG='T#]TLUPEF;/R95T5A:29[;OZ9&+K^-I=&R&IOG$B7WM7F;/3) [T#^,D
M5X=CE3'\@!#ZSOPAZ>F^&8DG6W"4B']5(88O,QV8E!$_C)I9G64E$87A18UM
MRGX6J%@VY_R"K98C!I\B$O#<ZC.J7;CW=3FO0V*>4=JVK&6E4-N./*M258CQ
M[R^90? ]_#B0Q ^7?\[.!?O9\EDX]*G^%9=) \'#C4PYHW-,2GCHHUN!'_>/
M$&_FJYR_+)A+63:&71X&V&02KA(!0.GO/@P(Q(064&NC'H)#L\* U&O1BAW:
MMI/$M?_FR.E*IS9GLG5\0P0GNZ8O^:UIEQ<<NR+/YR&$H-/6H%(/]?A; #.+
M,%K:4<?TVDO.JI %4QLJ9[GOHTKSAC4;RJ2>57 LT8 )^9A*I[$<$Z8C8#NE
M>95(NY9 2AMS]GUSB3M;W+348R?KMWTP8WL^PPKT2A"SX*D.G%2!T#)Z6#M<
MTHP%A55.N#_K!G%K[J6!?I4W>EX" L\%&RD7 <QF&$L(XG8+;ROJ.QPW14X8
M"\-=[!R6=E7.D&6732R+4'#IWUPF[  P'(DMO7T(;A-*-B/NPM;<1B^V1O2H
MV<<(=+LX05VQ-E:2_M:I)M8(*:21^'2B5SV2PTIZEB-AZ^;A2LNF2X'CD8.'
M940&,!?72! /UC6ZYBP)"X:GJO2Z(AE72XA-S=5,)?^6CMR,II3HB"JIW(FN
M1N/*5W"7%$@?P!0:KH 6X#WJ#,?-B'-\G))88E*]"7MP0MH7^.P31WA)U&4H
M:89YXD'B4VM"(:2/LR+$G/E4'C2K<]0-APLB<2UK)B&L_^C[(@4G@VM3U0C(
M-YS9:)7&L88NCRD:#4U'^47,!DB:$0TX8\>T6U2<GHN%>%]F49QY:J2BF41D
M0BA/4129_S9)\EH4_T#$SFZYKXSO#ZNH/ .*T,,#C@"QI6O#ESS%-&/1<==4
MRTR>JPH\-GS_\R#F@.-Q[;?"V6&)82/HA*TJ;37[+/@#$VSX+@GMU^N0A'T;
M#;CMC]_4)Z<U],829"VQ%.(*6>=":X%%0;H&9"E;$>^FK.:X6)1IX$(P:E#9
M'<8;9GRFBA;;D(6J? 0FT.YP="[=ENN#9TVDXN.A09/B)L:$>],8LT6Y@5\S
M8^2]VX:D&FW"UZ''?6N'E#C*'N]B,>VD:1*J=MIF?@E+9UM;NI?#8R9+P[-E
M4C@I770(NIPQ/VT.L0G>6D62+RUZ+)@+/0,5 G 3.NIZ GV_<1 "<'%6$N'X
M?T,!5(Y<ORBFIH>^,>.W?6KH,F;,T&QSQT7N+D/39N<(:^#-,._#[KV^^D/\
M28@:2FU&$'])+T6-8$8PPD20=9E/Q;<PMXKB<S+1JP)[P?[MA?8P+*BJUS0D
MPQ82*_N)YTH*EZ-89S>,(NQQ2"%N+1O9Z9/H#=Z76"%N!<*FL(I\"9<A@<U7
MQ,KC7"V>2]690AHJSL81#!Z/%H-GB$5BD57T3WB'NO9$AJL1K-^1?YB3BWX;
M_"8[0J:XY@]I6DEUG7Z20$6Z-\7!ZIJ@+_]VW!'>[1\=A3Z\MS$#YG&T(@FR
MQC'D!T8V)WH C@G@FF-B$I\2T!S8> N3EMC0238NI(@N!:?1S(0@+#+%B<+O
M_=:E9ZXDCOF70@OX):_ $J_;.NR)XD>Y0G-@,L$Y=. T!(9877E:"M?I[[:!
M?P(2TG YBV#]8?C]B):63S-&AVN)R>$-SQ#OWSI2#.S^:#6(W/0Q6F_;C>I"
MSAP+MXL$+%W&4I@7BZK(1"0,8P/X1R4>2+-5D;5"T.;(<'@<(?4_JBIKA[KL
M,=VK/ORB%AWD,K,C9W\;-Z3=[5PIXT$)WE)=<H$$ZKY"K@$ZB7ZBW;LJ"F+.
M"HQDB7%5T0!1RB?Q).5,02&9+SK($/[!6J][GC>IP=5<ZG6MVFZ3)#48@MIS
MQ<V$G@,ME^0YO3\W[XHYX9R5%@FS)Q6X@6<JPE"Q'4M9MIJ60:OD'8FLEDJF
M9+XEOYIVK+HJZHM-)C(P'B8RUS42,"V^BY''J46U*%@2]ZYFF^Q<N1NX<KC;
MG?/>M(\<'"< V:O5%3P@(]!4Y]7!=D7?1FPA-H^5S*P^UB?EW),M].8HA2F4
M%6[S!*@D#'=4GI(%3=0 XX2P@%#L31Q,MSHV,P]T&UV+?O^-$OEH.EX2KH[&
M!PZXUIHHP5M;F3A&L/TJA,4E 00YP!)6=39XV:QSW5*7C8UI"E"'1<2EE"2-
M[!W#$*BM;T2U&$? A*5U59XA)0[G220\W $0;@I >+(#(.P "%?;U&^T/1'$
MR_G;D ^%_6EQ!,A#\E+*?'OPQ8_>)/I-W'/B0:1!(0 L);9AFCB,,PWLQ;#(
M+SOL' #1K\;2T%IX+P^EW>$U6Y$O8F)$QT$C@W5Z0F%G<]!XRK!#X[__.OH*
M2NC5RXA0@DX(#85&4$#Q(U34]EZ0#!KK:/@6;/*>A0.LQ'(A0=O!^BI)>%8O
MK5JM_3S.6MYVTACSN:PNBBR5Z)DZL-L<J7LX/P>W2>5#>+VB?JNF$:NA-_G4
M@@,(.NXYHDPN0\,^XM41LFU;=!A2DUF.<=?8IS^TH2E8A.M=<J59D$88-0_Y
M\-1.,&5G(-S%.B0_H')"\Y:($JGL/ A=&VM4VI?B:CM@"^)K\;"<Q1C*PCDJ
M*:IHG9 W6).R6G+%5%V-V!;7>I .?\/S@8%CV&&@"-.>-!2#XC7>KE?<?!=0
MB<FL_ SW/OS7":4P_$N=5P7L?$P=JP([C;Z!.&.9_SE\YE.!/P>" P)KH/8)
M9=!,71C!!\^V@#,,@?(A>>U0)^')5E5,K[.V 1\Z$JMLHU]]%-H[D?\QZ;'!
M^98PT54ZSK1+9ECST:X5)U_5X^T.J>A\"A1YNRU&0A;.^>NR1D(U-KX6T6M>
M4/P!ZJUCC_AU-B,93ZYG'H1"M!<*58$/?O_R2;1$G Z;0[-IK$KL]_O[+^S'
M1C>3L,;Z)V ?6$--5G %$.0(9:B8R8^O%\_LB7$[G'46,:$_&AUX?G&9!UMC
M9PM-!4!MY @JNC:"D!*A<J!00YOHT%I*7 TPJ"=89=Q<=]F2,4DS*8+_EDGA
M0')5W$*H_^K2"LNLC46SBPMB@@:O9NA%M+Y-1'A2:9\@+VE5?8[UO_W$<MK&
MWZ8%E>>%=IJ2<U654DH(3S;]R(CS$M(8#Y=S4'37M >%=2J2;6LIP:ERRI;,
M\R*9$A_4RA0H&B'DYE&1\6HH?@SWP2*?\W8@"#GR:+ _9]*Z\),!ID>:,. 3
M4\JDC? !A1T*-:6&Z+$C#Y+6:3 PDN'%D0[EF#&C1FO7<ZOF/;? JP7PU$D5
M$C_DEI*!<,PIE+>:>".WT/M=XUO%/H>SD.Q=R@&_O$'@>A= GO[7=U?'%@?/
M7KS\[EHWM/Q+6ZWN33 \=F-?%OQ](G;A3SY#<N1Q@+"!7N>$56@=3\#_5."%
M1[_ ^^ __1F\F5\Q;8L #6Y4IQ*2)\?WH&2ZD229:XH%>@]ZIG'/#>1H]&>W
MX4L:R<MNHU/SJW@:C-EF^0G?)&Q@IV+?K.JL7 ?>&5F!Z>LR>RL0(KA7#68#
M T8D^IRMC0>$G8S9&>,8?S[Y>.PRD-Q3%*L.JAF4L*E2V[A"Q>S=OH(@GN4U
M; .UYXJ%C_]&1^9<CHR@54.HM#34"B,MCJ@D\.JO/8H'Y2SV]3?[^B';&=/;
MDQ1'3Z7G(G.E&*U]B+84VES5?(9QY2G'-@RG)0:X8+J)AK[6;CT&!:MZ'(FQ
MDC^AODJSAI<ZRZU>A<NA8T&2JO$%9HCA'8G-&Q^*ET%0\?'*G)6EA;)'V$@S
M:/*9:VKZ!YN?#=/34JAL$'W/Y"J"UU(,7 K[ZA^^4Z'WJW33T78'A]()8$OO
M2%=BGJ",'!/>&6XH@P^QN6T+&U$XY4BGB:GG!1R3KNKO.AO,\\81B@FEY$>:
MZ@BQR%()2]_<;@^)V154VW6\[BAD)5)1!*JBTXLV:5GZ]@9Z9&)XY+D!>1U=
MKU?&6\?1I/K4OHIL,:$Y8@9V2E*QBFL6'9V\PE,];,\P"!33J.+0?;('G&R\
M4BO:9D=L!!]H(RI3LWK\853AT<@#?*Z*$EG_UVBSC!=FM&JKI"P>)'-BM4.L
M4:;=K &@9VD*PT7Y>RS20IIN]$>'?AE1-TG ^Y;,:DJH8:F3J1+S)CN4(,52
MI,J-:?3?YM6L4TEQYPD:Y6)6D"\0GI,3//X__./!YN3:CFMDE[(SWQ.437*1
MF4U].?9(,TU]YGVV' R8T X,=VE15X,T*HS: 8>K)MVFHF. (MAQ-N/8D?;O
MCCBNN-_#$6AY>-DPGQ<K!L%NF:_GE-QO+_"F-Z?1KH#53ME/QE0HNX[TR69!
MX*(,[K#M=-P"Z:,O>>N(<0H"<'/#SL 8:M0=TDHA^ST"3\&^:[C7S[6?U=6%
M=)>QL[!V9S'KP9,VKY'S,^,1=RFU\4PU//"!>\,][-Y5R,T5=%9AJT^U"0JP
MI>NM[2[D%R5-N\'<Q^2-6!W(04\1)ME)E?*<ND"]7_/V])7]0Y_$3)<L7*CY
M:$36X_D-:_B.ZT1(T.:Y5+SXZJL946,(#'A_N^UV'>?6VE&ZQZ7>,\ORE6"^
M?"I<4*+]?JJN<2X=8;O@6.@<^&U94;C)UU#@XY"RA)\J+3K@^&]V;VM2GI;3
MILN\'XMM@#W/E,2E*_CP?[*QI.P#9)S*&[BG&U4N>DC3?E9GF<)KM2&2LD^Y
M@F=PS@4Z%U[KV!Q*>M<F<!.9'5T0\?I\)O"=W'L]K4-'R11L-G+AM8T674*8
M&OI)[MT@!2$R$^SZNCXI>BFFPLW;A9!48>:/N2 W*G&R"=KA.VZ*[WBZPW?L
M\!WW%M_A1-8=>1,5]TS+F@U0N6">*FN^T<,&"]0YL*VW)VC0''*4 ;<LD7R9
M86JD]<]UT==:?!<3'%CVS<V,V^C<A*#A_JWIS#!L6M3+;;,@YV=N55PP92/=
MK.8N0 ?O];@V5L9VD+0T9P=-1.N:S03XHWDC\IMM(MJUL8;0WD#-*>%.RUQ.
MH6\6XWU)_I1UIQZ:S([M7Y2M9UQIW_.K$ ?V+EPW+#&X>@@E_%0UR^E7Z69L
MA$H!TQM!2J,WGZU7(?QSX"8PY>SJ\NI\"!MZ+TG,"%GT00WSS( B K/;FU+'
MQV/L6-K\(:E8>/!L[+FM5:R.N1^Q)4Q_6U%])/C.>*;-J]N&* 3O8-M$S#::
ME-'E#.C2QA=5:@[:MNO :;XIM[&)*J."TUMD!Q93(5_U<4>7M/)+RAB(WNB<
MI>]GA#S@T$NM\>."835.\<"\1U5[8;:Q;;;LQ3.AF-OF?N5A'9A8GYG*I1R;
M-=:=\-MX9#S<:H3+>L7Q<6<RH"%%N^TC1 H=PY,S1J3C<X+C:WS;PZ4:'+U%
MOLV9N]<V=;"1PS7I$TF9RN/@OK:EVIOVT/QEJKB<T1==+3.;8T5.OL'15V M
M+2RTS_)ZUBU%'SFZH,52VNZN,7VF#FT20II)^L:<FM[O]@K 7/KJ?>:NJX.!
MJTF<7$DK]$E);Z\Z-0K- I54/G <6\T"-[ "AB&FRM%ME#MFF5#7W JUNM6"
ME6"R8:C"A&YTF6/'QASD2.!UY6DPL8XP'E^Y9SW)(@X,BK^*THJF3GOH!LUS
ML1!XR(42/L6LB%HX)5!"UFX15ZJH,\^+F-J\+;JG3=A?%U]2R;CLKO-5NFE(
M#A6@I5UWDSW?RV7>JB(;OF[PEC9;B<G)K&;B$KQ/%+UL_'%'1T%ORNEFYIP;
MK@#E&,MV6(2BI"1F4V7G-+'6D1F:37FXJA3A8&[XYN(H-FC[_G6#'+1#)T7Y
MX9M*I^0Y;D,75=CD^7#I8NF&O&2'D1B;IN8Y:JW7ZBEHCVEL4J4^.T]$_VXV
MY\,1WW*OC"1C1^[X:Y\QY\_U+C0?O]/F9J2?+$?X>\QZ(OUF0EF@=C3M0P>\
M;A;1ZR)I %$8$/6)LN/B<(ZU[^*3?/*$4PL]<>J&"!QP1-EYPH>@MRVF67N!
M' N#>9"^N<NGB7*V>IM@4E<[FP,Z%*0H,(1HEQ8Y?^=2:2R]V?^XGR[6E;V=
M TZJ_BW;#"CK*+?@O*@?;O#>*SQ Y=FC(INW/SQ]TIN)1_LOOME4D#3-LT-]
MEZ\_A'!N]I],GN)<./89@R)!]BV(@YJ&S'G?8: F=++5%YG>U.3--<@U,.Y6
MZ"%:AYG 41V_$*2M3?LE_4=!('I*3LH(FS")A)R+77M]#;?=GKG=GAEQLEQ
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M\!\2@!L D&$GP]\=T$V8*IO"S700\_Q+EFHO8Y!=<B ?!3DP9J /C:'B;W\
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MQ'^'_<S_^V)1%?!Y-E?64]S&,_)S66!D0<MW 7XZO>8,C4X<A6EXNFC ^D
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MI^\,!A]QI:02Z;U3T6X.O,-<=TB+C2#3-FUS$C G/%-7-8A%[JX/8T>F8*
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ML!P[XM#. A0K&$DZ-B26*B<:C2$^CL00+RI37JCMOP9@SF#BL<E)&'5J_(6
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M<I_21"MS/NP65-(^3@4_')]T:6<(&J4+'>G21SG;I%Y5=+5>JI+$$.ODV-8
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M8'4G].=4OM-H];<W:7QDB0&1C!=LA&TV)M3L. [GN7JK_W&,HZ7C</$V2H@
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MS?"/13KZ'I (XVP-?@GK:_33YEEZD86S'8R7KA]XP_S3BVZ[<]@WX6,)J"Z
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M?S3\T?!'PQ\_I6/7G:[0V;["]F:@3C-0IQFH\Y@#=>Z!5.O5[I\Q.D3N@!2
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M!W^46? KA@4PB,+_>3(BUNMUNIW@%?Y2.*3F/?86 Y64JP'<^P?DB-DX=2,
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M#FR9P6TFG;=2QWIU!#I11!D'R=1RT-)CHZ4\"$O?S,^"W#I1L=^]ET3%HX>
M/CV,,U+_\BI*V^[H1&-U@)& /!85&%],%!K98&JA51[A)W19PP5;,4.ZD'";
MHPRL=WQ +#_"V/;G!(,ES-UXXS]G$6P>OF+>]26&C;Z2N+!V \3O^@)F2W"B
M_7%D>?>#WVQ 2O(32L+)<#GE7[I&QP8^SZN>7) O\D+-.%[$<E6O& T]-;9K
M/<$*$();?H79B8*(+U]R5W:JEPQ"0O[^Z81VFCMKUIL5B8%Q?A#T)#.\K+!-
M&7WZ[/P>-"J<1:;&.AR>K?C9ER_^SUB9 B7LQE"<HH))E!J#-(MUGM5\09]L
M3AH9/AR!A,2,%'X5CAFD%<-/7UL@1?:E&$#D'UCE**:47_BE171] 5C$*NFC
M]M:;8II-BVEZ33%-4TRSM1&CSU8ZY.J"1+5;>V)SN^BBZL"#2K*4Y+%X52L4
MSA6:WB]Z[?[^43#DC$4+_WN_*PEJ^2.)(?S[T4!_S^3@.(>MZH&F,:W6H__+
M\6!$K&UIGQ)D3KS81:_Y) "WDSP)4%RC+)KK@ H5TRSF7(]IPI2.17]G)^<F
M]6F"01M36L@<4A:;2M@O=AP!"=>;LA^%W@XO.U<50R#7^1LP:%3.3O^XX@89
MC0:N*ZP"<T:ZQ%4K_*_^:ERWY)0=?VTD\"ZV,DNYLDYH!7M0.HR" D8KGR5S
MF\G4W!]\$9*?$\FW\R9LN'G#IN? '!B8?'-".264#E%XD8 )D;_Y*A;-[^ >
MS345\L?+G7#ZIML[/E<2F>P>'NZ_&G,2D_Y]\5I?\/.4C$3X:DF!5XQS83 1
M_6D*MM)A>A) RTH;#^ H"/,&Q0:H@MLP24U&M3(9!>W!!",4#COY-]BQ?(VU
MC\4:.KIJW[;Z&=9\/G.>TJI)\N 6S5+MH^V.C=@C0SH<*XS*8"1.<?$F1FU(
M.N&35 A^D'G<.,JY[+*-R61=@4D%H7$())E$& L'6URB1:EW"M:\%XXTU3;"
MEV/-E_*!MK?1>9];"G#Y&WS^[NOOCB?!/ML(?G%!I2=6E%.H(H^ 6\,,B_(3
M\AUP^>$(]AR!5!WI#HV,DO1P!JP.=-A'_SJ<H9]!3&*H EJ4!]JT@]-/YUB^
M!;8U"7>BGKM<BI.+V.5KH OT90X.E^&$DG(P3];KH#51=3^&[G2P%L\/(^JC
M$I?HOJ]E7Z?3QTN/+O/:Q^*@'H_2NV@@H ^-=]3<)CZ_&CF $; TD<HGRGFX
MQZ9_3I5X,_!9Z=I/J/92"*H+DZGH25[#I<08IV # 3QJO!)Q.#01 <WCG.KE
M'%.2)O25-]Z'[>"W%/B88_.K'F!#O+ G=^?&C%A)#U\*<A)++B9^?*%T"P[U
M-HDEC-TRN)AE.5JQ+H._*!QIKKA.A7)Q,W;_8'TXV6]Y.9Q%16&KA_1-:]7>
M+R.4\#1\YJ_;LL@]S)_,X\B^I'HOZ]B 7ZW&')SQ/JK7*/3BC$LS*B]@"CA4
MM24?IC$+5\JVXECJ/N)%2ZI.@?H89&&27<!S01*D;T6AZ.@PI:6I:#<=\PNM
MT<LQ8B: T]#DT4)X(<]1U192M[HLUH[=Y!'S U7YPY/=#<*BCBWT1C!/L31?
MN1E2SP"N84)\Q J&L\' B&:3D;"S532Z H;R1W0/?0I2GD6G>@P]3 ;L&H-A
M2^7BAN;BY[* VY!MDPVHEU1A!ZZIQ@2Z_CL9,9@W,=&ZU#M-,$ZBF1A_J.3P
M&!W#25L)\',;672:%$E>I!G?AGAA=26(=U2_^#.1%EH9:*M+?,<\G/GB @2(
M7^P;RE7UMPP2;)D5T>]7IO^E92\(\70./YJ56(SR8Z04BS\M[*E&4*L^3WK!
M10V#2?2#2_]4/DWC\9+DP6^! (;KZH:@N5(Z$U=2^H)26]O[Z42'GU]C;!IM
ME$*JC;5T"OF$J!F)Y?)")QO]S=(ZK<K%W\LF"EVZ+:J ;K71O\5BKJLDM,'N
MZA5;VXX+RLA]IVK(6(M0L,_ J6@'OW.X :5P-)$]S.9EH;_'1)=^AW)VK2TQ
MCTO^8H7N+6]M.F*1!X>=E_IY6M2-%-5>)%6^V5*1=.VEM_Y0C5_'FI_X&FP&
MZK$.+RXP+UV8BLBT*B[0U@(C%OPE1S+ 'X>*-$&,105TA0<O,3-"5YS^>_^E
MG5]9=W36%3%2TTR^M X>F@C+GY,Y:#TM8&@24^PN%77;T/T'S$Z^/<+=Z-[W
MQ0G1=Y:E0RVC$2TRKF@@FJKEIY'"%RDV0P,7OT2M!"@&6.MKUZ+Z>$X=Y]?L
M2W?*O0U>=5]SK-(OX&)OA*ZQ*RVKSV*KXE7/><88L5&TO^:<OQL 9-&]YCNT
MQZYS_FYWS]+>*F  F5_D;H00L1S+&S*8MO3>;FA*O*N6L9Y/O1#<%ID89XDQ
M**BL(_Q.U\&-I2Q'B<?@B(_$$/#RT4XX!IZ$D9$:8\6S4XCKV)@(E\I_X0W4
M%V0\NSB]DLLOS6*FXB+XDD7(T&GP&92O"?QW6Z;8M]\*WIU_=&/AF;*,Z(5Y
MC#JT75M>\[")"VE-QKT\3K?&ETRGOD].3^B]'\"[ \WO2\?ZVLY+<JZ]LD-\
M@N,><?!;W^*QC42E(RQCIE1N0IUTF"!<31(W"*??.U,@%<8$I="J$1N]@5'"
MQL=7"[<DD>NPJ&Q)?C1V*BE74@8I@EXQ/S3"-THZ'=48RV^A[OO9/-)5GW\'
MFG#8[81^V18*;Z<@N?9*?C3$%C'L-IA=MV<\$(^WR4_ (C851Q<1LA?+8,5%
M6#77DMZS7%OG,?5?IUKSPKOXS3X[UWR!*T&6+I:YT5C8EL;X+^PEU/( &^I
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MUY43#M2ZAHM;[06K+&!9M'RUHL7&H>"O:PD:_C%<.*]/[\MR8,O[IFVCXS9
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ME.F0EC0=^B:3=]=Q8#AMEJ_YQ9.T,X-0=EE?HQO$<YT)DXSJO,2JDOZR"7I
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M1]V)$A E( =IUBOM]ROY:)-\Z.-N3PF($I!C;EW9T+(2D#8)B#IAU W>J>D
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MI!(J]>3S"-5WH3ES&/SOW+[__N_P'_G&VO27MBL30G1#IMW8[IRYX6U_1+E
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MFN\]\)^-T\GV/"7PQ<CV243+B& W'\3M6A9\]8! Z@4$LB V9)44>#=?VT%
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MGR!((&A@7??,C>"[N/%2T\S\'C:=C9RD@8 ,\'$:]]!@W7T#Y=&-^C3YK+$
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M,W*H#78L5GY:7H!]OS:>CZW-PM!A:[83JL*HX+WI1!1>U4R,?)FNI=*C3BH
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M U5WN/*P,LGBI7N.*9]"8T=*'C)GLS+]-;P94< CN(H#^PL5?7V)-=]'+DU
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M "O!FO<$/R/='H)C&%I_1'9@QR@E+P?#_L[44OV8=KI+!$F3E!@)\<#Z.=[
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MAC5][%T2^3R>%(>.UZ:SP0Z/ML52"64[+):D$++01'VWTTT<%<O20R$XH.5
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M#;L6;A<B9%*DR$1;S/!<J9%'WWR986E_=Z<J+ZP00+'1K6@NBZ[O+.M?1C-
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M HONXZ*-: Q>.AKRPJVQ>"A"P7HV^[\&Z1V0:3Z*)E;#E+%&BCRMP9>KS^=
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M-LO(810FE\)#-6&].R"]UK*S=G!:)U8XLG1802UH!2\.J@8G>6OV]V:]->O
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M(6M<4C3XCU]6"(UVCGYI MU-H+N:C2:?%.ED8YR ]?EJ5Q=?+D_/KH*33^]
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MC;A$JF(44+(_NBR.=HX,QUG/QR(A<%?*'W;V_/NSUHA@&WQ&Y .E723XI$Z
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MJ22"'4:,0(;I8:^'Q721[KE3RHT55<_I)ZPOZDR!LO6&5S,:M"DM*?J2A9?
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MZQ^TN\KWCDL8WG-ON%X<T[M8?/1S&WDT2-0/B43=[V<E9CX/G1[W')]/AWP
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M.0W!P?%9E/)"A(&1!5OSAC,I$WZER4'#ZA,_ _=X_U=Z^/CHUQ;A"&CLX*9
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M# <3$Y_E]T.'K8J-= %,U.RPN\';2#)HG,Q>9>"Z,6><+O?^+*0$>_)W8):
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MJPCP9YM$V87E)7PJ34&PETOBX)VBKA+UHXF!IK5]LZNM.?JC2&&_/=@FTHI
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MR_.3%<(?V[?$=R>?SL\^\+__J\W_/3WY='KVX>/Y P(!/-W*K\)R/ V#J[+
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MIZN2XVBF$,[L%T'>!S+&1(7[1WID*7H-NAN5!'DDJB/V$#^GC:(6YEMFG--
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MH']4XIL5]BYY>8U1VZR..P0S3BFG8*3+PX>,!2L, TP1CUH&ST257<OD@QN
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M5(QW)MQI%Z7">0URWJR9 SPZ;)TQ$!'.44*+01EM@<2(-!*""9RK^%8Q*PW
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M'$_>IQL?^FM93D6#FTN#VYHU7-D0;(+$ ;BG 9CS.FEP@D/T3%L?F;1"MZO
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M8W;E88V"V15C]O Z9E54D8",$-:YA4QD$ADK!9+<VQ253B&WD*'M8$:![*.
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MR"7"$=<.(ZM,0%I&BSF..EB^L\?E=OB*BGMW^VV$ N;[ G/+3J L<!4T0)B
MML$#)<CF6F[86!] [?#" 9CE7>HQ%# _ 3NA0/B^(-Q.W(I*@!9%D29:($Z9
M1M8ZESM:!Z\CEEK(G3UVYUKMVWK*8U'L8C-P5 OA".9QQ]OA:>>\&N2#3G5
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M)5KG0L38L1Y6-/SV13[??C08P=U'@\Z+^;:7DY*$MM=Y.X(W:JOQV6SFKT_
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M-BD:B),\@=PEHW<EF=>S-5_6Q14]YE=R^/$#IB0:1ECN+ 1[%AA9R'B:4,+
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MJ,D-6]N!OJDZ,#O'-;7?WC8_/+Q5[.?I^>H/+XY//I+#K^\^'YU\Y$=_OOH
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M-N<PS4A=!].%*EV? 5B\S-U3>:W9'6#CHXW.%4TK(UM2\;)83K#Q ';-DJ8
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M;>X>@6GEY_ISVN8^=<L^]RW[F%25 $;>:42RA56[_IK8M 0[$W5XQ$LE2K7
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MOA=G:>H1+A./*1IY/DVD\H.(Q"'H[EFV&8 P@.H7ZD_[B6:&6XP4_@9[P#Z
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M0P.OQ^(X\\(X%HF?:LD#\N@)B3\[TN?.H>D>:2?W7:2\:=G2[[[ZV:V5'!U
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MO8H$"WS%XB_ES_BV"UI](6GTW::?(TU8)OTH\A@%19\P*CSF9\P+_$P1F<B
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MHDFF=,XX+/7?[I-17W&$MORO46%T7I>)L)?,Y6E';@/LO-LZ+J8C:+?X0<]
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MC![HX'/IX.+C>4 "S6,N/5#FN4>H)AX<D?0BXC,?[BJG7#QZ0N/;8](914B
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MVS%DD[<"]U35'Q:I!P*Y 8' ?)Z>:^;[0H-F%T8IZ'A2A1ZG- -%S]=1$$@
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M:@#2_8#TPQ9E.TX$Y4&6>)'0(%IFC&+SO<B3+.2QS[(P2$#9SOS/AM$A"G^
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M[H,SZT\.>["G!#0<JO<QIO1H-"L\TA=VL?&0!CR.6M*7X>T;1T",%%F2="K
M=H=DW#<S#Y&N1\QNT5KH963K@3-[Z^E6>>HP=< 5G?3<.1F]\SP*JZ6V6&.F
M'>7!.UF&Q_(!5QD>PU/GY&PZ6'8C1%9N[IO#;DT/.]UB*QI'V_OZ9W^_V67[
M6S"*YB9M?/A"=C]\P;O-_3;\YGOCZN3[_O'OQXVK=AON@>N?A[_Y[Y]'[C2T
M=X_#2>.X<53?VL/[S2]\O_E1-$Z_\$:NQFC^<5K_4&>[7[^(^M7'[_^]VAG4
M6_C[7\WM0?UJ$^_"/0^L(LFG$%&$%45<&HV,EP99HRGC24BFQ=H&>:?Q+,?&
M V!Z80U;1*MP[57ML >JUO^=GJ:%'G%%8>.\'_Z.O4*3GQ<[Z)W0,0*-H3^:
MV06NAS&$"EQ!Q8.@HO%^$BJ\.*!&:"NX0"[PG!\:*+(>6^12DMQ+ J]!#CE9
MG\/*,M\;67 +K2VH$=7.7^W\E3J/U/G&SG](#IC7*;&0D"4YW5OS )IL)?),
M:LXTZ+.PU<Y?[?R+[_S3F!$BX2%19Z/DQ%H;E8F<<&T4EIRZ43K<@ZHH9]+A
M/L6<-0"S=IT7=_V=<8;<BN?&OC18[-[8^_?$08Q,844%4E@0Q#EL^X >#@%6
M*(&5$TZ1M0U#;ZO ?8V=?^&P2"K^;_7"(HWNMXE,0C(.CMQ\G^$G1T>F)NA1
M-M+]D[Q"8#?71G("C",:DXJ)<$>#X48:SZR7TF+'[=!&&B</$88K&VD)8*\^
M&QT).E!LP9CE,9/.6N&1ELDCDH,C-F2QRR[/.ZQGRPH>92/=HV&+:-7/9B/-
M>\05A8W;HR-/Q(XJ.O)24'$S.G+X_<"X)+06$NGH= ZD&N08"RA1EJC506"M
M 2KHNIHMH%W01IJ_A?[0Z$BU\U<[_T^MSC>C(^P 8^E\B!8)(7-T!'MD&9&(
M$AF=5,Y%4NW\U<[_].@(]<I@F0('8>-466<TED1X#1ZW3D8/HR/34%%%1UX/
M+&Y&1_S5@2'6X BHGEADN8S!(@?+AX(VFFL/5D%FSE!B-I#Z>CO_FTD:N5EG
M>1T=F:F_?*G<$;K8),]%\Q6"O%O.D2@3QG'LF.14&VLT<8FHI"A@H.9#2XG>
M1N+R>$LIM;['@*YBKUL920OAWL>)\,@VJS>_D -+N)(B<*0BB^#ST)0KJRWR
M&#P>)5PTB9;M%0G];8DBP]6)575B];!<E2>AU!.B,?<@5A6E>1AB74=I +&.
M-R_!4E-:$2618YE+-D2.M, ,_E0XM_?R29.?&+$J&Z2R059<HV_8(.![8<^]
M3M8C2A0!C<82688U\N"&A<"33\;^Q!I=V2 _BPWR+ U'J[C0*V+3[@UK8T<<
MA*!IIKU%%!8P]RP-N6>I0$1%XCC%GLGGB0NM<-;,"]/@W5)'- H&U6;B0*]T
M2C8L6AO2<#!8S- ]SZ0>1>':HTK:7A,.YZ_#8O8:-Q0+G9S$QG =G0E4!A5I
M#%H;B<5T[O'SV6O5Z=H3\VH^#X'Q^ 2>H<X.N* ^&HX1^%R9F-PHY&3 B#!A
M$W-&).K6-L0[79VN/5*U?H[3M05AX_9(SA.QH\JK>3&HN)R""NF%)2RSA3.E
M$'?1(L-)0$Q)HV2RRMM0Y-7PV=SCD0Z\AJG_IG)Z*FNELE9^$@CZ.)T+) X<
M<S:G_" B!08(T@II"_]$RC%-BCCXXR6ME2=?H_#Q?BGX_B8)?&]TD'U2MV2Y
M=B]QX9)U2V8_O%OR'ZV.[7A8BT_@:[:^Y<E?(AK0O:%J=G'C^)_C_0^@1L>_
MG]:OZJ R?QSM;FU>U4^WR=[QT4E]JWU2__#/25:S&S2@QQ]IXVOC9._JXV7]
MP]Y5_>I3&]28U[?JEWO-?UJ['SY>['[]>+'_M:@Q^KZ[]>5 >TD<YD6/F00[
M?!1(!\<0#S)ADY*6.>WI9B=B8A(5$A,NA>21<<NE5-00"7C+J#335*&;[]_O
M?FDT/]<^;;_?WOEG\_>_MA_1+_G^N]X<I=."2T,$BR%R)K&F&EXQ\'M(2BZY
MM9?CG]WTON#*S<VY^W]U05,V.V&.-+YM8=P[H!9C)S# ?&)@:29'D$E*(,8<
MAF5.$8>9_MM+RD-[UFO!XI[9=L$VV^V,VC;;H2C4>N-5KQ4=+8ZZ%YT1D_P$
MB>T;8:&5>MW0Q]&/_E1\L90^)ZOIK6:+>3P9X6L2<$W&B!?AWUJ*R/@SDP;>
MZM+=X]4MWZH^--C_D =^"AG=*DX<640-1C@/-L\]H8J7^N9+IT"_1ACJ;[!A
M<SN7.3O_HJ>+#Q;=98N0/U.>P<.??UGB6$N3A#!R0:Z=C0^];K___KS7 ^%<
ME;YVCW-+AN&KB[W3?XX:5_G[[9/=K1V\U]RYV/M:SZ$HNG?U>ZMQ]9'N-T^N
M]BZGPU>_M_:_;K/LQH#+PNO'GX[@OD=[5R?P_?WC^@<8W]9^>[?9.)XZ;+MJ
M7&U?'"C&N6:.(F6)0]P[A4QT'GQN6$_/HM+" YR_4UP^4Q["(IO<,B=/58CW
MYA"/>RDTL\%)CKFET22G>,#8Y>S@R$.!> ]H%%LAW@LBWN44XB41E2.YQ9_)
M]7A:%57Y$E'%:(1%Q#:0C'AR#K79DB+>SY66-5]-M_L#D/_<&2F=#\Z++HJ^
M"P-LQ?ZM'MI=B>P/3=Y8:<!ZJHDV./*_CB?^CV+>/XVG_8]>]W2$9)O]/LQ+
M#,WN^VZGE6*OPJF%<.KCK&4F:9*>DX1@@U&(<Z^0H]HAP25QQ',JN5G;('SV
M6/'GR2YX\PK\5(NC4N"74^!I0X,X0:/C%CF3#+A6V"$;>42 P3YXHHD7((&$
MJ252X+<0]6H4G4#[@]Q8L=L;E+U ^W$P:,?3.'W^!1]]L^WA8:]MM[L7MN,?
M:7+\A+5SSVER9 ""5Y/0!4N5$R8_%0OU^7J)KAVGO^UE_@^LTS^C9=H<KU*%
M80MAV)=9(T13;#DS"278@1"/42(KK$$4$^&$\H1SM[;!]1+5J%35L$MC@U0:
M_?H:/6V5"&I]M-@BJDS.FW8661PQDB+ (E-83P)N!6-+I-$_V]GAR@UX%=FP
M;^E%.GO2^:[6B8,E*@:XP2WUI-SZ.]/KE_V4XIDJEYYQ@I9E0U^\[NG%#F[S
M[EX=8CSW+GXXY]A6.L*L""@QHA!7,B!'HP<SW0B;J$DVQ7R(8?CL1KY$6/?B
M2OS*@<T*SBLX?W8X_W&GTA6<_R XGW;*\I+%J#WBN8$$)S(A)R-%3#"K93!*
MFU!DX:C;VVU5<+Z@1WEWC=O=Y0Q+4LXQ=F<&N=E]+M8X.^_US_,A>;>7=ZQV
M]#>H3(:'.P7CE?JM7W/G?;AH/]=_I):'@>5K9/:? ?P/+@,_[9[W:D?=_EEK
M +@Q_&'-=;LG9>"\%U.^"7RWU:F=W9Y0NEZ[(]OT'?S8M\_SNM9<"T8=KK^5
M;^)A,6% @()3G[ZKV7[M(K;;^;]QG")@3\O?AO-82[WN*3Q_JQ?RX+$! >H-
M+F&HE['7+^:I%P>];M:F;[%FP_%Y?U"$I-X5DW$]R'ZME8K9* 2L-NAF&.ZW
M0%*'I6!]&!^\%5KY3]LN1M[MM"^+PIDSV^_;PY@+;6"4,7^[%\L*W9J+,(S\
ME<M\X^(K>3UG+@^/LUZ[3H3(=RM6N#RJ&#YS'O1A[,#/VG#KT37R^IR>M5N^
M-<@%0#[F3V#!^[EC^+7XV%J $?E\-A+.AZ+3O6M9:S"ZH]C+5Y@X'RFF-2OU
M()VWQS];7Z1@:$DT["O,2;L/4]#K?H-YK*6R-"ZO+LQ=?U \[4B[LG#X(]MK
M@7SEQ8=-N],_SW,?6OUB#O)U,L56/T_K]<?#"091/NH6ZW#>*2:WF/O+8C:S
M#!U%VQX<^:(H*_:^%0H+[U\.UP.$8Q=&< 9PZ2^SO'2ZA9B6F# )![G::Z0B
M<1![IX6RPU?_WSG 92KO..]1?\OWZQ7B^@[T#M:XN$EYDI8_ZU\+(NAK)X(T
MGQ42#)K=B]]BYSSVUVOU?/P&5QQDI2HT/Q^UC16XU(!8GM+!Z]&<%D\^+$0;
MC=N.'VB,4F-TBP#]+4",_-O\1/488$MH%<L!"Y''G#5UD&O<\J5'%QAI(HRT
M63S2Z.]:.8!!!+DLYNL4=/VP&'%>^N%PLUZ>GL5.O]#2/.CUVN?N:1P]\9']
M-I2J #/2A@D*(_F"68]PL5ZM6VA5__SLK R07P_JA@B-[Y^GI'\$#Y1 "?,@
MQL_:BZU3!Q)07*8H^;.]<O WIAAF&);HQBR-I/)VO5T>)<V@WLI5C8-"0K[!
MXW3/^S>G=31Q(+E'+7\$ZM0^*X&NG+]2<.>O8+F-P*.V#HLU&"EL5O,!R$V>
MR6\%S+K+\0S^\++QZSK>W2POF_U^'.0"WN*OOUJVD/U6[#??? EOLWZ@N''@
M!AF4N*:(&YN059X@CIW#,J@DB9ZNU-98XLBD-(1+S@5QW 7XNLMQ%A,HF2[Y
MS?6UJ9NWP:Q-PQK7\U/8WT"<^Y-25I@U[8RL8'A=@UBQ@L6'[>OE&V%>WDA!
M?3N7^>)@RA6&<2&BO]MVL1-]/HJQV)_;Q=N@Y.\SH'=[G98=P^(\I?CU[K+W
M!8M[YU;)WSN755%P511<%0571<%+OJI54? +%07_%-F&I4WVZT,$YDGU(X_B
M@7IH#M0/&>0S)1V4!QUTG8HEEX3"**_Y,J ^M/2>1,2Y9$<\52>_.PYI%(E*
M)6*9]X93(K3SD48*AK )7";W/&?N/\4YS!G<IW&\N_7E^W[SJ-WXL(?WM_Z$
ML?UYM'?\1VOO],_3^O$>WSO=N=I_/W4.<PK/1.N\T?RCG4D ]X\_G=1/=V!L
M?[3J7_^$W^Y=-HZ/6GO'C9.YU="4$ZT#.-R1Z(2XD 8YHA@R+.J@K!22Y>0X
MN4PI^Q7+<84\=_80Y89IHP31S'(LA",4'&Z:.'?@A$?W/,?#%?(LACS3)\"*
M>JZ2C"A297*'<(^<C9F1 1OI/6&18$">.>>_*U\LM#(&W$[G6QR>#99G>X5!
MMZ A5[7>66TXU=Y3;8W$ 7,>"-%<"<>5TTQ:K\+3DB<;W8ZO$/41B#JG?MIA
M3:QU&,%_<TZ-TL@Q)\&TX]%+R;Q,8FV#F"?;<LM7NU2!ST\*/M8X$<%L"YJ#
M^6:U#3Q0GC SF%#%Y)-LN0I\'@\^T^:<%8)IR12*FG'$G>=(ATB0,E()3 !^
MM%W;H&0)RZQ&]QJ?L)=TO4O"3K\LUW@+H>N)!((GQ:^7)41=1:%GHM 32095
M*/J-!(2,4<1& J:#4#Q189-TUFF<M/,V";NH!S,LV*Y"08^Q'?RLXR*"XI0:
M<%<,=HAKIY 3--/(>*.-=2ZJD(F?9EM:54'H"G.6$W-\Q,+II+&*G&.F#4LA
M*1=$\M8[L7 0NL*<IV'.M+^"P44A27#D9>ZFEW-.K?$486VD3LZS6'!5T2?[
M*\L:?F9+CB.EV=;N=@Y1SGM_E.%617]6&T0=DS)G$5#%.8]!6A:U%A)+[(Q+
ME#S4<)OPZZJ8SR,Q=$Y-OO>2AQ@"L@R0DVNK<[\RBR*SQ"O,#?-\;4,N4\BG
MBC=7B',7XB2E0Y0< (:03&!I';;*@4E@A.#<I(>:;17B/ OBS)2-.T-2$( S
M1-H<9:;(:D?!4R06UB6"MY@1Y[EXS)^_\GJFC^AU+?9L?]&;<6E.UU6.M9UU
M^T6][:]%S4OK6[PN[OB?M1L_'):&X.N?6-?OML\'M__DMKK4&QG62U($9_04
MA=3$OT?CJ/Z9/8S(]:(]03;!Z'^U[0M[V5_[Y>9SPT-/S?.B4_2@"4GIAU0F
MP'R4@P!,ZI;ET[^".,=>_A:,QB[+4&I'O8RS_^<!;7/QVD91Q9>KQ-YGC.[D
MI!.[,6_1YY9?O5K3T4S[>%VH."Y?SS20?W1[[\O:WO>V%ZLJQ>;A@1'4$>$M
MT@8+!':^0X[Y@ (-0<)6'#6?J3I<PI+<>8609[W8+YN-GO<FR!IR"7*_]B]G
M^R7A1#\."26N*\?C]UR,&\>5NZ.:\;YMV\QD#N\#KI5962YV8FIE^H:B>KH5
M)Y.U9B_Y[ZGJYSRVZ\+\HDIS6'T^JOE](WU/A5R77#]_U2!=YT:N2HGCB@U6
MX(==]LW4'Q*QFI6C>]'V^K7M@F9B5$5:/FI52OIS5416I:3/4DI:3=R#)PZ_
MN1K<[2E;$^R\'U^0NQ)M !Z.N:]>.US-9S6?;S%A[\L,2UR5J?=&LF8$L9Y$
MBY.5DA.;-)-!1XT359@E[^8&W>XZA_E/02"88VV[O4/;:5T5\<'K=W-,KE_T
MHOU)#F>ZI+'EOS>./=\_WC_9@WO5OWZA>\<?KQK-+Q?UJ_V3_:V3[WO-C]_W
M6].<OE]PXVJ;-JZ.3ANGGUKP7-_WF_NMQE:=-)J;5_#>R2[<O['UQ^G<6G(7
M;3**"^1YT/DXV"/G.$,N&4ZUI-Q[N;8AEJK]6Y7&5P'2G6E\@IL0*7&*1$ZQ
MT5PR0A15*GK&B2H B8P Z0$'PQ4@_3A FNE'&3BW+B3D.$V(DQ21)1+P*7)#
M/6PPE( (2K%,)>85(%6 =!<@1< A@662A.5:AFBH :/))44<%EB4@(1'@(0K
M0'I%0&K,%#K(J*0V'"FE'.(L B"!J"*EC4N8!NVL T BRV0AO37.B_>3U-NW
M.:#CB7CSO3)C4$H$!7:^,CP9:WSRP4C-#+..^E1Y;,N"1W,8(S!U7*?@D5"2
M@,=&/+(F282E-XIBS;T&/-(_80)OI<#C/"?M"AXFJES@C@9+#%>86\*=4:#<
ME8>S1 H\T]L6%BLR;)"E)B N@@0/QPMD><)<N4A\\&L;/R/C2Z7 XR(9*AS3
M#*ND*6=,9!*@Y"CS)F$<!*X\@N51X!F/ !M* K$><44TXD9HY#S3H,"4:@HZ
M+ 3-I<_+I,&+<-N#ON5*PP4B$U5'R)>;H&7!P*=WA'Q,LG:%@:^ @5_F<! S
M:P)C!+%(P M1S.=>D!CQ1!*S@DIP3-8V)*TZ0:Y0@+F"\0K&%X9QR:DPGH/]
M*CV74ANC-/54)$V449%5ON@2P?B,+RHIB5Q&%(CCB$>?^7P(14X1;IVR1A"^
MMJ'FF+(5C%<POB1@5<'X,\"X-MD<)YPPSWD$4]PRQ7VB1&'&*&951&)Y8'PF
M(B'!@1+)<F039H@32Y$1BB/PK33'D7$1',"XY!6,OTQ?]OG< (5PWU]$;<S:
MO66;\F;5YI#_]H4QIJBA;>PVMVO\AS>1_52V9?ZCUSW-A>59?K^V $G.^S =
ML;<\!=DG(PCA]:L_3_=/=\A^\^2ROO41UZ]V+G>;FQCN"O<#=6]F!@T876NZ
M(/L08 ;N=/Q/>[>Y<]'8^GA5/]X1< VZGYDWFGND_G7G^_ZQO_SO5?U[XVKG
MP)/DO142V6@2XAQF4JM 461$@AT7%.=BNFVL<D3C_/]@Z7&IHQ568^P8>.TR
M,]%/%W"_WVTT/VV^;]9^W_QKL_%^^_/=W5CGUO???\^IUK:6$$E="IPD;B)V
M5 JB8I(Q!BR%OXOF0;Y&@_;Y2O*?4<_NW;*T.[>S_QP/<Y>.%6PWOSGLG3[1
MP'?<Z7W8MC>47>&'_:=SR7I9$W\1R\;BN1^[:[7;P^KUP9$=C-JTG\8X&';]
M[H16.5?#;M?#OV$>"Y@>=IXO6H;;\C<Q%]&7?=G+=N^Y8A[FO-4-15MT/\2.
M84.4]=H?PVKZ>2O4+U?HW;!O^HU?7E?W7_>XAS&,GF_N-%P<=8M!] ?PY#"^
M3&N?Q]?J#+\R[AV?;YBL'W56OO_AUFN[=S_$N*_R]'-<Q.*6Q<.$XMYS.@ N
MW-L91CQ3$5R^R "?>\?G8,!Z;?,,9NI[4??6OJS=:J]VSO.5IDQ6PIAF5'!J
M7.+,$4, \0#LN"!)8G=+DQ,ZR?@Q;RLI>F'^'7NY+-(>QF;W]_@ICII@Q]#L
M7O<CR#]K=0S>RN0T(RL6T3>W!\%UMDXNP?0%LWF/[&Z='"B:L%<X(46Y1&#=
M,&0L,TAP3CAG,5ALUS:TGC%(_R=+^#T*>:LLSX..C#WW84>G!(?>Q#)/*.Y0
M4_."@[H42UXSN!9@T==7$;W[M=#J^_-^O]3W1G<0:^3=?9,^G(4,V.%;H>K#
MZ8,I!J.LF/;ZYM]_3Q"JM."S^!T>L5\J<^[FGK_V?O>?G:W:IB]Q);N3O]6.
MNA=@X?7>P190RS;Z<*V&]QK"U'@(X;R@0LD7NRQ(".)\$H*YD%-@[ZEM=?(E
MBB&/[S*^@;N\=SZ*$<56@98 QQ:\C&Y^Y;OG9]=#+.Z=!2S??,0,TXO]\_:@
MG'YXWN[YH#^ [^3OCRA3+^^!T/5:L]@&1L\QLRAW_IR,YS,[2["D$[HT0=JZ
M*.ROSUB /] CN!6[-SMA1.5WN61L3:_A''PY(!9+:BU#++F(N",<:98,XLPJ
MQZVR)LIIP]M'X;FA-$:5:9>Y<\Y3*@E.@6"MW8JP.W7/8JD>F2*IW>WGUZZ4
MV<*JG-Y!BN_-T81W644N(D"'S99>;(&%--PK_-"]Z8S,Q&OM&-ZIUB^TX]V8
MNNE>6+'](8R^%1XG*M>E4BO"803H2\UC!_33#)9I_F,&^S Q6"2CZ>X#F$=\
M]<$L*J5^O Z+RFB#K&W.;?[YPC/QFGPRXYF8H/BM%5X$^:TV;,]0VQP9@84Y
M6X^AE;WQ:M;FS]I?F>2_F4G^'S!O;X&^9V1LU\#.KCV4^>FY.<Q7]F3WF0C.
M5^_@]LFIY($3*9VW.%''0]*.R90$ R_*&*^T>2C[^:WNU%(V4'^<(S4ZJ-T[
M_73<^/#'\?Z'O>_P?5S_4/^>N=#KS2]TO[G#&\=P[Z_UB[W/TP>U_[3RH?#>
MU\;)_C&,Y_CCQ=[5=A[;]T9SOUT_/H2QMH_VKGX_*JK;6],=-Z64.G&!A) 2
M\:@I<DXQ%&7"%A,7K/-K&T239TH=7YJ4E@K7*EQ;'EP;AX<J8'L<L#6F@2TP
MIPSU&(&T!L2Q]<A(YI# . JN!$M&K6UH)2M@JX"M K8?#FR3#6Q2MW=J<TSW
M^^#7U/H> [J*O6Z%>0MAWLZ@WMP9UL'DJ'K]JK%Y$))Q08F$N+<:\602,HX1
M)'02)&#">60YSPU<9OK;JB#?,U%7+C5.W7&P]BBW_9Z,[0<5/C^4Y6FEP<^S
M2,'5(5:KP)UV%G/)% _">T9EC _M#EAYJ\\-<!]GO55!$U,")T1-/BW,-&R.
MB @V7C NV>!"8ME;_0E[/%<:^Q(:.^N'5;;*LZCRC'\F*558.HP4B1;,%6^1
M92'W3R;PFGK#,NG(,UDJE3J_<76NO(_G#R5/>1_UPP-C&?&P-9>9_MQ$!SJ=
MHR^"12.#EE0OI4[_7*>!\\].=SJ^%VT_UOX%2E2\^G=U'OB"E9XK&UYZ<B$G
M%3[)$)GSQG"LL?,X):I($(E$Y>G"M"HC4=X:"O).YU;GJT+UA5#]RZS+Y8RB
M,5B-DG(2<24\,D%1E"L<)%?4<.;6-E:ZCK.*X%<0NX00^Z\%,%8%EWESH[,T
M<B%!7Y50WEA, ]9>Z0=@;!\>&%X]#FS'AG8%N L"[HQCK%)0@A.!O,(>@1^D
MD*8N(>XXSQ6JPADZ_^!RQJ"K$*]"O%5"O$6X^KPB/FCBB)2<.ZL-LU91(1S6
M04;Y@XS*"9RKP@C/$^.?#",T#T7]XP'F5G&C.'(AAP9)D,@18A!FDFE'L2!6
MWQY&J S/V^(;HX&,:Y+*BIQG#FB^T#4F)FT.Y4HURA\\RI\K9/:P!'K\&@&S
M939?GBGE:BDME&?H0DF954(G%< E$TYKC"VUQD?#L:>^.-=X &U9E5CPW$:'
MGXUR<2<H!OL1X2# Z2*YX61,$LD@@PE.Q,A8[@(^2P^Q\CT0*@"J *C*5W]I
M!)H)^QCF$E$\(<EM0-Q8G?O>!F0M2UPJ6#$'""3(D]M,5@A4(=#/A$"3J1T5
M""T 0GO3*1RX?GB@+=/:4H<B<QIQKV5&((HX9LI@CBE7N6R&F"6"H;>4'_ZT
M8NXJ*6T)2F(JY^TIJ'7XBC7,51KIV]38RMMYHLJ^7G5NI;)O7&6KS._GCY[.
M9GZ_:-UIE?F]PIG?51.@%YB@9=DBGI[8J*W0.&AI."7<):VYQ298XZ@CP07]
M@&9N3TILK++(%]\A3F9=-&^-=+ -(!6E0QS<-60,-4@3S5@@)(J<TD-GN[H]
M-J=Q!9JJ57A:X>E+ITVZW'_+16YI")RK !X69SXP3Q-68'@OW!NS2@__L4@Z
MXSD3EY@+1B)L T:<J.PY)XUHD)YCSZU6@*1,SGK.*YL866%YA>5O!<L7LHVC
M42H%HXUW/!AF<&($,^%S$1#\[T?;QA6J/_H(XT;2^\E%X^,!LP3+@#6R+E/;
M:.*0@<7+W8\)8S$$36XY>%U!$_D!#2L?VFA2+$]/O<U3=]ZV@V[OLI;[R:YP
M/[W<NFWZ:4;M0  [ND]NO;3D799N>_:JP](#.BS-]MB\OW7/S58_(CFB<_<E
M(1P77CA!K3=<)!IUB+D!_*HW]YF<\%$/GCN%[LWUWQ%X7>/'-9^I6MK</UCQ
MT,O.<7]&T@';]3V.TKQOKD:;G*5M<U(UA_GAS6%>0>I7[*"Q:CBSM)GDJQ<(
M>7(>B>5.!:<%-HIP99E6RN5 MTG4:&Y9E?HU)]2Q_^&?D_UFG<*]CO::A_#^
M1['[8>^RWOS]I'[Z\6KW*[RF=3S^S76HXV3_ZZ=V_6H/GNN/H]VM3T?[6R=\
M_WCG>_W#Q\O]K;J U_#IQ\NY'6=(M X+II!/T2.>B$2..8JPE,ZJ0+SR81ZA
MU)+6UE>P5L':"L/:&TJ/>RG$:[R?9G1RU"7C,4J9RH1KA9$+B2(3=)#<I,BU
M6[FF#$MA)*]P(4_5Z.&%X=01*2S6'+Q'R5DDCC 3B B),\L<$15M_-)AZ9P.
M$(:I((SR2-L8$1<Z(,VC1#%8$3E3T0>^C(G&E3JOHCI7UM&S:_2,=80989@E
M@I@-'*PC;)$66B/O';:,&R<P7AV-KJ*$]\5I1SDE57"P(@I]B2PI)XB@QBMN
M".$B4"VL8EA*D13SE(6*&GDYMXIY7/0"!^$<0R9:<*2%R>V"HD7"1B6XT3@D
M/R]T6!$C5WBWTGBW2%&M<CIZ+,$_HESZX+STR7&:M"4T>5X1(Z\(^LT8RB1Y
M0B2SF0X^$\-[CZSV'$E-N.9811%B18N\'!;\Z"L5U?+JC;)RX19-]*B(D2M6
MP 7Z@3$IO0$+Q-'(C7>6,X\9V.^)!!I"JGA)7\WJF,.,C'74T6&%C-,<<1P"
ML@F,1\D#<508ZG+EMF%+Q =8 5 %0*\.0#\A+>E+8=",Y\,9)3YQ@BPW 7'O
M&'(2_DG$2D,%3U&:M0V]_!A4I4=4/*=+!855ZNS2XN <HE,2@Q>4*80QIXA'
M[Y#!@B!N"4M6.1NX>(;4V2KMX8TK;)7V\.RZ/&/3F."P5=PCF21H<'(.:28Q
M@I5S6 :O@S!5VL,JQLR6-NVAHI>IZ&46V&J89Y$%XH2+D<?H-&PXD5%GDU(V
M:E/1RRSG9C.'?C$R05C$"05,-.+2<03[BT9$&^.\\PI3,!SU3\$M4V%JA:E+
MBZE),.EC("(FPZ6DCG.&B6'<6A)LQ!6F+BNFSN8M)^^U%PY1RDG.6U;(2D&1
M8LP3<,LQJ,'<H.1/@ZG/8/3/<H!-L@?->V>"[V:HA9RNJ\Q&<];M%_11O_9B
M&[[\+5Z3T/S/3<:@X4SBZY]8!Y-V/KC])[=Q==U@PU@2)B)C;E($3?Y[-$Y-
M.;.'$3G BA-D$XS^5]N^L)?]M5]N/C<\]-0\+SI%#YJ0E)Z#&63>?)2#")GV
MJA"A7T'!8B]_"T9CEV4HM:->WB#^3XL9Y3 &P]NGQ$4PSGCA)1?&68:ID@<$
MKVTT"Q:G;LK$7(-,_?6_O]B->8L^EXY+6T)@ZTF!D\1-Q(Y*051,,L: I?#3
M=%PI>NLYY=3CQ+V3)BFAA>':Q&Q*ZKO$0"X//1_,%3Q*;SXMW]R)^FEYR(93
M4427U&\C_KLL5/UWUR1E-G/?ORLO,F0=RJ_;W<YA_B4VL+*]T_FD9F^3M(RI
M=6[DBI"6$;8NB*D&6PU64/6@RZX&=5NIS*]#0O;I&DA?F8KM-6=A3,56=$\9
MD;#]K^O]LO&E UM$.X;:I_@M@H51S=(U8=WEC9D:GIH7K[<B[-:]:M;NG[4Q
MT=_]\_9SG3I5E'Q+FT6Y>H'.IW=^M^!5"BJ9C(PKEZP(,?"4DHY)**.>DJ9P
MO<=NYKC%9G8PLF?S1[?W'G2]-?BKV^__9#E'?/_K'MV':^]='8K]TX]X[QC&
M\/7+Q5YSC^P=?X'W_CG>_;!_W'@_'>8\:N_#Z':_-HYWM]JG^UN?6G7ZS]%^
M\_>CQO$_+7BNT_VO=;Y_6L<WZ/JNZJ2QM4T/P/4U7K!,N*(2XBHW[9(T(&Q8
M9F>PW BQMD'U:O-659A78=XR8]Y/VC/^Q6!M?'HSAC5//<'"H!AS J4A 0&6
M24 Y@[UWVA#.<\_X"M8J6*M@[4?!VL^:(OYRN#9MK@5,D]4&<$TS@[@(!%DG
M'=*).1PL93:!S*G93)\*URI<JW#MN7'MYZL"?#%HVYTVV0SU428JD>&9_2EX
M@9Q)#CD-8LVCERIGS!.Q*M#VELKY*K;C%T8WE:SS&L.#$LJ)IR92P7&06G&#
M(_9/H4>M G _#/8^S@;@.'=)B\103L;/>882664IDE(3IBAF@=&U#::6OD:H
MTN:EU.8JM/0TA9T)+<DD/'9<(<9#0IQSBXQ0!'EIA?22A&3H<]@IE<*^386M
M@B9/U=CI+=9CS[DW'J58M*12 6FF!*+1:"H),R0XT%B"*Y6M5+:*![R.UL[$
M ZS@,= @D+8"(TZE1I8S@;!W5.(<_[08M/;)K$#/J+0_5\K1_ 2M42%:[5]A
M6(HV4_!4170KZNL?0'V=$M,^EV@$'#DAR7AGC/0D>!,#-P^GOAX<^0?64UZ'
M0BH\7PC/O]P(=.PV/3M07 J?DD;84HM@ 14@NR,(UC,PL,=H4F1M8_;DJF*V
MKD[-*HQ]L0KVIX/LDRK8BW!5!;8+@NUDD K 5AQ0ZK13EJ"@<2:0X^#R"H<1
M48R2)%6*RJQM/%_Q>H5URZ7R;Q;K%HD($,M!$Z@06G)ME+8F<!UIH%%B9N./
M;Z52H=QB*->:0KFHL<9)!B2#$HB'F"F$DT$\6HU=H@IK,"D9J6S*"F<KG'TU
MFU+ZQ&7$UGDC>*#6"))Y+Y3!A@LO==6B;UD1=W?:KE2&1AR]0=0RC+@@#ID0
M(@(A 5>!6DNC6]N@*V!75IV<JE&^R5'^7(<450>KJH',<Q\5&VD#5T%%YC$'
MTT7;Q#Q5A"E%G,'\*0UDJN3*'V:N^-GD2D6X,!)S1#FVB',AD"5>H^B,3B1&
M3;58VQ!RZ3O+5.!4@=./!Z<J5_1I^#.3*QHH]5ASBX*)'/!'2V0%=TAY'(*F
MB< "@KOTY,2S"G\J_/D)\*=*?7TJ $T;0%@H3278/H%0 ""E/3)$:J3 ^,%2
M6NI490!5 /3JS[9L %0E\CX:@V82>4,(/!@%5@]W!G$?-'+8$GCEE2/>$V;4
MV@99)@QZ2[6[52O.E><CJ()*/PS/#F>#2MIIIBVAB!.M$,=$(:NQ0498+@C'
M3#G]')1Y5371V]3F*@KS-(6=K=@EAD<9&"+>8,09(TA3;A!-' 2!:A%H? XR
MN$IAWZ;"5F&+IVKL]!8;F4P8RX2D<SIKK$9680$N@XTA4IU;ZSX'S5FEL6]<
M8RL__]%*.^/G*^>U3]BAE*Q#7+B$8-]-B$M8/QIY,"8M&3'&SY4+LPH%NU5#
MU:JAZ@*;0(S$48^98<EP^-<:#EL""4(K*R*7BS=4K8I_?_C><#)5_'OX_< P
MBATQ$9F08\!<Y6ZJ'",GL>/8!5 !.S=F\M-T4ZT M0+4GQ)0J_K>'X^G-^M[
M 4\#CA('*Y'CN;\!PQA98@*R7)&0\K&H-<]9AU'!:06G;P5.%T!3KK7P6#BK
M>.!$$BNP,YPD+Z0EF+,'H&E5T/:B0#IMF)(DL94RH*@<19P:A33&#E&CC7;)
MNTASAN8L4\+*EA!74%Y!^5N!\D4L8V63 R"WTLO$#>..:).8A@L+XJ+U/]HR
MKD#]L:"^.VT= XI[B6E$0BF-N T*&9(L D<GP[JQVMJUC5E:B!6TCHL(]B^#
M'*6"_X;6MXWBJ;)DMSKGMMRJX.W1HYS:WF&K,QIQ+G?^;?A6'J,8(5VK$V)G
M\"N3!?"^\!Y'L^HVCV(MM%**O=CQ<%D7!Q<Q=FH#>+][%CLP<37;@0VEW>WG
MU\ZV;?'%;JJ!>K52[DJA*5&_]0L]+YH*V^Q]]LO?C=YK#_6N!;^UO5@[ZX%&
M]^"!:KW8MH,8:H,NO!G/[.4IS$F_EKH]&$6W'^'>K>*=BZ-N\=-A[^M6IV;#
MMSR:=S5_9#N'<&5X+_8'<.4!_#%QX=,XZ+5\'BDVOSD !Q"ZV/O6@B=Y5XSS
M_&SX8>K!B.$Z@WC8*]9U_$48C1T4 QA<GF5)@;%WNB"++;AC)S\V7 <^?I<G
MKQ=A_/"R%WWWL ,+$FI=D+!B7L]B#SX\S2.O=1U(6WD?>+O5+49[<=3R1_FK
MH\E9K^V>]T;S#0,ZS%,TGO?>=;OTFW,^7(<+& U\Z:S;R[-A^[4SVQOD!>SF
M@=:&)W.C;[?*Q;?>=T]!("_SJL.="YTJIO/W4@1JGX\B?+^<OA;\<'P=^+O=
M[1P.)W00>Z?SQ>#6<<T7FENDJ;32AMVKRS^F[IY7H7\6 7R^Q?;ENT6?<'T,
M5X7>WZWE2Z+6.YT:C.HH3V9^U,MH>_U:A&&%VAW-9(HYSKONN[&L3<CO_WT-
M$M$''2\/^Y)_&H]UK58HV !&\GWP:^?\%(7N  VOO_(;__Y_C[ __:=COYKS
MW>/#JSK\<N_XG_9N<^>BL?7QJGZ\(^ :%*XGLA%0_[KS??_87_[W"JZS=7+9
M./:X :_K6X<'#EQK:B1'Q+J N%(262T34@2\,O@'DYPU_K*1SVKE7V3EG3-4
M!8T$51YQYAQRSB?$O(I"N. 8YG-KEFY)+  4:V?9 ,CIE:M2;I@7-N\IOGT>
MRCU[TK(8;1DA M;TX//1+T?X?KE>:QZU^N/W0=3ZL-WV)\P'N-^*F WS;('A
MMX:;_T.W&OD:.\V,[U?L-"/UA!T#UF4%M\JO-Q;&GH(UTKHJES!^!SGMQTF)
M&$OJV!0!H^G\#/[,4@FRN,@NJ8VDT1!.F.<\\F@M4]PGL.HP8Q27<4T\PLJ'
M%%O9L]8 _!=XDM&ZY&79G'BH"B#G R2\W]P\$,0'8IA DJ9,=<AS(2?/W1$#
MUMC3*)1>+'2=5QAS!ENAXD0Y ZL,<F@=BT;#K18WA*HE?MH2PS)H1FQ$0C*&
M.'84V<0H(E1&;G,K.!,66F+)J3">6YNDYU)J8Y2FGHJDB3(J+GXZ42WQ$Y?8
M<2>%I@H%9G*/4V9S*:1 L"Q"QPB^";=K&_Q^R^8>4R>;#=8OZF6598 C7PNO
MUS8'#W3*\DW..\,M*N]!0W/X>C,JMZ'"L5YD(R*,:48%I\8EL 2)(2I0IW*A
M5<JI0P_NVC-?<ALY%Z$2V'D""V.].CFP>>Y%9&!\PX[#*?R39Q\IE73.R[:,
MYKRM68F]*8]94A99=NY!39@-3G+,+6Q4R2D>,';!"!9Y>'#N=[7L"R][8VOO
M0'AJ%.P=2&&>>R\EV(I"/A4-/F@3$_A@;.ZIZ(UEGPYO92DH$ #<HCX8US=C
M:ZW.-W!U2E\I?[., 3XN]C?EKLR/B!<K"]:/PSBRX%/B(F1>6N$E%\99AJF2
M!R!H:P]R>R;"Z$,6T=?P>AJ[S>V:6*\-E:UQ#BC<\L]@^MU4K*U6_ZS;M^T/
MO>[Y67^G\*)A3>#MX3S'L N>8S';_?QNN]L_[\4FC.'W=M>?O*Y>@?[LC/2*
M-JY.*.C-Y>X'T*%3T"O0K;VO.W"?3ZV]JSJK7VVSQH=M4G\_K5=[;+>Y!WJS
MPT&'Z/[61]"=3T>@9\>-#W\>UZ_\5;WI\5[SRP7L_W ??R!UR(*ED=(^(.YR
M^QL'<.JLH-9I9["T)1064[B9X<E%4,:4#$]1@B]FG/=<18R3@#<\\VNU"&AU
MEE.;>^=Q;6/S\^?MYN?:9F.K]M?.YN\[?^TT=[8_U_ZS_==6[8_=3[7/FW]M
MC_1V*!X;-]5E2EO*I;IW&*OC56<,:<?";\Z!#D#ZC#^W;D]'W7ZQBTSM499'
MH1T6W@%>Z*@-\4Y'AQG6UK@PLJ[UT+K&^N9FM=/X8S(E'58"K*S=])_AS?I_
M='N?;4X]G]BGX)E]WJLNNKT  #K>IO";4Z?M"]@:2;VY3>M7=5H_WCN K8G"
M['KDDP5+Q6#8LFRRB*L<[@U$!*[6-A)L13.;5JW> DD;QLML+]K::,F'ASNQ
M-["P XVB+=TQLM7^E24H_Y+BWXJKU,8+6+Q+?OMW[2BV0\U=UKKGO?&GM6MT
M')V:Y3UN\_P0+.>QB4V*'?2\/<C;'7R<KS ,"0V&$4V;-]/1D9+]7CO, \U!
MOJ%4+V)U2:^C)QI,.X%Y$+#3,Y<4;(8ADQJ(AV1 W-PE/L!@,O7$;B>+\F[Z
MNY>G+I^-K83Y]=IR+7(T/%!PV@GF"%L,+J.V"6D= P)KA<,G5'&FP67$L^'P
MVH0W./("[W4""9@.JQ<JW2F?<'#4B[%V"E\_&KF[?YYWXO I\;NAMWIQVQ:0
M7Y_:XVZO-2C"]UG?SGN'63E]CI/[;+2")UT" /SX'.Y1ALOK,?P-GD6!%^_A
MNY_/NH.:Z\&?_;MT/W]]\]2= [!T>Y?%+T=XT!\9S#70KN[TB".8S3"$\=!M
M[>^C5MN&V#X[:ME)+'/GK7:VS1Z*0^NU8>"YE^?/EH@R$6B>GK"Y$[08\!AB
MM'-&.NP9SSDZS%B"6:12"NE%JH#G18'GRU6CN7.07% :M@"DN70(/'*%C/ $
M7$)"K:+.@MNPMD%F7?_:I-<_E)\%!4+DTU_&LJ,"7HK@1DB&L;>8R2 L6?RL
MMA*(IPK$WH&.1G ?%!)):\23E<A2 P:7Q,PQ9ZBF<WM_C.7A#A 9@Q3(RB20
MY;^+76D%-Z4L<_UY#]T'4>W['KA4H!^N^RV649')L^A.'!2*TQ_9<K ;^'&\
M8Z1<(*4WWH/)!.-WE)=T;\SD\P#^4YB>\,.)C: \J5[ 8'BX8E-O+0E8<^,%
MQXX;)H0)X#51+YP=]ER[_6!QPFD::7914+8##]CJY4=Y?P3R,*W5J?4=+*:K
MV.N^887>@3%_/*#Y0(B+A%3,2IQ9D8P6#GD<F+8Z)(/=0H=,3GB9P AU7GE.
M+&S<1F@CL#9&"N/P/5!=K>A35]21&*5)#FD6(N*97MQXJY%AH+.$)\&276A%
M:0BYJ$D'SC7/;#L^'TM%S(VRQ@]7]/:3X6I%G[JB@209C=*PLUJ%N%,1.94(
M"DY;B:GU++"UC4;W$<>$M=9X%7*.$2S#* WJO$@>">>]O$TL?F@(6T8&[!LY
MTVW;Z>1KMG)@OS4X[\7IP/R/#5)_]D<QG&=S;Z%P-7S</8WCS7%XLE <+&QV
MPF8(1?#%MJ_#VOVW'=?>.V"4")OR*9%7#'%*+#+4YC\S7Y,7D44\':>>-.*6
MQ&++-0>IF]E3"R7(B>NCLZI^3L Z[PQNI@RV"E&II5[W=!2US[^\#A"^J[DB
MWW[TS8']GDVY"2W)-4.MU/(V:R08:MU.<;=A],&=]V&4_6&NWC O/7O9[<N<
MW@]"G>.1Z==%S..;]1ZYVUWQH*-:E[)B!::\;<_Z\=?1B]_R[=KV\M=6IYBX
MXD>_W;Q\+A^9JE8I5K;\^+>+5A@<Y<JL=5P6V@Z9EX9W'GZ\7GPT58%3?B;D
MNN3ZUH_Q.KGUL[LN2^@Z-_)1E[W[,\%NO^E;&:S #[OL/51<"S)NE1+W2B1W
M\\MSQP]%Q$.>J@REO<QSZ0<54^X5!L'V#8,@DX??>-"WLXP3!<P+%/G=O\0_
MIF#V84N<+:GG>N"'M+7\F2;N0?SYU<3-3AQ>!$!&5@BX#??0"JSR-ZM)J";A
M=1A*)UR'X250_OZO<EU-A]81O,=>PU<K@&,JVZ+VKZ%?!HY:E?3P&C&$DO7A
M[*C1_'C5V-H6]=./M$&_8!BKV/WZZ;1Q]0?\YH3O?OT(UZQ?UJ=9'TZW26.K
MCNO-D\O]K3VVW_S(]HY/Q/X'>/JO?Q[O-@\%O/]][VKG(O>FKX]8'XY/KAI7
MVQ=_L4_M^)]/E_M?PYFC7#:N/-FC'^$W==(X_?.HL76"=[?@F9O[QS W5_6<
MDW_:.-[?^CW5K^K/D6AQ(_EF>'+U[ZE4U,68)5:/HN:9>I>M'@/-DPG/*9$^
M,1NUR.7(N#A\5]@):[B47)&%*[+*0&;&HC]ZW=.=#@A@*YQG>HC/UT&G]Z.8
MT]8PG+2;=GO_B>TP3$#<_GYGL/3W(KQ5WJEIOU<HMBB*?;Z)8@<!&^-3<,A:
M1A&7)""#J4(X14ZXI89*M[9!GJME[$_&^57AY=O!RV>WW"J\7 &\O)S"2QVH
MQ($X1)FSB!/#D9-)(!&D<B$:XJ,!LTT\N>U$!9@58*XV8'HLDHT&$T8#]X+G
MJLI  HZ4:NZI6YC5H0+,Y0?,QK2!2:CWG."$$FR6X.?"*RV)1P1$P'*F$HE^
M;4.J5<'+*DQ834(U"=4D5)-03<(MDS#+CWNC]ODNOMRAK<7INLK936# %-E_
MOQ897*UO\3JIZ7]NGIX,4Z+P]4^L@\WO?'#[3VXK9;AQ=KLDJ7(P^JG ]L2_
MB[ KZ#&[PE'O^N3I,"+7B_8$V=S0_%?;OK"7_;5?;DX7S-74\BPZLP^:QY2>
MX_A[WC26@\A5'*6Q^VM13YB_!:.QRS*4VE$ONP__Y_[5)'AMHUDD$Y8DS(.<
MROB_O]B->:*R*F0:\H>3:7R*_4'OW ^*W.OK-/G-3MC-'"B;F4"E*.E91B*-
MPY$7= &?7>Y__<+WFYOYX WO-X^.=C_L?*\W/_+=K<W+O6.X[O$7TI@AJ-F$
M<?S9AN^WZUO_'.]O?6J#)\7WCK>_-[8.>7WKSQ8\PV6C^87^]PK\J>.] VLY
M)0&\%NVD0-P)AC2\1#($XC(I4=!IFDBC.,0C,82D!2>:FQ!RY83&+E,=.CN=
MH+Q3_WMSYU-]N]$LR#0^;7]N?OKROOGETT[C0^W]?S8_?=C^_*[X://]QR\[
MGW>:.[L-]&G[K\WF]E;M_>[GYN='\&S</\J;3Y6<-M%[D#^O.0_>)JLH]X$H
M"7]KLD*\'!-LES-E"D4AW 1]=AOVWC#!#C2'OZSFHK?G_5A4,R2X7.V;;9^7
M#/$E$>OPY]U>[; H#"@*J4>7#.!QEN76=E!<PMM>KRBB*S/!B\*)3+.>APT>
M:L:]3 H[>:\)\M8B=QL@M1AWD3 ^.&KUPO!Q,@G29<V>G?5LJV_;_7?YEW#%
M5O\(O@ZK=A('$\,O*OJ*.P['^RX_1"9Y[74*^O<0O\5V]PQ^>SV"7!UXGJLP
MBNI";_M'M=3N7O2+0?=O&;8'22C):'/I>'ZOU[+MB63X6O_<]>/_.\]+57+%
MP@7KMG.92Q$'W5Y9XPZC/#\]*\L+\R7S^OIR6L?W>C=,K1\5H P'FUH=V_'Y
MIB471G]4,WI=ZOBN=M2]F'JO(+8=%^H/:R'+2]Z@USV*MCTX*JK78<W/ 8DO
M:X->S'7[>>"]>)B+\\M<_OQ&ODS'%B,;%<"WRP<8)N2/J3F*XLMB==9K.YTQ
MBPA,?![QX/8Y+R:K%-LCT) XI!5P^466Y^LRS\LI?JSAE VZ-3L4&C"(,XFO
MS0&4UEDN,FCUA]1:(-B=3, %7XU9V-OCJQ;C+0=X/=K) 6;2XH)TN-N9TJ[1
M@X/QUJZ=E:DOE\7P049:9R712:J=#UKMDF_XWJ%DC9J @PF0"-U8:N P]:?4
MTA'?[:@QQ)18@)Z4]QS.U;!6(W,^YU^^&_8X\-WSS)80"_$>P+R! *[7-GVF
M18 O9SJS&VL_5JG\X,7HACI^4T[[1\5U,P/%43=#4*X B>UV_N+INXF[7L=/
M09O;PPJ08K)AILOI@'L44[Z*M=&Y:\3$HH)0%=39L1#\ OE 2^$+O>ZWHJ"F
M5S1'Z.<2FJ%$@JD*EYVHMH%7(X 84N5,3GRYJC<$%RY^V+.GI9ZW,J5.X='E
M5B-%)7KFVS@M:>K&3-DAYI4I*W>L/VH!S)9,FR-Y'?>^.,UL(&6M3K[3<2R"
MJ!D*TE"U)MXMKITE^30."BCOQ,-B,",HZGI_WBN',83.X@&'(GP^:'>[)^]&
M?U]/;*$(>==$-_;+_,"'W6ZX:('DG=K+\O)COI'\3E$16+/C8K<\M]=&ZFA3
MGM&6T0:QBC)Y-]OINV+&YQ9YC<C?BU*LVZOAA_PJS\O#/*?:=D0E]JEH8))5
MZ?.0469%R,1>VJ68:$%P[.&SS8/D<."6)F0)#9E,#%ZEX%%,TBH+[H;,W"<%
MW=!L-F!O/.]C*I_:L O,/-Z==S,$0 6'4-GF9+T4P R7XVO9<7.:+(99O/K9
M+"AK;LL./H6LCC5\ F@MJ/(ER&I!\G--*92_;CO@A[1G43FS08PO90M$V07#
M;JPEDTJRBFK_==3C8-@YJ42^THR &1UO U,(&!-,S'!Z,LEIWJUO%'Y>[SAC
M,J7AOM2?Y-V8@!';+ULKE;9H69%=-EBZ>>M<6)UO[,\+K^B;A=&?YY]GKM7^
MS8M.&M5%'+& +KCDQ'V'QF.Q8\%]8'"'\"QE6Z/^8.BAP/.63*ZUT5!@A^Z?
MYT?LC\S#TF$9/5G__"P+Z8TG+/>M#[^_7Z^]'[/J33Y;X2QX,!5+.WIX\U&]
M;+DJ-W;QL54*5YS7-&.JO\5HCHL=;P6[6N0BO*D:O#F;U0JJX=9-YH&'$ ]<
M3*K6),:%^=;*@X1K0::J9VNCD$E ;P0"/\?!H$2>ZY#@W]D>[F=5RDP$UT^2
M2:U7I;K@Q7?W,9%58ZM.ZE=?#GS"B2KCD#>,()Z<1-9:V-V#D<Y$*:7./7_I
M;*;_%+WUT.XK(/65Q&9N#+GH>%/)PT/D 2R_ ZFID(Y$)+UPB&-CD"81(QF]
MYDKRX!U=VR!$/Z3!U%POZ55%XR'L.Y5XW"(>S?J!H"PDS@.R+D7$ R%(8\,0
M2=+[J#"3!.#"W-<#(5/<ST:U%^Z,\-S2\?N08>1]]]2U.H6=-K&Q?"KWQ@I0
M%I 8?V!)LOGD!@FF+4@,=<AJK)$7(6(![J0U\ZDS9R3F'FMEO;8S*U)C@IJ%
M.GZIR+B.B29AN/'):>:]=9RYI!EQBQ<?5:BSB Q]P;M-#[)SB!M;FZQ^>)#S
M,(5Q,-M,@0@!S"#+=$0ZB6B\"\F&L+:A9]DV;XK0B,KQHM<:C&C"0_>BD*W1
M@<2(>[,$HU$ _CI<W^[ZT1E*MQ-'S$3E\4)_R&O9ZHU=KC!YUC9V@X>!QUZ\
M[O%['PUQ?7S8%+[%7G\<"QUZT?,.MLX[(2<1GQ=!V^L3KM&AQ#6M^^3Q7JS9
MP\->#KA.G/'=.,P8_VX8W;WU('+.D>#X'.#F%)7CG3R$^PI.;6P7$>5K;WR"
M'&ITG%:T5&JY\\+L'+**CF;H^JQL/%=#+ C#WO/C3I;]83ODB]B#)1GDCI2U
M;]WV>7;IPGD<71D\P1!/Q^& T[,X*-#H7?:D+V(9$BI.J7JUMG7=4>2D.,PI
MX_&C61Q=:KVV>?UAX<6=GX7Q6HSFZ/J4;_IHZ<&K,1JRS4<EK<%XLNY<[>MS
MX?7:[W,/D*</=<LY'!W/W"M,MXPV1]]O8><;.[DC;;[NBSXF>2W/8\O3LH7%
M>3A?!4%XT3RT/[Q9J;QSS)81$UDYKCS(A>B=&<."I428-%P3I:,4PBI)P<)*
M+*J'=O4J]IA^H]L9MFNM=I?[=Y?Z9>/BP/@0E98:"24\XF!)@H$"OH_ARC%I
M S="@X%R:Q' F.'[SB.3N=;)0N3"M!2TK,2]5DEUMY"@.4.P<#X)&ARG7.4_
M@TQ<8:<(H[ZR:E[*,FZ>B-WFX8%3(D8?#(K8"3!KDD 6.XF4)R01'7TR LR:
M>R(OY9YZCP&QF-?-".4X.:83N%0!*_"N0HQ"8T*%$\->F96DO("D'&_"/3</
M@C?&Y/8#@?@$/I00R&F54-*)6?"M#)9X;>/!@G)+DXV%_6_8G[07U/J (P>9
M!5O<&.D)##<";/)*3EY23J[J!SQR$ X;D .10!R0'FDK?68US]TB0I BSNM*
M<(N<#,]=K[V0%3Q*^33W\.-&DL)"/5ASC,D(PE(47/A@P35-GF,2F6+)+PZ-
M5:SZD:&EX^T#+!7(NPPHZ,S?KV+!M SB[F-P $RA/+NXSW #$8BG9^WN9<Q0
MF%W5[$P,,^ 6$8Z8&QHZ6/8D& =QU%9S"4B(K=(BI,4MK$HX'BL<7PX<84PX
MBA%E(K>7#!;9H"W"449K#36A.,BX;].<:EDR .&XSFH=9QN$TU:G5:0+Y*2
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M?IZT2 15*2J?<_F\15PYBXSC&DEFE&**2N5$F?*E3CE(?\ZC5,C@Y'-%>8*
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M/%F.+*,F5Q>.S$@C-/4YI5JM4=AKP9Z"/<\?D%^PYZG8,\Y.B.%2**!XWI"
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M7EL6WFN_QY*R&B94[VY@B)D,2'A15?S8SM4JKNU-K;VLDJ%F>[W87YL4A]>
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MO<5#UX$ZK,Z>+8['M^EX7*D]^^]N$V3VS+:*_W$AN/XZ:<9RRSC5V"/8:S7
M-8](8PJV+&5" WC#XH'4$;(FE6$*!A4,>ED[MF#04S%HLD%#D $GQ9#0,2"N
M4D36&8J()T2F:*0Q&8-XB?XH&/1:,&BE]FO!H"=CT$1=!9="C$0@X$,2<6P
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M^#.>-CO=VOEI+_KS[,<_[?3CG=UQ@5"*>4X$U^5(_ZF@L7":^UN?S^=.(GZ
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MS 8G.<XME$QRB@>,73"" :M\C$L435V^IDZ6M%(V1ZE%E))UN=650D8J 18
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M#'(9DWRT1$81(K>Z B')90&AXC.J2%SL]3[4?CGO=L&RJ9UENZ9S^L;<0R]
MUS)WW@7J_'W$'"Y+P<;YL'%:]6F"+5,Q9Z"07,5/>8P,T02I"&LHJ:#<Y?-M
M/IF$4B)5?ACM71;/*=J[6NV=8#9.4>>2P#D5)C.;:)%-RB/"!-4A"BM4KAW/
MUDE[WYX+Z%WM-/9KG53SWZ<3,Q([U^GW.^T/#.8_=,Y=*]Z0NZ>9:FLWB__Y
M@A.T+MB^-HZTV;"]V+)+1/QI59<3R[T$'$?)<R!M5 AD)7&(>*RH9-'R7,B5
M\'>&\1_'EEV"1K^PQZU@>\'VM?5/%FQ_"6R?8/,9P6.R%$7E(LK]V)'3RN0,
M$FU<P!:,\<I/*<CD<6[!]@5-D7_U+3ST)B5M,*V-\S9,A;^7KMFVW</FZ6B\
M<@2PPP1.)I\A>W,",>B=Y-T_A\F[53QG%=PV_.#K:>_N1_=S\!Y\P5Q.Y_G?
M<$+ JC?<.85W.>O'G(PZ$#:"W^6$0O*N=A%K\&HQMN'][-E9MW,)>-2/K:O:
M?\X!I3$%L*$%8=H"<!+K9"ZKS2/A+JH4R !*L2%XGI"8+_'LO.N/ $?#K];'
M>7)VS"O%T?LU<N!YQY^N]]O;5_M;@(U;7XX:6Q]SJ4=1;P.N?OMZW;C^>%6_
MKFKDP!A.KAK'GC1V/:Y??SH@+EH)ZX&4\D!VG0= 3-S 7T'<.,^N#]!E\GY:
MC]B::[9:>='![NX?Q?S?::XM@,U/G?-^KP_Z ?#Q##+R:-YSD8SY)*-Q_/&
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M,;)<J:>-ZVTP1@2L <]!2XP [<R1HCQPY)A43FO,>,A''>\5UPL8(V,"/Z!
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MD#B*F+1L]="K[RRNOL$%6)EQJ+Q^._CWJQU$#)AY\&5G'9^+C#J#ZLNK! ^
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MV<UM\#(&MM3OG4U#6QD_GE5!O_1(*B/'MUKOXJB37E$1_=R%XRI.]%T:7[W
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M^>Y=7G#HOSJ*KD09?]U!XK'/]7O7^-_6?&CY^D7%K%(>8T=D#GH%39-+EOI
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M0XB1,H\55P9H@ ) !!.<A4!QDO>T>VDR%7\(C#R:YXLN).L\]TB70+3# =G
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M#-A=R0J9$A;0!OY%N.I?@[TQB.?/3D+V;@X.CT$R7HO]#V\_P?O;WF$@SSX
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M(ZAK+JB?=]LQ8<N5P @,30N022QR >P%&:*EBE# 4U#33&QR?5NOH<H&[;5
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MP>%;O/_A=3L:F5PT&,7$%.+,,F0=-[G<Q5N"/8V2?%$*Z"\-_*\._(=(L#5
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M66 I/EH[JU]^V:>24.5SE3))-% "(1&P!/A1!;!DF&,XFGL-EU+2IJ, _=;
MEW':[A0R6#H=NG%8D6'HZFC5MGVO?1475P@Q_-)Z#V!4^/P*GV#AO&ATK6LT
M04)R58J?C6Z6B*$WH_1_-%KYH" _SFD3'F4!G1LW=PSLTRY,5=$Z^7KFBY$.
M,,#?_+2]WF!WSU@?"T$<<8 TACZ6?]P+)OUNN-M"Q1L98N):4LVMMCHWR64D
M.*&Y#/*Q&JE(W@62M6:S[?/8QR/*QGE^&2># ?EQ88""50 DZWA?>1.%RUE9
M6-+<(X$A)W(!0T5@78K3)%!F?(RE"9+>A!?+4\F#E<Z$&"GS6/%<.D0I4"V:
M8!8"Q4D^PHHJ>7A)>8![[CM&8)=*@KR+N3Z0U\A1":^PUTJ[$'#B( ]CJE4-
MY*$ C&E$0D3/G%)9"# '8FPEIDX:8/\1?A'P(_Z'2B1>5B1V]UW*E>I<0(FI
M7-$Q4*0Y42ARH!"&*&UC6%IE8XJ:#D4"%'(L9_VNYAKU+  ?[CVLEC(!C"6M
MG4;.# ?IPM:GX.'Q2;*" V$WD0GEB*1\?W,R#;0Q.-;Y5I[9C!>RK?: [10D
MMKO3[MGFS?<_@QK?:O=V(SR<;Q^T@ Y,R%T_MD36+^H[W_=Y3)3G&A-"YMS#
M)!P"W%)(:* ;&(/IXF1NNON@1/;RFH# =*X6X#9W&F%:65:OZX[F-VUV6YUG
MT2T_X;)\7UUMD,58<KMLP\'/N=K1()?M^AQZ;(+CDYC3*TEJ:6O]WNX,?I4_
M-SX%,G/-CRZPEVO[*3>#]S&!A(*=!=PJ^U\!48TR/$1J 95RLNR*'DE\+,CZ
M':LE?Z:,LNP72W3+CAF8#IRNJ!P]?=KN%LOSJ1!D0-A?SQJA=PBV1S8M;GYQ
M8/G@ZZ]8UVTW^[W[OW*?S62;C8/6IVQWQ<Z\6%&$X#NS>.//P\[P<4YAAR+7
MB?88V02/_\DVS^Q%=^F7VP.'4=^9Z&GG:*(92>DI,Z(G"24O'@*42[LL?/BI
MGUN(YD_!T]AY>93:82>#X7\U6*XMB",+/@$;"<:9#(? 2YQEF"JY3_#2ZHYU
MS2*6X7,&4C!Y_^<7NSINT>_LGQ*? &(MIB%J;0CW-+@4@DW!!"E# N!=&D0V
M]P$J,\AQ3CG1\ B*1(Z9U882S0SUH(Y84.JV&,S)+@#,KOG8Z=G&T/\RWHTX
M\,D49.N&R[&,22E"D(L(E'ZS!^2DB$HIBW9V<VSVT2!4RX:C?K=71''=*OMW
M)QK<UF"/',?>E0.C5?I#2[=1LHU.[:=M]N.UPZCP/L&]LEO[I%3/AYUV_Z!T
M"O6[L;QL/8M![;/M--NU;N.DW[3E91]2NUS2:#!G'"0.2*XS/%J82NM8-#H0
M\X#:+?ST@R.$[?2 .W[$A_DW#*]TB':[_9/R=X4P[\!S_0;6S/''TZ%B>V?M
M8E\S O8H<;D^+<FV!T-:)8L"%I2 ]A0FZ;L;4[NH<N/M8&$9,9@G@401."R7
M#RD1M@1RX^UI7K%.'^#N&RBK1FKX'!S8:)WV0<+[W=(1F4V4G\/%N2M_0W]8
MF1J1TR4;K8-/=S7X- ['P:]Z[=-/8IC;,P:H'AO?ZO_T"B2\4NP=P%,$$-.T
MI]WX:?CBU]#HGC;MQ:=&JP"*XDN_WGZLK-F MO9@=IH#M5X@6?GV0.D9L\*)
MR'JOUX'_P_#& Y6X4JC$7WIA]#W!5F"![WT;KSSU/<'$D[[YT,,2MB+QTR[[
MCAZ6:?T2#XOI9 _T2R%BI9B!(.>]]?\MP9:^HF]%@MPG7"/%!AI>[RD?)6+D
ML_3T/']Z#,N]LTG*_3%K)7^73:F[.KY@G[N%?W_CEG^_QLCR%1*]\CQ>?W2
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MK>6":$8L22HH(AZ2TV>QU>UA]%3QK!F1;@GL6'D-]N+#R>H!V]XYV"=,>Y,
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MXB[FFKW ,Q6U6K.@+<M!%$8O,\5'!;%]O0JU0?;'0#8!&Q_&Q3A8L@RN+N:
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M./*6"U!XT2-+2436>,6C"9X5]7M'"_?>9X*#UCGM1-2SYYE&7JT&_) #E(J
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M*R5%'(N(M.0&V6B]8;":V@/SH#.K!SM''JMJ#\^0?E1[^-7V\ @9,21)E7Q
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M*Q1B^5>[V^O$7J,33T X1X_BNY]+L?WW0&H;L;OT3G*-FGLGW\^WU[^?[?Z
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ML8H(,^: LI.0<DQ_$4M,?YU1X=&)=])"5H&IH.G]0=/FE>OA1Z-WV+A^Y_/
MW+B)514F38=)6Y_O8)(RAEH6)2),1O3_L_>V36WERMKP7W'EG/NI^ZZ*LO72
M>LN<2E5F2&8S-8;)A$PV?*'T&DP,YA@(@5__M)9- K9),!A8!M7L'0RVU]*2
MU)>NEKJO!A& .*X"D29&)K3FFJMGKZZ*8JIH- =E//='L1O3C[ES^S[Y%$J=
MO1DE[QRF<#SL'?5257B^<X5GD[E55FG@$;(.ED-VQNG((U-:A3LFNG7QF&?Q
MZ$X36B6=$-$KHIDL^<\&B&4LD6CP!Q6XLDB<B+Q*-5<,668,J8ST#D%EBI'2
MD)0QE!'#-!!((1#TE#-)R@>>K4B&%D9Z58S=DP.5I[!1N9+\T6V)62V!-(<(
M=?36.:=$\AD<#]8:Z;+RF3./[J&LQ*Q%&/INFICQY*AS61 N@)?D)$L,#YF(
M($PV+!M7JFCH6D:M8L@R8T@E9G<(*M-;A5SYF!B0*+(GH)(BSJ'+EQ)W-EO#
MK* (*K5DVA/:,WO=/TK#_5$ZW868P>KUWC&X,L] 4A$9#^CU9N:,QI6=@C B
M<18J06L3EGZ8)FB4:<NU\T0XG0@$GH@QTA*J U/12F.T0RRM/FZ%D"6&D,K/
M[A!3IO@9*Z4Q?6($&*22R<R)8S86R9+$O)8J0=DXJR6$'IDJ],:L')#SA()A
M^IXZT=OO'!S[?I,NL+>'8U=T#KZDG5[HI\/GG</T:9@^-4D:A^G E22%_FD'
MFX?F&8N681%<.!S)(1T,>U]*$L/,"[E^DP$RRN0H+3B_AC_%+PYR.BSM=/T+
MC''\D>9E[@WWQKD: [\[2F-MTB'*=2]%GO?2*%-C@%__VMLK.I&-?,-Y8D7)
M-1D<'XW2*HH\!<[BXS1*34E?#P:E0LGH1E/]M^=ZB$N-]$7G)/7[XZAXG!!I
M6 3"FERER?2/DMVTETJ_'^VDPPO-/[SB+A=&J5_H%O9WH\?1:Y)-\B@N<U:
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M*!PF)S20Q&(@(!-%?H8.6, A]$FF'*1Y]LK,4$H\-Y3V(.%]F.H#GT%5H*Y
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M"BL=# Y[Y3,OF^;VOJ1?3GKQ:.?<';GPQ3%]HM^_XCS2NN.CJ[]R%?$:4;J
MCYB&;:%BC*F)7KSP[\ZWZ*,#]PDY_3"YS\1E;/Y+US]QIX?/_G7YP?&I)SIZ
MWCZZ5H_D?),>,=?HD%$C2B;B2 #A)3H :5@^A:UQ;6E*9V=8 /B_>L)J3VD2
M,>0,14;'!AD42.N=H$5PFZ'?M5'\A;)+_EL![T98RKV:->@3]C-"4NXY2PEA
MG J*9-OC$B)<8 R,UYRI[V1@[(),U%I0/%G\'F!+@6EO(3E\6.=%LB8R.S,_
M\?+B\#[LI'C<3^OY;0_7HO0G6FM<W3]R^Y]Z^&"CY*7F&3?PMK_V!^'SDUL$
M L=%P*?,(8$AGGM ZD8C\2K&4C5!60@Y!(]3)^%*>5 RP8;'Z;))M@21T#G$
M5;[?'YPTLFEE8 \[!\/!EUY,N(J,"$"9GL/TR0UC$P&%*\T0WSN?$^-\XY>7
M)_F/T6?\I^*YRU&(96,VWU:!QJ_'/NB[@\/T\OS%+^>'<;W]YDF:+_UR^?(%
M!B?<^J:K1V^/$=+:%T:* I+C4[SQC<?X^:+!SXD]BM%[4KW00ESY-GW!KGSO
M1Y=E_(5DZD:7_?%[4O"[:*Q0=GD:*YFYUF5_<JP[9QSJ:,(MVJQ_NI;-5SS^
M!\\T9DX/\E17'$67>K#_XX?_>H5D=GB*[6Y^>;U7A,7F>-AK1,4N5;]<<.#.
M.P3;=M;@]A/NEK5T-+*#7P>#STW'_./ZQY>E_1]73/H5I6._^W<==.V*,\=?
MWB9"?9[*'FTY";LE3MY728[:G[4_?]R?B\S 4.VO>[T^V]GHG/2.=CJY<5$[
MQX<I'_<[?715#V\&;,M0N:4MUWAJE==_<XU,)WX#78=!/CHI&ZEA<#@M&3Y/
M#[0M>J96;OC!T8NRH 0%R9VBD+UUD4<>E,*_6BVXNFY$X@^VU!K?YBED3 _$
MVDK<*6$S:QMO^VN[JQ3;!.L;7;JVLBG6=O_YW-WH[W8_KNUU)T-G=@-=XV]+
MV SK?OS N[M_[Z[M?I+=LW=T#9\%V_P5G_'K)M\\^<_9ZCALYLT1MO=L[>S-
MR7;R12?9>:)=+&5EK"4^)D-XP(&U4>)0LF>OV',MIX4,EUY\M(+3,H'3/+IE
M]X!.%W88+FXN5+Q:*%Z=3N*5H9+:Y(ACU!-PI1*SHH)D;3QS&1$KT8)7?$8E
MY@<17JU0]02AJEU(M9:.*O#,"3QKDT2)0\B:\DRLT)I 8I3XH"4Q- GOE#'.
MQ&>O)-PZZ[&EHL]+X9;B)TJO/S6]YGDBYHR2,@%()AGHY(S35NJLDC6 ZZA;
MG-M6 6<.P'DW[9F!-=II&@@%STN:=43 49:8; &L]EQ:\^P5MVU*LZX"S L7
M8+Y[>[W2D:D6/)\%3_HJW'@T5*=(#"*A!2>%QNN1-S@&R;G@6..KP&T\E6J\
M3WJMK=1^?CN=HO8F@PE&1Y*,, 18#L2S:$F2RD,PR4:GBIW:%JVT3^W$J3GS
MK#7@KH*:$#QEHI%%DJ"%,S[)#,Z(J+D5^=K"WY76+Q1L/DS3>BNC9$$$PKT0
M!()4I&0NDY"MB4X8L"(\>V6GY;Z7_K3ED5OK/*S^'LRULOH%&? DJZ<)F+3<
M$AXBLGKK!+&T",#@6&9=,DR+S*)^7,</C]QVVV6ZE=3/;Z93I!Z:8T+MB2MB
M(. @$&N](C(%3570UG&#I/[6-=W;NETOEH'0_R2(L8E>O,U>_BU4FY8:I)@0
M1G )W/H,PC/+=.1>.Y L*^JA!F>U#\,VIWV%["37.FIBG-4$3.;$"66(42+%
M&)%U%(4Y_IR)Z6(6-]N::(>2VP)W&!\5 LSC8MP#!-0(J/L A4G_0TNI(&9#
M(F-(;%ARQ"O)B-5.YY L> @E @KX-"C,?:Y0\:#->- N.*ANR_S6/>6V6.V-
M:.*QM6 $5,C$H<6CVR),E,G+ .+9*\WH4BSX"ZD@M0PU@![3-6HVW7='M(B1
MU(RZFE%WY[-P8^AB:M;:FVUX/(V]5QUI4%$$HR+82+U+X!R-$;PP/.GKDIC5
M;U8]D\B\^1KZQZ4;'YE"\WW1FC<GW]7RNZ?=E<]B[?4V.*XI3X9H*(EFR5-B
MJ/($C/.*"QS,<FS";E\UIAZ>W'M"OD&;^Z4.4[N'J>+L8\39#Y,X&W, %IP@
M K0@H*,C)FM&A+7X3G81B@/9+IRM>2HU=G8"@JCSD=K(K+(:@G>6>IDTYXDR
M9PU<N^!1A:#[I'H;KT_6WFT+GD FX4GRR1%0%*F>E:QL4W/!H[)>N%*,0[0H
MGK8&O]\=U:O#5'&VXNP"J=[:QFN^=K*=#0Z;IXHH:Y#J6<5+9  E.1N;( ?&
MO&D;SCZU?;V:M_!#^!$F64@E*\YER SP82553 A(5M!T;?6#"C]W"S]?9] \
MIQ5-R422=&0$9$E0AD@)X\EQEH6C 3W--@58UHVBNI_W:(:IHNQC1-DIDJ=B
MC-8'1X37F8 3F3@+Y1A%<>1]2/$<;1?*UC#V&=$#-93]@0/7*G;=+7:=7F2(
M8^Q*C%JKF2 LI40@&"#.J4 HTSAR*G#-4@EF@Z4(9JO1J@^X>5B'MLU#6_'\
M,>+Y%!=-P4$6/A$.'CW^;"AQU#$2(T@E;/!:P/+@^4*W(MO#4V<7_KF"IS[O
M[*>I,E$_ZX!;0%?K^F5N%=IK/GQ;\'KV4S\(7L_('YV!TC5W;&$0?C9!R47W
M9-LZ'4.T0&1R31BF(-XH@SCN0S29*1]R22DU<EJ!YMQ4'H8\WF0[HQVL\9;2
MWA5NEQUN:][N4\3>[B7L77NW;8*01NA$$BB+V)LLPB[31"<5\"\N4LIOG[E;
MH:]"7WN>N@5,<RT=59YYQUCWX3+6G6S[*!PWBA$+%'EF]HE8)0.^LH$SK[-F
M;H1UTYL%E6?>01;U A,V+SRMP$>*@^.RH7#I<1\ZI_01-O$GVU6Q=WC0=Z?%
MD'ZR2B_S)Y]H;6IVJ]K4K58;:,LUJNI!K2%<%0_N,PFNUA"^X2.VQ>.[?>T[
M?#IJ?'0BHMN7F37>1&:<,<*E($?))ZS*5+;*VQ,3H>!T_=VV<$Q$;R1!]YT2
M !6+N(,C*?)$G8V.0N/M:7UKW:KVQ1E7>%HF>)JKBO#=XU/=B[\7Q.I.(A;.
MVJ)! \2+S F4<C^FO)(I<:=<2(J5FC_/F9H62EAF(?\*5LL$5NW"JBKP>1/H
M^3 )/3QX;HU,A"ON"$B=B+&.$L\CUSYJGS(O:;M5H:4JM+08<&@ DS)H[SV'
MG+W)17E:.JV#-=2JQ3EO%7+F@1R8\,_8VNMM*YE"1RP1R8TGD&Q19+&>,$UM
MT DXX"C56L)+:+#SN#/W8+&UZMBB;+@[:<.1)2<DT@8T6$; 44\<MY8DZW2&
MX-&1*<)NBU#]K^;[--?;2O!O8JD?)BTU>>&XYIDP)0T!+2-QB5I"@6L6%3#T
MR4KI,=VBU?:IG3Y579X?@HU1,GJ9,[76@>3"1*,HZ."ESR+3!9[,5+B9!V[D
M#')/%;.<*THR3E8"0#GQ@@')*N(8VBQU"2N^/;=OWV;F([?7>;C]/1ALY?:+
M,N$I;B]D<A +K3<IHG_.=#D_%<CM8_+6((.@\=DKPQ[54<0CM]YV&6^E]C<Q
MU"EJ'T-T*7A'<&FE!*0PQ$0EB7$^VT2=-@Z0VM\Z ;ZM6_?M27._HHS.X,CU
M.X-:6_CNP H">K7"1:^ @N/)9J\A4NJCE2)!K$%;[<.RU:\3J>"P]FZ;@5&)
M<4DL9&0>&C*^TI'8X&*6P4$0LJDNK):CV& 5\;D_=^,>0*!&1MT++'0G80&'
MT4O#@3#.D.)$Z8@MX0F)T:RRM"D7P4GV7.AIEE/K"S\J1&@7(%07YB;V_6'2
MOBDU(2>6"(M.H0M#*7$N %JZME*"!0;JV2MM;BTI>Y\B7K?+C5V&_+3'=(V:
M:U<K##_X-9[:B6>M,'P-&L.S]R8&Z@0H,,&A)VP]-9YRXVP0]+HTIJJ3WBVQ
MH1/GH'S]W7;F,E.N Z$9' &C)#HNT9.L#77>,.=CV9NET\)V]2"TW09<*Y(L
MQ3!5G'V,.'M9VJG[>MNKK%..CD@HR;Z2&V(#&*(X9*ES$KZ1=FH5SM;\E1I/
M.P%!*;I 59+")0%<"\.-YC&P:)!(!.,J!+4#@M@LJD<5I=)'8HU!".*0B$]*
M$>=P^$0*--%2>N[V$%0#XI>"ZM5AJCA;<?;6.#M%]81&@H[#A52/H4O-FBQE
MXTFD0K DDHF0VX:S3VU?KV8R_!!^I/'2!%M2[A5(;W!Y$99&(2,(G;BL\-,.
M^.$S:)[74F01$U'&,*1YQA&+P$.LTD(J$Y+F2/-NG495-XJ6@N358:HH6U'V
MUB@[1?("B*A!&I*,E 0R9(*,/1!FG/7H41NC6X:R-:2]UAEN:P!;1;"[13 Q
M5=3L];:U)DEOD1TR!\@3(R76&2"&\@Q,)2>4+'4II_/GVAC25J-6:YWA.K05
MSY\,GD\Q4G#)JNPB 2$X >D<,3XQ(K7(7&?&<DC+@^=/JL[P#]GJ#<LJ^<'1
MT6!OJDI.+0YWVZYI"]C?NG3<XL"^%BF^9_R'R<S4[LDV8T(PCRP>>5P@0',B
M'H>/^ PY1943X[0I4JRG5X"E+1YW*U-NN:IX!?*G#.0UL?@IHOKEQ.)N*7_L
M:(B2$64"LOJ0D=7;Y E+4BD<:1 NW#ZQN()J!=6G *HM8,>UL/+=H^CEO9'U
M=]M2QJ@E2R1FAB@*8(D-U)'D4PP> D\I-865[?2)7>7&<^_;_.O(X>WP9^Q]
M>77>H6O'>]@)X=P&Q[].&%U9TB@($%8#T]Y"<M@SSHMD361V>Z54,Z>,,O*]
MK/EE>WL?=E(\[J=!_@&;>7M\=#Q,%XG,FZ\':?\P;92&;V![?NT/PN<E-;BM
M_^S0L/?/OOMHC]?WWL#6[J^?MW8WH?OQG5C;^+O7W?UC9VWE]>G:RM;.VMX_
M>^LK6Y^['__I_^<L,#06HTS*V@"QW"4"*7%B0' BE'$&-!=!NF>=A*AT@/U^
M-#PN@X\C?3XOFPE33E?WCUX*U:S.]VP[O-C.F\,CA$_DJYW<C';'71CNSB!?
MV&F[NH)KQQV6CYZ7%A[9HV#/1R_*'.R<N.93>=#O#TXNI* W<_]"M^RYX:?>
M_KE5%K&%7\9_*J8H1]H+9?I]L^^1H6)_]=W!87IY_N*7\QK/O?WFJ9LO_7+Y
M\B7^<L).FV$9O?W+22\>[12,>4%'Z^)XIW5\Y_';+YJW)E!G])[0+SB%*]^F
M+]B5[_WHLOH%-?I&5_WQ>U)<?<_:UMK6VM;6M=5>#UVND+)A/Y"RF;.L_0@R
M%[V(F5OPOXO/-,0U9^)4^P?/%W!-3L.'><(?''U=0[;EYZ?Z>CD[8#.YX6'G
MS7YI\33/6$3//()9\B?RN&&GZ:I+/?+4K7^.*7"95$Y[?S,<P)_/B;O9S+G>
MG$#R+:ZC]W2=!WYJ'0>UXV[6<;)VW,TZ3M6.NUG'Z9OB_X(BJ%IRQC%[A7Q]
MY9;.[8*G?CYUVG8&M* RW]=__K8<]-PZYI4)8027P*W/(#RS3$?NM0/)LJ(>
MFH,>7D5X1Z<X<GVC"]VS=WB=G?[6QR[MKORSN[G[YK3;M&MG;_-LE:Z=_;VS
MU9L\Q?DLNV>?SM965D_7?_\'V_WN9.WC6J^[L?IU_>,?V):M7;RO6/O][=Y_
MSE;')SAOCK"]9VMG;TZV/96*F;+SGZ0CP%U):96<9"LL R.SR:'$M]Y:=W]>
M4UB.$^\*:172%@AI,\[.UO#^&R>I_R5UL3$[CZ9,X?U!WND$Y&F54V!6$Y9+
MA;,@$?*LT01G-H\ARR(14PHGW3JDOT)>A;P*>?-#7MF1W#@95*2;$^G6)LF=
MX\"\=(ID&2D!;RSQ1D;":?(4L8[FJ!#IV*(2ZBO25:1KTX,O!]+M#%.J6#<O
MUDVR.FI%LC(ZH@QC!(<P$&M\1D?6.BY3D5Q'1]::"G45ZBK4/0S4O1T<#RO2
MS8ETZY.LSC*K= */KJM I$L1D0X8$"7P)8,8P;"9%;HKTE6DJTAW/TB'GZU(
M-^].W;?TZU7\7OC:?;W-DQ)>2$$"M;&DF-!2&%@3+[45Z-EREN.S5VI11<XK
MUE6L:].#MQ[K7N>C-*R =V/ ZTX"7C8I">H3T:R4DQ!%;TCS0#Q7D5%CP05;
M(ECLLB#>-5+7?IS.TY+$IX^I,TQA\&D?OQ,O9SVED2V44)G_GB<7]B9I>3\R
MW8OVN9XGK?=QI\/>/#OOS<GZQF>&W(,7#ZN[$;9MH$Q99!E6-,)?((FEP1&F
MP$:9DN,R/WO%]%6E!G#V]?&WYW/-!@5<V@#.915 *6.M-CS@G0S35B?1S 9V
M/ANND2)=9\--9L,F[;[;MK94[V&<F*1*4(P!X@.^4E%GS45422/K9&9Z,[$S
M'ON.VX]S#;^Q!0T8,!$ $B*!$QI"YDQ3(3@=#3\]'WY:A_^NAG_]];:E(M#(
M!)'H91 (*A,7.254,F>T1R/%SI]I_]^&O[??.=I)'1?"8 \7J].2AO+;8+]9
M7IOLV?='^&,/U[0F$W;]( V;D2H9K\/FJZ=-!DO"=2_^*%'V>:>@03/=RKQX
MCHO4X4'"UGQ)_=,7E]-F2VO+I.OM'[M1$GY9>9L1QB7(4YI$##F#C-;;((,"
M:;T3E&NUS85\]M/T6W4Y^W9<^OR>)2F:U7IM?>--AXD7G3O.BV\JGHQ,:J5W
M&/J#P^-A>S+=SSZ<FP^:S%:_N_%:;.&]-L\^(:7=/%W_B*:PLH;7^< V/[Z#
M]8^KL/7;I/F@R>Q]^-I=B9^W-M9VUU>0TNZNRJW?L=T<V[SQS\[6RB=LP\[G
M_YQU3]<W/C&DSK"^@L^V^V';69U9MIGDH$MYM)2)\4AJN7):9QJ3#'($A3@K
M4WQ=$(D;+XS---C@(>*X6(W()!B.%@<FXV2:_/K&O]_\W7G]_OV;C?=3Y/*2
M!4P8P&AX?GZ[R\T3S#@*V26F,FB<)\HZ9D!2*96123^[+S&&]7QA^K5+8^'!
M9U[8%M)DI%.!&): @&.6&*$#<<"CE5&R"&$)!!<V<"TX&/;V0^_ ]3ME.1GL
MGR\;(VW3<#P<XE_.9?A_NO3\ZOIN/Z3.^YW4R/:GHN+PU*06E'G!K%F2Q&U<
MR"2S2]18+N9),U]  N9//VIOGJ+[D*E*/TY=OF;_/>@6;TW*74C"&J^9?C?K
M.#:/Q3R*]+V_ANG X8B-MR6O+L%3#Z#J 53[#J#&TW=\P/3;B-RV9TOJAI[-
M^&@)T'NAZ[]OPM;*FY/UE0]T;>_MWOK&!]D]>W/:Y5V^OH(_=__X_.TXZMO1
MTL[GS=UWL(4_\9ZPMO&.;W[<E&L;9<]Z]:S(/N+/T^[>WV5/^ZC;&T<-G:U*
MO(_8=LXPEC(ETFA)_G_VOK2IK219^Z\HF#MO]$103.V+^P81M*$]=+1$V\;M
MP5\<M2)A(7&U&,.O?[/.D820A(V,P!(^<V]CD,Y22^:3:V5R(<$0EU@CQI*7
MDDJB)5BN0 6;$EBJD*Q"LO7NUU,AV2J0K/%R!LF25TIZY1!F3B&>@D%6"8D(
M<50(YPPS"50_\>!.X$\:(G]X#\FUQIV7<$7>ACLJ2'S/M!_2BNQY-QQ;E2HV
MWK3WK4'SY; _Z)Z/O,V-.*C@['O@['!>,1/1$1V813Y2CKCB&AD!Z.8%]09'
M2TQ@V9)]L&+VE<ZS&] \\'ES[*I4CHIC5\^Q<PJ(B=P)9@2* *^(>V>0@]U!
M5K*DG8I1JIP?9!Z<H[="COT9'%\O80RIV^NT;.VBU_W< JVMEF(.GW5/>_8\
MY^_%UN<<;'H4G]B]T&S!LCX_--,L1FLCQCYP#GJ(\28&[VGPDNEHXGWUCSWO
M8>T&_3>3C:M@[#MA[/64XG%RU3A[??4Q6!X%(QA)1ACBS&!D00@A3K0Q6#DC
M'-G:97)5U0'6R.E3L>J851W8"@XV6A@2.1"$)9Q:[P*HG1+L!G)?Q:-BU16R
MZHW&4; J_\@PPP$KCQS)+@_-##*1>>2M%QPG[JWCP*IJ5<[;RJMQ/T:[H?9^
M+?6ZYZ.,G-,N#+*3LSO'ND?E\%AKA\>@Z5],[>7OL)6O)GOXUV@+*S3['C2K
MSWL\HF$DY^:A*&A$7 6,M%0$>2Z<8M1:PUE.KW^PXE%Y/-:791_J\:A8]A%9
M=L[EH:6EV7)#@6F-N/4:.4<#PD(EKX@#(HXYYK).+/LSN#Q>#6W/ E=5'HWU
M5S#^:E[U6[YE.WN=\ J6\.)EQBM[&F\VL<*KA_HV1GA%>9 ^%SV4AE($>@6H
M&)90! 1E R/,82=RC5>V1@93Q;1KJ&)43/L$7HX1TV(% !ML0B[X7-A*4F2"
M2\B01*FG8"+X'%?!JZKV4GDY[L=RC6X'7=A!*_LS'AI#J>RC)\[A*(X(3AE*
M%4PM!5/OYG6+$*3625$4 V.(&["%-$L.$=BR$!.W,>JM76:JA(UGS)ZK2MBH
MV/.![#FG13 <1<2"H\0(1UQKT"(H,"I.W@9*/.$TQTKH@^MC5JZ*I9BKH/3*
M2[$Q.D-95J#>ZOO8;MM.[ XK2^>[,.ID7H50) D;943<6L H9PC2'%,DN)4X
M<!.\L5N["^H+5=Z)9\.L*]4@*F9=&;/.*11$,.*,"4@EAH%CG4=6!XT$_/!:
M6N($V=H5E5?BR4H\W>@3,\5/'L,E\:W[1L>#1G5+&.Q8Z YS%92\!'<?'EKK
MLX.+5_S^9P=7N33K OB+U^3':F<3C-^(:GX;(0#\E+96_]*X/F ?A;+)*@%V
MI.;9X<,L,L%(^)-HRH7@/+BM7;*ME)B3 6.6^1'*R/?9LZM@VA_LIJH@NX+L
ME4#V(^CH%60_ F3?Z.P9LNODHZ0 SH0DA DGH+-'C!SF"@7EO*!6>>5UAFRQ
M(&.I@NP5UW=?7'=V-*G1]#G=4;GFWT6WW\K7O.C%MLU5;&]*_?WS=GW&T6SQ
MS2W6P=R&@[MON:NZ_*WR56M2]['HRGFK>N_4SV;OIA[::42N%^TG9',OAA>V
M?6FO^EO_OCUQF/7,0B^[1O=:D90>I40<+$@Y",#';EDH^05P0>SEJV T=EV&
M4FOVLMSXQ[?K*1.\M5N4;,UU//.IW5S3\W__;7<7;?K"LK4_K QM3HLY['R.
M_4%1OWJO$PKQUNAV1L9X59!V04':TX\,\XAIXOFP,$<\>(6T\A113821 ;[4
M9,,+TK9NR*(H25X>AZD*TRY1/E7A':/DZJNRTAUNON^Q/Z"$;![L_8KS_C0E
M4*L"MIN\>\^TN&I5E;:J2GM/R[9N>Y_B2 I'4!3!9)M/(?W6A*MBC#]=,<95
M14UNZ._MA/QN3);GXG&C\/E5_?R U&G]RPD]P1^.#T1NF51_7[]L[+\F)V<'
M OX5\ZT+/X !DULJY7?]?O;A[ V\^U-NF?3EY'H/-_;_;L'?\&^[;%TXVY5:
M184)B0&!K:L13UH@9X) /F$E<;0FF9QV5Y67K1#M)T>T5045*D1;+:)=S2 :
M#4$D[S!RB5#$([4HUY9%27'IG2(T<;>UNUF-6)]-3M!B+CSXOV%K<'7+#=7*
MO.BGW4S-:-N#IK>]6(,K%NJAU3F'5:M?Y<[4XZ#9#5/.XY\B#/I$$%:?5\J,
M3\[X@)$%X8*X%0; C$E$4Y0^L(!I<:)R6ZQ5K<KJL-*::AP5$S\%$\_J(<8H
MR2)F*"4&EE6(N4"TP(@3%I411H%FDIE88[E&3/PS^+2.NP/;GM8VODN/6(DE
MN-'XM"HEX\]NY_0X]LXK;'H4;'H]KV!(JJ5*EB!-@T#<$P_8A -B/C%NF:$:
M\XQ-DFZ,G?0##CK]Q*R_*M6D8OW'9OU9M41)%0G3!!D/N@GLG4/.88*2SW6$
M<612TD(M(?-9\6O*^C^#B^2E[3=K_<)'F.OC?[;M89&#UFZE"*H,?%/DX%S
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M6Y_C8<=WSV.C.UBCJMZG(_SH7C8H\/DQ?'_=;GYX]1K7SWYOG[P'_CX__-*
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ML5=""8NS.22V\8)4O!_4T[8@Y#5UCE40]900!39;--@$D13A,DI'$U/&1$]
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M<^E,<DPCD;@&I .XLPX;Y%+$VEI&?4J ='>FZ53E!Y\!*V.<@K2,1(P#=X0
M'S,,OQAM1.[*\C067L7*2['RG!%GG 2UQ LD=.Y[X7! .D6/G"-1"2(9EL#*
M^JY,FHJ3GP$G>Y_]U<GF-#L>4[ ^)$6D-\%(K_@3V285)R_'R;-"61FLI4P>
M244%XEA0I(/'"%,.]J7T4AJV9IS\O$IU+N;#$2^4J7;=03/VP$X;]OQW6AH_
M2QFP!X,:U8G%H,'XYH+SR)S$TBC+##8J>E99&NL':J_G+0UFHI38"21IT2<Z
M8F2"<X@*K 78&<)YM[5+V8H<*FOD0ZXX>:*><(9!"Y&><,<YP4X3G#F9<VN,
MY4]T/J/BY*4X><[0T%C"[B2#B,OE=5FRR'JLD8A4.^RXEC@ )\_7\*LX^=EP
M,N>)>&-4TC1RJ9E+)A&70O!6!.^>J,-=Q<G+<?*L3,8JQ,0E 1O#>P28;$$F
MIX2B%($8;YUQ8>%QK*J'7%62LUB$C8U_5^5Z'JU<#R.4XQQ42,[P@)51/,0H
M-$@!X<2H0%N50+DQ@N/=O#'GN8O16(7  %>(ZQ"0 Z&!HG4X2I9\I/$9]')?
MFUH]%=Q7<+^N<.^DBLI:P8QB7#"FO?>@/;*$O7)8NRH_=-/@?L[BEPEK@ZE
ML+L.<2(U,B(P1)V0L,B4*EZTNE:D@OL*[BNX?\YPG[!RPEGNE#6YZ;U)PD05
M*/.:),)TE?ZZ<7 _%W\6BD>O/8(M9:#=@V*OHS2(,A&]I-HZ6\ ]5O.=ERJX
M7W4ESF=6(05XO)5RZ/QGKXPB=[#\O@JD7_^.:?[3%QO9J,%6E5&JRB@;6*>B
MJHQ254;YF2JC_,B40W_ELU93ED7IUW*57T)^K1U'4+8>(_FP.O9:'7N=+0/
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MR8\$;^T>%R4TNRF7ZAS XO;_]]]V=]&FS_!/*1LPU3KF(O#6,*YELEHZ@6'
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M1GF'$ID_74YPB"2#P20$*D%DL.0"J  !I\2-23[*2G"LE! ^?0%"2$2Q'+1
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MSB<H9>0XJR!#0:>?L6*<DP \6L)"H99EK2V+8.#R4:R^#(CNW.1?%-74/V=
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MCPA=S8W=9&6N[104E"V'RJY*HP\G0M!=%7CI[47NTS,%?MF,;X%Y4>CNA7$
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M4CHH[:*G3GI#1B1J*A)]4A*]/OUH7=+41XFP4 [QP"DRP0MDI0A12Q6XD #
M=W6"'P-P<:IB$D.]T4EGU=H-]6W?$2&=<U];4*U*$_Q;X<[IPT0WFOKHF3=B
M:WO$DZ7[--<^.!T5Q9V8N@.P-TI[NNB/$$H/</85W19QW>%@7, D69_=5P6#
M%U[Q\O3*V)LR#N./#=A\=Q'0AHFZPK<4RL!V+K\ 4X>'V"\UL*5;@^D(\,B7
M!79E>] LS,S1<;"Q ZMT>2U:QU%4QL6Q_VWL%)QX>0MAZB*8AI^GBJE,/'0%
MZ0VG'/+]^=U8&'\ >KXYJC7E]1W%=;IE[8E).8L<&)ITN9B89YM(Y?DQHQ7I
M3J<,9/>FRP[+UJ!TSD[%O$J')XRB4+#@WW%TXK8;\Q?RKQ(M1N&3?.OH--5T
MW'[LF<T45N!Z87O?%43;+I.TMXNX$)#]L' -EP>\;IUOWAZ-(G[)>MSXT7!?
M<7)LNR2>T2Q'I4,F?I^\US?'VR:GRTJG_*0&\:CH<.D]F#HRMEW[A8YF[FUV
M,)7S+IW%TS._28G_A<TLU720HUCIPETU&)]_+'8@CQ+V'X:25Z:4V;_P!6\N
MXQ#%.@*9W\ #?%*P[&4K[UUV?95>P4M;>+@S70^!^">I&G/M?1XQ)>]M]J4,
MV_$HW3:Z8,%_NYJRP7[NK+R3C\F3R+0%7=-IL*0$YT@K'%"03G-*!6.2S6;9
M32/3FL!0=N&E;KO=O2S<A[;L^P.8DA$@LV<GBZ[;CF"7?8V%3EI$WSJ%4+V)
MT;BR[$"!)G!_9^3++>1)&;^<CLU/]S@JRQY-CA:7]^=,B/R"&P?,BV7@?BJA
M5A2K7,YQDE=4M+"#U6[;BWY\,?[EU]#J7[3MU8M6IUBSXJ9?;S\^)];,M*\K
M-K7\^B;G9@>7>3>YF=U-5[W1USO%5S,=]\KOF-KA1M[Y-=XA=W[WM<<2O".,
M^*['?OT[P>Y^:378:K /&ZS$_%Z/+7I&CEAM0=_<F;:4W^IA6_+RJK'YFXEG
M!6 L;LJYW)Q&:8X_9%9S 81B5J.B-/UR=G;POZ[W[]W?QA*E^*N;RB__*D+G
M2RS ;,_C35^K/UOCL/)HM3JA6*!;\?CBDY=9<O[$*_72]IO%0OPU\HK\Q&M1
MA.A^XODO1)B#\0GD;BKI9!Y;OB$YOMEQ?1/:HN<3B+6#6Y' <5=-^G@=TZN.
M\<^D8[QW48K I4P\<6F"QDD:E7(/#RJQ8O>M([8XGKLW>&E[O5R1X._<56#C
MXP:3IO#G?[3K9X?LY/@UC.$UKE^?7IX<GY /9[^?P7^MHU=_MQOGAY>-M_--
MX4_.WUW5ST*SL;]WU=A_?7VT_UNS<?;W>?U] _X[Y!_>OZ.YP?Q_K^NCAO '
M@_K9I^O&]<'E1RVQ84)(1'.I&:X,1MI;BXP*# MF$M=I:U?I3>D'_YW /"O@
M*F"K@&VVG$B4$6NJ(G:2JZ0UY\[X%(R@Q-!XGXK!V7,,O\U"W2O;ZF2X>U/Z
MN(Z[-TK]VXD;K(*Z9:'N:@;JK+)*4N*1=MPCKG-(53GX$6*TSCAE. 6HNZML
M0 5U%=1M,M3]\K18=Z_LO)$E7F';DMC6F%7CK(B2AL 1BRX@'J1$FD?8G2BH
MP]%H1>]H7/ZO"M<J7-MD7/L1L):K.RV&M,*S5N'9LG@VJZMI9Q6102-%7.ZY
M(P(RTC*D4@!(8X3Z@+=V[\I!KB"M@K2?!=*P8SG1G.F8:_8SES!.U+!@8G#
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M=I,4IRD*Q&,^YY.<(LTM048SQ@SS!JS8G(L_Z63.G(M? *@ T!,PBDI@_4&
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M3A);H1H>H=K4N=:W-! O\#8O>+MILPF.B:'.H\0CV&R6*61LXHAY$A,02]C
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M S>SCV$M.#47G)I2R"J#UD$IAPRF8%=@)I%U!*-L F*J-,4ZK*RJ>74O6J*
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M:,"QY3$P9&@$H];:J#QV8,KX:9D"=R]E+-'Z)9;PAYZF6"3\L25\ZZ:$4^^
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MEL(Y1$SRB'-GD,%:(L-Q8-Y[T)MX955/IA ",[9:F?1AT*UD#CBM2M./N9U
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M*QWA=.8VB[>@Y279KAFV?V<B_5W1"*[]>T3%$L"="^3N30G@8L^B#P%IS 1
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M86\H,1\=%BEQS#FPJ6;&*VPXIYQ'*N)=O:')7NVC]17[[!;8H+D%J)4D*"S
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M!]6  K.&2R5FT4DU@JQI^@B3:O@:P?RG+GOS>X+-O^G;6:QYAAE )<6]MAE
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MY>X)S++-ZKP_13_H%NTD:C-L(0"<,=Q1>T>L4Z"<B3Q2EQJ)-*8\5TEY(27
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M,4>BX9>&;?R[TSMK]FVK<046C5X\*BYQTH'/-K[#KX-N+,+4'S]][C6:O=X
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M>DXM"T[JG"P[70S02(/L>>\,,UBRRW]T#(V*"!HE$?1NUEQNI)B@05*"$F/
M .0D"1=,2%12'"0FBL6?HYA,)SEV4!'*=GLSZ_&=LZS.?,IZS#6_('"9S[[!
M\TXW]&*[)J A >T?'"9+O"8N  '9B'AP0$ !2,EBYZU,W(K<OKA_#%;4- T-
MR0/4EW8&E7!U"HW4[9PV/@.- !Y]!C#J'%TTWG<[@[.UQI?8.+/-L)!C^9YT
M-!U3^<M>%-;[?F>CA,VA9A![L,S>2XFN/"<);7Z ZVT?.DR%PB(@K!781$!#
MH#\ $ 6NF '%5 OJLHK,IPFH<BJO-G(E90Z1YQ#Q4(RM%CZ';$S/D6% =KWL
M(/##Z&2&J;%8WC#VMVC\3G(+EAV6TKO ?99LSL#O\% ,2YU8:6;?3F+OJ_O7
MI'074@(#X)!Q1S1H$PC,6U! ;3#(.:H1J!B>@+'#E2,KZZ#MS26ETJ-DCXZZ
M\2C'E MB*EWN.5UBEC_I*OP]KC=-4MHXG8WK6MFG\QS$-<.0V;AZUKWT)[RW
M?VS;!./*O-_MM,<><+MZOI%;H*;2.U"IV-O_<(BCCREZ I*2$P1Z5D"&>PWX
MYS GD=- P:Z@=-HC,$&E8[19TN)U.*L2S7+20^.\V<_(Z.%4B_0HL".&H>2,
M>FG0K4)<WP$IFZD9RS3:,9VN*%'/,;'"!7O6Z?93!]9RUUR<97)??YECZUSC
MV9Q,?)6A]W/::Y22R!0PQQ1.%B "C!\2L6048^&<O"63XV[::Z5_A%HO+7CL
M\\7NYM%A"DIH[P4":]TBK@)&.G*+ J5:6Y%4\MFPF9YC=),9 VIL9W $?)3Y
MH%DFI_6[0(CE=WL_DW<Q5&:+0H*AU!EEKQ<!CT7UCWM2W9UDQ;LJ$E+\L9_W
MH&RF1VHQ< <2Q3O[&X<T1&6DBD@F K8W(0PYQ1-223M/O0!=1:^LR^E:IKNH
MO9/"8*U15<%<>7MRJ<;M,+C$P/<Q1Z6!P3X#=1Z512 [L7_<J9&P(+/\^^;G
M0ZN)"1*,*J7R^'#')#)1ND+OT-)I12685[.4C1N0$ BC3+@YSQ@5OS<[@UYV
M!YWG]&.;5>)9!%50YC(#76W4WQ_<#H#JOATRX[&/4B. L3RTWE#0=FU"DC!L
MC?*YU>2-X/82]<KM]H2L+V/]O3'O<R;QHGYMA+P/ZV#/[EP9)5%$\J25UL'%
MI(0RF EO:3D0#E8[>R!<K7 N3/ [E]]^[%P>'-JDI*>*(BT"11R "1E!#0)+
M7/"8*YXX75G7,SP/M_C-AT6EUSYVENVO*VOL%Z#PUE6<..N?V25!2PIL?'JW
MV:C.KGB9_/;/TK\Z/-CJW<:8&[PDX/_'*F7USS_?%:NY_1M\[!N_5*N !0QO
MO-;8JTS5^3&GI66$>9&FFA-*3KC<O=PX!$GL"0D:V9#[J MLLZ,C(*J3I=YK
MIR,!TVL&],_GA-5Y*L72D4BMHRY&,G@'2,9KRX)4'"G,$H"GXV"M1X5B,D!)
MWKIDXLJZF,XMOX:4+X4F9H4;:V(HB&%W_]NA<)AA$3G8*L0B'C3@!XT4Y5XM
MFLIHDTN 'S/"04-BZ/5SU*;RNX\'%7MYLTOG:3N>Y^+1H?@9CP(-BE8,E0?T
M"O(;[TH/Z%$I[#2LY[=>(_YHPNT D4X'/3]H=7K?8BOFY@Z5<&YD-;$@S_@#
M5-)0%=&4Z7I9&QRZ89NE/,^F^I=<$ILKA$O+_JRT2A:UCIS025K/&=A(\$-9
MIP2+P6/*B7'1WC:N_9&L(_.&27QW<_MB;_/HT,H ".-M5A$5XM8YI)7AB)"8
M>)#&495'K:\1.D-*NIN]/_V15V?:"?0R;:JA&W[85V52IRT4R8=VHBIC-;5$
M.)(2UYH[&Q6Q,N&4@@S6+\P]M1/U@3D)UK%U2 E7@2:)B" YO]9+9+41H'$Z
M[J,Q@C"WLJ[FYPZ,\\OB"J:K#O5AB6=,C1CURJU4B2O(K:WPZ[H#W]O_?"B$
M!RFG' K4.B 'QY##$:P03. _8Z+"<G;8IS/HGP$?9CGK1GM<R.WOMIO=FXVS
MXXM>TS<!8\Z*;V7#>]& #QGWPY,'\<,?5]VD'HT$KS393AJVKNK5"7*W M3&
M^<ZE/TP^:5GT']4< "H!;3KN0)MUWAH J!R,G)L@UQMZ6X:'?$LJY?\-;'?:
MJ'D,4KC!*5@3Q@S"V.$[FQO\4%LJ<L0%>2LHXB9W$I"!(<]%U,QZCX, :CCO
M/%4TYEE5HCK<\B!J$,@]0@*+G@;$!%C*W J,- $*LQ3;I(RF.)&5=3I#[KVR
M< M>G0BO_)S3, /;; ^1<AY4"\V,(I%S@&],$\.Y,L1)@7$9<\1##]%4(]DZ
MPK(XC</U=T\.#@F..@3-D)99M[/!(Y.3SB/57F$N>0I@-/.%_,HW1T[PS9&3
MZ1!((9VO],0RM%?ZFZ;S1OVX]5<VR;R(8=0G:_+^"V>*WI-2G\*"?=.^H$S6
MESN'@7@.IX21H<R 2A <LAQ+Q+2R25/!)"E]03,B)B7LC1Q"56?:HFPKW=-[
M:*5,GGBL1"[. M:2H)MHX@RS3#(G%I[V4GL/'X)B]C8/#D62.M @D?%&(QZ2
M1MJ!L-><R!"4CB8KD60-FWG->$844U9QI4&[3!/.E%,0#=#&,6#9:@%H5=>^
MP>G9,-7X60EI 1CZ\ZKUW'8[=X^;L$]JG7(>F>T?'5KC"?/1() 5%G$F@>"D
MI(@D#C3'M4R& 9E-=RJXWO4L>Z@+"3;L$%:TS)A1K?Y2=,X9[F@\Y8[^Z?2>
M.1Y%KX,(2IH4'.6&)ZMS3G.,F(>8K'"W<%'M4?P)+J [^P>'2E-'%<9Y6'($
M\:P5&%5&(2>,]T9&YKG.U6EW]2C^4O5@+PWV'%&LNJ3/"33^<_7!G9!XK?SU
M>J731+CD*HEXK,QD<27TGG1;AU&>@,IS#:9@T47!46+1(T[!MK)8&)2P<BR0
MG)L!6*^GJ?QZ<[\7".@S&G0#AQ:]-PN.NLX61?[F"-O'V#I_K6IY.T+^:XVK
M2PVJZ! ;RB;)HW[5-R0WC?I@E<T^QWIPC_%P[K#5ZPW-R@D^'CX,7.5[T=^J
MTXO7>GDW>T7-:TY2RBV8KQK>[L^]6($$&2"&/4RO043N4]V*5>O2LNU5M_!+
MMIJGP+'=BR+!H4*^LVYGN/B\?[U"!3WO=+^5JF@Y)\/9EFW[8@]!MK9R=^%&
MQ^4[YT\5N155P]*J*4ZUQ&I'1B<"-SN#%9<=K?.!%T9[;E4]FB51' /0=NEH
M+_M'PG'8]E'SJO%V"<GS#JW8N6Z$_8FKU7[/W\;5JA5EOL)PZU>O#J3*8;&^
M:/[=+KK^9"LOSWHI.X?-:@!?B(^!.XF^7Q#F:-0Z4)*/HR[<O5[U\4*^5+M6
M;'[5[&QXCF,[',-:XU/1K7MTT5Q<"&?BXC4ZZG5RT^;>4$SE_A!PE5R&6#W3
M6%O[W!*ZV0FC9NEE"_/A@P_:Q;D"&V6(AZ^,8FB+3'3).EG5>K[X7M&2'58U
M.IJK0RE5UCM0-KG&G[E9TZ#5'_5J+S]Y18X%7?3BM9TKOU)>T!8)'4 .W9C7
M Z_\; 'Z3_4YNDLE^E_59FV,CF7CZF%J:7M[TXSLR?2'F'OJHZ7(4,Y!VB:#
M#+$.:4O =K?&&6=7UF_MI%LWGGV QK.J;CQ;-YZ=WR_L#OV_'K?AW"=_',.@
M%??2QU%GDNUB1DHNTB][G0\-]XWVN,=KHU0XB^=_TYWI3@X.F0Q@>$J*'/<,
M\>A=-N UP*[ )"5M$YGJ-#?.KTL"5W]=*='9O,C*7^LV'3W[&_K'$V9\D5X\
MX3?HW46-*K2>JHTM+M1$FV_3RF-9?EW$_!MKC">*_2SF#%Z)G6*V80[.V;->
M_'7XRV^AV3MKV8M?F^UB=XHO_7;]\AEW)^8:%L=7OGT%R6NXA.4\Y?!J'F/U
M]EKQUL2LQO(](=<DUW/?QFMD[GLW79;0-6[D3UWVYO<$FW_3M[)8@>]VV6+D
M9440,V8:WSJ?G8BIS\X8-5SI0!-$>MH,H14?&EDF9>WLB;H'!?]O7>/_!K#^
MM:&E=]R<.\Y6?IS')>0>(UEG3;&>-V1U<L+J<I]O!N\'>=JYE/\:MXS46[;H
MEN%%$&-Z]K'W,8Z-B']>*+G;=.=W.:R<4W\*5?S.4YZK)[W;R=]Y8/VS[L3=
M!]8O]O"WCJU^UJ=>P"^7L/))8&5H(F"E!K!7?:YGU,QS[$2X;;K5#3&P:>,P
M:\9W, \K\BT_^>*]=-60>O+UI'4*U\!?3SS8AA[O??E,]S8_,/C\R<[F?^!:
M?Q\?7/[GV^@[HR'U<*\O!VQW\R-\_W->A_BZ?\!W-SW8E? \IV!S?OGC9 =L
MT/]>;E<#ZK?Z.[D=[N76^2%)T7/A(F(^)^)Z)Y#-[?^YIH;%Y#6S0*AL7M+$
MXW#0W0? CSCI)F%U&VI/"KR??HBW#H.O%PD9$]HP3C,><AVB,X[QA#D5,3EB
M\>S!)#42+C$27DP@H;8N,9E;/BF:$'=4(:USSG82Q#-C#1-J95U,MY9_8"2L
MP; &P^4&0\*9P=;;2(7GUBL3J/7:1\Z#(5;J @Q_+C6J!L-G </=2;50),,\
MI@[I0!3B)-=G2661E92*P(U0%*^LSQV>NG1@N+!AGXK_7I1A_]?,;*&Y+B&Z
MV-//A.\7#6/+:-T.S_"OE@4P:X>MX3'6D+80I.U,6[K,&JRUDXC">>=>30'9
M0!Q20.2)L4!*_6ZZ\\:"D#8;.1Y5A9NXY5P'[IMG^64TXVJ6?S"6GS3IC" T
M"H61A[-&/.4>C]FD@_/&&J?($T\KZ_K>SJV:Y9>7Y9?16*E9_J%8?LIP23%Z
MA7,S1N)3]F<[9'P>4L (EBD*Z:@ PV6Z>_SSL?Q;"#KNS2Y,^"GC9,;COS[8
M6D;C9'MT?+6'93&@^C!MCECG$_<B(<JE!G-$".04L8CA2&20RDD*Y@A]( ?+
M$CF4:QY?9FNDYO%[\/BD_9%SM:TV&CE0,1'7 B.;G "U1(JHA?+&9ONCYO'7
MR^/+:'[4//[S/#YE<$1,/*6.(LE#0#PZ@EQ2$FD<!.;8DQ3TS.[OS\?D;R$8
M,JP K<,?CVUA7$U]KJ%D 2CY/&T2Z"18,'F@""<$<<((,LFZG)HGM>584:KS
M2*9Y72UJ?^4K8,N',@IJMOQ9MIS4XKVD/.JDD<CMV4&?$R#<F0!+/7F:I&2.
MDI5U*>O(X2MFRX?2XZ_8\C4WGWAJGIW.7XK48",3BE%E>6H#LCYH)%WTT@M)
MB<Z] %>%GFXQ_>(C 27SX1D:^GA9.#+3=<=+$"-H==I'J!^[I\\6(BCKKI<?
MDI8Q1%"<X6ZG[%U:IV/^%)P=7%D&EP?PV<_TT"3.#741):$UXMHE9(@FB%).
MX;RU(]2LK)N'RDW_.2P;\<W+\B2^%'9?QFA!S>X/PNX7$^SNB<,.^X 4L0;8
M/7ID54Q(4<H$5Q:('=A=F>GAS#6_OQI^7\;(0<WO#\'ONY/B'90WG"P.B%J3
M2V^C0TZ%A )C.AJIC*/I 8MP'X+='RB&\$)-E;^NAE8=QU99;=&_:)P6D[(;
MS?;W6/68?/KPP[/"VR]/:+[D<40/FY0Y/--_PY%N7YWA=OMS>[R'[49*\$WX
MK4:^GS9L1D49G L>M4.:.86X-!II12)27EDE2002D;E/RW2AV3^?QD'S<TK.
ML[M57PP*W->JJ5'@!:+ 9(1%"2^< @# 4G/$L1;(>6J0]MY3( W  ;6RSJ>3
MMFL06%H0>$)+9RDP8#R<DYH_8D"7L=NIL>%G;:-1@R(7"9'$@3%D>,Z,,,@Q
M(A"WH#%H"V1"?>Z/J$%5_.U98SGW-)!>8%7'L)7<V-B0-U;1\90&SR.VS1A[
MHT:LA1#+3]LTP9B80("AI/)LHA@T,M@QQ QS42;IG>6@S4P'GN^NS=09WTO,
MY\L8J*GY_/Y\/FFU4"%]P#(@23Q%/+F(;)0$29$"Q5YPT&%7UNGT%-R:SU\%
MGR]C@*;F\WOS^71)N231<LJ1E@SLCA B,H(PI#'7,FA-,8LSY[@_"Y^_A>*.
M/T<Y8O>U/%YN[NI+MSRNHL@U6/TL6!U-&Q_<F,2XET@3)4$I,0J4$N(0Q88G
MD5MA1+NR3F9,P7XB7VJ=I_[VK(^:UQ^$UR<-$$*B%I1*Y!FQH)A0"BJ*3T@;
MXU4BQ(405M;5=+E8S>JO@M67T0"I6?TA6'W*!F&66BZ#R1FAKLH0T[EY)?6&
M4!T4T?0Y(Z1U'<L5"W^,(<;38CK@W#GIS?8P9ZP8OCPV(+LW<+UF:-KNLP13
M7DS>R$-FCVU<39H<#HS^*X^FW!A-IKPZTMUK)[H]/-#M]E9QG'OIW=AA?AH[
MRQH#%\+ ;S-,&]!GM"8&>0P_..81&><5TIXIZ;70UH*Z0_1]])TZ(7Z)>?XA
M<\5JGE]*GI\T<6(P@.I*(J)X[J[##5@W#B,1 U&*)PJ( #S/IBO?:IY_%3S_
MD+EA-<\O(\]/V3HR)"<P-LA8JQ"W42 3F$=*8R8522H& ;:.NH\+<_DJ898Z
MX+([QXZI8R[/$7,9P[&]]">\MW]LV[#"OV(WS]B=#5U_V&;W;]L:Q!J@%@*H
MK?,"G J0@O5<^A\[&X>,16QU3"A2IQ$W1B)KA,GN&(M%"D;[7+:BEL0?4[M>
ME\T4J;E[>;A[9XJ[@[8T-_QRBCC$,2@@UC*&DD@Z!6ZM=V%EW=PGX:-F[B5F
M[D>,J]3,_<3,_7F2N0EFFFDED!2"Y2J2B*P3&A&I*&'< 6P7%:?+P=QOHHK$
M]HX;9[895AOMV"\"(OD56X49ZXJ2N4"E<?326B&) "U$4+ U$HD4&_A!@R6'
MF]G&P 03=#=CXR][412Z[7>J(.\0PF)O-_;W4CZJ8?BW!J/%P.C'##LB$"G
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M_C%\[X_3W?=PK\L=MK=YQ'?H']^^OM^YW-W?@'7_IS6=P_,-?_WR1VOO_8&
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MV,7CE2]VT!I>=B%WUBU8EA +[N<MV"E,$E1REMS9DZRT9D+@78QA26Y8E1O
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MTA;&9*7\40-/&Z&;1-K]1EI/(NT.(&W6(<&T$-8US"M6:?#_^8%5-+>DG\A
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MJ!:UB;[2:"0>KBUN%87A\UA%SBR/$9-L>!+_]AS_?%_BW];C'S(,6[<TL.L
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MUAGG& W'C5EWH]S]2@3A;.S!^)0F[:;L[F%K= /&>\:B$.S,\53R0^$U)&"
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M,P)')9YGJ XH%]4U-0_YQ =6-=>14;I&!)*)^H.0OB83]?=DJU1S02R)25"
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M1TVM0Y1Q[H>W>-C-ZUV 2DG)X+D6E&Y.DL+#3,$IU5@6[A!8= 1JXY)M)85
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M$$QJ\BG >=,53KEK*7N-\3]/D$/$YF2-&^&,8.$T$*-;GA!%Y*430+3B22=
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MBVQ=Z$=%\UI=,BKLM%CF"*37$.9V;P/:WU;F_E?60H$.9=54C&;FOOEQB'S
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M<V]7?GH#8QF -+LU?O[+_P%02P,$%     @ !(]15E<Y3AJ;0@  EK$" !0
M  !T:&,M,C R,C$R,S%?8V%L+GAM;.U]67=;.9+F>_V*G)S7B4KL2YVNZB/;
M<I;.L2V/[*SJ?N+!$K Y19%JDG*F^]=/@-2^<L$EKSQSNMHI4=*]'Q ?@(A
M+/_V[W^<CG[ZAM/9<#+^Z\_\S^SGGW"<)GDX_O+7GW_[_!;<S__^MS_]Z=_^
M!\!_O#IY]].;23H_Q?'\I]=3#'/,/_T^G'_]Z9\99__ZJ4PGIS_]<S+]U_!;
M /C;XH]>3\Z^3X=?OLY_$DS(NS^=_@4U1B%B!)=R N6%A8 Z 7)99 HR2>3_
MZ\M?BD9O$ N8F!0HB1*B5!FL5%HI@][RM'CH:#C^UU_J/S',\"<:W'BV^/:O
M/W^=S\_^\LLOO__^^Y__B-/1GR?3+[\(QN0OE[_]\\6O_W'O]W^7B]_FWOM?
M%C^]^M79\*%?I,?R7_[C_;M/Z2N>!AB.9_,P3O4%L^%?9HL/WTU2F"_F_%E<
M/SWZ&_4[N/PUJ!\!%R#YG_^8Y9__]J>??EI.QW0RPA,L/]7__G9R=.N5<QSC
M_"N&T?SKG]/D])?Z.[^\/O[PZ?C=T9N#SX=O7AV\._CP^O#3WP\//W^B$2R>
M./]^AG_]>38\/1OAY6=?IUC^^O/\:R(@0G"QA/$_'W_6+]<(4QBE\]%B0M[1
M]Q=/K%B:@<4_Z*\S+N?E\KVC2;KU2Z,JE<GT\B]'(>)H\>G@? 9?0C@;O!N&
M.!P-YT.<'8SSI_DD_>OK9)1I 1W^U_EP_GU@4$:AO(82A  5T8/31@/S6 37
MW%CK;D]9'>",1KB0;0FSN!#PQ0M_J9/Y"X[FL\M/%M.[F-I5,2UGNLF8!Z58
M+I6S(+AQH$)FX'+DX),HR7L5G2G=#>_V2&ZPYF":?II,:<BTA_W\T^]8=YR+
M[6R))4S3/3K=7DP7O_'+[/ST=/%,&,[Q]/+OZ][6(1/FDS93OA0I#65;F9]@
M1MJFX@@_3.@\&,]I;NAWOQR-YSC%V7PYQM=A.OU.GQZ<3L['\X$I3#N4&8P7
M'E02&F+R%C3C(OEBA ^A,3DVP;D*B\2/P*+.A=B,;O<'?C1.H_.JAGR<3!>R
MF<^GPW@^KZ/Y/'EX/ /TR+2-EM0')4$Q0:LD)P8FE, 8"R[SU@1L@WP52LH?
M@9)[$'0SDKZ>G)X.YU7[K1/SFF 1)-*6ZR9M,/)0- >6D#9IKRS06DF09-'2
M<.&T;WWL/P%G%3JI'X%.K432C",'LQG.9Z_/IU/"- @BRJBT@&A"!%62@!!-
M 5Z,9E'EY*5OS(I; +9F?)A]K?-*_ZG"^A9&BYF>7QX9_PBC<QR@\4ZA"2"1
MEJ#R@0%92AYD0A,UYU@*;\W]58#U25O<G!?W*-]<)NW(GU)5(68GF)" 5;T#
MYY=C+K1)1\\#"/2%MNSB(>2@P,D2G+.LL.:&T5-X^J0$MB-',PDTX\31^!N]
M>S+]3D &25HM1;)@A4<:FE$0%=.@G1'9:!6D;LV!F^_ODY;53N8;SW S&1_/
MO^+T]H!<DE(Z31J9<HO#E[B6M(/$/!?%Z1*#;BSI^RCZI :UD_>6L]U8U1GX
MPJ(7+D/Q3I.]2):CC\5"9)F[4$A[,Z83':>MJL:<+T4X"\8:DDA4"*%P!)&$
MM5S3B%)KQ];:7-VMLK*69.\=1!M/;C-^OIN,OWS&Z6G='V=7-L+UR3BK^V7(
MAJ?",J#/M%_F>O\0=09I4Q8*0V;%MO9GKH"K?]K)5FQH+HIF)'F#!8FC^6B<
M)J?X.?RQ'&W%8Y0G/4D48(8EPN,BQ!(R:&.53\([EEH;;X^CZ9_JLA4A&DU[
M,QK\.IGDWX>CT4!&EU*2$5#7DQ19@>@XZ4]6":6#4\&WMF4OW]T_;64K$6\T
MI0W-CGD8?QG2WG+%K,,_+AR-5\B<%2B-U) P>Z):*1"8RL!L%":[Q)"W5E)7
MP;4*$?3+(4)S430CR<?IY RG\^\?1V$\IP.I^E/.ZNE$7[\=CNN=_3L,,SRI
M$WU<?ILM1W!0YJ2 IW1^6N6"^0V>33$-ER(:YX/3ZLC^[\6W@^2C<=$)\(R,
M,F6SAJ"*!I%C(*7=)]U\/^E^5*L0U+P<@O:,!AU>J@V2838IU."*5J!,I&5&
M"CC$( 0OGA0M;*WNMH]'J$[_R7CQW*6S,]-@/))ED2(3=,)H&E_F&8+A9'9P
MLK%9:Q/T+H8^F6];ROVA.Y:-I[N=MR'G81U[&'T,0](;7X>SX3R,!I;3$:&J
MK9#)5E#,!W &+0@GM4]&(E>IM=W^,)0^V6R-*=!B\EO>,EQNN0M7&/&3-MZO
M.)X-O^'2H'@WF54UX[B093$HUDB1R:!P*=/>*Z.$R+V ZO-&SJ,T1K2_>%@'
M8I^,N];,Z5!8#8.=YF$XQGP8IF-22F>W#O4R3,/Y %&KQ'0!,DH9Z:=!@:<'
M 7?):J^CM*RU>_!Y5'VR&!OSIK%(FE'E\Y0TP?/I]\5PER?C\E#TW(K$L6IX
M(H#2F$CW3 &L#C[DZ*S.K6W)Q["L:3_"2^)%D_EOYV*^CFVY='5GD2UWA?2B
MHLF0+=%#M)Y#3I;^'HL7D37FP7T4K5SG;S#.%[$&B^-^800=Q]'PRT+PUY=9
M5CJM:2'2D5_(N%$<0J A.X=9)J^T9+DC'_I* /NDFV_)F,<<Z^T%U3PHY&/X
M7EW]5U="UB;GC =C:.DK4U>N\1(\C3<C%X%A:\?(PTCZI+8W9D>#J6]&@\/3
ML]'D.^()+@[Q!T8JN?.&]FD0A2$H)3G$K(BG1K"B44C/6M^W/ NJ3YIY8W*T
M%4@[IQ6.RM&8COCJ=CO!&4Z_71,W2(TE),*2)2BG$'PN&:3*)C!%]D%S'>L)
M.'W2OAMSHY406E[G+ *_[^QD/#*'PAC:ORR9 $)D"$(+<-8$IS(F9EN;]@\C
MZ=.536,N-)CZMH%F#XVOY(3&"Z"#+=/X,)"*DVHV)%.1D/B<6O/@$2A]NAII
M3(06D]\P%V,\GX8T_^=P_O7U^6P^.;W&]OTJX-5F+DU <(K3L56L A?102%X
MLFB=,+:^[5@%URH<L2^3(\W%TK<,LZQJ%$-1$ L/I E91QN@-&"T$BYJZ5+S
MN-8N,LS:7"8R;5@4":P1#A3/!ER-ZK.+5'V>$@]QQY>)?;MXZYQCS^?7K26F
M9LOM_7 \F2XFX&)0VJMBC"PUSIFV%CHKR-ZDY9^LDME)[X)N?4]W%T.?+/T>
M4&4K$77A0AV$&$(*9&:RD&DT,6J(SFL@^@:N<@B\^3W^H\4%FCB#2Y J^$C&
M44ID00LZY+Q"6GJ%Z\QD<=JUSD?>3"7=@_MS+6D_41]AD[EN'F/^M/]UH#D-
M1II$1C+6Z#:9P =F0&F5K%/!(</6/%@)69^VQ&;<:"^33KU;=6N_-*JSRDXG
M"\8%,JIM+."ELC5[2UN6!7.F]2'Y-**>^C^WXD=#&;2+1*T!$8NPP865_7$R
MFT]Q/IQB#4.L%]YCS*]P3%_,:Y3B[,9<W(2N14A><XA"<% H+3B12><307$9
M2HKM@TU; .^I)W4KENU>HMWEQ-S$5G-,DRF&3E00L18DXMQ#\"H!-XFEXJ3Q
MJO45]S.0>NI^W8I +:70F0/V!E6==2&HD$"X5&BL!B%HM( L$5$1A8FMHP >
M1]-3-^Q6A&@T][MQP=X IW7D7*<,WEI2KQ(:\-6]*$J,,0G#;&[MG%\16D\=
ML5NQI NIW*',O_UR=[[>T?>-ZDU^^DS_OC_\\/G3\=OCCX<G!Y^/Z*>WD:Q=
M>/*1AW90@7(5^(U*45Z&1G[$Z:>O88IOAJ/S.>9!K7WE&!:R?!U)EG$RA'V4
MD")7DDX&CK*UL?D(E.UO?2_C@]_2>EE6=SJG]QR?X71IQ=$++]ZU>.^ 8S$I
MU3)2K&10+@6(N@2P*1?I> S&MP[371MDG_PQ+3AT_\*X2ZDU#"FX"?/-<):6
M2#%? [T,2[\+V+HH9"D*<@PU55TI<(5Q<,FA849&;%[M;0NX?7+R=$^X[B39
M3HM>PJI^_$OD T6$%US1F_.B8%=->T^(-0_"*5+K4FZ>Q_0 C+:+:GFQ\9Y.
MS$F^4?IAP) ;FWR&PF.M:%M(]V T\RRX( LI.-:V'NM*P/JT,V_+D:<720O)
MM'.BASB9+NJ!+"(1#_\XP_$,!]%SD4+,P+R.0&-/X#574 B5BQ:U]LTCZ1]$
MLN;^V6T^16M>-)C\=M[Q\[.S$1E ER"T16NM9D",K/'JV4&LUHK1V6:KR+I5
MK379.Q#6]'^_+-%O,]UM/4JO)[-%XOT2R-4X!]YPH96,P%GU:U1O5R24D(3G
MP6J;.&]^*#Z!9TT_]<MB0S-!-/1#7Q=4H*]'^%!E!<7)/M &(0LZK!0=7Q"T
M"^!XK:5GG-3-LP96P=6K'+S65&DNF*TI,_^:!B>DQ4S/T_Q\2B/]A//Y:''7
M<G1Z%H;3^M7'Z>3;L%[*U.)C!XE4H-DBJ[V2?L!LSJ9.@+?1D^;C$KC(- 2N
MH]2:,X-WMII['J>M0:SIM7X9I-FM:-I5! O#<1WSA5[T>?*. "UC!ZX',""5
M&%FQQ&HE:F%#5@/@A8=<2VZ6F(CPS<N%K0*L3Y[MUKM/>\DTV7X^X+PB(Q!A
MA*^)R9/1,%\6 WJ#Z>8GQ^5M2)?>_GI1IY.6M?@KS450%3.=LIHG[YBA&0IR
MA9UGT_>O0A7WPJBR,WDT+$'Q#<?G^&$ROW2:WKW$&5C.N?6U[(Y19)M;P2%B
MU&"$LERX$KUHK0P_CVH5]O@7QIZ.9-*:*X^!NBJN5ZN4T?]RK:MBR8PG=(3,
MUIH+CB<(@G 7[95AGAG6W)+: .9*#CCVLNG4F=A:ED4LP_EBO*%XIKS/('/6
MQ._@P;-0JS<G08@RZR"B[.KMW5\?;A1S3V+F3M3T)1]<=8V19A%5@8!"D3'L
MC<BMTUZZ&4F?W-T;<F[]N\?.1;Z7"\I!4AP]_0/"\]KW0=!&X8R G%(IFGZ0
MFP?9K(.O3U>0G5"MH7CV0R 7)!:?1*W)S\E><AXBHY,M)2^3U %U;NUKWYQ
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MPEK?3##LQ\1OKA^\R/.RJ]6S\G&Y)Y+M?==:;4A%.<4=*0])1P8J:=J(N2]
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M]='[)* ^F<N=;S'M1-/.Z1IF7S\MZ$I3?=$]Y]VPX-%X=CZM=5H&6AO&6?:
MJ49QR)3 <\D@"H(E=!"R^=WALZ#Z9&MWSIJV(FK&G ?&/<A21FF)O3&%LBA>
M!='6*W&-R9#QEZUN'47X (P^F=^=LV-;,73*!YN+CXS>C.A)SR[2@ZN7Y&B8
M\#+2AB9:9Q4_RX?U1_8^3/]%)C-)ZQ.FBV[>-T[Y(+66!3DX4]OB)%]HD*:
MX:@X#XRGY@6$GT;4<QMO+5;<I7M#631C?JUN-O_^'N=?)_G6.#$'[9B&$+D&
M5?-*O;06.-D1DF>IG&J]&SX"I>>&W%:,:#'[73LACSZ\/GY_^/G@/PX_?9Q.
MO@UG],@PSF^P(/$V?PY_X!:NQW6>WLCAN/& &KD9+SS-1V-"A/2VB]O(BXX
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M?&R?D/8\KEY<5/>-LO?=]8T%W,35=2O?^!/.YZ-%@LG1Z5D83NM75\WGERD
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M?6'>9U=NPN[QQ61">'X>3!,,_PMALL DDR^E!/)%LJ;%).O"HK2&2:L5H8I
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MP'@H03NG<XZ\'=-W1C\LNC<1[1+.-SH6NP7LW7@Z@^'_-_@\-R<,!*Y0<F9
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MA=]Z:VX+Y(>M>3M@MZ%GNYC%&YS5D*1S?#V>3I^<P 0SXGG]\8'96!O)^G3
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M,,TN+WS>EJ,\_CR7<?63E,V.2]#,<4&V37:%!94RD]DEEP7W179:%6C &[I
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M,18"F>L\CV@!I&:YV%J0,YL:(*AJX9%(TA&<.]W8\U@9Y %:*]LAK&%$YUJ
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M_HBCK8)T7KPV(ZJ'&ZQ'H%X#O5%+NPO<GJ[05X2ZF^OTWJCOKF+->-L#=3/
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MNXI#$BE*ZWUB2=>4MAPDBQ E*TI#D;&F)=X)'N_8'^+V.+ON-; 2!8_VB=A
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M#UBR/"TI#L3"_G_VWFRYK5Q)&WV5CK[/O3$/$=T7+I>]?Y]PV?YMU^[H<\/
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MC#FY)%J_(SY&TVG HJGDUT!C]W:C:V[E52?4NU&H4A\[ XN01)U%J90!ARD
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M"1!9SA!DL,*YXIWO5&OSB.9N+#K<_;F3V*<M9-;0V%H2<M&8;T5('6PH:QU
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MUE+D#(:E6@->T_<]B=D$QGQ0%A4V-Y&>X"2'G="\%V4?RB2'F^D)P>;D4#K
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M.BIRI),CB3KLPQC>.L=POQP_M:US8!BZNX/<D$^HA6$,EH6:@B-!V1+!!Q.
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M!^FXIPNPMLPW=?JBI4L1<R35WRBGU[.<._8/>FC5YRX+/=-Y:RWN$'D=-S,
M)V49_X)Q_O-J3N;B:JOP8[&QM@D?.R_;7R;(?A182Q$1+A?#5>UT*W7DRD?G
M/*G$-FNZ)$3>F"*R,X(A<D=<Y!)5HC/BE64Z@6;1&<V2#(B&]/E86I=5'RAW
M9/.$3M3<04+.I RT_VPB ^T\HXT+;^M4DP&FOA[M[/-])>:I8\YWX<HP6OQL
M/OI:"_$V'MB;QA$2E+-T.;#B9&WH29!CG8=(]X,RD)0QOO\FOMVP_AKBU0/?
M&EH FS6.5?^/C9 OI E!.V%9RK(FHUC'@JYSA346H=#%I/.35+L'EST&:>F#
MEP^J?NT8,8C5^"#<MZ3!?/H77G['-Y/Q_,OL A+(9$)F8#RIR;R&F:Q13!4+
MC@Q>JVW_HZEW@GSB,G@(Q@[2/>M!^/^%,/WTK\E%1@\\.3I-%FH/UHPL9B(;
M+SG3\Z^]D0<6QVNDOZ6P%1L':8[_.&J2)KS0R!/:H!G6N>B:U]8AF<Z0 ,D]
MUZI ;)W2]E2LOP6P'2L'&;+W*.X_)U?3"Z,2:DU@E0^D3B2D"QP5,LC:EF2R
M#KYU8X(G0OTM@,T8.<CHIL=AC[[CA?<E$^#$.)@:!*$#%$,ARO&H-&),&/MO
MO=()ZF_Y:\;(0?IF/PB[0OYS-$MP63<P^_0%IPAECM,+'DE[R";3%BPR,JHL
M T7GR!HOK8S>:]O_@-RG8?\MH?VQNH<NC1L;'W6:BJU0*"B.- Q>%-WU5C%P
M61()N0@J6B\'L%HZ@CT&H>S?X=<'YP:QDO^\JO&E.A+D:K;TA5\$ 5;$)!AW
MT=0,<3*FM.),);+EC9$AQ/YOP/NXCD&0>F'SX\&*_7C47\+]YO:>&]*$7UY-
MI_23UR.(H\M%#LR%]5&F3*I"=D@[@)1K'4)F(4EO('NTT#H"N#_J7T4&!^9O
M'PG:.^[@#O2WDW%:[N<"M?36:"(:J-K'F2,+1#^F=<Y2.A=L\ZK6)L!_RVE?
M7#Z ]_"Z%]#TY60\GX[BU:+11_6_WVJU%R))A3)99H4D;0:,('(:P[#XH%26
M1HFA_=@=8/\J8CHTAWOP+^Y6!<2=\5 \,J]JEIJ/E@6)DGFC442?C"RMZ^V>
M<3> ?4R1_OARY-T K-*"0W),800Z#S8PCSHP+97F)AA19/_EO<^G+F\GSG?K
M!K +!X8L_.Z"ZU?N!K 3W[I6@#^%Z$,*!3CEDK..80K(M-&<Q2 E<Z4.O"/]
MS_M?L1M +[*P"ZT/T0T $R_&N\5@GL*T(\W?YZ29U5('E 4LM'9P/:-N #MQ
M;]=N +N0OH<,VYNTWQ<_;G[YCQ%.:9$O/U[C=[Q<G I,X,D4="P%$$PC/9;1
M<L-"MEYS%P1WK3O?=D-V^KI&#QSJP;MT ^T-0MWX,M!T#^_UB>H"MB>%9">@
MA]%2^N#X-J'JC5T]/&.[@<[9<"^%8BAK+),.'?/.<;IG@TA&2"U$Z\+>(Y"M
M1Y2>HQ.M7;C4ITB=C[]=S6<+"HA5KVC/"VAG64E@"!H]RJ%6(QO.%4<C+)C6
M-20/P!E>'^J1D=M$9D\N]*D?W8$FKZ$IJXIPB$QJ4AIT EY/B6?*T<:YYEK%
MUOV-'X#SJPG(4[@PT VBKJ$!2B$+)B9!:3(<:+>USSS+2M 5RFMHNC>M^3Z<
M7TU GL*%03),MC?TB4(K#%;41,$Z:T5E@DJ_DL([BYA$:!XE.+E^:_O86GWQ
MJH<8Z?:6"UV _>ZWMA<[._?2>@HO!NVWEG0N%K-F262Z=$%*%I*(#(MS)3A'
M9ZAU.YOGVV^M'QG9A06'[[<64\)<"%Y4M;"L#ABEF]6Q(A*$3 ^J+OU/5G@N
M_=9V8NU^_=9VX<LA^ZUYF7,2M=$R]\"TE86%3,]S2=[+6 I ^MUOK;7D-.!%
M#S?/WQ__FGS'Z;B:!6>?<9SJ]F^[?=W%&:/*QC)7.S'KY!.+F2<F=(Z006IK
M6M\Y7;&=BLSTPHL>K*F7D^FWR91VOA&<R"IKH6G+I%(Q+;5D@!88SS&X4$!8
MV;IV\T% IR(=[:C>AR4TI:=PCLL[KE8&W#Z)2DEI(PN^)@@N)@EFD>D?TABC
M+#>I>4+]%BRG(@A-:#U(L?<'A,M7LSF!7;F!C-;*HF8^N]J.D/3VB!CK1/5@
M+) 0R_X;=ZZC.A6Y:$S_'LJQ_X'Y,]Z56)N5UPX,"R;5&%=.+#C@S)D4M S@
M>6FMB*YC.!7N[T7;K:7/K=MQOO_P[OVK#Y_^Z^SM'Z_^X^_S]V]>O?WT<O+U
MVV2\7[_-;M]MTU#S"7M8ZYB)6E@#V2@IO-9&!24R>*=3",0TH2ZZ+;'ODSWY
MAM/YPM$R)Y.VOB??OB[JI58IX JS=RH!LP9)J>#<,!]M8#QH'DTTQ4#KX-KC
MJ/975;:L\-=T,IM=B +1*)#,8<AU7@@=(.(/*T5%"[Q$&YL[XQY$=( +JJUD
MW-=?FC&@CV#S:%S+;%XCS/##Z/.7^;OR]PP7]_4++),IGJ5T]?7JLG83./LZ
MF<Y'_[>8WTKW;; *?&"&"]*^2J+[-BG' CVMA7XK2VZ=R_M4K"<G4H,PK8^8
MP#:RT*]WV=,?^&V*:;38$_VK/VU1HB_.@F8*K&-:H67T]@<69!8B:<M1M Z
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M:T/D/HK3EX:GD/N^ +AVA34_$6"Q^YL!\:/QYUM*+"/]B1OD3B@RH6OM"!?
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M5."1].(8@[KHO,K>:N>J==@R.C[Y^FV*7^H%]QW/Q[1IK(,Q;O7YHE.VI68
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MTS5W86W1/*G"/-#KIG/U]:-33-IL3$A!&NA2[+C#DJ?'_D;D;?SN;[@!:\'
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M6ZMMWDRKOSX>$SHMX]I88SGR#QR]4R(SZ8*M 8Q4&[4:EB,XXU/,HGG-\8.
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MK3QQY^-K90H_X-?;9(J_%A.$LM-&F,B\PW+]/A>Z+TLH3J"R4F#K-*6&\$]
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MT1GSG".[E&()=&"RY"RC0YZ:UOW)SQ(W:9_JG4&%\MBX20^U8=IDM2B%,Y$
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M<"+,<1HW(;EBH:C(@A?)&?1;<@T=7,IMG__80[=ZL7S6F%^->Y_N'@06LK6
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MSJ*HI%T+5-*197Z/QS>*R/MPM7%FY@.A1:QP.3)A&<_F7]8WC\TJ@ZO 7%!
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M?G-0: E]N48(<>MGKP*/:MH4%Q^LA$T3Z< YR8F^V4U2!APR\^O^L>7T6,P
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M7(@]@Q.:;1]R_U^^9^;_#NERS6&[, ;:-S]'\XAI:'$G#II=#M)K8W*#]$7
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ME-^WTQ>D+_IL=LJ(/)[QZ?N3BB/)\GZ5&(VA5HUE:)GZJ;KQXNU_UKXS]">
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ME7CXM?5]XUC""3OX&:0U9\2]:O]82C7%!ET-[_5!MW.,XE[[@!BIY6IKC?7
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M3EHC3(&=S$?=3$/U;YE2!!MCAQZI)>AI.M'X7XE\Q=#'<KCMHS6J*Y&U,-
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M8OYV4%#Z!=PPX',UX+]]-QC7PZ..&7/UUZ>$#XX['K=1:V]+6-.UNY<*JV#
M:<9P60\'-X]L8$UWW2+)!PK@DRMQ9Y;[Y2Y[0UZQI\FC=+@SL8CEO[O(2^_*
MGGMJ1"-8OGG88^O2%4=9,UO%Z/]B$,\-!'$H6-=?6XIN/*8JV_*'&6W.:)=E
M6P1XL15[W!$20F\H@.\]TJ/M)O6OT2IT^4<;GBA$)D0ZYB65G/$I+9QU3TV>
M'#6AFZH@W99%Z2\J],48#4$:2"OYY$-(/.TW%$%[!Q0[6\KG4J=@>C#(9KF,
MIB1'6Y2W%P0E6Y,@/BT3B+*E2\^[:2A)V:%$16\">4&?@T@YV,K3LZ:T?V<2
M_D.$R*+I%)HK>\=NRSX_D9:=+1/]4GGMMA<D7$S-:['YJ*'Y-1D>\;/&Z:#Q
M>?%+_;1J+9^<J!=M^YVO%80AQ@*N6Q]S"""@F'BA-4FA+R#) "P KYQF82>T
MI[6BYX#H4/2%,C=#4% 'AOF0H'GKV5Y%!5,2%D!\YI=8ZR C-M88+YME&,Y2
M\7SUWX!!/M"T49TGXK3\ ;0M6ZTO[PD73M%+/(5I>$VV";A*O<;A@'L=?Q^0
M#N$@10HO;D(L(D?PI*G^A6' =X=Z$\'+]+&L6P@7#'^,;CK-.\6B$&::NY4G
MXJ R@"7BN=TV8V3JIDGCT=<-E0EX(M"F*<$P(.F#.*'QF3K?GSC2E/!3X=+N
M,MWRUYL)K_ !9HQ.3R,N]C1;5+" !S@!Z62K2<<SHV!=$&O6\*2 NQ+(^E,B
MX\)[U6$G0Z615P[ ?.7FN@'?PQT7UE8.31R/6KK^P27W4_G;775;3:S4O(@<
M8EU-S*/68/=FQHWQ5:/=;K-1U06*)KII05!-3?/VXS<M"<PT.4M^+[G14;)>
M"\?[Z U6_$'"SQ<[^:(P<65+'_&([<!GH0V;_MG52TXPAG;G*_N[G@_#U\A_
M]NJK/GXVK1^ J:&]@@'W9;5PT_93#V\Q'LX&@I0=K33NS3]=WG3! I#A[-[
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M WN^QU/I[X#L,DO:>?WD@:H:8RO/!6BN)O/<80I43P[J#*7KBWGF@KHT/Z
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MQ1CNR]!1SIFV]#ERG]*6#6U;^V4Z%*" );:045/5[57P]Z>YY2C _?F"$8(
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M*.1H1($\*% B4&TV+<>FZLJ Q(,R.Y#N84:GC*8YXW8,,--&PX"=H'KTI^R
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MRO(*68%H<M"'ZTS7Q2C)%>[?N5"_*-<EVNN++RU.Y.8P:,#&>P<NSKS1.!0
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M?!]%Q_.9Y,X,K0$[XF\YRQ%&!L,F7Y-E#"/E9*@,\A+O7$5R8<+4,8/ASYX
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MO*SV]G1=S#SOZ&Q-'?WO"WP_$22,MMA:"%O.MR>RW,R_<#((TA^9C1*:$._
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M&7CG!-D6(YTN2&'4^Z$TZT5BN"8M"@#X77U%$A"\^<%X1AT\OTQZ33G]# 5
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MI+)GY41OVE=2Y I!V#FVNK1>+/B7X--MYCH\W-DV&[:&40K%=WV?.$I4Y1#
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M:RK!MG>UU3?F.K=@,1F/Q#ZC#6^3K4RXX6"HY-#XG*U76_>B !_\40"D%PH
M"T,2RB\O[659F0HG1H(J9<2)32>*S4EL;I#'^R5PG%[IX=-V+J:OEZ7GL+4"
M3R9T)^VQK.KF2%DS>[9T[#S??9K(N& Y<U808VR'F!7$+)QS,+X><_2&M^I&
M_FN@=&HBZ@HWX09XE5^QF4QTUD>56[6XAEUA ;K^RP[>.0O#2\X3Y_R$"[L
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MT'YHJ5Y-YG<:0-GV]X49A@SW4-)MC3/!Q9NF+7,(U*7#=V"!A]2_ZAAEBF*
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MI6R9(@IL%FV-U;5*^<YI^Z0,2(<8NU.V-X.IV@6OK1J*]-^R_O#%:;Z_\@
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M@I1@_5@J(Y7 76HOLM-F*CS 5D$F:8M#4PUNT#5C9J/S+(35]6V]Z]G4)2!
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M^FP58L,)YM_EJIHYR8>R#VZ^7RG[^QT(D7B<$PXXD!0H.]#^]E# <>IIKH?
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MYTG&F=#N4\J' GZ3"C*T9N,?69@P[$$4Y[Y@Z\&$%)*S'D[_HS4"4P^?$1_
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M2;T U@[WN7@CR71JZ$&HMBB!JCLR[46@MBI0T,E%U5NFY>:GY?LKIE9B%_"
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M6="/HW6P?(.2I4\MKKSZS(#80>WH4?7R?M/'X_9;F5MV8.<Y]SEUY;K(=$?
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MIL/%CSR3,_F=HIO2%/:@_536_F06597!;LK*DH<\Z!ZY 53:891NDQ4"%OP
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MB>WO61YV(>?(N26YT66&04J54&^1<S'_-S&_I\_YSI7OF<NX:7M> X*G_1Y
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M,HEONYVD5,5VV?H%;#419ABYV>_:+/M[;< )C[F)^/ ZI08Q:M47T_M4WM[
M?JB[!SS<W(WY3J?&6S^_.QZ#^?V9TVM?;*7^8*F_!_=H9,8"(I7Y,#5IR]!
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M+45!WM9?JL07S]50$/3^BN^\Z?-4,F;Y@Z_V9DK7$, 61"AI7^KEJDZ5]=N
M)>=!M9RW(L5T"?Y<_#CUY4G/HIB]<L;K,9T?^3T>"2V"UX!]TIW]B[/>=$P
M*B" 'R- O?\YP#&R10!XF"1G=#!40K_7\@V'-H"KY ()7RH"GW3;^BG+DF^W
MW\ ^G/=[AT!6))V\R)^+K8%K>W\/65 =$(BA:MM&;^6(!L;FM9N" T^FK<^-
MI%N#+)#P#&7V <JG72HL#8!SR=)+3@];-/XJ>V1HL-NTH#_7A2>_?'^,GB .
M='DW;L'>&A!7KDZ%ZM2*4V%_C]7\[*[]]#2*XV4.0!C] !__V\U:]^T<Q&8L
M3ZMUEE:9;8ZQ_DT%"SQZT\MW 2_FXJSNZU0_5'Q_K)/5ABS*19EI($A)3&Q/
M;HO:B&J"U+V&:F57KEAK!VU__U#I%/RHVXKOBL1C:XL=J]GUY_A-HZ_3]>9E
MKJ;V1?;;PV?T--Y'S5T>3FG2/ZMO_-(Q)UQ*]L9P)L734[BY/X8[:40]@/2T
MY?=>#'JG]( (.]ZO39K(T/Y<%3O#&6'6#7301]3E&WRZHT.]UE&,LM7M:DN:
MDD=B)F;'W]@3D73M:"2H2UD7Z?AHJ=)LX_OF G[A(G"W 2ND_X.4NSVR)CD
M/ZOLX@B<^6*US+,6(5Q"&IMJ\#,@IY(!^_*-6K:5'2MR_A&"L%\PDKH$:0H
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MU?D=0KK0!;Q;YUM'Y]#=LI#FA@3+R]^>M!YG%1$D+14#I4JYY&1J1A\_:$W
M,!'UV<AIR%YMI+Y6^S''(F3*!#/Y_R*%\/AKG+N\S"H/]:"JVH-RGQD$.\9/
M'S+%B-FE;@DHTOFOKB#^PWWX2O\N:] (P>'.P>PK=_!@&7$K->C&$'<'SEH#
M_ZL[%PCB]>=V]=ZCA;8>_!8@R_2KWY._P%JV9#D"%^=VH_-3PUL?7IA0-.[)
MUXD-%?A8J<C\V->O\VRR,Y IF7].7$1]E3W0*Z%XN?1AJ'W+0*BD>9%M..7%
M;XR%-T6H6[$DKQF#&>C0L=#XPH;=L%WF"K_ 691.PM_.MR<+E-*9OC<B(?BM
M[_7PP'R*ND_B;A:P?3+O*#9D'2%735?,RJ":Y0UN"(*A_.WBYN'NT3R[W<;
M/?>4X+8YTT)V4[$L$HPQ#OB0&WD;RQ@0*'EQ\PS$[]1I^>;<7/Y(^^W!#0/0
MN0Q(U=7(RF/Q]M@!Z_'JN!!7)0->U5.![[=6*B_&'HIF.YRF50SLTM]/W!"_
MO<ZYD-=H"F&:+BH*QDBL$O)$EK="9R[KFN+F&M!W:"$"S_K 0(RPI PT] LD
M1^^&X)X/+6DPQOG"LOGJU2F<(E:,$C_86';O<=U([R<_L&,!#./W6G*WI%G
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MQ<,AE>SN1;9ZE;V(6E.-62-TPSH<.:N 38(N*\O4+%'8N)1\]_[$?0KY? T
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MU=W]-TID$5H;^@<7["6X_T9+C-3N-:*2III,8[XHQX60EDRYL0G7_;%C9+Y
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MD"^9TJ0@E$[1(2S*J8MHX1JP@ZFX1!_(;TX(;3#(DZ'!2KO-0!OJ",&O&+7
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MK(%=)Z#-[*(]'L8=GY37J19).(KI-5M+70WMSVL/+T>+>92]2&T"LN0E'AG
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M@:^#]&'96";C>G5I2_N@A>M<^#QF***-1O1LUSBXDBFHR+ [2[OE1Z0%I !
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MEZ?&N6Q+.-9"S-*$GNQ5X36@W,BTF^2^"M"@=NIDTG:E\;.H-GV?J!@GQ%T
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M&9<<X9^<-E)UB4"F)NU0:\S/*UBER7&-R&N 4R=J]$<%OPH-6X_T\A"/X[.
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M>R6^$,VIC/2Y[4+""_WO;1_B04JOQ6. X;BG$Q6/-L;WIHCR)/QT'[OM3IS
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M;@VLC_$X%\-[M)D ;6F&P43LZ5 #CB]3'"@)G@SH/8R6,XT'G0H1BWG,W%R
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M?.N3QN%=).^+<AHTL&@#7^96+YVX]8/.1\*])+QK8%!_@]"B3%W56<EIP8"
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M(-8.]+V0>N8"D&C@C-T\EWN+ A-];KZ*D(R?_1]J)//O#BIO.*M= &*<?ET
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M@R/((1TXT%$KA%^O>R$4U6P^*$=6_/?RX0%6B@QSJZ*'>3N[SQJ_2/36? "
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MS< =Z!]J=;%Q\"939T='$4URJB8Z^'!,@["CT*$BV]K,6LNZN!79DPR6P L
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MK[<6!7F*6.!DW45:.@XP$-:TAKVF>/PQ'!]J"T!A: H3#<VMP1U[',#:>OX
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MY_0W;S0\NW=%$9ZXURCM?M2GZN HG-S#?:]>D&\V6F2J=5T>WW4Y'&%:5%!
M<L/^4<6G1>-@FWP!FS.4,7^C3G$S(& =.X>/C0M=M..<=/I-/SN)$Y4PEM_P
M#^&$2+K5U410B''[H+_=@"2C2^R'Y=.-^3@&J:DCWN<.'(%B/:^>V<=:KEC5
MO?U%8-[OB:6(7PJ5-+Z/-MUOZ1"]KT]:_K2X?TGPL_C.3<S&?L,65WZJVJ+=
MZW69!Z6-:^8OO!>@+GOS:<(.G8E\Q^R?BA"R21Z1,&*20+I4Z;(HM#;(L/Z]
M>VNS$F)M]-"([GR   <@'2$:C[*Z%S%46EJBI?FY^ZV\9V20K\"-[6$&T]EE
M5^IS^>JK56/*P.P5(WUY@!=C!@KV[.-L>&Q%.UZ36E@([OJH*U^ ./<+'?1J
M4=>S6+>7DU9\B:AO-7PA5<F0!TA0F]<D/ R_??D&DN@%/@)P1GEV;1T9<DFE
M3Q0\\?O)V0>[N*$I0[6>S[IUUM=B.=[FG8!]I+3@RP"E*,2KI1XH6(K%'GLT
M#N-W:U[NF(4:^!*_ZMYV<BB,,&LF7IM )\Z"X,K9XJ^PQY*^386.1W4+AJ^M
M?=E+JIV#J4\%SNSL!7S\?F(X22G6LUNQ#^I+.IBUV1YZI:U GW*J"&.ID!K6
M<YR1 Z\_SS#YI=0^8J$86*K&0.:"9(VYX Z+.$#(65&X?=S)K<0PSL??7VC)
M;E>[8F2_D3H6LZ.'"A6%QO4,WC @+@XS1IAO@;AA;:^DP0B9#->;$?W]=&SV
MI90"C\_>7O?]!H?U2<5K2I5)*G,'.4LR*DLK?_O-=;/Q=O@WM&_@F9I[/^S)
M8^@KX97C/>G1H=9[5/AX*40BVOU*0^+9I% ^UQU.P=BR8*['.VMQ(!@H'*+F
MK$RFL7Y9R'Y$W/\?WB?+A> _WV/X"-#(,H0#+ H,WM"HTRJYMG04*Q%[=N:%
M&*^/$)M3UA)^,2QX[0812RJ@LP@RXRU(FI!S4^HG,)HX.2*#&M2?[D"\(>';
M)/KIH<67Q[U:FS(:_/WZ9Q?*,K&KHT$-.RED<8D?HQ9DOZ/9$*J"H3X*IR /
MWBWOBYB-";]-'TA[T;9%26W<G#E_WWUR%VE9!LBL@_?S@RF6MQ]#7LBX;:.U
M1*H6IAUHYW0WG[ZJ=&7BZSSY0D+M=;Q6<IRYT<VY96N["FT!W=AQV.[)7+"P
MBVUZB /TDG9.->AHB<0[16TZZ;10\*0'7N5H  " %TF'A5'/QT(:VB^I_A_P
M;OK_^(CM<,^38ROH]N0$@/!+%KV-G0H(1(XC[DDD=?_(*&IZO#H4F>'SCGMM
M9<Z=,:#"93"T83)Y[G*#R[L_$^)>U1&S5!]85G^6L[JRFZ@EUA(!'4!H/N+(
M+RE4T-TXF&^<8.;U2GWOHR:RC_QM:-HRK> W-@:3JNM/I2,$(SNJYRF]GU:/
M5>G:U!6X5/R:"B+EJP."'0:$.]\=L4]5L^J]F)C5- 2_Q $^M+8D'9_"T=B3
MN&JL;B$Q3;F=1:S+MBG[UXL)J^LB[(/FM[$4"!\/^A#0,Y3&MF5M[-;05KR6
MYJ1RJ7NWJ(,<>I2BQQV\1#].QRUL!Y^"O"7V'I;;R<[MS%XQ_)YFRJ,G&B(K
M7-[32/-R6>#""V[!F><IW<M*\J*0O9(CO?;&?QHJ/B8ULDY_+WS88/A"$.(N
M-:V-6%USP 'T3U]*%'V>\KIY][2RWZG4TXNVOU"-7>><,\G+;W4*= TL"1W(
M/A43JVZT_E(QE #M#QD=*W>&?-H>2+">^0AL7;]C,1X5'5U[^2$"TTM$_+Z<
M3X<W:N],] _P+#H\D:7&G&+R![@FA*6ET$$M[XYOB1K(A7XERJ7YA<&O(7VT
M([&Q*^I2I58O&89VYF]5B!5[,SG<8.ZKL R1'ZAY#67&($N+D[R%E[SFB8U]
MOO<%]?*SV L42=_ &H=[&A9W-/"G75]JV7D$K:.$&_=&8?*N>W(]OJ4L1A@-
M6=VEL"7;3&4>M4]C2H^VY&BM/;Q>ZT#E_;(67FA>5AI88&=.'55EJ<B8L 6"
M%=LNRI23AR8*Y\_;'HMTG7Q/N.O+S66V)-]B@)Y^Z2+^?#-H,R</JJ$M0S^M
M:./L533C=VPG0.D(6_KL3^%;#^O5?N0H%!__0HU)0$TPWE[<DATT('3[$!KD
M6.Y[>XS%9+_'*:=FY\E5'$!B*)_+[")@\8)/!81D!HLXG$S'G)J'%!H%7K-.
MCIG!AQ#K#Z905&<I(&QUY(9.1<42TWF*% XP MPKT.N.;WE9A6=S!<N_^J,/
M[VUU^>Q?4'?H-GB1ZGV$Y=NJX0WZC7ECA79>>VK]I[-P:26,(#JD.[/&S"F]
MJ)>/!HW88K2/3%=>Z6CB:5^ZV*"KS3T\P31@]I*34Y6/TNN 03(WP11&7=)S
MBR;V"D>: <S Q0&33=^ &8\J!^=\.Q+)1,&0,\].M8H1$QT[NZ6J,-(ZVFM
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M?]N#MGBY0BF0R@YNW;32 J,>5>K2;B0!LS^DD>+J_#,V!E/'NQLJ>>9V><1
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M:"ZF%NNZUDB$NNK)6%*)7!TI&IV>97:9\L+28,H,W$IJ)]:L"Z$4:!^,:.&
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MG^$ WR+W"_B'(Z0?[?><^J_/8+M&0.O,F)P_S_FDD2IBAQEQABVK:\?J"3B
M+'!%\6^ CK>G1F<6?>D.E2BHU&7@[ 8.P/EWH!6!?RC'2OS;FIJ+F._00<53
MC3_/6D#&+XX;BMQU@7T#6RF"6']0=^2?YQ_HPXQ(%7&+&5Y[J/D&[) ,^_+/
M\ZL@/"9/C1[>16?GOXT[X^\$R$ASX-'IOB-.:IJ4L+JX"M[0\ E5W(4R@7:
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M=X-:_ CZ6K"HH[T'',AZCABNVV@QR)U9B1G]U[:ST,-B1OM_CGV$_6X?H;'
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MO9MS@+BZM/.N .$#>\-/?,,/R3VD,NO (8'4*N9O_%"M5P"R&3J)1#IQ3[7
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MP4QN31?3-@AD5 Q[-+K"R8XC29P5^N][4^&83%WM* ?SC1MV9K%9929MY0W
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M6 6*WCE_,Z0C$SN-@4$Y$,4<'@]4Z;AF+?U%!:4E#/:A)K8IJ]EN,3:DE%>
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M]^^<?>X_=]SSQQICC;QOVEIKSO>9<SYSSAB]E:3BGUM_*]N,+J#Y6]GFZM3
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M?9P2>[+KNZOW/9>)'>)DQG1E>TZO"[RP)+,0.&Y=\]F7PRG"L)> 2/7"OYV
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M4]3BR;@B6X<NI5"Y>D8PN^/?!53F&_8KML6*T<YN IL'^3L-\,[](L*&K(T
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M5A>QUO9 W5=27(HD'3#VYP6/5K5(!O^.&4I8]^W:3U'CX(KL/!OY$;H4XTL
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M4[_/^BN_;W8X6SLH'/T]%,?WUI+]Q=^YN\,[@EEN9%/I)>0$F)9^SU?J7!U
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M2\ #(][39QUFRY!94KA-\P&N23CX$G#[<V[-JL;ZU00G2-HYQ1\T*/(:KPA
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M4JXVHODT98S]*RN'U?IO:4=LE;]IE0E3GJ7Q9EDA<(]T7)6JNJ_M+6L*%,V
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M/;Z)IW'K$.U<ZOQX)!ZN&]>2_')'-.0N^;O&4;O;UR$M878U91.X=BVQK@%
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M85X=36!JE\IODM K\!Z$1-()U=]+:RWL(^Q#SH?JO%H"J\+A=&<7$CM0@4M
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M@4">O N O1+-[2[P_0E(;$+FT@1,R=A@@/"J*='9NG,H8R7LCS'\^&-F3K>
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MZ-QPF!/WQ@<6K;I]*ESR#MJ'Y:#\*$AD<R+QY)9WL<]TS7D#?._TK_L+ZP&
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M;A:"L%G KOYU I8P'A4"OZCSRRD"\6Z361EL#150/O-0G_D/#.7^%^[KFJ*
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M3+$E>3)D\ZZ?"_[U$.0;;$)PLPQ+K?(/+A#,-@92^D;+]_B1J=DN ?S9$BX
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MRI?Z=WE48&+334)QYU'??0LRP[JRC+W6LZ<P7R\*7&RPU^HHG/_3&)FGUP6
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MHP0F:HT6V,QFX?[]+T->ZN):AN-X-L;0MM!-.7B[3;#$2E;4R%-I)F14L^M
ME+LQ[KTR-J42MHX>@MG-"!.9/S#$YG@_AY_9@1WL_8]RWHGC=DM6C/1(5P9Z
MH\Y*Y%A6FT0"9:IP",R>"6:YP]#L8[5I[]S^;Z_3/->O\U>.N7P^)^T/M,H>
MX(PZTB51+&E!DL>L'6!]MM"?!#?++V=FN$MH$8O&9Q71.*03[FR.>_!V>R4
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M60ZI]-S'K;S*/?O ]K'.7<W+I!3T;+TW6U_NW#J+X:I5-<L/QJ+P&2L+ZIN
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M:7I 0QUHRWJT*DWU,#M,RG$LX'6UO;-9L+)N ^_!J*N93L3=7AVYRQDW@JV
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M2;-NWFPHC]!!)$UX4E/DZX[@:'H#^O.>IH!T:A#6"<%&[^'':L"AAD^C"-E
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M8= &G BPA&&5M/$$Z"*(4&^]E3[58.1N8'QNPI(Y$ 'P?GP8$8#*(%P?)@)
M\)-S-%6BB@A[M133JVLAA.?,(4!!>\!_;(,#R=Z<H"JN[-&X&PH_P1,!'= S
M/Q":$K1_0@1\) )P!_XFWE1/V4;I?YNR+-"5?2* DP@X7#VWXR0)\#^WYT2%
M[KX%"[4!35RY!?6^=[V['W3FEX.1;>(Q'PZ:=:YN+ /#21+/GXZF$T]6-!;
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M.XG*;&GGXUSG/UXG\1_D\<7JG0BC+ 2EI"[XT%OBUU7@C'[_JNJ2!27+<E*
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MINL^;U53E[@,1P0&ZMQX?UE)\P:>KV=*V '22'N%FW6[RVF?O=Q>/CN.P]J
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M300T; SF\+;=-5_RKH[[7Z90.FQQ326+W@G_73?<\O0WQI[U*$";+6\LP;!
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MX*/V-N/)]MU\%4;"R7CE07'_+R*@DA1V(%L%-(-I8Q[1G*.NWAI%*=)<-2Z
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MZ00C"A?UIY<#],V!T._QEU^,H>\6C 7-@],\RH("37W5SM@3Z'S6PDI%=[C
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M\U_EJ YN&B\=;IB*Z$XP37F^:?Y+$G45E/%"FCZBN @4?Z/1\= A,E:SX6M
MU:IN7BI[[YVC:(?^<GGTSMV=^&$(6_G/;5^CNR+\>/$Q=+0N0=QMD5HV;US[
MQ" W@[3QMW)%;A4%?=R0"=OEEV)U^"V3L;PL_G07V39GV\ EO5WY:P#Q0'X'
MLEX&HML>IX_F<UR1SLU09 U@OS",#CY66.2G^/-'\O6#N@W"K5H%2/2+)6 D
MI">2H:IALL]9):LL::$MCSEIB83SR:N8WB;*KGUQ4O()ZA6FL+:I*134B5$
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M^Z/M"XQ[;O[9B*^O%I8(&J;2?"$C57[0)[.-B\ENW-)OZD.'/D/!+M^1<M>
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M!OJ:3@POG@ARQI,23 K)5NL.RQ-IJ-J9RO.J+)>G6A.+Q]0@'&+#7]W,&%W
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MJ-F&\\$3U&P7_2VUG8<<C'1BIGZQ!:@$FV,1A OC91FG*!T-F-0\T2L%"@]
MQ/RAX  4:(E1*=R@V9/-+2Q YKAR<:J@RJ;3<-Z9SPUQDM43"; 6;0C3R)+#
MW/? I]&'F[+MBB89'/NY;<R'3K#\2\<4D,"L,ESY&+0VV3B+N/+9DB$IRW45
M"RO G:FV7_TQO 8DZ@*;MC8&0(J3@8E^#PJ9'&05.YL^;!]L$K[@YWY09;,<
M0 #,;W4Y,ZSZ8Z[A)$25RLZQZ1-*0(O=/"U\[;I@[J/AO&);$T^[C#=ZUSB
M5G38:W)2UE>CZD I^^[1^Z!#T9M;O N,N"*_!CS8DH_B"E<WQ:>&:%<FZ;<%
MC=R=XQF@4&F4O2IJ]4'\V"-!S$*-B+:H*UY? _Q!Q]AUBO5)O@2:3WFFOW_T
M.V>:G4'0B$))4*3%?V#OOH.:X+I&T0=1$ 4B2&^1)B(@2.\!D2Y5>A40:0+2
M>Q&DEP@(*"BABG000N^]AQYZ";TGU @A')][[YR9>^>\Y]SO?M_,\[SW^,?O
M3QB&[++6SMYK9:>$//O[.UO\\4^7F!(-6/57^WZ5<C@L&[FQNT5BI9]IKZ?Z
MPTCYK@?KXP"@E0D^I]YCWU"S,-IC+AIEPZB_ZGQ]_I^T" IV=ZD:>_Q@H (
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M4F+T:"-1[]FZ?FUT[2I,//KQG?_H$<'?1M[%*553E;BH68PBA_/@=ALE#SO
M?Q1)PJ0!W*76X[<YYPVSPJI.B""?&BZ9'^^;=:!#.\!O*R#Z[P6$RF?X\)-
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MFO)7M_9'+^7A-2\X+UPPH;LOMKLT MZ=>VD/<!#W)&SO:^KGJTM6B+$=#(&
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M'@X5HS\[_A__2^2%BW8CYISWGY>Z!$^O!9 89\? "JDV,\P-5?/G!;5+Z7^
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M@ :K*/R5+[#UE7X%QHM0ZZBO)YW^@?07T)4]FG/%P6<MK'N&U3*V^0,#F5F
MW_$WBC-!?YZ_WI[+ELT8D.L^#((R/@M6#0Q&9/IKHQ^,.5J@SKY%WA]@>A>[
M:N].A#F57C):P]$,K7O/J1\V#)H/"Q?#*9>D\Y!JZBOQ7NHK@<'+@<'Z8@7)
MT;M8#M22)EJ0RW6X6D_MW-HE)<C#;'6)I>Z*4$--WZB\T@WV\ M9Q03G P8_
MQ%AY>PHJ5RM3:>26KEDPZ5,9)FLWE()PQ#E=SJ_/VVSFG.#WO5<.PUC9E;E#
MXB5ZAZTS:1&N@O[:4X+F3Z5RO_^K3'DK$E\,@P+LGX_6N/02@\F@O9JL'6\/
M.<9+L^NJ/W9)OJ!E] WAVH+<QD1):F2U^69R1ZPE$Z)J=S%>3-W-+F6:&%;_
M=D?MP:]9.E_T1XZ FPF_-(E/H__M7[QHN\DP7 -BN&=MK6IEH5SA3#U-K^U<
MX ZT$Y;,.5%G]?A]9M> X09]69:?Y?WE;90#U?Y"A?P?C88MSGW1UX IG$(]
M\\/5?FMV&U<_*6&JJJ9Q3<C/^0Y6HV:!:C'IBT 2^&A$GO^5(*^S8()2'EM<
M],^,3@8R<V4CPZXS=P>;0;%C2\**3=9I4+Z;&1AM+(L;0(-F5[7+S8$BTV %
M$ )=ZI4C%)6\+.4C*85T,"Z(G_,<U*[)KJ'%D@)7S)_UL S0B?.Y6]09JLLR
M93<;70-8ZC6 6)DI?Y%[X8L>:=/NX<M4NA=N"2>$%!0!A EF:NCT3LUYJ>HD
M_ C;].'/9<SJM[5^/<5V6=J#J6"7EYY1=(OP=VU^MKW.0Y]74:5""[EO/-F_
MQ2MSL$&U_4:8Q?6+O!4FMA=O1'AWF,T+MEI]R[P%NB -HCMV!*FF&DTZOLVZ
M!AA*?%B(#ZW#$FBLF+4456D-41;C.\(*N1\UMUI6YS#993^68+E+_]+'CQB\
M]!:4[[LLS>(088!FVXJ@JGX]U][\WILM0 D<SC4NR9^Y,YHTP47V2S^B=_!(
M0,EU;3WJ5$AWJ3%!,"65T=&9?;U3\WFX\NM7T443B2[OM[\BZC :*\WIF3/=
MYWQ= ?X=O-PQ=3H7CR3Q#J<:+]N,)(TD73!0O:2],[V]0#@5_W'S[65??"Q$
M5M,['?FFI+07W<%E8.093=5!AALG#>*^LRDLY:<?(7,T:/1Q?/)I7,TMBO?[
M&= PG_@*U.+8Q:^YCHMFJ"0W/\_B&O7+K=O#BHBTU9(34PW-E^Q-80N]D@?Q
M5/Z7*,YC;V<]6&SCK/7:T_@2]H:P*WF 6HFWAAX*IW::U /2$/0?O08LR44O
M3>5> SZDMWH:%7U#S+I#7W^#Z\F=*V-[D&JOM\Q$)]T)CL:"JF9/'(PAWVX?
M2+4 IQI*'B)4T(KA'C].E'!#4LN0P0I+X<Z5GS1!/X.>2&@2U+0W"?:LT(M9
MFZ1D**^>+><?#7F>FJM5Q+P8WR]AIHF^/25T@1<+]:V49?X;KJ7\\>_KAKX(
MLD2*2K#^N:Y$.>8P(P)[@5#5/<PT3C=DM08FBQ).%?*O)SY4V3KNYU1)9B,+
M$<TMTV5H^[^JX=]0]1DJZ73C9:?A ZFL2G/8(CLZWQPPXV("FWU%+A4/(7 H
MAM+C9-]!]?>$R&FOG/FQX//FQ1GV=7E;?Z D3O2D5 5=OZ%0M? -(H[2/=I>
MY!H[8'O ,EBHD>F<"BX1Z)KU&<.J%1B357'O]8-GK.J"GG&Q'GS=)"QU@*&S
M_]K.,[?-6&+?Z&G\7/13:J*Y\KD&]#B$,1)RY>X0*D]R'U)ZT?OHJ377BO6L
MCC4GES>':E6&;RS*LO'_>&TQKS_P"\OEU1$H-.G/^ZGJB]'\UW0?A34LX4U0
M%O:23SJZE!79W42:OE+'70.I6K2@=.O5=.W9[@;3K3T)%+0?>Z9'KVK QLKT
MAK;B@""HNS9 4;M^LG1QY\ SPW-GS&T\?\3OSDV],FT,>W[UOOJOU/7VU@@$
M)OT:8%WVY(YAL*:RE)1:P/WE)D(<V1*ID1%9E,N&*N[2->@)X8J,@&=*]*-[
M?W<D]Y^ERR.G%J,=FUO4>Y,KO@AZ#=#\O8UXPF3T?U:JTMLN/U/)W FL*P;1
M;SWU+I*KKXH-;PP]3R ^8B"%1JY> R9->5STZ3Z<T>T/%O+/]3[VBU_*I'2)
M^=;G_ FUH5TL1\PG^B"684S?"_VR?5-M@G72(C(/=LC_$#S9%_LQL"FPKI2\
M4O#.HQ(-XBU^3))A345D,FF0SP.0"^$BV,3]G"58PCR\7F;L9"[.T[IS;..N
MC.\JYO^LY_]=>>W(_B!?4CZG&J:9XMG/$J7_'=!MG^PK:-$'$DAQK7-0K;MD
MRKK9N:);=\$$/"X5/FQS=$&SJ/'>XLG]-._$F U^VH,+/2W-KLFIH2M-YYD0
MI4N;E8H,.N^=U2B7Q'E\\[[*WFZ.@-I3G0>1"6U&#Y:4QN1#.-FL(BUB71J8
M\AFEGO;B"\Y(RF5Z:YR+\X38I\:<P^Z.)L,+>4]IL/8@.@>M[>K=E1*>:H-9
M; TY+P'2;/VO\VW$%E?<!:E44>S\-J\TBW?XKRA'%:6(<PL\PBUPB:+SZN&]
M.;[7DQQ6UP UOFO (%UE)E9H"H;1<X^7,/:\_&E28;HD@R?DH(=1*[4KKZJ(
M=$Y04&GM\93^ !P7!&"PCOD.F(C.-!/7^ZW-5?3LYJX2D.-0-:AR XKQM+0A
M=SY.3M52& [RX/CD<C@N77O8Y1)F2!-RVZ*-,$0:-HH1Z,*7JW=0;=O<.C>,
M1Q*L ;SG"=_Z>8#" 'Z+T "J/"MGC[M.T:\-*2[)TBH-,LC'0?)CS>VOCRW"
M]>XI]PS1,P[\<NI9,7X6(O]WGRO^\>\E-R_[(X-&I/LO'MX,;; ')[N![X6>
MKE=:5VQ:7-G','WNNU2,34T7^F*\8<ZL>HZ]RS<"3=96\YE.E]0+UR?:M;Q&
MNK._I_0C;Y_W$2?D%W%2DKCG!VCA_=5(3>=,W]'*@V%[4D-#:UZ'0MM^I]45
M3"XI6J]77#-5A'L?Z-_9(Q^$-$> XT# P\QZAZ8;IQ4V!:43S@<OQ+2ECB&=
M=P[TND%D=B)T/'UW-_S/CD#++N/8RP0SL)NS2]Z2\LW"D?G62^.*FTPMB-.R
M)R[KR?&U U\(<O*'\I8T[,3?IE$_ZMB^ G<7(5R0D8BN1:9J- . OE:F9H(L
MP)=K=1RKF%7*]-<WMXFSB\8#D9EA=,JYKW[\%6A' _8"*3$VEPYFU(FECMP5
MS+TK4(SB*9:PQ.]CL3.1MR^8>,OS3#G\H_]1+S@._O**L)RR4I9E]!^PL_Q7
MZ&,]IJ:UZ 5SGH@5^^V3E0EY'RC+1SU+83A@ UT#=!W'3;V(R1*V[ I$]QZ6
MNEX,3LV>U!A)C5P#Y+_XP_Q=?^)W +-PNBMIS:G2,7\U)2V=R7+,'XGO]"/[
MG6LB8S0%)]U-?)Q(%5M @PC*55-B[YSGN)$PMX+I4G9-L12PUH$X+G R-\?[
MF.5E9:5D$>H"48(Q5_@=**EVS"1X[J2NNEUT@:POK@$0F!N8!,N?BM H6LJ_
MN)70J\>@^F"-MY8!5,I5UM3HMYN:)G?\='L:J%*H\^O;M+K>@[\J08NU5U4-
MR9XTB>@WFO^R>#M&?/Z*R&BHB,O)N8K':=3U=>)H--Y$<A_^<9>U\;)UCUOW
ME]C8P1[N'K:,_-\!D= ("P*K$B,>$;) ?!"!*9?!/V9%4?;K.Z(@.C$::(TD
MSCM/LFT_00]?WP,S6*$I-Q@Y:O%Z\F@$,Z/Y.2/12[%FH/ >3=C$*QFH_?S/
M0I1(L+1S >%)F?B5PT2@L'V"9%I@1MR7E^YC5ABWX):IQH:3S)RE9KH=M0*,
M=-_7)#;F3(ZK\?<7EO6%JX'W9X3*0E^]H3E>\Y$Y&UZZ2FF@^W.YYH__N,24
M:!EYH7J3AWV:XC:B]NO.DKSBB^"/>)'AUIM'YL/U%^H.2D,=EB8O1>GCF XF
M@E$B6$+HNN[KN*R$A&Y:]3&IW=%A!RY-%%:$\]UH7&*_G$WU"G0S;3O.:V)H
M?,_%70>AYV;8MSZ8#J+MED5F81T*MW=>/Z[0TR.\>4^64=[&7VXDO"Z/Q'>&
M<+8$8;WF@%6=N0:0XI941JT?=1E8O&^C=-9H% ]8&F[(<5X8H#UHT1BN*+@E
MY)KS1,\%?/=U75(GN6&QN6U%;50B&G2PUT,<T+:*NV6P^ 0UGT$[E5<ED4'P
M:SGI<LLWD#5_Q2R'Z4N^M_8P<DZ5/6._L8\-_OCK_HL+-^Q.=4EN6:P@OM51
MG *"WZA.=&$'*G=%F.=R*3(PZ#Q89M7S>XK>PZBZ,3KM2'\QU@QZ&+1!.'&I
M3[T"OC/OG61J3%Y"KN#V;KHM3K:-J4<RZ*)H2U75H+C$LN;]S7>=663ZF?B9
MQ0EOTU(24SZ'_-T?^7\9SD<WPNMHTU5J :MW&X[^>EZP*GB)&#_0?KW?P?OC
M@*NI'C(,2WF*M=4_IMPTFT3(+<:\Z,X;5PC/\G%>[[&S(I^;45"]/>%X*XH-
M.H&#0>4I)VE^%+$*'_[0DJ>TO%.39Q80H1EN=2[;$0#T+5 \*DBL+W_K<QY7
M!<8H8A6]WE*_)5Y\*YU.G_#+%7RG4\]VP= @IZ#WP7+HKEG^JB,OCAQT)V_>
MRF/CR_F5$2OBJ#L(?]=,?]=,)Y6K D'M[JL0BDY!CBU83.P'(FK>2ZK!>L\9
MB2[(]&#.<;)9'N/%M&P6G37$?"TH,L1Q&4]VPG,$ D'W;:U&7T!PO-]U3"0(
M5P,#JXZO3\+N^HD2'MJ\B^F6Z=L)B#@JG-P!$TH*&VY.O5&G?FJ\YH5[B(-&
M90(UQO>RQ]_R[%O01--,"3&U6A9KDWZJ(O^['S?_\6_L4Y7V#2(>EB\#DEH-
M9#7<F5]]=:S48'K:#^)4OL85$EJ"2XQS\[WF]>0?CN[-.@O.92452+>$R0F_
M=Q!L?Y7'?BS9WKK)(;;&-)DO+VWG=9?U\U2C=/54AO5/*N8!_E4.PN]2$:?%
MM]_X&:8H]>G+(<::Z,I/@<2*/N_&G^.4)9.[99V-MO)U_?D%/OEF?P7,.Z>J
MP*@0(NKL=5_?B9 ^34+D[P2HN8^$&VB*$2^3="G@"?9FS1827>:N,KC,G13(
MN]4$D OJ_XY<<OFR_P%)T7\1O*<FYI&"L/$W"K$5ALH2&L[':?OV)5/06\><
M&<P/%].CD%4?ZAA[/_E I+,;N.#$1O,'MHA>MZNV(YQNC$C8H=7'PEL)?L(R
M0Y[=Q=9KELA1B+RTK=FB'$.D%J(PS=I)Z7>L'ER3MQA#7[XGTMGQ.MJ74LIA
M".NX4KG2Y+(2&Y0U=#GG>?IR3KH'TMXPFZXSIM^U"$K26#:?>V.L('6EC[X&
MX,_6<3W#'0E]*-[S7N#A3JA2[]W1_;0<PB>;6\J:VY*U=;P[6](4UW+19TQ?
MT1Z_=HDW%,"8MUV^+1[0].WGVQ"*VSDMH*E:>)@TF;CT9P^N#W->GCFO+/H5
M)P(YRM9-M[9??,S+CK[YM\^//_[XIYO"JY6$J'@\?(3_8>KM4,E)KL)H^[ G
M.1^P]'&8%]U5CNGVS\*K]5\]S5S1MFQ*HS,TK %3/01-="\WXO,E<][\U5*J
M]T[BHDWU%_;8?7<Q2D8*Z&<:<_)&\<3'WB%=3XDW'<> OVPXSEM FZ?%2^$X
M,FFVJ9OCW]_R*-GQBWKN05?W>WP/!><B6_SLW$.,N1+6^^/&,ZX!81Z!H!''
M1K&\+BO;VU%BW$L^TZ<<BXW]']<2)FG=6)5E= '$>"/:8]I35G_W@_\__OAW
M<0_27\=+7M(_0/SBGFQ?% L#3AJ+,'WQ]J/,[AQ+(?F:UT/5+P;'"?2,T]J>
MIZW;:J6[FHD'#'>-=;[R;;KAA1Y(X#RZS4U4W21\VN0XNR<!>+_T \2_;I!*
MYOY>3)R4O12K58=4;N=>?DA4'+&YN'/H$(G:49K-54_P>>]*<PWP8BWQ/-U$
M8.)6RJNTY-W2_OZ+*G_\\6_B]0[UV+2]5A]+S72UHPT^L[*4QAI8?.K[3X)>
MU@=G@N/EG^%"3" ^OJ/^3<]W3W=-;DV M^_[R&8\& IO$Z/=->T:3G?V8G/D
M-L8VAW* D@V/NN=?67U_VF6GGE_I];Q?L@=J.#,0())\Y\#9K&/7&(J*J(O2
MF)5)JIWK<D]H3]BT?[Q9.AKM79AL)_4AL_[3R8*P%/_$\Z\9Q8LP%SO;8L:Y
M!L&_>WG[XX\__OCCCS_^^..//_[XXX\__OA'X!10L,6SS9U_- 3@H?A4]??=
MN516E;E%\4GSQO]?+I#^\;\';6T$>!5.9]<"E.0HP,3H)0U45$3VK[C4P>7E
MX6@!2JT#>8#\*CS2#(1QR&HN0_*H\(@/^A>:LZ\['V1#OJ1/ P,)U/PAJX>8
M1P0Y+I+5.)*1!U75A$1^1??98J6>VSXKN*A$#"]1-G,Y0*FQAM*P$O4V92['
M-\4O]"HR(D./^I8K:(4&[.H=-V!!MY+#BA$UE=6])?LC?:PUY[J*;".$Y?.X
M&1!5Z4->4%1.S<MK #=RO$0)=#[Q&@>;]-8X.T(O)HB3V ^HH6]5!_IWG=D%
MOD]:!T73;9S I^'([WGY,3G9QC.)#2EWBZ93Y# W/*%6T<<:#%AA-+C#4?YM
MHVJ.R?9+:?_J9-EX$X_I'95JT2T-(\ 5/4;B4@DCM\I24OI-8GMVVA2>N[AB
MW<KPB36"T=?U:>(MWY:%LNY=^MTX_B/Z 8DH'J=,%[:7S[I,:9ANLWX,HKMB
MO$K&24%C RD2!W0\F!Z-)>OM9L=\AM_EP_^NU('7*HI#4> =5&GSRJK^!PZN
M_T/K"SO@7U8L8:?<!%%*NCQ, ?_D9N-T8SG(T)7,SHB6@I=9G"[C&W>![E?!
M@4HC<NF7,(8>>D#1J3-JZ!WU$C5L][NTJO$,KP6#+&1CII2UU"^I[QJP.]4<
ML2*EWRD?%Y;^(CK0CNA.\(63I,UL2)QMX&-,(M6 60\?;K?]\Q4 7.(A#NIV
M3Y2'Z%?=*[@&I,;X?Y0N5'<Y 8>Y^D9T@.]MCWQ12\T(+9M9(UTZA[_$Z#]N
M+;JG,$9$" ,$R%H%./\PRNNJZI-\PE\:P5*L#\\@1'_"W9^@=A-,(6=0(W6[
M!MS GPALDMI=VM]07HE7FI9TRDK^M';/YZ8FB\J_? >N_2;X_W[C^L78R-_]
M=/&/_\V9,P6UR6*MN>F"PK \Q.E6M3Y"=Y-Q9X-L,I?6N:*G@+.R\MT5".:1
M7JIDH""J-%?_BLY16M7#:2XGR840E6R+O[:D?GJ!?TF.92Y'(3IV@V@6C(MG
M-ZH8N@3B7U63P+3<QEVT.^,S?^R;0R<O_"X?>V<C.I?PL$]&E+ZKTI!\V (^
M[2.;"SW0MPIJ#0/X3I&X@<APC-L@"DEVOTP'32+'4HI?KE:\S@])9S3/K.%(
M?N#-T(DW7P3[B)VYXRNZ@RLE&&X!7B?:XJ,/.XW8>\+]90NVSOT"$?D+JG;"
MXPG-(H^GL;)E\E>I6&O>D$!1;TOWI-?4Y_AJM=KO:!\R$P2$?G(NC%YKYO2.
M!E)AE=$*E0Y#)6=Y+I(<-]\()T3?S[ATT0LDL7/;-:=JI+=Q:LA-TH=)\=\H
M+AS4* <DG60"I^R-5(P *IO^'FCZ]B5B05JA,FKO"#748C)M6\/$0>+M 4]-
M@]B*O1RV,\H16*"PK3AC#Y8B"7>'!/F-NKM^:+TEQ%^P9FS.SO/8D:5_UKU&
M*6?USI%DY,'T0EPK65@KX5+,->#6HZMT^I<.0(R1L*7'3H]Z$UD@^2]ZH/FA
M?BU6 I.UPAN3P81;0-E$5AW>MV.R>U]Z,C.EHWRCB&8.Y-%JS:Y^FUATHU'!
M&<,!W%N5_E"OA;'(+ZDO'17T\E)U&:<5(/)O]SOJ;@(O<[1JW,$-@X'9*.?0
M['J(8OR.7^.B"ONGQK+:]7)^"D>MC'<Y;!E*A#FC)H$5Z)A6,WJT=7Z81Q ]
MQED5+3_7Q=@<Y5-DW.$GH#)GJ?/^JP0UVRV JSJ!0_GOQ6[UM"S6# ^U%%,B
MR57DO=219A[]9/'1?I7J@M$B_4R:WAQY+O?*=-V#1_A)K4-VF)Z>##J,5TZ<
M<5<@\UBC0-ZO&. <+&9Z_\$Q/?M+_UAJE[;68742@-.HR<)A9]EMNV:RT"ZO
MP,>C//Z\D@Z"1O.SL9S6;&_Y2RM3IG6"E1XLOS=* T:ZEU':GJ4U1Q48[M*I
M(8D<RXHYE)>_ !64[R5;')  ;+5,6F)_#P7>E9%(3%G7+##\9B;--:#:0]11
M).3=[6,:FX3H"E GZ*[:BA^4O >IQJ)!:I2C*EU>,TJOE*!@F.8X1X'7QX:6
MH?]5QE-Y]:.9<@=$LX'1=5Z5H/4/(%V^$%46J--L4&"?6_]R(T2%@)O/5;04
MT8:31"$ZU3@NC=LS6,8:U?)\XH!S50[3I<O'!/SIJY9UM+2T<);FYZBE/>BE
M]'9+]<(2A%N:S7 >JY"D53<1\7[<N,K.:H*121G:2P@7O;4^[<N0Z!F7B;\?
M;21KT/P(W1+A#WQ3D\&*.&D!S@J[N!2:*3K2=@L<2^#-![KCU<B[X.YC^I9!
MH!<?,58]3 QHAI\VEG;BL*9Q88&OM^<WL["0/ _JV;#2+S8\"^N#PBD53[8Y
MOK6S\!98M5+@648?%X%G)5:$<PI)^,>1$:%/8"PREPS2#ZI\?KJ\+U?.6*WQ
M/9%_U7K/%<A*@7<$W&_Y/9SQK@'A0FC%<'<(1N8:L,*+FZU,.1S&35]2)U6T
M[\^M*3>(#;M*)Y^BRGHU,#SGV$^'X>9GA/77@-%=\S)W &R-SGG?$075P\Q?
M VX[2NIO8.64\VH<Z2_%]RR55NR^^G3S<D6.IDN@7-[#*7<G?Q&A-G$O';VN
M 19Q^M< -6H*O(M?)M< 2*-/EC\?RJD$67;?/.B-+9T.P<;185^B^>.GD]4*
MQ4.(S)M3.(?6%F<KZ/0F<AB\1<2!^U"%M^1/B3E=UIAE;:\Q8\/XE?[UA#Y[
M=K$9*@2?WJR>$^]AB$U_$T>S8AV[1NR_X$HJ=:,9< T(>1S45XS)Q_5(E%TQ
M5Y2U5,K<E7^7UM)3%FX&FB)(*O271V6D%Z9PGM$/.<URGI,657P55OS.5579
M7#/AR%Q?E2%19/=)TNW9RNC$"7/$3;]H0$:T"O+T, Y*BN4I"K+>-9-"=2<4
M''"=<5U9+A+5 )3I:3M> _P\!?%F1W7W/.Z::H]Q%4E\+MVW-AT=PH]0--?L
M".%*'VM^XDUOA@Y8"A-<HO/VTT*K9;FX9<WNE*OZ$<E% &_4><PJ#2LR;N$7
M9]<>4OF_1A$&.R<.=.)$44L1O(S)>DMZDR7[KRT['M_H74Y49*E7XS :/[V2
MIK_BOYC3JOCL%+TS9IW"P538K\2Z+4.!M5[EH5XY#SL%DV$@VJ%*(R?31LB#
ML[45%MF)C,V1WY,'+]$A R.!'FA= C5RXUA1A)&OT%0)#/N.;",];&H,F3>T
M5A-T1U8^8?OY;PM!+Q6P8)1S%V](!C>JIY-$35#CMKDQ[QQ,[$D.S%@FD3N*
M-YVCM^'U\[<U# !9RO66BJ!V\P^@2DC;TKV!95"DN%<,5OK)>M-4H[J'L5U)
MEG>6GK4/B[2)*H.Q2;@8WL#]$#Z\D\455?.$%MCA/JLU$HAYQ-L.VN.-IKJ
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MU\T9+ML/7>3ZI&"IMX6MWWLS54CCH*[\H)VD" LH7U\]OR.A)#0]+T-&LD4
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MG\")[(_Q?F+/3 AZ.9MNP/9<\RS P8GV,48."[ \!1?*//BO_<!V+3;-++
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M=3K7I:QA,'?&"JO;YWWS.?_OBK!. +R@@!X_:=(6S12\76XJX'CAKI;!'19
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M&Z+&R>3W'%8ETL@1+Q/4_#%-A\L5,XENUP*P)+<11-=W*COY;D>C&')U'&M
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M%U[VY]R5!AT/0 H@[LY!I(/4+?+?4>_([G<A\WL>#<U),<H,'3;-X1'P$18
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MO<EMJ[>GC]N<N2_H8V$@!]25.'##HY,:@)\1&\E+:J$"[EAHNHE!>:#KK]K
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M=$/_MFMC72,W)DAVW8N<$RM2X;,6/Q:Q &>BLZ/\C\&$,1^\I:^3_*>=5:;
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MD__$?&B?=CAZJ_^4AWDA?.T+ZH\O_&.;?2U+>G7$>H5IG(\C$R=Z61D\:#(
MAL3;A_:\9Q_5IDF;G#K^?=D$_AT-GW]\DWNVKWWSYF[_K5VW[AF*"&JXN+Y@
M>!LI)_RA=GW+VO2N&S/E,KEMUG[O>)[UC_GGY'O;5S L11L:(0=_7M\]?_/]
MP^_[+F<857P^;+9/54KF?6&RZ&W[:7VOF/-<$V0]0G_&"!YXW/5>I^1WKMZI
M>^=.W=+V]JZXII'[P&'BL2Z#5:LL&/@.7UIST8'3&\O)P>'&C]^WS1/YL72Q
MK/+1?U*7_O@NF[PC.FM:I]7B9.GI!=;1=Q+ZHUZN6, _\PFP397[[^RE++8O
M?_0V"D]PN[I_3\2NYW\C9J<_[IM3\FCOX0/V/#6J']8[Q\H?O"=SV<9X6?/D
M_&512[C>_GUVBQ%8"V1NJGV] A@;);"0 39O,S,6\!M]F/_F^H?+!_XS")F>
MEW_Q3V##]H]]6PM5SS[;K)"9;N3Y_92XBHOT#H<%3Y[M-9I&>:".XE$\BD?Q
M*![%HW@4C^)1/(I'\2@>Q:-X%(_BD8O_WP0 4$L#!!0    (  2/45;NC'G6
MJ5P! /FT 0 3    =&AC+3(P,C(Q,C,Q7V<R+FIP9^R[5U@34=<V''KOO4B4
M(B!-J0I(1+J(-*4*4>DB( (2-"84Z0(" @I*5%!$P$CO1+J*B-()+0E6!)E8
MPFB2X1O?[R\G_\'WOR?OR;.Y5JZ4V;/7VJO=]\RP,[]#08@?LW>R1W!P<B#.
MP'^(G>\(4>O@F',AB! $/#AV%A$V"$Z.?^/?*^>_P<WU[Y6'FYN+FY>'E_>_
MA$^ 'Q8^7EY^(7X!P7\#?B<L)"C\[\._D_SOJ9P\7%P\@GR\?(+_O\?."X0$
M/]=U;I"+0Q7!*<'!)<&Q,X1 PCKR_)=Z'(C_:W!P<G'S\/+!:@C!![2*P^IS
M<<%*\\ :P[]>@W]'<$OP2.XY8,TKY7Z63S56VC"E\ &_VM'&?AF/]X"ZT;E+
MJ0*"LG+R"HH:>S6UM/<9FYB:'3QD;F-K9^_@Z'3,\^0I+V\?7[^@X)#0L/"(
M\W'Q"9<3,4E7TJZG9V1F9><4%=\J*2V[?:?\857UH\<U3VJ?-C6WM+:U=W1V
M#0P.#8^,OGSU>G)J>F9V;GZ!3*6M??CXZ?.7K^OT'S]__69L@W_^_K.+ \'%
M\7^/_T^[)&"[./_Y@.^?71R<B?\.D.#FV7. 5]+:G>]LK)2J80J_]-'"!XW]
M FI&'H#,N4OO!675C:D:]'^F_9=E_V>&I?ZW+/M_#/M_[2(CA+DX8.=Q22!0
M"#;K88X6XC_R/R9<XSN(\W@RDQ'.SL;)G,9>8#_%'?@""0$S/:E[KCU]/?P]
M='>AL/B(HG^VH[!MK%JGX(G] BH&%"*H:[9!IVUQ&HP$V% 21P]S43=*X5-E
MTE2Z@9A3+MJ;L867L4\^5%J<ZXAI<9(<DOND*[>7M!L^A)1MM@IX;H$6SB](
M3?B1.;,=A @DCWG5TBLVT$XRJ<HS.U'LV65HB_,V,_,:/EWX<ZC1_I*X]R^O
MH*.5[M;M\HOY![X>4;G&/ A-[R X29'(-'?<.SP'*RFJ 33\Q'1K:Z9SANA]
MMQI.T&OY465J)'='^#:.2TOXH,G:"M\.(K4'>D52LG2BH<2@,?.P JO]_52E
MXDC:83RU(%6_==>^28K("'?OF9L!3NTB;<L?U?>K'2*FD"@?\ZSQE+(=!.!@
MX;I@P_#H( S^E1M&Y9;?ZZO:E?Q#=L*9U#%MDMMKA310.:UGG,UOG7Q&3(''
M)X>I!(F000>J:]HJ8$]**4>GMWPY&Q4W,(J>V9N'B*SH_OJA(S&.=9RK_DQE
MKB+13IKC.ZI)DR7-Q7!F=]:;U*)"MW+WKY/+,@S\)H9Q"M.Z^L:;04<[O8+#
MB;KZ:_DTSEV[#%^U-.WGWC3Y@&QS9<EY0P);3 36 YU&:"7F]@10=UV*/) 4
M(C.:W*I [6DS=%*<$'XW1'^9_O#FQ84_29RDO21*-5ZFQV8'P0WN(-):>B3H
MB922H?+S6)LNH#K0>*H^V['5PL5N;2HFJ,B$.E:OL_\EBF1;O(6(W-@"#48W
MA'808CR]X" %)?*%%$DO2\.']?(-]_%)C'9Y]S7-FK05+2,^M##&8SF?Q?8Y
MOF*V</PMI)#DP2":9EH+(4M%</;L=$M4XO$TMTD3H= WB5[-]DUV^U367[X>
MG)][N:(->PU6K-\$>X#I=QHW^([E3N=MI!NN#GT>K!HD\Z6:**U:>$@FQ<0H
M-PX$G2OBM3^S>*KPA_U403:)LKP%ZN@WTI"@FE@V3M:8'HF4Q@D&^F,\7_P]
MO-09Y=L: 4U0YRM(98Q7+E5GD/I*(4$K?2YT_(MQ).,\O!M-.$&6R/O60PD\
MP.9HNMY60F1*=JO%R+M)Y[JOUT(Z.I+"XI8_!AU!/J?C^Z_B*81V=(M7 U/M
M:QS+>=IJ[Y?BI<%:C-(QT*DA8-V]MTMA+Z=\U)UJP>0^SXLZJ0+<BK\)\UN0
M8 A3#+?2E=].W5J(69O))SW#1-S!VE!SE\VWCL^T3#8E18<T]>4HS'BY%A+.
MN@UI']KM37,81.=""%!J!\&7AST&%M.-/+I;WF]LF:1WE(\Z=O7=,@*OR1S)
MF#VD@2VR6K^;2/2'M]$7-XIN16V*P).DL0[P%PWA2,Z>(&"50F3T=9JD?[[Q
M2RA/,49:;Z;8U[;1;VG?\6_J-9OUPZ:U6;RJ1V6345%]FBPG(*R?E+&R&^RD
M(_USCP,[B/1?_@W^IZ=#41JMCWI<=">1(;9!H#O034.G0D8L8V![>"OC[]*5
MLLP>SX=^ZV25!V++G2T=V:$YUM /\[M7YX;Q0 ">FW61W4@*NQ8)"?0R];_Q
M+@X'Z@/VM32"E+.B;,Q&GLFIAA96JJG3D_,ND='5E6=S &JJ!-H,WU^YVCY-
MVD4ZUYO(4*-#]>,T?)IY?CSF&7J[.=RLR&*D(]JG_Y)F%L.V:!E#2[8:9#]$
M43I6GWMOU##M(E:;\*-10:.*!D,B(9O>1P$:RWSZ>\@,SYM-GFY_8_&NM^HE
MBB9:)WR/_>;VJE\%_)"@YE8&9/1EM7EB!)5MI0H&K2$EI*$7DU;[6(=GL0>[
MDD/G&V2&?]=?_B WP!FL$-1.E/FC!.^W6N1?[W04Y</6 FI8<7/0)NCQET#N
MKMZ2/4F"=L@;)F:7^9.;Q>_?U5+_A2@GP<>+X-[M((1(E,Y5.9P(-$ "G /T
MMV@3!3T&M>M=!5F_]5!.Y9.+MFVW_(^\'S],MI?@>MKR[&*6AXEZ=Q0"V49J
MT]PD &$,:= IB;[*2,T=,EV1F)+Q]YXS1HN>/G_@Z_KDJ*3Q6'3]E_H?^S(6
M\Y-4>]#459:<#22P3+=AX+K8M98&=*$A/) Z3-1/J_GFC>.?5C4?:?IT0*7L
M+)?=9W0 Z7;WN71D\H>;$ED_MT"]@A1+)Z ;$J&!)<#$2.#>J$AO8&O@GM3Q
MF832T+W0IQ7:@':T0/2);7M<TI].X@@^%=6TM5E#-X#X#P!FC#YV=ORXL\_<
M#B)LBZPTI*+9^:[EJFMK .];@KKBC<OSJ BF<5M5_%F?C7N+$:>P"/P1\\\L
MF2!&+!CW)+S<;)./0LR"-XS8X_F4_+5/LIV^G1(=5>S?TU&BFD,6RL(NQAX*
M\SA39'M+*W2AU:?@L0[=B*$))W@1/@@%[FO/^(6?KX($'8 ?R PKD^G69?TH
MY-#E)@%CG=YS;QE*%;X2GWA=3&-:;"N\ NB_/??K2K/A;L"G LT0)$G!2% ]
M9HB8A>+[77'/8.C*H@\8YSJK^T%;+Q5]NMKSS8V>:D+8SQ)E<?=E'^4G]\7<
M=Q"93=#+E;W@,A'W%L_QC.5)#QN&I)!TKWFL/M#RMZ$M:_&.;:+9?;WJ2[(.
M:(.W!IV[CJ56BQ8PSL%)6P"]W$&TU@RYBK.DP+-TT4]C-+GK/@72K$/TZ-RX
MJF_D,TJ7ML(2E6/4,?%6%_S7AK)_8@=1LG )?8 6L-2F&(#JO"5T(8>I!P&N
MHX$'9Q-VA6[L_JD1KLD4=AR?.__H^9XKG!L.*X? "DBT$4RC%<S[0X)T@(^Q
M!?)@XO$*_J"53D5=KL,!=L_\ZNMNS46H4:/][F+'H65Q_DN\6ER_VQDKL)HS
MT  2.%&0)8L6147N(*0PW0-EY?5BIGF8%<[I9Q=:Y=\]*;S?D2J7?S2][%+&
M4G?9[NC3;+X@^N +%370((S.I,Y\G,AEF=1^%3]??GCN>H,?Y&(_>::^R%H9
M;]SI)9*N]%Q,@=:G^5]-_062GT2I1TKA9'%OD9+?]8W?UV&5Z;-$ZN%+QGL#
MI$XYDP39Y=]"C]SDT!FAWXW.]Y66.:> MT!1KJ, #[$\ N! 7!3S@4\%=YM^
MY\?7Y 8;:+*M0'3KD]-2D??7C=J^L#K]$5_;NV=MB]/SG;AN/G0ZAL!]P+U"
MM6X-Q"RBJ?"^0/P^F I(HOM.I86(PQ!.KGNR;][#(<=&.M$Q?[W)?MT_VO!
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M[8'5W-8 @^-S.(T[]2P9RN)F]*^UH3T_SC;GV.?OEV@V[MYSPJSK0QCC)R1
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M?L P*?GHA_L6R2-'EHR8"LQ+N'&4()[R]-_#A#L(9>BMK-7^3*;F:+G*N%I
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M=0*-D/TI,B]6Y'8-WL&<F/@0U9,\GL_%\LC_KDWAFV_[BJ5L<B;PD;2%//3
M^J( ,3EI/?,)ZLOZA%"DK+/[%9*7<36ZM.&MMK.?LS!T4>UWX>5+%JBS!*&6
M.&YX5]UP7VM<\(TG$]6A)2]E2,E8LJ:$*Q+C\QST9CZ!52U6L;W/DN1,D&E"
ML*K<=)Y'GG'6GW4\T-ZIP_<K'O?79>AW^(!^AFJ+_%J.;-6FB8TH:[MOV7X0
M/5]]5\2Q]_*1R/UZ';&<'GF)H;1,LU=#EG?D9J0*R"9]?0&GU_"K\H/_*$B
M3C(Q3E*O(65^P4*D.,(DCB7\G>W[9W<3BP;SZX>RPEE3YBI"E;<$=OK37OQQ
MS^ I@%\++T7,()TYUG8\&)VE08L[H'D3M!P2G@T6N1O-.$H_SLZ,W1K#68#M
MSH8E&KV_P,XY^@.)M]R.F*T\:.J+O ,B,QO.L3:;P85(RO=($CC4&;(:WOAC
M*V2EZDXJG>NKSEN3/:Z<<-_^^JY@FC?V\5+YF+D,# ?(QGV2K_D:90I2!HH5
M5[GOAXL[OS+#21!__^$B$97#T6E=6?\F-^WBRD3TW/8OO?;.CRVWZ-0)W11Z
M8RK@+.4D!7U3!Y]&##DII7"1E%M'B 1=SR^DT#9YXJBGINA63*K"\RYV?W;.
M$$8UJQB"VKQ[LWL(FB$.!VQ# %?K+L?=[;D^4AT0?:PZZ'F[51Z?.YOJR'CA
MVCD_%=$$2$+RS)T_ZT+/;I(FJ0 &1@J#[I\9&A+K/.0,[!XI1K9ZMB+BM0NK
M60U^>'I__/B&$V)"'H<H^Q'.8)KU,,PF?(;G;#P,M<?83@5PK%$!K)BY!4PH
MJ/Q7K4AR"X(!89]NCSN78B-TE#/BCK(=T&FRBB9,1O-Q&_8FN"EP!@=UX]/F
M%9IG8]$L[C?(?(2V\,:<#G^)])X1 _)(M3ZGMJNL"TV3]#4:==["?)6\$CN,
M"V;<#BZ&:/X XE(!40$7;HV<BYV -G1)YAA"!Z/'=L*PNI_,DW<C=\LY1Y?=
M-T6.]4E]1/;3<%)#&97 =[U*JAO= "FT^8L_V(JB7-/AZ/E>52,,I9TS KO
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MTH/PO:?PAV+G<YG(O=1]Z8:.2VF+>Z6?_+9T+"$:]3EU6LKY$H,Z=V.C[P9
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M4@&O'W5A8KQFR_Q:+FECXYKJA<EZ9N3[)7V"I3BM!:#RS!37!L>TQI#JFF[
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M<+ABL\)[XCSAD'FBA2VIL-C/UZ=X,6Y\IMN!2U,!,FT8;#1B;9TB2P5@?:B
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M@>ZE8H"D>H3;NA_T*ER"+$^<QSCB89T(E@?E&[IAJI];&Q*F(,1G2%'()L-
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MN$HCC,JV%]'6$-V)-8J_O2+\*D[&?!CZ@V]GKS#\5R8BX9"KQ7D;YJ_GJIM
M/\=EZ\$SYWZWJS6VBSZ$05+5;4/G2+H\0Q)#[@5S^RN*:LS8EL@2I0?Z#EH;
MWE?_LL<QKQ4HS_Z1R\.>#S3LSM%_S'#_-^OO)\3BESP6J!/H?=XU^#U*M]V-
M[5H;3=NL1?5SHBO6JHJ]\CQ356?&@?S2XG:*X')][KB\(^VGH1\_%)<A_>>9
M,AL7AM[F(KE"W$X3PSD@KO!IJ&/2)8C,N(I5= ]G>RX: V\*W-?VRQ=?+EI^
M/\>_(..);M9(R%H-2C: 0YT-9MT((:>E$+: 10,4U>)QM(JI@X^]:KE$Q7KZ
ML=%LS--\;<\#?O97@&6EQ;<7=LS)PB0U,BU.HG.4:$AA(BICPD =.S2Q=M>L
MG%G'-@Y$>G<(FV_E?]\73UO>=Z;"+)\!WA9 .\01+J-Q5N8[%_!YA$.B=B&8
M"U-?(GO<!:5VM56N8LM,+'Z/RPG?GQF2 MY6*7%P-0^AX<6J']C>:/#JL;D-
MN@CM )\!G-!SXQ9WQ<FT^/Q%GKVN,G&#I_5N =53W3OELP^\!0 =XD-B>"37
MBTPM#LD6P.E[T$O0KW;NI%DV3#3ENM(YJG!4+B%Y 3B^[CU:&S 7UORM?]+U
M]8S2LM#\K4QW\\ &P+WGO"*F']MO,GX(!ORD7@7])W4W.37Z?Z$7P5-J>1(S
MA&X2Y CZM80QV%XI?X94W7NCQKW>?.D0+V=DN2/VXJVY\;H->U)%2-B-IW^M
MH#P%Y >XA/,A.VJ):_209;\FW6_O^W.H5$M1T]8$/VG^X0S0U4:A.0/\G%M"
MD,4JH;UMX^<(Q$ 4VDUP^T*^.'FXI2@$7L+#RV.=4EM>"%V1,C".Y#A25-U"
M;_VG-]4R_TCY">4@&[M5HB#_$#D_SH/7GD6T_&ZXMV[F%-6:57F%>MEX<G&1
M7/H'40M":JLQ;YB%<^("4V63.,&QQAZ8!!KZ)]5!F?KA%L9[D@HCDA^D.LX
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M$$?A"^,[ME:C?@-1Q>N^(^8S?-8$G-S>D2D=FV8:UR5FS9F>+B>UKG^+I3P
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M$WZ.]JE2SJ-J"?!*6]?CR9?G2QR6[=X^C+Z=J/B.V,V+:8VAG ,2),3)W%3
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MF4/3.T"?+I?D9[W.WWV3XRCZ)+Z!3RRI2!&466@[KYBHWMAH(:V-52\_1D3
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M>T'A2Q7'I=EI61GE!^,>3RZPO?+^S( :@URAS("QYJ/\L).XD7HL%8"'DR-
M4K!GS=C0.E_H3]K$:I@>L_E1)2+UK"%!M"=^)C/OUJO;'E5CL^8N">?N_SD!
M[UL@?IK 3W,A!G*V$G N#1\\)2N&I32+)E4I&SVDW\WU9W^S4=<4JW@J0_74
M.=[7B0JU4E+G6)?17EV(,R0A[#:%&WM?L:BHK\@[].*GG,]+?J-M(Z9/#P4K
M"I$*6.#.);;DJQ3AK>DPNLDG8ZW,F",2N'C1E>EW(Q]I&H]?WWS_0IA>JV+
MN?9B+0L^M87#(6>9Q+Z*W\("21RF^##XG"*Z\05MZK*ZBO<<YR6=SL9 "Y()
MRNF=+Y;N80+OQ3F!Q=:%FX8!(4F<![VHG<4JTLUID+#J]BQ1VRT/- ;B@,;O
M7<,]J6)M<W<4W:URY1L(>EA\4R5L2HE_6D51N4[W?O[G^7LI%N3<=A!)CEQ&
M.0VUQB<0Y*L;BM!>O"X?W+)$5[L< Z)U/EOKK@F:6+[>KRP,>,<Z\F]N"7(:
M[@EHV+<WK+92DNE2F_WV7+&K5#3EPZF\J17X1VX2AW 'N$&UGRT13D<"8E&]
M[8)M!/G*S3F'%MF$IQ?&C69WT1E.+N]91VJ"O"M.I[G+O80E)%_3IL0?6>.;
M:#Z3 9U?X4[V1\90 ;08N\V+LUN-FHG8*<CNMZ;0-S3$C^JX7K*+JK.1$;%J
M;=T7B7?T\$P>3+MU+WS%NH32C6IH[%@F2("W9]]1)A&UTV5!JC&_QJ0]7,OM
MSLCZ;97F]&L7?;G^1J3FT\7G7PH?IK^UN?<\@ I@#N,@Z*W\CG'&HL+1N5=E
ME*42-NE[UG4/BD-W?4*<W^W8BP9E/J<"7,_ O+UP0(=:K%"!2M(*A'L435;9
MTK=N^S2SWMC8J&I\EI%'<LW!2/LM_1NONO1O^8?K-.F- #9"GO]9(X?7'E#&
M$"RMC$B"KP%(?/+016F9O5<@L+.R^BSK?C][<X^1Y)&JO."("]V""_)-ZY_J
M1R)TNH04'/N*Z?8JQC26PD30J71PS=/ <465VW1+-P;H \UBC!K>=KNQN3#:
M*'RMT$\1,):J.+&+.!6F1%(@%X2=(_BNHCH1G)W54+O>K%L:&5'E\R>Y0H(L
M%%(KZ839FC]W*'RXTG%.!^"O]&^=V'97QE.XOC'UIZ5/S?N \WTC/2?R.*]+
MASX7P2/IR"]1*^^%3I!KVM5@C@3@"A401;F*W=GK3'(V&?\U"[-[D)'J,!IX
MME9*YTR ?\)0TCVE;)O(B._W?4[L'5H/HNI'21RU?<N 5M\J&)A,HT(/1N.7
M!61:@1X"2QHH[-7Z.JM@*0.FA:OY ]Z7Z]<V7HG<Y7?W"[#(NMS#?;(-C!<D
MU[?_J9Q]G0IX,LR +R3GU1L-M(*KXQS=C<V_70\IL;^UKKXC\^ALIVA2YZG3
M3L)G*P<'>^@:)T"T6Z]/*"B'/:B-]JYR.W[*I5H]D<8;?=D0D)MLZO!KW'H$
M> &^DJ\1^+P.S/4S#$A@Q"#YEFF,YGPQ%O(<IKX2932LU\>-QWL;ATB[BF=R
MYK95KO]<LEG/?,0OR:@.7?7TQ=/2?C@2:HI'DM_![A(%8;;D7"TO+&25._+P
M\71U*\/JIQ7?4M?;6\#YI]4>BP5-2?9C]Q)]EB5#JRWHMJY(K2/Y:$/34_H,
ML\.IZA-XL< >^/E#1'CR(T)!M8OJ](>B7,Q\PMO#K3/KS_R9OUT=')"^V%>Q
M+O)(]_6;F84P5I(#P1M'1%O'M*N0+N$L&YK0<$[7<V[!7%4N)D/9KB\U5,[0
MF[ R?3A;R/G@S.7G&H;_U@80R4S5\W/S _Y7FNY];3FSZOP(,,KT+@/4<2'$
M^@7E,P1[)P5 ^;8L )(GL6'A750 %R'@]TI?;8EK\';[U0]&!K+.+=$VZ?F1
MFAJ]:WV5?,:57=?W9=0!OX^EUB!S&Q0FFU6OYP[JT^U "HVV?7#N]4KF=F!K
M2/82A!"XYN:DM#D+HSRYQAY_>F6[?_ Y53*IOEGSBO'Y1\PO'!!$5LK<,AU\
MY1TM@#R)()J'C=H6?5\"SMRJJ2\N>WJQ;:(ZWU< GRE_^D%JWTHXG<*K:"LG
MIT<GYC<13##A0IC9%$C.IEMMNCY4A9E_QG4@L?N\*,"D7QP9O"FUP18'QIH)
M:G;8 A/\P6RD4SCK)"]:KHF=@,IV@ 2P-XK6"U:9B2%JQ6T92FE#\2-+T[[^
M7M('1C4LKR-S6KT;U8DT(M-IW2I.M*9\!4F2D]NOAHWDJ1)D<0E=P0KNU@YT
MN(5GZI-*Q?XI.PW6*KMC"WW5/RIUU;U>M\]<.?$KG?-@;X?F2O1LA!"B*F42
M=89&LO;.P61PT>\K81 <1[-) G)^,X'KE:N(U3H&HH#1/:W'V,AXX9/(2QO#
M#\#K__?V^/^R*:QC-.V"9(JLI?BX'PH\W;[&B[:XT/_MI*D;%CS+3&$ZOP*<
MYU^-Z0._^%/3%+/,ND3BF?;;D;7/[&U@=!7=_OUL2*'N3HSSO=9/4Q$&]6_T
M03K]%X6H !U8!9%&6CN-M#RPS/T:,]U4 $V2X<\2JG!=6YWXL>'5"BK@Y+R=
MCG-^W<NJKCGIS M2#@Y!%W3D&QKUG SRI:\_DZ(IBX?+\W8K7B0.(/[I5[B;
MZ>R616MV]_&/#)6ZJ:N1W,W^DR:.>>/K%[]<N+=P[MH3<[G!+Y65US1#%=&F
MD7XI\1HE?<QJSGS3R.).Q^ ==?DWCT3>,7[[_FO/7A2&QHE3F(1+H,PW<9XE
M:!JGSKN"JZ(@<'Q>] 2&[KPS%JV3L(=P+V>.F8]]J4'>-O-S(YY5:WFN 9<^
MODS+3%;9 #^DL?@KOR.I )IBF6/H!=?,]")G)_IH]XLB#S75-7;;Z@C33&;0
MB'X]4D-N&%Q?G--\,[7(&=M_=3]S;NT:Z&-^.R^Y!+S2 ,:.W'5?/G_X1P;N
M]:7PD/BQT257,^,I\H00DSH^F!CO;555KH;Q+XW<&2^;F^N_6D2^6:A0 &QL
M>T4!.5KI<=WHE)AV!9(T3D #%=UJF3_O-L=:YGG&J,(H-N->X8GG4J\?/+LF
M_!X0+D'W[K]W^RHR'+SR9GD_PY0@P4U.":.YY&1P._[E9V''"]%/!<N'GYL^
MS1$(L]RWWC8F"H2-TV;E[YU:XHVP"3#[.E;I6+7?WE=O,LWDJ__0@&>=8LD]
MY2Q=V+S:^-87^T0[^:<75T"Z - +PC#.%+VW/85ML264802O9BPQ:O5,^(7(
M_<X:>:\H_<QVON>3XN+"[;%>/O)&H%G>KP/XMC4VX#>%T9BF/H=QP,1VJ4VN
M?4+E ))T U<=5_!%2+@*,B2ZC+<O$P"-/_B8B#S^/]A[SZ@F@ZA=-(J"@!BE
M*BTJ3:5)5UI$I(D840$!(2K21(B(0)"0*+V*@(" $)4F4B(E@+3048I(AU#2
M%*5$$DMX)84;O_OCN^><=>]WU[IKW7-^G!_#N[)60F9F/WOOY\GLF1DXTRE&
M=C:BJ[-/\W'JA8IDNQ,&P-%0:8RO.T8$B5:-H7Q+,(UX&1#^TU_C^T?#ER2?
MG(-$UFV?].$C;<_MK0XX:M"-O,B(.2R+ V21N4)6W&9S0Y0Y4Z$+P)<C8WJ=
MS87&:QJXAJ1S$T?9'G&%)5>$57+"IB@-^;[Y%PXZ/?7U<P:QTN>TR3\J&!*L
M8$9N]X8X?""R9LX?Z\=T+M[_%_&G,C>@VGJ#-^_I$*S-;<!E8<@+05 RUFT:
M^KT)R=?;,+V91<\CV%Y#HLHP3V)\'1>JG%A@XF#-I=_(YBI>379.C4R<7X'K
M8+J4H5[:Z?!WONN;E1PA8*X*:>-BY&DX;6KE785TXZTT*9REUW@*Q4<^F/]:
M_U3>).C@8,UIT'<^BRF'2*+L&#"6/-,ZA1$R6,],3U6J9ZCU)&K.^&97!4@,
ME+FVW6GN?+00\64O*&?]H<@?TF.L$ ?"-D=),=([,0G31=9QY%&Q:]_SSYT#
M6>&KA/=&#-Q_(VSV4;49G$ZH3T_K.(V>A.SF1+U9S;\,B%+0I95 EN-X6=&5
M< Q5L(Z][_G:P?2ADUUB2\7J>K8'[5E1;^ZY1I7]UU6+@!)/.&T;=/PV/QD_
MQLQNDM.Y-I4;_GNC#76.^701JV9WL3YV#7R%JZ![2;4#=&TV%#T/;5"CZS'-
M$0*P8E3HC'Z4G3Y=Z'I;SIJE<6B,:XGO2'V:5EO?;%^]=/<^@2\W!+Y#4DF2
M/$7>"%P4CTLN.C(^%TC.&G8PLJD'1U2M2N@.[*YNLX\Q6^P=D7?$+86''MJ
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MC2F54TL)8)<MA(HVOD<J'J)/('(^G;E';_8ZT?Q%8!D'J.4^Z>!'>Q7T7E0
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M.^F!TY"L,#P9%9=I.WVS727;VVXGJC9;LSU">RZ O,F1FNDA2;9I![ OH8(
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MN<(8HO!>RZ0?N%YH\>./PWE56FC5Y5WU<>]=%;06[Q>Y-P7RAZD(6+##..&
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M19X7IX7KM:%E&#.L=_]J+CFN@ #;F;,'P!FEM4$PC-&>S7QL-X%X=(W<MYD
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MVE_;5,'CITC\!CV=[0]T]_0IZG(3VKP9X,XMJ;:Z #OF<;(L+A&QI/K$Q"3
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MZ9;OOUL?7O_>?2-@^5HBQ:_O_)4QU7'8(+T45S#C]44[#<*PAR:YJ=8:OF+
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M7L+U9$^W](_>"QYU-Q;*/I\82GSY[;BV6-:4&;[']*6A>V1$B]!:8^)[#."
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M@>]3N0M=A8(B&O$88DY\B%12Y)AC!P8!8HAB5W(5M<L/<: GFYDT3W*(G:!
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MN4@SFM[C]67VB?^HKK_S]0/_/<^JVW*%@\ 1 2>0."&6-GE((8Z3!+I1S*(
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MTBH*!24Q5?&]G*M$I-*:\WVJ(JPYP[X0*+#R:C?J=6F$W I]!N[;HFAX*S?
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MCFSR :\W]9$M7J_S[VH']O,X!L2(WU:/#3%&+[.9$2-"TK4DQFQV<)"<;NM
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M<Y/IXH9,?@*I2/$V$%!?$$G>/L]8QR]"_DW.%/9)8E.?/';^MHJB* Q=$L.
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M8H2"P%E5*A.HX8P?12PKHM@*-]W$T*E0 =?Z_-,_NJ'S+Y9$,<Y@)2&1S8L
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M(/,#\2&12&2>?GSHJ=7]_69M]B1?27E=?J_UF?(_R&HKU!;&9 E9<H;CA+
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MCK#M>&Z3N16QK>'Z5=OK#UT(\^%0\<HQ5MQZ2.Q,]S& 'GVM;D1N;[-W0B]
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MB/I/]0%ORKKX+\'_(,5:OWY5%E6QOGVW+=6?7T59;/@;(3>F!L@R#5"6L""
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MY7TO7+XS&9J3HR7%21;0,(28H1RBB!-(11;"F*82IT@(C*RFLD>9YD8!G5I
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MDE1RF,?*K%(65\*HTXV-\UW.C2E[$IJ:J4I$-PJT0#E+PC1-<@$9H9DNE1!
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MN"6K]R;Q1A-K)0/&$LXCF,:Y5)L2BB'-60JS/)9QQC&/ Z< -G<1YL9/>PW
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MH-4!7*]!HP7HJ6%/.L[C<I[*QT1[9%YW!GI F39GQ.TY?TSD)UH _'WJ3LO
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M'Z\R!L 3!:_X ]HIGL45L1/!+=9-31;IXJI</^S%^=UAEN9WL2XVI<F@U:8
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M".8LY3##+(]TZ#Q.G;+R.DLP-VNT4T"[A9Z&P%;@6H)/BOI7X+NHZY6)4ZJ
M&DGU8&-1F6%T#(-T'C([ZAUU($8FV_X8:.G!$_%UN&)/@=9('2</SV 4?448
M.O<_;>#@4'A>Q ,.;FA ,9KBU]=-L:Z_Z[(V^GRV#7CY+M;%IOQS70FV+07_
MHJRK=UNAAB1N[Z='(I D#D+(&(L@8CB 6$8$RBQ'.(P0"G*K"+]+A)@;7::_
M9TGP/P%7AJD6TJ&BRM!1.$U_4V$[-@,6OX#1 1@E3$1)%YL'&CW 3A&@-5F
M=^T8#,C,,'@P'$K>3# HKY,24T\!T$:S@JH9&[TU4\9^-RV:K9NY+Z'?V&?"
M5*\4]:.G3)B70GRJAL[0IJ>KJW.A\D]J[5S:UF55&=]N[FFQ-A^QMD!OUWK_
M\)'K;T469!]VI$NU*3&4 ?II?YU3_9N: [T8I6K)>)(S+O6M?+UNB9C#' <Y
MC**,X1@SE@NGE)DCR3FWI:UQCQ;[^#\R(*7F6&-JMPF8P4B-O%#NRDSV5%R
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M_4GM7S?<T;VIL4UZ'-KC8TSFU!JKTW5LS1\ZI8+?+?E9EW2ZTX7LOVQ[9/%
MQE&<^C")?:H8GB!(=;(4\ST_B5$41:%5<>?>V>;&]5=?+ZY_NP2WY__WY<V0
MTGB'0#6^$W4#U?B7H4W6)^A(.E+O,2-0G-:(.S37.Y1Z.Z+V_HIMQQX:D/2B
MD/*.U'[P"/?2 %.H?$(&D8PX3&640(S#Q.=A(I%O[",:S#<WYM 2 R>U24S
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M;#(=9Z4WYM_%G2X/M\Z?@=H(,B&X/24< MOP;.-T ,<^T*@E!)V<=/<ML(_
MX.K8XL LTYY5]*OZYH#BR,>'ALG2\FI5E'EU15S7XN&Z/)Z'$HA1@B"*,(:8
M1@CZ:93(*&3"3ZW:TNZ98VY[A^[^61\^P')[^+"3?& )I7T0FW'"B<!->.90
M878["+,! :L'47$6C?IVAHE#30^J^#:.]/!'!Y;/T>T7ZS*JQ;?U,F//NT,S
MIG8+(4UC7;.-0X2X#],XP9#Z:9PR%/O<CVVHH6>NN5%$+:1EC94>*,THP!%
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M_M!H UIUP%8?\$>KD6$4^(G6.[XT3V.3D1?A,<UA1<*GH]E#MR<,/AFQG@Y
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MW;1SHP M-:QN5[B2NTI,TKGN;)/G.N[CL6[9:4<)I@80(N*$$QCY^BP&4V4
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M,"HX%(ZJPU"W0:C[[V:W:SQ&G"=Q[$,2D$#1!I4PY8D/<<*C&$N9<&F5=.I
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MY.>#CMI03.C#C9X;-;HWL(_QI)_?R7"DZ=X V6)0]]>J]Q+%E\_E?%'\TTR
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MY76"DJ8<TW0YZA</Y?5/\JPO"$S2RV(YGU6;H148I1@A@F$<19IM/" 0TUC
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MK02HM= 4-TH/8!0!6I..O!U=1LS.2^EY''JV+?T,00<2@,X@>B,'<)=@8-*
MSA"])Q/HWE37)*I2_JVL3,)I-1$ASW*49E"P((4HQ 3F44)ACA#'! <X#JS*
M&.YM?6Q&;GV>]M2*Z)IMLXG=Z0.SLQ#IV=RLP?B;#S!<<XLZ@O(QT2^S]Q^.
MIQB6@V"<S 3:?&?@5)\]XK[/Y=GW4,=DG17/RG:)[CLQU<<QNGYW96(^Z$:$
M2+7B DIY'L<XUI5:A?+V& LAB;B #$54QGD4L<"IOL=YXHS-)AI)(=V.[ML(
M .S*SG3FH-DY?,,-1=_[2C,*G\X9!??L'B_@^4KV.4^887-_O #W+A7(3ZO=
M3.R! AIWJUC^.U$MI_H<39^L?24OE9+R4E\,,TV<IX]%E@OUJZ_%<U&OS97:
M9?-$RB2#.$D#97=)!#')0YA1B0.1D0S)P,7N]B#CV(SQ6A?#';\H 0%3K8B)
MLJT5,-16:Q7<K'(?XVQGJC]X]'JVWT>J):TT!"L-S>T#^-H.[%I+<+\>XZ\6
M8^QL\WL<!4\+01\2#KHZ] CQ[I+19U>=\^IU4:5&$IV_^ETL?HAY4?*"-;_5
M*]DDBT46AE$.8YX3B$A*U.) !)01BH7@<<A2,5F4FA3+SA.T[-C)XJ^Z[W$7
M+A8Z/-6(V5;+ TP)"GXI#,^D(U.[]0!8.M@]P-JS*6Y$;BVPR9 W)45!*_?J
M3U<&YYKV^S#.7=+FG4#SER]OU^W0B?).8.S)D'=[OZ/A4E--W^M=Z4)Q\[?F
MFC+A/*&!LDU(T 2B* P@H1A#AD7&":,9SG*GHX-]O8S-"?TB%&QDZFAW]N)G
M:63.1:5OB]+(9QR[R^7BR13B.IVAX6XXC@'ARTKL[6-8DW!,S7?S_^C#76LP
MO#3;YUNI&3@G&"DU)!,PI%D($4I3B"6C,&8XSJ(@#''FE#2PV\'8IOA:/KW3
M<*='?@>@W40_!Y:>Y_@V(I^/(=*AXL)^M;U56]AI?N!*"_N5>U]EX<!S'>-,
M#U'DJ)^_%#--2F&"7.^*QZ?%K?R]JB]4+Z6:7I>,+9^7YE1MD\A*O7GYK*FJ
M_UG?86&19HS3&,9)H(P""SC,(\%A(#$B/(A(C(4;JW?_0KO,J&&HP%N=#<>+
M:!6^ *3>YER J:@J0-;:*7.T0RY&-A0$O_SW]$)99/W^9\',:O __UN8!O\K
M#B_J'_0$,>_]]^0"I\'Q)T/'_=4 WQV*@S#A&8(B$@@BFF-($IQ P3D2+$GC
MF#AMC<?UU0VVJ=[[W8UNL.T6SG$-8<]+\0ZYW<4VNYWY5Z-SPX)OM(:EA$KO
M.E)*O:-5!QNZ@W><A9OJ>PSW'FRH?$6(]R_PL$'E@PW NSCTX7KNNN]Y%;.E
MN!//=3;\#S$W2?)*L'75 9WGR908#\6S>N16WNN(9TG,@?*#/C:>,,Q$SG.U
M/2(XTQ=[!.),8L@3E.5QRM)04+?=D@^QQK?',EKI"Z!&+["AV%;ICE8W4"MG
MV),VU -_& 6=R^-Y&6S;G=W00]C[?G"PT>NPG_0)MK==J!>A!MZ[^@3R_8[7
M:^L=2XJ9Q,_-U:=Z$#\7GQ0,_YA$>8:%I#F,,D0@"@2&>9H'D&0XDB3,.>).
MI0B/=38V\_SU^O+^^MZQ)M4Q,.T,I2^(>C9_;1KWEJ-=*5.F9 5&6(_VS 83
M7W6ECG4U;!DI"Z7?58VR>:>;G6B2)7>R#^I;',19%E&<PHA* 5$8$4ADJMR_
M(!,229E%TO$@[$AOXSO!,L*Z&8IC:.8YYIDF* J8\IE1&G&(DRB$0<@P1S$F
M@7"Z:_"$Y1 VMTVWWDEK\H>MG0WVA%C/)O@ 6#U<.UK@X<G\'NMI4.MKH?*N
M\;5YQ3VC_*K>]1>OXEI*Y0G6D0VW\I+75#^7/XMJ$F>2<IQD, QE )' $F+"
M0RAE0A,I\H#&5AD,MAV.S6ZL90:UT!=-+(^)GFP$!W]HT1WRT:V@/VY1^@"T
M9[/B!4NG;'87@,Y(<[?J9K#\=Q>E-Q/CG=[S%:.Y><1X*W^H'N?W8OY:,*$C
MJ^KXN$DH9!3J$D@Y0C%$"=(Q$A&%E"8\DYPG"74Z]>LFQMA,TU;@]XL6&52U
MS.9ZT[T"4I>AL7-[^@>\9].U/[)S4PEMPXP:H-%CN!!/%RQ["_BT$N*#PS]=
M@#H=#.K46E?*2K/5;NLSO;6I5]_5UOOA3S%]%=_*V>*IFM D#7*, ABD4:YV
M=E)'BZ8)3&2>!'DH>"20&VFE7<=CLXGJ0XU=.10M(3YNZ?H$;J #MX8M<27Z
M19L.6ND8]I\+4,L/:@5Z0MF5J](_V@.S57I"O0-CI1MT)SDK+9L;F+723<GW
MO)6.[[N;^8TR?/6^WFSVOY:SQP<Q?]ZHS#?)4QK07'#(DC""2)),.<#*Y"=Q
ME#'*&<MY;&OCK7L=FX&OCZ:F2E"HNGL&T[6H]A;)'O/31K\7)/OW9M?5/5M^
MIQI9+3C0DF]6_>P#67M#WPO" UGYAR<!%@ID87;4@)@0;TWK0LG4W&Y53T+7
MK25UXJW^"WG6Z0;MOW0"PK,)(I-+7<' M#9?YVJ3Q6)>T.7"I/ V%2;657 !
M%8L_A9B97^LW*:F*NN:A_LVC<F;G9#I]TT&PRIRJ7M0/NGL=3*"VE#-6O$Q%
M\Y8NX:YVEL\O9/;V;^J?AV=B4X[ISV(Z!5RPN0F56\MO9*U3#-632KIJJ9ZN
M.]F0?2Y>M4'Q17?C_!D=6?'LVQILN7-6;W.M<W_9V_E/52V?:_KGWW49)C)E
MYA!J]M@\M(Y7N".+'7Z*FUG];4W2@ 9I3B1$F <0Y3R$>9ZJ/5#. UT[.TM9
M=.8!D0\YQ[:8;I7>*QHAP5S)?_;9D9=A[7RX-/1@?<SITUI+\+NII+C6<_7H
M9K387;/*; U[JVZO!U0^QZ._$RPO4G[T$9=/J"W.P+QVUVU1N:Q=ENI.,%&\
M:N?BMWE955=+M:+-%A,6ACP(9*0V2U$($144XI0+&,DL#V628V)'EFW7W=A,
M_ ^%M$E=:*167E4KMIN-/X&RG:GVAUW/%K<5%*PEO5#.M"R5![LJ/6UX_>MS
M7K5OJM0>JE'$GRVU \R323S1V:"6S4[Q70-E^98O.W/)U= K0T:F:P:U#?+'
M- ^S0 0PDP&'* U2F*>40AJ)*%(6*%:_.<_P'.U_;)9HSY0":P7 A@:=B1]=
M1ZBKT?*&^_!6[ S(/1@O*^!ZLV;'>_]@\V8%S6E[9]>,>["8)NPR?*#W3,S(
MO"A-B%)$F8QDPB&+0P81H8$FK\"01&F*9!**G%GQ+![L86Q&K)7-.>)K/W['
M#9 75'HV,;: .(5M'57ZC#BM_>T.%IAU5*W-2*SC#W8]>J.+FYFR ^;8^TYP
M4>_;?LP+)GX(]3G,%N113/(\C8,TCB"11$UI+!BD.(^4ZQ)SG"8IRE.GQ!S+
M?L<VT=>"ZG-PY>N_K$1U/1NSP]WVK,L[FKV?7=$%6(ML2$E;9(W4)@CT%+0=
M#J&<@/)VJ&37Z\"'1$Y0O#_T<7N]:RTE?1WT0'XJ5T:I54SK)/2K)\U#?C-[
M=T'Q'V2ZK-/4V]WX)!!)F&4DAT$H=#V1@$"L3!=$/"<1QH0@XD3Z?+Y(8S-J
MM>@5*&;@M146D%9:UU)*9P^8G<D;=AAZMH9U9+6.@*_5,C?PYEQ^6[L+4.NG
MAVK/;3U8*;D^C3+AJ$N?AT_^D/=6G>EL@08NUN0+P/>UF[RU?$;2YJJH;RU.
M4Z:]28CC,<:AV@'"*,O,WA!#FA,,@RBG@> Y%HE52*IUCV.SMG5 S;H:=2.L
M(03ND'=X%&P[4^H5PIXMY2YZC;W\I9'WU[Z2$6W@\9F2>+2_X1,3;=3?FYYH
M]6(W6[,N/;)Y>[A1H^;3V[OJ))=_DCDW_^<_ZB*\AOFHVMAP941$,<HSF',>
M0Q2G"<2!H##%B"&BK%.*G>X%>Y%R;#:M$;/S;KB?H;2S?A\^0'T?Q6T4<MH*
M\=BLYD3?P-Z"3UK%B_H_H!WD6M=^]N>]#H8G^]R/C(/:]%YAWET'^NWL'!*B
MU>*TRYR3,1*$,8EAGB411,HIA3CF#.9I1*.,2!P@I\S2X]V-S9IW)R(Z"*B=
M*?8'4\\VM<W26?NA ] 1G<+%*R'1P<X^@)+HE.+[28E.OM7]PN1RQJ^(*21J
MVEX'LU63&"4"41Q EN$0(ID@2+,PAUG&$X:8R (4N%41.M:=D^48@.;XZRKL
MWYW!_P2P]A<A?N :XOY#)US4A,%K(?W>=9S&PN,5QY'.!K_9.*WXO@L-B[>Z
M68T''=&ZG+_=+Y0%4F[0<SG39V]B$A(:,9JJ_27)<Z@L!X,D10DD"6=93!GG
M$9_,Q*/.];&S&(>ZLOKX<?WQ;W;8X[V#$0Y46E!]HKUH)-^@XD_0110F%WD6
M@DK[B)4-RS[*+V+UVQ1AJY="-SMU<"CM+-19PS.,;6I%!$;&"U!+>6%N%SSN
M]4XAX<DR'>QF4)MT2ME=:W3R>?>4XK\),ET\7:D)<375P=]7Y<R$?U4-+>S5
M&YN*AJJBI:^+1(0((APJ5!.(DC35EBF&F!&6Y(&D*+'*H.K8_]AV1K4*0.L
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M)[.:R)1'3) 4!I$N_)#3!!(F,<PQ%ASE**59Z,C6>JBOL1E#O25\:<0%>MA
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MG*0Q2A'A$<Q1Q)4K%R:0T"B$F/ T$3A!Q*W2XOYNQF;EMJ0$6LS&1W!,V#D
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M('3Z=OLJZDMM?;M=;R TD?]OFCQ6;R,:9H(DR0.:B 22)$XA"C&!E$AME&G
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M4*2$R-3>U8I$K4<9Q[8,K*0%3[6XFA=4\[CKZ!E##UJ90WHU"76LP-S$Q^C
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M4&^E86[XT+^H><S+Z93,*YUE7]./6"ZXYP^7R^UQSX,PS 9YLY[]H<S8I@I
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MDI,8$L0SB!DF41B)G 167,\G^AG;1-\4$Q@Y.V88'\+5SLGP@%;?-PX=@.K
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M8^^YGHW10$YK!ZR<'->C.!SQ6?>_-YB[>E3L34_U^(/=G-1OQ:R<%XNW545
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M<ZK-A!I>0!+8^:529E9K+2NES51UVYSZ$8:KDM.A"'4P(JMRGOX (!E!*6X
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MB*,\QX532R^_8:>V-!G)@14=-+)? 2U]\ZV92JY6 6 T<"=)CVDXOUP- ^[
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ME<R\"I^?'&UJU+(3M@ZE!%9</S(Y#:\;E00#;6 B.8P7^$'+6OUE $O#"9=
M1')ZK%%IQ$GMUR3B=I-_C?3WB[7MZK[MR/"Q7,C;M7RJ9IBS)(Z5J6&(!-2&
M"()8Y2G$19XA;AI?$J>^EZ>'F1IIU))VFY* WXRPP$KK:(J<0?8T;83#:^A=
M2$^HO*JPGT>B5U'V$X\=K4;[>=6Z)=L=KKZ@ J#-DKE9/ID#LMHT6:WT7-LR
M@S]]WUUR7S<XO#;UBFI?=65R:Z2X7MCC-<-0#TOSJ[O-NC)%*,O%XR>;$#++
M6*14IKDDHD+O=' F(>&T@#R.X@1G68ICKYW.6()/C:)JN>U)N&PD-QYF$X]J
MHKQLE98ZTLO\6/N6^Z?<C/9ZN!E34YST@7G6Z@/K5,"NTJ"CM6V<U;FNT1Q8
MU:^:L\#J"G3>G?>==\?\6E^U ^$*U# $+@(YXL2%+#$YAMCC%[ <<3(.EL<<
M<WS_5*T# ?Z[,,$VM.1%D;!,T9R0B,.T(!E$"=/K6Z&M9D$H8C&+"TZ<Z^EY
MCSZU1:I;S>UUVE8WI<4]A<A_0DZO*(/#//"R<!C5G?AMSM EM?+\,7=/VQH4
M^[>KDV<*XI4'\Q07NZFI4Q8#53SI#>2)-"[_9XZ6QM5;W6X:5_^']%E)^/))
M_KRAICVP;/M7YUQ1%B4"IBICQL="(99I B/).-/[H2*.G0NB'!QA:BM"+238
M2NG#0H< =&'W"V$9G,%?(M*C'LIA:'Q(^$*(WJ9Z5%DC][A%CCZN9--%I*Y&
M6N]KN%RMJ0FS^OJ]*GE)%^$X]P1N)WGUT'TC<N<)L5_RXZD+^W*@IMK/\IM<
M;.3-<C[7AKM^9UZ_NPP+E O$8!X1XR62'+(<IQ!K^QE)E8FX< J)]AIUHEQI
M;(=&=+"3O3^%NN#O2JN!41V':J_/ -J;@5V0]67EP B_*5/7>5<U\'P'_);
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MZEX=KLBYT_FJR8_=J3V1N7??/$SE'1AIOS&)=\%KLS+&!)W8WPPZ_&A;HC%
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MWZE?J[KB8]-G<R'N=O&(,UD0DL<QAK$J!$0J+2 M4 XQ4:G +(YI[!2:T%>
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M 1PJBS?^=9.G\ENKDB>E])U -]X985H&)J=!9Z1/GN(E>(9+8>PEQ=C9C9=
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MT?E/FTH/6U4W^J%R=;MX^"I-R!:;E_Q.W7_5^[7G9W-!XTCF*4YSJ0J8\D)
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M+6U4DI49E%9H6ZRP_HUGA<)C:+N[A2_$< 3_;VOQ7-4U^K3)4XL9ULU[ H>
M_MQ#HXSNN#VAZB$/[:G+>W?'Y-)TQK,%R,OJ'Q^W';DSQ'$J)84Y00HBB?2V
M+!,*2AHGD?Y]S(0G31P;:GI,T9$4&%'=6G?[(NQ*#2%P&YP=^D'6IPOF&33"
M-;\\-M#8/2_/*'R@U>6Y.X)N8&99QHB,F(!90@5$G.00"ZQ@DE%%L4($1S+
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MYSUL9#JF"B2X:9H-9Q]U%9NONAS2=U6#H-DZB.JBK_(+>, -;YN#"88X#V@
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M;P/9IRZV#[@5EX]DLU3OW_/WC?1%5L]77.5?-VVNOFJ,_GU#FI*5>"77>(N
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MCF >IBF,0IQ2GF2J[I3I&F&<"'-C\&^<\O*'.ABS<#A'HG_:X_>/J6?J:14
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M;HY(R7+P20EK'#"OR6SD4T8VF7[^_HB7RSZ&9,$CC"*>A##,"]WW0ZY*(Y9
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M7I\;-@/!+?H-&Z)_FHH]8.J9DG=P;F4&O=!ZL]PKHA9=G-TC^SY<7>U[?P>
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MHTF4)6EGC.O*<-/7DRGZ\:<SA!RQ_;D6IWHUGV$",W_?.:B^3[;VM08XV0[
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MP_!XE7U?LA*OK)L,6MK2;,_%GX4\4\]I*WC.1!B#F[,D ZO!)\X?& /,V]2
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MF$1&QQU'QIB;&]6*":[T,K$5U#S*^Q".QS]\1^CX/DAX"\SIGFC&")F'O3M
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MT5S_(3V=4O4++BG_IG8./]:J9? "9P05,<NA$ 3)5:[@<E$E_XFB@!=9EM"
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M9Q!1G,,BHP%,,(N2-*0HSXV3,O8-,+?9O)-1[V5W8EJWQ]@+Y/%9U 4\GJ?
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M.A.BUXFCSRKDQ ZY.J*^JC-E*9R^$YO.5*9CSXV8H]0A]M/DHZY?[&<G_2K
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MX+FY-(=HX+E-/!"+7Q"9DT>FA"%,^,""2#GFVK-C-J>NXQ9;;PS*EK36@Y*
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MT_'IV=YVOM,+3ZSF2+V&\DI6;'UGZ^4HW<OIW(]_FTVO+N_V11V42M8C*FC
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M.>[R=HT*:2S7Z)<D+YJ"UTA<N3P4I05+&;<RM] ][WFB*O0U6O^"M8>S,>9
M8T272K RY"X2RR&7$I;DI4XZAMI[PFOHZW8#J(N?-?V+VM%3C_W?WXZ//_[M
MX!!=RH_'Y[\/3@_*V?)O!Q_*T4HIY=DF/'[ID=6"YE?17BN4GD[3GZ/Q&/%Q
M@(1/OHY*(6XS[N\.)K=P3$R5:_B)F) 1)1&=#Z=+?WH:&(9=S*A8>TK JPC<
M.0#?Y&4KYY]!,R@ME4 E658G2D(Q3U2"H+("$V1MX_8Z"CL.VUO#UJ.(OCV]
M]=C8-59B:[NV^MNU3-B3%-6*Z*\5T'B_U_GBT3_1_9W!I1^E^^-*UV!,JUS2
MNZASG<K!5<HDI*2(X;I,(7>V_LVX'4G>U:*M??C*J:V0+D0OB(G9$ND2(RYX
M2\!)#.0X1.UK&_3G*>HX(G]#?#VT814UU6.;M;>__^7SEZ:0KS$6^\>?3TX'
MOP^.S@[^&!P>GVUCR5Y^9L6+=:^AOMX]NZN+JR;L;T!2T@$S^ :3^>@[+%M,
M'$[GRW:YY_['79]))CR-@A)F0B*E707QA@'ATD LO29T]<KP+4G=N7W8X]>4
M*ZAWJR?*$*/#Y4(#^A4R1D]P,5$B7$[<B"1\]3#T)9HZOWW7.J8>M0>KJ:4>
MV[BCP7E)0.V5KB*G@S\&1U^V.I==^YA:ENQE&M_X4IYTC$L$%T&%EP87HM22
M!B# E(#8-*"H/X"N7Y?R3(S4:,L)&.^(3"(2EPS''5]ZIHV36K^Q"'IBK-K
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MS 842^<PNWG5,-E'1/**BBGD5_.(X&3QP&T(7&=AB]LHA6!/H(V=L-9>^EM
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MPN@ 8<^&Q[GG<M5J02>?0!FNP+M00!8ID1=;N&FMNO;.$^LG;WT?^ZN96#J
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M/.'U-]:;EHP'C)9N&U:;RJ48P&<ZY-(@CT5Y)T-KN[H)X>/&:PX%Y/%DW0'
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M*.8LUYJ[^R<L6J\PU8M?%4$G+!>Z^#E"RL00&TC?Q]:>9D/R-P*M?76@'4O
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M1H\2TA]T=I'RXQWM]F#YB+A)>7+^+E_@Y5NZ\9??5R<IB<B=PP3>25+&3#K
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M)=JXKD_J*AK(5KO I4)=6@]\WXRR;JM9MT')T]6LS832@6GW_-08R>C01N=
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MC; Y_\86_ ^OZ;3W&*TLH#5*4%*3W\I)TQ6NR6G%XKAI(OC^LA%V%OS._.O
MWGSFTKL+[ ;D4L<<()6:X,]I8U@;95G&.,'<^X ;9:BT\7W>]9:1,)8+OIN
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M^/,ASU<;/&>^:(E(;EEMP*=J^RTG; 9;\^"5L<GP0:'T#&WC^K-#X:J5,#H
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MB!XK<W ;K'1@>APHP\;%(I5F$KQ.IAID#+RD.]$J;C%JU"*_OJ#'_YS,P:U
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MQ-?I[,MRDDM*.7%?JS$LJ!PUQ(R:*)/.<:.T*J)G2#VRG19]FSW%/A]&!@W
MZ3>RV&_GR^7[V880(HW,;[V5(*5+V;)(1 A6&^*%!)XI6^UM<(5A-+'O:NB'
M=].B;>H'3#U)8&\L_<!%G _2WNO6=*R)MXE\&ILAI)Q!D2* DP4ABI!L2,:*
MWH/W1S<T=M;O<)CJ3PX-F*B'&BQ2D)$$EDR6MHXG53%"T,Z X:$(M,YS-NP
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M;\QM !K;FZ7W/W QJRW/-\UWZ/A<5\7.R^+R)V]F&?_\],_P_1JQ*IEH@TW
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M^!UP]4,!_DF?DS'_GP-?-:_5V;^8U1>QZ2J<O<4;&?++%Y'P'-)J4A1RJWD
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MZL*'2YP_<//C!IU'Q.S#J?C'%'\#SN9FY_3+ZYOI++G*:"6D5&<6I!(A6"4
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M*>0BD@-93:/R@;SBC.05ZVQT]B7GEN_*'B/MV=P1#(+P<11R)[BU<ZNP]Z/
MK2#TTF5^E$=,A\*+L,0C3BX+<X+<:>E!IDP.@Q$INKZ[%QV7PA,]^AK5S/'
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MB"#1=P#'/1]].A7P^Z+B4'XV8#*VU?N_3A>8Z#<OJOB-4UR+6E9=YQ:KHLC
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M#SRZH<9;JAT+D?T+;V0;>#56[<-BOJA=:NXC[8*NQ#S/%$BGHBUYUV[=CM"
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M]#S-[BY]%RUXJQ<\B3Q$8:T"K5(FCS>62EH&DWG-L//*Z;ZODQ_?46L>XP@
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MB? +:>V*%W)OD]#9 [F\&I24LO;G13(;T#J%14?=VLAZC)Z1!T@,#*]FFN@
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M]8(Y*#FG@%X+V;P\O%O']-A0:Z67#B#VB E\4W]1>XA5" *D960&:^L@QN#
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M-(B>C9$[:(R,W6)JNZBI ^/]L;#T?0&^HX?K\[_P_ ?^/IM>?%V<F=I[(7(
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MC;QUI;7%TUX)';QK:]K71\U&XT-T"-;6V<[.!/"A#D2E@V8T'1"76C<H_$)
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MP&EM/5M-[11*"<L49%DGF^4HP<5<AR/&PN@RU>%N=/SP<5U/4C5NVN5([]%
M2NH>=E>[#BV:X(L&%5V-:R"#4%(&9P-WN22F5.M13MO0-:X3WQH+.T%M#\5T
M +8/EQ<KEM97=)%291T*Y)3\:J:+BZI 83$SYK-6L76)S!T2>H;0/CJ^6Q%Z
M@,#'#OR$Z9?5*7)%\8P,0:1Z85M%#[G7'D1 S2+)0]\UDO8+[%Q]<-P4\1$]
MK/U$W ,NUG!F1J.7B8$6CN#,Z*:-V3-(*G+TP9 AV0P98QO0>RKKKKKWD-S(
M"E^OKKRJ95=>21XUN9.!_(;@3-W$8T ;GYE.0C"U59+J"97_\M&1E;Z/RF8M
MY->!Q?#4;?CVND*Y%F\RKP(DX\G"PI+(W>-U&2%*'YC!D%H/6=^:N'%K0H[L
M(PVCL@ZPN)F=)2O7&6"9,1MO:ES<U0GD04!D(4')7I18L##3NB5W"[+ZSG;N
M"8C9L-H9.8;X_\XFTXN_DW0OYW@=.[NUA;=66.E2 GB=)*BD-3A!\LJ%9Z]=
M$!GO-%]NC!P^\9D>JRT.4.EL&/EV<#?]/IG.5IM75T)Z^;5:#F^F]>Q]6WJ
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M*)2.L75V97]J^TT%[H*GS;?:X-H[=-C&YY:UC]L^&]?_Z*_7QK7<-?>J6%W
M*D10*DL(EBM E62428?(6@_J:D?]Z 4] \+YZ-KMP%UY@)T'!')RE9JJGMME
M[::X^??IO)UA89(C1C*4+ -5&TF=R+5]%&WAPKC 6Z=RFC+0R65]9!0^=!B.
M#HDNRBH?8']SK (79SDG[9!SX (EJ"@5N$1N0O2<+'R;T36?<;,CB9W<V5VB
MNHE:^[W'[\[_6?UC:TV<V6Q*"+96.]=9U9$C..L*"(E*1A11-\^\[T/GZ./L
M.L9O.P5W:&O_RNJ[676P+]/%))[?<.AS9-X%""ED$JF.M9V/K+Y0R_9#MGFX
M$-?3Y(T^Y:YCY!ZLSI$[<D]+02+^!_YB[SS-XWJY] ^L44GZ&RM!+QM7SHJ,
M(G%3P,C:=H@^0^0AD".319%>NZ2W:>@=@+31Y^6-B>0>U#TRVG<XQ&\G%Y,O
MRS\]8TIB#N23"UWH.%O!Z\8G3X@-Q<4L3&';;(;>Z^.C3\,;&['#J^S9WL#?
M)T3IRZ^!+*?:%%BU<CTL>-E+6%9-8>MS*I+1AI'QY'DFF>A0P).0P)>8;"XI
M6&\&O99WHW?<)>D=(+]+8'0Q.'J'.V&YD/Y%6) \;KU<+V>+B[/@54Y\.8N#
M80VU>HBR"' N)Z>2<44/EHDZA/!QM[D_/W.\$03Z#8]<C>.^U?1YLEC@Q:).
MY5Z)_/Q\]J\P37B6M9+92P.V" :J:$W&6B2'.J!'#$$6-UA/YO_?WI<UMY$D
M:;[O?W&SN(^7-:.N:JY)I)J4IFV>8'%2Z($ -0"JB_/KQP, [RL!1"*#-5O=
M)9$$*]./+SS<(_S8F>IAA\VWC?B^E-^FI_YU/I[-_S.Y^9U#SJ-I?$((:3'R
M3 84M@5K1"Z']@1<Z89#/'/46:=RV,-OWX:4@8?:-^#,'%J?S9\#KG+VCN(_
M+Q?+52/(44Q.*&($H"=FRI Q"LY%"<I+J1/)EE9O?=R1M&[H_5]ZH;B7'EOR
M*1YD]GF5..5$05X=NK,4P7M#RZZA%4;51C[LRC=HUB7]7W/SMX>>WD8&Y@E&
MJ*[$O552+A\]K8<<RY<I/D!294H9[8I)(%-P&,?(DO/-&93Z5N432<34SL?O
M(:GRGI_P8+4=G7T\/RJ<*B>B4Z6KD97H Z S:[@V$$5@-D1"A.MRM_#*:QK)
MH-E3TT_Z7Q7D.G!H\#BP>1C[7+N/Z_.M^XW3KC\KOQM"^1Q-^!=<WK,XDDYI
M;24!%&9 X;($GE$+21)OB>/<:-T!7+T1V$@*3$58MJ'+:H#N=5^\K?^8Y4?1
MOIO&SV/GT>58CBOU,-OA?3WLK?MR?8#=-])R_4D2!(4H$RR6GHN:8US*@V>,
M*%9]9G&/)0UWRXP>"?SHGL!O)& H)52I#(:4@2M></!)$S TV#+0E^=0O5/4
M]F2VNZMO@Z"7^IGUH:\&8M276;P1(L8[)GL'1 ET89BR8'$[ N^TY)F'Q%3M
M8?>="&NG,UDO\-@*CKOHJ@$ /F*D+./-SS8.]1FJ=?Y[=7J)OLC\TDT6^*/E
M_#(L+^?HEI3KV(NT&!ETAW"5,T L1>1<EVFIA.'*I]K8').)M6\=ZU'?,I1W
M@M8S!=4'UO.;1?B-U_YI-O\PN_3+?#G9>.(H@<A<()F7RO/2D(-Z<,(ZR%G2
M3(WS+M=V"NIST4Y?H)807TWO Q\E/.+^2XKC@*HYBK\+>U_=U?I07TEJE+4$
M+#$6!*44K'$!+!/9".6#"OZ5R&J;][73:* NZGJ3^9NUH.=IDH^G& RL+N@Y
M-<&4NP&G<:L0V9J2,QX@A*R)$8&)6+N'7P6RAZT/:-5&[J[9UHSBZHKS\VQZ
M\2W-?]Z)%T8LY4PCR6"%7.50:7 28U<JF+"$91MSE_/2SB\<-GW_P&:QBM3?
MAEV\5U0PC9N[B<77&<HT+<?S]>3,S4]'3$=//8V0/4<G0PF#_'L"!"7O:2+6
MR]KU?K5Y&#:KOPF+V9_.WP;FG]@Q5BM^)!)-4D@%P99L;.(Y^'("XVS@@KL8
M&.FK^^0.Y Z;I=\$DJMHLK4]_[H2]Z:TYN=XK=91$M%93P5$DRF&=RZ#%Q&7
MHE.$,B<)BZ]=,FWWQF'SW0^\Z]>1>XLF<),F-;TH_9;N5J$L1IDH*C+UH#G7
MN%!X:8[I$TCJ6.3.TIAZ/REZGKQAL\\','&5--4B"#O[(2\4C:0DM1,A0TJE
M19.2%EP4% SA6J+0&4T#G.!OS<? .>E-;-W]*K^U/?UL?/%C>9J_X[/+',&;
M*\!3/]G4S2Y&+@?O;+FQT$Z!$*3,/@@:"'>&"59ZA<9==O<.[QXXS?S &WUM
M9;1H;==N, W"AFPP8B.J)#>D!#[BGI&8%T0FEH.HW=SD:4H&3B0?8B??6@$M
MPNB/.?HA(\0\$=8;T*%TW"PE0"9R9,4$J;FF14!]PVA%23<8O<';F8H*:*"=
M>)>"2!*#5;@,@*[:5TL9P*RZ;48?DO$V&-;7C)I]RUWI7^E"94_5M%/L]XBS
MD[0<64*E3BQ )*4/OT8N; HH*JEXSMH:)VHGICU%1S=8O<'KDVK";\!J/2.E
MI[+TDLH)[2^!F%% @ED4E4!&&;4Q^Y"]\J8RK+I3UW+>S,&2'O?56EO.V!UN
MOLYGO])\>?5UXJ9+E&<9&/^K7-B,@D#3'+,K'B:N7QL#6&,89))-\!H_Z6WJ
M6T<2F\QAW!LISYO"ZFIK%I5_S&;QW^/)!#D[1I5.+TH3F)MC]7O?CXAVSDMI
MD>%,<%O0!D-K5[KC!DV(H)F9'O?DW8ANTJ8>!KE]J;:=([H[S!Y/?Z=--X%R
M(+1J,+!F3>L4!8L>F#$965-EW(XRZ!XKG7'5DB >I#Z\=CK7Y;5-9B/6PEW?
M:F@280\.'Z\_N7IP_BA5#$Q(#3%0=(E<<F"UCQ"5+AU7,LUAR_RNK6EH,K>P
M?^SUH*!FM^WU(26+RJMD)$2'T9\($>,TR]$;E\H1IHP@M,=3XH?D-)EI>)BM
M=GMU-(2LFR++NPF3VIM@31GQ3E<C%KD 5Y:*((9XRQV:[MJM;%ZBI\GDO[ZP
MM;="&CB3>5I,(V^CR($G*%W=02CT BQQ!L$0+<DA<7&@4+?)'+S#&*NME# @
ME)Z^ GZZ2Y3USCF.8DDR8/Q"*$HI.8S*L_*ZI!\PNE.MT5L;A;9+47Q?<FYQ
MB[L]XV;,(^8]AQ2M .&3+SW ,G"!\:[W,693>WC3\]0,<[[6F^)?V]=VTT*+
M>+IC5E?L<-RAF4V0G; E^42#LR:"Y#%$:K7S6AS0:^J*K.JF:C!D[:&/0;NT
MWQ78@V7R@"5-J**!.=R\%0K)A PN: F9666\LHRS+LW<.KULF$.LOL'3CZS?
M1I_(QTD#I1_4]^D<Q7LQ'?_W2N+7*9U5.F+M],8>>F+MS_D!NF*AK1(FJPC*
M9O3,231@9;F'9\Y29G3R_4U1[6O0-SYZW??U(DW#U;?2A6XD@W,V90I&.K=V
M4W&OUR4W6'K"?+:V-SX?$M-NAZMMT/!LZ]N]9-^ R[4:TUDN%&XJ+([*@)>5
MC3Y/%^63HS_'BY&BDCJ3,4[V*">AJ ;KF0!"-!?4&(T"JPRICJ0U K#]@##K
M7RLM@&U-^A-,?9C]=./I*-JLG5 <8KGI%QJ#;/0_++H%.2KJN/.AMN%ZC:9A
MX=4+$!Z"K:96VD'94]W0OZ2?/LU'D6<FG*; ,\6E28,"ZR(#'4AR3'DJ?.V\
M[5>)&AAG53'P-, J*:0!A#UE]-%Y3L>X5A<C)EV2K.1YD%"B8NW :_0P8M9"
M1LUDY+5/*5XDJ)'CU*H;9#T-- "G;3M.CXQD@KKL0.>5M;<:3- $G R94A$T
MY;6WR6UI;,\KVQ$>LP/JJODN]BC7>4G^^)#6?Z]Y_'"9OLV>[1*P&'$FK9"R
MS ,QJT;^%#S5#(Q2.BFT_50^:!^R8P_[G<AKSSSNA]16--D\F%]JX[\:6+H>
MIC3_QVR^_#%)B\44_SW-WZ>7R_&DG&BMG/.3M'S<G&#V&WD8$:>E]BR#INC+
M")$86%0D<&:=TE0HET,5W/?-R;#9ED,MD:;P,7P]6:W9&(OC:;$L 8DZ2PX%
MM<DC?*(L9J2BERQ*"M'&TKRU3*=27( ,Q <?21(/^UKT-OUD"[*'31!M<;GT
MJ_D&7/@NY:/!>>N$,6"$\*5A' &;4@#E-5?H"F;YT UJIK*WM[32_ASUVAII
M &0/ICSF9V[7/OX9)I>Q'.*L5N+B:YHOW7B*/RC[EON)XBV_?I:6E_/IXFPV
MF7Q:]U(:*8Q'HG(&I!<E=]NCO(T6L"I0$=IXKVN7;_;-T["9K?W!NRDL-+ V
MGN%_E)++WM,,(3+<1SSAX!VZ7%Y*XFQD*<?:177/D#+LB4A;>)G55][.&$3G
M?#PKOOI\V2<2SU*\#*LH^BPM+B?%&GQ"+7UVOQ;I-!_]^C49A^(LE:#A<HD_
MNAMW"Q:RX%F#HUJ#R(1BR,T"4!VY\9HXFFH/T^R!C6%/6M[B"C@8:-JUX-<'
M5?<EL!K2_G6U<O%WO\X6XS7/67.I"!J+$&31@4G@DA7 M/2&"2T\K^UCUZ![
MV .6M[@R^H-%NTMAA#XAH84-O9J(6[H0>8U!"_,A&YJMD:+VS>(^SDQO1QQO
M$;!;*6]/9^;C=+]TZ5=8^?;#+?\QNYS$XY^_7%A^S#F5=('5E'FW3",=,(K)
MF@(5IG3&EPX,"0%"\MD082RGM6L_=J-TV"JU_H+# ^BM72NY-O\/[[=&AIID
MDO20=.GBQ;T!Y\I7-%'*?&8ZUJZXW8K 85O*'QR+%;34+@1OI/DU3=UD56^Z
M:A*SNE9=#61(<125SRIR!IR(5485KC:7(TJ6NFB5UKCJ#N:JODKNL!WG#P[/
MZAI\XV!UF2L77 *^BB4#5QA+&@I,4:*]EQA-'FA+[P[67BM]3DX_NVFAZSTJ
M<KR\-Y*@2F%/EQ?T4,>S-5\'*-LQJJ0W>PV$HK\L2CV:D226;[417LA0O5E&
MCV4[SX^R6*=%<ETLEHBXMI(O&Y\!PQTZ9=Y''RBE3M5>:J^0U$@NWY[(>&CY
M:^JA >M^6VIYN?PQFY?&3*4PP$M'B;0!J+.EKTDH1^@J@*2)>24)>E>UK_2>
MIF18$%55]G.YR+M+ODG\;#+_D7-C/340O2V7Y(R!84J#\5P(E$T@U2^%GZ.E
M$4.TAYY?A<X.0F\ /$@U>E_C\+Z<L\VO-E4=*J?,2.3(1, 0+JZ&S7D!3O"0
M\1]I+:V,G"<):0TVN^CX87;+W@)O #6K_,C2^AI_<_+_+N?C11RO;KLV[&0D
M-Q!OT127]!SN,QB1)$A"@HM)9V9K6YY72&HD5[PFDFHJH0%,/;_1WYX7B!08
M49E#X@&#V10\6!TB*)&%-8D857U:6@>RAL56GPY2;9TT +/S\<5TG,?!36_R
M7I\[KUB<);>835&*5U^1_U57Z-5]U/6]%6KV>LS;"*,7;A51D+5&"^YY NLU
MA>!<-"R[S%GM0\&>6&G5W]\1<@^M9@/Z;V 9O#"64Y?J-J%PHRAU#8(P"H[Z
M!,JDF)QU+MG:*4M[SDL=P+;6 6,E+0Q<L/4\%^>7_I\I+.]6W8RX8)RI,G68
M)8&,"0HV2 V<&9Y%SEH^["_X9&7(5B\=-DNG+Q3U*_MF074R6S[%&Z5$$)[1
M[)+2%$BC*^T<FF(2= Z..&X>MAC<$E=/OW?8?)IAH%5! PUL@8_J3- ?P-"L
M.,WELG)5!%4F]=XSRX91$DM0%3!.*ZF9#KR0%M"/SM1QD27O?7!D!SJ'K0WJ
M>]OL77,MHO,%7T%)ZLH"@T"U*4-J OC@ KH.DK"LK:6\]9'WO17R'!R+E?2T
M,P1_I[F?W0-A_>OTCT=G)\<G?YQ__7CV_O3+E].3\[\=G7W<_?;\Y>?5NBS?
M@NI*=^,?W;PDK9:<J=48^-MVY")88S0!YA(I7;\XV!@,>$ICLC)P36HWY7N.
MEGT-U<FJ)<7L9RIX/_J-LMQ4#L]^_IQ-SY>S\%\_9A-<Y(MW;C$.-R)0&-PH
M2BA$6:8U^!S!.FL!HQOG&'.>^MJM<'8D==@#D2H8>FBU#J&T!C;16QY+C<%3
M;<Q&,BNNG%5@B"VI8"A ZR0%8P5';A.SL?:1\NM4#8NX@X#CR?O4:IJJN'ON
MX<*-)Y<E2_L\A<OY>L*(4QEC)"/!&>5!F#*&PF0%TIOB 9# 4_7!5(^H&/9,
M;0AT[:F)!BQ9=ZFM>$UQ%*P7+ 0"-.501A G<#9P8,P&&26ACM2^P]^:R&'/
MY89 8K]Z;&"^U3]2F3:8XA%:4G>13B[+7?1I7KDNB]/+Y6+IIJ6R:\/>;6K@
M*A2[D;&P1%%F*1"3RBQ,FL%SF5#&)$;CRA!A4AF]=2@?UKCVXBP.H-(&+&Y7
MKE>V8:2XIRG: #EE#8)S"U8S529H"FT8<BAK'\%L1>"P'N40"-H1Q-NKLPE?
M\TGV-N)\Q.-1_.?E>ACQR(4B2]S&I"ES8J(OE8,E 2E[$1().HG:#NF.I YK
M6%M%<&45MVMWGV-TE+@A7GE<FTFA?Q2"!"M5!,Z)2UYQ3GDXC.5]CL1AO=Q6
MD5M)I0VXO(^CRUNIA9+&R4OK (P21 P:?%()W7@,,Z6EPMCJTX*?I698'/;B
MFE82?0-F[_4#,!3<RCE926_D7:*$F81,:62*BH!20].>0TK$J2AB]9.D+4D<
MUN6LA8RMSREW5].@CF3)^%CWE=@8YGNRNUFTF];X/MEL0@+J!,?-(*&!CMF#
M2](%20A^_""__\E<FZ[O&];UJXRDW@3]5HS8W6U_9$I) @\!B*1EJV<2?$@"
MK$4/@S*A>/7F'EL3.>R^.:0AVUE5#0_]_'1T?/8?1Y^_?_SR\>C\^QG^=?+M
M?/?4A1<?5RMSH3O-E1(7/KGQO+1=3K?AP"WLO/?4.F*@-(] A\TQ]-5LJ6%R
M,I6A9;SZF<%+].QKM&Z>O<[?*155M]-NOR177A9/IV=E_<U+:#V-)[.2_[_^
MMFSVFU*;Y).7+# (OGBR"!$TU*J<W!O-+9-&N]I7+M6(']9;JX:WAV9N&.4V
ML!5_G<_0DB^OOD[<=(E<??S7Y?A7.0]Z=_4-'[$N@%9"!Y8PB,^E_0ZG:,Q9
MI" Y)28X+SBOO9 [D-4($@\+F%F_VFL9D(6A33FL)=F89 0H7@Z9@@]@ H9,
ME"C%5"XI'O%0@+PE:UA 5H="5ZCMJ)>!ZT;^-EO\&J,/^>X2I5K.FY"E+RF.
M@YO<<+8ID+9,!RE2AL!+-4R($HR2!JB2+!HOLE1=9M1T?V.C0-I5T;/>I=Z
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MI,1!&AT\I=(F_:8*I@<LV=\*,K4*IK?17P,X?3%X,X+)D*P I[, $0D#8YV
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MW";EDO7.U3[&?YJ2)@8/[X> AY:H@L@;<+M>'LK-G @RHGRR];B;9V?!!&,
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M,[*7.G=R.;:1;1N')'];W96?SR:7J]/=SY_?7WM/@O+@2$2;*06(% AN@CZ
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ME<6:A8^3\<_-H* -,SZY;!2)@$PA,XYK\(HFX!X=;1)\9@^CD;W1\R)!P]4
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M_A+$-KF?QAJ7'DFWN)_V[TV9OWQU^3]02P,$%     @ !(]15H"V%?$#(0
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M7]<^[<U%-D4B"Q;%&P!)YK3'@NG!&PG"Z/%8Q1H>@$%SF)OQKI\L@N51L#'
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M3HE@U:><.#X0N9R"/DU$(6]@M7&I^//"TO.0BB:+>2(2'TIC2XP4.WIQQSY
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M^30<5Y V461Y1%YB-R5>95;VE6=@L@VBFM#IH=,('4M@%EF92*,5AW+8<+(
MS^!'=\:PQ"2-R4BE@,22B/C4^Y+ZO%?.T&'LY_?170/\)T&>@]UG,S.O9&;2
MP'L.$H8*(?1T=?Q0W>!)+TM!(5*#+=4JOFL&V]OM#H?MWLYAYYEC*L)#[(59
M,3^=9P5E+/FSR'-\ QH-C)S@*JF\,NSAQA.&I0JYM+2ZV@F!F4-F7@W53Z$A
M8!HX7X,;N>6A^B.H3WQN[ESBKBSH#02=R ^1L1\F*PO@5N#<Q\8>'3I;NX0]
MCK#H$9=>7"E/O)V*B4$?/$4VD8J!XH#.9NN4X E;<^T29 )/4.FF8&,+%^%O
M!C_G6"V8,&24I.Z<N/0;PJP(E@EZ]IV5,\:,%"V3X&AC1R:[(GT-JCF.9D:@
M6_&@#HY=Z9=%P:L:EJNA/4#I!"$7!9\>&Z-UZ$CI$D:[5-==\;&=L;5!]FAF
M*C9IY1*-6>,1X#!&3?A@!)1,1]*&:#JGK *X%ELQ=2>CRQ1(=5 F9-VG@!YU
MW&,&\U=20%"UJ_@HF^F(&MV/WE2_VU3QP3#7A=-P3I:[#6FS.XS(\R;7?IZ!
M40@\VZ,C?L#LA2F=D\0[$DC:D&S! A7>L=$H4]&8EK/D,"L)4Y)<S-N_"&,E
M"8K%L=04HW6S0VN5E_NE)<(WR!IJS/";%NML+WZ[_U!RE[HDFCMT9'.):#YF
M/HTZ<$SB"(1&/JT'#*C62%\!+J(8A[R68!0[#P_;!F!7Q[&KYXV/:]4HP<-9
M+N$Q,BH0=* P:7J)?K*AZBAYOHPJ)'M&FS?E!BQZG</;U U $W(F9H,!@C9W
M)B+-S!@N][$<.(IY $#&HB>AD;=#DO#NXOU:9TDXYLWUA%*K;<%8C=);O&6^
M:$2? A+V9OX^UD&LV7ASTVGS7?//M!ERP=D.+P9L.<!H$3[%\OZQX;0.G?I8
M(@S>:LXX<YXYI #GBUNY%VX1A?7=E(FU8<*].U7I\C$2G98F^(N]NZSI#>A1
MPE3(Q^:A./QJJR"+^]<LN/&QD7R'DE"7D/QIBB?KQ$?\Q6=<=HW89=V^5V-L
M#,&JA.=>UN?.5(<G7WP,=#:@R/G5')FI86S/-F#F8SBQ'D4$$0[R?JPM0/O
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MB@ 6?Z<3)%C$M;8?(T?XF(AUWO'>R3]^.GK^:N^ ?H 4O_>#EE-_&DVA&+^
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M$KD= _4%@4*,8A0O1Z,8Q*I.3-:>?Z$BHGOX,Q5J.(K-E 9@?1WDDPR'X =
M3I2PD%%JQAI/KD+('R+82-#Q\Q3>!R"G/<$+N)BLNIL ;^$=C[:TNB)!+ $V
M42*P+. R)?D\8K)H1;C/.(:'8#!U'\$<?47S)Z;*B3:6;1P^(K:!0KZ$F[JS
MT(97OU8>\D>!XO"DV4 !3*TI4''2/MW'<[@V.5*I+ >6B,0$" 0P1!0KF9@
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MF4^P(LMLJBC?1^8S#XU2T,KU"&93]\#DR.1L>CUD_S8-+C'I$+[N8(5Y)"/
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MH],=8'Y+V :O(:2<+2,-(^2;*X!'C<%%IQF_\[7(J8:&RL-,W3GU;*:!B)>
M*[UHJK8WV<5;X):2#XG)-S9<6=S=WE0Z&5=0<MN;#NOL+=DB3&8+XD."6!7Q
M??9/B+051+=.'UL^M &87*<W-0"9-]8VV9S:"LMMD[8'[GI=3[<E3;!%>#)Q
M1 SRF)WBK:!4-[EKR9E:2VPX!,_5\CD0LF/&*A 2S)H#A&QDT L7('3X%"#T
M=P^&C0D1^E']-^=;%_O:;UQ*@UNP1 H+PW)Q+:J='/B('G(&]7P19NKR6VE9
M$!YYRQ;FS <RF>.5OBX6#N\1DM8]TQ 1>Z51(9\:Q"P[.<L"J+K,.>%/1'A
ML>V)X\L]X\(34_6./74*GIOUC\5D/IPT]LB9;W-*G*S0@$"EU!4D:".8K9<3
MUV!UR3I+2W2U<3!1'M8+ROY%]!72!%#&6V7_J/5JM&7/J,OQFLLSEOD8V)HQ
M6TR;GWHK_UBUM[Z]9TM<8$UV9($7.K.%""O** N>65!$$C:W=;"]=;Y-]AZ+
M(5>8"8:UP&X00PHN,;G-Z?C83DLB]]SA(,01L&!*O*FHQTE!+EL8S[;Y]$W:
ML-4%\E1;([OK"G[5*\7;U99K%1'9]]5P82M2S&'/,M\6+J:B6-<UY0F$HCHU
MU>V UF#-$,'!++1&E.BT</76_K9M^S>Y"*)@Z#]S-M32E\Z^-O9ME:W[=MS4
MJHUVOL+&2PJ\:&V;:T-K7N_G&X75DNC6M]+R]["%#0B*XN3 4H"SQF!_53W(
MY1>NHXUFNRBBYGK?#^N_M65H3?!8:1(4UK9RADHY-IHK!&'/#U-T\E:H"MJ"
ML0_F9**&9+C6:Y=ZAE<*CP.7HO2!JH.A$:(8[*D1XI?32G/0U7+7;-16?I<5
M3A#<#.G5&/!A;[>LOA=VQRC;)Y.Y2MUCI!8WUI"+&YCB"F*#1=48MYDUN269
M(@M1W(((D_K$?9ZVQ;LB18U^:%)LY(H%P*VPSJV\%S4Q)V'4F:[+EJLXQQCT
MXH1*CL+G5$:(B),K6O6+ >9S0W:&;3)^F!@-XQUO?.#6A/,MG>O[5/N,3?M4
MF(SSM0V@-];0W)R*AROHNG--MM>JZ/X8\UZH)1/\SYU":T9M#NKK,Z9B>Z@G
M%?#'JH!7/5N=TE&9R)6R1*G>9EV1V$0B>@<.-"_(8DM6U 4YZ%Z>9V,ILA"$
M*S+B\L#5X2Q5I]1V#A? KH\E%ZG5.X)^U#8NN*, .K@Q=:"[4+2PSK#MM=@Z
MV7;"9$=A_W!ZC%@!ER&L!UT72<QY%S#Y=*>'?'+KX,B/5W9I7#H<8\*,1;EZ
M(/4'NUTU4=4U2#MB-]"3YO/C-)^%.-0U,#%*2!;F'2ZU9J!_*2Z5+U*?S!Z9
M3T@IF8-4:V,+D&-!  .(4)C>6:->>[7<"8PSTAT7@5>Y*\AN]?X8B#]C2A6R
MYU+IYD*:L&>!#2+60Y@))7GJ2Q;8":M(M6#O:6GF6'@R)9YBTY<'@CPZ(.H]
MX$:B(^0TU(<C0;[1[C87HYL7#W25B%BK N\">#;!56>NE@(6L;%-/[C@+<._
M;V*^"*OP^1*C.HI1R19H7N20(#B1OJW'6@"IP28'UZ?!=QVW'7_#\L*!_S^P
MY6 +8DLHR;RMG9KJ'IT]/O>2CXXJ[Y*FJY\*8>A!+= -RRGO=MG>Z\TEK)9-
M65_H:L9K7GGP@TQD7Z45%1);R2'[\"7/66Q/5=_ 7ZUZU?:/**M!&Q]J<9.B
M9D+I7XO.OFU/:5.UW.:4+5^NY=[Z1NP<0GXG[\7O #8#$W?7'F;U>60U@+'E
MV:$%N#5K#.XHVU:>)6E.ZK<2U,D>)Q1VY32KFKZPNWH_@54!@,..T5Q$[@NU
M%(/R2ON912W<%C5I<[$T; IWN,+]VC6V7[9M8QU%"41!5X\#1EL\NF-%=4>'
M>A0(J7V@&<Z 6)K.Z*F%QKZ6I;&QII;TN 0^Z("JQ7)*[L5<Q\1X2:S6]SND
M8L'"$GPWL[G?W/E#C:3+*,<J<JY=Y=;R76^W+&/'\U02P)K(&"S(F(35*QGE
MULY1FBUH6NI:W7:%)(BTZFHSOHE%!3&24Z!<,4C)][#9;E'G)I#Y/ Q]\FWF
M35#"!559)*+47WMQ:=>_8CGDOTK#WC7QIJKPJS3IK"@#HR[J*_XX;/#@;Y$<
M'J#N*>(=]L/\(-,O(/3^1OVX 6ED[-UE0W*X68($..-'(@RV"IY%-%<D E!L
M-CQPZ5@;:RE__HAD"&Z<C+26P 2O)O!AK$5RJ'BV"*Q]H^3,.G;*I59U+Q (
ME!Z5K)!!GQDJ#6DZ% -'QDXW8@+LWO5D3L,A<$0_@E<JL3BJ7R(O#P?NE36*
M:E99YY>V>$D3CGWUHBK;SP>@7%F1"=A27'AAQE=#&ANRL.)S=D168&A46AM@
MEN[Z:EYLZNIJ-'5UG/JCR>W6 CS6U-"(&@Q6%XT^Y=QP2TX[$1K:9#8H!V.)
MI)SO@6W/E$Y;E+9#\H<<EH>210/5+6).F M=_T')->M29# GMR/7N$@"!<Z)
MFPN,N"<;2YU>/"+J=![+24=&7]9+D!#B"8"<R.]JE2%*<"0>@!;E6!A'<\A]
MXI 0*8[7U2IE;P-X+&$>U1J2T,LD499OF3Q$.HV*(6HVD47V(?>K#>$8GR]K
M/^,(*LE82G>'*CZ96$=3%GY=/>@NR+5E3S-:<"5;U3=9PP!Z[I8X7SLZC#CR
M3J P)@4/DG?.8Q2N>S 39K=_6!>7*\1![:2V>C5MV.*Y6Q;N@96P:5O4&J>"
M H>L#%$AQ :$J*QV50V(82%5+K.7@?R(0' J1@Q+3M*;CH@@YZA\2@M!CK3N
M[UUX[EHV1K]TV1AG46Y-AT7,/ :T]H);^64U+^)2_,LD'F?4BM6!\LAK<<S!
M2.=DTR0OS<\3:\MBT&C@:GSCDZQ,@X@<-'+WV2.8/%+SO<PR$VF^QJJW/@#9
MMOA,FG8%N7#=F8^R60TR9CW[D?MZMITMN?A#IONGW/W-TH^NP@@(I&JMTO*2
M@L:$N?,>@I:XGL(;\?5/R1FH$WA0R]B:7>J%G-E0Q5!0>3!2DLP35&F>7!4H
M!"<[9)/298 C+BI<!P5OPI!6*2,N4W8'"("2.@)BL4T%Y)-\902:JNM-3C4&
M;%^Z/6,)N9?*@H5$G:'05<"V(ZPU0!^.)*S%)EO19Q1'JE09B&B/TUNDDD43
M,\3.:)JAWP70N4B3.L73Q4O(4EA]D"&'[U X0ZIV4%UE4Q <04HB.K$Z\BOK
MS)EGJIH"OCG6'#CG)?O%TVV-XH)->!BV1A0BM='>&@TYY++L.6\#7%9J0.'!
M)RQ+GC^V;6;H$U/$W5*%(H^QDUL":85]761T\_?<=9(&AM7A5K']=[!3FK-5
MJ;E:7FMW'D,V5I0^?42B]!W<?=8#K.=LDO67_^5"T9X0H?!F0UESN]24 3/C
MWHU.*PUK.@ FJ@2$X0Z%QH'Z"AI=7Q&'!^Z<]E5;O-=#C5"I* :/9 BB%V@L
M)C62&*(3K3'S%<.CT;C<0D46F[73>'W=6QCQLW_0/@SK?&\LP .8-07BE[>]
M9NT$KN<C63PNK5/&=7:GFUIS!B3BP9A,L"%34&0^B9S>-5.8/0SZMB(X63&B
M0#QL48UL.*NL)3(9RU0K#GEBXT\&. $?VEKNQ*4GR(<C&4<D:3LGBVT-GPFG
MY?IH\+)M/,6C C=,,I/.JXHS2>(MBX>^#Q&]74;%VJ[:%%-!>+:YS&._.27C
ME^+2M;'H0P(,VXS7BSG7!@7[OF]@,8<AV+P:0-89=DL;,CMY*;]!^:!IVIPH
M"V+71&V0*#F;\V(MHW;DFI?"5Y#ON((+<UD>DE.;R=1!0KY)?8]NDJ0W%Q&:
M4UY[*2*<85>,H5IW^X2W9;H < (=E5D 51\A1GVF8QM#[J&?6GMX8:54>7PR
M0(VYK)1[2+M(7*ZK.P]&.@V KU-G?_0ZK%..V<'"+A*GG\[A+H,\/8KY9CAV
MR3,616H$%I99==>D"R,M-A>EFE,5:BE*W5)F2Q.TDBNV]I%-V 1!Q;7XH#,7
M>NH3XR* V9QT!31?)TS6N5]C/K61ID4"0-DK*%):)R#[:=!Q")7<-PG(/\&W
M^&H9I6<_=.;RU9:*+_JU+EP&>_96&S$S*PS(RR;?XLB %@?(V>):=DF6IX7U
M4SA;/ALMD(A0)*+U+50:%E6698T^&-J-1A(;R>4F0F=M'&;:V]6AF8MWN[&H
MWYR:-$M1_YPA(:H47%J/BP^@<C0-=7AJ2L1Y%FAUD&,)*E.9;T>0A)NUEG]X
M7:M*LR\.#O2OD2"*[,O'DGM!\>?,9UF39R-5E/DJ\YF'1BGH>WH$LZE[8'+D
M%#"]GBYMR@D:DV/1*3)-9 18:8H-Y"K1CH1IJU./L3:QKQ#&C<N23&>YSU"4
M3U%PE2BXPZ<HN.^)J]9$L AZ79BF1\/YYYB=,I-F/$ZF5;B>?Z=.S_2^>Y@8
M!.(>V@KQ+>9=F\MAFI,)OI3#O-4<_FV-@7C9UORW;L/?(ECJV!43OX#UME9J
M,NF"*W12I-[)["QT5;-$B]R8/D^$AV(K>U!:POY,%SRXN<#=G 20Y1;N!&O\
MB,_XB4MT:!A8R]#0H(8=TYU:[SLMO0B7SO#EJQ_,&-,<8.J$ S<"'< AR%#F
M&'$4!AH!608:/M29:I7HTBH38FV61"HF,D7G*!FHB;^405 :W5#D2.5:V^SF
M;#F4U7:+@=4/UKFY"-*<Z.:E"/(+L7@$K?=RTC#,\ 2?Y1"R(K0<60_TXP@V
MUO6A'RS7L%W+AAWD-E[@6HUE5[:\!:V2>6E5AYA5%+2-QSHB',.Q%@/K7!KS
M2E5=OT)Z_(J!#@[7U_3F$BM:I2;1D;BE<D3 9KF(VCJC!F_9,UXN#CWI7W^8
M#]_!7U&%._IC*MPN\C?X,<B'\9O_!U!+ P04    "  $CU%61-NR6.$-  !R
M5   %0   '1H8RTR,#(R,3(S,65X,3!Y+FAT;>U<ZW/;-A+_?G\%ZEQ39T9/
M6WY$<CRC).XDO:3QQ;[+]-,-1$(B:I!@ ="R^M??[@*D*$=R[4Q221EG'#U(
M/'87^_CM M3)#Z\_O+K\[?R,)2Y5[/P_+]^]?<5VFNWVI_U7[?;KR]?LS>7[
M=ZS7ZG39I>&9E4[JC*MV^^S7';:3.)?WV^WI=-J:[K>TF;0O/[9QJ%Y;:6U%
M*W;QSND)7H%7P>/3?YS\T&RRUSHJ4I$Y%AG!G8A9864V89]B8:]8LQE:O=+Y
MS,A)XMA>9V^??=+F2EYS?]])I\1I.<Y)VW\_:=,D)R,=STY/8GG-9/QB1^YW
MQ1'O='D<[1_TCD:'ST4\CGO\^*AWO-_CT?A_72"R#<U]'^MF2KS826763 3.
MW^_N';:ZQ[D;3&7LDGZWT_EQ9Z&M$S>NR96<9'VB&.Z.-? 7;D=::=-_TJ%_
M [S3'/-4JEG_ITN9"LM^%5/V4:<\^ZEA0<I-*XP<^X96_BE@1IB<ODX]14<P
MCI*9J"@DDLYN$CF2CG4[N[-G)VWLL(2Q&K$1"$\8H%:F$\:5>[&C]$3;UN_Y
M9(=9$RU^]]W#C,^/\YM!RLT$Q#32SNFT?P!$7@OC9,15F(#F\K>#\ [W>OG-
M,GDO(\MS,#*G#V)F WI5?>\:]ULK2>^VDNRADOPL1J;@9L:ZQPVTK+T5=&T2
MS>^DY>QGK3>$G*=/GG<'PS@VPEKV(94.?!A<VQ]L*7V;M-0?SYX^.3@>/'W2
M/>PL>3W7/@8Q/69G-R(JG+P6[+\R$NP<V)4Q&&8#0D>:"A-)KMB'7!B./>P6
M,/]:<,-0V1ML"ZA]RWC*8J'P$@1QIUEN=*J=8#-=X%>7")9_^8*QJ70)NQ29
M<'[QWPB(44G$C6"[.#;TRGDV>]9B[!*^CK52>HI((A6I-C 8,&.)"G#6J64\
MBUFDLUCZX8$BETC+1)HK/2- HL=C85H/DGTI]9S',<S=5&(, D*T0/%"9LAA
MOXE7_GY8$-S!\=[>867\?[^J#!9ETVL=E-*)1:3]:O<+$)3!GCNGI9&OCV(4
M&G@A]E"5;;!I(HPW@*E4"M7-R:P0: Y&Y-HX_)2*!KO@13KC7K$O"L=!7V'0
M1(JZG7P8CV%:0YK[V7@C 9@---[;WA3P,4R!]J=F3&;LI;9.9PWV?OBHT&M6
MZ+.YASF#]7.S#=!L\JOL):9>"!,NA+D&5;.@UR8/+#PL"#WJS5?7FPMP"XZ]
MAAQY Q3F/3=1PKH;F#0L7VU$!R*SO!Y)'A5Y/8K\DEL!$4]!WKE^3?ZM#,Y&
M1 *C+,_@+RL@DH^03DMT(CS\Y^%!IP$D-5C.9WRD!,95'@&',<\ #A! K2%1
M7)?NT< "7Q"QN8FQGP%8"LB81P[]:X-%A3&@0!"D1Q+(%5=JUF"V&/TN(@('
M/,^5C&@VQV]HCD0KE+8%H/NHR>O5Y*%7E+<9EH!0><X5J,_N\.WYL_5K-CN#
M_"4BLG[AF:_R>'_=0$AJ0*',!*)^Q&W"1CHK(">:HIJ2.0">/#KX$?6>VM9L
MH47Y%?#((%T"L#O6)D4#:&*;V \7U=PM<]*#4K0-'@&HO18AORHMK38*FVBN
MK)]#04N%S<!P=.$\8;& D6.&XT(3(S"QXV52Z1+NV P2Y\KX:#BTU&66&4L;
M&8&=6VR(O(,( +#7["_5L03431,T8)A(%:@@D%X:!GIA.%B_S%"V0&OF**U\
M^J1W-(#[8RY5883'^"!HE.,?P"Y O@83D&U&D'8:DI62GO="8@H-&*S%SCD6
M3V7N>0L,H-1C#9J2:0>MN>&9$\*SC8YK8?U2'HM')[%V)W'A='3UF8^X !_A
M=6X#/$45!$=H41$FLT!_3%H^CX=>N_ :JB(Z$I8#+QG:0S2+5 B!V"'/C;Z1
M*6!5-D$=93%^O.8*DE4,I5T*I/"_Q3Z 5?"Y[<604T\R[S"HO$Z3R5)Z5*A!
M0U("M-O81.;,"9ZNCKY*PU)AR:?N95KL##P1>8I&O1=,CTW1 AG6LN1(>G/U
MO'L&,/]VLYPX\==WYXX!4GX8SZ#!6EKXFD,@UPCO-?]2]WSS:M2S1A"EEPM,
MAMLH !)(F" <&+TLW8/G KH7+;\VP<J"EP6/!%/#+,&WU* &+BOXF; QAQW]
M^'QB!/END-]<.I5*P*(#@>DR#[7<.6U!XO 2,N.Q=-M0,/X-[:(JL9;%(1NJ
M0UZ=E:#5PI88=XQ(($RC5QH%/B'61E=\(NK!+J%2JZ\["35&,ZV:DS$D7F4L
M2X"<L@0\$DI/(?X,:<'+YN9^VDFQ?+5. G).^8STB (T3(<Z2*9+F\@4#V<
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MQ\9"Z6R&13]H@:6[<F\-^#=B7 "XKU73V>]ZA,-#WK]LC[Y<AIQ<!>["\_G
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MG]-Y'QFVN/7"D.C!EZ[Q.D!/I_ZK$FSW&^?@-&)?.F \N@==%R >*@^NJ31
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MY]K ??(^SQQPQD<S*6X3?[L\WUL+"/$0R(G09K(M0,(^)E\&R/Y6  G;.IT
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M"DP@90MJVFJU0I?5\[I7_,7SMZ_V]M[!GS\YQ)Q!;>(-/*HF\2$W3@FSQ>#
M3V$.U(1A)6<7N;,Z-['7J/DX0AN"4%,XX,%E?I"$6L&I!ZLRP2&?.6D=.Y)\
MHK2%YT([:$8$L8!#/6=6\ -:#X)R% M$#-.YE;'DBO6R#'Z)!>M%%UBYHI?Q
M,9^BCC8>!P96NN@$%&&?B\/#/CL<1%AI@5R($@+15A@(^_.3TU!BX$C<BTS/
MO#Y!I(D0<!/">2UH @X"M4-@IX8AN0CH&6%$+@)Z'K@A'L#- ]%1Q(ZGLTS/
MA=@FF12V&1Z'PLM"<?U@7::[^ON__[K[VNM"K^L@/K;LH5:+7_P5/K8ZR]WZ
M7WE4+KS]_ZFI7WG&)V)G; 2_V^&W3I@_>?; Y_;9_W KQ1?>E?3OE[]-^O>D
M?U]2">G?_WOU[\-V/P[[T<X5!YI+Q(2SH4@D=P9Q\9<*.@")$>O%,7R@\G+T
M78;DDF&F",##[:U4<)-@I06*TDH<G,(]/S'%IK-%O1=[@RF11 F.%B*$*61Y
M?'=(U9].S(&;.1IPV$7C$&"$]:)CX@WBC0H:#5D@;4XOQL2Q4\5H)@ -F9MW
M (>PK=$!',(^#X=9?GOK-;LN[KB3@@V-G'(SKV-2K$-NI+#1 ,1H??>@=<)Z
M*I99YL%1#<E2?PEJYFB L3++L$>1"-'%&BI>41!"7+% Q4)[@Z@"/564TV_M
M1F86:3/39KUZB,,T-.#20D<+%FC3%E0U;0.B&:&NKY%FOIY<#.*+$V[XI%CC
MBC5[06S1@D,5?RRV^R+-69!/T0:%GM8[?K&&($02+3P,N;GS?D3/6AU+[HKK
MPR7$$\AYHBZ'U!J 95F$@A!BC!NX050A"?GFG6V')!2*H ]%KM@Q]U)?ONW;
ML@_7'@Q#A(1!S18W_L9()+S=9(O6WK"-0)10 F$^%N9.R=LM>OW#-@(5/0H@
M]+GRCB6/X:%H[@,W*5S<W@((V&$NZXX:H@;$U%"G(8Y$?$?3'KBIH37L4=T5
MQ ZXV>%2."XS  8W4QY3/(&;'T8S;9SMP)$,VQ+$#7YISW3&(B/$'?MH)D7[
MU+;M^V$;A/8-'"SR3NWQKU9;'>+^B"Y7ZX9]4$J4W',;YQDWE70HS]CQIUAD
MF? SI-RQD13&<+AJ]+U,!&+A<?3C8A%W_&',=X92)%-=7C0 ()<"J<0R9J,<
M[A\S1\PM-#G68$4D0"E^Y69W4X5A6V0@K5\0)E$S2-GK7R@3)/=>I2"!P-8*
M;N*T=>T@9I#W\#8R04X=#4A<*B"H&7/%HE1F"=KVS:%0RLXS.#'(XQJ AO$;
M]:H;=N=TT$-,%A3*K *C\-%]H LD"OS1UW8FG0>,GH(%*&M*W,&N.3@9<_;_
M<G@F-^]@G5;89J$4*D#CI,].AFB]BTY\SK!/@4= ?5ELT?P?MA$H]CB(4IYI
MQ<[D?:%/@)00:*?[0=0_;RD=D6OP VW,J/_*IH43_V8S%<_T:FW- >WTH)T>
MM-.#=GK03H^?T#F*^M>G["J/+=AD>P\A;%M07@GP,#C;B5)XFHEF V[NA&-G
MX+N@'12FA!)@0O-&_# &6P P%#AYI8H53JJ(X!ENM<%>P/+ :!6PV$ D1<]5
M/3B.E#2H<>91A'0Z"A*V;<C=V(0/H]E[(=BAS+)25!5K.9Q(9 &2Z52KAU+\
M+((?AY]0'C65'MJ62C9A&X?*704^<K]QSH-#B3+ K[ QS+A"ZX=T4OD(^W@L
ML-%TS^A;=J8M.^%.XY50I "F1(<7,3'%#5+=+'D^92-?J@$205LK&W S!^),
M<#-'B8UCE\K8,J]TXOONZOXJI+Q!0<L"&2>9'L-]<IA;^!%KL6<]+L4L'V<R
M]A>L;W4?IC*3LYFW#?%(@Q9:.$4,TF"B%O3&[F]0E:6%"2(((H@:#$._R;+8
M(52$L3%'31/4TKL 1E-'J;=!$'$0<3R%#[1QR:FO)&E)00C XE+<"Y4+%LWC
M3'3A=P9N%LJ"ML!QS;-<[!QR*Y):W@*EFT'9SP4F;M[WN\]SA6V:[Y;G"OO4
M1)?G/>MM,I!Q*B?\VY:=AFV#C1\=&7. %V[XO+M6P+"M0>T9JX#8%)F@;?*B
MC ;  _ZB@\AD I$(X(.(@T*3%CB<T=*QXR0O<Y_LQ?/]M^\:F36$E$$^!L!"
M3GPK%U %6GZ@9&<! ]_:]^+YZS?O>F/#/^NZHEHMN<2:P:#&SX.C0<3JV^-2
MQ*+00%DT@0Z-F$K1DHF.],YBK*WMFJ),C'9SR81]B#R"R.\@OV,%$GUN9D <
M'Y6$)[-+G>5$*D0J7T*0CITV=FD: 2#B1,S1%FB["G7#/ATU,I;S'_#JN=$V
MEEY)W#["+%@)A7(D3P#'$XM.A'6:B(6(91T?%\:E>N:_1K1"M+)NA6,O^A+I
M\7AE$1O*A$HG6]C"/A45'K0/?FK9AO?%&[6VLB'>B-.E7D/8AV49*:OSUVB]
M$1+TV 20_AS^?\P-N"&(R8.J.<NHN#@LBCHG_SQ'W!Q"A+$)&HO^H:V+?&$;
MA1R.C?!H[6?LRC$-VSH_%(TX/?N[0#(5)K?%M7+8'[%1C_5Y;J=>'@HG?_P(
M&X!_)#C\);)LBYUJ89-$!V#XF;B!.($VI#RV(66?-J3$M"&%-J30AA3:D(+#
M2V3@%!3. 7B)YS=L(#/I(,8D7Y%\11\X7,"S95K?L2$W=W"3D_.(ERK:N!C%
M0*SN,]$$7IIHWQQ%'L[*9(LF"N*'GXD?KE*=6Z\K?,'OT&JZ$4LL@^+&=VS>
M^\*XS#*THP(_ E7\O24M'R[.(!P3S<P1R<3^"%SQ]Z)BV(_03CRCYX3WTO@Z
M=ZIE+-J+U+AQ2AB+D!"HP;\E(E-VY39M_MZQ'.5F0F(JI,+D33"(:FB@[< E
MM:6#]]HX=BC\,IMZYJ<#@>"P;4*.!7P4QZ7R"K"9F"^TN)HI97^9+,^/(:0/
M\C8*L)BY*)HK;_14J!?/W[[:>_/.=B/F%[9ESH%;J2&WQLAW4/0+VRA=PB/L
M@W+"30(N"/<2]'6$TK-60SCK\,JC]#(^YE/4O'$" :R1<:WB=JJLDRYW G'W
M/DT>UR9@)8&^SS/7['>.O2.R1!U8G8].</)3')42)[[0SHXYN!OGVHHB@+E*
MC>:.N 0UEVB=L!%<LP;B6D5BTY0?W0P,[Y>*HL43*UE0LO3@Q CNI9*.>)9Q
MVW8Y%N7Y;RN[A6T7] G3&AB%I_$@K&-]G5OOEFX+C+#M@KY!XR3/;JLZ;*?*
M-V%;92"M]?^;S21FUNC[M)>XEUDF&L?S!#[?#+&7\4.)$_S=Z( O3H3:I'""
ME#C0.QJEV/A./W>?1<9Z_2&M\R4=>H!%Q/J29X*GM/6;<A< ASZ[RF/KT^(-
M''"VB'<CI!?VB>A'YZP:/SO.V)!;C;6D2O[# @KM123Y&"L_H,]0M!!1V(*H
M >,P:H&"(7@+Q:(X%DE':A8H!U K()P)P:Z,N)>*? 7,A% 4- 2W6^S^(#8(
MG@U&N<I\PXS7LR$Z0!PZG/&Q-MR!EX XX?@C4,+?CH2VDC;21",Q N"@ZHNJ
MEXAUD'T.VR:4;P1<%&MQ%XEGK"W8M,0%L%!.;I3;LF]$EBEA[0IK>(@,,9(%
M#9 6]V@JVJV4I\KFAJM8L$B;F7<W5P5G<9@EXG-X#79J?>B%V\]8@*-J@&'5
M;!RY&8AY8P,LHO<#O'I8Y&YLQ,31L(^6)GRCK<[-ABY;VN!1FJEXIM>TP2.F
M#1ZTP8,V>- &#P2.T@8GH9J$)M^1?,<V+"B=37'F9ER4$WR6_6<Y"_Q_B3F(
M.38BA*B#J*,-C#.=2RNY(E^#&&,)&'6NA@B#"*.-BV692&(-8HTV.I;GY8D[
MB#O:Z+@2RO=;"$&T0;2Q#(QBU(O8@MA"L-'@A)UB[>LGN8 U*&R!A; -01*'
M:UBX)EX@7A#L8T2U$/(:UGIU/ZI$F <C'7P4+W (GW[^"^/L4MH[=BF<4$7A
MN1"U0\@AU\),X8>(0WPG=P?B=6&;@OBC&0>I1>MP-^S2 .$*&OKG6Z$A;&,0
M/:P#HNGK![N@I0E*83X.#&JS(-IX'!W;9KG#M@KQ!B"C4L6]!(2PH=$S_VR(
MM4LHPPF0J/?%)?5>P='<.C'=8@P];(MTJ;D?]O%H8V.Q]+K)=]%>!MK+L!DC
M%X<OGK]^\^[DG^=>),TI83 +GQ"A/ F6M7T>K-B:OO=N,8:$EF=H)>578@9K
M79:X98$3%Z>QCN]8.?@Y<D8(5X8ZQ]9_"6V80\)*!4"V2Z>'_>$I^^$!<,-.
MAFA9@%*C)03.MH% V!^?6  @H+,YBXRVMHO-HV';HE?LM\#M%>AIW</5Y"J\
M-,@(8HN>@LA#TLH'O%2A[_U^<QT[#:BHEM%BY8I28Q(W5Q1X..,JP<H)Y$%X
M&)1N SL2]R+3LV)I'%P9-W[3_3#50LE/:&F"HHP60"ZC06LC,4[&("]"Y]9G
ML OE@H>"(Q8U,9=@) G:&5-A8C03L8388]Y%+!JV28@G:DSDRDCKE?_O@2RT
MP=N>1;X$H&)T.8!_?R>,*I1*$3-$5V6LL _%Z91/BOG"<L44=^R0?_*_NY99
MQB?4E45=60 2!0=E()+6^ACL<<B F[G?'8.9.SZ\_XL-Q%0;Z1LYL5<_J"VB
MP(3.C1(^ )DN#;-3#>2)J(3VA90V*I[I-]H7$M.^$-H70OM":%\( K?IC$]R
MQ<&/3/P35=-B>)-4Y$66H+@3#UJW6O1K?-1+;2EIA9DSY*V VY 4"BBIO1D.
MQ>U:3F.CI0K26'P$&%TL"0G<+K4%4+.&MG[3]50Z^ VY%^1>M'+[\;F?\QO
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MJ;(A-TZ!2[J\99L$HW'RA1%3"6YG+[I8\(;%G@(A/Z.-C2J2!6]4-1NMR,W
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M%S;<[6'D#/25$@^$T4P[/^S>R^U6*GEA6X)&SY;1,!#362K1=G!2$%+ 82K
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MG%X$+:QIU&]7M3Y+</A6&ZD56EF3;K2!PSXD YE \'GOQRV^AYYXZ,8AQ7D
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M7K# &3+*I&HH5Z15$%W4>%J"*[YE(1JC3)2\3 0O:.-;,G4=^84%T$F.Z:[
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MW'P*]B6G/_Q<'A ]"7+U7B6<-3S ;3Q!1RM6U/8H/.M"%5V ,=23S5 %6)0
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M2$\XJYHLR9G\7Q?)AD.W\2UWFK#1C9W\N,[-JNZTR(_T\SBR)IECZZMY!G_
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M\I;(!'^SN>AUT'4*LC-IRJI&:NJ-P@GHN;D"N=PNVAQXT!4-!=LBNQ(^1#W
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MZ!,>!%RR!76;[S=$N[1N%\199BWPE +59&S&,RDV5W-<V!C93S,#JQ$+0(%
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MZ=H#@((?KVM&EE'K(/0_U^A%A@<!K/KIX7'T3G*O8K<.G-=!*HC<1DS2?6&
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M+FAT;5!+ 0(4 Q0    (  2/45;W:8>HP2L  )8$ @ 0              "
M ;R-!@!T:&,M,C R,C$R,S$N>'-D4$L! A0#%     @ !(]15E<Y3AJ;0@
MEK$" !0              ( !J[D& '1H8RTR,#(R,3(S,5]C86PN>&UL4$L!
M A0#%     @ !(]15A)D+UTP! $ ^W + !0              ( !>/P& '1H
M8RTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ !(]15H?2?_]N9P0 S?H%
M !,              ( !V@ ( '1H8RTR,#(R,3(S,5]G,2YJ<&=02P$"% ,4
M    "  $CU%6[HQYUJE< 0#YM $ $P              @ %Y: P =&AC+3(P
M,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    (  2/459D#L4ILD8" #(M%P 4
M          "  5/%#0!T:&,M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M  2/459T)S>@\&X! %"8$  4              "  3<,$ !T:&,M,C R,C$R
M,S%?<')E+GAM;%!+ 0(4 Q0    (  2/45;8U(!]'0T  %1+   6
M      "  5E[$0!T:&,M,C R,C$R,S%E>#$P;&PN:'1M4$L! A0#%     @
M!(]15H"V%?$#(0  WO\  !8              ( !JH@1 '1H8RTR,#(R,3(S
M,65X,3!M;2YH=&U02P$"% ,4    "  $CU%60*BE[WPC  #<_0  %@
M        @ 'AJ1$ =&AC+3(P,C(Q,C,Q97@Q,'-S+FAT;5!+ 0(4 Q0    (
M  2/459$V[)8X0T  ')4   5              "  9'-$0!T:&,M,C R,C$R
M,S%E>#$P>2YH=&U02P$"% ,4    "  $CU%6/ "'G2U/  !@P@D %
M        @ &EVQ$ =&AC+3(P,C(Q,C,Q97@R,2YH=&U02P$"% ,4    "  $
MCU%66 U JGH#  !P"0  %               @ $$*Q( =&AC+3(P,C(Q,C,Q
M97@R,RYH=&U02P$"% ,4    "  $CU%61Y3+CQ$(   %)@  %0
M    @ &P+A( =&AC+3(P,C(Q,C,Q97@S,6$N:'1M4$L! A0#%     @ !(]1
M5J V  (5"   J24  !4              ( !]#82 '1H8RTR,#(R,3(S,65X
M,S%B+FAT;5!+ 0(4 Q0    (  2/458M)4D0G04  -45   4
M  "  3P_$@!T:&,M,C R,C$R,S%E>#,R+FAT;5!+ 0(4 Q0    (  2/459(
M#K0LTC$   DJ 0 4              "  0M%$@!T:&,M,C R,C$R,S%E>#1A
:+FAT;5!+!08     $@ 2 *,$   /=Q(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
